<SEC-DOCUMENT>0001104659-24-108585.txt : 20241015
<SEC-HEADER>0001104659-24-108585.hdr.sgml : 20241015
<ACCEPTANCE-DATETIME>20241015161129
ACCESSION NUMBER:		0001104659-24-108585
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		86
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20241015
DATE AS OF CHANGE:		20241015

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inventiva S.A.
		CENTRAL INDEX KEY:			0001756594
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39374
		FILM NUMBER:		241371953

	BUSINESS ADDRESS:	
		STREET 1:		50 RUE DE DIJON
		CITY:			DAIX
		STATE:			I0
		ZIP:			21121
		BUSINESS PHONE:		33380447500

	MAIL ADDRESS:	
		STREET 1:		50 RUE DE DIJON
		CITY:			DAIX
		STATE:			I0
		ZIP:			21121
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>iva-20240630x6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.8.0.95 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 10/15/2024 9:52:16 AM -->
<!-- iXBRL Library version: 1.0.9027.2259 -->
<!-- iXBRL Service Job ID: 173141b6-1ebb-47d4-99fc-9933b28cddd5 -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:iva="http://www.inventivapharma.com/20240630" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="dei:DocumentPeriodEndDate" id="Tc_zODG2TrfOkm1o5H9ooyWBQ_1_1">2024-06-30</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="dei:AmendmentFlag" id="Tc_8MeKvnBeMECOc40fhq9FUw_2_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="dei:CurrentFiscalYearEndDate" id="Tc_2nzr9Ey5qk-lHXO5sYJAMA_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="dei:DocumentFiscalYearFocus" id="Tc_h4bAUDlQ0EWpG9eb5WqHfg_4_1">2024</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="dei:DocumentFiscalPeriodFocus" id="Tc_Qklv8IQB30SeVCYsxsYSlw_5_1">Q2</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="dei:EntityCentralIndexKey" id="Tc_Ufoj0p44JUS46oRtaTtzDg_6_1">0001756594</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="iva-20240630.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_28_2022_To_11_28_2022_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_ixbJJMHX7k-KJKKJhzrKQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:LongTermFinancialDebtDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:WarrantAgreementWithEuropeanInvestmentBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-28</xbrli:startDate><xbrli:endDate>2022-11-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20232ShareWarrantPlanMember_WOiJYiWPuUu4IuMxaS3vvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iva:DavidNikodemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa20232ShareWarrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20231ShareWarrantPlanMember_sPDxxV-HME-NOFivUfGJlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iva:DavidNikodemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa20231ShareWarrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_TXDD0JbjtEiPdT8-3ZzhYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iva:DavidNikodemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BsaShareWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_ue4H16UnJE-nSbm-Rv4i6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iva:DavidNikodemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BsaShareWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_hhwziOnPqEKcNx_7cuH5Ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iva:DavidNikodemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BsaShareWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_ServiceProvidersMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_DIqvoK9pK0yZ6htGpUYXzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iva:ServiceProvidersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BsaShareWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DirectorsMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_tc0AHGj00kS5B7lAXTpurw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iva:DirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BsaShareWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_IuzMYL65X0qu-JY8V6n_lw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_CSHhFS0Lg0Gzg_yzNEELZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_28_2022_To_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_3hNTQf5aEEemSQq6uYohDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-28</xbrli:startDate><xbrli:endDate>2022-11-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_16_2024_To_5_16_2024_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember_VYGeDPPB2Ea8OgJWmGctxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-16</xbrli:startDate><xbrli:endDate>2024-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_16_2024_To_5_16_2024_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember_2N4OlKpMhUqSYqUX-EXpVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-16</xbrli:startDate><xbrli:endDate>2024-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_7_1_2022_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_mT6R0SioNkS8Jv1u9vcknw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:WarrantAgreementWithEuropeanInvestmentBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_1_2022_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember__QhdYl76K0agjKJOQ6cDBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:LongTermFinancialDebtDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:WarrantAgreementWithEuropeanInvestmentBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_14_2024_To_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember_cd3Fteojp0CtXUqdXRXY6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-14</xbrli:startDate><xbrli:endDate>2024-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_RoyaltyCertificatesLiabilitiesMember_mEPm5drgy0O0deuPued1-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:RoyaltyCertificatesLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_11_2023_To_10_11_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_LicensingAgreementWithHepalysMember_srt_OwnershipAxis_iva_HepalysPharmaIncMember_CJxE3L2F106Ij0r9Bq2I1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:LicensingAgreementWithHepalysMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-11</xbrli:startDate><xbrli:endDate>2023-10-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_11_2024_To_10_11_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingThroughFundRaisingMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_srt_StatementScenarioAxis_iva_ScenarioTwoMember_kF0Cffov6EiCtat91NJ6hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:FinancingThroughFundRaisingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:LicensingAndCollaborationAgreementWithCttqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">iva:ScenarioTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-11</xbrli:startDate><xbrli:endDate>2024-10-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_11_2024_To_10_11_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingThroughFundRaisingMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_srt_StatementScenarioAxis_iva_ScenarioThreeMember_2KTwko-jbE6IA2FjFwUN0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:FinancingThroughFundRaisingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:LicensingAndCollaborationAgreementWithCttqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">iva:ScenarioThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-11</xbrli:startDate><xbrli:endDate>2024-10-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_11_2024_To_10_11_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingThroughFundRaisingMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_srt_StatementScenarioAxis_iva_ScenarioOneMember_NOafy3B1GU-pPX7_lNErFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:FinancingThroughFundRaisingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:LicensingAndCollaborationAgreementWithCttqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">iva:ScenarioOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-11</xbrli:startDate><xbrli:endDate>2024-10-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_TxixfQbZCE2_vJzh9SnQSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_5_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_PresentationOfResultsFromStudyMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember_rLZHQc4OiUGVcCmKg1glHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:PresentationOfResultsFromStudyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_BorrowingsByNameAxis_iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember_5BKdyoSBV0uhtWALpjAz8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_tfmxFNVVb0CS5hG6C3JkAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:LicensingAndCollaborationAgreementWithCttqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ServiceContractWithAvantSanteMember_cAPxNDRt4k2GvvKof24NwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:ServiceContractWithAvantSanteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_26_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_LicensingAgreementWithHepalysMember_srt_OwnershipAxis_iva_HepalysPharmaIncMember_rVQ3vZD64EmRdCdx3kiaUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:LicensingAgreementWithHepalysMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_7_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember_nuFto-sydEusuJsG2ypBGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_FredericCrenMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnits2023Member_rz9Dt9fkhka9C49bx8Vmng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iva:FredericCrenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:LongTermIncentivePlanInPerformanceUnits2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_11_2023_To_10_11_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_0ACGkUM49U6-A_OhxFep5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-11</xbrli:startDate><xbrli:endDate>2023-10-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnitsMember_Zf-6fi4mZkOtN6iPVLbVdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:LongTermIncentivePlanInPerformanceUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_16_2024_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_xI1dcdJgHkqTYSB3mreY5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_16_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_VAiorYC4kkm95pO29VSpPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_Wd7CtxBOkEO4WumvaOj3bA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2022_To_6_30_2022_ifrs-full_BorrowingsByNameAxis_iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember_rVGAMd543kWMTqS80gXZVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2022_To_6_30_2022_ifrs-full_BorrowingsByNameAxis_iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember_pRmHDD5O_EOFWPfNYEeiDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2022_To_6_30_2022_ifrs-full_BorrowingsByNameAxis_iva_FinancingFromSyndicateOfFrenchBanksMember_age9N1IGyke_9J5_9xJiwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinancingFromSyndicateOfFrenchBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingAgreementInThreePhasesMember_7BaMct8ywUiT7daaU6IKqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:FinancingAgreementInThreePhasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_16_2022_To_5_16_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_iCBdyRK5rUeePAFm5LecHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-16</xbrli:startDate><xbrli:endDate>2022-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2024_To_2_1_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember_v79EQ1VlWE-l9YiRgeueOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember_fPmzQ4Ci5kCG21AG1O_ehw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:ContractCroWithPharmaceuticalResearchAssociatesB.vMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember_srRYIfYrLkGZMnq0Z1Nr_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:ContractCroWithPharmaceuticalResearchAssociatesB.vMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_11_2024_To_10_11_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingThroughFundRaisingMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_QkHCyd9NWU6y7zXQYpg3Tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:FinancingThroughFundRaisingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:LicensingAndCollaborationAgreementWithCttqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-11</xbrli:startDate><xbrli:endDate>2024-10-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_18_2024_To_7_18_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfRoyaltyCertificatesMember_MVb6HJyb-0ClrMuNDVzHFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:IssuanceOfRoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-18</xbrli:startDate><xbrli:endDate>2024-07-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_31_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember_VgrKJISxZU2hIPTccHR6Jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember_PRoFZMRi1kONFrYjiuvhAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_1_1_2024__TV_WDfEOkuUvGKOfMbQLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_1_2023_XlsK7X7SLkSjPHI4C13dFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_X8oeeeGhTk-MdYqDOV-oxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_18_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_LicensingAgreementWithHepalysMember_rgk-qPK2CUyR7D5r7W0aMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:LicensingAgreementWithHepalysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_iva_FibroscanMachinesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_u7Et-MI930eFeqmMLXteeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iva:FibroscanMachinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_iva_FibroscanMachinesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_zqYECmxrlUilNWtPkw19_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iva:FibroscanMachinesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_RightofuseAssetsMember_PXbF8eDw90i06AiOGDMO3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_uKuO3UuYNECV4Eoeqzpd4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_7mIiNwJvsE-YWS6Oz_X7Sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_EIAsynD95kCXlu8TLaft8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_18_2024_To_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_DrawdownOfBorrowingsMember_qBP5Y6KUBkGy4f5mXUW39g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:DrawdownOfBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-18</xbrli:startDate><xbrli:endDate>2024-01-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_18_2024_To_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_CZeedY0HkUOxo7vg14rQ7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-18</xbrli:startDate><xbrli:endDate>2024-01-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_8_2022_To_12_8_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_Oji8AIqwMEebyNKqGL3bwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-08</xbrli:startDate><xbrli:endDate>2022-12-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_14_2024_To_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember_imkRzVTcgUy0kGwnaok3JA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:IssuanceOfSharesOrWarrantsSubjectToConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-14</xbrli:startDate><xbrli:endDate>2024-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_IGbGo6uT7EO_KIZuumIllA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:WarrantAgreementWithEuropeanInvestmentBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_e2AEajgpOke0pQ8o_y36nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:WarrantAgreementWithEuropeanInvestmentBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember_hobGW-4SUUqZmnmtlP6zCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:IssuanceOfSharesOrWarrantsSubjectToConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_YCO92YM7_064nsFEWIY8Jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:LongTermFinancialDebtDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:WarrantAgreementWithEuropeanInvestmentBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_3_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_rb4eejdyHUKzT5ws_uabwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_QTQ5vqXpNE2ib3CFSHvYaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:LongTermFinancialDebtDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:WarrantAgreementWithEuropeanInvestmentBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_ifrs-full_BorrowingsByNameAxis_iva_EquityRecoveryLoansMember_FFIOm4lTLk6UQV8mUsy60w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:EquityRecoveryLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_rbMHeXRpfEGsAR3PJoBgWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_EFM8TpwCpkqu7FVPRM1rTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_V_UnvG7OVU6Postqxl9qTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ldh6EouHQke8vr_BH-JvxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lpf5jlqhR0GVIbvPIhKnYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_JPcx_xU0GEGgRDmKGGAdGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-18</xbrli:startDate><xbrli:endDate>2024-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember_tSDasQf4-kCHQTZLajBCXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-18</xbrli:startDate><xbrli:endDate>2024-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_YgdXCEYNr0mNt92Z5wU9hQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-18</xbrli:startDate><xbrli:endDate>2024-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_ChiaTaiTianqingMember_hYhPgbJT90qw9Zp638JTYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">iva:ChiaTaiTianqingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2021_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ContractCroWithResearchAssociatesGroupeB.vMember_Kg0rzj_ifUatIDFJkolJ6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:ContractCroWithResearchAssociatesGroupeB.vMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_PharmaceuticalResearchAssociatesMember_IkzQwodT60qRBSBD6WG1Kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">iva:PharmaceuticalResearchAssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_PharmaceuticalResearchAssociatesMember_Co4XPbAvCk2OhAlYe5P1VA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">iva:PharmaceuticalResearchAssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_4_2024_To_1_4_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_fmkw3aWeOU-HD1uNZ91qIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:WarrantAgreementWithEuropeanInvestmentBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-04</xbrli:startDate><xbrli:endDate>2024-01-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_7_1_2022_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_XoSz7rHj_Umg-MPSR-Funw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:LongTermFinancialDebtDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:WarrantAgreementWithEuropeanInvestmentBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_14_2024_To_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember_cl4oX3dadE-dg27_9dl-_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-14</xbrli:startDate><xbrli:endDate>2024-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_2nmqoYhWkkOgh_AeHuYFnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:LongTermFinancialDebtDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:WarrantAgreementWithEuropeanInvestmentBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-04</xbrli:startDate><xbrli:endDate>2024-01-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_28_2022_To_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_FvqTByEiaEuWx4OtWlgNhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:LongTermFinancialDebtDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:WarrantAgreementWithEuropeanInvestmentBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-28</xbrli:startDate><xbrli:endDate>2022-11-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2024_To_1_3_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_uBe1VaT84EOT7MGXjouVfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-03</xbrli:startDate><xbrli:endDate>2024-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_18_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfRoyaltyCertificatesMember_eaHX-tuX_E2XdHMM79Knaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:IssuanceOfRoyaltyCertificatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_18_2024_To_1_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_O2DSQ9PKd0mIC5PRzMA_Qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:LicensingAndCollaborationAgreementWithCttqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-18</xbrli:startDate><xbrli:endDate>2024-01-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingAgreementInThreePhasesMember_d8wjd7CfTESZ1LkHSB77Cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:FinancingAgreementInThreePhasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_T--Cv137BUS8bbvsblFtMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2024Member_o0JPxKp_cEaymg2N36omtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2022Member_lXOe9V-g3Uq8tzFzKYE_rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20232ShareWarrantPlanMember_CWi27vgj8Eqzm6adcBi83g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iva:DavidNikodemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa20232ShareWarrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20231ShareWarrantPlanMember_r1Qe82njGE25vu439VQ9xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iva:DavidNikodemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa20231ShareWarrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanThreeMonthsMember_2nR6xWsu-0CvgK_C4H2nmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanThreeMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanThreeMonthsMember_--thiluYlEKqu2SkZv1ljQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanThreeMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_MaturityAxis_iva_LaterThanTwoMonthsMember_C5lqESZnOEmaIeMKVhSS8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">iva:LaterThanTwoMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneMonthMember_F44q34_t8kGRdNbcbz0SsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_PQdCvCveh0GtnvbOTvZTxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanTwoMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneMonthMember_L3zFOF6AbEGJqyvX3ksALQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_pgS3JPFyOUuBb8uDOr_KNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanTwoMonthsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_oxFIDH8XQUKPgIUFQceRfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_RoyaltyCertificatesLiabilitiesMember_ifrs-full_UnobservableInputsAxis_ifrs-full_DiscountRateMeasurementInputMember_qerPupsvsEe_tn0yX52pFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:RoyaltyCertificatesLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinancingFromSyndicateOfFrenchBanksMember_b3jNddOSCEqLn7eTIlNpJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinancingFromSyndicateOfFrenchBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_iva_InventivaIncMember_y49k90Wj0kC3K8Qnf_pclA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">iva:InventivaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_wYI-vlX-bEu9MV9dohB57g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_CpOwuIhEIkSyaCaql_vmYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_mbEhqIy-C0eGw1aDWsHwyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_2B9cJfzZu0-9iYr6nqkzSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_15_2024_To_1_15_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_9LZhfVa98kGYF3dksXsUBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-15</xbrli:startDate><xbrli:endDate>2024-01-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_18_2024_To_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_Dck8WdQ5LUKx_AFlTUOcAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-18</xbrli:startDate><xbrli:endDate>2024-01-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_f6IGXbNrJUeuXFjO7KpMzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-04</xbrli:startDate><xbrli:endDate>2024-01-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lX6me24ptE-Xl7VzcNGlCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2020_To_5_31_2020_ifrs-full_BorrowingsByNameAxis_iva_FinancingFromSyndicateOfFrenchBanksMember_tgQsngIelEWdVjh0z4mOYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinancingFromSyndicateOfFrenchBanksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember_vlcJPhOGqkmmq2I0namEtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember_ZCF8RxUM3UKzcBgb7Q57Xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_25_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_31pg2jjAP0SNXoJC-UbdfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_8tc8znfKVkWA4XCDKyyrhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:LicensingAndCollaborationAgreementWithCttqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_I0kItXo1cEqfFv1DgQ0yfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20232Member_PqpzKUoY40ObENgyoIJeMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBonusShareAwardPlan20232Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20231Member_oKFel_ng9UWwaxcU0ACQvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBonusShareAwardPlan20231Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20232ShareWarrantPlanMember_XsJfOiE5YUuSxAlo8TUGSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa20232ShareWarrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20231ShareWarrantPlanMember_5P4HYxa_X02-U_TBazJ3bA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa20231ShareWarrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BonusShareAwardPlansMember_m2JRheJguUWiLC2OX9PVmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BonusShareAwardPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019TerMember_TDxn8LM_90OZE-wvpQKC8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewShareWarrantPlansBsa2019TerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019Member_KvhW3CTGVkaWP5uQm6usPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewShareWarrantPlansBsa2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019BisMember_U_5IV4QgEke3Pdy5mT4eiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewShareWarrantPlansBsa2019BisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBsa2021ShareWarrantPlanMember_3S7BOByx_EaWFm05q97Pbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBsa2021ShareWarrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlanAga2021BisMember_d8RDeqcJHUuuc8eyxeiD5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBonusShareAwardPlanAga2021BisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlanAga20211Member_eh-BJlC8R0G04APW_IIiGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBonusShareAwardPlanAga20211Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20232Member_FIpiNio7XkaVcs3vwtxlaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBonusShareAwardPlan20232Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20231Member_OTdPP5Od7kuR-ubUIX8ZDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBonusShareAwardPlan20231Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnitsMember_S5ghW2BBqEaaOZO3f2CIIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:LongTermIncentivePlanInPerformanceUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnits2023Member_bHs6Y4UJuEK6wcGSke6uGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:LongTermIncentivePlanInPerformanceUnits2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspcePlansMember_9R_vfCR8mE6QceWJxeNh0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BspcePlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspceAndBsaShareWarrantsMember_AXg3-r_gg0WamRv2dUykVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BspceAndBsaShareWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bspce2021PlanMember_XXFm1fZ4IkuZuyUISjqE5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bspce2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaPlansMember_8Ot2N8tWskGDuiWnohiHRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BsaPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20232ShareWarrantPlanMember_TAkktSsoVU2p7FMQN4IObg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa20232ShareWarrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20231ShareWarrantPlanMember_47_9YfgmmkGE6SeeBfb7Ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa20231ShareWarrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2018PlanMember_-NNjSxGS3kGycvP-YnC6BA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa2018PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2017PlanMember_ps8c_6VsskWjdjMuB0dgAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa2017PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BonusShareAwardPlansMember_mvV1f-1wH0ac-WZpqG9HRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BonusShareAwardPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20232Member_-sKnyEocNkawleXgjslx_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBonusShareAwardPlan20232Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnitsMember_PlmUtIqdxEmw3YH5g0akfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:LongTermIncentivePlanInPerformanceUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_25_2024_To_3_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_FredericCrenMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnits2023Member_hzRrxOsqEEe8Ngy7ccwfuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iva:FredericCrenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:LongTermIncentivePlanInPerformanceUnits2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-25</xbrli:startDate><xbrli:endDate>2024-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlanAga2021BisMember_NCJt9ZQOW0SLSy6T5SliZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBonusShareAwardPlanAga2021BisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlanAga20211Member_Bsp6KVWZMUiZgeIpAPgY1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBonusShareAwardPlanAga20211Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019TerMember_jiHAAcRQ-UOqoX3-IPHL7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewShareWarrantPlansBsa2019TerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019Member_wyeHPWxpTUKLa573kCA9hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewShareWarrantPlansBsa2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019BisMember_MIIhZy39AEC1hyqkLyXkqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewShareWarrantPlansBsa2019BisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBsa2021ShareWarrantPlanMember_yiiLVd_BA0S9s5AhG-VVqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBsa2021ShareWarrantPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspcePlansMember_Ga9Y5xtaaE6GziTOhOfOyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BspcePlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspceAndBsaShareWarrantsMember_bFYuyd66F0KcdJonswP3bA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BspceAndBsaShareWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bspce2021PlanMember_RcSn_5JQpk-SYrZAPBf-2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bspce2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaPlansMember_lUa0fx_8UUGbYRQd155C8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BsaPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2018PlanMember_ptHXov2J-0Wu9MZq69AtRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa2018PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2017PlanMember_weg2ddPVA0SxiMSra8AqSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa2017PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2024Member_SKyx2I-L-E2qRPd_8ZtRDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2022Member_rqfjl8o2ykC3r6A9zJWDeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BonusShareAwardPlansMember_4W-wr4J7bkuA5horxzjQWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BonusShareAwardPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_dei_LegalEntityAxis_iva_InventivaS.aMember_Cyc1aEXngEiGaWWQTrmH-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">iva:InventivaS.aMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_dei_LegalEntityAxis_iva_InventivaIncMember_yX8YJNqJxEeoquiF4wd66g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">iva:InventivaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_dei_LegalEntityAxis_iva_InventivaS.aMember_3oaek7qY7U2QTmeeOlV98g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">iva:InventivaS.aMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_dei_LegalEntityAxis_iva_InventivaIncMember_dCL3wkeOIU-E_D6kZe7BxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">iva:InventivaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_HZvpAkHv40a_7feAGh0Gmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_18_2024_u8VUV2GPAUmg3FPfMqwLIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-01-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_BorrowingsByNameAxis_iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember_C9WbfUum90KUsBfHNequkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_16_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_m_1J6hotsk-dhzgHfJ6CBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_iva_InventivaIncMember_DGOb9XXQ8UK2Bub8zM5nQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">iva:InventivaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_25_2024_To_3_25_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_NWloX1BI0US4Lo97RBCE_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-25</xbrli:startDate><xbrli:endDate>2024-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_25_2024_To_3_25_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_eylYkv54iU6BbmTMEduewg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-25</xbrli:startDate><xbrli:endDate>2024-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_40Ly7mN0VUychMdZQFU0jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_hPvzcNBD1029LdKD5pm-Fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_7knLDQKU6EWqcXxngWZMRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_SNcEwTle60O3eQH3YNWEsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_gFqLBMPU_kmKcAPYZiVbAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_na6RZmuG5U2D4vmO3x7mnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_OjiU0SQcREq22dnbIpV6fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Aga2021Aga2021BisMember_94cRMy8qbkmwpgWKKI0Dmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Aga2021Aga2021BisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_25_2024_To_3_25_2024_avq7MDuDZ0qTbuTPxd88pQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-25</xbrli:startDate><xbrli:endDate>2024-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_InventivaIncMember_CsDcvL6WIEe96pAzGCSMYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">iva:InventivaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_Nnjp7bngW0Ga6BDie0V6fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_y3OYJVLzE0-whh_qoWeSDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueMember_4SVWIFElkkKFKpxz6K2mDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueMember_1nI2yYCJCEKKgVIHzRJEzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_1QUlLx6Y0E-OzYbHdIU-FQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:LongTermFinancialDebtDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_ShorttermBorrowingsMember_q5wyxdtsjkC9ATGXwBJ1zQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_LongtermBorrowingsMember_KhP49WhAa0S2SqllGaAZ3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_EnC60jgh0EOHmRak6HvHFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_TradePayablesMember_DT34R3eKL0K1egtpaQCcgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:TradePayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_RoyaltyCertificatesLiabilitiesMember_tzXibduYxE6YsqSgIdTn3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:RoyaltyCertificatesLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_OtherMiscellaneousPayablesMember_17V3AWgX9UGIGzCdKUHVpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:OtherMiscellaneousPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_DerivativeInstrumentsMember_USWamMRH70e5dMBuXB1kfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:DerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_ShorttermBorrowingsMember_HbTI56G8V0OVuMMfgkPm9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_LongtermBorrowingsMember_3_c4ZNJ7IkuGUZRsgL5KeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ad_CUhpQSUWO9uvSqmVOjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_sO3Ilng9LUyGbmS3dP5aqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:LongTermFinancialDebtDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_iiyUwIL1okucU3luLH42uQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_TradePayablesMember_hHYqQE9Yj0e7HSqbpfQXSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:TradePayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_RoyaltyCertificatesLiabilitiesMember_WaIiYd4PIUyNoJBmB4iA4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:RoyaltyCertificatesLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_OtherMiscellaneousPayablesMember_XvcehwIoO02CIQ32YJIxyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:OtherMiscellaneousPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_ShorttermBorrowingsMember_NB0TWpTDvU2mM9PCPaNmTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_LongtermBorrowingsMember_1DesxSZs7UeHW8u3NH0eGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_DerivativeInstrumentsMember_uAo9ZMcdJEO8cLUT1lE0MA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:DerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_TradePayablesMember_5cmgPsH920CfGPmJBDOp-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:TradePayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_RoyaltyCertificatesLiabilitiesMember_Sn-nL6ck_UCopAUgyhyLIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:RoyaltyCertificatesLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_OtherMiscellaneousPayablesMember_oeFuIUG-QkqzWRNtsHuxmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:OtherMiscellaneousPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_DerivativeInstrumentsMember_DXqbqfuw00aAGXk5irtJtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:DerivativeInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_ShorttermBorrowingsMember_cHoNbFS0eUyuodyG6femhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_LongtermBorrowingsMember_LdqaexFubUm5bmzDhGaIFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_Ju8a20CjNUGvFkUgBgWStw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_tIb2x3EdLUOAPCEztcL7wA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_OtherReceivablesMember_X545crJT6E-s_K-iPNVWJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:OtherReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_IfrsCashAndCashEquivalentsMember_3DbfsjKIuEeTh95AuBI8Dw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AdvancePaymentMember_NT4vZl9PbkGiPUjsmpSqhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:AdvancePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AccruedIncomeMember_Ahk1q2K--0uCVDs0WN2cnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:AccruedIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_TradeReceivablesMember_1-tjX8tbt0GXwG43E2l8Mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_iva_OtherReceivablesMember_8JkciAHeZUmN1wIn0UqhJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:OtherReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_iva_IfrsCashAndCashEquivalentsMember_gUhZ2pkRhkGxOpcwP54F6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AdvancePaymentMember_Sx8nhE1j8ESlCSB49JWGVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:AdvancePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AccruedIncomeMember_rFAULMOIG0-nNmzcBonheQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:AccruedIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_TradeReceivablesMember_UhBYZg6XLkqb9t3xvxBEUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_xqxoBDc1zUiTY3urkmymcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_ShortTermDepositAccountsMember_374tsJrTKk6fJow5yHyCDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:ShortTermDepositAccountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_OtherReceivablesMember_nOSt24rbu06dp175BFWIVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:OtherReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_LongTermSecurityDepositsMember_VROn8csSH0i28NXJGx3Amg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:LongTermSecurityDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_LongTermDepositAccountsMember_fo_XM5MB2kOMXwNZMOkI5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:LongTermDepositAccountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_IfrsCashAndCashEquivalentsMember_OARfL4lhGkWF8cdGOx-xCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AdvancePaymentMember_qXVB1LZ70EWDaFdvLxmc5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:AdvancePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_TradeReceivablesMember_9Se6Eh9LEEyShj3tyGuJAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_ShortTermDepositAccountsMember_XX7WnZfsDkussQqjcn130w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:ShortTermDepositAccountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_OtherReceivablesMember_YRoI5LsEsEySxVU2J2oZVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:OtherReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_LongTermSecurityDepositsMember_Noxm4K7bX0S6jyxwkUADrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:LongTermSecurityDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_LongTermDepositAccountsMember_nJntFM5UfE6dEPYXAe50tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:LongTermDepositAccountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_IfrsCashAndCashEquivalentsMember_vrZZqx47o0a1hsDxw-vIxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AdvancePaymentMember_FkwbWhKujke__64KGmRGog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:AdvancePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_TradeReceivablesMember_HDaVOBXSAEmTDP24XH8uQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_RtETuwSwJkCED4F2iCpqkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20231Member_7wRF3k96VkCeUYr4WvCKSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBonusShareAwardPlan20231Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_jiMyqJklS0yKSmn3ylKVjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iva:RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_wKPlEEy3A0SN-8jmJn4iCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_9dAqjQ8yFEOk2IPndtMWDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_LdYbre3bB0WUz88niJNlag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_NJmuaXv-XEWsTA9f3Xh5nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_IZqZC00jTUqIta0YcIIbug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iva:RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_cgKVo_3CWUmvwiGobzgKyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember__9pAKUrAQ0enxQqBYLGv9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_nwf6v9oBck-wKZOxfPU3tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_4J3_ocxV5ka2EE64Vzyuyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_oIEPc_uew0yPdBw1zj31_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iva:RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_7UXPGS9t8E2u0eKxHUgg6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_c6YRrAmJtkGBVTOn_KinpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_M0g6jdiCfU26v1gbb-hQNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_K1Cg_Yt_SUKODSLGGBA5mQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_hBnlt8OLjkOaEtHFXq1FfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iva:RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_RyNlENHuY0axEQhwJsaZbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_fEy91Y6Yw0uMQLNC3PBBYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_s4VMant100Wa1D_e2buNrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_1unH-qq8aU-PC_sPZcCATg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_0VRJS0P300WTp8zcUcUTug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_hTRe72PPekW3DzP4m38ewQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">iva:IfrsSalesAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">iva:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">iva:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_vilht6HmAUelr2hSPT_U_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">iva:IfrsSalesAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">iva:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">iva:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20231Member_dcxbZ8fZnk-mVxqgCGeiKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBonusShareAwardPlan20231Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnits2023Member_JOCpA6ku3UiPydoMyQrkIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:LongTermIncentivePlanInPerformanceUnits2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspceAndBsaShareWarrantsMember_ChRxu3v9XU-QJcAaOJ0AgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BspceAndBsaShareWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_ZxMBck8Vv06CkTltj3JJkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:LicensingAndCollaborationAgreementWithCttqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_PharmaceuticalResearchAssociatesMember_qjG6YqkiB02s-QfK34PDzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">iva:PharmaceuticalResearchAssociatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_ContractManufacturingOrganizationsMember_H1GPzHoVzEiBnJra2bMeWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">iva:ContractManufacturingOrganizationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ContractCroWithResearchAssociatesGroupeB.vMember_z4AQiAhloUi2lSaBmH0sqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:ContractCroWithResearchAssociatesGroupeB.vMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_ClinicalTrialsMember_RKIovK8rokChycQgZSo2TQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">iva:ClinicalTrialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_ifrs-full_OtherContingentLiabilitiesMember_0hDuEC30xECEsYnHHr_kTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:OtherContingentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_ifrs-full_LeaseLiabilitiesMember_ida2CTwucUi4-oggFUrF2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_ContractManufacturingOrganizationsMember_e2L2HwPp40Smxh2nqL1VkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">iva:ContractManufacturingOrganizationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_ClinicalTrialsMember_ETYrQdfyDE6P4TNS-pt20A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">iva:ClinicalTrialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_ifrs-full_OtherContingentLiabilitiesMember_UcOuCRDpIESuiNmpO5AzcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:OtherContingentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_ifrs-full_LeaseLiabilitiesMember_8rBg4KqmyUuYuPxVzu5jrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_dXCJhRzOSE-KI_4aE3GtUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iva:RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_buEEww87HUSIzmB9VHw_tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_7hzuZ7YABk6ls6oQfoETnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_yfheuy_9XU2H9yN_qkSwMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iva:RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_XLIDsKCJTEm0UB5CIk-Tiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_SN5Ac_HGGEqXPhg8nVP1RQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_aUv8mHsKXUaaSWrxnxqKLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_ifrs-full_LeaseLiabilitiesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_dYFp-ujODEWkgQn22I6RnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_ifrs-full_LeaseLiabilitiesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_GsWMv1_qikSzfG5Yj-NJvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_DrawdownOfBorrowingsMember_MLnrGxu8pEeScrxg9appZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:DrawdownOfBorrowingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_3l6sO3DqI0iZ8EqJu2kuhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_8_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_NZ-ZgvUE8kOsb70mJ03KSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_KCZ_rlJbTkm1DXPXbOCPUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_yNqR8syCVkyKUkjoBw5nlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_RoyaltyCertificatesLiabilitiesMember_MLWq4MeMoEelhaSNDyM6mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:RoyaltyCertificatesLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_o2Fe8k_JVUOuzAwFE3EH9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_BwJ5AiMcPkmDzrV1KCPF7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_1fmInCo2D0yp8z7M1kVwrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_De4o7giPiEinOd0qNd9GCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_ll91CELP_0CkxmWGnSWYxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_RoyaltyCertificatesLiabilitiesMember_BjRDFB3IN0mcC4Ynuq2iZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:RoyaltyCertificatesLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_GSGDF0mlWkuIQruwBsMsBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_mhRLXXxIVUimCeRsLCjpAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_C0Ff4EWJsU2Ar98sMx82wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_Ue5U6HHvckKiur1A8cLvgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2023_ifrs-full_ClassesOfLiabilitiesAxis_iva_RoyaltyCertificateLiabilitiesMember_h1XHuxF4ukeRQuZnn7VzCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">iva:RoyaltyCertificateLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022__ShBeryiXEKxoX7Xx7OS6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_18_2024_To_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_EpuGEvGLYke1tVD4Ocdy8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-18</xbrli:startDate><xbrli:endDate>2024-01-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_0umwc-ynPU6vJhwvCODdKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_iva_FibroscanMachinesMember_HHDa7KgacE6IN6Bk1COxoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iva:FibroscanMachinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001756594</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_JOwtQ6IgC0eWFrNP-6PTMA_18_4" toRefs="_2aada350_c4ae_4dac_b34c_b7eaeff83c4c" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_TWUGjU3b4EOxZ-G96gQhvA_18_2" toRefs="_2aada350_c4ae_4dac_b34c_b7eaeff83c4c" order="1"/><xbrli:unit id="Unit_Standard_item_EtvJ8tlaoECD45kd85NcIQ"><xbrli:measure>iva:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_entity_-MmOzsDakEmzabilM8ZRiQ"><xbrli:measure>iva:entity</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_tranche_EQcocZ7SkkmFtux0nXQhjQ"><xbrli:measure>iva:tranche</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_loan_rE4-q-dHoUqS2Tn_Pp9_NQ"><xbrli:measure>iva:loan</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_agreement_ds7eY0UVBEmjbbj4M4LxNQ"><xbrli:measure>iva:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_plan_EJ5kyu86bkGE5-lgkh4BhQ"><xbrli:measure>iva:plan</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_site_EHdbjuNCVEq0aAm2HNh22w"><xbrli:measure>iva:site</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_JPY_shares_y82NH3aOoUmAVzUuXy27vw"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_D_UN8jRVLLaEed_W_JH8a6Og"><xbrli:measure>iva:D</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_EUR_USD_sLQkfMeGDkaNmYTZmSqm9Q"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Divide_USD_EUR_wuIAVjvD9UylZ02vyQPaBQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_X6E05lIDQEullbfuSGuJCw"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_employee_t09Loy2TV0yh-O2RJe0wMQ"><xbrli:measure>iva:employee</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_g_TXQl02imeU2G21yIajn9zQ"><xbrli:measure>utr:g</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5e2067ab_7be9_4dd5_b758_158ea099bffa"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="dei:DocumentType" id="Narr_onsub5DjyE29dgA3aOe8cg"><b style="font-weight:bold;">6-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REPORT OF FOREIGN PRIVATE ISSUER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO RULE 13a-16 OR 15d-16</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the month of October 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Commission File Number: 001-39374</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:24pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="dei:EntityRegistrantName" id="Narr_TNjndEwCCkKK_Y7-DMGW3A"><b style="font-weight:bold;">Inventiva S.A.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Translation of registrant&#8217;s name into English)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">50 rue de Dijon</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">21121 Daix France</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">+33 3 80 44 75 00</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive office)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Form 20-F <span style="font-family:'Segoe UI Symbol';">&#9746;</span> Form 40-F <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_03119a30_27a9_4997_bb79_e23db3a268dc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On October 14, 2024, the Registrant issued the Interim Financial Report for the Six Months Ended June 30, 2024 (the &#8220;Interim Financial Report&#8221;). A copy of the Interim Financial Report is attached to this Report as exhibit 99.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_890de4b0_72b5_4903_ad73_a881c6ca91e3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;INDEX</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:12.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:85.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:12.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">No.</b></p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:85.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:bottom;width:12.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="iva-20240630xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Interim Financial Report</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:12.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.INS XBRL</p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Instance Document.</p></td></tr><tr><td style="vertical-align:bottom;width:12.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.SCH XBRL</p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Taxonomy Extension Schema Document.</p></td></tr><tr><td style="vertical-align:bottom;width:12.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.CAL XBRL</p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Taxonomy Extension Calculation Linkbase Document.</p></td></tr><tr><td style="vertical-align:bottom;width:12.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.DEF XBRL</p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Taxonomy Extension Definition Linkbase Document.</p></td></tr><tr><td style="vertical-align:bottom;width:12.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.IAB XBRL</p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Taxonomy Extension Labels Linkbase Document.</p></td></tr><tr><td style="vertical-align:bottom;width:12.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.PRE XBRL</p></td><td style="vertical-align:top;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Taxonomy Extension Presentation Linkbase Document</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_226b9bc4_2b73_449f_9a5d_06458657e00c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inventiva S.A.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant)</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: October 15, 2024</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Fr&#233;d&#233;ric Cren</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Fr&#233;d&#233;ric Cren</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>iva-20240630xex99d1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.8.0.95 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 10/15/2024 9:51:26 AM -->
<!-- iXBRL Library version: 1.0.9027.2259 -->
<!-- iXBRL Service Job ID: 173141b6-1ebb-47d4-99fc-9933b28cddd5 -->
<html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iva="http://www.inventivapharma.com/20240630" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" id="Hidden_9rDgFmQBEUmZjQqm7DwPdg">9125000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ" decimals="-3" name="ifrs-full:Equity" id="Hidden_tuNLjyeUjUStSiiPLbEZGg">21194000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" name="ifrs-full:Borrowings" id="Hidden_VVi9UZTcQEKJWAcPl8yJKQ">54083000</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_iva_FibroscanMachinesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_zqYECmxrlUilNWtPkw19_A" name="iva:LeaseTerm" id="Hidden_YoTGSGWkUUCAhZ-9bE1tcw">P3Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" name="ifrs-full:Borrowings" id="Hidden_EHsAFhljaE2ILeQMiCBC4Q">54083000</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="iva-20240630.xsd"/></ix:references><ix:resources></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:87pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_Hlk179868254"></a><a id="_3d5b285e_2a38_494e_80ea_6f080dde90ff"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="iva-20240630xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:86.25pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:198pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">INVENTIVA S.A.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:11pt;">A joint-stock company (</span><i style="font-size:11pt;font-style:italic;">soci&#233;t&#233; anonyme</i><span style="font-size:11pt;">) with a share capital of 524,771.88 euros</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:11pt;">Registered office: 50, rue de Dijon, 21121 Daix, France</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 48pt 0pt;"><span style="font-size:11pt;">Dijon Trade and Companies Register 537 530 255</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:14pt;font-weight:bold;">INTERIM FINANCIAL REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 19pt 0pt;"><b style="font-size:14pt;font-weight:bold;">FOR THE SIX&#160;MONTHS ENDED JUNE&#160;30, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="TOC"></a><a id="_33f8ef7e_3883_43ba_9885_545608ebdd91"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Table of contents</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#a1InterimFinancialReport_895214"><b style="font-style:normal;font-weight:bold;">1.</b></a></p></td><td colspan="2" style="vertical-align:top;width:95.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#a1InterimFinancialReport_895214"><b style="font-style:normal;font-weight:bold;">Interim Financial Report</b></a></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;">3</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#a11Generaloverviewofactivities_723197"><span style="font-style:normal;font-weight:normal;">1.1.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#a11Generaloverviewofactivities_723197"><span style="font-style:normal;font-weight:normal;">General overview of activities</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#a12Significanteventsinthefirsthalfof2023"><span style="font-style:normal;font-weight:normal;">1.2.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#a12Significanteventsinthefirsthalfof2023"><span style="font-style:normal;font-weight:normal;">Significant events in the first half of 2024</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#a13Recenteventsandprospects_526546"><span style="font-style:normal;font-weight:normal;">1.3.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#a13Recenteventsandprospects_526546"><span style="font-style:normal;font-weight:normal;">Recent events and prospects</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8</p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#a14Riskfactors_163550"><span style="font-style:normal;font-weight:normal;">1.4.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#a14Riskfactors_163550"><span style="font-style:normal;font-weight:normal;">Risk factors</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">9</p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#a15Earningsanalysis_415075"><span style="font-style:normal;font-weight:normal;">1.5.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#a15Earningsanalysis_415075"><span style="font-style:normal;font-weight:normal;">Earnings analysis</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">11</p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#a16Analysisofthefinancialsituation_29934"><span style="font-style:normal;font-weight:normal;">1.6.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#a16Analysisofthefinancialsituation_29934"><span style="font-style:normal;font-weight:normal;">Analysis of the financial situation</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">16</p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#a2Cashflowandequity_110805"><b style="font-style:normal;font-weight:bold;">2.</b></a></p></td><td colspan="2" style="vertical-align:top;width:95.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#a2Cashflowandequity_110805"><b style="font-style:normal;font-weight:bold;">Cash flow and equity</b></a></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;">19</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#a21Cashandcashequivalents_105520"><span style="font-style:normal;font-weight:normal;">2.1.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#a21Cashandcashequivalents_105520"><span style="font-style:normal;font-weight:normal;">Cash and cash equivalents</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">19</p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#a22Cashflowanalysis_550189"><span style="font-style:normal;font-weight:normal;">2.2.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#a22Cashflowanalysis_550189"><span style="font-style:normal;font-weight:normal;">Cash flow analysis</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">21</p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#a23Anticipatedsourcesoffunds_500046"><span style="font-style:normal;font-weight:normal;">2.3.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#a23Anticipatedsourcesoffunds_500046"><span style="font-style:normal;font-weight:normal;">Anticipated sources of funds</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">22</p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#a3Unauditedinterimcondensedconsolidatedf"><b style="font-style:normal;font-weight:bold;">3.</b></a></p></td><td colspan="2" style="vertical-align:top;width:95.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#a3Unauditedinterimcondensedconsolidatedf"><b style="font-style:normal;font-weight:bold;">Unaudited interim condensed consolidated financial statements</b></a></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;">24</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 25.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 25.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#StatutoryAuditorsReviewReportontheHalfye"><span style="font-style:normal;font-weight:normal;">3.1.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#StatutoryAuditorsReviewReportontheHalfye"><span style="font-style:normal;font-weight:normal;">Statutory Auditors&#8217; Review Report on the Half-yearly Financial Information</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">24</p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#InterimCondensedConsolidatedfinancialsta"><span style="font-style:normal;font-weight:normal;">3.2.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#InterimCondensedConsolidatedfinancialsta"><span style="font-style:normal;font-weight:normal;">Interim Condensed Consolidated financial statement</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">25</p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#a4Otherinformation_924742"><b style="font-style:normal;font-weight:bold;">4.</b></a></p></td><td colspan="2" style="vertical-align:top;width:95.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#a4Otherinformation_924742"><b style="font-style:normal;font-weight:bold;">Other information</b></a></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;">62</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#a41Tableofdelegations_447465"><span style="font-style:normal;font-weight:normal;">4.1.</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:93.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><a href="#a41Tableofdelegations_447465"><span style="font-style:normal;font-weight:normal;">Table of delegations</span></a></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">62</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e034ccea_abcf_438c_804b_869c08caf173"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Definitions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In this half-yearly report (the &#8220;<b style="font-weight:bold;">Interim Financial Report&#8221;</b>), and unless otherwise specified, the terms <b style="font-weight:bold;">Inventiva</b> or the <b style="font-weight:bold;">Company</b> are taken to mean the company Inventiva S.A. with its registered office at 50, rue de Dijon, 21121 Daix, France, and which is listed with the Dijon Trade and Companies Register under number 537 530&#160;255 and its subsidiary, 100% owned, Inventiva&#160;Inc. with its registered office at 10-34 44<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>&#160;Dr, Long Island City, 11101 New York, USA, created in January&#160;2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain terms used in this Interim Financial Report are defined in the Company&#8217;s annual report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission on April 3, 2024 (&#8220;the Annual Report&#8221;).</p><a id="_104deba8_7165_4889_8a9a_e7f6244c6aba"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SPECIAL NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This document contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, that are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. All statements other than present and historical facts and conditions contained in this document, including statements regarding our future results of operations and financial positions, business strategy, plans and our objectives for future operations, are forward-looking statements. When used in this document, the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;continue&#8221;, &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal&#8221;, &#8220;intend,&#8221; &#8220;is designed to,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;objective,&#8221; &#8220;should,&#8221; &#8220;target&#8221;, or the negative of these and similar expressions identify forward-looking statements. Forward-looking statements include, but are not limited to, statements about:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our plans to develop and commercialize our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of, design, duration, recruitment costs, screening and enrollment of our planned and ongoing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trial data releases and publications, the information, insights and impacts that may be gathered from our planned and ongoing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of any planned investigational new drug (&#8220;IND&#8221;) application or new drug application (&#8220;NDA&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our plans to research, develop and commercialize our current and future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expectations with respect to the benefits of our existing and future partnerships, including our partnerships with Chia Tai Tianqing Pharmaceutical Group, Co., LTD. (&#8220;CTTQ&#8221;), and with Hepalys Pharma, Inc. (&#8220;Hepalys&#8221;), on the clinical development, commercialization and regulatory approvals of our product candidates, including potential acceleration of the commercialization of lanifibranor in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan, Japan and South Korea, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully cooperate with existing partners or enter into new partnerships, and to fulfill our obligations under any such partnership agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential for further development of odiparcil;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to potentially enter into a partnership with a third party for the development and commercialization of odiparcil;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical utility, potential benefits and market acceptance of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our commercialization, marketing and manufacturing capabilities and strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to identify additional products or product candidates with significant commercial potential;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations related to the sufficiency of our capital resources and our ability to continue as a going concern, including our expectations with respect to raising of additional funds, executing any potential transactions and achievement of milestones and operating targets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expected use of proceeds from any financing transactions, including capital increases, royalty certificates and debt financing, and our ability to fulfill our obligations under any such agreements, including our ability to repay debt in a timely manner, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expectations with respect to the Tranche 2 and Tranche 3 Events (as defined below), and the exercise of the warrants and other rights to subscribe to ordinary shares by investors,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments and projections relating to our competitors and our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of government laws and regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effects of the epidemics or pandemics on our business and, operations and clinical development timelines and plans;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our intellectual property position;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our estimate regarding future revenue, expenses, capital requirements and need for additional financing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unfavorable conditions in our industry, the global economy or global supply chain, including financial and credit market fluctuations, international trade relations, political turmoil, natural catastrophes, warfare (such as the conflict involving Russia and Ukraine, the state of war between Israel and Hamas and the related risk of a larger conflict), and terrorist attacks; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other risks and uncertainties, including those listed in our Annual Report and Section 1.4 hereof under the caption &#8220;Risk Factors.&#8221;</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We encourage you to read and carefully consider all of the risk factors disclosed in &#8220;Item&#160;3.D&#8212;Risk Factors&#8221; of our Annual Report and Section 1.4 hereof, for a discussion of the risks and uncertainties material to our business, including important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this document will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. These forward-looking statements represent our plans, objectives, estimates, expectations and intentions only as of the date of this filing. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">You should read this document and the documents that we reference herein completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Market and competitive position</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This Interim Financial Report also contains information about the Company&#8217;s activities and the markets on which it operates. This information comes from studies or surveys carried out internally or externally. Other information contained in this Interim Financial Report is available to the general public. The Company considers that all of this information is reliable, but it has not been verified by an independent expert. The Company cannot guarantee that a third party using different methods to gather, analyze or calculate market data would obtain the same results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Rounding of figures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain figures (including data expressed in thousands or millions of euros or dollars) and the&#160;percentages presented in this Interim Financial Report have been rounded up or down. Accordingly, totals given may vary slightly from those obtained by adding the exact (unrounded) values of those same figures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Abbreviations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain figures are given in thousands or millions of euros and are indicated as &#8364;&#160;thousand or &#8364;&#160;million respectively in this Interim Financial Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_197cb80f_e32c_4bf1_af78_e1667c483da1"></a><a id="a1InterimFinancialReport_895214"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.</b></span><b style="font-weight:bold;">Interim Financial Report</b></p><a id="a11Generaloverviewofactivities_723197"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.1.&#160;&#160;&#160;&#160;General overview of activities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inventiva S.A. is a public limited company registered and domiciled in France. Its head office is located at 50 rue de Dijon, 21121 Daix. The consolidated &#64257;nancial statements of the company Inventiva include Inventiva S.A. and its subsidiary Inventiva Inc., created in January 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inventiva&#8217;s ordinary shares have been listed on compartment B of Euronext Paris regulated market since February 2017 and Inventiva&#8217;s American Depositary Shares (&#8220;ADSs&#8221;), each representing one ordinary share, have been listed on the Nasdaq Global Market since July 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (&#8220;MASH&#8221;), also known as non-alcoholic steatohepatitis (&#8220;NASH&#8221;) and other diseases with significant unmet medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing lanifibranor for the treatment of MASH/NASH, as well as a pipeline of earlier stage programs in oncology discovery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Lanifibranor, its lead product candidate, is being developed for the treatment of patients with MASH/NASH, a chronic and progressive liver disease. In 2020, the Company announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with MASH/NASH and announced that the U.S. Food and Drug Administration ("FDA") had granted the Company the status of Breakthrough Therapy and Fast Track designation. The Company initiated the pivotal Phase III trial of lanifibranor in MASH/NASH (&#8220;NATiV3&#8221;) in the second half of 2021. In March 2024, the Company announced positive results from its Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and Type 2 Diabetes (&#8220;DT2&#8221;) (&#8220;LEGEND&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the first half of 2022, the Company faced delays in its NATiV3 trial that were primarily due to a higher than originally projected screen failure rate resulting in slower than anticipated enrollment rate. In addition, the Company experienced slower than predicted site activation, screening and enrollment due to negative impacts from the COVID-19 pandemic, mainly during the years 2020 and 2021, and the Company was unable to conduct clinical trial activities at sites originally located in Ukraine due to the war between Ukraine and Russia and made the decision to put recruitment for its NATiV3 trial in Ukraine on hold and close all sites in Russia. Global geopolitical events that continue to impact the markets (including Russia's invasion of Ukraine or the state of war between Israel and Hamas) could affect the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2023, the Company amended the protocol for the NATiV3 trial in part to potentially accelerate enrollment and identified additional sites to help compensate for the inability to use sites in Ukraine and Russia. The revised study design limits the planned duration of the trial to 120 weeks instead of up to seven years, reduces the number of biopsies from three to two and included a 48-week active treatment extension study. The Company expects that the changes to the clinical development plan of lanifibranor, including plans for a new Phase III trial in patients with MASH/NASH and compensated cirrhosis, will be beneficial to the lanifibranor clinical program by reducing the number of biopsies and the trial duration, eventually offering all patients in the trial access to treatment and potentially expanding the addressable patient population beyond patients with F2 and F3 fibrosis to patients with NASH and compensated cirrhosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">In September 2022, the Company entered into a license and collaboration agreement with Chia Tai Tianqing Pharmaceutical (Guangzhou), Co., LTD (&#8220;CTTQ&#8221;), a Sino Biopharm group company, to develop and commercialize, subject to regulatory approval, lanifibranor for the treatment of MASH/NASH and other metabolic diseases in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan (&#8220;CTTQ Territory&#8221;). In May 2023, the Company announced that CTTQ had received the Investigational New Drug (&#8220;IND&#8221;) approval from the Chinese National Medicine Products Administration (&#8220;NMPA&#8221;) allowing CTTQ to initiate the clinical development of lanifibranor in MASH/NASH in mainland China. CTTQ is participating in the ongoing NATiV3 Phase III trial and is conducting a Phase I clinical pharmacology study. In the framework of its participation in the Company&#8217;s NATiV3 Phase III global clinical trials, pursuant to the terms of the agreement, CTTQ bears all costs associated with these trials conducted in the CTTQ Territory. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">On September 20, 2023, the Company and Hepalys Pharma, Inc. (&#8220;Hepalys&#8221;) announced an exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea (the &#8220;Hepalys License Agreement&#8221;). Hepalys is a new company created by Catalys Pacific Fund II, LP (&#8220;Catalys&#8221;). Under the Hepalys License Agreement, the Company received a $10 million upfront payment (equal to &#8364;9.5 million) on October 18, 2023, and is eligible to receive up to $231 million if certain clinical, regulatory and commercial conditions are met; in addition to tiered royalties from mid double digits to low twenties based on net sales of lanifibranor in Japan and South Korea, subject to regulatory approval. In parallel with the Hepalys License Agreement, the Company entered into an option agreement with Catalys to acquire 30% of the shares of Hepalys (the &#8220;Catalys Option Agreement&#8221;). The Company exercised that option on September 26, 2023, with an effective date of October 11, 2023, at an aggregate exercise price of &#165;300 (equal to &#8364;1.90). Also on September 20, 2023, the Company entered into a shareholders agreement with Catalys and Hepalys (the &#8220;Catalys Shareholders Agreement&#8221;). Pursuant to the Catalys Shareholders Agreement, the Company has the option to acquire all outstanding shares of Hepalys at a pre-agreed multiple of post-money valuation and the Company has a right of first refusal if Hepalys receives an offer for the license or rights related to lanifibranor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">In the first quarter of 2024, following a routine visit during Company&#8217;s NATiV3 clinical trial of lanifibranor in MASH/NASH, a Suspected Unexpected Serious Adverse Reaction (&#8220;SUSAR&#8221;) was reported in a patient. As a result of this SUSAR, the Company decided to voluntarily pause screening and randomization to implement changes to the enrollment criteria to exclude patients diagnosed or with a predisposition to autoimmune liver or thyroid disease and more frequent liver monitoring for patients enrolled in the trial as recommended by the Data Monitoring Committee<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup> (&#8220;DMC&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">On March 7, 2024, the Company announced that screening activities had resumed in American sites under central Institutional Review Board (&#8220;IRB&#8221;). The impact of the pause on the overall timeline of the trial remains unclear, as new exclusion criteria were added, which may increase the screen failure rate, and the SUSAR, new exclusion criteria and increased liver monitoring may discourage potential trial participants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">On March 18, 2024, the Company announced positive results from its LEGEND proof-of-concept study combining lanifibranor with empagliflozin in patients with MASH /NASH and DT2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">The Company expects the first visit of the last patient to be in the fourth quarter of 2024 (versus the first quarter of 2024 as previously announced) and to complete randomization in the first half of 2025. Due to a delay of around 3 to 5 months in recruitment, the Company is currently targeting the topline results for the second half of 2026 (versus the beginning of the second half of 2026 as previously announced).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">If the results of the trial confirm sufficient clinical benefit and a continued good safety profile, the Company plans to file an application for accelerated approval in the United States and conditional authorization in the European Union for the marketing of lanifibranor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">The Company&#8217;s pipeline also includes odiparcil, which it was previously developing for the treatment of patients with mucopolysaccharidosis type VI (&#8220;MPS VI&#8221;), a group of rare genetic diseases. As announced in 2020, the Company decided to focus its clinical efforts on the development of lanifibranor. Based on feedback from the FDA, the Company believes there is potential for an efficient development pathway for odiparcil for the treatment of MPS VI and it continues to review potential options to further develop odiparcil for the treatment of MPS VI, which may include pursuing or creating a partnership, license or other transaction.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup> <span style="font-size:10pt;">A DMC is an independent group of experts who monitor patient safety and treatment efficacy data while a clinical trial is ongoing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="a12Significanteventsinthefirsthalfof2023"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.2.&#160;&#160;&#160;&#160;Significant events in the first half of 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.2.1.</b></span><b style="font-weight:bold;">Operations and product portfolio</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Treatment-related Suspected Unexpected Serious Adverse Reaction in the first quarter of 2024</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 15, 2024, the Company announced that an adverse event of elevated aminotransferases in liver tests was reported in a patient enrolled in the NATiV3 trial following a scheduled visit. The patient had been without clinical symptoms throughout the period of observation. This event has been assessed as a treatment-related SUSAR. Other milder cases of elevation of aminotransferases among trial participants have also been reported in the trial. The Company decided to voluntarily pause screening and randomization to implement changes to the enrollment criteria to exclude patients diagnosed or with a predisposition to autoimmune liver or thyroid disease and more frequent liver monitoring for patients enrolled in the trial as recommended by the DMC in the first quarter of 2024. Patients already enrolled in the Phase III NATiV3 trial continued to receive treatment under the new liver monitoring schedule recommended by the DMC. This SUSAR is the first reported in all clinical trials with lanifibranor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 7, 2024, the Company received approval from the central IRB overseeing clinical research in the United States to resume screening activities in its sites. This was an important milestone as 152 sites of the NATiV3 clinical trial sites are operating under central IRB and have so far randomized over 60% of the patients in the main cohort. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Due to a delay of around 3 to 5 months in recruitment, the Company is currently targeting the first visit of the last patient for the fourth quarter of 2024, completion of randomization in the first half of 2025 and the main results are expected for the second half of 2026 (versus the beginning of the second half of 2026 as previously disclosed).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Company presented the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 18, 2024, the Company announced positive results from its LEGEND proof-of-concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and type 2 diabetes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The LEGEND trial was designed as a multi-center, randomized, 24-week treatment, placebo-controlled Phase II Proof-of-Concept trial to assess the safety and efficacy of lanifibranor in combination with the SGLT2 inhibitor empagliflozin for the treatment of patients with non-cirrhotic MASH/NASH and T2D. The trial was double-blind for the placebo arm and lanifibranor (800mg daily) arm, and open-label for the combination of lanifibranor (800mg daily) and empagliflozin (10 mg daily) arm. The diagnosis of non-cirrhotic MASH/NASH was based on historic histology evaluation or a combination of non-invasive methods including diagnostic methods including imaging. As planned per protocol, the interim analysis was done once half of the 63 planned randomized patients with MASH completed the 24-week treatment period or prematurely discontinued from treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The study achieved the primary efficacy endpoint with an absolute reduction in Hemoglobin A1c (HbA1c) of 1.14% and 1.59% in patients with MASH and T2D treated with lanifibranor (800mg daily) or in combination with empagliflozin (10mg daily) at week 24 compared to an increase of 0.26% observed in the placebo arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The study also demonstrated a statistically significant reduction in hepatic steatosis measured by MRI-PDFF, in patients treated with lanifibranor alone and in combination with empagliflozin, -47% and -38% respectively, compared to placebo (0%). 83% and 67% of patients treated with lanifibranor alone or in combination with empagliflozin respectively, showed a reduction greater or equal to 30% of their hepatic fat, compared to 0% in the placebo arm. In addition, the study demonstrated a statistically significant effect on several secondary and exploratory endpoints, including liver enzymes (alanine aminotransferase (&#8220;ALT&#8221;) and aspartate aminotransferase (&#8220;AST&#8221;)), insulin resistance (HOMA-IR), HDL, and adiponectin. &#160;Markers of liver inflammation and fibrosis (corrected T1 relaxation time (cT1) assessed by LiverMultiScan&#174;) were assessed for the first time with lanifibranor and showed a significant effect with lanifibranor alone and in combination with empagliflozin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The study also demonstrated that patients treated with lanifibranor in combination with empagliflozin maintained a stable weight throughout the 24 weeks study, addressing the moderate, metabolically healthy, weight gain that can be observed in some patients treated </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">with lanifibranor alone. Furthermore, these results demonstrated a significant relative reduction in the VAT/SAT ratio (visceral and subcutaneous adipose tissue) in patients treated with lanifibranor alone or in combination with empagliflozin, -5% and -17% respectively, compared to an increase of 11% in patients under placebo. This result reflects a shift from pro-inflammatory visceral fat towards metabolically healthy adipose tissue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The treatment with lanifibranor 800mg/daily alone and in combination with empagliflozin 10mg/daily for 24 weeks appears to be well tolerated, with no safety concerns reported.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Given that the primary endpoint of LEGEND was met, and statistically significant results were achieved on several key additional markers, the Company has decided to stop the recruitment as defined per protocol. More details on these results are expected to be presented in upcoming scientific conferences and submitted for publication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Additional results from NATIVE Phase IIb clinical trial</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 13, 2024, the Company announced the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Improvements were observed for insulin resistance (insulin levels, HOMA-IR), lipid metabolism (triglycerides, HDL-cholesterol, apolipoproteins), control of glycemia (HbA1c, fasting glucose (FG) levels), systemic inflammation (hs-CRP, ferritin), hepatic steatosis and diastolic blood pressure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 16, 2024, the Company announced the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The DMC recommended to continue the clinical trial without further modification of the protocol, as amended immediately after learning about the SUSAR based on the pre-planned review of safety data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients that have been treated for more than 48 and 72 weeks, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The patient who experienced the adverse event of increased liver test results, which was reported as a SUSAR, had been without clinical symptoms throughout the period of observation and has fully recovered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.2.2.</b></span><b style="font-weight:bold;">Other events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Company issued 3,144,654 warrants to EIB in connection with the drawdown of Tranche B</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 4, 2024, the Company issued 3,144,654 additional warrants to the European Investment Bank (&#8220;EIB&#8221;) and such warrants (the &#8220;EIB Tranche B Warrants&#8221;), in accordance with the terms of the 6<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> resolution of the combined general meeting of shareholders of January 25, 2023 and Article L.225-138 of the French Commercial Code, as a condition to the drawdown of the second tranche of &#8364;25.0 million (&#8220;Tranche B&#8221;) under the finance contract between the Company and EIB (&#8220;Finance Contract&#8221;). The 3,144,654 shares underlying the EIB Tranche B Warrants represented approximately 6.07% of the Company's then-outstanding share capital. If all the warrants issued to the EIB in connection with drawdown of the first tranche of &#8364;25.0 million (&#8220;Tranche A&#8221;) under the Finance Contract (the &#8220;EIB Tranche A Warrants&#8221; and, together with the EIB Tranche B Warrants, the &#8220;EIB Warrants&#8221;) and the EIB Tranche B Warrants were exercised, the EIB would hold approximately 11.3% of the Company's share capital as of June 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The exercise price of the EIB Tranche B Warrants is equal to &#8364;3.95 and corresponds to 95% of the volume-weighted average price of the Company's shares on the regulated market of Euronext Paris during the last trading session preceding the decision to issue the warrants (i.e. January 3, 2024).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The EIB Tranche B Warrants have a maturity of twelve years and shall be exercisable following the earliest to occur of (i) the maturity date of Tranche A (i.e., on December 8, 2026), (ii) a change of control event, (iii) an event of default under the Finance Contract, or (iv) a repayment demand by EIB under the Finance Contract. The EIB Warrants will automatically be deemed null and void if not exercised within the twelve-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">EIB has a put option which may require the Company to repurchase all or part of the unexercised EIB Tranche B Warrants then exercisable at their intrinsic value (subject to a cap equal to the amount drawn under the Finance Contract) under certain circumstances (for example, in the event of a change of control or on the maturity date of Tranche A or in the event of default). The Company (or a substitute third party) has a call option to require EIB to sell all shares and other securities of the Company, including the EIB Warrants, to the Company, subject to certain terms and conditions. In addition, the Company has a right of first refusal to buy-back all EIB Tranche B Warrants offered for sale to a third party, subject to certain terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On the basis of the 3,144,654 new shares of the Company issuable upon exercise of all the EIB Tranche B Warrants at a price of &#8364;3.95 per new share, the Company could potentially receive gross proceeds of up to &#8364;12,421,383. There is no assurance that EIB will exercise any or all of the EIB Warrants or that the Company will receive any proceeds from the exercise of the warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The exercise ratio of EIB Tranche A Warrants has been adjusted following the issue of EIB Tranche B Warrants. As of the date of authorization of the issuance of these financial statements, one EIB Tranche A Warrant entitles its holder to subscribe for 1.27 ordinary shares in the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Company drew down Tranche B of &#8364;25 million under Finance Contract with EIB</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 18, 2024, the Company drew down Tranche B under the Finance Contract for an amount of &#8364;25 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">After the drawdown of Tranche A in December 2022, the Company had an option to access further &#8364;25 million tranche, Tranche B, subject to the achievement of certain conditions precedent. Following the achievement of those conditions, the Company decided to draw on Tranche B. The Company intends to use the proceeds to fund part of NATiV3.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Tranche B carries a 7% interest capitalized annually and repayment in fine. The repayment is due in January 2027, three years after its disbursement. The disbursement of Tranche B was subject to, among other conditions, (i) the full drawdown of Tranche A, (ii) the receipt by the Company from the date of the Finance Contract of an aggregate amount of at least &#8364;70 million (inclusive of the &#8364;18 million that was a condition for the disbursement of Tranche A), paid either in exchange for shares of the Company, or through upfront or milestone payments, (iii) an out-licensing, partnership or royalty transaction with an upfront payment of at least &#8364;10 million, (iv) operational criteria based on patient enrollment and number of sites activated in the Company&#8217;s NATiV3 Phase III clinical trial of lanifibranor in patients with MASH/NASH and (v) the Company issuing EIB Tranche B Warrants (see above - <i style="font-style:italic;">The Company issued 3,144,654 warrants to European Investment Bank in connection with the drawdown of Tranche B</i>) in accordance with the terms and conditions of the warrant agreement entered into on July 1, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Tranche B of &#8364;25 million was recognized as financial debt at amortized cost, which takes into account the fair value of the derivative instrument (warrants) at inception and the borrowing costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On June 12, 2024, the Company and EIB amended the warrant to modify the rules for adjusting the exercise ratios of the EIB Warrants.</p><a id="a13Recenteventsandprospects_526546"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">1.3.&#160;&#160;&#160;&#160;Recent events and prospects</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.3.1.</b></span><b style="font-weight:bold;">Operations and product portfolio</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Update on NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On July 5, 2024, the Company provided an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH. Recruitment in NATiV3 clinical trial continues in both cohorts with over 80% of the targeted number of patients enrolled in the main cohort and 100% in the exploratory cohort of NATiV3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The first visit of the last patient of NATiV3 is anticipated to occur during the fourth quarter of 2024, and topline results are expected in the second half of 2026. The Company strengthened its patent portfolio with a new patent in Japan that provides intellectual property rights on the potential use of lanifibranor for the treatment of patients with cirrhosis until 2039, excluding any potential patent term adjustments or extensions that may provide additional protection until 2043.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.3.2.</b></span><b style="font-weight:bold;">Other events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Issuance of royalty certificates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On July 18, 2024, the Company announced the issuance of 201 royalty certificates (&#8220;2024 Royalty Certificates&#8221;) for aggregate gross proceeds of approximately &#8364;20.1 million. Royalties amount to 3% on future net sales of lanifibranor in the United States of America, the European Union and the United Kingdom over a 14-year term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Approving of patent application</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On July 25, 2024 the Company announces that the Japan Patent Office (&#8220;JPO&#8221;) approved Inventiva&#8217;s patent application No. JP 2019-203498, protecting the use of lanifibranor for the treatment of patients with cirrhosis. This new patent will be valid until November 8, 2039, excluding any potential patent term adjustments or extensions that may provide additional protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Financing in three tranches for a maximum amount of &#8364;348 million</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company announced the following financing on 14 October 2024 structured in three tranches:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 8pt 0pt;">(i) the issuance , through a capital increase without preferential subscription rights reserved to a specific category of beneficiaries (&#8220;<i style="font-style:italic;">&#224; cat&#233;gorie de personnes</i>&#8221;), of new ordinary shares at a gross value, including issuance premium, of &#8364;94.1 million through the issuance of 34,600,507 new ordinary shares, par value &#8364;0.01 per share (each, a &#8220;<b style="font-weight:bold;">T1 New Shares</b>&#8221;), and 35,399,481 prefunded warrants to subscribe for shares in the Company at a price outstanding of &#8364;0.01 per new ordinary share, each giving the right, in the event of exercise, to one new ordinary share (the &#8220;<b style="font-weight:bold;">T1 BSAs</b>&#8221;);</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:justify;margin:0pt 0pt 8pt 0pt;">(ii) the issuance, in a second phase, as part of a new capital increase without preferential subscription rights reserved to certain identified investors (&#8220;<i style="font-style:italic;">&#224; personne d&#233;nomm&#233;e</i>&#8221;), of new ordinary shares, par value &#8364;0.01 per share or of prefunded warrants to subscribe for ordinary shares of the Company (each, a &#8220;<b style="font-weight:bold;">T1bis New Shares</b>&#8221;), for a total amount of &#8364;21.4 million (excluding exercise of pre-funded warrants);</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:justify;margin:0pt 0pt 8pt 0pt;">(iii) the issuance, in a third phase, as part of a new capital increase without preferential subscription rights reserved to certain identified investors (&#8220;<i style="font-style:italic;">&#224; personne d&#233;nomm&#233;e</i>&#8221;) subject to operational conditions to be met and the adoption of the necessary resolutions by the Shareholders' Meeting to be held before December 16, 2024, (or prefunded warrants) to which share warrants (the &#8220;<b style="font-weight:bold;">ABSAs</b>&#8221;) are attached for a total amount of &#8364;116,000,000. Each ABSA will consist of a number of new ordinary shares with a par value of &#8364;0.01 (or pre-funded warrants) to be determined by the Company's Board of Directors (each, a &#8220;<b style="font-weight:bold;">T2 New Share</b>&#8221;) to which will be attached a number warrants exercisable at an exercise price of &#8364;1.50 (each, a &#8220;<b style="font-weight:bold;">T3 BSA</b>&#8221;) allowing the subscription of a number of new ordinary shares of the Company for a maximum total amount of &#8364;116,000,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:justify;margin:0pt 0pt 8pt 0pt;">The subscription agreements for the T1 New Shares and the T1 BSA were signed on October 11, 2024, and the settlement-delivery of the T1 New Shares and the T1 BSA is expected to take place on October 17, 2024, subject to the absence of any material adverse event between the signing of the agreements and the settlement-delivery of the T1 New Shares and the T1 BSA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Amendment to the exclusive license and collaboration agreement with CTTQ</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:justify;margin:0pt 0pt 8pt 0pt;">On October 11, 2024, the Company has entered into an amendment (the &#8220;<b style="font-weight:bold;">Amendment</b>&#8221;) to the exclusive license and collaboration agreement with Chia Tai Tianqing Pharmaceutical Group, Co., Ltd (&#8220;<b style="font-weight:bold;">CTTQ</b>&#8221;), dated September 21, 2022, as amended. Under the Amendment, if the Company receives subscription commitments, before December 31, 2024, from investors to subscribe to a fundraising, in two or three tranches, for a total gross amount of at least &#8364;180,000,000 (the &#8220;<b style="font-weight:bold;">Fund Raising</b>&#8221;), CTTQ shall pay to the Company (i) $10,000,000 within 30 days of settlement-delivery of the T1 New Shares and T1 Warrants in the event of the issuance of the first tranche of the Fund Raising to be paid by CTTQ, (ii) $10,000,000 in the event of the issuance of the second tranche of the Fund Raising, and (iii) $10,000,000 upon publication by the Company of the pivotal data announcing that the primary endpoint or one of the two key secondary endpoints of NATiV3, with one of the dosing regimens tested in the trial, have been met. Under the terms of the Amendment, the total amount of potential clinical, regulatory and commercial milestone payments remains unchanged, while the royalties that Inventiva is likely to receive have been reduced to a low figure.</p><a id="a14Riskfactors_163550"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;">1.4.</b></span><b style="font-weight:bold;">Risk factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:justify;margin:0pt 0pt 8pt 0pt;">The Company&#8217;s business faces significant risks. You should carefully consider all of the information set forth in this document and in the Company&#8217;s other filings with the United States Securities and Exchange Commission, or the SEC, including the risk factors which the Company faces and which are faced by the Company&#8217;s industry described in Chapter 2 of the Company&#8217;s 2023 Universal Registration Document Part I, Item 1A. &#8220; Risk Factors&#8221; of the Company&#8217;s Annual Report on Form 20-F for the fiscal year ended December 31, 2023, in addition to the following risk factors. Our business, financial condition or results of operations could be materially adversely affected by any of these risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Please refer to chapter 2.1 of the 2023 Universal Registration Document and as amended in Section 5 of the amendment to the universal document as filed with the AMF under number D.24-0227-A01 on October 14, 2024 (the "Amendment to the 2023 Universal Registration Document "), which are incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The risk factor in the 2023 Universal Registration Document amended in the context of the Amendment to the 2023 Universal Registration Document is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Liquidity risk: the Company believes that it will be able to finance its activities until the end of the second half of 2025, and there is doubt regarding our ability to continue as a going concern.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of 30 June 2024, the Company had cash and cash equivalents of &#8364;10.1 million, compared to &#8364;26.9 million, and &#8364;9.0 million of long-term deposit<sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">2 </sup>as of December 31, 2023. </p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> The long-term deposit had a two year-term, were accessible prior to the expiration of the term with a notice period of 31 days and were considered as liquid by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of the date of this document, the Company believes, taking into account its current cost structure and forecast expenditure commitments, and the events after the reporting period presented in Note 6.4 &#8211; <i style="font-style:italic;">Events after the reporting period</i> of the section 3.2 &#8211; <i style="font-style:italic;">Interim Condensed Consolidated financial statements</i> as <i style="font-style:italic;">of June 30, 2024</i>, mainly the issue of royalty certificates and the T1 capital increase, that it will have sufficient net working capital to meet its current obligations until the end of the second half of 2025. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accordingly, our current cash position will not be sufficient to cover operating needs for at least the next 12 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This estimate is based on the Company&#8217;s current business plan and excludes (i) other expenses related to the potential development of odiparcil or resulting from any potential in-licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue, (ii) any potential milestone payments that may be received or paid by the Company or potential additional financing, including the issue of tranches 1bis and 2 as described in Note 6.4 &#8211; <i style="font-style:italic;">Events after the reporting period </i>of the section 3.2 &#8211;<i style="font-style:italic;"> Interim Condensed Consolidated financial statements </i>as<i style="font-style:italic;"> of June 30, 2024</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In order to finance its activities, the Company needs to raise additional funds, and is currently actively reviewing potential financing (including debt, equity and equity-linked or other instruments) and strategic options (for more on complementary financing, see section 2.3 of this document).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company may have based itself on incorrect assumptions and may have to use its resources sooner than expected. Although the Company is actively discussing financial and strategic options for financing its activities beyond its cash horizon, notably with its financial partners and financial advisors, the Company cannot guarantee that it will be able to obtain the necessary financing, through any of the foregoing measures or otherwise, to meet its needs or to obtain funds at acceptable terms and conditions, on a timely basis, or at all. If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any approved product or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could impair our growth prospects. The perception that we may be unable to continue as a going concern may impede our ability to pursue any potential strategic opportunities or operate our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Ultimately, if we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Risks associated with seeking and arranging financing and risks associated with uncertain additional financing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The development of the Company's programs has required, and will continue to require, significant financial investment, particularly for Phase III of lanifibranor, its YAP/TEAD program and the continued development of a portfolio of products at the preclinical stage. The Company will require additional funding as its clinical programs reach advanced stages of development, in particular to complete its clinical trials and, if successful, to manufacture and market the Company's drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To meet this financing requirement, the Company needs to raise additional funds, and continues to actively explore financing options (including debt, equity-linked or other instruments) and strategic options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">However, taking on additional debt could lead to an increase in financial expenses and could also result in the Company having to comply with certain additional covenants, such as limitations on the Company's ability to take on additional debt or to carry out certain transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Similarly, the conclusion of a financing agreement could be accompanied by undertakings limiting the Company's ability to acquire or grant intellectual property rights, particularly if it has to provide security and accept other operating restrictions that could have a negative impact on the Company's ability to continue its business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">It should be noted that additional financing, particularly in the form of equity instruments, could result in significant dilution. In addition, financing in the form of financial debt would worsen the Company's financial structure. The need for and pursuit of additional financing could also divert the Company's management from its day-to-day activities, which could affect the future development and marketing of its drug candidates.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company will also need additional funds to consider the pre-commercialisation and subsequent commercialisation of its drug candidate, or to make new investments that are unknown at this time or difficult to assess because they relate to projects in development. It is difficult to anticipate precisely all the costs associated with the preclinical and clinical development of the Company's products while some of its products are still at an early stage of development. The amount and timing of future additional funding requirements will depend in particular on the Company's ability to achieve milestones under its existing collaboration agreements, but also on the operating conditions associated with the Transaction and its ability to enter into new agreements, on market acceptance of any approved drug candidates, on the Company's need for and ability to recruit additional management and scientific personnel, and on the Company's ability to implement additional internal systems and infrastructure, including in its financial and IT management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If the Company is unable to find such additional financing on acceptable terms or in a timely manner, particularly given the generally unfavorable environment for financing companies in the biotechnology sector, its business, organisation, results and development could be adversely affected, and it could be forced to delay or halt one or more of its research programs, the development or marketing of any approved products, not be able to expand its activities or take advantage of its commercial opportunities as desired. The Company may also have to implement a plan to reduce and manage its fixed costs or enter into new collaboration agreements that may be less favorable to it than those it could have obtained in a different context, which could harm its growth prospects or commercial activities, as set out in the liquidity risk factor above.</p><a id="a15Earningsanalysis_415075"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.5.&#160;&#160;&#160;&#160;Earnings analysis</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.5.1.</b></span><b style="font-weight:bold;">Revenue and other income</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Operating income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 41</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,901</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 41</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1,901</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,630</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,631</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Subsidies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 58</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,087</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Other income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 2,693</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 4,721</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total revenue and other income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 2,734</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 6,622</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recorded minimal revenues in the first half of 2024, as compared to &#8364;1.9 million for the same period in 2023. The &#8364;1.9 million revenue as of June 30, 2023, was mainly related to the milestone payment the Company invoiced to CTTQ for $2.1 million on May 22, 2023, following the IND approval from the NMPA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other income decreased by &#8364;2.0 million, or 43%, compared to the first half of 2023. &#160;Other income are mainly composed of research tax credits. The Research Tax Credit ("CIR") generated over the first six months of the fiscal year amounts to &#8364;2.7 million in 2024 as in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, other operating income are composed of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The R&amp;D Tax Research Credit from Inventiva Inc amounting to &#8364;1.0 million, compared to &#8364;0.8 million in tax income as of June 30, 2024;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The re-invoicing to CTTQ for a portion of the expenses incurred, amounting to &#8364;0.3 million as of June 30, 2023, under Phase I of the ongoing Phase III pharmacological clinical trial NATiV3, and the re-invoicing to CTTQ for specific expenses related </span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to CRO provisions amounting to &#8364;0.7 million, compared to &#8364;2.6 million in CTTQ re-invoicing as of June 30, 2024, accounted as a reduction in research and development expenses.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.5.2.</b></span><b style="font-weight:bold;">Operating expenses</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (46,822)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (54,062)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Marketing&#160;&#8211; Business development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (598)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (705)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (7,701)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6,812)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (55,122)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (61,580)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024, the decrease in operating expenses of &#8364;6.5 million, or 10%, compared to the first half of 2023 is mainly driven by the decrease in research and development expenses of &#8364;7.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.5.2.1.</b></span><b style="font-weight:bold;">Research and development expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses for the six&#160;months ended June&#160;30, 2024 break down as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Research and development expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Studies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (34,073)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (42,847)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Personnel costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (7,637)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (7,065)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Depreciation, amortization, and provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,732)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,061)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Disposables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (887)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (943)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Patents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (643)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (257)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Maintenance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (526)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (459)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Energy and liquids</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (447)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (479)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">IT systems</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (405)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (440)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (118)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (61)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (352)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (450)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total research and development expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (46,822)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (54,062)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The decrease in R&amp;D expenses is primarily due to the temporary pause in the recruitment of the patients in the NATiV3 Phase III clinical trial of lanifibranor in MASH/NASH following the SUSAR reported in the first quarter of 2024 and, to a lesser extent, due to the completion of the LEGEND trial with lanifibranor and empagliflozin in patients with MASH/NASH and DT2. R&amp;D expenses are expected to increase in the second half of 2024 following the effective restart of patient recruitment in NATiV3, as well as the planned clinical development activities and related costs associated with NATiV3 for the second half of 2024 including costs related to the SUSAR protocol change and the reactivation of sites and patient recruitment. The &#8364;7.2 million (13%) decrease in research and development expenses as compared to the six months ended June 30, 2023, was primarily driven by:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a &#8364;8.8 million decrease in spending on studies in research and development for lanifibranor, mainly for the NATiV3 Phase III trial of lanifibranor in patients with MASH/NASH and Phase IIa LEGEND trial of lanifibranor in combination with empagliflozin; and</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a &#8364;0.7 million increase in depreciation and amortization costs mainly related to the right of use of Fibroscans equipment; and</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a &#8364;0.6 million increase in personnel costs mainly due to salary increases and bonuses.</p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The main expenses incurred in connection with the Company&#8217;s research and development activities in the six months ended June 30, 2024, are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#7f7f7f;font-family:'Wingdings 3';font-weight:bold;">&#161;</b><b style="font-weight:bold;"> Lanifibranor</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical trial-related expenses for lanifibranor development decreased by &#8364;7.1 million compared to the first half of 2023, totaling &#8364;34.8 million in the first half of 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Costs relating to lanifibranor&#8217;s development in the first half of 2024 can be broken down into two main categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">activities related to clinical studies amounted to &#8364;28.5 million, mainly including the NATiV3 Phase III trial in MASH/NASH, the LEGEND Phase IIa trial in patients with MASH/NASH and T2D, and Phase I studies as detailed below; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">development activities amounted to &#8364;6.2 million, mainly including pharmaceutical development and non-clinical, preclinical pharmacology and toxicology trials in animals and the activities related to regulatory consulting.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Costs linked to clinical trial activities included the following developments over the six months ended June 30, 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Treatments for MASH/NASH</i><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Costs related to the NATiV3 Phase III trial related to the qualification and opening of investigator sites, regulatory submissions and patient recruitments, leasing of Fibroscans equipment, the expenses related to packaging campaigns for the treatment units, costs related to biopsy slides reading and consulting including committees.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">LEGEND Phase IIa trial of lanifibranor in combination with empagliflozin in patients with MASH/NASH and T2D</i></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:17.85pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:17.85pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The completion of the LEGEND Phase IIa trial with regulatory submissions, the monitoring of patients recruited into the study, and generation of the results of the Interim Analysis carried out in the first quarter of 2024. Other expenses for the period include packaging and distribution costs for treatment units, and pharmacokinetics analysis.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase I studies</i></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The completion of the Renal Impairment study, with CRO expenses related to statistical analyses and drafting of the Clinical Study Report (&#8220;CSR&#8221;); and</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Data Management activities and the preparation of the CSR for the Hepatic Impairment study, as well as the bioanalysis and pharmacokinetics analysis expenses.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="color:#7f7f7f;font-family:'Wingdings 3';font-weight:bold;">&#161;</b><b style="font-weight:bold;"> </b><b style="font-weight:bold;">YAP-TEAD</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Trial-related expenses for the YAP-TEAD project increased by &#8364;0.2 million compared to the first half of 2023, totaling &#8364;0.6 million in the first half of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Costs incurred are mainly related to chemistry studies, biophysic and bio pharmaco study.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.5.2.2.</b></span><b style="font-weight:bold;">Marketing and business development expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Marketing and business development expenses break down as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">For the first six&#160;months ended June&#160;30, 2024, and June&#160;30, 2023</i></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Marketing &#8211; Business development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Personnel costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (153)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (126)</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">IT systems</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (9)</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (437)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (570)</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total marketing and business development expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (598)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (705)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Marketing and business development expenses for the first half of 2024 decreased by &#8364;0.1 million compared to the first half of 2023 mainly due to the decrease by &#8364;0.1 million of fees related to the business development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.5.2.3.</b></span><b style="font-weight:bold;">General and administrative expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses are mainly composed of administrative staff costs, support costs (mainly consisting of security costs, taxes and various rentals), non-scientific IT costs and consulting fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses break down as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">For the first six months ended June 30, 2024, and June 30, 2023</i></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">General and administrative expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Consulting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,675)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,884)</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Personnel costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,600)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,347)</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Insurances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (921)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,121)</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Support costs (including taxes)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (375)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (343)</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Depreciation, amortization and provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (122)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (104)</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">IT systems</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (33)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (50)</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (975)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (964)</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total general and administrative expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (7,701)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (6,812)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses for the first half of 2024 increased by &#8364;0.9 million compared to the first half of 2023 mainly due to the increase in consulting fees by &#8364;0.8 million related to the double listing, personnel costs by &#8364;0.3 million and the decrease of insurances expenses by &#8364;0.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.5.3.</b></span><b style="font-weight:bold;">Other operating income and expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other operating income and expenses break down as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other operating income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 160</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (22)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (44)</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Other operating income and expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 138</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (44)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the first half of 2024, other operating income and expenses are mainly due to disposal of assets and transaction costs.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the first half of 2023, other operating income and expenses are exclusively due to transaction costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.5.4.</b></span><b style="font-weight:bold;">Financial income and expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial income and expenses break down as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Financial income and expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Income from cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 430</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 564</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Foreign exchange gains</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 157</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 187</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Fair value gains</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,506</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,623</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total financial income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 9,093</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 2,373</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Interest cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5,218)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,941)</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Foreign exchange losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (323)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (683)</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Other financial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (46)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (23)</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total financial expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (5,586)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (2,646)</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Net financial income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 3,507</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (273)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net financial income for the first six months of 2024 increased by &#8364;3.8 million compared to the first half of 2023. This increase is mainly due to:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">fair value gains by &#8364;8.5 million related to change in fair value of:</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">o</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the EIB Tranche A Warrants; as of June 30, 2024, the fair value amounted to &#8364;6.7 million, a decrease by &#8364;3.5 million since December 31, 2023 (see note 4.9 <span style="font-family:'Sitka Subheading';">&#8211;</span> <i style="font-style:italic;">Shareholders</i><i style="font-family:'Sitka Subheading';font-style:italic;">&#8217;</i><i style="font-style:italic;"> equity</i> of the <i style="font-style:italic;">Unaudited interim condensed consolidated financial statements as of June 30, 2024</i>);</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">o</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the EIB Tranche B Warrants since the initiation, as of June 30, 2024, the fair value amounted to &#8364;6.8 million, a decrease by &#8364;5.0 million since the grant date (see note 4.9 <span style="font-family:'Sitka Subheading';">&#8211;</span> <i style="font-style:italic;">Shareholders</i><i style="font-family:'Sitka Subheading';font-style:italic;">&#8217;</i><i style="font-style:italic;"> equity</i> of the <i style="font-style:italic;">Unaudited interim condensed consolidated financial statements as of June 30, 2024</i>)</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">increase in interest cost for the first six months of 2024 by &#8364;3.3 million compared to June 30, 2023 mainly due to:</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">o</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The increase in interest expenses on the EIB loan by &#8364;2.3 million, with (i) 2.1 million euros in interest expense for Tranche A over the first six months of 2024 compared with 1.7 million euros over the first six months of 2023, an increase of 0.4 million euros, and (ii) 1.9 million euros for Tranche B over the first six months of 2024 (and an increase of the same amount, Tranche B having been subscribed in 2024);</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">o</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">and interest on 2023 royalty certificates of 0.9 million euros in the first six months of 2024 (compared with 0 in the first six months of 2023, as the royalty certificates were issued in the last six months of 2023).</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">foreign exchange result of the first six months of 2024 as a result of the unfavorable position of the foreign currency term deposit contracts at the maturity date for &#8364;0.3 million.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.5.5.</b></span><b style="font-weight:bold;">Income tax</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with IAS 34, the income tax recognized in the financial statements for each interim period is adjusted based on a best estimate calculated by applying the expected weighted average tax rate for the entire year. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Current taxes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As the imputation of tax benefits on tax losses of Inventiva S.A., at short or mid-term, were considered unlikely due to the growth phase of the Company and regarding the nil projected tax rate as of December 31, 2024, no current taxes were recorded as of June 30, 2024, for Inventiva S.A. However, a &#8364;119 thousand tax expense was recorded related to Inventiva Inc (mainly due to the bonuses).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Deferred taxes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inventiva S.A. recorded tax losses in the first half of 2024. As recovery of these losses in future periods is considered unlikely due to the uncertainty inherent to the Company&#8217;s activity, no deferred tax assets were recognized on this basis on June 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.5.6.</b></span><b style="font-weight:bold;">Net loss for the period</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recorded a net loss of &#8364;49.0 million in the first half of 2024 versus a net loss of &#8364;55.3 million in the first half of 2023, which was a decrease in net loss of &#8364;6.2 million year over year.</p><a id="a16Analysisofthefinancialsituation_29934"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.6.&#160;&#160;&#160;&#160;Analysis of the financial situation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.6.1.</b></span><b style="font-weight:bold;">Non-current assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">Non-current assets mainly consist of: </p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">other non-current assets mainly comprising term accounts with progressive interest rates.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">property, plant, and equipment, mainly comprising assets acquired on the incorporation of the Company and the right of use from Fibroscans leasing. </p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">investments accounted for using equity method related to investment in Hepalys; and</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">intangible assets, mainly comprising the compound and software library.</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec.&#160;31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 451</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 541</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,979</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,126</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 210</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 225</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Investments accounted for using the equity method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,131</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,425</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,047</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,055</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 10,818</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 21,372</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Non-current assets decreased by &#8364;10.6 million (49%) compared to December 31, 2023. This was mainly attributable to:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the decrease by &#8364;9.0 million of long-term deposit accounts with more than a year of maturity, related to the early closure of a &#8364;9 million two-year deposit forward contract (see note 4.5 &#8211; <i style="font-style:italic;">Other non-current assets</i> of the <i style="font-style:italic;">Unaudited interim condensed consolidated financial statements as of June 30, 2024</i>); and</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the decrease in property, plant and equipment mainly due to the depreciation of &#8364;1.2 million of the right of use related to Fibroscan.</p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.6.2.</b></span><b style="font-weight:bold;">Current assets</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec.&#160;31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 393</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 417</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 809</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,807</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,704</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,352</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,554</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,696</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and&#160;cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,147</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26,918</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 28,608</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 48,189</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Current assets decreased by &#8364;19.6 million (41%) compared to December 31, 2023. This was mainly attributable to the &#8364;16.8 million (62%) decrease in cash and cash equivalents and the &#8364;3.0 million decrease in trade receivables, both related to the Company&#8217;s activity (see section 2 <i style="font-style:italic;">Cash flow and equity</i>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024, tax receivables are mainly composed of research tax credits receivable in the amount of &#8364;2.7 million corresponding to the 2024 CIR as of June 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The &#8364;2.9 million increase in other current assets is mainly due to:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">an increase in other receivable by &#8364;1.8 million including an increase in prepaid expenses by &#8364;2.4 million mainly related to trial costs incurred under NATiV3 Phase III global trial; and</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">an increase in current accrued income by &#8364;0.6 million which included the rebilling to CTTQ of specific costs (see note 4.7 &#8211; <i style="font-style:italic;">Trade receivables, tax receivables and other current assets</i> of the <i style="font-style:italic;">Unaudited interim condensed consolidated financial statements as of June 30, 2024</i>); and</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">a decrease in sales tax receivable by &#8364;1.8 million.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.6.3.</b></span><b style="font-weight:bold;">Shareholders&#8217; equity</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Shareholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec.&#160;31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 525</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 521</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Premiums related to share capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 201,859</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 201,862</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (232,789)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (124,584)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency translation reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 375</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 596</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (49,029)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (110,426)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total shareholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (79,060)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (32,032)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 30, 2024, shareholders&#8217; equity decreased by &#8364;47.0 million, or 147%, compared to December 31, 2023. This change is mainly due to the net loss of the first six months of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Changes in shareholders&#8217; equity during the first six months of 2024 are described in further detail in note 4.9 &#8211; <i style="font-style:italic;">Shareholders&#8217; equity</i> of the <i style="font-style:italic;">Unaudited interim condensed consolidated financial statements as of June 30, 2024,</i> and in section 2 <i style="font-style:italic;">Cash flow and equity </i>of this document.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.6.4.</b></span><b style="font-weight:bold;">Non-current liabilities</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Non-current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec.&#160;31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 46,846</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 32,181</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Royalty certificates liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,263</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,327</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivatives instruments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,569</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,265</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provisions for retirement benefit obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,555</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,559</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 76</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 70</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,032</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,032</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total non-current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 70,340</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 51,434</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 8pt 0pt;">The &#8364;18.9 million (37%) increase of non-current liabilities compared to December 31, 2023, is mainly due to the &#8364;14.7 million increase of long-term debt (the drawdown of Tranche B subscription), the &#8364;3.3 million increase of derivatives instruments (change in fair value) and the &#8364;0.9 million increase of 2023 Royalty Certificates liabilities related to the interests (see note 4.10 &#8211; <i style="font-style:italic;">Financial debt</i> of the <i style="font-style:italic;">Unaudited interim condensed consolidated financial statements</i> <i style="font-style:italic;">as of June 30, 2024</i>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">1.6.5.</b></span><b style="font-weight:bold;">Current liabilities</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec.&#160;31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,726</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,308</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 36,583</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 37,679</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,834</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,165</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 48,146</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 50,158</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Current liabilities decreased by &#8364;2.0 million (4%) for the six months ended June 30, 2024, compared to December 31, 2023. This change is mainly due to:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the &#8364;1.1 million decrease in trade payables (see note 4.14 &#8211; Trade payables and short-term contract liabilities of the Unaudited interim condensed consolidated financial statements as of June 30, 2024); and</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the &#8364;1.4 million decrease in sales tax payables (including in other current liabilities) (see note 4.13 &#8211; <i style="font-style:italic;">Other current and non-current liabilities</i> of the <i style="font-style:italic;">Unaudited interim condensed consolidated financial statements as of June 30, 2024</i>); and</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">the &#8364;0.4 million increase of short-term debt (see note 4.10 &#8211; <i style="font-style:italic;">Financial debt</i> of the <i style="font-style:italic;">Unaudited interim condensed consolidated financial statements as of June 30, 2024</i>).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_6509b0ec_68de_4cda_a676_9b82c664d3b5"></a><a id="a2Cashflowandequity_110805"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.</b></span><b style="font-weight:bold;">Cash flow and equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This section discusses the Company&#8217;s shareholders&#8217; equity, cash position and sources of funding for the six&#160;months ended June&#160;30, 2024, and the fiscal&#160;year ended December&#160;31, 2023.</p><a id="a21Cashandcashequivalents_105520"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.1.</b></span><b style="font-weight:bold;">Cash and cash equivalents</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Net cash and cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec.&#160;31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Other cash equivalents<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,273</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17,933</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cash at bank and at hand</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,212</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,985</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Bank overdrafts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,338)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Cash and&#160;cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 10,147</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 26,918</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Since its inception, the Company has financed its growth through successive capital increases (see section 4.5. <i style="font-style:italic;">Cash flow and equity</i> of the 2023 Universal Registration Document), debt, collaboration and license agreements and reimbursements of CIR receivables. The Company continues to pursue its research and development activities for its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024, cash and cash equivalents amounted to &#8364;10.1 million compared to &#8364;26.9 million as of December 31, 2023, with a decrease of &#8364;16.8 million (62%), mainly related to the Company&#8217;s ongoing research activities, in particular the NATiV3 Phase III trial with lanifibranor for the treatment of MASH/NASH and, to a lesser extent, to the Phase IIa LEGEND trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash at hand and marketable securities held by the Company are generally invested in short-term deposit accounts that are readily convertible into known amounts of cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash at hand and marketable securities are used to finance the Company&#8217;s activities, in particular its R&amp;D costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">After deducting debt, the Company has a net cash deficit as of June 30, 2024, of &#8364;1.3 million due to bank overdrafts. Borrowings are set out in section 2.1.2 <i style="font-style:italic;">Financing from bank loans </i>below.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Analysis of debt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Short-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,726</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,308</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 67,677</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 48,773</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total debt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 73,404</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 54,082</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (10,147)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (26,918)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Net debt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 63,256</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 27,164</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net debt is a non-standard measure that includes cash and cash equivalents, long-term financial debt, long-term financial debt - derivative instruments, liabilities under royalty certificates, and short-term financial debt.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Here are no restrictions on the use of the Company&#8217;s cash and cash equivalents resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.1.1.</b></span><b style="font-weight:bold;">Equity financing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024, the Company&#8217;s share capital increased by &#8364;3.6 thousand compared to December 31, 2023, and set at &#8364;524.8 thousand (see note 4.9 &#8211; <i style="font-style:italic;">Shareholders&#8217; equity </i>of the<i style="font-style:italic;"> Unaudited interim condensed consolidated financial statements as of June 30, 2024</i>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.1.2.</b></span><b style="font-weight:bold;">Financing from bank loans</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:30.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exchange</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Debt&#160;carried on the</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Debt&#160;carried on</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Analysis of debt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">balance&#160;sheet at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Proceeds</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Repayments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">gain/losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">the balance</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec.&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(+)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(-)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">capitalize</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Variation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(+/-)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">sheet on</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,566</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 345</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,173)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,762</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PGE SG 2020 (state-guaranteed)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,096</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (417)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,679</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PGE BPI France 2020 (state-guaranteed)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,269</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (413)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,856</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PGE CA 2020 (state-guaranteed)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,096</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (347)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,748</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PPR CA 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,780</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,780</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PPR SG 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,780</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,780</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PGE BPI France 2022 (state-guaranteed)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,780</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,780</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EIB borowing Tranche A 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,400</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,374</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,774</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EIB borowing Tranche B 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,102</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,102</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EIB Warrants 2022 and 2024 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,265</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,809</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (8,506)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,569</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Royalty certificates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,327</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 936</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,263</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,724</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (36)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 623</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,311</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total Debt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 54,082</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 25,256</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (2,386)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 4,933</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (8,506)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 24</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 73,404</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Corresponding to accrued interests payable on loans.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 16, 2022, the Company entered into the Finance Contract with EIB for up to &#8364;50 million, divided into two tranches of &#8364;25 million each. On January 18, 2024, the Company received the disbursement of Tranche B (see Note 1.2. &#8211; <i style="font-style:italic;">Significant events in the first half of 2024</i> of this document and note 4.10 &#8211; <i style="font-style:italic;">Financial debt</i> of the <i style="font-style:italic;">Unaudited interim condensed consolidated financial statements as of June 30, 2024</i>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s loans and debt maturity profile as of June&#160;30, 2024, is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less&#160;than</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Between 1&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Between 3&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">More&#160;than</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">one&#160;year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;3&#160;years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;5&#160;years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">five&#160;years</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Bank borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,229</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 36,164</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,225</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 890</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Derivatives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,569</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other loans and similar borrowings<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 42</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,260</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,455</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,306</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Royalty certificates liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,263</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total Debt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 5,726</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 57,299</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 2,225</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 8,153</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Including accrued interests payable on loans.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.1.3.</b></span><b style="font-weight:bold;">Financing from Research Tax Credits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Due to its status as a European small and medium-sized enterprise (&#8220;SME&#8221;), the Company receives payment for research tax credits granted in the previous period. Consequently, cash proceeds from research tax credits in a given period correspond to the amount of credits calculated on eligible expenditure for the previous period.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024, Tax credits related to the 2024 CIR are set at &#8364;2.7 million. CIR tax credit amounted to &#8364;5.3 million for the year ended December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research tax credits during the six&#160;months ended June&#160;30, 2024, and June&#160;30, 2023 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Financing from research tax credits</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income statement impact of research tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,630</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,631</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash flow impact of research tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,333</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,220</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The decrease of &#8364;1.0 million compared to the first half of 2023 is primarily attributable to the decrease in research and development expenses incurred by the Company.</p><a id="a22Cashflowanalysis_550189"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.2.</b></span><b style="font-weight:bold;">Cash flow analysis</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table sets forth the Company&#8217;s cash flow for the first half of 2024 and the first half of 2023:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Cash flow</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (48,342)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (45,233)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash from (used in) investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,912</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (7,702)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash from (used in) financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,568</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,153)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net increase (decrease) in cash and cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (16,863)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (55,088)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the first six months of 2024 and 2023, the main financing needs of the Company related to its operating activities, including its working capital requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.2.1.</b></span><b style="font-weight:bold;">Cash flow linked to operating activities</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss for the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (49,029)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (55,269)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Elimination of non-cash or non-operating</b> <b style="font-weight:bold;">income and expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation, amortization and provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,878</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,138</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred and current taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (35)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,657)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,643)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of net debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,180</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,900</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">IFRS 2 expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,238</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,046</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unrealized foreign exchange losses/(gains)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (73)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 503</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value variation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (8,506)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,623)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows used in operations before tax, interest and changes in working capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (50,939)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (54,965)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increase (decrease) in operating and other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,075</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,322)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Increase) decrease in operating and other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,409)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,147</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increase (decrease) in inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (28)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax credit received</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,333</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,220</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,426)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,285)</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Tax, interest and changes in operating working capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 2,597</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 9,732</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net cash used in operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (48,342)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (45,233)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities amounted to &#8364;48.3 million in the first half of 2024, compared to &#8364;45.2 million for the first half of 2023, a decrease of 3.1 million euros due to changes in working capital requirements, and in particular linked to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A decrease in trade receivables of 0 million euros as of June 30, 2024, compared with 2.2 million euros at June 30, 2023, corresponding to a milestone payment from CTTQ received on July 20, 2023.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">0.9 million euros increase in future fund-raising costs (other liabilities)</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">However, the operating expenses, excluding depreciation, amortization, provision, and IFRS 2 expenses for the first half of 2024 decreased by &#8364;7.3 million compared to the first half of 2023. The decrease mainly related to R&amp;D expenses over the period is primarily due to the temporary pause in the recruitment of the patients in the NATiV3 Phase III clinical trial related to the SUSAR (see Note 1.2. &#8211; <i style="font-style:italic;">Significant events in the first half of 2024 </i>of this document) and, to a lesser extent, due to the completion of the LEGEND Phase IIa trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.2.2.</b></span><b style="font-weight:bold;">Cash flow linked to investing activities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash flow used in investing activities over the periods presented was as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchases of property, plant and equipment and intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (255)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (230)</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Disposals of property, plant and equipment and intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 90</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 130</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Increase)/decrease in current term accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 70</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 998</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net change in other non-current financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,008</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (8,600)</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net cash used in investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 8,912</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (7,702)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the first half of 2024, net cash from investing activities amounted to &#8364;8.9 million, compared to &#8364;7.7 million used in the first half of 2023 the change is mainly related to the early closure of a &#8364;9 million two-year deposit forward contract (see note 4.5 &#8211; <i style="font-style:italic;">Other non-current assets </i>of the<i style="font-style:italic;"> Unaudited interim condensed consolidated financial statements as of June 30, 2024</i>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.2.3.</b></span><b style="font-weight:bold;">Cash flow linked to financing activities</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:74.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Capital increase</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Subscription of borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,911</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Repayment of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,177)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,448)</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Repayment of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,173)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (707)</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net cash (from) used in financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 22,568</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (2,153)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Net cash from financing activities amounted to &#8364;22.6 million in the first half of 2024, compared to &#8364;2.2 million used for the first half of 2023. The change is mainly related to the company&#8217;s drawdown of Tranche B, amounting to &#8364;25 million, under the Finance Contract (see Note 1.2. &#8211; <i style="font-style:italic;">Significant events in the first half of 2024</i> of this document).</p><a id="a23Anticipatedsourcesoffunds_500046"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.3.</b></span><b style="font-weight:bold;">Anticipated sources of funds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">From inception, the Company has financed its growth through successive capital increases, debt, collaboration and license agreements and reimbursements of CIR receivables. The Company continues to pursue its research and development activities for its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has incurred operating losses and negative cash flows from operations since inception due to the innovative nature of the product candidates it is developing, which necessitates a research and development phase spanning several years. The Company does not expect to generate revenue from product sales in the near future. With the biopharmaceutical industry's product development phases </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">requiring increasing investments, the Company's financing needs will continue to grow as clinical trials of the Company's drug candidates progress and the Company invests to develop existing and new product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As of June 30, 2024, the Company had &#8364;10.1 million of available cash and cash equivalents, consisting of cash and short-term deposit accounts that are liquid and easily convertible within 3 months without penalty or risk of change in value (refer to Note 4.8 &#8211; <i style="font-style:italic;">Cash and Cash equivalents</i> of the section 3.2 &#8211; <i style="font-style:italic;">Interim Condensed Consolidated financial statements </i>as<i style="font-style:italic;"> of June 30, 2024</i>). In accordance with IAS 7.8, bank overdrafts which are repayable on demand are included as a component of cash and cash equivalents in the amount of &#8364;1.3 million as of June 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">As of the date of authorization of the issuance of these financial statements, given its current cost structure, its projected expenditure commitments, and the events after the reporting period presented in Note 6.4 &#8211; <i style="font-style:italic;">Events after the reporting period </i>of the section 3.2 &#8211; <i style="font-style:italic;">Interim Condensed Consolidated financial statements </i>as<i style="font-style:italic;"> of June 30, 2024</i>, mainly the issue of royalty certificates and the T1 capital increase, the Company estimates that it should have sufficient funds to finance its activities through the end of the second half of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Accordingly, as of the date of authorization of the issuance of these financial statements, the Company's current cash and cash equivalents are not expected to be sufficient to cover its operating needs for at least the next 12 months. These events and conditions indicate that an uncertainty exists that may cast significant doubt on the Company&#8217;s ability to continue as a going concern and, therefore, the Company may be unable to realize its assets and discharge its liabilities in the normal course of business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">This estimate is based on the Company&#8217;s current business plan and excludes (i) other expenses related to the potential development of odiparcil or resulting from any potential in-licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue, (ii) any potential milestone payments that may be received or paid by the Company or potential additional financing, including the issue of tranches 1bis and 2 as described in Note 6.4 &#8211; <i style="font-style:italic;">Events after the reporting period </i>of the section 3.2 &#8211; <i style="font-style:italic;">Interim Condensed Consolidated financial statements </i>as<i style="font-style:italic;"> of June 30, 2024</i>. The Company may have based this estimate on assumptions that may prove to be incorrect, and the Company may end up using its resources sooner than anticipated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Based on the above, the unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2024, have been prepared on a going concern basis assuming the Company will continue to operate for the foreseeable future. As such, they do not include any adjustments related to the amount or classification of assets and liabilities that may be required if the Company were not able to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_236c048e_825b_42d2_b22f_638bf19b6ac3"></a><a id="a3Unauditedinterimcondensedconsolidatedf"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.</b></span><b style="font-weight:bold;">Unaudited interim condensed consolidated financial statements</b></p><a id="StatutoryAuditorsReviewReportontheHalfye"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.1.</b></span><b style="font-weight:bold;">Statutory Auditors&#8217; Review Report on the Half-yearly Financial Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Statutory Auditors&#8217; Review Report on the Half-yearly Financial Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">For the period from January 1 to June 30, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">To the Shareholders,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In compliance with the assignment entrusted to us by General Annual Meeting and in accordance with the requirements of article L. 451-1-2 III of the French Monetary and Financial Code (&#8220;<i style="font-style:italic;">Code mon&#233;taire et financier</i>&#8221;), we hereby report to you on:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the review of the accompanying condensed half-yearly consolidated financial statements of Inventiva S.A., for the period from January 1 to June 30, 2024,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the verification of the information presented in the half-yearly management report.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">These condensed half-yearly consolidated financial statements are the responsibility of the Board of Directors. Our role is to express a conclusion on these financial statements based on our review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">I</b></span><b style="font-weight:bold;">Conclusion on the financial statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">We conducted our review in accordance with professional standards applicable in France. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with professional standards applicable in France and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed half-yearly consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34 - standard of the IFRSs as adopted by the European Union applicable to interim financial information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Without qualifying our conclusion, we draw your attention to the matter set out in note 3.4 to the condensed half-yearly consolidated financial statements regarding events and conditions indicating that an uncertainty exists that may cast doubt on the Company&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">II</b></span><b style="font-weight:bold;">Specific verification</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">We have also verified the information presented in the half-yearly management report on the condensed half-yearly consolidated financial statements subject to our review. We have no matters to report as to its fair presentation and consistency with the condensed half-yearly consolidated financial statements.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:48.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Paris La D&#233;fense, October 14,2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Paris, October 14, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:48.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">KPMG SA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LCA Audit</p></td></tr><tr><td style="vertical-align:bottom;width:48.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Philippe Grandclerc</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lison Dahan Chouraki</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_9155611a_9781_4f0d_bb10_1fe90dac4eea"></a><a id="InterimCondensedConsolidatedfinancialsta"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.2.</b></span><b style="font-weight:bold;">Interim Condensed Consolidated financial statement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Table of contents</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:10.8pt;"><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><div style="height:10.8pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">3.2.</b></p></div></div></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><div style="height:10.8pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">Interim Condensed Consolidated financial statement</b></p></div></div></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><div style="height:10.8pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:10.8pt;"><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><div style="height:10.8pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><div style="height:10.8pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="font-weight:bold;margin-left:0pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><div style="height:10.8pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:91.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Note1Companyinformation_347558"><span style="font-style:normal;font-weight:normal;">Note&#160;1. Company information</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:91.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#Companyinformation_789826"><span style="font-style:normal;font-weight:normal;">1.1</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#Companyinformation_789826"><span style="font-style:normal;font-weight:normal;">Company information</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#Significanteventsinthefirsthalfof2023_30"><span style="font-style:normal;font-weight:normal;">1.2</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#Significanteventsinthefirsthalfof2023_30"><span style="font-style:normal;font-weight:normal;">Significant events in the first half of 2024</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:91.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Note2Basisofpreparationandstatementofcom"><span style="font-style:normal;font-weight:normal;">Note&#160;2. Basis of preparation and statement of compliance</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">36</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:91.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a21Basisofpreparationfortheconsolidatedf"><span style="font-style:normal;font-weight:normal;">2.1.</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a21Basisofpreparationfortheconsolidatedf"><span style="font-style:normal;font-weight:normal;">Basis of preparation for the consolidated financial statements</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">36</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a22Statementofcompliance_924465"><span style="font-style:normal;font-weight:normal;">2.2.</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a22Statementofcompliance_924465"><span style="font-style:normal;font-weight:normal;">Statement of compliance</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">37</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a23Scopeandmethodofconsolidation_257208"><span style="font-style:normal;font-weight:normal;">2.3.</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a23Scopeandmethodofconsolidation_257208"><span style="font-style:normal;font-weight:normal;">Scope and method of consolidation</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">37</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a24Foreigncurrencytranslation_186469"><span style="font-style:normal;font-weight:normal;">2.4</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a24Foreigncurrencytranslation_186469"><span style="font-style:normal;font-weight:normal;">Foreign currency translation</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">38</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:91.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Note3Accountingprinciples_829015"><span style="font-style:normal;font-weight:normal;">Note&#160;3. Accounting principles</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">39</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:91.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a31Useofestimatesandjudgment_712581"><span style="font-style:normal;font-weight:normal;">3.1.</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a31Useofestimatesandjudgment_712581"><span style="font-style:normal;font-weight:normal;">Use of estimates and judgment</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">39</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a32Fairvaluemeasurement_381951"><span style="font-style:normal;font-weight:normal;">3.2.</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a32Fairvaluemeasurement_381951"><span style="font-style:normal;font-weight:normal;">Fair value measurement</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">39</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a33Specificdisclosurerequirementsforunau"><span style="font-style:normal;font-weight:normal;">3.3.</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a33Specificdisclosurerequirementsforunau"><span style="font-style:normal;font-weight:normal;">Specific disclosure requirements for unaudited interim financial statements</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">40</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a34Goingconcern_369577"><span style="font-style:normal;font-weight:normal;">3.4.</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a34Goingconcern_369577"><span style="font-style:normal;font-weight:normal;">Going concern</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">40</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:91.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Note4Notestotheinterimcondensedconsolida"><span style="font-style:normal;font-weight:normal;">Note&#160;4. Notes to the interim condensed consolidated statement of financial position</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">41</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:91.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a41Intangibleassets_687247"><span style="font-style:normal;font-weight:normal;">4.1</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a41Intangibleassets_687247"><span style="font-style:normal;font-weight:normal;">Intangible assets</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">41</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a42Propertyplantandequipment_330952"><span style="font-style:normal;font-weight:normal;">4.2</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a42Propertyplantandequipment_330952"><span style="font-style:normal;font-weight:normal;">Property, plant and equipment</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">41</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a43Deferredtaxasset_13515"><span style="font-style:normal;font-weight:normal;">4.3</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a43Deferredtaxasset_13515"><span style="font-style:normal;font-weight:normal;">Deferred tax asset</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">41</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a44Investmentsaccountedforusingtheequity"><span style="font-style:normal;font-weight:normal;">4.4</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a44Investmentsaccountedforusingtheequity"><span style="font-style:normal;font-weight:normal;">Investments accounted for using the equity method</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">41</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a45Othernoncurrentassets_102407"><span style="font-style:normal;font-weight:normal;">4.5</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a45Othernoncurrentassets_102407"><span style="font-style:normal;font-weight:normal;">Other non-current assets</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">42</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a46Inventories_58573"><span style="font-style:normal;font-weight:normal;">4.6</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a46Inventories_58573"><span style="font-style:normal;font-weight:normal;">Inventories</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">43</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a47Tradereceivablestaxreceivablesandothe"><span style="font-style:normal;font-weight:normal;">4.7</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a47Tradereceivablestaxreceivablesandothe"><span style="font-style:normal;font-weight:normal;">Trade receivables, tax receivables and other current assets</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">43</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a48Cashandcashequivalents_167227"><span style="font-style:normal;font-weight:normal;">4.8</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a48Cashandcashequivalents_167227"><span style="font-style:normal;font-weight:normal;">Cash and cash equivalents</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">44</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a49Shareholdersequity_517906"><span style="font-style:normal;font-weight:normal;">4.9</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a49Shareholdersequity_517906"><span style="font-style:normal;font-weight:normal;">Shareholders&#8217; equity</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">44</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#Financialdebt_754284"><span style="font-style:normal;font-weight:normal;">4.10</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#Financialdebt_754284"><span style="font-style:normal;font-weight:normal;">Financial debt</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">47</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a410Provisions_458607"><span style="font-style:normal;font-weight:normal;">4.11</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a410Provisions_458607"><span style="font-style:normal;font-weight:normal;">Provisions</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">51</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#Provisionsforretirementbenefitobligation"><span style="font-style:normal;font-weight:normal;">4.12</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#Provisionsforretirementbenefitobligation"><span style="font-style:normal;font-weight:normal;">Provisions for retirement benefit obligations</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">51</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a413Othercurrentandnoncurrentliabilities"><span style="font-style:normal;font-weight:normal;">4.13</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a413Othercurrentandnoncurrentliabilities"><span style="font-style:normal;font-weight:normal;">Other current and non-current liabilities</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">52</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#Tradepayablesandshorttermcontractliabili"><span style="font-style:normal;font-weight:normal;">4.14</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#Tradepayablesandshorttermcontractliabili"><span style="font-style:normal;font-weight:normal;">Trade payables and short-term contract liabilities</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">53</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a413Financialassetsandliabilities_918893"><span style="font-style:normal;font-weight:normal;">4.15</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a413Financialassetsandliabilities_918893"><span style="font-style:normal;font-weight:normal;">Financial assets and liabilities</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">54</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:91.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Note5Notestotheincomestatement_682370"><span style="font-style:normal;font-weight:normal;">Note&#160;5. Notes to the interim condensed consolidated statement of (income) loss</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">55</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:91.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a51Revenuesandotherincome_556689"><span style="font-style:normal;font-weight:normal;">5.1</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a51Revenuesandotherincome_556689"><span style="font-style:normal;font-weight:normal;">Revenues and other income</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">55</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a52Operatingexpenses_153201"><span style="font-style:normal;font-weight:normal;">5.2</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a52Operatingexpenses_153201"><span style="font-style:normal;font-weight:normal;">Operating expenses</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">56</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a53Otheroperatingincomeandexpenses_16516"><span style="font-style:normal;font-weight:normal;">5.3</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a53Otheroperatingincomeandexpenses_16516"><span style="font-style:normal;font-weight:normal;">Other operating income and expenses</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">57</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a54Financialincomeandexpenses_936320"><span style="font-style:normal;font-weight:normal;">5.4</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a54Financialincomeandexpenses_936320"><span style="font-style:normal;font-weight:normal;">Financial income and expenses</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">57</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a55ShareofnetprofitEquitymethod_315105"><span style="font-style:normal;font-weight:normal;">5.5</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a55ShareofnetprofitEquitymethod_315105"><span style="font-style:normal;font-weight:normal;">Share of net profit &#8211; Equity method</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">58</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a55Incometax_735835"><span style="font-style:normal;font-weight:normal;">5.6</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a55Incometax_735835"><span style="font-style:normal;font-weight:normal;">Income tax</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">58</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a56Basicanddilutedlosspershare_651103"><span style="font-style:normal;font-weight:normal;">5.7</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a56Basicanddilutedlosspershare_651103"><span style="font-style:normal;font-weight:normal;">Basic and diluted loss per share</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">58</p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:91.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Note6Otherfinancialinformation_416041"><span style="font-style:normal;font-weight:normal;">Note&#160;6. Other financial information</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">59</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:91.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a61Commitmentsrelatedtooperationalactivi"><span style="font-style:normal;font-weight:normal;">6.1</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a61Commitmentsrelatedtooperationalactivi"><span style="font-style:normal;font-weight:normal;">Commitments related to operational activities</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">59</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a62Relatedpartytransactions_386542"><span style="font-style:normal;font-weight:normal;">6.2.</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a62Relatedpartytransactions_386542"><span style="font-style:normal;font-weight:normal;">Related-party transactions</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">60</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#a63Financialriskmanagement_835623"><span style="font-style:normal;font-weight:normal;">6.3</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#a63Financialriskmanagement_835623"><span style="font-style:normal;font-weight:normal;">Financial risk management</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">60</p></td></tr><tr><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#EventsAftertheReportingDate_738140"><span style="font-style:normal;font-weight:normal;">6.4</span></a></p></td><td style="vertical-align:top;width:88.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 7.2pt;"><a href="#EventsAftertheReportingDate_738140"><span style="font-style:normal;font-weight:normal;">Events after the reporting date</span></a></p></td><td style="vertical-align:top;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">60</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_07196d71_cbad_4c7a_8552_22e03cd27a30"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Unaudited interim condensed consolidated statement of financial position </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="font-style:italic;">(in thousands of euros)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_f4bdc26a_88ae_4a38_bf8e_1467e9a3b7ef"></a><a id="Tc_AZngU8SfzEWLYSIn-NqZKA_1_0"></a><a id="Tc_lPIZE1DtZ0-S3YgfzxN8zg_1_2"></a><a id="Tc_dG8CNRZv0EWrvkMDyGr1AQ_1_4"></a><a id="Tc_4OmfzqWgIUaoi0e5fSgkXQ_1_6"></a><a id="Tc_gHEUEPv3aE-2qm6VsSVUHA_2_0"></a><a id="Tc_iyYrLKPh8UWgKUiPClPE2g_2_2"></a><a id="Tc_k_r9BdFMC0q3IYXfe95_6Q_3_0"></a><a id="Tc_BiBsqb8VAEGPqiM0sJ3Lag_3_2"></a><a id="Tc_y8-A72pJe0CaiMyA_cJOVw_4_0"></a><a id="Tc_sD5S0XOwwU-akS4KJsaNEg_4_2"></a><a id="Tc_UWkNgyckMUyc4Cs-8gdspg_5_0"></a><a id="Tc_WmmCfZ0kMEqRsKJrRL9zlA_5_2"></a><a id="Tc_-oM6DdLAMU-RS7kfOArpmg_6_0"></a><a id="Tc_-m6M3IeuOkOvMbq0qbkqgA_6_2"></a><a id="Tc_Wt63mzOF7E2O52WEjW9W1A_7_0"></a><a id="Tc_up1iNx6zKkyAKeT5mhFBuw_8_0"></a><a id="Tc_FVSCKWZxkUGO9viByZWF5A_8_2"></a><a id="Tc_sgQyQM4O6Ua24MeUZcTndQ_9_0"></a><a id="Tc_fcSosf6jO06LGp_i8BqPbw_9_2"></a><a id="Tc_mObCJEWyWE6qkGviA5Mwyg_10_0"></a><a id="Tc_bcia7uQTfUSib8glZT-d3w_10_2"></a><a id="Tc_RjMd90AqT0qU4MGbGnhgWQ_11_0"></a><a id="Tc_Tm89-S9Lgk2LhIxeMi68kg_11_2"></a><a id="Tc_D8Ryzt9Yrk2NkwsLYM0GAg_12_0"></a><a id="Tc__NU63dqdZkusNdPEGtIpuQ_12_2"></a><a id="Tc_AICdiWR8YkSbFQm-09iQpw_13_0"></a><a id="Tc_0dqWLPbW5UOEsGh55_46cQ_14_0"></a><a id="Tc_heeUeTsdyUmXZVcnym6BiQ_16_0"></a><a id="Tc_xqPPkiZniUWfVVLBAKOj8g_17_0"></a><a id="Tc_CHNvtqtNGka9RLaGxkuGCg_18_0"></a><a id="Tc_9x49mKOudkm6f6jkogdp0A_19_0"></a><a id="Tc_vDdR2aimLUCBOmrZ7lIrDA_20_0"></a><a id="Tc_npOTkT5yUEO1MbFQRuPANA_21_0"></a><a id="Tc_jJHTBJn_N0adjik1gykvdQ_21_2"></a><a id="Tc_G0duO-kVQk24QnSzb5v5gA_22_0"></a><a id="Tc_GZe5fh-cZkCheVQTaws1OQ_22_2"></a><a id="Tc_McXFKs6xIkmQvpPQu6CXwg_23_0"></a><a id="Tc_n5LNga2dMEuggMYif8_wdw_23_2"></a><a id="Tc_HfCM2sDLrUOfPXN8Cvq2dw_24_0"></a><a id="Tc_1tuI-AyIuUeP9zxVP4kGhg_24_2"></a><a id="Tc_CDJ_-n9BD0Wi6MfwHRTIUg_25_0"></a><a id="Tc_AUHIJmxLhUGi3eRqAI7pUw_25_2"></a><a id="Tc_MRbAbtGqAk2aLurwgFMmjw_26_0"></a><a id="Tc_seH4KoG7KE-YQfPjZUQYJQ_27_0"></a><a id="Tc_EVY6rxdVFESLX0agLsiJaQ_27_2"></a><a id="Tc_-1yj6CsGXE6A5SBRbwvr4Q_28_0"></a><a id="Tc_qy397buFRkWpMwXVXklJSA_29_0"></a><a id="Tc_5fKTLLnxI0qg8d0BRMn2mg_29_2"></a><a id="Tc_RT6RKbcuQUutPVNDAXF-1g_30_0"></a><a id="Tc_ptWf4Cuaf0C4RGDT9L5Lvg_30_2"></a><a id="Tc_h0WxZkWG50KDlDbWu7yxQQ_31_0"></a><a id="Tc_FgWJtpDH1E-bypQ6Tffi1g_31_2"></a><a id="Tc_alTQ9OQLQEeD1hXLBXHMjA_32_0"></a><a id="Tc_39kk__-JcEKVk8WyP5tANQ_32_2"></a><a id="Tc_gbAlpmYBIE23fxAkTeEyRw_33_0"></a><a id="Tc_gbURHOsDw0KMQXAXPcfGJg_34_0"></a><a id="Tc_2UZ9DjSQ5Uu3kdyMob2dfA_35_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Notes</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">4.1</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_VYxDjgD-EEW4XzmW6kxpQQ_2_4">451</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_7EJWMAnjeEmYrw7b_JJw7g_2_6">541</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">4.2</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="Tc_QfuJ5E-bck-_8F10kvGExw_3_4">7,979</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="Tc_OlTfRUur9kCSWazQL0Eoqw_3_6">9,125</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">4.3</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxAssets" scale="3" id="Tc_k0Xi2uSwkkGN8TRyVkwYBw_4_4">210</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DeferredTaxAssets" scale="3" id="Tc_rqwfu8imRUm38uCfe5Hy6w_4_6">225</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investments accounted for using the equity method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">4.4</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="3" id="Tc_6Tc0UN7dekqDHCUbMN5npw_5_4">1,131</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="3" id="Tc_qIMrebn1e0WMDqu8fXMfSg_5_6">1,425</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other non&#8209;current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">4.5</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentAssets" scale="3" id="Tc_tPJuAWt2SkaSd9pNm4xCZA_6_4">1,047</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentAssets" scale="3" id="Tc_YlSYnBGkKUat8yN8MEMSCQ_6_6">10,055</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total non</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssets" scale="3" id="Tc_KhAsZz0Lokqq4plompWg1g_7_4">10,818</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssets" scale="3" id="Tc_x6xV8IxPa0Cd6oZSWXNmvA_7_6">21,371</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">4.6</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Inventories" scale="3" id="Tc_LzgkgJWpdkarnb5aPmE6Pw_8_4">393</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Inventories" scale="3" id="Tc_lK-yTMbsC0OX21KW3xE2kA_8_6">417</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Trade receivables and others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">4.7</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentReceivables" scale="3" id="Tc_ejaE84ZELUSbnC9i6trA9w_9_4">809</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentReceivables" scale="3" id="Tc_EZRy19IMT0uW_Bobn8CB7Q_9_6">3,807</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">4.7</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxAssetsCurrent" scale="3" id="Tc_nkmvoPQyEU-C4NiqSlRf1A_10_4">2,704</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxAssetsCurrent" scale="3" id="Tc_zGUppoBQMEOxv0IwbAROgQ_10_6">5,352</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">4.7</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentAssets" scale="3" id="Tc_NI1uNpW3kkanqmxQ7mKTtA_11_4">14,554</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentAssets" scale="3" id="Tc_FdnuaTxZEEeaamnm1B2gHw_11_6">11,696</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">4.8</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_7Cr43t17JkaaZVV0MwjLmA_12_4">10,147</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_NibWOs0wt0uP15ww_sDLUg_12_6">26,918</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" scale="3" id="Tc_PlKcwJC_UEy0Ix-3NqSs7w_13_4">28,608</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" scale="3" id="Tc_SUXDrsjCZUWZr5jG6zD-CQ_13_6">48,189</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="3" id="Tc_b8yEo33S5UyNJTiTffZoWA_14_4">39,426</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="3" id="Tc_AtBaJ3IXZ0e2vsf-iaM7jA_14_6">69,561</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssuedCapital" scale="3" id="Tc_NmBm3saD8k-FQSrQa5_Evg_16_4">525</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssuedCapital" scale="3" id="Tc_aF2BvKx1ske3ZPbYpbZb9g_16_6">521</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Premiums related to share capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:SharePremium" scale="3" id="Tc_6y333sIj3Emacg5HWaEB0Q_17_4">201,859</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:SharePremium" scale="3" id="Tc_gMfTkgkOMkOCHgW7dtG-og_17_6">201,862</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="iva:RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares" sign="-" scale="3" id="Tc_Q3FF9dpLbUaMh3nofyyQ3w_18_4">232,789</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="iva:RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares" sign="-" scale="3" id="Tc_2ClFF5x1OE-IKYq4szRk2g_18_6">124,584</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Translation reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" scale="3" id="Tc_gd108Xld_06zwAv6FmgQJw_19_4">375</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ReserveOfExchangeDifferencesOnTranslation" scale="3" id="Tc_ir4QFj-KKEipa92vcqWO9w_19_6">596</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RetainedEarningsProfitLossForReportingPeriod" sign="-" scale="3" id="Tc_cZe_05rl10usSs4yg3sQ2Q_20_4">49,029</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RetainedEarningsProfitLossForReportingPeriod" sign="-" scale="3" id="Tc_wxuRaKk8ok-58JEBDK3L7A_20_6">110,426</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shareholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">4.9</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_MLyVapl2Zkqu_5_x7tiFUg_21_4">79,060</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_tDJ7KDIfcUK_xjEw3SNGDw_21_6">32,032</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">4.10</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="iva:NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities" scale="3" id="Tc_Dg0xse5ncUeJuiyou22Dtg_22_4">46,846</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="iva:NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities" scale="3" id="Tc_rnkISbaCqUeC1dQHBuo2Hg_22_6">32,181</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term debt - derivatives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">4.10</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" scale="3" id="Tc_lE9HjN0m-0mZE6Kwp350aQ_23_4">13,569</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" scale="3" id="Tc_SoiLZ4QDFEuNKVaE30RJ6A_23_6">10,265</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalty certificates liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">4.10</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="iva:NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued" scale="3" id="Tc_83YJ2PC8QkGGRAuMM_J8jA_24_4">7,263</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="iva:NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued" scale="3" id="Tc_4R4VHx1bkkeKLTXeo7fYxA_24_6">6,327</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provisions for retirement benefit obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">4.12</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentProvisionsForEmployeeBenefits" scale="3" id="Tc_4r8l8LEOD0-nx9z2BdFLLw_25_4">1,555</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentProvisionsForEmployeeBenefits" scale="3" id="Tc_w85pQw4_IESP7ju6Izd7Rg_25_6">1,559</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long&#8209;term contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentContractLiabilities" scale="3" id="Tc_R7L1nBv68UWPMeaVlmC2Eg_26_4">76</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentContractLiabilities" scale="3" id="Tc_kPlwD2K6U0eSxEJVcnWPrg_26_6">70</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">4.13</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentLiabilities" scale="3" id="Tc_4f8BvzBxf02aDzzp8PlZUw_27_4">1,032</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentLiabilities" scale="3" id="Tc_kMiL4sRwvUCZ2lUDzY45oA_27_6">1,032</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total non</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLiabilities" scale="3" id="Tc_W6ZbnwgSuU6HXjElU9koyA_28_4">70,340</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLiabilities" scale="3" id="Tc_lhaaj13IaUGtYWSNa5r_-w_28_6">51,434</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short&#8209;term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">4.10</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="iva:CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities" scale="3" id="Tc_R9nS9C4RjUiFejJBXHfQoQ_29_4">5,726</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="iva:CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities" scale="3" id="Tc_gwcA5c72C0yuZPphEH09sQ_29_6">5,308</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">4.14</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" id="Tc_6i4wsR-KIkqiopUJixjnow_30_4">36,583</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" id="Tc_nJcz6fstXkKlKx2nMG4Sqg_30_6">37,679</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Short&#8209;term contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">4.14</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentContractLiabilities" scale="3" id="Tc_zYlVa4eWq0yEei63PRD7QQ_31_4">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentContractLiabilities" scale="3" id="Tc_3324QysLS0aHoagJIJpqQQ_31_6">6</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">4.13</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="Tc_ZSHk5U6gWEKZO2Ed78POrg_32_4">5,834</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="Tc_6STPiRI0cE-jHrMYuecEBQ_32_6">7,165</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLiabilities" scale="3" id="Tc_KgoYstMkmUmQTUTfaG1kRQ_33_4">48,146</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLiabilities" scale="3" id="Tc_Hya81dVsA0eoLc835OowJA_33_6">50,158</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="3" id="Tc_WuIR_aAFVU2wRrLaevB_5Q_34_4">118,486</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="3" id="Tc_A9xBxUEtLUOLToaW9Aq1GA_34_6">101,592</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total equity and liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="3" id="Tc_kcEHhd2Sg0eXYpnfmDluuQ_35_4">39,426</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="3" id="Tc_xqc28PnwLU-fZZl3sj6NYg_35_6">69,561</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The accompanying notes form an integral part of these financial statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_9d6d3e1d_0b3b_4256_abfa_d0a55e58fd10"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Unaudited interim condensed consolidated statement of income (loss) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="font-style:italic;">(in thousands of euros)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_f8798dce_d522_4cf1_b4c6_8cb0f76bdb40"></a><a id="_9faff03e_304a_40f1_9cdf_8f9cb83b6840"></a><a id="Tc_ZOkK-b_9FE6jYliWHjVgMg_1_4"></a><a id="Tc_069gMMFacUKpFg0C-1Xy1A_2_2"></a><a id="Tc_PsYFoNM8WUC8lMLX2_JcpA_2_4"></a><a id="Tc__oQddZvypUipEIKLe4qIvQ_2_6"></a><a id="Tc_fO40HTmHN0CVs5NTr9uV4A_3_0"></a><a id="Tc_Hnher7cvvE65KZFFyrhkWw_3_2"></a><a id="Tc_ey47evmvxkeVQdpOQ9t74w_4_0"></a><a id="Tc_FXxuU6qhm0mf0pOsRAWjvQ_4_2"></a><a id="Tc_C4GlEKURfUWYdg8De9sgLA_5_0"></a><a id="Tc_-G6iGI7RuUuOUlPGAUnqGA_6_0"></a><a id="Tc_plcEjFCCqECmc8tbK7hpwQ_6_2"></a><a id="Tc_cZGWcnDL2U-yHkaITDImPg_7_0"></a><a id="Tc_ED9HMtNFYkq9uamMtbEY5w_7_2"></a><a id="Tc_Vk42OlCZJU-ajP-t1Kigvw_8_0"></a><a id="Tc_MlrO6o99e0q8TpmRnFvcuA_8_2"></a><a id="Tc_cu3FMZt1IUeKe8texZd8vg_9_0"></a><a id="Tc_lfFeKnictUqVpUbBZBqU-Q_9_2"></a><a id="Tc_JBNpB-gKG0ic_HWIUllXiw_10_0"></a><a id="Tc_beJyUiGGME6H8h0_BbYlTQ_11_0"></a><a id="Tc_QTNAdJRseUqkgRdH_p0u8A_11_2"></a><a id="Tc_02OZherLMUGQeBtwRkc0HQ_12_0"></a><a id="Tc_POUtCKDLmkyWnITGafqFUg_12_2"></a><a id="Tc_t3vkoSKaoEuYdjKC1sIMdw_13_0"></a><a id="Tc_XBIbEWuNFUu4Mm_NrS0XvA_14_0"></a><a id="Tc_W8JOoQY6wEmk-AGqXiJ7VA_14_2"></a><a id="Tc_9iLdeoJ_lkWciqvyRm7Jig_14_6"></a><a id="Tc_XbznJlimxkW4LiyUGMK_NA_15_0"></a><a id="Tc_vnH3XOXI5E-Kl_0p90yofg_15_2"></a><a id="Tc_F2vQ326peUy-T71PjBlUnA_16_0"></a><a id="Tc_TVgM5jAGRkSyqtsPaSiOmQ_17_0"></a><a id="Tc_UpQp5P9nbE2yVMkvgIe0Fg_18_0"></a><a id="Tc_kP0i0RDyMEKsg-kkpr2wBQ_18_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Notes</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">5.1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Revenue" scale="3" id="Tc_fFHML_VhbkKMkl98mMX3jA_3_4">41</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Revenue" scale="3" id="Tc_8Wtn25q7cUCxbOYlgl5RdA_3_6">1,901</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">5.1</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:OtherIncomeFromOrdinaryActivities" scale="3" id="Tc_4q1Sv-CsL0ifbW3AbQmKVA_4_4">2,693</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="iva:OtherIncomeFromOrdinaryActivities" scale="3" id="Tc_Qsv3IqnF8keytYNvKRYlrw_4_6">4,721</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues and other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueAndOperatingIncome" scale="3" id="Tc_d87MWVsQGEuPFwO1dvNW1w_5_4">2,734</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueAndOperatingIncome" scale="3" id="Tc_AtWb2xYvKkWowhuK0PfGFA_5_6">6,622</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">5.2</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" id="Tc_O6h29RBHhkKMfXnLcOq3Ow_6_4">46,822</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" id="Tc__7Kakv3Amk6FkRbAXivTUg_6_6">54,062</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketing &#8212; Business development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">5.2</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" id="Tc_3vQUQitlqEOhluyu7ZNGPg_7_4">598</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" id="Tc_3iqh4GyZk02wlCieKVIJZw_7_6">705</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">5.2</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" id="Tc_PeqQuPBTJ0uAAg3FiAif3w_8_4">7,701</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" id="Tc_J6EIga0WeUOlBvlLiLBcLA_8_6">6,812</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other operating income (expenses)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">5.3</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherOperatingIncomeExpense" scale="3" id="Tc_6CvytaKy4kqsDxOuwPkncA_9_4">138</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherOperatingIncomeExpense" sign="-" scale="3" id="Tc_0N2deoThU0aDfTwJLvUmdQ_9_6">44</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net operating loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" sign="-" scale="3" id="Tc_te-W9up0wEyPOv915m0qKQ_10_4">52,249</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" sign="-" scale="3" id="Tc_aobvZUBaUEGwEicBCYRk7Q_10_6">55,003</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financial income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">5.4</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="3" id="Tc__McHQb1Lx0eUnfbOOtW-gA_11_4">9,093</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="3" id="Tc_G6BwbAHrwEqDCNDXmYZsVA_11_6">2,373</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">5.4</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="3" id="Tc_dEWOC1Bg6kKpML3sV4i4YA_12_4">5,586</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="3" id="Tc_DZajbXz1YEWl_-eIpO5fwQ_12_6">2,646</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net financial income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncomeCost" scale="3" id="Tc_mNMV294-akiD7Stcb97uLw_13_4">3,507</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncomeCost" sign="-" scale="3" id="Tc_k8TQlg5MUUmTZ7F-NmcQEg_13_6">273</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share of net loss - Equity method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">5.5</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" sign="-" scale="3" id="Tc_CcJeL-Imyk6XdvYGPHsm-Q_14_4">168</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">5.6</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="Tc_pVj_z_8bD0is7hG7VtSDbw_15_4">119</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" sign="-" scale="3" id="Tc_YJm2Nboe3EaMhbH7mTkqcg_15_6">7</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss for the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_uFazCaAzsE-GlRnzJLndBg_16_4">49,029</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_xcw4005xLEyZSikHVDXKwg_16_6">55,269</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Basic/diluted loss per share (euros/share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Tc_7WNXPWdt10qeif166XN3Sw_17_4"><ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" scale="0" id="Tc_7WNXPWdt10qeif166XN3Sw_17_4_2">0.94</ix:nonFraction></ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Tc_3GC88Yvc10OC7z1JxejGCQ_17_6"><ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" scale="0" id="Tc_3GC88Yvc10OC7z1JxejGCQ_17_6_2">1.31</ix:nonFraction></ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average number of shares outstanding used to calculate basic/diluted loss per share </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">5.7</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageShares" scale="0" id="Tc_GbxkG1rUoUGUDNMOfYFwRA_18_4"><ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" id="Tc_GbxkG1rUoUGUDNMOfYFwRA_18_4_2">51,982,093</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageShares" scale="0" id="Tc_wX18z8y9oUiEEcMkIm923A_18_6"><ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" id="Tc_wX18z8y9oUiEEcMkIm923A_18_6_2">42,044,796</ix:nonFraction></ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The accompanying notes form an integral part of these financial statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_38fbe070_a6db_488f_8467_90c5bae4db7b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Unaudited interim condensed consolidated statement of comprehensive (income) loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="font-style:italic;">(in thousands of euros)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_092edc1b_1cd0_4ef1_abe7_5dc555abb479"></a><a id="Tc_fhka9_fUukuyGE4TJHfVWg_1_2"></a><a id="Tc_zg6Dwh2nMEeuqx2MLFCSPw_2_2"></a><a id="Tc_Zt32H1une0u7uZ3SL39TWQ_2_4"></a><a id="Tc_NOVLFjTKGkG1cAHayeu3Yw_3_0"></a><a id="Tc_q-Qe96rFckCtajKtQOxCZw_4_0"></a><a id="Tc_pmH7isvFJEWgTiRFLBkGaw_5_0"></a><a id="Tc_w4EeZBbpZ0CHxj5tomIzcQ_5_4"></a><a id="Tc_OmGzwDIY_0S6hjOCcphXxg_6_0"></a><a id="Tc_-_sDoekTw0Sst8Vjs_0PNg_7_0"></a><a id="Tc_va_wXwxFhEOLlTLC1bU-ig_8_0"></a><a id="Tc_EYkt0Su2k0KqdchZ8ap-aw_9_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss for the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_mOkZblWSTU2djOxYrYd-dQ_3_2">49,029</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_L6bC0DK99UGZcVoFnACx8g_3_4">55,269</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Items that will be reclassified subsequently to profit or loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" sign="-" scale="3" id="Tc_2BL3GkH8hEKdK5lDChP8pA_4_2">220</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" scale="3" id="Tc_fGqpe2JZoU2xHiX7CN2Tgw_4_4">104</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Currency translation differences - equity method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" sign="-" scale="3" id="Tc_pOpQFtu2gUu44oVjefep5Q_5_2">286</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Currency translation differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="Tc_T_1I5X6RXkWzYT8ptTOc4A_6_2">66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="Tc_fyTdxBpHzk6xwvQt5ytQ8g_6_4">104</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Items that will not be reclassified subsequently to profit or loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" scale="3" id="Tc_WvpDv4OkDUez8LstpclGZA_7_2">74</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" sign="-" scale="3" id="Tc_8Nb6yxjmMU-2MhGZ1EklKQ_7_4">14</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Remeasurement of defined benefit plans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" scale="3" id="Tc_ao-9qRoaoEibnwRbwmEyeg_8_2">74</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" sign="-" scale="3" id="Tc_dG4aZwrwa0OuBDtgKZZG8Q_8_4">14</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total comprehensive loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_BovdknLhtkG4tOoAHXt9Ow_9_2">49,175</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_OnlcGdOoUEmv3equ47jT2Q_9_4">55,179</ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The accompanying notes form an integral part of these financial statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_afc9ef25_73ab_408c_b011_cd089d983ac5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unaudited interim condensed consolidated statement of changes in shareholders&#8217; equity </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">(in thousands of euros)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_23b52dbd_7036_4d19_98af_232b39be436c"></a><a id="Tc_sNebmxe-NECbRJvXezzfKQ_1_6"></a><a id="Tc_9uxm0MD-ZkmXhUSaCGlDVg_1_8"></a><a id="Tc_-Ks0dR-p10G8Vwv69qh7sw_2_4"></a><a id="Tc_B8rPqRcdlUOlIjqvpB96vg_2_6"></a><a id="Tc_grNIzf8UrUmpjtW-opgvdw_2_8"></a><a id="Tc_PBTgBV9tU0aKbA6gdKqJMw_2_10"></a><a id="Tc_DpKkyK2RDECZYdPmJh6wzw_2_14"></a><a id="Tc_ONAQI60m6ke23M6albVIdA_3_2"></a><a id="Tc_Ip4Cbr0FHUSqW5QF2AokwA_3_4"></a><a id="Tc_FUjtok2BF0u5lRaSY94VJQ_3_6"></a><a id="Tc_AyaMsTEsckqm_GtrxExqGg_3_8"></a><a id="Tc_9m5zc-gDoUOL_ORuyx3C1g_3_10"></a><a id="Tc_oFNzfet5p0aYWwkp0DJWwg_3_12"></a><a id="Tc_haw65iZS5UOIM3eAHLuctQ_3_14"></a><a id="Tc_XOx5TTva50SkiawLhNA8YA_4_0"></a><a id="Tc_zlK6C01Csk--HHJ42HBYkA_5_0"></a><a id="Tc_p5cZK3uhSUWWHRaHwxDOFA_5_4"></a><a id="Tc_XvfFZ3lPWkmYpfVrrugTkA_5_6"></a><a id="Tc_ap6CTBC-PEqxOkpLK20awA_5_10"></a><a id="Tc_byhl71AuPEKqXG5CNE01Vg_5_12"></a><a id="Tc_rXFtYvBGgUmiEIiErE6E2w_6_0"></a><a id="Tc_W9WJGo-e8kueVyHrj3nWMw_6_4"></a><a id="Tc_awa7cnHFH0y3N1ulyJtZcA_6_6"></a><a id="Tc_9JhR2tIqNEStzHJuYImN7w_6_8"></a><a id="Tc_nB1vD9E7JEyKMETJC0qPJg_6_10"></a><a id="Tc_WfHmKv9EOkuCv3xP0nqWDA_7_0"></a><a id="Tc_dYHZ7IQucUqc4RrX5NUVtA_7_4"></a><a id="Tc_fN8BIhID006OfrJp5kTYUg_7_6"></a><a id="Tc_hzs5cW7nMEKeOnyHjxe_zA_7_8"></a><a id="Tc_qrIpjlWadUihRHxe2CaOWw_7_12"></a><a id="Tc_eCd16mgl0km7Elh1VL3hdA_8_0"></a><a id="Tc_IlTGBHTb1keMaWyOqy6kvg_8_4"></a><a id="Tc_pK22SMZbXUGdSe1IDZ-G8A_8_6"></a><a id="Tc_GPi9JZt6-kqaCU3hYUImsA_9_0"></a><a id="Tc_FgOeaJyKD0SLTixbh7K_8g_9_4"></a><a id="Tc_rCs2j7M6y02CfLLU-oQ72g_9_6"></a><a id="Tc_vkcxpY8eEkaNQ7LzflPaaA_9_10"></a><a id="Tc_vgLXPFbUiEqZO0fw28DhEA_9_14"></a><a id="Tc_vNZk9iLZ3km8PGzd43v-mw_10_0"></a><a id="Tc_AgbhdFiNa06rO_MppAzedw_10_2"></a><a id="Tc_7nHwhVCTDEuim3dmDDn7yQ_10_4"></a><a id="Tc_kbWoklLzp0iN5UuNBHH4Pw_10_6"></a><a id="Tc_ud5uRWdgw0ev_R52lOyP0A_10_8"></a><a id="Tc_VBMeZ3pBE0CwGVd6VoFo6Q_10_10"></a><a id="Tc_yPz1G-_0-02qjG2ld3uGfg_11_0"></a><a id="Tc_-IMLBrDGCU-nVFQ_J__nQQ_11_8"></a><a id="Tc_DjRwO6XmZ0Krun-YfSbxsQ_11_10"></a><a id="Tc_YEwIzKzYlk6AtIAxjdGMEA_12_0"></a><a id="Tc_eJ1XDo0ZYkyfl0QoKWG02g_12_4"></a><a id="Tc_6zRXuzGy5EaRBC6L8Gm-eg_12_6"></a><a id="Tc_rnr0vG7NvEOj--K3sXdXWw_12_8"></a><a id="Tc_5C5RLGlhP0inDGs_858S7w_12_10"></a><a id="Tc_wabn-9cSo0W_dRcFzFrN-g_13_0"></a><a id="Tc_Kex3uDh_4E-3So_sah02oQ_13_4"></a><a id="Tc_TZdR_tLQwEWODkOiGfFUgQ_13_6"></a><a id="Tc_-sEKqqaU5UyhTiha-RYmKQ_13_8"></a><a id="Tc_Lfv839E_Lkaop6KgUPtd0g_13_10"></a><a id="Tc_beo_K06JSUmZNb_SmKv8ig_14_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Premiums</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;<b style="font-weight:bold;">related&#160;to</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(loss) for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Translation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shareholders&#8217;</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Notes</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share&#160;capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reserves</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reserves</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">At January 1,  2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_4J3_ocxV5ka2EE64Vzyuyw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_0ulf_4FWdEi1fhQcWI5mWg_4_4">521</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_cgKVo_3CWUmvwiGobzgKyg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_rRe6ptfpAkG8K9j_04a_bQ_4_6">201,862</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember__9pAKUrAQ0enxQqBYLGv9A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_Yat_E06fRUOUnmsEIcwxww_4_8">110,426</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_nwf6v9oBck-wKZOxfPU3tw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_6lVwgyVF-0iaSAki60kgqQ_4_10">596</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_IZqZC00jTUqIta0YcIIbug" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_8HEs2h-5dkqcSiRLc_z6mw_4_12">124,584</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_7eTWYNdUM0G8THXPfwGJ0Q_4_14">32,032</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Net income (loss) for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_buEEww87HUSIzmB9VHw_tg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_XjaWyeFXNU216XGsbKjSxA_5_8">49,029</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_Zg-FWl5h4E2BbZJnsCFsRA_5_14">49,029</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:32.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Remeasurement of defined benefit plans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_dXCJhRzOSE-KI_4aE3GtUQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" scale="3" id="Tc_gIbKSOqrxkiMAE9T8ZAcEA_6_12">74</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" scale="3" id="Tc_Sb0hoGAYHkW6cPYeclOI_A_6_14">74</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Currency translation differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_7hzuZ7YABk6ls6oQfoETnw" decimals="-3" format="ixt:numdotdecimal" name="iva:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod" sign="-" scale="3" id="Tc_j8UDhib3bE2s3383MOpKSw_7_10">220</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod" sign="-" scale="3" id="Tc__LbKTpDVo0-Yilsxpw83xA_7_14">220</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:32.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Total comprehensive income (loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_buEEww87HUSIzmB9VHw_tg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_v_VbX8S1Z0e2gj0Fsx76xg_8_8">49,029</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_7hzuZ7YABk6ls6oQfoETnw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_jBYQFZk5W0KhckG8MI4EdA_8_10">220</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_dXCJhRzOSE-KI_4aE3GtUQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="3" id="Tc_jgj0iHgblEilnCesy2bkHQ_8_12">74</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_18JRxu2xc0iZQUeAGYMhWA_8_14">49,175</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Appropriation of 2023 net income (loss) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_buEEww87HUSIzmB9VHw_tg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings" scale="3" id="Tc_nS5IY_Mnq0-D-QLFrZoJ7g_9_8">110,426</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_dXCJhRzOSE-KI_4aE3GtUQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings" sign="-" scale="3" id="Tc_ohzyyCPea0qDnB-kCeE5vw_9_12">110,426</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:32.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Share-based payment compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><i style="font-style:italic;">4.9</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_dXCJhRzOSE-KI_4aE3GtUQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" id="Tc_l6cb-nxTkU-6c1zzOu4T6g_10_12">2,238</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" id="Tc_BGu88dHMHkWv5qXSvYPSoA_10_14">2,238</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">BSA share warrants subscription premium</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_EIAsynD95kCXlu8TLaft8A" decimals="-3" format="ixt:numdotdecimal" name="iva:IncreaseDecreaseThroughShareWarrantsSubscriptionPremium" scale="3" id="Tc_ebe9wcVDXkyOlXb-9iXSxw_11_4">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_7mIiNwJvsE-YWS6Oz_X7Sw" decimals="-3" format="ixt:numdotdecimal" name="iva:IncreaseDecreaseThroughShareWarrantsSubscriptionPremium" sign="-" scale="3" id="Tc_F8umWXBXKUWjuelgWwtx3Q_11_6">4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_dXCJhRzOSE-KI_4aE3GtUQ" decimals="-3" format="ixt:numdotdecimal" name="iva:IncreaseDecreaseThroughShareWarrantsSubscriptionPremium" scale="3" id="Tc_eJvJ_PcZWUyBwNkFpS0PGg_11_12">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:IncreaseDecreaseThroughShareWarrantsSubscriptionPremium" scale="3" id="Tc_dMe1q7j2eU-qWdYGk6Fb_g_11_14">6</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:32.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Treasury shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_dXCJhRzOSE-KI_4aE3GtUQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" sign="-" scale="3" id="Tc_w_iBMQ6CUkCh6Br8Dzl3Xw_12_12">138</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" sign="-" scale="3" id="Tc_liI_dw7-8EC-MbpNEwgouQ_12_14">138</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_dXCJhRzOSE-KI_4aE3GtUQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" scale="3" id="Tc_zsL14tc5BUKAgpNA9Arurw_13_12">41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" scale="3" id="Tc_haHQs6tn60et11GxfRTFFw_13_14">41</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:32.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_NJmuaXv-XEWsTA9f3Xh5nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_aLPRM5qsG0mrkzBpGGWjWQ_14_4">525</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_wKPlEEy3A0SN-8jmJn4iCw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_a-Wqv-bq8k-P8N9LDHYJ_A_14_6">201,859</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_9dAqjQ8yFEOk2IPndtMWDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_i5sFGxmkD06siSLQ4IEE8w_14_8">49,029</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_LdYbre3bB0WUz88niJNlag" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_gPnVwiBjOkWQWflFEECDdA_14_10">375</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_jiMyqJklS0yKSmn3ylKVjw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_fgvi9LqzQU6CJQdnwtu1Sw_14_12">232,789</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_RQ9G6dLq3UuEmOwVb5F5gA_14_14">79,060</ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_0d92f6a7_cc1b_4e8a_b42a_73b078607443"></a><a id="Tc_tNMxFjHk1UWujNXvkz2rPg_1_6"></a><a id="Tc_g9ZeYWvpt0SzfI2Dqn9exA_1_8"></a><a id="Tc_BfeizmH_NE-YpZwkMaDVtw_2_4"></a><a id="Tc_hrIl4FM9D0iG8A3BoH--ig_2_6"></a><a id="Tc_FQNQlb8jQESFCHG5wTGLag_2_8"></a><a id="Tc_CLQKb3jufUSbgkcJDhvHcA_2_10"></a><a id="Tc_1I8J3anOZUGCEVisQcgfEg_2_14"></a><a id="Tc_idLH25683Uu4MTSeiAqHxg_3_2"></a><a id="Tc_uBzYa1zFpki8rtpzVGUsig_3_4"></a><a id="Tc_0XQAiExbtka5NTGYyfV-Qw_3_6"></a><a id="Tc_JkG6CXLZO0WFznHOphN7yQ_3_8"></a><a id="Tc_SXrDdcL6HkyHdNtFUrYMYg_3_10"></a><a id="Tc_C4Lk8w5sjUSuyWBLJjjfXg_3_12"></a><a id="Tc_Lkan517AmU6gU9ycQwDOCQ_3_14"></a><a id="Tc_P4eZ1DIrg0a8WFwvh0Tm-w_4_0"></a><a id="Tc_wIXnKwqQxka1miPd9OfHog_5_0"></a><a id="Tc_efGOxDHrQEuhztT-yx-i2A_5_4"></a><a id="Tc_NTBgKkyp90-LaFHJrwFCCw_5_6"></a><a id="Tc_8YEii_RTH0KiPsrVhYBDZQ_5_10"></a><a id="Tc_1Sh5DsKbrEqogeLzcFpL5g_5_12"></a><a id="Tc_ZTGm_Y8jIkeiWl-ujdF6MQ_6_0"></a><a id="Tc_Rdds2AK3D0m1ah3l1zVAag_6_4"></a><a id="Tc_syZa9iNf2E2pcG_DwCn4Dg_6_6"></a><a id="Tc_gqjSaO-27UCTa55foF1-2A_6_8"></a><a id="Tc_onjlqCkD50SkPpitpRjzfA_6_10"></a><a id="Tc_BY72UvxEDkOCjEszBB7X_Q_7_0"></a><a id="Tc_yNxiZxXBEEWu6AusNUHBvg_7_4"></a><a id="Tc_MdIqLHyijUCAmgaJjq34_g_7_6"></a><a id="Tc_M_myvEtrQU24LfewgQZIrA_7_8"></a><a id="Tc_sVya0FpFqUqFLaJeW1mfuA_7_12"></a><a id="Tc_oJv7tuik20yPUMUXkzelJA_8_0"></a><a id="Tc_ZN9oM55H40SunYUzmcJiYQ_8_4"></a><a id="Tc_6EPnNSwEUkGrD6ULHsYX3A_8_6"></a><a id="Tc_RQL1Ei7CTEOvorg_mq9BhQ_9_0"></a><a id="Tc_2BEFAGK16ESUi3vBj_IkgA_9_4"></a><a id="Tc_xlyrjYBcOkWk-Y1Gz8aOZA_9_6"></a><a id="Tc_s9jRbmC5pEiy4N40ry_ZhQ_9_10"></a><a id="Tc_Xy81pVtbOkaP74WYcf0STw_9_14"></a><a id="Tc_0YJxk7rowESNKeL2MrcOZA_10_0"></a><a id="Tc_Hj_6KwAE-U6jFESNd1bJqw_10_2"></a><a id="Tc_fipJB87UfkqdEG9I0KOW2w_10_4"></a><a id="Tc_JauMHJFcikKZ38XsbqfCZQ_10_6"></a><a id="Tc_gYhotkXQq0KbuTClmSmdhg_10_8"></a><a id="Tc_9QcgPXyPjESv3uIFWYVF8Q_10_10"></a><a id="Tc_QipkJW1vvEqtEDTdY5Ytmw_11_0"></a><a id="Tc_J8fZlT0FA0mqvv6z0MFpWA_11_4"></a><a id="Tc_PW8UyHSPhUCRvLhcPTzSXg_11_6"></a><a id="Tc_j3WApIlzw0apP7gKc6k6JA_11_8"></a><a id="Tc_zgcOfOtkAUeDnYAz6dBBmQ_11_10"></a><a id="Tc_4IXN5sExcE-U8FybFaejeg_12_0"></a><a id="Tc_njaHVVUrW0i3CkEEljZ3bA_12_4"></a><a id="Tc_Mk_xKZrLz0qpW7qGZIFQ2w_12_6"></a><a id="Tc_ZgpATV27HkGtcrM5HAhpug_12_8"></a><a id="Tc_tF8tZ1KcsUuhgWCDdIUZuA_12_10"></a><a id="Tc_dehLlWmAI0Gjs8NxVfedQQ_13_0"></a><a id="Tc_Rv5IsgGq5U-StKbM4VwItQ_13_4"></a><a id="Tc_DYpctWNESEioyw-lpiklvA_13_6"></a><a id="Tc_h3_qsc7LiE2QMPOTw6qqbQ_13_8"></a><a id="Tc_XYKUobLEQEWBgJRJ5f-PGQ_13_10"></a><a id="Tc_KWvr-3qi4kObr6Tr9c3mqQ_14_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Premiums</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;<b style="font-weight:bold;">related&#160;to</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(loss) for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Translation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shareholders&#8217;</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Notes</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share&#160;capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reserves</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reserves</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">At January 1, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_0VRJS0P300WTp8zcUcUTug" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc__TlfpxNho0iDF3uSj_q_lg_4_4">421</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_fEy91Y6Yw0uMQLNC3PBBYg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_OY35qjmcWUyDpfoobI7Vdg_4_6">173,886</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_s4VMant100Wa1D_e2buNrQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_NpT3XLMZ9UeULwIakdwsMw_4_8">54,274</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_1unH-qq8aU-PC_sPZcCATg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_lGmUwZxu5EuBQcvsHDKrMQ_4_10">271</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_hBnlt8OLjkOaEtHFXq1FfQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_FeVB8U49lEmcJfQX8LtTZw_4_12">74,286</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2022__ShBeryiXEKxoX7Xx7OS6A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_L-vegZcTGEu9XfQIN_wlIg_4_14">45,476</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Net income (loss) for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_XLIDsKCJTEm0UB5CIk-Tiw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_cX0S6eAsKEW--93ePVDD-A_5_8">55,269</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_f-Rd4ZribUWyFT1Yi7N8iQ_5_14">55,269</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:32.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Remeasurement of defined benefit plans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_yfheuy_9XU2H9yN_qkSwMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" sign="-" scale="3" id="Tc_FSn156uwp0mzeuumqUM2xQ_6_12">14</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" sign="-" scale="3" id="Tc_VQFkdQDnu0iClxOSmp2u5Q_6_14">14</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Currency translation differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_SN5Ac_HGGEqXPhg8nVP1RQ" decimals="-3" format="ixt:numdotdecimal" name="iva:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod" scale="3" id="Tc_v9i26wk8WUOny-9AlQhXzA_7_10">104</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="iva:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod" scale="3" id="Tc_z4-0xkLfFkmNCqFPrVdOPA_7_14">104</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Total comprehensive income (loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_XLIDsKCJTEm0UB5CIk-Tiw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_qFFNZrQHLE6jI80mWFABag_8_8">55,269</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_SN5Ac_HGGEqXPhg8nVP1RQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="3" id="Tc_X8yOl6Ni1kao5DILF6Rwjg_8_10">104</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_yfheuy_9XU2H9yN_qkSwMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_Gfix3wNsh06pB19dzPzlVA_8_12">14</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_FNIdtXbeu0SBbAZiAEQylw_8_14">55,179</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Appropriation of 2022 net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_XLIDsKCJTEm0UB5CIk-Tiw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings" scale="3" id="Tc_EScjV5gje02wcqd1zj79bw_9_8">54,274</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_yfheuy_9XU2H9yN_qkSwMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings" sign="-" scale="3" id="Tc_0MKw0g2gkkmmOzmRpmZBSw_9_12">54,274</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Share-based payment compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><i style="font-style:italic;">4.9</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_yfheuy_9XU2H9yN_qkSwMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" id="Tc_D4cKrlI-7kqjZ64y4AnXVg_10_12">2,046</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" id="Tc_93V0TJFY9k6vpkFIsjJmaA_10_14">2,046</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">BSA share warrants subscription premium</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_yfheuy_9XU2H9yN_qkSwMA" decimals="-3" format="ixt:numdotdecimal" name="iva:IncreaseDecreaseThroughShareWarrantsSubscriptionPremium" scale="3" id="Tc_r2j_XAgpj0iEnMnJ8XUJsw_11_12">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="iva:IncreaseDecreaseThroughShareWarrantsSubscriptionPremium" scale="3" id="Tc_CIbYhwR95kC36c7zQd1E6Q_11_14">2</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Treasury shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_yfheuy_9XU2H9yN_qkSwMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" scale="3" id="Tc_nw_m7EzkqUCdhX9oDUPGFQ_12_12">10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions" scale="3" id="Tc_adbIP01UW0CdTT9Jv998CQ_12_14">10</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_yfheuy_9XU2H9yN_qkSwMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" sign="-" scale="3" id="Tc_0lc7owCxf0WyyVQELwz2kA_13_12">22</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity" sign="-" scale="3" id="Tc_ARjG_T8Ef0edMEjA8J17AQ_13_14">22</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">At June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_K1Cg_Yt_SUKODSLGGBA5mQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_NwNlgN9370CP3E7a3iq_dg_14_4">421</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_7UXPGS9t8E2u0eKxHUgg6Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_xtosC7pEzEC7sAmNfMQPPA_14_6">173,886</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_c6YRrAmJtkGBVTOn_KinpA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_1YIrRq_9NECWaQjSg0gkhg_14_8">55,269</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_M0g6jdiCfU26v1gbb-hQNA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_ARqXIWvrcUO80xKjodYLLg_14_10">168</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_oIEPc_uew0yPdBw1zj31_A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_yYHmghmzuUCotvdSenlitQ_14_12">126,537</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2023_aUv8mHsKXUaaSWrxnxqKLg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_t0nvTXDu0EShIq9NNOtabQ_14_14">7,667</ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">The accompanying notes form an integral part of these financial statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_9142d202_e221_4741_8114_de679f8a501f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Unaudited interim condensed consolidated statement of cash flows </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="font-style:italic;">(in thousands of euros)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b0bda35f_dffa_4893_8325_922bcf0ff5c5"></a><a id="Tc_5_uD_sahC0aRr5zkHtcdYw_1_2"></a><a id="Tc_hSECYZDbU0eZ6qX-1unxZQ_1_4"></a><a id="Tc_M4l0bGwGnE2LMUuP5urJ3g_2_0"></a><a id="Tc_D2EHvWa9uUORYtNgIFnmcg_3_0"></a><a id="Tc_hO_mEXi0LUS6qUV8lKXXLw_4_0"></a><a id="Tc_TIhR_4tPtUaix0Ozo1RUoQ_5_0"></a><a id="Tc_5-skaQDb-06o3cd4zpPrFA_6_0"></a><a id="Tc_KgYDEJ-4tEetuNo_45BW9w_7_0"></a><a id="Tc_kvD42ZA7jkuTO_PnRYxslQ_8_0"></a><a id="Tc_9MVOr2UuGEKQb7wpStDYWw_9_0"></a><a id="Tc_ZfLPpCu9K0-3pyrXpxsrmw_9_4"></a><a id="Tc_z2vAsTdBsEOzs6MCR6xaCg_10_0"></a><a id="Tc_cuTAPMLODkWUEIlcuU1mNQ_11_0"></a><a id="Tc_rpmRtam7P0ahAi25gBGu7A_12_0"></a><a id="Tc_FEue5Qm2u0q44lIqqiUweQ_12_2"></a><a id="Tc_X5qfnT3d_EWFmJQpd7o-nQ_13_0"></a><a id="Tc_pMNgetq8IkO5Ai5-_15rUg_14_0"></a><a id="Tc_iD09viIR6EqPyJgojxKdDA_15_0"></a><a id="Tc_0fquaA4UnE628jgK_NQqmw_16_0"></a><a id="Tc_sK-2xYvMck6QIteU489YCQ_17_0"></a><a id="Tc_vCq0Jlf-YEWj9oRylHYzmw_18_0"></a><a id="Tc_0OnOwsWCgkmYjiNtg6ZeOA_19_0"></a><a id="Tc_aYOVuc6Bu06gK5FQn-VZGQ_20_0"></a><a id="Tc_F5g3oL021ECOQmaLBbvEfQ_21_0"></a><a id="Tc_RT2Y1rOf9Ui9GEq75h0mIQ_22_0"></a><a id="Tc_Uz6BJaPPr0G8BVNJUywrTQ_23_0"></a><a id="Tc_nbnXgE9mF0a0VSDp2Sxnpw_24_0"></a><a id="Tc_zaak-YOYVku6fUsBLb24Qw_25_0"></a><a id="Tc_SPta-pTe_UmwgTspGhnMCQ_26_0"></a><a id="Tc_9zuloYyzh02JD06RlAG5fQ_27_0"></a><a id="Tc_4-M-cgmQwUqk7IAQOUZcGg_27_4"></a><a id="Tc_json5n93JEqrI5LUcF2-YA_28_0"></a><a id="Tc_Jssq1mGP6E-0HjGtiWMX9w_29_0"></a><a id="Tc_9-xEPJQ2xUGYPUPeiulQbw_30_0"></a><a id="Tc_tz-kg_uf_0eU9rc76yhalQ_32_0"></a><a id="Tc_KOFDS5TsukW9NRqFx_78vA_33_0"></a><a id="Tc_ucS7qCOt9kCmChHGn4LnZQ_34_0"></a><a id="Tc_vXm492KenUOKu5cK_Vxu3g_35_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss for the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_gPEwBQ-W8E-3JDd5-WOMZA_2_2">49,029</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_mL7jyxwY5UCGMo69XZfUUQ_2_4">55,269</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Elimination of non-cash or non-operating income and expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation, amortization and provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:AdjustmentsForDepreciationAmortisationAndProvisions" scale="3" id="Tc_oR_WmnyUjka77tOOnVk1Qg_4_2">1,878</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="iva:AdjustmentsForDepreciationAmortisationAndProvisions" scale="3" id="Tc_2-v5XxaTb0qdpBd1GplpyA_4_4">1,138</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred and current taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForIncomeTaxExpense" scale="3" id="Tc_8xNXm7rtVU-8TQ6xSBuf3g_5_2">22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForIncomeTaxExpense" sign="-" scale="3" id="Tc_8KNbBKmXHkqTmeX7PyOAuQ_5_4">35</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:AdjustmentsForTaxCredits" sign="-" scale="3" id="Tc_e4lYO5cruk610GKi6cHDkA_6_2">2,657</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="iva:AdjustmentsForTaxCredits" sign="-" scale="3" id="Tc_9GTzzh_mOEyzRPKidoXlOg_6_4">3,643</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cost of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" sign="-" scale="3" id="Tc_6tGhgq0FOkma7_Xogvbfew_7_2">5,180</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" sign="-" scale="3" id="Tc_RgE2djdRxEmDuPP8iQMm1g_7_4">1,900</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share&#8209;based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" id="Tc_ZyiOJ9sNUkGO5ICC5j7pug_8_2">2,238</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" id="Tc_3s33ApejNE6CARcSg6IiGw_8_4">2,046</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share of net profit of associates and joint ventures accounted for using the equity method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForUndistributedProfitsOfAssociates" sign="-" scale="3" id="Tc_myVqa5kqw0O-pt_-WaOmjA_9_2">8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exchange (gains) / losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" sign="-" scale="3" id="Tc_wtNx_rx6aEyb7zsV_XJg_A_10_2">73</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="3" id="Tc_Hu6nso5_X0qeyIst0l4cEQ_10_4">503</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fair value variation through profit and loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForFairValueGainsLosses" sign="-" scale="3" id="Tc_RARE1rJ1ekSDsBloSITB0A_11_2">8,506</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForFairValueGainsLosses" sign="-" scale="3" id="Tc_lD8mIx9Gu0Ck3nA-AnfB3w_11_4">1,623</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherAdjustmentsForNoncashItems" scale="3" id="Tc_TOJ4H7G7PECzsOGlNWsCIQ_12_4">18</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows used in operations before tax, interest and changes in working capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" sign="-" scale="3" id="Tc_dhT4KJQKZ0WbLn_NJaqtPw_13_2">50,939</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" sign="-" scale="3" id="Tc_OxFqnDV_f0SXinuQUCs_Ag_13_4">54,965</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Decrease / (increase) in operating and other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" scale="3" id="Tc_gHHyg550p0-3gxZvCuUMaQ_14_2">4,075</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" sign="-" scale="3" id="Tc_orwci5fQ-UqtNptnbTYQyg_14_4">2,322</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Increase / (decrease) in operating and other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" sign="-" scale="3" id="Tc_aeBd4GLUXU-sACx2WVFfQw_15_2">2,409</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" id="Tc_wPhfvMGLTEuR32OlrODryA_15_4">8,147</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Decrease / (increase) in inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="3" id="Tc_7fHgQwG9_UK3myFyonK2ig_16_2">24</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" sign="-" scale="3" id="Tc_PxlYCw6aGkqMJUjZxmwBeA_16_4">28</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Tax credit received</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" sign="-" scale="3" id="Tc_uXeETYQlKUWMo_G5R6wX4w_17_2">5,333</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" sign="-" scale="3" id="Tc_EgPiC6ksYUe3Syzql-Qk1A_17_4">5,220</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" sign="-" scale="3" id="Tc_TWUGjU3b4EOxZ-G96gQhvA_18_2">4,426</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" sign="-" scale="3" id="Tc_JOwtQ6IgC0eWFrNP-6PTMA_18_4">1,285</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Tax, interest and changes in operating working capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInWorkingCapital" sign="-" scale="3" id="Tc_KMtGp9sqi0a-bxzrxWWe_w_19_2">2,597</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInWorkingCapital" sign="-" scale="3" id="Tc_xZ1bhfjjZUGFh0VrF-05Bw_19_4">9,732</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net cash used in operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" sign="-" scale="3" id="Tc_7PDFFOvTf0avMWqae7MFKA_20_2">48,342</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" sign="-" scale="3" id="Tc_YBCg2_o2AECWFdFtl6Aj7w_20_4">45,233</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchases of property, plant and equipment and intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" scale="3" id="Tc_XE8bZa9y6Em_t__MhDiM8A_21_2">255</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="iva:PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" scale="3" id="Tc_lYD-LEAmcEGc9lYUsonxCw_21_4">230</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Disposals of property, plant and equipment and intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" scale="3" id="Tc_soX0TsZI-kW4uLzUuK9z7Q_22_2">90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="iva:ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" scale="3" id="Tc_Z3-0s-qRXUamYQ9vdo46hQ_22_4">130</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Decrease / (Increase) in short-term deposit accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" scale="3" id="Tc_mOewzsdI3UqMzQkDAgsenw_23_2">70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" scale="3" id="Tc_p0BsZsqzQkCV-aJPlSGsJQ_23_4">998</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increase / (Decrease) in other non-current financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" scale="3" id="Tc_CxSmd8Xr7EyDxhG9UYo7Ow_24_2">9,008</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" sign="-" scale="3" id="Tc_ve63TCBLrEGdMNsmTA9ImA_24_4">8,600</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net cash from (used in) investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" id="Tc_zPiVSCclI0mJnZHPOullTw_25_2">8,912</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" sign="-" scale="3" id="Tc_IxaIigaEDUmUx8HYyixroA_25_4">7,702</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Capital increase net of transaction cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:NetProceedsFromIssuingShares" scale="3" id="Tc_BGItyY-0r0W9NUR8uNVRrQ_26_2">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="iva:NetProceedsFromIssuingShares" scale="3" id="Tc_TB0CywfNZU2HUTvzctDL7g_26_4">2</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Subscription of borrowings and warrants net of transaction cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" scale="3" id="Tc_V9vGeKiTxEmcZ5RG720HQg_27_2">24,911</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Repayment of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" scale="3" id="Tc_qJeg7bb4rUKykWa38TOieQ_28_2">1,177</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" scale="3" id="Tc_qvY28Jh4MUe8ixZB319UFQ_28_4">1,448</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Repayment of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="Tc_4AKYW3laskWdX-dR38BC2Q_29_2">1,173</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="Tc_MAe8Uybsp0SBNv2z8RfpNA_29_4">707</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net cash from (used in) financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" id="Tc_iTa6uOmGpEqfMB1lwy3vMg_30_2">22,568</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" sign="-" scale="3" id="Tc_gkIfIvdzpkGkwCgIIbg8gw_30_4">2,153</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net increase (decrease) in cash and cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" sign="-" scale="3" id="Tc_KZFjmOnwh0SUcPGr2D8WNQ_32_2">16,863</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" sign="-" scale="3" id="Tc_sEzFU3wDv0Co_lTj-F6pcg_32_4">55,087</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents at beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_Nipljd7GhEKXm_9sYoaanw_33_2">26,918</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2022__ShBeryiXEKxoX7Xx7OS6A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_j9Mf_P1W50msYUSoo7VSLw_33_4">86,736</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exchange gains / (losses)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="Tc_s5hZKw4h10-uSnpByJp3_A_34_2">92</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" sign="-" scale="3" id="Tc_4XBmfdX64kqRkhlMhJpRvw_34_4">409</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net cash and cash equivalents at the end of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_PMUZU_ZuuU6NeSsMtMWExw_35_2">10,147</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2023_aUv8mHsKXUaaSWrxnxqKLg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_qClyp_QUhkWV3oDCZoMPng_35_4">31,240</ix:nonFraction></b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><ix:footnote xml:lang="en-US" id="_2aada350_c4ae_4dac_b34c_b7eaeff83c4c">Mainly include an increase in prepaid expense</ix:footnote></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:center;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The accompanying notes form an integral part of these financial statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_478a2804_987b_43b8_9410_cf787f24c610"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Notes to the unaudited interim condensed consolidated financial statements</p><a id="Note1Companyinformation_347558"></a><a id="Companyinformation_789826"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="iva:CompanyInformationTextBlock" id="Tb_NzCgCGX1ukq6tjXoJaeCxw" continuedAt="Tb_NzCgCGX1ukq6tjXoJaeCxw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;1.&#160;&#160;&#160;&#160;Company information</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.1</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Company information</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inventiva S.A. is a public limited company registered and domiciled in France. Its head office is located at 50 rue de Dijon, 21121 Daix. The consolidated &#64257;nancial statements of the company Inventiva include Inventiva S.A. and its subsidiary Inventiva Inc., created in January 2021 (the group is designated as &#8220;Inventiva&#8221; or the &#8220;Company&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inventiva&#8217;s ordinary shares have been listed on compartment B of Euronext Paris regulated market since February 2017 and Inventiva&#8217;s American Depositary Shares (&#8220;ADSs&#8221;), each representing one ordinary share, have been listed on the Nasdaq Global Market since July 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (&#8220;MASH&#8221;), also known as non-alcoholic steatohepatitis (&#8220;NASH&#8221;) and other diseases with significant unmet medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing lanifibranor for the treatment of MASH/NASH, as well as a pipeline of earlier stage programs in oncology discovery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Lanifibranor, its lead product candidate, is being developed for the treatment of patients with MASH/NASH, a chronic and progressive liver disease. In 2020, the Company announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with MASH/NASH and announced that the U.S. Food and Drug Administration ("FDA") had granted the Company the status of Breakthrough Therapy and Fast Track designation. The Company initiated the pivotal Phase III trial of lanifibranor in MASH/NASH (&#8220;NATiV3&#8221;) in the second half of 2021. In March 2024, the Company announced positive results from its Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and Type 2 Diabetes (&#8220;DT2&#8221;) (&#8220;LEGEND&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the first half of 2022, the Company faced delays in its NATiV3 trial that were primarily due to a higher than originally projected screen failure rate resulting in slower than anticipated enrollment rate. In addition, the Company experienced slower than predicted site activation, screening and enrollment due to negative impacts from the COVID-19 pandemic, mainly during the years 2020 and 2021, and the Company was unable to conduct clinical trial activities at sites originally located in Ukraine due to the war between Ukraine and Russia and made the decision to put recruitment for its NATiV3 trial in Ukraine on hold and close all sites in Russia. Global geopolitical events that continue to impact the markets (including Russia's invasion of Ukraine or the state of war between Israel and Hamas) could affect the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2023, the Company amended the protocol for the NATiV3 trial in part to potentially accelerate enrollment and identified additional sites to help compensate for the inability to use sites in Ukraine and Russia. The revised study design limits the planned duration of the trial to <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember_PRoFZMRi1kONFrYjiuvhAw" format="ixt-sec:durweek" name="iva:MaximumDurationOfClinicalTrial" id="Narr_UXmnSSXunUmsO71P5HGcVA">120</ix:nonNumeric> weeks instead of up to <ix:nonNumeric contextRef="Duration_1_1_2023_To_1_31_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember_VgrKJISxZU2hIPTccHR6Jw" format="ixt-sec:durwordsen" name="iva:MaximumDurationOfClinicalTrial" id="Narr_CrMzSDcob0mI4yK9rw1f5A">seven years</ix:nonNumeric>, reduces the number of biopsies from <ix:nonFraction unitRef="Unit_Standard_item_EtvJ8tlaoECD45kd85NcIQ" contextRef="Duration_1_1_2023_To_1_31_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember_VgrKJISxZU2hIPTccHR6Jw" decimals="INF" format="ixt-sec:numwordsen" name="iva:NumberOfBiopsiesUnderClinicalTrials" scale="0" id="Narr_9RMfx4-R90eCpH8Kaj2QZQ">three</ix:nonFraction> to <ix:nonFraction unitRef="Unit_Standard_item_EtvJ8tlaoECD45kd85NcIQ" contextRef="Duration_2_1_2024_To_2_1_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember_v79EQ1VlWE-l9YiRgeueOg" decimals="INF" format="ixt-sec:numwordsen" name="iva:NumberOfBiopsiesUnderClinicalTrials" scale="0" id="Narr_DyI9yh0bU0W7-lt7-eS_ug">two</ix:nonFraction> and included a <ix:nonNumeric contextRef="Duration_1_1_2023_To_1_31_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember_VgrKJISxZU2hIPTccHR6Jw" format="ixt-sec:durweek" name="iva:NumberOfWeeksUnderActiveTreatmentExtensionStudy" id="Narr_THAo7lT6Q0CGBYkndFU85g">48</ix:nonNumeric>-week active treatment extension study. The Company expects that the changes to the clinical development plan of lanifibranor, including plans for a new Phase III trial in patients with MASH/NASH and compensated cirrhosis, will be beneficial to the lanifibranor clinical program by reducing the number of biopsies and the trial duration, eventually offering all patients in the trial access to treatment and potentially expanding the addressable patient population beyond patients with F2 and F3 fibrosis to patients with MASH/NASH and compensated cirrhosis.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_NzCgCGX1ukq6tjXoJaeCxw_cont1" continuedAt="Tb_NzCgCGX1ukq6tjXoJaeCxw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In September 2022, the Company entered into a license and collaboration agreement with Chia Tai Tianqing Pharmaceutical Group, Co., LTD (&#8220;CTTQ&#8221;), a Sino Biopharm group company, to develop and commercialize, subject to regulatory approval, lanifibranor for the treatment of MASH/NASH and other metabolic diseases in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan (&#8220;CTTQ Territory&#8221;). In May 2023, the Company announced that CTTQ had received the Investigational New Drug (&#8220;IND&#8221;) approval from the Chinese National Medicine Products Administration (&#8220;NMPA&#8221;) allowing CTTQ to initiate the clinical development of lanifibranor in MASH/NASH in mainland China. CTTQ is participating in the ongoing NATiV3 Phase III trial and is conducting a Phase I clinical pharmacology study. In the framework of its participation in the Company&#8217;s NATiV3 Phase III global clinical trials, pursuant to the terms of the agreement, CTTQ bears all costs associated with these trials conducted in the CTTQ Territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In September 2023, the Company and Hepalys Pharma, Inc. (&#8220;Hepalys&#8221;) announced an exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea (the &#8220;Hepalys License Agreement&#8221;). Hepalys is a new company created by Catalys Pacific Fund II, LP (&#8220;Catalys&#8221;). Under the Hepalys License Agreement, the Company received a $<ix:nonFraction unitRef="Unit_Standard_USD_X6E05lIDQEullbfuSGuJCw" contextRef="As_Of_10_18_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_LicensingAgreementWithHepalysMember_rgk-qPK2CUyR7D5r7W0aMQ" decimals="-6" format="ixt:numdotdecimal" name="iva:LicenseAndCollaborationAgreementUpfrontFeeReceivable" scale="6" id="Narr_R5W5t3wzKkiiEMmxQ6eLww">10</ix:nonFraction> million upfront payment (equal to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_10_18_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_LicensingAgreementWithHepalysMember_rgk-qPK2CUyR7D5r7W0aMQ" decimals="-5" format="ixt:numdotdecimal" name="iva:LicenseAndCollaborationAgreementUpfrontFeeReceivable" scale="6" id="Narr_YHdFqEOYeUawil5vOCLyhA">9.5</ix:nonFraction> million) on October 18, 2023, and is eligible to receive up to $<ix:nonFraction unitRef="Unit_Standard_USD_X6E05lIDQEullbfuSGuJCw" contextRef="As_Of_10_18_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_LicensingAgreementWithHepalysMember_rgk-qPK2CUyR7D5r7W0aMQ" decimals="-6" format="ixt:numdotdecimal" name="iva:LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones" scale="6" id="Narr_9ZY5TXIrA0Oxg8EtOc2VtA">231</ix:nonFraction> million if certain clinical, regulatory and commercial conditions are met; in addition to tiered royalties from mid double digits to low twenties based on net sales of lanifibranor in Japan and South Korea, subject to regulatory approval. In parallel with the Hepalys License Agreement, the Company entered into an option agreement with Catalys to acquire <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_9_26_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_LicensingAgreementWithHepalysMember_srt_OwnershipAxis_iva_HepalysPharmaIncMember_rVQ3vZD64EmRdCdx3kiaUQ" decimals="2" format="ixt:numdotdecimal" name="iva:OptionToAcquireSharesInCompanyPercentage" scale="-2" id="Narr_TRIdffzg_k2bnH9NFirX6Q">30</ix:nonFraction>% of the shares of Hepalys (the &#8220;Catalys Option Agreement&#8221;). The Company exercised that option on September 26, 2023, with an effective date of October 11, 2023, at an aggregate exercise price of &#165;<ix:nonFraction unitRef="Unit_Divide_JPY_shares_y82NH3aOoUmAVzUuXy27vw" contextRef="Duration_10_11_2023_To_10_11_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_LicensingAgreementWithHepalysMember_srt_OwnershipAxis_iva_HepalysPharmaIncMember_CJxE3L2F106Ij0r9Bq2I1Q" decimals="0" format="ixt:numdotdecimal" name="iva:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare" scale="0" id="Narr_cF0eX2wZZ0-sDVH36DT2Ag">300</ix:nonFraction> (equal to &#8364;<ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="Duration_10_11_2023_To_10_11_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_LicensingAgreementWithHepalysMember_srt_OwnershipAxis_iva_HepalysPharmaIncMember_CJxE3L2F106Ij0r9Bq2I1Q" decimals="2" format="ixt:numdotdecimal" name="iva:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare" scale="0" id="Narr_b7apoOr_8kuXtC8xDXDaSg">1.90</ix:nonFraction>). Also on September 20, 2023, the Company entered into a shareholders agreement with Catalys and Hepalys (the &#8220;Catalys Shareholders Agreement&#8221;). Pursuant to the Catalys Shareholders Agreement, the Company has the option to acquire all outstanding shares of Hepalys at a pre-agreed multiple of post-money valuation and the Company has a right of first refusal if Hepalys receives an offer for the license or rights related to lanifibranor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In the first quarter of 2024, following a routine visit during the Company&#8217;s NATiV3 clinical trial of lanifibranor in MASH/NASH, a Suspected Unexpected Serious Adverse Reaction (&#8220;SUSAR&#8221;) was reported in a patient. As a result of this SUSAR, the Company decided to voluntarily pause screening and randomization to implement changes to the enrollment criteria to exclude patients diagnosed or with a predisposition to autoimmune liver or thyroid disease and more frequent liver monitoring for patients enrolled in the trial as recommended by the Data Monitoring Committee (&#8220;DMC&#8221;)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On March 7, 2024, the Company announced that screening activities had resumed in American sites under central Institutional Review Board (&#8220;IRB&#8221;). The impact of the pause on the overall timeline of the trial remains unclear, as new exclusion criteria were added, which may increase the screen failure rate, and the SUSAR, new exclusion criteria and increased liver monitoring may discourage potential trial participants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On March 18, 2024, the Company announced positive results from its LEGEND proof-of-concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and DT2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company expects the first visit of the last patient to be in the fourth quarter of 2024 and to complete randomization in the first half of 2025. Due to a delay of around 3 to 5 months in recruitment, the Company is currently targeting the first visit of the last patient for the second half of 2024 and the publication of the main results for the beginning of the second half of 2026. The publication of the topline results of the part 1 of the NATiV3 trial is targeted for the second half of 2026 (versus the beginning of the second half of 2026 as previously announced). If the results of the trial confirm sufficient clinical benefit and a continued good safety profile, the Company plans to file an application for accelerated approval in the United States and conditional authorization in the European Union for the marketing of lanifibranor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s pipeline also includes odiparcil, which it was previously developing for the treatment of patients with mucopolysaccharidosis type VI (&#8220;MPS VI&#8221;), a group of rare genetic diseases. As announced in 2020, the Company decided to focus its clinical efforts on the development of lanifibranor. Based on feedback from the FDA, the Company believes there is potential for an efficient development pathway for odiparcil for the treatment of MPS VI and it continues to review potential options to further develop odiparcil for the treatment of MPS VI, which may include pursuing or creating a partnership, license or other transaction.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup><i style="font-style:italic;"> </i>A DMC is an independent group of experts who monitor patient safety and treatment efficacy data while a clinical trial is ongoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Significanteventsinthefirsthalfof2023_30"></a><ix:continuation id="Tb_NzCgCGX1ukq6tjXoJaeCxw_cont2" continuedAt="Tb_NzCgCGX1ukq6tjXoJaeCxw_cont3"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.2</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Significant events in the first half of 2024</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Company issued </span><span style="font-style:italic;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_f6IGXbNrJUeuXFjO7KpMzA" decimals="INF" format="ixt:numdotdecimal" name="iva:NumberOfWarrantsIssued" scale="0" id="Narr_BX66aBSsz0awVCRe09JqzA">3,144,654</ix:nonFraction></span><span style="font-style:italic;font-weight:bold;"> warrants to EIB in connection with the drawdown of Tranche B (see Note 4.10 Financial debt)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 4, 2024, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_f6IGXbNrJUeuXFjO7KpMzA" decimals="INF" format="ixt:numdotdecimal" name="iva:NumberOfWarrantsIssued" scale="0" id="Narr_u5RHcyOlqkyRr_kul8-KqQ">3,144,654</ix:nonFraction> additional warrants to the European Investment Bank (&#8220;<b style="font-weight:bold;">EIB</b>&#8221;) and such warrants, the &#8220;<b style="font-weight:bold;">EIB Tranche B Warrants</b>&#8221;, in accordance with the terms of the 6<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> resolution of the combined general meeting of shareholders of January 25, 2023 and Article L.225-138 of the French Commercial Code, as a condition to the drawdown of the second tranche of &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_f6IGXbNrJUeuXFjO7KpMzA" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" scale="6" id="Narr_mWLMr0DyO0C3mOt1o2jRAA">25.0</ix:nonFraction> million (&#8220;Tranche B&#8221;) under the finance contract between the Company and EIB (&#8220;Finance Contract&#8221;). The <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_V_UnvG7OVU6Postqxl9qTw" decimals="INF" format="ixt:numdotdecimal" name="iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_zK3PkPhGAECYXMPINEKfug">3,144,654</ix:nonFraction> shares underlying the EIB Tranche B Warrants represented approximately <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_f6IGXbNrJUeuXFjO7KpMzA" decimals="4" format="ixt:numdotdecimal" name="iva:PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants" scale="-2" id="Narr_wtXU4JjM00inhpL6yizpOw">6.07</ix:nonFraction>% of the Company's then-outstanding share capital. If all the warrants issued to the EIB in connection with drawdown of the first tranche of &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lX6me24ptE-Xl7VzcNGlCA" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" scale="6" id="Narr_RKyJU4PQhkKaxyVedfE_cA">25.0</ix:nonFraction> million (&#8220;Tranche A&#8221;) under the Finance Contract (the &#8220;EIB Tranche A Warrants&#8221; and, together with the EIB Tranche B Warrants, the &#8220;EIB Warrants&#8221;) and the EIB Tranche B Warrants were exercised, the EIB would hold approximately <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_TxixfQbZCE2_vJzh9SnQSQ" decimals="3" format="ixt:numdotdecimal" name="iva:PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised" scale="-2" id="Narr_0_uH32Mhv0aZ8BQOx4bNaA">9.9</ix:nonFraction>% of the Company's share capital as of June 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">The exercise price of the EIB Tranche B Warrants is equal to &#8364;<ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_1_3_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_rb4eejdyHUKzT5ws_uabwg" decimals="2" format="ixt:numdotdecimal" name="iva:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" scale="0" id="Narr_FGR_1jos6k209YvqyVc2Qg">3.95</ix:nonFraction> and corresponds to <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_3_2024_To_1_3_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_uBe1VaT84EOT7MGXjouVfw" decimals="2" format="ixt:numdotdecimal" name="iva:ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares" scale="-2" id="Narr_taeQvGdsOUaRIUjuazNByg">95</ix:nonFraction>% of the volume-weighted average price of the Company's shares on the regulated market of Euronext Paris during the last trading session preceding the decision to issue the warrants (i.e. January 3, 2024).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">The EIB Tranche B Warrants have a maturity of <ix:nonNumeric contextRef="Duration_1_4_2024_To_1_4_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_fmkw3aWeOU-HD1uNZ91qIw" format="ixt-sec:durwordsen" name="iva:ClassOfWarrantOrRightMaturityTerm" id="Narr_11g0rKjaEkO6uf0e4HUHnQ">twelve years</ix:nonNumeric> and shall be exercisable following the earliest to occur of (i) the maturity date of Tranche A (i.e., on December 8, 2026), (ii) a change of control event, (iii) an event of default under the Finance Contract, or (iv) a repayment demand by EIB under the Finance Contract. The EIB Warrants will automatically be deemed null and void if not exercised within the <ix:nonNumeric contextRef="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_f6IGXbNrJUeuXFjO7KpMzA" format="ixt-sec:durwordsen" name="iva:WarrantsTerm" id="Narr_jLGUMcBqwUSYxjZBsbbvEw">twelve-year</ix:nonNumeric> period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">EIB has a put option which may require the Company to repurchase all or part of the unexercised EIB Tranche B Warrants then exercisable at their intrinsic value (subject to a cap equal to the amount drawn under the Finance Contract) under certain circumstances (for example, in the event of a change of control or on the maturity date of Tranche A or in the event of default). The Company (or a substitute third party) has a call option to require EIB to sell all shares and other securities of the Company, including the EIB Warrants, to the Company, subject to certain terms and conditions. In addition, the Company has a right of first refusal to buy-back all EIB Tranche B Warrants offered for sale to a third party, subject to certain terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">On the basis of the <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_f6IGXbNrJUeuXFjO7KpMzA" decimals="INF" format="ixt:numdotdecimal" name="iva:SharesIssuableUponExerciseOfWarrants" scale="0" id="Narr_8cgMukPlX02yEHniTkG78w">3,144,654</ix:nonFraction> new shares of the Company issuable upon exercise of all the EIB Tranche B Warrants at a price of &#8364;<ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_V_UnvG7OVU6Postqxl9qTw" decimals="2" format="ixt:numdotdecimal" name="iva:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" scale="0" id="Narr_Nap-LpyvS0qyvAgWHhC1wA">3.95</ix:nonFraction> per new share, the Company could potentially receive gross proceeds of up to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_f6IGXbNrJUeuXFjO7KpMzA" decimals="0" format="ixt:numdotdecimal" name="iva:MaximumGrossProceedsReceivableUponExerciseOfWarrants" scale="0" id="Narr_p5clXEh1C0GTcbQaTUPYpQ">12,421,383</ix:nonFraction>. There is no assurance that EIB will exercise any or all of the EIB Warrants or that the Company will receive any proceeds from the exercise of the warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">The exercise ratio of EIB Tranche A Warrants has been adjusted following the issue of Tranche B Tranche B Warrants. As of the date of authorization of the issuance of these financial statements, one EIB Tranche A Warrant entitles its holder to subscribe for <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_IGbGo6uT7EO_KIZuumIllA" decimals="INF" format="ixt:numdotdecimal" name="iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_cXwRhuRvGEGLMYI6mH0f3Q">1.27</ix:nonFraction> ordinary shares in the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Company draws down Tranche B of </span><span style="font-style:italic;font-weight:bold;">&#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_18_2024_To_1_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_O2DSQ9PKd0mIC5PRzMA_Qw" decimals="-5" format="ixt:numdotdecimal" name="iva:AmountInvoicedToCounterpartyForInitialPayment" scale="6" id="Narr_XQtJs7I00kqi8_kxeC6x4Q">25</ix:nonFraction></span><span style="font-style:italic;font-weight:bold;"> million under Finance Contract with EIB (see Note 4.10 Financial debt)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">On January 18, 2024, the Company drew down Tranche B of &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_18_2024_To_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_Dck8WdQ5LUKx_AFlTUOcAA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" scale="6" id="Narr_3RRmQXk_9E6PGS4JZARO8Q">25</ix:nonFraction> million under the Finance Contract with EIB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">After the drawdown of Tranche A in December 2022, the Company had an option to access further &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_18_2024_To_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_Dck8WdQ5LUKx_AFlTUOcAA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" scale="6" id="Narr_1RIYN2DQ6EGbV1muBkz61Q">25</ix:nonFraction> million tranche, Tranche B, subject to the achievement of certain conditions precedent. Following the achievement of those conditions, the Company decided to draw on Tranche B. The Company intends to use the proceeds to fund part of NATiV3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">Tranche B carries a <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_3l6sO3DqI0iZ8EqJu2kuhQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="Narr_Y03Y-ehKEEancy49DN-uqg">7</ix:nonFraction>% interest capitalized annually and repayment in fine. The repayment is due in January 2027, <ix:nonNumeric contextRef="Duration_1_18_2024_To_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_CZeedY0HkUOxo7vg14rQ7w" format="ixt-sec:durwordsen" name="iva:IfrsDebtInstrumentTerm" id="Narr_s-iAUhVJq0SM_CNRqQctzQ">three years</ix:nonNumeric> after its disbursement. The disbursement of Tranche B was subject to, among other conditions, (i) the full drawdown of Tranche A, (ii) the receipt by the Company from the date of the Finance Contract of an aggregate amount of at least &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_3l6sO3DqI0iZ8EqJu2kuhQ" decimals="-6" format="ixt:numdotdecimal" name="iva:AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments" scale="6" id="Narr_GBeMmOo_D0io952HaLVUmQ">70</ix:nonFraction> million (inclusive of the &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_T--Cv137BUS8bbvsblFtMg" decimals="-6" format="ixt:numdotdecimal" name="iva:AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments" scale="6" id="Narr_4SfIyxHpHUubQuoiEmp9Dw">18</ix:nonFraction> million that was a condition for the disbursement of Tranche A), paid either in exchange for shares of the Company, or through upfront or milestone payments, (iii) an out-licensing, partnership or royalty transaction with an upfront payment of at least &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_18_2024_To_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_CZeedY0HkUOxo7vg14rQ7w" decimals="-6" format="ixt:numdotdecimal" name="iva:MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction" scale="6" id="Narr_RJ_ahLSTx06AhODGk7dc3g">10</ix:nonFraction> million, (iv) operational criteria based on patient enrollment and number of sites activated in the Company&#8217;s NATiV3 Phase III clinical trial of lanifibranor in patients with NASH and (v) the Company issuing EIB Tranche B Warrants (see above - <i style="font-style:italic;">The Company issued </i><i style="font-style:italic;"><ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_1_18_2024_To_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_CZeedY0HkUOxo7vg14rQ7w" decimals="INF" format="ixt:numdotdecimal" name="iva:NumberOfWarrantsIssued" scale="0" id="Narr_BMSDNaVfAUm3l5T-I6eR8g">3,144,654</ix:nonFraction></i><i style="font-style:italic;"> warrants to EIB in connection with the drawdown of Tranche B</i>) in accordance with the terms and conditions of the warrant agreement entered into on July 1, 2022.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_NzCgCGX1ukq6tjXoJaeCxw_cont3" continuedAt="Tb_NzCgCGX1ukq6tjXoJaeCxw_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Tranche B of &#8364;<ix:nonFraction unitRef="Unit_Standard_USD_X6E05lIDQEullbfuSGuJCw" contextRef="As_Of_1_18_2024_u8VUV2GPAUmg3FPfMqwLIg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NotionalAmount" scale="6" id="Narr_BP7S7Bt4Sk-pwDh7Ub49zQ">25</ix:nonFraction> million was recognized as financial debt at amortized cost, which takes into account the fair value of the derivative instrument (warrants) at inception and the borrowing costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 12, 2024, the Company and EIB amended the warrant agreement to modify the rules for adjusting the exercise ratios of the EIB Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Treatment-related Suspected Unexpected Serious Adverse Reaction in the first quarter of 2024</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 15, 2024, the Company announced that an adverse event of elevated aminotransferases in liver tests was reported in a patient enrolled in the NATiV3 trial following a scheduled visit. The patient had been without clinical symptoms throughout the period of observation. This event has been assessed as a treatment-related SUSAR. Other milder cases of elevation of aminotransferases among trial participants have also been reported in the trial. The Company decided to voluntarily pause screening and randomization to implement changes to the enrollment criteria to exclude patients diagnosed or with a predisposition to autoimmune liver or thyroid disease and more frequent liver monitoring for patients enrolled in the trial as recommended by the DMC in the first quarter of 2024. Patients enrolled in the trial continued to receive treatment under the new liver monitoring schedule recommended by the DMC. This SUSAR is the first reported in all clinical trials with lanifibranor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 7, 2024, the Company received approval from the central IRB overseeing clinical research in the United States to resume screening activities in its sites. This was an important milestone as <ix:nonFraction unitRef="Unit_Standard_site_EHdbjuNCVEq0aAm2HNh22w" contextRef="As_Of_3_7_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember_nuFto-sydEusuJsG2ypBGg" decimals="INF" format="ixt:numdotdecimal" name="iva:NumberOfSitesOperatingUnderCentralIrbOverseeing" scale="0" id="Narr_DDHBRehBCkeZm3UPwCxIuQ">152</ix:nonFraction> sites of the NATiV3 clinical trial sites are operating under central IRB and have so far randomized over <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_3_7_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember_nuFto-sydEusuJsG2ypBGg" decimals="2" format="ixt:numdotdecimal" name="iva:PercentageOfPatientsRandomizedInMainCohort" scale="-2" id="Narr_4YrPC4p-6kGWdsU8zHmmBw">60</ix:nonFraction>% of the patients in the main cohort.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Due to a delay of around 3 to 5 months in recruitment, the Company is currently targeting the first visit of the last patient for the second half of 2024, to complete randomization in the first half of 2025 and the main results for the second half of 2026 (versus the beginning of the second half of 2026 as previously disclosed).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Company presented the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 18, 2024, the Company announced positive results from its LEGEND proof-of-concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The LEGEND trial was designed as a multi-center, randomized, 24-week treatment, placebo-controlled Phase II Proof-of-Concept trial to assess the safety and efficacy of lanifibranor in combination with the SGLT2 inhibitor empagliflozin for the treatment of patients with non-cirrhotic MASH/NASH and T2D. The trial was double-blind for the placebo arm and lanifibranor (<ix:nonFraction unitRef="Unit_Standard_g_TXQl02imeU2G21yIajn9zQ" contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_YgdXCEYNr0mNt92Z5wU9hQ" decimals="1" format="ixt:numdotdecimal" name="iva:DailyDoseOfLanifibranorInTrial" scale="-3" id="Narr_sR8ZniczqkGxAruAl6u-RA">800</ix:nonFraction>mg daily) arm, and open-label for the combination of lanifibranor (<ix:nonFraction unitRef="Unit_Standard_g_TXQl02imeU2G21yIajn9zQ" contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember_tSDasQf4-kCHQTZLajBCXw" decimals="1" format="ixt:numdotdecimal" name="iva:DailyDoseOfLanifibranorInTrial" scale="-3" id="Narr_zmAub5vzUUyWvCygeDDKag">800</ix:nonFraction>mg daily) and empagliflozin (<ix:nonFraction unitRef="Unit_Standard_g_TXQl02imeU2G21yIajn9zQ" contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_YgdXCEYNr0mNt92Z5wU9hQ" decimals="2" format="ixt:numdotdecimal" name="iva:DailyDoseOfEmpagliflozinInTrial" scale="-3" id="Narr_w8AJwuEL9k6O5y5Pnl7ueg">10</ix:nonFraction>mg daily) arm. The diagnosis of non-cirrhotic MASH/NASH was based on historic histology evaluation or a combination of non-invasive methods including diagnostic methods including imaging. As planned per protocol, the interim analysis was done once half of the <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_Wd7CtxBOkEO4WumvaOj3bA" decimals="INF" format="ixt:numdotdecimal" name="iva:NumberOfPatientsRandomizedClinicalTrialMainCohort" scale="0" id="Narr_obTzB_3YWEGFH78rpX_O-w">63</ix:nonFraction> planned randomized patients with MASH completed the 24-week treatment period or prematurely discontinued from treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The study achieved the primary efficacy endpoint with an absolute reduction in Hemoglobin A1c (HbA1c) of <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember_tSDasQf4-kCHQTZLajBCXw" decimals="4" format="ixt:numdotdecimal" name="iva:DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d" scale="-2" id="Narr_Yn61cN5ubEaNLZlCYYkYbQ">1.14</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_YgdXCEYNr0mNt92Z5wU9hQ" decimals="4" format="ixt:numdotdecimal" name="iva:DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d" scale="-2" id="Narr_s22I1g5DlkayTS6d6_PR3Q">1.59</ix:nonFraction>% in patients with MASH and T2D treated with lanifibranor (<ix:nonFraction unitRef="Unit_Standard_g_TXQl02imeU2G21yIajn9zQ" contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_YgdXCEYNr0mNt92Z5wU9hQ" decimals="1" format="ixt:numdotdecimal" name="iva:DailyDoseOfLanifibranorInTrial" scale="-3" id="Narr_CmOLxiuzdUqM4_bRmuaiHw">800</ix:nonFraction>mg daily) or in combination with empagliflozin (<ix:nonFraction unitRef="Unit_Standard_g_TXQl02imeU2G21yIajn9zQ" contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_YgdXCEYNr0mNt92Z5wU9hQ" decimals="2" format="ixt:numdotdecimal" name="iva:DailyDoseOfEmpagliflozinInTrial" scale="-3" id="Narr_fB7FkmI760GmVfpXX11pcg">10</ix:nonFraction>mg daily) at week 24 compared to an increase of <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_JPcx_xU0GEGgRDmKGGAdGA" decimals="4" format="ixt:numdotdecimal" name="iva:DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d" scale="-2" id="Narr_SEp0rLnRt0KBcQLtC_Zo5Q">0.26</ix:nonFraction>% observed in the placebo arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The study also demonstrated a statistically significant reduction in hepatic steatosis measured by MRI-PDFF, in patients treated with lanifibranor alone and in combination with empagliflozin, -<ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember_tSDasQf4-kCHQTZLajBCXw" decimals="2" format="ixt:numdotdecimal" name="iva:DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff" sign="-" scale="-2" id="Narr_FvlFdaOfLkGb7DKDWhgskQ">47</ix:nonFraction>% and -<ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_YgdXCEYNr0mNt92Z5wU9hQ" decimals="2" format="ixt:numdotdecimal" name="iva:DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff" sign="-" scale="-2" id="Narr_ipdcQJIQIUaOv7PrPkjfqA">38</ix:nonFraction>% respectively, compared to placebo (<ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_JPcx_xU0GEGgRDmKGGAdGA" decimals="2" format="ixt:numdotdecimal" name="iva:DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff" scale="-2" id="Narr_LNzCXTG2BEiZXe1cIPXsvg">0</ix:nonFraction>%). <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember_tSDasQf4-kCHQTZLajBCXw" decimals="2" format="ixt:numdotdecimal" name="iva:PercentageOfPatientsTreatedInTrial" scale="-2" id="Narr_9-I2AR6iu0qWBRORcsLpDA">83</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_YgdXCEYNr0mNt92Z5wU9hQ" decimals="2" format="ixt:numdotdecimal" name="iva:PercentageOfPatientsTreatedInTrial" scale="-2" id="Narr_jTXHtsNWAECOm8cthAhapw">67</ix:nonFraction>% of patients treated with lanifibranor alone or in combination with empagliflozin respectively, showed a reduction greater or equal to <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember_tSDasQf4-kCHQTZLajBCXw" decimals="2" format="ixt:numdotdecimal" name="iva:DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy" scale="-2" id="Narr_qrKRpcPivEOk_ZzFULvCNw">30</ix:nonFraction>% of their hepatic fat, compared to <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_JPcx_xU0GEGgRDmKGGAdGA" decimals="2" format="ixt:numdotdecimal" name="iva:DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy" scale="-2" id="Narr_TlSk4s7QO0m2yQ4Ush1blw">0</ix:nonFraction>% in the placebo arm. In addition, the study demonstrated a statistically significant effect on several secondary and exploratory endpoints, including liver enzymes (alanine aminotransferase (&#8220;ALT&#8221;) and aspartate aminotransferase (&#8220;AST&#8221;)), insulin resistance (HOMA-IR), HDL, and adiponectin. Markers of liver inflammation and fibrosis (corrected T1 relaxation time (cT1) assessed by LiverMultiScan&#174;) were assessed for the first time with lanifibranor and showed a significant effect with lanifibranor alone and in combination with empagliflozin.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_NzCgCGX1ukq6tjXoJaeCxw_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The study also demonstrated that patients treated with lanifibranor in combination with empagliflozin maintained a stable weight throughout the 24 weeks study, addressing the moderate, metabolically healthy, weight gain that can be observed in some patients treated with lanifibranor alone. Furthermore, these results demonstrated a significant relative reduction in the VAT/SAT ratio (visceral and subcutaneous adipose tissue) in patients treated with lanifibranor alone or in combination with empagliflozin, -<ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember_tSDasQf4-kCHQTZLajBCXw" decimals="2" format="ixt:numdotdecimal" name="iva:DemonstratedSignificantRelativeReductionInVatSatRatioInPatients" sign="-" scale="-2" id="Narr_mt6Ax8olP0GLxOHZaj7GEw">5</ix:nonFraction>% and -<ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_YgdXCEYNr0mNt92Z5wU9hQ" decimals="2" format="ixt:numdotdecimal" name="iva:DemonstratedSignificantRelativeReductionInVatSatRatioInPatients" sign="-" scale="-2" id="Narr_dCR6MQPQcEWD-9QBIAflCA">17</ix:nonFraction>% respectively, compared to an increase of <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_JPcx_xU0GEGgRDmKGGAdGA" decimals="2" format="ixt:numdotdecimal" name="iva:DemonstratedSignificantRelativeReductionInVatSatRatioInPatients" scale="-2" id="Narr_gt3SXB07sk-cwRYICbYh1w">11</ix:nonFraction>% in patients under placebo. This result reflects a shift from pro-inflammatory visceral fat towards metabolically healthy adipose tissue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The treatment with lanifibranor <ix:nonFraction unitRef="Unit_Standard_g_TXQl02imeU2G21yIajn9zQ" contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember_tSDasQf4-kCHQTZLajBCXw" decimals="1" format="ixt:numdotdecimal" name="iva:DailyDoseOfLanifibranorInTrial" scale="-3" id="Narr_vTW5h9E4aE63otm_zPz_sQ">800</ix:nonFraction>mg/daily alone and in combination with empagliflozin <ix:nonFraction unitRef="Unit_Standard_g_TXQl02imeU2G21yIajn9zQ" contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_YgdXCEYNr0mNt92Z5wU9hQ" decimals="2" format="ixt:numdotdecimal" name="iva:DailyDoseOfEmpagliflozinInTrial" scale="-3" id="Narr_bVloj9-NkUS1RPs5z1sESQ">10</ix:nonFraction>mg/daily for <ix:nonNumeric contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_YgdXCEYNr0mNt92Z5wU9hQ" format="ixt-sec:durweek" name="iva:TreatmentPeriodUnderStudy" id="Narr_gngW1OdmdUiNLBpbTrw-mg">24</ix:nonNumeric> weeks appears to be well tolerated, with no safety concerns reported.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Given that the primary endpoint of LEGEND was met, and statistically significant results were achieved on several key additional markers, the Company has decided to stop the recruitment as defined per protocol. More details on these results are expected to be presented in upcoming scientific conferences and submitted for publication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Additional results from NATIVE Phase IIb clinical trial</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 13, 2024, the Company announced the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Improvements were observed for insulin resistance (insulin levels, HOMA-IR), lipid metabolism (triglycerides, HDL-cholesterol, apolipoproteins), control of glycemia (HbA1c, fasting glucose (FG) levels), systemic inflammation (hs-CRP, ferritin), hepatic steatosis and diastolic blood pressure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 16, 2024, the Company announced the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">The DMC recommended to continue the clinical trial without further modification of the protocol, as amended immediately after learning about SUSAR, based on the pre-planned review of safety data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">The recommendation was based on the unblinded review by the DMC of safety data from more than <ix:nonFraction unitRef="Unit_Standard_item_EtvJ8tlaoECD45kd85NcIQ" contextRef="As_Of_5_16_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_VAiorYC4kkm95pO29VSpPA" decimals="INF" format="ixt:numdotdecimal" name="iva:NumberOfPatientsRandomizedForTreatment" scale="0" id="Narr_9ezjyu8H90Grh9ncQ85HQQ">900</ix:nonFraction> patients randomized in the main and exploratory cohorts, including more than <ix:nonFraction unitRef="Unit_Standard_item_EtvJ8tlaoECD45kd85NcIQ" contextRef="As_Of_5_16_2024_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_xI1dcdJgHkqTYSB3mreY5A" decimals="INF" format="ixt:numdotdecimal" name="iva:NumberOfPatientsToBeTreatedForFortyEightWeeks" scale="0" id="Narr_DL5fNX1XuUuAfKznPn74gQ">360</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_item_EtvJ8tlaoECD45kd85NcIQ" contextRef="As_Of_5_16_2024_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_xI1dcdJgHkqTYSB3mreY5A" decimals="INF" format="ixt:numdotdecimal" name="iva:NumberOfPatientsToBeTreatedForSeventyTwoWeeks" scale="0" id="Narr_cJA1JyU6i0yPaqTBAqM9hw">80</ix:nonFraction> patients that have been treated for more than <ix:nonNumeric contextRef="Duration_5_16_2024_To_5_16_2024_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember_2N4OlKpMhUqSYqUX-EXpVQ" format="ixt-sec:durweek" name="iva:TreatmentPeriodUnderStudy" id="Narr_F7YEBgqySEOf5jJaz9Mg0g">48</ix:nonNumeric> and <ix:nonNumeric contextRef="Duration_5_16_2024_To_5_16_2024_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember_VYGeDPPB2Ea8OgJWmGctxw" format="ixt-sec:durweek" name="iva:TreatmentPeriodUnderStudy" id="Narr_2gnXje66S06HQBEyqZcIzw">72</ix:nonNumeric> weeks, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The patient who experienced the adverse event of increased liver test results, which was reported as a SUSAR, had been without clinical symptoms throughout the period of observation and has fully recovered.</p></ix:continuation><a id="Note2Basisofpreparationandstatementofcom"></a><a id="a21Basisofpreparationfortheconsolidatedf"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="ifrs-full:StatementOfIFRSCompliance" id="Tb_wl6lTuITWkCcze3lc9m6pQ" continuedAt="Tb_wl6lTuITWkCcze3lc9m6pQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;2.&#160;&#160;&#160;&#160;Basis of preparation and statement of compliance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.1.</b></span>Basis of preparation for the consolidated financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has prepared these unaudited interim condensed consolidated financial statements in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;) as adopted by the European Union and IFRS Accounting Standards as issued by the International Accounting Standard Board (&#8220;IASB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These unaudited interim condensed consolidated financial statements as of June 30, 2024 were approved by the Board of Directors of the Company on 14 October, 2024.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="a22Statementofcompliance_924465"></a><a id="a23Scopeandmethodofconsolidation_257208"></a><ix:continuation id="Tb_wl6lTuITWkCcze3lc9m6pQ_cont1" continuedAt="Tb_wl6lTuITWkCcze3lc9m6pQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.2.</b></span><b style="font-weight:bold;">Statement of compliance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These unaudited interim condensed consolidated financial statements were prepared in compliance with <i style="font-style:italic;">International Accounting Standards (IAS)&#160;34 &#8212; Interim Financial Reporting</i>, which provides for the presentation of selected explanatory notes. The accompanying notes do not contain all the disclosures required for annual financial statements and should therefore be read in conjunction with the Company&#8217;s financial statements prepared in accordance with IFRS &#174;Accounting Standards, referred to as IFRS as of and for the year ended December&#160;31, 2023 except for the accounting principles described in Note 3 &#8211; <i style="font-style:italic;">Accounting principles</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IFRS Accounting Standards basis adopted</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accounting policies applied by the Company in the preparation of the unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2024, are identical to those used in the annual financial statements prepared in accordance with IFRS Accounting Standards as of and for the year ended December 31, 2023, with the exception of specific provisions for the preparation of unaudited interim condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Standards, amendments to existing standards and interpretations published by the IASB whose application has been mandatory since January 1, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The application of standards, amendments to existing standards and interpretations whose application has been mandatory since January 1, 2024 in the European Union primarily concern:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendment to IFRS 16 &#8211; Lease liability in a sale and leaseback</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendment to IAS 1 &#8211; Non-current liabilities with covenants</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendment to IAS 7 and IFRS 7 &#8211; Supplier finance arrangements</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Those amendments had no material impact on the Company&#8217;s unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2024. As of June 30, 2024, the IASB had not published any amendments that would be expected to have a material impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Standards, amendments to existing standards and interpretations published by the IASB whose application is not yet mandatory</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The new standards, interpretations and amendments to existing standards that have been published but are not yet applicable concern:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendments to IAS 21 &#8211; Lack of Exchangeability</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendment to IFRS 9 and IFRS 7 &#8211; Classification and Measurement of Financial Instruments</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">New Standard &#8211; IFRS 18 &#8211; Presentation and Disclosure in Financial Statements</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">New standard &#8211; IFRS 19 Subsidiaries without Public Accountability: Disclosures</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These new standards, interpretations and amendments are under analysis to see if there are applicable to Inventiva.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.3.</b></span><b style="font-weight:bold;">Scope and method of consolidation</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Accounting policy</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with IFRS 10 <i style="font-style:italic;">Consolidated Financial Statements</i>, an entity (subsidiary) is consolidated when it is controlled by the company (the parent). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Subsidiaries are all entities over which the Company has control. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and could affect those returns through its power to direct the activities of the entity. Subsidiaries are consolidated from the date on which control is transferred to the Company. They are deconsolidated from the date such control ceases.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_ca4a4f89_12b5_44fd_90ab_38a6bb2f8c1a"></a><a id="Tc_uc0g4HDfeUS7waYFWSJ0gA_1_4"></a><a id="Tc_Oteaai-3AUuHko1jIq8Yzg_2_2"></a><a id="Tc_-9v2WT0wtki48aYK44oPDQ_2_4"></a><a id="Tc_5ik4DsqbTUetb1HShNdFGg_3_2"></a><a id="Tc_sFZIlmrfb0ynrT5izhb0Zg_3_4"></a><a id="Tc_LZqJZZrW80eyWCZOB8Qkcw_3_6"></a><a id="Tc_vOlklDqtXEOD9eSGlmMwIg_4_0"></a><a id="Tc_Eg7TeT7IYECsh_021Blebw_4_2"></a><a id="Tc_jq5LJjrxXEuBXz1R2nQflA_4_5"></a><a id="Tc_Gc_CAsmhxEC4Sd0bcF8x1A_4_6"></a><a id="a24Foreigncurrencytranslation_186469"></a><a id="Tc_p2pHv_t0KEWcLPvFMj2zKw_1_0"></a><a id="Tc_8n0NIEKh10ainRj64iXjfg_1_2"></a><a id="Tc_EaA_VxM5oUW-9fos5_ym1Q_1_4"></a><a id="Tc_Im5fjWpyaU63L7Glflnhfg_1_6"></a><a id="Tc_0QTcbqOmgUGOcMEG9ZRdAg_2_0"></a><a id="Tc_ENteYZJIQUaq4jFU3TEolA_3_0"></a><ix:continuation id="Tb_wl6lTuITWkCcze3lc9m6pQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All intercompany transactions, balances, and unrealized gains on transactions between group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries are consistent with the policies adopted by the Company. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Consolidated entities</i></td></tr></table><div style="margin-top:12pt;"></div><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory" id="Group_aaicjSTVr02euFCtcNNjrw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024, the scope of consolidation consists of <ix:nonFraction unitRef="Unit_Standard_entity_-MmOzsDakEmzabilM8ZRiQ" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="INF" format="ixt-sec:numwordsen" name="iva:NumberOfEntitiesBeingConsolidated" scale="0" id="Narr_lGH75e-ci0is-rYCR7yuAw">two</ix:nonFraction> entities, the parent, Inventiva S.A. and its <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_iva_InventivaIncMember_y49k90Wj0kC3K8Qnf_pclA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="Narr_YwsryvAIK0O-YqkWPaPVbg">100</ix:nonFraction>% owned subsidiary, Inventiva Inc., for which <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_iva_InventivaIncMember_DGOb9XXQ8UK2Bub8zM5nQg" decimals="-3" format="ixt-sec:numwordsen" name="ifrs-full:NoncontrollingInterests" scale="3" id="Narr_qfzrG2Y9WkSlihHYnT1u7g">no</ix:nonFraction> non-controlling interest is recognized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ownership&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounting&#160;Method</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">INVENTIVA Inc.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">01/05/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_iva_InventivaIncMember_y49k90Wj0kC3K8Qnf_pclA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="Tc_iIHreCt_Kk2-nTnpCHq9yg_4_4">100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">Fully Consolidated</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Interests in associates and joint ventures</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Hepalys is incorporated and has its principal place of business in Japan. The Company&#8217;s proportion of ownership interest is </span><span style="font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_wYI-vlX-bEu9MV9dohB57g" decimals="3" format="ixt:numdotdecimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="Narr_tdrAGuEj00SbD8ZfczZscg">14.6</ix:nonFraction>%</span><span style="font-weight:normal;"> and is the same as the proportion of voting rights held. In accordance with IAS 28 </span><i style="font-style:italic;font-weight:normal;">Investments in Associates and Joint Ventures</i><span style="font-weight:normal;">, Hepalys is an associate of the Company and is accounted for using the equity method (see Note 4.4. &#8211; </span><i style="font-style:italic;font-weight:normal;">Investments accounted for using the equity method</i><span style="font-weight:normal;">).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.4</b></span>Foreign currency translation</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Functional and presentation currency</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s consolidated financial statements are presented in euros, which is also the functional currency of the parent company, Inventiva S.A. The functional currency of Inventiva Inc. is the U.S. dollar. All amounts presented in these notes to the consolidated financial statements are denominated in euros unless otherwise stated.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Translation of financial statements into presentation currency</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The results and financial position of foreign operations that have a functional currency different from the presentation currency are translated into euros, the presentation currency, as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Assets and liabilities for each balance sheet presented are translated at the closing rate on the date of that balance sheet, </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Income and expenses for each statement of (income) loss and statement of comprehensive (income) loss are translated at average exchange rates (which is an approximate value of the exchange rate on the transaction date in the absence of significant fluctuations. Income and expenses are translated at the transaction dates if the exchange rates fluctuate significantly), and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All resulting exchange differences are recognized in other comprehensive income.</span></td></tr></table><div style="margin-top:10pt;"></div><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" id="Tb_tXtJEeMcaEu0B6IrmvV0mw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Exchange rate (USD per EUR)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;June 30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Average exchange rate for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_USD_sLQkfMeGDkaNmYTZmSqm9Q" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="Tc_LoRCxZjIY0aAN1lXD-8n2g_2_2">1.0813</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_EUR_wuIAVjvD9UylZ02vyQPaBQ" contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="Tc_G7NfV0ZiKk209RSl2ZTDcA_2_4">1.0803</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_USD_sLQkfMeGDkaNmYTZmSqm9Q" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="Tc_ptOR1MoCNEigYLfJ_6_6iw_2_6">1.0807</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Exchange rate at period end</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_USD_sLQkfMeGDkaNmYTZmSqm9Q" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="Tc_pbQbPwy8VUG75mM4eKxOkg_3_2">1.0705</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_EUR_wuIAVjvD9UylZ02vyQPaBQ" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="Tc_iwMvRgdKiES85Ttp1CsrgA_3_4">1.1050</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_USD_sLQkfMeGDkaNmYTZmSqm9Q" contextRef="As_Of_6_30_2023_aUv8mHsKXUaaSWrxnxqKLg" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="Tc_Bx6ZSPI4AkSz9NZudXz-2g_3_6">1.0866</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Note3Accountingprinciples_829015"></a><a id="a31Useofestimatesandjudgment_712581"></a><a id="a32Fairvaluemeasurement_381951"></a><a id="Tc_5Bp7boPsZ0aPazjw6GTYKA_1_0"></a><a id="Tc_2VDOQ_QQ8Uei_WRfxOwvNw_1_2"></a><a id="Tc_89TbpQlB8Eegx6RcHxDOLw_1_4"></a><a id="Tc_6BvK6DwXtUi3IReNLt5DbQ_1_6"></a><a id="Tc_1y-nRwULHUmvphOXk5DceQ_2_0"></a><a id="Tc_f-VznCkYZEyt0nnt4PBa-A_3_0"></a><a id="Tc_vhULcu8HgEWhrlPHF22MLg_3_2"></a><a id="Tc_6dCdz_qymUuNIE2S9bNCmQ_3_4"></a><a id="Tc_aZBoHxauaUuzlCwzP8zRNA_4_0"></a><a id="Tc_qrxlRt-ZhEiBq4mPiS4zLA_4_2"></a><a id="Tc_VTjc5lWUtU68JRRd8DoyLA_4_4"></a><a id="Tc_0YrnMIszQ0i4ug9fNRj1MA_1_0"></a><a id="Tc_9fq2eVs5o0OdhE1YTKcEug_1_2"></a><a id="Tc_qGx0q1g97EWypEnGifiLdg_1_4"></a><a id="Tc_S5QdfRKutUqEAXxZuha3yw_1_6"></a><a id="Tc__ioNyW4AJ0af8imbDlE__g_2_0"></a><a id="Tc_sv0RO0fuak6gsRvQidYxUg_3_0"></a><a id="Tc_p8o-J_Aj5UaDjYtbSh4xtA_3_2"></a><a id="Tc_JSKrvR0WmkSnQO5x3Dm7pw_3_4"></a><a id="Tc_NHWPLe60ZECFYCVTY-mXVg_4_0"></a><a id="Tc_HEJrFmiXkUW0azPc4p_vig_4_2"></a><a id="Tc_zGOHBfEG4kyznpBAWzYRgA_4_4"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory" id="Tb_fdhQOKqhzka8-K0dOCWaeA" continuedAt="Tb_fdhQOKqhzka8-K0dOCWaeA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;3.&#160;&#160;&#160;&#160;Accounting principles</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory" id="Tb_1JmMGE1Q9kSNtiejogZjSg" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">3.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Use of estimates and judgment</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements requires management to make judgments and estimates and apply assumptions that can affect the carrying amounts of assets, liabilities, income and expenses, as well as the information presented in the accompanying notes. Actual reported values may differ from the accounting estimates made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There have been no significant changes in the material judgments and main estimates used by management when applying the Company&#8217;s accounting policies in the preparation of these unaudited interim condensed consolidated financial statements from those described in the annual financial statements prepared in accordance with IFRS Accounting Standards for the year ended December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The conflict in Ukraine and the state of war between Israel and Hamas have not led to any material changes in the estimates or judgements made by management in the preparation of the Company&#8217;s unaudited interim condensed consolidated financial statements.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" id="Tb_oo5QTdlkoEeCpQqvaSjyaA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.2.</b></span>Fair value measurement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the table below, financial instruments are measured at fair value according to a hierarchy comprising three levels of valuation inputs:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2: Inputs other than quoted market prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3: Unobservable inputs for the asset or liability.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The table below presents the financial assets and liabilities of the Company measured at fair value as of June 30, 2024:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory" id="Group_HUDtZb43Ak-2XJ3ICTk7Ew" continuedAt="Group_HUDtZb43Ak-2XJ3ICTk7Ew_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">At June 30, 2024 (in thousands of euros)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Financial liabilities at fair value through profit or loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term financial debt - derivatives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_1QUlLx6Y0E-OzYbHdIU-FQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_uy3oGQpfmUqgGdwUTCDAVQ_3_6">13,569</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_EnC60jgh0EOHmRak6HvHFw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_sDiecUlygkiVT-pmbqzkfQ_4_6">13,569</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The table below presents the financial assets and liabilities of the Company measured at fair value as of December 31, 2023:</p><ix:continuation id="Group_HUDtZb43Ak-2XJ3ICTk7Ew_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">At December 31, 2023 (in thousands of euros)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Financial liabilities at fair value through profit or loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term financial debt &#8211; derivatives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_sO3Ilng9LUyGbmS3dP5aqw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_JQYBuW51bE2p2dH1pGAP-w_3_6">10,265</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_iiyUwIL1okucU3luLH42uQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_LOPCVVztt0uJF4duEy7kaw_4_6">10,265</ix:nonFraction></b></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="a33Specificdisclosurerequirementsforunau"></a><a id="a34Goingconcern_369577"></a><ix:continuation id="Tb_fdhQOKqhzka8-K0dOCWaeA_cont1" continuedAt="Tb_fdhQOKqhzka8-K0dOCWaeA_cont2"><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="iva:DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock" id="Tb_PcT3YiGdt0eQPhM-MQgtww" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.3.</b></span>Specific disclosure requirements for unaudited interim financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Seasonality of operations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s operations are not subject to material seasonal fluctuations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Income tax</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Income tax is recognized in the financial statements for each interim period. The amount corresponds to a best estimate calculated by applying the expected weighted average tax rate for the entire year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The income tax amount recorded as due for an interim period may have to be adjusted in the subsequent interim period of the same year if the estimated annual average tax rate changes.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="ifrs-full:DisclosureOfGoingConcernExplanatory" id="Tb_GJ7QH64HuUmbRIDhCOFWjw" continuedAt="Tb_GJ7QH64HuUmbRIDhCOFWjw_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">3.4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Going concern</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From inception, the Company has financed its growth through successive capital increases, debt, collaboration and license agreements and reimbursements of CIR receivables. The Company continues to pursue its research and development activities for its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has incurred operating losses and negative cash flows from operations since inception due to the innovative nature of the product candidates it is developing, which necessitates a research and development phase spanning several years. The Company does not expect to generate revenue from product sales in the near future. With the biopharmaceutical industry's product development phases requiring increasing investments, the Company's financing needs will continue to grow as clinical trials of the Company's drug candidates progress and the Company invests to develop existing and new product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024, the Company had &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="6" id="Narr_x_m-sVbvVEOw_8P9nGXlZA">10.1</ix:nonFraction> million of available cash and cash equivalents, consisting of cash and short-term deposit accounts that are liquid and easily convertible within 3 months without penalty or risk of change in value (refer to Note 4.8 &#8211; <i style="font-style:italic;">Cash and Cash equivalents</i>). In accordance with IAS 7.8, bank overdrafts which are repayable on demand are included as a component of cash and cash equivalents in the amount of &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="Narr_e94Mr5jXUEaJmTDpS2SXlg">1.3</ix:nonFraction> million as of June 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of the date of authorization of the issuance of these financial statements, given its current cost structure, its projected expenditure commitments, and the events after the reporting period presented in Note 6.4 - <i style="font-style:italic;">Events after the reporting period</i>, mainly the issue of royalty certificates and the T1 capital increase, the Company estimates that it should have sufficient funds to finance its activities through the end of the second half of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accordingly, as of the date of authorization of the issuance of these financial statements, the Company's current cash and cash equivalents are not expected to be sufficient to cover its operating needs for at least the next 12 months. These events and conditions indicate that an uncertainty exists that may cast significant doubt on the Company&#8217;s ability to continue as a going concern and, therefore, the Company may be unable to realize its assets and discharge its liabilities in the normal course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This estimate is based on the Company&#8217;s current business plan and excludes (i) other expenses related to the potential development of odiparcil or resulting from any potential in-licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue, (ii) any potential milestone payments that may be received or paid by the Company or potential additional financing, including the issue of tranches 1bis and 2 as described in Note 6.4 &#8211; <i style="font-style:italic;">Events after the reporting period</i>. The Company may have based this estimate on assumptions that may prove to be incorrect, and the Company may end up using its resources sooner than anticipated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Based on the above, the unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2024, have been prepared on a going concern basis assuming the Company will continue to operate for the foreseeable future. As such, they do not include any adjustments related to the amount or classification of assets and liabilities that may be required if the Company were not able to continue as a going concern.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_fdhQOKqhzka8-K0dOCWaeA_cont2"><ix:continuation id="Tb_GJ7QH64HuUmbRIDhCOFWjw_cont1"></ix:continuation></ix:continuation><a id="Note4Notestotheinterimcondensedconsolida"></a><a id="a41Intangibleassets_687247"></a><a id="Tc_2JiYVwtOfEWouJ4APBkZnw_1_0"></a><a id="Tc_GW92pcBT_Emeb0UAeGmDVQ_1_2"></a><a id="Tc_FN--cEYA_kyMFs_eGyWJAA_1_4"></a><a id="Tc_raPjaedZZ0ajfXk7OOkO7w_2_0"></a><a id="Tc_zMKyQFh-J0OZ8P8FpZHUgA_3_0"></a><a id="Tc_nTuqh8j5Hk-A--hBQZPX8Q_4_0"></a><a id="a42Propertyplantandequipment_330952"></a><a id="Tc_atDXdHOFOESPXN5jo6aBaA_1_0"></a><a id="Tc_Sya4cNflEkCLsiwofmWl4w_1_2"></a><a id="Tc_B8GoS8vzx0KlDL6uvaIWLQ_1_4"></a><a id="Tc_PPSFCUHP1Um3PTiftuKGxQ_2_0"></a><a id="Tc_ZF4keOVGbkGgoYF-10JMxw_3_0"></a><a id="Tc_wacs4TrpI0mnqAjaFWcFbw_4_0"></a><a id="a43Deferredtaxasset_13515"></a><a id="a44Investmentsaccountedforusingtheequity"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock" id="Tb_W2fxsSQu5Uq8FHoj32PADQ" continuedAt="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;4.&#160;&#160;&#160;&#160;<b style="color:#212529;font-weight:bold;">Notes to the interim condensed consolidated statement of financial position</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.1</b></span>Intangible assets</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" id="Tb_2NY3KSucI0mePNy2tlOwfQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_SNcEwTle60O3eQH3YNWEsw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_fKFKYY7HGEexsJAaiPo5XA_2_2">3,947</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_na6RZmuG5U2D4vmO3x7mnw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_lZobkBjLyEKEtWr4sn5y0w_2_4">3,926</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_gFqLBMPU_kmKcAPYZiVbAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" sign="-" scale="3" id="Tc_TX6wl-A0R0Wm3oAVes_xYQ_3_2">3,496</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_OjiU0SQcREq22dnbIpV6fg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" sign="-" scale="3" id="Tc_LPvcFUdOREG_7KfbuTF3ig_3_4">3,384</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Intangible assets, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_oh59QuCz4ESJJGH31Zkdog_4_2">451</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_CwEKEGa6aUeMyGo4No6lWw_4_4">541</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.2</b></span>Property, plant and equipment</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" id="Group_KqSUeLmZXkq_ApI9xYNIJw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, plant and equipment, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_mbEhqIy-C0eGw1aDWsHwyA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="Tc_sEHXG0Rc10yJp_G9aq5ywA_2_2">20,376</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_2B9cJfzZu0-9iYr6nqkzSg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="Tc_hXlL-Yupp0S-3136gIzyYg_2_4">19,840</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation and impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_gFqLBMPU_kmKcAPYZiVbAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" sign="-" scale="3" id="Tc_OkHHw27hDE2hUm55ITKwhg_3_2">12,396</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_OjiU0SQcREq22dnbIpV6fg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" sign="-" scale="3" id="Tc_FUlKrpZpjU2a56B87DuDxA_3_4">10,714</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Property, plant and equipment, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets" scale="3" id="Tc_fMqWwGT8B0msKp2GOths_w_4_2">7,979</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_9rDgFmQBEUmZjQqm7DwPdg;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> 9,126</b></span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of June 30, 2024, the gross value of property, plant and equipment increased by &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:ChangesInPropertyPlantAndEquipment" scale="6" id="Narr_NXX3WXMMsECG7C8sA3FPMQ">0.5</ix:nonFraction> million mainly due to the recognition of the right of use related to the Fibroscans lease agreement for &#160;&#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_iva_FibroscanMachinesMember_HHDa7KgacE6IN6Bk1COxoQ" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:AdditionsToRightofuseAssets" scale="6" id="Narr_Ms3byD0zbkeZKvIStyTYVA">0.4</ix:nonFraction> million. Depreciation and impairment increased by &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_uKuO3UuYNECV4Eoeqzpd4g" decimals="-5" format="ixt:numdotdecimal" name="iva:IncreasesInPropertyPlantAndEquipment" scale="6" id="Narr_qAfeGmM4Vk-nq3t7tS0-1g">1.7</ix:nonFraction> million mainly due to the depreciation of &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_RightofuseAssetsMember_PXbF8eDw90i06AiOGDMO3g" decimals="-5" format="ixt:numdotdecimal" name="iva:IncreasesInPropertyPlantAndEquipment" scale="6" id="Narr_LIpPkslCr0iHdMPWeLAYrw">1.2</ix:nonFraction> million of the right of use and &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_iva_FibroscanMachinesMember_HHDa7KgacE6IN6Bk1COxoQ" decimals="-5" format="ixt:numdotdecimal" name="iva:IncreasesInPropertyPlantAndEquipment" scale="6" id="Narr_WUP1YY_p-kG8lUEyd_EBSw">0.3</ix:nonFraction> million due to an impairment of the right of use related to Fibroscan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.3</b></span>Deferred tax asset</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inventiva S.A. and Inventiva Inc. are taxed as two separate entities and cannot apply the tax consolidation. For each entity, the deferred tax assets and deferred tax liabilities are offset in the consolidated financial statements. Deferred tax assets are recognized only when an entity has sufficient evidence that it will have a sufficient taxable benefit available to use the unused tax losses in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As recovery of these losses in future periods is considered unlikely due to the uncertainty inherent to the Inventiva S.A.&#8217;s activity, deferred tax assets were recognized on this basis on June 30, 2024 only for Inventiva Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.4</b></span>Investments accounted for using the equity method</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inventiva became an equity shareholder in Hepalys with the acquisition of <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_10_11_2023_To_10_11_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_0ACGkUM49U6-A_OhxFep5w" decimals="INF" format="ixt:numdotdecimal" name="iva:NumberOfSharesAcquiredInAssociate" scale="0" id="Narr_AEWpPVR-uUWf_Z7bxw6QHQ">1,500,000</ix:nonFraction> ordinary shares on October 11, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 15, 2024, Hepalys&#8217;s shareholders approved a capital increase of &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_15_2024_To_1_15_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_9LZhfVa98kGYF3dksXsUBw" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="6" id="Narr_crGglUzZp02wmI6w415XyA">1.6</ix:nonFraction> million by issuing new shares to a new investor, NVCC. Inventiva opted not to participate in this capital increase. Consequently, the Company&#8217;s ownership in Hepalys was diluted to <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_15_2024_To_1_15_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_9LZhfVa98kGYF3dksXsUBw" decimals="3" format="ixt:numdotdecimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="Narr_BIeEhJJpvUam05LITWkiZQ">14.6</ix:nonFraction>%. As of June 30, 2024, the Company holds <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ" decimals="3" format="ixt:numdotdecimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="Narr_y9FdSpKCU0qAcpzTRKHKGA">14.6</ix:nonFraction>% of Hepalys's shares, down from <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_I0kItXo1cEqfFv1DgQ0yfA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="Narr_7SoQXB3QvUy4coagEHK3Hg">15</ix:nonFraction>% ownership as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company analyzed its ownership of Hepalys and concluded that, as of June 30, 2024, it has a significant influence but not control or joint control of Hepalys. The significant influence is reflected through the ownership of percentage of interests held, the percentage of potential voting rights owned by the Company including the option, under the Catalys Shareholders Agreement, to acquire all outstanding shares of Hepalys at a pre-agreed multiple of post-money valuation that was exercisable as at June 30, 2024, as well as the active participation in the business of Hepalys in the framework of the Hepalys License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The investment in Hepalys is accounted for using the equity method of accounting as of June 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The tables below provide the summarized statement of financial position of Hepalys. The disclosed information reflects the amounts presented in the financial statements of Hepalys and not the Company's share of those amounts. They have been amended to reflect adjustments made by the Company when using the equity method, in this case fair value adjustments. The tables below provide also the </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_Fs5ppgR0WkWR3-bc_556eg_1_0"></a><a id="Tc_DoHMMLs_dUSlEDwYcueSYQ_1_2"></a><a id="Tc_L_FHiZOjEUC3HJFoAmtZ8A_1_4"></a><a id="Tc_jG62YFWjbUyXqQeuUVPCng_2_0"></a><a id="Tc_acD80hZQ40CuUGCmlg-gPQ_3_0"></a><a id="Tc_SA9FB4nxAUmSklR1BYfEtQ_4_0"></a><a id="Tc_TS4ORvNyVEGDLiBfb9HlbQ_5_0"></a><a id="Tc_Q56V4no86k2tb5FvuaBFsg_6_0"></a><a id="Tc_nYksVN63t0i70oTTSFycgw_7_0"></a><a id="Tc_YyF9GrE0sE-d93WpozRQQA_8_0"></a><a id="Tc_cXMb3_2Y6U-EQXnlLlAp4g_10_0"></a><a id="Tc_Pbu2lgkQd0mprYGhtlsAkg_11_0"></a><a id="Tc_blMiHpi4AEaBiFj5E9tTEA_12_0"></a><a id="Tc_jIbKi6lU5kCZe7Oa-pxlLQ_12_4"></a><a id="Tc_7jgzNEM2w0aQeHzFjyb9ug_13_0"></a><a id="Tc_W8y-Rhs420ugHymrEIuZJw_14_0"></a><a id="Tc_ODPNQXB7a0uD0HEds5K3iA_15_0"></a><a id="Tc_gJwW8Yf8CEeZ3UMdYegRAg_15_2"></a><a id="Tc_Sw4up8E2rEyCSej2e_dDYA_16_0"></a><a id="Tc_W_G4WaGbaEi6bXeCZ575Vg_17_0"></a><a id="Tc_AJ9CRqtvQ0SeitAIXhMO8w_17_2"></a><a id="Tc_O5zO1aY4Z0u72stneD3gjw_17_4"></a><a id="Tc_dwqjLcIoIkK6iz4HtPQOnw_18_0"></a><a id="Tc_ql9LxlWmxkyNuW9pfFkVtw_19_0"></a><a id="Tc_3ZZVTPfjjkuQKApoVycHDQ_20_0"></a><a id="Tc_CJs0W0YW40yVRYWEUVbhbw_21_0"></a><a id="Tc_UlvnBHEiJEeghSHofaiRMA_23_0"></a><a id="Tc_8gg-usUAxEGiU_dJJ3fhDw_24_0"></a><a id="Tc_oGfjM0Vjg0eCQzW5VsC_JA_25_0"></a><a id="Tc_Nya-dv72gE69EHwGiJimOg_26_0"></a><a id="Tc_xuwjSiMglEGoQ2_k4eCRQw_27_0"></a><a id="Tc_cvaheuv8-Uucefo8WXgx-Q_29_0"></a><a id="Tc_0Vm50fuKKEO5-eTd_8Kfaw_29_3"></a><a id="Tc_d7noYHUdV0mj1m6N1Wpc1g_29_5"></a><a id="Tc_9bIod8jPvEapU4L3atR8nQ_30_0"></a><a id="Tc_xRa0FhGlPkC6j_bDj5YAtg_31_0"></a><a id="Tc_XRuqAPPLXUuiZCncRKnsjA_32_0"></a><a id="Tc_cltaPUmJMUOdBQt1WhHH7g_33_0"></a><a id="Tc_f8qwfhV1-0-Orba2JP8sVA_34_0"></a><a id="a45Othernoncurrentassets_102407"></a><a id="Tc_YhPDBiBzx0CDQDCEm1LtSg_1_0"></a><a id="Tc_t7k5tJCYqUmtCeleWhfXAw_1_2"></a><a id="Tc_sVPGw-G1FkyIZNMYZSfnBA_1_4"></a><a id="Tc_97fCgtvoOE-OUGN7i_fSMw_2_0"></a><a id="Tc_BaZZl2jRWk--YcCKXPJ0XA_2_2"></a><a id="Tc_jKFRAwwz2EeL82qT_ZvPVA_3_0"></a><a id="Tc_slRCOknOy0Ox4RtrHZTjSQ_4_0"></a><a id="Tc_QYdFMjePQkCToSrw8QAbsg_4_2"></a><a id="Tc_pN5A25_Hg0eZTqetLDLiTQ_4_4"></a><a id="Tc_FSDozjcOZEuq9HSsT8TVuQ_5_0"></a><a id="Tc_t2Ovy6VzVkGUuQo-IEiEwQ_5_2"></a><a id="Tc_rIzdBZY8J0mLeQia0xOfzw_6_0"></a><ix:continuation id="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont1" continuedAt="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">reconciliation between the Hepalys statement of financial position and the carrying amount in the Company statement of financial position.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="ifrs-full:DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory" id="Tb_nu4XPU_GAUKKQZAGnhBCQw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands of euros)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_Myqvsmo7hU-GJXliYFcJNg_2_2">17,217</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc__BLeO1KNX0qZxgoais6FdQ_2_4">20,278</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total non</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA" decimals="-3" format="ixt:numdotdecimal" name="iva:NonCurrentAssetsExcludingDeferredAssets" scale="3" id="Tc_I0MT8SwRp0uZhFDrV7fadg_3_2">17,217</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ" decimals="-3" format="ixt:numdotdecimal" name="iva:NonCurrentAssetsExcludingDeferredAssets" scale="3" id="Tc_H-GXJyIwE0O8oPmM35qIOw_3_4">20,278</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentAssets" scale="3" id="Tc_JDcGlRXws0i8oSCpEfoBmA_4_2">17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentAssets" scale="3" id="Tc_iQ3JPNsOGUSHNxZWtbLweA_4_4">44</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_VIM0__NjK0e5ym8ZBwvckw_5_2">1,997</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_q-IZs7q9I0KtcvVV7qDNcQ_5_4">1,082</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA" decimals="-3" format="ixt:numdotdecimal" name="iva:CurrentAssetsExcludingDeferredAssets" scale="3" id="Tc_GJTrdzEVW0KSiDypvDz9VA_6_2">2,015</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ" decimals="-3" format="ixt:numdotdecimal" name="iva:CurrentAssetsExcludingDeferredAssets" scale="3" id="Tc_taILsWCP4k2JuR_ooLxofw_6_4">1,126</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA" decimals="-3" format="ixt:numdotdecimal" name="iva:DeferredAssets" scale="3" id="Tc_skQsnaQO8EOBmGriVdJuTA_7_2">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ" decimals="-3" format="ixt:numdotdecimal" name="iva:DeferredAssets" scale="3" id="Tc_Yc5ks7vLvEKaPiE9bw98pg_7_4">41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="3" id="Tc_bFN9kTX0Q0ulLpfwGPd-hg_8_2">19,233</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="3" id="Tc_uboyc7sMjEeytzqQkVcRUw_8_4">21,444</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssuedCapital" scale="3" id="Tc_VR2Kz0BJH0acScSA2pI8uw_10_2">523</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssuedCapital" scale="3" id="Tc_bERWx8BjREWkbXGEOBbcmA_10_4">640</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CapitalReserve" scale="3" id="Tc_g09Eyvfx5kykCPLpCbL0xQ_11_2">20,379</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CapitalReserve" scale="3" id="Tc_m8mCQ9fhg0GyUDaggPp5fw_11_4">22,655</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital surplus-others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA" decimals="-3" format="ixt:numdotdecimal" name="iva:CapitalSurplusOthers" scale="3" id="Tc_OS3QAvNox0O4T6hAej_qdA_12_2">774</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Earnings brought forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriod" sign="-" scale="3" id="Tc_al5vJxn-2U-OC5yYCT3ulQ_13_2">1,018</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriod" sign="-" scale="3" id="Tc_0ZM7q-U7BkaB9zAas1xqyQ_13_4">178</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RetainedEarningsProfitLossForReportingPeriod" sign="-" scale="3" id="Tc_qbTFBY-8Hk2pN2GhPzKJBw_14_2">1,444</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RetainedEarningsProfitLossForReportingPeriod" sign="-" scale="3" id="Tc_e7imXRuQSECHdh3PeDTnkg_14_4">1,111</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Treasury Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TreasuryShares" scale="3" id="Tc_469a94_GgUWaR7oVx5-ZOQ_15_4">812</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shareholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_mRhU6p2Oi0O8ccfaIOmUTA_16_2">19,214</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_tGmfYbzc70ucCa3G-nWgfA_16_4">21,194</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total non</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" id="Tc_KG9wg-ZWRkei0xXLcciuOQ_18_2">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" id="Tc_a-PvAnoMuEiJIfYQ9UWlAg_18_4">237</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="Tc_Cch3uJ5-gkuKEHJy8vLKcA_19_2">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="Tc_ilzLUgNupkSKKds3Cf54dA_19_4">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLiabilities" scale="3" id="Tc_RW6MxItkv0qCyc0T0eHEWw_20_2">19</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLiabilities" scale="3" id="Tc_316OpchHQEagAKQihqpSpQ_20_4">250</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total equity and liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="3" id="Tc_SJ4GPAUhuUePCoF5nEAgGQ_21_2">19,233</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="3" id="Tc_rCdrbB_CNEeziInWfrNpUg_21_4">21,444</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Opening net assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_tuNLjyeUjUStSiiPLbEZGg;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> 21,122</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_RyNlENHuY0axEQhwJsaZbA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_weqK1WGTlECCFa1vtd17_A_23_4">22,645</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_JQqaQxgK4k2sa_RVgziKNw_24_2">1,509</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_I0kItXo1cEqfFv1DgQ0yfA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_Wcrsn-IwX0Og8-lxHYcPtQ_24_4">879</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" sign="-" scale="3" id="Tc_QQTUdivHB0uQP64QWOFmJg_25_2">1,964</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_I0kItXo1cEqfFv1DgQ0yfA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="Tc_Axh8x9p1g0SvWL5VV8nHfg_25_4">247</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital variations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ" decimals="-3" format="ixt:numdotdecimal" name="iva:IncreaseDecreaseThroughCapitalVariations" scale="3" id="Tc_NFMpHJzkL0ahFhII9c6VMg_26_2">1,566</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_I0kItXo1cEqfFv1DgQ0yfA" decimals="-3" format="ixt:numdotdecimal" name="iva:IncreaseDecreaseThroughCapitalVariations" sign="-" scale="3" id="Tc_r92A8pw4c0WNXGa8ZV0Pcw_26_4">819</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Closing net assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_QUFfJK7X50ug_PpBeIxGAA_27_2">19,214</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_sUKc4KgAHUS9dsl8atYNiA_27_4">21,194</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Group's share in </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_wYI-vlX-bEu9MV9dohB57g" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="Tc_s8Bg4bN5ckCmoh_VMzQsKQ_29_2">15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_CpOwuIhEIkSyaCaql_vmYA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="Tc_2dKRCtgHzEuZ_iws_jYIIQ_29_4">15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands of euros)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Group's share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_Nnjp7bngW0Ga6BDie0V6fw" decimals="-3" format="ixt:numdotdecimal" name="iva:EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod" scale="3" id="Tc_vneZpeJj7U2VsVkXaGjk6A_31_2">2,813</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_y3OYJVLzE0-whh_qoWeSDg" decimals="-3" format="ixt:numdotdecimal" name="iva:EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod" scale="3" id="Tc_T78qSH9pnUqgY1R9SVpMFQ_31_4">3,267</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Elimination of unrealised profit on downstream sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_Nnjp7bngW0Ga6BDie0V6fw" decimals="-3" format="ixt:numdotdecimal" name="iva:IntercompanyEliminationsInAssociates" scale="3" id="Tc_LZSFtYamokWHjUfYDBjFvg_32_2">1,718</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_y3OYJVLzE0-whh_qoWeSDg" decimals="-3" format="ixt:numdotdecimal" name="iva:IntercompanyEliminationsInAssociates" scale="3" id="Tc_oxcnnJ0Ek0iPaWxm3sVLwA_32_4">1,881</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_Nnjp7bngW0Ga6BDie0V6fw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Goodwill" scale="3" id="Tc_vX6-2JZqFkKsnCh6QUkM9w_33_2">37</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_y3OYJVLzE0-whh_qoWeSDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Goodwill" scale="3" id="Tc_RcFuC5f8g0a8o66rpU5RnQ_33_4">39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_Nnjp7bngW0Ga6BDie0V6fw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="3" id="Tc_wgZxKIQwqE6MvVYE8DKx0A_34_2">1,131</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_y3OYJVLzE0-whh_qoWeSDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="3" id="Tc_9ppYaw-e_0OjlpFwAtAxuw_34_4">1,425</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.5</b></span>Other non-current assets</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock" id="Tb_S0CWSpptp0OrJ4utg0Muaw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term deposit accounts<span style="display:inline-block;width:32.36pt;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="iva:NonCurrentLongTermDepositsFromCustomers" scale="3" id="Tc_ZGdFDFVMB0-d_NKripD5lg_2_4">9,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Advance payments &#8211; non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="iva:NonCurrentAdvancesToSuppliers" scale="3" id="Tc_HE9-HZiJAkOVIXJzX0soew_3_2">1,047</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="iva:NonCurrentAdvancesToSuppliers" scale="3" id="Tc_KZ_yAdZnlkyztdqh1i33jw_3_4">1,047</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="iva:NonCurrentSecurityDeposits" scale="3" id="Tc_-94Kk9W_AUKMu3gXYJshiA_5_4">8</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other non</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentAssets" scale="3" id="Tc_D1tw1SshX0Ovnb2lUjIpsg_6_2">1,047</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentAssets" scale="3" id="Tc_vbQQ0FR5r0eiBD84nf2aew_6_4">10,055</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="a46Inventories_58573"></a><a id="Tc_8Nb43ZLHWECFEEvaKl3ziA_1_0"></a><a id="Tc_BF9wR57nCE-KmBeA7u1IoQ_1_2"></a><a id="Tc_KlQkEaCOXU62lM_9_y_BDQ_1_4"></a><a id="Tc_cPE4mfMLfkGW313hOrotJA_2_0"></a><a id="Tc_SB897NgTV0WiUdFdobXRnw_3_0"></a><a id="Tc_Hg95A5Ry7kStNB2AHF3gYw_4_0"></a><a id="a47Tradereceivablestaxreceivablesandothe"></a><a id="Tc_q3Hu-BiekEq7JXVHYW-Fkg_1_0"></a><a id="Tc_xKc9R4n-bUiAh9keRj_24A_1_2"></a><a id="Tc_WeLVHxuCt0OncwhhfkNKAQ_1_4"></a><a id="Tc_Qb8bKF1D6U-bY45Sowr8_w_2_0"></a><a id="Tc_xUWvKcEhxkm7mPWJFHWfRA_3_0"></a><a id="Tc_K1-Zd5qkEEKIcs8jjeLxJA_3_2"></a><a id="Tc_2-Bk-mNExkuzZahOFM_yyA_3_4"></a><a id="Tc_JbiOgrHUVUSYIF3C2KwIoA_4_0"></a><a id="Tc_9NM0va2ISU-48ztcsKMXUQ_4_2"></a><a id="Tc_x-qwF0L47EyyNKMxeeEUXg_4_4"></a><a id="Tc_xPUl-fYW7UqqZqZ7EcFAgQ_5_0"></a><a id="Tc_e4XFibIICkGY3PW8d2j8Iw_5_2"></a><a id="Tc_9Blkzwq1IUGDG3strYrJ6A_5_4"></a><a id="Tc_Rd3LKhQCkEKtOW4ho8tV-w_6_0"></a><a id="Tc_KVMZtIXcYUGw3nahf1Ss8Q_2_0"></a><a id="Tc_kewLD3UTGk2qVsLGj_Cg1g_2_2"></a><a id="Tc_8kOZjWy3hU6SvEyyboo5HQ_2_4"></a><a id="Tc_5XUtcTeuDkeZv4ifx-z6WA_3_0"></a><a id="Tc_-I8duoACWEO8d8XGkyChig_4_0"></a><a id="Tc_wY5TtncXCEq1oO8ptDzeQQ_5_0"></a><a id="Tc_j7ZiYts66kSLclgMBLRTkQ_6_0"></a><a id="Tc_CH_QkQUZ7km2id1IIPOEyA_7_0"></a><a id="Tc_KjWkYzj5LUicUs8pZr_C-Q_7_2"></a><a id="Tc_f3fYHuQnTk2eVkQZpss4bQ_8_0"></a><a id="Tc_3fBN_UYQ9kW3GiocQxjq3w_9_0"></a><a id="Tc_xBixSNvjfEqe8d4hdxzXQQ_10_0"></a><a id="Tc_J6gp8zkh1EOYsc0pUfhx4w_11_0"></a><a id="Tc_YGDsJodzhEma33FjXDR8Lw_12_0"></a><a id="Tc_3GUF_6RbD0-fXwDXo4ioxA_13_0"></a><ix:continuation id="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont2" continuedAt="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024, long-term deposit accounts with more than a year of maturity decreased by &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-5" format="ixt:numdotdecimal" name="iva:IncreaseDecreaseInLongTermDepositAccounts" scale="6" id="Narr_F4C8ZAVXAkK0oeD_QJjhBQ">9.0</ix:nonFraction> million, related to the early closure of a &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:LongtermDeposits" scale="6" id="Narr_dhYaiALh5UijUCcg3x9vsg">9.0</ix:nonFraction> million <ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" format="ixt-sec:durwordsen" name="iva:LongTermDepositsTerm" id="Narr_fu8rlW33gEOvcsRFXN6lQQ">two-year</ix:nonNumeric> deposit forward contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024 and December 31, 2023, non-current advances to suppliers amounted to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember_fPmzQ4Ci5kCG21AG1O_ehw" decimals="-5" format="ixt:numdotdecimal" name="iva:NonCurrentAdvancesToSuppliers" scale="6" id="Narr_0Gn9DFI-90GRnPGRLS0JPw"><ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember_srRYIfYrLkGZMnq0Z1Nr_w" decimals="-5" format="ixt:numdotdecimal" name="iva:NonCurrentAdvancesToSuppliers" scale="6" id="Narr_B03s_rj8_EKIA_euuOntjA">1.0</ix:nonFraction></ix:nonFraction> million, corresponding to the advance paid under the contract research organization (&#8220;<b style="font-weight:bold;">CRO</b>&#8221;) contract with Pharmaceutical Research Associates Groupe B.V (&#8220;PRA&#8221;) (see Note 6.1 &#8211; <i style="font-style:italic;">Commitments related to operational activities</i>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.6</b></span>Inventories</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="iva:IfrsScheduleOfInventoryCurrentTableTextBlock" id="Tb_QOceNNEpi0u37Ls1ZkfvYA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_SNcEwTle60O3eQH3YNWEsw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Inventories" scale="3" id="Tc_zLIFwutvy0y1FEFTwXCwLw_2_2">402</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_na6RZmuG5U2D4vmO3x7mnw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Inventories" scale="3" id="Tc_m6gYib9qDkuZpQgphhZwJg_2_4">426</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inventories write&#8209;down</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_40Ly7mN0VUychMdZQFU0jg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Inventories" sign="-" scale="3" id="Tc_1MXVCze3oUqJAh5lvY78Ww_3_2">9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_hPvzcNBD1029LdKD5pm-Fw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Inventories" sign="-" scale="3" id="Tc_fOfI3x_G3EaXcDwtvtzObg_3_4">9</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Inventories</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Inventories" scale="3" id="Tc_VYjcW24fpkOc8T0nFljHrA_4_2">393</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Inventories" scale="3" id="Tc_lkoVYHsN6EuVB_CL13uA9Q_4_4">417</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.7</b></span>Trade receivables, tax receivables and other current assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Trade receivables</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables break down as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="iva:DisclosureOfTradeReceivablesTableTextBlock" id="Tb_8zX9e-34x0Ge_lcjdeb_Yw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3&#160;months or less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanThreeMonthsMember_2nR6xWsu-0CvgK_C4H2nmQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentReceivables" scale="3" id="Tc_e3Ju3vcnUEyHgVh7FO5QHg_2_2">809</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanThreeMonthsMember_--thiluYlEKqu2SkZv1ljQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentReceivables" scale="3" id="Tc_l3BBn17qWUGNtOFyfBQCWw_2_4">3,807</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Between 3 and 6&#160;months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Between 6 and 12&#160;months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">More than 12&#160;months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Trade receivables</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentReceivables" scale="3" id="Tc_t-2fHgFHwEqyK7057zMd3w_6_2">809</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentReceivables" scale="3" id="Tc_Q4tw6G-XKkCAW14t76KDDw_6_4">3,807</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The average payment period is <ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" format="ixt-sec:durwordsen" name="iva:CurrentTradeReceivablesAveragePaymentPeriod" id="Narr_63un3OFOAUi1BsdCzLhUcA">30 days</ix:nonNumeric>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024, trade receivables decreased by &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-5" format="ixt:numdotdecimal" name="iva:IncreaseDecreaseInTradeAndOtherCurrentReceivables" sign="-" scale="6" id="Narr_QsMKOhFMXE2TjZxmqp0E9w">3.0</ix:nonFraction> million mainly due to the receipt of a payment from CTTQ for the reinvoicing of specific costs related to the NATiV3 trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><i style="font-style:italic;font-weight:normal;">Tax receivables and Other current assets</i></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory" id="Tb_ncmxLu4Q10yYJUVjOltOaQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-variant:small-caps;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CIR and other research tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="iva:CirAndOtherResearchTaxCreditsReceivable" scale="3" id="Tc_yH93a6escUamuHwYFixMBg_3_2">2,657</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="iva:CirAndOtherResearchTaxCreditsReceivable" scale="3" id="Tc_SufGEAyWuk6Lp7d-s1mcWA_3_4">5,333</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="iva:OtherCurrentTaxReceivables" scale="3" id="Tc_XCALXfHLUUaPP6sYlz-GmA_4_2">47</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="iva:OtherCurrentTaxReceivables" scale="3" id="Tc_fjDkOug-CEavtG0vkkyeyQ_4_4">19</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Tax receivables</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxAssetsCurrent" scale="3" id="Tc_UuBM9tTULUmkfWuDbGGlog_5_2">2,704</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxAssetsCurrent" scale="3" id="Tc_4qFIEeoYAk6MLzQ1GjmPjg_5_4">5,352</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepaidExpenses" scale="3" id="Tc_e9D5q_7dAE6918OvejTNdg_6_2">7,039</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepaidExpenses" scale="3" id="Tc_RpinGn2JeUaurAA2g_8JVA_6_4">4,656</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term deposit accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="iva:ShortTermDepositAccountsCurrent" scale="3" id="Tc_B9xTL2fBg0iiBsVNeKxA-A_7_4">70</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current accrued income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentAccruedIncomeIncludingCurrentContractAssets" scale="3" id="Tc_MgG7TDw2OUmgZmffX751lA_8_2">1,687</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentAccruedIncomeIncludingCurrentContractAssets" scale="3" id="Tc_PUMj7cOUKE-jUzTq3bm42w_8_4">1,047</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liquidity agreement - Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="iva:CashUnderLiquidityAgreementCurrent" scale="3" id="Tc_Cp1wTzwaXEeVDcUZ76WIWA_9_2">289</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="iva:CashUnderLiquidityAgreementCurrent" scale="3" id="Tc_sHRlnfePn0q2fa5QBGA43g_9_4">422</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales tax receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="iva:SalesTaxReceivableCurrent" scale="3" id="Tc_SYbh9edrsUKcudbG907lDg_10_2">3,311</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="iva:SalesTaxReceivableCurrent" scale="3" id="Tc_Q5BCm5oQdkOgT4qf-aa-OA_10_4">5,066</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentReceivables" scale="3" id="Tc_LX5whK3bq0y3-ld0ZLRIpA_11_2">2,229</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentReceivables" scale="3" id="Tc_ie9K_YNAg0eIgFwablyePQ_11_4">435</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentAssets" scale="3" id="Tc_85mNANC4R0C2UTFM1tf9Xg_12_2">14,554</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentAssets" scale="3" id="Tc_2ufMm2L1S0O5oMOrdk28SA_12_4">11,696</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other current assets and receivables</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="iva:OtherCurrentAssetsAndReceivables" scale="3" id="Tc_exBBTuY6bkyzdwGSX6MHbQ_13_2">17,258</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="iva:OtherCurrentAssetsAndReceivables" scale="3" id="Tc_shz52Ne20kCyonYAzesCSA_13_4">17,048</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024, tax receivables are mainly composed of research tax credits receivable in the amount of &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_ZxMBck8Vv06CkTltj3JJkg" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:CurrentAccruedIncomeIncludingCurrentContractAssets" scale="6" id="Narr_G_aHUDF_c0CqxDXpPVlpIA">2.7</ix:nonFraction> million corresponding to the 2024 CIR as of June 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prepaid expenses, which increased by about &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-5" format="ixt:numdotdecimal" name="iva:IncreaseDecreaseInShortTermDepositAccounts" scale="6" id="Narr_YwEzn58vJ0CBEgzEqIGzwA">2.4</ix:nonFraction> million, are mainly composed of costs related to the NATiV3 Phase III clinical trial.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="a48Cashandcashequivalents_167227"></a><a id="_14e3cdd0_80d6_4ec2_b852_facf7bb95e66"></a><a id="Tc_x4fMcfHfGE2okhyb4uMQgA_1_0"></a><a id="Tc__WzMPryB0E67w0RNZ33PXg_2_0"></a><a id="Tc_ZU83laPKGE2nt6lvl1kwAw_2_2"></a><a id="Tc_2UZERT5U8UySoGF6FWb5jA_2_4"></a><a id="Tc_Dd_pNez_kkyavg3m3Qa3TQ_3_0"></a><a id="Tc_Kc0fUsgSl029ICdnVAm40Q_4_0"></a><a id="Tc_XkF6s7EKWku3TIeYeMR3LQ_5_0"></a><a id="Tc_KRreIda6PkydrFgvFD8Z0A_5_4"></a><a id="Tc_MjAmQqC1DEqtjKZbYQl-nQ_6_0"></a><a id="a49Shareholdersequity_517906"></a><a id="Tc_c2PTptLcD0-AuLp4_Syf8w_1_6"></a><a id="Tc__VucoH289Ey7Gp-MomWoHQ_2_4"></a><a id="Tc_fwcU0AUj1UukYy_3zl4-iQ_2_6"></a><a id="Tc_v24I0e262UqcLZ5xR8g0mw_2_8"></a><a id="Tc_aQ1FQPN9R0KkAbVxWxJoPQ_2_10"></a><a id="Tc_LEo4XL2lS0q0kR7tosRliQ_3_0"></a><a id="Tc_l6OVQ7wmkkCkwsScGVwcPg_3_2"></a><a id="Tc_0esVmA8vTkeX04AEPZ93zw_3_4"></a><a id="Tc_51nc2MFhbk-H15LrKkc6Rg_3_6"></a><a id="Tc_XdgSDqqngkqigTJX72w97w_3_8"></a><a id="Tc_XIHFSxPtsE2mEDG7EgTpdA_3_10"></a><a id="Tc_Rss7QrKxC02kOZCZfljgGw_4_0"></a><a id="Tc_eIJaKV8xUE2WiOal-1wGMA_5_0"></a><a id="Tc_ltMIAy9cR0G_qNt6rkqpYw_5_2"></a><a id="Tc_BjDhU-9JHU23FSJV0P3sTA_6_0"></a><ix:continuation id="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont3" continuedAt="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.8</b></span>Cash and cash equivalents</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="iva:DisclosureOfCashAndCashEquivalentsTableTextBlock" id="Tb_wHRCLgUJGECnzDKjV1f2Ew" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net cash and cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other cash equivalents<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" id="Tc_uHtsvTOQ10CKI_uwyb5l0A_3_2">10,273</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="3" id="Tc_GXgVPDxbDUOhsNk4ze5zSw_3_4">17,933</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash at bank and at hand</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Cash" scale="3" id="Tc_ZzKDwO-bh02J7sNTgeNILA_4_2">1,212</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Cash" scale="3" id="Tc_FsShiKvo8Em-DlpXYA8tww_4_4">8,985</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Bank overdrafts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="3" id="Tc_D0cpAwx9v0e9T2ab6YAoqA_5_2">1,338</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_k-td-xK_GUi_AIYFhcJXNQ_6_2">10,147</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_MY5YYY5BmEO2NYkK2WPQpQ_6_4">26,918</ix:nonFraction></b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other cash equivalents correspond to short-term bank deposits.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with IAS 7.8, bank overdrafts which are repayable on demand are included as a component of cash and cash equivalents in the amount of &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:BankOverdraftsClassifiedAsCashEquivalents" scale="6" id="Narr_-DuoQHCvsEa09p1_4_UUkw">1.3</ix:nonFraction> million as of June 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.9</b></span>Shareholders&#8217; equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">Share capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The share capital is set at &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssuedCapital" scale="0" id="Narr_PmjRzCjIHUi1-7aEMShwsw">524,772</ix:nonFraction>&#160;at June 30, 2024 divided into <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" id="Narr_xXQy8HQgeEKp-8Z0SpfNQw">52,477,188</ix:nonFraction> fully authorized, subscribed and paid-up shares with a nominal value of &#8364;<ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:ParValuePerShare" scale="0" id="Narr_iR9qxg4lcUKeOQc364Ln_A">0.01</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Share capital variation during the first six months of 2024 is set forth in the table below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">In euros, except number of shares</i></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="Tb_n6vwj1f_sU24eHkRviH6tA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:23.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Premiums&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">related&#160;to&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nominal&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:23.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nature&#160;of&#160;the&#160;transactions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share&#160;capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td></tr><tr><td style="vertical-align:bottom;width:23.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2023</p></td><td style="vertical-align:bottom;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_4J3_ocxV5ka2EE64Vzyuyw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="Tc_UokxfPctqUWSyolNr6N7iw_4_4">521,158</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_cgKVo_3CWUmvwiGobzgKyg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="Tc_vF9GPBEnoEqaEBp6iqU7qA_4_6">201,862,263</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" id="Tc_mPh7yHdZXEqwaJYpNHlEmg_4_8">52,115,807</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_4J3_ocxV5ka2EE64Vzyuyw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:ParValuePerShare" scale="0" id="Tc_yq4zu3BZFUmUlTu3q63whw_4_10">0.01</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AGA 2021 &amp; AGA 2021 bis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_3_25_2024_To_3_25_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_eylYkv54iU6BbmTMEduewg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="Tc_Tde80VIuuki5_X90XaZ66g_5_4">3,614</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_3_25_2024_To_3_25_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_NWloX1BI0US4Lo97RBCE_g" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" sign="-" scale="0" id="Tc_3IIEDjqT70ieeRFG1QN4Ow_5_6">3,614</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_3_25_2024_To_3_25_2024_avq7MDuDZ0qTbuTPxd88pQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding" scale="0" id="Tc_uZyC_VKWXEKXvs49DZQDsg_5_8">361,381</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_3_25_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_31pg2jjAP0SNXoJC-UbdfQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:ParValuePerShare" scale="0" id="Tc_eETYbsFsEUOdzVcNIRXMzg_5_10">0.01</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance at June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_NJmuaXv-XEWsTA9f3Xh5nw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="Tc_GV5E7F2OikKo_OTzwU6KVQ_6_4">524,772</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_wKPlEEy3A0SN-8jmJn4iCw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="Tc_1nUpoS-0BECuk6LNCDAarQ_6_6">201,858,649</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" id="Tc_sDbQxSm8S0Kf3KUr21-VTQ_6_8">52,477,188</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_NJmuaXv-XEWsTA9f3Xh5nw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:ParValuePerShare" scale="0" id="Tc_s3IxEfhRxkyooNZzznDFQw_6_10">0.01</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">Liquidity agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 19, 2018, the Company entered into a liquidity agreement with Kepler Cheuvreux, replacing the previous liquidity agreement with Oddo BHF. This agreement with Kepler Cheuvreux, as amended in 2019, automatically renews for <ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_X8oeeeGhTk-MdYqDOV-oxQ" format="ixt-sec:durwordsen" name="iva:LiquidityAgreementTerm" id="Narr_-gsszcRTfEWmU4kyo89Pig">12-month</ix:nonNumeric> periods unless terminated by either party. Under the terms of the agreement, the investment services provider (&#8220;ISP&#8221;) is authorized to buy and sell the Company&#8217;s treasury shares without interference from the Company in order to ensure the liquidity of the shares on the Euronext market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The liquidity agreement with Kepler Cheuvreux was extended for a new period of <ix:nonNumeric contextRef="Duration_1_1_2023_To_1_1_2023_XlsK7X7SLkSjPHI4C13dFw" format="ixt-sec:durwordsen" name="iva:LiquidityAgreementTerm" id="Narr_A3JpE3QquEGaAkBO6lMRCw">12 months</ix:nonNumeric> from January 1, 2023, and has been renewed again for a new period of <ix:nonNumeric contextRef="Duration_1_1_2024_To_1_1_2024__TV_WDfEOkuUvGKOfMbQLg" format="ixt-sec:durwordsen" name="iva:LiquidityAgreementTerm" id="Narr_LZMpw3JCfEyBGfpdzx0uSA">12 months</ix:nonNumeric> from January 1, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At June 30, 2024, treasury shares acquired by the Company through its ISP, as well as the gains or losses resulting from share purchase, sale, issue and cancellation transactions during the first six months of 2024, were accounted for as a deduction from equity. Consequently, these transactions had no impact on the Company&#8217;s results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Options and share warrants (BSA and BSPCE)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Share-based payments correspond to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BSA share warrants granted to Company directors in 2017, with a subscription price set at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;<ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_12_31_2017_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DirectorsMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_tc0AHGj00kS5B7lAXTpurw" decimals="3" format="ixt:numdotdecimal" name="iva:WarrantsSubscriptionPrice" scale="0" id="Narr_bD1v90o6ZESj7hZnTXqrxg">0.534</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BSA share warrants granted to Company service providers in 2018, with a subscription price set at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;<ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_ServiceProvidersMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_DIqvoK9pK0yZ6htGpUYXzw" decimals="2" format="ixt:numdotdecimal" name="iva:WarrantsSubscriptionPrice" scale="0" id="Narr_Y7tDoZguJkmNJg-xy9qEhg">0.48</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_IsaN0uid-ky2OLiSfcqI1w_1_4"></a><a id="Tc_H08NFe1-tk6cK3edxw7pVw_1_6"></a><a id="Tc_U-T-CM1kTk2qXEJjLVt0Zg_1_14"></a><a id="Tc_TYHclapuSE-3N6NDp6r0wA_1_16"></a><a id="Tc_e1vsvWwgqk20ebf9ZEYNBg_2_4"></a><a id="Tc_87h_R_NPfUuckS60MEOQuQ_2_6"></a><a id="Tc_rVpIOfmm1Uyg0bxBSUbizg_2_12"></a><a id="Tc_2Tzen7Wm_Uqb27KEPLZyjQ_2_14"></a><a id="Tc_cvcEo561_U6sZsXJQCbj-A_2_16"></a><a id="Tc_8ayP8UH8JUqGqdruBrX5kA_3_0"></a><a id="Tc_V_LMs6PJwkOAqbbz4Tuw_w_3_2"></a><a id="Tc_injlbgnvl02vIH7M7sDLJw_3_4"></a><a id="Tc_ZKPxMc8Ab0q8jhc9MG0Dpg_3_6"></a><a id="Tc_trlTe3IvnE6AojAbQMYPdQ_3_8"></a><a id="Tc_l72GcnTkkUqmmFwzlAscbA_3_10"></a><a id="Tc_fWbaU-fOlkyDLdL7hP93sg_3_12"></a><a id="Tc_7NUu72msFEessZrbOVBvAw_3_14"></a><a id="Tc_d1UZ9C8BQk-uNGN7eXf3Uw_3_16"></a><a id="Tc_QYJD63iPKEqcYDa0zKGNbA_4_0"></a><a id="Tc_-3gKwTS3u0KizKpDwYHtDQ_4_2"></a><a id="Tc_qt3a693RrEOp7oDobqNpig_4_8"></a><a id="Tc_HcDVUPG190yCdccCiFJ4zg_4_10"></a><a id="Tc_pMNIEHVaNUyueR2JLiN1aw_4_12"></a><a id="Tc_wlNZQdfrg0KipUkbkVDgMQ_5_0"></a><a id="Tc_Ii2NSsZJh0qnk3ha1fi12g_5_8"></a><a id="Tc_fECY514RUka6y_0T-71YeQ_5_10"></a><a id="Tc_S69AUdTo-0O9fJPYhNx7Rw_5_12"></a><a id="Tc_McAAsdOPj0ik6OxkwhOhUA_6_0"></a><a id="Tc_RrQsivOWgEOckKn_zkm9Hg_6_2"></a><a id="Tc_cnnvVnvE1kWPyCW6w3o5vw_6_8"></a><a id="Tc_MwdDSOO02EyR3J6AsQqL8A_6_10"></a><a id="Tc_kgJbpDfe3kitS2z9fwtKZQ_6_12"></a><a id="Tc_Y8ev_hDzV06mcRpAFjwfCA_7_0"></a><a id="Tc_vUh11cs7kUiN_3j-tP1sig_7_2"></a><a id="Tc__oraawJ73ESsjEws1hUS5g_7_8"></a><a id="Tc_85TKMmA0dEiEN7R99QLgvA_7_10"></a><a id="Tc_m6zeJixFz06D7YaonkD9_g_7_12"></a><a id="Tc_NrXuaH4GyEiDFsXSX5VvJQ_8_0"></a><a id="Tc_Xe88OHdktUuMQdYyN43bFg_8_2"></a><a id="Tc_vIVEXnjzSEWJvNyCYeFyQg_8_8"></a><a id="Tc_b3WdgK_gj0u5Ccadus1Nqg_8_10"></a><a id="Tc_-tFOyacbOkWYOBb7cbkw-w_8_12"></a><a id="Tc_TbXZ9S5sFUSzgcaVbhMLZQ_9_0"></a><a id="Tc_IUW1TOcPVUeC1-RwF4pl2g_9_2"></a><a id="Tc_jKk25BpjsE6ZU2Sgzv1FYg_9_8"></a><a id="Tc_cZc33v5ne0a_Jw0wQ9VrLA_9_10"></a><a id="Tc_uzJo7B9HCkm2W5Y0i1ob8A_9_12"></a><a id="Tc_GlMkNQVqKE6aO1zJu8AZsQ_10_0"></a><a id="Tc_vj3YaNlhmUKKubrCbZ92yA_10_2"></a><a id="Tc_QxMPZIwbS0uphd98WvtXQQ_10_8"></a><a id="Tc_YWm2DV-3fEaISJgqzBBhkw_10_10"></a><a id="Tc_9ylx6zmEo0-L5VC0LZ48Sg_10_12"></a><a id="Tc_011zulZoMEuFXcAatfr2yw_11_0"></a><a id="Tc_LlRmSCRnU0Cd5D750wsI3Q_11_2"></a><a id="Tc_AkgBWXiirUavgtQ3Kuvbpg_11_8"></a><a id="Tc_5jpZxx5_hEu0Aur7petUlA_11_10"></a><a id="Tc_L51dmsiLEk2EDwScej9z1A_11_12"></a><a id="Tc_4_LBqw4bjEaVOvqoU_fXoA_12_0"></a><a id="Tc_7sgMXyP0OkWr8o2jP7unEA_12_2"></a><a id="Tc_prIW_fgzG0aGhMvrHAAWkA_12_8"></a><a id="Tc_OWlkFDapwUGgiXjDZ8JioQ_12_10"></a><a id="Tc_u50ES57fN0q-QyeIlD2rmQ_12_12"></a><a id="Tc_fwQZbvXQOEKi-q2WXhTnng_12_16"></a><a id="Tc_VyYH4zaU-EKF1f4WG0kEWQ_13_0"></a><a id="Tc_dXXC7FBuxU23hzCAj0p_yQ_13_2"></a><a id="Tc_-VORXPWw9kGyd69pEuOoJw_13_16"></a><a id="Tc_qqbeBgUtNUaZW9ZUg15ejA_14_0"></a><a id="Tc_iXNLR7qxbEGKAW1x15a4Fw_14_8"></a><a id="Tc_EqGtvuiPgkSxDICTaE9zFw_14_10"></a><a id="Tc_X4jdXcTZxEWyJMhYoIQacA_14_12"></a><a id="Tc_sriDDYisrUeOk9CUADZrBQ_15_0"></a><a id="Tc_Qo6vHEYWr0yX6mZEEQPCSw_15_8"></a><a id="Tc_kevIJZxrXUCfyqo8GUGDCw_15_10"></a><a id="Tc_iFuTzvEx_k-5l6zaGHJyIQ_15_12"></a><ix:continuation id="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont4" continuedAt="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont5"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BSA share warrants granted in 2019 to David Nikodem, a member of Sapidus Consulting Group LLC, a service provider of Inventiva, with a subscription price set at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;<ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_hhwziOnPqEKcNx_7cuH5Ug" decimals="2" format="ixt:numdotdecimal" name="iva:WarrantsSubscriptionPrice" scale="0" id="Narr_gmaGO_ypWEOygjY2P0ZvJw">0.18</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BSA share warrants granted in 2020 to David Nikodem, a member of Sapidus Consulting Group LLC, and J&#233;r&#233;my Goldberg, a member of PG Healthcare LLC, both service providers of Inventiva, with a subscription price set at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;<ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_12_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_ue4H16UnJE-nSbm-Rv4i6Q" decimals="2" format="ixt:numdotdecimal" name="iva:WarrantsSubscriptionPrice" scale="0" id="Narr_-i_mwJEyrEa11v0PuY4f_w">0.29</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BSPCE founder share warrants granted in 2021, to Frederic Cren and Pierre Broqua, Company&#8217;s Directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BSA share warrants granted in 2021 to David Nikodem, a member of Sapidus Consulting Group LLC, a service provider of Inventiva, and ISLS Consulting with a subscription price set at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;<ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_TXDD0JbjtEiPdT8-3ZzhYA" decimals="2" format="ixt:numdotdecimal" name="iva:WarrantsSubscriptionPrice" scale="0" id="Narr_WLVYvn1YVU-AAfY6XBQXrA">2.45</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BSA share warrants granted in 2023 to David Nikodem, a member of Sapidus Consulting Group LLC, a service provider of Inventiva, with a subscription price set at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;<ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20231ShareWarrantPlanMember_sPDxxV-HME-NOFivUfGJlA" decimals="2" format="ixt:numdotdecimal" name="iva:WarrantsSubscriptionPrice" scale="0" id="Narr_8uRvvvWjsUWA_zHHW86oPQ">0.20</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;<ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20231ShareWarrantPlanMember_r1Qe82njGE25vu439VQ9xg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" scale="0" id="Narr__VaE2empb0aFuuYoYBmbWw">2.51</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BSA share warrants granted in 2023 to David Nikodem, a member of Sapidus Consulting Group LLC, a service provider of Inventiva, with a subscription price set at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;<ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20232ShareWarrantPlanMember_WOiJYiWPuUu4IuMxaS3vvg" decimals="2" format="ixt:numdotdecimal" name="iva:WarrantsSubscriptionPrice" scale="0" id="Narr_ucR30CVtk0-O6FjxmaZNjA">0.31</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;<ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20232ShareWarrantPlanMember_CWi27vgj8Eqzm6adcBi83g" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" scale="0" id="Narr_0pdtuJ2KOUmZd1o9Ty4Z3A">3.91</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">BSA and BSPCE plan characteristics</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of January 1, 2024, one BSPCE share warrant plan was outstanding: BSPCE 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The BSPCE and BSA share warrant plans are described in the note 12.3 &#8220;<i style="font-style:italic;">Share warrants</i> <i style="font-style:italic;">plans</i>&#8221; of the 2023 annual financial statements. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="INF" format="ixt-sec:numwordsen" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Narr_pW0w8yNWWEOQjysUklxMUA">No</ix:nonFraction> new share warrants plan has been attributed in the first six months of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;">Movements in BSPCE share warrants and BSA share warrants (in number of shares issuable upon exercise)</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspceAndBsaShareWarrantsMember_ChRxu3v9XU-QJcAaOJ0AgA" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" id="Group_ObzK56fSxk28WOWl-xdk6g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at Jan&#160;1,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Forfeited /</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in euros)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issued</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercised</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Lapsed</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSPCE - Plan 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">04/16/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bspce2021PlanMember_RcSn_5JQpk-SYrZAPBf-2g" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="Tc_SrZP9A_IyESduQTU1PHdIg_4_4">11.74</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bspce2021PlanMember_XXFm1fZ4IkuZuyUISjqE5A" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_sFswchMeQkiv9r8aCEKN-Q_4_6">430,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bspce2021PlanMember_RcSn_5JQpk-SYrZAPBf-2g" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_d8LuV8QMDEy3ATiCZXeFXA_4_14">430,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bspce2021PlanMember_RcSn_5JQpk-SYrZAPBf-2g" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" scale="0" id="Tc_rxemUeuU60qJlfbv3y5knA_4_16">430,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TOTAL BSPCE share warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspcePlansMember_9R_vfCR8mE6QceWJxeNh0A" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_MujW0ZjVh06DvFCYfiuhEg_5_6">430,000</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspcePlansMember_Ga9Y5xtaaE6GziTOhOfOyw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_-9iokdYNZUW65uiW8TQnLw_5_14">430,000</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspcePlansMember_Ga9Y5xtaaE6GziTOhOfOyw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" scale="0" id="Tc_8IpuWyZa302V6ONn4h9UGQ_5_16">430,000</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSA&#160;- Plan 2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/29/2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2017PlanMember_weg2ddPVA0SxiMSra8AqSg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="Tc_qV9i-7d4JEa5pCQaoz1Qpg_6_4">6.68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2017PlanMember_ps8c_6VsskWjdjMuB0dgAw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_wMvOUAvg5U2Jlyn0NrQiow_6_6">130,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2017PlanMember_weg2ddPVA0SxiMSra8AqSg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_xeJPIQg8WEOcqCRfD1C-oQ_6_14">130,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2017PlanMember_weg2ddPVA0SxiMSra8AqSg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" scale="0" id="Tc_Y4vLaT9SvkaZhse2oz-bxw_6_16">130,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSA&#160;- Plan 2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/14/2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2018PlanMember_ptHXov2J-0Wu9MZq69AtRw" decimals="3" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="Tc_Yvqtl40ffkiqyZXH77lahg_7_4">6.07</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2018PlanMember_-NNjSxGS3kGycvP-YnC6BA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_VXuk38Y9kk2dA3SYJ54iRQ_7_6">116,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2018PlanMember_ptHXov2J-0Wu9MZq69AtRw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_H9X4lGpjuEGLARIdYbYDlA_7_14">116,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2018PlanMember_ptHXov2J-0Wu9MZq69AtRw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" scale="0" id="Tc_IeIdVs94wEa1WAaPhm5TZg_7_16">116,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSA 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">06/28/2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019Member_wyeHPWxpTUKLa573kCA9hg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="Tc_wTXONOIhKEudc5BtzSr_9A_8_4">2.20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019Member_KvhW3CTGVkaWP5uQm6usPQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_zKTXyUT6REKW18WsJFeoEg_8_6">10,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019Member_wyeHPWxpTUKLa573kCA9hg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_lkh3Zs6q0EayBUDYxX0e3A_8_14">10,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019Member_wyeHPWxpTUKLa573kCA9hg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" scale="0" id="Tc_dImNUx6izEaV97aKaY8TSQ_8_16">10,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSA 2019 bis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/09/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019BisMember_MIIhZy39AEC1hyqkLyXkqA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="Tc_26v73__qQ0K7HyV5ajOzaQ_9_4">3.68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019BisMember_U_5IV4QgEke3Pdy5mT4eiw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_bmlag9Pe10Kb8EdqTInJrg_9_6">10,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019BisMember_MIIhZy39AEC1hyqkLyXkqA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_8cfygDOFHUutceFl7E750g_9_14">10,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019BisMember_MIIhZy39AEC1hyqkLyXkqA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" scale="0" id="Tc_CAtruIxEF0ibG6oAzAE-ig_9_16">10,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSA 2019 ter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/09/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019TerMember_jiHAAcRQ-UOqoX3-IPHL7Q" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="Tc_ah0uxTqG80u0d59xmjxPuw_10_4">3.68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019TerMember_TDxn8LM_90OZE-wvpQKC8g" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_lQ58r775F0mk-104hcwFAg_10_6">36,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019TerMember_jiHAAcRQ-UOqoX3-IPHL7Q" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_vgB8fH6or0aLlg1qYIWbrA_10_14">36,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019TerMember_jiHAAcRQ-UOqoX3-IPHL7Q" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" scale="0" id="Tc_B6uBbn5vBEml9pky1ILUIg_10_16">36,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSA 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">04/16/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBsa2021ShareWarrantPlanMember_yiiLVd_BA0S9s5AhG-VVqg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="Tc_Ca822OyTOE6LVDMoTgP6MQ_11_4">11.74</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBsa2021ShareWarrantPlanMember_3S7BOByx_EaWFm05q97Pbw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_heE2OwQ2Yket05DvOrgomw_11_6">14,333</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBsa2021ShareWarrantPlanMember_yiiLVd_BA0S9s5AhG-VVqg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_u5pvb2qKhU2uhU1v_LzgHA_11_14">14,333</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBsa2021ShareWarrantPlanMember_yiiLVd_BA0S9s5AhG-VVqg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" scale="0" id="Tc_-RKnJY0yl0-_yzwrFcoKwg_11_16">14,333</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSA 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/25/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20231ShareWarrantPlanMember_5P4HYxa_X02-U_TBazJ3bA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="Tc_7EjURt4keEmmlbUM0pBpEw_12_4">2.51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20231ShareWarrantPlanMember_47_9YfgmmkGE6SeeBfb7Ig" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_C84637mHd0WFNK7_XXCVtA_12_6">10,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20231ShareWarrantPlanMember_5P4HYxa_X02-U_TBazJ3bA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_h5_ISYIyP0ORB8jhmUyrUA_12_14">10,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSA 2023 - 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/15/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20232ShareWarrantPlanMember_XsJfOiE5YUuSxAlo8TUGSQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="Tc_8yHx3hkUJEmoYUucLSZ-ww_13_4">3.91</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20232ShareWarrantPlanMember_TAkktSsoVU2p7FMQN4IObg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_mFKG3BYt_UOeu1k32EU7uw_13_6">20,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20232ShareWarrantPlanMember_XsJfOiE5YUuSxAlo8TUGSQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_5CMuxhi0XE-6xbsDVdbN7w_13_14">20,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TOTAL BSA share warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaPlansMember_8Ot2N8tWskGDuiWnohiHRw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_pTxP2_LKSUuX5zMymCFIVw_14_6">346,333</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaPlansMember_lUa0fx_8UUGbYRQd155C8g" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_5XdkVwbIGU6skwFS_iR9fA_14_14">346,333</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaPlansMember_lUa0fx_8UUGbYRQd155C8g" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" scale="0" id="Tc_X7bFDpXICE24Nc6IRrU6ug_14_16">316,333</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total share warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspceAndBsaShareWarrantsMember_AXg3-r_gg0WamRv2dUykVQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_nwS4SivnL0KWrv5vJ3th9A_15_6">776,333</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspceAndBsaShareWarrantsMember_bFYuyd66F0KcdJonswP3bA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_-7tGaAZQFkmFUXT0hiU0PA_15_14">776,333</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspceAndBsaShareWarrantsMember_bFYuyd66F0KcdJonswP3bA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" scale="0" id="Tc_GNebjCZFHkyKagk0M5Gw1A_15_16">746,333</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At June 30, 2024, a total of <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaPlansMember_lUa0fx_8UUGbYRQd155C8g" decimals="INF" format="ixt:numdotdecimal" name="iva:IfrsClassOfWarrantOrRightOutstanding" scale="0" id="Narr_ffA1HEN2tkS7tEzgTOMjiA">430,000</ix:nonFraction> BSPCEs (or <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspcePlansMember_Ga9Y5xtaaE6GziTOhOfOyw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Narr_IPAuoMuUskSsj3tAdPnE1A">430,000</ix:nonFraction> shares) and <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaPlansMember_lUa0fx_8UUGbYRQd155C8g" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Narr_HqH3q7tCC0SqI12j7mZyxg">346,333</ix:nonFraction> BSAs were outstanding, corresponding to a total of <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspceAndBsaShareWarrantsMember_bFYuyd66F0KcdJonswP3bA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Narr_Mt3XcQ-2UkqydaFdn_ZiiA">776,333</ix:nonFraction> shares, the maximum number of shares to be issued when all related conditions are met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Free share awards</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AGA free share award plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of January 1, 2024, four free share award plans were outstanding: AGA 2021-1, AGA 2021-bis, AGA 2023-1, and AGA 2023-2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="INF" format="ixt-sec:numwordsen" name="iva:NumberOfAwardPlansAttributed" scale="0" id="Narr_koazVkK9v02v0qP57EprBg">No</ix:nonFraction> bonus share award plan has been attributed in the first six months of 2024.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_LLTqkvEqNEeNqHVoxDnS0w_1_4"></a><a id="Tc_8_4-1EbRAUif8B-o5LaW0g_1_6"></a><a id="Tc_qiFuJich1ka4bEvbOFW7gA_1_14"></a><a id="Tc_lkR6gLNk80uK46Asy3YxOA_2_4"></a><a id="Tc_1iY6NvYNN0ukw_GxoyzC0g_2_6"></a><a id="Tc_CaETJ4YYjUyMQJGCsMOpbw_2_12"></a><a id="Tc_KWk6Fr31H06jSbiMFUJkGQ_2_14"></a><a id="Tc_JhV2y-XzBEeQJw2-rsSrpQ_3_0"></a><a id="Tc_Lf8Nx0Kh5UapKrRJc4c09Q_3_2"></a><a id="Tc_PAx6vE1THkSNm7NVDQybqQ_3_4"></a><a id="Tc_uwjsVC-DuEOCVfSa8YBvfg_3_6"></a><a id="Tc_w6Voav23z06OKQHuBl9mXg_3_8"></a><a id="Tc_DLHyDe3N8Umf4lPVfiMX1A_3_10"></a><a id="Tc_D5OnH1q3qEGIiMddWWFOlA_3_12"></a><a id="Tc_ltfadCnW_kW0keW_F3R4Pw_3_14"></a><a id="Tc_oHLkEvREQUqxO8l_j4CzwA_4_0"></a><a id="Tc_Ti1w8K-EiEOc0bQUWvQ4iA_4_2"></a><a id="Tc_99hNiqPy5Uqjo_4Lq8Qq-w_4_8"></a><a id="Tc_-WBNKDY_VEasllPA8Z6IlA_4_14"></a><a id="Tc_CHYw19rvBkCH8UAsykZOxQ_5_0"></a><a id="Tc_JVMZ0ef8mEaFOZZ3-YQYqQ_5_2"></a><a id="Tc_oFjfSCU5fEOKOU7FCTa9TQ_5_8"></a><a id="Tc_itpY2SDpdkqKLOtB75n1Sw_5_12"></a><a id="Tc_e6_74V15hU2FvG_utZdzMw_5_14"></a><a id="Tc_6Imyp3knCk2N9YIh8TiQSQ_6_0"></a><a id="Tc_lTUVvQyyPEiCoPkTkoZz5Q_6_2"></a><a id="Tc_5c6w1xk4B0ezY4YKJRFvZw_6_10"></a><a id="Tc_gKM8gDl9ykO7sPIbRG2zvw_6_12"></a><a id="Tc_RlC2BN-iikGz7oVMQ5OCdA_7_0"></a><a id="Tc_01uvAAXEY0i2EcElPr7OoQ_7_2"></a><a id="Tc_RQX6cVQie0mhIXY5dRDhZw_7_8"></a><a id="Tc_7s57W4s-WUSZ3v9TrVWdzg_7_10"></a><a id="Tc_Z-9zXfGRykWMgpG-Lv-DrA_8_0"></a><a id="_0b232723_1775_48d0_966a_cb9b8950c7b8"></a><a id="Tc_8q29yOzcJk-CiJzBgGzNBg_1_4"></a><a id="Tc_oH1DydSfjESCKR-4MEGksg_1_6"></a><a id="Tc_ZKMf7rY0DUeFG1QV0IpMYg_1_14"></a><a id="Tc_u_-rkyk0ukOVF5ZuqOYZWQ_1_16"></a><a id="Tc_LchXFciIk0K89BFwdM_9pw_2_2"></a><a id="Tc__AwcLXVjbEWs6btgTKLpuQ_2_4"></a><a id="Tc_xyCuXyNsw0WyZ-Kf_CB8xg_2_6"></a><a id="Tc_TBl0dhKgZUyjeuwV61Qjag_2_14"></a><a id="Tc_p9v2HcBd_kiURxf9mAiH1w_2_16"></a><a id="Tc_YtFvhEuBbkijMdEintog6g_3_0"></a><a id="Tc_JxCv_DAVs0Ggvt9DpIiKlQ_3_2"></a><a id="Tc_zz6tacZlTES2f7KgG3yfhA_3_4"></a><a id="Tc_23k5yfuoX0CaNvf6mmPrUA_3_6"></a><a id="Tc_gnA6n6V6AkG_cDMHLjrgiw_3_8"></a><a id="Tc_jN6LmPTAakiQVQlcrUi8Eg_3_10"></a><a id="Tc_ch37CnsBi0OKDb5Qeo9aww_3_12"></a><a id="Tc__0tHlmXWP0yC7R24RnaHDw_3_14"></a><a id="Tc_w74G7KMoHESLp4jCrpcQSg_3_16"></a><a id="Tc_YTVZ3tRQ-0CN6RZoPyv6sQ_4_0"></a><a id="Tc_kB6POas7g0iiA1Zkx3Jy8A_4_2"></a><a id="Tc_bbKs13RVzUWQEeJEHAiXHg_4_8"></a><a id="Tc_Tf4ur3VW3Uapkbx3nuMTyA_4_10"></a><a id="Tc_KixyJgqCVEmRrEfsaA_xYg_4_14"></a><a id="Tc_8sq4LNbsQEi7UGlhXjipGg_4_16"></a><a id="Tc_of0AmZR9sUWGMGf6zOByfg_5_0"></a><a id="Tc_OaiC8J0aVEWfBFZaamJcYA_5_8"></a><a id="Tc_da-MHjQWkUiqdjPiGMnBHQ_5_10"></a><a id="Tc_HCMVYsurp0iRaGFtydFvwQ_5_14"></a><a id="Tc_1-qqxJjYBUS6oZjbQSJT0A_5_16"></a><ix:continuation id="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont5" continuedAt="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont6"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;">Movements in AGA free shares (in number of shares issuable upon exercise)</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20231Member_dcxbZ8fZnk-mVxqgCGeiKQ" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" id="Group_Eh8smjht5k6DkYZPT81TaQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at grant date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at Jan&#160;1,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Forfeited /</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in euros)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Granted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Vested</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Lapsed</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AGA&#160;- Plan 2021 - 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">04/16/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlanAga20211Member_Bsp6KVWZMUiZgeIpAPgY1Q" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" id="Tc_olA5KjFXrUeguTr03VyKFw_4_4">11.30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlanAga20211Member_eh-BJlC8R0G04APW_IIiGQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc__PT8q_iPYUKfvPsBC-WG3Q_4_6">297,599</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlanAga20211Member_Bsp6KVWZMUiZgeIpAPgY1Q" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" scale="0" id="Tc_Rxq9fQ6nBUKrs7nE2h2xSA_4_10">296,166</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlanAga20211Member_Bsp6KVWZMUiZgeIpAPgY1Q" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" scale="0" id="Tc_YMn6sbHT0kyHha-bPAFzOw_4_12">1,433</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AGA&#160;- Plan 2021 - bis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/08/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlanAga2021BisMember_NCJt9ZQOW0SLSy6T5SliZA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" id="Tc_TmSdYifc0kaN2sBqYR_icQ_5_4">12.20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlanAga2021BisMember_d8RDeqcJHUuuc8eyxeiD5w" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_AlKpsgUGWEu88dtHCuiv6g_5_6">65,215</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlanAga2021BisMember_NCJt9ZQOW0SLSy6T5SliZA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" scale="0" id="Tc_3BUH4vY51kWxsNII-JFjCw_5_10">65,215</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AGA 2023-1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/25/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20231Member_dcxbZ8fZnk-mVxqgCGeiKQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" id="Tc_-rg6TJsgMkSR4nhCmyWJlw_6_4">2.60</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20231Member_OTdPP5Od7kuR-ubUIX8ZDg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_9khjczkEdkyxWu5TYNyShA_6_6">300,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20231Member_dcxbZ8fZnk-mVxqgCGeiKQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Tc_gYQXhj8X_UOO98HSedLXtw_6_8">300,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20231Member_oKFel_ng9UWwaxcU0ACQvw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_V_aqGX1WF0u8TU-8cPdTkw_6_14">600,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AGA 2023-2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/15/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20232Member_-sKnyEocNkawleXgjslx_A" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" id="Tc_dqZ0xLpork-2cegUrXIZHg_7_4">3.90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20232Member_FIpiNio7XkaVcs3vwtxlaQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_QQee2EIzZ0muQ12MPV9wow_7_6">748,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20232Member_-sKnyEocNkawleXgjslx_A" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" scale="0" id="Tc_EMUg92yWhUKfbj_1KB5_Fw_7_12">23,350</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20232Member_PqpzKUoY40ObENgyoIJeMQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_SgIwjNpbFkiKdihe7QU_EA_7_14">724,650</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TOTAL free shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BonusShareAwardPlansMember_mvV1f-1wH0ac-WZpqG9HRQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_TmkvzoT9uEm3WrU09UZr7Q_8_6">1,410,814</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BonusShareAwardPlansMember_4W-wr4J7bkuA5horxzjQWQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Tc_jlKBHXUAFkWrwLTIH1FYVA_8_8">300,000</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BonusShareAwardPlansMember_4W-wr4J7bkuA5horxzjQWQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" scale="0" id="Tc_Mnu37sDL1kWjf5nOLzhGmw_8_10">361,381</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BonusShareAwardPlansMember_4W-wr4J7bkuA5horxzjQWQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" scale="0" id="Tc_sbhSZGQoUEGbNenCkdLe0A_8_12">24,783</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BonusShareAwardPlansMember_m2JRheJguUWiLC2OX9PVmw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_Yv4iBrsCikGBEPJ36Opw4A_8_14">1,324,650</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At June 30, 2024, a total of <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BonusShareAwardPlansMember_m2JRheJguUWiLC2OX9PVmw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Narr_zdMPLjAVH0CpRQ0Kp2ppyQ">1,324,650</ix:nonFraction> AGA bonus shares were outstanding. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Following the amendment of article L. 225-197-1 II of the French Commercial Code by law no. 2023-1107 of November 29, 2023, the Board of Directors decided on 25 March 2024 to grant <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_3_25_2024_To_3_25_2024_avq7MDuDZ0qTbuTPxd88pQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_NRFLUVah6EaUuXULnpxDkg">300,000</ix:nonFraction> free shares to Frederic Cren in substitution for the PAGUP 2023. This allocation is governed by the regulations of the AGA 2023-1 plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Following the AGA 2021 and AGA 2021 bis acquisition period, a total of <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Aga2021Aga2021BisMember_94cRMy8qbkmwpgWKKI0Dmw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" scale="0" id="Narr_OPZ491uDzE6bKK-w7t7TLg">361,381</ix:nonFraction> shares were definitively acquired, resulting in a capital increase of &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Aga2021Aga2021BisMember_94cRMy8qbkmwpgWKKI0Dmw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" id="Narr_eNISM_bjQEGVfKnPoAEgFQ">3,613.81</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upon the completion of the acquisition period for the AGA 2021 and AGA 2021 bis plans, a total of <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Aga2021Aga2021BisMember_94cRMy8qbkmwpgWKKI0Dmw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" scale="0" id="Narr_2QoHwBtHyU-DPqNucCYsnw">361,381</ix:nonFraction> shares were acquired, resulting in a capital increase of &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Aga2021Aga2021BisMember_94cRMy8qbkmwpgWKKI0Dmw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" id="Narr_oryTEskKV0SFp68kiLL6CA">3,613.81</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The free share award plan is described in the Note 12.4 &#8220;Bonus share award plans&#8221; of the annual consolidated financial statements for the year ended on December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Share-based compensation expense with respect to AGA bonus shares and BSA share warrants totaled &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="Narr_FdmikPTU1UON9SyNxLMMyg">2.2</ix:nonFraction> million for the six months ended June 30, 2024, compared to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20231Member_7wRF3k96VkCeUYr4WvCKSg" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="Narr_02sHp7BFzU-tnpR_NSaI3w">2.0</ix:nonFraction> million for the six months ended June 30, 2023. They are recognized in personnel costs (see Note 5.2 &#8211; <i style="font-style:italic;">Operating expenses</i>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Performance units (&#8220;PAGUP&#8221;)</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnits2023Member_JOCpA6ku3UiPydoMyQrkIg" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" id="Tb_ay7MsI-b2EK7cmoYEWpNsQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of January 1, 2024, <ix:nonFraction unitRef="Unit_Standard_plan_EJ5kyu86bkGE5-lgkh4BhQ" contextRef="As_Of_1_1_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnitsMember_Zf-6fi4mZkOtN6iPVLbVdw" decimals="INF" format="ixt-sec:numwordsen" name="iva:NumberOfPlansOutstanding" scale="0" id="Narr_xRCOlIHTy0mjQlnUQ_YXeQ">one</ix:nonFraction> performance units plan was outstanding: PAGUP 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnitsMember_PlmUtIqdxEmw3YH5g0akfg" decimals="INF" format="ixt-sec:numwordsen" name="iva:NumberOfAwardPlansAttributed" scale="0" id="Narr_HAzUrCXqsUyhhIFWq2m0Dg">No</ix:nonFraction> performance units award plan has been attributed in the first six months of 2024.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:29.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reference</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price (in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at&#160;Jan&#160;1,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at&#160;June&#160;30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">euros)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issued</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercised</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Convert AGA</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PAGUP 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/25/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnits2023Member_JOCpA6ku3UiPydoMyQrkIg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" id="Tc_5tcC0DevpEaET1SCQVmKxw_4_4">2.60</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnits2023Member_bHs6Y4UJuEK6wcGSke6uGA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_uN4DlrpLVESNqRRnr604vg_4_6">300,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnits2023Member_JOCpA6ku3UiPydoMyQrkIg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" scale="0" id="Tc_kSKb6nETC0mJJtUQJPnziw_4_12">300,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TOTAL PAGUP</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnitsMember_S5ghW2BBqEaaOZO3f2CIIQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Tc_SUxF_fCFAkS5W9gXActAdg_5_6">300,000</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnitsMember_PlmUtIqdxEmw3YH5g0akfg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" scale="0" id="Tc_EeMVGijbokqqX6YjwNy3mw_5_12">300,000</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At June 30, 2024, <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="INF" format="ixt-sec:numwordsen" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" scale="0" id="Narr_frWTtlb7gE-LP_s20CZ0Wg">no</ix:nonFraction> PAGUP shares were outstanding. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Following the changes introduced by the French law no.2023-1107, the PAGUP 2023 granted on May 25, 2023 can be converted into AGAs. On March 25, 2024, the Board of Directors converted <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="As_Of_3_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_FredericCrenMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnits2023Member_rz9Dt9fkhka9C49bx8Vmng" decimals="INF" format="ixt:numdotdecimal" name="iva:NumberOfSharesConverted" scale="0" id="Narr_gDzY7qMEzUa8xRP_WBWTkg">300,000</ix:nonFraction> free shares (governed by the AGA 2023-1 regulations) to Fr&#233;d&#233;ric Cren, thereby lapsing the <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_3_25_2024_To_3_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_FredericCrenMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnits2023Member_hzRrxOsqEEe8Ngy7ccwfuw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" scale="0" id="Narr_nWkvVmfxCUa0tMpMAPDP5w">300,000</ix:nonFraction> PAGUP 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The performance units plan is described in the Note 12.5 &#8220;Performance units&#8221; of the annual consolidated financial statements for the year ended on December 31, 2023.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_4.10_Financial_debt"></a><a id="a49Financialdebt_888496"></a><a id="Financialdebt_754284"></a><a id="_3e796a80_52c1_4e12_bbb3_215ade4e4457"></a><a id="Tc_nLGLOojOL0eFniuTuKC8sw_1_0"></a><a id="Tc_Fh9L_v61f0ufSJ4G8--bnA_1_2"></a><a id="Tc_VAZodMLgT0aerFoNig_H7Q_1_4"></a><a id="Tc_X7Bcsd1g0UWIzzovbRgx7w_2_0"></a><a id="Tc_kNwoj0C4oUK7qO-ruYhYnw_3_0"></a><a id="Tc_1HKJeWv8ZU2U3BYJInxsxQ_4_0"></a><a id="Tc_EVJRsXobN0qk5rRNPAPYCg_5_0"></a><a id="Tc_maRQUloo9EWq8u6hds8NDA_6_0"></a><a id="Tc_A9X5TB841EqGs12VTF_KCw_7_0"></a><a id="Tc_fSSpwYEHg0WFQBLscs4vdw_1_0"></a><a id="Tc_1MYub3m0JkeW_T-9RgVT5g_1_2"></a><a id="Tc_F5m498QU0UOsqIfdxQe7CQ_1_4"></a><a id="Tc_o6eqq7HQ-k6gK47h-6u1Aw_2_0"></a><a id="Tc_AaZWoSI-vUyOA55U1zVRZg_3_0"></a><a id="Tc_julOhFuT-kqm4TPSXBV27Q_3_4"></a><a id="Tc_7ca1friQRUarxj_8RQjygg_4_0"></a><a id="Tc_dBBgQlYxS0qLqQF4CR2ccQ_4_4"></a><a id="Tc_1k2EQCbyF0anzOMrJDTuDA_5_0"></a><a id="Tc_4Mhz28uUH0yCQNxWdWX2_Q_6_0"></a><a id="Tc_CqhoA1-puEuRJx52R8OA-g_6_2"></a><a id="Tc_22aqdriewEewQBqavEdLWw_7_0"></a><a id="Tc_SvZKp2JKuE6e6QmqAPNALg_8_0"></a><a id="Tc_h30ZKp0d8E2Ho3x5vmAHjw_9_0"></a><a id="Tc_c1Ja6-QFFUmlaFYI7R1TiA_10_0"></a><a id="Tc_begjYyhqlESkwLY4z3SNYQ_11_0"></a><a id="Tc_zjIebCUtdkCfziR6Mdn68A_12_0"></a><a id="Tc_ZU0xQatoxESTAG5gnJp5Fg_13_0"></a><ix:continuation id="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont6" continuedAt="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont7"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.10</b></span>Financial debt</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory" id="Tb_9Y5KlPdCzUm9w5730DXvfA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Bank borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LoansReceived" scale="3" id="Tc_1Ciq5vID50ygAln6Oh114Q_2_2">42,509</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LoansReceived" scale="3" id="Tc_TJOKh_FuRUGxt3Q9g1NV2A_2_4">27,206</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Derivatives instruments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" scale="3" id="Tc_TfxHbWZXckOTUVfQ1mwgQA_3_2">13,569</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" scale="3" id="Tc_Zzx8zbegUkqFxFLpMgoWfg_3_4">10,265</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other loans and similar borrowings<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherBorrowings" scale="3" id="Tc_3W1QRxOnekqytlv9wF7IHg_4_2">4,302</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherBorrowings" scale="3" id="Tc_aaPPQSdLRku5W9Z5p7SSDw_4_4">3,719</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LeaseLiabilities" scale="3" id="Tc_Cl8cHJSYW0W9srmBiZxlFw_5_2">5,761</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LeaseLiabilities" scale="3" id="Tc_n0P0tpIgu0WTTiFb3ZOQdA_5_4">6,565</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalty certificates liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="iva:NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued" scale="3" id="Tc_EoUMzQYJUkqKBAjOFVOsjw_6_2">7,263</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="iva:NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued" scale="3" id="Tc_12PE9YXF5EK8BC9jrAv9gQ_6_4">6,327</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total debt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Borrowings" scale="3" id="Tc_sn4X4xfpskmB9bGewx11iw_7_2">73,404</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_VVi9UZTcQEKJWAcPl8yJKQ;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> 54,082</b></span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:italic;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">include accrued interests.</i></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Movements in the period break down as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="iva:DisclosureOfChangesInBorrowingsTableTextBlock" id="Tb_AlAi80OtDUSEtW5zkNUZ8Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">January 1, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Borrowings" scale="3" id="Tc_ren-pNL6WU6vUGRr9K7CpQ_2_2">54,083</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2022__ShBeryiXEKxoX7Xx7OS6A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Borrowings" scale="3" id="Tc_vFG_f3BTkkuRBoPLFUzK6g_2_4">44,390</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Subscription of derivatives instruments<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments" scale="3" id="Tc_auTBxKwjQEGyzxBuqa8hvQ_3_2">11,809</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Subscription of bank borrowings<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:Increaseinborrowingsthroughborrowingsreceived" scale="3" id="Tc_ZqK_cQ_WzEO96mnTuVWF0A_4_2">13,102</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Subscription of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:SubscriptionOfLeaseLiabilities" scale="3" id="Tc_XNMS_rW-OEas1QyCz89-cA_5_2">345</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA" decimals="-3" format="ixt:numdotdecimal" name="iva:SubscriptionOfLeaseLiabilities" scale="3" id="Tc_4-1t1IBiNUSWpctxqC-0rw_5_4">3,706</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Issue of royalty certificates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA" decimals="-3" format="ixt:numdotdecimal" name="iva:IssueOfRoyaltyCertificates" scale="3" id="Tc_skefifQSCUqkpXKZD1BMtg_6_4">5,100</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Repayment of bank borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings" scale="3" id="Tc_IKGN-RrlJ064ekZ7wTMATQ_7_2">1,177</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA" decimals="-3" format="ixt:numdotdecimal" name="iva:DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings" scale="3" id="Tc_xcVmPmT6wUOtNPknZVzKSQ_7_4">2,485</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Repayment of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities" scale="3" id="Tc_xAA0b8nxckaIq4g9-YYQzA_8_2">1,173</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA" decimals="-3" format="ixt:numdotdecimal" name="iva:DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities" scale="3" id="Tc_ROik2OJisE6ZNEu0HCCcZg_8_4">1,612</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Interests on royalty certificates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:InterestOnRoyaltyCertificates" scale="3" id="Tc_NQwvw7Lk8EGr1ZR8iOAinA_9_2">936</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA" decimals="-3" format="ixt:numdotdecimal" name="iva:InterestOnRoyaltyCertificates" scale="3" id="Tc_W5PtJnGxrkG_0UYNEOi8RA_9_4">1,227</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Capitalized interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:IncreaseInBorrowingsThroughCapitalizedInterest" scale="3" id="Tc_V9uehGNfhU2WNxEka56u-Q_10_2">3,961</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA" decimals="-3" format="ixt:numdotdecimal" name="iva:IncreaseInBorrowingsThroughCapitalizedInterest" scale="3" id="Tc_r4kwdPjtbU-lygG99o5UEw_10_4">3,405</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Change in fair value of derivatives instruments<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments" sign="-" scale="3" id="Tc_OtcVFi_BrEiKeK-tDe_5zQ_11_2">8,506</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA" decimals="-3" format="ixt:numdotdecimal" name="iva:IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments" scale="3" id="Tc_EeFdgWjGckWQQMeRjCEoow_11_4">389</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Exchange rate change</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates" scale="3" id="Tc_pSSAnVC9_0yRJ8u4OeNikA_12_2">24</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA" decimals="-3" format="ixt:numdotdecimal" name="iva:IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates" sign="-" scale="3" id="Tc_mBuAoNcT50O7o99cJvhxXw_12_4">38</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Borrowings" scale="3" id="Tc_9k2gYw2ZYUug5_249Ijrpg_13_2">73,404</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Borrowings" scale="3" id="Tc_KiY9re9oKk-akz-WCXMa7w_13_4">54,083</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">(1)</sup><span style="display:inline-block;width:10.42pt;"></span><i style="font-style:italic;">Net proceed</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="display:inline-block;width:10.42pt;"></span><i style="font-style:italic;">EIB&#8217;s loan and warrants.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">French state-guaranteed loan (&#8220;PGE&#8221;) and equity recovery loans (&#8220;PPR&#8221;)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2020, the Company entered into <ix:nonFraction unitRef="Unit_Standard_agreement_ds7eY0UVBEmjbbj4M4LxNQ" contextRef="Duration_5_1_2020_To_5_31_2020_ifrs-full_BorrowingsByNameAxis_iva_FinancingFromSyndicateOfFrenchBanksMember_tgQsngIelEWdVjh0z4mOYQ" decimals="0" format="ixt-sec:numwordsen" name="iva:NumberOfLoansObtainedGuaranteedByFrenchState" scale="0" id="Narr_gZQTYXW48U6dVVoxqQLexg">three</ix:nonFraction> credit agreements pursuant to which it received &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_5_1_2020_To_5_31_2020_ifrs-full_BorrowingsByNameAxis_iva_FinancingFromSyndicateOfFrenchBanksMember_tgQsngIelEWdVjh0z4mOYQ" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" scale="6" id="Narr_6xFX2TznLkudpy5umLB2Pw">10.0</ix:nonFraction> million in the form of state-guaranteed loans (<i style="font-style:italic;">Pr&#234;ts Garantis par l&#8217;Etat</i>, or &#8220;PGE&#8221;) which are provided by a syndicate of French banks and guaranteed by the French government in the context of the COVID-19 pandemic and were initially set to mature in May 2021. These loans were extended until the third quarter of 2022. The amendments provide for reimbursements to be made over <ix:nonNumeric contextRef="Duration_5_1_2020_To_5_31_2020_ifrs-full_BorrowingsByNameAxis_iva_FinancingFromSyndicateOfFrenchBanksMember_tgQsngIelEWdVjh0z4mOYQ" format="ixt-sec:durwordsen" name="iva:BorrowingsMaximumExtensionTerm" id="Narr_ltxb78CjMUWme4D6C7pPlA"><ix:nonNumeric contextRef="Duration_5_1_2020_To_5_31_2020_ifrs-full_BorrowingsByNameAxis_iva_FinancingFromSyndicateOfFrenchBanksMember_tgQsngIelEWdVjh0z4mOYQ" format="ixt-sec:durwordsen" name="iva:BorrowingsMaximumExtensionTerm" id="Narr_Cxe9f7oEUE-CIFnTIXHOBQ">four years</ix:nonNumeric></ix:nonNumeric>, beginning in July 2022 for the loan from Cr&#233;dit Agricole and in September 2022 for the loans from Bpifrance and Soci&#233;t&#233; G&#233;n&#233;rale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2022, the Company entered into <ix:nonFraction unitRef="Unit_Standard_loan_rE4-q-dHoUqS2Tn_Pp9_NQ" contextRef="Duration_6_1_2022_To_6_30_2022_ifrs-full_BorrowingsByNameAxis_iva_FinancingFromSyndicateOfFrenchBanksMember_age9N1IGyke_9J5_9xJiwA" decimals="0" format="ixt-sec:numwordsen" name="iva:NumberOfLoanAgreements" scale="0" id="Narr_Zr9ZNGo7fEqmev1hJxPsOQ">three</ix:nonFraction> loan agreements with a syndicate of French banks for a total amount of &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2022_ifrs-full_BorrowingsByNameAxis_iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember_C9WbfUum90KUsBfHNequkg" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:NotionalAmount" scale="6" id="Narr_xS2SNKyk5UycaOAHrnU2fQ">5.3</ix:nonFraction> million. <ix:nonFraction unitRef="Unit_Standard_loan_rE4-q-dHoUqS2Tn_Pp9_NQ" contextRef="Duration_6_1_2022_To_6_30_2022_ifrs-full_BorrowingsByNameAxis_iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember_pRmHDD5O_EOFWPfNYEeiDw" decimals="0" format="ixt-sec:numwordsen" name="iva:NumberOfLoanAgreements" scale="0" id="Narr_MUIM9UKuQUaBcVurFwQ-4g">One</ix:nonFraction> loan agreement was part of a state-guaranteed PGE loan facility with Bpifrance and the other <ix:nonFraction unitRef="Unit_Standard_loan_rE4-q-dHoUqS2Tn_Pp9_NQ" contextRef="Duration_6_1_2022_To_6_30_2022_ifrs-full_BorrowingsByNameAxis_iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember_rVGAMd543kWMTqS80gXZVA" decimals="0" format="ixt-sec:numwordsen" name="iva:NumberOfLoanAgreements" scale="0" id="Narr_hUB6WWdhFUGH1qLkwCTEuQ">two</ix:nonFraction> loan agreements were part of a stimulus economic plan (<i style="font-style:italic;">Pr&#234;ts Participatifs Relance</i>, or &#8220;PPR&#8221;) granted by Cr&#233;dit Agricole Champagne-Bourgogne and Soci&#233;t&#233; G&#233;n&#233;rale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The PGE loan granted by Bpifrance in 2022 is guaranteed up to <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_BorrowingsByNameAxis_iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember_5BKdyoSBV0uhtWALpjAz8A" decimals="2" format="ixt:numdotdecimal" name="iva:PercentageOfLoanGuaranteedByFrenchState" scale="-2" id="Narr_tYmr5lrKrEqS6mDWuMWUWg">90</ix:nonFraction>% by the French government with an initial term of twelve months. In May 2023, the Company exercised the option to extend the maturity to align with the 2020 PGE, until May 2026. The two PPR loans are guaranteed predominantly by the French government and feature an <ix:nonNumeric contextRef="Duration_5_1_2023_To_5_31_2023_ifrs-full_BorrowingsByNameAxis_iva_EquityRecoveryLoansMember_FFIOm4lTLk6UQV8mUsy60w" format="ixt-sec:durwordsen" name="iva:FinancingPeriodOfLoan" id="Narr_6mpahCKQWk6Hl8QMqmnRcA">eight-year</ix:nonNumeric> financing period and a <ix:nonNumeric contextRef="Duration_5_1_2023_To_5_31_2023_ifrs-full_BorrowingsByNameAxis_iva_EquityRecoveryLoansMember_FFIOm4lTLk6UQV8mUsy60w" format="ixt-sec:durwordsen" name="iva:RepaymentPeriodOfLoan" id="Narr_ydZsETqzG0-LSOkDbCKLMQ">four-year</ix:nonNumeric> repayment period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The PGE repayments in the first six months of 2024 amounted to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinancingFromSyndicateOfFrenchBanksMember_b3jNddOSCEqLn7eTIlNpJw" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" scale="6" id="Narr_NcpSOzSvBE-17FlkOVKHuA">1.2</ix:nonFraction> million.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont7" continuedAt="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont8"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Credit facility agreement with the European Investment Bank</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 16, 2022, the Company entered into the Finance Contract with the EIB for up to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_5_16_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_m_1J6hotsk-dhzgHfJ6CBA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NotionalAmount" scale="6" id="Narr_K7hdsHFG5EqhqQbtkX4omw">50</ix:nonFraction> million, divided into <ix:nonFraction unitRef="Unit_Standard_tranche_EQcocZ7SkkmFtux0nXQhjQ" contextRef="Duration_5_16_2022_To_5_16_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_iCBdyRK5rUeePAFm5LecHg" decimals="INF" format="ixt-sec:numwordsen" name="iva:NumberOfEqualTranches" scale="0" id="Narr_gFIA6jfqK0CjfpY0vlLg2w">two</ix:nonFraction> tranches of &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_5_16_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_m_1J6hotsk-dhzgHfJ6CBA" decimals="-6" format="ixt:numdotdecimal" name="iva:NotionalAmountPerTranche" scale="6" id="Narr_cgjkbXJGZE2f3yxNtfhxlw">25</ix:nonFraction> million each. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On December 8, 2022, the Company received the disbursement of Tranche A. Capitalized interest for Tranche A is </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_12_8_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_NZ-ZgvUE8kOsb70mJ03KSw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="Narr_36FmphlPt0mETskA92GkMg">8</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and repayment is due in December 2026, </span><ix:nonNumeric contextRef="Duration_12_8_2022_To_12_8_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_Oji8AIqwMEebyNKqGL3bwA" format="ixt-sec:durwordsen" name="iva:IfrsDebtInstrumentTerm" id="Narr_AtuuxEvetkqSc-aeYS3QEw"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four years</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> after its disbursement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On January 18, 2024, the Company received the disbursement of Tranche B (see Note 1.2. &#8211; </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Significant events in the first six months of 2024</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">). Capitalized interest for Tranche B is </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_DrawdownOfBorrowingsMember_MLnrGxu8pEeScrxg9appZw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="Narr_AJs_DaejeUWtXI0wB_sXmA">7</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and repayment is due in January 2027, </span><ix:nonNumeric contextRef="Duration_1_18_2024_To_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_DrawdownOfBorrowingsMember_qBP5Y6KUBkGy4f5mXUW39g" format="ixt-sec:durwordsen" name="iva:IfrsDebtInstrumentTerm" id="Narr_zMulVsKTBEuW1LD-mhhA0g"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three years</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> after its disbursement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Finance Contract may, in certain circumstances, be prepaid, in whole or in part, for a prepayment fee, either at the election of the Company or as a result of EIB&#8217;s demand following certain prepayment events, including a change of control or change in senior management of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Subject to certain terms and conditions, upon the occurrence of usual events of default (i.e., including payment default, misrepresentation, cross default), EIB may demand immediate repayment by the Company of all or part of the outstanding loan. As of June 30, 2024 there was no demand of reimbursement of the outstanding loan. Tranche A of &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_yNqR8syCVkyKUkjoBw5nlA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NotionalAmount" scale="6" id="Narr_2P8vMcl5V0mC0r0hJa6vBQ">25</ix:nonFraction> million was recognized as financial debt at amortized cost, which takes into account the fair value of the derivative instrument (EIB Warrants) at inception and the borrowing costs of &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_0umwc-ynPU6vJhwvCODdKw" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:BorrowingCostsIncurred" scale="6" id="Narr_UZkXqpvim0aPwZImf-uSpQ">0.1</ix:nonFraction> million. The amortized cost of the loan is &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_ll91CELP_0CkxmWGnSWYxw" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:Borrowings" scale="6" id="Narr_c9V_gN11mUeJSXqq20jWuA">15.4</ix:nonFraction> million on December 31, 2023, and is &#8364; <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_yNqR8syCVkyKUkjoBw5nlA" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:Borrowings" scale="6" id="Narr_kggvS2wzXkGkC102UcOeAg">21.1</ix:nonFraction> million on June 30, 2024, with an effective interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_yNqR8syCVkyKUkjoBw5nlA" decimals="3" format="ixt:numdotdecimal" name="iva:BorrowingsEffectiveInterestRate" scale="-2" id="Narr_5IDsAGgMTkaaTUIEco20nA"><ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_ll91CELP_0CkxmWGnSWYxw" decimals="3" format="ixt:numdotdecimal" name="iva:BorrowingsEffectiveInterestRate" scale="-2" id="Narr_D7_NT5u0P0CTiegSHXlacQ">21.9</ix:nonFraction></ix:nonFraction>%. The fair value of the loan as of June 30, 2024, amount to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueMember_1nI2yYCJCEKKgVIHzRJEzA" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="6" id="Narr__uJp5d8pn0qAoxbUwQQxvQ">20.6</ix:nonFraction> million, with a market rate of <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueMember_1nI2yYCJCEKKgVIHzRJEzA" decimals="3" format="ixt:numdotdecimal" name="iva:BorrowingsActualizationRate" scale="-2" id="Narr_wj-XP0Dwvkq-r1n5exfGaw">22.9</ix:nonFraction>%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Tranche B of &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_HZvpAkHv40a_7feAGh0Gmg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NotionalAmount" scale="6" id="Narr_OTaLzXzfPkKJ0j3bUVSY6g">25</ix:nonFraction> million was recognized as financial debt at amortized cost, which takes into account the fair value of the derivative instrument (EIB Warrants) at inception and the borrowing costs of &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_18_2024_To_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_EpuGEvGLYke1tVD4Ocdy8Q" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:BorrowingCostsIncurred" scale="6" id="Narr_dy7ErOIJTkex-X0EoAAWzA">0.1</ix:nonFraction> million. The amortized cost of the loan is &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_KCZ_rlJbTkm1DXPXbOCPUg" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:Borrowings" scale="6" id="Narr_Jfp45C80n0WLjS2s4QQASg">15.0</ix:nonFraction> million on June 30, 2024, with an effective interest rate of &#160;<ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_KCZ_rlJbTkm1DXPXbOCPUg" decimals="3" format="ixt:numdotdecimal" name="iva:BorrowingsEffectiveInterestRate" scale="-2" id="Narr_DNXrJmIFT0y3GkvuRL0tIA">32.7</ix:nonFraction>%. The fair value of the loan as of June 30, 2024, amount to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueMember_4SVWIFElkkKFKpxz6K2mDw" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="6" id="Narr_q33CHbIBkEupQo3ZuShCdQ">14.7</ix:nonFraction> million, with a market rate of <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueMember_4SVWIFElkkKFKpxz6K2mDw" decimals="3" format="ixt:numdotdecimal" name="iva:BorrowingsActualizationRate" scale="-2" id="Narr_SZUhKKFXKkiqcOY0pEmRfQ">33.2</ix:nonFraction>%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The capitalized interest for both Tranche A and Tranche B in the period amounted to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_7knLDQKU6EWqcXxngWZMRA" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:InterestCostsCapitalised" scale="6" id="Narr_q5AqoKiSSE6uxCf6E6hgQg">4.0</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Derivatives</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On July 1, 2022, in connection with the Finance Contract (see section above &#8220;Credit facility agreement with the European Investment Bank&#8221;), the Company entered into a warrant agreement as a condition to the funding of the two tranches of the credit facility. Each EIB Warrant has a subscription price of &#8364;<ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_7_1_2022_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember__QhdYl76K0agjKJOQ6cDBQ" decimals="2" format="ixt:numdotdecimal" name="iva:SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted" scale="0" id="Narr_Xhf6WXgTEUaBb-XxX8NQuA">0.01</ix:nonFraction> and gives the right to subscribe to one share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The number of EIB Warrants issued to EIB was determined based on (i) the aggregate amount raised by the Company through one or more equity offerings, or through upfront or milestone payments, from the date of the Finance Contract to the time of the disbursement of the relevant tranche, and (ii)(a) the average price per share paid for the Company&#8217;s shares in its most recent qualifying equity offering or (ii)(b) for Tranche A only, in case of no qualifying equity offering, the volume weighted average price per share of the Company over the last <ix:nonNumeric contextRef="Duration_7_1_2022_To_7_1_2022_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_mT6R0SioNkS8Jv1u9vcknw" format="ixt-sec:durday" name="iva:TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued" id="Narr_DCdqCN-rlkiCLZqcE4Rz4A">180</ix:nonNumeric> calendar days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The EIB Warrants have a maturity of &#160;<ix:nonNumeric contextRef="Duration_7_1_2022_To_7_1_2022_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_XoSz7rHj_Umg-MPSR-Funw" format="ixt-sec:durwordsen" name="iva:ClassOfWarrantOrRightMaturityTerm" id="Narr_1h-64P0QHEeKZFerbS4TGw">twelve years</ix:nonNumeric> and are exercisable following the earliest to occur of (i) a change of control event, (ii) the maturity date of Tranche A, (iii) an event of default under the Finance Contract, or (iv) a repayment demand by the EIB under the Finance Contract. The EIB Warrants shall automatically be deemed null and void if they are not exercised within the <ix:nonNumeric contextRef="Duration_7_1_2022_To_7_1_2022_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_XoSz7rHj_Umg-MPSR-Funw" format="ixt-sec:durwordsen" name="iva:ClassOfWarrantOrRightMaturityTerm" id="Narr_hiAj5NzMyUyVnQRkF_durg">twelve-year</ix:nonNumeric> period. Each EIB Warrant will entitle EIB to <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_7_1_2022_To_7_1_2022_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_XoSz7rHj_Umg-MPSR-Funw" decimals="INF" format="ixt-sec:numwordsen" name="iva:NumberOfSharesPerOtherEquityInstrumentGranted" scale="0" id="Narr_69mVzpTUc0-Pc0Kj-_G_WA">one</ix:nonFraction> ordinary share of the Company in exchange for the exercise price (subject to anti-dilutive provisions). However, the exercise ratio of EIB Tranche A warrants has been adjusted on December 31, 2023 following the September 5, 2023 capital increase; One EIB Tranche A Warrant entitles its holder to subscribe for <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_e2AEajgpOke0pQ8o_y36nw" decimals="2" format="ixt:numdotdecimal" name="iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_Rj7JMiviR0mYUiiNRzd9qQ">1.20</ix:nonFraction> ordinary shares in the Company. EIB is entitled to a put option at its intrinsic value to require the Company to buy back the exercisable EIB Warrants not yet exercised in certain of these occurrences.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont8" continuedAt="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont9"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 28, 2022, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_11_28_2022_To_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_FvqTByEiaEuWx4OtWlgNhA" decimals="INF" format="ixt:numdotdecimal" name="iva:ClassOfWarrantOrRightGranted" scale="0" id="Narr_NoPpdwCGMUCKQRSQZysnzA">2,266,023</ix:nonFraction> EIB Tranche A Warrants to EIB, in accordance with the terms of the 25th resolution of the Combined General Shareholders' Meeting of May 19, 2022 and Article L. 225-138 of the French Commercial Code, as a condition to the financing of Tranche A, representing approximately <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_11_28_2022_To_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_FvqTByEiaEuWx4OtWlgNhA" decimals="3" format="ixt:numdotdecimal" name="iva:PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants" scale="-2" id="Narr_DEl3_rNah0aaNSq-0EI0xQ">4.7</ix:nonFraction>% of the Company&#8217;s share capital as of June 30, 2024. The exercise price of the EIB Tranche A Warrants is &#8364;<ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_QTQ5vqXpNE2ib3CFSHvYaw" decimals="4" format="ixt:numdotdecimal" name="iva:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" scale="0" id="Narr_NvesCX4_20iUeHMFKIE6vA">4.0152</ix:nonFraction>, if and when they may be exercised. The potential gross proceeds if all EIB Tranche A Warrants were exercised would amount to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_11_28_2022_To_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_FvqTByEiaEuWx4OtWlgNhA" decimals="-5" format="ixt:numdotdecimal" name="iva:MaximumPotentialGrossProceedsFromExerciseOfWarrants" scale="6" id="Narr_TUEPiVyggUqZtjPDh6WZPQ">9.1</ix:nonFraction> million. The transactions costs for the issuance of the EIB Tranche A Warrants amounted to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_11_28_2022_To_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_FvqTByEiaEuWx4OtWlgNhA" decimals="-3" format="ixt:numdotdecimal" name="iva:TransactionCostsOnIssueOfWarrants" scale="3" id="Narr_M-iTbdjBBUm1yEkOy7vXsA">56</ix:nonFraction> thousands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 4, 2024, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_2nmqoYhWkkOgh_AeHuYFnQ" decimals="INF" format="ixt:numdotdecimal" name="iva:ClassOfWarrantOrRightGranted" scale="0" id="Narr__lfkNnoO4kCmVVdH-5l1NA">3,144,654</ix:nonFraction> EIB Tranche B Warrants to EIB, representing approximately <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_2nmqoYhWkkOgh_AeHuYFnQ" decimals="3" format="ixt:numdotdecimal" name="iva:PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants" scale="-2" id="Narr_u5RjKAEMeUOTtoGsrs6zMA">5.2</ix:nonFraction>% of the Company&#8217;s share capital as of June 30, 2024, in accordance with the terms of the 6<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> resolution of the Combined General Shareholders' Meeting of January 25, 2023, and Article L. 225-138 of the French Commercial Code. The exercise price of the EIB Tranche B Warrants is &#8364;<ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_YCO92YM7_064nsFEWIY8Jw" decimals="2" format="ixt:numdotdecimal" name="iva:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" scale="0" id="Narr_vDhRktBldU6FwxHSEp-frQ">3.95</ix:nonFraction>, if and when they may be exercised. The potential gross proceeds if all EIB &#160;Tranche B Warrants were exercised would amount to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_2nmqoYhWkkOgh_AeHuYFnQ" decimals="-5" format="ixt:numdotdecimal" name="iva:MaximumPotentialGrossProceedsFromExerciseOfWarrants" scale="6" id="Narr_5NZbbQkTAk6zDEz10sCNVg">12.4</ix:nonFraction> million. The transactions costs for the issuance of the EIB Tranche B Warrants amounted to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_2nmqoYhWkkOgh_AeHuYFnQ" decimals="-3" format="ixt:numdotdecimal" name="iva:TransactionCostsOnIssueOfWarrants" scale="3" id="Narr_HIOTqcyT-E-U1Ip7lx05VQ">90</ix:nonFraction> thousands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The EIB Warrants do not meet the &#8220;fixed for fixed&#8221; criteria (non-cash settlement option which may result in exchanging a variable number of shares for a variable price) and are accounted for as standalone derivative instruments. The Company&#8217;s put options meet the definition of a derivative that are valued with the EIB Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The warrant agreement includes a put option: EIB may request the Company to buy back the EIB Warrants in cash. In this context the purchase price will be defined as the difference between the volume weighted average of the trading price of the ordinary shares over the last <ix:nonFraction unitRef="Unit_Standard_D_UN8jRVLLaEed_W_JH8a6Og" contextRef="Duration_11_28_2022_To_11_28_2022_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_ixbJJMHX7k-KJKKJhzrKQw" decimals="INF" format="ixt:numdotdecimal" name="iva:WarrantsThresholdTradingDays" scale="0" id="Narr_YxOSjZZr-EmRoGICvQbxlg">90</ix:nonFraction> trading days and the strike price. The amount is capped, and EIB may exercise the EIB Warrants for which they did not exercise the put option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At inception, the financial debts are split between i) a debt component accounted for at amortized cost, and ii) a premium corresponding to the initial fair value of attached EIB Warrants (then remeasured at fair value through profit and loss) including a component corresponding to the put options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Valuation approach</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of the EIB Warrants has been estimated based on a Longstaff Schwartz approach, including the put option and the attached cap.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This approach enables the estimation of the value of American options (that may be exercised during a specific period of time) with complex way of exercise (the warrant holder may exercise the warrants on the market based on the Company&#8217;s share price or exercise the put option based on the <ix:nonFraction unitRef="Unit_Standard_D_UN8jRVLLaEed_W_JH8a6Og" contextRef="Duration_11_28_2022_To_11_28_2022_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_ixbJJMHX7k-KJKKJhzrKQw" decimals="INF" format="ixt:numdotdecimal" name="iva:WarrantsThresholdTradingDays" scale="0" id="Narr_hExtM_3rLk6L_M3XtPoFKA">90</ix:nonFraction> days average share price of the Company).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Longstaff Schwartz approach is also based on the value of the underlying equity instrument at the valuation date, the volatility observed on the historical share price of the Company, and the contractual lifespan associated equity instruments.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_8f4db344_24cb_4bfc_94b9_7c1c5457d1d8"></a><a id="Tc_F4DOlcT4vk-xtK3-ViZV4g_1_2"></a><a id="Tc_n7vREzuB_UC_mNd0TkkSZw_1_4"></a><a id="Tc_r2rBK-0oWk2E4yQI9zPGUw_2_0"></a><a id="Tc_b7JylSQ_A0SEXWfti6E8mw_2_2"></a><a id="Tc_ZTkD27l5HEedskHxOiyk4Q_2_4"></a><a id="Tc_Z9F8hSj4gk2fXRFqqpHlAg_3_0"></a><a id="Tc_hFHryrjEhkeR7op_Py77Kw_3_2"></a><a id="Tc_z5BNGsthsE-BDy7hdODUlA_3_4"></a><a id="Tc_wM97v3CqD06qzsGnaJJTnQ_4_0"></a><a id="Tc__skvgeTFq0SzTqVYqkCWfw_5_0"></a><a id="Tc_bUReIBy3hUOLeVptjhCuNA_6_0"></a><a id="Tc_EL6w3WJkTUWjjpp4kHvrIA_7_0"></a><a id="Tc_Pv-_Jb8czEOucCJwpC-nKg_8_0"></a><a id="Tc_vwNemz9y_EW8RPUVV_Axmg_8_2"></a><a id="Tc_-xBeNiYiuE-LpdlRyOSLwA_8_4"></a><a id="_5a8273bb_e98d_4e1f_a1d5_fcd9ca6ede55"></a><a id="Tc_YbFnVFgK5kaRKbcUhrXTCA_1_2"></a><a id="Tc_wyKNTvdVt02fNlUdrbw4_g_2_0"></a><a id="Tc_PN_sXRUFS0O2IOjSkPlB_A_2_2"></a><a id="Tc_JMVE5W87d0O46NwqvERlYg_2_4"></a><a id="Tc_uJBCr3LSrkeZwG-sET4AeA_2_6"></a><a id="Tc_fHSLyZyqZkKWQ7PNqss5cA_3_0"></a><a id="Tc_dgVMMOEu7kCbMKYtivYszw_4_0"></a><a id="Tc_h2SjLuWuSkSfMInO2E9sTw_5_0"></a><a id="Tc_mWfvwDyQpUm6yr84uKpguQ_6_0"></a><a id="Tc_rY7EItchD0efRwpPKTCPWQ_7_0"></a><a id="Tc_oJMLdRssTEOTtTDQiB2u3Q_7_3"></a><a id="Tc_6-Ql5gztnE6GSaBzFMhqUQ_7_5"></a><a id="Tc_qepMS0R2QUeFARhWUVLXVw_7_7"></a><a id="Tc_ItKjF5_v1EeVblLWxTlf-w_8_0"></a><a id="Tc_Wsb_r39SHkq7cgfg22_XGQ_9_0"></a><a id="Tc_7k8Z1t4lI0G9TS4piqKDtQ_9_2"></a><a id="Tc_8xbrgsgwcUegkl2kz1KsFg_9_4"></a><a id="Tc_xO8YuD6kr0yOnQR0cDyIiQ_9_6"></a><a id="Tc_60zM6KKoq0a96fdCCYnLdg_10_0"></a><a id="Tc_DIjLjerOrESkEFETEcs2qA_10_2"></a><a id="Tc_XB-pCWdpF0Cmx_IVbyavQA_10_4"></a><a id="Tc_VYfDH8LeJU-VZ0_CJCfk3A_10_6"></a><a id="Tc_AnYudHv2zUKxlpQe5VgjRg_11_0"></a><a id="Tc_pqc0KMQWjUGo5noa-6ttuQ_12_0"></a><a id="_9648e994_5309_42af_9d67_12fc8f2555f9"></a><a id="Tc_5mXGUQ6G_U60hxnATXXfGg_1_2"></a><a id="Tc_OuyurUoH8k-wP5YqbCbmfQ_2_0"></a><a id="Tc_NdPddIbiO0-snEhYRA-MPw_2_2"></a><a id="Tc_U8He7Eb9M0OwynkfGlnlkw_2_4"></a><a id="Tc_DtU4bUPfcEyE6VqaxB6kXw_3_0"></a><a id="Tc_TO-TPOoqEkWls5DIoid5Nw_4_0"></a><a id="Tc_7v-zI4xzjESkzFVGa2PGRQ_5_0"></a><a id="Tc_J7Ni4RqNW0O2KoFWoFC0BA_6_0"></a><a id="Tc_FcoTo_VXpUeifCthdnEsFQ_7_0"></a><a id="Tc_M34tS5oJDE2bDm_6PC_mBA_7_3"></a><a id="Tc_18naebS6pEKKvKjKwv0-tA_7_5"></a><a id="Tc_hEPn4Rz5S0mMBlEqNILsKQ_8_0"></a><a id="Tc_bsgxSLOzhUSf-gznQjSQsA_9_0"></a><a id="Tc_cL-wFpwJEkCj6IOdRpfGyA_9_2"></a><a id="Tc_1izkapqE2021SnSMdurEbg_9_4"></a><a id="Tc_z4IvigTAzk-Fu1RByPNUJA_10_0"></a><a id="Tc_KxPqhYtj8UW0XsNtMhUazw_10_2"></a><a id="Tc_OIsq1iLOuU2RSmGm89bR3A_10_4"></a><a id="Tc_GPoeyaAPlEmZY5vQIA21DQ_11_0"></a><a id="Tc_eB6Mr9tVOkGzzUlnwS39hQ_12_0"></a><ix:continuation id="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont9" continuedAt="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont10"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The hypothesis and results are detailed in the following tables:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="iva:DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock" id="Tb_vcx65z1y40-zgHnk-LDwhw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BSA 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BSA 2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Grant date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11/28/2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">01/04/2024</p></td></tr><tr><td style="vertical-align:bottom;width:65.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expiration date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11/28/2034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">01/04/2036</p></td></tr><tr><td style="vertical-align:bottom;width:65.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Number of BSA issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2022Member_rqfjl8o2ykC3r6A9zJWDeQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Tc_IJEo5qkh1UOtgULz8Ojw5Q_4_2">2,266,023</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2024Member_SKyx2I-L-E2qRPd_8ZtRDQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Tc_pMILG-C2NkOJIs-FPmF2_A_4_4">3,144,654</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Number of shares per BSA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2022Member_lXOe9V-g3Uq8tzFzKYE_rw" decimals="0" format="ixt:numdotdecimal" name="iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Tc_nmdX6hBMf06uyg-O4EtakA_5_2">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2024Member_o0JPxKp_cEaymg2N36omtQ" decimals="0" format="ixt:numdotdecimal" name="iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Tc_vI1Wx3plAkGVE1MY3OfwRg_5_4">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Subscription premium price per share (&#8364;)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2022Member_lXOe9V-g3Uq8tzFzKYE_rw" decimals="2" format="ixt:numdotdecimal" name="iva:SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted" scale="0" id="Tc_0pbR7PUyx06WKUNJXD4Zvg_6_2">0.01</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2024Member_o0JPxKp_cEaymg2N36omtQ" decimals="2" format="ixt:numdotdecimal" name="iva:SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted" scale="0" id="Tc_slvYieah5UCTQrx1d2PM6g_6_4">0.01</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Exercise price per share (&#8364;)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2022Member_lXOe9V-g3Uq8tzFzKYE_rw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="Tc_86Z-96VKT0yK6Lhl68ni1w_7_2">4.02</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2024Member_o0JPxKp_cEaymg2N36omtQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="Tc_YCF7l-6FtUWHDxhHQTaLrg_7_4">3.95</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Valuation method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Longstaff Schwartz</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Longstaff Schwartz</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;November&#160;28,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">EIB Tranche A Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;(Grant&#160;Date)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Number of BSA outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="As_Of_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lpf5jlqhR0GVIbvPIhKnYw" decimals="INF" format="ixt:numdotdecimal" name="iva:IfrsClassOfWarrantOrRightOutstanding" scale="0" id="Tc_Q8HrdidQ1kS4H9L3U_Nm9w_3_2">2,266,023</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ldh6EouHQke8vr_BH-JvxQ" decimals="INF" format="ixt:numdotdecimal" name="iva:IfrsClassOfWarrantOrRightOutstanding" scale="0" id="Tc_HMUMUFb02Uez6mJMGlb3kQ_3_4">2,266,023</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_EFM8TpwCpkqu7FVPRM1rTQ" decimals="INF" format="ixt:numdotdecimal" name="iva:IfrsClassOfWarrantOrRightOutstanding" scale="0" id="Tc_gS093KdbK0ajdpWUW-pQRA_3_6">2,266,023</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Number of shares per BSA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="As_Of_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lpf5jlqhR0GVIbvPIhKnYw" decimals="2" format="ixt:numdotdecimal" name="iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Tc_sQxUcwcMH0CbvJP9pZlL2A_4_2">1.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ldh6EouHQke8vr_BH-JvxQ" decimals="2" format="ixt:numdotdecimal" name="iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Tc_3nGYrfTNnUSNT91etaZ-Fw_4_4">1.20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_EFM8TpwCpkqu7FVPRM1rTQ" decimals="2" format="ixt:numdotdecimal" name="iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Tc__EMDxv-Pi0yEOEMGwbPQxw_4_6">1.27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock price (&#8364;)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lpf5jlqhR0GVIbvPIhKnYw" decimals="2" format="ixt:numdotdecimal" name="iva:WarrantsStockPrice" scale="0" id="Tc_qos2RFNwXE28MmXWrSQcAQ_5_2">4.13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ldh6EouHQke8vr_BH-JvxQ" decimals="2" format="ixt:numdotdecimal" name="iva:WarrantsStockPrice" scale="0" id="Tc_OjpM1lbFn06DvCl9oYhemg_5_4">4.10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_EFM8TpwCpkqu7FVPRM1rTQ" decimals="2" format="ixt:numdotdecimal" name="iva:WarrantsStockPrice" scale="0" id="Tc_sp8ha_mSP0-R11Sbd_fTMA_5_6">2.79</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maturity (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_11_28_2022_To_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_3hNTQf5aEEemSQq6uYohDA" format="ixt-sec:duryear" name="iva:WarrantAverageLife" id="Tc_UQ2guG79dESNtQd1Q5Gfkg_6_2"> 12</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_CSHhFS0Lg0Gzg_yzNEELZQ" format="ixt-sec:duryear" name="iva:WarrantAverageLife" id="Tc_Wspmtr-MCkSUR4usXNK3Sw_6_4"> 10.9</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lX6me24ptE-Xl7VzcNGlCA" format="ixt-sec:duryear" name="iva:WarrantAverageLife" id="Tc_qqozQYndg0qAYgWSaLM8_g_6_6"> 10.4</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lpf5jlqhR0GVIbvPIhKnYw" decimals="2" format="ixt:numdotdecimal" name="iva:ExpectedVolatility" scale="-2" id="Tc_RjNW41fDtUehYbYzIV-MGA_7_2">68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ldh6EouHQke8vr_BH-JvxQ" decimals="2" format="ixt:numdotdecimal" name="iva:ExpectedVolatility" scale="-2" id="Tc_QNXWE3ZOM06L4dDLl-zB-g_7_4">62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_EFM8TpwCpkqu7FVPRM1rTQ" decimals="3" format="ixt:numdotdecimal" name="iva:ExpectedVolatility" scale="-2" id="Tc_MDRjOaAxa0KjNVkDz0Pd7A_7_6">59.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cap of the put option (m&#8364;)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lpf5jlqhR0GVIbvPIhKnYw" decimals="1" format="ixt:numdotdecimal" name="iva:WarrantsCapOfPutOption" scale="0" id="Tc_Ww56_2AxDkSI0QDCIv8ujw_8_2">25.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ldh6EouHQke8vr_BH-JvxQ" decimals="1" format="ixt:numdotdecimal" name="iva:WarrantsCapOfPutOption" scale="0" id="Tc_igi6pg9chEeUU3u5Qqza5A_8_4">25.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_EFM8TpwCpkqu7FVPRM1rTQ" decimals="1" format="ixt:numdotdecimal" name="iva:WarrantsCapOfPutOption" scale="0" id="Tc_wEh-Qx8boUqG8TbWcKr8yw_8_6">25.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Euribor 6M</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Euribor 6M</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Euribor 6M</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Fair Value (k&#8364;)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lpf5jlqhR0GVIbvPIhKnYw" decimals="-3" format="ixt:numdotdecimal" name="iva:FairValueOfWarrantsOutstanding" scale="3" id="Tc_8aEkWM9GbkiMPc-Xiea5qA_11_2">9,469</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ldh6EouHQke8vr_BH-JvxQ" decimals="-3" format="ixt:numdotdecimal" name="iva:FairValueOfWarrantsOutstanding" scale="3" id="Tc_SE0oRmnwakS-AedKs28YTQ_11_4">10,266</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_EFM8TpwCpkqu7FVPRM1rTQ" decimals="-3" format="ixt:numdotdecimal" name="iva:FairValueOfWarrantsOutstanding" scale="3" id="Tc_NpeuFf64C0SsA8X3gm7AMw_11_6">6,738</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Unit fair value (&#8364;)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lpf5jlqhR0GVIbvPIhKnYw" decimals="4" format="ixt:numdotdecimal" name="iva:WarrantsUnitFairValue" scale="-2" id="Tc_ceLd-01KQUu29UW53yMH4g_12_2">4.18</ix:nonFraction></i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ldh6EouHQke8vr_BH-JvxQ" decimals="4" format="ixt:numdotdecimal" name="iva:WarrantsUnitFairValue" scale="-2" id="Tc_ZJvuXSqJ7UuWR2KKVwKxbg_12_4">4.53</ix:nonFraction></i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_EFM8TpwCpkqu7FVPRM1rTQ" decimals="4" format="ixt:numdotdecimal" name="iva:WarrantsUnitFairValue" scale="-2" id="Tc_qC4Ht0bxDU2g93AD1ikrmw_12_6">2.97</ix:nonFraction></i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;January 4,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">EIB Tranche B Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;(Grant&#160;Date)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;June 30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Number of BSA outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_V_UnvG7OVU6Postqxl9qTw" decimals="INF" format="ixt:numdotdecimal" name="iva:IfrsClassOfWarrantOrRightOutstanding" scale="0" id="Tc_WxOXN_1wsk2fVqTzq3HfNQ_3_2">3,144,654</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_rbMHeXRpfEGsAR3PJoBgWg" decimals="INF" format="ixt:numdotdecimal" name="iva:IfrsClassOfWarrantOrRightOutstanding" scale="0" id="Tc_ctAgbj5kiUOzRUvh6UV7xA_3_4">3,144,654</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Number of shares per BSA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_V_UnvG7OVU6Postqxl9qTw" decimals="2" format="ixt:numdotdecimal" name="iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Tc_ySGPc0unK0-at0MufKGqBw_4_2">1.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_rbMHeXRpfEGsAR3PJoBgWg" decimals="2" format="ixt:numdotdecimal" name="iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Tc_i2N8s6639kaALnvAzyjH-g_4_4">1.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock price (&#8364;)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_V_UnvG7OVU6Postqxl9qTw" decimals="2" format="ixt:numdotdecimal" name="iva:WarrantsStockPrice" scale="0" id="Tc_z9ReFZqoQkqfeLyA5KYZhw_5_2">4.12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_rbMHeXRpfEGsAR3PJoBgWg" decimals="2" format="ixt:numdotdecimal" name="iva:WarrantsStockPrice" scale="0" id="Tc_ZHE-0SPuJUm2IDbrTxy_Hg_5_4">2.79</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maturity (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_f6IGXbNrJUeuXFjO7KpMzA" format="ixt-sec:duryear" name="iva:WarrantAverageLife" id="Tc_O24pMw0jCkW0KUVJGZxluw_6_2"> 12</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_IuzMYL65X0qu-JY8V6n_lw" format="ixt-sec:duryear" name="iva:WarrantAverageLife" id="Tc_h5Niox4Tx0GjEdY8BfrKSg_6_4"> 11.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_V_UnvG7OVU6Postqxl9qTw" decimals="2" format="ixt:numdotdecimal" name="iva:ExpectedVolatility" scale="-2" id="Tc_n-X4RbicL0WzdjILurRtwA_7_2">62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_rbMHeXRpfEGsAR3PJoBgWg" decimals="3" format="ixt:numdotdecimal" name="iva:ExpectedVolatility" scale="-2" id="Tc_J_oIzhE550m225eYMCMu_w_7_4">59.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cap of the put option (m&#8364;)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_V_UnvG7OVU6Postqxl9qTw" decimals="1" format="ixt:numdotdecimal" name="iva:WarrantsCapOfPutOption" scale="0" id="Tc_jGosOM14cU6XSQPbd_UssQ_8_2">25.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_rbMHeXRpfEGsAR3PJoBgWg" decimals="1" format="ixt:numdotdecimal" name="iva:WarrantsCapOfPutOption" scale="0" id="Tc_dBO4x_AKCUuLJEqVMrGx0A_8_4">25.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Euribor 6M</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Euribor 6M</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Fair Value (k&#8364;)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_V_UnvG7OVU6Postqxl9qTw" decimals="-3" format="ixt:numdotdecimal" name="iva:FairValueOfWarrantsOutstanding" scale="3" id="Tc_U7Mbw5UT4EqS78iF9ptFYg_11_2">11,809</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_rbMHeXRpfEGsAR3PJoBgWg" decimals="-3" format="ixt:numdotdecimal" name="iva:FairValueOfWarrantsOutstanding" scale="3" id="Tc_8h4ZIs_Pa06NLrcQGXgtaw_11_4">6,830</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Unit fair value (&#8364;)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_V_UnvG7OVU6Postqxl9qTw" decimals="4" format="ixt:numdotdecimal" name="iva:WarrantsUnitFairValue" scale="-2" id="Tc_3U6dXzqVrkK_btt9UAifTA_12_2">3.76</ix:nonFraction></i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_rbMHeXRpfEGsAR3PJoBgWg" decimals="4" format="ixt:numdotdecimal" name="iva:WarrantsUnitFairValue" scale="-2" id="Tc_Gc_p6o8XWEaChm5_k4iZDA_12_4">2.17</ix:nonFraction></i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Lease liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Lease liabilities amount to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:LeaseLiabilities" scale="6" id="Narr_hJXDPFboeEOc-NWYoIOToQ">5.8</ix:nonFraction> million as of June 30, 2024, and decreased by &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA" decimals="-5" format="ixt:numdotdecimal" name="iva:IncreaseDecreaseInLeaseLiabilities" sign="-" scale="6" id="Narr_EVaZ50LrLUy_AJ5yAHBw6Q">0.8</ix:nonFraction> million compared to December 31, 2023. The lease liabilities are recognized each time a new Fibroscans is leased, on a period of <span style="-sec-ix-hidden:Hidden_YoTGSGWkUUCAhZ-9bE1tcw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> or <ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_iva_FibroscanMachinesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_u7Et-MI930eFeqmMLXteeg" format="ixt-sec:durwordsen" name="iva:LeaseTerm" id="Narr_YVjI7Pm5Z02QPg5CuHbu_Q">four years</ix:nonNumeric> regarding the location of use. Lease liabilities are calculated using specific discount rates, in connection with the geographic area, the maturity of the debt, and the commencement date, according to the method described in Note 3.2 of the consolidated financial statements as of December 31, 2023. The rates for contracts in progress as of June 30, 2024 range from <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_ifrs-full_LeaseLiabilitiesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_GsWMv1_qikSzfG5Yj-NJvg" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="Narr_NStT6oYiu027XLGjA2cYMw">1.89</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_ifrs-full_LeaseLiabilitiesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_dYFp-ujODEWkgQn22I6RnQ" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="Narr_O76qJzaEdUurHMav2isOHw">5.18</ix:nonFraction>%.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_1b6dd48f_e8be_4e66_b1af_260331b078c0"></a><a id="Tc_F6EuJJDYNUWKBoelu8PS2g_1_0"></a><a id="Tc_mx178LYFzkaOzvAFccvz7w_1_4"></a><a id="Tc_aKQgpV9qokWROxJ7Mw_ftA_1_6"></a><a id="Tc_1OwqJCTIR0Gr4oaC-ylk8g_1_8"></a><a id="Tc_UzuHtvK0qEGa6VkXAqJRaQ_1_10"></a><a id="Tc_qCcwcVLicU-dMSMxW0gMPQ_2_0"></a><a id="Tc_U5e-TI1r80mk9RzBHY-c-A_2_2"></a><a id="Tc_l5gI9QFUAUaZ8SmCwJWwcQ_2_4"></a><a id="Tc_73nk_alK1kWf1Dn4vdDFfQ_2_6"></a><a id="Tc_HUy34izOKkuQhIJfmC8fXw_2_8"></a><a id="Tc_8kLD2zK_i0iyDPplZQrM_w_2_10"></a><a id="Tc__frDlU0rX0OhFnAO18IxMg_3_0"></a><a id="Tc_VIsvSg5GOEaDJo8YwpaH3g_4_0"></a><a id="Tc_j9WTYC9U50mF6rG0Y1ynBg_4_4"></a><a id="Tc_1W36767RCE-xuWF7ngrKJw_4_8"></a><a id="Tc_TZpqy9J_1kSjXdGrF3EMMg_4_10"></a><a id="Tc_6uHzpXbnYE2PX_DO0CcbQQ_5_0"></a><a id="Tc_RRsb-hea0k-YOMJzmfMr6w_5_8"></a><a id="Tc_YL75sWYHXkK90p5NzbKiqw_5_10"></a><a id="Tc_CZy6gYX0a0WEyMfR46XNqg_6_0"></a><a id="Tc_o7NeWVTE10-kRDm2WuxXpg_6_8"></a><a id="Tc_Wdr7tX2j5Euchaz2wI8NNg_6_10"></a><a id="Tc_13RTatvCuEelj1OFln24Qw_7_0"></a><a id="Tc_lfaYTZe240ul9I-uz0-rwA_7_4"></a><a id="Tc_GPzBiDxZ_UGI0yWAb9v1LQ_7_6"></a><a id="Tc_9B0H74fMSkuD2wO34ub6XQ_7_8"></a><a id="Tc_lth4FKCBok6nzPlkZ081jg_8_0"></a><a id="_65ab7ffa_7df8_490a_aa8c_1cd9b1206e0d"></a><a id="Tc_m4EBVRiB4kSLOPA9l1h5mw_1_0"></a><a id="Tc_Af6TJbtkJECwCI5ppISImg_1_4"></a><a id="Tc_kaG6HdejLkWxczi6p4WkXA_1_6"></a><a id="Tc_4dXk5jEUkE-suuPk-o-YgQ_1_8"></a><a id="Tc_PpVHgotc00qHgHdB-RSQmA_1_10"></a><a id="Tc_RHVvY3V2VUmilyNtdEHvFg_2_0"></a><a id="Tc_9Clz9FUN-U6G0cKFnPLq8A_2_2"></a><a id="Tc_bcHWSYnBekWwHk_gkO7LDw_2_4"></a><a id="Tc_h0PslPeDck-zdaazdPavsA_2_6"></a><a id="Tc_Z8Jd1j_QyE-Bbz9YC8u_4w_2_8"></a><a id="Tc_FqZP8e2eXkaS6LdWmKmNHQ_2_10"></a><a id="Tc_3lwgIxVSvE6iC42Sl0o3BQ_3_0"></a><a id="Tc_g1T0V6fHGkiRwXJZoeTUgQ_4_0"></a><a id="Tc_k_0OHjwd9kmA76uYrPBmdw_4_4"></a><a id="Tc_MiM2Fyr2e0aw7bDd5D6JoA_4_6"></a><a id="Tc_uogcrwpIVUSvSu0Zu49UiA_4_10"></a><a id="Tc_Iy9jQLCHCEa2k_TJasyF3Q_5_0"></a><a id="Tc_-u2-TVaYikOhLM99r9CPiQ_5_6"></a><a id="Tc_LqT1AQqDn0u-LznTjXqMrw_5_10"></a><a id="Tc_D-tLIydpbke0VKtq-RA5oQ_6_0"></a><a id="Tc_soZv2tSRiEq7gIJ5ueV4dA_6_8"></a><a id="Tc_g4tQg1ykm0m1UhOnsjRDMQ_6_10"></a><a id="Tc_HQNlqdJ1PUWDEWNnDxnZFg_7_0"></a><a id="Tc_FZ4Y68gHHUeqU_gtl-s-oQ_7_4"></a><a id="Tc_M-RYOpZJGUW4XwUDduq41A_7_6"></a><a id="Tc_luMMjNKg1UyG50OyyiK5gw_7_8"></a><a id="Tc_j4l1uAu0eUqSFA3Tp3dQwA_8_0"></a><a id="a410Provisions_458607"></a><a id="_4.12_Provisions_for"></a><a id="a411Provisionsforretirementbenefitobliga"></a><a id="Provisionsforretirementbenefitobligation"></a><ix:continuation id="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont10" continuedAt="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont11"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The breakdown between long-term and short-term debt is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities" id="Tb_2QrKLgieJUC04ljUPtM5gw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Less than</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Between</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Between</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">More than</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1 year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1 and 3 years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> 3 and 5 years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">5 years</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Bank borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LoansReceived" scale="3" id="Tc_MBBdK9kEVESCRXyS3shcmw_3_2">42,509</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_o2Fe8k_JVUOuzAwFE3EH9g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LoansReceived" scale="3" id="Tc_uzmixvYnzESGgwbRBnMISA_3_4">3,229</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_1fmInCo2D0yp8z7M1kVwrg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LoansReceived" scale="3" id="Tc_osheILzpck-frN3XJV4Qhg_3_6">36,164</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_BwJ5AiMcPkmDzrV1KCPF7Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LoansReceived" scale="3" id="Tc_5eNbwXv1hkiJEf5cDJtC9w_3_8">2,225</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_De4o7giPiEinOd0qNd9GCA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LoansReceived" scale="3" id="Tc_8Iv6Tmsib0O5K1RuS6Vy_Q_3_10">890</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Derivatives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" scale="3" id="Tc_3x5oup0ZAkmV-Oq9QKQaHA_4_2">13,569</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_1fmInCo2D0yp8z7M1kVwrg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" scale="3" id="Tc_RMECbYw9eECGHlOjaBHgRA_4_6">13,569</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherBorrowings" scale="3" id="Tc_rDQuCSFbikygAsNfwaKP2A_5_2">4,302</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_o2Fe8k_JVUOuzAwFE3EH9g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherBorrowings" scale="3" id="Tc_7M2G7KJWkkmOUcOsQBvelA_5_4">42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_1fmInCo2D0yp8z7M1kVwrg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherBorrowings" scale="3" id="Tc_zJ8InSbNDEuIZ_-09Tl2mw_5_6">4,260</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LeaseLiabilities" scale="3" id="Tc_rA3M0S0d3E6TSsGMOctvjA_6_2">5,761</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_o2Fe8k_JVUOuzAwFE3EH9g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LeaseLiabilities" scale="3" id="Tc_FRGdV1QQikmckL21k9LHDQ_6_4">2,455</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_1fmInCo2D0yp8z7M1kVwrg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LeaseLiabilities" scale="3" id="Tc_llmpOZRq4Em-Hd5JEBEm6A_6_6">3,306</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalty certificates liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="iva:NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued" scale="3" id="Tc_6kgxncLLjku5u5QDFD__JA_7_2">7,263</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_De4o7giPiEinOd0qNd9GCA" decimals="-3" format="ixt:numdotdecimal" name="iva:NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued" scale="3" id="Tc_B4cWlJHaBk2pNIRTmEb2rg_7_10">7,263</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total debt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Borrowings" scale="3" id="Tc_HI7ozYvgckuYv9Q1aq7dqQ_8_2">73,404</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_o2Fe8k_JVUOuzAwFE3EH9g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Borrowings" scale="3" id="Tc_fMZLu61vqUqtqhIZH3EtHg_8_4">5,726</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_1fmInCo2D0yp8z7M1kVwrg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Borrowings" scale="3" id="Tc_fA1Y0txlSk2uxXmZbJCc8Q_8_6">57,299</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_BwJ5AiMcPkmDzrV1KCPF7Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Borrowings" scale="3" id="Tc_Nye7n6wPAESyzpMLO_OLDw_8_8">2,225</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_De4o7giPiEinOd0qNd9GCA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Borrowings" scale="3" id="Tc_Cm0L9umsXU-FAWrPWGbQlQ_8_10">8,153</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Between</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Between</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">More than</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1 year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1 and 3 years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">3 and 5 years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> 5 years</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bank borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LoansReceived" scale="3" id="Tc_0QQVwLuM80uhZtUHbOJupA_3_2">27,206</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_GSGDF0mlWkuIQruwBsMsBA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LoansReceived" scale="3" id="Tc_3jwbJX3CqUGTmg3hbk5yGA_3_4">2,928</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_C0Ff4EWJsU2Ar98sMx82wg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LoansReceived" scale="3" id="Tc_x1p73mOPX0S-Gb_liiPXng_3_6">4,872</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_mhRLXXxIVUimCeRsLCjpAQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LoansReceived" scale="3" id="Tc_GDT3JMcTFUiwVsDXGjUh1A_3_8">17,848</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_Ue5U6HHvckKiur1A8cLvgw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LoansReceived" scale="3" id="Tc_M2g_vALL0EyWE-jUpXb_VQ_3_10">1,558</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivatives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" scale="3" id="Tc_HNOVsNbh_0q0hrQ_dbJ0dg_4_2">10,265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_mhRLXXxIVUimCeRsLCjpAQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" scale="3" id="Tc_2NoZjV6cJEC_HrVPgkzryQ_4_8">10,265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other loans and similar borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherBorrowings" scale="3" id="Tc_ioRwSHX5Y0SH1If2HfoyqA_5_2">3,719</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_GSGDF0mlWkuIQruwBsMsBA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherBorrowings" scale="3" id="Tc_68ZWJRfqE0SZ4536jOl64g_5_4">82</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_mhRLXXxIVUimCeRsLCjpAQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherBorrowings" scale="3" id="Tc_0nbG0Yt-mEybNUDBnU-MLw_5_8">3,636</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LeaseLiabilities" scale="3" id="Tc_5nSAlDl9F0iMxukjdEtT_A_6_2">6,565</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_GSGDF0mlWkuIQruwBsMsBA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LeaseLiabilities" scale="3" id="Tc_lgzYM9yMX0ComZfIQXZQQg_6_4">2,298</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_C0Ff4EWJsU2Ar98sMx82wg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LeaseLiabilities" scale="3" id="Tc_7Xfjo10rv0ClWtMVdQdknw_6_6">4,267</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Royalty certificates liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="iva:NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued" scale="3" id="Tc_sspKhFVrAUugSwsBJtqyWg_7_2">6,327</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_Ue5U6HHvckKiur1A8cLvgw" decimals="-3" format="ixt:numdotdecimal" name="iva:NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued" scale="3" id="Tc_wXX6zU4350KRsjrsb7Bhug_7_10">6,327</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total debt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_EHsAFhljaE2ILeQMiCBC4Q;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> 54,082</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_GSGDF0mlWkuIQruwBsMsBA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Borrowings" scale="3" id="Tc_OtqNpbpEq0GgEwOaTQ1zAA_8_4">5,308</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_C0Ff4EWJsU2Ar98sMx82wg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Borrowings" scale="3" id="Tc_OLbJ5jB7LUut0OBvB1DEJQ_8_6">9,140</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_mhRLXXxIVUimCeRsLCjpAQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Borrowings" scale="3" id="Tc_4s4EOBa-306dSmlDEIX3jw_8_8">31,749</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_Ue5U6HHvckKiur1A8cLvgw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Borrowings" scale="3" id="Tc_GZKv9gV3_kqdDbiACtDmcA_8_10">7,885</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The maturity of long-term debt and of short-term borrowings and debt is determined according to contractual repayment terms as of June 30, 2024 and December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Royalty Certificates liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On August 31, 2023, the Company announced the issuance of the royalty certificates (&#8220;2023 Royalty Certificates&#8221;) for an aggregate amount of &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_8_31_2023_ifrs-full_ClassesOfLiabilitiesAxis_iva_RoyaltyCertificateLiabilitiesMember_h1XHuxF4ukeRQuZnn7VzCw" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:NotionalAmount" scale="6" id="Narr_0Xd5HUWw4EmgaCSg-Cz_0w">5.1</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The 2023 Royalty Certificates are accounted at the inception at the fair value (&#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_8_31_2023_ifrs-full_ClassesOfLiabilitiesAxis_iva_RoyaltyCertificateLiabilitiesMember_h1XHuxF4ukeRQuZnn7VzCw" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:Borrowings" scale="6" id="Narr_V_4SX-ZSOUmHO2cOm87hYg">5.1</ix:nonFraction> million on August 31, 2023), and then at the amortized cost (&#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_RoyaltyCertificatesLiabilitiesMember_MLWq4MeMoEelhaSNDyM6mw" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:Borrowings" scale="6" id="Narr_z_5q7iIRnkaY-LOGowWTZg">7.3</ix:nonFraction> million on June 30, 2024 vs. &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_RoyaltyCertificatesLiabilitiesMember_BjRDFB3IN0mcC4Ynuq2iZQ" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:Borrowings" scale="6" id="Narr_nqft7Qx-DESTYFg_CKNETA">6.3</ix:nonFraction> million on December 31, 2023) with an effective interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_RoyaltyCertificatesLiabilitiesMember_mEPm5drgy0O0deuPued1-Q" decimals="3" format="ixt:numdotdecimal" name="iva:RoyaltyCertificatesEffectiveInterestRate" scale="-2" id="Narr_TR2P4a1rOUevi0LkCJl3ew">31.9</ix:nonFraction>%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fair value as of June 30, 2024</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On June 30, 2024, the fair value of the 2023 Royalty Certificates, calculated using discounted cash flow approach, amounts to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_RoyaltyCertificatesLiabilitiesMember_MLWq4MeMoEelhaSNDyM6mw" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="6" id="Narr_msWMn334XkOgzL25vex9ww">9.1</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The fair value corresponds to the net present value of royalties, which depend on assumptions made by the Company with regards to the probability of success of its studies, the markets sales of lanifibranor and the discount rate (<ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_RoyaltyCertificatesLiabilitiesMember_ifrs-full_UnobservableInputsAxis_ifrs-full_DiscountRateMeasurementInputMember_qerPupsvsEe_tn0yX52pFQ" decimals="1" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Narr_8Vue_Q-wlkqb8FhE0UjUyw">27.9</ix:nonFraction>%). The discount rate has been estimated based on a reconciliation between the Company&#8217;s business plan and the Company&#8217;s market capitalization as of June 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.11</b></span>Provisions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-5" format="ixt-sec:numwordsen" name="ifrs-full:OtherProvisions" scale="6" id="Narr_9tIyyTwmbUuYq9N13N3MlQ"><ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-5" format="ixt-sec:numwordsen" name="ifrs-full:OtherProvisions" scale="6" id="Narr_K3ybfaXR_0WWxPb2M48QrA">no</ix:nonFraction></ix:nonFraction> provisions as of June 30, 2024, and December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.12</b></span>Provisions for retirement benefit obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Retirement benefit obligations are determined based on the rights set forth in the national collective bargaining agreement for the French pharmaceutical industry (IDCC 176/Brochure 3104) and in accordance with IAS 19 &#8211; <i style="font-style:italic;">Employee Benefits</i>. These rights depend on the employee&#8217;s final salary and seniority within the Company at his/her retirement date.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_Qjv0jDQ6WUyrA2WDE36NEg_1_0"></a><a id="Tc_CZBC7S6EZ0WYWiSCJ079dg_1_2"></a><a id="Tc_-cwrb00FWkKsdpXZaOpOuw_1_4"></a><a id="Tc_tZ7IjueSfEeF6M41HWlTeg_2_0"></a><a id="Tc_u0MkVVrIkk6P4rbmPPhSgg_3_0"></a><a id="Tc_OMtjzlTTN0qMXKlhL7JkYQ_1_0"></a><a id="Tc_APyjGUsJ7kS_pRIlqTZ1eA_1_2"></a><a id="Tc_EXcWt0SfAU-lIqbW3iMVyg_1_4"></a><a id="Tc_noGGnzb-P0qggYgEoTUGUw_2_0"></a><a id="Tc_rCpAX5sREkqJRZIyCU7f1w_3_0"></a><a id="Tc_Kc6lRH_H-UyA2QstUqtluw_4_0"></a><a id="Tc_077KiJUt9Ee7vi6uCRUbwg_5_0"></a><a id="Tc_7l7HstIb-0yBvnRtQt9L0A_1_0"></a><a id="Tc_hE9X7qGDrESCJ2LFGrSVcg_1_2"></a><a id="Tc_YUhWeNbx7EC1_uoSgRdUcg_1_4"></a><a id="Tc_qqj-Y1HyVUiTOWFlKTCBOw_2_0"></a><a id="Tc_dUdW11TfPECQewYfA5v4HQ_3_0"></a><a id="Tc_mncKmo5UfUKWYmuSqSF-xg_4_0"></a><a id="Tc_Yd9QIRPm_k28XOjtVyR0Ew_4_4"></a><a id="Tc__BZNj6mZYkirQhpJPfpY6w_5_0"></a><a id="a413Othercurrentandnoncurrentliabilities"></a><a id="Tc_Nly3M-tH30yR4zjFNr2N8w_1_0"></a><a id="Tc_TAoAHOQoTEGYv3a8ZxQz-A_1_2"></a><a id="Tc_FXHlWlibOU6C3M1ShRKDJA_1_4"></a><a id="Tc_3yZ2s2AMxkqfnuKG9jk8nw_2_0"></a><a id="Tc_yLuO-CSjikeov-WI_AcLjA_3_0"></a><a id="Tc_GBh_8tuyGkaJjTkLK3k0-w_4_0"></a><a id="Tc_qLaxhDmunkqvilRK8kD5mA_5_0"></a><a id="Tc_m3LEDoCH3kejp4lXEhfSGg_6_0"></a><a id="Tc_760V4YgXvkG_SEgH_I0klQ_7_0"></a><ix:continuation id="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont11" continuedAt="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont12"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net provision</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The provision recorded in respect of defined benefit schemes at the end of each reporting period is shown in the table below:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="iva:DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory" id="Tb_itY3hlszIEKZ3-ryj0kmHQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Retirement benefit obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="3" id="Tc_FvDOezAwzEya8TpyZLFRpg_2_2">1,555</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DefinedBenefitObligationAtPresentValue" scale="3" id="Tc_xGyg6ptheESlZ92FpuwZ2Q_2_4">1,559</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total obligation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="3" id="Tc_5eSaiQCdUE-KdG_TvMePqQ_3_2">1,555</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="3" id="Tc_yVfqC5fBjkGZy0oG7RPLWQ_3_4">1,559</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Given the absence of plan assets at June 30, 2024 and December 31, 2023, the total amount of the provision corresponds to the estimated obligation at those dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in the net provision</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Changes in the provision recorded in respect of defined benefit schemes break down as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="iva:DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory" id="Tb_9_YvchsFWUWtJyTUBlFuJA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Provision at beginning of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="3" id="Tc_gQdZg2LUkUO5LIMR8T-oXA_2_2">1,559</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2022__ShBeryiXEKxoX7Xx7OS6A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="3" id="Tc_tnBWeSJpo0i1M3eD8HhlDA_2_4">1,234</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expense for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss" scale="3" id="Tc_BK1vfqlZqU2bxFhLvsalhw_3_2">70</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss" scale="3" id="Tc_E4PgZN2rDUqMioZNUCnsvA_3_4">228</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Actuarial gains or losses recognized in other comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" scale="3" id="Tc_SK_ytCydNEG0RRdtC422zw_4_2">74</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" sign="-" scale="3" id="Tc_uQ3wxztSxk6j3-h2PIWQQQ_4_4">97</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Provision at end of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="3" id="Tc_AQsT53Mw6k6OawXSjFPj5A_5_2">1,555</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:LiabilityAssetOfDefinedBenefitPlans" scale="3" id="Tc_QbebMeiLVEWUz53jLuZuMg_5_4">1,559</ix:nonFraction>)</b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Breakdown of expense recognized for the period</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="iva:DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory" id="Tb_Z0W683OYZUqRE6jF75C1xw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Service cost for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentServiceCostDefinedBenefitPlans" scale="3" id="Tc_outIUzTlJEOzJdnGhfwT-g_2_2">104</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentServiceCostDefinedBenefitPlans" scale="3" id="Tc_HoPYBNl3U0CauwaLNS96og_2_4">183</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest cost for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestExpenseDefinedBenefitPlans" scale="3" id="Tc_BRYd9Vd9uE27WvZQAgNarQ_3_2">25</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestExpenseDefinedBenefitPlans" scale="3" id="Tc_kms-Fsl3Bk-1cETdUhOeLA_3_4">46</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Benefits for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans" sign="-" scale="3" id="Tc_Aj9bE3M33UKUIoUg6F0KPg_4_2">59</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" scale="3" id="Tc_OQPtKpClYkOm4q6DRSH9rg_5_2">70</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans" scale="3" id="Tc_YPuXSwuB0kKSkoDHFsIwOw_5_4">228</ix:nonFraction>)</b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.13</b></span><b style="font-weight:bold;">Other current and non-current liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other non-current liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024 and December 31, 2023 non-current liabilities amount to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_ZxMBck8Vv06CkTltj3JJkg" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentLiabilities" scale="6" id="Narr_Urtko8hYSUOTjMN0c1B0bA"><ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_8tc8znfKVkWA4XCDKyyrhw" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentLiabilities" scale="6" id="Narr_MmS7sfsi20Gp203Y2licAA">1.0</ix:nonFraction></ix:nonFraction> million related to an agreement with CTTQ dated December 20, 2023 pursuant to which CTTQ paid the Company an advance for certain costs related to the NATiV3 clinical trial that the Company will incur and reinvoice to CTTQ.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="font-style:italic;">Other current liabilities</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory" id="Tb_U2c68ZUgvEqI9vmzVxNY9A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee&#8209;related payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="iva:EmployeeRelatedPayables" scale="3" id="Tc_p5WeURVGGkO20ussSGDrEQ_2_2">1,739</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="iva:EmployeeRelatedPayables" scale="3" id="Tc_7Nyq1gXReE2v9eAUF3_ltw_2_4">1,869</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued payroll and other employee-related taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="iva:AccruedPayrollAndOtherEmployeeRelatedTaxes" scale="3" id="Tc_s5NVrTNz9UikUeKXmKosrQ_3_2">1,801</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="iva:AccruedPayrollAndOtherEmployeeRelatedTaxes" scale="3" id="Tc_9yLSJrNNskKED8OuD14cPA_3_4">1,540</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales tax payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentValueAddedTaxPayables" scale="3" id="Tc_QH3g9T0F5EivASrZeFoSlA_4_2">2,140</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentValueAddedTaxPayables" scale="3" id="Tc_nvJqMF3sSU-289eVqut8kg_4_4">3,569</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued taxes and employee-related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="iva:OtherAccruedTaxesAndEmployeeRelatedExpenses" scale="3" id="Tc_rWZMbksSqkiVD1A6pnOjPg_5_2">142</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="iva:OtherAccruedTaxesAndEmployeeRelatedExpenses" scale="3" id="Tc_V4Wo5ZLCzE-KudQP2Ep3wQ_5_4">164</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other miscellaneous payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentPayables" scale="3" id="Tc_qU5Maiw3a0-tPkF3gkPTRg_6_2">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentPayables" scale="3" id="Tc_U8ig8xHvYkOioxU1z-Pj3g_6_4">23</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="Tc_vTljXZFWS0e5UUnJeMeqCw_7_2">5,834</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="Tc_RWPeAVFqYEKphu-BlYNVKg_7_4">7,165</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">No discounting has been performed on other current liabilities as their maturity is less than one year at the end of the period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accrued payroll and other employee-related taxes mainly relate to payables to social security and employee-benefit organizations such as URSSAF, KLESIA and APGIS for the first half of 2024.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="a412Tradepayablesandothercurrentliabilit"></a><a id="Tradepayablesandshorttermcontractliabili"></a><a id="Tc_HfOQv7IQqUuHvzKLHu2bFw_1_0"></a><a id="Tc_v0T_aQNoJEG-o4_vSLKhDQ_1_2"></a><a id="Tc_ELOhRXdiAUuaKojfOpKb8Q_1_4"></a><a id="Tc_3OPi6nN6XUSzS6bMYTajQw_2_0"></a><a id="Tc_VyxOIFroLEmnYHVtT6ZZUg_3_0"></a><a id="Tc_fPS58y9-yUylRD43CoWR0g_4_0"></a><a id="Tc_C4MIcITkU0Gl6mOXLG5Xew_4_2"></a><a id="Tc_KgcYD-0OikWtqXpFygNowQ_4_4"></a><a id="Tc_obPK1LQbKkSeh8IprYWw8g_5_0"></a><a id="Tc_x0qzhMFnhkubPARP1Vfo6A_1_0"></a><a id="Tc_yluU-SIggUmtXCssBALy7Q_1_2"></a><a id="Tc_h9tinJChhUmVTbQjDEf9HQ_1_4"></a><a id="Tc_TkMAWEj7pkGrRghB0rS6og_2_0"></a><a id="Tc_kVtXpQNWqEKQFCSV5zPaiA_3_0"></a><a id="Tc_JFXJbwSHCEWhtl3gvubWkw_4_0"></a><a id="Tc_aFhJ-itm4kuTmndH0KnnFg_4_4"></a><a id="Tc_g81_qTalx0ieHlleSDaVKA_5_0"></a><ix:continuation id="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont12" continuedAt="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont13"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Other accrued taxes and employee-related expenses concern provisions for payroll taxes, such as professional training charges, apprenticeship tax, the employer&#8217;s contribution to construction investment in France and the payroll tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.14</b></span>Trade payables and short-term contract liabilities</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock" id="Tb_eZacGoOw9EqCkQc8KDz_Fw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" id="Tc_hJa4pCIzJ0uaA_hZdvqeww_2_2">36,583</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="3" id="Tc_eXFNfK2eSEuBvFx2JLb4FA_2_4">37,679</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentContractLiabilities" scale="3" id="Tc_vK0Fv9c8CUmHm9PcTu4QpQ_3_2">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentContractLiabilities" scale="3" id="Tc_cQBIxp3kdUGBif6pdy3Gpw_3_4">6</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Trade payables and other current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="iva:TradePayablesAndOtherCurrentLiabilities" scale="3" id="Tc_zm1BU-7z4E-Eb7jqIdSzOA_5_2">36,586</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="iva:TradePayablesAndOtherCurrentLiabilities" scale="3" id="Tc_opg5A0T6mkC5ipQsHoL3XA_5_4">37,685</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">No calculations have been made to discount trade payables to present value as payment is due within one year at the end of the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Trade payables</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Trade payables break down as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" id="Tb_q-105LEs4k2N_W0bMF3GQA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Due in 30 days</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneMonthMember_F44q34_t8kGRdNbcbz0SsA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" id="Tc_U3Ho-sFYXUCEl4toByJWzA_2_2">26,217</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneMonthMember_L3zFOF6AbEGJqyvX3ksALQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" id="Tc_iNpZUW3w5EOGzelyIcTjhQ_2_4">24,995</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Due in 30-60 days</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_PQdCvCveh0GtnvbOTvZTxg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" id="Tc__KLVJ0TwkkawlZczTt8NQQ_3_2">10,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_pgS3JPFyOUuBb8uDOr_KNw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" id="Tc_rkVHFsB0Yk6IOwoUgtPVHA_3_4">12,684</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Due in more than 60 days</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_iva_LaterThanTwoMonthsMember_C5lqESZnOEmaIeMKVhSS8Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" id="Tc_U2WqgttELkmAhRoE8GOLkg_4_2">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Trade payable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" id="Tc_9KbviufLYUuVpH9EZu9cUQ_5_2">36,583</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" id="Tc_NjAB_X5Rx0GyceFucHHYSA_5_4">37,679</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024, trade payables mainly included accrued liabilities for &#160;&#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:AccrualsClassifiedAsCurrent" scale="6" id="Narr_FvMxz7ZprkefxC3qt_aGeA">24.0</ix:nonFraction> million of which &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-5" format="ixt:numdotdecimal" name="iva:AccrualsClassifiedAsCurrentRelatingToScientificProjects" scale="6" id="Narr_aICmefT3Tka6vHxHQn-Y5A">20.2</ix:nonFraction> million relate to scientific projects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of June 30, 2024, trade payables decreased by &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-5" format="ixt:numdotdecimal" name="iva:IncreaseDecreaseInTradeAccountsPayable" sign="-" scale="6" id="Narr_swXpe2Ue106ljkboFM8cXA">1.1</ix:nonFraction> million compared to December 31, 2023. Trade payables, which depend on the frequency of CRO invoicing, were relatively stable (down by less than 3%).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="a413Financialassetsandliabilities_918893"></a><a id="_8e728073_cf19_4335_b56d_8ca3855b7427"></a><a id="Tc_hkJymA7aMEec9Mmf6r_nsg_1_2"></a><a id="Tc_NjtzxDZ-GkS0FMnAx0bgow_2_4"></a><a id="Tc_veaxJk3XC0K8uTVTDuyX1Q_3_2"></a><a id="Tc_YIB11W5duEmOfDbpuJL2Sw_3_4"></a><a id="Tc_YNyEW71jd0Sv4wcHDdegVQ_3_6"></a><a id="Tc_mTjRogzijEaycArljGVRgw_4_2"></a><a id="Tc_caAR58bzTkW0hvvUqZrQZg_4_4"></a><a id="Tc_FeQXJ8wWEUaSIdw7vM68Sw_4_6"></a><a id="Tc_CtcGz3tJzEicNrwwOQ1dCg_4_8"></a><a id="Tc_4JDR_eZoXEGOP-1i5v9cqQ_5_2"></a><a id="Tc_HEGSHBR7BkuLJOT-YBUGlw_5_4"></a><a id="Tc_2iEtIlerFE66HfG-n5iyBg_5_6"></a><a id="Tc_3j47riuZv0GEvHTAcA18uA_5_8"></a><a id="Tc_KP_fnXzaG0izAooHFFrKcA_6_2"></a><a id="Tc_NN5BMpjAKECUqwyqpjm5tQ_6_4"></a><a id="Tc__ecKSJYMe0CCJx1vWNouBQ_6_6"></a><a id="Tc_E198d6jiTkWHrDtw1HeyDQ_6_8"></a><a id="Tc_BGMlYS_tBUKCuGy0kXE4gA_7_0"></a><a id="Tc_EVPQscVZ1UWpD9-4dvgtZQ_7_2"></a><a id="Tc_0ZIiFU5FEEeZZRWEjTKI4w_7_4"></a><a id="Tc_PWgwG2aqcU-BifvywYltOw_7_6"></a><a id="Tc_ycstZAHMyEaSkKpSSW2d9w_7_8"></a><a id="Tc_2X4Joj-FH0yJVLPZgr8dQg_7_10"></a><a id="Tc_wVezz1I8W0a6b4lrBY8xRw_8_0"></a><a id="Tc_AwX4BEgaV0ypA3Pxh1_Yvg_8_2"></a><a id="Tc_WgMVrYsu-kOtgr-NqHupMw_8_4"></a><a id="Tc_xDq5MUHiRUC5hSzpJoQCzQ_8_6"></a><a id="Tc_IemZqcS6OE6Rs3kAaqFgtA_8_8"></a><a id="Tc_ZCWv_l2zG0StXla5OB6MDA_8_10"></a><a id="Tc_7ANpkQA710yMo6ViMUwA4Q_9_0"></a><a id="Tc_bzpaa1xOo0WVHdo7rByioQ_9_2"></a><a id="Tc_Kv8HrfujlUi8UfUQp_e4ww_9_4"></a><a id="Tc_IqF4S4eTTkOh2yY4fitPAw_9_6"></a><a id="Tc_X97f0qlqHESYxj6Cb9viuw_9_8"></a><a id="Tc_kGDsknO54U2nzezmw77n4g_9_10"></a><a id="Tc__NvTygqQwk6mK9TXoTG9Kg_10_0"></a><a id="Tc_-PBieSaq4USEHkBNJNlOkQ_10_4"></a><a id="Tc_S3fTIAGMIk66VdDjrMRHUg_10_8"></a><a id="Tc_GNz8kX1M2UeYusd31rXCyg_11_0"></a><a id="Tc_BzpNMRcA7kmL8TT26uSoBA_11_4"></a><a id="Tc_oQNGvUpie0aXZv6l1-LBmA_11_8"></a><a id="Tc_jL5yOoxxREiSU4IZrAYn2Q_12_0"></a><a id="Tc__WezqwkbcUKtAS5bmuad5A_12_2"></a><a id="Tc_pkRIeYds7EOvLhb3kH9Lbg_12_4"></a><a id="Tc_KG2WIH-fBUi-OpUnXhy9aQ_12_6"></a><a id="Tc_LVn302xE_EKEpp3c3jU7lg_12_8"></a><a id="Tc_b10EUtklHECFSXVMiige0w_12_10"></a><a id="Tc_mlrD_m6u9EWOmQqZ_ThYrw_13_0"></a><a id="Tc_JW4MNORSLEa1oy0zts3WyA_13_4"></a><a id="Tc_AOWBT-p1ok-GFy8GNIBV_g_13_8"></a><a id="Tc_4aDM1N-CJE6jRHWZqA8bCw_14_0"></a><a id="Tc_Q9sp5ckj6EKRLNwjPp9kUA_14_4"></a><a id="Tc_Huu9oUrytUKMHJQNMTKYtw_14_8"></a><a id="Tc_OdLVrZ41V0e4M7ktfnrA7g_15_0"></a><a id="Tc_3l59khaBf0aiRZqSf055LQ_15_4"></a><a id="Tc_nyzzp7uS80yH_TpV048hIw_15_8"></a><a id="Tc_z1Xzf4szPES7Z2gWhWhKKA_16_0"></a><a id="Tc_XxsmtSV_1EqFaPsrTHIC_g_16_4"></a><a id="Tc_pgxG0a50pke7RMAGP7YU0g_16_8"></a><a id="Tc_yzaK2zBdmkq8J2IoLKV3xg_18_0"></a><a id="Tc_3EAZEi_3-kikn5TzdTzxIg_19_0"></a><a id="Tc_fj_7uY5r3USU1KbyAKaRZw_19_4"></a><a id="Tc_0g8p9t0plE6S9nXjzfrquQ_19_6"></a><a id="Tc_fX__n9QF7kSb5PiTPXkfrg_20_0"></a><a id="Tc_v2N_qugrrUKGe4pMrhkaWw_20_6"></a><a id="Tc_nksENQSn1kGU_Ck3bzJqIw_20_8"></a><a id="Tc_2JoAkPpiU06ISslXapEDvQ_21_0"></a><a id="Tc_oWT3RgTPyUmbgZi3kHT3VA_21_4"></a><a id="Tc_6FYS2NID4UyUJ2YgMFbkug_21_6"></a><a id="Tc_nRMBIr9jnkaI-Jx94LUirA_22_0"></a><a id="Tc_UKEe5i3oFEqZMjFfTikT7g_22_4"></a><a id="Tc_sV7P7huG0EyLunzoBMZAkw_22_6"></a><a id="Tc_NTCXCX8DR0y_zOW9PUjNfg_23_0"></a><a id="Tc_7uGtjU-SrkaSJOvFaW6hTw_23_4"></a><a id="Tc_XLKjxhbmQUSKTCYPelM1MA_23_6"></a><a id="Tc_UCDd-ead9keon0X2wkdWqA_24_0"></a><a id="Tc_nqT0LiYBcE-r28elkhCUCg_24_4"></a><a id="Tc_JzvQjo-wkUOBH7cH6Gt_lg_24_6"></a><a id="Tc_K2uk1V5JtES7VJLx4_ce0Q_25_0"></a><a id="Tc_Mlt65pcOVUCDAES68b-1Wg_25_6"></a><ix:continuation id="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont13" continuedAt="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont14"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.15</b></span>Financial assets and liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The table below presents the carrying amount of financial assets and liabilities by IFRS 9 accounting category:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" id="Group_I7bbA6lcz0ylRY7g1M2WDA" continuedAt="Group_I7bbA6lcz0ylRY7g1M2WDA_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:49.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Financial</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Book value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">assets/liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Financial </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">on the</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">carried at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> statement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">carrieds at </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> carried at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> of financial</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> through</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">profit or loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term accrued income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term deposit accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Advance payment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AdvancePaymentMember_Sx8nhE1j8ESlCSB49JWGVQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_iQD3a6ljfU6sAeaR1pJi9w_10_2">1,047</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AdvancePaymentMember_NT4vZl9PbkGiPUjsmpSqhg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_qRNErQJFJ0eMKOD-WsUdkQ_10_6">1,047</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AdvancePaymentMember_Sx8nhE1j8ESlCSB49JWGVQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" id="Tc_qN8ALsBvhk6f-EggjkoeVA_10_10">1,047</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current accrued income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AccruedIncomeMember_rFAULMOIG0-nNmzcBonheQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_TH0KuiiOd0CTqcRt1op7lA_11_2">1,687</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AccruedIncomeMember_Ahk1q2K--0uCVDs0WN2cnA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_UUpI24pd9UigQOTchKDOYA_11_6">1,687</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AccruedIncomeMember_rFAULMOIG0-nNmzcBonheQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" id="Tc_HF5MwrcOBE2yumNq1NAwZg_11_10">1,687</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term deposit accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_TradeReceivablesMember_UhBYZg6XLkqb9t3xvxBEUA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_6Q5m1pfS5kOnbYW7yl2t1g_13_2">809</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_TradeReceivablesMember_1-tjX8tbt0GXwG43E2l8Mg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_RnsXyo0NLESndy69SIb6Ig_13_6">809</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_TradeReceivablesMember_UhBYZg6XLkqb9t3xvxBEUA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" id="Tc_LxGg_cJ0pUeLEK0gjFwwQQ_13_10">809</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_iva_OtherReceivablesMember_8JkciAHeZUmN1wIn0UqhJA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_KtKMNXKmn0y8pTB0Ag4bLg_14_2">2,518</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_OtherReceivablesMember_X545crJT6E-s_K-iPNVWJw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_XXBAez69H0KDFQXjN6f8nw_14_6">2,518</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_iva_OtherReceivablesMember_8JkciAHeZUmN1wIn0UqhJA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" id="Tc_Le7cr3pIH02HP20dBpKbTg_14_10">2,518</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_iva_IfrsCashAndCashEquivalentsMember_gUhZ2pkRhkGxOpcwP54F6A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_0fYxnkgyz0Gjp1T4jZTd_A_15_2">10,147</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_IfrsCashAndCashEquivalentsMember_3DbfsjKIuEeTh95AuBI8Dw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_kG9gY1ETVUGGkpIONwPzrg_15_6">10,147</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_iva_IfrsCashAndCashEquivalentsMember_gUhZ2pkRhkGxOpcwP54F6A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" id="Tc_O4vbwrX1Zky5SynTXNGDKg_15_10">10,147</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_NtDp_NR6jUidog--iI6Itg_16_2">16,208</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_xqxoBDc1zUiTY3urkmymcw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_OEWFmXhUOkWh9wZmymtVGg_16_6">16,208</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" id="Tc_KBc37KH6oECx9ic_TUlnHw_16_10">16,208</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_LongtermBorrowingsMember_3_c4ZNJ7IkuGUZRsgL5KeA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_t_yW9x6I_0-rqtWUfAs7cw_19_2">46,846</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_LongtermBorrowingsMember_KhP49WhAa0S2SqllGaAZ3A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_QwnNi8Y5O0yPJ-yMMmMPKQ_19_8">46,846</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_LongtermBorrowingsMember_3_c4ZNJ7IkuGUZRsgL5KeA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="3" id="Tc__9oKYP7LZUe9A5xsJo6Khg_19_10">45,994</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative instruments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_DerivativeInstrumentsMember_USWamMRH70e5dMBuXB1kfg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_O6Hd3bFLFkKcNajG2Mfmzg_20_2">13,569</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_DerivativeInstrumentsMember_USWamMRH70e5dMBuXB1kfg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_dBNqRrumqkeaM3NoAC2yKQ_20_4">13,569</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_DerivativeInstrumentsMember_USWamMRH70e5dMBuXB1kfg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="3" id="Tc_AGcOruLIykWjj-fmDm24LA_20_10">13,569</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Royalty certificates liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_RoyaltyCertificatesLiabilitiesMember_tzXibduYxE6YsqSgIdTn3A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_7IvVzRsz10SYVD6XEAc8Hg_21_2">7,263</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_RoyaltyCertificatesLiabilitiesMember_tzXibduYxE6YsqSgIdTn3A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_1Sz7QzgtsUSS0duW7FRlpA_21_8">7,263</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_RoyaltyCertificatesLiabilitiesMember_tzXibduYxE6YsqSgIdTn3A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="3" id="Tc_wGjwPI1K8U2KKpu25G6xEQ_21_10">9,050</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_ShorttermBorrowingsMember_HbTI56G8V0OVuMMfgkPm9w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_pZXZdDBaGkWYbAnDdoF2AQ_22_2">5,726</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_ShorttermBorrowingsMember_q5wyxdtsjkC9ATGXwBJ1zQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_nf5fU9MpFkq2Ghwt3KHJcA_22_8">5,726</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_ShorttermBorrowingsMember_HbTI56G8V0OVuMMfgkPm9w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="3" id="Tc_96xDWIkCIEOBJkBbK5DzWw_22_10">5,726</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_TradePayablesMember_DT34R3eKL0K1egtpaQCcgw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_hW_FIHvF3kSSRYGRYpOAXQ_23_2">36,583</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_TradePayablesMember_DT34R3eKL0K1egtpaQCcgw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_3wdefbUY5kyz61OyBZtnbA_23_8">36,583</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_TradePayablesMember_DT34R3eKL0K1egtpaQCcgw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="3" id="Tc_3pcDD9wjHEawJ3Rs-eu_qg_23_10">36,583</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other miscellaneous payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_OtherMiscellaneousPayablesMember_17V3AWgX9UGIGzCdKUHVpA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_k3oe4eWXHEyDaSvBQwu_OQ_24_2">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_OtherMiscellaneousPayablesMember_17V3AWgX9UGIGzCdKUHVpA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_ds3AmoZhUEGe_PlWYcwxBg_24_8">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_OtherMiscellaneousPayablesMember_17V3AWgX9UGIGzCdKUHVpA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="3" id="Tc_GQLaIFBR30ODOubIpdsGng_24_10">12</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_38dGII73dEaQYz0K8olqXQ_25_2">109,998</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ad_CUhpQSUWO9uvSqmVOjw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_hlxKNtszZ0G58Iz9hdsIfw_25_4">13,569</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_xqxoBDc1zUiTY3urkmymcw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_pEi7ehW_U06rXH0yIMPuGA_25_8">96,429</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="3" id="Tc_eY9Mgc_b5UGepZU0gj8uIA_25_10">110,933</ix:nonFraction></b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><i style="font-style:italic;">See Note 4.10 Financial debt detailing amortized cost and fair value of the Credit facility with the EIB</i></p></td></tr></table></ix:nonNumeric><ix:continuation id="Group_I7bbA6lcz0ylRY7g1M2WDA_2" continuedAt="Group_I7bbA6lcz0ylRY7g1M2WDA_2_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_BEhJmD7Mi0qy5FGYoXkPBA_1_2"></a><a id="Tc_i6l86e0UE0KOVRV0AqtJyw_2_4"></a><a id="Tc_2ooZuFJ_2Ui2kLw8jm-BuA_3_2"></a><a id="Tc_6mcO1KtInEWrPmQWdBgrsA_3_4"></a><a id="Tc_4RJKoq8cSUqyzfMm9du6iw_3_6"></a><a id="Tc_CwXqfvd14kCo2U7l7jPzJA_4_2"></a><a id="Tc_DMdv1cH_zUmYlllxQXdb9w_4_4"></a><a id="Tc_bPyEK8fzCUeEWfAA5TfUgQ_4_6"></a><a id="Tc_ZDKvpuizpECTna_8pru6Gw_4_8"></a><a id="Tc_8T-gJL44CUi_YN-wk34G9Q_5_2"></a><a id="Tc_kW8Mfiuk5UGAlB0yGXjbrg_5_4"></a><a id="Tc_u0oJ_TPaUEGGneULX3H20Q_5_6"></a><a id="Tc_rNfKFwPL80yJBc_vvh22YA_5_8"></a><a id="Tc_CN3lgw0dE0yKU00HzcCHEg_6_2"></a><a id="Tc_qILX5dt8r0KOVKrrx9kd5A_6_4"></a><a id="Tc_BaTcWzMJi0upp34oUbq4CQ_6_6"></a><a id="Tc_Ty3E1uMCQUubOiULTVfr2g_6_8"></a><a id="Tc_hw5xm-H5mUy8B_rtVPbkwQ_7_0"></a><a id="Tc_fGXGSDTOd0WkdUqtYy9fnQ_7_2"></a><a id="Tc_GGuddehJ1U-PfmuKXa0aBw_7_4"></a><a id="Tc_EMAK8Nhy3Uqf46C-qQn98A_7_6"></a><a id="Tc_cw3AaQ-QmEqMrkmFWTgBHw_7_8"></a><a id="Tc_-Nzajc2ktUSGAIl9HMxMqg_7_10"></a><a id="Tc_Jrc99RbHc0q7fldSJec7Yw_8_0"></a><a id="Tc_Ugp4gkYzL06HpiCsEKFpxA_8_4"></a><a id="Tc_JFxz3b4q20SsVGzewNJTmw_8_8"></a><a id="Tc_chwLDY1iJ0ePpKcZF2spMA_9_0"></a><a id="Tc_Kpuwg5lZnECCicfh3ucfyA_9_4"></a><a id="Tc_5DLtMWJFgEil8kk8SFSNuQ_9_8"></a><a id="Tc_TsCtSu-B4067qFpdUAPGnQ_10_0"></a><a id="Tc_zbbrkFQY3kqvykI3p1iG8w_10_4"></a><a id="Tc_KvA3AYX5t0qpoLIUcpmUsw_10_8"></a><a id="Tc_IE_zMO6y2UqcQx3P3OtmHQ_11_0"></a><a id="Tc_OIDEZ-9Lg0SJIi56t8Wwiw_11_4"></a><a id="Tc_DhdZE97_fEG8BNYqtzg-ow_11_8"></a><a id="Tc_7j-rI52g5USkYLpWXJ8W6w_12_0"></a><a id="Tc_p5Vwfv_H-kiqNa1K1YqFzg_12_4"></a><a id="Tc_sLkALQ-4X06bpS927CP76A_12_8"></a><a id="Tc_fLikT55jJUGFXIUeEIBB2g_13_0"></a><a id="Tc_NB0vbA7T4Ea6wv7xesJs-Q_13_4"></a><a id="Tc_m7p5GRSQdU-DmamLoOzLXA_13_8"></a><a id="Tc_a3jUC4LO702jmkKfY1NCPg_14_0"></a><a id="Tc_W2XtpP4a-kOtfvI9kuwvLg_14_4"></a><a id="Tc_1anyoe1smUOqk2-oNeNcxw_14_8"></a><a id="Tc_YHZbTecx2UyIBK0hxlhTuA_15_0"></a><a id="Tc_OG7iQJ30cUuoFCmuy9cFPw_15_4"></a><a id="Tc_QfhNUhGTuEWZsKdF4PtUeA_15_8"></a><a id="Tc_WBPZWNDhg0unMsJ_NeM6pQ_17_0"></a><a id="Tc_UV1nTTggHUupyqFpUF3XPg_18_0"></a><a id="Tc_c7azeIZbOU6ea-RomqHzTg_18_4"></a><a id="Tc_iF5YrpdlIkajdS2D5zrSjw_18_6"></a><a id="Tc_EXCYWloiJESCJbDM3-YB0A_19_0"></a><a id="Tc_UM-t2MycDEWUJBGdyXFPgw_19_6"></a><a id="Tc_BNdbCDLrrUmt6DgcVcrGJA_19_8"></a><a id="Tc_MqXsKTzeL0qZ0YgmrgcMIQ_20_0"></a><a id="Tc_hQPOk-8cJ0uvnGP1ER1gNQ_20_4"></a><a id="Tc_h489MyUXf0iUO85orHZWWw_20_6"></a><a id="Tc_87MUj8ON1kC-wRjjkDND7Q_21_0"></a><a id="Tc_a9GT0vrlNEq_aXMilRcm_g_21_4"></a><a id="Tc_UFxbY70qdEyt07lMg1Kl-A_21_6"></a><a id="Tc_i_uQOqrD-0KYBygQv3vteA_22_0"></a><a id="Tc_argoOCIDekWqsc55cTSVtA_22_4"></a><a id="Tc_sV23UiT92kuMPOm04UqTqw_22_6"></a><a id="Tc_aWQgTyW8oEmHQUeFHIkfdg_23_0"></a><a id="Tc_yFwFrDiIDEmoFAvVAvBbJw_23_4"></a><a id="Tc_re_7bbFDxkOOKAsrKNj7gQ_23_6"></a><a id="Tc_4SNCPNrYCEmZ5gmY83jmiw_24_0"></a><a id="Tc_n6eJUbwuYk6xAPYOQJ5YHw_24_6"></a><ix:continuation id="Tb_W2fxsSQu5Uq8FHoj32PADQ_cont14"><ix:continuation id="Group_I7bbA6lcz0ylRY7g1M2WDA_2_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:49.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Financial</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Book Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">assets/liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Financial</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">on the</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">carried at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> assets </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">statement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">carrieds at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> carried at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of financial</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">through</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">profit or loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term deposit accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_LongTermDepositAccountsMember_nJntFM5UfE6dEPYXAe50tg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_fZvSiZ5Dq0evhkJMnl7Z6w_8_2">9,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_LongTermDepositAccountsMember_fo_XM5MB2kOMXwNZMOkI5g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_6e1goRscwkSKXZtmsJYCfw_8_6">9,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_LongTermDepositAccountsMember_nJntFM5UfE6dEPYXAe50tg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" id="Tc_aK7MHgUB4ky9ccqsmWy86A_8_10">9,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_LongTermSecurityDepositsMember_Noxm4K7bX0S6jyxwkUADrg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_Y9awdcChXkWyUjEoTMpvAQ_9_2">8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_LongTermSecurityDepositsMember_VROn8csSH0i28NXJGx3Amg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_EIME4aNe_UmbI7CVyyAliA_9_6">8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_LongTermSecurityDepositsMember_Noxm4K7bX0S6jyxwkUADrg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" id="Tc_5OUXgK6YFke7nG7rzeFRKw_9_10">8</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Advance payment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AdvancePaymentMember_FkwbWhKujke__64KGmRGog" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_07pBw8fhrEKafzx8oyM0xQ_10_2">1,047</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AdvancePaymentMember_qXVB1LZ70EWDaFdvLxmc5Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_dVe2MIHMiEG_wWSrwhLBSg_10_6">1,047</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AdvancePaymentMember_FkwbWhKujke__64KGmRGog" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" id="Tc_3ARvzItFo0WQyLgFm4qs0Q_10_10">1,047</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term deposit accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_ShortTermDepositAccountsMember_XX7WnZfsDkussQqjcn130w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_7MSbuQXHok6wAv-ctoP2YQ_11_2">70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_ShortTermDepositAccountsMember_374tsJrTKk6fJow5yHyCDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_gfXUTsyhyUqHsiulAxUxLQ_11_6">70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_ShortTermDepositAccountsMember_XX7WnZfsDkussQqjcn130w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" id="Tc_Z5nQLBp50EeABVPfATAXsg_11_10">70</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_TradeReceivablesMember_HDaVOBXSAEmTDP24XH8uQQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_JP1X57AbMk621FQ5nt-1_g_12_2">3,807</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_TradeReceivablesMember_9Se6Eh9LEEyShj3tyGuJAg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_XfooHZ8-SEGj4a4jZk-clg_12_6">3,807</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_TradeReceivablesMember_HDaVOBXSAEmTDP24XH8uQQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" id="Tc_3-dXre4zQk2dg8xBdDLcRA_12_10">3,807</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_OtherReceivablesMember_YRoI5LsEsEySxVU2J2oZVw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_LOqJExAYUkWP6NzcbRmOXg_13_2">857</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_OtherReceivablesMember_nOSt24rbu06dp175BFWIVg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_b5me_10mW0KfNVWEP2sDzg_13_6">857</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_OtherReceivablesMember_YRoI5LsEsEySxVU2J2oZVw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" id="Tc_to5F9lG6K0yGJHYAV6pR0g_13_10">857</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_IfrsCashAndCashEquivalentsMember_vrZZqx47o0a1hsDxw-vIxA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_hR97XKPsqkWk_mYh68RY6Q_14_2">26,918</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_IfrsCashAndCashEquivalentsMember_OARfL4lhGkWF8cdGOx-xCQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_-HbJoJias0SOMoKv4axjGg_14_6">26,918</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_IfrsCashAndCashEquivalentsMember_vrZZqx47o0a1hsDxw-vIxA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" id="Tc_oFt_tMW9a0KEgh_VRti8AQ_14_10">26,918</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_DW49MvthZkSRA1VNj2G1Ug_15_2">41,706</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_RtETuwSwJkCED4F2iCpqkA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="3" id="Tc_Fer_kVX0wUuPRmAuK1GrgQ_15_6">41,706</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssetsAtFairValue" scale="3" id="Tc_dMOjuddheEqlB0NMLfk5ow_15_10">41,706</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_LongtermBorrowingsMember_LdqaexFubUm5bmzDhGaIFQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_eBrmu057_kqU-bCbdDTNXQ_18_2">32,181</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_LongtermBorrowingsMember_1DesxSZs7UeHW8u3NH0eGg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_AL0ZPxn2YkOSBwg8MucYEg_18_8">32,181</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_LongtermBorrowingsMember_LdqaexFubUm5bmzDhGaIFQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="3" id="Tc__hK6pT4ml06XQ3Fnc8eUJQ_18_10">29,701</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative instruments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_DerivativeInstrumentsMember_DXqbqfuw00aAGXk5irtJtw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_MAozsp5xKE-Y_y7ahasmtQ_19_2">10,265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_DerivativeInstrumentsMember_uAo9ZMcdJEO8cLUT1lE0MA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_7CJ1FV66oUm0mnB3UHkXPg_19_4">10,265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_DerivativeInstrumentsMember_DXqbqfuw00aAGXk5irtJtw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="3" id="Tc_wu9A5CxarkqyX6zCuSvtRA_19_10">10,265</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Royalty certificates liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_RoyaltyCertificatesLiabilitiesMember_Sn-nL6ck_UCopAUgyhyLIw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_GMux-DYZyUy1uecHahHx-Q_20_2">6,327</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_RoyaltyCertificatesLiabilitiesMember_WaIiYd4PIUyNoJBmB4iA4A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_KM9fxhmwc0CV9lptW4iBew_20_8">6,327</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_RoyaltyCertificatesLiabilitiesMember_Sn-nL6ck_UCopAUgyhyLIw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="3" id="Tc_mAwhU9tGU0O-0iNlZycPDA_20_10">9,617</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_ShorttermBorrowingsMember_cHoNbFS0eUyuodyG6femhw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_2JkKS4HHKkegGbujPeMYNQ_21_2">5,308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_ShorttermBorrowingsMember_NB0TWpTDvU2mM9PCPaNmTg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_eBBG3UUWEEmlcJOC7t-KRg_21_8">5,308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_ShorttermBorrowingsMember_cHoNbFS0eUyuodyG6femhw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="3" id="Tc_a7gI-UKf10WLNYymmw6_SQ_21_10">5,308</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_TradePayablesMember_5cmgPsH920CfGPmJBDOp-w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_RiOJ2XTQlkiwe4lyydYXlg_22_2">37,679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_TradePayablesMember_hHYqQE9Yj0e7HSqbpfQXSg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_ftfx4N1e8UurUf8d4yalsA_22_8">37,679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_TradePayablesMember_5cmgPsH920CfGPmJBDOp-w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="3" id="Tc_yZ_rdrz1b0C3VG99a_NvKw_22_10">37,679</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other miscellaneous payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_OtherMiscellaneousPayablesMember_oeFuIUG-QkqzWRNtsHuxmQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_iJldYYyCZEqaBwHOnNVH1g_23_2">23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_OtherMiscellaneousPayablesMember_XvcehwIoO02CIQ32YJIxyg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_nirxdqJ9HE--g5pgmPf6zg_23_8">23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_OtherMiscellaneousPayablesMember_oeFuIUG-QkqzWRNtsHuxmQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="3" id="Tc_E1BWB_d81kqaKvUetHjhcQ_23_10">23</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_N_XtJioBYkWCPq4dvwSjkA_24_2">91,784</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_tIb2x3EdLUOAPCEztcL7wA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_xgo_4OQ4nEGu9vC_st9cOA_24_4">10,265</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_Ju8a20CjNUGvFkUgBgWStw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="3" id="Tc_mhEb-uA2vkO9750Lflrt4w_24_8">81,518</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="3" id="Tc_PeItg8WKc0mfWoApsOJ8jw_24_10">92,594</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Note5Notestotheincomestatement_682370"></a><a id="a51Revenuesandotherincome_556689"></a><a id="Tc_hKQUmek9M02xiBf5uATOJQ_1_0"></a><a id="Tc_T9CXnRv_00q3-4vtJav2QQ_1_2"></a><a id="Tc_4UcjUg6SKEu_Qrt7vxdwNQ_2_0"></a><a id="Tc_iD8lADiEq0q65zcI9rkRwQ_2_2"></a><a id="Tc_nG6IuKoDA0K0s3ZzWNRVSQ_2_4"></a><a id="Tc_ioOTLc65yE-fbZTe9lliGw_3_0"></a><a id="Tc_l-RHXjor1kWPa5wx_63kRg_4_0"></a><a id="Tc_u5PLUh_RiEKp1aFUvj1Vbg_5_0"></a><a id="Tc_jV6oWvyTxkeWzWqneBVPkQ_6_0"></a><a id="Tc_nSc8wW4bwEypYKyV3rtC5w_7_0"></a><a id="Tc_0pSt3oBURU2Q2YA8-2ocWw_8_0"></a><a id="Tc_1Qz9C5t5ykSGRl7WtQFmRw_9_0"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="iva:DisclosureOfComponentsOfIncomeStatementTextBlock" id="Tb_VtQgwOgrwES3kUb4kGluAg" continuedAt="Tb_VtQgwOgrwES3kUb4kGluAg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Note 5.</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Notes to the interim condensed consolidated statement of (income) loss</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.1</b></span><b style="font-weight:bold;">Revenues and other income</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">For the six months ended June 30, 2024, and June 30, 2023</i></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="iva:RevenueAndOtherIncomeTableTextBlock" id="Tb_JGKP0fU_e0eTV0Nao-mCjQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Operating income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_szMl1nTEZkSpUWUaCcMP_w_3_2">41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_7Mval74YOkmaMtPcs9VCfg_3_4">1,901</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Revenue" scale="3" id="Tc_vMIgqiKprEut_lclwgao7w_4_2">41</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Revenue" scale="3" id="Tc_PZN8w8sVnEWY455X_taXjw_4_4">1,901</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:CurrentTaxCreditResearchIncome" scale="3" id="Tc_dRQ8f7l9jUyIpC6vBYKChg_5_2">2,630</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="iva:CurrentTaxCreditResearchIncome" scale="3" id="Tc_fLDvYJbFGkCxWFywBaSMmg_5_4">3,631</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Subsidies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:SubsidiesIncome" scale="3" id="Tc_5bqSetbAQEmzLxZR0jmLDQ_6_2">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="iva:SubsidiesIncome" scale="3" id="Tc_kug5gpZUl0qWsBF8FMFubQ_6_4">3</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:IfrsOtherOperatingIncome" scale="3" id="Tc_-1rRNt777EqGLJEgorcpXw_7_2">58</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="iva:IfrsOtherOperatingIncome" scale="3" id="Tc_7M7sobUa8kaHI74FG_4wQA_7_4">1,087</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:OtherIncomeFromOrdinaryActivities" scale="3" id="Tc_zt9S_vMCJkOtICb3wfVRAA_8_2">2,693</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="iva:OtherIncomeFromOrdinaryActivities" scale="3" id="Tc_yQRHVkjtt0KJe68GxYiegw_8_4">4,721</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total revenue and other income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueAndOperatingIncome" scale="3" id="Tc_0RItwKIai0GZwMtDc5-QQA_9_2">2,734</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueAndOperatingIncome" scale="3" id="Tc_EctURxUzPk6pqOBaz0wP3g_9_4">6,622</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other operating income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Research Tax Credit (&#8220;CIR&#8221;) generated over the first six months of the fiscal year amounts to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-5" format="ixt:numdotdecimal" name="iva:CurrentTaxCreditResearchCurrentYear" scale="6" id="Narr_E7Yo3kip8EKUhjeiAvIu0Q">2.7</ix:nonFraction> million in 2024 as in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, other operating income are composed of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The R&amp;D Tax Research Credit from Inventiva Inc amounting to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_InventivaIncMember_yX8YJNqJxEeoquiF4wd66g" decimals="-5" format="ixt:numdotdecimal" name="iva:CirAndOtherResearchTaxCreditsReceivable" scale="6" id="Narr_-eLLghvcJ02VjYpG6xvnkA">1.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million, compared to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_InventivaIncMember_CsDcvL6WIEe96pAzGCSMYw" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="Narr_9StjVcZ9XESZQxr13jqLRw">0.8</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million in tax income as of June 30, 2024;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The re-invoicing to CTTQ for a portion of the expenses incurred, amounting to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_tfmxFNVVb0CS5hG6C3JkAQ" decimals="-5" format="ixt:numdotdecimal" name="iva:OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement" scale="6" id="Narr_4IERyTGvBUWNaAy7HtlGpQ">0.3</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million as of June 30, 2023, under Phase I of the ongoing Phase III pharmacological clinical trial NATiV3, and the re-invoicing to CTTQ for specific expenses related to CRO provisions amounting to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ServiceContractWithAvantSanteMember_cAPxNDRt4k2GvvKof24NwQ" decimals="-5" format="ixt:numdotdecimal" name="iva:OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement" scale="6" id="Narr_wZ9ER9fynk2rsSGLfFMsyA">0.7</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million, compared to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_ZxMBck8Vv06CkTltj3JJkg" decimals="-5" format="ixt:numdotdecimal" name="iva:OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement" scale="6" id="Narr_uY2FtyizFEeGSSCAQgbeGQ">2.6</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million in CTTQ re-invoicing as of June 30, 2024, accounted as a reduction in research and development expenses.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="a52Operatingexpenses_153201"></a><a id="_c603534c_6b54_47b1_8528_c2eae00b620b"></a><a id="Tc_1hWjUiLxt0qY5wmZQ7Nr3Q_1_2"></a><a id="Tc_59DQYvRW9ESixlbqel1B5A_1_4"></a><a id="Tc_LMM-oMQ2p0eh47YxPVnMxQ_1_6"></a><a id="Tc_MP9pNTWZ2EGfXHtuSlGKQg_2_0"></a><a id="Tc_jfKS-z9jskeu8nx8T1kptQ_2_2"></a><a id="Tc_UBzx4tf4EkuvOF_oEJK9tg_2_4"></a><a id="Tc_oio1AAXyq0q2ABOJblFUAA_2_6"></a><a id="Tc_iU2iruDdwECmEtlGylQARA_3_0"></a><a id="Tc_6WDwmK3k00yNYa5LiNlrHQ_3_2"></a><a id="Tc_JFlQIJb-7U2wO3QN2eivsA_3_4"></a><a id="Tc_GTjrO0mIX0GWzJDdVqrWMA_3_6"></a><a id="Tc_1m18_eq6fEaZfDebee6R9w_3_8"></a><a id="Tc_ceIs28GZPUiUPRjAfiUVZg_4_0"></a><a id="Tc__SBkivWT3UifaLACaTb2EA_4_4"></a><a id="Tc_2qla4nSuY02muLY6hH23LQ_4_6"></a><a id="Tc_AAmI1XzM8k-SPNKb4yy_yQ_5_0"></a><a id="Tc_TxyO3YVoT0KyiKC5QcfRrQ_5_4"></a><a id="Tc_N-N9oCvLPkCCkb-Ygxk9yw_5_6"></a><a id="Tc_b-irlGhquUyFuRlO_WJWHg_6_0"></a><a id="Tc_tAjLnqfSckqtAnpWnGaAzQ_6_4"></a><a id="Tc_1lA4qCCIdUm-WImbdg1giQ_6_6"></a><a id="Tc_KUTAAzqgV0y57aN-MEQjFA_7_0"></a><a id="Tc_1nqtVlP450-7fdE-_icI5A_7_4"></a><a id="Tc_Pw-BZ5WsH0mTymZ3c86LQw_7_6"></a><a id="Tc_-f7yMg_2YUGkYd35EUaHGA_8_0"></a><a id="Tc_L1lD61fIlkubPQDVTQ8zTA_8_4"></a><a id="Tc_CcgDNrK6c0WqjKdBKE_IeQ_8_6"></a><a id="Tc_kWAm5Rjt00aXm8QadvAQhQ_9_0"></a><a id="Tc_2w6QyJaqrESl9aWITKv9YQ_10_0"></a><a id="Tc_q4i7mWIUl0-wAtZxBfQIWw_11_0"></a><a id="Tc_FtfqLXV2xEmGrJA5UTBp5Q_11_2"></a><a id="Tc_5n36RDQ2akK7VXj_ywmrAQ_11_4"></a><a id="Tc_0AnwotqpBkekywuxucAR6A_12_0"></a><a id="Tc_IzR8iVdVaEWZOxPPwfoarw_13_0"></a><a id="Tc_kgrzQ6JuL0SDFErIoTidhQ_13_4"></a><a id="Tc_xPs_w_OJ90Ocj_J9JRojNQ_14_0"></a><a id="Tc_Ik94C2lTHUCaU1YH9pFOyw_14_2"></a><a id="Tc_fKpydHVAbU2rlGhpA-mEjw_14_4"></a><a id="Tc_Q-oEteq-wkqQrkECm7BOLQ_15_0"></a><a id="Tc_kjOobxh8A0CJk__iR0XP1Q_16_0"></a><a id="_9f16dbb7_01dc_462e_bfeb_6154b740d3e5"></a><a id="Tc_c47bFZBuNE-jPQwiLaO3Dw_1_2"></a><a id="Tc_9x7JzEk_pk-LrFsf5VocvA_1_4"></a><a id="Tc_KDfDMrysfkm5tlsh5sDYxw_1_6"></a><a id="Tc_-W1qODduJkaCnENw53-jew_2_0"></a><a id="Tc_cjLQ7Vfyj0K9eEelSnDB-Q_2_2"></a><a id="Tc_KY-a7nVtXEyqbG2QfHunjQ_2_4"></a><a id="Tc_pn9eTjRlA0qaDJ8iS9YKpw_2_6"></a><a id="Tc_F60R1OBMTkaajtII7FQKrA_3_0"></a><a id="Tc_OzBHGRhURU60Wy6qW5Dzqg_3_2"></a><a id="Tc_Z10psIx-aEutbAgG31rh2g_3_4"></a><a id="Tc_s-AtsboCIkqg-WvqzTXU9w_3_6"></a><a id="Tc_hzia5zQkjkazd6jqhokrfw_3_8"></a><a id="Tc_vktDZssifkO1rNF_z4n91g_4_0"></a><a id="Tc_f89tj2PedU6neKmqS-BPEg_4_4"></a><a id="Tc_a1sxJZJo6k6SiJdnGAYFOQ_4_6"></a><a id="Tc_LcGLRxEzyUe-CBXIiLg07A_5_0"></a><a id="Tc_c-u5Wn8wUUSJ9-rsshaH2g_5_4"></a><a id="Tc_4rFoCM-H7k63PDHeDRyPFw_5_6"></a><a id="Tc_Do8H4uT6Dk-xYVcr1rmgjQ_6_0"></a><a id="Tc_59LHlZR2v0K_IyNTpqDO_w_6_4"></a><a id="Tc_gvfR5muTI02ShcmKoB-HHw_6_6"></a><a id="Tc_OQfOnQaOo0uZ-s9riNuOuQ_7_0"></a><a id="Tc_GhCBLg0qNE68QolcSQIIxw_7_4"></a><a id="Tc_61XYf3YhZ0agt-90St-agQ_7_6"></a><a id="Tc_sNyNvHp7XEWgUDdoDRLF-w_8_0"></a><a id="Tc_1WjyZtEsNE-xZQ_ABMBPmw_8_4"></a><a id="Tc_zKocdVyN4kGc-qrq7THZnQ_8_6"></a><a id="Tc_-4DfA-vfz0yA1l63O7ixHA_9_0"></a><a id="Tc_os3IUx5seEGn3DdVZ9zcZA_9_4"></a><a id="Tc_hPUEqcfJqEWY0_kg9bC8ZQ_10_0"></a><a id="Tc_d3HHfTOAo0Kg2jZFPfGpng_11_0"></a><a id="Tc_UXG04BF4MUeYIb83XPE5IQ_11_2"></a><a id="Tc_jzEFIlcZ9k-PdfQr1A6mdA_11_4"></a><a id="Tc_i5xRdSb1JE-W9gFERA6ikw_12_0"></a><a id="Tc_9WiabABtMEaKQgY0T0XEWQ_13_0"></a><a id="Tc_ylBdxlDGQ06wnfZXVgt7mA_13_4"></a><a id="Tc_04H0kskddU-pMH1oKkFDzw_14_0"></a><a id="Tc_JYmR7Od120-FCAMlFU1I9Q_14_2"></a><a id="Tc_H2jNdAfSVUaCHLd_tTTbqQ_14_4"></a><a id="Tc_TCWyvzeNsEKqYYWSVAm7sg_15_0"></a><a id="Tc_XTIDzRzGNUuLb500uD75_A_16_0"></a><a id="Tc_Uoicii21jkWhCdGjTdV3LA_1_4"></a><a id="Tc_WcLJzFgO2k69RRPxLakqtw_2_2"></a><a id="Tc_7ANguqwjvUGnxDEsRiJ9tA_2_4"></a><a id="Tc_0d0Op6oghkyAkHv4Jbt0Eg_2_6"></a><a id="Tc_zJMUvGIETE6PoKIC2i9_EA_3_0"></a><a id="Tc_SrEKAuBKz0uXZcAkTHnoLg_3_2"></a><a id="Tc_15-jWCdZH0iMeujsngEX8A_3_4"></a><a id="Tc_Wk5HHBGR7EiFMTPZLh4J6w_3_6"></a><a id="Tc_pJm-yEV8AESjoKaFnWxzgA_4_0"></a><a id="Tc_sqXEVhWvT0uFBffp9Ym7cA_4_2"></a><a id="Tc_CsSgPuanPUCeRBMdZmYd7A_4_4"></a><a id="Tc_qHXdmme3yUibKpYWkHGhOQ_4_6"></a><a id="Tc_zwZt1VTO40C9UnTaMnFu5g_4_8"></a><a id="Tc_QSuI_i92N0evwNNxu6DWUA_5_0"></a><a id="Tc_TUVRvEGztkyxP4tg4ctiuQ_6_0"></a><a id="Tc_cE2my008Bka3LODALbuekQ_7_0"></a><a id="Tc_Qv5XILYHLkSDKQqL-ngBbg_7_4"></a><a id="Tc_mLtjCmI8WEqGeladpJCu3w_8_0"></a><a id="Tc_UWgCM4t17U-qx4vGn-dc0A_9_0"></a><ix:continuation id="Tb_VtQgwOgrwES3kUb4kGluAg_cont1" continuedAt="Tb_VtQgwOgrwES3kUb4kGluAg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.2</b></span><b style="font-weight:bold;">Operating expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">For the six months ended June 30, 2024 and June 30, 2023</i></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="iva:ResearchAndDevelopmentMarketingTableTextBlock" id="Tb_2z2jxUhVxUu1eCC5a79yEw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Research&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Marketing&#160;&#8211;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">General&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six months ended June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Business</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">administrative</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Disposables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA" decimals="-3" format="ixt:numdotdecimal" name="iva:Disposables" scale="3" id="Tc_uhnew7qNdEOVUzeWQmSKjw_4_2">887</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:Disposables" scale="3" id="Tc_bkG4rVN190murpgzPZxnRQ_4_8">887</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Energy and liquids</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA" decimals="-3" format="ixt:numdotdecimal" name="iva:EnergyAndLiquids" scale="3" id="Tc_ipVVlxHBM0ioPJ6hMWSVTg_5_2">447</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:EnergyAndLiquids" scale="3" id="Tc_1YXbc1_x_EmGzjWoBD_Phw_5_8">447</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Patents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA" decimals="-3" format="ixt:numdotdecimal" name="iva:Patents" scale="3" id="Tc_fMhCURC9REuEu4xPWCD0CQ_6_2">643</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:Patents" scale="3" id="Tc_K3jzwHreHkGWqgjh9C3jvQ_6_8">643</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Studies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA" decimals="-3" format="ixt:numdotdecimal" name="iva:Studies" scale="3" id="Tc_821CE75x_kekh8sym9g6qg_7_2">34,073</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:Studies" scale="3" id="Tc_2NDC6tiB00iWA2FHhAZptw_7_8">34,073</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Maintenance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RepairsAndMaintenanceExpense" scale="3" id="Tc_y1GOhj6Sc0eZmRTX5Wyi2g_8_2">526</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RepairsAndMaintenanceExpense" scale="3" id="Tc_HJjFDP8Zmk2j_sASLdoWeA_8_8">526</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA" decimals="-3" format="ixt:numdotdecimal" name="iva:Fees" scale="3" id="Tc_zsYchosqpUusl_zO8FyBsQ_9_2">118</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_hTRe72PPekW3DzP4m38ewQ" decimals="-3" format="ixt:numdotdecimal" name="iva:Fees" scale="3" id="Tc_Aq_AzLc19Eup00aOSqh7Pg_9_4">2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg" decimals="-3" format="ixt:numdotdecimal" name="iva:Fees" scale="3" id="Tc_35HRL0-CBUWLnWG4zH_v-Q_9_6">2,675</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:Fees" scale="3" id="Tc_k7fzYR0MkUeDookT7a3qTA_9_8">2,795</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">IT systems</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA" decimals="-3" format="ixt:numdotdecimal" name="iva:ItSystems" scale="3" id="Tc_s0vx7wPVUkOS4kHsRZXFVw_10_2">405</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_hTRe72PPekW3DzP4m38ewQ" decimals="-3" format="ixt:numdotdecimal" name="iva:ItSystems" scale="3" id="Tc_k4yFbDtVkkSg7jLsE1oegw_10_4">6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg" decimals="-3" format="ixt:numdotdecimal" name="iva:ItSystems" scale="3" id="Tc_uIIbc8qSYUOtK37BDs1OEg_10_6">33</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:ItSystems" scale="3" id="Tc_z8zX2cfSDkuLoAGSmooJWA_10_8">444</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Support costs (including taxes)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg" decimals="-3" format="ixt:numdotdecimal" name="iva:SupportCosts" scale="3" id="Tc_94UpcMCJzkSzLY2kw7mNxQ_11_6">375</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:SupportCosts" scale="3" id="Tc_4mi3NlCRhUCw-a8t-GJ5wg_11_8">375</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Personnel costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" id="Tc_cTv193VLY0iO0N7rmXsm-Q_12_2">7,637</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_hTRe72PPekW3DzP4m38ewQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" id="Tc__HqvyQjMRkyON9TSu7VjXA_12_4">153</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" id="Tc_b3r8Uu8pgEigDQxyaHd-Ng_12_6">2,600</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" id="Tc_5jUl_OBmnU6dLKiFA1svfw_12_8">10,391</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation, amortization and provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA" decimals="-3" format="ixt:numdotdecimal" name="iva:DepreciationAmortizationAndProvisions" scale="3" id="Tc_RZ6sxIrEWUqDja0-XPQ8vg_13_2">1,732</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg" decimals="-3" format="ixt:numdotdecimal" name="iva:DepreciationAmortizationAndProvisions" scale="3" id="Tc_AvEbpUDKlkWiEilWkyQV_w_13_6">122</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:DepreciationAmortizationAndProvisions" scale="3" id="Tc_tG2g1H_pZECE8ASUYcFb_A_13_8">1,854</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Insurances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InsuranceExpense" scale="3" id="Tc_pelBefyQ6U-SV1RPsQg_Uw_14_6">921</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InsuranceExpense" scale="3" id="Tc_OBYg6pq6p0mPk8UlNZOVJA_14_8">921</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA" decimals="-3" format="ixt:numdotdecimal" name="iva:OtherOperatingExpenses" scale="3" id="Tc_BdzbKYdavkGfppWqJr6zig_15_2">352</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_hTRe72PPekW3DzP4m38ewQ" decimals="-3" format="ixt:numdotdecimal" name="iva:OtherOperatingExpenses" scale="3" id="Tc_OpZggUSxlUG0wZVe9gq8rQ_15_4">437</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg" decimals="-3" format="ixt:numdotdecimal" name="iva:OtherOperatingExpenses" scale="3" id="Tc_b2DHQwLowES-aZRjsUoH1w_15_6">975</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:OtherOperatingExpenses" scale="3" id="Tc_tG7U4lFxO0u64iU9wgdg8A_15_8">1,764</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA" decimals="-3" format="ixt:numdotdecimal" name="iva:OperatingExpenseExcludingOtherOperatingIncomeExpense" scale="3" id="Tc_ZHaS17f9k0inHP0OY9to1g_16_2">46,822</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_hTRe72PPekW3DzP4m38ewQ" decimals="-3" format="ixt:numdotdecimal" name="iva:OperatingExpenseExcludingOtherOperatingIncomeExpense" scale="3" id="Tc_uGulyfdTrUCamANqDMs5fw_16_4">598</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg" decimals="-3" format="ixt:numdotdecimal" name="iva:OperatingExpenseExcludingOtherOperatingIncomeExpense" scale="3" id="Tc_dlEa7qlPCUiAL6scPaqDgw_16_6">7,701</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:OperatingExpenseExcludingOtherOperatingIncomeExpense" scale="3" id="Tc_Loa5oFNGBUOYUdV6gxNi1w_16_8">55,122</ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Research&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Marketing&#160;&#8211;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">General&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six months ended June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Business</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">administrative</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">en milliers d'euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Disposables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw" decimals="-3" format="ixt:numdotdecimal" name="iva:Disposables" scale="3" id="Tc_svRbtCXxkkeXTRdFp9XDFA_4_2">943</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="iva:Disposables" scale="3" id="Tc_rPEo7c3JqkCuYibA2ahYyg_4_8">943</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Energy and liquids</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw" decimals="-3" format="ixt:numdotdecimal" name="iva:EnergyAndLiquids" scale="3" id="Tc_t46XMjzveUW-QEu99VI9eQ_5_2">479</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="iva:EnergyAndLiquids" scale="3" id="Tc_yEVmeSX8Gk6F2izVLb9snA_5_8">479</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Patents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw" decimals="-3" format="ixt:numdotdecimal" name="iva:Patents" scale="3" id="Tc_PUz52kyYOkiVQfb83S3C6Q_6_2">257</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="iva:Patents" scale="3" id="Tc_kmSjDyVnD0SLsy4zZKaOoQ_6_8">257</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Studies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw" decimals="-3" format="ixt:numdotdecimal" name="iva:Studies" scale="3" id="Tc_T4sypuz6YEuCrghVFMwkVw_7_2">42,847</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="iva:Studies" scale="3" id="Tc_oFeVSRpbjUKI-D1WDLjETQ_7_8">42,847</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Maintenance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RepairsAndMaintenanceExpense" scale="3" id="Tc_9XRMzKycv0SRgQyKcvFgAg_8_2">459</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RepairsAndMaintenanceExpense" scale="3" id="Tc_ArFSPcFRMkO857RNucu1tQ_8_8">459</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw" decimals="-3" format="ixt:numdotdecimal" name="iva:Fees" scale="3" id="Tc_WyCH3K0wj0WBu4Xe9Q1DHg_9_2">61</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g" decimals="-3" format="ixt:numdotdecimal" name="iva:Fees" scale="3" id="Tc_8e8OBLRyv0CMbc-f1UpNFw_9_6">1,884</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="iva:Fees" scale="3" id="Tc_hON56dyDIkWZsOhS6jH-tA_9_8">1,945</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">IT systems</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw" decimals="-3" format="ixt:numdotdecimal" name="iva:ItSystems" scale="3" id="Tc_ELLPPBaXI0qie5DicC1sdA_10_2">440</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_vilht6HmAUelr2hSPT_U_w" decimals="-3" format="ixt:numdotdecimal" name="iva:ItSystems" scale="3" id="Tc_e2FDT7EaNk--stnPDKYNdA_10_4">9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g" decimals="-3" format="ixt:numdotdecimal" name="iva:ItSystems" scale="3" id="Tc_UvtVe_9eCUypCZpdfPJt4g_10_6">50</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="iva:ItSystems" scale="3" id="Tc_6-HFy9Cd00u81TsJDrF9NQ_10_8">498</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Support costs (including taxes)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g" decimals="-3" format="ixt:numdotdecimal" name="iva:SupportCosts" scale="3" id="Tc_FMoi3FP-9UK0aO7RR_DBHg_11_6">343</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="iva:SupportCosts" scale="3" id="Tc_VbrI6lQZDkmNA5vSSriY4Q_11_8">343</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Personnel costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" id="Tc_lQ9d_pf9w0O4sws6Ov6-BA_12_2">7,065</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_vilht6HmAUelr2hSPT_U_w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" id="Tc_vNy9tgkJT0OwTJ-3G6Awbw_12_4">126</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" id="Tc_AMgWfJzgsEarbIUvAy7hrg_12_6">2,347</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" id="Tc_xKhVYZJpxkmEAezNwIumiA_12_8">9,538</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Depreciation, amortization and provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw" decimals="-3" format="ixt:numdotdecimal" name="iva:DepreciationAmortizationAndProvisions" scale="3" id="Tc_ZxLgeM-hAkm6tSeIEhQ65Q_13_2">1,061</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g" decimals="-3" format="ixt:numdotdecimal" name="iva:DepreciationAmortizationAndProvisions" scale="3" id="Tc_a34QF1OXREKX8nNI9LdVbA_13_6">104</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="iva:DepreciationAmortizationAndProvisions" scale="3" id="Tc_RZph67r4VkOcPQJRD5tquw_13_8">1,166</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Insurances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InsuranceExpense" scale="3" id="Tc_4GaHcAF9B0mwBxS2jBJYTw_14_6">1,121</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InsuranceExpense" scale="3" id="Tc__xZRcqq_REKdGnZMKHeW8A_14_8">1,121</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Other operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw" decimals="-3" format="ixt:numdotdecimal" name="iva:OtherOperatingExpenses" scale="3" id="Tc_OgKxODTPYk-NOTJAWT1dLg_15_2">450</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_vilht6HmAUelr2hSPT_U_w" decimals="-3" format="ixt:numdotdecimal" name="iva:OtherOperatingExpenses" scale="3" id="Tc_29lWrqHXmEG7G40rkC3AaA_15_4">570</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g" decimals="-3" format="ixt:numdotdecimal" name="iva:OtherOperatingExpenses" scale="3" id="Tc_MBu-h1Q2LEWsybcsIWCe6Q_15_6">964</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="iva:OtherOperatingExpenses" scale="3" id="Tc_YEicAZlM40SVwICdQWuYdg_15_8">1,985</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw" decimals="-3" format="ixt:numdotdecimal" name="iva:OperatingExpenseExcludingOtherOperatingIncomeExpense" scale="3" id="Tc_mHv3IH2EukOtSM82BXnL2Q_16_2">54,062</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_vilht6HmAUelr2hSPT_U_w" decimals="-3" format="ixt:numdotdecimal" name="iva:OperatingExpenseExcludingOtherOperatingIncomeExpense" scale="3" id="Tc_lYKg_ZSfbkayvWnv4VMc_Q_16_4">705</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g" decimals="-3" format="ixt:numdotdecimal" name="iva:OperatingExpenseExcludingOtherOperatingIncomeExpense" scale="3" id="Tc_5NKJ4fgIxUSSzeXiDwdKng_16_6">6,812</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="iva:OperatingExpenseExcludingOtherOperatingIncomeExpense" scale="3" id="Tc_7ssVlLK55UOz-dLpsoKovA_16_8">61,580</ix:nonFraction>)</b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-style:italic;">Personnel costs and headcount</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="iva:PersonnelCostsAndHeadcount" id="Group_t1D2uEQm0USgOJpJdNSKUg" continuedAt="Group_t1D2uEQm0USgOJpJdNSKUg_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Marketing - </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Research and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Business</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">General and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six months ended June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">administrative</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Wages, salaries and similar costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:WagesAndSalaries" scale="3" id="Tc__e7eZIslcka8aNNUAAnmBg_5_2">4,824</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_hTRe72PPekW3DzP4m38ewQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:WagesAndSalaries" scale="3" id="Tc_K_-O-yHmhU6Y2HMu-sQjtg_5_4">120</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:WagesAndSalaries" scale="3" id="Tc_8WtPBkR-iky4bj8VQE2PPw_5_6">1,237</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:WagesAndSalaries" scale="3" id="Tc_XxJGzzkou023_G59-e0lfQ_5_8">6,181</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA" decimals="-3" format="ixt:numdotdecimal" name="iva:PayrollTaxes" scale="3" id="Tc_en1vtP6BREaYgwNWbwbTzg_6_2">1,312</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_hTRe72PPekW3DzP4m38ewQ" decimals="-3" format="ixt:numdotdecimal" name="iva:PayrollTaxes" scale="3" id="Tc_AQqyFG3ORk2bsFFKv_HTUg_6_4">10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg" decimals="-3" format="ixt:numdotdecimal" name="iva:PayrollTaxes" scale="3" id="Tc_Fyek47q48UyRwXFcy03j9Q_6_6">563</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:PayrollTaxes" scale="3" id="Tc_UQmjj_p6hUWl4zvc5MFb8w_6_8">1,886</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provisions for retirement benefit obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PostemploymentBenefitExpenseInProfitOrLoss" scale="3" id="Tc_SbbILS4f6kOXxNzZ4hqI1A_7_2">51</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PostemploymentBenefitExpenseInProfitOrLoss" scale="3" id="Tc_Bd5OECv2Z0SdH4d9aLb0SA_7_6">35</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PostemploymentBenefitExpenseInProfitOrLoss" scale="3" id="Tc_iwO7SBzZy0aVDsaXBUfkOA_7_8">86</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" id="Tc_LVWihdDLGkaqglEoCHvJrg_8_2">1,450</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_hTRe72PPekW3DzP4m38ewQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" id="Tc_LoPpUdDahECREjXNda1xWA_8_4">24</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" id="Tc_tSBClmyFykKuDG3CYqDurg_8_6">765</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" id="Tc_aXGPr-wu1kCvMOiWahzqTA_8_8">2,238</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total personnel costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" id="Tc_oXfb7pynkkKtBmeQSnmouw_9_2">7,637</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_hTRe72PPekW3DzP4m38ewQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" id="Tc_YSJi_a-YW0CPjicTf_xfwA_9_4">153</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" id="Tc_-jwQ89KlEUO-8LLS43yJKA_9_6">2,600</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" id="Tc_CWNANopA20W6klWljHvvIg_9_8">10,391</ix:nonFraction>)</b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_bLvYdJvDTEq0_E99jMxuTQ_1_4"></a><a id="Tc_HK8x6-7ynEyRDMRlYmmxOQ_2_2"></a><a id="Tc_haOp5nz3yUiGFi6ZpftDBQ_2_4"></a><a id="Tc_X3Q-BCZ9eUyF_CywcWw58Q_2_6"></a><a id="Tc_3hWHglm8gkioryPOoMHC8w_3_0"></a><a id="Tc_73yZ8Wmzg0yatiPSZxtuew_3_2"></a><a id="Tc_JfxBVotK70qRll1VgrOORQ_3_4"></a><a id="Tc_SmTXfaVXykKwixpsqZna1w_3_6"></a><a id="Tc_ZZR_J4lpMkGCy4QvG5Lw6w_4_0"></a><a id="Tc_wy6b6tooUkKpAQImRIoBow_4_2"></a><a id="Tc_g5pnx0rT_kCPaj55q7vr9w_4_4"></a><a id="Tc_RzuXOLOefEyBbA9PoW5nAA_4_6"></a><a id="Tc_PMvRlWy99EypDCU7gDdUIA_4_8"></a><a id="Tc_vYo-tB-ZTEyn2QnmH9lKTQ_5_0"></a><a id="Tc_83qSwr_Wi0iHWvriZAY9mQ_6_0"></a><a id="Tc_KGmIRiETLEi1oUogV6CmAg_7_0"></a><a id="Tc_1cdNTJSJUUqnWmEDyVsw4Q_7_4"></a><a id="Tc_W4pN2BiVbkGfwSiB9Mchig_8_0"></a><a id="Tc_azBizcl-V0G7fx7tUb03SA_9_0"></a><a id="a53Otheroperatingincomeandexpenses_16516"></a><a id="Tc_lb-rRoBSDESDQ_tHBXhotA_1_2"></a><a id="Tc_NBz_SQLm5ky0CIf4vyfeKA_2_0"></a><a id="Tc_RXwqQIM4B0eOMggZ8Mthuw_2_2"></a><a id="Tc_r3Dctb2EfU2B4JWU9NmjMg_2_4"></a><a id="Tc_YdXwW3eHvkyj215dGraj7Q_3_0"></a><a id="Tc_0nRZikaXxkm-lerLU-DMBw_3_4"></a><a id="Tc_thB7KiJaRU6BFC2lWE_VEw_4_0"></a><a id="Tc_171Wy15LeU-5Vuap9MNQgw_5_0"></a><a id="a54Financialincomeandexpenses_936320"></a><a id="Tc_HIC3PuBCKEyhvKiuNQyXLw_1_2"></a><a id="Tc_gWrers1jjUmwORNfu_eBqw_2_0"></a><a id="Tc_4UFePprE4EaITsogNtRbzw_2_2"></a><a id="Tc_I5EkI3dwqUm5vWL5RTu9eA_2_4"></a><a id="Tc_IO9ECn2ONUW7JnipjWWpHQ_3_0"></a><a id="Tc_AWxb8PCytEiNCEC5BIolKw_4_0"></a><a id="Tc_E1U_UkIHe0ank0z14fBeww_5_0"></a><a id="Tc__kU9KY_W_0GVP9FnqJdaSg_6_0"></a><a id="Tc_Pd9QOu132UG7ufHg02ZVmw_7_0"></a><a id="Tc_NYQokBiBjk-mhl3xxM9TZA_8_0"></a><a id="Tc_mc3x1ZjHkUiS0IzqM6ERpw_9_0"></a><a id="Tc_p2RdtLClOESTk0kAMWOqWA_10_0"></a><a id="Tc_tmHunbTQJkuvDZtxHTbKjw_11_0"></a><ix:continuation id="Tb_VtQgwOgrwES3kUb4kGluAg_cont2" continuedAt="Tb_VtQgwOgrwES3kUb4kGluAg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company has <ix:nonFraction unitRef="Unit_Standard_employee_t09Loy2TV0yh-O2RJe0wMQ" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfEmployees" scale="0" id="Narr_Q9eqSD8EiEy-KwusplpvPg">123</ix:nonFraction> employees as of June 30, 2024, of which <ix:nonFraction unitRef="Unit_Standard_employee_t09Loy2TV0yh-O2RJe0wMQ" contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_InventivaS.aMember_Cyc1aEXngEiGaWWQTrmH-A" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfEmployees" scale="0" id="Narr_SPcQrZzWOUmp1MpGDeQ2uw">112</ix:nonFraction> are employed by Inventiva S.A. and <ix:nonFraction unitRef="Unit_Standard_employee_t09Loy2TV0yh-O2RJe0wMQ" contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_InventivaIncMember_yX8YJNqJxEeoquiF4wd66g" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfEmployees" scale="0" id="Narr_pAOHToGeZkiDfAGPWQqvAQ">11</ix:nonFraction> are employed by Inventiva Inc.</p><ix:continuation id="Group_t1D2uEQm0USgOJpJdNSKUg_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Marketing -</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Research and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Business</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">General and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> administrative</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Wages, salaries and similar costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:WagesAndSalaries" scale="3" id="Tc_34zemMrAH0mkmExxTtSvUg_5_2">4,399</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_vilht6HmAUelr2hSPT_U_w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:WagesAndSalaries" scale="3" id="Tc_QkUHTNL4nE6-un8Tyc2T5g_5_4">104</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:WagesAndSalaries" scale="3" id="Tc_1zYK5tzDp0eX4NKLiIoe6w_5_6">1,191</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:WagesAndSalaries" scale="3" id="Tc_x9_bHrGmzki2xY_5jzH-Pw_5_8">5,694</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payroll taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw" decimals="-3" format="ixt:numdotdecimal" name="iva:PayrollTaxes" scale="3" id="Tc_YxDIjAWvCUaB1vnh55Y6hQ_6_2">1,222</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_vilht6HmAUelr2hSPT_U_w" decimals="-3" format="ixt:numdotdecimal" name="iva:PayrollTaxes" scale="3" id="Tc_GoDhc7xY1E6FhpdtKO2CGw_6_4">10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g" decimals="-3" format="ixt:numdotdecimal" name="iva:PayrollTaxes" scale="3" id="Tc_cDm19Xt8NU2R-2xJUEdzaw_6_6">476</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="iva:PayrollTaxes" scale="3" id="Tc_kcgvDIcyvEar6afatVjTAA_6_8">1,708</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provisions for retirement benefit obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PostemploymentBenefitExpenseInProfitOrLoss" scale="3" id="Tc_tVqGujUIAU2Tn1jQCj1qxQ_7_2">61</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PostemploymentBenefitExpenseInProfitOrLoss" scale="3" id="Tc_cSHSF8Itp0mywWUJZM53Cg_7_6">29</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PostemploymentBenefitExpenseInProfitOrLoss" scale="3" id="Tc_mvgfoggZE0ug4l8xxQk9Ew_7_8">90</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" id="Tc_Li5UAWk9o0OnVwcu69eX1w_8_2">1,383</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_vilht6HmAUelr2hSPT_U_w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" id="Tc_lm1GCObnd0iCn8gS6e8mVQ_8_4">13</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" id="Tc_kGH28at96k-QwRe7QpTgrw_8_6">650</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" id="Tc_Q4HhdxlqfEy3wNS2769s3A_8_8">2,046</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total personnel costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" id="Tc_-tSIiIS7D0-8mOREROdvyQ_9_2">7,065</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_vilht6HmAUelr2hSPT_U_w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" id="Tc_Lr7tiEgD6kef_XE0bVpCng_9_4">126</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" id="Tc_MWlR6Z2DEUOGlZlG-Cq4Cw_9_6">2,347</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" id="Tc_E435wzLUREWRbUqOU7XwVQ_9_8">9,538</ix:nonFraction>)</b></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company had <ix:nonFraction unitRef="Unit_Standard_employee_t09Loy2TV0yh-O2RJe0wMQ" contextRef="As_Of_6_30_2023_aUv8mHsKXUaaSWrxnxqKLg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfEmployees" scale="0" id="Narr_VAAPwjvtAkyFGUD9QdCUOg">117</ix:nonFraction> employees as of June 30, 2023, including <ix:nonFraction unitRef="Unit_Standard_employee_t09Loy2TV0yh-O2RJe0wMQ" contextRef="As_Of_6_30_2023_dei_LegalEntityAxis_iva_InventivaS.aMember_3oaek7qY7U2QTmeeOlV98g" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfEmployees" scale="0" id="Narr_Xrl7lA-vnUiSOZnLt9w03Q">105</ix:nonFraction> people employed by Inventiva S.A. and <ix:nonFraction unitRef="Unit_Standard_employee_t09Loy2TV0yh-O2RJe0wMQ" contextRef="As_Of_6_30_2023_dei_LegalEntityAxis_iva_InventivaIncMember_dCL3wkeOIU-E_D6kZe7BxQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfEmployees" scale="0" id="Narr_KQVcQFalsUeXFahbfLpoBQ">12</ix:nonFraction> people employed by Inventiva Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.3</b></span>Other operating income and expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other operating income and expenses break down as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock" id="Tb_cLABaFsmJE2dfIo2RDkXPA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other operating income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="Tc_HS6J34bwuk6mP-dVnmhV4A_3_2">160</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="3" id="Tc_r-t8WHIy00ia3WJyzgR5Og_4_2">22</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="3" id="Tc_rMPzfxKz1kOYoEdP_9_ZeA_4_4">44</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other operating income and expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherOperatingIncomeExpense" scale="3" id="Tc_Wbf_W-cC1UWB5RbSpT9uDw_5_2">138</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherOperatingIncomeExpense" sign="-" scale="3" id="Tc_0aGo02CVd0yxAz0oHr4dTw_5_4">44</ix:nonFraction>)</b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.4</b></span>Financial income and expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">For the six months ended June 30, 2024 and June 30, 2023</i></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="iva:FinancialIncomeAndExpensesTableTextBlock" id="Tb_LQtadgmQQE6JJOjLZ8qXjA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income from cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestIncomeOnCashAndCashEquivalents" scale="3" id="Tc_0SNEQga3f0yVhMI9iZSEjQ_3_2">430</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestIncomeOnCashAndCashEquivalents" scale="3" id="Tc_dCTdWTokmkyUX5q7G8TF_g_3_4">564</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign exchange gains</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ForeignExchangeGain" scale="3" id="Tc_QPnrCnm6dEqenj3GoR01BA_4_2">157</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ForeignExchangeGain" scale="3" id="Tc_ZP1wHdJfZ0-aHMgai9urcg_4_4">187</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gain on fair value variation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="iva:FairValueVariationGains" scale="3" id="Tc_4hiO7NJhUUCdVohySv3vOQ_5_2">8,506</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="iva:FairValueVariationGains" scale="3" id="Tc_xkds9Piti0WsBVyn3QhEwA_5_4">1,623</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="3" id="Tc_-SoLj_e5zUmQDj_Bm8ayZQ_6_2">9,093</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="3" id="Tc_31mqaW5oOUis4fbSUvtDmw_6_4">2,373</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestExpense" scale="3" id="Tc_DD0lpxEjQU6fhGXtmF2A9g_7_2">5,218</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestExpense" scale="3" id="Tc_JsIbDjU_q0eG9pdbR7QLtw_7_4">1,941</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign exchange losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ForeignExchangeLoss" scale="3" id="Tc_LAUSDDTwBEeZL4gFLOjM6A_8_2">323</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ForeignExchangeLoss" scale="3" id="Tc_bgfkLfnTFEm0b8w3i5r8QQ_8_4">683</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other financial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherFinanceCost" scale="3" id="Tc_HBkjlxZW6UuJVh2tx2jVnQ_9_2">46</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherFinanceCost" scale="3" id="Tc_7VNqVsduA06_COz2mDIF8Q_9_4">23</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="3" id="Tc_dtVCKnsBt0Cc1EnyqWeSnw_10_2">5,586</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="3" id="Tc_Ks-HuxyHRECiMUn0MPx3Pg_10_4">2,646</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net financial income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncomeCost" scale="3" id="Tc_qANhEHNS9UGA1rQQQWqOyQ_11_2">3,507</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncomeCost" sign="-" scale="3" id="Tc_cqtxqhsznEqcOERosTsBSw_11_4">273</ix:nonFraction>)</b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the first six months of 2024, financial income is mainly composed of a &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-5" format="ixt:numdotdecimal" name="iva:IfrsFairValueAdjustmentOfWarrants" scale="6" id="Narr_yxpDYW3LoEi22q3G97gpYQ">8.5</ix:nonFraction> million change in fair value of the EIB Warrants issued in connection with Tranches A and B.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Financial expenses mainly include exchange losses, financial interests related to PGE and PPR credit agreements and the financing agreement with the EIB, and financial interests related to lease liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="a55ShareofnetprofitEquitymethod_315105"></a><a id="Tc_snKg7lcPxUWoIIDI4Pd1dQ_1_0"></a><a id="Tc_ncgB1yivt0-BAokfYepeFA_2_0"></a><a id="Tc_r7MY41stEk-egeDVFiU_Pw_3_0"></a><a id="Tc_SPMbj14DeUuLaacu7PoaHg_4_0"></a><a id="Tc_TzBSnW2ZkEqLfBjdGsrMqA_5_0"></a><a id="Tc_FN_48HKsHESf8GjeQsn4jg_6_0"></a><a id="Tc_CrvnTSABXkq85f9eyf76Ww_7_0"></a><a id="Tc_Vu-7bIXFHUGr61-xlJRBhg_8_0"></a><a id="Tc_nrqXLcXBmEeDIj6LHNsxUA_8_2"></a><a id="Tc_DLJoQEhHhUu1Ey0GG4iStQ_9_0"></a><a id="Tc_ovJEEpzcUE-AESCSAcTGlA_10_0"></a><a id="Tc_XFcXnHSl0Uq0_SUbRrZW4Q_11_0"></a><a id="Tc_0tiNktKp1km8QLQuzEYUyg_12_0"></a><a id="Tc_36kV2YDV7U2AdbtO_wH_WQ_13_0"></a><a id="Tc_hVzz397X6kqxpBBOU66NWg_13_3"></a><a id="Tc_oi7h6UH7DkSOyZn69yW6GQ_14_0"></a><a id="Tc_t4QVzIbA0UqfVHupWffELg_15_0"></a><a id="Tc_BUSxLTMs6Ue9OyVqcRINnA_16_0"></a><a id="a55Incometax_735835"></a><a id="a56Basicanddilutedlosspershare_651103"></a><a id="_9e8d9833_192c_46f0_8bba_3ddf519d7662"></a><a id="_a88a07d9_fd62_4222_8a87_447d9b86430b"></a><a id="Tc_3F4AqqcQakmfP9Z4UnLlsQ_1_2"></a><a id="Tc_uI9_arB2DkiMQusEePti1g_2_2"></a><a id="Tc_1XU5Rw8n0kmuxsUcT2yhqg_2_4"></a><a id="Tc_xRFDMc_2MECTuGrBEz_AkA_3_0"></a><a id="Tc_elzK990tOEebPpDfhAwQww_4_0"></a><a id="Tc_nC1hOcC1TEe2P5tsue1qAg_5_0"></a><ix:continuation id="Tb_VtQgwOgrwES3kUb4kGluAg_cont3" continuedAt="Tb_VtQgwOgrwES3kUb4kGluAg_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.5</b></span>Share of net profit &#8211; Equity method</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The tables below provide the summarized statement of income (loss) for the associate Hepalys. The information disclosed reflects the amounts presented in the financial statements of Hepalys and not the Company's share of those amounts. They have been amended to reflect adjustments made by the Company when using the equity method, in this case fair value adjustments. The tables below provide also the reconciliation between Hepalys' loss and the share of net loss recognized in the Company statement of financial position.</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="iva:DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock" id="Tb_FUzQ0WfY2kStPOpDJhKXTg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:98.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands of euros)</i> <b style="font-weight:bold;">For the period started January 1, 2024, to June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" id="Tc_yuNi4m28WE6_hK4qLm_b1g_2_2">51</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" id="Tc_0Ogv8TqpWEqLdOy23_NjAg_3_2">1,475</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net operating loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" sign="-" scale="3" id="Tc_zQAd-nq9aEK6Ekt6n2BWXA_4_2">1,526</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Financial income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="3" id="Tc_87MVFODIRkqAvnwko3A4aw_5_2">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Financial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="3" id="Tc_ME8Py6RnZ0Ck0aOqJPE69Q_6_2">3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net financial income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncomeCost" scale="3" id="Tc_O7KYrnEvmkSZzpMdS_7g3w_7_2">17</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Income (expense) tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss for the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_ImnB4SuhZkqJeLfvE9hzTA_9_2">1,509</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exchange difference on translation of foreign operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" sign="-" scale="3" id="Tc_wzkFXdeiP0uc3DAOLniGIg_10_2">1,964</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Items that will be reclassified subsequently to profit or loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" sign="-" scale="3" id="Tc_v1kqECpzNEq6GhX-vUIerQ_11_2">3,473</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total comprehensive loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_BVH6IBrmKUaD3kYc_XfyDg_12_2">3,473</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Group's share in </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_wYI-vlX-bEu9MV9dohB57g" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="Tc_VP9Co8q5S0G7ejVutKr1Ug_13_2">14.64</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Share of net profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_wYI-vlX-bEu9MV9dohB57g" decimals="-3" format="ixt:numdotdecimal" name="iva:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations" scale="3" id="Tc_ANUbomMR7EaEemm91TNvAw_14_2">235</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Elimination of downstream sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_wYI-vlX-bEu9MV9dohB57g" decimals="-3" format="ixt:numdotdecimal" name="iva:EliminationOfDownstreamSales" scale="3" id="Tc_d56HvwFPlk24VQzZWxcy-w_15_2">66</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Share of net profit - Equity method</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_wYI-vlX-bEu9MV9dohB57g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" scale="3" id="Tc_hiwvzrUYJkq1zcEqvt0KrA_16_2">168</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In 2024, Hepalys did not generate any sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.6</b></span>Income tax</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The income tax calculation for interim periods is set out in Note 3.3 &#8211; <i style="font-style:italic;">Specific disclosure requirements for unaudited interim financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As the imputation of tax benefits on tax losses of Inventiva S.A., at short or mid-term, were considered unlikely due to the growth phase of the Company and regarding the <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_1_2024_To_12_31_2024_oxFIDH8XQUKPgIUFQceRfA" decimals="2" format="ixt-sec:numwordsen" name="ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" scale="-2" id="Narr_U8URKTLddkSakvNLL_Sy2Q">nil</ix:nonFraction> projected tax rate as of December 31, 2024, <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt-sec:numwordsen" name="ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" scale="3" id="Narr_ZklF7vdhhEaZPxcnXaYNLw">no</ix:nonFraction> current taxes were recorded as of June 30, 2024, for Inventiva S.A.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="Narr_2s9YVqXuNEyWIGcybDf_uQ">119</ix:nonFraction> thousand income tax recorded was related Inventiva Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.7</b></span><b style="font-weight:bold;">Basic and diluted loss per share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic earnings (loss) per share are calculated by dividing net income (loss) attributable to owners of the Company by the weighted average number of ordinary shares outstanding during the six-month period ended June 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">For the six months ended June 30, 2024 and June 30, 2023</i></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="ifrs-full:EarningsPerShareExplanatory" id="Tb_JHZ7byDsyUGyg7zUKcFqBg" continuedAt="Tb_JHZ7byDsyUGyg7zUKcFqBg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss for the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_DQhTRkV7A0-qtJj4UFc1IQ_3_2">49,029</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_A21lGxZ1PE2Lk-6lyB2brA_3_4">55,269</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average number of shares outstanding used to calculate basic/diluted loss per share<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageShares" scale="0" id="Tc_gETjJLhWHEWqNcz1wu3ngw_4_2"><ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" id="Tc_gETjJLhWHEWqNcz1wu3ngw_4_2_2">51,982,093</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageShares" scale="0" id="Tc_1I_Ext8SC0-ynUHbx6TUWQ_4_4"><ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" id="Tc_1I_Ext8SC0-ynUHbx6TUWQ_4_4_2">42,044,796</ix:nonFraction></ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Basic/diluted loss per share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Tc_01DAIR9xQEikBaTS326m1Q_5_2"><ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" scale="0" id="Tc_01DAIR9xQEikBaTS326m1Q_5_2_2">0.94</ix:nonFraction></ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Tc_eDxqHAVzNU2aJ1sD4L-99w_5_4"><ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" scale="0" id="Tc_eDxqHAVzNU2aJ1sD4L-99w_5_4_2">1.31</ix:nonFraction></ix:nonFraction>)</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><i style="font-style:italic;">In accordance with IAS 33.19, basic/diluted earnings per share exclude treasury shares held by the Group as of June 30, 2024 and 2023</i>.</p></td></tr></table></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_VtQgwOgrwES3kUb4kGluAg_cont4"><ix:continuation id="Tb_JHZ7byDsyUGyg7zUKcFqBg_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As a loss was recorded in the first six months of 2024 and 2023, diluted earnings (loss) per share are the same as basic earnings (loss) per share. Share-based payment plans (BSAs, BSPCEs, AGAs and PAGUP) are not included as their effects would be anti-dilutive.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Note6Otherfinancialinformation_416041"></a><a id="a61Commitmentsrelatedtooperationalactivi"></a><a id="_996c90b4_4916_4f01_95d1_07d2903449bf"></a><a id="Tc_QWRyVEYArkqThLxgHDlc9Q_1_0"></a><a id="Tc_kd5oi63InkStSN0-lFPaBQ_1_2"></a><a id="Tc_7JTLFqchMkiZr_Ersx7xuQ_1_4"></a><a id="Tc_cJrDPjiA4EKJmZLM3kud_g_2_0"></a><a id="Tc_t7wJIq6IbEuwRcVCJWQiMA_3_0"></a><a id="Tc_A5ngaBQke0S6GNRtFt_lag_4_0"></a><a id="Tc_JamoGNywB06PPhi9Z7HoEA_5_0"></a><a id="Tc_tKmyl7rIBUWyJ3qAFQg9hA_6_0"></a><a id="Tc_rfaRjfF77UC6ZiZMEFe97g_7_0"></a><a id="Tc_cG-PxkzqGEeApIbc4WF7OQ_8_0"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="iva:DisclosureOfOtherFinancialInformationTextblock" id="Tb_LKaeaGOaY0C8RDgV_4PCIg" continuedAt="Tb_LKaeaGOaY0C8RDgV_4PCIg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 6.&#160;&#160;&#160;&#160;Other financial information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.1</b></span><b style="font-weight:bold;">Commitments related to operational activities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obligations under the terms of subcontracting agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the ordinary course of its business, the Company enters into agreements with CROs for clinical trials, as well as with contract manufacturing organizations (&#8220;CMOs&#8221;) for clinical and commercial supply manufacturing, commercial and pre-commercial activities, research and development activities and other services and products for operating purposes. The Company&#8217;s agreements generally provide for termination with specified periods of advance notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Such agreements are generally cancellable contracts and are not included in the description of the Company&#8217;s contractual obligations and commitments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Commitments given and received</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA" name="ifrs-full:DisclosureOfContingentLiabilitiesExplanatory" id="Tb_VWZOnsFS90iZB-YPfw8l9g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CRO<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_ClinicalTrialsMember_RKIovK8rokChycQgZSo2TQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ContractualCapitalCommitments" scale="3" id="Tc_5lBCKWfYv0GMQORja9MJdg_2_2">175,461</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_ClinicalTrialsMember_ETYrQdfyDE6P4TNS-pt20A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ContractualCapitalCommitments" scale="3" id="Tc_xIwNVaqHC0CiXVrhaZQypw_2_4">183,366</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CMO</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_ContractManufacturingOrganizationsMember_H1GPzHoVzEiBnJra2bMeWA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ContractualCapitalCommitments" scale="3" id="Tc_Bablq-16RUG91lTezGVQ7w_3_2">6,846</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_ContractManufacturingOrganizationsMember_e2L2HwPp40Smxh2nqL1VkQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ContractualCapitalCommitments" scale="3" id="Tc_UOXwTOZQ_EWrMClVNvNX8Q_3_4">5,733</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_ifrs-full_LeaseLiabilitiesMember_ida2CTwucUi4-oggFUrF2g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ContractualCapitalCommitments" scale="3" id="Tc_W5DPODtsX0qXhX1zyu_YhQ_4_2">7,592</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_ifrs-full_LeaseLiabilitiesMember_8rBg4KqmyUuYuPxVzu5jrg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ContractualCapitalCommitments" scale="3" id="Tc_I5Otr-gTI0qDLsBe7R4_Xw_4_4">8,595</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_ifrs-full_OtherContingentLiabilitiesMember_0hDuEC30xECEsYnHHr_kTA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ContractualCapitalCommitments" scale="3" id="Tc_vpTxbJKJ0EuPfkv0AwAlYA_5_2">20,361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_ifrs-full_OtherContingentLiabilitiesMember_UcOuCRDpIESuiNmpO5AzcQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ContractualCapitalCommitments" scale="3" id="Tc_f0W0WqPYaEC8NtFqvUU42A_5_4">23,442</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total commitments given</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ContractualCapitalCommitments" scale="3" id="Tc_VpbBYSOE2ECu_bGs22XzzA_6_2">210,261</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ContractualCapitalCommitments" scale="3" id="Tc_Hb5pDHNaqk-sY180362J9w_6_4">221,136</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:71.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agreements concerning the provision of facilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="iva:AgreementsConcerningProvisionOfFacilities" scale="3" id="Tc_7CKDU-QwlUmizEBSPryYgA_7_2">296</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="iva:AgreementsConcerningProvisionOfFacilities" scale="3" id="Tc_XUD_tnr9ikCcClAfaPoSJg_7_4">260</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total commitments received</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ" decimals="-3" format="ixt:numdotdecimal" name="iva:ContractualCapitalCommitmentReceived" scale="3" id="Tc_IyWRc7hKmEWH-lMHpsfdug_8_2">296</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ" decimals="-3" format="ixt:numdotdecimal" name="iva:ContractualCapitalCommitmentReceived" scale="3" id="Tc_5zoeRo886Uyzw1BCaNrrRA_8_4">260</ix:nonFraction></b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">Including CRO with Pharmaceutical Research Associates B.V.</i></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CRO Contract with Pharmaceutical Research Associates Group B.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In April 2021, in connection with the NATiV3 Phase III trial in MASH/NASH, the Company entered into an agreement, with retroactive effect in January 2021, with PRA, acting as a CRO. The contract aims to support the regulatory approval of lanifibranor in adult patients in Europe and in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also entered into a CRO agreement with PRA in connection with the LEGEND Phase IIa clinical trial, effective January 14, 2022. Under the terms of the agreement, PRA will conduct a clinical trial to evaluate the benefit for patients of the combination of lanifibranor with empagliflozin, an SGLT2 inhibitor, in patients with T2D and non-cirrhotic MASH/NASH. The commitment to PRA under this agreement amounts to an aggregate of &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_4_30_2021_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ContractCroWithResearchAssociatesGroupeB.vMember_Kg0rzj_ifUatIDFJkolJ6g" decimals="-5" format="ixt:numdotdecimal" name="iva:CommitmentsAmountPayableForServicesReceivedUnderContract" scale="6" id="Narr_ZNhrBzsZTEapfEvz3tF5VQ">13.3</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 26, 2023, in connection with the NATiV3 Phase III trial in MASH/NASH, the Company entered into a new amendment to the April 2021 agreement with retroactive effect in January 2021 with PRA. The amendment updates the provisions relating to study information following changes to the trial protocol. In June 2024, the Company entered into a new amendment, the new commitment amount to PRA is &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_PharmaceuticalResearchAssociatesMember_qjG6YqkiB02s-QfK34PDzg" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:ContractualCapitalCommitments" scale="6" id="Narr_FGS9r6Vos0SIxWyaLr4k7g">254.3</ix:nonFraction>, with a bonus or malus will decrease from &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_PharmaceuticalResearchAssociatesMember_IkzQwodT60qRBSBD6WG1Kw" decimals="-5" format="ixt:numdotdecimal" name="iva:CommitmentContractualBonusOrMalusCappedAmount" scale="6" id="Narr_MUvPSAoOL02FbEqpJ-20xg">3.4</ix:nonFraction> million to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_PharmaceuticalResearchAssociatesMember_Co4XPbAvCk2OhAlYe5P1VA" decimals="-5" format="ixt:numdotdecimal" name="iva:CommitmentContractualBonusOrMalusCappedAmount" scale="6" id="Narr_6IYqN7Vmj0-5OaUMknwnbw">0.7</ix:nonFraction> million in 2026. The commitment also includes &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_ChiaTaiTianqingMember_hYhPgbJT90qw9Zp638JTYA" decimals="-5" format="ixt:numdotdecimal" name="iva:CommitmentsAmountPayableForServicesReceivedUnderContract" scale="6" id="Narr__4z7XKW40EG2_Lj5FjU73A">20.2</ix:nonFraction> million to be paid by CTTQ.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024, the amount remaining to be paid under the contract is &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ContractCroWithResearchAssociatesGroupeB.vMember_z4AQiAhloUi2lSaBmH0sqA" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:ContractualCapitalCommitments" scale="6" id="Narr_IoyC9HnZ9ESychV7fgfVOg">158.6</ix:nonFraction> million.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="a62Relatedpartytransactions_386542"></a><a id="a63Financialriskmanagement_835623"></a><a id="EventsAftertheReportingDate_738140"></a><a id="a64Eventsafterthereportingdate_353768"></a><ix:continuation id="Tb_LKaeaGOaY0C8RDgV_4PCIg_cont1" continuedAt="Tb_LKaeaGOaY0C8RDgV_4PCIg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.2.</b></span>Related-party transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">No other new material transactions were entered into with related parties of the Company during the first six months of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.3</b></span>Financial risk management</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Through its business activities, the Company is exposed to various types of financial risk: foreign exchange risk, credit risk and liquidity risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The financial risks are those described in the financial statements prepared in accordance with IFRS for the year ended December 31, 2023, as updated for risks regarding liquidity which are described in the Note 3.4 &#8212; <i style="font-style:italic;">Going Concern</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.4</b></span>Events after the reporting date</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Update on NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">On July 5, 2024, the Company provided an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH. Recruitment in NATiV3 clinical trial continues in both cohorts with over <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_7_5_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_PresentationOfResultsFromStudyMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember_rLZHQc4OiUGVcCmKg1glHQ" decimals="2" format="ixt:numdotdecimal" name="iva:PercentageOfPatientsInTrialEnrolledInMainCohort" scale="-2" id="Narr_kHxlpW2Q0kCZtsyMCMjQcw">80</ix:nonFraction>% of the targeted number of patients enrolled in the main cohort and <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_7_5_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_PresentationOfResultsFromStudyMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember_rLZHQc4OiUGVcCmKg1glHQ" decimals="INF" format="ixt:numdotdecimal" name="iva:PercentageOfPatientsInTrialEnrolledInExploratoryCohort" scale="-2" id="Narr_D7Yq5LwUoEiv9Xip763i_Q">100</ix:nonFraction>% in the exploratory cohort of NATiV3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">The first visit of the last patient of NATiV3 is anticipated to occur during the fourth quarter of 2024, and topline results are expected at the beginning of the second half of 2026. The Company&#8217;s patent portfolio strengthened with new a patent secured in Japan that that provides intellectual property rights on protects the potential use of lanifibranor for the treatment of patients with cirrhosis until 2039, excluding any potential patent term adjustments or extensions that may provide additional protection until 2043.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Issuance of royalty certificates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">On July 18, 2024, the Company announced the issuance of <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_7_18_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfRoyaltyCertificatesMember_eaHX-tuX_E2XdHMM79Knaw" decimals="INF" format="ixt:numdotdecimal" name="iva:NumberOfRoyaltyCertificatesIssued" scale="0" id="Narr_TRSGtxC-TkiFb8eBhn2Y1A">201</ix:nonFraction> royalty certificates (the &#8220;<b style="font-weight:bold;">2024 Royalty Certificates</b>&#8221;) for aggregate gross proceeds of approximately &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_7_18_2024_To_7_18_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfRoyaltyCertificatesMember_MVb6HJyb-0ClrMuNDVzHFA" decimals="-5" format="ixt:numdotdecimal" name="iva:ProceedsFromFinancing" scale="6" id="Narr_4b656DJukkmVrrVL3X-TyQ">20.1</ix:nonFraction> million. The 2024 Royalty Certificates will provide the holders thereof with the right to an annual payment of royalties equal to <ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="As_Of_7_18_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfRoyaltyCertificatesMember_eaHX-tuX_E2XdHMM79Knaw" decimals="INF" format="ixt:numdotdecimal" name="iva:AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor" scale="-2" id="Narr_3nEw6EGrY0mC3ZYQzt_y-w">3</ix:nonFraction>% of the future net sales, if any, of lanifibranor beginning on the fiscal year following the start of the sales of lanifibranor following the granting of the market authorization for lanifibranor in (i) the United States of America, (ii) the countries of the European Union or (iii) the United Kingdom, whichever occurs the first, if at all. The 2024 Royalty Certificates have a term of <ix:nonNumeric contextRef="Duration_7_18_2024_To_7_18_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfRoyaltyCertificatesMember_MVb6HJyb-0ClrMuNDVzHFA" format="ixt-sec:durwordsen" name="iva:MaximumDurationOfClinicalTrial" id="Narr_LU2362ak-U6wiWys17NQ2A">14 years</ix:nonNumeric> following the date of issue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Approving of patent application</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">On July 25, 2024 the Company announced that the Japan Patent Office (&#8220;JPO&#8221;) approved Inventiva&#8217;s patent application No. JP 2019-203498, protecting the use of lanifibranor for the treatment of patients with cirrhosis. This new patent will be valid until November 8, 2039, excluding any potential patent term adjustments or extensions that may provide additional protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Financing in </span><span style="font-style:italic;font-weight:bold;"><ix:nonFraction unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingAgreementInThreePhasesMember_7BaMct8ywUiT7daaU6IKqw" decimals="INF" format="ixt-sec:numwordsen" name="iva:NumberOfEqualTranches" scale="0" id="Narr_wM42o14tA0GULlLv0t-BsA">three</ix:nonFraction></span><span style="font-style:italic;font-weight:bold;"> tranches for a maximum amount of </span><span style="font-style:italic;font-weight:bold;">&#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="As_Of_6_30_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingAgreementInThreePhasesMember_d8wjd7CfTESZ1LkHSB77Cw" decimals="-5" format="ixt:numdotdecimal" name="iva:AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany" scale="6" id="Narr_pWbXJ1zutkibY3vdJndRjA">348</ix:nonFraction></span><span style="font-style:italic;font-weight:bold;"> million</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company announced the following financing on 14 October 2024 structured in three tranches:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">(i) the issuance , through a capital increase without preferential subscription rights reserved to a specific category of beneficiaries (&#8220;<i style="font-style:italic;">&#224; cat&#233;gorie de personnes</i>&#8221;), of new ordinary shares at a gross value, including issuance premium, of &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_10_14_2024_To_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember_cl4oX3dadE-dg27_9dl-_w" decimals="-5" format="ixt:numdotdecimal" name="iva:StockIssuedDuringPeriodValue" scale="6" id="Narr_8MaeS0gaPUuRBGr084U_CA">94.1</ix:nonFraction> million through the issuance of <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_10_14_2024_To_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember_cl4oX3dadE-dg27_9dl-_w" decimals="INF" format="ixt:numdotdecimal" name="iva:StockIssuedDuringPeriodShares" scale="0" id="Narr_KzROLtQS1EilbND_fRGH4A">34,600,507</ix:nonFraction> new ordinary shares, par value &#8364;<ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember_vlcJPhOGqkmmq2I0namEtA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ParValuePerShare" scale="0" id="Narr__FYg2gb5zEK9dDFLrlKj_g">0.01</ix:nonFraction> per share (each, a &#8220;<b style="font-weight:bold;">T1 New Shares</b>&#8221;), and <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="Duration_10_14_2024_To_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember_cl4oX3dadE-dg27_9dl-_w" decimals="INF" format="ixt:numdotdecimal" name="iva:ClassOfWarrantOrRightGranted" scale="0" id="Narr_V5xZhGd2TUSW4D_U06X0EQ">35,399,481</ix:nonFraction> &#160;prefunded warrants to subscribe for shares in the Company at a price outstanding of &#8364;<ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember_vlcJPhOGqkmmq2I0namEtA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ParValuePerShare" scale="0" id="Narr_0rWUsJTlO0S99buY1EPvzw">0.01</ix:nonFraction> per new ordinary share, each giving the right, in the event of exercise, to <ix:nonFraction unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ" contextRef="As_Of_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember_vlcJPhOGqkmmq2I0namEtA" decimals="INF" format="ixt-sec:numwordsen" name="iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_ReZ8DYt1JkC04oGhTAQkOg">one</ix:nonFraction> new ordinary share (the &#8220;<b style="font-weight:bold;">T1 BSAs</b>&#8221;);</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2024 ||</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_573993cd_54e6_498a_9e59_d9b1ce3dbc15"></a><ix:continuation id="Tb_LKaeaGOaY0C8RDgV_4PCIg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">(ii) the issuance, in a second phase, as part of a new capital increase without preferential subscription rights reserved to certain identified investors (&#8220;<i style="font-style:italic;">&#224; personne d&#233;nomm&#233;e</i>&#8221;), of new ordinary shares, par value &#8364;<ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember_ZCF8RxUM3UKzcBgb7Q57Xg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ParValuePerShare" scale="0" id="Narr_ux_w8SUWpUOHYbhCAKoi6A">0.01</ix:nonFraction> per share or of prefunded warrants to subscribe for ordinary shares of the Company (each, a &#8220;<b style="font-weight:bold;">T1bis New Shares</b>&#8221;), for a total amount of &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_10_14_2024_To_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember_cd3Fteojp0CtXUqdXRXY6Q" decimals="-5" format="ixt:numdotdecimal" name="iva:StockIssuedDuringPeriodValue" scale="6" id="Narr_UrmThq31tEG0TFtuSLiY4A">21.4</ix:nonFraction> &#160;million (excluding exercise of pre-funded warrants);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">(iii) the issuance, in a third phase, as part of a new capital increase without preferential subscription rights reserved to certain identified investors (&#8220;<i style="font-style:italic;">&#224; personne d&#233;nomm&#233;e</i>&#8221;) subject to operational conditions to be met and the adoption of the necessary resolutions by the Shareholders' Meeting to be held before December 16, 2024, (or prefunded warrants) to which share warrants (the &#8220;<b style="font-weight:bold;">ABSAs</b>&#8221;) are attached for a total amount of &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_10_14_2024_To_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember_imkRzVTcgUy0kGwnaok3JA" decimals="0" format="ixt:numdotdecimal" name="iva:StockIssuedDuringPeriodValue" scale="0" id="Narr_kze1oslnn0CFDGBI7ZlbfA">116,000,000</ix:nonFraction>. Each ABSA will consist of a number of new ordinary shares with a par value of &#8364;0.01 (or pre-funded warrants) to be determined by the Company's Board of Directors (each, a &#8220;<b style="font-weight:bold;">T2 New Share</b>&#8221;) to which will be attached a number warrants exercisable at an exercise price of &#8364;<ix:nonFraction unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A" contextRef="As_Of_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember_hobGW-4SUUqZmnmtlP6zCA" decimals="2" format="ixt:numdotdecimal" name="iva:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" scale="0" id="Narr_xOge3gNeakee8CXxmJuE5w">1.50</ix:nonFraction> (each, a &#8220;<b style="font-weight:bold;">T3 BSA</b>&#8221;) allowing the subscription of a number of new ordinary shares of the Company for a maximum total amount of &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_10_14_2024_To_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember_imkRzVTcgUy0kGwnaok3JA" decimals="0" format="ixt:numdotdecimal" name="iva:IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_KKnUE0ZCGE2a_Np_VgREaw">116,000,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">The subscription agreements for the T1 New Shares and the T1 BSA were signed on October 11, 2024, and the settlement-delivery of the T1 New Shares and the T1 BSA is expected to take place on October 17, 2024, subject to the absence of any material adverse event between the signing of the agreements and the settlement-delivery of the T1 New Shares and the T1 BSA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Amendment to the exclusive license and collaboration agreement with CTTQ</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt;">On October 11, 2024, the Company has entered into an amendment (the &#8220;<b style="font-weight:bold;">Amendment</b>&#8221;) to the exclusive license and collaboration agreement with Chia Tai Tianqing Pharmaceutical Group, Co., Ltd (&#8220;<b style="font-weight:bold;">CTTQ</b>&#8221;), dated September 21, 2022, as amended. Under the Amendment, if the Company receives subscription commitments, before December 31, 2024, from investors to subscribe to a fundraising, in two or three tranches, for a total gross amount of at least &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_10_11_2024_To_10_11_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingThroughFundRaisingMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_QkHCyd9NWU6y7zXQYpg3Tg" decimals="0" format="ixt:numdotdecimal" name="iva:MinimumAmountCommittedForFundRaising" scale="0" id="Narr_r6I48xLy2kafXg93-CylsQ">180,000,000</ix:nonFraction> (the &#8220;<b style="font-weight:bold;">Fund Raising</b>&#8221;), CTTQ shall pay to the Company (i) $<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_10_11_2024_To_10_11_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingThroughFundRaisingMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_srt_StatementScenarioAxis_iva_ScenarioOneMember_NOafy3B1GU-pPX7_lNErFQ" decimals="0" format="ixt:numdotdecimal" name="iva:ProceedsFromLicensingArrangements" scale="0" id="Narr_0hJWETvWBEKMeAKlPCbvZg">10,000,000</ix:nonFraction> within <ix:nonNumeric contextRef="Duration_10_11_2024_To_10_11_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingThroughFundRaisingMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_srt_StatementScenarioAxis_iva_ScenarioOneMember_NOafy3B1GU-pPX7_lNErFQ" format="ixt-sec:durwordsen" name="iva:PeriodWithinWhichPaymentIsReceivedFromSettlement" id="Narr_KZtIN1CouEC7cUbpXFfzeA">30 days</ix:nonNumeric> of settlement-delivery of the T1 New Shares and T1 Warrants in the event of the issuance of the first tranche of the Fund Raising to be paid by CTTQ, (ii) $<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_10_11_2024_To_10_11_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingThroughFundRaisingMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_srt_StatementScenarioAxis_iva_ScenarioTwoMember_kF0Cffov6EiCtat91NJ6hw" decimals="0" format="ixt:numdotdecimal" name="iva:ProceedsFromLicensingArrangements" scale="0" id="Narr_-HW5-GsVD0uUM58Ek0Xqeg">10,000,000</ix:nonFraction> in the event of the issuance of the second tranche of the Fund Raising, and (iii) $<ix:nonFraction unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A" contextRef="Duration_10_11_2024_To_10_11_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingThroughFundRaisingMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_srt_StatementScenarioAxis_iva_ScenarioThreeMember_2KTwko-jbE6IA2FjFwUN0A" decimals="0" format="ixt:numdotdecimal" name="iva:ProceedsFromLicensingArrangements" scale="0" id="Narr_pmgWiGWF4k60O80m0sOp8A">10,000,000</ix:nonFraction> upon publication by the Company of the pivotal data announcing that the primary endpoint or one of the two key secondary endpoints of NATiV3, with one of the dosing regimens tested in the trial, have been met. Under the terms of the Amendment, the total amount of potential clinical, regulatory and commercial milestone payments remains unchanged, while the royalties that Inventiva is likely to receive have been reduced to a low figure.</p></ix:continuation><a id="Notes_End"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_214a4be7_a4cb_4aba_912b_fa3af6b2c896"></a><a id="a4Otherinformation_924742"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.</b></span><b style="font-weight:bold;">Other information</b></p><a id="a41Tableofdelegations_447465"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.1.</b></span><b style="font-weight:bold;">Table of delegations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 20, 2024, shareholders met in a Combined General Meeting to determine the financial authorizations to be granted to the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The current delegations and their use are presented in the table below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#424242;font-weight:bold;">Financial authorizations </b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">approved by the Combined </b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">General Shareholders&#8217; Meeting </b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">of June 20, 2024</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#424242;font-weight:bold;">&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">Resolution</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">Period of </b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">validity from </b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">June 20, 2024</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.01%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">Maximum </b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">nominal amount</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.27%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">Maximum</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">common nominal </b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">amount</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">Methods of </b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">determining </b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">the issue </b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">price</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">Use of the </b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">delegation</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:middle;width:25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;width:13.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;width:13.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;width:11.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;width:7.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;width:8.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;width:8.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:middle;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Delegation of authority to the Board of Directors to increase the share capital by issuance of ordinary shares or securities giving access to ordinary shares, to be issued immediately or in the future by the Company, with shareholders&#8217; preemptive subscription rights, in accordance with the provisions of articles L.225-129 and L.22-10-49 and seq. of the French Commercial Code, and in particular articles L.225-129-2, L.225-132 to L.225-134, and the provisions of articles L.228-91 and seq. of the French Commercial Code</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Twenty-first resolution</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">26&#160;months</span></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Capital increase: EUR 700,000</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Securities giving access to capital to be issued: EUR 150,000,000</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#221f1f;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#221f1f;">Capital increase: EUR 700,000</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Securities giving access to capital to be issued: EUR 150,000,000</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">None</span></p></td></tr><tr><td style="vertical-align:middle;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#424242;">Delegation of authority to the Board of Directors to increase the share capital of the Company by issuance of</span><span style="color:#424242;"><br/></span><span style="color:#424242;">ordinary shares or securities giving access to the share capital of the Company, immediately or in the future, without shareholders&#8217; preemptive subscription rights, by way of public offerings, excluding offers referred to</span><span style="color:#424242;"><br/></span><span style="color:#424242;">in Article&#160;L.411-2- 1&#176; of the French </span><i style="color:#424242;font-style:italic;">Code mon&#233;taire et financie</i><span style="color:#424242;">r, in accordance with the provisions of Articles L.225-129 and L.22-10-49 and seq. of the French Commercial Code, and in particular Articles L.225-129-2, L.22-10-51 and L.22-10-52, and with the provisions of Articles L.228-91 and seq. of the French Commercial Code</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#424242;white-space:pre-wrap;">Twenty-second  resolution</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="color:#424242;">26&#160;months</span></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="color:#221f1f;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#221f1f;">Capital increase: EUR 700,000</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#424242;">Securities giving access to capital to be issued: EUR 150,000,000 </span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#221f1f;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#221f1f;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#424242;">Refer to (1)&#160;below</span></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#424242;">None</span></p></td></tr><tr><td style="vertical-align:middle;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Delegation of authority to the Board of Directors to increase the share capital by issuance of ordinary shares or securities giving access to ordinary shares, to be issued immediately or in the future by the Company, without shareholders&#8217; preemptive subscription rights, by way of public offerings referred to in Article&#160;L.411-2 1&#176; of the French </span><i style="color:#424242;font-style:italic;">Code mon&#233;taire et financier</i><span style="color:#424242;">, in accordance with the provisions of articles L.225-129 and seq. and article L.22-10-49 of the French Commercial Code, and in particular articles L.225-129-2, L.22-10-51 and L.22-10-52, and the provisions of articles L.228-91 and seq. of the French Commercial Code</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Twenty-third resolution</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">26&#160;months</span></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Capital increase: EUR 625,000 and up to the limit of 30% of the share capital per&#160;year.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Securities giving access to the capital to be issued: EUR 150,000,000</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#221f1f;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#221f1f;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Refer to (1)&#160;below</span></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">None</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#424242;font-weight:bold;">Financial authorizations </b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">approved by the Combined </b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">General Shareholders&#8217; Meeting </b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">of June 20, 2024</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#424242;font-weight:bold;">&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">Resolution</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">Period of </b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">validity from </b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">June 20, 2024</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.01%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">Maximum </b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">nominal amount</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.27%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">Maximum</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">common nominal </b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">amount</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.65%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">Methods of </b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">determining </b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">the issue </b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">price</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">Use of the </b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">delegation</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:middle;width:25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;width:13.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;width:13.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;width:11.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;width:7.72%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;width:8.86%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;width:8.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:middle;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#424242;">Authorization and/or delegation to the Board of Directors to set the issuance price on the capital increases by way of public offerings, without shareholders&#8217; preemptive rights, pursuant to the terms set by the General Shareholders' Meeting, and up to the limit of 10% of the share capital, in accordance with the provisions of Article L.22-10-52 of the French Commercial Code</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#424242;">Twenty-fourth resolution</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="color:#424242;">26&#160;months</span></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#424242;">10% of the share capital per 12-month period from June 20, 2024</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#221f1f;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#221f1f;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#424242;">Refer to (2)&#160;below</span></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#424242;">None</span></p></td></tr><tr><td style="vertical-align:middle;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#424242;">Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to ordinary shares of the Company, immediately or in the future, reserved for certain specific categories of beneficiaries, without shareholders&#8217; preemptive subscription rights</span><sup style="color:#424242;font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">4</sup><span style="color:#424242;"> , in accordance with Articles L.225-129 and seq. and L.22-10-49 of the French Commercial Code, and in particular Articles L.225-129-2, L.225-129-4, L.22-10-51, L.225-138, L.228-91 and seq. of the French Commercial Code</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#424242;">Twenty-fifth resolution</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="color:#424242;">18&#160;months</span></p></td><td style="vertical-align:top;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#424242;">Capital increase: EUR 700,000</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#424242;">Securities giving access to the capital to be issued: EUR 150,000,000</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#221f1f;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#221f1f;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#424242;">Refer to (3)&#160;below</span></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#424242;white-space:pre-wrap;">Decision of the Board of Directors on 11/10/2024: issue of 34.600.507  T1 New Shares and 35.399.481 T1 Warrants.</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">4</sup><span style="display:inline-block;width:8.3pt;"></span>The categories of beneficiaries must have one of the following characteristics: (i) natural or legal persons (including companies), trusts or investment funds, or other investment vehicles, in any form, established under French or foreign law, which regularly invest in the pharmaceutical, biotechnological or medical technology sectors; and/or (ii) companies, institutions or entities, in any form, French or foreign, exercising a significant part of its activities in the pharmaceutical, cosmetic or chemical sectors, or medical devices and/or technologies, or researching in such sectors; and/or (iii) French or foreign investment services companies, or any foreign establishment having an equivalent status, able to guarantee the completion of an issue intended to be placed with the persons referred to in (i) and/or (ii) above, and, in this context, to subscribe to the securities that are being issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:40.05pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#424242;font-weight:bold;">Financial authorizations</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">approved by the Combined</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">General Shareholders&#8217; Meeting</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">of June 20, 2024</b></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.3%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#424242;font-weight:bold;">&#160;&#160;&#160;</b></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">Resolution</b></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.67%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#424242;font-weight:bold;">&#160;&#160;&#160;</b></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">Period of</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">validity from</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">June&#160;20, 2024</b></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.67%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#424242;font-weight:bold;">&#160;&#160;&#160;</b></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">Maximum</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">nominal amount</b></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#424242;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">Maximum</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">common</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">nominal</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">amount</b></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.25%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#424242;font-weight:bold;">&#160;&#160;&#160;</b></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">Methods of</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">determining</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">the issue</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">price</b></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.01%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#424242;font-weight:bold;">&#160;&#160;&#160;</b></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">Use of the</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">delegation</b></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.05%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr style="height:45.05pt;"><td style="vertical-align:middle;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Delegation of authority to the Board of Directors to decide to issue ordinary shares to be issued immediately or in the future by the Company, without shareholders&#8217; preemptive subscription right in favor of a category of persons meeting certain specified characteristics in the context of an equity financing agreement on the American market known as &#8220;At-the-market&#8221; or &#8220;ATM&#8221; </span></p></td><td style="vertical-align:middle;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">&#160;&#160;&#160;</span></p></td><td style="vertical-align:middle;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Twenty-sixth resolution</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">&#160;&#160;&#160;</span></p></td><td style="vertical-align:middle;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">18&#160;months</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">&#160;&#160;&#160;</span></p></td><td style="vertical-align:middle;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Capital increase: EUR 250,000,000</span></p></td><td style="vertical-align:middle;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#221f1f;">&#160;&#160;&#160;</span></p></td><td style="vertical-align:top;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Refer to (4)&#160;below</span></p></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">&#160;&#160;&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">None</span></p></td></tr><tr style="height:45.05pt;"><td style="vertical-align:middle;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Authorization to the Board of Directors to increase the number of securities to be issued as part of share capital increases with or without shareholders&#8217; preemptive subscription rights, in accordance with Articles L.225-135-1 and R.225-118 of the French Commercial Code</span></p></td><td style="vertical-align:middle;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Twenty-seventh resolution</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">26&#160;months or 18&#160;months (if used in the context of resolution 25 or resolution 26)</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">15% of the initial issuance</span></p></td><td style="vertical-align:middle;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#221f1f;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Same price as the initial issuance</span></p></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">None</span></p></td></tr><tr style="height:31.95pt;"><td style="vertical-align:middle;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to ordinary shares of the Company, immediately or in the future, as part of a public exchange offer initiated by the Company, in accordance with Articles L.225-129 and seq. and L.22-10-49 of the French Commercial Code, in particular Articles L.225-129-2 and L.22-10-54, and Articles L.228-91 and seq. of the French Commercial Code</span></p></td><td style="vertical-align:middle;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Twenty-eight resolution</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">26&#160;months</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Capital increase: EUR 420,000 Securities giving access to the capital to be issued: EUR 150,000,000</span></p></td><td style="vertical-align:middle;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">None</span></p></td></tr><tr style="height:31.95pt;"><td style="vertical-align:middle;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;white-space:pre-wrap;">Delegation of authority to the Board of Directors to increase the share capital of the company by issuance of ordinary shares or securities giving access to ordinary shares of the Company, immediately or in the future, in consideration for contributions in kind up  within the limits set by laws and regulations, excluding the case of a public exchange offer initiated by the Company, in accordance with the provisions of Articles L.225-129 et seq. and L.22-10-49 of the French Commercial Code, in particular Articles L.225-129-2 and L.22-10-53, and the provisions of Articles L.228-91 and seq. of the French Commercial Code</span></p></td><td style="vertical-align:middle;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Twenty-ninth resolution</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">26&#160;months</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Capital increase: within the limit provided for by the laws and regulations in force at the time this delegation is used (currently ten (10) % of the share capital over a twelve (12) month period)Securities giving access to the capital to be issued: EUR 150,000,000</span></p></td><td style="vertical-align:middle;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">None</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:40.05pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#424242;font-weight:bold;">Financial authorizations</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">approved by the Combined</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">General Shareholders&#8217; Meeting</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">of June 20, 2024</b></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.3%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#424242;font-weight:bold;">&#160;&#160;&#160;</b></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">Resolution</b></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.67%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#424242;font-weight:bold;">&#160;&#160;&#160;</b></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">Period of</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">validity from</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">June&#160;20, 2024</b></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.67%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#424242;font-weight:bold;">&#160;&#160;&#160;</b></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">Maximum</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">nominal amount</b></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#424242;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">Maximum</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">common</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">nominal</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">amount</b></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.25%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#424242;font-weight:bold;">&#160;&#160;&#160;</b></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">Methods of</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">determining</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">the issue</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">price</b></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.01%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="color:#424242;font-weight:bold;">&#160;&#160;&#160;</b></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:40.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#424242;font-weight:bold;">Use of the</b><b style="color:#424242;font-weight:bold;"><br/></b><b style="color:#424242;font-weight:bold;">delegation</b></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.68%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:13.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.65%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.05%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.25%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#424242;font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr style="height:31.95pt;"><td style="vertical-align:middle;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Delegation of authority granted to the Board of Directors to increase the share capital by issuing ordinary shares or securities giving access to ordinary shares to be issued immediately or in the future by the Company reserved for members of a company savings plan to be set up by the Company in accordance with the conditions set out in Articles L.3332-18 and seq. of the French Labour Code, without shareholders' pre-emptive subscription rights.</span></p></td><td style="vertical-align:middle;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Thirtieth resolution</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">26&#160;months</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Capital increase: EUR 3,000 </span></p></td><td style="vertical-align:middle;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Refer to (5)&#160;below</span></p></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">None</span></p></td></tr><tr style="height:31.95pt;"><td style="vertical-align:middle;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Authorization to the Board of Directors to increase the share capital of the Company by incorporating reserves, profits or premiums, in accordance with the provisions of Articles L.225-129-2 and L.22-10-5 of the French Commercial Code</span></p></td><td style="vertical-align:middle;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Thirty-first resolution</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">26&#160;months</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Capital increase: EUR 20,000</span></p></td><td style="vertical-align:middle;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">None</span></p></td></tr><tr style="height:31.95pt;"><td style="vertical-align:middle;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Authorization for the Board of Directors to grant free shares to employees and/or certain corporate officers, in accordance with Articles L.225-110-59 and L.225-197-2 of the French Commercial Code</span></p></td><td style="vertical-align:middle;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Thirty-second resolution</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">38&#160;months</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Capital increase: 5% of the share capital on the date of the Board of Directors&#8217; decision to grant them </span></p></td><td style="vertical-align:middle;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">N/A</span></p></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">None</span></p></td></tr><tr style="height:31.95pt;"><td style="vertical-align:middle;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Authorization to the Board of Directors to grant company's' share subscription and/or purchase options to corporate officers and employees of the Company or of companies in the group, entailing the waiver by the shareholders of their preemptive subscription rights to the shares issued as a result of the exercise of subscription options, in accordance with Articles L.225-177 and seq. and L. 22-10-56 of the French Commercial Code</span></p></td><td style="vertical-align:middle;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Thirty-third resolution</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">38&#160;months</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Capital increase: 5% of the share capital on the date of the Board of Directors&#8217; decision to grant them</span></p></td><td style="vertical-align:middle;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Capital increase: EUR 700,000</span></p></td><td style="vertical-align:top;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Refer to (6)&#160;below</span></p></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">None</span></p></td></tr><tr style="height:31.95pt;"><td style="vertical-align:middle;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Delegation of authority to the Board of Directors to decide on the issue of ordinary share subscription warrants, without shareholders' preemptive subscription rights, to the benefit of categories of persons</span><sup style="color:#424242;font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">5</sup><span style="color:#424242;"> , in accordance with Articles L.225-138, L.225-129-2 and L.228-91 and seq. of the French Commercial Code</span></p></td><td style="vertical-align:middle;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Thirty-fourth resolution</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">18&#160;months</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:13.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">600,000 ordinary share subscription warrants &#160;Capital increase: EUR 6,000</span></p></td><td style="vertical-align:middle;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">Refer to (7)&#160;below</span></p></td><td style="vertical-align:middle;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="color:#424242;">None</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">5</sup><span style="display:inline-block;width:8.3pt;"></span>Targeted categories: (i) executive employees or executive officers or members of the Company's management team who are not corporate officers, or (ii) members of the Board of Directors (including members of any research committee or those serving as censor) in office on the date of grant of the warrants, who are not executive officers of the Company or one of its subsidiaries, or consultants, managers or partners of companies providing services to the Company that have entered into a consulting or service agreement with the Company in force at the time of use of this delegation by the Board of Directors, or (iii) employees of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The issue price will be determined as follows: (i) the issue price of the shares to be issued under this resolution will be at least equal to the minimum authorized by the legislation in force (as of the date hereof, the weighted average of the prices for the last three trading sessions on the regulated market of Euronext in Paris preceding the start of the public offering, possibly reduced by a maximum discount of 10%), and (ii) the issue price of the securities to be issued under this resolution other than shares shall be such that the amount received immediately by the Company plus, where applicable, any amount that may be received subsequently by the Company is, for each share issued as a result of the issue of these securities, at least equal to the amount referred to in (i) above.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The combined General Meeting of June 20, 2024 delegated to the Board of Directors the power to set the issue price of the shares within the limit provided for by the laws and regulations in force at the time this delegation is used (currently ten (10) % of the share capital over a twelve (12) month period), in accordance with the following conditions: (a) the issue price must be at least equal to: (i) either the volume-weighted average price of the Company's shares on the regulated market of Euronext in Paris during the last trading session prior to the setting of the issue price; or (ii) the volume-weighted average price of the Company's shares on the regulated market of Euronext in Paris over a period chosen by the Board of Directors comprising between three and seven consecutive trading sessions out of the last 30 trading sessions prior to the setting of the issue price; possibly reduced by a maximum discount of 15%, the Board of Directors being free to use either of the two options set out above; and (b) the issue price of securities other than shares shall be such that the amount received immediately by the Company plus, where applicable, any amount that may be received subsequently by the Company is, for each share issued as a result of the issue of these securities, at least equal to the amount referred to in (a) above. In the absence of a minimum amount provided for by the laws and regulations in force as referred to in the 22nd and 23rd resolutions, the Board of Directors is empowered to set the issue price of the securities to be issued under these resolutions in accordance with the following conditions: (i) the issue price must be at least equal to: (a) either the volume-weighted average price of the Company's shares on the regulated market of Euronext in Paris during the last trading session prior to the setting of the issue price, or (b) the volume-weighted average of the Company's share prices on the regulated market of Euronext in Paris selected from a period comprising between three and seven consecutive trading sessions among the last 30 trading sessions prior to the setting of the issue price, possibly reduced by a maximum discount of 15%, the Board of Directors being free to use either of the two formulas set out above, and (ii) the issue price of the securities to be issued under this resolution, other than shares, will be such that the amount immediately received by the Company plus, where applicable, any amount that may subsequently be received by the Company is, for each share issued as a result of the issue of these securities, at least equal to the amount referred to in paragraph (i) above.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The issue price must be at least equal to : (a) either the volume-weighted average price of the Company's shares on the regulated market of Euronext in Paris during the last trading session preceding the setting of the issue price; or (b) the volume-weighted average price of the Company's shares on the regulated market of Euronext in Paris during 3 consecutive trading sessions chosen from among the last 30 trading sessions preceding the setting of the issue price; possibly reduced by a maximum discount of 15%, the Board of Directors being free to use either of the two options set out above; and (ii) (a) the issue price of shares that may result from the exercise, conversion, exchange or redemption of securities giving access to the Company's capital issued under this authorization may be set, at the discretion of the Board of Directors, by reference to a calculation formula defined by the Board and applicable after the issue of said securities (for example, on exercise, conversion, redemption or exchange), in which case the maximum discount referred to above may be applied, if the Board of Directors deems it appropriate, on the date of application of the said formula (and not on the date of issue of the securities), and (b) the issue price of the securities to be issued under this resolution, other than shares, shall be such that the amount immediately received by the Company plus, if applicable, the amount that may subsequently be received by the Company is, for each share issued as a result of the issue of these securities, at least equal to the amount referred to in paragraph (i) above.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The issue price must be at least equal to : (i) either the volume-weighted average price of the Company's shares on the regulated market of Euronext in Paris during the last trading session preceding the setting of the issue price; or (ii) the volume-weighted average price of the Company's shares on the regulated market of Euronext in Paris during 3 consecutive trading sessions chosen from among the last 30 trading sessions preceding the setting of the issue price; possibly reduced by a maximum discount of 15%, the Board of Directors being free to use either of the two options set out above</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The issue price(s) of the new shares or securities to be issued pursuant to this resolution will be determined in accordance with Article L.3332-19 of the French Labour Code, and resolves to set the maximum discount at 20%. However, the General Meeting expressly authorizes the Board of Directors to reduce or waive the discount, in particular to take account of the regulations applicable in the countries where the offer will be implemented.</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The exercise price of the options granted under this resolution will be set by the Board of Directors as follows: (i) the exercise price of options to subscribe for ordinary shares may not be less than 80% of the average of the prices quoted for the Company's shares on the regulated market Euronext Paris over the twenty (20) trading sessions preceding the day on which the options are granted, and (ii) the exercise price of options to purchase shares may not be less than 80% of the average purchase price of the shares held by the Company under Article L. 22-10-61 of the French Commercial Code or, as the case may be, of the share buyback program authorized by the 19th resolution submitted to this General Meeting (i.e. January 25, 2023) under Article L.22-10-62 of the French Commercial Code or of any share buyback program applicable previously or subsequently.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The issue price of a BSA 2024 will be determined by the Board of Directors on the date of issue of the BSA 2024, depending on their characteristics, and will in any event be at least equal to 8% of the market value of an ordinary share in the Company on the date of allocation of the BSA 2024, this market value corresponding to the weighted average of the prices for the last twenty (20) trading sessions preceding the date of allocation of the said BSA 2024 by the Board of Directors for as long as the Company's shares are admitted to trading on the regulated market of Euronext in Paris.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>iva-20240630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/15/2024 9:52:36 AM-->
<!--Modified on: 10/15/2024 9:52:36 AM-->
<xsd:schema targetNamespace="http://www.inventivapharma.com/20240630" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:fact-explanatoryFact="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt="http://fasb.org/srt/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iva="http://www.inventivapharma.com/20240630">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" id="StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition">
        <link:definition>00100 - Statement - Unaudited interim condensed consolidated statement of financial position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" id="StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss">
        <link:definition>00200 - Statement - Unaudited interim condensed consolidated statement of income (loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" id="StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss">
        <link:definition>00300 - Statement - Unaudited interim condensed consolidated statement of comprehensive (income) loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" id="StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows">
        <link:definition>00500 - Statement - Unaudited interim condensed consolidated statement of cash flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails">
        <link:definition>40405 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Investments accounted for using the equity method - investment in Hepalys accounted for using equity method of accounting (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails">
        <link:definition>40410 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets- Other Current Assets and Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails">
        <link:definition>40412 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Cash and cash equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails">
        <link:definition>40419 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Financial debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails">
        <link:definition>40429 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Breakdown of expense recognized for the year (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails">
        <link:definition>40430 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Other current and non-current liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails">
        <link:definition>40432 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade payables, short-term contract liabilities and other current liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails">
        <link:definition>40501 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Revenues and other income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails">
        <link:definition>40503 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Operating expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails">
        <link:definition>40504 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Operating expenses - Personnel costs and headcount (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails">
        <link:definition>40505 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Other operating income and expenses - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails">
        <link:definition>40506 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Financial income and expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails">
        <link:definition>40507 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Share of net profit - Equity method (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" id="DisclosureOtherFinancialInformationDetails">
        <link:definition>40601 - Disclosure - Other financial information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" id="StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity">
        <link:definition>00400 - Statement - Unaudited interim condensed consolidated statement of changes in shareholders' equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables">
        <link:definition>30403 - Disclosure - Notes to the interim condensed consolidated statement of financial position (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" id="DisclosureCompanyInformationDetails">
        <link:definition>40101 - Disclosure - Company information - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details" id="DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details">
        <link:definition>40102 - Disclosure - Company information - Significant events in the first half of 2024 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" id="DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails">
        <link:definition>40201 - Disclosure - Basis of preparation and statement of compliance - Significant Investments In Subsidiaries (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" id="DisclosureAccountingPrinciplesFairValueMeasurementDetails">
        <link:definition>40301 - Disclosure - Accounting Principles - Fair value measurement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" id="DisclosureAccountingPrinciplesGoingConcernDetails">
        <link:definition>40302 - Disclosure - Accounting principles - Going concern (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails">
        <link:definition>40401 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Intangible assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails">
        <link:definition>40402 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Property, plant, and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails">
        <link:definition>40403 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Property, plant, and equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails">
        <link:definition>40404 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Investments accounted for using the equity method - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails">
        <link:definition>40407 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Other non-current assets - Long-term deposit accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInventoriesDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInventoriesDetails">
        <link:definition>40408 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails">
        <link:definition>40409 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets - Trade Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails">
        <link:definition>40411 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityShareCapitalDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityShareCapitalDetails">
        <link:definition>40413 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Share capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails">
        <link:definition>40414 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Changes in share capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails">
        <link:definition>40416 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Options and share warrants (BSA and BSPCE) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails">
        <link:definition>40417 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Movements in BSPCE and BSA share warrants (in number of shares issuable upon exercise) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails">
        <link:definition>40418 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Free share awards and Performance units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails">
        <link:definition>40421 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - French state-guaranteed loan ("PGE") and equity recovery loans ("PPR") (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails">
        <link:definition>40422 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Credit facility agreement with the European Investment Bank (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails">
        <link:definition>40423 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Derivatives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails">
        <link:definition>40424 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails">
        <link:definition>40425 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Maturity of long-term debt and of short-term borrowings and debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails">
        <link:definition>40426 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Royalty Certificates liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsNetProvisionDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsNetProvisionDetails">
        <link:definition>40427 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Net provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsChangesInNetProvisionDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsChangesInNetProvisionDetails">
        <link:definition>40428 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Changes in the net provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails">
        <link:definition>40431 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Other current and non-current liabilities - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails">
        <link:definition>40433 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade payables break down (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails">
        <link:definition>40434 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails">
        <link:definition>40502 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" id="DisclosureOtherFinancialInformationEventsAfterReportingDateDetails">
        <link:definition>40602 - Disclosure - Other financial information - Events after the reporting date (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureCompanyInformation" id="DisclosureCompanyInformation">
        <link:definition>10101 - Disclosure - Company information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfCompliance" id="DisclosureBasisOfPreparationAndStatementOfCompliance">
        <link:definition>10201 - Disclosure - Basis of preparation and statement of compliance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureAccountingPrinciples" id="DisclosureAccountingPrinciples">
        <link:definition>10301 - Disclosure - Accounting Principles</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPosition" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPosition">
        <link:definition>10401 - Disclosure - Notes to the interim condensed consolidated statement of financial position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLoss" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLoss">
        <link:definition>10501 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureOtherFinancialInformation" id="DisclosureOtherFinancialInformation">
        <link:definition>10601 - Disclosure - Other financial information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" id="DisclosureAccountingPrinciplesPolicies">
        <link:definition>20302 - Disclosure - Accounting Principles (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceTables" id="DisclosureBasisOfPreparationAndStatementOfComplianceTables">
        <link:definition>30203 - Disclosure - Basis of preparation and statement of compliance (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesTables" id="DisclosureAccountingPrinciplesTables">
        <link:definition>30303 - Disclosure - Accounting Principles (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables">
        <link:definition>30503 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationTables" id="DisclosureOtherFinancialInformationTables">
        <link:definition>30603 - Disclosure - Other financial information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails" id="DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails">
        <link:definition>40202 - Disclosure - Basis of preparation and statement of compliance - Foreign Exchange Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsDetails">
        <link:definition>40406 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Other non-current assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityLiquidityAgreementDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityLiquidityAgreementDetails">
        <link:definition>40415 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Liquidity agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails" id="DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails">
        <link:definition>40420 - Disclosure - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Movements in the period break down (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossIncomeTaxDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossIncomeTaxDetails">
        <link:definition>40508 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Income tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossBasicAndDilutedLossPerShareDetails" id="DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossBasicAndDilutedLossPerShareDetails">
        <link:definition>40509 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Basic and diluted loss per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="iva-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="iva-20240630_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="iva-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="iva-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.inventivapharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:import namespace="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd" />
  <xsd:element name="RevenueAndOperatingIncomeAbstract" id="iva_RevenueAndOperatingIncomeAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AdjustmentsForTaxCredits" id="iva_AdjustmentsForTaxCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="StatementOfComplianceAbstract" id="iva_StatementOfComplianceAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccountingPrinciplesAbstract" id="iva_AccountingPrinciplesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LongTermDepositAccountsMember" id="iva_LongTermDepositAccountsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfOtherNoncurrentAssetsTableTextBlock" id="iva_DisclosureOfOtherNoncurrentAssetsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncreaseDecreaseThroughShareWarrantsSubscriptionPremium" id="iva_IncreaseDecreaseThroughShareWarrantsSubscriptionPremium" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="NonCurrentSecurityDeposits" id="iva_NonCurrentSecurityDeposits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="OtherNonCurrentAssetsTable" id="iva_OtherNonCurrentAssetsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherNonCurrentAssetsLineItems" id="iva_OtherNonCurrentAssetsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsScheduleOfInventoryCurrentTableTextBlock" id="iva_IfrsScheduleOfInventoryCurrentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfInventoryDisclosureTable" id="iva_ScheduleOfInventoryDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfInventoryDisclosureLineItems" id="iva_ScheduleOfInventoryDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfTradeReceivablesTableTextBlock" id="iva_DisclosureOfTradeReceivablesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable" id="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems" id="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CurrentTradeReceivablesAveragePaymentPeriod" id="iva_CurrentTradeReceivablesAveragePaymentPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherCurrentTaxReceivables" id="iva_OtherCurrentTaxReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="OtherCurrentAssetsAndReceivables" id="iva_OtherCurrentAssetsAndReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="CurrentTaxCreditResearchCurrentYear" id="iva_CurrentTaxCreditResearchCurrentYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="DisclosureOfCashAndCashEquivalentsTableTextBlock" id="iva_DisclosureOfCashAndCashEquivalentsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CompanyInformationAbstract" id="iva_CompanyInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CompanyInformationTextBlock" id="iva_CompanyInformationTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsSaleOfStockAxis" id="iva_IfrsSaleOfStockAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsSaleOfStockDomain" id="iva_IfrsSaleOfStockDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodShares" id="iva_StockIssuedDuringPeriodShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" id="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" id="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" id="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedIncomeMember" id="iva_AccruedIncomeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherReceivablesMember" id="iva_OtherReceivablesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsCashAndCashEquivalentsMember" id="iva_IfrsCashAndCashEquivalentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TradePayablesMember" id="iva_TradePayablesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherMiscellaneousPayablesMember" id="iva_OtherMiscellaneousPayablesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FinancialIncomeAndExpensesTableTextBlock" id="iva_FinancialIncomeAndExpensesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ResearchAndDevelopmentMarketingTableTextBlock" id="iva_ResearchAndDevelopmentMarketingTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RevenueAndOtherIncomeTableTextBlock" id="iva_RevenueAndOtherIncomeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CurrentTaxCreditResearchIncome" id="iva_CurrentTaxCreditResearchIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="SubsidiesIncome" id="iva_SubsidiesIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="NewShareWarrantPlansBsa2019Member" id="iva_NewShareWarrantPlansBsa2019Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DavidNikodemMember" id="iva_DavidNikodemMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory" id="iva_DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory" id="iva_DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory" id="iva_DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfOtherOperatingIncomeExpenseTableTextBlock" id="iva_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfChangesInBorrowingsTableTextBlock" id="iva_DisclosureOfChangesInBorrowingsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock" id="iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TradePayablesAndOtherCurrentLiabilities" id="iva_TradePayablesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="LaterThanTwoMonthsMember" id="iva_LaterThanTwoMonthsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherAccruedTaxesAndEmployeeRelatedExpenses" id="iva_OtherAccruedTaxesAndEmployeeRelatedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="RepaymentPeriodOfLoan" id="iva_RepaymentPeriodOfLoan" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" id="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BspceAndBsaShareWarrantsMember" id="iva_BspceAndBsaShareWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BonusShareAwardPlansMember" id="iva_BonusShareAwardPlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BsaShareWarrantsMember" id="iva_BsaShareWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BspcePlansMember" id="iva_BspcePlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsClassOfWarrantOrRightOutstanding" id="iva_IfrsClassOfWarrantOrRightOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" id="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" id="iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="IfrsVestingAxis" id="iva_IfrsVestingAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsVestingDomain" id="iva_IfrsVestingDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BsaPlansMember" id="iva_BsaPlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Bsa2017PlanMember" id="iva_Bsa2017PlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Bsa2018PlanMember" id="iva_Bsa2018PlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NonCurrentLongTermDepositsFromCustomers" id="iva_NonCurrentLongTermDepositsFromCustomers" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="PersonnelCostsAndHeadcount" id="iva_PersonnelCostsAndHeadcount" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AdjustmentsForDepreciationAmortisationAndProvisions" id="iva_AdjustmentsForDepreciationAmortisationAndProvisions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="SalesTaxReceivableCurrent" id="iva_SalesTaxReceivableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="EmployeeRelatedPayables" id="iva_EmployeeRelatedPayables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="Disposables" id="iva_Disposables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="EnergyAndLiquids" id="iva_EnergyAndLiquids" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="Patents" id="iva_Patents" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="Studies" id="iva_Studies" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="Fees" id="iva_Fees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ItSystems" id="iva_ItSystems" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="SupportCosts" id="iva_SupportCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DepreciationAmortizationAndProvisions" id="iva_DepreciationAmortizationAndProvisions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="OtherOperatingExpenses" id="iva_OtherOperatingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DirectorsMember" id="iva_DirectorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ServiceProvidersMember" id="iva_ServiceProvidersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PayrollTaxes" id="iva_PayrollTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="NewShareWarrantPlansBsa2019BisMember" id="iva_NewShareWarrantPlansBsa2019BisMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NewShareWarrantPlansBsa2019TerMember" id="iva_NewShareWarrantPlansBsa2019TerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LiquidityAgreementTerm" id="iva_LiquidityAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FinancingFromSyndicateOfFrenchBanksMember" id="iva_FinancingFromSyndicateOfFrenchBanksMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BorrowingsMaximumExtensionTerm" id="iva_BorrowingsMaximumExtensionTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PledgeAxis" id="iva_PledgeAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PledgeDomain" id="iva_PledgeDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShortTermDepositAccountsMember" id="iva_ShortTermDepositAccountsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FairValueVariationGains" id="iva_FairValueVariationGains" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="IfrsOtherOperatingIncome" id="iva_IfrsOtherOperatingIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="AttributionOfExpensesByNatureToTheirsFunctionAxis" id="iva_AttributionOfExpensesByNatureToTheirsFunctionAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AttributionOfExpensesByNatureToTheirsFunctionDomain" id="iva_AttributionOfExpensesByNatureToTheirsFunctionDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FibroscanMachinesMember" id="iva_FibroscanMachinesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsBalanceSheetLocationAxis" id="iva_IfrsBalanceSheetLocationAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsBalanceSheetLocationDomain" id="iva_IfrsBalanceSheetLocationDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsIncomeStatementLocationAxis" id="iva_IfrsIncomeStatementLocationAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsIncomeStatementLocationDomain" id="iva_IfrsIncomeStatementLocationDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShortTermDepositAccountsCurrent" id="iva_ShortTermDepositAccountsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="CashUnderLiquidityAgreementCurrent" id="iva_CashUnderLiquidityAgreementCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted" id="iva_SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="NumberOfAwardPlansAttributed" id="iva_NumberOfAwardPlansAttributed" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfSharesPerOtherEquityInstrumentGranted" id="iva_NumberOfSharesPerOtherEquityInstrumentGranted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" id="iva_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="OperatingExpenseExcludingOtherOperatingIncomeExpense" id="iva_OperatingExpenseExcludingOtherOperatingIncomeExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="NumberOfLoansObtainedGuaranteedByFrenchState" id="iva_NumberOfLoansObtainedGuaranteedByFrenchState" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LongTermSecurityDepositsMember" id="iva_LongTermSecurityDepositsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="InventivaIncMember" id="iva_InventivaIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Bspce2021PlanMember" id="iva_Bspce2021PlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NewBsa2021ShareWarrantPlanMember" id="iva_NewBsa2021ShareWarrantPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ClassOfWarrantOrRightGranted" id="iva_ClassOfWarrantOrRightGranted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="WarrantsSubscriptionPrice" id="iva_WarrantsSubscriptionPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ExpectedVolatility" id="iva_ExpectedVolatility" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="NewBonusShareAwardPlanAga20211Member" id="iva_NewBonusShareAwardPlanAga20211Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NewBonusShareAwardPlanAga2021BisMember" id="iva_NewBonusShareAwardPlanAga2021BisMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ContractCroWithResearchAssociatesGroupeB.vMember" id="iva_ContractCroWithResearchAssociatesGroupeB.vMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommitmentsAmountPayableForServicesReceivedUnderContract" id="iva_CommitmentsAmountPayableForServicesReceivedUnderContract" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares" id="iva_RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="OtherIncomeFromOrdinaryActivities" id="iva_OtherIncomeFromOrdinaryActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember" id="iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncreasesInPropertyPlantAndEquipment" id="iva_IncreasesInPropertyPlantAndEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="InventivaS.aMember" id="iva_InventivaS.aMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NonCurrentAdvancesToSuppliers" id="iva_NonCurrentAdvancesToSuppliers" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="AccruedPayrollAndOtherEmployeeRelatedTaxes" id="iva_AccruedPayrollAndOtherEmployeeRelatedTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="IfrsResearchAndDevelopmentExpenseMember" id="iva_IfrsResearchAndDevelopmentExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsSalesAndMarketingExpenseMember" id="iva_IfrsSalesAndMarketingExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsGeneralAndAdministrativeExpenseMember" id="iva_IfrsGeneralAndAdministrativeExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" id="iva_ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="TradePayableAndOtherCurrentLiabilitiesTable" id="iva_TradePayableAndOtherCurrentLiabilitiesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TradePayableAndOtherCurrentLiabilitiesLineItems" id="iva_TradePayableAndOtherCurrentLiabilitiesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicensingAndCollaborationAgreementWithCttqMember" id="iva_LicensingAndCollaborationAgreementWithCttqMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ContractCroWithPharmaceuticalResearchAssociatesB.vMember" id="iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FinanceContractWithEuropeanInvestmentBankFirstTrancheMember" id="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="WarrantAgreementWithEuropeanInvestmentBankMember" id="iva_WarrantAgreementWithEuropeanInvestmentBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsDebtInstrumentTerm" id="iva_IfrsDebtInstrumentTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments" id="iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants" id="iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares" id="iva_ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ClassOfWarrantOrRightMaturityTerm" id="iva_ClassOfWarrantOrRightMaturityTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MaximumPotentialGrossProceedsFromExerciseOfWarrants" id="iva_MaximumPotentialGrossProceedsFromExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="FinanceContractWithEuropeanInvestmentBankSecondTrancheMember" id="iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfEqualTranches" id="iva_NumberOfEqualTranches" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction" id="iva_MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="LoanAgreementsWithSyndicateOfFrenchBanksMember" id="iva_LoanAgreementsWithSyndicateOfFrenchBanksMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EquityRecoveryLoansMember" id="iva_EquityRecoveryLoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfLoanAgreements" id="iva_NumberOfLoanAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FinancingPeriodOfLoan" id="iva_FinancingPeriodOfLoan" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfLoanGuaranteedByFrenchState" id="iva_PercentageOfLoanGuaranteedByFrenchState" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued" id="iva_TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="WarrantAverageLife" id="iva_WarrantAverageLife" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FinanceContractWithEuropeanInvestmentBankMember" id="iva_FinanceContractWithEuropeanInvestmentBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NotionalAmountPerTranche" id="iva_NotionalAmountPerTranche" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember" id="iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember" id="iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfEntitiesBeingConsolidated" id="iva_NumberOfEntitiesBeingConsolidated" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities" id="iva_DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IncreaseInBorrowingsThroughCapitalizedInterest" id="iva_IncreaseInBorrowingsThroughCapitalizedInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="LongTermFinancialDebtDerivativesMember" id="iva_LongTermFinancialDebtDerivativesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CirAndOtherResearchTaxCreditsReceivable" id="iva_CirAndOtherResearchTaxCreditsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates" id="iva_IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="TypesOfRevenuesAxis" id="iva_TypesOfRevenuesAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TypesOfRevenuesDomain" id="iva_TypesOfRevenuesDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAndCollaborationAgreementUpfrontFeeReceivable" id="iva_LicenseAndCollaborationAgreementUpfrontFeeReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="AdvancePaymentMember" id="iva_AdvancePaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfWarrantsIssued" id="iva_NumberOfWarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IncreaseDecreaseInLongTermDepositAccounts" id="iva_IncreaseDecreaseInLongTermDepositAccounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="Bsa2022Member" id="iva_Bsa2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BorrowingsEffectiveInterestRate" id="iva_BorrowingsEffectiveInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="LeaseTerm" id="iva_LeaseTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IncreaseDecreaseInTradeAccountsPayable" id="iva_IncreaseDecreaseInTradeAccountsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ProceedsFromLicensingArrangements" id="iva_ProceedsFromLicensingArrangements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NetProceedsFromIssuingShares" id="iva_NetProceedsFromIssuingShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DerivativeInstrumentsMember" id="iva_DerivativeInstrumentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AmountInvoicedToCounterpartyForInitialPayment" id="iva_AmountInvoicedToCounterpartyForInitialPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments" id="iva_IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ServiceContractWithAvantSanteMember" id="iva_ServiceContractWithAvantSanteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsThresholdTradingDays" id="iva_WarrantsThresholdTradingDays" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock" id="iva_DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember" id="iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LicensingAgreementWithHepalysMember" id="iva_LicensingAgreementWithHepalysMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="HepalysPharmaIncMember" id="iva_HepalysPharmaIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Bsa20231ShareWarrantPlanMember" id="iva_Bsa20231ShareWarrantPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NewBonusShareAwardPlan20231Member" id="iva_NewBonusShareAwardPlan20231Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LongTermIncentivePlanInPerformanceUnits2023Member" id="iva_LongTermIncentivePlanInPerformanceUnits2023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MaximumDurationOfClinicalTrial" id="iva_MaximumDurationOfClinicalTrial" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfWeeksUnderActiveTreatmentExtensionStudy" id="iva_NumberOfWeeksUnderActiveTreatmentExtensionStudy" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones" id="iva_LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock" id="iva_DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LongTermDepositsTerm" id="iva_LongTermDepositsTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ProceedsFromFinancing" id="iva_ProceedsFromFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OtherFinancialInformationAbstract" id="iva_OtherFinancialInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ClinicalTrialsMember" id="iva_ClinicalTrialsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ContractManufacturingOrganizationsMember" id="iva_ContractManufacturingOrganizationsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AgreementsConcerningProvisionOfFacilities" id="iva_AgreementsConcerningProvisionOfFacilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ContractualCapitalCommitmentReceived" id="iva_ContractualCapitalCommitmentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PharmaceuticalResearchAssociatesMember" id="iva_PharmaceuticalResearchAssociatesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommitmentContractualBonusOrMalusCappedAmount" id="iva_CommitmentContractualBonusOrMalusCappedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisclosureOfComponentsOfIncomeStatementTextBlock" id="iva_DisclosureOfComponentsOfIncomeStatementTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ComponentsOfIncomeStatementAbstract" id="iva_ComponentsOfIncomeStatementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsotherFinancialInformationTable" id="iva_IfrsotherFinancialInformationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsotherFinancialInformationLineItems" id="iva_IfrsotherFinancialInformationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NotesToConsolidatedBalanceSheet" id="iva_NotesToConsolidatedBalanceSheet" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IncreaseDecreaseInShortTermDepositAccounts" id="iva_IncreaseDecreaseInShortTermDepositAccounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NumberOfBiopsiesUnderClinicalTrials" id="iva_NumberOfBiopsiesUnderClinicalTrials" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement" id="iva_OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement" id="iva_OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SubscriptionOfLeaseLiabilities" id="iva_SubscriptionOfLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LongTermIncentivePlanInPerformanceUnitsMember" id="iva_LongTermIncentivePlanInPerformanceUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AccrualsClassifiedAsCurrentRelatingToScientificProjects" id="iva_AccrualsClassifiedAsCurrentRelatingToScientificProjects" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OptionToAcquireSharesInCompanyPercentage" id="iva_OptionToAcquireSharesInCompanyPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued" id="iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="WarrantsTerm" id="iva_WarrantsTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SharesIssuableUponExerciseOfWarrants" id="iva_SharesIssuableUponExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MaximumGrossProceedsReceivableUponExerciseOfWarrants" id="iva_MaximumGrossProceedsReceivableUponExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RoyaltyCertificatesLiabilitiesMember" id="iva_RoyaltyCertificatesLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Bsa20232ShareWarrantPlanMember" id="iva_Bsa20232ShareWarrantPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NewBonusShareAwardPlan20232Member" id="iva_NewBonusShareAwardPlan20232Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor" id="iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="RoyaltyCertificateLiabilitiesMember" id="iva_RoyaltyCertificateLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RoyaltyCertificatesEffectiveInterestRate" id="iva_RoyaltyCertificatesEffectiveInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IncreaseDecreaseInLeaseLiabilities" id="iva_IncreaseDecreaseInLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments" id="iva_IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="Increaseinborrowingsthroughborrowingsreceived" id="iva_Increaseinborrowingsthroughborrowingsreceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IssueOfRoyaltyCertificates" id="iva_IssueOfRoyaltyCertificates" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NumberOfPatientsRandomizedClinicalTrialMainCohort" id="iva_NumberOfPatientsRandomizedClinicalTrialMainCohort" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember" id="iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare" id="iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember" id="iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy" id="iva_DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DailyDoseOfLanifibranorInTrial" id="iva_DailyDoseOfLanifibranorInTrial" type="dtr-types:massItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfSharesAcquiredInAssociate" id="iva_NumberOfSharesAcquiredInAssociate" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="FredericCrenMember" id="iva_FredericCrenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DrawdownOfBorrowingsMember" id="iva_DrawdownOfBorrowingsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised" id="iva_PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element id="iva_DeprecatedAmountsArisingFromInsuranceContractsAxis" name="DeprecatedAmountsArisingFromInsuranceContractsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" />
  <xsd:element id="iva_DeprecatedNetAmountArisingFromInsuranceContractsMember" name="DeprecatedNetAmountArisingFromInsuranceContractsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" />
  <xsd:element name="DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock" id="iva_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EliminationOfDownstreamSales" id="iva_EliminationOfDownstreamSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IntercompanyEliminationsInAssociates" id="iva_IntercompanyEliminationsInAssociates" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="WarrantsStockPrice" id="iva_WarrantsStockPrice" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="WarrantsCapOfPutOption" id="iva_WarrantsCapOfPutOption" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="WarrantsUnitFairValue" id="iva_WarrantsUnitFairValue" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="InterestOnRoyaltyCertificates" id="iva_InterestOnRoyaltyCertificates" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="BorrowingsActualizationRate" id="iva_BorrowingsActualizationRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod" id="iva_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="TreatmentPeriodUnderStudy" id="iva_TreatmentPeriodUnderStudy" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TransactionCostsOnIssueOfWarrants" id="iva_TransactionCostsOnIssueOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IncreaseDecreaseThroughCapitalVariations" id="iva_IncreaseDecreaseThroughCapitalVariations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FairValueOfWarrantsOutstanding" id="iva_FairValueOfWarrantsOutstanding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations" id="iva_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NumberOfPlansOutstanding" id="iva_NumberOfPlansOutstanding" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NonCurrentAssetsExcludingDeferredAssets" id="iva_NonCurrentAssetsExcludingDeferredAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CurrentAssetsExcludingDeferredAssets" id="iva_CurrentAssetsExcludingDeferredAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DeferredAssets" id="iva_DeferredAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NumberOfSitesOperatingUnderCentralIrbOverseeing" id="iva_NumberOfSitesOperatingUnderCentralIrbOverseeing" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="PercentageOfPatientsRandomizedInMainCohort" id="iva_PercentageOfPatientsRandomizedInMainCohort" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember" id="iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PresentationOfResultsFromStudyMember" id="iva_PresentationOfResultsFromStudyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities" id="iva_NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities" id="iva_CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings" id="iva_DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod" id="iva_EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" id="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock" id="iva_DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DisclosureOfOtherFinancialInformationTextblock" id="iva_DisclosureOfOtherFinancialInformationTextblock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="DailyDoseOfEmpagliflozinInTrial" id="iva_DailyDoseOfEmpagliflozinInTrial" type="dtr-types:massItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d" id="iva_DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember" id="iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d" id="iva_DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff" id="iva_DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PercentageOfPatientsTreatedInTrial" id="iva_PercentageOfPatientsTreatedInTrial" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DemonstratedSignificantRelativeReductionInVatSatRatioInPatients" id="iva_DemonstratedSignificantRelativeReductionInVatSatRatioInPatients" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember" id="iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfPatientsRandomizedForTreatment" id="iva_NumberOfPatientsRandomizedForTreatment" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfPatientsToBeTreatedForFortyEightWeeks" id="iva_NumberOfPatientsToBeTreatedForFortyEightWeeks" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfPatientsToBeTreatedForSeventyTwoWeeks" id="iva_NumberOfPatientsToBeTreatedForSeventyTwoWeeks" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="CapitalSurplusOthers" id="iva_CapitalSurplusOthers" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IncreaseDecreaseInTradeAndOtherCurrentReceivables" id="iva_IncreaseDecreaseInTradeAndOtherCurrentReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IfrsFairValueAdjustmentOfWarrants" id="iva_IfrsFairValueAdjustmentOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="Aga2021Aga2021BisMember" id="iva_Aga2021Aga2021BisMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PercentageOfPatientsInTrialEnrolledInMainCohort" id="iva_PercentageOfPatientsInTrialEnrolledInMainCohort" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="PercentageOfPatientsInTrialEnrolledInExploratoryCohort" id="iva_PercentageOfPatientsInTrialEnrolledInExploratoryCohort" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="IssuanceOfRoyaltyCertificatesMember" id="iva_IssuanceOfRoyaltyCertificatesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfRoyaltyCertificatesIssued" id="iva_NumberOfRoyaltyCertificatesIssued" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="FinancingAgreementInThreePhasesMember" id="iva_FinancingAgreementInThreePhasesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany" id="iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="StockIssuedDuringPeriodValue" id="iva_StockIssuedDuringPeriodValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember" id="iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember" id="iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IssuanceOfSharesOrWarrantsSubjectToConditionsMember" id="iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights" id="iva_IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="MinimumAmountCommittedForFundRaising" id="iva_MinimumAmountCommittedForFundRaising" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FinancingThroughFundRaisingMember" id="iva_FinancingThroughFundRaisingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PeriodWithinWhichPaymentIsReceivedFromSettlement" id="iva_PeriodWithinWhichPaymentIsReceivedFromSettlement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ScenarioTwoMember" id="iva_ScenarioTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ScenarioOneMember" id="iva_ScenarioOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ScenarioThreeMember" id="iva_ScenarioThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ChiaTaiTianqingMember" id="iva_ChiaTaiTianqingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfSharesConverted" id="iva_NumberOfSharesConverted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="Bsa2024Member" id="iva_Bsa2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>iva-20240630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/15/2024 9:52:36 AM-->
<!--Modified on: 10/15/2024 9:52:36 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" roleURI="http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" roleURI="http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" roleURI="http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" roleURI="http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureOtherFinancialInformationDetails" roleURI="http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" xlink:type="extended" xlink:title="00100 - Statement - Unaudited interim condensed consolidated statement of financial position" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets_638645827457199811" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="ifrs-full_NoncurrentAssets_638645827457199811" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_638645827457199811" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638645827457199811" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_638645827457199811" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets" xlink:label="ifrs-full_DeferredTaxAssets_638645827457199811" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638645827457199811" xlink:to="ifrs-full_DeferredTaxAssets_638645827457199811" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_638645827457199811" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638645827457199811" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_638645827457199811" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets_638645827457199811" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638645827457199811" xlink:to="ifrs-full_OtherNoncurrentAssets_638645827457199811" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:label="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_638645827457210405" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638645827457199811" xlink:to="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_638645827457210405" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets_638645827457210405" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="ifrs-full_CurrentAssets_638645827457210405" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories_638645827457210405" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638645827457210405" xlink:to="ifrs-full_Inventories_638645827457210405" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_638645827457210405" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638645827457210405" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_638645827457210405" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets" xlink:label="ifrs-full_OtherCurrentAssets_638645827457210405" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638645827457210405" xlink:to="ifrs-full_OtherCurrentAssets_638645827457210405" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638645827457210405" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638645827457210405" xlink:to="ifrs-full_CashAndCashEquivalents_638645827457210405" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="ifrs-full_CurrentTaxAssetsCurrent_638645827457219892" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638645827457210405" xlink:to="ifrs-full_CurrentTaxAssetsCurrent_638645827457219892" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="EquityAndLiabilities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638645827457219892" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EquityAndLiabilities" xlink:to="ifrs-full_Equity_638645827457219892" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital_638645827457219892" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638645827457219892" xlink:to="ifrs-full_IssuedCapital_638645827457219892" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremium" xlink:label="ifrs-full_SharePremium_638645827457219892" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638645827457219892" xlink:to="ifrs-full_SharePremium_638645827457219892" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares" xlink:label="iva_RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares_638645827457229821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638645827457219892" xlink:to="iva_RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares_638645827457229821" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_638645827457229821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638645827457219892" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_638645827457229821" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsProfitLossForReportingPeriod" xlink:label="ifrs-full_RetainedEarningsProfitLossForReportingPeriod_638645827457229821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638645827457219892" xlink:to="ifrs-full_RetainedEarningsProfitLossForReportingPeriod_638645827457229821" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities_638645827457229821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EquityAndLiabilities" xlink:to="ifrs-full_Liabilities_638645827457229821" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities_638645827457229821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities_638645827457229821" xlink:to="ifrs-full_NoncurrentLiabilities_638645827457229821" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities_638645827457239539" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_638645827457229821" xlink:to="ifrs-full_NoncurrentDerivativeFinancialLiabilities_638645827457239539" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued" xlink:label="iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued_638645827457239539" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_638645827457229821" xlink:to="iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued_638645827457239539" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities_638645827457239539" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_638645827457229821" xlink:to="ifrs-full_NoncurrentContractLiabilities_638645827457239539" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:label="ifrs-full_NoncurrentProvisionsForEmployeeBenefits_638645827457239539" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_638645827457229821" xlink:to="ifrs-full_NoncurrentProvisionsForEmployeeBenefits_638645827457239539" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities" xlink:label="iva_NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities_638645827457239539" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_638645827457229821" xlink:to="iva_NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities_638645827457239539" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="ifrs-full_OtherNoncurrentLiabilities_638645827457239539" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_638645827457229821" xlink:to="ifrs-full_OtherNoncurrentLiabilities_638645827457239539" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities_638645827457249803" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities_638645827457229821" xlink:to="ifrs-full_CurrentLiabilities_638645827457249803" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_638645827457249803" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638645827457249803" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_638645827457249803" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities_638645827457249803" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638645827457249803" xlink:to="ifrs-full_CurrentContractLiabilities_638645827457249803" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities_638645827457249803" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638645827457249803" xlink:to="ifrs-full_OtherCurrentLiabilities_638645827457249803" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities" xlink:label="iva_CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities_638645827457249803" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638645827457249803" xlink:to="iva_CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities_638645827457249803" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" xlink:type="extended" xlink:title="00200 - Statement - Unaudited interim condensed consolidated statement of income (loss)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ProfitLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost_638645827457259834" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProfitLoss" xlink:to="ifrs-full_FinanceIncomeCost_638645827457259834" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_638645827457259834" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncomeCost_638645827457259834" xlink:to="ifrs-full_FinanceCosts_638645827457259834" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_638645827457259834" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncomeCost_638645827457259834" xlink:to="ifrs-full_FinanceIncome_638645827457259834" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_638645827457259834" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProfitLoss" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_638645827457259834" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_638645827457259834" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638645827457259834" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_638645827457259834" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="ifrs-full_SalesAndMarketingExpense_638645827457259834" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638645827457259834" xlink:to="ifrs-full_SalesAndMarketingExpense_638645827457259834" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_638645827457259834" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638645827457259834" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_638645827457259834" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense" xlink:label="ifrs-full_OtherOperatingIncomeExpense_638645827457269823" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638645827457259834" xlink:to="ifrs-full_OtherOperatingIncomeExpense_638645827457269823" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueAndOperatingIncome" xlink:label="ifrs-full_RevenueAndOperatingIncome_638645827457269823" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638645827457259834" xlink:to="ifrs-full_RevenueAndOperatingIncome_638645827457269823" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherIncomeFromOrdinaryActivities" xlink:label="iva_OtherIncomeFromOrdinaryActivities_638645827457269823" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_RevenueAndOperatingIncome_638645827457269823" xlink:to="iva_OtherIncomeFromOrdinaryActivities_638645827457269823" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue_638645827457269823" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_RevenueAndOperatingIncome_638645827457269823" xlink:to="ifrs-full_Revenue_638645827457269823" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_638645827457269823" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProfitLoss" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_638645827457269823" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_638645827457269823" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProfitLoss" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_638645827457269823" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" xlink:type="extended" xlink:title="00300 - Statement - Unaudited interim condensed consolidated statement of comprehensive (income) loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_638645827457279835" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_638645827457279835" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_638645827457279835" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_638645827457279835" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_638645827457279835" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax_638645827457279835" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_638645827457279835" xlink:to="ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax_638645827457279835" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_638645827457279835" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_638645827457279835" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_638645827457279835" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_638645827457279835" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_638645827457279835" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638645827457279835" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ProfitLoss_638645827457279835" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Unaudited interim condensed consolidated statement of cash flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_638645827457279835" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_638645827457279835" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_638645827457279835" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638645827457279835" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_638645827457279835" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_638645827457289821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638645827457279835" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_638645827457289821" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_638645827457289821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638645827457279835" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_638645827457289821" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NetProceedsFromIssuingShares" xlink:label="iva_NetProceedsFromIssuingShares_638645827457289821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638645827457279835" xlink:to="iva_NetProceedsFromIssuingShares_638645827457289821" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_638645827457289821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_638645827457289821" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="iva_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities_638645827457289821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_638645827457289821" xlink:to="iva_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities_638645827457289821" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="iva_ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities_638645827457289821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_638645827457289821" xlink:to="iva_ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities_638645827457289821" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_638645827457289821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_638645827457289821" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_638645827457289821" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:label="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities_638645827457289821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_638645827457289821" xlink:to="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities_638645827457289821" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_638645827457299799" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_638645827457299799" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital_638645827457299799" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638645827457299799" xlink:to="ifrs-full_IncreaseDecreaseInWorkingCapital_638645827457299799" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:label="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_638645827457299799" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInWorkingCapital_638645827457299799" xlink:to="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_638645827457299799" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_638645827457299799" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInWorkingCapital_638645827457299799" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_638645827457299799" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_638645827457299799" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInWorkingCapital_638645827457299799" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_638645827457299799" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_638645827457299799" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInWorkingCapital_638645827457299799" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_638645827457299799" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_638645827457309891" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInWorkingCapital_638645827457299799" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_638645827457309891" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:label="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_638645827457309891" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638645827457299799" xlink:to="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_638645827457309891" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:label="ifrs-full_AdjustmentsForFairValueGainsLosses_638645827457309891" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_638645827457309891" xlink:to="ifrs-full_AdjustmentsForFairValueGainsLosses_638645827457309891" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638645827457309891" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_638645827457309891" xlink:to="ifrs-full_ProfitLoss_638645827457309891" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_638645827457309891" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_638645827457309891" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_638645827457309891" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAdjustmentsForNoncashItems" xlink:label="ifrs-full_OtherAdjustmentsForNoncashItems_638645827457309891" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_638645827457309891" xlink:to="ifrs-full_OtherAdjustmentsForNoncashItems_638645827457309891" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_638645827457319811" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_638645827457309891" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_638645827457319811" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_638645827457319811" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_638645827457309891" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost_638645827457319811" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AdjustmentsForTaxCredits" xlink:label="iva_AdjustmentsForTaxCredits_638645827457319811" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_638645827457309891" xlink:to="iva_AdjustmentsForTaxCredits_638645827457319811" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:label="ifrs-full_AdjustmentsForIncomeTaxExpense_638645827457319811" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_638645827457309891" xlink:to="ifrs-full_AdjustmentsForIncomeTaxExpense_638645827457319811" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AdjustmentsForDepreciationAmortisationAndProvisions" xlink:label="iva_AdjustmentsForDepreciationAmortisationAndProvisions_638645827457319811" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_638645827457309891" xlink:to="iva_AdjustmentsForDepreciationAmortisationAndProvisions_638645827457319811" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUndistributedProfitsOfAssociates" xlink:label="ifrs-full_AdjustmentsForUndistributedProfitsOfAssociates_638645827457329528" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_638645827457309891" xlink:to="ifrs-full_AdjustmentsForUndistributedProfitsOfAssociates_638645827457329528" order="10" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" xlink:type="extended" xlink:title="40405 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Investments accounted for using the equity method - investment in Hepalys accounted for using equity method of accounting (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NonCurrentAssetsExcludingDeferredAssets" xlink:label="iva_NonCurrentAssetsExcludingDeferredAssets_638645827457329528" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="iva_NonCurrentAssetsExcludingDeferredAssets_638645827457329528" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_638645827457329528" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="iva_NonCurrentAssetsExcludingDeferredAssets_638645827457329528" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_638645827457329528" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CurrentAssetsExcludingDeferredAssets" xlink:label="iva_CurrentAssetsExcludingDeferredAssets_638645827457329528" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="iva_CurrentAssetsExcludingDeferredAssets_638645827457329528" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DeferredAssets" xlink:label="iva_DeferredAssets_638645827457329528" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="iva_DeferredAssets_638645827457329528" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" xlink:type="extended" xlink:title="40410 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets- Other Current Assets and Receivables (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherCurrentAssetsAndReceivables" xlink:label="iva_OtherCurrentAssetsAndReceivables" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets" xlink:label="ifrs-full_OtherCurrentAssets_638645827457339801" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="iva_OtherCurrentAssetsAndReceivables" xlink:to="ifrs-full_OtherCurrentAssets_638645827457339801" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="ifrs-full_CurrentPrepaidExpenses_638645827457339801" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentAssets_638645827457339801" xlink:to="ifrs-full_CurrentPrepaidExpenses_638645827457339801" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ShortTermDepositAccountsCurrent" xlink:label="iva_ShortTermDepositAccountsCurrent_638645827457339801" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentAssets_638645827457339801" xlink:to="iva_ShortTermDepositAccountsCurrent_638645827457339801" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets" xlink:label="ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets_638645827457339801" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentAssets_638645827457339801" xlink:to="ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets_638645827457339801" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CashUnderLiquidityAgreementCurrent" xlink:label="iva_CashUnderLiquidityAgreementCurrent_638645827457339801" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentAssets_638645827457339801" xlink:to="iva_CashUnderLiquidityAgreementCurrent_638645827457339801" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_SalesTaxReceivableCurrent" xlink:label="iva_SalesTaxReceivableCurrent_638645827457339801" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentAssets_638645827457339801" xlink:to="iva_SalesTaxReceivableCurrent_638645827457339801" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables_638645827457350027" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentAssets_638645827457339801" xlink:to="ifrs-full_OtherCurrentReceivables_638645827457350027" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="ifrs-full_CurrentTaxAssetsCurrent_638645827457350027" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="iva_OtherCurrentAssetsAndReceivables" xlink:to="ifrs-full_CurrentTaxAssetsCurrent_638645827457350027" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CirAndOtherResearchTaxCreditsReceivable" xlink:label="iva_CirAndOtherResearchTaxCreditsReceivable_638645827457350027" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentTaxAssetsCurrent_638645827457350027" xlink:to="iva_CirAndOtherResearchTaxCreditsReceivable_638645827457350027" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherCurrentTaxReceivables" xlink:label="iva_OtherCurrentTaxReceivables_638645827457350027" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentTaxAssetsCurrent_638645827457350027" xlink:to="iva_OtherCurrentTaxReceivables_638645827457350027" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails" xlink:type="extended" xlink:title="40412 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Cash and cash equivalents (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash" xlink:label="ifrs-full_Cash_638645827457350027" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashAndCashEquivalents_1" xlink:to="ifrs-full_Cash_638645827457350027" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_638645827457350027" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashAndCashEquivalents_1" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_638645827457350027" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:label="ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_638645827457359832" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashAndCashEquivalents_1" xlink:to="ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_638645827457359832" order="3" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails" xlink:type="extended" xlink:title="40419 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Financial debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities_638645827457359832" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Borrowings" xlink:to="ifrs-full_LeaseLiabilities_638645827457359832" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities_638645827457359832" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Borrowings" xlink:to="ifrs-full_NoncurrentDerivativeFinancialLiabilities_638645827457359832" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LoansReceived" xlink:label="ifrs-full_LoansReceived_638645827457359832" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Borrowings" xlink:to="ifrs-full_LoansReceived_638645827457359832" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued" xlink:label="iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued_638645827457359832" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Borrowings" xlink:to="iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued_638645827457359832" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherBorrowings" xlink:label="ifrs-full_OtherBorrowings_638645827457359832" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Borrowings" xlink:to="ifrs-full_OtherBorrowings_638645827457359832" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails" xlink:type="extended" xlink:title="40429 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Breakdown of expense recognized for the year (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans" xlink:label="ifrs-full_PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans_638645827457369537" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:to="ifrs-full_PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans_638645827457369537" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseDefinedBenefitPlans" xlink:label="ifrs-full_InterestExpenseDefinedBenefitPlans_638645827457369537" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:to="ifrs-full_InterestExpenseDefinedBenefitPlans_638645827457369537" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentServiceCostDefinedBenefitPlans" xlink:label="ifrs-full_CurrentServiceCostDefinedBenefitPlans_638645827457369537" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:to="ifrs-full_CurrentServiceCostDefinedBenefitPlans_638645827457369537" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40430 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Other current and non-current liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="OtherCurrentLiabilities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentValueAddedTaxPayables" xlink:label="ifrs-full_CurrentValueAddedTaxPayables_638645827457369537" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherCurrentLiabilities" xlink:to="ifrs-full_CurrentValueAddedTaxPayables_638645827457369537" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentPayables" xlink:label="ifrs-full_OtherCurrentPayables_638645827457369537" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentPayables_638645827457369537" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherAccruedTaxesAndEmployeeRelatedExpenses" xlink:label="iva_OtherAccruedTaxesAndEmployeeRelatedExpenses_638645827457379846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherCurrentLiabilities" xlink:to="iva_OtherAccruedTaxesAndEmployeeRelatedExpenses_638645827457379846" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AccruedPayrollAndOtherEmployeeRelatedTaxes" xlink:label="iva_AccruedPayrollAndOtherEmployeeRelatedTaxes_638645827457379846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherCurrentLiabilities" xlink:to="iva_AccruedPayrollAndOtherEmployeeRelatedTaxes_638645827457379846" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_EmployeeRelatedPayables" xlink:label="iva_EmployeeRelatedPayables_638645827457379846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherCurrentLiabilities" xlink:to="iva_EmployeeRelatedPayables_638645827457379846" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40432 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade payables, short-term contract liabilities and other current liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradePayablesAndOtherCurrentLiabilities" xlink:label="TradePayablesAndOtherCurrentLiabilities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities_638645827457379846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="TradePayablesAndOtherCurrentLiabilities" xlink:to="ifrs-full_CurrentContractLiabilities_638645827457379846" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_638645827457379846" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="TradePayablesAndOtherCurrentLiabilities" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_638645827457379846" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Revenues and other income (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherIncomeFromOrdinaryActivities" xlink:label="OtherIncomeFromOrdinaryActivities" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsOtherOperatingIncome" xlink:label="iva_IfrsOtherOperatingIncome_638645827457389946" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherIncomeFromOrdinaryActivities" xlink:to="iva_IfrsOtherOperatingIncome_638645827457389946" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_SubsidiesIncome" xlink:label="iva_SubsidiesIncome_638645827457389946" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherIncomeFromOrdinaryActivities" xlink:to="iva_SubsidiesIncome_638645827457389946" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CurrentTaxCreditResearchIncome" xlink:label="iva_CurrentTaxCreditResearchIncome_638645827457389946" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherIncomeFromOrdinaryActivities" xlink:to="iva_CurrentTaxCreditResearchIncome_638645827457389946" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="Revenue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_638645827457389946" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Revenue" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_638645827457389946" order="1" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Operating expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OperatingExpenseExcludingOtherOperatingIncomeExpense" xlink:label="OperatingExpenseExcludingOtherOperatingIncomeExpense" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DepreciationAmortizationAndProvisions" xlink:label="iva_DepreciationAmortizationAndProvisions_638645827457399911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenseExcludingOtherOperatingIncomeExpense" xlink:to="iva_DepreciationAmortizationAndProvisions_638645827457399911" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Disposables" xlink:label="iva_Disposables_638645827457399911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenseExcludingOtherOperatingIncomeExpense" xlink:to="iva_Disposables_638645827457399911" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense_638645827457399911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenseExcludingOtherOperatingIncomeExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_638645827457399911" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_EnergyAndLiquids" xlink:label="iva_EnergyAndLiquids_638645827457399911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenseExcludingOtherOperatingIncomeExpense" xlink:to="iva_EnergyAndLiquids_638645827457399911" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Fees" xlink:label="iva_Fees_638645827457399911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenseExcludingOtherOperatingIncomeExpense" xlink:to="iva_Fees_638645827457399911" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ItSystems" xlink:label="iva_ItSystems_638645827457399911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenseExcludingOtherOperatingIncomeExpense" xlink:to="iva_ItSystems_638645827457399911" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherOperatingExpenses" xlink:label="iva_OtherOperatingExpenses_638645827457399911" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenseExcludingOtherOperatingIncomeExpense" xlink:to="iva_OtherOperatingExpenses_638645827457399911" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Patents" xlink:label="iva_Patents_638645827457409805" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenseExcludingOtherOperatingIncomeExpense" xlink:to="iva_Patents_638645827457409805" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepairsAndMaintenanceExpense" xlink:label="ifrs-full_RepairsAndMaintenanceExpense_638645827457409805" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenseExcludingOtherOperatingIncomeExpense" xlink:to="ifrs-full_RepairsAndMaintenanceExpense_638645827457409805" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Studies" xlink:label="iva_Studies_638645827457409805" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenseExcludingOtherOperatingIncomeExpense" xlink:to="iva_Studies_638645827457409805" order="10" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_SupportCosts" xlink:label="iva_SupportCosts_638645827457409805" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenseExcludingOtherOperatingIncomeExpense" xlink:to="iva_SupportCosts_638645827457409805" order="11" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InsuranceExpense" xlink:label="ifrs-full_InsuranceExpense_638645827457409805" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenseExcludingOtherOperatingIncomeExpense" xlink:to="ifrs-full_InsuranceExpense_638645827457409805" order="12" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails" xlink:type="extended" xlink:title="40504 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Operating expenses - Personnel costs and headcount (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="EmployeeBenefitsExpense" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_638645827457409805" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EmployeeBenefitsExpense" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_638645827457409805" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PayrollTaxes" xlink:label="iva_PayrollTaxes_638645827457419821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EmployeeBenefitsExpense" xlink:to="iva_PayrollTaxes_638645827457419821" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WagesAndSalaries" xlink:label="ifrs-full_WagesAndSalaries_638645827457419821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EmployeeBenefitsExpense" xlink:to="ifrs-full_WagesAndSalaries_638645827457419821" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss" xlink:label="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss_638645827457419821" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EmployeeBenefitsExpense" xlink:to="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss_638645827457419821" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails" xlink:type="extended" xlink:title="40505 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Other operating income and expenses - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense" xlink:label="ifrs-full_OtherOperatingIncomeExpense" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense_638645827457639618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherOperatingIncomeExpense" xlink:to="ifrs-full_MiscellaneousOtherOperatingExpense_638645827457639618" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_638645827457639618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherOperatingIncomeExpense" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome_638645827457639618" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" xlink:type="extended" xlink:title="40506 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Financial income and expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpense" xlink:label="ifrs-full_InterestExpense_638645827457639618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts_1" xlink:to="ifrs-full_InterestExpense_638645827457639618" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignExchangeLoss" xlink:label="ifrs-full_ForeignExchangeLoss_638645827457639618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts_1" xlink:to="ifrs-full_ForeignExchangeLoss_638645827457639618" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceCost" xlink:label="ifrs-full_OtherFinanceCost_638645827457639618" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts_1" xlink:to="ifrs-full_OtherFinanceCost_638645827457639618" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:label="ifrs-full_InterestIncomeOnCashAndCashEquivalents_638645827457649933" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncome_1" xlink:to="ifrs-full_InterestIncomeOnCashAndCashEquivalents_638645827457649933" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FairValueVariationGains" xlink:label="iva_FairValueVariationGains_638645827457649933" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncome_1" xlink:to="iva_FairValueVariationGains_638645827457649933" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignExchangeGain" xlink:label="ifrs-full_ForeignExchangeGain_638645827457649933" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncome_1" xlink:to="ifrs-full_ForeignExchangeGain_638645827457649933" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails" xlink:type="extended" xlink:title="40507 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Share of net profit - Equity method (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations" xlink:label="iva_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations_638645827457649933" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:to="iva_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations_638645827457649933" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_EliminationOfDownstreamSales" xlink:label="iva_EliminationOfDownstreamSales_638645827457649933" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:to="iva_EliminationOfDownstreamSales_638645827457649933" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Other financial information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ContractualCapitalCommitmentReceived" xlink:label="iva_ContractualCapitalCommitmentReceived" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AgreementsConcerningProvisionOfFacilities" xlink:label="iva_AgreementsConcerningProvisionOfFacilities_638645827457659822" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="iva_ContractualCapitalCommitmentReceived" xlink:to="iva_AgreementsConcerningProvisionOfFacilities_638645827457659822" order="1" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>iva-20240630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/15/2024 9:52:36 AM-->
<!--Modified on: 10/15/2024 9:52:36 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" roleURI="http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureCompanyInformationDetails" roleURI="http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details" roleURI="http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureAccountingPrinciplesFairValueMeasurementDetails" roleURI="http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInventoriesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInventoriesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureOtherFinancialInformationDetails" roleURI="http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" roleURI="http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.inventivapharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.inventivapharma.com/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ComponentsOfEquityAxis" xlink:title="ComponentsOfEquityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="EquityMember" xlink:title="EquityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ComponentsOfEquityAxis" xlink:to="EquityMember" xlink:title="definition: ComponentsOfEquityAxis to EquityMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="TypesOfSharebasedPaymentArrangementsAxis" xlink:title="TypesOfSharebasedPaymentArrangementsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="SharebasedPaymentArrangementsMember" xlink:title="SharebasedPaymentArrangementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfSharebasedPaymentArrangementsAxis" xlink:to="SharebasedPaymentArrangementsMember" xlink:title="definition: TypesOfSharebasedPaymentArrangementsAxis to SharebasedPaymentArrangementsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="NonadjustingEventsAfterReportingPeriodAxis" xlink:title="NonadjustingEventsAfterReportingPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="NonadjustingEventsMember" xlink:title="NonadjustingEventsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="NonadjustingEventsAfterReportingPeriodAxis" xlink:to="NonadjustingEventsMember" xlink:title="definition: NonadjustingEventsAfterReportingPeriodAxis to NonadjustingEventsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="CategoriesOfRelatedPartiesAxis" xlink:title="CategoriesOfRelatedPartiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="EntitysTotalForRelatedPartiesMember" xlink:title="EntitysTotalForRelatedPartiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CategoriesOfRelatedPartiesAxis" xlink:to="EntitysTotalForRelatedPartiesMember" xlink:title="definition: CategoriesOfRelatedPartiesAxis to EntitysTotalForRelatedPartiesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="definition: RangeAxis to RangesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsVestingAxis" xlink:label="IfrsVestingAxis" xlink:title="IfrsVestingAxis" />
    <link:loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsVestingDomain" xlink:label="IfrsVestingDomain" xlink:title="IfrsVestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IfrsVestingAxis" xlink:to="IfrsVestingDomain" xlink:title="definition: IfrsVestingAxis to IfrsVestingDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsSaleOfStockAxis" xlink:label="IfrsSaleOfStockAxis" xlink:title="IfrsSaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsSaleOfStockDomain" xlink:label="IfrsSaleOfStockDomain" xlink:title="IfrsSaleOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IfrsSaleOfStockAxis" xlink:to="IfrsSaleOfStockDomain" xlink:title="definition: IfrsSaleOfStockAxis to IfrsSaleOfStockDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DeprecatedAmountsArisingFromInsuranceContractsAxis" xlink:label="iva_DeprecatedAmountsArisingFromInsuranceContractsAxis" xlink:title="AmountsArisingFromInsuranceContractsAxis" />
    <link:loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DeprecatedNetAmountArisingFromInsuranceContractsMember" xlink:label="iva_DeprecatedNetAmountArisingFromInsuranceContractsMember" xlink:title="NetAmountArisingFromInsuranceContractsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="iva_DeprecatedAmountsArisingFromInsuranceContractsAxis" xlink:to="iva_DeprecatedNetAmountArisingFromInsuranceContractsMember" xlink:title="definition: AmountsArisingFromInsuranceContractsAxis to NetAmountArisingFromInsuranceContractsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ClassesOfShareCapitalAxis" xlink:title="ClassesOfShareCapitalAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ClassesOfShareCapitalMember" xlink:title="ClassesOfShareCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfShareCapitalAxis" xlink:to="ClassesOfShareCapitalMember" xlink:title="definition: ClassesOfShareCapitalAxis to ClassesOfShareCapitalMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsBalanceSheetLocationAxis" xlink:label="IfrsBalanceSheetLocationAxis" xlink:title="IfrsBalanceSheetLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsBalanceSheetLocationDomain" xlink:label="IfrsBalanceSheetLocationDomain" xlink:title="IfrsBalanceSheetLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IfrsBalanceSheetLocationAxis" xlink:to="IfrsBalanceSheetLocationDomain" xlink:title="definition: IfrsBalanceSheetLocationAxis to IfrsBalanceSheetLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:title="AttributionOfExpensesByNatureToTheirFunctionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="LineItemsByFunctionMember" xlink:title="LineItemsByFunctionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="LineItemsByFunctionMember" xlink:title="definition: AttributionOfExpensesByNatureToTheirFunctionAxis to LineItemsByFunctionMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnderlyingEquityInstrumentAndDepositaryReceiptsAxis" xlink:label="UnderlyingEquityInstrumentAndDepositaryReceiptsAxis" xlink:title="UnderlyingEquityInstrumentAndDepositaryReceiptsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnderlyingEquityInstrumentMember" xlink:label="UnderlyingEquityInstrumentMember" xlink:title="UnderlyingEquityInstrumentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="UnderlyingEquityInstrumentAndDepositaryReceiptsAxis" xlink:to="UnderlyingEquityInstrumentMember" xlink:title="definition: UnderlyingEquityInstrumentAndDepositaryReceiptsAxis to UnderlyingEquityInstrumentMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis" xlink:label="CounterpartiesAxis" xlink:title="CounterpartiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember" xlink:label="CounterpartiesMember" xlink:title="CounterpartiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartiesAxis" xlink:to="CounterpartiesMember" xlink:title="definition: CounterpartiesAxis to CounterpartiesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="ClassesOfProvisionsAxis" xlink:title="ClassesOfProvisionsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember" xlink:label="OtherProvisionsMember" xlink:title="OtherProvisionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfProvisionsAxis" xlink:to="OtherProvisionsMember" xlink:title="definition: ClassesOfProvisionsAxis to OtherProvisionsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PledgeAxis" xlink:label="PledgeAxis" xlink:title="PledgeAxis" />
    <link:loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PledgeDomain" xlink:label="PledgeDomain" xlink:title="PledgeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PledgeAxis" xlink:to="PledgeDomain" xlink:title="definition: PledgeAxis to PledgeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:title="IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" />
    <link:loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:title="IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:to="IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:title="definition: IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis to IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="SignificantInvestmentsInSubsidiariesAxis" xlink:title="SignificantInvestmentsInSubsidiariesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="EntitysTotalForSubsidiariesMember" xlink:title="EntitysTotalForSubsidiariesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SignificantInvestmentsInSubsidiariesAxis" xlink:to="EntitysTotalForSubsidiariesMember" xlink:title="definition: SignificantInvestmentsInSubsidiariesAxis to EntitysTotalForSubsidiariesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="BorrowingsByNameAxis" xlink:title="BorrowingsByNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="BorrowingsByNameMember" xlink:title="BorrowingsByNameMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BorrowingsByNameAxis" xlink:to="BorrowingsByNameMember" xlink:title="definition: BorrowingsByNameAxis to BorrowingsByNameMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InitiallyAppliedIFRSsAxis" xlink:label="InitiallyAppliedIFRSsAxis" xlink:title="InitiallyAppliedIFRSsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InitiallyAppliedIFRSsMember" xlink:label="InitiallyAppliedIFRSsMember" xlink:title="InitiallyAppliedIFRSsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="InitiallyAppliedIFRSsAxis" xlink:to="InitiallyAppliedIFRSsMember" xlink:title="definition: InitiallyAppliedIFRSsAxis to InitiallyAppliedIFRSsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="MaturityAxis" xlink:title="MaturityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="AggregatedTimeBandsMember" xlink:title="AggregatedTimeBandsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MaturityAxis" xlink:to="AggregatedTimeBandsMember" xlink:title="definition: MaturityAxis to AggregatedTimeBandsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:label="CumulativeEffectAtDateOfInitialApplicationAxis" xlink:title="CumulativeEffectAtDateOfInitialApplicationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:label="OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:title="OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CumulativeEffectAtDateOfInitialApplicationAxis" xlink:to="OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:title="definition: CumulativeEffectAtDateOfInitialApplicationAxis to OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ClassesOfFinancialLiabilitiesAxis" xlink:title="ClassesOfFinancialLiabilitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="FinancialLiabilitiesMember" xlink:title="FinancialLiabilitiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfFinancialLiabilitiesAxis" xlink:to="FinancialLiabilitiesMember" xlink:title="definition: ClassesOfFinancialLiabilitiesAxis to FinancialLiabilitiesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ClassesOfPropertyPlantAndEquipmentAxis" xlink:title="ClassesOfPropertyPlantAndEquipmentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="PropertyPlantAndEquipmentMember" xlink:title="PropertyPlantAndEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="PropertyPlantAndEquipmentMember" xlink:title="definition: ClassesOfPropertyPlantAndEquipmentAxis to PropertyPlantAndEquipmentMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:title="ClassesOfIntangibleAssetsOtherThanGoodwillAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="IntangibleAssetsOtherThanGoodwillMember" xlink:title="IntangibleAssetsOtherThanGoodwillMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="IntangibleAssetsOtherThanGoodwillMember" xlink:title="definition: ClassesOfIntangibleAssetsOtherThanGoodwillAxis to IntangibleAssetsOtherThanGoodwillMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:title="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="CarryingAmountMember" xlink:title="CarryingAmountMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="CarryingAmountMember" xlink:title="definition: CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis to CarryingAmountMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="LevelsOfFairValueHierarchyAxis" xlink:title="LevelsOfFairValueHierarchyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="AllLevelsOfFairValueHierarchyMember" xlink:title="AllLevelsOfFairValueHierarchyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LevelsOfFairValueHierarchyAxis" xlink:to="AllLevelsOfFairValueHierarchyMember" xlink:title="definition: LevelsOfFairValueHierarchyAxis to AllLevelsOfFairValueHierarchyMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis" xlink:label="MeasurementAxis" xlink:title="MeasurementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="AggregatedMeasurementMember" xlink:title="AggregatedMeasurementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MeasurementAxis" xlink:to="AggregatedMeasurementMember" xlink:title="definition: MeasurementAxis to AggregatedMeasurementMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="CategoriesOfFinancialAssetsAxis" xlink:title="CategoriesOfFinancialAssetsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="FinancialAssetsCategoryMember" xlink:title="FinancialAssetsCategoryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CategoriesOfFinancialAssetsAxis" xlink:to="FinancialAssetsCategoryMember" xlink:title="definition: CategoriesOfFinancialAssetsAxis to FinancialAssetsCategoryMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ClassesOfAssetsAxis" xlink:title="ClassesOfAssetsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ClassesOfAssetsMember" xlink:title="ClassesOfAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfAssetsAxis" xlink:to="ClassesOfAssetsMember" xlink:title="definition: ClassesOfAssetsAxis to ClassesOfAssetsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ClassesOfFinancialAssetsAxis" xlink:title="ClassesOfFinancialAssetsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember" xlink:label="FinancialAssetsMember" xlink:title="FinancialAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfFinancialAssetsAxis" xlink:to="FinancialAssetsMember" xlink:title="definition: ClassesOfFinancialAssetsAxis to FinancialAssetsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="CategoriesOfFinancialLiabilitiesAxis" xlink:title="CategoriesOfFinancialLiabilitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="FinancialLiabilitiesCategoryMember" xlink:title="FinancialLiabilitiesCategoryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CategoriesOfFinancialLiabilitiesAxis" xlink:to="FinancialLiabilitiesCategoryMember" xlink:title="definition: CategoriesOfFinancialLiabilitiesAxis to FinancialLiabilitiesCategoryMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ClassesOfFinancialInstrumentsAxis" xlink:title="ClassesOfFinancialInstrumentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ClassesOfFinancialInstrumentsMember" xlink:title="ClassesOfFinancialInstrumentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfFinancialInstrumentsAxis" xlink:to="ClassesOfFinancialInstrumentsMember" xlink:title="definition: ClassesOfFinancialInstrumentsAxis to ClassesOfFinancialInstrumentsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:label="NetDefinedBenefitLiabilityAssetAxis" xlink:title="NetDefinedBenefitLiabilityAssetAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:label="NetDefinedBenefitLiabilityAssetMember" xlink:title="NetDefinedBenefitLiabilityAssetMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="NetDefinedBenefitLiabilityAssetAxis" xlink:to="NetDefinedBenefitLiabilityAssetMember" xlink:title="definition: NetDefinedBenefitLiabilityAssetAxis to NetDefinedBenefitLiabilityAssetMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionsAxis" xlink:label="ActuarialAssumptionsAxis" xlink:title="ActuarialAssumptionsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ActuarialAssumptionsMember" xlink:label="ActuarialAssumptionsMember" xlink:title="ActuarialAssumptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ActuarialAssumptionsAxis" xlink:to="ActuarialAssumptionsMember" xlink:title="definition: ActuarialAssumptionsAxis to ActuarialAssumptionsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ProductsAndServicesAxis" xlink:title="ProductsAndServicesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ProductsAndServicesMember" xlink:title="ProductsAndServicesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductsAndServicesAxis" xlink:to="ProductsAndServicesMember" xlink:title="definition: ProductsAndServicesAxis to ProductsAndServicesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TypesOfRevenuesAxis" xlink:label="TypesOfRevenuesAxis" xlink:title="TypesOfRevenuesAxis" />
    <link:loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TypesOfRevenuesDomain" xlink:label="TypesOfRevenuesDomain" xlink:title="TypesOfRevenuesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfRevenuesAxis" xlink:to="TypesOfRevenuesDomain" xlink:title="definition: TypesOfRevenuesAxis to TypesOfRevenuesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="CurrencyAxis" xlink:title="CurrencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="AllCurrenciesDomain" xlink:title="AllCurrenciesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CurrencyAxis" xlink:to="AllCurrenciesDomain" xlink:title="definition: CurrencyAxis to AllCurrenciesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="TypesOfRisksAxis" xlink:title="TypesOfRisksAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember" xlink:label="TypesOfRisksMember" xlink:title="TypesOfRisksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfRisksAxis" xlink:to="TypesOfRisksMember" xlink:title="definition: TypesOfRisksAxis to TypesOfRisksMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsIncomeStatementLocationAxis" xlink:label="IfrsIncomeStatementLocationAxis" xlink:title="IfrsIncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsIncomeStatementLocationDomain" xlink:label="IfrsIncomeStatementLocationDomain" xlink:title="IfrsIncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IfrsIncomeStatementLocationAxis" xlink:to="IfrsIncomeStatementLocationDomain" xlink:title="definition: IfrsIncomeStatementLocationAxis to IfrsIncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AttributionOfExpensesByNatureToTheirsFunctionAxis" xlink:label="AttributionOfExpensesByNatureToTheirsFunctionAxis" xlink:title="AttributionOfExpensesByNatureToTheirsFunctionAxis" />
    <link:loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AttributionOfExpensesByNatureToTheirsFunctionDomain" xlink:label="AttributionOfExpensesByNatureToTheirsFunctionDomain" xlink:title="AttributionOfExpensesByNatureToTheirsFunctionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AttributionOfExpensesByNatureToTheirsFunctionAxis" xlink:to="AttributionOfExpensesByNatureToTheirsFunctionDomain" xlink:title="definition: AttributionOfExpensesByNatureToTheirsFunctionAxis to AttributionOfExpensesByNatureToTheirsFunctionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ConsolidatedStructuredEntitiesAxis" xlink:label="ConsolidatedStructuredEntitiesAxis" xlink:title="ConsolidatedStructuredEntitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:label="EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:title="EntitysTotalForConsolidatedStructuredEntitiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidatedStructuredEntitiesAxis" xlink:to="EntitysTotalForConsolidatedStructuredEntitiesMember" xlink:title="definition: ConsolidatedStructuredEntitiesAxis to EntitysTotalForConsolidatedStructuredEntitiesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ConsolidatedAndSeparateFinancialStatementsAxis" xlink:label="ConsolidatedAndSeparateFinancialStatementsAxis" xlink:title="ConsolidatedAndSeparateFinancialStatementsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ConsolidatedMember" xlink:label="ConsolidatedMember" xlink:title="ConsolidatedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidatedAndSeparateFinancialStatementsAxis" xlink:to="ConsolidatedMember" xlink:title="definition: ConsolidatedAndSeparateFinancialStatementsAxis to ConsolidatedMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="EntityAddressesAddressTypeAxis" xlink:title="EntityAddressesAddressTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="AddressTypeDomain" xlink:title="AddressTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="EntityAddressesAddressTypeAxis" xlink:to="AddressTypeDomain" xlink:title="definition: EntityAddressesAddressTypeAxis to AddressTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis_1" xlink:title="ifrs-full_GeographicalAreasAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember_1" xlink:title="ifrs-full_GeographicalAreasMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_GeographicalAreasAxis_1" xlink:to="ifrs-full_GeographicalAreasMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_GeographicalAreasAxis_1 To ifrs-full_GeographicalAreasMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_1" xlink:title="srt_OwnershipAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_1" xlink:title="srt_OwnershipDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_OwnershipAxis_1" xlink:to="srt_OwnershipDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_OwnershipAxis_1 To srt_OwnershipDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis_1" xlink:title="ifrs-full_SignificantInvestmentsInAssociatesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="ifrs-full_EntitysTotalForAssociatesMember_1" xlink:title="ifrs-full_EntitysTotalForAssociatesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis_1" xlink:to="ifrs-full_EntitysTotalForAssociatesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_SignificantInvestmentsInAssociatesAxis_1 To ifrs-full_EntitysTotalForAssociatesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfOrdinarySharesAxis" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis_1" xlink:title="ifrs-full_ClassesOfOrdinarySharesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember_1" xlink:title="ifrs-full_OrdinarySharesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis_1" xlink:to="ifrs-full_OrdinarySharesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfOrdinarySharesAxis_1 To ifrs-full_OrdinarySharesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="ifrs-full_UnobservableInputsAxis_1" xlink:title="ifrs-full_UnobservableInputsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="ifrs-full_UnobservableInputsMember_1" xlink:title="ifrs-full_UnobservableInputsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_UnobservableInputsAxis_1" xlink:to="ifrs-full_UnobservableInputsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_UnobservableInputsAxis_1 To ifrs-full_UnobservableInputsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis_1" xlink:title="ifrs-full_BusinessCombinationsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_1" xlink:title="ifrs-full_EntitysTotalForBusinessCombinationsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_BusinessCombinationsAxis_1" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_BusinessCombinationsAxis_1 To ifrs-full_EntitysTotalForBusinessCombinationsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis_1" xlink:title="ifrs-full_ClassesOfLiabilitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember" xlink:label="ifrs-full_LiabilitiesMember_1" xlink:title="ifrs-full_LiabilitiesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis_1" xlink:to="ifrs-full_LiabilitiesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfLiabilitiesAxis_1 To ifrs-full_LiabilitiesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1" xlink:title="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" xlink:title="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1 To ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_1" xlink:title="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember_1" xlink:title="ifrs-full_IntangibleAssetsAndGoodwillMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_1" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_1 To ifrs-full_IntangibleAssetsAndGoodwillMember_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - Unaudited interim condensed consolidated statement of changes in shareholders' equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_SharePremiumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember" xlink:label="ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember" xlink:label="iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_EquityMember" xlink:to="iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod" xlink:label="iva_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="iva_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings" xlink:label="ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseDecreaseThroughShareWarrantsSubscriptionPremium" xlink:label="iva_IncreaseDecreaseThroughShareWarrantsSubscriptionPremium" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="iva_IncreaseDecreaseThroughShareWarrantsSubscriptionPremium" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" xlink:type="extended" xlink:title="30403 - Disclosure - Notes to the interim condensed consolidated statement of financial position (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BspceAndBsaShareWarrantsMember" xlink:label="iva_BspceAndBsaShareWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="iva_BspceAndBsaShareWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewBonusShareAwardPlan20231Member" xlink:label="iva_NewBonusShareAwardPlan20231Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="iva_NewBonusShareAwardPlan20231Member" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LongTermIncentivePlanInPerformanceUnits2023Member" xlink:label="iva_LongTermIncentivePlanInPerformanceUnits2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="iva_LongTermIncentivePlanInPerformanceUnits2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory" xlink:label="ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xlink:label="iva_DisclosureOfOtherNoncurrentAssetsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="iva_DisclosureOfOtherNoncurrentAssetsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsScheduleOfInventoryCurrentTableTextBlock" xlink:label="iva_IfrsScheduleOfInventoryCurrentTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="iva_IfrsScheduleOfInventoryCurrentTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfTradeReceivablesTableTextBlock" xlink:label="iva_DisclosureOfTradeReceivablesTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="iva_DisclosureOfTradeReceivablesTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfCashAndCashEquivalentsTableTextBlock" xlink:label="iva_DisclosureOfCashAndCashEquivalentsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="iva_DisclosureOfCashAndCashEquivalentsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfChangesInBorrowingsTableTextBlock" xlink:label="iva_DisclosureOfChangesInBorrowingsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="iva_DisclosureOfChangesInBorrowingsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock" xlink:label="iva_DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="iva_DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory" xlink:label="iva_DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="iva_DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory" xlink:label="iva_DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="iva_DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory" xlink:label="iva_DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="iva_DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:label="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Company information - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember" xlink:label="iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember" xlink:label="iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember" xlink:label="iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember" xlink:label="iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember" xlink:label="iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LicensingAgreementWithHepalysMember" xlink:label="iva_LicensingAgreementWithHepalysMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="iva_LicensingAgreementWithHepalysMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xlink:to="srt_OwnershipAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_HepalysPharmaIncMember" xlink:label="iva_HepalysPharmaIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="iva_HepalysPharmaIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xlink:to="ifrs-full_BorrowingsByNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="iva_FinanceContractWithEuropeanInvestmentBankMember" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_MaximumDurationOfClinicalTrial" xlink:label="iva_MaximumDurationOfClinicalTrial" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_MaximumDurationOfClinicalTrial" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfBiopsiesUnderClinicalTrials" xlink:label="iva_NumberOfBiopsiesUnderClinicalTrials" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_NumberOfBiopsiesUnderClinicalTrials" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfWeeksUnderActiveTreatmentExtensionStudy" xlink:label="iva_NumberOfWeeksUnderActiveTreatmentExtensionStudy" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_NumberOfWeeksUnderActiveTreatmentExtensionStudy" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LicenseAndCollaborationAgreementUpfrontFeeReceivable" xlink:label="iva_LicenseAndCollaborationAgreementUpfrontFeeReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_LicenseAndCollaborationAgreementUpfrontFeeReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones" xlink:label="iva_LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OptionToAcquireSharesInCompanyPercentage" xlink:label="iva_OptionToAcquireSharesInCompanyPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_OptionToAcquireSharesInCompanyPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare" xlink:label="iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfPatientsRandomizedClinicalTrialMainCohort" xlink:label="iva_NumberOfPatientsRandomizedClinicalTrialMainCohort" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_NumberOfPatientsRandomizedClinicalTrialMainCohort" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="ifrs-full_NotionalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy" xlink:label="iva_DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DailyDoseOfLanifibranorInTrial" xlink:label="iva_DailyDoseOfLanifibranorInTrial" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_DailyDoseOfLanifibranorInTrial" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DailyDoseOfEmpagliflozinInTrial" xlink:label="iva_DailyDoseOfEmpagliflozinInTrial" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_DailyDoseOfEmpagliflozinInTrial" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d" xlink:label="iva_DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d" xlink:label="iva_DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff" xlink:label="iva_DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PercentageOfPatientsTreatedInTrial" xlink:label="iva_PercentageOfPatientsTreatedInTrial" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_PercentageOfPatientsTreatedInTrial" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DemonstratedSignificantRelativeReductionInVatSatRatioInPatients" xlink:label="iva_DemonstratedSignificantRelativeReductionInVatSatRatioInPatients" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_DemonstratedSignificantRelativeReductionInVatSatRatioInPatients" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TreatmentPeriodUnderStudy" xlink:label="iva_TreatmentPeriodUnderStudy" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_TreatmentPeriodUnderStudy" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfPatientsRandomizedForTreatment" xlink:label="iva_NumberOfPatientsRandomizedForTreatment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_NumberOfPatientsRandomizedForTreatment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfPatientsToBeTreatedForFortyEightWeeks" xlink:label="iva_NumberOfPatientsToBeTreatedForFortyEightWeeks" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_NumberOfPatientsToBeTreatedForFortyEightWeeks" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfPatientsToBeTreatedForSeventyTwoWeeks" xlink:label="iva_NumberOfPatientsToBeTreatedForSeventyTwoWeeks" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_NumberOfPatientsToBeTreatedForSeventyTwoWeeks" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details" xlink:type="extended" xlink:title="40102 - Disclosure - Company information - Significant events in the first half of 2024 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DrawdownOfBorrowingsMember" xlink:label="iva_DrawdownOfBorrowingsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="iva_DrawdownOfBorrowingsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantAgreementWithEuropeanInvestmentBankMember" xlink:label="iva_WarrantAgreementWithEuropeanInvestmentBankMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="iva_WarrantAgreementWithEuropeanInvestmentBankMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember" xlink:label="iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember" xlink:label="iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xlink:to="ifrs-full_BorrowingsByNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="iva_FinanceContractWithEuropeanInvestmentBankMember" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="iva_FinanceContractWithEuropeanInvestmentBankMember" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfWarrantsIssued" xlink:label="iva_NumberOfWarrantsIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_NumberOfWarrantsIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants" xlink:label="iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised" xlink:label="iva_PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares" xlink:label="iva_ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ClassOfWarrantOrRightMaturityTerm" xlink:label="iva_ClassOfWarrantOrRightMaturityTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_ClassOfWarrantOrRightMaturityTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantsTerm" xlink:label="iva_WarrantsTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_WarrantsTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_SharesIssuableUponExerciseOfWarrants" xlink:label="iva_SharesIssuableUponExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_SharesIssuableUponExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_MaximumGrossProceedsReceivableUponExerciseOfWarrants" xlink:label="iva_MaximumGrossProceedsReceivableUponExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_MaximumGrossProceedsReceivableUponExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="ifrs-full_NotionalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AmountInvoicedToCounterpartyForInitialPayment" xlink:label="iva_AmountInvoicedToCounterpartyForInitialPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_AmountInvoicedToCounterpartyForInitialPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsDebtInstrumentTerm" xlink:label="iva_IfrsDebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_IfrsDebtInstrumentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments" xlink:label="iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction" xlink:label="iva_MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfSitesOperatingUnderCentralIrbOverseeing" xlink:label="iva_NumberOfSitesOperatingUnderCentralIrbOverseeing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_NumberOfSitesOperatingUnderCentralIrbOverseeing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PercentageOfPatientsRandomizedInMainCohort" xlink:label="iva_PercentageOfPatientsRandomizedInMainCohort" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_PercentageOfPatientsRandomizedInMainCohort" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TreatmentPeriodUnderStudy" xlink:label="iva_TreatmentPeriodUnderStudy" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_TreatmentPeriodUnderStudy" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Basis of preparation and statement of compliance - Significant Investments In Subsidiaries (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_InventivaIncMember" xlink:label="iva_InventivaIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="iva_InventivaIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="ifrs-full_EntitysTotalForAssociatesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_EntitysTotalForAssociatesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_HepalysPharmaIncMember" xlink:label="iva_HepalysPharmaIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForAssociatesMember" xlink:to="iva_HepalysPharmaIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfEntitiesBeingConsolidated" xlink:label="iva_NumberOfEntitiesBeingConsolidated" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="iva_NumberOfEntitiesBeingConsolidated" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterests" xlink:label="ifrs-full_NoncontrollingInterests" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_NoncontrollingInterests" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Accounting Principles - Fair value measurement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="ifrs-full_FinancialAssetsCategoryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsCategoryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_FinancialAssetsCategoryMember" xlink:to="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LongTermFinancialDebtDerivativesMember" xlink:label="iva_LongTermFinancialDebtDerivativesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="iva_LongTermFinancialDebtDerivativesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_FinancialLiabilities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Intangible assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xlink:label="ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Property, plant, and equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="ifrs-full_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_ConstructionInProgressMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:label="ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:label="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Property, plant, and equipment - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FibroscanMachinesMember" xlink:label="iva_FibroscanMachinesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="iva_FibroscanMachinesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="ifrs-full_RightofuseAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_RightofuseAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInPropertyPlantAndEquipment" xlink:label="ifrs-full_ChangesInPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_ChangesInPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="ifrs-full_AdditionsToRightofuseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_AdditionsToRightofuseAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreasesInPropertyPlantAndEquipment" xlink:label="iva_IncreasesInPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="iva_IncreasesInPropertyPlantAndEquipment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails" xlink:type="extended" xlink:title="40404 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Investments accounted for using the equity method - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_HepalysPharmaIncMember" xlink:label="iva_HepalysPharmaIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="iva_HepalysPharmaIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OptionToAcquireSharesInCompanyPercentage" xlink:label="iva_OptionToAcquireSharesInCompanyPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="iva_OptionToAcquireSharesInCompanyPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare" xlink:label="iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfSharesAcquiredInAssociate" xlink:label="iva_NumberOfSharesAcquiredInAssociate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="iva_NumberOfSharesAcquiredInAssociate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" xlink:type="extended" xlink:title="40405 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Investments accounted for using the equity method - investment in Hepalys accounted for using equity method of accounting (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_HepalysPharmaIncMember" xlink:label="iva_HepalysPharmaIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="iva_HepalysPharmaIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="ifrs-full_EntitysTotalForAssociatesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_EntitysTotalForAssociatesMember" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForAssociatesMember" xlink:to="iva_HepalysPharmaIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NonCurrentAssetsExcludingDeferredAssets" xlink:label="iva_NonCurrentAssetsExcludingDeferredAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="iva_NonCurrentAssetsExcludingDeferredAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets" xlink:label="ifrs-full_OtherCurrentAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_OtherCurrentAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_CashAndCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CurrentAssetsExcludingDeferredAssets" xlink:label="iva_CurrentAssetsExcludingDeferredAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="iva_CurrentAssetsExcludingDeferredAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DeferredAssets" xlink:label="iva_DeferredAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="iva_DeferredAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_IssuedCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalReserve" xlink:label="ifrs-full_CapitalReserve" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_CapitalReserve" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CapitalSurplusOthers" xlink:label="iva_CapitalSurplusOthers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="iva_CapitalSurplusOthers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod" xlink:label="ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsProfitLossForReportingPeriod" xlink:label="ifrs-full_RetainedEarningsProfitLossForReportingPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_RetainedEarningsProfitLossForReportingPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_TreasuryShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_Equity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_NoncurrentLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_OtherCurrentLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_CurrentLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_EquityAndLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseDecreaseThroughCapitalVariations" xlink:label="iva_IncreaseDecreaseThroughCapitalVariations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="iva_IncreaseDecreaseThroughCapitalVariations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod" xlink:label="iva_EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="iva_EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IntercompanyEliminationsInAssociates" xlink:label="iva_IntercompanyEliminationsInAssociates" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="iva_IntercompanyEliminationsInAssociates" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill" xlink:label="ifrs-full_Goodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_Goodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails" xlink:type="extended" xlink:title="40407 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Other non-current assets - Long-term deposit accounts (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherNonCurrentAssetsTable" xlink:label="iva_OtherNonCurrentAssetsTable" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="iva_OtherNonCurrentAssetsTable" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember" xlink:label="iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherNonCurrentAssetsLineItems" xlink:label="iva_OtherNonCurrentAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="iva_OtherNonCurrentAssetsLineItems" xlink:to="iva_OtherNonCurrentAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseDecreaseInLongTermDepositAccounts" xlink:label="iva_IncreaseDecreaseInLongTermDepositAccounts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="iva_OtherNonCurrentAssetsLineItems" xlink:to="iva_IncreaseDecreaseInLongTermDepositAccounts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermDeposits" xlink:label="ifrs-full_LongtermDeposits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="iva_OtherNonCurrentAssetsLineItems" xlink:to="ifrs-full_LongtermDeposits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LongTermDepositsTerm" xlink:label="iva_LongTermDepositsTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="iva_OtherNonCurrentAssetsLineItems" xlink:to="iva_LongTermDepositsTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NonCurrentAdvancesToSuppliers" xlink:label="iva_NonCurrentAdvancesToSuppliers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="iva_OtherNonCurrentAssetsLineItems" xlink:to="iva_NonCurrentAdvancesToSuppliers" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInventoriesDetails" xlink:type="extended" xlink:title="40408 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Inventories (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ScheduleOfInventoryDisclosureTable" xlink:label="iva_ScheduleOfInventoryDisclosureTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="iva_ScheduleOfInventoryDisclosureTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedImpairmentMember" xlink:label="ifrs-full_AccumulatedImpairmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_AccumulatedImpairmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ScheduleOfInventoryDisclosureLineItems" xlink:label="iva_ScheduleOfInventoryDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="iva_ScheduleOfInventoryDisclosureLineItems" xlink:to="iva_ScheduleOfInventoryDisclosureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="iva_ScheduleOfInventoryDisclosureLineItems" xlink:to="ifrs-full_Inventories" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" xlink:type="extended" xlink:title="40409 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets - Trade Receivables (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable" xlink:label="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable" xlink:to="ifrs-full_MaturityAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanThreeMonthsMember" xlink:label="ifrs-full_NotLaterThanThreeMonthsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanThreeMonthsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems" xlink:label="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems" xlink:to="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" xlink:type="extended" xlink:title="40410 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets- Other Current Assets and Receivables (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable" xlink:label="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LicensingAndCollaborationAgreementWithCttqMember" xlink:label="iva_LicensingAndCollaborationAgreementWithCttqMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="iva_LicensingAndCollaborationAgreementWithCttqMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems" xlink:label="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems" xlink:to="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CirAndOtherResearchTaxCreditsReceivable" xlink:label="iva_CirAndOtherResearchTaxCreditsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems" xlink:to="iva_CirAndOtherResearchTaxCreditsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherCurrentTaxReceivables" xlink:label="iva_OtherCurrentTaxReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems" xlink:to="iva_OtherCurrentTaxReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="ifrs-full_CurrentTaxAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems" xlink:to="ifrs-full_CurrentTaxAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="ifrs-full_CurrentPrepaidExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems" xlink:to="ifrs-full_CurrentPrepaidExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ShortTermDepositAccountsCurrent" xlink:label="iva_ShortTermDepositAccountsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems" xlink:to="iva_ShortTermDepositAccountsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets" xlink:label="ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems" xlink:to="ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CashUnderLiquidityAgreementCurrent" xlink:label="iva_CashUnderLiquidityAgreementCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems" xlink:to="iva_CashUnderLiquidityAgreementCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_SalesTaxReceivableCurrent" xlink:label="iva_SalesTaxReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems" xlink:to="iva_SalesTaxReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems" xlink:to="ifrs-full_OtherCurrentReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets" xlink:label="ifrs-full_OtherCurrentAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems" xlink:to="ifrs-full_OtherCurrentAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherCurrentAssetsAndReceivables" xlink:label="iva_OtherCurrentAssetsAndReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems" xlink:to="iva_OtherCurrentAssetsAndReceivables" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails" xlink:type="extended" xlink:title="40414 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Changes in share capital (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_SharePremiumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_Equity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ParValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_IssueOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails" xlink:type="extended" xlink:title="40416 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Options and share warrants (BSA and BSPCE) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BsaShareWarrantsMember" xlink:label="iva_BsaShareWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="iva_BsaShareWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Bsa20231ShareWarrantPlanMember" xlink:label="iva_Bsa20231ShareWarrantPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="iva_Bsa20231ShareWarrantPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Bsa20232ShareWarrantPlanMember" xlink:label="iva_Bsa20232ShareWarrantPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="iva_Bsa20232ShareWarrantPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DirectorsMember" xlink:label="iva_DirectorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="iva_DirectorsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ServiceProvidersMember" xlink:label="iva_ServiceProvidersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="iva_ServiceProvidersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DavidNikodemMember" xlink:label="iva_DavidNikodemMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="iva_DavidNikodemMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantsSubscriptionPrice" xlink:label="iva_WarrantsSubscriptionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="iva_WarrantsSubscriptionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" xlink:type="extended" xlink:title="40417 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Movements in BSPCE and BSA share warrants (in number of shares issuable upon exercise) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BspceAndBsaShareWarrantsMember" xlink:label="iva_BspceAndBsaShareWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="iva_BspceAndBsaShareWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BspcePlansMember" xlink:label="iva_BspcePlansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="iva_BspceAndBsaShareWarrantsMember" xlink:to="iva_BspcePlansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Bspce2021PlanMember" xlink:label="iva_Bspce2021PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="iva_BspcePlansMember" xlink:to="iva_Bspce2021PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BsaPlansMember" xlink:label="iva_BsaPlansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="iva_BspceAndBsaShareWarrantsMember" xlink:to="iva_BsaPlansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Bsa2017PlanMember" xlink:label="iva_Bsa2017PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="iva_BsaPlansMember" xlink:to="iva_Bsa2017PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Bsa2018PlanMember" xlink:label="iva_Bsa2018PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="iva_BsaPlansMember" xlink:to="iva_Bsa2018PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewShareWarrantPlansBsa2019Member" xlink:label="iva_NewShareWarrantPlansBsa2019Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="iva_BsaPlansMember" xlink:to="iva_NewShareWarrantPlansBsa2019Member" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewShareWarrantPlansBsa2019BisMember" xlink:label="iva_NewShareWarrantPlansBsa2019BisMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="iva_BsaPlansMember" xlink:to="iva_NewShareWarrantPlansBsa2019BisMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewShareWarrantPlansBsa2019TerMember" xlink:label="iva_NewShareWarrantPlansBsa2019TerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="iva_BsaPlansMember" xlink:to="iva_NewShareWarrantPlansBsa2019TerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewBsa2021ShareWarrantPlanMember" xlink:label="iva_NewBsa2021ShareWarrantPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="iva_BsaPlansMember" xlink:to="iva_NewBsa2021ShareWarrantPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Bsa20231ShareWarrantPlanMember" xlink:label="iva_Bsa20231ShareWarrantPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="iva_BsaPlansMember" xlink:to="iva_Bsa20231ShareWarrantPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Bsa20232ShareWarrantPlanMember" xlink:label="iva_Bsa20232ShareWarrantPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="iva_BsaPlansMember" xlink:to="iva_Bsa20232ShareWarrantPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightOutstanding" xlink:label="iva_IfrsClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="iva_IfrsClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails" xlink:type="extended" xlink:title="40418 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Free share awards and Performance units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BonusShareAwardPlansMember" xlink:label="iva_BonusShareAwardPlansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="iva_BonusShareAwardPlansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewBonusShareAwardPlanAga20211Member" xlink:label="iva_NewBonusShareAwardPlanAga20211Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="iva_NewBonusShareAwardPlanAga20211Member" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewBonusShareAwardPlanAga2021BisMember" xlink:label="iva_NewBonusShareAwardPlanAga2021BisMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="iva_NewBonusShareAwardPlanAga2021BisMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewBonusShareAwardPlan20231Member" xlink:label="iva_NewBonusShareAwardPlan20231Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="iva_NewBonusShareAwardPlan20231Member" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewBonusShareAwardPlan20232Member" xlink:label="iva_NewBonusShareAwardPlan20232Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="iva_NewBonusShareAwardPlan20232Member" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LongTermIncentivePlanInPerformanceUnitsMember" xlink:label="iva_LongTermIncentivePlanInPerformanceUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="iva_LongTermIncentivePlanInPerformanceUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LongTermIncentivePlanInPerformanceUnits2023Member" xlink:label="iva_LongTermIncentivePlanInPerformanceUnits2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="iva_LongTermIncentivePlanInPerformanceUnits2023Member" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Aga2021Aga2021BisMember" xlink:label="iva_Aga2021Aga2021BisMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="iva_Aga2021Aga2021BisMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FredericCrenMember" xlink:label="iva_FredericCrenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="iva_FredericCrenMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfPlansOutstanding" xlink:label="iva_NumberOfPlansOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="iva_NumberOfPlansOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfAwardPlansAttributed" xlink:label="iva_NumberOfAwardPlansAttributed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="iva_NumberOfAwardPlansAttributed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageSharePrice2019" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfSharesConverted" xlink:label="iva_NumberOfSharesConverted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="iva_NumberOfSharesConverted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" xlink:type="extended" xlink:title="40421 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - French state-guaranteed loan (&quot;PGE&quot;) and equity recovery loans (&quot;PPR&quot;) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LicensingAndCollaborationAgreementWithCttqMember" xlink:label="iva_LicensingAndCollaborationAgreementWithCttqMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="iva_LicensingAndCollaborationAgreementWithCttqMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_BorrowingsByNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LoanAgreementsWithSyndicateOfFrenchBanksMember" xlink:label="iva_LoanAgreementsWithSyndicateOfFrenchBanksMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="iva_LoanAgreementsWithSyndicateOfFrenchBanksMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember" xlink:label="iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="iva_LoanAgreementsWithSyndicateOfFrenchBanksMember" xlink:to="iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember" xlink:label="iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="iva_LoanAgreementsWithSyndicateOfFrenchBanksMember" xlink:to="iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_EquityRecoveryLoansMember" xlink:label="iva_EquityRecoveryLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="iva_EquityRecoveryLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinancingFromSyndicateOfFrenchBanksMember" xlink:label="iva_FinancingFromSyndicateOfFrenchBanksMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="iva_FinancingFromSyndicateOfFrenchBanksMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfLoansObtainedGuaranteedByFrenchState" xlink:label="iva_NumberOfLoansObtainedGuaranteedByFrenchState" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_NumberOfLoansObtainedGuaranteedByFrenchState" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AmountInvoicedToCounterpartyForInitialPayment" xlink:label="iva_AmountInvoicedToCounterpartyForInitialPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_AmountInvoicedToCounterpartyForInitialPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BorrowingsMaximumExtensionTerm" xlink:label="iva_BorrowingsMaximumExtensionTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_BorrowingsMaximumExtensionTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfLoanAgreements" xlink:label="iva_NumberOfLoanAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_NumberOfLoanAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_NotionalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PercentageOfLoanGuaranteedByFrenchState" xlink:label="iva_PercentageOfLoanGuaranteedByFrenchState" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_PercentageOfLoanGuaranteedByFrenchState" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinancingPeriodOfLoan" xlink:label="iva_FinancingPeriodOfLoan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_FinancingPeriodOfLoan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_RepaymentPeriodOfLoan" xlink:label="iva_RepaymentPeriodOfLoan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_RepaymentPeriodOfLoan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" xlink:type="extended" xlink:title="40422 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Credit facility agreement with the European Investment Bank (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_BorrowingsByNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="iva_FinanceContractWithEuropeanInvestmentBankMember" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="iva_FinanceContractWithEuropeanInvestmentBankMember" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_NotionalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfEqualTranches" xlink:label="iva_NumberOfEqualTranches" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_NumberOfEqualTranches" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotionalAmountPerTranche" xlink:label="iva_NotionalAmountPerTranche" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_NotionalAmountPerTranche" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsDebtInstrumentTerm" xlink:label="iva_IfrsDebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_IfrsDebtInstrumentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_Borrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BorrowingsEffectiveInterestRate" xlink:label="iva_BorrowingsEffectiveInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_BorrowingsEffectiveInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BorrowingsActualizationRate" xlink:label="iva_BorrowingsActualizationRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_BorrowingsActualizationRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingCostsIncurred" xlink:label="ifrs-full_BorrowingCostsIncurred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_BorrowingCostsIncurred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestCostsCapitalised" xlink:label="ifrs-full_InterestCostsCapitalised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_InterestCostsCapitalised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" xlink:type="extended" xlink:title="40423 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Derivatives (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantAgreementWithEuropeanInvestmentBankMember" xlink:label="iva_WarrantAgreementWithEuropeanInvestmentBankMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="iva_WarrantAgreementWithEuropeanInvestmentBankMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LongTermFinancialDebtDerivativesMember" xlink:label="iva_LongTermFinancialDebtDerivativesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="iva_LongTermFinancialDebtDerivativesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Bsa2022Member" xlink:label="iva_Bsa2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="iva_Bsa2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Bsa2024Member" xlink:label="iva_Bsa2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="iva_Bsa2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_BorrowingsByNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantsSubscriptionPrice" xlink:label="iva_WarrantsSubscriptionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_WarrantsSubscriptionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ClassOfWarrantOrRightGranted" xlink:label="iva_ClassOfWarrantOrRightGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_ClassOfWarrantOrRightGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants" xlink:label="iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_MaximumPotentialGrossProceedsFromExerciseOfWarrants" xlink:label="iva_MaximumPotentialGrossProceedsFromExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_MaximumPotentialGrossProceedsFromExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TransactionCostsOnIssueOfWarrants" xlink:label="iva_TransactionCostsOnIssueOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_TransactionCostsOnIssueOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantsThresholdTradingDays" xlink:label="iva_WarrantsThresholdTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_WarrantsThresholdTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted" xlink:label="iva_SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightOutstanding" xlink:label="iva_IfrsClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_IfrsClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantsStockPrice" xlink:label="iva_WarrantsStockPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_WarrantsStockPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantAverageLife" xlink:label="iva_WarrantAverageLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_WarrantAverageLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ExpectedVolatility" xlink:label="iva_ExpectedVolatility" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_ExpectedVolatility" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantsCapOfPutOption" xlink:label="iva_WarrantsCapOfPutOption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_WarrantsCapOfPutOption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FairValueOfWarrantsOutstanding" xlink:label="iva_FairValueOfWarrantsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_FairValueOfWarrantsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantsUnitFairValue" xlink:label="iva_WarrantsUnitFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_WarrantsUnitFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued" xlink:label="iva_TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ClassOfWarrantOrRightMaturityTerm" xlink:label="iva_ClassOfWarrantOrRightMaturityTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_ClassOfWarrantOrRightMaturityTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfSharesPerOtherEquityInstrumentGranted" xlink:label="iva_NumberOfSharesPerOtherEquityInstrumentGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_NumberOfSharesPerOtherEquityInstrumentGranted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="40424 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Lease liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_BorrowingsByNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="ifrs-full_LeaseLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="ifrs-full_LeaseLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FibroscanMachinesMember" xlink:label="iva_FibroscanMachinesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="iva_FibroscanMachinesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_LeaseLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseDecreaseInLeaseLiabilities" xlink:label="iva_IncreaseDecreaseInLeaseLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_IncreaseDecreaseInLeaseLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="ifrs-full_AdditionsToRightofuseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_AdditionsToRightofuseAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LeaseTerm" xlink:label="iva_LeaseTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_LeaseTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" xlink:type="extended" xlink:title="40425 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Maturity of long-term debt and of short-term borrowings and debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_MaturityAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanFiveYearsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanFiveYearsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LoansReceived" xlink:label="ifrs-full_LoansReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_LoansReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_NoncurrentDerivativeFinancialLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherBorrowings" xlink:label="ifrs-full_OtherBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_OtherBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_LeaseLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued" xlink:label="iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_Borrowings" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails" xlink:type="extended" xlink:title="40426 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Royalty Certificates liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember" xlink:label="ifrs-full_LiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_LiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_RoyaltyCertificateLiabilitiesMember" xlink:label="iva_RoyaltyCertificateLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_LiabilitiesMember" xlink:to="iva_RoyaltyCertificateLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="ifrs-full_UnobservableInputsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_UnobservableInputsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="ifrs-full_UnobservableInputsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_UnobservableInputsAxis" xlink:to="ifrs-full_UnobservableInputsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DiscountRateMeasurementInputMember" xlink:label="ifrs-full_DiscountRateMeasurementInputMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_UnobservableInputsMember" xlink:to="ifrs-full_DiscountRateMeasurementInputMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_BorrowingsByNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_RoyaltyCertificatesLiabilitiesMember" xlink:label="iva_RoyaltyCertificatesLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="iva_RoyaltyCertificatesLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor" xlink:label="iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_FinancialLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_RoyaltyCertificatesEffectiveInterestRate" xlink:label="iva_RoyaltyCertificatesEffectiveInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="iva_RoyaltyCertificatesEffectiveInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantUnobservableInputLiabilities" xlink:label="ifrs-full_SignificantUnobservableInputLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_SignificantUnobservableInputLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_Borrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_NotionalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails" xlink:type="extended" xlink:title="40431 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Other current and non-current liabilities - Additional information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradePayableAndOtherCurrentLiabilitiesTable" xlink:label="iva_TradePayableAndOtherCurrentLiabilitiesTable" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="iva_TradePayableAndOtherCurrentLiabilitiesTable" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LicensingAndCollaborationAgreementWithCttqMember" xlink:label="iva_LicensingAndCollaborationAgreementWithCttqMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="iva_LicensingAndCollaborationAgreementWithCttqMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradePayableAndOtherCurrentLiabilitiesLineItems" xlink:label="iva_TradePayableAndOtherCurrentLiabilitiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="iva_TradePayableAndOtherCurrentLiabilitiesLineItems" xlink:to="iva_TradePayableAndOtherCurrentLiabilitiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="ifrs-full_OtherNoncurrentLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="iva_TradePayableAndOtherCurrentLiabilitiesLineItems" xlink:to="ifrs-full_OtherNoncurrentLiabilities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails" xlink:type="extended" xlink:title="40433 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade payables break down (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradePayableAndOtherCurrentLiabilitiesTable" xlink:label="iva_TradePayableAndOtherCurrentLiabilitiesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="iva_TradePayableAndOtherCurrentLiabilitiesTable" xlink:to="ifrs-full_MaturityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneMonthMember" xlink:label="ifrs-full_NotLaterThanOneMonthMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneMonthMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember" xlink:label="ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LaterThanTwoMonthsMember" xlink:label="iva_LaterThanTwoMonthsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="iva_LaterThanTwoMonthsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradePayableAndOtherCurrentLiabilitiesLineItems" xlink:label="iva_TradePayableAndOtherCurrentLiabilitiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="iva_TradePayableAndOtherCurrentLiabilitiesLineItems" xlink:to="iva_TradePayableAndOtherCurrentLiabilitiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="iva_TradePayableAndOtherCurrentLiabilitiesLineItems" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseDecreaseInTradeAccountsPayable" xlink:label="iva_IncreaseDecreaseInTradeAccountsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="iva_TradePayableAndOtherCurrentLiabilitiesLineItems" xlink:to="iva_IncreaseDecreaseInTradeAccountsPayable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="40434 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial assets and liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember" xlink:label="ifrs-full_FinancialAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LongTermDepositAccountsMember" xlink:label="iva_LongTermDepositAccountsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="iva_LongTermDepositAccountsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LongTermSecurityDepositsMember" xlink:label="iva_LongTermSecurityDepositsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="iva_LongTermSecurityDepositsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AdvancePaymentMember" xlink:label="iva_AdvancePaymentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="iva_AdvancePaymentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AccruedIncomeMember" xlink:label="iva_AccruedIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="iva_AccruedIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ShortTermDepositAccountsMember" xlink:label="iva_ShortTermDepositAccountsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="iva_ShortTermDepositAccountsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeReceivablesMember" xlink:label="ifrs-full_TradeReceivablesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="ifrs-full_TradeReceivablesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherReceivablesMember" xlink:label="iva_OtherReceivablesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="iva_OtherReceivablesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCashAndCashEquivalentsMember" xlink:label="iva_IfrsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="iva_IfrsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="ifrs-full_FinancialAssetsCategoryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsCategoryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_FinancialAssetsCategoryMember" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_FinancialAssetsCategoryMember" xlink:to="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowingsMember" xlink:label="ifrs-full_LongtermBorrowingsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="ifrs-full_LongtermBorrowingsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DerivativeInstrumentsMember" xlink:label="iva_DerivativeInstrumentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="iva_DerivativeInstrumentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_RoyaltyCertificatesLiabilitiesMember" xlink:label="iva_RoyaltyCertificatesLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="iva_RoyaltyCertificatesLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermBorrowingsMember" xlink:label="ifrs-full_ShorttermBorrowingsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="ifrs-full_ShorttermBorrowingsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradePayablesMember" xlink:label="iva_TradePayablesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="iva_TradePayablesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherMiscellaneousPayablesMember" xlink:label="iva_OtherMiscellaneousPayablesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="iva_OtherMiscellaneousPayablesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_FinancialAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_FinancialLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="ifrs-full_FinancialAssetsAtFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_FinancialAssetsAtFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Narratives (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:label="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LicensingAndCollaborationAgreementWithCttqMember" xlink:label="iva_LicensingAndCollaborationAgreementWithCttqMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="iva_LicensingAndCollaborationAgreementWithCttqMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ServiceContractWithAvantSanteMember" xlink:label="iva_ServiceContractWithAvantSanteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="iva_ServiceContractWithAvantSanteMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_InventivaIncMember" xlink:label="iva_InventivaIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="iva_InventivaIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:label="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ProceedsFromLicensingArrangements" xlink:label="iva_ProceedsFromLicensingArrangements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="iva_ProceedsFromLicensingArrangements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CurrentTaxCreditResearchCurrentYear" xlink:label="iva_CurrentTaxCreditResearchCurrentYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="iva_CurrentTaxCreditResearchCurrentYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement" xlink:label="iva_OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="iva_OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement" xlink:label="iva_OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="iva_OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CirAndOtherResearchTaxCreditsReceivable" xlink:label="iva_CirAndOtherResearchTaxCreditsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="iva_CirAndOtherResearchTaxCreditsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Operating expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:label="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="ifrs-full_LineItemsByFunctionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_LineItemsByFunctionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsResearchAndDevelopmentExpenseMember" xlink:label="iva_IfrsResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_LineItemsByFunctionMember" xlink:to="iva_IfrsResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsSalesAndMarketingExpenseMember" xlink:label="iva_IfrsSalesAndMarketingExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_LineItemsByFunctionMember" xlink:to="iva_IfrsSalesAndMarketingExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsGeneralAndAdministrativeExpenseMember" xlink:label="iva_IfrsGeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_LineItemsByFunctionMember" xlink:to="iva_IfrsGeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:label="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Disposables" xlink:label="iva_Disposables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="iva_Disposables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_EnergyAndLiquids" xlink:label="iva_EnergyAndLiquids" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="iva_EnergyAndLiquids" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Patents" xlink:label="iva_Patents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="iva_Patents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Studies" xlink:label="iva_Studies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="iva_Studies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepairsAndMaintenanceExpense" xlink:label="ifrs-full_RepairsAndMaintenanceExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="ifrs-full_RepairsAndMaintenanceExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Fees" xlink:label="iva_Fees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="iva_Fees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ItSystems" xlink:label="iva_ItSystems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="iva_ItSystems" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_SupportCosts" xlink:label="iva_SupportCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="iva_SupportCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="ifrs-full_EmployeeBenefitsExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DepreciationAmortizationAndProvisions" xlink:label="iva_DepreciationAmortizationAndProvisions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="iva_DepreciationAmortizationAndProvisions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InsuranceExpense" xlink:label="ifrs-full_InsuranceExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="ifrs-full_InsuranceExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherOperatingExpenses" xlink:label="iva_OtherOperatingExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="iva_OtherOperatingExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OperatingExpenseExcludingOtherOperatingIncomeExpense" xlink:label="iva_OperatingExpenseExcludingOtherOperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="iva_OperatingExpenseExcludingOtherOperatingIncomeExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails" xlink:type="extended" xlink:title="40504 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Operating expenses - Personnel costs and headcount (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:label="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="ifrs-full_LineItemsByFunctionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_LineItemsByFunctionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsResearchAndDevelopmentExpenseMember" xlink:label="iva_IfrsResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_LineItemsByFunctionMember" xlink:to="iva_IfrsResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsSalesAndMarketingExpenseMember" xlink:label="iva_IfrsSalesAndMarketingExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_LineItemsByFunctionMember" xlink:to="iva_IfrsSalesAndMarketingExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsGeneralAndAdministrativeExpenseMember" xlink:label="iva_IfrsGeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_LineItemsByFunctionMember" xlink:to="iva_IfrsGeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_InventivaS.aMember" xlink:label="iva_InventivaS.aMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="iva_InventivaS.aMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_InventivaIncMember" xlink:label="iva_InventivaIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_EntityDomain" xlink:to="iva_InventivaIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:label="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfEmployees" xlink:label="ifrs-full_NumberOfEmployees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="ifrs-full_NumberOfEmployees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WagesAndSalaries" xlink:label="ifrs-full_WagesAndSalaries" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="ifrs-full_WagesAndSalaries" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PayrollTaxes" xlink:label="iva_PayrollTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="iva_PayrollTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss" xlink:label="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="ifrs-full_EmployeeBenefitsExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails" xlink:type="extended" xlink:title="40507 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Share of net profit - Equity method (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_HepalysPharmaIncMember" xlink:label="iva_HepalysPharmaIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="iva_HepalysPharmaIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="ifrs-full_EntitysTotalForAssociatesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_EntitysTotalForAssociatesMember" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForAssociatesMember" xlink:to="iva_HepalysPharmaIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_FinanceIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_FinanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_FinanceIncomeCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_ComprehensiveIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations" xlink:label="iva_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="iva_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_EliminationOfDownstreamSales" xlink:label="iva_EliminationOfDownstreamSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="iva_EliminationOfDownstreamSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Other financial information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="ifrs-full_EntitysTotalForAssociatesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_EntitysTotalForAssociatesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ClinicalTrialsMember" xlink:label="iva_ClinicalTrialsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForAssociatesMember" xlink:to="iva_ClinicalTrialsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ContractManufacturingOrganizationsMember" xlink:label="iva_ContractManufacturingOrganizationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EntitysTotalForAssociatesMember" xlink:to="iva_ContractManufacturingOrganizationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="ifrs-full_LeaseLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_EntitysTotalForAssociatesMember" xlink:to="ifrs-full_LeaseLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherContingentLiabilitiesMember" xlink:label="ifrs-full_OtherContingentLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_EntitysTotalForAssociatesMember" xlink:to="ifrs-full_OtherContingentLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PharmaceuticalResearchAssociatesMember" xlink:label="iva_PharmaceuticalResearchAssociatesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_EntitysTotalForAssociatesMember" xlink:to="iva_PharmaceuticalResearchAssociatesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ChiaTaiTianqingMember" xlink:label="iva_ChiaTaiTianqingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_EntitysTotalForAssociatesMember" xlink:to="iva_ChiaTaiTianqingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ContractCroWithResearchAssociatesGroupeB.vMember" xlink:label="iva_ContractCroWithResearchAssociatesGroupeB.vMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="iva_ContractCroWithResearchAssociatesGroupeB.vMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractualCapitalCommitments" xlink:label="ifrs-full_ContractualCapitalCommitments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_ContractualCapitalCommitments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AgreementsConcerningProvisionOfFacilities" xlink:label="iva_AgreementsConcerningProvisionOfFacilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="iva_AgreementsConcerningProvisionOfFacilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ContractualCapitalCommitmentReceived" xlink:label="iva_ContractualCapitalCommitmentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="iva_ContractualCapitalCommitmentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CommitmentsAmountPayableForServicesReceivedUnderContract" xlink:label="iva_CommitmentsAmountPayableForServicesReceivedUnderContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="iva_CommitmentsAmountPayableForServicesReceivedUnderContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CommitmentContractualBonusOrMalusCappedAmount" xlink:label="iva_CommitmentContractualBonusOrMalusCappedAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="iva_CommitmentContractualBonusOrMalusCappedAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Other financial information - Events after the reporting date (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsotherFinancialInformationTable" xlink:label="iva_IfrsotherFinancialInformationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="iva_IfrsotherFinancialInformationTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember" xlink:label="iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PresentationOfResultsFromStudyMember" xlink:label="iva_PresentationOfResultsFromStudyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="iva_PresentationOfResultsFromStudyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IssuanceOfRoyaltyCertificatesMember" xlink:label="iva_IssuanceOfRoyaltyCertificatesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="iva_IssuanceOfRoyaltyCertificatesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinancingAgreementInThreePhasesMember" xlink:label="iva_FinancingAgreementInThreePhasesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="iva_FinancingAgreementInThreePhasesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember" xlink:label="iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="iva_FinancingAgreementInThreePhasesMember" xlink:to="iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember" xlink:label="iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="iva_FinancingAgreementInThreePhasesMember" xlink:to="iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember" xlink:label="iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="iva_FinancingAgreementInThreePhasesMember" xlink:to="iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinancingThroughFundRaisingMember" xlink:label="iva_FinancingThroughFundRaisingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="iva_FinancingThroughFundRaisingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="iva_IfrsotherFinancialInformationTable" xlink:to="ifrs-full_BorrowingsByNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="iva_IfrsotherFinancialInformationTable" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember" xlink:label="iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LicensingAndCollaborationAgreementWithCttqMember" xlink:label="iva_LicensingAndCollaborationAgreementWithCttqMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="iva_LicensingAndCollaborationAgreementWithCttqMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantAgreementWithEuropeanInvestmentBankMember" xlink:label="iva_WarrantAgreementWithEuropeanInvestmentBankMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="iva_WarrantAgreementWithEuropeanInvestmentBankMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="iva_IfrsotherFinancialInformationTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ScenarioOneMember" xlink:label="iva_ScenarioOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="iva_ScenarioOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ScenarioTwoMember" xlink:label="iva_ScenarioTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="iva_ScenarioTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ScenarioThreeMember" xlink:label="iva_ScenarioThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="iva_ScenarioThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsotherFinancialInformationLineItems" xlink:label="iva_IfrsotherFinancialInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="iva_IfrsotherFinancialInformationLineItems" xlink:to="iva_IfrsotherFinancialInformationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PercentageOfPatientsInTrialEnrolledInMainCohort" xlink:label="iva_PercentageOfPatientsInTrialEnrolledInMainCohort" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="iva_IfrsotherFinancialInformationLineItems" xlink:to="iva_PercentageOfPatientsInTrialEnrolledInMainCohort" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PercentageOfPatientsInTrialEnrolledInExploratoryCohort" xlink:label="iva_PercentageOfPatientsInTrialEnrolledInExploratoryCohort" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="iva_IfrsotherFinancialInformationLineItems" xlink:to="iva_PercentageOfPatientsInTrialEnrolledInExploratoryCohort" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfRoyaltyCertificatesIssued" xlink:label="iva_NumberOfRoyaltyCertificatesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="iva_IfrsotherFinancialInformationLineItems" xlink:to="iva_NumberOfRoyaltyCertificatesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ProceedsFromFinancing" xlink:label="iva_ProceedsFromFinancing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="iva_IfrsotherFinancialInformationLineItems" xlink:to="iva_ProceedsFromFinancing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor" xlink:label="iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="iva_IfrsotherFinancialInformationLineItems" xlink:to="iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_MaximumDurationOfClinicalTrial" xlink:label="iva_MaximumDurationOfClinicalTrial" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="iva_IfrsotherFinancialInformationLineItems" xlink:to="iva_MaximumDurationOfClinicalTrial" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfEqualTranches" xlink:label="iva_NumberOfEqualTranches" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="iva_IfrsotherFinancialInformationLineItems" xlink:to="iva_NumberOfEqualTranches" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany" xlink:label="iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="iva_IfrsotherFinancialInformationLineItems" xlink:to="iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_StockIssuedDuringPeriodValue" xlink:label="iva_StockIssuedDuringPeriodValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="iva_IfrsotherFinancialInformationLineItems" xlink:to="iva_StockIssuedDuringPeriodValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_StockIssuedDuringPeriodShares" xlink:label="iva_StockIssuedDuringPeriodShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="iva_IfrsotherFinancialInformationLineItems" xlink:to="iva_StockIssuedDuringPeriodShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="iva_IfrsotherFinancialInformationLineItems" xlink:to="ifrs-full_ParValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ClassOfWarrantOrRightGranted" xlink:label="iva_ClassOfWarrantOrRightGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="iva_IfrsotherFinancialInformationLineItems" xlink:to="iva_ClassOfWarrantOrRightGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="iva_IfrsotherFinancialInformationLineItems" xlink:to="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="iva_IfrsotherFinancialInformationLineItems" xlink:to="iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="iva_IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="iva_IfrsotherFinancialInformationLineItems" xlink:to="iva_IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_MinimumAmountCommittedForFundRaising" xlink:label="iva_MinimumAmountCommittedForFundRaising" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="iva_IfrsotherFinancialInformationLineItems" xlink:to="iva_MinimumAmountCommittedForFundRaising" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ProceedsFromLicensingArrangements" xlink:label="iva_ProceedsFromLicensingArrangements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="iva_IfrsotherFinancialInformationLineItems" xlink:to="iva_ProceedsFromLicensingArrangements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PeriodWithinWhichPaymentIsReceivedFromSettlement" xlink:label="iva_PeriodWithinWhichPaymentIsReceivedFromSettlement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="iva_IfrsotherFinancialInformationLineItems" xlink:to="iva_PeriodWithinWhichPaymentIsReceivedFromSettlement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="iva_IfrsotherFinancialInformationLineItems" xlink:to="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>iva-20240630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/15/2024 9:52:36 AM-->
<!--Modified on: 10/15/2024 9:52:36 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unaudited interim condensed consolidated statement of financial position</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncurrent assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:label="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:to="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment including right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets" xlink:label="ifrs-full_DeferredTaxAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxAssets" xlink:to="ifrs-full_DeferredTaxAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DeferredTaxAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments accounted for using equity method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments accounted for using the equity method</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other noncurrent assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Inventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Inventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other current receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="ifrs-full_CurrentTaxAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxAssetsCurrent" xlink:to="ifrs-full_CurrentTaxAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current tax assets, current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTaxAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentTaxAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets" xlink:label="ifrs-full_OtherCurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash and cash equivalents at the end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity and liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremium" xlink:label="ifrs-full_SharePremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Premiums related to share capital</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares" xlink:label="iva_RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares" xlink:to="iva_RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A component of equity representing retained earnings excluding profit (loss) for the reporting period, and treasury shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained earnings excluding profit (loss) for the reporting period and treasury shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reserves</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reserve of exchange differences on translation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Translation reserve</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsProfitLossForReportingPeriod" xlink:label="ifrs-full_RetainedEarningsProfitLossForReportingPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsProfitLossForReportingPeriod" xlink:to="ifrs-full_RetainedEarningsProfitLossForReportingPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsProfitLossForReportingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained earnings, profit (loss) for reporting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarningsProfitLossForReportingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss for the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncurrent liabilities</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities" xlink:label="iva_NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities" xlink:to="iva_NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current portion of non-current borrowings and non-current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current portion of non-current borrowings and non-current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:to="ifrs-full_NoncurrentDerivativeFinancialLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current derivative financial liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivatives instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt - derivatives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivatives</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued" xlink:label="iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued" xlink:to="iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The non-current portion of non-current royalty certificates issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current Portion of Non-current Royalty Certificates Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty certificates liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:label="ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:to="ifrs-full_NoncurrentProvisionsForEmployeeBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentProvisionsForEmployeeBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current provisions for employee benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentProvisionsForEmployeeBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisions for retirement benefit obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentContractLiabilities" xlink:to="ifrs-full_NoncurrentContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term contract liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="ifrs-full_OtherNoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentLiabilities" xlink:to="ifrs-full_OtherNoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities" xlink:label="iva_CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities" xlink:to="iva_CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current borrowings and current portion of non-current borrowings and current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current borrowings and current portion of non-current borrowings and current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shortterm debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade payables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentContractLiabilities" xlink:to="ifrs-full_CurrentContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term contract liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity and liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total equity and liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total equity and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unaudited interim condensed consolidated statement of income (loss)</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_RevenueAndOperatingIncomeAbstract" xlink:label="iva_RevenueAndOperatingIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_RevenueAndOperatingIncomeAbstract" xlink:to="iva_RevenueAndOperatingIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_RevenueAndOperatingIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_RevenueAndOperatingIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue And Operating Income [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_RevenueAndOperatingIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues and other income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenue</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherIncomeFromOrdinaryActivities" xlink:label="iva_OtherIncomeFromOrdinaryActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_OtherIncomeFromOrdinaryActivities" xlink:to="iva_OtherIncomeFromOrdinaryActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_OtherIncomeFromOrdinaryActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of other income from ordinary activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_OtherIncomeFromOrdinaryActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income from ordinary activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_OtherIncomeFromOrdinaryActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="iva_OtherIncomeFromOrdinaryActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueAndOperatingIncome" xlink:label="ifrs-full_RevenueAndOperatingIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAndOperatingIncome" xlink:to="ifrs-full_RevenueAndOperatingIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueAndOperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue and other operating income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_RevenueAndOperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues and other income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="ifrs-full_SalesAndMarketingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales and marketing expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketing - Business development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense" xlink:label="ifrs-full_OtherOperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherOperatingIncomeExpense" xlink:to="ifrs-full_OtherOperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherOperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other operating income (expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherOperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other operating income (expenses)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherOperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other operating income and expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss) from operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total financial income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total financial expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceIncomeCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncomeCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance income (cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceIncomeCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net financial income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_FinanceIncomeCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net financial income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share of profit (loss) of associates accounted for using equity method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share of net profit - Equity method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share of net loss - Equity method</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss for the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic earnings (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted earnings (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of ordinary shares used in calculating basic earnings per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of shares outstanding used to calculate basic loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjusted weighted average number of ordinary shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of shares outstanding used to calculate diluted loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unaudited interim condensed consolidated statement of comprehensive (income) loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income that will be reclassified to profit or loss, net of tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Items that will be reclassified subsequently to profit or loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Items that will be reclassified subsequently to profit or loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share of other comprehensive income of associates and joint ventures accounted for using equity method that will be reclassified to profit or loss, net of tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency translation differences - equity method</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income, net of tax, exchange differences on translation of foreign operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency translation differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exchange difference on translation of foreign operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income that will not be reclassified to profit or loss, net of tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Items that will not be reclassified subsequently to profit or loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Items that will not be reclassified subsequently to profit or loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remeasurement of defined benefit plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unaudited interim condensed consolidated statement of changes in shareholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of equity [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremiumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Premiums related to share capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember" xlink:label="ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember" xlink:to="ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained earnings, profit (loss) for reporting period [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net profit (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reserve of exchange differences on translation [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Translation reserves</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember" xlink:label="iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember" xlink:to="iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represent a component of equity consisting of retained earnings excluding the current reporting period, and treasury shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained earnings excluding profit (loss) from current reporting period and treasury shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reserves</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of fully authorized, subscribed and paid up shares</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod" xlink:label="iva_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod" xlink:to="iva_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income, net of tax, exchange differences on translation of foreign operations including effects of translation of investments accounted for using equity method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income, net of tax, exchange differences on translation of foreign operations including effects of translation of investments accounted for using equity method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency translation differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings" xlink:label="ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings" xlink:to="ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through appropriation of retained earnings, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Appropriation of net income (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through share-based payment transactions, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment compensation expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital increase arising from the vesting of bonus share awards</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseDecreaseThroughShareWarrantsSubscriptionPremium" xlink:label="iva_IncreaseDecreaseThroughShareWarrantsSubscriptionPremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IncreaseDecreaseThroughShareWarrantsSubscriptionPremium" xlink:to="iva_IncreaseDecreaseThroughShareWarrantsSubscriptionPremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IncreaseDecreaseThroughShareWarrantsSubscriptionPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase decrease in reserves resulting from BSA share warrants subscription premium.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IncreaseDecreaseThroughShareWarrantsSubscriptionPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) Through Share Warrants Subscription Premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IncreaseDecreaseThroughShareWarrantsSubscriptionPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BSA share warrants subscription premium</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through treasury share transactions, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through other changes, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unaudited interim condensed consolidated statement of cash flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) operating activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile profit (loss) [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Elimination of non-cash or non-operating income and expenses</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AdjustmentsForDepreciationAmortisationAndProvisions" xlink:label="iva_AdjustmentsForDepreciationAmortisationAndProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_AdjustmentsForDepreciationAmortisationAndProvisions" xlink:to="iva_AdjustmentsForDepreciationAmortisationAndProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_AdjustmentsForDepreciationAmortisationAndProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for depreciation, amortisation expense and provisions to reconcile profit (loss) to net cash flow from (used in) operating activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_AdjustmentsForDepreciationAmortisationAndProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for Depreciation, Amortisation and Provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_AdjustmentsForDepreciationAmortisationAndProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, amortization and provisions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:label="ifrs-full_AdjustmentsForIncomeTaxExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:to="ifrs-full_AdjustmentsForIncomeTaxExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncomeTaxExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncomeTaxExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred and current taxes</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AdjustmentsForTaxCredits" xlink:label="iva_AdjustmentsForTaxCredits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_AdjustmentsForTaxCredits" xlink:to="iva_AdjustmentsForTaxCredits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_AdjustmentsForTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for tax credit to reconcile profit (loss) to net cash flow from (used in) operating activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_AdjustmentsForTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments For Tax Credits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_AdjustmentsForTaxCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for finance income (cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for share-based payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sharebased compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUndistributedProfitsOfAssociates" xlink:label="ifrs-full_AdjustmentsForUndistributedProfitsOfAssociates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForUndistributedProfitsOfAssociates" xlink:to="ifrs-full_AdjustmentsForUndistributedProfitsOfAssociates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForUndistributedProfitsOfAssociates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for undistributed profits of associates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForUndistributedProfitsOfAssociates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share of net profit of associates and joint ventures accounted for using the equity method</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for unrealised foreign exchange losses (gains)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exchange (gains) / losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:label="ifrs-full_AdjustmentsForFairValueGainsLosses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:to="ifrs-full_AdjustmentsForFairValueGainsLosses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForFairValueGainsLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for fair value losses (gains)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForFairValueGainsLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value variation through profit and loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAdjustmentsForNoncashItems" xlink:label="ifrs-full_OtherAdjustmentsForNoncashItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAdjustmentsForNoncashItems" xlink:to="ifrs-full_OtherAdjustmentsForNoncashItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherAdjustmentsForNoncashItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other adjustments for non-cash items</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherAdjustmentsForNoncashItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:label="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows used in operations before tax, interest and changes in working capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows used in operations before tax, interest and changes in working capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for decrease (increase) in trade and other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease / (increase) in operating and other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for increase (decrease) in trade and other payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase / (decrease) in operating and other payables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for decrease (increase) in inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease / (increase) in inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes paid (refund), classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:label="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:to="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other inflows (outflows) of cash, classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:to="ifrs-full_IncreaseDecreaseInWorkingCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in working capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax, interest and changes in operating working capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) investing activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows used in investing activities</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="iva_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="iva_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Of Property Plant And Equipment And Intangible Assets Classified As Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Of Property Plant And Equipment And Intangible Assets Classified As Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iva_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property, plant and equipment and intangible assets</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="iva_ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="iva_ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from the disposal of property, plant and equipment and intangible assets, classified as investing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Sales Of Property Plant And Equipment And Intangible Assets Classified As Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposals of property, plant and equipment and intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) decrease (increase) in short-term deposits and investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease / (Increase) in short-term deposit accounts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:label="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:to="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other inflows (outflows) of cash, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase / (Decrease) in other non-current financial assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash from (used in) investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) financing activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows used in financing activities</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NetProceedsFromIssuingShares" xlink:label="iva_NetProceedsFromIssuingShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NetProceedsFromIssuingShares" xlink:to="iva_NetProceedsFromIssuingShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NetProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of net proceeds from issuing shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NetProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Proceeds From Issuing Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_NetProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital increase net of transaction cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from borrowings, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subscription of borrowings and warrants net of transaction cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan obtained</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of borrowings, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of borrowings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of lease liabilities, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash from (used in) financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase (decrease) in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rate changes on cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exchange gains / (losses)</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CompanyInformationAbstract" xlink:label="iva_CompanyInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_CompanyInformationAbstract" xlink:to="iva_CompanyInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_CompanyInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_CompanyInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Company information</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CompanyInformationTextBlock" xlink:label="iva_CompanyInformationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_CompanyInformationTextBlock" xlink:to="iva_CompanyInformationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_CompanyInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure on company information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_CompanyInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Company Information [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_CompanyInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Company information</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_StatementOfComplianceAbstract" xlink:label="iva_StatementOfComplianceAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_StatementOfComplianceAbstract" xlink:to="iva_StatementOfComplianceAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_StatementOfComplianceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_StatementOfComplianceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of preparation and statement of compliance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfIFRSCompliance" xlink:label="ifrs-full_StatementOfIFRSCompliance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfIFRSCompliance" xlink:to="ifrs-full_StatementOfIFRSCompliance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfIFRSCompliance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of IFRS compliance [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_StatementOfIFRSCompliance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of preparation and statement of compliance</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AccountingPrinciplesAbstract" xlink:label="iva_AccountingPrinciplesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_AccountingPrinciplesAbstract" xlink:to="iva_AccountingPrinciplesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_AccountingPrinciplesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_AccountingPrinciplesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Principles</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:to="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of material accounting policy information [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting principles</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:to="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes to the interim condensed consolidated statement of financial position</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock" xlink:label="iva_DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock" xlink:to="iva_DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for notes to the interim consolidated balance sheet.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Notes to the Interim Condensed Consolidated Statement of Financial Position [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes to the interim condensed consolidated statement of financial position</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ComponentsOfIncomeStatementAbstract" xlink:label="iva_ComponentsOfIncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ComponentsOfIncomeStatementAbstract" xlink:to="iva_ComponentsOfIncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ComponentsOfIncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ComponentsOfIncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes to the interim condensed consolidated statement of (income) loss</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfComponentsOfIncomeStatementTextBlock" xlink:label="iva_DisclosureOfComponentsOfIncomeStatementTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DisclosureOfComponentsOfIncomeStatementTextBlock" xlink:to="iva_DisclosureOfComponentsOfIncomeStatementTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DisclosureOfComponentsOfIncomeStatementTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for components of income statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DisclosureOfComponentsOfIncomeStatementTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Components Of Income Statement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_DisclosureOfComponentsOfIncomeStatementTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes to the interim condensed consolidated statement of (income) loss</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherFinancialInformationAbstract" xlink:label="iva_OtherFinancialInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_OtherFinancialInformationAbstract" xlink:to="iva_OtherFinancialInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_OtherFinancialInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_OtherFinancialInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other financial information</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfOtherFinancialInformationTextblock" xlink:label="iva_DisclosureOfOtherFinancialInformationTextblock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DisclosureOfOtherFinancialInformationTextblock" xlink:to="iva_DisclosureOfOtherFinancialInformationTextblock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DisclosureOfOtherFinancialInformationTextblock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for other financial information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DisclosureOfOtherFinancialInformationTextblock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Other Financial Information [TextBlock]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_DisclosureOfOtherFinancialInformationTextblock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other financial information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting judgements and estimates [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of estimates and judgment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for fair value measurement [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value measurement</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock" xlink:label="iva_DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock" xlink:to="iva_DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Specific disclosure requirements for unaudited interim financial statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description Of Accounting Policy For Specific Disclosure Requirements For Unaudited Interim Financial Statements [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Specific disclosure requirements for unaudited interim financial statements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGoingConcernExplanatory" xlink:label="ifrs-full_DisclosureOfGoingConcernExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGoingConcernExplanatory" xlink:to="ifrs-full_DisclosureOfGoingConcernExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGoingConcernExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of going concern [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGoingConcernExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Going concern</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory" xlink:label="ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory" xlink:to="ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of interests in subsidiaries [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of subsidiaries</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:label="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:to="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of effect of changes in foreign exchange rates [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of exchange rates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of fair value of financial instruments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of financial assets and liabilities measured at fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of terms and conditions of share-based payment arrangement [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of share-based payment arrangements [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sharebased compensation expense</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BspceAndBsaShareWarrantsMember" xlink:label="iva_BspceAndBsaShareWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_BspceAndBsaShareWarrantsMember" xlink:to="iva_BspceAndBsaShareWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_BspceAndBsaShareWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for BSPCE and BSA share warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_BspceAndBsaShareWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BSPCE and BSA Share Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_BspceAndBsaShareWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BSPCE share warrants and BSA share warrants</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewBonusShareAwardPlan20231Member" xlink:label="iva_NewBonusShareAwardPlan20231Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NewBonusShareAwardPlan20231Member" xlink:to="iva_NewBonusShareAwardPlan20231Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NewBonusShareAwardPlan20231Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for New bonus share award plans (AGA 2023-1).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NewBonusShareAwardPlan20231Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Bonus Share Award Plan 2023-1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_NewBonusShareAwardPlan20231Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AGA Plan 2023-1</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LongTermIncentivePlanInPerformanceUnits2023Member" xlink:label="iva_LongTermIncentivePlanInPerformanceUnits2023Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_LongTermIncentivePlanInPerformanceUnits2023Member" xlink:to="iva_LongTermIncentivePlanInPerformanceUnits2023Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_LongTermIncentivePlanInPerformanceUnits2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for 2023 long-term incentive plan in performance units or "PAGUP 2023".</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_LongTermIncentivePlanInPerformanceUnits2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Incentive Plan In Performance Units, 2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_LongTermIncentivePlanInPerformanceUnits2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PAGUP 2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of terms and conditions of share-based payment arrangement [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes to the interim condensed consolidated statement of financial position</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about intangible assets [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about property, plant and equipment [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory" xlink:label="ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory" xlink:to="ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of reconciliation of summarised financial information of associate accounted for using equity method to carrying amount of interest in associate [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of investment in Hepalys is accounted for using the equity method of accounting</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xlink:label="iva_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xlink:to="iva_DisclosureOfOtherNoncurrentAssetsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DisclosureOfOtherNoncurrentAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of other non current assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DisclosureOfOtherNoncurrentAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Other Noncurrent Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_DisclosureOfOtherNoncurrentAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of other non current assets</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsScheduleOfInventoryCurrentTableTextBlock" xlink:label="iva_IfrsScheduleOfInventoryCurrentTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IfrsScheduleOfInventoryCurrentTableTextBlock" xlink:to="iva_IfrsScheduleOfInventoryCurrentTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IfrsScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IfrsScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IfrsScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of inventories</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfTradeReceivablesTableTextBlock" xlink:label="iva_DisclosureOfTradeReceivablesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DisclosureOfTradeReceivablesTableTextBlock" xlink:to="iva_DisclosureOfTradeReceivablesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DisclosureOfTradeReceivablesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of trade receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DisclosureOfTradeReceivablesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Trade Receivables [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_DisclosureOfTradeReceivablesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of trade receivables and others break down</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of other current assets [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of other current assets and receivables</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfCashAndCashEquivalentsTableTextBlock" xlink:label="iva_DisclosureOfCashAndCashEquivalentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DisclosureOfCashAndCashEquivalentsTableTextBlock" xlink:to="iva_DisclosureOfCashAndCashEquivalentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DisclosureOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of cash and cash equivalents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DisclosureOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Cash And Cash Equivalents [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_DisclosureOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of classes of share capital [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of changes in share capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of movements in BSPCE and BSA share warrants and Bonus shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about borrowings [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of debt</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfChangesInBorrowingsTableTextBlock" xlink:label="iva_DisclosureOfChangesInBorrowingsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DisclosureOfChangesInBorrowingsTableTextBlock" xlink:to="iva_DisclosureOfChangesInBorrowingsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DisclosureOfChangesInBorrowingsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of changes in borrowings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DisclosureOfChangesInBorrowingsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Changes In Borrowings [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_DisclosureOfChangesInBorrowingsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of movements in the period break down</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock" xlink:label="iva_DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock" xlink:to="iva_DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of valuation approach for BSA share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of valuation approach for BSA share-based payment arrangement [table text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of valuation approach for BSA arrangement</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory" xlink:label="iva_DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory" xlink:to="iva_DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The disclosure of detailed information about provision recorded in respect of defined benefit schemes at the end of each reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Provision Recorded In Respect Of Defined Benefit Schemes At End Of Each Reporting Period, Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of provision recorded in respect of defined benefit schemes at the end of each reporting period</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory" xlink:label="iva_DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory" xlink:to="iva_DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The disclosure of detailed information about change in the provision recorded in respect of defined benefit schemes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Changes In Provision Recorded In Respect Of Defined Benefit Schemes, Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of change in the provision recorded in respect of defined benefit schemes</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory" xlink:label="iva_DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory" xlink:to="iva_DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The disclosure of detailed information about expense recognized in the statement of income (loss) for Retirement Benefit Obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Expenses Recognized In Statement Of Income (Loss) For Retirement Benefit Obligations, Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of expense recognized in the statement of income (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:label="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:to="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of maturity analysis for non-derivative financial liabilities [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of maturity of long-term and short-term debt</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure for trade payables and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Trade Payables and Other Current Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of trade payables and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of trade and other payables [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of trade payables break down by payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of other current liabilities [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about financial instruments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of financial assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_RevenueAndOtherIncomeTableTextBlock" xlink:label="iva_RevenueAndOtherIncomeTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_RevenueAndOtherIncomeTableTextBlock" xlink:to="iva_RevenueAndOtherIncomeTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_RevenueAndOtherIncomeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of revenue and other income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_RevenueAndOtherIncomeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue and Other Income [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_RevenueAndOtherIncomeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of revenues and other income</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ResearchAndDevelopmentMarketingTableTextBlock" xlink:label="iva_ResearchAndDevelopmentMarketingTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ResearchAndDevelopmentMarketingTableTextBlock" xlink:to="iva_ResearchAndDevelopmentMarketingTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ResearchAndDevelopmentMarketingTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of Research and Development, Marketing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ResearchAndDevelopmentMarketingTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development, Marketing [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_ResearchAndDevelopmentMarketingTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of research and development, marketing</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PersonnelCostsAndHeadcount" xlink:label="iva_PersonnelCostsAndHeadcount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_PersonnelCostsAndHeadcount" xlink:to="iva_PersonnelCostsAndHeadcount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_PersonnelCostsAndHeadcount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel costs and headcount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_PersonnelCostsAndHeadcount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel costs and headcount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_PersonnelCostsAndHeadcount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of personnel costs and headcount</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock" xlink:label="iva_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock" xlink:to="iva_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of other operating income (expense).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Other Operating Income Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of other operating income and expenses</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinancialIncomeAndExpensesTableTextBlock" xlink:label="iva_FinancialIncomeAndExpensesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_FinancialIncomeAndExpensesTableTextBlock" xlink:to="iva_FinancialIncomeAndExpensesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_FinancialIncomeAndExpensesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of financial income and expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_FinancialIncomeAndExpensesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Income and Expenses [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_FinancialIncomeAndExpensesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of financial income and expenses</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock" xlink:label="iva_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock" xlink:to="iva_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of share of profit loss of associates and joint ventures accounted for using equity method investments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method Investments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of share of net profit - Equity method</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="ifrs-full_EarningsPerShareExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings per share [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of basic and diluted loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of contingent liabilities [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of commitments given and received</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember" xlink:label="iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember" xlink:to="iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for the Phase II clinical trial evaluating lanifibranor in patients with T2D and nonalcoholic fatty liver disease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Phase II clinical trial evaluating lanifibranor in patients with T2D and nonalcoholic fatty liver disease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Phase II clinical trial evaluating lanifibranor in patients with T2D and nonalcoholic fatty liver disease</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember" xlink:label="iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember" xlink:to="iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to the LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Combination of lanifibranor</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember" xlink:label="iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember" xlink:to="iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for phase II clinical trial evaluating placebo in patients with MASH/NASH and T2D.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Phase II Clinical Trial Evaluating Placebo In Patients With MASH/NASH And T2D [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Phase II Clinical Trial Evaluating Placebo In Patients With MASH/NASH And T2D</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember" xlink:label="iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember" xlink:to="iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for NATiV3 Phase III clinical trial with lanifibranor in patients with
MASH/NASH.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NATiV3 Phase III Clinical Trial With Lanifibranor In Patients With MASH/NASH [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NATiV3 Phase III clinical trial</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_RangesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ranges [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-adjusting events after reporting period [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="ifrs-full_NonadjustingEventsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-adjusting events after reporting period [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NonadjustingEventsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-adjusting events after reporting period [member]</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember" xlink:label="iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember" xlink:to="iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for indication of continuation of recruitment for Phase III trial NATiV3 of lanifibranor in non-cirrhotic NASH.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indication Of Continuation Of Recruitment For Phase Iii Trial Nativ3 Of Lanifibranor In Non-Cirrhotic NashASH [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indication of continuation of recruitment for Phase III trial NATiV3 of lanifibranor in non-cirrhotic NASH</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LicensingAgreementWithHepalysMember" xlink:label="iva_LicensingAgreementWithHepalysMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_LicensingAgreementWithHepalysMember" xlink:to="iva_LicensingAgreementWithHepalysMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_LicensingAgreementWithHepalysMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Licensing agreement with Hepalys.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_LicensingAgreementWithHepalysMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing Agreement With Hepalys [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_LicensingAgreementWithHepalysMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing agreement with Hepalys</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership [Domain]</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_HepalysPharmaIncMember" xlink:label="iva_HepalysPharmaIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_HepalysPharmaIncMember" xlink:to="iva_HepalysPharmaIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_HepalysPharmaIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Hepalys Pharma, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_HepalysPharmaIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hepalys Pharma, Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_HepalysPharmaIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hepalys Pharma, Inc</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsByNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings by name [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="ifrs-full_BorrowingsByNameMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsByNameMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings by name [member]</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_FinanceContractWithEuropeanInvestmentBankMember" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for the Finance contract with the European Investment Bank</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance contract with European Investment Bank [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance contract with EIB</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to first tranche of the finance contract with European Investment Bank ("EIB").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Contract With European Investment Bank, First Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance contract with EIB, first tranche (Tranche A)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance contract with EIB, Tranche A</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to second tranche of the finance contract with European investment bank ("EIB").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Contract With European Investment Bank, Second Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance contract with EIB, second tranche (Tranche B)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance contract with EIB, Tranche B</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Collaborative Arrangement And Arrangement Other Than Collaborative [Line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangements</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_MaximumDurationOfClinicalTrial" xlink:label="iva_MaximumDurationOfClinicalTrial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_MaximumDurationOfClinicalTrial" xlink:to="iva_MaximumDurationOfClinicalTrial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_MaximumDurationOfClinicalTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum duration of the clinical trial of the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_MaximumDurationOfClinicalTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Duration Of The Clinical Trial</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_MaximumDurationOfClinicalTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum duration of Phase III trial</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfBiopsiesUnderClinicalTrials" xlink:label="iva_NumberOfBiopsiesUnderClinicalTrials" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NumberOfBiopsiesUnderClinicalTrials" xlink:to="iva_NumberOfBiopsiesUnderClinicalTrials_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NumberOfBiopsiesUnderClinicalTrials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">It represents the  number of clinical trial.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NumberOfBiopsiesUnderClinicalTrials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Biopsies Under Clinical Trials</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_NumberOfBiopsiesUnderClinicalTrials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Biopsies Under the Phase III trial</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfWeeksUnderActiveTreatmentExtensionStudy" xlink:label="iva_NumberOfWeeksUnderActiveTreatmentExtensionStudy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NumberOfWeeksUnderActiveTreatmentExtensionStudy" xlink:to="iva_NumberOfWeeksUnderActiveTreatmentExtensionStudy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NumberOfWeeksUnderActiveTreatmentExtensionStudy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of weeks under the active treatment extension study of the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NumberOfWeeksUnderActiveTreatmentExtensionStudy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Weeks Under The Active Treatment Extension Study</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_NumberOfWeeksUnderActiveTreatmentExtensionStudy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of weeks under the active treatment extension study</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LicenseAndCollaborationAgreementUpfrontFeeReceivable" xlink:label="iva_LicenseAndCollaborationAgreementUpfrontFeeReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_LicenseAndCollaborationAgreementUpfrontFeeReceivable" xlink:to="iva_LicenseAndCollaborationAgreementUpfrontFeeReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_LicenseAndCollaborationAgreementUpfrontFeeReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of upfront fee receivable by the entity, pursuant to licensing and collaborative arrangements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_LicenseAndCollaborationAgreementUpfrontFeeReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License And Collaboration Agreement Upfront Fee Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_LicenseAndCollaborationAgreementUpfrontFeeReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront payment receivable</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones" xlink:label="iva_LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones" xlink:to="iva_LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum additional amount receivable by the entity, upon the achievement of certain milestones, pursuant to licensing and collaborative arrangements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License And Collaboration Agreement, Maximum Additional Amount Receivable Upon Achievement Of Certain Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum milestone payments receivable</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OptionToAcquireSharesInCompanyPercentage" xlink:label="iva_OptionToAcquireSharesInCompanyPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_OptionToAcquireSharesInCompanyPercentage" xlink:to="iva_OptionToAcquireSharesInCompanyPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_OptionToAcquireSharesInCompanyPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option to acquire shares in company, percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_OptionToAcquireSharesInCompanyPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option to acquire shares in company, percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_OptionToAcquireSharesInCompanyPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_OptionToAcquireSharesInCompanyPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option to acquire shares in company, percentage</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare" xlink:label="iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare" xlink:to="iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of interests in investments accounted for using equity method, price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of interests in investments accounted for using equity method, price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of interests in investments accounted for using equity method, price per share</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares underlying in EIB</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfPatientsRandomizedClinicalTrialMainCohort" xlink:label="iva_NumberOfPatientsRandomizedClinicalTrialMainCohort" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NumberOfPatientsRandomizedClinicalTrialMainCohort" xlink:to="iva_NumberOfPatientsRandomizedClinicalTrialMainCohort_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NumberOfPatientsRandomizedClinicalTrialMainCohort_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of subjects randomized for main cohort.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NumberOfPatientsRandomizedClinicalTrialMainCohort_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Patients Randomized, Clinical Trial, Main Cohort</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_NumberOfPatientsRandomizedClinicalTrialMainCohort_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of patients in main cohort</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotionalAmount" xlink:to="ifrs-full_NotionalAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotionalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notional Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NotionalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notional amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NotionalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total amount of loan</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy" xlink:label="iva_DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy" xlink:to="iva_DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Demonstrated reduction of hepatic fat measured by proton magnetic resonance spectroscopy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Demonstrated reduction of hepatic fat measured by proton magnetic resonance spectroscopy</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DailyDoseOfLanifibranorInTrial" xlink:label="iva_DailyDoseOfLanifibranorInTrial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DailyDoseOfLanifibranorInTrial" xlink:to="iva_DailyDoseOfLanifibranorInTrial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DailyDoseOfLanifibranorInTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Daily dose of lanifibranor in trial</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DailyDoseOfLanifibranorInTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Daily dose of lanifibranor in trial</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DailyDoseOfEmpagliflozinInTrial" xlink:label="iva_DailyDoseOfEmpagliflozinInTrial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DailyDoseOfEmpagliflozinInTrial" xlink:to="iva_DailyDoseOfEmpagliflozinInTrial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DailyDoseOfEmpagliflozinInTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of daily dosage of empagliflozin in the trial.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DailyDoseOfEmpagliflozinInTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Daily Dose Of Empagliflozin In Trial</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_DailyDoseOfEmpagliflozinInTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Daily dose of empagliflozin in trial</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d" xlink:label="iva_DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d" xlink:to="iva_DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of reduction in Hemoglobin among  patients with MASH and T2D.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Demonstrated Reduction of Hemoglobin in Patients With MASH And T2D</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage reduction in results on treatments</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d" xlink:label="iva_DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d" xlink:to="iva_DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of increase of Hemoglobin in patients with MASH and T2D.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Demonstrated Increase of Hemoglobin in Patients With MASH And T2D</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of increase observed in the placebo arm</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff" xlink:label="iva_DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff" xlink:to="iva_DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of reduction in Hepatic Steatosis measured by MRI-PDFF.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Demonstrated Reduction Of Hepatic Steatosis Measured By MRI-PDFF</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction in hepatic steatosis (in percent)</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PercentageOfPatientsTreatedInTrial" xlink:label="iva_PercentageOfPatientsTreatedInTrial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_PercentageOfPatientsTreatedInTrial" xlink:to="iva_PercentageOfPatientsTreatedInTrial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_PercentageOfPatientsTreatedInTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of patients treated in this trial.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_PercentageOfPatientsTreatedInTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Patients Treated in The Trial</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_PercentageOfPatientsTreatedInTrial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of patients treated in trial</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DemonstratedSignificantRelativeReductionInVatSatRatioInPatients" xlink:label="iva_DemonstratedSignificantRelativeReductionInVatSatRatioInPatients" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DemonstratedSignificantRelativeReductionInVatSatRatioInPatients" xlink:to="iva_DemonstratedSignificantRelativeReductionInVatSatRatioInPatients_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DemonstratedSignificantRelativeReductionInVatSatRatioInPatients_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of significant relative reduction in VAT / SAT ratio in patients.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DemonstratedSignificantRelativeReductionInVatSatRatioInPatients_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Demonstrated Significant Relative Reduction in VAT/SAT Ratio in Patients</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_DemonstratedSignificantRelativeReductionInVatSatRatioInPatients_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant relative reduction in VAT/SAT ratio (in percent)</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TreatmentPeriodUnderStudy" xlink:label="iva_TreatmentPeriodUnderStudy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_TreatmentPeriodUnderStudy" xlink:to="iva_TreatmentPeriodUnderStudy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_TreatmentPeriodUnderStudy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treatment period under study</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_TreatmentPeriodUnderStudy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treatment period under study</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfPatientsRandomizedForTreatment" xlink:label="iva_NumberOfPatientsRandomizedForTreatment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NumberOfPatientsRandomizedForTreatment" xlink:to="iva_NumberOfPatientsRandomizedForTreatment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NumberOfPatientsRandomizedForTreatment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of patients randomized for treatment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NumberOfPatientsRandomizedForTreatment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Patients Randomized For Treatment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_NumberOfPatientsRandomizedForTreatment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of patients randomized</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfPatientsToBeTreatedForFortyEightWeeks" xlink:label="iva_NumberOfPatientsToBeTreatedForFortyEightWeeks" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NumberOfPatientsToBeTreatedForFortyEightWeeks" xlink:to="iva_NumberOfPatientsToBeTreatedForFortyEightWeeks_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NumberOfPatientsToBeTreatedForFortyEightWeeks_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of patients to be treated for 48 weeks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NumberOfPatientsToBeTreatedForFortyEightWeeks_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Patients to Be Treated For Forty Eight Weeks</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_NumberOfPatientsToBeTreatedForFortyEightWeeks_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of patients to be treated for 48 weeks</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfPatientsToBeTreatedForSeventyTwoWeeks" xlink:label="iva_NumberOfPatientsToBeTreatedForSeventyTwoWeeks" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NumberOfPatientsToBeTreatedForSeventyTwoWeeks" xlink:to="iva_NumberOfPatientsToBeTreatedForSeventyTwoWeeks_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NumberOfPatientsToBeTreatedForSeventyTwoWeeks_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of patients to be treated for 72 weeks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NumberOfPatientsToBeTreatedForSeventyTwoWeeks_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Patients to Be Treated For Seventy Two Weeks</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_NumberOfPatientsToBeTreatedForSeventyTwoWeeks_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of patients to be treated for 72 weeks</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DrawdownOfBorrowingsMember" xlink:label="iva_DrawdownOfBorrowingsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DrawdownOfBorrowingsMember" xlink:to="iva_DrawdownOfBorrowingsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DrawdownOfBorrowingsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for drawdown of borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DrawdownOfBorrowingsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Drawdown of borrowings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_DrawdownOfBorrowingsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Drawdown of borrowings</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantAgreementWithEuropeanInvestmentBankMember" xlink:label="iva_WarrantAgreementWithEuropeanInvestmentBankMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_WarrantAgreementWithEuropeanInvestmentBankMember" xlink:to="iva_WarrantAgreementWithEuropeanInvestmentBankMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_WarrantAgreementWithEuropeanInvestmentBankMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Warrant agreement with the European Investment Bank.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_WarrantAgreementWithEuropeanInvestmentBankMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Agreement With The European Investment Bank [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_WarrantAgreementWithEuropeanInvestmentBankMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant agreement with the European Investment Bank</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember" xlink:label="iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember" xlink:to="iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to the NATiV3 Phase III trial of lanifibranor in non-cirrhotic NASH</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NATiV3 Phase III trial of lanifibranor in non-cirrhotic NASH [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NATiV3 Phase III trial of lanifibranor in non-cirrhotic NASH</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Categories of financial liabilities [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities, category [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities at amortised cost, class [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities at amortized cost</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfWarrantsIssued" xlink:label="iva_NumberOfWarrantsIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NumberOfWarrantsIssued" xlink:to="iva_NumberOfWarrantsIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NumberOfWarrantsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NumberOfWarrantsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_NumberOfWarrantsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants issued</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants" xlink:label="iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants" xlink:to="iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Company's share capital outstanding, issued as warrants by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Company's Share Capital Outstanding, Issued As Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of company's share capital outstanding, issued as warrants</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised" xlink:label="iva_PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised" xlink:to="iva_PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of share capital held by counterparty if all outstanding warrants are exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of share capital held by counterparty if all outstanding warrants are exercised</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price per share or per unit of warrants or rights outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of warrant</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares" xlink:label="iva_ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares" xlink:to="iva_ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of warrants issued, represented as a percentage of volume-weighted average price of the Company's shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Exercise Price Of Warrants As A Percentage Of Volume-Weighted Average Price Of The Company's Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of warrants as a percentage of volume-weighted average price of the Company's shares</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ClassOfWarrantOrRightMaturityTerm" xlink:label="iva_ClassOfWarrantOrRightMaturityTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ClassOfWarrantOrRightMaturityTerm" xlink:to="iva_ClassOfWarrantOrRightMaturityTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ClassOfWarrantOrRightMaturityTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturity term of the warrants issued by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ClassOfWarrantOrRightMaturityTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right, Maturity Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_ClassOfWarrantOrRightMaturityTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturity term of warrants</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantsTerm" xlink:label="iva_WarrantsTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_WarrantsTerm" xlink:to="iva_WarrantsTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_WarrantsTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_WarrantsTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_WarrantsTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of warrants</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_SharesIssuableUponExerciseOfWarrants" xlink:label="iva_SharesIssuableUponExerciseOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_SharesIssuableUponExerciseOfWarrants" xlink:to="iva_SharesIssuableUponExerciseOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_SharesIssuableUponExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issuable upon exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_SharesIssuableUponExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issuable Upon Exercise of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_SharesIssuableUponExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issuable upon exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_MaximumGrossProceedsReceivableUponExerciseOfWarrants" xlink:label="iva_MaximumGrossProceedsReceivableUponExerciseOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_MaximumGrossProceedsReceivableUponExerciseOfWarrants" xlink:to="iva_MaximumGrossProceedsReceivableUponExerciseOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_MaximumGrossProceedsReceivableUponExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum gross proceeds from receivable upon exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_MaximumGrossProceedsReceivableUponExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Gross Proceeds Receivable upon Exercise of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_MaximumGrossProceedsReceivableUponExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum gross proceeds</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AmountInvoicedToCounterpartyForInitialPayment" xlink:label="iva_AmountInvoicedToCounterpartyForInitialPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_AmountInvoicedToCounterpartyForInitialPayment" xlink:to="iva_AmountInvoicedToCounterpartyForInitialPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_AmountInvoicedToCounterpartyForInitialPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This amount represents the information of invoiced to counterparty for initial payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_AmountInvoicedToCounterpartyForInitialPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount Invoiced To Counterparty For Initial Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_AmountInvoicedToCounterpartyForInitialPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount invoiced to counterparty for milestone payment</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares per warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares per instrument</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings, interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsDebtInstrumentTerm" xlink:label="iva_IfrsDebtInstrumentTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IfrsDebtInstrumentTerm" xlink:to="iva_IfrsDebtInstrumentTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IfrsDebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IfrsDebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Debt Instrument, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_IfrsDebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturity term after the disbursement of the tranche</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments" xlink:label="iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments" xlink:to="iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate amount to be received by the company, either in exchange for new shares of the Company or through the receipt of upfront or milestone payments, pursuant to the debt arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Amount To Be Received Either In Exchange For New Shares Of The Company Or Through The Receipt Of Upfront Or Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate amount to be received under the conditions precedent to the EIB Financing</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction" xlink:label="iva_MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction" xlink:to="iva_MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of minimum upfront payments for out-licensing, partnership or royalty transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Upfront Payments For Out-Licensing, Partnership Or Royalty Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum upfront payments for out-licensing, partnership or royalty transaction</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfSitesOperatingUnderCentralIrbOverseeing" xlink:label="iva_NumberOfSitesOperatingUnderCentralIrbOverseeing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NumberOfSitesOperatingUnderCentralIrbOverseeing" xlink:to="iva_NumberOfSitesOperatingUnderCentralIrbOverseeing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NumberOfSitesOperatingUnderCentralIrbOverseeing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of sites operating under central IRB overseeing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NumberOfSitesOperatingUnderCentralIrbOverseeing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of sites operating under central IRB overseeing</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PercentageOfPatientsRandomizedInMainCohort" xlink:label="iva_PercentageOfPatientsRandomizedInMainCohort" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_PercentageOfPatientsRandomizedInMainCohort" xlink:to="iva_PercentageOfPatientsRandomizedInMainCohort_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_PercentageOfPatientsRandomizedInMainCohort_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of patients randomized in the main cohort</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_PercentageOfPatientsRandomizedInMainCohort_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of patients randomized in the main cohort</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of subsidiaries [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiaries [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's total for subsidiaries [member]</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_InventivaIncMember" xlink:label="iva_InventivaIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_InventivaIncMember" xlink:to="iva_InventivaIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_InventivaIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Inventiva Inc, U.S. affiliate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_InventivaIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventiva Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_InventivaIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventiva Inc.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Associates [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="ifrs-full_EntitysTotalForAssociatesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForAssociatesMember" xlink:to="ifrs-full_EntitysTotalForAssociatesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForAssociatesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's total for associates [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of subsidiaries [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General principles and statement of compliance</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfEntitiesBeingConsolidated" xlink:label="iva_NumberOfEntitiesBeingConsolidated" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NumberOfEntitiesBeingConsolidated" xlink:to="iva_NumberOfEntitiesBeingConsolidated_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NumberOfEntitiesBeingConsolidated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of entities being consolidated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NumberOfEntitiesBeingConsolidated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of entities being consolidated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_NumberOfEntitiesBeingConsolidated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of entities being consolidated</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proportion of ownership interest in subsidiary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of ownership interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterests" xlink:label="ifrs-full_NoncontrollingInterests" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncontrollingInterests" xlink:to="ifrs-full_NoncontrollingInterests_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncontrollingInterests_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-controlling interests</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncontrollingInterests_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-controlling interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proportion of ownership interest in associate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Group's share in %</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proportion of ownership interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignExchangeRatesAbstract" xlink:label="ifrs-full_ForeignExchangeRatesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ForeignExchangeRatesAbstract" xlink:to="ifrs-full_ForeignExchangeRatesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ForeignExchangeRatesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exchange rate (USD per EUR)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageForeignExchangeRate" xlink:label="ifrs-full_AverageForeignExchangeRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AverageForeignExchangeRate" xlink:to="ifrs-full_AverageForeignExchangeRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AverageForeignExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average foreign exchange rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AverageForeignExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average exchange rate for the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="ifrs-full_ClosingForeignExchangeRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClosingForeignExchangeRate" xlink:to="ifrs-full_ClosingForeignExchangeRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClosingForeignExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing foreign exchange rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ClosingForeignExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exchange rate at period end</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about financial instruments [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Levels of fair value hierarchy [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">All levels of fair value hierarchy [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Categories of financial assets [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="ifrs-full_FinancialAssetsCategoryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsCategoryMember" xlink:to="ifrs-full_FinancialAssetsCategoryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsCategoryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets, category [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:to="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets carried at fair value through profit or loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets carried at fair value through profit or loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities at fair value through profit or loss, category [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities carried at fair value through profit or loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of financial liabilities [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="ifrs-full_FinancialLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities, class [member]</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LongTermFinancialDebtDerivativesMember" xlink:label="iva_LongTermFinancialDebtDerivativesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_LongTermFinancialDebtDerivativesMember" xlink:to="iva_LongTermFinancialDebtDerivativesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_LongTermFinancialDebtDerivativesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Long-term financial debt, derivatives.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_LongTermFinancialDebtDerivativesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivatives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_LongTermFinancialDebtDerivativesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term financial debt - derivatives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about financial instruments [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency forwards contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:label="ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:to="ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bank overdrafts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bank overdrafts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bank overdrafts inclusive of cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about intangible assets [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_CarryingAmountMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CarryingAmountMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying amount [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossCarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GrossCarryingAmountMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GrossCarryingAmountMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated depreciation, amortisation and impairment [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and impairment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about intangible assets [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xlink:label="ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xlink:to="ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of changes in intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about property, plant and equipment [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of property, plant and equipment [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="ifrs-full_ConstructionInProgressMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ConstructionInProgressMember" xlink:to="ifrs-full_ConstructionInProgressMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment in progress</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about property, plant and equipment [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:label="ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of changes in property, plant and equipment [abstract]</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FibroscanMachinesMember" xlink:label="iva_FibroscanMachinesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_FibroscanMachinesMember" xlink:to="iva_FibroscanMachinesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_FibroscanMachinesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for fibroscan machines.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_FibroscanMachinesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fibroscan machines</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="ifrs-full_RightofuseAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssetsMember" xlink:to="ifrs-full_RightofuseAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RightofuseAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right of use</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInPropertyPlantAndEquipment" xlink:label="ifrs-full_ChangesInPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ChangesInPropertyPlantAndEquipment" xlink:to="ifrs-full_ChangesInPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ChangesInPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ChangesInPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in net value of property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="ifrs-full_AdditionsToRightofuseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsToRightofuseAssets" xlink:to="ifrs-full_AdditionsToRightofuseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsToRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions To Right of use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsToRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions to right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreasesInPropertyPlantAndEquipment" xlink:label="iva_IncreasesInPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IncreasesInPropertyPlantAndEquipment" xlink:to="iva_IncreasesInPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IncreasesInPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of increases in property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IncreasesInPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increases in property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IncreasesInPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of associates [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other financial information [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments accounted for using the equity method</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfSharesAcquiredInAssociate" xlink:label="iva_NumberOfSharesAcquiredInAssociate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NumberOfSharesAcquiredInAssociate" xlink:to="iva_NumberOfSharesAcquiredInAssociate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NumberOfSharesAcquiredInAssociate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares acquired in associate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NumberOfSharesAcquiredInAssociate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares acquired in associate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_NumberOfSharesAcquiredInAssociate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares acquired in associate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuing shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital increase</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NonCurrentAssetsExcludingDeferredAssets" xlink:label="iva_NonCurrentAssetsExcludingDeferredAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NonCurrentAssetsExcludingDeferredAssets" xlink:to="iva_NonCurrentAssetsExcludingDeferredAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NonCurrentAssetsExcludingDeferredAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets excluding deferred assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NonCurrentAssetsExcludingDeferredAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets excluding deferred assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="iva_NonCurrentAssetsExcludingDeferredAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current assets</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CurrentAssetsExcludingDeferredAssets" xlink:label="iva_CurrentAssetsExcludingDeferredAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_CurrentAssetsExcludingDeferredAssets" xlink:to="iva_CurrentAssetsExcludingDeferredAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_CurrentAssetsExcludingDeferredAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets excluding deferred assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_CurrentAssetsExcludingDeferredAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets excluding deferred assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="iva_CurrentAssetsExcludingDeferredAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DeferredAssets" xlink:label="iva_DeferredAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DeferredAssets" xlink:to="iva_DeferredAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DeferredAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DeferredAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalReserve" xlink:label="ifrs-full_CapitalReserve" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalReserve" xlink:to="ifrs-full_CapitalReserve_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CapitalReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CapitalReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital reserve</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CapitalSurplusOthers" xlink:label="iva_CapitalSurplusOthers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_CapitalSurplusOthers" xlink:to="iva_CapitalSurplusOthers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_CapitalSurplusOthers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A component of equity representing the capital surplus-others.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_CapitalSurplusOthers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Surplus Others</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_CapitalSurplusOthers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital surplus-others</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod" xlink:label="ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod" xlink:to="ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained earnings, excluding profit (loss) for reporting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings brought forward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TreasuryShares" xlink:to="ifrs-full_TreasuryShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_TreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseDecreaseThroughCapitalVariations" xlink:label="iva_IncreaseDecreaseThroughCapitalVariations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IncreaseDecreaseThroughCapitalVariations" xlink:to="iva_IncreaseDecreaseThroughCapitalVariations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IncreaseDecreaseThroughCapitalVariations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through capital variations, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IncreaseDecreaseThroughCapitalVariations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through capital variations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IncreaseDecreaseThroughCapitalVariations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital variations</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod" xlink:label="iva_EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod" xlink:to="iva_EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's share of net assets in investments accounted for using the equity method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's share of net assets in investments accounted for using the equity method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Group's share</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IntercompanyEliminationsInAssociates" xlink:label="iva_IntercompanyEliminationsInAssociates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IntercompanyEliminationsInAssociates" xlink:to="iva_IntercompanyEliminationsInAssociates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IntercompanyEliminationsInAssociates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of intercompany eliminations in associates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IntercompanyEliminationsInAssociates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intercompany Eliminations in Associates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iva_IntercompanyEliminationsInAssociates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Elimination of unrealised profit on downstream sales</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill" xlink:label="ifrs-full_Goodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Goodwill" xlink:to="ifrs-full_Goodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NonCurrentLongTermDepositsFromCustomers" xlink:label="iva_NonCurrentLongTermDepositsFromCustomers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NonCurrentLongTermDepositsFromCustomers" xlink:to="iva_NonCurrentLongTermDepositsFromCustomers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NonCurrentLongTermDepositsFromCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">It represents information about non current long term deposits from customers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NonCurrentLongTermDepositsFromCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Current Long Term Deposits From Customers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_NonCurrentLongTermDepositsFromCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Longterm deposit accounts</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NonCurrentAdvancesToSuppliers" xlink:label="iva_NonCurrentAdvancesToSuppliers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NonCurrentAdvancesToSuppliers" xlink:to="iva_NonCurrentAdvancesToSuppliers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NonCurrentAdvancesToSuppliers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount represents the non current advances of suppliers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NonCurrentAdvancesToSuppliers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Current Advances To Suppliers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_NonCurrentAdvancesToSuppliers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advance payments - non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_NonCurrentAdvancesToSuppliers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current advances to suppliers</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NonCurrentSecurityDeposits" xlink:label="iva_NonCurrentSecurityDeposits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NonCurrentSecurityDeposits" xlink:to="iva_NonCurrentSecurityDeposits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NonCurrentSecurityDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The non-current amount of security deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NonCurrentSecurityDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current Security Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_NonCurrentSecurityDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security deposits</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherNonCurrentAssetsTable" xlink:label="iva_OtherNonCurrentAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_OtherNonCurrentAssetsTable" xlink:to="iva_OtherNonCurrentAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_OtherNonCurrentAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule disclosing information related to other non-current assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_OtherNonCurrentAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Non Current Assets [Table]</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember" xlink:label="iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember" xlink:to="iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Contract CRO with PRA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract CRO With Pharmaceutical Research Associates B.V [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract CRO with Pharmaceutical Research Associates B.V.</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherNonCurrentAssetsLineItems" xlink:label="iva_OtherNonCurrentAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_OtherNonCurrentAssetsLineItems" xlink:to="iva_OtherNonCurrentAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_OtherNonCurrentAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_OtherNonCurrentAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Non Current Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_OtherNonCurrentAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Non Current Assets</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseDecreaseInLongTermDepositAccounts" xlink:label="iva_IncreaseDecreaseInLongTermDepositAccounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IncreaseDecreaseInLongTermDepositAccounts" xlink:to="iva_IncreaseDecreaseInLongTermDepositAccounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IncreaseDecreaseInLongTermDepositAccounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in long-term deposit accounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IncreaseDecreaseInLongTermDepositAccounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in long-term deposit accounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IncreaseDecreaseInLongTermDepositAccounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in long-term deposit accounts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermDeposits" xlink:label="ifrs-full_LongtermDeposits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LongtermDeposits" xlink:to="ifrs-full_LongtermDeposits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LongtermDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term deposits</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LongTermDepositsTerm" xlink:label="iva_LongTermDepositsTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_LongTermDepositsTerm" xlink:to="iva_LongTermDepositsTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_LongTermDepositsTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of the long-term deposits of the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_LongTermDepositsTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Deposits Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_LongTermDepositsTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of long-term deposit</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ScheduleOfInventoryDisclosureTable" xlink:label="iva_ScheduleOfInventoryDisclosureTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ScheduleOfInventoryDisclosureTable" xlink:to="iva_ScheduleOfInventoryDisclosureTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ScheduleOfInventoryDisclosureTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule disclosing information related to inventories.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ScheduleOfInventoryDisclosureTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory Disclosure [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedImpairmentMember" xlink:label="ifrs-full_AccumulatedImpairmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedImpairmentMember" xlink:to="ifrs-full_AccumulatedImpairmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccumulatedImpairmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories write-down</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ScheduleOfInventoryDisclosureLineItems" xlink:label="iva_ScheduleOfInventoryDisclosureLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ScheduleOfInventoryDisclosureLineItems" xlink:to="iva_ScheduleOfInventoryDisclosureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ScheduleOfInventoryDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ScheduleOfInventoryDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_ScheduleOfInventoryDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable" xlink:label="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable" xlink:to="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule disclosing information related to trade receivables and other current assets and receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade Receivables and Other Current Assets and Receivables [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaturityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturity [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_AggregatedTimeBandsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AggregatedTimeBandsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregated time bands [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanThreeMonthsMember" xlink:label="ifrs-full_NotLaterThanThreeMonthsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanThreeMonthsMember" xlink:to="ifrs-full_NotLaterThanThreeMonthsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotLaterThanThreeMonthsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">3 months or less</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems" xlink:label="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems" xlink:to="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade Receivables and Other Current Assets and Receivables [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade receivables, tax receivables and other current assets</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LicensingAndCollaborationAgreementWithCttqMember" xlink:label="iva_LicensingAndCollaborationAgreementWithCttqMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_LicensingAndCollaborationAgreementWithCttqMember" xlink:to="iva_LicensingAndCollaborationAgreementWithCttqMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_LicensingAndCollaborationAgreementWithCttqMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Licensing and collaboration agreement with CTTQ.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_LicensingAndCollaborationAgreementWithCttqMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing and collaboration agreement with CTTQ [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_LicensingAndCollaborationAgreementWithCttqMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing and collaboration agreement with CTTQ</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CirAndOtherResearchTaxCreditsReceivable" xlink:label="iva_CirAndOtherResearchTaxCreditsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_CirAndOtherResearchTaxCreditsReceivable" xlink:to="iva_CirAndOtherResearchTaxCreditsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_CirAndOtherResearchTaxCreditsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of CIR and other research tax credits receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_CirAndOtherResearchTaxCreditsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CIR and Other Research Tax Credits Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_CirAndOtherResearchTaxCreditsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CIR and other research tax credits receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_CirAndOtherResearchTaxCreditsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax research credit</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherCurrentTaxReceivables" xlink:label="iva_OtherCurrentTaxReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_OtherCurrentTaxReceivables" xlink:to="iva_OtherCurrentTaxReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_OtherCurrentTaxReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of other tax receivables, classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_OtherCurrentTaxReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Tax Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_OtherCurrentTaxReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="ifrs-full_CurrentPrepaidExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ShortTermDepositAccountsCurrent" xlink:label="iva_ShortTermDepositAccountsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ShortTermDepositAccountsCurrent" xlink:to="iva_ShortTermDepositAccountsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ShortTermDepositAccountsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of short term deposits accounts, classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ShortTermDepositAccountsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-Term Deposit Accounts, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_ShortTermDepositAccountsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term deposit accounts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets" xlink:label="ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets" xlink:to="ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current accrued income including current contract assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current accrued income</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CashUnderLiquidityAgreementCurrent" xlink:label="iva_CashUnderLiquidityAgreementCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_CashUnderLiquidityAgreementCurrent" xlink:to="iva_CashUnderLiquidityAgreementCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_CashUnderLiquidityAgreementCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cash under liquidity agreement, classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_CashUnderLiquidityAgreementCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Under Liquidity Agreement, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_CashUnderLiquidityAgreementCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity agreement - Cash</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_SalesTaxReceivableCurrent" xlink:label="iva_SalesTaxReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_SalesTaxReceivableCurrent" xlink:to="iva_SalesTaxReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_SalesTaxReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of sales tax receivables, classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_SalesTaxReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Tax Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_SalesTaxReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales tax receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherCurrentAssetsAndReceivables" xlink:label="iva_OtherCurrentAssetsAndReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_OtherCurrentAssetsAndReceivables" xlink:to="iva_OtherCurrentAssetsAndReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_OtherCurrentAssetsAndReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of other current assets and receivables as of balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_OtherCurrentAssetsAndReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Assets And Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="iva_OtherCurrentAssetsAndReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current assets and receivables</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseDecreaseInShortTermDepositAccounts" xlink:label="iva_IncreaseDecreaseInShortTermDepositAccounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IncreaseDecreaseInShortTermDepositAccounts" xlink:to="iva_IncreaseDecreaseInShortTermDepositAccounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IncreaseDecreaseInShortTermDepositAccounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in short-term deposit accounts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IncreaseDecreaseInShortTermDepositAccounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) In Short-Term Deposit Accounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IncreaseDecreaseInShortTermDepositAccounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in short-term deposit accounts</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CurrentTaxCreditResearchCurrentYear" xlink:label="iva_CurrentTaxCreditResearchCurrentYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_CurrentTaxCreditResearchCurrentYear" xlink:to="iva_CurrentTaxCreditResearchCurrentYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_CurrentTaxCreditResearchCurrentYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of tax credit research from current year, classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_CurrentTaxCreditResearchCurrentYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Tax Credit Research, Current Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_CurrentTaxCreditResearchCurrentYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivable for current year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_CurrentTaxCreditResearchCurrentYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credits of current year</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseDecreaseInTradeAndOtherCurrentReceivables" xlink:label="iva_IncreaseDecreaseInTradeAndOtherCurrentReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IncreaseDecreaseInTradeAndOtherCurrentReceivables" xlink:to="iva_IncreaseDecreaseInTradeAndOtherCurrentReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IncreaseDecreaseInTradeAndOtherCurrentReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in trade and other current receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IncreaseDecreaseInTradeAndOtherCurrentReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Trade and other current receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IncreaseDecreaseInTradeAndOtherCurrentReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade receivables decreased</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CurrentTradeReceivablesAveragePaymentPeriod" xlink:label="iva_CurrentTradeReceivablesAveragePaymentPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_CurrentTradeReceivablesAveragePaymentPeriod" xlink:to="iva_CurrentTradeReceivablesAveragePaymentPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_CurrentTradeReceivablesAveragePaymentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the average payment period for trade receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_CurrentTradeReceivablesAveragePaymentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Trade Receivables, Average Payment Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_CurrentTradeReceivablesAveragePaymentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average payment period for trade receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term deposits, classified as cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash" xlink:label="ifrs-full_Cash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Cash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Cash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash at bank and at hand</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of classes of share capital [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of classes of share capital [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Par value per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Par value of share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nominal value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issue of equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issue of ordinary shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in number of shares outstanding</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LiquidityAgreementTerm" xlink:label="iva_LiquidityAgreementTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_LiquidityAgreementTerm" xlink:to="iva_LiquidityAgreementTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_LiquidityAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of days used to determine liquidity agreement term  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_LiquidityAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity Agreement Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_LiquidityAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity agreement term</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BsaShareWarrantsMember" xlink:label="iva_BsaShareWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_BsaShareWarrantsMember" xlink:to="iva_BsaShareWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_BsaShareWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for BSA share warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_BsaShareWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BSA share warrants</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Bsa20231ShareWarrantPlanMember" xlink:label="iva_Bsa20231ShareWarrantPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_Bsa20231ShareWarrantPlanMember" xlink:to="iva_Bsa20231ShareWarrantPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_Bsa20231ShareWarrantPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for BSA 2023-1 share warrants plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_Bsa20231ShareWarrantPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BSA 2023-1 Share Warrant Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_Bsa20231ShareWarrantPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BSA 2023 plan</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Bsa20232ShareWarrantPlanMember" xlink:label="iva_Bsa20232ShareWarrantPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_Bsa20232ShareWarrantPlanMember" xlink:to="iva_Bsa20232ShareWarrantPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_Bsa20232ShareWarrantPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for BSA 2023-2 share warrants plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_Bsa20232ShareWarrantPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BSA 2023-2 Share Warrant Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_Bsa20232ShareWarrantPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BSA- 2 2023 plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Categories of related parties [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's total for related parties [member]</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DirectorsMember" xlink:label="iva_DirectorsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DirectorsMember" xlink:to="iva_DirectorsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DirectorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DirectorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_DirectorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Directors</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ServiceProvidersMember" xlink:label="iva_ServiceProvidersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ServiceProvidersMember" xlink:to="iva_ServiceProvidersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ServiceProvidersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to service providers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ServiceProvidersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service Providers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_ServiceProvidersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service providers</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DavidNikodemMember" xlink:label="iva_DavidNikodemMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DavidNikodemMember" xlink:to="iva_DavidNikodemMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DavidNikodemMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for David Nikodem, a member of Sapidus Consulting Group LLC, a service provider to the Company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DavidNikodemMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">David Nikodem</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_DavidNikodemMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">David Nikodem</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantsSubscriptionPrice" xlink:label="iva_WarrantsSubscriptionPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_WarrantsSubscriptionPrice" xlink:to="iva_WarrantsSubscriptionPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_WarrantsSubscriptionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The subscription price per warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_WarrantsSubscriptionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants, Subscription Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_WarrantsSubscriptionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subscription price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of other equity instruments expired in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Instruments lapsed</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToConsolidatedBalanceSheet" xlink:label="iva_NotesToConsolidatedBalanceSheet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NotesToConsolidatedBalanceSheet" xlink:to="iva_NotesToConsolidatedBalanceSheet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NotesToConsolidatedBalanceSheet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NotesToConsolidatedBalanceSheet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade payables, short-term contract liabilities and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BspcePlansMember" xlink:label="iva_BspcePlansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_BspcePlansMember" xlink:to="iva_BspcePlansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_BspcePlansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for BSPCE plans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_BspcePlansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BSPCE plans</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Bspce2021PlanMember" xlink:label="iva_Bspce2021PlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_Bspce2021PlanMember" xlink:to="iva_Bspce2021PlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_Bspce2021PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for BSPCE 2021 plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_Bspce2021PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BSPCE 2021</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BsaPlansMember" xlink:label="iva_BsaPlansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_BsaPlansMember" xlink:to="iva_BsaPlansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_BsaPlansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for BSA plans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_BsaPlansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BSA plans</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Bsa2017PlanMember" xlink:label="iva_Bsa2017PlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_Bsa2017PlanMember" xlink:to="iva_Bsa2017PlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_Bsa2017PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for BSA - 2017 plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_Bsa2017PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BSA - 2017 plan</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Bsa2018PlanMember" xlink:label="iva_Bsa2018PlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_Bsa2018PlanMember" xlink:to="iva_Bsa2018PlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_Bsa2018PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for BSA - 2018 plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_Bsa2018PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BSA - 2018 plan</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewShareWarrantPlansBsa2019Member" xlink:label="iva_NewShareWarrantPlansBsa2019Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NewShareWarrantPlansBsa2019Member" xlink:to="iva_NewShareWarrantPlansBsa2019Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NewShareWarrantPlansBsa2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for new share warrant plans ("BSA 2019").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NewShareWarrantPlansBsa2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BSA 2019</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewShareWarrantPlansBsa2019BisMember" xlink:label="iva_NewShareWarrantPlansBsa2019BisMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NewShareWarrantPlansBsa2019BisMember" xlink:to="iva_NewShareWarrantPlansBsa2019BisMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NewShareWarrantPlansBsa2019BisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for a new share warrant plan ("BSA 2019 bis).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NewShareWarrantPlansBsa2019BisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BSA 2019 bis</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewShareWarrantPlansBsa2019TerMember" xlink:label="iva_NewShareWarrantPlansBsa2019TerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NewShareWarrantPlansBsa2019TerMember" xlink:to="iva_NewShareWarrantPlansBsa2019TerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NewShareWarrantPlansBsa2019TerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for a new share warrant plan ("BSA 2019 ter).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NewShareWarrantPlansBsa2019TerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BSA 2019 ter</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewBsa2021ShareWarrantPlanMember" xlink:label="iva_NewBsa2021ShareWarrantPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NewBsa2021ShareWarrantPlanMember" xlink:to="iva_NewBsa2021ShareWarrantPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NewBsa2021ShareWarrantPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for new BSA 2021 share warrant plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NewBsa2021ShareWarrantPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BSA 2021</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price (in euros)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of other equity instruments outstanding in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of other equity instruments granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of equity instruments granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of other equity instruments exercised or vested in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised/Vesting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of other equity instruments forfeited in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited/ Lapsed</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of other equity instruments exercisable in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of exercisable shares</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightOutstanding" xlink:label="iva_IfrsClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IfrsClassOfWarrantOrRightOutstanding" xlink:to="iva_IfrsClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IfrsClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants or rights outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IfrsClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IfrsClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share warrants outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_IfrsClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of BSA outstanding</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BonusShareAwardPlansMember" xlink:label="iva_BonusShareAwardPlansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_BonusShareAwardPlansMember" xlink:to="iva_BonusShareAwardPlansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_BonusShareAwardPlansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for bonus share award plans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_BonusShareAwardPlansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bonus Share Award Plans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_BonusShareAwardPlansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bonus share award plans</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewBonusShareAwardPlanAga20211Member" xlink:label="iva_NewBonusShareAwardPlanAga20211Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NewBonusShareAwardPlanAga20211Member" xlink:to="iva_NewBonusShareAwardPlanAga20211Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NewBonusShareAwardPlanAga20211Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for New bonus share award plans (AGA 2021-1)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NewBonusShareAwardPlanAga20211Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AGA 2021-1</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewBonusShareAwardPlanAga2021BisMember" xlink:label="iva_NewBonusShareAwardPlanAga2021BisMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NewBonusShareAwardPlanAga2021BisMember" xlink:to="iva_NewBonusShareAwardPlanAga2021BisMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NewBonusShareAwardPlanAga2021BisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for New bonus share award plans (AGA 2021-bis).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NewBonusShareAwardPlanAga2021BisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AGA 2021-bis</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewBonusShareAwardPlan20232Member" xlink:label="iva_NewBonusShareAwardPlan20232Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NewBonusShareAwardPlan20232Member" xlink:to="iva_NewBonusShareAwardPlan20232Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NewBonusShareAwardPlan20232Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for New bonus share award plans (AGA 2023-2).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NewBonusShareAwardPlan20232Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AGA 2023-2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_NewBonusShareAwardPlan20232Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AGA 2023-2</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LongTermIncentivePlanInPerformanceUnitsMember" xlink:label="iva_LongTermIncentivePlanInPerformanceUnitsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_LongTermIncentivePlanInPerformanceUnitsMember" xlink:to="iva_LongTermIncentivePlanInPerformanceUnitsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_LongTermIncentivePlanInPerformanceUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for long-term incentive plan in performance units or "PAGUP".</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_LongTermIncentivePlanInPerformanceUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Incentive Plan In Performance Units [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_LongTermIncentivePlanInPerformanceUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PAGUP</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Aga2021Aga2021BisMember" xlink:label="iva_Aga2021Aga2021BisMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_Aga2021Aga2021BisMember" xlink:to="iva_Aga2021Aga2021BisMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_Aga2021Aga2021BisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for AGA 2021 &amp; AGA 2021 bis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_Aga2021Aga2021BisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AGA 2021 &amp; AGA 2021 bis [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_Aga2021Aga2021BisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AGA 2021 &amp; AGA 2021 bis</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FredericCrenMember" xlink:label="iva_FredericCrenMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_FredericCrenMember" xlink:to="iva_FredericCrenMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_FredericCrenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Frederic Cren</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_FredericCrenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Frederic Cren [Member]</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfPlansOutstanding" xlink:label="iva_NumberOfPlansOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NumberOfPlansOutstanding" xlink:to="iva_NumberOfPlansOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NumberOfPlansOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of plans outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NumberOfPlansOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of plans outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_NumberOfPlansOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of award plans outstanding</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfAwardPlansAttributed" xlink:label="iva_NumberOfAwardPlansAttributed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NumberOfAwardPlansAttributed" xlink:to="iva_NumberOfAwardPlansAttributed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NumberOfAwardPlansAttributed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of award plans attributed during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NumberOfAwardPlansAttributed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Award Plans Attributed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_NumberOfAwardPlansAttributed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of plans attributed</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePrice2019" xlink:to="ifrs-full_WeightedAverageSharePrice2019_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageSharePrice2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average share price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WeightedAverageSharePrice2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock price at grant date (in euros)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense from share-based payment transactions</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfSharesConverted" xlink:label="iva_NumberOfSharesConverted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NumberOfSharesConverted" xlink:to="iva_NumberOfSharesConverted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NumberOfSharesConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">It represents the information relating to number of shares converted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NumberOfSharesConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_NumberOfSharesConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares converted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about borrowings [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about borrowings [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Guarantee Details</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LoansReceived" xlink:label="ifrs-full_LoansReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LoansReceived" xlink:to="ifrs-full_LoansReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LoansReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LoansReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bank borrowings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherBorrowings" xlink:label="ifrs-full_OtherBorrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherBorrowings" xlink:to="ifrs-full_OtherBorrowings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other loans and similar borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other loans and similar borrowings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Borrowings" xlink:to="ifrs-full_Borrowings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Borrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Borrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Borrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Borrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Borrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total debt</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments" xlink:label="iva_IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments" xlink:to="iva_IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase in borrowings through Subscription of derivatives instruments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in Borrowings Through Subscription Of Derivatives Instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subscription of derivatives instruments</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Increaseinborrowingsthroughborrowingsreceived" xlink:label="iva_Increaseinborrowingsthroughborrowingsreceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_Increaseinborrowingsthroughborrowingsreceived" xlink:to="iva_Increaseinborrowingsthroughborrowingsreceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_Increaseinborrowingsthroughborrowingsreceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase in borrowings through borrowings received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_Increaseinborrowingsthroughborrowingsreceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IncreaseInBorrowingsThroughBorrowingsReceived</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_Increaseinborrowingsthroughborrowingsreceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subscription of bank borrowings</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_SubscriptionOfLeaseLiabilities" xlink:label="iva_SubscriptionOfLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_SubscriptionOfLeaseLiabilities" xlink:to="iva_SubscriptionOfLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_SubscriptionOfLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of subscription of lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_SubscriptionOfLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subscription Of Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_SubscriptionOfLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subscription of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IssueOfRoyaltyCertificates" xlink:label="iva_IssueOfRoyaltyCertificates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IssueOfRoyaltyCertificates" xlink:to="iva_IssueOfRoyaltyCertificates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IssueOfRoyaltyCertificates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of increase in borrowings through issue of royalty certificates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IssueOfRoyaltyCertificates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issue of Royalty Certificates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IssueOfRoyaltyCertificates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issue of royalty certificates</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities" xlink:label="iva_DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities" xlink:to="iva_DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of decrease in borrowings through repayment of lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in borrowings through repayment of lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iva_DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_InterestOnRoyaltyCertificates" xlink:label="iva_InterestOnRoyaltyCertificates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_InterestOnRoyaltyCertificates" xlink:to="iva_InterestOnRoyaltyCertificates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_InterestOnRoyaltyCertificates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase in borrowings through interests on royalty certificates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_InterestOnRoyaltyCertificates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest On Royalty Certificates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_InterestOnRoyaltyCertificates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issue of royalty certificates</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings" xlink:label="iva_DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings" xlink:to="iva_DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of decrease in borrowings through repayments of bank borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in borrowings through repayments of bank borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iva_DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of bank borrowings</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseInBorrowingsThroughCapitalizedInterest" xlink:label="iva_IncreaseInBorrowingsThroughCapitalizedInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IncreaseInBorrowingsThroughCapitalizedInterest" xlink:to="iva_IncreaseInBorrowingsThroughCapitalizedInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IncreaseInBorrowingsThroughCapitalizedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase in borrowings through capitalized interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IncreaseInBorrowingsThroughCapitalizedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in borrowings through capitalized interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IncreaseInBorrowingsThroughCapitalizedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized interests</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments" xlink:label="iva_IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments" xlink:to="iva_IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase or decrease in borrowings due to change in fair value of derivatives instruments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Or Decrease In Borrowings Due To Change in Fair Value of Derivatives Instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of derivatives instruments</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates" xlink:label="iva_IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates" xlink:to="iva_IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase or decrease in borrowings due to exchange rate change.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase or Decrease in Borrowings Due to Changes in Exchange Rates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exchange rate change</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LoanAgreementsWithSyndicateOfFrenchBanksMember" xlink:label="iva_LoanAgreementsWithSyndicateOfFrenchBanksMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_LoanAgreementsWithSyndicateOfFrenchBanksMember" xlink:to="iva_LoanAgreementsWithSyndicateOfFrenchBanksMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_LoanAgreementsWithSyndicateOfFrenchBanksMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for loan agreements with a syndicate of French banks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_LoanAgreementsWithSyndicateOfFrenchBanksMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan Agreements With Syndicate of French Banks [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_LoanAgreementsWithSyndicateOfFrenchBanksMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan agreements with a syndicate of French banks</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember" xlink:label="iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember" xlink:to="iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for loan agreements with a syndicate of French banks, under a stimulus economic plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan agreements with syndicate of French banks, under stimulus economic plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan agreements with syndicate of French banks, under stimulus economic plan</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember" xlink:label="iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember" xlink:to="iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat)</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_EquityRecoveryLoansMember" xlink:label="iva_EquityRecoveryLoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_EquityRecoveryLoansMember" xlink:to="iva_EquityRecoveryLoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_EquityRecoveryLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for equity recovery loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_EquityRecoveryLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Recovery Loans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_EquityRecoveryLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity recovery loans</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinancingFromSyndicateOfFrenchBanksMember" xlink:label="iva_FinancingFromSyndicateOfFrenchBanksMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_FinancingFromSyndicateOfFrenchBanksMember" xlink:to="iva_FinancingFromSyndicateOfFrenchBanksMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_FinancingFromSyndicateOfFrenchBanksMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for financing from a syndicate of French banks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_FinancingFromSyndicateOfFrenchBanksMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing from a syndicate of French banks</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfLoansObtainedGuaranteedByFrenchState" xlink:label="iva_NumberOfLoansObtainedGuaranteedByFrenchState" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NumberOfLoansObtainedGuaranteedByFrenchState" xlink:to="iva_NumberOfLoansObtainedGuaranteedByFrenchState_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NumberOfLoansObtainedGuaranteedByFrenchState_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of loans obtained which are guaranteed by the french state.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NumberOfLoansObtainedGuaranteedByFrenchState_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Loans Obtained Guaranteed By The French State</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_NumberOfLoansObtainedGuaranteedByFrenchState_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of loans obtained guaranteed by the french state</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BorrowingsMaximumExtensionTerm" xlink:label="iva_BorrowingsMaximumExtensionTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_BorrowingsMaximumExtensionTerm" xlink:to="iva_BorrowingsMaximumExtensionTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_BorrowingsMaximumExtensionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period up to which the maturity term of the borrowings can be extended.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_BorrowingsMaximumExtensionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings, Maximum Extension Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_BorrowingsMaximumExtensionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extension of term of debt</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfLoanAgreements" xlink:label="iva_NumberOfLoanAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NumberOfLoanAgreements" xlink:to="iva_NumberOfLoanAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NumberOfLoanAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of loan agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NumberOfLoanAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Loan Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_NumberOfLoanAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of loan agreements</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PercentageOfLoanGuaranteedByFrenchState" xlink:label="iva_PercentageOfLoanGuaranteedByFrenchState" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_PercentageOfLoanGuaranteedByFrenchState" xlink:to="iva_PercentageOfLoanGuaranteedByFrenchState_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_PercentageOfLoanGuaranteedByFrenchState_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of loan guaranteed by French state.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_PercentageOfLoanGuaranteedByFrenchState_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Loan Guaranteed by French State</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_PercentageOfLoanGuaranteedByFrenchState_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of loan guaranteed by French state</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinancingPeriodOfLoan" xlink:label="iva_FinancingPeriodOfLoan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_FinancingPeriodOfLoan" xlink:to="iva_FinancingPeriodOfLoan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_FinancingPeriodOfLoan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the financing period of loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_FinancingPeriodOfLoan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing Period of Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_FinancingPeriodOfLoan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing period of loan</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_RepaymentPeriodOfLoan" xlink:label="iva_RepaymentPeriodOfLoan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_RepaymentPeriodOfLoan" xlink:to="iva_RepaymentPeriodOfLoan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_RepaymentPeriodOfLoan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period for repayment of loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_RepaymentPeriodOfLoan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment Period of Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_RepaymentPeriodOfLoan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment period for loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities at fair value, class [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities at fair value</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfEqualTranches" xlink:label="iva_NumberOfEqualTranches" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NumberOfEqualTranches" xlink:to="iva_NumberOfEqualTranches_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NumberOfEqualTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represent the information of number of equal tranches .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NumberOfEqualTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Equal Tranches</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_NumberOfEqualTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of equal tranches</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotionalAmountPerTranche" xlink:label="iva_NotionalAmountPerTranche" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NotionalAmountPerTranche" xlink:to="iva_NotionalAmountPerTranche_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NotionalAmountPerTranche_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notional amount per tranche</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NotionalAmountPerTranche_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notional Amount Per Tranche</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_NotionalAmountPerTranche_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notional amount per tranche</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BorrowingsEffectiveInterestRate" xlink:label="iva_BorrowingsEffectiveInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_BorrowingsEffectiveInterestRate" xlink:to="iva_BorrowingsEffectiveInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_BorrowingsEffectiveInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The effective interest rate on borrowings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_BorrowingsEffectiveInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings, effective interest rate</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BorrowingsActualizationRate" xlink:label="iva_BorrowingsActualizationRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_BorrowingsActualizationRate" xlink:to="iva_BorrowingsActualizationRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_BorrowingsActualizationRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The actualization interest rate on borrowings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_BorrowingsActualizationRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings, Actualization Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_BorrowingsActualizationRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Actualization rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingCostsIncurred" xlink:label="ifrs-full_BorrowingCostsIncurred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingCostsIncurred" xlink:to="ifrs-full_BorrowingCostsIncurred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingCostsIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowing costs incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BorrowingCostsIncurred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowing costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestCostsCapitalised" xlink:label="ifrs-full_InterestCostsCapitalised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestCostsCapitalised" xlink:to="ifrs-full_InterestCostsCapitalised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestCostsCapitalised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest costs capitalised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestCostsCapitalised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtFairValue" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities, at fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities, at fair value</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Bsa2022Member" xlink:label="iva_Bsa2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_Bsa2022Member" xlink:to="iva_Bsa2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_Bsa2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for the BSA 2022 share-based payment plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_Bsa2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BSA 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_Bsa2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BSA 2022</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Bsa2024Member" xlink:label="iva_Bsa2024Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_Bsa2024Member" xlink:to="iva_Bsa2024Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_Bsa2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for the BSA 2024 share-based payment plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_Bsa2024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BSA 2024 [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of share capital [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_ClassesOfShareCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share capital [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ClassOfWarrantOrRightGranted" xlink:label="iva_ClassOfWarrantOrRightGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ClassOfWarrantOrRightGranted" xlink:to="iva_ClassOfWarrantOrRightGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ClassOfWarrantOrRightGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants or rights granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ClassOfWarrantOrRightGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_ClassOfWarrantOrRightGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_ClassOfWarrantOrRightGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants issued</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_MaximumPotentialGrossProceedsFromExerciseOfWarrants" xlink:label="iva_MaximumPotentialGrossProceedsFromExerciseOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_MaximumPotentialGrossProceedsFromExerciseOfWarrants" xlink:to="iva_MaximumPotentialGrossProceedsFromExerciseOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_MaximumPotentialGrossProceedsFromExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum potential amount of gross proceeds that the company will receive from exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_MaximumPotentialGrossProceedsFromExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Potential Gross Proceeds From Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_MaximumPotentialGrossProceedsFromExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum potential gross proceeds from exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TransactionCostsOnIssueOfWarrants" xlink:label="iva_TransactionCostsOnIssueOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_TransactionCostsOnIssueOfWarrants" xlink:to="iva_TransactionCostsOnIssueOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_TransactionCostsOnIssueOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction costs on issue of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_TransactionCostsOnIssueOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction costs on issue of warrants</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantsThresholdTradingDays" xlink:label="iva_WarrantsThresholdTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_WarrantsThresholdTradingDays" xlink:to="iva_WarrantsThresholdTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_WarrantsThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold number of specified trading days that common stock price to conversion price of warrants must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_WarrantsThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants, Threshold Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_WarrantsThresholdTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold trading days of warrants</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted" xlink:label="iva_SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted" xlink:to="iva_SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subscription premium price per share of other equity instruments granted in share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subscription Premium Price Per Share Of Other Equity Instruments Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subscription premium price per share (&#x20AC;)</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantsStockPrice" xlink:label="iva_WarrantsStockPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_WarrantsStockPrice" xlink:to="iva_WarrantsStockPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_WarrantsStockPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock price used to calculate fair value of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_WarrantsStockPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants, Stock Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_WarrantsStockPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock price (&#x20AC;)</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantAverageLife" xlink:label="iva_WarrantAverageLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_WarrantAverageLife" xlink:to="iva_WarrantAverageLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_WarrantAverageLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average life used to calculate fair value of warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_WarrantAverageLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Average Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_WarrantAverageLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturity (years)</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ExpectedVolatility" xlink:label="iva_ExpectedVolatility" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ExpectedVolatility" xlink:to="iva_ExpectedVolatility_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ExpectedVolatility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility used to calculate fair value of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ExpectedVolatility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_ExpectedVolatility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantsCapOfPutOption" xlink:label="iva_WarrantsCapOfPutOption" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_WarrantsCapOfPutOption" xlink:to="iva_WarrantsCapOfPutOption_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_WarrantsCapOfPutOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cap of the put option used to calculate fair value of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_WarrantsCapOfPutOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants, Cap of Put Option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_WarrantsCapOfPutOption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cap of the put option (m&#x20AC;)</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FairValueOfWarrantsOutstanding" xlink:label="iva_FairValueOfWarrantsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_FairValueOfWarrantsOutstanding" xlink:to="iva_FairValueOfWarrantsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_FairValueOfWarrantsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of warrants outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_FairValueOfWarrantsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of warrants outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_FairValueOfWarrantsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value (k&#x20AC;)</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantsUnitFairValue" xlink:label="iva_WarrantsUnitFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_WarrantsUnitFairValue" xlink:to="iva_WarrantsUnitFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_WarrantsUnitFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The fair value per warranty unit outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_WarrantsUnitFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants, Unit Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_WarrantsUnitFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unit fair value</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued" xlink:label="iva_TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued" xlink:to="iva_TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the term over which volume weighted average price per share to determine number of warrants to be issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Over Which Volume Weighted Average Price Per Share To Determine Number Of Warrants To Be Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term over which volume weighted average price per share to determine number of warrants to be issued</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfSharesPerOtherEquityInstrumentGranted" xlink:label="iva_NumberOfSharesPerOtherEquityInstrumentGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NumberOfSharesPerOtherEquityInstrumentGranted" xlink:to="iva_NumberOfSharesPerOtherEquityInstrumentGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NumberOfSharesPerOtherEquityInstrumentGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares that each equity instruments other than share options granted in a share-based payment arrangement, entitles the holder.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NumberOfSharesPerOtherEquityInstrumentGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Shares Per Other Equity Instrument Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_NumberOfSharesPerOtherEquityInstrumentGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares per AGA</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="ifrs-full_LeaseLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilitiesMember" xlink:to="ifrs-full_LeaseLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_LeaseLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseDecreaseInLeaseLiabilities" xlink:label="iva_IncreaseDecreaseInLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IncreaseDecreaseInLeaseLiabilities" xlink:to="iva_IncreaseDecreaseInLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IncreaseDecreaseInLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) in lease liabilities during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IncreaseDecreaseInLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IncreaseDecreaseInLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in lease liabilities</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LeaseTerm" xlink:label="iva_LeaseTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_LeaseTerm" xlink:to="iva_LeaseTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_LeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_LeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_LeaseTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less than 1 year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Between 1 and 3 years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Between 3 and 5 years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanFiveYearsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanFiveYearsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanFiveYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">More than 5 years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of liabilities [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember" xlink:label="ifrs-full_LiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesMember" xlink:to="ifrs-full_LiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities [member]</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_RoyaltyCertificateLiabilitiesMember" xlink:label="iva_RoyaltyCertificateLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_RoyaltyCertificateLiabilitiesMember" xlink:to="iva_RoyaltyCertificateLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_RoyaltyCertificateLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Royalty Certificate Liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_RoyaltyCertificateLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Certificate Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_RoyaltyCertificateLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Certificate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="ifrs-full_UnobservableInputsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnobservableInputsAxis" xlink:to="ifrs-full_UnobservableInputsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_UnobservableInputsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unobservable inputs [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="ifrs-full_UnobservableInputsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnobservableInputsMember" xlink:to="ifrs-full_UnobservableInputsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_UnobservableInputsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unobservable inputs [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DiscountRateMeasurementInputMember" xlink:label="ifrs-full_DiscountRateMeasurementInputMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DiscountRateMeasurementInputMember" xlink:to="ifrs-full_DiscountRateMeasurementInputMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DiscountRateMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount rate, measurement input [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DiscountRateMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount rate</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_RoyaltyCertificatesLiabilitiesMember" xlink:label="iva_RoyaltyCertificatesLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_RoyaltyCertificatesLiabilitiesMember" xlink:to="iva_RoyaltyCertificatesLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_RoyaltyCertificatesLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for royalty certificates liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_RoyaltyCertificatesLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Certificates Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_RoyaltyCertificatesLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty certificates liabilities</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor" xlink:label="iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor" xlink:to="iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of annual royalty on future net sales of Lanifibranor.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual Royalty Percentage on Future Net Sales of Lanifibranor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual royalty percentage</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_RoyaltyCertificatesEffectiveInterestRate" xlink:label="iva_RoyaltyCertificatesEffectiveInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_RoyaltyCertificatesEffectiveInterestRate" xlink:to="iva_RoyaltyCertificatesEffectiveInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_RoyaltyCertificatesEffectiveInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective interest rate on royalty certificates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_RoyaltyCertificatesEffectiveInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Certificates, Effective Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_RoyaltyCertificatesEffectiveInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty certificates, effective interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantUnobservableInputLiabilities" xlink:label="ifrs-full_SignificantUnobservableInputLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SignificantUnobservableInputLiabilities" xlink:to="ifrs-full_SignificantUnobservableInputLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SignificantUnobservableInputLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Unobservable Input Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SignificantUnobservableInputLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant unobservable input, liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansTable" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of defined benefit plans [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems" xlink:to="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDefinedBenefitPlansLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of defined benefit plans [line items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisions" xlink:label="ifrs-full_OtherProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherProvisions" xlink:to="ifrs-full_OtherProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="ifrs-full_DefinedBenefitObligationAtPresentValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:to="ifrs-full_DefinedBenefitObligationAtPresentValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DefinedBenefitObligationAtPresentValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined benefit obligation, at present value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DefinedBenefitObligationAtPresentValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement benefit obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:to="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net defined benefit liability (asset)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss" xlink:label="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss" xlink:to="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense for the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:label="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:to="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Actuarial gains or losses recognized in other comprehensive income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentServiceCostDefinedBenefitPlans" xlink:label="ifrs-full_CurrentServiceCostDefinedBenefitPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentServiceCostDefinedBenefitPlans" xlink:to="ifrs-full_CurrentServiceCostDefinedBenefitPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentServiceCostDefinedBenefitPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current service cost, defined benefit plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_CurrentServiceCostDefinedBenefitPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service cost for the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseDefinedBenefitPlans" xlink:label="ifrs-full_InterestExpenseDefinedBenefitPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseDefinedBenefitPlans" xlink:to="ifrs-full_InterestExpenseDefinedBenefitPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpenseDefinedBenefitPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense, defined benefit plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestExpenseDefinedBenefitPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest cost for the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans" xlink:label="ifrs-full_PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans" xlink:to="ifrs-full_PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Past service cost and losses (gains) arising from settlements, defined benefit plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Benefits for the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:to="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Post-employment benefit expense, defined benefit plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_EmployeeRelatedPayables" xlink:label="iva_EmployeeRelatedPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_EmployeeRelatedPayables" xlink:to="iva_EmployeeRelatedPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_EmployeeRelatedPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount pertaining to employee related payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_EmployeeRelatedPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee related payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_EmployeeRelatedPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employeerelated payables</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AccruedPayrollAndOtherEmployeeRelatedTaxes" xlink:label="iva_AccruedPayrollAndOtherEmployeeRelatedTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_AccruedPayrollAndOtherEmployeeRelatedTaxes" xlink:to="iva_AccruedPayrollAndOtherEmployeeRelatedTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_AccruedPayrollAndOtherEmployeeRelatedTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount pertaining to accrued payroll and other employee related taxes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_AccruedPayrollAndOtherEmployeeRelatedTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued payroll and other employeerelated taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_AccruedPayrollAndOtherEmployeeRelatedTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued payroll and other employeerelated taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentValueAddedTaxPayables" xlink:label="ifrs-full_CurrentValueAddedTaxPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentValueAddedTaxPayables" xlink:to="ifrs-full_CurrentValueAddedTaxPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentValueAddedTaxPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current value added tax payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentValueAddedTaxPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">VAT payables</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherAccruedTaxesAndEmployeeRelatedExpenses" xlink:label="iva_OtherAccruedTaxesAndEmployeeRelatedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_OtherAccruedTaxesAndEmployeeRelatedExpenses" xlink:to="iva_OtherAccruedTaxesAndEmployeeRelatedExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_OtherAccruedTaxesAndEmployeeRelatedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of accrued taxes and employee related expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_OtherAccruedTaxesAndEmployeeRelatedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued taxes And Employee Related Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_OtherAccruedTaxesAndEmployeeRelatedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other accrued taxes and employeerelated expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentPayables" xlink:label="ifrs-full_OtherCurrentPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentPayables" xlink:to="ifrs-full_OtherCurrentPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other miscellaneous payables</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradePayableAndOtherCurrentLiabilitiesTable" xlink:label="iva_TradePayableAndOtherCurrentLiabilitiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_TradePayableAndOtherCurrentLiabilitiesTable" xlink:to="iva_TradePayableAndOtherCurrentLiabilitiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_TradePayableAndOtherCurrentLiabilitiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_TradePayableAndOtherCurrentLiabilitiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade Payable And Other Current Liabilities [Table]</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradePayableAndOtherCurrentLiabilitiesLineItems" xlink:label="iva_TradePayableAndOtherCurrentLiabilitiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_TradePayableAndOtherCurrentLiabilitiesLineItems" xlink:to="iva_TradePayableAndOtherCurrentLiabilitiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_TradePayableAndOtherCurrentLiabilitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_TradePayableAndOtherCurrentLiabilitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade Payable And Other Current Liabilities [Line Items]</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradePayablesAndOtherCurrentLiabilities" xlink:label="iva_TradePayablesAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_TradePayablesAndOtherCurrentLiabilities" xlink:to="iva_TradePayablesAndOtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_TradePayablesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of trade payables and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_TradePayablesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade Payables And Other Current Liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="iva_TradePayablesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade payables and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccrualsClassifiedAsCurrent" xlink:to="ifrs-full_AccrualsClassifiedAsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accruals classified as current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AccrualsClassifiedAsCurrentRelatingToScientificProjects" xlink:label="iva_AccrualsClassifiedAsCurrentRelatingToScientificProjects" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_AccrualsClassifiedAsCurrentRelatingToScientificProjects" xlink:to="iva_AccrualsClassifiedAsCurrentRelatingToScientificProjects_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_AccrualsClassifiedAsCurrentRelatingToScientificProjects_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of accruals classified as current relating to scientific projects</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_AccrualsClassifiedAsCurrentRelatingToScientificProjects_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accruals classified as current relating to scientific projects</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_AccrualsClassifiedAsCurrentRelatingToScientificProjects_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities relating to scientific projects</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneMonthMember" xlink:label="ifrs-full_NotLaterThanOneMonthMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanOneMonthMember" xlink:to="ifrs-full_NotLaterThanOneMonthMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotLaterThanOneMonthMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due in 30 days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NotLaterThanOneMonthMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due in 30 days</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember" xlink:label="ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember" xlink:to="ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due in 30 60 days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due in 30-60 days</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LaterThanTwoMonthsMember" xlink:label="iva_LaterThanTwoMonthsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_LaterThanTwoMonthsMember" xlink:to="iva_LaterThanTwoMonthsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_LaterThanTwoMonthsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for a time band of later than two months.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_LaterThanTwoMonthsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due in more than 60 days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_LaterThanTwoMonthsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due in more than 60 days</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other current payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade payable</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseDecreaseInTradeAccountsPayable" xlink:label="iva_IncreaseDecreaseInTradeAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IncreaseDecreaseInTradeAccountsPayable" xlink:to="iva_IncreaseDecreaseInTradeAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IncreaseDecreaseInTradeAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in trade accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IncreaseDecreaseInTradeAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in trade accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IncreaseDecreaseInTradeAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in trade accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of financial assets [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember" xlink:label="ifrs-full_FinancialAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="ifrs-full_FinancialAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets, class [member]</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LongTermDepositAccountsMember" xlink:label="iva_LongTermDepositAccountsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_LongTermDepositAccountsMember" xlink:to="iva_LongTermDepositAccountsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_LongTermDepositAccountsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for long term deposit accounts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_LongTermDepositAccountsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term deposit accounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_LongTermDepositAccountsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term deposit accounts</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LongTermSecurityDepositsMember" xlink:label="iva_LongTermSecurityDepositsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_LongTermSecurityDepositsMember" xlink:to="iva_LongTermSecurityDepositsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_LongTermSecurityDepositsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for long-term security deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_LongTermSecurityDepositsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term security deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_LongTermSecurityDepositsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term security deposits</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AdvancePaymentMember" xlink:label="iva_AdvancePaymentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_AdvancePaymentMember" xlink:to="iva_AdvancePaymentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_AdvancePaymentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for advance payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_AdvancePaymentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advance payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_AdvancePaymentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advance payment</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AccruedIncomeMember" xlink:label="iva_AccruedIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_AccruedIncomeMember" xlink:to="iva_AccruedIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_AccruedIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for accrued income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_AccruedIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current accrued income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_AccruedIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current accrued income</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ShortTermDepositAccountsMember" xlink:label="iva_ShortTermDepositAccountsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ShortTermDepositAccountsMember" xlink:to="iva_ShortTermDepositAccountsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ShortTermDepositAccountsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for short-term deposit accounts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ShortTermDepositAccountsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shortterm deposit accounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_ShortTermDepositAccountsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term deposit accounts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeReceivablesMember" xlink:label="ifrs-full_TradeReceivablesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeReceivablesMember" xlink:to="ifrs-full_TradeReceivablesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeReceivablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeReceivablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade receivables</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherReceivablesMember" xlink:label="iva_OtherReceivablesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_OtherReceivablesMember" xlink:to="iva_OtherReceivablesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_OtherReceivablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for other receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_OtherReceivablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_OtherReceivablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCashAndCashEquivalentsMember" xlink:label="iva_IfrsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IfrsCashAndCashEquivalentsMember" xlink:to="iva_IfrsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IfrsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for cash and cash equivalents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IfrsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IfrsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets carried at amortized cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets carried at amortized cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowingsMember" xlink:label="ifrs-full_LongtermBorrowingsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LongtermBorrowingsMember" xlink:to="ifrs-full_LongtermBorrowingsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LongtermBorrowingsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LongtermBorrowingsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DerivativeInstrumentsMember" xlink:label="iva_DerivativeInstrumentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DerivativeInstrumentsMember" xlink:to="iva_DerivativeInstrumentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DerivativeInstrumentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for derivative instruments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DerivativeInstrumentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_DerivativeInstrumentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermBorrowingsMember" xlink:label="ifrs-full_ShorttermBorrowingsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermBorrowingsMember" xlink:to="ifrs-full_ShorttermBorrowingsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermBorrowingsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermBorrowingsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term debt</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradePayablesMember" xlink:label="iva_TradePayablesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_TradePayablesMember" xlink:to="iva_TradePayablesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_TradePayablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for trade payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_TradePayablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_TradePayablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade payables</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherMiscellaneousPayablesMember" xlink:label="iva_OtherMiscellaneousPayablesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_OtherMiscellaneousPayablesMember" xlink:to="iva_OtherMiscellaneousPayablesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_OtherMiscellaneousPayablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for other miscellaneous payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_OtherMiscellaneousPayablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other miscellaneous payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_OtherMiscellaneousPayablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other miscellaneous payables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities carried at amortized cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities carried at amortized cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_FinancialAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="ifrs-full_FinancialAssetsAtFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtFairValue" xlink:to="ifrs-full_FinancialAssetsAtFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsAtFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets, at fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialAssetsAtFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets, at fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromContractsWithCustomers" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from contracts with customers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CurrentTaxCreditResearchIncome" xlink:label="iva_CurrentTaxCreditResearchIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_CurrentTaxCreditResearchIncome" xlink:to="iva_CurrentTaxCreditResearchIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_CurrentTaxCreditResearchIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of income from tax credit research.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_CurrentTaxCreditResearchIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Tax Credit Research Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_CurrentTaxCreditResearchIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credits</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_SubsidiesIncome" xlink:label="iva_SubsidiesIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_SubsidiesIncome" xlink:to="iva_SubsidiesIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_SubsidiesIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of income from subsidies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_SubsidiesIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidies income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_SubsidiesIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidies</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsOtherOperatingIncome" xlink:label="iva_IfrsOtherOperatingIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IfrsOtherOperatingIncome" xlink:to="iva_IfrsOtherOperatingIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IfrsOtherOperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IfrsOtherOperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Other Operating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IfrsOtherOperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:label="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:to="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of attribution of expenses by nature to their function [table]</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ServiceContractWithAvantSanteMember" xlink:label="iva_ServiceContractWithAvantSanteMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ServiceContractWithAvantSanteMember" xlink:to="iva_ServiceContractWithAvantSanteMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ServiceContractWithAvantSanteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for service contract with Avant Sante.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ServiceContractWithAvantSanteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service contract with Avant Sante [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_ServiceContractWithAvantSanteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service contract with Avant Sante</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:label="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:to="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of attribution of expenses by nature to their function [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes to the income statement</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ProceedsFromLicensingArrangements" xlink:label="iva_ProceedsFromLicensingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ProceedsFromLicensingArrangements" xlink:to="iva_ProceedsFromLicensingArrangements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ProceedsFromLicensingArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount paid on licensing arrangements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ProceedsFromLicensingArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Licensing Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_ProceedsFromLicensingArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount received on licensing arrangements</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement" xlink:label="iva_OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement" xlink:to="iva_OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount related to reinvoicing of share of costs incurred under the licensing and collaboration agreements included in other income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Income, Relating To Reinvoicing Of Share Of Costs Under Licensing And Collaboration Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reinvoicing of share of costs incurred included in other income</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement" xlink:label="iva_OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement" xlink:to="iva_OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount related to reinvoicing of specific costs incurred on services with customer research organization accrued liabilities included in other income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Income, Reinvoicing Of Specific Costs Under Service Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reinvoicing of specific costs related to CRO accrued liabilities included in other income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Attribution of expenses by nature to their function [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="ifrs-full_LineItemsByFunctionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LineItemsByFunctionMember" xlink:to="ifrs-full_LineItemsByFunctionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LineItemsByFunctionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items by function [member]</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsResearchAndDevelopmentExpenseMember" xlink:label="iva_IfrsResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IfrsResearchAndDevelopmentExpenseMember" xlink:to="iva_IfrsResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IfrsResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for research and development expense member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IfrsResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IfrsResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development costs</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsSalesAndMarketingExpenseMember" xlink:label="iva_IfrsSalesAndMarketingExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IfrsSalesAndMarketingExpenseMember" xlink:to="iva_IfrsSalesAndMarketingExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IfrsSalesAndMarketingExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for sales and marketing expense member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IfrsSalesAndMarketingExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketing - Business development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IfrsSalesAndMarketingExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketing - Business development expenses</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsGeneralAndAdministrativeExpenseMember" xlink:label="iva_IfrsGeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IfrsGeneralAndAdministrativeExpenseMember" xlink:to="iva_IfrsGeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IfrsGeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for general and administrative expense member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IfrsGeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Disposables" xlink:label="iva_Disposables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_Disposables" xlink:to="iva_Disposables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_Disposables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to disposables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_Disposables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iva_Disposables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposables</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_EnergyAndLiquids" xlink:label="iva_EnergyAndLiquids" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_EnergyAndLiquids" xlink:to="iva_EnergyAndLiquids_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_EnergyAndLiquids_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to energy and liquids.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_EnergyAndLiquids_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Energy and liquids</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iva_EnergyAndLiquids_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Energy and liquids</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Patents" xlink:label="iva_Patents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_Patents" xlink:to="iva_Patents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_Patents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to patents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_Patents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iva_Patents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patents</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Studies" xlink:label="iva_Studies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_Studies" xlink:to="iva_Studies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_Studies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to studies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_Studies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Studies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iva_Studies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Studies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepairsAndMaintenanceExpense" xlink:label="ifrs-full_RepairsAndMaintenanceExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepairsAndMaintenanceExpense" xlink:to="ifrs-full_RepairsAndMaintenanceExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RepairsAndMaintenanceExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repairs and maintenance expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_RepairsAndMaintenanceExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maintenance</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Fees" xlink:label="iva_Fees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_Fees" xlink:to="iva_Fees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_Fees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_Fees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iva_Fees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fees</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ItSystems" xlink:label="iva_ItSystems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ItSystems" xlink:to="iva_ItSystems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ItSystems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to it systems.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ItSystems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IT Systems</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iva_ItSystems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IT systems</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_SupportCosts" xlink:label="iva_SupportCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_SupportCosts" xlink:to="iva_SupportCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_SupportCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to support costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_SupportCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Support costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iva_SupportCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Support costs (including taxes)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee benefits expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total personnel costs</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DepreciationAmortizationAndProvisions" xlink:label="iva_DepreciationAmortizationAndProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_DepreciationAmortizationAndProvisions" xlink:to="iva_DepreciationAmortizationAndProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_DepreciationAmortizationAndProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to depreciation, amortization and provisions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_DepreciationAmortizationAndProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, amortization and provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iva_DepreciationAmortizationAndProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, amortization and provisions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InsuranceExpense" xlink:label="ifrs-full_InsuranceExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InsuranceExpense" xlink:to="ifrs-full_InsuranceExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InsuranceExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Insurance expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InsuranceExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Insurances</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherOperatingExpenses" xlink:label="iva_OtherOperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_OtherOperatingExpenses" xlink:to="iva_OtherOperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_OtherOperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to other operating expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_OtherOperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iva_OtherOperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other operating expenses</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OperatingExpenseExcludingOtherOperatingIncomeExpense" xlink:label="iva_OperatingExpenseExcludingOtherOperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_OperatingExpenseExcludingOtherOperatingIncomeExpense" xlink:to="iva_OperatingExpenseExcludingOtherOperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_OperatingExpenseExcludingOtherOperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to amount of all operating expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_OperatingExpenseExcludingOtherOperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expense Excluding Other Operating Income Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="iva_OperatingExpenseExcludingOtherOperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_InventivaS.aMember" xlink:label="iva_InventivaS.aMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_InventivaS.aMember" xlink:to="iva_InventivaS.aMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_InventivaS.aMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Inventiva S.A, U.S. affiliate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_InventivaS.aMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventiva S.A [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfEmployees" xlink:label="ifrs-full_NumberOfEmployees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfEmployees" xlink:to="ifrs-full_NumberOfEmployees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WagesAndSalaries" xlink:label="ifrs-full_WagesAndSalaries" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WagesAndSalaries" xlink:to="ifrs-full_WagesAndSalaries_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WagesAndSalaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Wages and salaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_WagesAndSalaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Wages, salaries and similar costs</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PayrollTaxes" xlink:label="iva_PayrollTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_PayrollTaxes" xlink:to="iva_PayrollTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_PayrollTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A class of employee benefits expense that represents payroll taxes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_PayrollTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payroll taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iva_PayrollTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payroll taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss" xlink:label="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss" xlink:to="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Post-employment benefit expense in profit or loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisions for retirement benefit obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense from share-based payment transactions with employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="ifrs-full_DisclosureOfOtherProvisionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherProvisionsTable" xlink:to="ifrs-full_DisclosureOfOtherProvisionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherProvisionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of other provisions [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="ifrs-full_DisclosureOfOtherProvisionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="ifrs-full_DisclosureOfOtherProvisionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherProvisionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of other provisions [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherProvisionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other operating income and expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MiscellaneousOtherOperatingIncome" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Miscellaneous other operating income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other operating income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MiscellaneousOtherOperatingExpense" xlink:to="ifrs-full_MiscellaneousOtherOperatingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Miscellaneous other operating expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:label="ifrs-full_InterestIncomeOnCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:to="ifrs-full_InterestIncomeOnCashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestIncomeOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income on cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestIncomeOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income from cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignExchangeGain" xlink:label="ifrs-full_ForeignExchangeGain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ForeignExchangeGain" xlink:to="ifrs-full_ForeignExchangeGain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ForeignExchangeGain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange gain</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ForeignExchangeGain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange gains</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FairValueVariationGains" xlink:label="iva_FairValueVariationGains" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_FairValueVariationGains" xlink:to="iva_FairValueVariationGains_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_FairValueVariationGains_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of gains recognized for variation in fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_FairValueVariationGains_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Variation Gains</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_FairValueVariationGains_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on fair value variation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpense" xlink:label="ifrs-full_InterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpense" xlink:to="ifrs-full_InterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignExchangeLoss" xlink:label="ifrs-full_ForeignExchangeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ForeignExchangeLoss" xlink:to="ifrs-full_ForeignExchangeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ForeignExchangeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ForeignExchangeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceCost" xlink:label="ifrs-full_OtherFinanceCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinanceCost" xlink:to="ifrs-full_OtherFinanceCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherFinanceCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other finance cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_OtherFinanceCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other financial expenses</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsFairValueAdjustmentOfWarrants" xlink:label="iva_IfrsFairValueAdjustmentOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IfrsFairValueAdjustmentOfWarrants" xlink:to="iva_IfrsFairValueAdjustmentOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IfrsFairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense (income) related to adjustment to fair value of warrant liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IfrsFairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IfrsFairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of the EIB warrants</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations" xlink:label="iva_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations" xlink:to="iva_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share of profit (loss) of associates accounted for using equity method before eliminations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share of profit (loss) of associates accounted for using equity method before eliminations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share of net profit</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_EliminationOfDownstreamSales" xlink:label="iva_EliminationOfDownstreamSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_EliminationOfDownstreamSales" xlink:to="iva_EliminationOfDownstreamSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_EliminationOfDownstreamSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of elimination of downstream sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_EliminationOfDownstreamSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Elimination Of Downstream Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iva_EliminationOfDownstreamSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Elimination of downstream sales</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:to="ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax rate effect of adjustments for current tax of prior periods</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Projected tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:to="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current tax expense (income) and adjustments for current tax of prior periods</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current taxes</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ClinicalTrialsMember" xlink:label="iva_ClinicalTrialsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ClinicalTrialsMember" xlink:to="iva_ClinicalTrialsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ClinicalTrialsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Clinical Trials(CRO).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ClinicalTrialsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical Trials [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_ClinicalTrialsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CRO</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ContractManufacturingOrganizationsMember" xlink:label="iva_ContractManufacturingOrganizationsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ContractManufacturingOrganizationsMember" xlink:to="iva_ContractManufacturingOrganizationsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ContractManufacturingOrganizationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Contract Manufacturing Organizations(CMO).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ContractManufacturingOrganizationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Manufacturing Organizations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_ContractManufacturingOrganizationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CMO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherContingentLiabilitiesMember" xlink:label="ifrs-full_OtherContingentLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherContingentLiabilitiesMember" xlink:to="ifrs-full_OtherContingentLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherContingentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other contingent liabilities [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherContingentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PharmaceuticalResearchAssociatesMember" xlink:label="iva_PharmaceuticalResearchAssociatesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_PharmaceuticalResearchAssociatesMember" xlink:to="iva_PharmaceuticalResearchAssociatesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_PharmaceuticalResearchAssociatesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Pharmaceutical Research Associates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_PharmaceuticalResearchAssociatesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pharmaceutical Research Associates [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_PharmaceuticalResearchAssociatesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pharmaceutical Research Associates</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ChiaTaiTianqingMember" xlink:label="iva_ChiaTaiTianqingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ChiaTaiTianqingMember" xlink:to="iva_ChiaTaiTianqingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ChiaTaiTianqingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">It Represents the member of chia tai tianqing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ChiaTaiTianqingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chia Tai Tianqing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_ChiaTaiTianqingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CTTQ</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ContractCroWithResearchAssociatesGroupeB.vMember" xlink:label="iva_ContractCroWithResearchAssociatesGroupeB.vMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ContractCroWithResearchAssociatesGroupeB.vMember" xlink:to="iva_ContractCroWithResearchAssociatesGroupeB.vMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ContractCroWithResearchAssociatesGroupeB.vMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Contract CRO with PRA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ContractCroWithResearchAssociatesGroupeB.vMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract CRO with Pharmaceutical Research Associates B.V.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_ContractCroWithResearchAssociatesGroupeB.vMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract CRO with Pharmaceutical Research Associates B.V.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractualCapitalCommitments" xlink:label="ifrs-full_ContractualCapitalCommitments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContractualCapitalCommitments" xlink:to="ifrs-full_ContractualCapitalCommitments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ContractualCapitalCommitments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual capital commitments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ContractualCapitalCommitments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total commitments given</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AgreementsConcerningProvisionOfFacilities" xlink:label="iva_AgreementsConcerningProvisionOfFacilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_AgreementsConcerningProvisionOfFacilities" xlink:to="iva_AgreementsConcerningProvisionOfFacilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_AgreementsConcerningProvisionOfFacilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of agreements concerning provision of facilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_AgreementsConcerningProvisionOfFacilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreements concerning the provision of facilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_AgreementsConcerningProvisionOfFacilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreements concerning the provision of facilities</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ContractualCapitalCommitmentReceived" xlink:label="iva_ContractualCapitalCommitmentReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ContractualCapitalCommitmentReceived" xlink:to="iva_ContractualCapitalCommitmentReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ContractualCapitalCommitmentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of contractual capital commitment received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ContractualCapitalCommitmentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Capital Commitment Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="iva_ContractualCapitalCommitmentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total commitments received</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CommitmentsAmountPayableForServicesReceivedUnderContract" xlink:label="iva_CommitmentsAmountPayableForServicesReceivedUnderContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_CommitmentsAmountPayableForServicesReceivedUnderContract" xlink:to="iva_CommitmentsAmountPayableForServicesReceivedUnderContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_CommitmentsAmountPayableForServicesReceivedUnderContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitment amount payable for services received under contract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_CommitmentsAmountPayableForServicesReceivedUnderContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments Amount Payable For Services Received Under Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iva_CommitmentsAmountPayableForServicesReceivedUnderContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount committed to pay</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CommitmentContractualBonusOrMalusCappedAmount" xlink:label="iva_CommitmentContractualBonusOrMalusCappedAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_CommitmentContractualBonusOrMalusCappedAmount" xlink:to="iva_CommitmentContractualBonusOrMalusCappedAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_CommitmentContractualBonusOrMalusCappedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of commitment contractual bonus or malus capped amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_CommitmentContractualBonusOrMalusCappedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitment Contractual Bonus Or Malus Capped Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_CommitmentContractualBonusOrMalusCappedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bonus or malus capped amount</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsotherFinancialInformationTable" xlink:label="iva_IfrsotherFinancialInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IfrsotherFinancialInformationTable" xlink:to="iva_IfrsotherFinancialInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IfrsotherFinancialInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule disclosing information related to other financial information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IfrsotherFinancialInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRSOther Financial Information [Table]</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PresentationOfResultsFromStudyMember" xlink:label="iva_PresentationOfResultsFromStudyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_PresentationOfResultsFromStudyMember" xlink:to="iva_PresentationOfResultsFromStudyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_PresentationOfResultsFromStudyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to the presentation of results from a study.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_PresentationOfResultsFromStudyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Presentation of results from study [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_PresentationOfResultsFromStudyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Presentation of results from study</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IssuanceOfRoyaltyCertificatesMember" xlink:label="iva_IssuanceOfRoyaltyCertificatesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IssuanceOfRoyaltyCertificatesMember" xlink:to="iva_IssuanceOfRoyaltyCertificatesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IssuanceOfRoyaltyCertificatesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for issuance of royalty certificates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IssuanceOfRoyaltyCertificatesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Royalty Certificates [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IssuanceOfRoyaltyCertificatesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of royalty certificates</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinancingAgreementInThreePhasesMember" xlink:label="iva_FinancingAgreementInThreePhasesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_FinancingAgreementInThreePhasesMember" xlink:to="iva_FinancingAgreementInThreePhasesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_FinancingAgreementInThreePhasesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for financing agreement entered in three phases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_FinancingAgreementInThreePhasesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing Agreement in Three Phases [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_FinancingAgreementInThreePhasesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing agreement in three phases</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember" xlink:label="iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember" xlink:to="iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for issue of shares without preferential subscription rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Shares Without Preferential Subscription Rights [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of shares without preferential subscription rights</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember" xlink:label="iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember" xlink:to="iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for issue of shares or warrants without preferential subscription rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Shares or Warrants Without Preferential Subscription Rights [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of shares or warrants without preferential subscription rights</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember" xlink:label="iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember" xlink:to="iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for issue of shares or warrants subject to conditions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Shares or Warrants Subject to Conditions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of shares or warrants subject to conditions</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinancingThroughFundRaisingMember" xlink:label="iva_FinancingThroughFundRaisingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_FinancingThroughFundRaisingMember" xlink:to="iva_FinancingThroughFundRaisingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_FinancingThroughFundRaisingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for financing through fund raising.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_FinancingThroughFundRaisingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing Through Fund Raising [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_FinancingThroughFundRaisingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing through fund raising</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ScenarioOneMember" xlink:label="iva_ScenarioOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ScenarioOneMember" xlink:to="iva_ScenarioOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ScenarioOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for scenario one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ScenarioOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_ScenarioOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First tranche</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ScenarioTwoMember" xlink:label="iva_ScenarioTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ScenarioTwoMember" xlink:to="iva_ScenarioTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ScenarioTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for scenario two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ScenarioTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_ScenarioTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second tranche</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ScenarioThreeMember" xlink:label="iva_ScenarioThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ScenarioThreeMember" xlink:to="iva_ScenarioThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ScenarioThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for scenario three.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ScenarioThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_ScenarioThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third tranche upon publication of pivotal data</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsotherFinancialInformationLineItems" xlink:label="iva_IfrsotherFinancialInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IfrsotherFinancialInformationLineItems" xlink:to="iva_IfrsotherFinancialInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IfrsotherFinancialInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IfrsotherFinancialInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRSOther Financial Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IfrsotherFinancialInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Events after the reporting date</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PercentageOfPatientsInTrialEnrolledInMainCohort" xlink:label="iva_PercentageOfPatientsInTrialEnrolledInMainCohort" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_PercentageOfPatientsInTrialEnrolledInMainCohort" xlink:to="iva_PercentageOfPatientsInTrialEnrolledInMainCohort_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_PercentageOfPatientsInTrialEnrolledInMainCohort_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of patients in trail enrolled in main cohort.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_PercentageOfPatientsInTrialEnrolledInMainCohort_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Patients in Trial, Enrolled in Main Cohort</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_PercentageOfPatientsInTrialEnrolledInMainCohort_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of patients in trial, enrolled in main cohort</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PercentageOfPatientsInTrialEnrolledInExploratoryCohort" xlink:label="iva_PercentageOfPatientsInTrialEnrolledInExploratoryCohort" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_PercentageOfPatientsInTrialEnrolledInExploratoryCohort" xlink:to="iva_PercentageOfPatientsInTrialEnrolledInExploratoryCohort_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_PercentageOfPatientsInTrialEnrolledInExploratoryCohort_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of patients in trail enrolled in exploratory cohort.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_PercentageOfPatientsInTrialEnrolledInExploratoryCohort_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Patients in Trial, Enrolled in Exploratory Cohort</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_PercentageOfPatientsInTrialEnrolledInExploratoryCohort_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of patients in trial, enrolled in exploratory cohort</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfRoyaltyCertificatesIssued" xlink:label="iva_NumberOfRoyaltyCertificatesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_NumberOfRoyaltyCertificatesIssued" xlink:to="iva_NumberOfRoyaltyCertificatesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_NumberOfRoyaltyCertificatesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of royalty certificates issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_NumberOfRoyaltyCertificatesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Royalty Certificates Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_NumberOfRoyaltyCertificatesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of royalty certificates issued</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ProceedsFromFinancing" xlink:label="iva_ProceedsFromFinancing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_ProceedsFromFinancing" xlink:to="iva_ProceedsFromFinancing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_ProceedsFromFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cash proceeds from financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_ProceedsFromFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_ProceedsFromFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross cash proceeds</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany" xlink:label="iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany" xlink:to="iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate amount to be received by the company, either in exchange for new shares or warrants of the Company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Amount To Be Received Either In Exchange For New Shares or Warrants Of The Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate amount to be received either in exchange for new shares or warrants</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_StockIssuedDuringPeriodValue" xlink:label="iva_StockIssuedDuringPeriodValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_StockIssuedDuringPeriodValue" xlink:to="iva_StockIssuedDuringPeriodValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_StockIssuedDuringPeriodValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_StockIssuedDuringPeriodValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_StockIssuedDuringPeriodValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issued during period</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_StockIssuedDuringPeriodShares" xlink:label="iva_StockIssuedDuringPeriodShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_StockIssuedDuringPeriodShares" xlink:to="iva_StockIssuedDuringPeriodShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_StockIssuedDuringPeriodShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_StockIssuedDuringPeriodShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_StockIssuedDuringPeriodShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued during the period</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="iva_IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="iva_IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of securities into which the class of warrant or right may be converted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Class of Warrant or Right, Value of Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of warrant or right, value of number of securities</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_MinimumAmountCommittedForFundRaising" xlink:label="iva_MinimumAmountCommittedForFundRaising" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_MinimumAmountCommittedForFundRaising" xlink:to="iva_MinimumAmountCommittedForFundRaising_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_MinimumAmountCommittedForFundRaising_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum amount committed for borrowing under the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_MinimumAmountCommittedForFundRaising_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Amount Committed For Fund Raising</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_MinimumAmountCommittedForFundRaising_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum amount committed for fund raising</label>
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PeriodWithinWhichPaymentIsReceivedFromSettlement" xlink:label="iva_PeriodWithinWhichPaymentIsReceivedFromSettlement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iva_PeriodWithinWhichPaymentIsReceivedFromSettlement" xlink:to="iva_PeriodWithinWhichPaymentIsReceivedFromSettlement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iva_PeriodWithinWhichPaymentIsReceivedFromSettlement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period within which the payment is made from settlement date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iva_PeriodWithinWhichPaymentIsReceivedFromSettlement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period Within Which Payment is Received From Settlement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iva_PeriodWithinWhichPaymentIsReceivedFromSettlement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Received from settlement</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>iva-20240630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/15/2024 9:52:36 AM-->
<!--Modified on: 10/15/2024 9:52:36 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" roleURI="http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" roleURI="http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" roleURI="http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" roleURI="http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" roleURI="http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureCompanyInformation" roleURI="http://www.inventivapharma.com/role/DisclosureCompanyInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureBasisOfPreparationAndStatementOfCompliance" roleURI="http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfCompliance" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureAccountingPrinciples" roleURI="http://www.inventivapharma.com/role/DisclosureAccountingPrinciples" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPosition" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPosition" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLoss" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureOtherFinancialInformation" roleURI="http://www.inventivapharma.com/role/DisclosureOtherFinancialInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureAccountingPrinciplesPolicies" roleURI="http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureBasisOfPreparationAndStatementOfComplianceTables" roleURI="http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureAccountingPrinciplesTables" roleURI="http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureOtherFinancialInformationTables" roleURI="http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureCompanyInformationDetails" roleURI="http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details" roleURI="http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureAccountingPrinciplesFairValueMeasurementDetails" roleURI="http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureAccountingPrinciplesGoingConcernDetails" roleURI="http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInventoriesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInventoriesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityShareCapitalDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityShareCapitalDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityLiquidityAgreementDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityLiquidityAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails" roleURI="http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsNetProvisionDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsNetProvisionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsChangesInNetProvisionDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsChangesInNetProvisionDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossIncomeTaxDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossIncomeTaxDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossBasicAndDilutedLossPerShareDetails" roleURI="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossBasicAndDilutedLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureOtherFinancialInformationDetails" roleURI="http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="iva-20240630.xsd#DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" roleURI="http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638645827458969935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638645827458969935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638645827458969935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638645827458969935" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638645827458969935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638645827458969935" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638645827458969935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638645827458969935" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638645827458979838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638645827458979838" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638645827458979838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638645827458979838" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638645827458979838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638645827458979838" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638645827458979838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638645827458979838" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" xlink:type="extended" xlink:title="00100 - Statement - Unaudited interim condensed consolidated statement of financial position" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract_638645827458979838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_AssetsAbstract_638645827458979838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract_638645827458979838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_638645827458979838" xlink:to="ifrs-full_NoncurrentAssetsAbstract_638645827458979838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_638645827458979838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638645827458979838" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_638645827458979838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:label="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_638645827458979838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638645827458979838" xlink:to="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_638645827458979838" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxAssets" xlink:label="ifrs-full_DeferredTaxAssets_638645827458979838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638645827458979838" xlink:to="ifrs-full_DeferredTaxAssets_638645827458979838" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_638645827458979838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638645827458979838" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_638645827458979838" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets_638645827458979838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638645827458979838" xlink:to="ifrs-full_OtherNoncurrentAssets_638645827458979838" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets_638645827458989864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638645827458979838" xlink:to="ifrs-full_NoncurrentAssets_638645827458989864" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract_638645827458989864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_638645827458979838" xlink:to="ifrs-full_CurrentAssetsAbstract_638645827458989864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories_638645827458989864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638645827458989864" xlink:to="ifrs-full_Inventories_638645827458989864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_638645827458989864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638645827458989864" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_638645827458989864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="ifrs-full_CurrentTaxAssetsCurrent_638645827458989864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638645827458989864" xlink:to="ifrs-full_CurrentTaxAssetsCurrent_638645827458989864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets" xlink:label="ifrs-full_OtherCurrentAssets_638645827458989864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638645827458989864" xlink:to="ifrs-full_OtherCurrentAssets_638645827458989864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638645827458989864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638645827458989864" xlink:to="ifrs-full_CashAndCashEquivalents_638645827458989864" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets_638645827458989864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638645827458989864" xlink:to="ifrs-full_CurrentAssets_638645827458989864" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets_638645827458999951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_638645827458979838" xlink:to="ifrs-full_Assets_638645827458999951" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_638645827458999951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_638645827458999951" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract_638645827458999951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_638645827458999951" xlink:to="ifrs-full_EquityAbstract_638645827458999951" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital_638645827458999951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638645827458999951" xlink:to="ifrs-full_IssuedCapital_638645827458999951" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremium" xlink:label="ifrs-full_SharePremium_638645827458999951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638645827458999951" xlink:to="ifrs-full_SharePremium_638645827458999951" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares" xlink:label="iva_RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares_638645827458999951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638645827458999951" xlink:to="iva_RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares_638645827458999951" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslation" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_638645827458999951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638645827458999951" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslation_638645827458999951" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsProfitLossForReportingPeriod" xlink:label="ifrs-full_RetainedEarningsProfitLossForReportingPeriod_638645827458999951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638645827458999951" xlink:to="ifrs-full_RetainedEarningsProfitLossForReportingPeriod_638645827458999951" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638645827459009882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638645827458999951" xlink:to="ifrs-full_Equity_638645827459009882" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_638645827459009882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_638645827458999951" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_638645827459009882" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities" xlink:label="iva_NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities_638645827459009882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_638645827459009882" xlink:to="iva_NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities_638645827459009882" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities_638645827459009882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_638645827459009882" xlink:to="ifrs-full_NoncurrentDerivativeFinancialLiabilities_638645827459009882" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued" xlink:label="iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued_638645827459009882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_638645827459009882" xlink:to="iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued_638645827459009882" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentProvisionsForEmployeeBenefits" xlink:label="ifrs-full_NoncurrentProvisionsForEmployeeBenefits_638645827459009882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_638645827459009882" xlink:to="ifrs-full_NoncurrentProvisionsForEmployeeBenefits_638645827459009882" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities_638645827459009882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_638645827459009882" xlink:to="ifrs-full_NoncurrentContractLiabilities_638645827459009882" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="ifrs-full_OtherNoncurrentLiabilities_638645827459009882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_638645827459009882" xlink:to="ifrs-full_OtherNoncurrentLiabilities_638645827459009882" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities_638645827459020067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_638645827459009882" xlink:to="ifrs-full_NoncurrentLiabilities_638645827459020067" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_638645827459020067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_638645827458999951" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_638645827459020067" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities" xlink:label="iva_CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities_638645827459020067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638645827459020067" xlink:to="iva_CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities_638645827459020067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_638645827459020067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638645827459020067" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_638645827459020067" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities_638645827459020067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638645827459020067" xlink:to="ifrs-full_CurrentContractLiabilities_638645827459020067" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities_638645827459020067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638645827459020067" xlink:to="ifrs-full_OtherCurrentLiabilities_638645827459020067" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities_638645827459020067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638645827459020067" xlink:to="ifrs-full_CurrentLiabilities_638645827459020067" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities_638645827459030042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638645827459020067" xlink:to="ifrs-full_Liabilities_638645827459030042" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities_638645827459030042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_638645827458999951" xlink:to="ifrs-full_EquityAndLiabilities_638645827459030042" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss" xlink:type="extended" xlink:title="00200 - Statement - Unaudited interim condensed consolidated statement of income (loss)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_RevenueAndOperatingIncomeAbstract" xlink:label="iva_RevenueAndOperatingIncomeAbstract_638645827459030042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="iva_RevenueAndOperatingIncomeAbstract_638645827459030042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue_638645827459030042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_RevenueAndOperatingIncomeAbstract_638645827459030042" xlink:to="ifrs-full_Revenue_638645827459030042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherIncomeFromOrdinaryActivities" xlink:label="iva_OtherIncomeFromOrdinaryActivities_638645827459030042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_RevenueAndOperatingIncomeAbstract_638645827459030042" xlink:to="iva_OtherIncomeFromOrdinaryActivities_638645827459030042" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueAndOperatingIncome" xlink:label="ifrs-full_RevenueAndOperatingIncome_638645827459030042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_RevenueAndOperatingIncomeAbstract_638645827459030042" xlink:to="ifrs-full_RevenueAndOperatingIncome_638645827459030042" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_638645827459030042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_638645827459030042" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="ifrs-full_SalesAndMarketingExpense_638645827459039869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ifrs-full_SalesAndMarketingExpense_638645827459039869" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_638645827459039869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_638645827459039869" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense" xlink:label="ifrs-full_OtherOperatingIncomeExpense_638645827459039869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ifrs-full_OtherOperatingIncomeExpense_638645827459039869" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_638645827459039869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_638645827459039869" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_638645827459039869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ifrs-full_FinanceIncome_638645827459039869" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_638645827459039869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ifrs-full_FinanceCosts_638645827459039869" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost_638645827459039869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ifrs-full_FinanceIncomeCost_638645827459039869" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_638645827459039869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_638645827459039869" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_638645827459039869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_638645827459039869" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638645827459039869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLoss_638645827459039869" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare_638645827459039869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare_638645827459039869" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare_638645827459039869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare_638645827459039869" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares_638645827459049876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ifrs-full_WeightedAverageShares_638645827459049876" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="ifrs-full_AdjustedWeightedAverageShares_638645827459049876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ifrs-full_AdjustedWeightedAverageShares_638645827459049876" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" xlink:type="extended" xlink:title="00300 - Statement - Unaudited interim condensed consolidated statement of comprehensive (income) loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="StatementOfComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638645827459049876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ProfitLoss_638645827459049876" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_638645827459049876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_638645827459049876" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax_638645827459049876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax_638645827459049876" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_638645827459049876" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_638645827459049876" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_638645827459059776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_638645827459059776" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_638645827459059776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_638645827459059776" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome_638645827459059776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ComprehensiveIncome_638645827459059776" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" xlink:type="extended" xlink:title="00400 - Statement - Unaudited interim condensed consolidated statement of changes in shareholders' equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="StatementOfChangesInEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable_638645827459059776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable_638645827459059776" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis_638645827459059776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_638645827459059776" xlink:to="ifrs-full_ComponentsOfEquityAxis_638645827459059776" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember_638645827459059776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638645827459059776" xlink:to="ifrs-full_IssuedCapitalMember_638645827459059776" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember_638645827459059776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638645827459059776" xlink:to="ifrs-full_SharePremiumMember_638645827459059776" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember" xlink:label="ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_638645827459059776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638645827459059776" xlink:to="ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_638645827459059776" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_638645827459059776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638645827459059776" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_638645827459059776" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember" xlink:label="iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_638645827459059776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638645827459059776" xlink:to="iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_638645827459059776" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_638645827459059776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638645827459059776" xlink:to="ifrs-full_EquityMember_638645827459059776" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_638645827459059776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_638645827459059776" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_638645827459059776" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638645827459069530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638645827459059776" xlink:to="ifrs-full_Equity_638645827459069530" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding_638645827459069530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638645827459059776" xlink:to="ifrs-full_NumberOfSharesOutstanding_638645827459069530" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638645827459069530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638645827459059776" xlink:to="ifrs-full_ProfitLoss_638645827459069530" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_638645827459069530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638645827459059776" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans_638645827459069530" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod" xlink:label="iva_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod_638645827459069530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638645827459059776" xlink:to="iva_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod_638645827459069530" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome_638645827459069530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638645827459059776" xlink:to="ifrs-full_ComprehensiveIncome_638645827459069530" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings" xlink:label="ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings_638645827459069530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638645827459059776" xlink:to="ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings_638645827459069530" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_638645827459069530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638645827459059776" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_638645827459069530" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseDecreaseThroughShareWarrantsSubscriptionPremium" xlink:label="iva_IncreaseDecreaseThroughShareWarrantsSubscriptionPremium_638645827459069530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638645827459059776" xlink:to="iva_IncreaseDecreaseThroughShareWarrantsSubscriptionPremium_638645827459069530" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_638645827459069530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638645827459059776" xlink:to="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_638645827459069530" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_638645827459079532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638645827459059776" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity_638645827459079532" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding_638645827459079532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638645827459059776" xlink:to="ifrs-full_NumberOfSharesOutstanding_638645827459079532" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638645827459079532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638645827459059776" xlink:to="ifrs-full_Equity_638645827459079532" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows" xlink:type="extended" xlink:title="00500 - Statement - Unaudited interim condensed consolidated statement of cash flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638645827459079532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638645827459079532" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638645827459079532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638645827459079532" xlink:to="ifrs-full_ProfitLoss_638645827459079532" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638645827459079532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638645827459079532" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638645827459079532" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AdjustmentsForDepreciationAmortisationAndProvisions" xlink:label="iva_AdjustmentsForDepreciationAmortisationAndProvisions_638645827459079532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638645827459079532" xlink:to="iva_AdjustmentsForDepreciationAmortisationAndProvisions_638645827459079532" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:label="ifrs-full_AdjustmentsForIncomeTaxExpense_638645827459079532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638645827459079532" xlink:to="ifrs-full_AdjustmentsForIncomeTaxExpense_638645827459079532" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AdjustmentsForTaxCredits" xlink:label="iva_AdjustmentsForTaxCredits_638645827459079532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638645827459079532" xlink:to="iva_AdjustmentsForTaxCredits_638645827459079532" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_638645827459089532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638645827459079532" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost_638645827459089532" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_638645827459089532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638645827459079532" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_638645827459089532" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUndistributedProfitsOfAssociates" xlink:label="ifrs-full_AdjustmentsForUndistributedProfitsOfAssociates_638645827459089532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638645827459079532" xlink:to="ifrs-full_AdjustmentsForUndistributedProfitsOfAssociates_638645827459089532" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_638645827459089532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638645827459079532" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_638645827459089532" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFairValueGainsLosses" xlink:label="ifrs-full_AdjustmentsForFairValueGainsLosses_638645827459089532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638645827459079532" xlink:to="ifrs-full_AdjustmentsForFairValueGainsLosses_638645827459089532" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAdjustmentsForNoncashItems" xlink:label="ifrs-full_OtherAdjustmentsForNoncashItems_638645827459089532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638645827459079532" xlink:to="ifrs-full_OtherAdjustmentsForNoncashItems_638645827459089532" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:label="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_638645827459089532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638645827459079532" xlink:to="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_638645827459089532" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_638645827459089532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_638645827459089532" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_638645827459089532" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_638645827459089532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_638645827459089532" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_638645827459089532" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_638645827459089532" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_638645827459089532" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_638645827459089532" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_638645827459099572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_638645827459089532" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_638645827459099572" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities" xlink:label="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_638645827459099572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_638645827459089532" xlink:to="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities_638645827459099572" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital_638645827459099572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_638645827459089532" xlink:to="ifrs-full_IncreaseDecreaseInWorkingCapital_638645827459099572" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_638645827459099572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638645827459079532" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_638645827459099572" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638645827459099572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638645827459099572" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="iva_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities_638645827459099572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638645827459099572" xlink:to="iva_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities_638645827459099572" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="iva_ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities_638645827459099572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638645827459099572" xlink:to="iva_ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities_638645827459099572" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_638645827459109582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638645827459099572" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments_638645827459109582" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities" xlink:label="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities_638645827459109582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638645827459099572" xlink:to="ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities_638645827459109582" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_638645827459109582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638645827459099572" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_638645827459109582" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638645827459109582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638645827459109582" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NetProceedsFromIssuingShares" xlink:label="iva_NetProceedsFromIssuingShares_638645827459109582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638645827459109582" xlink:to="iva_NetProceedsFromIssuingShares_638645827459109582" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_638645827459109582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638645827459109582" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_638645827459109582" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_638645827459119507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638645827459109582" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_638645827459119507" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_638645827459119507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638645827459109582" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_638645827459119507" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_638645827459119507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638645827459109582" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_638645827459119507" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_638645827459119507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_638645827459119507" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638645827459119507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_638645827459119507" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_638645827459119507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_638645827459119507" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_6386458274591195071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_6386458274591195071" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureCompanyInformation" xlink:type="extended" xlink:title="10101 - Disclosure - Company information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CompanyInformationAbstract" xlink:label="CompanyInformationAbstract" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CompanyInformationTextBlock" xlink:label="iva_CompanyInformationTextBlock_638645827459129509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompanyInformationAbstract" xlink:to="iva_CompanyInformationTextBlock_638645827459129509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfCompliance" xlink:type="extended" xlink:title="10201 - Disclosure - Basis of preparation and statement of compliance" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_StatementOfComplianceAbstract" xlink:label="StatementOfComplianceAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfIFRSCompliance" xlink:label="ifrs-full_StatementOfIFRSCompliance_638645827459129509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComplianceAbstract" xlink:to="ifrs-full_StatementOfIFRSCompliance_638645827459129509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureAccountingPrinciples" xlink:type="extended" xlink:title="10301 - Disclosure - Accounting Principles" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AccountingPrinciplesAbstract" xlink:label="AccountingPrinciplesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_638645827459139477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPrinciplesAbstract" xlink:to="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_638645827459139477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPosition" xlink:type="extended" xlink:title="10401 - Disclosure - Notes to the interim condensed consolidated statement of financial position" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock" xlink:label="iva_DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock_638645827459139477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:to="iva_DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock_638645827459139477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLoss" xlink:type="extended" xlink:title="10501 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ComponentsOfIncomeStatementAbstract" xlink:label="iva_ComponentsOfIncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfComponentsOfIncomeStatementTextBlock" xlink:label="iva_DisclosureOfComponentsOfIncomeStatementTextBlock_638645827459189529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract" xlink:to="iva_DisclosureOfComponentsOfIncomeStatementTextBlock_638645827459189529" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureOtherFinancialInformation" xlink:type="extended" xlink:title="10601 - Disclosure - Other financial information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherFinancialInformationAbstract" xlink:label="iva_OtherFinancialInformationAbstract" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfOtherFinancialInformationTextblock" xlink:label="iva_DisclosureOfOtherFinancialInformationTextblock_638645827459189529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_OtherFinancialInformationAbstract" xlink:to="iva_DisclosureOfOtherFinancialInformationTextblock_638645827459189529" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" xlink:type="extended" xlink:title="20302 - Disclosure - Accounting Principles (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AccountingPrinciplesAbstract" xlink:label="AccountingPrinciplesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_638645827459189529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPrinciplesAbstract" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_638645827459189529" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_638645827459189529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPrinciplesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_638645827459189529" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock" xlink:label="iva_DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock_638645827459189529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPrinciplesAbstract" xlink:to="iva_DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock_638645827459189529" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGoingConcernExplanatory" xlink:label="ifrs-full_DisclosureOfGoingConcernExplanatory_638645827459189529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPrinciplesAbstract" xlink:to="ifrs-full_DisclosureOfGoingConcernExplanatory_638645827459189529" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceTables" xlink:type="extended" xlink:title="30203 - Disclosure - Basis of preparation and statement of compliance (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_StatementOfComplianceAbstract" xlink:label="StatementOfComplianceAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory" xlink:label="ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory_638645827459199674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComplianceAbstract" xlink:to="ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory_638645827459199674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:label="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_638645827459199674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComplianceAbstract" xlink:to="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory_638645827459199674" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesTables" xlink:type="extended" xlink:title="30303 - Disclosure - Accounting Principles (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AccountingPrinciplesAbstract" xlink:label="AccountingPrinciplesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_638645827459199674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPrinciplesAbstract" xlink:to="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_638645827459199674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables" xlink:type="extended" xlink:title="30403 - Disclosure - Notes to the interim condensed consolidated statement of financial position (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638645827459199674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_1" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638645827459199674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638645827459199674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638645827459199674" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638645827459199674" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638645827459199674" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638645827459199674" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638645827459199674" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BspceAndBsaShareWarrantsMember" xlink:label="iva_BspceAndBsaShareWarrantsMember_638645827459209815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638645827459199674" xlink:to="iva_BspceAndBsaShareWarrantsMember_638645827459209815" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewBonusShareAwardPlan20231Member" xlink:label="iva_NewBonusShareAwardPlan20231Member_638645827459209815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638645827459199674" xlink:to="iva_NewBonusShareAwardPlan20231Member_638645827459209815" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LongTermIncentivePlanInPerformanceUnits2023Member" xlink:label="iva_LongTermIncentivePlanInPerformanceUnits2023Member_638645827459209815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638645827459199674" xlink:to="iva_LongTermIncentivePlanInPerformanceUnits2023Member_638645827459209815" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459209815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638645827459199674" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459209815" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_638645827459209815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459209815" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_638645827459209815" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_638645827459209815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459209815" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_638645827459209815" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory" xlink:label="ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory_638645827459209815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459209815" xlink:to="ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory_638645827459209815" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfOtherNoncurrentAssetsTableTextBlock" xlink:label="iva_DisclosureOfOtherNoncurrentAssetsTableTextBlock_638645827459209815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459209815" xlink:to="iva_DisclosureOfOtherNoncurrentAssetsTableTextBlock_638645827459209815" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsScheduleOfInventoryCurrentTableTextBlock" xlink:label="iva_IfrsScheduleOfInventoryCurrentTableTextBlock_638645827459209815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459209815" xlink:to="iva_IfrsScheduleOfInventoryCurrentTableTextBlock_638645827459209815" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfTradeReceivablesTableTextBlock" xlink:label="iva_DisclosureOfTradeReceivablesTableTextBlock_638645827459209815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459209815" xlink:to="iva_DisclosureOfTradeReceivablesTableTextBlock_638645827459209815" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_638645827459209815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459209815" xlink:to="ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory_638645827459209815" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfCashAndCashEquivalentsTableTextBlock" xlink:label="iva_DisclosureOfCashAndCashEquivalentsTableTextBlock_638645827459209815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459209815" xlink:to="iva_DisclosureOfCashAndCashEquivalentsTableTextBlock_638645827459209815" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_638645827459209815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459209815" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_638645827459209815" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_638645827459209815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459209815" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_638645827459209815" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_638645827459219835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459209815" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory_638645827459219835" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfChangesInBorrowingsTableTextBlock" xlink:label="iva_DisclosureOfChangesInBorrowingsTableTextBlock_638645827459219835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459209815" xlink:to="iva_DisclosureOfChangesInBorrowingsTableTextBlock_638645827459219835" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock" xlink:label="iva_DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock_638645827459219835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459209815" xlink:to="iva_DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock_638645827459219835" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory" xlink:label="iva_DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory_638645827459219835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459209815" xlink:to="iva_DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory_638645827459219835" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory" xlink:label="iva_DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory_638645827459219835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459209815" xlink:to="iva_DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory_638645827459219835" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory" xlink:label="iva_DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory_638645827459219835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459209815" xlink:to="iva_DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory_638645827459219835" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities" xlink:label="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_638645827459219835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459209815" xlink:to="ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities_638645827459219835" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock_638645827459219835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459209815" xlink:to="iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock_638645827459219835" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_638645827459219835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459209815" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_638645827459219835" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory_638645827459229864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459209815" xlink:to="ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory_638645827459229864" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_638645827459229864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459209815" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_638645827459229864" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables" xlink:type="extended" xlink:title="30503 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ComponentsOfIncomeStatementAbstract" xlink:label="iva_ComponentsOfIncomeStatementAbstract_1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_RevenueAndOtherIncomeTableTextBlock" xlink:label="iva_RevenueAndOtherIncomeTableTextBlock_638645827459229864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_1" xlink:to="iva_RevenueAndOtherIncomeTableTextBlock_638645827459229864" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ResearchAndDevelopmentMarketingTableTextBlock" xlink:label="iva_ResearchAndDevelopmentMarketingTableTextBlock_638645827459229864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_1" xlink:to="iva_ResearchAndDevelopmentMarketingTableTextBlock_638645827459229864" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PersonnelCostsAndHeadcount" xlink:label="iva_PersonnelCostsAndHeadcount_638645827459229864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_1" xlink:to="iva_PersonnelCostsAndHeadcount_638645827459229864" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock" xlink:label="iva_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock_638645827459229864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_1" xlink:to="iva_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock_638645827459229864" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinancialIncomeAndExpensesTableTextBlock" xlink:label="iva_FinancialIncomeAndExpensesTableTextBlock_638645827459229864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_1" xlink:to="iva_FinancialIncomeAndExpensesTableTextBlock_638645827459229864" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock" xlink:label="iva_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock_638645827459229864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_1" xlink:to="iva_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock_638645827459229864" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="ifrs-full_EarningsPerShareExplanatory_638645827459229864" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_1" xlink:to="ifrs-full_EarningsPerShareExplanatory_638645827459229864" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationTables" xlink:type="extended" xlink:title="30603 - Disclosure - Other financial information (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherFinancialInformationAbstract" xlink:label="iva_OtherFinancialInformationAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_638645827459239522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_OtherFinancialInformationAbstract_1" xlink:to="ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_638645827459239522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Company information - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CompanyInformationAbstract" xlink:label="CompanyInformationAbstract" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_638645827459239522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompanyInformationAbstract" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_638645827459239522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827459239522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_638645827459239522" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827459239522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459239522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827459239522" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459239522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember" xlink:label="iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember_638645827459239522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459239522" xlink:to="iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember_638645827459239522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember" xlink:label="iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_638645827459239522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459239522" xlink:to="iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_638645827459239522" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember" xlink:label="iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_638645827459239522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459239522" xlink:to="iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_638645827459239522" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember" xlink:label="iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember_638645827459239522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459239522" xlink:to="iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember_638645827459239522" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_638645827459239522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_638645827459239522" xlink:to="ifrs-full_RangeAxis_638645827459239522" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638645827459239522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_638645827459239522" xlink:to="ifrs-full_RangesMember_638645827459239522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember_638645827459249867" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638645827459239522" xlink:to="ifrs-full_TopOfRangeMember_638645827459249867" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember_638645827459249867" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638645827459239522" xlink:to="ifrs-full_BottomOfRangeMember_638645827459249867" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638645827459249867" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_638645827459239522" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638645827459249867" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember_638645827459249867" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638645827459249867" xlink:to="ifrs-full_NonadjustingEventsMember_638645827459249867" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember" xlink:label="iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember_638645827459249867" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember_638645827459249867" xlink:to="iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember_638645827459249867" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LicensingAgreementWithHepalysMember" xlink:label="iva_LicensingAgreementWithHepalysMember_638645827459249867" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember_638645827459249867" xlink:to="iva_LicensingAgreementWithHepalysMember_638645827459249867" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_638645827459249867" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_638645827459239522" xlink:to="srt_OwnershipAxis_638645827459249867" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_638645827459249867" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_638645827459249867" xlink:to="srt_OwnershipDomain_638645827459249867" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_HepalysPharmaIncMember" xlink:label="iva_HepalysPharmaIncMember_638645827459260268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_638645827459249867" xlink:to="iva_HepalysPharmaIncMember_638645827459260268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis_638645827459260268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_638645827459239522" xlink:to="ifrs-full_BorrowingsByNameAxis_638645827459260268" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember_638645827459260268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis_638645827459260268" xlink:to="ifrs-full_BorrowingsByNameMember_638645827459260268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankMember_638645827459260268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember_638645827459260268" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankMember_638645827459260268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_638645827459260268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_FinanceContractWithEuropeanInvestmentBankMember_638645827459260268" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_638645827459260268" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_638645827459260268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember_638645827459260268" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_638645827459260268" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459260268" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_638645827459239522" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459260268" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_MaximumDurationOfClinicalTrial" xlink:label="iva_MaximumDurationOfClinicalTrial_638645827459269578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459260268" xlink:to="iva_MaximumDurationOfClinicalTrial_638645827459269578" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfBiopsiesUnderClinicalTrials" xlink:label="iva_NumberOfBiopsiesUnderClinicalTrials_638645827459269578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459260268" xlink:to="iva_NumberOfBiopsiesUnderClinicalTrials_638645827459269578" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfWeeksUnderActiveTreatmentExtensionStudy" xlink:label="iva_NumberOfWeeksUnderActiveTreatmentExtensionStudy_638645827459269578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459260268" xlink:to="iva_NumberOfWeeksUnderActiveTreatmentExtensionStudy_638645827459269578" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LicenseAndCollaborationAgreementUpfrontFeeReceivable" xlink:label="iva_LicenseAndCollaborationAgreementUpfrontFeeReceivable_638645827459269578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459260268" xlink:to="iva_LicenseAndCollaborationAgreementUpfrontFeeReceivable_638645827459269578" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones" xlink:label="iva_LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones_638645827459269578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459260268" xlink:to="iva_LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones_638645827459269578" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OptionToAcquireSharesInCompanyPercentage" xlink:label="iva_OptionToAcquireSharesInCompanyPercentage_638645827459269578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459260268" xlink:to="iva_OptionToAcquireSharesInCompanyPercentage_638645827459269578" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare" xlink:label="iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare_638645827459269578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459260268" xlink:to="iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare_638645827459269578" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_638645827459279541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459260268" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_638645827459279541" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638645827459279541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459260268" xlink:to="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638645827459279541" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfPatientsRandomizedClinicalTrialMainCohort" xlink:label="iva_NumberOfPatientsRandomizedClinicalTrialMainCohort_638645827459279541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459260268" xlink:to="iva_NumberOfPatientsRandomizedClinicalTrialMainCohort_638645827459279541" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount_638645827459279541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459260268" xlink:to="ifrs-full_NotionalAmount_638645827459279541" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy" xlink:label="iva_DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy_638645827459279541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459260268" xlink:to="iva_DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy_638645827459279541" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DailyDoseOfLanifibranorInTrial" xlink:label="iva_DailyDoseOfLanifibranorInTrial_638645827459279541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459260268" xlink:to="iva_DailyDoseOfLanifibranorInTrial_638645827459279541" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DailyDoseOfEmpagliflozinInTrial" xlink:label="iva_DailyDoseOfEmpagliflozinInTrial_638645827459289698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459260268" xlink:to="iva_DailyDoseOfEmpagliflozinInTrial_638645827459289698" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d" xlink:label="iva_DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d_638645827459289698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459260268" xlink:to="iva_DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d_638645827459289698" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d" xlink:label="iva_DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d_638645827459289698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459260268" xlink:to="iva_DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d_638645827459289698" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff" xlink:label="iva_DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff_638645827459289698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459260268" xlink:to="iva_DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff_638645827459289698" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PercentageOfPatientsTreatedInTrial" xlink:label="iva_PercentageOfPatientsTreatedInTrial_638645827459289698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459260268" xlink:to="iva_PercentageOfPatientsTreatedInTrial_638645827459289698" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DemonstratedSignificantRelativeReductionInVatSatRatioInPatients" xlink:label="iva_DemonstratedSignificantRelativeReductionInVatSatRatioInPatients_638645827459289698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459260268" xlink:to="iva_DemonstratedSignificantRelativeReductionInVatSatRatioInPatients_638645827459289698" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TreatmentPeriodUnderStudy" xlink:label="iva_TreatmentPeriodUnderStudy_638645827459289698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459260268" xlink:to="iva_TreatmentPeriodUnderStudy_638645827459289698" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfPatientsRandomizedForTreatment" xlink:label="iva_NumberOfPatientsRandomizedForTreatment_638645827459299830" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459260268" xlink:to="iva_NumberOfPatientsRandomizedForTreatment_638645827459299830" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfPatientsToBeTreatedForFortyEightWeeks" xlink:label="iva_NumberOfPatientsToBeTreatedForFortyEightWeeks_638645827459299830" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459260268" xlink:to="iva_NumberOfPatientsToBeTreatedForFortyEightWeeks_638645827459299830" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfPatientsToBeTreatedForSeventyTwoWeeks" xlink:label="iva_NumberOfPatientsToBeTreatedForSeventyTwoWeeks_638645827459299830" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459260268" xlink:to="iva_NumberOfPatientsToBeTreatedForSeventyTwoWeeks_638645827459299830" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details" xlink:type="extended" xlink:title="40102 - Disclosure - Company information - Significant events in the first half of 2024 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CompanyInformationAbstract" xlink:label="iva_CompanyInformationAbstract_4" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_638645827459299830" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_CompanyInformationAbstract_4" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_638645827459299830" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638645827459299830" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_638645827459299830" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638645827459299830" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember_638645827459310009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638645827459299830" xlink:to="ifrs-full_NonadjustingEventsMember_638645827459310009" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DrawdownOfBorrowingsMember" xlink:label="iva_DrawdownOfBorrowingsMember_638645827459310009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember_638645827459310009" xlink:to="iva_DrawdownOfBorrowingsMember_638645827459310009" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827459310009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_638645827459299830" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827459310009" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459310009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827459310009" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459310009" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantAgreementWithEuropeanInvestmentBankMember" xlink:label="iva_WarrantAgreementWithEuropeanInvestmentBankMember_638645827459310009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459310009" xlink:to="iva_WarrantAgreementWithEuropeanInvestmentBankMember_638645827459310009" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember" xlink:label="iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember_638645827459310009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459310009" xlink:to="iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember_638645827459310009" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember" xlink:label="iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_638645827459310009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459310009" xlink:to="iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_638645827459310009" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis_638645827459310009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_638645827459299830" xlink:to="ifrs-full_BorrowingsByNameAxis_638645827459310009" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember_638645827459310009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis_638645827459310009" xlink:to="ifrs-full_BorrowingsByNameMember_638645827459310009" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankMember_638645827459310009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember_638645827459310009" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankMember_638645827459310009" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_638645827459310009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_FinanceContractWithEuropeanInvestmentBankMember_638645827459310009" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_638645827459310009" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_638645827459310009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_FinanceContractWithEuropeanInvestmentBankMember_638645827459310009" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_638645827459310009" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_638645827459319669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_638645827459299830" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_638645827459319669" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember_638645827459319669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_638645827459319669" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember_638645827459319669" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_638645827459319669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember_638645827459319669" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_638645827459319669" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459319669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_638645827459299830" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459319669" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfWarrantsIssued" xlink:label="iva_NumberOfWarrantsIssued_638645827459319669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459319669" xlink:to="iva_NumberOfWarrantsIssued_638645827459319669" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants" xlink:label="iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants_638645827459319669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459319669" xlink:to="iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants_638645827459319669" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised" xlink:label="iva_PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised_638645827459319669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459319669" xlink:to="iva_PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised_638645827459319669" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_638645827459319669" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459319669" xlink:to="iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_638645827459319669" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares" xlink:label="iva_ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares_638645827459329625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459319669" xlink:to="iva_ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares_638645827459329625" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ClassOfWarrantOrRightMaturityTerm" xlink:label="iva_ClassOfWarrantOrRightMaturityTerm_638645827459329625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459319669" xlink:to="iva_ClassOfWarrantOrRightMaturityTerm_638645827459329625" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantsTerm" xlink:label="iva_WarrantsTerm_638645827459329625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459319669" xlink:to="iva_WarrantsTerm_638645827459329625" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_SharesIssuableUponExerciseOfWarrants" xlink:label="iva_SharesIssuableUponExerciseOfWarrants_638645827459329625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459319669" xlink:to="iva_SharesIssuableUponExerciseOfWarrants_638645827459329625" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_MaximumGrossProceedsReceivableUponExerciseOfWarrants" xlink:label="iva_MaximumGrossProceedsReceivableUponExerciseOfWarrants_638645827459329625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459319669" xlink:to="iva_MaximumGrossProceedsReceivableUponExerciseOfWarrants_638645827459329625" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount_638645827459329625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459319669" xlink:to="ifrs-full_NotionalAmount_638645827459329625" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_638645827459329625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459319669" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_638645827459329625" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AmountInvoicedToCounterpartyForInitialPayment" xlink:label="iva_AmountInvoicedToCounterpartyForInitialPayment_638645827459329625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459319669" xlink:to="iva_AmountInvoicedToCounterpartyForInitialPayment_638645827459329625" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638645827459339650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459319669" xlink:to="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638645827459339650" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate_638645827459339650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459319669" xlink:to="ifrs-full_BorrowingsInterestRate_638645827459339650" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsDebtInstrumentTerm" xlink:label="iva_IfrsDebtInstrumentTerm_638645827459339650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459319669" xlink:to="iva_IfrsDebtInstrumentTerm_638645827459339650" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments" xlink:label="iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments_638645827459339650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459319669" xlink:to="iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments_638645827459339650" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction" xlink:label="iva_MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction_638645827459339650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459319669" xlink:to="iva_MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction_638645827459339650" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfSitesOperatingUnderCentralIrbOverseeing" xlink:label="iva_NumberOfSitesOperatingUnderCentralIrbOverseeing_638645827459339650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459319669" xlink:to="iva_NumberOfSitesOperatingUnderCentralIrbOverseeing_638645827459339650" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PercentageOfPatientsRandomizedInMainCohort" xlink:label="iva_PercentageOfPatientsRandomizedInMainCohort_638645827459339650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459319669" xlink:to="iva_PercentageOfPatientsRandomizedInMainCohort_638645827459339650" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TreatmentPeriodUnderStudy" xlink:label="iva_TreatmentPeriodUnderStudy_638645827459349513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_638645827459319669" xlink:to="iva_TreatmentPeriodUnderStudy_638645827459349513" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Basis of preparation and statement of compliance - Significant Investments In Subsidiaries (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_StatementOfComplianceAbstract" xlink:label="StatementOfComplianceAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_638645827459349513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComplianceAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_638645827459349513" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_638645827459349513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_638645827459349513" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_638645827459349513" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember_638645827459349513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_638645827459349513" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember_638645827459349513" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_InventivaIncMember" xlink:label="iva_InventivaIncMember_638645827459349513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember_638645827459349513" xlink:to="iva_InventivaIncMember_638645827459349513" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis_638645827459349513" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_638645827459349513" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis_638645827459349513" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="ifrs-full_EntitysTotalForAssociatesMember_638645827459359646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis_638645827459349513" xlink:to="ifrs-full_EntitysTotalForAssociatesMember_638645827459359646" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_HepalysPharmaIncMember" xlink:label="iva_HepalysPharmaIncMember_638645827459359646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForAssociatesMember_638645827459359646" xlink:to="iva_HepalysPharmaIncMember_638645827459359646" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_638645827459359646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_638645827459349513" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_638645827459359646" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfEntitiesBeingConsolidated" xlink:label="iva_NumberOfEntitiesBeingConsolidated_638645827459359646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_638645827459359646" xlink:to="iva_NumberOfEntitiesBeingConsolidated_638645827459359646" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_638645827459359646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_638645827459359646" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_638645827459359646" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncontrollingInterests" xlink:label="ifrs-full_NoncontrollingInterests_638645827459359646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_638645827459359646" xlink:to="ifrs-full_NoncontrollingInterests_638645827459359646" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_638645827459359646" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_638645827459359646" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate_638645827459359646" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Basis of preparation and statement of compliance - Foreign Exchange Rates (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignExchangeRatesAbstract" xlink:label="ForeignExchangeRatesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageForeignExchangeRate" xlink:label="ifrs-full_AverageForeignExchangeRate_638645827459369506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ForeignExchangeRatesAbstract" xlink:to="ifrs-full_AverageForeignExchangeRate_638645827459369506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="ifrs-full_ClosingForeignExchangeRate_638645827459369506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ForeignExchangeRatesAbstract" xlink:to="ifrs-full_ClosingForeignExchangeRate_638645827459369506" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Accounting Principles - Fair value measurement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AccountingPrinciplesAbstract" xlink:label="AccountingPrinciplesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable_638645827459369506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPrinciplesAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable_638645827459369506" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_638645827459369506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_638645827459369506" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis_638645827459369506" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember_638645827459369506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis_638645827459369506" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember_638645827459369506" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_638645827459369506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember_638645827459369506" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_638645827459369506" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis_638645827459369506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_638645827459369506" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAxis_638645827459369506" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="ifrs-full_FinancialAssetsCategoryMember_638645827459369506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis_638645827459369506" xlink:to="ifrs-full_FinancialAssetsCategoryMember_638645827459369506" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_638645827459369506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsCategoryMember_638645827459369506" xlink:to="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_638645827459369506" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_638645827459369506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_638645827459369506" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_638645827459369506" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember_638645827459369506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_638645827459369506" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember_638645827459369506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_638645827459379509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember_638645827459369506" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_638645827459379509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis_638645827459379509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_638645827459369506" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis_638645827459379509" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember_638645827459379509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis_638645827459379509" xlink:to="ifrs-full_FinancialLiabilitiesMember_638645827459379509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LongTermFinancialDebtDerivativesMember" xlink:label="iva_LongTermFinancialDebtDerivativesMember_638645827459379509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesMember_638645827459379509" xlink:to="iva_LongTermFinancialDebtDerivativesMember_638645827459379509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638645827459379509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_638645827459369506" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638645827459379509" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities_638645827459379509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638645827459379509" xlink:to="ifrs-full_FinancialLiabilities_638645827459379509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Accounting principles - Going concern (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AccountingPrinciplesAbstract" xlink:label="iva_AccountingPrinciplesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638645827459379509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_AccountingPrinciplesAbstract_1" xlink:to="ifrs-full_CashAndCashEquivalents_638645827459379509" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:label="ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_638645827459379509" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_AccountingPrinciplesAbstract_1" xlink:to="ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_638645827459379509" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Intangible assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable_638645827459389585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_2" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable_638645827459389585" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_638645827459389585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable_638645827459389585" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_638645827459389585" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember_638645827459389585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_638645827459389585" xlink:to="ifrs-full_CarryingAmountMember_638645827459389585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember_638645827459389585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember_638645827459389585" xlink:to="ifrs-full_GrossCarryingAmountMember_638645827459389585" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_638645827459389585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember_638645827459389585" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_638645827459389585" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638645827459389585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable_638645827459389585" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638645827459389585" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract" xlink:label="ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_638645827459389585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638645827459389585" xlink:to="ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_638645827459389585" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_638645827459389585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_638645827459389585" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_638645827459389585" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_6386458274593895851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract_638645827459389585" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_6386458274593895851" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Property, plant, and equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638645827459399540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_3" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638645827459399540" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638645827459399540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638645827459399540" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638645827459399540" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_638645827459399540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638645827459399540" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_638645827459399540" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="ifrs-full_ConstructionInProgressMember_638645827459399540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_638645827459399540" xlink:to="ifrs-full_ConstructionInProgressMember_638645827459399540" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_638645827459399540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638645827459399540" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_638645827459399540" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember_638645827459399540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_638645827459399540" xlink:to="ifrs-full_CarryingAmountMember_638645827459399540" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember_638645827459399540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember_638645827459399540" xlink:to="ifrs-full_GrossCarryingAmountMember_638645827459399540" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_638645827459399540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember_638645827459399540" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_638645827459399540" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638645827459399540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638645827459399540" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638645827459399540" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:label="ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_638645827459399540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638645827459399540" xlink:to="ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_638645827459399540" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:label="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_638645827459399540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_638645827459399540" xlink:to="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_638645827459399540" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets" xlink:label="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_638645827459409904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_638645827459399540" xlink:to="ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets_638645827459409904" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Property, plant, and equipment - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638645827459409904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_4" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638645827459409904" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638645827459409904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638645827459409904" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638645827459409904" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_638645827459409904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638645827459409904" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_638645827459409904" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FibroscanMachinesMember" xlink:label="iva_FibroscanMachinesMember_638645827459409904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_638645827459409904" xlink:to="iva_FibroscanMachinesMember_638645827459409904" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_638645827459409904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638645827459409904" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_638645827459409904" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember_638645827459409904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_638645827459409904" xlink:to="ifrs-full_CarryingAmountMember_638645827459409904" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_638645827459419821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember_638645827459409904" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_638645827459419821" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="ifrs-full_RightofuseAssetsMember_638645827459419821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember_638645827459409904" xlink:to="ifrs-full_RightofuseAssetsMember_638645827459419821" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638645827459419821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638645827459409904" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638645827459419821" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInPropertyPlantAndEquipment" xlink:label="ifrs-full_ChangesInPropertyPlantAndEquipment_638645827459419821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638645827459419821" xlink:to="ifrs-full_ChangesInPropertyPlantAndEquipment_638645827459419821" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="ifrs-full_AdditionsToRightofuseAssets_638645827459419821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638645827459419821" xlink:to="ifrs-full_AdditionsToRightofuseAssets_638645827459419821" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreasesInPropertyPlantAndEquipment" xlink:label="iva_IncreasesInPropertyPlantAndEquipment_638645827459419821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638645827459419821" xlink:to="iva_IncreasesInPropertyPlantAndEquipment_638645827459419821" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails" xlink:type="extended" xlink:title="40404 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Investments accounted for using the equity method - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_638645827459429616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_5" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_638645827459429616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638645827459429616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_638645827459429616" xlink:to="dei_LegalEntityAxis_638645827459429616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638645827459429616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638645827459429616" xlink:to="dei_EntityDomain_638645827459429616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_HepalysPharmaIncMember" xlink:label="iva_HepalysPharmaIncMember_638645827459429616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638645827459429616" xlink:to="iva_HepalysPharmaIncMember_638645827459429616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459429616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_638645827459429616" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459429616" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OptionToAcquireSharesInCompanyPercentage" xlink:label="iva_OptionToAcquireSharesInCompanyPercentage_638645827459429616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459429616" xlink:to="iva_OptionToAcquireSharesInCompanyPercentage_638645827459429616" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare" xlink:label="iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare_638645827459429616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459429616" xlink:to="iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare_638645827459429616" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfSharesAcquiredInAssociate" xlink:label="iva_NumberOfSharesAcquiredInAssociate_638645827459429616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459429616" xlink:to="iva_NumberOfSharesAcquiredInAssociate_638645827459429616" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares_638645827459429616" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459429616" xlink:to="ifrs-full_ProceedsFromIssuingShares_638645827459429616" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_638645827459439497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459429616" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate_638645827459439497" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" xlink:type="extended" xlink:title="40405 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Investments accounted for using the equity method - investment in Hepalys accounted for using equity method of accounting (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_638645827459439497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_6" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_638645827459439497" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638645827459439497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_638645827459439497" xlink:to="dei_LegalEntityAxis_638645827459439497" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638645827459439497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638645827459439497" xlink:to="dei_EntityDomain_638645827459439497" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_HepalysPharmaIncMember" xlink:label="iva_HepalysPharmaIncMember_638645827459439497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638645827459439497" xlink:to="iva_HepalysPharmaIncMember_638645827459439497" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis_638645827459439497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_638645827459439497" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis_638645827459439497" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="ifrs-full_EntitysTotalForAssociatesMember_638645827459439497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis_638645827459439497" xlink:to="ifrs-full_EntitysTotalForAssociatesMember_638645827459439497" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_HepalysPharmaIncMember" xlink:label="iva_HepalysPharmaIncMember_6386458274594394971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForAssociatesMember_638645827459439497" xlink:to="iva_HepalysPharmaIncMember_6386458274594394971" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_638645827459439497" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_638645827459439497" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_638645827459439497" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NonCurrentAssetsExcludingDeferredAssets" xlink:label="iva_NonCurrentAssetsExcludingDeferredAssets_638645827459449489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="iva_NonCurrentAssetsExcludingDeferredAssets_638645827459449489" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets" xlink:label="ifrs-full_OtherCurrentAssets_638645827459449489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="ifrs-full_OtherCurrentAssets_638645827459449489" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638645827459449489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="ifrs-full_CashAndCashEquivalents_638645827459449489" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CurrentAssetsExcludingDeferredAssets" xlink:label="iva_CurrentAssetsExcludingDeferredAssets_638645827459449489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="iva_CurrentAssetsExcludingDeferredAssets_638645827459449489" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DeferredAssets" xlink:label="iva_DeferredAssets_638645827459449489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="iva_DeferredAssets_638645827459449489" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets_638645827459449489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="ifrs-full_Assets_638645827459449489" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital_638645827459449489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="ifrs-full_IssuedCapital_638645827459449489" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CapitalReserve" xlink:label="ifrs-full_CapitalReserve_638645827459449489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="ifrs-full_CapitalReserve_638645827459449489" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CapitalSurplusOthers" xlink:label="iva_CapitalSurplusOthers_638645827459459826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="iva_CapitalSurplusOthers_638645827459459826" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod" xlink:label="ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod_638645827459459826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod_638645827459459826" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsProfitLossForReportingPeriod" xlink:label="ifrs-full_RetainedEarningsProfitLossForReportingPeriod_638645827459459826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="ifrs-full_RetainedEarningsProfitLossForReportingPeriod_638645827459459826" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares_638645827459459826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="ifrs-full_TreasuryShares_638645827459459826" order="13" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638645827459459826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="ifrs-full_Equity_638645827459459826" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities_638645827459459826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="ifrs-full_NoncurrentLiabilities_638645827459459826" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_638645827459459826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_638645827459459826" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities_638645827459459826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="ifrs-full_OtherCurrentLiabilities_638645827459459826" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities_638645827459469555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="ifrs-full_CurrentLiabilities_638645827459469555" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities_638645827459469555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="ifrs-full_EquityAndLiabilities_638645827459469555" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638645827459469555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="ifrs-full_Equity_638645827459469555" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638645827459469555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="ifrs-full_ProfitLoss_638645827459469555" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome_638645827459469555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="ifrs-full_OtherComprehensiveIncome_638645827459469555" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseDecreaseThroughCapitalVariations" xlink:label="iva_IncreaseDecreaseThroughCapitalVariations_638645827459469555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="iva_IncreaseDecreaseThroughCapitalVariations_638645827459469555" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_6386458274594695551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="ifrs-full_Equity_6386458274594695551" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_638645827459469555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate_638645827459469555" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod" xlink:label="iva_EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod_638645827459479769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="iva_EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod_638645827459479769" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IntercompanyEliminationsInAssociates" xlink:label="iva_IntercompanyEliminationsInAssociates_638645827459479769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="iva_IntercompanyEliminationsInAssociates_638645827459479769" order="27" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Goodwill" xlink:label="ifrs-full_Goodwill_638645827459479769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="ifrs-full_Goodwill_638645827459479769" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_638645827459479769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827459439497" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_638645827459479769" order="29" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsDetails" xlink:type="extended" xlink:title="40406 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Other non-current assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_7" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NonCurrentLongTermDepositsFromCustomers" xlink:label="iva_NonCurrentLongTermDepositsFromCustomers_638645827459489478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_7" xlink:to="iva_NonCurrentLongTermDepositsFromCustomers_638645827459489478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NonCurrentAdvancesToSuppliers" xlink:label="iva_NonCurrentAdvancesToSuppliers_638645827459489478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_7" xlink:to="iva_NonCurrentAdvancesToSuppliers_638645827459489478" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NonCurrentSecurityDeposits" xlink:label="iva_NonCurrentSecurityDeposits_638645827459489478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_7" xlink:to="iva_NonCurrentSecurityDeposits_638645827459489478" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets_638645827459489478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_7" xlink:to="ifrs-full_OtherNoncurrentAssets_638645827459489478" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails" xlink:type="extended" xlink:title="40407 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Other non-current assets - Long-term deposit accounts (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_8" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherNonCurrentAssetsTable" xlink:label="iva_OtherNonCurrentAssetsTable_638645827459489478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_8" xlink:to="iva_OtherNonCurrentAssetsTable_638645827459489478" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827459489478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_OtherNonCurrentAssetsTable_638645827459489478" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827459489478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459489478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827459489478" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459489478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember" xlink:label="iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember_638645827459489478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459489478" xlink:to="iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember_638645827459489478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherNonCurrentAssetsLineItems" xlink:label="iva_OtherNonCurrentAssetsLineItems_638645827459489478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_OtherNonCurrentAssetsTable_638645827459489478" xlink:to="iva_OtherNonCurrentAssetsLineItems_638645827459489478" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseDecreaseInLongTermDepositAccounts" xlink:label="iva_IncreaseDecreaseInLongTermDepositAccounts_638645827459489478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_OtherNonCurrentAssetsLineItems_638645827459489478" xlink:to="iva_IncreaseDecreaseInLongTermDepositAccounts_638645827459489478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermDeposits" xlink:label="ifrs-full_LongtermDeposits_638645827459489478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_OtherNonCurrentAssetsLineItems_638645827459489478" xlink:to="ifrs-full_LongtermDeposits_638645827459489478" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LongTermDepositsTerm" xlink:label="iva_LongTermDepositsTerm_638645827459489478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_OtherNonCurrentAssetsLineItems_638645827459489478" xlink:to="iva_LongTermDepositsTerm_638645827459489478" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NonCurrentAdvancesToSuppliers" xlink:label="iva_NonCurrentAdvancesToSuppliers_638645827459489478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_OtherNonCurrentAssetsLineItems_638645827459489478" xlink:to="iva_NonCurrentAdvancesToSuppliers_638645827459489478" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInventoriesDetails" xlink:type="extended" xlink:title="40408 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Inventories (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_9" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ScheduleOfInventoryDisclosureTable" xlink:label="iva_ScheduleOfInventoryDisclosureTable_638645827459499584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_9" xlink:to="iva_ScheduleOfInventoryDisclosureTable_638645827459499584" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_638645827459499584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ScheduleOfInventoryDisclosureTable_638645827459499584" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_638645827459499584" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember_638645827459499584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_638645827459499584" xlink:to="ifrs-full_CarryingAmountMember_638645827459499584" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember_638645827459499584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember_638645827459499584" xlink:to="ifrs-full_GrossCarryingAmountMember_638645827459499584" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedImpairmentMember" xlink:label="ifrs-full_AccumulatedImpairmentMember_638645827459499584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember_638645827459499584" xlink:to="ifrs-full_AccumulatedImpairmentMember_638645827459499584" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ScheduleOfInventoryDisclosureLineItems" xlink:label="iva_ScheduleOfInventoryDisclosureLineItems_638645827459499584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ScheduleOfInventoryDisclosureTable_638645827459499584" xlink:to="iva_ScheduleOfInventoryDisclosureLineItems_638645827459499584" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories_638645827459499584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ScheduleOfInventoryDisclosureLineItems_638645827459499584" xlink:to="ifrs-full_Inventories_638645827459499584" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" xlink:type="extended" xlink:title="40409 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets - Trade Receivables (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_10" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable" xlink:label="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable_638645827459499584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_10" xlink:to="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable_638645827459499584" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis_638645827459499584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable_638645827459499584" xlink:to="ifrs-full_MaturityAxis_638645827459499584" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember_638645827459499584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis_638645827459499584" xlink:to="ifrs-full_AggregatedTimeBandsMember_638645827459499584" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanThreeMonthsMember" xlink:label="ifrs-full_NotLaterThanThreeMonthsMember_638645827459499584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember_638645827459499584" xlink:to="ifrs-full_NotLaterThanThreeMonthsMember_638645827459499584" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems" xlink:label="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems_638645827459509477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable_638645827459499584" xlink:to="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems_638645827459509477" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_638645827459509477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems_638645827459509477" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_638645827459509477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" xlink:type="extended" xlink:title="40410 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets- Other Current Assets and Receivables (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_11" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable" xlink:label="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable_638645827459509477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_11" xlink:to="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable_638645827459509477" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827459509477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable_638645827459509477" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827459509477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459509477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827459509477" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459509477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LicensingAndCollaborationAgreementWithCttqMember" xlink:label="iva_LicensingAndCollaborationAgreementWithCttqMember_638645827459509477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459509477" xlink:to="iva_LicensingAndCollaborationAgreementWithCttqMember_638645827459509477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems" xlink:label="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems_638645827459509477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable_638645827459509477" xlink:to="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems_638645827459509477" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CirAndOtherResearchTaxCreditsReceivable" xlink:label="iva_CirAndOtherResearchTaxCreditsReceivable_638645827459509477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems_638645827459509477" xlink:to="iva_CirAndOtherResearchTaxCreditsReceivable_638645827459509477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherCurrentTaxReceivables" xlink:label="iva_OtherCurrentTaxReceivables_638645827459509477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems_638645827459509477" xlink:to="iva_OtherCurrentTaxReceivables_638645827459509477" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="ifrs-full_CurrentTaxAssetsCurrent_638645827459509477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems_638645827459509477" xlink:to="ifrs-full_CurrentTaxAssetsCurrent_638645827459509477" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="ifrs-full_CurrentPrepaidExpenses_638645827459509477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems_638645827459509477" xlink:to="ifrs-full_CurrentPrepaidExpenses_638645827459509477" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ShortTermDepositAccountsCurrent" xlink:label="iva_ShortTermDepositAccountsCurrent_638645827459509477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems_638645827459509477" xlink:to="iva_ShortTermDepositAccountsCurrent_638645827459509477" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets" xlink:label="ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets_638645827459519609" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems_638645827459509477" xlink:to="ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets_638645827459519609" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CashUnderLiquidityAgreementCurrent" xlink:label="iva_CashUnderLiquidityAgreementCurrent_638645827459519609" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems_638645827459509477" xlink:to="iva_CashUnderLiquidityAgreementCurrent_638645827459519609" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_SalesTaxReceivableCurrent" xlink:label="iva_SalesTaxReceivableCurrent_638645827459519609" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems_638645827459509477" xlink:to="iva_SalesTaxReceivableCurrent_638645827459519609" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables_638645827459519609" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems_638645827459509477" xlink:to="ifrs-full_OtherCurrentReceivables_638645827459519609" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets" xlink:label="ifrs-full_OtherCurrentAssets_638645827459519609" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems_638645827459509477" xlink:to="ifrs-full_OtherCurrentAssets_638645827459519609" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherCurrentAssetsAndReceivables" xlink:label="iva_OtherCurrentAssetsAndReceivables_638645827459519609" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems_638645827459509477" xlink:to="iva_OtherCurrentAssetsAndReceivables_638645827459519609" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" xlink:type="extended" xlink:title="40411 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_12" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseDecreaseInShortTermDepositAccounts" xlink:label="iva_IncreaseDecreaseInShortTermDepositAccounts_638645827459519609" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_12" xlink:to="iva_IncreaseDecreaseInShortTermDepositAccounts_638645827459519609" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CurrentTaxCreditResearchCurrentYear" xlink:label="iva_CurrentTaxCreditResearchCurrentYear_638645827459529514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_12" xlink:to="iva_CurrentTaxCreditResearchCurrentYear_638645827459529514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseDecreaseInTradeAndOtherCurrentReceivables" xlink:label="iva_IncreaseDecreaseInTradeAndOtherCurrentReceivables_638645827459529514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_12" xlink:to="iva_IncreaseDecreaseInTradeAndOtherCurrentReceivables_638645827459529514" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CurrentTradeReceivablesAveragePaymentPeriod" xlink:label="iva_CurrentTradeReceivablesAveragePaymentPeriod_638645827459529514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_12" xlink:to="iva_CurrentTradeReceivablesAveragePaymentPeriod_638645827459529514" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails" xlink:type="extended" xlink:title="40412 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Cash and cash equivalents (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_13" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_638645827459529514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_13" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_638645827459529514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash" xlink:label="ifrs-full_Cash_638645827459529514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_13" xlink:to="ifrs-full_Cash_638645827459529514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BankOverdraftsClassifiedAsCashEquivalents" xlink:label="ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_638645827459529514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_13" xlink:to="ifrs-full_BankOverdraftsClassifiedAsCashEquivalents_638645827459529514" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638645827459529514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_13" xlink:to="ifrs-full_CashAndCashEquivalents_638645827459529514" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityShareCapitalDetails" xlink:type="extended" xlink:title="40413 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Share capital (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_15" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital_638645827459529514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_15" xlink:to="ifrs-full_IssuedCapital_638645827459529514" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding_638645827459529514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_15" xlink:to="ifrs-full_NumberOfSharesOutstanding_638645827459529514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare_638645827459539494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_15" xlink:to="ifrs-full_ParValuePerShare_638645827459539494" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails" xlink:type="extended" xlink:title="40414 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Changes in share capital (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_16" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638645827459539494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_16" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638645827459539494" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis_638645827459539494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638645827459539494" xlink:to="ifrs-full_ComponentsOfEquityAxis_638645827459539494" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_638645827459539494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638645827459539494" xlink:to="ifrs-full_EquityMember_638645827459539494" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember_638645827459539494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember_638645827459539494" xlink:to="ifrs-full_IssuedCapitalMember_638645827459539494" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember_638645827459539494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember_638645827459539494" xlink:to="ifrs-full_SharePremiumMember_638645827459539494" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638645827459539494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638645827459539494" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638645827459539494" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638645827459539494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638645827459539494" xlink:to="ifrs-full_Equity_638645827459539494" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding_638645827459539494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638645827459539494" xlink:to="ifrs-full_NumberOfSharesOutstanding_638645827459539494" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare_638645827459539494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638645827459539494" xlink:to="ifrs-full_ParValuePerShare_638645827459539494" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity_638645827459539494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638645827459539494" xlink:to="ifrs-full_IssueOfEquity_638645827459539494" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_638645827459539494" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638645827459539494" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding_638645827459539494" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityLiquidityAgreementDetails" xlink:type="extended" xlink:title="40415 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Liquidity agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_17" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LiquidityAgreementTerm" xlink:label="iva_LiquidityAgreementTerm_638645827459549486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_17" xlink:to="iva_LiquidityAgreementTerm_638645827459549486" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails" xlink:type="extended" xlink:title="40416 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Options and share warrants (BSA and BSPCE) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_18" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638645827459549486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_18" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638645827459549486" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638645827459549486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638645827459549486" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638645827459549486" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638645827459549486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638645827459549486" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638645827459549486" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BsaShareWarrantsMember" xlink:label="iva_BsaShareWarrantsMember_638645827459549486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638645827459549486" xlink:to="iva_BsaShareWarrantsMember_638645827459549486" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Bsa20231ShareWarrantPlanMember" xlink:label="iva_Bsa20231ShareWarrantPlanMember_638645827459549486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638645827459549486" xlink:to="iva_Bsa20231ShareWarrantPlanMember_638645827459549486" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Bsa20232ShareWarrantPlanMember" xlink:label="iva_Bsa20232ShareWarrantPlanMember_638645827459549486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638645827459549486" xlink:to="iva_Bsa20232ShareWarrantPlanMember_638645827459549486" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_638645827459549486" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638645827459549486" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_638645827459549486" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_638645827459559499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_638645827459549486" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_638645827459559499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DirectorsMember" xlink:label="iva_DirectorsMember_638645827459559499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638645827459559499" xlink:to="iva_DirectorsMember_638645827459559499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ServiceProvidersMember" xlink:label="iva_ServiceProvidersMember_638645827459559499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638645827459559499" xlink:to="iva_ServiceProvidersMember_638645827459559499" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DavidNikodemMember" xlink:label="iva_DavidNikodemMember_638645827459559499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638645827459559499" xlink:to="iva_DavidNikodemMember_638645827459559499" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638645827459559499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638645827459549486" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638645827459559499" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantsSubscriptionPrice" xlink:label="iva_WarrantsSubscriptionPrice_638645827459559499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638645827459559499" xlink:to="iva_WarrantsSubscriptionPrice_638645827459559499" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_638645827459559499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638645827459559499" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_638645827459559499" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_638645827459559499" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638645827459559499" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_638645827459559499" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails" xlink:type="extended" xlink:title="40417 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Movements in BSPCE and BSA share warrants (in number of shares issuable upon exercise) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToConsolidatedBalanceSheet" xlink:label="iva_NotesToConsolidatedBalanceSheet_16" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638645827459569496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToConsolidatedBalanceSheet_16" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638645827459569496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638645827459569496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638645827459569496" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638645827459569496" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638645827459569496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638645827459569496" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638645827459569496" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BspceAndBsaShareWarrantsMember" xlink:label="iva_BspceAndBsaShareWarrantsMember_638645827459569496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638645827459569496" xlink:to="iva_BspceAndBsaShareWarrantsMember_638645827459569496" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BspcePlansMember" xlink:label="iva_BspcePlansMember_638645827459569496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_BspceAndBsaShareWarrantsMember_638645827459569496" xlink:to="iva_BspcePlansMember_638645827459569496" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Bspce2021PlanMember" xlink:label="iva_Bspce2021PlanMember_638645827459569496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_BspcePlansMember_638645827459569496" xlink:to="iva_Bspce2021PlanMember_638645827459569496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BsaPlansMember" xlink:label="iva_BsaPlansMember_638645827459569496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_BspceAndBsaShareWarrantsMember_638645827459569496" xlink:to="iva_BsaPlansMember_638645827459569496" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Bsa2017PlanMember" xlink:label="iva_Bsa2017PlanMember_638645827459579709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_BsaPlansMember_638645827459569496" xlink:to="iva_Bsa2017PlanMember_638645827459579709" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Bsa2018PlanMember" xlink:label="iva_Bsa2018PlanMember_638645827459579709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_BsaPlansMember_638645827459569496" xlink:to="iva_Bsa2018PlanMember_638645827459579709" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewShareWarrantPlansBsa2019Member" xlink:label="iva_NewShareWarrantPlansBsa2019Member_638645827459579709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_BsaPlansMember_638645827459569496" xlink:to="iva_NewShareWarrantPlansBsa2019Member_638645827459579709" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewShareWarrantPlansBsa2019BisMember" xlink:label="iva_NewShareWarrantPlansBsa2019BisMember_638645827459579709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_BsaPlansMember_638645827459569496" xlink:to="iva_NewShareWarrantPlansBsa2019BisMember_638645827459579709" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewShareWarrantPlansBsa2019TerMember" xlink:label="iva_NewShareWarrantPlansBsa2019TerMember_638645827459579709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_BsaPlansMember_638645827459569496" xlink:to="iva_NewShareWarrantPlansBsa2019TerMember_638645827459579709" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewBsa2021ShareWarrantPlanMember" xlink:label="iva_NewBsa2021ShareWarrantPlanMember_638645827459579709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_BsaPlansMember_638645827459569496" xlink:to="iva_NewBsa2021ShareWarrantPlanMember_638645827459579709" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Bsa20231ShareWarrantPlanMember" xlink:label="iva_Bsa20231ShareWarrantPlanMember_638645827459579709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_BsaPlansMember_638645827459569496" xlink:to="iva_Bsa20231ShareWarrantPlanMember_638645827459579709" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Bsa20232ShareWarrantPlanMember" xlink:label="iva_Bsa20232ShareWarrantPlanMember_638645827459579709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_BsaPlansMember_638645827459569496" xlink:to="iva_Bsa20232ShareWarrantPlanMember_638645827459579709" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459579709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638645827459569496" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459579709" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_638645827459589495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459579709" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_638645827459589495" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_638645827459589495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459579709" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_638645827459589495" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_638645827459589495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459579709" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_638645827459589495" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_638645827459589495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459579709" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_638645827459589495" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_638645827459589495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459579709" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_638645827459589495" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_6386458274595894951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459579709" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_6386458274595894951" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_638645827459589495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459579709" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_638645827459589495" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightOutstanding" xlink:label="iva_IfrsClassOfWarrantOrRightOutstanding_638645827459589495" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459579709" xlink:to="iva_IfrsClassOfWarrantOrRightOutstanding_638645827459589495" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails" xlink:type="extended" xlink:title="40418 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Free share awards and Performance units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_21" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638645827459599538" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_21" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638645827459599538" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638645827459599538" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638645827459599538" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638645827459599538" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638645827459599538" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638645827459599538" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638645827459599538" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BonusShareAwardPlansMember" xlink:label="iva_BonusShareAwardPlansMember_638645827459599538" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638645827459599538" xlink:to="iva_BonusShareAwardPlansMember_638645827459599538" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewBonusShareAwardPlanAga20211Member" xlink:label="iva_NewBonusShareAwardPlanAga20211Member_638645827459599538" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638645827459599538" xlink:to="iva_NewBonusShareAwardPlanAga20211Member_638645827459599538" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewBonusShareAwardPlanAga2021BisMember" xlink:label="iva_NewBonusShareAwardPlanAga2021BisMember_638645827459599538" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638645827459599538" xlink:to="iva_NewBonusShareAwardPlanAga2021BisMember_638645827459599538" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewBonusShareAwardPlan20231Member" xlink:label="iva_NewBonusShareAwardPlan20231Member_638645827459599538" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638645827459599538" xlink:to="iva_NewBonusShareAwardPlan20231Member_638645827459599538" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NewBonusShareAwardPlan20232Member" xlink:label="iva_NewBonusShareAwardPlan20232Member_638645827459599538" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638645827459599538" xlink:to="iva_NewBonusShareAwardPlan20232Member_638645827459599538" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LongTermIncentivePlanInPerformanceUnitsMember" xlink:label="iva_LongTermIncentivePlanInPerformanceUnitsMember_638645827459599538" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638645827459599538" xlink:to="iva_LongTermIncentivePlanInPerformanceUnitsMember_638645827459599538" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LongTermIncentivePlanInPerformanceUnits2023Member" xlink:label="iva_LongTermIncentivePlanInPerformanceUnits2023Member_638645827459609871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638645827459599538" xlink:to="iva_LongTermIncentivePlanInPerformanceUnits2023Member_638645827459609871" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Aga2021Aga2021BisMember" xlink:label="iva_Aga2021Aga2021BisMember_638645827459609871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638645827459599538" xlink:to="iva_Aga2021Aga2021BisMember_638645827459609871" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_638645827459609871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638645827459599538" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_638645827459609871" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_638645827459609871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_638645827459609871" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_638645827459609871" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FredericCrenMember" xlink:label="iva_FredericCrenMember_638645827459609871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638645827459609871" xlink:to="iva_FredericCrenMember_638645827459609871" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459609871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638645827459599538" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459609871" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfPlansOutstanding" xlink:label="iva_NumberOfPlansOutstanding_638645827459609871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459609871" xlink:to="iva_NumberOfPlansOutstanding_638645827459609871" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfAwardPlansAttributed" xlink:label="iva_NumberOfAwardPlansAttributed_638645827459609871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459609871" xlink:to="iva_NumberOfAwardPlansAttributed_638645827459609871" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019_638645827459609871" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459609871" xlink:to="ifrs-full_WeightedAverageSharePrice2019_638645827459609871" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_638645827459619961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459609871" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_638645827459619961" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_638645827459619961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459609871" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_638645827459619961" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_638645827459619961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459609871" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_638645827459619961" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_638645827459619961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459609871" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_638645827459619961" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_638645827459619961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459609871" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_638645827459619961" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_6386458274596199611" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459609871" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_6386458274596199611" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_638645827459619961" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459609871" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_638645827459619961" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_638645827459630063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459609871" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_638645827459630063" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638645827459630063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459609871" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638645827459630063" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfSharesConverted" xlink:label="iva_NumberOfSharesConverted_638645827459630063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459609871" xlink:to="iva_NumberOfSharesConverted_638645827459630063" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_638645827459630063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638645827459609871" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement_638645827459630063" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails" xlink:type="extended" xlink:title="40419 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Financial debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_23" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LoansReceived" xlink:label="ifrs-full_LoansReceived_638645827459630063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_23" xlink:to="ifrs-full_LoansReceived_638645827459630063" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities_638645827459630063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_23" xlink:to="ifrs-full_NoncurrentDerivativeFinancialLiabilities_638645827459630063" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherBorrowings" xlink:label="ifrs-full_OtherBorrowings_638645827459639893" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_23" xlink:to="ifrs-full_OtherBorrowings_638645827459639893" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities_638645827459639893" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_23" xlink:to="ifrs-full_LeaseLiabilities_638645827459639893" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued" xlink:label="iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued_638645827459639893" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_23" xlink:to="iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued_638645827459639893" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings_638645827459639893" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_23" xlink:to="ifrs-full_Borrowings_638645827459639893" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails" xlink:type="extended" xlink:title="40420 - Disclosure - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Movements in the period break down (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_39" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings_638645827459639893" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_39" xlink:to="ifrs-full_Borrowings_638645827459639893" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments" xlink:label="iva_IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments_638645827459639893" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_39" xlink:to="iva_IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments_638645827459639893" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Increaseinborrowingsthroughborrowingsreceived" xlink:label="iva_Increaseinborrowingsthroughborrowingsreceived_638645827459639893" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_39" xlink:to="iva_Increaseinborrowingsthroughborrowingsreceived_638645827459639893" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_SubscriptionOfLeaseLiabilities" xlink:label="iva_SubscriptionOfLeaseLiabilities_638645827459639893" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_39" xlink:to="iva_SubscriptionOfLeaseLiabilities_638645827459639893" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IssueOfRoyaltyCertificates" xlink:label="iva_IssueOfRoyaltyCertificates_638645827459709541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_39" xlink:to="iva_IssueOfRoyaltyCertificates_638645827459709541" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities" xlink:label="iva_DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities_638645827459709541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_39" xlink:to="iva_DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities_638645827459709541" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_InterestOnRoyaltyCertificates" xlink:label="iva_InterestOnRoyaltyCertificates_638645827459709541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_39" xlink:to="iva_InterestOnRoyaltyCertificates_638645827459709541" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings" xlink:label="iva_DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings_638645827459709541" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_39" xlink:to="iva_DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings_638645827459709541" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseInBorrowingsThroughCapitalizedInterest" xlink:label="iva_IncreaseInBorrowingsThroughCapitalizedInterest_638645827459719535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_39" xlink:to="iva_IncreaseInBorrowingsThroughCapitalizedInterest_638645827459719535" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments" xlink:label="iva_IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments_638645827459719535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_39" xlink:to="iva_IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments_638645827459719535" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates" xlink:label="iva_IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates_638645827459719535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_39" xlink:to="iva_IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates_638645827459719535" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings_638645827459719535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_39" xlink:to="ifrs-full_Borrowings_638645827459719535" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" xlink:type="extended" xlink:title="40421 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - French state-guaranteed loan (&quot;PGE&quot;) and equity recovery loans (&quot;PPR&quot;) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_25" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459719535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_25" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459719535" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827459719535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459719535" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827459719535" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459719535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827459719535" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459719535" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LicensingAndCollaborationAgreementWithCttqMember" xlink:label="iva_LicensingAndCollaborationAgreementWithCttqMember_638645827459719535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459719535" xlink:to="iva_LicensingAndCollaborationAgreementWithCttqMember_638645827459719535" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis_638645827459719535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459719535" xlink:to="ifrs-full_BorrowingsByNameAxis_638645827459719535" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember_638645827459719535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis_638645827459719535" xlink:to="ifrs-full_BorrowingsByNameMember_638645827459719535" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LoanAgreementsWithSyndicateOfFrenchBanksMember" xlink:label="iva_LoanAgreementsWithSyndicateOfFrenchBanksMember_638645827459719535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember_638645827459719535" xlink:to="iva_LoanAgreementsWithSyndicateOfFrenchBanksMember_638645827459719535" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember" xlink:label="iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember_638645827459719535" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_LoanAgreementsWithSyndicateOfFrenchBanksMember_638645827459719535" xlink:to="iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember_638645827459719535" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember" xlink:label="iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember_638645827459729824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_LoanAgreementsWithSyndicateOfFrenchBanksMember_638645827459719535" xlink:to="iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember_638645827459729824" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_EquityRecoveryLoansMember" xlink:label="iva_EquityRecoveryLoansMember_638645827459729824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember_638645827459719535" xlink:to="iva_EquityRecoveryLoansMember_638645827459729824" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinancingFromSyndicateOfFrenchBanksMember" xlink:label="iva_FinancingFromSyndicateOfFrenchBanksMember_638645827459729824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember_638645827459719535" xlink:to="iva_FinancingFromSyndicateOfFrenchBanksMember_638645827459729824" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459729824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459719535" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459729824" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfLoansObtainedGuaranteedByFrenchState" xlink:label="iva_NumberOfLoansObtainedGuaranteedByFrenchState_638645827459729824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459729824" xlink:to="iva_NumberOfLoansObtainedGuaranteedByFrenchState_638645827459729824" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AmountInvoicedToCounterpartyForInitialPayment" xlink:label="iva_AmountInvoicedToCounterpartyForInitialPayment_638645827459729824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459729824" xlink:to="iva_AmountInvoicedToCounterpartyForInitialPayment_638645827459729824" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_638645827459729824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459729824" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_638645827459729824" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BorrowingsMaximumExtensionTerm" xlink:label="iva_BorrowingsMaximumExtensionTerm_638645827459729824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459729824" xlink:to="iva_BorrowingsMaximumExtensionTerm_638645827459729824" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfLoanAgreements" xlink:label="iva_NumberOfLoanAgreements_638645827459729824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459729824" xlink:to="iva_NumberOfLoanAgreements_638645827459729824" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount_638645827459729824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459729824" xlink:to="ifrs-full_NotionalAmount_638645827459729824" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PercentageOfLoanGuaranteedByFrenchState" xlink:label="iva_PercentageOfLoanGuaranteedByFrenchState_638645827459729824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459729824" xlink:to="iva_PercentageOfLoanGuaranteedByFrenchState_638645827459729824" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinancingPeriodOfLoan" xlink:label="iva_FinancingPeriodOfLoan_638645827459729824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459729824" xlink:to="iva_FinancingPeriodOfLoan_638645827459729824" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_RepaymentPeriodOfLoan" xlink:label="iva_RepaymentPeriodOfLoan_638645827459739841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459729824" xlink:to="iva_RepaymentPeriodOfLoan_638645827459739841" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_638645827459739841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459729824" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_638645827459739841" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" xlink:type="extended" xlink:title="40422 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Credit facility agreement with the European Investment Bank (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_26" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459749550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_26" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459749550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis_638645827459749550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459749550" xlink:to="ifrs-full_BorrowingsByNameAxis_638645827459749550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember_638645827459749550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis_638645827459749550" xlink:to="ifrs-full_BorrowingsByNameMember_638645827459749550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankMember_638645827459749550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember_638645827459749550" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankMember_638645827459749550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_638645827459749550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_FinanceContractWithEuropeanInvestmentBankMember_638645827459749550" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_638645827459749550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_638645827459749550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_FinanceContractWithEuropeanInvestmentBankMember_638645827459749550" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_638645827459749550" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis_638645827459749550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459749550" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis_638645827459749550" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember_638645827459749550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis_638645827459749550" xlink:to="ifrs-full_FinancialLiabilitiesMember_638645827459749550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueMember_638645827459749550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesMember_638645827459749550" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueMember_638645827459749550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_638645827459749550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459749550" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_638645827459749550" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember_638645827459749550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_638645827459749550" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember_638645827459749550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_638645827459749550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember_638645827459749550" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_638645827459749550" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459749550" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459749550" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459749550" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount_638645827459759650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459749550" xlink:to="ifrs-full_NotionalAmount_638645827459759650" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfEqualTranches" xlink:label="iva_NumberOfEqualTranches_638645827459759650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459749550" xlink:to="iva_NumberOfEqualTranches_638645827459759650" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotionalAmountPerTranche" xlink:label="iva_NotionalAmountPerTranche_638645827459759650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459749550" xlink:to="iva_NotionalAmountPerTranche_638645827459759650" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate_638645827459759650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459749550" xlink:to="ifrs-full_BorrowingsInterestRate_638645827459759650" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsDebtInstrumentTerm" xlink:label="iva_IfrsDebtInstrumentTerm_638645827459759650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459749550" xlink:to="iva_IfrsDebtInstrumentTerm_638645827459759650" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings_638645827459759650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459749550" xlink:to="ifrs-full_Borrowings_638645827459759650" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BorrowingsEffectiveInterestRate" xlink:label="iva_BorrowingsEffectiveInterestRate_638645827459759650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459749550" xlink:to="iva_BorrowingsEffectiveInterestRate_638645827459759650" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_BorrowingsActualizationRate" xlink:label="iva_BorrowingsActualizationRate_638645827459759650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459749550" xlink:to="iva_BorrowingsActualizationRate_638645827459759650" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingCostsIncurred" xlink:label="ifrs-full_BorrowingCostsIncurred_638645827459759650" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459749550" xlink:to="ifrs-full_BorrowingCostsIncurred_638645827459759650" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestCostsCapitalised" xlink:label="ifrs-full_InterestCostsCapitalised_638645827459769895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459749550" xlink:to="ifrs-full_InterestCostsCapitalised_638645827459769895" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue_638645827459769895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459749550" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValue_638645827459769895" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails" xlink:type="extended" xlink:title="40423 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Derivatives (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_27" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459769895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_27" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459769895" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827459769895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459769895" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827459769895" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459769895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827459769895" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459769895" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantAgreementWithEuropeanInvestmentBankMember" xlink:label="iva_WarrantAgreementWithEuropeanInvestmentBankMember_638645827459769895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459769895" xlink:to="iva_WarrantAgreementWithEuropeanInvestmentBankMember_638645827459769895" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis_638645827459769895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459769895" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis_638645827459769895" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember_638645827459769895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis_638645827459769895" xlink:to="ifrs-full_FinancialLiabilitiesMember_638645827459769895" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LongTermFinancialDebtDerivativesMember" xlink:label="iva_LongTermFinancialDebtDerivativesMember_638645827459769895" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesMember_638645827459769895" xlink:to="iva_LongTermFinancialDebtDerivativesMember_638645827459769895" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638645827459779880" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459769895" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638645827459779880" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638645827459779880" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638645827459779880" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638645827459779880" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Bsa2022Member" xlink:label="iva_Bsa2022Member_638645827459779880" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638645827459779880" xlink:to="iva_Bsa2022Member_638645827459779880" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Bsa2024Member" xlink:label="iva_Bsa2024Member_638645827459779880" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638645827459779880" xlink:to="iva_Bsa2024Member_638645827459779880" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis_638645827459779880" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459769895" xlink:to="ifrs-full_BorrowingsByNameAxis_638645827459779880" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember_638645827459779880" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis_638645827459779880" xlink:to="ifrs-full_BorrowingsByNameMember_638645827459779880" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_638645827459779880" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember_638645827459779880" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_638645827459779880" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_638645827459779880" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember_638645827459779880" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_638645827459779880" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_638645827459779880" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459769895" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_638645827459779880" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember_638645827459779880" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis_638645827459779880" xlink:to="ifrs-full_ClassesOfShareCapitalMember_638645827459779880" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember_638645827459790029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_638645827459779880" xlink:to="ifrs-full_OrdinarySharesMember_638645827459790029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459790029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459769895" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459790029" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantsSubscriptionPrice" xlink:label="iva_WarrantsSubscriptionPrice_638645827459790029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459790029" xlink:to="iva_WarrantsSubscriptionPrice_638645827459790029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ClassOfWarrantOrRightGranted" xlink:label="iva_ClassOfWarrantOrRightGranted_638645827459790029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459790029" xlink:to="iva_ClassOfWarrantOrRightGranted_638645827459790029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants" xlink:label="iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants_638645827459790029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459790029" xlink:to="iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants_638645827459790029" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_638645827459790029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459790029" xlink:to="iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_638645827459790029" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_MaximumPotentialGrossProceedsFromExerciseOfWarrants" xlink:label="iva_MaximumPotentialGrossProceedsFromExerciseOfWarrants_638645827459790029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459790029" xlink:to="iva_MaximumPotentialGrossProceedsFromExerciseOfWarrants_638645827459790029" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TransactionCostsOnIssueOfWarrants" xlink:label="iva_TransactionCostsOnIssueOfWarrants_638645827459790029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459790029" xlink:to="iva_TransactionCostsOnIssueOfWarrants_638645827459790029" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantsThresholdTradingDays" xlink:label="iva_WarrantsThresholdTradingDays_638645827459799542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459790029" xlink:to="iva_WarrantsThresholdTradingDays_638645827459799542" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_638645827459799542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459790029" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_638645827459799542" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted" xlink:label="iva_SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted_638645827459799542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459790029" xlink:to="iva_SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted_638645827459799542" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_638645827459799542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459790029" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_638645827459799542" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightOutstanding" xlink:label="iva_IfrsClassOfWarrantOrRightOutstanding_638645827459799542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459790029" xlink:to="iva_IfrsClassOfWarrantOrRightOutstanding_638645827459799542" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638645827459799542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459790029" xlink:to="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638645827459799542" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantsStockPrice" xlink:label="iva_WarrantsStockPrice_638645827459799542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459790029" xlink:to="iva_WarrantsStockPrice_638645827459799542" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantAverageLife" xlink:label="iva_WarrantAverageLife_638645827459799542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459790029" xlink:to="iva_WarrantAverageLife_638645827459799542" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ExpectedVolatility" xlink:label="iva_ExpectedVolatility_638645827459799542" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459790029" xlink:to="iva_ExpectedVolatility_638645827459799542" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantsCapOfPutOption" xlink:label="iva_WarrantsCapOfPutOption_638645827459810181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459790029" xlink:to="iva_WarrantsCapOfPutOption_638645827459810181" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FairValueOfWarrantsOutstanding" xlink:label="iva_FairValueOfWarrantsOutstanding_638645827459810181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459790029" xlink:to="iva_FairValueOfWarrantsOutstanding_638645827459810181" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantsUnitFairValue" xlink:label="iva_WarrantsUnitFairValue_638645827459810181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459790029" xlink:to="iva_WarrantsUnitFairValue_638645827459810181" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued" xlink:label="iva_TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued_638645827459810181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459790029" xlink:to="iva_TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued_638645827459810181" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ClassOfWarrantOrRightMaturityTerm" xlink:label="iva_ClassOfWarrantOrRightMaturityTerm_638645827459810181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459790029" xlink:to="iva_ClassOfWarrantOrRightMaturityTerm_638645827459810181" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfSharesPerOtherEquityInstrumentGranted" xlink:label="iva_NumberOfSharesPerOtherEquityInstrumentGranted_638645827459810181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459790029" xlink:to="iva_NumberOfSharesPerOtherEquityInstrumentGranted_638645827459810181" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="40424 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Lease liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_28" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459819821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_28" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459819821" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis_638645827459819821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459819821" xlink:to="ifrs-full_BorrowingsByNameAxis_638645827459819821" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember_638645827459819821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis_638645827459819821" xlink:to="ifrs-full_BorrowingsByNameMember_638645827459819821" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="ifrs-full_LeaseLiabilitiesMember_638645827459819821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember_638645827459819821" xlink:to="ifrs-full_LeaseLiabilitiesMember_638645827459819821" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_638645827459819821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459819821" xlink:to="ifrs-full_RangeAxis_638645827459819821" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638645827459819821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_638645827459819821" xlink:to="ifrs-full_RangesMember_638645827459819821" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember_638645827459819821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638645827459819821" xlink:to="ifrs-full_BottomOfRangeMember_638645827459819821" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember_638645827459819821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638645827459819821" xlink:to="ifrs-full_TopOfRangeMember_638645827459819821" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638645827459819821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459819821" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638645827459819821" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_638645827459819821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638645827459819821" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_638645827459819821" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FibroscanMachinesMember" xlink:label="iva_FibroscanMachinesMember_638645827459829549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_638645827459819821" xlink:to="iva_FibroscanMachinesMember_638645827459829549" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459829549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459819821" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459829549" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities_638645827459829549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459829549" xlink:to="ifrs-full_LeaseLiabilities_638645827459829549" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseDecreaseInLeaseLiabilities" xlink:label="iva_IncreaseDecreaseInLeaseLiabilities_638645827459829549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459829549" xlink:to="iva_IncreaseDecreaseInLeaseLiabilities_638645827459829549" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="ifrs-full_AdditionsToRightofuseAssets_638645827459829549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459829549" xlink:to="ifrs-full_AdditionsToRightofuseAssets_638645827459829549" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LeaseTerm" xlink:label="iva_LeaseTerm_638645827459829549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459829549" xlink:to="iva_LeaseTerm_638645827459829549" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate_638645827459829549" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459829549" xlink:to="ifrs-full_BorrowingsInterestRate_638645827459829549" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" xlink:type="extended" xlink:title="40425 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Maturity of long-term debt and of short-term borrowings and debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_38" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459839540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_38" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459839540" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis_638645827459839540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459839540" xlink:to="ifrs-full_MaturityAxis_638645827459839540" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember_638645827459839540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis_638645827459839540" xlink:to="ifrs-full_AggregatedTimeBandsMember_638645827459839540" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember_638645827459839540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember_638645827459839540" xlink:to="ifrs-full_NotLaterThanOneYearMember_638645827459839540" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_638645827459839540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember_638645827459839540" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_638645827459839540" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_638645827459839540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember_638645827459839540" xlink:to="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_638645827459839540" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanFiveYearsMember_638645827459839540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember_638645827459839540" xlink:to="ifrs-full_LaterThanFiveYearsMember_638645827459839540" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459839540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459839540" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459839540" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LoansReceived" xlink:label="ifrs-full_LoansReceived_638645827459839540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459839540" xlink:to="ifrs-full_LoansReceived_638645827459839540" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities_638645827459839540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459839540" xlink:to="ifrs-full_NoncurrentDerivativeFinancialLiabilities_638645827459839540" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherBorrowings" xlink:label="ifrs-full_OtherBorrowings_638645827459839540" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459839540" xlink:to="ifrs-full_OtherBorrowings_638645827459839540" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities_638645827459849882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459839540" xlink:to="ifrs-full_LeaseLiabilities_638645827459849882" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued" xlink:label="iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued_638645827459849882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459839540" xlink:to="iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued_638645827459849882" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings_638645827459849882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459839540" xlink:to="ifrs-full_Borrowings_638645827459849882" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails" xlink:type="extended" xlink:title="40426 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Royalty Certificates liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_29" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459849882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_29" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459849882" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis_638645827459849882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459849882" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis_638645827459849882" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember" xlink:label="ifrs-full_LiabilitiesMember_638645827459849882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis_638645827459849882" xlink:to="ifrs-full_LiabilitiesMember_638645827459849882" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_RoyaltyCertificateLiabilitiesMember" xlink:label="iva_RoyaltyCertificateLiabilitiesMember_638645827459849882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesMember_638645827459849882" xlink:to="iva_RoyaltyCertificateLiabilitiesMember_638645827459849882" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis_638645827459849882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459849882" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis_638645827459849882" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember_638645827459849882" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis_638645827459849882" xlink:to="ifrs-full_FinancialLiabilitiesMember_638645827459849882" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueMember_638645827459859853" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesMember_638645827459849882" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueMember_638645827459859853" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="ifrs-full_UnobservableInputsAxis_638645827459859853" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459849882" xlink:to="ifrs-full_UnobservableInputsAxis_638645827459859853" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="ifrs-full_UnobservableInputsMember_638645827459859853" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsAxis_638645827459859853" xlink:to="ifrs-full_UnobservableInputsMember_638645827459859853" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DiscountRateMeasurementInputMember" xlink:label="ifrs-full_DiscountRateMeasurementInputMember_638645827459859853" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsMember_638645827459859853" xlink:to="ifrs-full_DiscountRateMeasurementInputMember_638645827459859853" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis_638645827459859853" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459849882" xlink:to="ifrs-full_BorrowingsByNameAxis_638645827459859853" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember_638645827459859853" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis_638645827459859853" xlink:to="ifrs-full_BorrowingsByNameMember_638645827459859853" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_RoyaltyCertificatesLiabilitiesMember" xlink:label="iva_RoyaltyCertificatesLiabilitiesMember_638645827459859853" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember_638645827459859853" xlink:to="iva_RoyaltyCertificatesLiabilitiesMember_638645827459859853" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459859853" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638645827459849882" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459859853" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor" xlink:label="iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor_638645827459870082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459859853" xlink:to="iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor_638645827459870082" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities_638645827459870082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459859853" xlink:to="ifrs-full_FinancialLiabilities_638645827459870082" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_RoyaltyCertificatesEffectiveInterestRate" xlink:label="iva_RoyaltyCertificatesEffectiveInterestRate_638645827459870082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459859853" xlink:to="iva_RoyaltyCertificatesEffectiveInterestRate_638645827459870082" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantUnobservableInputLiabilities" xlink:label="ifrs-full_SignificantUnobservableInputLiabilities_638645827459870082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459859853" xlink:to="ifrs-full_SignificantUnobservableInputLiabilities_638645827459870082" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings_638645827459870082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459859853" xlink:to="ifrs-full_Borrowings_638645827459870082" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount_638645827459870082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459859853" xlink:to="ifrs-full_NotionalAmount_638645827459870082" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue_638645827459870082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638645827459859853" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValue_638645827459870082" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsNetProvisionDetails" xlink:type="extended" xlink:title="40427 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Net provision (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_30" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisions" xlink:label="ifrs-full_OtherProvisions_638645827459879527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_30" xlink:to="ifrs-full_OtherProvisions_638645827459879527" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitObligationAtPresentValue" xlink:label="ifrs-full_DefinedBenefitObligationAtPresentValue_638645827459879527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_30" xlink:to="ifrs-full_DefinedBenefitObligationAtPresentValue_638645827459879527" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_638645827459879527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_30" xlink:to="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_638645827459879527" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsChangesInNetProvisionDetails" xlink:type="extended" xlink:title="40428 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Changes in the net provision (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_31" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_638645827459879527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_31" xlink:to="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_638645827459879527" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss" xlink:label="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss_638645827459879527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_31" xlink:to="ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss_638645827459879527" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset" xlink:label="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_638645827459879527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_31" xlink:to="ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_638645827459879527" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilityAssetOfDefinedBenefitPlans" xlink:label="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_6386458274598795271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_31" xlink:to="ifrs-full_LiabilityAssetOfDefinedBenefitPlans_6386458274598795271" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails" xlink:type="extended" xlink:title="40429 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Breakdown of expense recognized for the year (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_32" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentServiceCostDefinedBenefitPlans" xlink:label="ifrs-full_CurrentServiceCostDefinedBenefitPlans_638645827459879527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_32" xlink:to="ifrs-full_CurrentServiceCostDefinedBenefitPlans_638645827459879527" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseDefinedBenefitPlans" xlink:label="ifrs-full_InterestExpenseDefinedBenefitPlans_638645827459879527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_32" xlink:to="ifrs-full_InterestExpenseDefinedBenefitPlans_638645827459879527" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans" xlink:label="ifrs-full_PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans_638645827459890053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_32" xlink:to="ifrs-full_PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans_638645827459890053" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_638645827459890053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_32" xlink:to="ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans_638645827459890053" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40430 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Other current and non-current liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_33" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_EmployeeRelatedPayables" xlink:label="iva_EmployeeRelatedPayables_638645827459890053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_33" xlink:to="iva_EmployeeRelatedPayables_638645827459890053" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AccruedPayrollAndOtherEmployeeRelatedTaxes" xlink:label="iva_AccruedPayrollAndOtherEmployeeRelatedTaxes_638645827459890053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_33" xlink:to="iva_AccruedPayrollAndOtherEmployeeRelatedTaxes_638645827459890053" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentValueAddedTaxPayables" xlink:label="ifrs-full_CurrentValueAddedTaxPayables_638645827459890053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_33" xlink:to="ifrs-full_CurrentValueAddedTaxPayables_638645827459890053" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherAccruedTaxesAndEmployeeRelatedExpenses" xlink:label="iva_OtherAccruedTaxesAndEmployeeRelatedExpenses_638645827459890053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_33" xlink:to="iva_OtherAccruedTaxesAndEmployeeRelatedExpenses_638645827459890053" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentPayables" xlink:label="ifrs-full_OtherCurrentPayables_638645827459890053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_33" xlink:to="ifrs-full_OtherCurrentPayables_638645827459890053" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities_638645827459890053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_33" xlink:to="ifrs-full_OtherCurrentLiabilities_638645827459890053" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails" xlink:type="extended" xlink:title="40431 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Other current and non-current liabilities - Additional information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_34" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradePayableAndOtherCurrentLiabilitiesTable" xlink:label="iva_TradePayableAndOtherCurrentLiabilitiesTable_638645827459900565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_34" xlink:to="iva_TradePayableAndOtherCurrentLiabilitiesTable_638645827459900565" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827459900565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_TradePayableAndOtherCurrentLiabilitiesTable_638645827459900565" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827459900565" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459900565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827459900565" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459900565" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LicensingAndCollaborationAgreementWithCttqMember" xlink:label="iva_LicensingAndCollaborationAgreementWithCttqMember_638645827459900565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459900565" xlink:to="iva_LicensingAndCollaborationAgreementWithCttqMember_638645827459900565" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradePayableAndOtherCurrentLiabilitiesLineItems" xlink:label="iva_TradePayableAndOtherCurrentLiabilitiesLineItems_638645827459900565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_TradePayableAndOtherCurrentLiabilitiesTable_638645827459900565" xlink:to="iva_TradePayableAndOtherCurrentLiabilitiesLineItems_638645827459900565" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="ifrs-full_OtherNoncurrentLiabilities_638645827459900565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_TradePayableAndOtherCurrentLiabilitiesLineItems_638645827459900565" xlink:to="ifrs-full_OtherNoncurrentLiabilities_638645827459900565" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40432 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade payables, short-term contract liabilities and other current liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_35" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_638645827459900565" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_35" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_638645827459900565" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities_638645827459910042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_35" xlink:to="ifrs-full_CurrentContractLiabilities_638645827459910042" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities_638645827459910042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_35" xlink:to="ifrs-full_OtherCurrentLiabilities_638645827459910042" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradePayablesAndOtherCurrentLiabilities" xlink:label="iva_TradePayablesAndOtherCurrentLiabilities_638645827459910042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_35" xlink:to="iva_TradePayablesAndOtherCurrentLiabilities_638645827459910042" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent_638645827459910042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_35" xlink:to="ifrs-full_AccrualsClassifiedAsCurrent_638645827459910042" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AccrualsClassifiedAsCurrentRelatingToScientificProjects" xlink:label="iva_AccrualsClassifiedAsCurrentRelatingToScientificProjects_638645827459910042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_35" xlink:to="iva_AccrualsClassifiedAsCurrentRelatingToScientificProjects_638645827459910042" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails" xlink:type="extended" xlink:title="40433 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade payables break down (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_36" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradePayableAndOtherCurrentLiabilitiesTable" xlink:label="iva_TradePayableAndOtherCurrentLiabilitiesTable_638645827459910042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_36" xlink:to="iva_TradePayableAndOtherCurrentLiabilitiesTable_638645827459910042" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis_638645827459910042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_TradePayableAndOtherCurrentLiabilitiesTable_638645827459910042" xlink:to="ifrs-full_MaturityAxis_638645827459910042" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember_638645827459910042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis_638645827459910042" xlink:to="ifrs-full_AggregatedTimeBandsMember_638645827459910042" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneMonthMember" xlink:label="ifrs-full_NotLaterThanOneMonthMember_638645827459910042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember_638645827459910042" xlink:to="ifrs-full_NotLaterThanOneMonthMember_638645827459910042" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember" xlink:label="ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_638645827459919704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember_638645827459910042" xlink:to="ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_638645827459919704" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LaterThanTwoMonthsMember" xlink:label="iva_LaterThanTwoMonthsMember_638645827459919704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember_638645827459910042" xlink:to="iva_LaterThanTwoMonthsMember_638645827459919704" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradePayableAndOtherCurrentLiabilitiesLineItems" xlink:label="iva_TradePayableAndOtherCurrentLiabilitiesLineItems_638645827459919704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_TradePayableAndOtherCurrentLiabilitiesTable_638645827459910042" xlink:to="iva_TradePayableAndOtherCurrentLiabilitiesLineItems_638645827459919704" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_638645827459919704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_TradePayableAndOtherCurrentLiabilitiesLineItems_638645827459919704" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_638645827459919704" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IncreaseDecreaseInTradeAccountsPayable" xlink:label="iva_IncreaseDecreaseInTradeAccountsPayable_638645827459919704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_TradePayableAndOtherCurrentLiabilitiesLineItems_638645827459919704" xlink:to="iva_IncreaseDecreaseInTradeAccountsPayable_638645827459919704" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="40434 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial assets and liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract" xlink:label="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_37" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable_638645827459919704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract_37" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable_638645827459919704" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis_638645827459919704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_638645827459919704" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis_638645827459919704" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember" xlink:label="ifrs-full_FinancialAssetsMember_638645827459919704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis_638645827459919704" xlink:to="ifrs-full_FinancialAssetsMember_638645827459919704" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LongTermDepositAccountsMember" xlink:label="iva_LongTermDepositAccountsMember_638645827459919704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember_638645827459919704" xlink:to="iva_LongTermDepositAccountsMember_638645827459919704" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LongTermSecurityDepositsMember" xlink:label="iva_LongTermSecurityDepositsMember_638645827459919704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember_638645827459919704" xlink:to="iva_LongTermSecurityDepositsMember_638645827459919704" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AdvancePaymentMember" xlink:label="iva_AdvancePaymentMember_638645827459929798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember_638645827459919704" xlink:to="iva_AdvancePaymentMember_638645827459929798" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AccruedIncomeMember" xlink:label="iva_AccruedIncomeMember_638645827459929798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember_638645827459919704" xlink:to="iva_AccruedIncomeMember_638645827459929798" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ShortTermDepositAccountsMember" xlink:label="iva_ShortTermDepositAccountsMember_638645827459929798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember_638645827459919704" xlink:to="iva_ShortTermDepositAccountsMember_638645827459929798" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeReceivablesMember" xlink:label="ifrs-full_TradeReceivablesMember_638645827459929798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember_638645827459919704" xlink:to="ifrs-full_TradeReceivablesMember_638645827459929798" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherReceivablesMember" xlink:label="iva_OtherReceivablesMember_638645827459929798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember_638645827459919704" xlink:to="iva_OtherReceivablesMember_638645827459929798" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCashAndCashEquivalentsMember" xlink:label="iva_IfrsCashAndCashEquivalentsMember_638645827459929798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember_638645827459919704" xlink:to="iva_IfrsCashAndCashEquivalentsMember_638645827459929798" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis_638645827459929798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_638645827459919704" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAxis_638645827459929798" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="ifrs-full_FinancialAssetsCategoryMember_638645827459929798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis_638645827459929798" xlink:to="ifrs-full_FinancialAssetsCategoryMember_638645827459929798" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_638645827459929798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsCategoryMember_638645827459929798" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_638645827459929798" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember" xlink:label="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_638645827459929798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsCategoryMember_638645827459929798" xlink:to="ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_638645827459929798" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis_638645827459929798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_638645827459919704" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis_638645827459929798" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember_638645827459929798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis_638645827459929798" xlink:to="ifrs-full_FinancialLiabilitiesMember_638645827459929798" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowingsMember" xlink:label="ifrs-full_LongtermBorrowingsMember_638645827459939834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesMember_638645827459929798" xlink:to="ifrs-full_LongtermBorrowingsMember_638645827459939834" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DerivativeInstrumentsMember" xlink:label="iva_DerivativeInstrumentsMember_638645827459939834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesMember_638645827459929798" xlink:to="iva_DerivativeInstrumentsMember_638645827459939834" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_RoyaltyCertificatesLiabilitiesMember" xlink:label="iva_RoyaltyCertificatesLiabilitiesMember_638645827459939834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesMember_638645827459929798" xlink:to="iva_RoyaltyCertificatesLiabilitiesMember_638645827459939834" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermBorrowingsMember" xlink:label="ifrs-full_ShorttermBorrowingsMember_638645827459939834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesMember_638645827459929798" xlink:to="ifrs-full_ShorttermBorrowingsMember_638645827459939834" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_TradePayablesMember" xlink:label="iva_TradePayablesMember_638645827459939834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesMember_638645827459929798" xlink:to="iva_TradePayablesMember_638645827459939834" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherMiscellaneousPayablesMember" xlink:label="iva_OtherMiscellaneousPayablesMember_638645827459939834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesMember_638645827459929798" xlink:to="iva_OtherMiscellaneousPayablesMember_638645827459939834" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_638645827459939834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_638645827459919704" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_638645827459939834" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember_638645827459939834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_638645827459939834" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember_638645827459939834" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_638645827459950218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember_638645827459939834" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_638645827459950218" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_638645827459950218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember_638645827459939834" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_638645827459950218" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638645827459950218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_638645827459919704" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638645827459950218" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets_638645827459950218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638645827459950218" xlink:to="ifrs-full_FinancialAssets_638645827459950218" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities_638645827459950218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638645827459950218" xlink:to="ifrs-full_FinancialLiabilities_638645827459950218" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtFairValue" xlink:label="ifrs-full_FinancialAssetsAtFairValue_638645827459950218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638645827459950218" xlink:to="ifrs-full_FinancialAssetsAtFairValue_638645827459950218" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue_638645827459959783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638645827459950218" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValue_638645827459959783" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Revenues and other income (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ComponentsOfIncomeStatementAbstract" xlink:label="iva_ComponentsOfIncomeStatementAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_638645827459959783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_3" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_638645827459959783" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue_638645827459959783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_3" xlink:to="ifrs-full_Revenue_638645827459959783" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CurrentTaxCreditResearchIncome" xlink:label="iva_CurrentTaxCreditResearchIncome_638645827459959783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_3" xlink:to="iva_CurrentTaxCreditResearchIncome_638645827459959783" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_SubsidiesIncome" xlink:label="iva_SubsidiesIncome_638645827459959783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_3" xlink:to="iva_SubsidiesIncome_638645827459959783" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsOtherOperatingIncome" xlink:label="iva_IfrsOtherOperatingIncome_638645827459969748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_3" xlink:to="iva_IfrsOtherOperatingIncome_638645827459969748" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherIncomeFromOrdinaryActivities" xlink:label="iva_OtherIncomeFromOrdinaryActivities_638645827459969748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_3" xlink:to="iva_OtherIncomeFromOrdinaryActivities_638645827459969748" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueAndOperatingIncome" xlink:label="ifrs-full_RevenueAndOperatingIncome_638645827459969748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_3" xlink:to="ifrs-full_RevenueAndOperatingIncome_638645827459969748" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Narratives (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ComponentsOfIncomeStatementAbstract" xlink:label="iva_ComponentsOfIncomeStatementAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:label="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_638645827459969748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_2" xlink:to="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_638645827459969748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827459969748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_638645827459969748" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827459969748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459969748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827459969748" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459969748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LicensingAndCollaborationAgreementWithCttqMember" xlink:label="iva_LicensingAndCollaborationAgreementWithCttqMember_638645827459969748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459969748" xlink:to="iva_LicensingAndCollaborationAgreementWithCttqMember_638645827459969748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ServiceContractWithAvantSanteMember" xlink:label="iva_ServiceContractWithAvantSanteMember_638645827459969748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827459969748" xlink:to="iva_ServiceContractWithAvantSanteMember_638645827459969748" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638645827459969748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_638645827459969748" xlink:to="dei_LegalEntityAxis_638645827459969748" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638645827459969748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638645827459969748" xlink:to="dei_EntityDomain_638645827459969748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_InventivaIncMember" xlink:label="iva_InventivaIncMember_638645827459969748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638645827459969748" xlink:to="iva_InventivaIncMember_638645827459969748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:label="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827459979904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_638645827459969748" xlink:to="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827459979904" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ProceedsFromLicensingArrangements" xlink:label="iva_ProceedsFromLicensingArrangements_638645827459979904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827459979904" xlink:to="iva_ProceedsFromLicensingArrangements_638645827459979904" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CurrentTaxCreditResearchCurrentYear" xlink:label="iva_CurrentTaxCreditResearchCurrentYear_638645827459979904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827459979904" xlink:to="iva_CurrentTaxCreditResearchCurrentYear_638645827459979904" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement" xlink:label="iva_OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement_638645827459979904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827459979904" xlink:to="iva_OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement_638645827459979904" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement" xlink:label="iva_OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement_638645827459979904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827459979904" xlink:to="iva_OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement_638645827459979904" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CirAndOtherResearchTaxCreditsReceivable" xlink:label="iva_CirAndOtherResearchTaxCreditsReceivable_638645827459979904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827459979904" xlink:to="iva_CirAndOtherResearchTaxCreditsReceivable_638645827459979904" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_638645827459979904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827459979904" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_638645827459979904" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Operating expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ComponentsOfIncomeStatementAbstract" xlink:label="iva_ComponentsOfIncomeStatementAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:label="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_638645827459979904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_5" xlink:to="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_638645827459979904" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_638645827459979904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_638645827459979904" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_638645827459979904" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="ifrs-full_LineItemsByFunctionMember_638645827459979904" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_638645827459979904" xlink:to="ifrs-full_LineItemsByFunctionMember_638645827459979904" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsResearchAndDevelopmentExpenseMember" xlink:label="iva_IfrsResearchAndDevelopmentExpenseMember_638645827459989843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LineItemsByFunctionMember_638645827459979904" xlink:to="iva_IfrsResearchAndDevelopmentExpenseMember_638645827459989843" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsSalesAndMarketingExpenseMember" xlink:label="iva_IfrsSalesAndMarketingExpenseMember_638645827459989843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LineItemsByFunctionMember_638645827459979904" xlink:to="iva_IfrsSalesAndMarketingExpenseMember_638645827459989843" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsGeneralAndAdministrativeExpenseMember" xlink:label="iva_IfrsGeneralAndAdministrativeExpenseMember_638645827459989843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LineItemsByFunctionMember_638645827459979904" xlink:to="iva_IfrsGeneralAndAdministrativeExpenseMember_638645827459989843" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:label="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827459989843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_638645827459979904" xlink:to="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827459989843" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Disposables" xlink:label="iva_Disposables_638645827459989843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827459989843" xlink:to="iva_Disposables_638645827459989843" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_EnergyAndLiquids" xlink:label="iva_EnergyAndLiquids_638645827459989843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827459989843" xlink:to="iva_EnergyAndLiquids_638645827459989843" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Patents" xlink:label="iva_Patents_638645827459989843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827459989843" xlink:to="iva_Patents_638645827459989843" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Studies" xlink:label="iva_Studies_638645827459989843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827459989843" xlink:to="iva_Studies_638645827459989843" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepairsAndMaintenanceExpense" xlink:label="ifrs-full_RepairsAndMaintenanceExpense_638645827459989843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827459989843" xlink:to="ifrs-full_RepairsAndMaintenanceExpense_638645827459989843" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Fees" xlink:label="iva_Fees_638645827459989843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827459989843" xlink:to="iva_Fees_638645827459989843" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ItSystems" xlink:label="iva_ItSystems_638645827459989843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827459989843" xlink:to="iva_ItSystems_638645827459989843" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_SupportCosts" xlink:label="iva_SupportCosts_638645827459989843" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827459989843" xlink:to="iva_SupportCosts_638645827459989843" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense_638645827459999926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827459989843" xlink:to="ifrs-full_EmployeeBenefitsExpense_638645827459999926" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_DepreciationAmortizationAndProvisions" xlink:label="iva_DepreciationAmortizationAndProvisions_638645827459999926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827459989843" xlink:to="iva_DepreciationAmortizationAndProvisions_638645827459999926" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InsuranceExpense" xlink:label="ifrs-full_InsuranceExpense_638645827459999926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827459989843" xlink:to="ifrs-full_InsuranceExpense_638645827459999926" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherOperatingExpenses" xlink:label="iva_OtherOperatingExpenses_638645827459999926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827459989843" xlink:to="iva_OtherOperatingExpenses_638645827459999926" order="12" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OperatingExpenseExcludingOtherOperatingIncomeExpense" xlink:label="iva_OperatingExpenseExcludingOtherOperatingIncomeExpense_638645827459999926" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827459989843" xlink:to="iva_OperatingExpenseExcludingOtherOperatingIncomeExpense_638645827459999926" order="13" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails" xlink:type="extended" xlink:title="40504 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Operating expenses - Personnel costs and headcount (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ComponentsOfIncomeStatementAbstract" xlink:label="iva_ComponentsOfIncomeStatementAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable" xlink:label="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_638645827460009870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_6" xlink:to="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_638645827460009870" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_638645827460009870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_638645827460009870" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_638645827460009870" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember" xlink:label="ifrs-full_LineItemsByFunctionMember_638645827460009870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_638645827460009870" xlink:to="ifrs-full_LineItemsByFunctionMember_638645827460009870" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsResearchAndDevelopmentExpenseMember" xlink:label="iva_IfrsResearchAndDevelopmentExpenseMember_638645827460009870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LineItemsByFunctionMember_638645827460009870" xlink:to="iva_IfrsResearchAndDevelopmentExpenseMember_638645827460009870" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsSalesAndMarketingExpenseMember" xlink:label="iva_IfrsSalesAndMarketingExpenseMember_638645827460009870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LineItemsByFunctionMember_638645827460009870" xlink:to="iva_IfrsSalesAndMarketingExpenseMember_638645827460009870" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsGeneralAndAdministrativeExpenseMember" xlink:label="iva_IfrsGeneralAndAdministrativeExpenseMember_638645827460009870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LineItemsByFunctionMember_638645827460009870" xlink:to="iva_IfrsGeneralAndAdministrativeExpenseMember_638645827460009870" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638645827460009870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_638645827460009870" xlink:to="dei_LegalEntityAxis_638645827460009870" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638645827460009870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638645827460009870" xlink:to="dei_EntityDomain_638645827460009870" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_InventivaS.aMember" xlink:label="iva_InventivaS.aMember_638645827460009870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638645827460009870" xlink:to="iva_InventivaS.aMember_638645827460009870" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_InventivaIncMember" xlink:label="iva_InventivaIncMember_638645827460009870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638645827460009870" xlink:to="iva_InventivaIncMember_638645827460009870" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems" xlink:label="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827460009870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable_638645827460009870" xlink:to="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827460009870" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfEmployees" xlink:label="ifrs-full_NumberOfEmployees_638645827460009870" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827460009870" xlink:to="ifrs-full_NumberOfEmployees_638645827460009870" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WagesAndSalaries" xlink:label="ifrs-full_WagesAndSalaries_638645827460019945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827460009870" xlink:to="ifrs-full_WagesAndSalaries_638645827460019945" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PayrollTaxes" xlink:label="iva_PayrollTaxes_638645827460019945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827460009870" xlink:to="iva_PayrollTaxes_638645827460019945" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss" xlink:label="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss_638645827460019945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827460009870" xlink:to="ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss_638645827460019945" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_638645827460019945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827460009870" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_638645827460019945" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense_638645827460019945" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems_638645827460009870" xlink:to="ifrs-full_EmployeeBenefitsExpense_638645827460019945" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails" xlink:type="extended" xlink:title="40505 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Other operating income and expenses - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ComponentsOfIncomeStatementAbstract" xlink:label="iva_ComponentsOfIncomeStatementAbstract_9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_638645827460029862" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_9" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome_638645827460029862" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense_638645827460029862" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_9" xlink:to="ifrs-full_MiscellaneousOtherOperatingExpense_638645827460029862" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense" xlink:label="ifrs-full_OtherOperatingIncomeExpense_638645827460029862" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_9" xlink:to="ifrs-full_OtherOperatingIncomeExpense_638645827460029862" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" xlink:type="extended" xlink:title="40506 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Financial income and expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ComponentsOfIncomeStatementAbstract" xlink:label="iva_ComponentsOfIncomeStatementAbstract_10" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:label="ifrs-full_InterestIncomeOnCashAndCashEquivalents_638645827460029862" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_10" xlink:to="ifrs-full_InterestIncomeOnCashAndCashEquivalents_638645827460029862" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignExchangeGain" xlink:label="ifrs-full_ForeignExchangeGain_638645827460029862" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_10" xlink:to="ifrs-full_ForeignExchangeGain_638645827460029862" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FairValueVariationGains" xlink:label="iva_FairValueVariationGains_638645827460029862" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_10" xlink:to="iva_FairValueVariationGains_638645827460029862" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_638645827460029862" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_10" xlink:to="ifrs-full_FinanceIncome_638645827460029862" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpense" xlink:label="ifrs-full_InterestExpense_638645827460029862" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_10" xlink:to="ifrs-full_InterestExpense_638645827460029862" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignExchangeLoss" xlink:label="ifrs-full_ForeignExchangeLoss_638645827460029862" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_10" xlink:to="ifrs-full_ForeignExchangeLoss_638645827460029862" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceCost" xlink:label="ifrs-full_OtherFinanceCost_638645827460029862" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_10" xlink:to="ifrs-full_OtherFinanceCost_638645827460029862" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_638645827460029862" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_10" xlink:to="ifrs-full_FinanceCosts_638645827460029862" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost_638645827460029862" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_10" xlink:to="ifrs-full_FinanceIncomeCost_638645827460029862" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsFairValueAdjustmentOfWarrants" xlink:label="iva_IfrsFairValueAdjustmentOfWarrants_638645827460029862" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_10" xlink:to="iva_IfrsFairValueAdjustmentOfWarrants_638645827460029862" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails" xlink:type="extended" xlink:title="40507 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Share of net profit - Equity method (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ComponentsOfIncomeStatementAbstract" xlink:label="iva_ComponentsOfIncomeStatementAbstract_11" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_638645827460039948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_11" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_638645827460039948" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638645827460039948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_638645827460039948" xlink:to="dei_LegalEntityAxis_638645827460039948" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638645827460039948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638645827460039948" xlink:to="dei_EntityDomain_638645827460039948" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_HepalysPharmaIncMember" xlink:label="iva_HepalysPharmaIncMember_638645827460039948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638645827460039948" xlink:to="iva_HepalysPharmaIncMember_638645827460039948" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis_638645827460039948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_638645827460039948" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis_638645827460039948" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="ifrs-full_EntitysTotalForAssociatesMember_638645827460039948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis_638645827460039948" xlink:to="ifrs-full_EntitysTotalForAssociatesMember_638645827460039948" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_HepalysPharmaIncMember" xlink:label="iva_HepalysPharmaIncMember_6386458274600399481" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForAssociatesMember_638645827460039948" xlink:to="iva_HepalysPharmaIncMember_6386458274600399481" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827460039948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_638645827460039948" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827460039948" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_638645827460049838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827460039948" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_638645827460049838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_638645827460049838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827460039948" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_638645827460049838" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_638645827460049838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827460039948" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_638645827460049838" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_638645827460049838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827460039948" xlink:to="ifrs-full_FinanceIncome_638645827460049838" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_638645827460049838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827460039948" xlink:to="ifrs-full_FinanceCosts_638645827460049838" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost_638645827460049838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827460039948" xlink:to="ifrs-full_FinanceIncomeCost_638645827460049838" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_638645827460049838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827460039948" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_638645827460049838" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638645827460049838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827460039948" xlink:to="ifrs-full_ProfitLoss_638645827460049838" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_638645827460049838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827460039948" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_638645827460049838" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_638645827460049838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827460039948" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_638645827460049838" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_638645827460059667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827460039948" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax_638645827460059667" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome_638645827460059667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827460039948" xlink:to="ifrs-full_ComprehensiveIncome_638645827460059667" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_638645827460059667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827460039948" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate_638645827460059667" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations" xlink:label="iva_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations_638645827460059667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827460039948" xlink:to="iva_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations_638645827460059667" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_EliminationOfDownstreamSales" xlink:label="iva_EliminationOfDownstreamSales_638645827460059667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827460039948" xlink:to="iva_EliminationOfDownstreamSales_638645827460059667" order="15" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_638645827460059667" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827460039948" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_638645827460059667" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossIncomeTaxDetails" xlink:type="extended" xlink:title="40508 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Income tax (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ComponentsOfIncomeStatementAbstract" xlink:label="iva_ComponentsOfIncomeStatementAbstract_8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods_638645827460074014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_8" xlink:to="ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods_638645827460074014" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_638645827460074014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_8" xlink:to="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_638645827460074014" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_638645827460074014" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_8" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_638645827460074014" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossBasicAndDilutedLossPerShareDetails" xlink:type="extended" xlink:title="40509 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Basic and diluted loss per share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ComponentsOfIncomeStatementAbstract" xlink:label="iva_ComponentsOfIncomeStatementAbstract_12" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638645827460080326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_12" xlink:to="ifrs-full_ProfitLoss_638645827460080326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares_638645827460080326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_12" xlink:to="ifrs-full_WeightedAverageShares_638645827460080326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="ifrs-full_AdjustedWeightedAverageShares_638645827460080326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_12" xlink:to="ifrs-full_AdjustedWeightedAverageShares_638645827460080326" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare_638645827460080326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_12" xlink:to="ifrs-full_BasicEarningsLossPerShare_638645827460080326" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare_638645827460080326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_ComponentsOfIncomeStatementAbstract_12" xlink:to="ifrs-full_DilutedEarningsLossPerShare_638645827460080326" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Other financial information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherFinancialInformationAbstract" xlink:label="iva_OtherFinancialInformationAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_638645827460080326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_OtherFinancialInformationAbstract_2" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_638645827460080326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis_638645827460089828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_638645827460080326" xlink:to="ifrs-full_SignificantInvestmentsInAssociatesAxis_638645827460089828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="ifrs-full_EntitysTotalForAssociatesMember_638645827460089828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis_638645827460089828" xlink:to="ifrs-full_EntitysTotalForAssociatesMember_638645827460089828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ClinicalTrialsMember" xlink:label="iva_ClinicalTrialsMember_638645827460089828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForAssociatesMember_638645827460089828" xlink:to="iva_ClinicalTrialsMember_638645827460089828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ContractManufacturingOrganizationsMember" xlink:label="iva_ContractManufacturingOrganizationsMember_638645827460089828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForAssociatesMember_638645827460089828" xlink:to="iva_ContractManufacturingOrganizationsMember_638645827460089828" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="ifrs-full_LeaseLiabilitiesMember_638645827460089828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForAssociatesMember_638645827460089828" xlink:to="ifrs-full_LeaseLiabilitiesMember_638645827460089828" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherContingentLiabilitiesMember" xlink:label="ifrs-full_OtherContingentLiabilitiesMember_638645827460089828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForAssociatesMember_638645827460089828" xlink:to="ifrs-full_OtherContingentLiabilitiesMember_638645827460089828" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PharmaceuticalResearchAssociatesMember" xlink:label="iva_PharmaceuticalResearchAssociatesMember_638645827460089828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForAssociatesMember_638645827460089828" xlink:to="iva_PharmaceuticalResearchAssociatesMember_638645827460089828" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ChiaTaiTianqingMember" xlink:label="iva_ChiaTaiTianqingMember_638645827460089828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForAssociatesMember_638645827460089828" xlink:to="iva_ChiaTaiTianqingMember_638645827460089828" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827460089828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_638645827460080326" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827460089828" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827460089828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827460089828" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827460089828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ContractCroWithResearchAssociatesGroupeB.vMember" xlink:label="iva_ContractCroWithResearchAssociatesGroupeB.vMember_638645827460089828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827460089828" xlink:to="iva_ContractCroWithResearchAssociatesGroupeB.vMember_638645827460089828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_638645827460089828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_638645827460080326" xlink:to="ifrs-full_RangeAxis_638645827460089828" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638645827460089828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_638645827460089828" xlink:to="ifrs-full_RangesMember_638645827460089828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember_638645827460099842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638645827460089828" xlink:to="ifrs-full_BottomOfRangeMember_638645827460099842" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember_638645827460099842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638645827460089828" xlink:to="ifrs-full_TopOfRangeMember_638645827460099842" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827460099842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_638645827460080326" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827460099842" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractualCapitalCommitments" xlink:label="ifrs-full_ContractualCapitalCommitments_638645827460099842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827460099842" xlink:to="ifrs-full_ContractualCapitalCommitments_638645827460099842" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AgreementsConcerningProvisionOfFacilities" xlink:label="iva_AgreementsConcerningProvisionOfFacilities_638645827460099842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827460099842" xlink:to="iva_AgreementsConcerningProvisionOfFacilities_638645827460099842" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ContractualCapitalCommitmentReceived" xlink:label="iva_ContractualCapitalCommitmentReceived_638645827460099842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827460099842" xlink:to="iva_ContractualCapitalCommitmentReceived_638645827460099842" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CommitmentsAmountPayableForServicesReceivedUnderContract" xlink:label="iva_CommitmentsAmountPayableForServicesReceivedUnderContract_638645827460099842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827460099842" xlink:to="iva_CommitmentsAmountPayableForServicesReceivedUnderContract_638645827460099842" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_CommitmentContractualBonusOrMalusCappedAmount" xlink:label="iva_CommitmentContractualBonusOrMalusCappedAmount_638645827460099842" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_638645827460099842" xlink:to="iva_CommitmentContractualBonusOrMalusCappedAmount_638645827460099842" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Other financial information - Events after the reporting date (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_OtherFinancialInformationAbstract" xlink:label="iva_OtherFinancialInformationAbstract_3" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsotherFinancialInformationTable" xlink:label="iva_IfrsotherFinancialInformationTable_638645827460109827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_OtherFinancialInformationAbstract_3" xlink:to="iva_IfrsotherFinancialInformationTable_638645827460109827" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638645827460109827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsotherFinancialInformationTable_638645827460109827" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638645827460109827" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember_638645827460109827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638645827460109827" xlink:to="ifrs-full_NonadjustingEventsMember_638645827460109827" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember" xlink:label="iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember_638645827460109827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember_638645827460109827" xlink:to="iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember_638645827460109827" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PresentationOfResultsFromStudyMember" xlink:label="iva_PresentationOfResultsFromStudyMember_638645827460109827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember_638645827460109827" xlink:to="iva_PresentationOfResultsFromStudyMember_638645827460109827" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IssuanceOfRoyaltyCertificatesMember" xlink:label="iva_IssuanceOfRoyaltyCertificatesMember_638645827460109827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember_638645827460109827" xlink:to="iva_IssuanceOfRoyaltyCertificatesMember_638645827460109827" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinancingAgreementInThreePhasesMember" xlink:label="iva_FinancingAgreementInThreePhasesMember_638645827460109827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember_638645827460109827" xlink:to="iva_FinancingAgreementInThreePhasesMember_638645827460109827" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember" xlink:label="iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember_638645827460109827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_FinancingAgreementInThreePhasesMember_638645827460109827" xlink:to="iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember_638645827460109827" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember" xlink:label="iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember_638645827460109827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_FinancingAgreementInThreePhasesMember_638645827460109827" xlink:to="iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember_638645827460109827" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember" xlink:label="iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember_638645827460119894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_FinancingAgreementInThreePhasesMember_638645827460109827" xlink:to="iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember_638645827460119894" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinancingThroughFundRaisingMember" xlink:label="iva_FinancingThroughFundRaisingMember_638645827460119894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember_638645827460109827" xlink:to="iva_FinancingThroughFundRaisingMember_638645827460119894" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis_638645827460119894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsotherFinancialInformationTable_638645827460109827" xlink:to="ifrs-full_BorrowingsByNameAxis_638645827460119894" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember_638645827460119894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis_638645827460119894" xlink:to="ifrs-full_BorrowingsByNameMember_638645827460119894" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember" xlink:label="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_638645827460119894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember_638645827460119894" xlink:to="iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_638645827460119894" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827460119894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsotherFinancialInformationTable_638645827460109827" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827460119894" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827460119894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_638645827460119894" xlink:to="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827460119894" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember" xlink:label="iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember_638645827460119894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827460119894" xlink:to="iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember_638645827460119894" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_LicensingAndCollaborationAgreementWithCttqMember" xlink:label="iva_LicensingAndCollaborationAgreementWithCttqMember_638645827460119894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827460119894" xlink:to="iva_LicensingAndCollaborationAgreementWithCttqMember_638645827460119894" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_WarrantAgreementWithEuropeanInvestmentBankMember" xlink:label="iva_WarrantAgreementWithEuropeanInvestmentBankMember_638645827460119894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_638645827460119894" xlink:to="iva_WarrantAgreementWithEuropeanInvestmentBankMember_638645827460119894" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638645827460119894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsotherFinancialInformationTable_638645827460109827" xlink:to="srt_StatementScenarioAxis_638645827460119894" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638645827460119894" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638645827460119894" xlink:to="srt_ScenarioUnspecifiedDomain_638645827460119894" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ScenarioOneMember" xlink:label="iva_ScenarioOneMember_638645827460129875" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638645827460119894" xlink:to="iva_ScenarioOneMember_638645827460129875" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ScenarioTwoMember" xlink:label="iva_ScenarioTwoMember_638645827460129875" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638645827460119894" xlink:to="iva_ScenarioTwoMember_638645827460129875" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ScenarioThreeMember" xlink:label="iva_ScenarioThreeMember_638645827460129875" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638645827460119894" xlink:to="iva_ScenarioThreeMember_638645827460129875" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsotherFinancialInformationLineItems" xlink:label="iva_IfrsotherFinancialInformationLineItems_638645827460129875" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsotherFinancialInformationTable_638645827460109827" xlink:to="iva_IfrsotherFinancialInformationLineItems_638645827460129875" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PercentageOfPatientsInTrialEnrolledInMainCohort" xlink:label="iva_PercentageOfPatientsInTrialEnrolledInMainCohort_638645827460129875" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsotherFinancialInformationLineItems_638645827460129875" xlink:to="iva_PercentageOfPatientsInTrialEnrolledInMainCohort_638645827460129875" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PercentageOfPatientsInTrialEnrolledInExploratoryCohort" xlink:label="iva_PercentageOfPatientsInTrialEnrolledInExploratoryCohort_638645827460129875" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsotherFinancialInformationLineItems_638645827460129875" xlink:to="iva_PercentageOfPatientsInTrialEnrolledInExploratoryCohort_638645827460129875" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfRoyaltyCertificatesIssued" xlink:label="iva_NumberOfRoyaltyCertificatesIssued_638645827460129875" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsotherFinancialInformationLineItems_638645827460129875" xlink:to="iva_NumberOfRoyaltyCertificatesIssued_638645827460129875" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ProceedsFromFinancing" xlink:label="iva_ProceedsFromFinancing_638645827460129875" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsotherFinancialInformationLineItems_638645827460129875" xlink:to="iva_ProceedsFromFinancing_638645827460129875" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor" xlink:label="iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor_638645827460129875" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsotherFinancialInformationLineItems_638645827460129875" xlink:to="iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor_638645827460129875" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_MaximumDurationOfClinicalTrial" xlink:label="iva_MaximumDurationOfClinicalTrial_638645827460139808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsotherFinancialInformationLineItems_638645827460129875" xlink:to="iva_MaximumDurationOfClinicalTrial_638645827460139808" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_NumberOfEqualTranches" xlink:label="iva_NumberOfEqualTranches_638645827460139808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsotherFinancialInformationLineItems_638645827460129875" xlink:to="iva_NumberOfEqualTranches_638645827460139808" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany" xlink:label="iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany_638645827460139808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsotherFinancialInformationLineItems_638645827460129875" xlink:to="iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany_638645827460139808" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_StockIssuedDuringPeriodValue" xlink:label="iva_StockIssuedDuringPeriodValue_638645827460139808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsotherFinancialInformationLineItems_638645827460129875" xlink:to="iva_StockIssuedDuringPeriodValue_638645827460139808" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_StockIssuedDuringPeriodShares" xlink:label="iva_StockIssuedDuringPeriodShares_638645827460139808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsotherFinancialInformationLineItems_638645827460129875" xlink:to="iva_StockIssuedDuringPeriodShares_638645827460139808" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare_638645827460139808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsotherFinancialInformationLineItems_638645827460129875" xlink:to="ifrs-full_ParValuePerShare_638645827460139808" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ClassOfWarrantOrRightGranted" xlink:label="iva_ClassOfWarrantOrRightGranted_638645827460139808" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsotherFinancialInformationLineItems_638645827460129875" xlink:to="iva_ClassOfWarrantOrRightGranted_638645827460139808" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638645827460149844" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsotherFinancialInformationLineItems_638645827460129875" xlink:to="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638645827460149844" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_638645827460149844" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsotherFinancialInformationLineItems_638645827460129875" xlink:to="iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_638645827460149844" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="iva_IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights_638645827460149844" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsotherFinancialInformationLineItems_638645827460129875" xlink:to="iva_IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights_638645827460149844" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_MinimumAmountCommittedForFundRaising" xlink:label="iva_MinimumAmountCommittedForFundRaising_638645827460149844" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsotherFinancialInformationLineItems_638645827460129875" xlink:to="iva_MinimumAmountCommittedForFundRaising_638645827460149844" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_ProceedsFromLicensingArrangements" xlink:label="iva_ProceedsFromLicensingArrangements_638645827460149844" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsotherFinancialInformationLineItems_638645827460129875" xlink:to="iva_ProceedsFromLicensingArrangements_638645827460149844" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_PeriodWithinWhichPaymentIsReceivedFromSettlement" xlink:label="iva_PeriodWithinWhichPaymentIsReceivedFromSettlement_638645827460149844" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsotherFinancialInformationLineItems_638645827460129875" xlink:to="iva_PeriodWithinWhichPaymentIsReceivedFromSettlement_638645827460149844" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="iva-20240630.xsd#iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638645827460149844" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="iva_IfrsotherFinancialInformationLineItems_638645827460129875" xlink:to="iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638645827460149844" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>iva-20240630xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 iva-20240630xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "M 8P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BFEL&D\P?WA^=2Y)=0'T4T'(SVIU-.X!1113 **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD)Q32^.3TJ7)+
M<!]%,\SZ4X'/_P!:A23V 6BBBJ **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH X/XR:K=Z/X+O+JQN9;2X1X@)8FVL,NH//OTKYVOOB-XGC
MM)W7Q!J 98V89EQR%)%?4'COP9;^.] N-(NKRZL(9F1C/9E5D7:P88+ CG&#
MQTKR]_V4M$='4^*O$9# J0;B'D$8/_+*ORSB7(LWS+&QK8*KRP72]BN:RLD=
MU\$M7O->^%7AG4-0N7O+VXLDDFGD.6=^Y/O7=U@^#/"]KX*\,:=H=G+)-:V$
M(@C>;!<J.F2 !G\*W-P]17Z/A(3IT(0J;I*Y(ZBD!STJ*2Y2+[Y"KG&YB *[
M )J*B$ZMC:0P/=>14@.1F@!:*3</44 @]#F@!:**0G% "T4FX>HI: "BFNVQ
M2<9]JC>Z2, LP0?[1 H FHJ))U89YP3C/:I: "BBDW#U% "T4F:B>[CB&78)
MVRQP/S- $U%0BX#*2!D=N>OXU*.10 M07%S%"C;WV<=3QCWI\DPC]">PS7P%
M^VQ^UU_:+W_P\\%7O^C?-#K.J6[_ 'R.&MHF';L[#KT'?(!]L^ /'ND?$;2;
MC5=$NUOM/CNY;,7,8.R1XFVN5)ZKNR >^*@^)U_<:=X)U>XM9WM[B*$M'+&<
M,IR.17CG_!/T!?V;-)&0!]NO,#IC]Z:]U\7>%X?%WA_4-*GN9[2&\C\MY[5@
MLB#(Y4D$9X[@]ZX,=2J5L/4I4W:36@T?+Q^(7B=3SX@OR,]YO_K5[E^SMK^H
M^)_A+HNHZK>2W]]*TPDGF.6;$K 9_  5S!_97T0\CQ7XC'?_ (^(?_C5>F_#
MSP/9?#KPG9:#87$]Q:6I?9+=%3(=SECD@ =3Z5^?\,9)FV68F<\?5YXM::M]
M@<G)['2C.:6DW#U%+7Z<(***3<!W%,!:*0$'H<TM !14;3!3T./4U&E['(Y5
M61OHX)H L45$)<MC&/KQ4M !1110 4444 %%%% !1110 4444 >&?MI^)]7\
M'_L\^(=5T+4[K1]3AGLUCO+*4QRH&N8U8!ATR"0?8U^:Z_M&_%3</^+B^)?_
M  8O7Z*_M[?\FQ>)_P#KXL?_ $KBK\IE^\*I ?L)^R[KVI>)OV>/!.JZO?W&
MIZG<Z:))[RZD+RRMN?YF8]3P*_,G5/VBOBG%JMZB?$3Q(J+<2JJC4'P '( K
M]*/V0O\ DV'P!_V"A_Z&]?DGK'_(8O\ _KYE_P#0VH ^HO"7[</B;P/\"SIJ
M:M=>(/'E]JER5U#59#/]AM=L01L'[S$[]JG@<D^A^=?%7Q)\5>.=1DO=?\1Z
MGJUS)U-Q=.1] @.T#T %>S?L7?L]:=\<O&^I77B%)9/#6API)/!&Y3[3,Y.R
M(L.0N%9CCG@#C-?H5)^S;\,)-$_LP^ _#_V0)LVK8J&QC^^/F_'.: /R1\,?
M$SQ;X*OH[S0O$NK:7<QGY6@NWV_0J25(]B,5^D'['O[3]W\=]%O=(U[RHO%>
MDHLD[P+M2\@8[1*JC[K X# <<@CK@?"'[3WPDMO@K\8]7\.6#.VE%([RQ\UM
MS""0$A2>^U@RY[[174_L):Y+HO[2_AR-)"D5_#=6<JC^,&(L ?HR*?PHL!VW
M[9'CKXF?"KXXZI:Z;XZ\16.B:G%'J-A;PWSK'$K#:Z*.P617X[ @55_9$_:4
M\9O\=_#^E^*?%VK:SI&L>9IYAU&Z,J)*RYB8!NAW*%S_ +5>X?\ !2/X;G7/
MAMHGC"WCW7.AW8@G8#_EWGP,GZ2*G_?1K\[M)U6XT/5++4K-REY93QW,$@."
M'1@RG\P*2 _=175NA!/2OE[]OOXP:K\,_AKI-CX?U:YTC7-9OPL=S9R^7*D$
M0WR$'J 28U_X%7T!X%\5V_C?P=HOB*S93:ZI917B8/3>@8C\"2/PK\W/^"@W
MCX>+/CN^D02;[3P[9I9@ \><_P"\E/U^9%_X":$!YQH?QT^+_B/6]/TFQ^(7
MB:2]O[B.U@3^T'Y=V"K^IK]:4N[;P!X*BEUK5R;32;)?M6I7\OS,(U >5V/4
MG!/N37YJ_L"_#D^-OCQ:ZO/&'L?#ENVHOD<><V4A'YEF_P" UZ[_ ,%)/BQ<
M6T>@_#VQG,<=Q'_:6IB,\2*&*P1GVR&<@^BT,#AOCU^W[XH\8:C<Z7X!FD\-
M>'T8HNH #[==#^]D_P"J![ #=ZD=*^7=6\6ZWKER\^IZYJ%_<.=S/=7DCDGU
M^9JZ?X(?"ZX^,OQ1T3PG#*;:.\D9[FXP"88$&Z1@#U.!@>Y%?JUX&_9[^'G@
M31HM/TOPEI?EHH5IKRU2XGE/=GD<%B2>O.,] *8'Y,>#_B]XU\ WT=YX?\5:
MIITB$':ET[Q-CLR,2K#V(K] ?V3?VSD^,5W'X4\6)#I_B[83;W$/R6^H #)V
MJ?N2 <E>AP2/2L3]M3]E;PS<?#O5/&GA71[;1];T=?M5U%81B**ZMQCS,H,*
M'0?,&&. P/6OSVTG5KS0=4M-3TZY>TU"SE2XMITX,<BD%6]L&@#]L_'U[/8^
M /$5U;3/!<0Z;<R12QG#(PB<J0?4$#\J_(.V_:/^*IAA)^(WB4DHI).HOZ"O
MU'TWQ]%\3_V;)/%,*A!JGAVXGD1>B2>0XD7\'##\*_'*W_X]H?\ KFO\A0D!
M]8R_MQ^*_#WP1\-^&]&U>XU'QC<1S/JFO:A^^EMP96\N--PPSE<')SM&.,]/
MFS7_ !SXB\5WKW.LZ_J6JW+MN:2[O))#GZ$X%?2O[#G[,NB?&*;5_$_BRV-]
MH>FSK:6]@6*I<S[0[&3')55*_+W+<\#%?;^O_LT?"_7-#DTRX\#Z)';,NP-:
MVBPRIZ%77#9'K0!^47@OXP^-OAWJ,5[X?\4:II\L9!\L7+21/CLT;$JP]B*_
M3G]E']H8?M ^"7NKQ([/Q'I3K;ZG:P$^6VX$I*@/17P>.Q!'I7YD?&7X>-\*
M/BCXE\*&1IH]-NS'#,XPTD) :-C[E6&?<&O?/^";VNR67QMU;3%+&'4=%E+#
M/&Z*6-@?K\Y_.@#RCQS^T#\2?^$I\0V*_$'Q +07UU"(%U%PHC\UEV@ ],<5
MY/7["?%OX4^#+?X;>,[U/".@"[72;V=9QI< D$GDN=X;9G=GG.<YK\>8SF-"
M>?E'7Z4 =CX;^,_CGP7I2:7H7C36-%TZ-F=;2RO6CC4L<DA1W)YK[9^'_P 3
M/%>H?L!>+/$T_B74[CQ' +[R=5>Y+7*;9U"[7ZC .*Z7]A?X<>%?$O[/6E7N
MK^&=&U2]:]NU:YO=/AFD($I !9E)XKO/VI?#FF>&?V7?B'9Z1I]II5D--D86
MUC;I#&"73)VJ ,GUH _-QOVC?BIN/_%Q?$O7_H(O7U[I>O>._&'[ D?BBQ\6
MZXGBO3+BZU!M1BNV^T3PQ74BO&S=2HC)(!Z;!Z5^?K_?;ZU^IW[#>G0ZM^RE
MH=E=(LMK<2:C%+&PX9&N90P/U!- 'YZG]HSXJ8(/Q'\3#W&HO7Z?_LK_ !+E
M^*?P,\,ZU>W)N=42(V5]*YRS3Q'8S$^K *W_  *ORA^)W@B?X;_$'Q%X7N P
M?2[Z6U4M_'$#E&_%"I_&OL7_ ()G^/\ #>+O!4\@R3'JUJA/7I', /\ OV?Q
MHZ ?>%S,L$#R.P1$!9F/0 <D_E7Y&?$?]J;XB>(/'WB'4M'\;Z[IFDW%_,]G
M:6MZR110[B$"@< ;0#^-?HA^U[\0S\.OV?\ Q7?12^5>WD']F6I[^;/\G'T4
MNWX'TK\AC\H^52P' '\A2 _1K_@G_JOCGQOI'BGQ3XH\4ZQK5EO33;"&_NFE
M0.HWRN 3U^9%S]?6LO\ :I_;DO? NNWO@[P"87U:T_=7^LSJ)4MY>\4*=&9>
M['(!XP><>]_ GX>WGPL_9ZT/0K.)5UN+36N'1L+OO)5,A#$],.P'X5\$3?L)
M?&R^FDN+C0K*6XE8R2R-JT!+.QRQ//<DF@#R/Q)\5_&_CF]\W6?%>M:K<.V
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MP4/_ $-Z_)/6/^0Q?_\ 7S+_ .AM7ZV?LA?\FP^ /^P4/_0WK\D]8_Y#%_\
M]?,O_H;4 ??G_!,2-3X-\=,0,_VI;C/M]G'^-?;#<+7Q1_P3#_Y$OQU_V%8/
M_2<5]KM]TTF!^:?_  4FB1/C7H;A0&?0H]Q]<328KS;]C,#_ (:8\"_]?,I_
M\@2UZ7_P4H_Y+1H'_8"3_P!'25YK^QG_ ,G,>!?^OB7_ -$2U2 _4OXG>"K;
MXC?#[7O#%WM$&JV4EKN89V,R_(WU#;3^%?BCJ-A<:1J-U8WB&&\M9G@G1A@K
M(C%6!^A!K]U'0N@ .*_*K]NWX=GP'\?]3O8(MECX@B75(>/E\P_),/P==W_
MQ4H#Z=_8.^*]M)^SMJEKJ4^U?!TT_G%N<6I5IT)_\B+_ ,!K\\/%?B6Y\9^*
M=7UZ\.ZZU2\EO),G)!D8MC\ 0/PK=\%?$_4O _A?QIH=EG[-XGL([&<[L; L
MH;<!ZE/,3_@?M7/^'= N_%GB'3-%L%W7NI74=I"JC^.1PJ_7!.?PIV _1_\
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MW_DW6#_L,7O_ *&M?3S_ ':E@?E#^W@H7]I[Q0  /]'LCQ_U[K6U_P $[?\
MDXQ?^P+>_P#H<-8W[>7_ "<_XG_Z][+_ -)TK9_X)V?\G&#_ + M[_Z'#1T
M_1;XQ?\ ))O&O_8$O?\ T0]?B9%_JD_W1_*OVS^,7_))O&O_ &!+W_T0]?B9
M%_JD_P!T?RH0'ZI_\$_?^3;-)_Z_KS_T<:ZO]L'_ )-H^(G_ &"W_P#0EKC?
M^"?5_!+^SC811N'>#4;R.0+U1C)NP?P8'\:[#]K]PW[-/Q$ !_Y!;]?]Y*.H
M'Y#O]]OK7ZL?L$?\FP^&O^OB_P#_ $KEK\IW^^WUK]6/V"/^38?#7_7Q?_\
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M\)_"FTO+7PIH=OHD%Y()ITMV<B1PNT$[B>W%=:V2IQU[4@/S5_X*4?\ ):-
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MRCJ9V_\ H.?UKU#X=_LW_#WX57"W7AOPO9V=^HP+Z;,]Q[X=R2O_  '% 'Y
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MJ*A)\E7L^OH8N+1V-%,5PQP""?2G9Q7Z"G<@6BH]P_O#\Z-Q]?UI7 DHJ+S
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MD;)6V%HHHK484444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A&:6BE8!N#2
MY/I2T46 ****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
, !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232124710400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Inventiva S.A.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001756594<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232123601392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited interim condensed consolidated statement of financial position - EUR (&#8364;)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Noncurrent assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">&#8364; 451,000<span></span>
</td>
<td class="nump">&#8364; 541,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Property, plant and equipment</a></td>
<td class="nump">7,979,000<span></span>
</td>
<td class="nump">9,125,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">210,000<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Investments accounted for using the equity method</a></td>
<td class="nump">1,131,000<span></span>
</td>
<td class="nump">1,425,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">1,047,000<span></span>
</td>
<td class="nump">10,055,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">10,818,000<span></span>
</td>
<td class="nump">21,371,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">393,000<span></span>
</td>
<td class="nump">417,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade receivables</a></td>
<td class="nump">809,000<span></span>
</td>
<td class="nump">3,807,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssetsCurrent', window );">Tax receivables</a></td>
<td class="nump">2,704,000<span></span>
</td>
<td class="nump">5,352,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">14,554,000<span></span>
</td>
<td class="nump">11,696,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">10,147,000<span></span>
</td>
<td class="nump">26,918,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">28,608,000<span></span>
</td>
<td class="nump">48,189,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">39,426,000<span></span>
</td>
<td class="nump">69,561,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">524,772<span></span>
</td>
<td class="nump">521,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Premiums related to share capital</a></td>
<td class="nump">201,859,000<span></span>
</td>
<td class="nump">201,862,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares', window );">Reserves</a></td>
<td class="num">(232,789,000)<span></span>
</td>
<td class="num">(124,584,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation', window );">Translation reserve</a></td>
<td class="nump">375,000<span></span>
</td>
<td class="nump">596,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarningsProfitLossForReportingPeriod', window );">Net loss for the period</a></td>
<td class="num">(49,029,000)<span></span>
</td>
<td class="num">(110,426,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Shareholders' equity</a></td>
<td class="num">(79,060,000)<span></span>
</td>
<td class="num">(32,032,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities', window );">Long-term debt</a></td>
<td class="nump">46,846,000<span></span>
</td>
<td class="nump">32,181,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities', window );">Long-term debt - derivatives</a></td>
<td class="nump">13,569,000<span></span>
</td>
<td class="nump">10,265,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued', window );">Royalty certificates liabilities</a></td>
<td class="nump">7,263,000<span></span>
</td>
<td class="nump">6,327,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisionsForEmployeeBenefits', window );">Provisions for retirement benefit obligations</a></td>
<td class="nump">1,555,000<span></span>
</td>
<td class="nump">1,559,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Long-term contract liabilities</a></td>
<td class="nump">76,000<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">1,032,000<span></span>
</td>
<td class="nump">1,032,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">70,340,000<span></span>
</td>
<td class="nump">51,434,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities', window );">Shortterm debt</a></td>
<td class="nump">5,726,000<span></span>
</td>
<td class="nump">5,308,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">36,583,000<span></span>
</td>
<td class="nump">37,679,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Short-term contract liabilities</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">5,834,000<span></span>
</td>
<td class="nump">7,165,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">48,146,000<span></span>
</td>
<td class="nump">50,158,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">118,486,000<span></span>
</td>
<td class="nump">101,592,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total equity and liabilities</a></td>
<td class="nump">&#8364; 39,426,000<span></span>
</td>
<td class="nump">&#8364; 69,561,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax assets. [Refer: Current tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisionsForEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisionsForEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant and equipment including right-of-use assets whose underlying assets would be presented as property, plant and equipment if they were owned. [Refer: Property, plant and equipment; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 52<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_52_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarningsProfitLossForReportingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity&#8217;s undistributed profit or loss for the reporting period. [Refer: Retained earnings; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarningsProfitLossForReportingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current borrowings and current portion of non-current borrowings and current lease liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-current portion of non-current borrowings and non-current lease liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current royalty certificates issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing retained earnings excluding profit (loss) for the reporting period, and treasury shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232124451056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited interim condensed consolidated statement of income (loss) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_RevenueAndOperatingIncomeAbstract', window );"><strong>Revenues and other income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">&#8364; 41<span></span>
</td>
<td class="nump">&#8364; 1,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_OtherIncomeFromOrdinaryActivities', window );">Other income</a></td>
<td class="nump">2,693<span></span>
</td>
<td class="nump">4,721<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAndOperatingIncome', window );">Total revenues and other income</a></td>
<td class="nump">2,734<span></span>
</td>
<td class="nump">6,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="num">(46,822)<span></span>
</td>
<td class="num">(54,062)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Marketing - Business development expenses</a></td>
<td class="num">(598)<span></span>
</td>
<td class="num">(705)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(7,701)<span></span>
</td>
<td class="num">(6,812)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Other operating income (expenses)</a></td>
<td class="nump">138<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Net operating loss</a></td>
<td class="num">(52,249)<span></span>
</td>
<td class="num">(55,003)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="nump">9,093<span></span>
</td>
<td class="nump">2,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="num">(5,586)<span></span>
</td>
<td class="num">(2,646)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Net financial income</a></td>
<td class="nump">3,507<span></span>
</td>
<td class="num">(273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod', window );">Share of net loss - Equity method</a></td>
<td class="num">(168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax</a></td>
<td class="num">(119)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">&#8364; (49,029)<span></span>
</td>
<td class="num">&#8364; (55,269)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per share</a></td>
<td class="num">&#8364; (0.94)<span></span>
</td>
<td class="num">&#8364; (1.31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted loss per share</a></td>
<td class="num">&#8364; (0.94)<span></span>
</td>
<td class="num">&#8364; (1.31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of shares outstanding used to calculate basic loss per share</a></td>
<td class="nump">51,982,093<span></span>
</td>
<td class="nump">42,044,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of shares outstanding used to calculate diluted loss per share</a></td>
<td class="nump">51,982,093<span></span>
</td>
<td class="nump">42,044,796<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income (expense) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2023-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAndOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of the entity's revenue and other operating income. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAndOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_OtherIncomeFromOrdinaryActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other income from ordinary activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_OtherIncomeFromOrdinaryActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_RevenueAndOperatingIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_RevenueAndOperatingIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232123883664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited interim condensed consolidated statement of comprehensive (income) loss<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Unaudited interim condensed consolidated statement of comprehensive (income) loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">&#8364; (49,029)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items that will be reclassified subsequently to profit or loss</a></td>
<td class="num">(220)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Currency translation differences - equity method</a></td>
<td class="num">(286)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation differences</a></td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax', window );">Items that will not be reclassified subsequently to profit or loss</a></td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Remeasurement of defined benefit plans</a></td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="num">&#8364; (49,175)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share of the other comprehensive income of associates and joint ventures accounted for using the equity method that will be reclassified to profit or loss, net of tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232121859872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited interim condensed consolidated statement of changes in shareholders' equity - EUR (&#8364;)<br></strong></div></th>
<th class="th"><div>Share capital</div></th>
<th class="th"><div>Premiums related to share capital</div></th>
<th class="th"><div>Net profit (loss)</div></th>
<th class="th"><div>Translation reserves</div></th>
<th class="th"><div>Reserves</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at the beginning at Dec. 31, 2022</a></td>
<td class="nump">&#8364; 421,000<span></span>
</td>
<td class="nump">&#8364; 173,886,000<span></span>
</td>
<td class="num">&#8364; (54,274,000)<span></span>
</td>
<td class="num">&#8364; (271,000)<span></span>
</td>
<td class="num">&#8364; (74,286,000)<span></span>
</td>
<td class="nump">&#8364; 45,476,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,269,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,269,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Remeasurement of defined benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,000)<span></span>
</td>
<td class="num">(14,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod', window );">Currency translation differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,269,000)<span></span>
</td>
<td class="nump">104,000<span></span>
</td>
<td class="num">(14,000)<span></span>
</td>
<td class="num">(55,179,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings', window );">Appropriation of net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,274,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,274,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payment compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,046,000<span></span>
</td>
<td class="nump">2,046,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IncreaseDecreaseThroughShareWarrantsSubscriptionPremium', window );">BSA share warrants subscription premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions', window );">Treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,000)<span></span>
</td>
<td class="num">(22,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at the end at Jun. 30, 2023</a></td>
<td class="nump">421,000<span></span>
</td>
<td class="nump">173,886,000<span></span>
</td>
<td class="num">(55,269,000)<span></span>
</td>
<td class="num">(168,000)<span></span>
</td>
<td class="num">(126,537,000)<span></span>
</td>
<td class="num">(7,667,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at the beginning at Dec. 31, 2022</a></td>
<td class="nump">421,000<span></span>
</td>
<td class="nump">173,886,000<span></span>
</td>
<td class="num">(54,274,000)<span></span>
</td>
<td class="num">(271,000)<span></span>
</td>
<td class="num">(74,286,000)<span></span>
</td>
<td class="nump">&#8364; 45,476,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance at the end (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,115,807<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at the end at Dec. 31, 2023</a></td>
<td class="nump">521,158<span></span>
</td>
<td class="nump">201,862,263<span></span>
</td>
<td class="num">(110,426,000)<span></span>
</td>
<td class="nump">596,000<span></span>
</td>
<td class="num">(124,584,000)<span></span>
</td>
<td class="num">&#8364; (32,032,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,029,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,029,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans', window );">Remeasurement of defined benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,000<span></span>
</td>
<td class="nump">74,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod', window );">Currency translation differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(220,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(220,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,029,000)<span></span>
</td>
<td class="num">(220,000)<span></span>
</td>
<td class="nump">74,000<span></span>
</td>
<td class="num">(49,175,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings', window );">Appropriation of net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,426,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(110,426,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payment compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,238,000<span></span>
</td>
<td class="nump">2,238,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IncreaseDecreaseThroughShareWarrantsSubscriptionPremium', window );">BSA share warrants subscription premium</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions', window );">Treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(138,000)<span></span>
</td>
<td class="num">(138,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,000<span></span>
</td>
<td class="nump">&#8364; 41,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance at the end (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,477,188<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at the end at Jun. 30, 2024</a></td>
<td class="nump">&#8364; 524,772<span></span>
</td>
<td class="nump">&#8364; 201,858,649<span></span>
</td>
<td class="num">&#8364; (49,029,000)<span></span>
</td>
<td class="nump">&#8364; 375,000<span></span>
</td>
<td class="num">&#8364; (232,789,000)<span></span>
</td>
<td class="num">&#8364; (79,060,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the appropriation of retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IncreaseDecreaseThroughShareWarrantsSubscriptionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase decrease in reserves resulting from BSA share warrants subscription premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IncreaseDecreaseThroughShareWarrantsSubscriptionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other comprehensive income, net of tax, exchange differences on translation of foreign operations including effects of translation of investments accounted for using equity method</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232120827776">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Unaudited interim condensed consolidated statement of cash flows - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (49,029)<span></span>
</td>
<td class="num">&#8364; (55,269)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Elimination of non-cash or non-operating income and expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_AdjustmentsForDepreciationAmortisationAndProvisions', window );">Depreciation, amortization and provisions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,878<span></span>
</td>
<td class="nump">1,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncomeTaxExpense', window );">Deferred and current taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_AdjustmentsForTaxCredits', window );">Tax credits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,657)<span></span>
</td>
<td class="num">(3,643)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncomeCost', window );">Cost of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,180<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Sharebased compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,238<span></span>
</td>
<td class="nump">2,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUndistributedProfitsOfAssociates', window );">Share of net profit of associates and joint ventures accounted for using the equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Exchange (gains) / losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(73)<span></span>
</td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFairValueGainsLosses', window );">Fair value variation through profit and loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(8,506)<span></span>
</td>
<td class="num">(1,623)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAdjustmentsForNoncashItems', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital', window );">Cash flows used in operations before tax, interest and changes in working capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(50,939)<span></span>
</td>
<td class="num">(54,965)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables', window );">Decrease / (increase) in operating and other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,075<span></span>
</td>
<td class="num">(2,322)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Increase / (decrease) in operating and other payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,409)<span></span>
</td>
<td class="nump">8,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Decrease / (increase) in inventories</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Tax credit received</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,333<span></span>
</td>
<td class="nump">5,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(4,426)<span></span>
</td>
<td class="num">(1,285)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInWorkingCapital', window );">Tax, interest and changes in operating working capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,597<span></span>
</td>
<td class="nump">9,732<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(48,342)<span></span>
</td>
<td class="num">(45,233)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows used in investing activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities', window );">Purchases of property, plant and equipment and intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(255)<span></span>
</td>
<td class="num">(230)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities', window );">Disposals of property, plant and equipment and intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">90<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments', window );">Decrease / (Increase) in short-term deposit accounts</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">70<span></span>
</td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities', window );">Increase / (Decrease) in other non-current financial assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,008<span></span>
</td>
<td class="num">(8,600)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash from (used in) investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,912<span></span>
</td>
<td class="num">(7,702)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows used in financing activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NetProceedsFromIssuingShares', window );">Capital increase net of transaction cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Subscription of borrowings and warrants net of transaction cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayment of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,177)<span></span>
</td>
<td class="num">(1,448)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Repayment of lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,173)<span></span>
</td>
<td class="num">(707)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash from (used in) financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,568<span></span>
</td>
<td class="num">(2,153)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(16,863)<span></span>
</td>
<td class="num">(55,087)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26,918<span></span>
</td>
<td class="nump">86,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Exchange gains / (losses)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">92<span></span>
</td>
<td class="num">(409)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Net cash and cash equivalents at the end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 10,147<span></span>
</td>
<td class="nump">&#8364; 31,240<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Mainly include an increase in prepaid expense</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFairValueGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for fair value losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFairValueGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUndistributedProfitsOfAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for undistributed profits of associates to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Associates [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUndistributedProfitsOfAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) from the entity's operations before changes in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 14<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAdjustmentsForNoncashItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAdjustmentsForNoncashItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inflows (outflows) of cash, classified as investing activities, that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inflows (outflows) of cash, classified as operating activities, that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 14<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_14&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_AdjustmentsForDepreciationAmortisationAndProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation, amortisation expense and provisions to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_AdjustmentsForDepreciationAmortisationAndProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_AdjustmentsForTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for tax credit to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_AdjustmentsForTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NetProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net proceeds from issuing shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NetProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the disposal of property, plant and equipment and intangible assets, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Of Property Plant And Equipment And Intangible Assets Classified As Investing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232125503936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_CompanyInformationAbstract', window );"><strong>Company information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_CompanyInformationTextBlock', window );">Company information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;1.&#160;&#160;&#160;&#160;Company information</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.1</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Company information</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inventiva S.A. is a public limited company registered and domiciled in France. Its head office is located at 50 rue de Dijon, 21121 Daix. The consolidated &#64257;nancial statements of the company Inventiva include Inventiva S.A. and its subsidiary Inventiva Inc., created in January 2021 (the group is designated as &#8220;Inventiva&#8221; or the &#8220;Company&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inventiva&#8217;s ordinary shares have been listed on compartment B of Euronext Paris regulated market since February 2017 and Inventiva&#8217;s American Depositary Shares (&#8220;ADSs&#8221;), each representing one ordinary share, have been listed on the Nasdaq Global Market since July 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (&#8220;MASH&#8221;), also known as non-alcoholic steatohepatitis (&#8220;NASH&#8221;) and other diseases with significant unmet medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing lanifibranor for the treatment of MASH/NASH, as well as a pipeline of earlier stage programs in oncology discovery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Lanifibranor, its lead product candidate, is being developed for the treatment of patients with MASH/NASH, a chronic and progressive liver disease. In 2020, the Company announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with MASH/NASH and announced that the U.S. Food and Drug Administration ("FDA") had granted the Company the status of Breakthrough Therapy and Fast Track designation. The Company initiated the pivotal Phase III trial of lanifibranor in MASH/NASH (&#8220;NATiV3&#8221;) in the second half of 2021. In March 2024, the Company announced positive results from its Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and Type 2 Diabetes (&#8220;DT2&#8221;) (&#8220;LEGEND&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the first half of 2022, the Company faced delays in its NATiV3 trial that were primarily due to a higher than originally projected screen failure rate resulting in slower than anticipated enrollment rate. In addition, the Company experienced slower than predicted site activation, screening and enrollment due to negative impacts from the COVID-19 pandemic, mainly during the years 2020 and 2021, and the Company was unable to conduct clinical trial activities at sites originally located in Ukraine due to the war between Ukraine and Russia and made the decision to put recruitment for its NATiV3 trial in Ukraine on hold and close all sites in Russia. Global geopolitical events that continue to impact the markets (including Russia's invasion of Ukraine or the state of war between Israel and Hamas) could affect the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2023, the Company amended the protocol for the NATiV3 trial in part to potentially accelerate enrollment and identified additional sites to help compensate for the inability to use sites in Ukraine and Russia. The revised study design limits the planned duration of the trial to 120 weeks instead of up to seven years, reduces the number of biopsies from three to two and included a 48-week active treatment extension study. The Company expects that the changes to the clinical development plan of lanifibranor, including plans for a new Phase III trial in patients with MASH/NASH and compensated cirrhosis, will be beneficial to the lanifibranor clinical program by reducing the number of biopsies and the trial duration, eventually offering all patients in the trial access to treatment and potentially expanding the addressable patient population beyond patients with F2 and F3 fibrosis to patients with MASH/NASH and compensated cirrhosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In September 2022, the Company entered into a license and collaboration agreement with Chia Tai Tianqing Pharmaceutical Group, Co., LTD (&#8220;CTTQ&#8221;), a Sino Biopharm group company, to develop and commercialize, subject to regulatory approval, lanifibranor for the treatment of MASH/NASH and other metabolic diseases in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan (&#8220;CTTQ Territory&#8221;). In May 2023, the Company announced that CTTQ had received the Investigational New Drug (&#8220;IND&#8221;) approval from the Chinese National Medicine Products Administration (&#8220;NMPA&#8221;) allowing CTTQ to initiate the clinical development of lanifibranor in MASH/NASH in mainland China. CTTQ is participating in the ongoing NATiV3 Phase III trial and is conducting a Phase I clinical pharmacology study. In the framework of its participation in the Company&#8217;s NATiV3 Phase III global clinical trials, pursuant to the terms of the agreement, CTTQ bears all costs associated with these trials conducted in the CTTQ Territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In September 2023, the Company and Hepalys Pharma, Inc. (&#8220;Hepalys&#8221;) announced an exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea (the &#8220;Hepalys License Agreement&#8221;). Hepalys is a new company created by Catalys Pacific Fund II, LP (&#8220;Catalys&#8221;). Under the Hepalys License Agreement, the Company received a $10 million upfront payment (equal to &#8364;9.5 million) on October 18, 2023, and is eligible to receive up to $231 million if certain clinical, regulatory and commercial conditions are met; in addition to tiered royalties from mid double digits to low twenties based on net sales of lanifibranor in Japan and South Korea, subject to regulatory approval. In parallel with the Hepalys License Agreement, the Company entered into an option agreement with Catalys to acquire 30% of the shares of Hepalys (the &#8220;Catalys Option Agreement&#8221;). The Company exercised that option on September 26, 2023, with an effective date of October 11, 2023, at an aggregate exercise price of &#165;300 (equal to &#8364;1.90). Also on September 20, 2023, the Company entered into a shareholders agreement with Catalys and Hepalys (the &#8220;Catalys Shareholders Agreement&#8221;). Pursuant to the Catalys Shareholders Agreement, the Company has the option to acquire all outstanding shares of Hepalys at a pre-agreed multiple of post-money valuation and the Company has a right of first refusal if Hepalys receives an offer for the license or rights related to lanifibranor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In the first quarter of 2024, following a routine visit during the Company&#8217;s NATiV3 clinical trial of lanifibranor in MASH/NASH, a Suspected Unexpected Serious Adverse Reaction (&#8220;SUSAR&#8221;) was reported in a patient. As a result of this SUSAR, the Company decided to voluntarily pause screening and randomization to implement changes to the enrollment criteria to exclude patients diagnosed or with a predisposition to autoimmune liver or thyroid disease and more frequent liver monitoring for patients enrolled in the trial as recommended by the Data Monitoring Committee (&#8220;DMC&#8221;)<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On March 7, 2024, the Company announced that screening activities had resumed in American sites under central Institutional Review Board (&#8220;IRB&#8221;). The impact of the pause on the overall timeline of the trial remains unclear, as new exclusion criteria were added, which may increase the screen failure rate, and the SUSAR, new exclusion criteria and increased liver monitoring may discourage potential trial participants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">On March 18, 2024, the Company announced positive results from its LEGEND proof-of-concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and DT2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company expects the first visit of the last patient to be in the fourth quarter of 2024 and to complete randomization in the first half of 2025. Due to a delay of around 3 to 5 months in recruitment, the Company is currently targeting the first visit of the last patient for the second half of 2024 and the publication of the main results for the beginning of the second half of 2026. The publication of the topline results of the part 1 of the NATiV3 trial is targeted for the second half of 2026 (versus the beginning of the second half of 2026 as previously announced). If the results of the trial confirm sufficient clinical benefit and a continued good safety profile, the Company plans to file an application for accelerated approval in the United States and conditional authorization in the European Union for the marketing of lanifibranor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s pipeline also includes odiparcil, which it was previously developing for the treatment of patients with mucopolysaccharidosis type VI (&#8220;MPS VI&#8221;), a group of rare genetic diseases. As announced in 2020, the Company decided to focus its clinical efforts on the development of lanifibranor. Based on feedback from the FDA, the Company believes there is potential for an efficient development pathway for odiparcil for the treatment of MPS VI and it continues to review potential options to further develop odiparcil for the treatment of MPS VI, which may include pursuing or creating a partnership, license or other transaction.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup><i style="font-style:italic;"> </i>A DMC is an independent group of experts who monitor patient safety and treatment efficacy data while a clinical trial is ongoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.2</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Significant events in the first half of 2024</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Company issued </span><span style="font-style:italic;font-weight:bold;">3,144,654</span><span style="font-style:italic;font-weight:bold;"> warrants to EIB in connection with the drawdown of Tranche B (see Note 4.10 Financial debt)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 4, 2024, the Company issued 3,144,654 additional warrants to the European Investment Bank (&#8220;<b style="font-weight:bold;">EIB</b>&#8221;) and such warrants, the &#8220;<b style="font-weight:bold;">EIB Tranche B Warrants</b>&#8221;, in accordance with the terms of the 6<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> resolution of the combined general meeting of shareholders of January 25, 2023 and Article L.225-138 of the French Commercial Code, as a condition to the drawdown of the second tranche of &#8364;25.0 million (&#8220;Tranche B&#8221;) under the finance contract between the Company and EIB (&#8220;Finance Contract&#8221;). The 3,144,654 shares underlying the EIB Tranche B Warrants represented approximately 6.07% of the Company's then-outstanding share capital. If all the warrants issued to the EIB in connection with drawdown of the first tranche of &#8364;25.0 million (&#8220;Tranche A&#8221;) under the Finance Contract (the &#8220;EIB Tranche A Warrants&#8221; and, together with the EIB Tranche B Warrants, the &#8220;EIB Warrants&#8221;) and the EIB Tranche B Warrants were exercised, the EIB would hold approximately 9.9% of the Company's share capital as of June 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">The exercise price of the EIB Tranche B Warrants is equal to &#8364;3.95 and corresponds to 95% of the volume-weighted average price of the Company's shares on the regulated market of Euronext Paris during the last trading session preceding the decision to issue the warrants (i.e. January 3, 2024).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">The EIB Tranche B Warrants have a maturity of twelve years and shall be exercisable following the earliest to occur of (i) the maturity date of Tranche A (i.e., on December 8, 2026), (ii) a change of control event, (iii) an event of default under the Finance Contract, or (iv) a repayment demand by EIB under the Finance Contract. The EIB Warrants will automatically be deemed null and void if not exercised within the twelve-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">EIB has a put option which may require the Company to repurchase all or part of the unexercised EIB Tranche B Warrants then exercisable at their intrinsic value (subject to a cap equal to the amount drawn under the Finance Contract) under certain circumstances (for example, in the event of a change of control or on the maturity date of Tranche A or in the event of default). The Company (or a substitute third party) has a call option to require EIB to sell all shares and other securities of the Company, including the EIB Warrants, to the Company, subject to certain terms and conditions. In addition, the Company has a right of first refusal to buy-back all EIB Tranche B Warrants offered for sale to a third party, subject to certain terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">On the basis of the 3,144,654 new shares of the Company issuable upon exercise of all the EIB Tranche B Warrants at a price of &#8364;3.95 per new share, the Company could potentially receive gross proceeds of up to &#8364;12,421,383. There is no assurance that EIB will exercise any or all of the EIB Warrants or that the Company will receive any proceeds from the exercise of the warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">The exercise ratio of EIB Tranche A Warrants has been adjusted following the issue of Tranche B Tranche B Warrants. As of the date of authorization of the issuance of these financial statements, one EIB Tranche A Warrant entitles its holder to subscribe for 1.27 ordinary shares in the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Company draws down Tranche B of </span><span style="font-style:italic;font-weight:bold;">&#8364;25</span><span style="font-style:italic;font-weight:bold;"> million under Finance Contract with EIB (see Note 4.10 Financial debt)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">On January 18, 2024, the Company drew down Tranche B of &#8364;25 million under the Finance Contract with EIB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">After the drawdown of Tranche A in December 2022, the Company had an option to access further &#8364;25 million tranche, Tranche B, subject to the achievement of certain conditions precedent. Following the achievement of those conditions, the Company decided to draw on Tranche B. The Company intends to use the proceeds to fund part of NATiV3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">Tranche B carries a 7% interest capitalized annually and repayment in fine. The repayment is due in January 2027, three years after its disbursement. The disbursement of Tranche B was subject to, among other conditions, (i) the full drawdown of Tranche A, (ii) the receipt by the Company from the date of the Finance Contract of an aggregate amount of at least &#8364;70 million (inclusive of the &#8364;18 million that was a condition for the disbursement of Tranche A), paid either in exchange for shares of the Company, or through upfront or milestone payments, (iii) an out-licensing, partnership or royalty transaction with an upfront payment of at least &#8364;10 million, (iv) operational criteria based on patient enrollment and number of sites activated in the Company&#8217;s NATiV3 Phase III clinical trial of lanifibranor in patients with NASH and (v) the Company issuing EIB Tranche B Warrants (see above - <i style="font-style:italic;">The Company issued </i><i style="font-style:italic;">3,144,654</i><i style="font-style:italic;"> warrants to EIB in connection with the drawdown of Tranche B</i>) in accordance with the terms and conditions of the warrant agreement entered into on July 1, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Tranche B of &#8364;25 million was recognized as financial debt at amortized cost, which takes into account the fair value of the derivative instrument (warrants) at inception and the borrowing costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 12, 2024, the Company and EIB amended the warrant agreement to modify the rules for adjusting the exercise ratios of the EIB Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Treatment-related Suspected Unexpected Serious Adverse Reaction in the first quarter of 2024</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 15, 2024, the Company announced that an adverse event of elevated aminotransferases in liver tests was reported in a patient enrolled in the NATiV3 trial following a scheduled visit. The patient had been without clinical symptoms throughout the period of observation. This event has been assessed as a treatment-related SUSAR. Other milder cases of elevation of aminotransferases among trial participants have also been reported in the trial. The Company decided to voluntarily pause screening and randomization to implement changes to the enrollment criteria to exclude patients diagnosed or with a predisposition to autoimmune liver or thyroid disease and more frequent liver monitoring for patients enrolled in the trial as recommended by the DMC in the first quarter of 2024. Patients enrolled in the trial continued to receive treatment under the new liver monitoring schedule recommended by the DMC. This SUSAR is the first reported in all clinical trials with lanifibranor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 7, 2024, the Company received approval from the central IRB overseeing clinical research in the United States to resume screening activities in its sites. This was an important milestone as 152 sites of the NATiV3 clinical trial sites are operating under central IRB and have so far randomized over 60% of the patients in the main cohort.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Due to a delay of around 3 to 5 months in recruitment, the Company is currently targeting the first visit of the last patient for the second half of 2024, to complete randomization in the first half of 2025 and the main results for the second half of 2026 (versus the beginning of the second half of 2026 as previously disclosed).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Company presented the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 18, 2024, the Company announced positive results from its LEGEND proof-of-concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The LEGEND trial was designed as a multi-center, randomized, 24-week treatment, placebo-controlled Phase II Proof-of-Concept trial to assess the safety and efficacy of lanifibranor in combination with the SGLT2 inhibitor empagliflozin for the treatment of patients with non-cirrhotic MASH/NASH and T2D. The trial was double-blind for the placebo arm and lanifibranor (800mg daily) arm, and open-label for the combination of lanifibranor (800mg daily) and empagliflozin (10mg daily) arm. The diagnosis of non-cirrhotic MASH/NASH was based on historic histology evaluation or a combination of non-invasive methods including diagnostic methods including imaging. As planned per protocol, the interim analysis was done once half of the 63 planned randomized patients with MASH completed the 24-week treatment period or prematurely discontinued from treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The study achieved the primary efficacy endpoint with an absolute reduction in Hemoglobin A1c (HbA1c) of 1.14% and 1.59% in patients with MASH and T2D treated with lanifibranor (800mg daily) or in combination with empagliflozin (10mg daily) at week 24 compared to an increase of 0.26% observed in the placebo arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The study also demonstrated a statistically significant reduction in hepatic steatosis measured by MRI-PDFF, in patients treated with lanifibranor alone and in combination with empagliflozin, -47% and -38% respectively, compared to placebo (0%). 83% and 67% of patients treated with lanifibranor alone or in combination with empagliflozin respectively, showed a reduction greater or equal to 30% of their hepatic fat, compared to 0% in the placebo arm. In addition, the study demonstrated a statistically significant effect on several secondary and exploratory endpoints, including liver enzymes (alanine aminotransferase (&#8220;ALT&#8221;) and aspartate aminotransferase (&#8220;AST&#8221;)), insulin resistance (HOMA-IR), HDL, and adiponectin. Markers of liver inflammation and fibrosis (corrected T1 relaxation time (cT1) assessed by LiverMultiScan&#174;) were assessed for the first time with lanifibranor and showed a significant effect with lanifibranor alone and in combination with empagliflozin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The study also demonstrated that patients treated with lanifibranor in combination with empagliflozin maintained a stable weight throughout the 24 weeks study, addressing the moderate, metabolically healthy, weight gain that can be observed in some patients treated with lanifibranor alone. Furthermore, these results demonstrated a significant relative reduction in the VAT/SAT ratio (visceral and subcutaneous adipose tissue) in patients treated with lanifibranor alone or in combination with empagliflozin, -5% and -17% respectively, compared to an increase of 11% in patients under placebo. This result reflects a shift from pro-inflammatory visceral fat towards metabolically healthy adipose tissue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The treatment with lanifibranor 800mg/daily alone and in combination with empagliflozin 10mg/daily for 24 weeks appears to be well tolerated, with no safety concerns reported.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Given that the primary endpoint of LEGEND was met, and statistically significant results were achieved on several key additional markers, the Company has decided to stop the recruitment as defined per protocol. More details on these results are expected to be presented in upcoming scientific conferences and submitted for publication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Additional results from NATIVE Phase IIb clinical trial</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 13, 2024, the Company announced the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Improvements were observed for insulin resistance (insulin levels, HOMA-IR), lipid metabolism (triglycerides, HDL-cholesterol, apolipoproteins), control of glycemia (HbA1c, fasting glucose (FG) levels), systemic inflammation (hs-CRP, ferritin), hepatic steatosis and diastolic blood pressure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 16, 2024, the Company announced the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">The DMC recommended to continue the clinical trial without further modification of the protocol, as amended immediately after learning about SUSAR, based on the pre-planned review of safety data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;">The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients that have been treated for more than 48 and 72 weeks, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The patient who experienced the adverse event of increased liver test results, which was reported as a SUSAR, had been without clinical symptoms throughout the period of observation and has fully recovered.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_CompanyInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_CompanyInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_CompanyInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on company information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_CompanyInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232125540064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation and statement of compliance<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_StatementOfComplianceAbstract', window );"><strong>Basis of preparation and statement of compliance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfIFRSCompliance', window );">Basis of preparation and statement of compliance</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;2.&#160;&#160;&#160;&#160;Basis of preparation and statement of compliance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.1.</b></span>Basis of preparation for the consolidated financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has prepared these unaudited interim condensed consolidated financial statements in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;) as adopted by the European Union and IFRS Accounting Standards as issued by the International Accounting Standard Board (&#8220;IASB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These unaudited interim condensed consolidated financial statements as of June 30, 2024 were approved by the Board of Directors of the Company on 14 October, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.2.</b></span><b style="font-weight:bold;">Statement of compliance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These unaudited interim condensed consolidated financial statements were prepared in compliance with <i style="font-style:italic;">International Accounting Standards (IAS)&#160;34 &#8212; Interim Financial Reporting</i>, which provides for the presentation of selected explanatory notes. The accompanying notes do not contain all the disclosures required for annual financial statements and should therefore be read in conjunction with the Company&#8217;s financial statements prepared in accordance with IFRS &#174;Accounting Standards, referred to as IFRS as of and for the year ended December&#160;31, 2023 except for the accounting principles described in Note 3 &#8211; <i style="font-style:italic;">Accounting principles</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">IFRS Accounting Standards basis adopted</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accounting policies applied by the Company in the preparation of the unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2024, are identical to those used in the annual financial statements prepared in accordance with IFRS Accounting Standards as of and for the year ended December 31, 2023, with the exception of specific provisions for the preparation of unaudited interim condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Standards, amendments to existing standards and interpretations published by the IASB whose application has been mandatory since January 1, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The application of standards, amendments to existing standards and interpretations whose application has been mandatory since January 1, 2024 in the European Union primarily concern:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendment to IFRS 16 &#8211; Lease liability in a sale and leaseback</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendment to IAS 1 &#8211; Non-current liabilities with covenants</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendment to IAS 7 and IFRS 7 &#8211; Supplier finance arrangements</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Those amendments had no material impact on the Company&#8217;s unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2024. As of June 30, 2024, the IASB had not published any amendments that would be expected to have a material impact on the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Standards, amendments to existing standards and interpretations published by the IASB whose application is not yet mandatory</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The new standards, interpretations and amendments to existing standards that have been published but are not yet applicable concern:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendments to IAS 21 &#8211; Lack of Exchangeability</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amendment to IFRS 9 and IFRS 7 &#8211; Classification and Measurement of Financial Instruments</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">New Standard &#8211; IFRS 18 &#8211; Presentation and Disclosure in Financial Statements</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">New standard &#8211; IFRS 19 Subsidiaries without Public Accountability: Disclosures</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These new standards, interpretations and amendments are under analysis to see if there are applicable to Inventiva.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.3.</b></span><b style="font-weight:bold;">Scope and method of consolidation</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Accounting policy</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with IFRS 10 <i style="font-style:italic;">Consolidated Financial Statements</i>, an entity (subsidiary) is consolidated when it is controlled by the company (the parent). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Subsidiaries are all entities over which the Company has control. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and could affect those returns through its power to direct the activities of the entity. Subsidiaries are consolidated from the date on which control is transferred to the Company. They are deconsolidated from the date such control ceases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All intercompany transactions, balances, and unrealized gains on transactions between group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries are consistent with the policies adopted by the Company. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Consolidated entities</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024, the scope of consolidation consists of two entities, the parent, Inventiva S.A. and its 100% owned subsidiary, Inventiva Inc., for which no non-controlling interest is recognized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ownership&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounting&#160;Method</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">INVENTIVA Inc.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">01/05/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">Fully Consolidated</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Interests in associates and joint ventures</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Hepalys is incorporated and has its principal place of business in Japan. The Company&#8217;s proportion of ownership interest is </span><span style="font-weight:normal;">14.6%</span><span style="font-weight:normal;"> and is the same as the proportion of voting rights held. In accordance with IAS 28 </span><i style="font-style:italic;font-weight:normal;">Investments in Associates and Joint Ventures</i><span style="font-weight:normal;">, Hepalys is an associate of the Company and is accounted for using the equity method (see Note 4.4. &#8211; </span><i style="font-style:italic;font-weight:normal;">Investments accounted for using the equity method</i><span style="font-weight:normal;">).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">2.4</b></span>Foreign currency translation</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Functional and presentation currency</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s consolidated financial statements are presented in euros, which is also the functional currency of the parent company, Inventiva S.A. The functional currency of Inventiva Inc. is the U.S. dollar. All amounts presented in these notes to the consolidated financial statements are denominated in euros unless otherwise stated.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Translation of financial statements into presentation currency</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The results and financial position of foreign operations that have a functional currency different from the presentation currency are translated into euros, the presentation currency, as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Assets and liabilities for each balance sheet presented are translated at the closing rate on the date of that balance sheet, </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Income and expenses for each statement of (income) loss and statement of comprehensive (income) loss are translated at average exchange rates (which is an approximate value of the exchange rate on the transaction date in the absence of significant fluctuations. Income and expenses are translated at the transaction dates if the exchange rates fluctuate significantly), and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All resulting exchange differences are recognized in other comprehensive income.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Exchange rate (USD per EUR)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;June 30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Average exchange rate for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.0813</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.0803</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.0807</p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Exchange rate at period end</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.0705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.1050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.0866</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfIFRSCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An explicit and unreserved statement of compliance with all the requirements of IFRSs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfIFRSCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_StatementOfComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>N/A</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_StatementOfComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232125549136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Principles<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_AccountingPrinciplesAbstract', window );"><strong>Accounting Principles</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory', window );">Accounting principles</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;3.&#160;&#160;&#160;&#160;Accounting principles</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">3.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Use of estimates and judgment</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements requires management to make judgments and estimates and apply assumptions that can affect the carrying amounts of assets, liabilities, income and expenses, as well as the information presented in the accompanying notes. Actual reported values may differ from the accounting estimates made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There have been no significant changes in the material judgments and main estimates used by management when applying the Company&#8217;s accounting policies in the preparation of these unaudited interim condensed consolidated financial statements from those described in the annual financial statements prepared in accordance with IFRS Accounting Standards for the year ended December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The conflict in Ukraine and the state of war between Israel and Hamas have not led to any material changes in the estimates or judgements made by management in the preparation of the Company&#8217;s unaudited interim condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.2.</b></span>Fair value measurement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the table below, financial instruments are measured at fair value according to a hierarchy comprising three levels of valuation inputs:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2: Inputs other than quoted market prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3: Unobservable inputs for the asset or liability.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The table below presents the financial assets and liabilities of the Company measured at fair value as of June 30, 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">At June 30, 2024 (in thousands of euros)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Financial liabilities at fair value through profit or loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term financial debt - derivatives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,569</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 13,569</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The table below presents the financial assets and liabilities of the Company measured at fair value as of December 31, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">At December 31, 2023 (in thousands of euros)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Financial liabilities at fair value through profit or loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term financial debt &#8211; derivatives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,265</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 10,265</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.3.</b></span>Specific disclosure requirements for unaudited interim financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Seasonality of operations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s operations are not subject to material seasonal fluctuations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Income tax</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Income tax is recognized in the financial statements for each interim period. The amount corresponds to a best estimate calculated by applying the expected weighted average tax rate for the entire year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The income tax amount recorded as due for an interim period may have to be adjusted in the subsequent interim period of the same year if the estimated annual average tax rate changes.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">3.4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Going concern</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From inception, the Company has financed its growth through successive capital increases, debt, collaboration and license agreements and reimbursements of CIR receivables. The Company continues to pursue its research and development activities for its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has incurred operating losses and negative cash flows from operations since inception due to the innovative nature of the product candidates it is developing, which necessitates a research and development phase spanning several years. The Company does not expect to generate revenue from product sales in the near future. With the biopharmaceutical industry's product development phases requiring increasing investments, the Company's financing needs will continue to grow as clinical trials of the Company's drug candidates progress and the Company invests to develop existing and new product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024, the Company had &#8364;10.1 million of available cash and cash equivalents, consisting of cash and short-term deposit accounts that are liquid and easily convertible within 3 months without penalty or risk of change in value (refer to Note 4.8 &#8211; <i style="font-style:italic;">Cash and Cash equivalents</i>). In accordance with IAS 7.8, bank overdrafts which are repayable on demand are included as a component of cash and cash equivalents in the amount of &#8364;1.3 million as of June 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of the date of authorization of the issuance of these financial statements, given its current cost structure, its projected expenditure commitments, and the events after the reporting period presented in Note 6.4 - <i style="font-style:italic;">Events after the reporting period</i>, mainly the issue of royalty certificates and the T1 capital increase, the Company estimates that it should have sufficient funds to finance its activities through the end of the second half of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accordingly, as of the date of authorization of the issuance of these financial statements, the Company's current cash and cash equivalents are not expected to be sufficient to cover its operating needs for at least the next 12 months. These events and conditions indicate that an uncertainty exists that may cast significant doubt on the Company&#8217;s ability to continue as a going concern and, therefore, the Company may be unable to realize its assets and discharge its liabilities in the normal course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This estimate is based on the Company&#8217;s current business plan and excludes (i) other expenses related to the potential development of odiparcil or resulting from any potential in-licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue, (ii) any potential milestone payments that may be received or paid by the Company or potential additional financing, including the issue of tranches 1bis and 2 as described in Note 6.4 &#8211; <i style="font-style:italic;">Events after the reporting period</i>. The Company may have based this estimate on assumptions that may prove to be incorrect, and the Company may end up using its resources sooner than anticipated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Based on the above, the unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2024, have been prepared on a going concern basis assuming the Company will continue to operate for the foreseeable future. As such, they do not include any adjustments related to the amount or classification of assets and liabilities that may be required if the Company were not able to continue as a going concern.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of material accounting policy information applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_AccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_AccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232121181456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock', window );">Notes to the interim condensed consolidated statement of financial position</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note&#160;4.&#160;&#160;&#160;&#160;<b style="color:#212529;font-weight:bold;">Notes to the interim condensed consolidated statement of financial position</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.1</b></span>Intangible assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,947</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,926</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,496)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,384)</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Intangible assets, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 451</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 541</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.2</b></span>Property, plant and equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, plant and equipment, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,840</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation and impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,396)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,714)</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Property, plant and equipment, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,979</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_9rDgFmQBEUmZjQqm7DwPdg;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> 9,126</b></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of June 30, 2024, the gross value of property, plant and equipment increased by &#8364;0.5 million mainly due to the recognition of the right of use related to the Fibroscans lease agreement for &#160;&#8364;0.4 million. Depreciation and impairment increased by &#8364;1.7 million mainly due to the depreciation of &#8364;1.2 million of the right of use and &#8364;0.3 million due to an impairment of the right of use related to Fibroscan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.3</b></span>Deferred tax asset</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inventiva S.A. and Inventiva Inc. are taxed as two separate entities and cannot apply the tax consolidation. For each entity, the deferred tax assets and deferred tax liabilities are offset in the consolidated financial statements. Deferred tax assets are recognized only when an entity has sufficient evidence that it will have a sufficient taxable benefit available to use the unused tax losses in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As recovery of these losses in future periods is considered unlikely due to the uncertainty inherent to the Inventiva S.A.&#8217;s activity, deferred tax assets were recognized on this basis on June 30, 2024 only for Inventiva Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.4</b></span>Investments accounted for using the equity method</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inventiva became an equity shareholder in Hepalys with the acquisition of 1,500,000 ordinary shares on October 11, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 15, 2024, Hepalys&#8217;s shareholders approved a capital increase of &#8364;1.6 million by issuing new shares to a new investor, NVCC. Inventiva opted not to participate in this capital increase. Consequently, the Company&#8217;s ownership in Hepalys was diluted to 14.6%. As of June 30, 2024, the Company holds 14.6% of Hepalys's shares, down from 15% ownership as of December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company analyzed its ownership of Hepalys and concluded that, as of June 30, 2024, it has a significant influence but not control or joint control of Hepalys. The significant influence is reflected through the ownership of percentage of interests held, the percentage of potential voting rights owned by the Company including the option, under the Catalys Shareholders Agreement, to acquire all outstanding shares of Hepalys at a pre-agreed multiple of post-money valuation that was exercisable as at June 30, 2024, as well as the active participation in the business of Hepalys in the framework of the Hepalys License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The investment in Hepalys is accounted for using the equity method of accounting as of June 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The tables below provide the summarized statement of financial position of Hepalys. The disclosed information reflects the amounts presented in the financial statements of Hepalys and not the Company's share of those amounts. They have been amended to reflect adjustments made by the Company when using the equity method, in this case fair value adjustments. The tables below provide also the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">reconciliation between the Hepalys statement of financial position and the carrying amount in the Company statement of financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands of euros)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total non</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 17,217</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 20,278</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,082</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,015</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,126</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 19,233</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 21,444</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 523</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 640</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,379</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital surplus-others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 774</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Earnings brought forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,018)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (178)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,444)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,111)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Treasury Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (812)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shareholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 19,214</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 21,194</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total non</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 19</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 250</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total equity and liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 19,233</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 21,444</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Opening net assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_tuNLjyeUjUStSiiPLbEZGg;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> 21,122</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 22,645</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,509)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (879)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,964)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital variations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,566</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (819)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Closing net assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 19,214</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 21,194</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Group's share in </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands of euros)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Group's share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,813</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 3,267</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Elimination of unrealised profit on downstream sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,718)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,881)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,131</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,425</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.5</b></span>Other non-current assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term deposit accounts<span style="display:inline-block;width:32.36pt;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,000</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Advance payments &#8211; non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,047</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,047</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other non</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,047</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 10,055</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024, long-term deposit accounts with more than a year of maturity decreased by &#8364;9.0 million, related to the early closure of a &#8364;9.0 million two-year deposit forward contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024 and December 31, 2023, non-current advances to suppliers amounted to &#8364;1.0 million, corresponding to the advance paid under the contract research organization (&#8220;<b style="font-weight:bold;">CRO</b>&#8221;) contract with Pharmaceutical Research Associates Groupe B.V (&#8220;PRA&#8221;) (see Note 6.1 &#8211; <i style="font-style:italic;">Commitments related to operational activities</i>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.6</b></span>Inventories</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 426</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inventories write&#8209;down</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Inventories</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 393</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 417</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.7</b></span>Trade receivables, tax receivables and other current assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Trade receivables</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables break down as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3&#160;months or less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,807</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Between 3 and 6&#160;months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Between 6 and 12&#160;months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">More than 12&#160;months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Trade receivables</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 809</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,807</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The average payment period is 30 days. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024, trade receivables decreased by &#8364;3.0 million mainly due to the receipt of a payment from CTTQ for the reinvoicing of specific costs related to the NATiV3 trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><i style="font-style:italic;font-weight:normal;">Tax receivables and Other current assets</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-variant:small-caps;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CIR and other research tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,333</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Tax receivables</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,704</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,352</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,039</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,656</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term deposit accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current accrued income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,047</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liquidity agreement - Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 289</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 422</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales tax receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,311</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,066</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,229</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 435</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 14,554</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 11,696</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other current assets and receivables</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 17,258</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 17,048</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024, tax receivables are mainly composed of research tax credits receivable in the amount of &#8364;2.7 million corresponding to the 2024 CIR as of June 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prepaid expenses, which increased by about &#8364;2.4 million, are mainly composed of costs related to the NATiV3 Phase III clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.8</b></span>Cash and cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net cash and cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other cash equivalents<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,933</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash at bank and at hand</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,985</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Bank overdrafts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,338)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 10,147</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 26,918</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other cash equivalents correspond to short-term bank deposits.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with IAS 7.8, bank overdrafts which are repayable on demand are included as a component of cash and cash equivalents in the amount of &#8364;1.3 million as of June 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.9</b></span>Shareholders&#8217; equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">Share capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The share capital is set at &#8364;524,772&#160;at June 30, 2024 divided into 52,477,188 fully authorized, subscribed and paid-up shares with a nominal value of &#8364;0.01.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Share capital variation during the first six months of 2024 is set forth in the table below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">In euros, except number of shares</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:23.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Premiums&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">related&#160;to&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nominal&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:23.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nature&#160;of&#160;the&#160;transactions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share&#160;capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td></tr><tr><td style="vertical-align:bottom;width:23.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2023</p></td><td style="vertical-align:bottom;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 521,158</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 201,862,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,115,807</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.01</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AGA 2021 &amp; AGA 2021 bis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,614</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,614)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 361,381</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.01</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance at June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 524,772</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 201,858,649</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 52,477,188</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 0.01</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">Liquidity agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 19, 2018, the Company entered into a liquidity agreement with Kepler Cheuvreux, replacing the previous liquidity agreement with Oddo BHF. This agreement with Kepler Cheuvreux, as amended in 2019, automatically renews for 12-month periods unless terminated by either party. Under the terms of the agreement, the investment services provider (&#8220;ISP&#8221;) is authorized to buy and sell the Company&#8217;s treasury shares without interference from the Company in order to ensure the liquidity of the shares on the Euronext market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The liquidity agreement with Kepler Cheuvreux was extended for a new period of 12 months from January 1, 2023, and has been renewed again for a new period of 12 months from January 1, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At June 30, 2024, treasury shares acquired by the Company through its ISP, as well as the gains or losses resulting from share purchase, sale, issue and cancellation transactions during the first six months of 2024, were accounted for as a deduction from equity. Consequently, these transactions had no impact on the Company&#8217;s results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Options and share warrants (BSA and BSPCE)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Share-based payments correspond to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BSA share warrants granted to Company directors in 2017, with a subscription price set at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;0.534</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BSA share warrants granted to Company service providers in 2018, with a subscription price set at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;0.48</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BSA share warrants granted in 2019 to David Nikodem, a member of Sapidus Consulting Group LLC, a service provider of Inventiva, with a subscription price set at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;0.18</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BSA share warrants granted in 2020 to David Nikodem, a member of Sapidus Consulting Group LLC, and J&#233;r&#233;my Goldberg, a member of PG Healthcare LLC, both service providers of Inventiva, with a subscription price set at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;0.29</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BSPCE founder share warrants granted in 2021, to Frederic Cren and Pierre Broqua, Company&#8217;s Directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BSA share warrants granted in 2021 to David Nikodem, a member of Sapidus Consulting Group LLC, a service provider of Inventiva, and ISLS Consulting with a subscription price set at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;2.45</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BSA share warrants granted in 2023 to David Nikodem, a member of Sapidus Consulting Group LLC, a service provider of Inventiva, with a subscription price set at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;0.20</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;2.51</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">-</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BSA share warrants granted in 2023 to David Nikodem, a member of Sapidus Consulting Group LLC, a service provider of Inventiva, with a subscription price set at </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;0.31</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;3.91</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">BSA and BSPCE plan characteristics</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of January 1, 2024, one BSPCE share warrant plan was outstanding: BSPCE 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The BSPCE and BSA share warrant plans are described in the note 12.3 &#8220;<i style="font-style:italic;">Share warrants</i> <i style="font-style:italic;">plans</i>&#8221; of the 2023 annual financial statements. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">No new share warrants plan has been attributed in the first six months of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;">Movements in BSPCE share warrants and BSA share warrants (in number of shares issuable upon exercise)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at Jan&#160;1,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Forfeited /</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in euros)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issued</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercised</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Lapsed</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSPCE - Plan 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">04/16/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 430,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 430,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 430,000</p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TOTAL BSPCE share warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 430,000</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 430,000</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 430,000</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSA&#160;- Plan 2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/29/2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130,000</p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSA&#160;- Plan 2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/14/2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 116,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 116,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 116,000</p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSA 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">06/28/2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,000</p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSA 2019 bis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/09/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,000</p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSA 2019 ter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/09/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,000</p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSA 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">04/16/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,333</p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSA 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/25/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSA 2023 - 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/15/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TOTAL BSA share warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 346,333</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 346,333</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 316,333</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total share warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 776,333</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 776,333</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 746,333</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At June 30, 2024, a total of 430,000 BSPCEs (or 430,000 shares) and 346,333 BSAs were outstanding, corresponding to a total of 776,333 shares, the maximum number of shares to be issued when all related conditions are met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Free share awards</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AGA free share award plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of January 1, 2024, four free share award plans were outstanding: AGA 2021-1, AGA 2021-bis, AGA 2023-1, and AGA 2023-2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">No bonus share award plan has been attributed in the first six months of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;">Movements in AGA free shares (in number of shares issuable upon exercise)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at grant date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at Jan&#160;1,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Forfeited /</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in euros)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Granted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Vested</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Lapsed</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AGA&#160;- Plan 2021 - 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">04/16/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 297,599</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (296,166)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,433)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AGA&#160;- Plan 2021 - bis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/08/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,215</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (65,215)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AGA 2023-1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/25/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 300,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 300,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 600,000</p></td></tr><tr><td style="vertical-align:bottom;width:26.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AGA 2023-2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/15/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 748,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23,350)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 724,650</p></td></tr><tr><td style="vertical-align:bottom;width:26.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TOTAL free shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,410,814</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 300,000</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (361,381)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (24,783)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,324,650</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At June 30, 2024, a total of 1,324,650 AGA bonus shares were outstanding. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Following the amendment of article L. 225-197-1 II of the French Commercial Code by law no. 2023-1107 of November 29, 2023, the Board of Directors decided on 25 March 2024 to grant 300,000 free shares to Frederic Cren in substitution for the PAGUP 2023. This allocation is governed by the regulations of the AGA 2023-1 plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Following the AGA 2021 and AGA 2021 bis acquisition period, a total of 361,381 shares were definitively acquired, resulting in a capital increase of &#8364;3,613.81.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upon the completion of the acquisition period for the AGA 2021 and AGA 2021 bis plans, a total of 361,381 shares were acquired, resulting in a capital increase of &#8364;3,613.81.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The free share award plan is described in the Note 12.4 &#8220;Bonus share award plans&#8221; of the annual consolidated financial statements for the year ended on December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Share-based compensation expense with respect to AGA bonus shares and BSA share warrants totaled &#8364;2.2 million for the six months ended June 30, 2024, compared to &#8364;2.0 million for the six months ended June 30, 2023. They are recognized in personnel costs (see Note 5.2 &#8211; <i style="font-style:italic;">Operating expenses</i>).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Performance units (&#8220;PAGUP&#8221;)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of January 1, 2024, one performance units plan was outstanding: PAGUP 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">No performance units award plan has been attributed in the first six months of 2024.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:29.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reference</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price (in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at&#160;Jan&#160;1,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at&#160;June&#160;30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">euros)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issued</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercised</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Convert AGA</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PAGUP 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/25/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 300,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (300,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TOTAL PAGUP</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 300,000</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (300,000)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At June 30, 2024, no PAGUP shares were outstanding. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Following the changes introduced by the French law no.2023-1107, the PAGUP 2023 granted on May 25, 2023 can be converted into AGAs. On March 25, 2024, the Board of Directors converted 300,000 free shares (governed by the AGA 2023-1 regulations) to Fr&#233;d&#233;ric Cren, thereby lapsing the 300,000 PAGUP 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The performance units plan is described in the Note 12.5 &#8220;Performance units&#8221; of the annual consolidated financial statements for the year ended on December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.10</b></span>Financial debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Bank borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,509</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,206</p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Derivatives instruments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,265</p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other loans and similar borrowings<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,302</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,719</p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,761</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,565</p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalty certificates liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,327</p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total debt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 73,404</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_VVi9UZTcQEKJWAcPl8yJKQ;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> 54,082</b></span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:italic;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">include accrued interests.</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Movements in the period break down as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">January 1, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 54,083</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 44,390</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Subscription of derivatives instruments<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Subscription of bank borrowings<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Subscription of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,706</p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Issue of royalty certificates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,100</p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Repayment of bank borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,177)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,485)</p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Repayment of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,173)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,612)</p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Interests on royalty certificates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 936</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,227</p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Capitalized interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,961</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,405</p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Change in fair value of derivatives instruments<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,506)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 389</p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Exchange rate change</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (38)</p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 73,404</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 54,083</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">(1)</sup><span style="display:inline-block;width:10.42pt;"></span><i style="font-style:italic;">Net proceed</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">(2)</sup><span style="display:inline-block;width:10.42pt;"></span><i style="font-style:italic;">EIB&#8217;s loan and warrants.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">French state-guaranteed loan (&#8220;PGE&#8221;) and equity recovery loans (&#8220;PPR&#8221;)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2020, the Company entered into three credit agreements pursuant to which it received &#8364;10.0 million in the form of state-guaranteed loans (<i style="font-style:italic;">Pr&#234;ts Garantis par l&#8217;Etat</i>, or &#8220;PGE&#8221;) which are provided by a syndicate of French banks and guaranteed by the French government in the context of the COVID-19 pandemic and were initially set to mature in May 2021. These loans were extended until the third quarter of 2022. The amendments provide for reimbursements to be made over four years, beginning in July 2022 for the loan from Cr&#233;dit Agricole and in September 2022 for the loans from Bpifrance and Soci&#233;t&#233; G&#233;n&#233;rale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2022, the Company entered into three loan agreements with a syndicate of French banks for a total amount of &#8364;5.3 million. One loan agreement was part of a state-guaranteed PGE loan facility with Bpifrance and the other two loan agreements were part of a stimulus economic plan (<i style="font-style:italic;">Pr&#234;ts Participatifs Relance</i>, or &#8220;PPR&#8221;) granted by Cr&#233;dit Agricole Champagne-Bourgogne and Soci&#233;t&#233; G&#233;n&#233;rale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The PGE loan granted by Bpifrance in 2022 is guaranteed up to 90% by the French government with an initial term of twelve months. In May 2023, the Company exercised the option to extend the maturity to align with the 2020 PGE, until May 2026. The two PPR loans are guaranteed predominantly by the French government and feature an eight-year financing period and a four-year repayment period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The PGE repayments in the first six months of 2024 amounted to &#8364;1.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Credit facility agreement with the European Investment Bank</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 16, 2022, the Company entered into the Finance Contract with the EIB for up to &#8364;50 million, divided into two tranches of &#8364;25 million each. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On December 8, 2022, the Company received the disbursement of Tranche A. Capitalized interest for Tranche A is </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and repayment is due in December 2026, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">four years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> after its disbursement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On January 18, 2024, the Company received the disbursement of Tranche B (see Note 1.2. &#8211; </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Significant events in the first six months of 2024</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">). Capitalized interest for Tranche B is </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">7%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and repayment is due in January 2027, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> after its disbursement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Finance Contract may, in certain circumstances, be prepaid, in whole or in part, for a prepayment fee, either at the election of the Company or as a result of EIB&#8217;s demand following certain prepayment events, including a change of control or change in senior management of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Subject to certain terms and conditions, upon the occurrence of usual events of default (i.e., including payment default, misrepresentation, cross default), EIB may demand immediate repayment by the Company of all or part of the outstanding loan. As of June 30, 2024 there was no demand of reimbursement of the outstanding loan. Tranche A of &#8364;25 million was recognized as financial debt at amortized cost, which takes into account the fair value of the derivative instrument (EIB Warrants) at inception and the borrowing costs of &#8364;0.1 million. The amortized cost of the loan is &#8364;15.4 million on December 31, 2023, and is &#8364; 21.1 million on June 30, 2024, with an effective interest rate of 21.9%. The fair value of the loan as of June 30, 2024, amount to &#8364;20.6 million, with a market rate of 22.9%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Tranche B of &#8364;25 million was recognized as financial debt at amortized cost, which takes into account the fair value of the derivative instrument (EIB Warrants) at inception and the borrowing costs of &#8364;0.1 million. The amortized cost of the loan is &#8364;15.0 million on June 30, 2024, with an effective interest rate of &#160;32.7%. The fair value of the loan as of June 30, 2024, amount to &#8364;14.7 million, with a market rate of 33.2%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The capitalized interest for both Tranche A and Tranche B in the period amounted to &#8364;4.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Derivatives</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On July 1, 2022, in connection with the Finance Contract (see section above &#8220;Credit facility agreement with the European Investment Bank&#8221;), the Company entered into a warrant agreement as a condition to the funding of the two tranches of the credit facility. Each EIB Warrant has a subscription price of &#8364;0.01 and gives the right to subscribe to one share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The number of EIB Warrants issued to EIB was determined based on (i) the aggregate amount raised by the Company through one or more equity offerings, or through upfront or milestone payments, from the date of the Finance Contract to the time of the disbursement of the relevant tranche, and (ii)(a) the average price per share paid for the Company&#8217;s shares in its most recent qualifying equity offering or (ii)(b) for Tranche A only, in case of no qualifying equity offering, the volume weighted average price per share of the Company over the last 180 calendar days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The EIB Warrants have a maturity of &#160;twelve years and are exercisable following the earliest to occur of (i) a change of control event, (ii) the maturity date of Tranche A, (iii) an event of default under the Finance Contract, or (iv) a repayment demand by the EIB under the Finance Contract. The EIB Warrants shall automatically be deemed null and void if they are not exercised within the twelve-year period. Each EIB Warrant will entitle EIB to one ordinary share of the Company in exchange for the exercise price (subject to anti-dilutive provisions). However, the exercise ratio of EIB Tranche A warrants has been adjusted on December 31, 2023 following the September 5, 2023 capital increase; One EIB Tranche A Warrant entitles its holder to subscribe for 1.20 ordinary shares in the Company. EIB is entitled to a put option at its intrinsic value to require the Company to buy back the exercisable EIB Warrants not yet exercised in certain of these occurrences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 28, 2022, the Company issued 2,266,023 EIB Tranche A Warrants to EIB, in accordance with the terms of the 25th resolution of the Combined General Shareholders' Meeting of May 19, 2022 and Article L. 225-138 of the French Commercial Code, as a condition to the financing of Tranche A, representing approximately 4.7% of the Company&#8217;s share capital as of June 30, 2024. The exercise price of the EIB Tranche A Warrants is &#8364;4.0152, if and when they may be exercised. The potential gross proceeds if all EIB Tranche A Warrants were exercised would amount to &#8364;9.1 million. The transactions costs for the issuance of the EIB Tranche A Warrants amounted to &#8364;56 thousands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 4, 2024, the Company issued 3,144,654 EIB Tranche B Warrants to EIB, representing approximately 5.2% of the Company&#8217;s share capital as of June 30, 2024, in accordance with the terms of the 6<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> resolution of the Combined General Shareholders' Meeting of January 25, 2023, and Article L. 225-138 of the French Commercial Code. The exercise price of the EIB Tranche B Warrants is &#8364;3.95, if and when they may be exercised. The potential gross proceeds if all EIB &#160;Tranche B Warrants were exercised would amount to &#8364;12.4 million. The transactions costs for the issuance of the EIB Tranche B Warrants amounted to &#8364;90 thousands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The EIB Warrants do not meet the &#8220;fixed for fixed&#8221; criteria (non-cash settlement option which may result in exchanging a variable number of shares for a variable price) and are accounted for as standalone derivative instruments. The Company&#8217;s put options meet the definition of a derivative that are valued with the EIB Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The warrant agreement includes a put option: EIB may request the Company to buy back the EIB Warrants in cash. In this context the purchase price will be defined as the difference between the volume weighted average of the trading price of the ordinary shares over the last 90 trading days and the strike price. The amount is capped, and EIB may exercise the EIB Warrants for which they did not exercise the put option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At inception, the financial debts are split between i) a debt component accounted for at amortized cost, and ii) a premium corresponding to the initial fair value of attached EIB Warrants (then remeasured at fair value through profit and loss) including a component corresponding to the put options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Valuation approach</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of the EIB Warrants has been estimated based on a Longstaff Schwartz approach, including the put option and the attached cap.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This approach enables the estimation of the value of American options (that may be exercised during a specific period of time) with complex way of exercise (the warrant holder may exercise the warrants on the market based on the Company&#8217;s share price or exercise the put option based on the 90 days average share price of the Company).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Longstaff Schwartz approach is also based on the value of the underlying equity instrument at the valuation date, the volatility observed on the historical share price of the Company, and the contractual lifespan associated equity instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The hypothesis and results are detailed in the following tables:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BSA 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BSA 2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Grant date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11/28/2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">01/04/2024</p></td></tr><tr><td style="vertical-align:bottom;width:65.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expiration date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11/28/2034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">01/04/2036</p></td></tr><tr><td style="vertical-align:bottom;width:65.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Number of BSA issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,266,023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,144,654</p></td></tr><tr><td style="vertical-align:bottom;width:65.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Number of shares per BSA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;width:65.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Subscription premium price per share (&#8364;)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.01</p></td></tr><tr><td style="vertical-align:bottom;width:65.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Exercise price per share (&#8364;)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.95</p></td></tr><tr><td style="vertical-align:bottom;width:65.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Valuation method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Longstaff Schwartz</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Longstaff Schwartz</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;November&#160;28,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">EIB Tranche A Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;(Grant&#160;Date)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Number of BSA outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,266,023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,266,023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,266,023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Number of shares per BSA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock price (&#8364;)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maturity (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cap of the put option (m&#8364;)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Euribor 6M</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Euribor 6M</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Euribor 6M</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Fair Value (k&#8364;)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 9,469</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 10,266</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 6,738</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Unit fair value (&#8364;)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-style:italic;"> 4.18</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-style:italic;"> 4.53</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-style:italic;"> 2.97</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;January 4,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">EIB Tranche B Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;(Grant&#160;Date)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;June 30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Number of BSA outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,144,654</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,144,654</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Number of shares per BSA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock price (&#8364;)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maturity (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cap of the put option (m&#8364;)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Euribor 6M</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Euribor 6M</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Fair Value (k&#8364;)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 11,809</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 6,830</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Unit fair value (&#8364;)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-style:italic;"> 3.76</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-style:italic;"> 2.17</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Lease liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Lease liabilities amount to &#8364;5.8 million as of June 30, 2024, and decreased by &#8364;0.8 million compared to December 31, 2023. The lease liabilities are recognized each time a new Fibroscans is leased, on a period of <span style="-sec-ix-hidden:Hidden_YoTGSGWkUUCAhZ-9bE1tcw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> or four years regarding the location of use. Lease liabilities are calculated using specific discount rates, in connection with the geographic area, the maturity of the debt, and the commencement date, according to the method described in Note 3.2 of the consolidated financial statements as of December 31, 2023. The rates for contracts in progress as of June 30, 2024 range from 1.89% to 5.18%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The breakdown between long-term and short-term debt is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Less than</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Between</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Between</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">More than</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1 year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1 and 3 years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> 3 and 5 years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">5 years</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Bank borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,509</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,229</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 36,164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 890</p></td></tr><tr><td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Derivatives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,302</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,761</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,455</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,306</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalty certificates liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,263</p></td></tr><tr><td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total debt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 73,404</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 5,726</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 57,299</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,225</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 8,153</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Between</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Between</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">More than</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1 year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1 and 3 years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">3 and 5 years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> 5 years</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bank borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,928</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,872</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,558</p></td></tr><tr><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivatives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other loans and similar borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,719</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,636</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,565</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,298</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,267</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Royalty certificates liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,327</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,327</p></td></tr><tr><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total debt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_EHsAFhljaE2ILeQMiCBC4Q;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> 54,082</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,308</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 9,140</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 31,749</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,885</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The maturity of long-term debt and of short-term borrowings and debt is determined according to contractual repayment terms as of June 30, 2024 and December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Royalty Certificates liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On August 31, 2023, the Company announced the issuance of the royalty certificates (&#8220;2023 Royalty Certificates&#8221;) for an aggregate amount of &#8364;5.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The 2023 Royalty Certificates are accounted at the inception at the fair value (&#8364;5.1 million on August 31, 2023), and then at the amortized cost (&#8364;7.3 million on June 30, 2024 vs. &#8364;6.3 million on December 31, 2023) with an effective interest rate of 31.9%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fair value as of June 30, 2024</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On June 30, 2024, the fair value of the 2023 Royalty Certificates, calculated using discounted cash flow approach, amounts to &#8364;9.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The fair value corresponds to the net present value of royalties, which depend on assumptions made by the Company with regards to the probability of success of its studies, the markets sales of lanifibranor and the discount rate (27.9%). The discount rate has been estimated based on a reconciliation between the Company&#8217;s business plan and the Company&#8217;s market capitalization as of June 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.11</b></span>Provisions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has no provisions as of June 30, 2024, and December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.12</b></span>Provisions for retirement benefit obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Retirement benefit obligations are determined based on the rights set forth in the national collective bargaining agreement for the French pharmaceutical industry (IDCC 176/Brochure 3104) and in accordance with IAS 19 &#8211; <i style="font-style:italic;">Employee Benefits</i>. These rights depend on the employee&#8217;s final salary and seniority within the Company at his/her retirement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net provision</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The provision recorded in respect of defined benefit schemes at the end of each reporting period is shown in the table below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Retirement benefit obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,555</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,559</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total obligation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,555</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,559</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Given the absence of plan assets at June 30, 2024 and December 31, 2023, the total amount of the provision corresponds to the estimated obligation at those dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in the net provision</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Changes in the provision recorded in respect of defined benefit schemes break down as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Provision at beginning of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,559)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,234)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expense for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (70)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (228)</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Actuarial gains or losses recognized in other comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (97)</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Provision at end of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,555)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,559)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Breakdown of expense recognized for the period</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Service cost for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (104)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (183)</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest cost for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (46)</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Benefits for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (70)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (228)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.13</b></span><b style="font-weight:bold;">Other current and non-current liabilities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other non-current liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024 and December 31, 2023 non-current liabilities amount to &#8364;1.0 million related to an agreement with CTTQ dated December 20, 2023 pursuant to which CTTQ paid the Company an advance for certain costs related to the NATiV3 clinical trial that the Company will incur and reinvoice to CTTQ.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="font-style:italic;">Other current liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee&#8209;related payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,739</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,869</p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued payroll and other employee-related taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,801</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,540</p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales tax payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,140</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,569</p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued taxes and employee-related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164</p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other miscellaneous payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23</p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,834</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,165</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">No discounting has been performed on other current liabilities as their maturity is less than one year at the end of the period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accrued payroll and other employee-related taxes mainly relate to payables to social security and employee-benefit organizations such as URSSAF, KLESIA and APGIS for the first half of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Other accrued taxes and employee-related expenses concern provisions for payroll taxes, such as professional training charges, apprenticeship tax, the employer&#8217;s contribution to construction investment in France and the payroll tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.14</b></span>Trade payables and short-term contract liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,679</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Trade payables and other current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 36,586</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 37,685</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">No calculations have been made to discount trade payables to present value as payment is due within one year at the end of the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Trade payables</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Trade payables break down as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Due in 30 days</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,995</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Due in 30-60 days</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,684</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Due in more than 60 days</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Trade payable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 36,583</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 37,679</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024, trade payables mainly included accrued liabilities for &#160;&#8364;24.0 million of which &#8364;20.2 million relate to scientific projects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of June 30, 2024, trade payables decreased by &#8364;1.1 million compared to December 31, 2023. Trade payables, which depend on the frequency of CRO invoicing, were relatively stable (down by less than 3%).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">4.15</b></span>Financial assets and liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The table below presents the carrying amount of financial assets and liabilities by IFRS 9 accounting category:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:49.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Financial</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Book value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">assets/liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Financial </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">on the</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">carried at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> statement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">carrieds at </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> carried at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> of financial</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> through</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">profit or loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term accrued income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term deposit accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Advance payment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,047</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,047</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,047</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current accrued income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,687</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term deposit accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 809</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,518</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,147</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 16,208</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 16,208</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 16,208</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,994</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative instruments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,569</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Royalty certificates liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,050</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,726</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">36,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">36,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">36,583</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other miscellaneous payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">109,998</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 13,569</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">96,429</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">110,933</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><i style="font-style:italic;">See Note 4.10 Financial debt detailing amortized cost and fair value of the Credit facility with the EIB</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:49.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Financial</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Book Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">assets/liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Financial</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">on the</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">carried at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> assets </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">statement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">carrieds at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> carried at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of financial</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">through</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">profit or loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term deposit accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Advance payment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,047</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,047</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,047</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term deposit accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,807</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,807</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,807</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 857</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,918</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,918</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,918</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 41,706</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 41,706</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 41,706</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,701</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative instruments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,265</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Royalty certificates liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,327</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,327</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,617</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,308</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,679</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other miscellaneous payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">23</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">91,784</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 10,265</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">81,518</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">92,594</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for notes to the interim consolidated balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232121625456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of (income) loss<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ComponentsOfIncomeStatementAbstract', window );"><strong>Notes to the interim condensed consolidated statement of (income) loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DisclosureOfComponentsOfIncomeStatementTextBlock', window );">Notes to the interim condensed consolidated statement of (income) loss</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Note 5.</b>&#160;&#160;&#160;&#160;<b style="font-weight:bold;">Notes to the interim condensed consolidated statement of (income) loss</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.1</b></span><b style="font-weight:bold;">Revenues and other income</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">For the six months ended June 30, 2024, and June 30, 2023</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Operating income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,901</p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 41</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,901</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,630</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,631</p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Subsidies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,087</p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,693</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,721</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total revenue and other income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,734</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 6,622</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other operating income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Research Tax Credit (&#8220;CIR&#8221;) generated over the first six months of the fiscal year amounts to &#8364;2.7 million in 2024 as in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, other operating income are composed of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The R&amp;D Tax Research Credit from Inventiva Inc amounting to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;1.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million, compared to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;0.8</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million in tax income as of June 30, 2024;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The re-invoicing to CTTQ for a portion of the expenses incurred, amounting to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;0.3</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million as of June 30, 2023, under Phase I of the ongoing Phase III pharmacological clinical trial NATiV3, and the re-invoicing to CTTQ for specific expenses related to CRO provisions amounting to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;0.7</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million, compared to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8364;2.6</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million in CTTQ re-invoicing as of June 30, 2024, accounted as a reduction in research and development expenses.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.2</b></span><b style="font-weight:bold;">Operating expenses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">For the six months ended June 30, 2024 and June 30, 2023</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Research&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Marketing&#160;&#8211;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">General&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six months ended June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Business</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">administrative</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Disposables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (887)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (887)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Energy and liquids</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (447)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (447)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Patents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (643)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (643)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Studies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34,073)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34,073)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Maintenance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (526)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (526)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (118)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,675)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,795)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">IT systems</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (405)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (444)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Support costs (including taxes)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (375)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (375)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Personnel costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,637)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (153)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,600)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,391)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation, amortization and provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,732)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (122)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,854)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Insurances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (921)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (921)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (352)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (437)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (975)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,764)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (46,822)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (598)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (7,701)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (55,122)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Research&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Marketing&#160;&#8211;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">General&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six months ended June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Business</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">administrative</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">en milliers d'euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Disposables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (943)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (943)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Energy and liquids</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (479)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (479)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Patents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (257)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (257)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Studies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (42,847)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (42,847)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Maintenance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (459)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (459)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (61)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,884)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,945)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">IT systems</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (440)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (50)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (498)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Support costs (including taxes)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (343)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (343)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Personnel costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,065)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (126)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,347)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,538)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Depreciation, amortization and provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,061)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (104)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,166)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Insurances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,121)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,121)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Other operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (450)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (570)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (964)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,985)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (54,062)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (705)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (6,812)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (61,580)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-style:italic;">Personnel costs and headcount</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Marketing - </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Research and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Business</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">General and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six months ended June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">administrative</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Wages, salaries and similar costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,824)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (120)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,237)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,181)</p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,312)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,886)</p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provisions for retirement benefit obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (35)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (86)</p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,450)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (765)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,238)</p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total personnel costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (7,637)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (153)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (2,600)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (10,391)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company has 123 employees as of June 30, 2024, of which 112 are employed by Inventiva S.A. and 11 are employed by Inventiva Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Marketing -</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Research and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Business</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">General and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> administrative</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Wages, salaries and similar costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,399)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (104)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,191)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (5,694)</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payroll taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,222)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (476)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,708)</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provisions for retirement benefit obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (61)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (90)</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,383)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (650)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (2,046)</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total personnel costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (7,065)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (126)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (2,347)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (9,538)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company had 117 employees as of June 30, 2023, including 105 people employed by Inventiva S.A. and 12 people employed by Inventiva Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.3</b></span>Other operating income and expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other operating income and expenses break down as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other operating income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (44)</p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other operating income and expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 138</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (44)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.4</b></span>Financial income and expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">For the six months ended June 30, 2024 and June 30, 2023</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income from cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 430</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 564</p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign exchange gains</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 157</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 187</p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gain on fair value variation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,623</p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 9,093</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,373</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,218)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,941)</p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign exchange losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (323)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (683)</p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other financial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (46)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23)</p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (5,586)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (2,646)</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net financial income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,507</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (273)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the first six months of 2024, financial income is mainly composed of a &#8364;8.5 million change in fair value of the EIB Warrants issued in connection with Tranches A and B.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Financial expenses mainly include exchange losses, financial interests related to PGE and PPR credit agreements and the financing agreement with the EIB, and financial interests related to lease liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.5</b></span>Share of net profit &#8211; Equity method</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The tables below provide the summarized statement of income (loss) for the associate Hepalys. The information disclosed reflects the amounts presented in the financial statements of Hepalys and not the Company's share of those amounts. They have been amended to reflect adjustments made by the Company when using the equity method, in this case fair value adjustments. The tables below provide also the reconciliation between Hepalys' loss and the share of net loss recognized in the Company statement of financial position.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:98.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands of euros)</i> <b style="font-weight:bold;">For the period started January 1, 2024, to June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,475)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net operating loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (1,526)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Financial income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Financial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net financial income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 17</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Income (expense) tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss for the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (1,509)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exchange difference on translation of foreign operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (1,964)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Items that will be reclassified subsequently to profit or loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (3,473)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total comprehensive loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (3,473)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Group's share in </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Share of net profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Elimination of downstream sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (66)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Share of net profit - Equity method</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 168</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In 2024, Hepalys did not generate any sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.6</b></span>Income tax</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The income tax calculation for interim periods is set out in Note 3.3 &#8211; <i style="font-style:italic;">Specific disclosure requirements for unaudited interim financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As the imputation of tax benefits on tax losses of Inventiva S.A., at short or mid-term, were considered unlikely due to the growth phase of the Company and regarding the nil projected tax rate as of December 31, 2024, no current taxes were recorded as of June 30, 2024, for Inventiva S.A.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The &#8364;119 thousand income tax recorded was related Inventiva Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">5.7</b></span><b style="font-weight:bold;">Basic and diluted loss per share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic earnings (loss) per share are calculated by dividing net income (loss) attributable to owners of the Company by the weighted average number of ordinary shares outstanding during the six-month period ended June 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">For the six months ended June 30, 2024 and June 30, 2023</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss for the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (49,029)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (55,269)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average number of shares outstanding used to calculate basic/diluted loss per share<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51,982,093</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,044,796</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Basic/diluted loss per share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (0.94)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1.31)</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><i style="font-style:italic;">In accordance with IAS 33.19, basic/diluted earnings per share exclude treasury shares held by the Group as of June 30, 2024 and 2023</i>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As a loss was recorded in the first six months of 2024 and 2023, diluted earnings (loss) per share are the same as basic earnings (loss) per share. Share-based payment plans (BSAs, BSPCEs, AGAs and PAGUP) are not included as their effects would be anti-dilutive.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_ComponentsOfIncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_ComponentsOfIncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DisclosureOfComponentsOfIncomeStatementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for components of income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DisclosureOfComponentsOfIncomeStatementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232124760736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other financial information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_OtherFinancialInformationAbstract', window );"><strong>Other financial information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DisclosureOfOtherFinancialInformationTextblock', window );">Other financial information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Note 6.&#160;&#160;&#160;&#160;Other financial information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.1</b></span><b style="font-weight:bold;">Commitments related to operational activities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obligations under the terms of subcontracting agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the ordinary course of its business, the Company enters into agreements with CROs for clinical trials, as well as with contract manufacturing organizations (&#8220;CMOs&#8221;) for clinical and commercial supply manufacturing, commercial and pre-commercial activities, research and development activities and other services and products for operating purposes. The Company&#8217;s agreements generally provide for termination with specified periods of advance notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Such agreements are generally cancellable contracts and are not included in the description of the Company&#8217;s contractual obligations and commitments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Commitments given and received</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CRO<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 175,461</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 183,366</p></td></tr><tr><td style="vertical-align:bottom;width:71.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CMO</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,733</p></td></tr><tr><td style="vertical-align:bottom;width:71.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,592</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,595</p></td></tr><tr><td style="vertical-align:bottom;width:71.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,442</p></td></tr><tr><td style="vertical-align:bottom;width:71.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total commitments given</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 210,261</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 221,136</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agreements concerning the provision of facilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 260</p></td></tr><tr><td style="vertical-align:bottom;width:71.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total commitments received</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 296</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 260</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">Including CRO with Pharmaceutical Research Associates B.V.</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CRO Contract with Pharmaceutical Research Associates Group B.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In April 2021, in connection with the NATiV3 Phase III trial in MASH/NASH, the Company entered into an agreement, with retroactive effect in January 2021, with PRA, acting as a CRO. The contract aims to support the regulatory approval of lanifibranor in adult patients in Europe and in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also entered into a CRO agreement with PRA in connection with the LEGEND Phase IIa clinical trial, effective January 14, 2022. Under the terms of the agreement, PRA will conduct a clinical trial to evaluate the benefit for patients of the combination of lanifibranor with empagliflozin, an SGLT2 inhibitor, in patients with T2D and non-cirrhotic MASH/NASH. The commitment to PRA under this agreement amounts to an aggregate of &#8364;13.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 26, 2023, in connection with the NATiV3 Phase III trial in MASH/NASH, the Company entered into a new amendment to the April 2021 agreement with retroactive effect in January 2021 with PRA. The amendment updates the provisions relating to study information following changes to the trial protocol. In June 2024, the Company entered into a new amendment, the new commitment amount to PRA is &#8364;254.3, with a bonus or malus will decrease from &#8364;3.4 million to &#8364;0.7 million in 2026. The commitment also includes &#8364;20.2 million to be paid by CTTQ.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024, the amount remaining to be paid under the contract is &#8364;158.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.2.</b></span>Related-party transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">No other new material transactions were entered into with related parties of the Company during the first six months of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.3</b></span>Financial risk management</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Through its business activities, the Company is exposed to various types of financial risk: foreign exchange risk, credit risk and liquidity risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The financial risks are those described in the financial statements prepared in accordance with IFRS for the year ended December 31, 2023, as updated for risks regarding liquidity which are described in the Note 3.4 &#8212; <i style="font-style:italic;">Going Concern</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.4</b></span>Events after the reporting date</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Update on NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">On July 5, 2024, the Company provided an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH. Recruitment in NATiV3 clinical trial continues in both cohorts with over 80% of the targeted number of patients enrolled in the main cohort and 100% in the exploratory cohort of NATiV3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">The first visit of the last patient of NATiV3 is anticipated to occur during the fourth quarter of 2024, and topline results are expected at the beginning of the second half of 2026. The Company&#8217;s patent portfolio strengthened with new a patent secured in Japan that that provides intellectual property rights on protects the potential use of lanifibranor for the treatment of patients with cirrhosis until 2039, excluding any potential patent term adjustments or extensions that may provide additional protection until 2043.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Issuance of royalty certificates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">On July 18, 2024, the Company announced the issuance of 201 royalty certificates (the &#8220;<b style="font-weight:bold;">2024 Royalty Certificates</b>&#8221;) for aggregate gross proceeds of approximately &#8364;20.1 million. The 2024 Royalty Certificates will provide the holders thereof with the right to an annual payment of royalties equal to 3% of the future net sales, if any, of lanifibranor beginning on the fiscal year following the start of the sales of lanifibranor following the granting of the market authorization for lanifibranor in (i) the United States of America, (ii) the countries of the European Union or (iii) the United Kingdom, whichever occurs the first, if at all. The 2024 Royalty Certificates have a term of 14 years following the date of issue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Approving of patent application</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">On July 25, 2024 the Company announced that the Japan Patent Office (&#8220;JPO&#8221;) approved Inventiva&#8217;s patent application No. JP 2019-203498, protecting the use of lanifibranor for the treatment of patients with cirrhosis. This new patent will be valid until November 8, 2039, excluding any potential patent term adjustments or extensions that may provide additional protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Financing in </span><span style="font-style:italic;font-weight:bold;">three</span><span style="font-style:italic;font-weight:bold;"> tranches for a maximum amount of </span><span style="font-style:italic;font-weight:bold;">&#8364;348</span><span style="font-style:italic;font-weight:bold;"> million</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company announced the following financing on 14 October 2024 structured in three tranches:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">(i) the issuance , through a capital increase without preferential subscription rights reserved to a specific category of beneficiaries (&#8220;<i style="font-style:italic;">&#224; cat&#233;gorie de personnes</i>&#8221;), of new ordinary shares at a gross value, including issuance premium, of &#8364;94.1 million through the issuance of 34,600,507 new ordinary shares, par value &#8364;0.01 per share (each, a &#8220;<b style="font-weight:bold;">T1 New Shares</b>&#8221;), and 35,399,481 &#160;prefunded warrants to subscribe for shares in the Company at a price outstanding of &#8364;0.01 per new ordinary share, each giving the right, in the event of exercise, to one new ordinary share (the &#8220;<b style="font-weight:bold;">T1 BSAs</b>&#8221;);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">(ii) the issuance, in a second phase, as part of a new capital increase without preferential subscription rights reserved to certain identified investors (&#8220;<i style="font-style:italic;">&#224; personne d&#233;nomm&#233;e</i>&#8221;), of new ordinary shares, par value &#8364;0.01 per share or of prefunded warrants to subscribe for ordinary shares of the Company (each, a &#8220;<b style="font-weight:bold;">T1bis New Shares</b>&#8221;), for a total amount of &#8364;21.4 &#160;million (excluding exercise of pre-funded warrants);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">(iii) the issuance, in a third phase, as part of a new capital increase without preferential subscription rights reserved to certain identified investors (&#8220;<i style="font-style:italic;">&#224; personne d&#233;nomm&#233;e</i>&#8221;) subject to operational conditions to be met and the adoption of the necessary resolutions by the Shareholders' Meeting to be held before December 16, 2024, (or prefunded warrants) to which share warrants (the &#8220;<b style="font-weight:bold;">ABSAs</b>&#8221;) are attached for a total amount of &#8364;116,000,000. Each ABSA will consist of a number of new ordinary shares with a par value of &#8364;0.01 (or pre-funded warrants) to be determined by the Company's Board of Directors (each, a &#8220;<b style="font-weight:bold;">T2 New Share</b>&#8221;) to which will be attached a number warrants exercisable at an exercise price of &#8364;1.50 (each, a &#8220;<b style="font-weight:bold;">T3 BSA</b>&#8221;) allowing the subscription of a number of new ordinary shares of the Company for a maximum total amount of &#8364;116,000,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">The subscription agreements for the T1 New Shares and the T1 BSA were signed on October 11, 2024, and the settlement-delivery of the T1 New Shares and the T1 BSA is expected to take place on October 17, 2024, subject to the absence of any material adverse event between the signing of the agreements and the settlement-delivery of the T1 New Shares and the T1 BSA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Amendment to the exclusive license and collaboration agreement with CTTQ</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt;">On October 11, 2024, the Company has entered into an amendment (the &#8220;<b style="font-weight:bold;">Amendment</b>&#8221;) to the exclusive license and collaboration agreement with Chia Tai Tianqing Pharmaceutical Group, Co., Ltd (&#8220;<b style="font-weight:bold;">CTTQ</b>&#8221;), dated September 21, 2022, as amended. Under the Amendment, if the Company receives subscription commitments, before December 31, 2024, from investors to subscribe to a fundraising, in two or three tranches, for a total gross amount of at least &#8364;180,000,000 (the &#8220;<b style="font-weight:bold;">Fund Raising</b>&#8221;), CTTQ shall pay to the Company (i) $10,000,000 within 30 days of settlement-delivery of the T1 New Shares and T1 Warrants in the event of the issuance of the first tranche of the Fund Raising to be paid by CTTQ, (ii) $10,000,000 in the event of the issuance of the second tranche of the Fund Raising, and (iii) $10,000,000 upon publication by the Company of the pivotal data announcing that the primary endpoint or one of the two key secondary endpoints of NATiV3, with one of the dosing regimens tested in the trial, have been met. Under the terms of the Amendment, the total amount of potential clinical, regulatory and commercial milestone payments remains unchanged, while the royalties that Inventiva is likely to receive have been reduced to a low figure.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DisclosureOfOtherFinancialInformationTextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other financial information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DisclosureOfOtherFinancialInformationTextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232124616192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Principles (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_AccountingPrinciplesAbstract', window );"><strong>Accounting Principles</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Use of estimates and judgment</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">3.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Use of estimates and judgment</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements requires management to make judgments and estimates and apply assumptions that can affect the carrying amounts of assets, liabilities, income and expenses, as well as the information presented in the accompanying notes. Actual reported values may differ from the accounting estimates made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There have been no significant changes in the material judgments and main estimates used by management when applying the Company&#8217;s accounting policies in the preparation of these unaudited interim condensed consolidated financial statements from those described in the annual financial statements prepared in accordance with IFRS Accounting Standards for the year ended December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The conflict in Ukraine and the state of war between Israel and Hamas have not led to any material changes in the estimates or judgements made by management in the preparation of the Company&#8217;s unaudited interim condensed consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory', window );">Fair value measurement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.2.</b></span>Fair value measurement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the table below, financial instruments are measured at fair value according to a hierarchy comprising three levels of valuation inputs:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;2: Inputs other than quoted market prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level&#160;3: Unobservable inputs for the asset or liability.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The table below presents the financial assets and liabilities of the Company measured at fair value as of June 30, 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">At June 30, 2024 (in thousands of euros)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Financial liabilities at fair value through profit or loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term financial debt - derivatives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,569</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 13,569</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The table below presents the financial assets and liabilities of the Company measured at fair value as of December 31, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">At December 31, 2023 (in thousands of euros)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Financial liabilities at fair value through profit or loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term financial debt &#8211; derivatives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,265</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 10,265</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock', window );">Specific disclosure requirements for unaudited interim financial statements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">3.3.</b></span>Specific disclosure requirements for unaudited interim financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Seasonality of operations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s operations are not subject to material seasonal fluctuations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Income tax</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Income tax is recognized in the financial statements for each interim period. The amount corresponds to a best estimate calculated by applying the expected weighted average tax rate for the entire year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The income tax amount recorded as due for an interim period may have to be adjusted in the subsequent interim period of the same year if the estimated annual average tax rate changes.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGoingConcernExplanatory', window );">Going concern</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">3.4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Going concern</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From inception, the Company has financed its growth through successive capital increases, debt, collaboration and license agreements and reimbursements of CIR receivables. The Company continues to pursue its research and development activities for its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has incurred operating losses and negative cash flows from operations since inception due to the innovative nature of the product candidates it is developing, which necessitates a research and development phase spanning several years. The Company does not expect to generate revenue from product sales in the near future. With the biopharmaceutical industry's product development phases requiring increasing investments, the Company's financing needs will continue to grow as clinical trials of the Company's drug candidates progress and the Company invests to develop existing and new product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024, the Company had &#8364;10.1 million of available cash and cash equivalents, consisting of cash and short-term deposit accounts that are liquid and easily convertible within 3 months without penalty or risk of change in value (refer to Note 4.8 &#8211; <i style="font-style:italic;">Cash and Cash equivalents</i>). In accordance with IAS 7.8, bank overdrafts which are repayable on demand are included as a component of cash and cash equivalents in the amount of &#8364;1.3 million as of June 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of the date of authorization of the issuance of these financial statements, given its current cost structure, its projected expenditure commitments, and the events after the reporting period presented in Note 6.4 - <i style="font-style:italic;">Events after the reporting period</i>, mainly the issue of royalty certificates and the T1 capital increase, the Company estimates that it should have sufficient funds to finance its activities through the end of the second half of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accordingly, as of the date of authorization of the issuance of these financial statements, the Company's current cash and cash equivalents are not expected to be sufficient to cover its operating needs for at least the next 12 months. These events and conditions indicate that an uncertainty exists that may cast significant doubt on the Company&#8217;s ability to continue as a going concern and, therefore, the Company may be unable to realize its assets and discharge its liabilities in the normal course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This estimate is based on the Company&#8217;s current business plan and excludes (i) other expenses related to the potential development of odiparcil or resulting from any potential in-licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue, (ii) any potential milestone payments that may be received or paid by the Company or potential additional financing, including the issue of tranches 1bis and 2 as described in Note 6.4 &#8211; <i style="font-style:italic;">Events after the reporting period</i>. The Company may have based this estimate on assumptions that may prove to be incorrect, and the Company may end up using its resources sooner than anticipated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Based on the above, the unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2024, have been prepared on a going concern basis assuming the Company will continue to operate for the foreseeable future. As such, they do not include any adjustments related to the amount or classification of assets and liabilities that may be required if the Company were not able to continue as a going concern.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGoingConcernExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGoingConcernExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_AccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_AccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific disclosure requirements for unaudited interim financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232122509040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation and statement of compliance (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_StatementOfComplianceAbstract', window );"><strong>Basis of preparation and statement of compliance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory', window );">Schedule of subsidiaries</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024, the scope of consolidation consists of two entities, the parent, Inventiva S.A. and its 100% owned subsidiary, Inventiva Inc., for which no non-controlling interest is recognized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percent&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ownership&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounting&#160;Method</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">INVENTIVA Inc.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">01/05/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">Fully Consolidated</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory', window );">Schedule of exchange rates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Exchange rate (USD per EUR)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;June 30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Average exchange rate for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.0813</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.0803</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.0807</p></td></tr><tr><td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Exchange rate at period end</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.0705</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.1050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.0866</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the effect of changes in foreign exchange rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS21_g51-57_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of interests in subsidiaries. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 2<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_2_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_StatementOfComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>N/A</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_StatementOfComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232124661216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Principles (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_AccountingPrinciplesAbstract', window );"><strong>Accounting Principles</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory', window );">Schedule of financial assets and liabilities measured at fair value</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">At June 30, 2024 (in thousands of euros)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">Financial liabilities at fair value through profit or loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term financial debt - derivatives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,569</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 13,569</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">At December 31, 2023 (in thousands of euros)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Financial liabilities at fair value through profit or loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term financial debt &#8211; derivatives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,265</p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 10,265</b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value of financial instruments. [Refer: Financial instruments, class [member]; At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_AccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_AccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232123595888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory', window );">Schedule of intangible assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,947</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,926</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,496)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,384)</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Intangible assets, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 451</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 541</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of property, plant and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, plant and equipment, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,840</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation and impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,396)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,714)</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Property, plant and equipment, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,979</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_9rDgFmQBEUmZjQqm7DwPdg;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> 9,126</b></span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory', window );">Schedule of investment in Hepalys is accounted for using the equity method of accounting</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands of euros)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total non</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 17,217</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 20,278</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,082</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,015</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,126</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 19,233</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 21,444</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 523</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 640</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,379</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital surplus-others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 774</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Earnings brought forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,018)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (178)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,444)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,111)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Treasury Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (812)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shareholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 19,214</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 21,194</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total non</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 19</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 250</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total equity and liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 19,233</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 21,444</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Opening net assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_tuNLjyeUjUStSiiPLbEZGg;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> 21,122</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 22,645</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,509)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (879)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,964)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Capital variations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,566</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (819)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Closing net assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 19,214</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 21,194</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Group's share in </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands of euros)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Group's share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,813</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 3,267</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Elimination of unrealised profit on downstream sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,718)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,881)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,131</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,425</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DisclosureOfOtherNoncurrentAssetsTableTextBlock', window );">Schedule of other non current assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term deposit accounts<span style="display:inline-block;width:32.36pt;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,000</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Advance payments &#8211; non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,047</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,047</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other non</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,047</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 10,055</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventories</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 426</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inventories write&#8209;down</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9)</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Inventories</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 393</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 417</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DisclosureOfTradeReceivablesTableTextBlock', window );">Schedule of trade receivables and others break down</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3&#160;months or less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,807</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Between 3 and 6&#160;months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">&#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Between 6 and 12&#160;months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">More than 12&#160;months</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Trade receivables</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 809</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,807</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory', window );">Schedule of other current assets and receivables</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-variant:small-caps;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CIR and other research tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,333</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Tax receivables</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,704</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,352</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,039</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,656</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term deposit accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current accrued income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,047</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liquidity agreement - Cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 289</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 422</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales tax receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,311</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,066</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,229</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 435</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 14,554</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 11,696</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other current assets and receivables</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 17,258</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 17,048</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DisclosureOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of cash and cash equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net cash and cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other cash equivalents<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,933</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash at bank and at hand</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,212</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,985</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Bank overdrafts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,338)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 10,147</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 26,918</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other cash equivalents correspond to short-term bank deposits.</span></td></tr></table><div style="margin-top:12pt;"></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Schedule of changes in share capital</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:23.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Premiums&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">related&#160;to&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nominal&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:23.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nature&#160;of&#160;the&#160;transactions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share&#160;capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value</b></p></td></tr><tr><td style="vertical-align:bottom;width:23.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at December 31, 2023</p></td><td style="vertical-align:bottom;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 521,158</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 201,862,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,115,807</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.01</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3/25/2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AGA 2021 &amp; AGA 2021 bis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,614</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,614)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 361,381</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.01</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance at June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 524,772</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 201,858,649</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 52,477,188</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 0.01</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory', window );">Schedule of debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Bank borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,509</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,206</p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Derivatives instruments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,265</p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other loans and similar borrowings<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,302</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,719</p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,761</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,565</p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalty certificates liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,327</p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total debt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 73,404</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_VVi9UZTcQEKJWAcPl8yJKQ;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> 54,082</b></span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:italic;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">include accrued interests.</i></td></tr></table><div style="margin-top:12pt;"></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DisclosureOfChangesInBorrowingsTableTextBlock', window );">Schedule of movements in the period break down</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">January 1, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 54,083</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 44,390</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Subscription of derivatives instruments<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Subscription of bank borrowings<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Subscription of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 345</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,706</p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Issue of royalty certificates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,100</p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Repayment of bank borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,177)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,485)</p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Repayment of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,173)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,612)</p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Interests on royalty certificates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 936</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,227</p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Capitalized interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,961</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,405</p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Change in fair value of derivatives instruments<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,506)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 389</p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Exchange rate change</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (38)</p></td></tr><tr><td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 73,404</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 54,083</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock', window );">Schedule of valuation approach for BSA arrangement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BSA 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BSA 2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Grant date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11/28/2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">01/04/2024</p></td></tr><tr><td style="vertical-align:bottom;width:65.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Expiration date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11/28/2034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">01/04/2036</p></td></tr><tr><td style="vertical-align:bottom;width:65.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Number of BSA issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,266,023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,144,654</p></td></tr><tr><td style="vertical-align:bottom;width:65.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Number of shares per BSA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;width:65.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Subscription premium price per share (&#8364;)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.01</p></td></tr><tr><td style="vertical-align:bottom;width:65.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Exercise price per share (&#8364;)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.95</p></td></tr><tr><td style="vertical-align:bottom;width:65.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Valuation method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Longstaff Schwartz</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Longstaff Schwartz</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;November&#160;28,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">EIB Tranche A Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;(Grant&#160;Date)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Number of BSA outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,266,023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,266,023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,266,023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Number of shares per BSA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock price (&#8364;)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maturity (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cap of the put option (m&#8364;)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Euribor 6M</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Euribor 6M</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Euribor 6M</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Fair Value (k&#8364;)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 9,469</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 10,266</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 6,738</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Unit fair value (&#8364;)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-style:italic;"> 4.18</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-style:italic;"> 4.53</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-style:italic;"> 2.97</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory', window );">Schedule of provision recorded in respect of defined benefit schemes at the end of each reporting period</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Retirement benefit obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,555</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,559</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total obligation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,555</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,559</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory', window );">Schedule of change in the provision recorded in respect of defined benefit schemes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Provision at beginning of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,559)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,234)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expense for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (70)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (228)</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Actuarial gains or losses recognized in other comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (97)</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Provision at end of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,555)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,559)</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory', window );">Schedule of expense recognized in the statement of income (loss)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Service cost for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (104)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (183)</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest cost for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (46)</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Benefits for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (70)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (228)</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities', window );">Schedule of maturity of long-term and short-term debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Less than</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Between</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Between</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">More than</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1 year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1 and 3 years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> 3 and 5 years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">5 years</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Bank borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42,509</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,229</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 36,164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,225</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 890</p></td></tr><tr><td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Derivatives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,302</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,761</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,455</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,306</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalty certificates liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,263</p></td></tr><tr><td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total debt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 73,404</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 5,726</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 57,299</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,225</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 8,153</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Between</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Between</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">More than</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1 year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1 and 3 years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">3 and 5 years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> 5 years</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Bank borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,928</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,872</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,848</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,558</p></td></tr><tr><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivatives</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other loans and similar borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,719</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,636</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,565</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,298</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,267</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:49.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Royalty certificates liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,327</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,327</p></td></tr><tr><td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total debt</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_EHsAFhljaE2ILeQMiCBC4Q;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> 54,082</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,308</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 9,140</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 31,749</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,885</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of trade payables and other current liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,679</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Trade payables and other current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 36,586</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 37,685</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">Schedule of trade payables break down by payment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Due in 30 days</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,995</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Due in 30-60 days</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,684</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Due in more than 60 days</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Trade payable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 36,583</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 37,679</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory', window );">Schedule of other current liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee&#8209;related payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,739</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,869</p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued payroll and other employee-related taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,801</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,540</p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales tax payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,140</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,569</p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued taxes and employee-related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164</p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other miscellaneous payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23</p></td></tr><tr><td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,834</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,165</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory', window );">Schedule of financial assets and liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:49.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Financial</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Book value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">assets/liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Financial </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">on the</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">carried at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> statement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">carrieds at </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> carried at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> of financial</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> through</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">profit or loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term accrued income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term deposit accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Advance payment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,047</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,047</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,047</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current accrued income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,687</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,687</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term deposit accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 809</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 809</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,518</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,147</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 16,208</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 16,208</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 16,208</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,994</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative instruments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,569</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Royalty certificates liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,050</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,726</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,726</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">36,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">36,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">36,583</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other miscellaneous payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">109,998</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 13,569</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">96,429</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">110,933</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><i style="font-style:italic;">See Note 4.10 Financial debt detailing amortized cost and fair value of the Credit facility with the EIB</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:49.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dec. 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Financial</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Book Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">assets/liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Financial</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">on the</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">carried at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> assets </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">statement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">carrieds at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> carried at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of financial</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">through</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">profit or loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term deposit accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Advance payment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,047</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,047</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,047</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term deposit accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,807</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,807</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,807</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 857</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,918</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,918</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,918</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 41,706</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 41,706</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 41,706</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term debt (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,701</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative instruments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,265</p></td></tr><tr><td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Royalty certificates liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,327</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,327</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,617</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,308</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,679</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other miscellaneous payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">23</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">91,784</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 10,265</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">81,518</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">92,594</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_BspceAndBsaShareWarrantsMember', window );">BSPCE share warrants and BSA share warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Schedule of movements in BSPCE and BSA share warrants and Bonus shares</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at Jan&#160;1,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Forfeited /</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in euros)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issued</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercised</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Lapsed</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSPCE - Plan 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">04/16/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 430,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 430,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 430,000</p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TOTAL BSPCE share warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 430,000</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 430,000</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 430,000</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSA&#160;- Plan 2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/29/2017</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130,000</p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSA&#160;- Plan 2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/14/2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 116,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 116,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 116,000</p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSA 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">06/28/2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,000</p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSA 2019 bis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/09/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,000</p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSA 2019 ter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">03/09/2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36,000</p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSA 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">04/16/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.74</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,333</p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSA 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/25/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BSA 2023 - 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/15/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TOTAL BSA share warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 346,333</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 346,333</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 316,333</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total share warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 776,333</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 776,333</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 746,333</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewBonusShareAwardPlan20231Member', window );">AGA Plan 2023-1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Schedule of movements in BSPCE and BSA share warrants and Bonus shares</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:26.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at grant date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at Jan&#160;1,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Forfeited /</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in euros)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Granted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Vested</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Lapsed</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AGA&#160;- Plan 2021 - 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">04/16/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 297,599</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (296,166)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,433)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AGA&#160;- Plan 2021 - bis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/08/2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,215</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (65,215)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AGA 2023-1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/25/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 300,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 300,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 600,000</p></td></tr><tr><td style="vertical-align:bottom;width:26.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">AGA 2023-2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/15/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 748,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23,350)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 724,650</p></td></tr><tr><td style="vertical-align:bottom;width:26.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TOTAL free shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,410,814</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 300,000</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (361,381)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (24,783)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,324,650</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_LongTermIncentivePlanInPerformanceUnits2023Member', window );">PAGUP 2023</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Schedule of movements in BSPCE and BSA share warrants and Bonus shares</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of January 1, 2024, one performance units plan was outstanding: PAGUP 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">No performance units award plan has been attributed in the first six months of 2024.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:29.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reference</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price (in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at&#160;Jan&#160;1,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">at&#160;June&#160;30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">euros)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issued</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercised</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Convert AGA</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PAGUP 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/25/2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 300,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (300,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:29.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TOTAL PAGUP</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 300,000</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (300,000)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Share capital [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35K<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35K&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other current assets. [Refer: Other current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other current liabilities. [Refer: Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the reconciliation of the summarised financial information of an associate accounted for using the equity method to the carrying amount of the reporting entity's interest in the associate. [Refer: Carrying amount [member]; Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B14<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B14_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DisclosureOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DisclosureOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DisclosureOfChangesInBorrowingsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of changes in borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DisclosureOfChangesInBorrowingsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about change in the provision recorded in respect of defined benefit schemes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about expense recognized in the statement of income (loss) for Retirement Benefit Obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DisclosureOfOtherNoncurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of other non current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DisclosureOfOtherNoncurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about provision recorded in respect of defined benefit schemes at the end of each reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for trade payables and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DisclosureOfTradeReceivablesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of trade receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DisclosureOfTradeReceivablesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of valuation approach for BSA share-based payment arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_BspceAndBsaShareWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_BspceAndBsaShareWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewBonusShareAwardPlan20231Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewBonusShareAwardPlan20231Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_LongTermIncentivePlanInPerformanceUnits2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_LongTermIncentivePlanInPerformanceUnits2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232120391216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of (income) loss (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ComponentsOfIncomeStatementAbstract', window );"><strong>Notes to the interim condensed consolidated statement of (income) loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_RevenueAndOtherIncomeTableTextBlock', window );">Schedule of revenues and other income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Operating income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,901</p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 41</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,901</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,630</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,631</p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Subsidies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,087</p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,693</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,721</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total revenue and other income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,734</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 6,622</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ResearchAndDevelopmentMarketingTableTextBlock', window );">Schedule of research and development, marketing</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Research&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Marketing&#160;&#8211;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">General&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six months ended June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Business</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">administrative</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Disposables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (887)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (887)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Energy and liquids</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (447)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (447)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Patents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (643)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (643)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Studies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34,073)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34,073)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Maintenance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (526)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (526)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (118)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,675)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,795)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">IT systems</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (405)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (444)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Support costs (including taxes)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (375)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (375)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Personnel costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,637)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (153)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,600)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,391)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation, amortization and provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,732)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (122)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,854)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Insurances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (921)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (921)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (352)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (437)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (975)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,764)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (46,822)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (598)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (7,701)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (55,122)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Research&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Marketing&#160;&#8211;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">General&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six months ended June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Business</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">administrative</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">en milliers d'euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Disposables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (943)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (943)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Energy and liquids</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (479)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (479)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Patents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (257)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (257)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Studies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (42,847)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (42,847)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Maintenance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (459)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (459)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (61)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,884)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,945)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">IT systems</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (440)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (50)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (498)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Support costs (including taxes)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (343)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (343)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Personnel costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,065)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (126)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,347)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,538)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Depreciation, amortization and provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,061)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (104)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,166)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Insurances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,121)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,121)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Other operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (450)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (570)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (964)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,985)</p></td></tr><tr><td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (54,062)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (705)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (6,812)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (61,580)</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_PersonnelCostsAndHeadcount', window );">Schedule of personnel costs and headcount</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Marketing - </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Research and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Business</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">General and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six months ended June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">administrative</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Wages, salaries and similar costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,824)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (120)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,237)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,181)</p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,312)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (563)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,886)</p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provisions for retirement benefit obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (35)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (86)</p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,450)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (765)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,238)</p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total personnel costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (7,637)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (153)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (2,600)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (10,391)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Marketing -</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Research and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Business</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">General and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">development</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> administrative</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Wages, salaries and similar costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,399)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (104)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,191)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (5,694)</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payroll taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,222)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (476)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,708)</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provisions for retirement benefit obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (61)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (90)</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,383)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (650)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (2,046)</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total personnel costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (7,065)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (126)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (2,347)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (9,538)</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock', window );">Schedule of other operating income and expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other operating income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 160</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (22)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (44)</p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other operating income and expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 138</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (44)</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_FinancialIncomeAndExpensesTableTextBlock', window );">Schedule of financial income and expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income from cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 430</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 564</p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign exchange gains</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 157</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 187</p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gain on fair value variation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,623</p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 9,093</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,373</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,218)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,941)</p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign exchange losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (323)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (683)</p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other financial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (46)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23)</p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (5,586)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (2,646)</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net financial income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,507</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (273)</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock', window );">Schedule of share of net profit - Equity method</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:98.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands of euros)</i> <b style="font-weight:bold;">For the period started January 1, 2024, to June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Research and development costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (51)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,475)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net operating loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (1,526)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Financial income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Financial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net financial income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 17</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Income (expense) tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss for the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (1,509)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exchange difference on translation of foreign operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (1,964)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Items that will be reclassified subsequently to profit or loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (3,473)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total comprehensive loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (3,473)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Group's share in </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Share of net profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Elimination of downstream sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (66)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Share of net profit - Equity method</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 168</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Schedule of basic and diluted loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss for the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (49,029)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (55,269)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average number of shares outstanding used to calculate basic/diluted loss per share<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51,982,093</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,044,796</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Basic/diluted loss per share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (0.94)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1.31)</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><i style="font-style:italic;">In accordance with IAS 33.19, basic/diluted earnings per share exclude treasury shares held by the Group as of June 30, 2024 and 2023</i>.</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_ComponentsOfIncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_ComponentsOfIncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of other operating income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of share of profit loss of associates and joint ventures accounted for using equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_FinancialIncomeAndExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of financial income and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_FinancialIncomeAndExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_PersonnelCostsAndHeadcount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Personnel costs and headcount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_PersonnelCostsAndHeadcount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_ResearchAndDevelopmentMarketingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of Research and Development, Marketing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_ResearchAndDevelopmentMarketingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_RevenueAndOtherIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue and other income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_RevenueAndOtherIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232124666432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other financial information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_OtherFinancialInformationAbstract', window );"><strong>Other financial information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory', window );">Schedule of commitments given and received</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">In thousands of euros</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CRO<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 175,461</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 183,366</p></td></tr><tr><td style="vertical-align:bottom;width:71.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CMO</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,733</p></td></tr><tr><td style="vertical-align:bottom;width:71.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,592</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,595</p></td></tr><tr><td style="vertical-align:bottom;width:71.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,442</p></td></tr><tr><td style="vertical-align:bottom;width:71.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total commitments given</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 210,261</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 221,136</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agreements concerning the provision of facilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 260</p></td></tr><tr><td style="vertical-align:bottom;width:71.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total commitments received</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 296</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 260</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><i style="font-style:italic;">Including CRO with Pharmaceutical Research Associates B.V.</i></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 86<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_86&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_OtherFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_OtherFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232119481184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company information - (Details)<br> &#8364; / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 16, 2024 </div>
<div>item</div>
</th>
<th class="th">
<div>Mar. 18, 2024 </div>
<div>EUR (&#8364;) </div>
<div>g</div>
</th>
<th class="th">
<div>Feb. 01, 2024 </div>
<div>item</div>
</th>
<th class="th">
<div>Jan. 18, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 04, 2024 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 11, 2023 </div>
<div>&#165; / shares</div>
</th>
<th class="th">
<div>Oct. 11, 2023 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>item</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th">
<div>Jan. 18, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 18, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 18, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 26, 2023</div></th>
<th class="th">
<div>May 16, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Loan obtained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 24,911,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Total amount of loan | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankMember', window );">Finance contract with EIB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Loan obtained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Total amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 50,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember', window );">Finance contract with EIB, first tranche (Tranche A)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Loan obtained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember', window );">Finance contract with EIB, second tranche (Tranche B)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Loan obtained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares underlying in EIB | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,144,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember', window );">Indication of continuation of recruitment for Phase III trial NATiV3 of lanifibranor in non-cirrhotic NASH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_MaximumDurationOfClinicalTrial', window );">Maximum duration of Phase III trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">840 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NumberOfBiopsiesUnderClinicalTrials', window );">Number of Biopsies Under the Phase III trial | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NumberOfWeeksUnderActiveTreatmentExtensionStudy', window );">Number of weeks under the active treatment extension study</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">336 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_LicensingAgreementWithHepalysMember', window );">Licensing agreement with Hepalys</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_LicenseAndCollaborationAgreementUpfrontFeeReceivable', window );">Upfront payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 9,500,000<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones', window );">Maximum milestone payments receivable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_LicensingAgreementWithHepalysMember', window );">Licensing agreement with Hepalys | Hepalys Pharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_OptionToAcquireSharesInCompanyPercentage', window );">Percent of acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare', window );">Purchase of interests in investments accounted for using equity method, price per share | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 300<span></span>
</td>
<td class="nump">&#8364; 1.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember', window );">Phase II clinical trial evaluating lanifibranor in patients with T2D and nonalcoholic fatty liver disease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy', window );">Demonstrated reduction of hepatic fat measured by proton magnetic resonance spectroscopy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DailyDoseOfLanifibranorInTrial', window );">Daily dose of lanifibranor in trial | g</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d', window );">Percentage reduction in results on treatments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.14%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff', window );">Reduction in hepatic steatosis (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_PercentageOfPatientsTreatedInTrial', window );">Percentage of patients treated in trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DemonstratedSignificantRelativeReductionInVatSatRatioInPatients', window );">Significant relative reduction in VAT/SAT ratio (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember', window );">Combination of lanifibranor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NumberOfPatientsRandomizedClinicalTrialMainCohort', window );">Number of patients in main cohort</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DailyDoseOfLanifibranorInTrial', window );">Daily dose of lanifibranor in trial | g</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DailyDoseOfEmpagliflozinInTrial', window );">Daily dose of empagliflozin in trial | g</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d', window );">Percentage reduction in results on treatments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff', window );">Reduction in hepatic steatosis (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_PercentageOfPatientsTreatedInTrial', window );">Percentage of patients treated in trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DemonstratedSignificantRelativeReductionInVatSatRatioInPatients', window );">Significant relative reduction in VAT/SAT ratio (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_TreatmentPeriodUnderStudy', window );">Treatment period under study</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">168 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember', window );">Phase II Clinical Trial Evaluating Placebo In Patients With MASH/NASH And T2D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy', window );">Demonstrated reduction of hepatic fat measured by proton magnetic resonance spectroscopy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d', window );">Percentage of increase observed in the placebo arm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.26%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff', window );">Reduction in hepatic steatosis (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DemonstratedSignificantRelativeReductionInVatSatRatioInPatients', window );">Significant relative reduction in VAT/SAT ratio (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NumberOfPatientsRandomizedForTreatment', window );">Number of patients randomized | item</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember', window );">Phase II Clinical Trial Evaluating Placebo In Patients With MASH/NASH And T2D | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NumberOfPatientsToBeTreatedForFortyEightWeeks', window );">Number of patients to be treated for 48 weeks | item</a></td>
<td class="nump">360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NumberOfPatientsToBeTreatedForSeventyTwoWeeks', window );">Number of patients to be treated for 72 weeks | item</a></td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember', window );">NATiV3 Phase III clinical trial | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_TreatmentPeriodUnderStudy', window );">Treatment period under study</a></td>
<td class="text">504 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember', window );">NATiV3 Phase III clinical trial | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_TreatmentPeriodUnderStudy', window );">Treatment period under study</a></td>
<td class="text">336 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DailyDoseOfEmpagliflozinInTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of daily dosage of empagliflozin in the trial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DailyDoseOfEmpagliflozinInTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:massItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DailyDoseOfLanifibranorInTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Daily dose of lanifibranor in trial</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DailyDoseOfLanifibranorInTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:massItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of increase of Hemoglobin in patients with MASH and T2D.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of reduction in Hemoglobin among  patients with MASH and T2D.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Demonstrated reduction of hepatic fat measured by proton magnetic resonance spectroscopy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of reduction in Hepatic Steatosis measured by MRI-PDFF.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DemonstratedSignificantRelativeReductionInVatSatRatioInPatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of significant relative reduction in VAT / SAT ratio in patients.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DemonstratedSignificantRelativeReductionInVatSatRatioInPatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum additional amount receivable by the entity, upon the achievement of certain milestones, pursuant to licensing and collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_LicenseAndCollaborationAgreementUpfrontFeeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront fee receivable by the entity, pursuant to licensing and collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_LicenseAndCollaborationAgreementUpfrontFeeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_MaximumDurationOfClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum duration of the clinical trial of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_MaximumDurationOfClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NumberOfBiopsiesUnderClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents the  number of clinical trial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NumberOfBiopsiesUnderClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NumberOfPatientsRandomizedClinicalTrialMainCohort">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of subjects randomized for main cohort.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NumberOfPatientsRandomizedClinicalTrialMainCohort</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NumberOfPatientsRandomizedForTreatment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of patients randomized for treatment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NumberOfPatientsRandomizedForTreatment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NumberOfPatientsToBeTreatedForFortyEightWeeks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of patients to be treated for 48 weeks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NumberOfPatientsToBeTreatedForFortyEightWeeks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NumberOfPatientsToBeTreatedForSeventyTwoWeeks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of patients to be treated for 72 weeks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NumberOfPatientsToBeTreatedForSeventyTwoWeeks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NumberOfWeeksUnderActiveTreatmentExtensionStudy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of weeks under the active treatment extension study of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NumberOfWeeksUnderActiveTreatmentExtensionStudy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_OptionToAcquireSharesInCompanyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option to acquire shares in company, percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_OptionToAcquireSharesInCompanyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_PercentageOfPatientsTreatedInTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of patients treated in this trial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_PercentageOfPatientsTreatedInTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of interests in investments accounted for using equity method, price per share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_TreatmentPeriodUnderStudy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treatment period under study</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_TreatmentPeriodUnderStudy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_LicensingAgreementWithHepalysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_LicensingAgreementWithHepalysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=iva_HepalysPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=iva_HepalysPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232117766624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company information - Significant events in the first half of 2024 (Details)<br> &#8364; / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 18, 2024</div></th>
<th class="th">
<div>Jan. 18, 2024 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 04, 2024 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 03, 2024 </div>
<div>&#8364; / shares</div>
</th>
<th class="th"><div>Dec. 08, 2022</div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 07, 2024 </div>
<div>site</div>
</th>
<th class="th">
<div>Jan. 18, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 28, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 16, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Subscription of borrowings and warrants net of transaction cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 24,911,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankMember', window );">Finance contract with EIB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised', window );">Percentage of share capital held by counterparty if all outstanding warrants are exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Subscription of borrowings and warrants net of transaction cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember', window );">Finance contract with EIB, first tranche (Tranche A)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Subscription of borrowings and warrants net of transaction cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares per instrument | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.20<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsDebtInstrumentTerm', window );">Maturity term after the disbursement of the tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments', window );">Aggregate amount to be received under the conditions precedent to the EIB Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember', window );">Finance contract with EIB, first tranche (Tranche A) | Financial liabilities at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember', window );">Finance contract with EIB, second tranche (Tranche B)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NumberOfWarrantsIssued', window );">Number of warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,144,654<span></span>
</td>
<td class="nump">3,144,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants', window );">Percentage of company's share capital outstanding, issued as warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.07%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise price of warrant | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.95<span></span>
</td>
<td class="nump">&#8364; 3.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares', window );">Exercise price of warrants as a percentage of volume-weighted average price of the Company's shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_WarrantsTerm', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_SharesIssuableUponExerciseOfWarrants', window );">Shares issuable upon exercise of warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,144,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_MaximumGrossProceedsReceivableUponExerciseOfWarrants', window );">Maximum gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12,421,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Subscription of borrowings and warrants net of transaction cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares per instrument | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsDebtInstrumentTerm', window );">Maturity term after the disbursement of the tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments', window );">Aggregate amount to be received under the conditions precedent to the EIB Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction', window );">Minimum upfront payments for out-licensing, partnership or royalty transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember', window );">Finance contract with EIB, second tranche (Tranche B) | Financial liabilities at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_WarrantAgreementWithEuropeanInvestmentBankMember', window );">Warrant agreement with the European Investment Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ClassOfWarrantOrRightMaturityTerm', window );">Maturity term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember', window );">NATiV3 Phase III trial of lanifibranor in non-cirrhotic NASH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NumberOfSitesOperatingUnderCentralIrbOverseeing', window );">Number of sites operating under central IRB overseeing | site</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_PercentageOfPatientsRandomizedInMainCohort', window );">Percentage of patients randomized in the main cohort</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember', window );">LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_TreatmentPeriodUnderStudy', window );">Treatment period under study</a></td>
<td class="text">168 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_DrawdownOfBorrowingsMember', window );">Drawdown of borrowings | Finance contract with EIB, second tranche (Tranche B)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsDebtInstrumentTerm', window );">Maturity term after the disbursement of the tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount to be received by the company, either in exchange for new shares of the Company or through the receipt of upfront or milestone payments, pursuant to the debt arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price of warrants issued, represented as a percentage of volume-weighted average price of the Company's shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_ClassOfWarrantOrRightMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity term of the warrants issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_ClassOfWarrantOrRightMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsDebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsDebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_MaximumGrossProceedsReceivableUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum gross proceeds from receivable upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_MaximumGrossProceedsReceivableUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of minimum upfront payments for out-licensing, partnership or royalty transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NumberOfSitesOperatingUnderCentralIrbOverseeing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of sites operating under central IRB overseeing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NumberOfSitesOperatingUnderCentralIrbOverseeing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Company's share capital outstanding, issued as warrants by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_PercentageOfPatientsRandomizedInMainCohort">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of patients randomized in the main cohort</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_PercentageOfPatientsRandomizedInMainCohort</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of share capital held by counterparty if all outstanding warrants are exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_SharesIssuableUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issuable upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_SharesIssuableUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_TreatmentPeriodUnderStudy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treatment period under study</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_TreatmentPeriodUnderStudy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_WarrantsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_WarrantsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_WarrantAgreementWithEuropeanInvestmentBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_WarrantAgreementWithEuropeanInvestmentBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_DrawdownOfBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_DrawdownOfBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232117093072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation and statement of compliance - Significant Investments In Subsidiaries (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>entity</div>
</th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>General principles and statement of compliance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NumberOfEntitiesBeingConsolidated', window );">Number of entities being consolidated | entity</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=iva_HepalysPharmaIncMember', window );">Hepalys Pharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>General principles and statement of compliance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Proportion of ownership interest</a></td>
<td class="nump">14.64%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=iva_InventivaIncMember', window );">Inventiva Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>General principles and statement of compliance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Percent of ownership interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncontrollingInterests', window );">Non-controlling interest | &#8364;</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 12<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_12_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 10<br> -IssueDate 2023-01-01<br> -Paragraph 22<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=10&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_22&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph q<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_q&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NumberOfEntitiesBeingConsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of entities being consolidated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NumberOfEntitiesBeingConsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=iva_HepalysPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=iva_HepalysPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=iva_InventivaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=iva_InventivaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232119243456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation and statement of compliance - Foreign Exchange Rates (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>&#8364; / $</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>&#8364; / $</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / &#8364;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ForeignExchangeRatesAbstract', window );"><strong>Exchange rate (USD per EUR)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average exchange rate for the period</a></td>
<td class="nump">1.0813<span></span>
</td>
<td class="nump">1.0807<span></span>
</td>
<td class="nump">1.0803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Exchange rate at period end</a></td>
<td class="nump">1.0705<span></span>
</td>
<td class="nump">1.0866<span></span>
</td>
<td class="nump">1.1050<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClosingForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClosingForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ForeignExchangeRatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ForeignExchangeRatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232131031648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounting Principles - Fair value measurement (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Foreign currency forwards contract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">&#8364; 109,998<span></span>
</td>
<td class="nump">&#8364; 91,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember', window );">Financial assets carried at fair value through profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Foreign currency forwards contract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">13,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 | Financial liabilities carried at fair value through profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Foreign currency forwards contract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 | Financial liabilities carried at fair value through profit or loss | Long-term financial debt - derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Foreign currency forwards contract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">13,569<span></span>
</td>
<td class="nump">&#8364; 10,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 | Financial assets carried at fair value through profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Foreign currency forwards contract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">&#8364; 13,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=iva_LongTermFinancialDebtDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=iva_LongTermFinancialDebtDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232120479552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounting principles - Going concern (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_AccountingPrinciplesAbstract', window );"><strong>Accounting Principles</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">&#8364; 10,147<span></span>
</td>
<td class="nump">&#8364; 26,918<span></span>
</td>
<td class="nump">&#8364; 31,240<span></span>
</td>
<td class="nump">&#8364; 86,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank overdrafts inclusive of cash and cash equivalents</a></td>
<td class="nump">&#8364; 1,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that has been withdrawn from an account in excess of existing cash balances. This is considered a short-term extension of credit by the bank. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BankOverdraftsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_AccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_AccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232120020080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Intangible assets (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at the beginning</a></td>
<td class="nump">&#8364; 541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at the end</a></td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at the beginning</a></td>
<td class="nump">3,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at the end</a></td>
<td class="nump">3,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at the beginning</a></td>
<td class="num">(3,384)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Balance at the end</a></td>
<td class="num">&#8364; (3,496)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232118866160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Property, plant, and equipment (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Balance at the beginning</a></td>
<td class="nump">&#8364; 9,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Balance at the end</a></td>
<td class="nump">7,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Depreciation and impairment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Balance at the beginning</a></td>
<td class="num">(10,714)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Balance at the end</a></td>
<td class="num">(12,396)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember', window );">Property, plant and equipment in progress | Gross</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Balance at the beginning</a></td>
<td class="nump">19,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets', window );">Balance at the end</a></td>
<td class="nump">&#8364; 20,376<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant and equipment including right-of-use assets whose underlying assets would be presented as property, plant and equipment if they were owned. [Refer: Property, plant and equipment; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232117712576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Property, plant, and equipment - Additional Information (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInPropertyPlantAndEquipment', window );">Increase in net value of property, plant and equipment</a></td>
<td class="nump">&#8364; 0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IncreasesInPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_RightofuseAssetsMember', window );">Right of use</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IncreasesInPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iva_FibroscanMachinesMember', window );">Fibroscan machines</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IncreasesInPropertyPlantAndEquipment', window );">Increases</a></td>
<td class="nump">&#8364; 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IncreasesInPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increases in property, plant and equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IncreasesInPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_RightofuseAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_RightofuseAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iva_FibroscanMachinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iva_FibroscanMachinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232230167792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Investments accounted for using the equity method - Additional Information (Details) - Hepalys Pharma, Inc [Member] - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 15, 2024</div></th>
<th class="th"><div>Oct. 11, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Investments accounted for using the equity method</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NumberOfSharesAcquiredInAssociate', window );">Number of shares acquired in associate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Capital increase</a></td>
<td class="nump">&#8364; 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Group's share in %</a></td>
<td class="nump">14.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.60%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NumberOfSharesAcquiredInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares acquired in associate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NumberOfSharesAcquiredInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=iva_HepalysPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=iva_HepalysPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232116732112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Investments accounted for using the equity method - investment in Hepalys accounted for using equity method of accounting (Details) - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 15, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Investments accounted for using the equity method</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 451,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 541,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,554,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,696,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,147,000<span></span>
</td>
<td class="nump">&#8364; 31,240,000<span></span>
</td>
<td class="nump">26,918,000<span></span>
</td>
<td class="nump">&#8364; 86,736,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,426,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,561,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Capital stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">521,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarningsProfitLossForReportingPeriod', window );">Net loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,029,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(110,426,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Shareholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(79,060,000)<span></span>
</td>
<td class="num">(7,667,000)<span></span>
</td>
<td class="num">(32,032,000)<span></span>
</td>
<td class="nump">45,476,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,434,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,583,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,679,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,834,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,146,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,158,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total equity and liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,426,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,561,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at the beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,032,000)<span></span>
</td>
<td class="nump">45,476,000<span></span>
</td>
<td class="nump">45,476,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,029,000)<span></span>
</td>
<td class="num">(55,269,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at the end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(79,060,000)<span></span>
</td>
<td class="num">(7,667,000)<span></span>
</td>
<td class="num">(32,032,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,131,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=iva_HepalysPharmaIncMember', window );">Hepalys Pharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Investments accounted for using the equity method</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Group's share in %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.64%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod', window );">Group's share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,813,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,267,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IntercompanyEliminationsInAssociates', window );">Elimination of unrealised profit on downstream sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,718,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,881,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,131,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=iva_HepalysPharmaIncMember', window );">Hepalys Pharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Investments accounted for using the equity method</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,217,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,278,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NonCurrentAssetsExcludingDeferredAssets', window );">Total non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,217,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,278,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,997,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,082,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_CurrentAssetsExcludingDeferredAssets', window );">Total current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,015,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DeferredAssets', window );">Deferred assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,233,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,444,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Capital stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">523,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CapitalReserve', window );">Capital reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,379,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,655,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_CapitalSurplusOthers', window );">Capital surplus-others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">774,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod', window );">Earnings brought forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,018,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(178,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarningsProfitLossForReportingPeriod', window );">Net loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,444,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,111,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Treasury Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(812,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Shareholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,214,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,194,000<span></span>
</td>
<td class="nump">&#8364; 22,645,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total equity and liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,233,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,444,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at the beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,194,000<span></span>
</td>
<td class="nump">&#8364; 22,645,000<span></span>
</td>
<td class="nump">22,645,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,509,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(879,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,964,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IncreaseDecreaseThroughCapitalVariations', window );">Capital variations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,566,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(819,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at the end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 19,214,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 21,194,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Group's share in %</a></td>
<td class="nump">14.60%<span></span>
</td>
<td class="nump">14.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the capital reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2023-01-01<br> -Paragraph 135<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=36&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_135_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2023-01-01<br> -Paragraph B67<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=3&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B67_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity&#8217;s cumulative undistributed earnings or deficit excluding the profit or loss for the reporting period. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarningsProfitLossForReportingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity&#8217;s undistributed profit or loss for the reporting period. [Refer: Retained earnings; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarningsProfitLossForReportingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An entity&#8217;s own equity instruments, held by the entity or other members of the consolidated group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_CapitalSurplusOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the capital surplus-others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_CapitalSurplusOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_CurrentAssetsExcludingDeferredAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current assets excluding deferred assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_CurrentAssetsExcludingDeferredAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DeferredAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DeferredAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's share of net assets in investments accounted for using the equity method</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IncreaseDecreaseThroughCapitalVariations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) through capital variations, equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IncreaseDecreaseThroughCapitalVariations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IntercompanyEliminationsInAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intercompany eliminations in associates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IntercompanyEliminationsInAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NonCurrentAssetsExcludingDeferredAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-current assets excluding deferred assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NonCurrentAssetsExcludingDeferredAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=iva_HepalysPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=iva_HepalysPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=iva_HepalysPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=iva_HepalysPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232123638144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Other non-current assets (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NonCurrentLongTermDepositsFromCustomers', window );">Longterm deposit accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 9,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NonCurrentAdvancesToSuppliers', window );">Advance payments - non-current</a></td>
<td class="nump">&#8364; 1,047<span></span>
</td>
<td class="nump">1,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NonCurrentSecurityDeposits', window );">Security deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other noncurrent assets</a></td>
<td class="nump">&#8364; 1,047<span></span>
</td>
<td class="nump">&#8364; 10,055<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NonCurrentAdvancesToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount represents the non current advances of suppliers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NonCurrentAdvancesToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NonCurrentLongTermDepositsFromCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents information about non current long term deposits from customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NonCurrentLongTermDepositsFromCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NonCurrentSecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current amount of security deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NonCurrentSecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232120392960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Other non-current assets - Long-term deposit accounts (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_OtherNonCurrentAssetsLineItems', window );"><strong>Other Non Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IncreaseDecreaseInLongTermDepositAccounts', window );">Increase (decrease) in long-term deposit accounts</a></td>
<td class="nump">&#8364; 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermDeposits', window );">Long-term deposits</a></td>
<td class="nump">&#8364; 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_LongTermDepositsTerm', window );">Period of long-term deposit</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NonCurrentAdvancesToSuppliers', window );">Non-current advances to suppliers</a></td>
<td class="nump">&#8364; 1,047<span></span>
</td>
<td class="nump">&#8364; 1,047<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember', window );">Contract CRO with Pharmaceutical Research Associates B.V.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_OtherNonCurrentAssetsLineItems', window );"><strong>Other Non Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NonCurrentAdvancesToSuppliers', window );">Non-current advances to suppliers</a></td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of long-term deposits held by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IncreaseDecreaseInLongTermDepositAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in long-term deposit accounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IncreaseDecreaseInLongTermDepositAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_LongTermDepositsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of the long-term deposits of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_LongTermDepositsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NonCurrentAdvancesToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount represents the non current advances of suppliers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NonCurrentAdvancesToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_OtherNonCurrentAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_OtherNonCurrentAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232123624256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Inventories (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ScheduleOfInventoryDisclosureLineItems', window );"><strong>Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">&#8364; 393<span></span>
</td>
<td class="nump">&#8364; 417<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Laboratory inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ScheduleOfInventoryDisclosureLineItems', window );"><strong>Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember', window );">Inventories write-down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ScheduleOfInventoryDisclosureLineItems', window );"><strong>Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="num">&#8364; (9)<span></span>
</td>
<td class="num">&#8364; (9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_ScheduleOfInventoryDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_ScheduleOfInventoryDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232124466416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets - Trade Receivables (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems', window );"><strong>Trade receivables, tax receivables and other current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade receivables</a></td>
<td class="nump">&#8364; 809<span></span>
</td>
<td class="nump">&#8364; 3,807<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanThreeMonthsMember', window );">3 months or less</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems', window );"><strong>Trade receivables, tax receivables and other current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade receivables</a></td>
<td class="nump">&#8364; 809<span></span>
</td>
<td class="nump">&#8364; 3,807<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanThreeMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanThreeMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232122308432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets- Other Current Assets and Receivables (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems', window );"><strong>Trade receivables, tax receivables and other current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_CirAndOtherResearchTaxCreditsReceivable', window );">CIR and other research tax credits receivable</a></td>
<td class="nump">&#8364; 2,657<span></span>
</td>
<td class="nump">&#8364; 5,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_OtherCurrentTaxReceivables', window );">Other</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssetsCurrent', window );">Tax receivables</a></td>
<td class="nump">2,704<span></span>
</td>
<td class="nump">5,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">7,039<span></span>
</td>
<td class="nump">4,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ShortTermDepositAccountsCurrent', window );">Short-term deposit accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets', window );">Current accrued income</a></td>
<td class="nump">1,687<span></span>
</td>
<td class="nump">1,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_CashUnderLiquidityAgreementCurrent', window );">Liquidity agreement - Cash</a></td>
<td class="nump">289<span></span>
</td>
<td class="nump">422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_SalesTaxReceivableCurrent', window );">Sales tax receivable</a></td>
<td class="nump">3,311<span></span>
</td>
<td class="nump">5,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">2,229<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">14,554<span></span>
</td>
<td class="nump">11,696<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_OtherCurrentAssetsAndReceivables', window );">Other current assets and receivables</a></td>
<td class="nump">17,258<span></span>
</td>
<td class="nump">&#8364; 17,048<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LicensingAndCollaborationAgreementWithCttqMember', window );">Licensing and collaboration agreement with CTTQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems', window );"><strong>Trade receivables, tax receivables and other current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets', window );">Current accrued income</a></td>
<td class="nump">&#8364; 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued income including current contract assets. [Refer: Accrued income including contract assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax assets. [Refer: Current tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_CashUnderLiquidityAgreementCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash under liquidity agreement, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_CashUnderLiquidityAgreementCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_CirAndOtherResearchTaxCreditsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of CIR and other research tax credits receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_CirAndOtherResearchTaxCreditsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_OtherCurrentAssetsAndReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other current assets and receivables as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_OtherCurrentAssetsAndReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_OtherCurrentTaxReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other tax receivables, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_OtherCurrentTaxReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_SalesTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of sales tax receivables, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_SalesTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_ShortTermDepositAccountsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short term deposits accounts, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_ShortTermDepositAccountsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LicensingAndCollaborationAgreementWithCttqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LicensingAndCollaborationAgreementWithCttqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232123678480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets - Additional Information (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IncreaseDecreaseInShortTermDepositAccounts', window );">Increase in short-term deposit accounts</a></td>
<td class="nump">&#8364; 2.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_CurrentTaxCreditResearchCurrentYear', window );">Receivable for current year</a></td>
<td class="nump">2.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IncreaseDecreaseInTradeAndOtherCurrentReceivables', window );">Trade receivables decreased</a></td>
<td class="num">&#8364; (3.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_CurrentTradeReceivablesAveragePaymentPeriod', window );">Average payment period for trade receivables</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_CurrentTaxCreditResearchCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax credit research from current year, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_CurrentTaxCreditResearchCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_CurrentTradeReceivablesAveragePaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the average payment period for trade receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_CurrentTradeReceivablesAveragePaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IncreaseDecreaseInShortTermDepositAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in short-term deposit accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IncreaseDecreaseInShortTermDepositAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IncreaseDecreaseInTradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in trade and other current receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IncreaseDecreaseInTradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232123587088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Cash and cash equivalents (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Other cash equivalents</a></td>
<td class="nump">&#8364; 10,273<span></span>
</td>
<td class="nump">&#8364; 17,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash at bank and at hand</a></td>
<td class="nump">1,212<span></span>
</td>
<td class="nump">8,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents', window );">Bank overdrafts</a></td>
<td class="num">(1,338)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">&#8364; 10,147<span></span>
</td>
<td class="nump">&#8364; 26,918<span></span>
</td>
<td class="nump">&#8364; 31,240<span></span>
</td>
<td class="nump">&#8364; 86,736<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BankOverdraftsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that has been withdrawn from an account in excess of existing cash balances. This is considered a short-term extension of credit by the bank. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BankOverdraftsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232122483232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Share capital (Details) - EUR (&#8364;)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Issued capital</a></td>
<td class="nump">&#8364; 524,772<span></span>
</td>
<td class="nump">&#8364; 521,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of fully authorized, subscribed and paid up shares</a></td>
<td class="nump">52,477,188<span></span>
</td>
<td class="nump">52,115,807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Nominal value</a></td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232130960736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Changes in share capital (Details) - EUR (&#8364;)<br></strong></div></th>
<th class="th"><div>Mar. 25, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Shareholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (79,060,000)<span></span>
</td>
<td class="num">&#8364; (32,032,000)<span></span>
</td>
<td class="num">&#8364; (7,667,000)<span></span>
</td>
<td class="nump">&#8364; 45,476,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,477,188<span></span>
</td>
<td class="nump">52,115,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Nominal value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Increase (decrease) in number of shares outstanding</a></td>
<td class="nump">361,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Shareholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 524,772<span></span>
</td>
<td class="nump">&#8364; 521,158<span></span>
</td>
<td class="nump">421,000<span></span>
</td>
<td class="nump">421,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Nominal value</a></td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of ordinary shares</a></td>
<td class="nump">&#8364; 3,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Premiums related to share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Shareholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 201,858,649<span></span>
</td>
<td class="nump">&#8364; 201,862,263<span></span>
</td>
<td class="nump">&#8364; 173,886,000<span></span>
</td>
<td class="nump">&#8364; 173,886,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of ordinary shares</a></td>
<td class="num">&#8364; (3,614)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232122025792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Liquidity agreement (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_LiquidityAgreementTerm', window );">Liquidity agreement term</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_LiquidityAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of days used to determine liquidity agreement term  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_LiquidityAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232123576656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Options and share warrants (BSA and BSPCE) (Details) - &#8364; / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_BsaShareWarrantsMember', window );">BSA share warrants | Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_WarrantsSubscriptionPrice', window );">Subscription price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_BsaShareWarrantsMember', window );">BSA share warrants | Service providers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_WarrantsSubscriptionPrice', window );">Subscription price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_BsaShareWarrantsMember', window );">BSA share warrants | David Nikodem</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_WarrantsSubscriptionPrice', window );">Subscription price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.45<span></span>
</td>
<td class="nump">&#8364; 0.29<span></span>
</td>
<td class="nump">&#8364; 0.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bsa20231ShareWarrantPlanMember', window );">BSA 2023 plan | David Nikodem</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_WarrantsSubscriptionPrice', window );">Subscription price per share</a></td>
<td class="nump">&#8364; 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Exercise price</a></td>
<td class="nump">2.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bsa20232ShareWarrantPlanMember', window );">BSA- 2 2023 plan | David Nikodem</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_WarrantsSubscriptionPrice', window );">Subscription price per share</a></td>
<td class="nump">0.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Exercise price</a></td>
<td class="nump">&#8364; 3.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_WarrantsSubscriptionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The subscription price per warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_WarrantsSubscriptionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_BsaShareWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_BsaShareWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=iva_DirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=iva_DirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=iva_ServiceProvidersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=iva_ServiceProvidersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=iva_DavidNikodemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=iva_DavidNikodemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bsa20231ShareWarrantPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bsa20231ShareWarrantPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bsa20232ShareWarrantPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bsa20232ShareWarrantPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232117740736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Movements in BSPCE and BSA share warrants (in number of shares issuable upon exercise) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 25, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued | shares</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Ending balance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_BspceAndBsaShareWarrantsMember', window );">BSPCE and BSA Share Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">776,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">776,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of exercisable shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">746,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_BspcePlansMember', window );">BSPCE plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of exercisable shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bspce2021PlanMember', window );">BSPCE 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Exercise price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of exercisable shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_BsaPlansMember', window );">BSA plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of exercisable shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsClassOfWarrantOrRightOutstanding', window );">Number of share warrants outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bsa2017PlanMember', window );">BSA - 2017 plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Exercise price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of exercisable shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bsa2018PlanMember', window );">BSA - 2018 plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Exercise price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of exercisable shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewShareWarrantPlansBsa2019Member', window );">BSA 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Exercise price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of exercisable shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewShareWarrantPlansBsa2019BisMember', window );">BSA 2019 bis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Exercise price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of exercisable shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewShareWarrantPlansBsa2019TerMember', window );">BSA 2019 ter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Exercise price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of exercisable shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewBsa2021ShareWarrantPlanMember', window );">BSA 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Exercise price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Number of exercisable shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bsa20231ShareWarrantPlanMember', window );">BSA 2023 plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Exercise price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bsa20232ShareWarrantPlanMember', window );">BSA- 2 2023 plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Exercise price (in euros)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_BspceAndBsaShareWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_BspceAndBsaShareWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_BspcePlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_BspcePlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bspce2021PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bspce2021PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_BsaPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_BsaPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bsa2017PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bsa2017PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bsa2018PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bsa2018PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewShareWarrantPlansBsa2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewShareWarrantPlansBsa2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewShareWarrantPlansBsa2019BisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewShareWarrantPlansBsa2019BisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewShareWarrantPlansBsa2019TerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewShareWarrantPlansBsa2019TerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewBsa2021ShareWarrantPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewBsa2021ShareWarrantPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bsa20231ShareWarrantPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bsa20231ShareWarrantPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bsa20232ShareWarrantPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bsa20232ShareWarrantPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232118955952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Free share awards and Performance units (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 25, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 01, 2024 </div>
<div>plan</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NumberOfAwardPlansAttributed', window );">Number of plans attributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Capital increase arising from the vesting of bonus share awards | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,238,000<span></span>
</td>
<td class="nump">&#8364; 2,046,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense from share-based payment transactions | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_BonusShareAwardPlansMember', window );">Bonus share award plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,410,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised/Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(361,381)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited/ Lapsed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,783)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,324,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewBonusShareAwardPlanAga20211Member', window );">AGA 2021-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Stock price at grant date (in euros) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised/Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(296,166)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited/ Lapsed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,433)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewBonusShareAwardPlanAga2021BisMember', window );">AGA 2021-bis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Stock price at grant date (in euros) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised/Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewBonusShareAwardPlan20231Member', window );">AGA Plan 2023-1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Stock price at grant date (in euros) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Expense from share-based payment transactions | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewBonusShareAwardPlan20232Member', window );">AGA 2023-2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Stock price at grant date (in euros) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">748,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited/ Lapsed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">724,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_LongTermIncentivePlanInPerformanceUnitsMember', window );">PAGUP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NumberOfPlansOutstanding', window );">Number of award plans outstanding | plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NumberOfAwardPlansAttributed', window );">Number of plans attributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited/ Lapsed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_LongTermIncentivePlanInPerformanceUnits2023Member', window );">PAGUP 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Stock price at grant date (in euros) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited/ Lapsed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_LongTermIncentivePlanInPerformanceUnits2023Member', window );">PAGUP 2023 | Frederic Cren [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NumberOfSharesConverted', window );">Number of shares converted</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement', window );">Instruments lapsed</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Aga2021Aga2021BisMember', window );">AGA 2021 &amp; AGA 2021 bis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised/Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(361,381)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Capital increase arising from the vesting of bonus share awards | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,613.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePrice2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePrice2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NumberOfAwardPlansAttributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of award plans attributed during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NumberOfAwardPlansAttributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NumberOfPlansOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plans outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NumberOfPlansOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NumberOfSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents the information relating to number of shares converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NumberOfSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_BonusShareAwardPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_BonusShareAwardPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewBonusShareAwardPlanAga20211Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewBonusShareAwardPlanAga20211Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewBonusShareAwardPlanAga2021BisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewBonusShareAwardPlanAga2021BisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewBonusShareAwardPlan20231Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewBonusShareAwardPlan20231Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewBonusShareAwardPlan20232Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_NewBonusShareAwardPlan20232Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_LongTermIncentivePlanInPerformanceUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_LongTermIncentivePlanInPerformanceUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_LongTermIncentivePlanInPerformanceUnits2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_LongTermIncentivePlanInPerformanceUnits2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=iva_FredericCrenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=iva_FredericCrenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Aga2021Aga2021BisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Aga2021Aga2021BisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232123613088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Financial debt - Financial debt (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LoansReceived', window );">Bank borrowings</a></td>
<td class="nump">&#8364; 42,509<span></span>
</td>
<td class="nump">&#8364; 27,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities', window );">Derivatives instruments</a></td>
<td class="nump">13,569<span></span>
</td>
<td class="nump">10,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other loans and similar borrowings</a></td>
<td class="nump">4,302<span></span>
</td>
<td class="nump">3,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">5,761<span></span>
</td>
<td class="nump">6,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued', window );">Royalty certificates liabilities</a></td>
<td class="nump">7,263<span></span>
</td>
<td class="nump">6,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">&#8364; 73,404<span></span>
</td>
<td class="nump">&#8364; 54,083<span></span>
</td>
<td class="nump">&#8364; 44,390<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LoansReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of loans received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LoansReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current royalty certificates issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232121790416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Movements in the period break down (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Beginning balance</a></td>
<td class="nump">&#8364; 54,083<span></span>
</td>
<td class="nump">&#8364; 44,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments', window );">Subscription of derivatives instruments</a></td>
<td class="nump">11,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_Increaseinborrowingsthroughborrowingsreceived', window );">Subscription of bank borrowings</a></td>
<td class="nump">13,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_SubscriptionOfLeaseLiabilities', window );">Subscription of lease liabilities</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">3,706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IssueOfRoyaltyCertificates', window );">Issue of royalty certificates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities', window );">Repayment of lease liabilities</a></td>
<td class="num">(1,173)<span></span>
</td>
<td class="num">(1,612)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_InterestOnRoyaltyCertificates', window );">Issue of royalty certificates</a></td>
<td class="nump">936<span></span>
</td>
<td class="nump">1,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings', window );">Repayment of bank borrowings</a></td>
<td class="num">(1,177)<span></span>
</td>
<td class="num">(2,485)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IncreaseInBorrowingsThroughCapitalizedInterest', window );">Capitalized interests</a></td>
<td class="nump">3,961<span></span>
</td>
<td class="nump">3,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments', window );">Change in fair value of derivatives instruments</a></td>
<td class="num">(8,506)<span></span>
</td>
<td class="nump">389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates', window );">Exchange rate change</a></td>
<td class="nump">24<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Ending balance</a></td>
<td class="nump">&#8364; 73,404<span></span>
</td>
<td class="nump">&#8364; 54,083<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in borrowings through repayment of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in borrowings through repayments of bank borrowings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IncreaseInBorrowingsThroughCapitalizedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in borrowings through capitalized interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IncreaseInBorrowingsThroughCapitalizedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in borrowings through Subscription of derivatives instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase or decrease in borrowings due to change in fair value of derivatives instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase or decrease in borrowings due to exchange rate change.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_Increaseinborrowingsthroughborrowingsreceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in borrowings through borrowings received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_Increaseinborrowingsthroughborrowingsreceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_InterestOnRoyaltyCertificates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in borrowings through interests on royalty certificates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_InterestOnRoyaltyCertificates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IssueOfRoyaltyCertificates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase in borrowings through issue of royalty certificates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IssueOfRoyaltyCertificates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_SubscriptionOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of subscription of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_SubscriptionOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232122182288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Financial debt - French state-guaranteed loan ("PGE") and equity recovery loans ("PPR") (Details)<br> &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 18, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;) </div>
<div>loan</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>EUR (&#8364;) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th">
<div>Jan. 18, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Guarantee Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Loan obtained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 24,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Total amount of loan | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayments of borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,177<span></span>
</td>
<td class="nump">&#8364; 1,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember', window );">Loan agreements with syndicate of French banks, under stimulus economic plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Guarantee Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NumberOfLoanAgreements', window );">Number of loan agreements | loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Total amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember', window );">Loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Guarantee Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NumberOfLoanAgreements', window );">Number of loan agreements | loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_PercentageOfLoanGuaranteedByFrenchState', window );">Percentage of loan guaranteed by French state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=iva_EquityRecoveryLoansMember', window );">Equity recovery loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Guarantee Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_FinancingPeriodOfLoan', window );">Financing period of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_RepaymentPeriodOfLoan', window );">Repayment period for loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=iva_FinancingFromSyndicateOfFrenchBanksMember', window );">Financing from a syndicate of French banks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Guarantee Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NumberOfLoansObtainedGuaranteedByFrenchState', window );">Number of loans obtained guaranteed by the french state | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Loan obtained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_BorrowingsMaximumExtensionTerm', window );">Extension of term of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NumberOfLoanAgreements', window );">Number of loan agreements | loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayments of borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LicensingAndCollaborationAgreementWithCttqMember', window );">Licensing and collaboration agreement with CTTQ [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Guarantee Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_AmountInvoicedToCounterpartyForInitialPayment', window );">Amount invoiced to counterparty for milestone payment</a></td>
<td class="nump">&#8364; 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_AmountInvoicedToCounterpartyForInitialPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This amount represents the information of invoiced to counterparty for initial payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_AmountInvoicedToCounterpartyForInitialPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_BorrowingsMaximumExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period up to which the maturity term of the borrowings can be extended.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_BorrowingsMaximumExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_FinancingPeriodOfLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the financing period of loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_FinancingPeriodOfLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NumberOfLoanAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of loan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NumberOfLoanAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NumberOfLoansObtainedGuaranteedByFrenchState">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of loans obtained which are guaranteed by the french state.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NumberOfLoansObtainedGuaranteedByFrenchState</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_PercentageOfLoanGuaranteedByFrenchState">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of loan guaranteed by French state.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_PercentageOfLoanGuaranteedByFrenchState</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_RepaymentPeriodOfLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period for repayment of loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_RepaymentPeriodOfLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=iva_EquityRecoveryLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=iva_EquityRecoveryLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=iva_FinancingFromSyndicateOfFrenchBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=iva_FinancingFromSyndicateOfFrenchBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LicensingAndCollaborationAgreementWithCttqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LicensingAndCollaborationAgreementWithCttqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232123619440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Financial debt - Credit facility agreement with the European Investment Bank (Details)<br> &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 18, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>Dec. 08, 2022</div></th>
<th class="th">
<div>May 16, 2022 </div>
<div>EUR (&#8364;) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 18, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Financial debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 73,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 54,083<span></span>
</td>
<td class="nump">&#8364; 44,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankMember', window );">Finance contract with EIB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Financial debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NumberOfEqualTranches', window );">Number of equal tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NotionalAmountPerTranche', window );">Notional amount per tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestCostsCapitalised', window );">Capitalized interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember', window );">Finance contract with EIB, Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Financial debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsDebtInstrumentTerm', window );">Maturity term after the disbursement of the tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember', window );">Finance contract with EIB, Tranche A | Financial liabilities at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Financial debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 21,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_BorrowingsEffectiveInterestRate', window );">Borrowings, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingCostsIncurred', window );">Borrowing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember', window );">Finance contract with EIB, Tranche A | Financial liabilities at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Financial debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_BorrowingsActualizationRate', window );">Actualization rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 20,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember', window );">Finance contract with EIB, Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Financial debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsDebtInstrumentTerm', window );">Maturity term after the disbursement of the tranche</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember', window );">Finance contract with EIB, Tranche B | Financial liabilities at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Financial debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">&#8364; 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_BorrowingsEffectiveInterestRate', window );">Borrowings, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingCostsIncurred', window );">Borrowing costs</a></td>
<td class="nump">&#8364; 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember', window );">Finance contract with EIB, Tranche B | Financial liabilities at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Financial debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_BorrowingsActualizationRate', window );">Actualization rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest and other costs that an entity incurs in connection with the borrowing of funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestCostsCapitalised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestCostsCapitalised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_BorrowingsActualizationRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The actualization interest rate on borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_BorrowingsActualizationRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_BorrowingsEffectiveInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate on borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_BorrowingsEffectiveInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsDebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsDebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NotionalAmountPerTranche">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notional amount per tranche</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NotionalAmountPerTranche</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NumberOfEqualTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the information of number of equal tranches .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NumberOfEqualTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232117628192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Financial debt - Derivatives (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 25, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 04, 2024 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 28, 2022 </div>
<div>EUR (&#8364;) </div>
<div>D </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 01, 2022 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 03, 2024 </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of equity instruments granted</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember', window );">Finance contract with EIB, Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsClassOfWarrantOrRightOutstanding', window );">Number of BSA outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,266,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,266,023<span></span>
</td>
<td class="nump">2,266,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares per instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.27<span></span>
</td>
<td class="nump">1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_WarrantsStockPrice', window );">Stock price (&#8364;)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.79<span></span>
</td>
<td class="nump">4.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_WarrantAverageLife', window );">Maturity (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 4 months 24 days<span></span>
</td>
<td class="text">10 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ExpectedVolatility', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.60%<span></span>
</td>
<td class="nump">62.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_WarrantsCapOfPutOption', window );">Cap of the put option (m&#8364;)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_FairValueOfWarrantsOutstanding', window );">Fair Value (k&#8364;) | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 9,469,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,738,000<span></span>
</td>
<td class="nump">&#8364; 10,266,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_WarrantsUnitFairValue', window );">Unit fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0297<span></span>
</td>
<td class="nump">0.0453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember', window );">Finance contract with EIB, Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants', window );">Percentage of company's share capital outstanding, issued as warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.07%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise price of warrant | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsClassOfWarrantOrRightOutstanding', window );">Number of BSA outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,144,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,144,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares per instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_WarrantsStockPrice', window );">Stock price (&#8364;) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_WarrantAverageLife', window );">Maturity (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ExpectedVolatility', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_WarrantsCapOfPutOption', window );">Cap of the put option (m&#8364;)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_FairValueOfWarrantsOutstanding', window );">Fair Value (k&#8364;) | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11,809,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,830,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_WarrantsUnitFairValue', window );">Unit fair value | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bsa2022Member', window );">BSA 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of equity instruments granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,266,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted', window );">Subscription premium price per share (&#8364;) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Exercise price (in euros) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares per instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bsa2024Member', window );">BSA 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of equity instruments granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,144,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted', window );">Subscription premium price per share (&#8364;) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Exercise price (in euros) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares per instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_WarrantAgreementWithEuropeanInvestmentBankMember', window );">Warrant agreement with the European Investment Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued', window );">Term over which volume weighted average price per share to determine number of warrants to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ClassOfWarrantOrRightMaturityTerm', window );">Maturity term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_WarrantAgreementWithEuropeanInvestmentBankMember', window );">Warrant agreement with the European Investment Bank | Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares per instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_WarrantAgreementWithEuropeanInvestmentBankMember', window );">Warrant agreement with the European Investment Bank | Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_WarrantsThresholdTradingDays', window );">Threshold trading days of warrants | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted', window );">Subscription premium price per share (&#8364;) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ClassOfWarrantOrRightMaturityTerm', window );">Maturity term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NumberOfSharesPerOtherEquityInstrumentGranted', window );">Number of shares per AGA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_WarrantAgreementWithEuropeanInvestmentBankMember', window );">Warrant agreement with the European Investment Bank | Derivatives | Finance contract with EIB, Tranche A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ClassOfWarrantOrRightGranted', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,266,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants', window );">Percentage of company's share capital outstanding, issued as warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise price of warrant | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4.0152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_MaximumPotentialGrossProceedsFromExerciseOfWarrants', window );">Maximum potential gross proceeds from exercise of warrants | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_TransactionCostsOnIssueOfWarrants', window );">Transaction costs on issue of warrants | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 56,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_WarrantAgreementWithEuropeanInvestmentBankMember', window );">Warrant agreement with the European Investment Bank | Derivatives | Finance contract with EIB, Tranche B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ClassOfWarrantOrRightGranted', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,144,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants', window );">Percentage of company's share capital outstanding, issued as warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise price of warrant | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_MaximumPotentialGrossProceedsFromExerciseOfWarrants', window );">Maximum potential gross proceeds from exercise of warrants | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_TransactionCostsOnIssueOfWarrants', window );">Transaction costs on issue of warrants | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_ClassOfWarrantOrRightGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_ClassOfWarrantOrRightGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_ClassOfWarrantOrRightMaturityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity term of the warrants issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_ClassOfWarrantOrRightMaturityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_ExpectedVolatility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected volatility used to calculate fair value of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_ExpectedVolatility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_FairValueOfWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_FairValueOfWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_MaximumPotentialGrossProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of gross proceeds that the company will receive from exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_MaximumPotentialGrossProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NumberOfSharesPerOtherEquityInstrumentGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that each equity instruments other than share options granted in a share-based payment arrangement, entitles the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NumberOfSharesPerOtherEquityInstrumentGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Company's share capital outstanding, issued as warrants by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subscription premium price per share of other equity instruments granted in share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the term over which volume weighted average price per share to determine number of warrants to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_TransactionCostsOnIssueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs on issue of warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_TransactionCostsOnIssueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_WarrantAverageLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average life used to calculate fair value of warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_WarrantAverageLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_WarrantsCapOfPutOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cap of the put option used to calculate fair value of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_WarrantsCapOfPutOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_WarrantsStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock price used to calculate fair value of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_WarrantsStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_WarrantsThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of warrants must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_WarrantsThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_WarrantsUnitFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value per warranty unit outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_WarrantsUnitFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bsa2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bsa2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bsa2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=iva_Bsa2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_WarrantAgreementWithEuropeanInvestmentBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_WarrantAgreementWithEuropeanInvestmentBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=iva_LongTermFinancialDebtDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=iva_LongTermFinancialDebtDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232125303936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Financial debt - Lease liabilities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">&#8364; 5,761<span></span>
</td>
<td class="nump">&#8364; 6,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IncreaseDecreaseInLeaseLiabilities', window );">Increase (decrease) in lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (800)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iva_FibroscanMachinesMember', window );">Fibroscan machines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">&#8364; 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum | Fibroscan machines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_LeaseTerm', window );">Lease term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum | Fibroscan machines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_LeaseTerm', window );">Lease term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="nump">1.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="nump">5.18%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in lease liabilities during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_LeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_LeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iva_FibroscanMachinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=iva_FibroscanMachinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232123377056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Maturity of long-term debt and of short-term borrowings and debt (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LoansReceived', window );">Bank borrowings</a></td>
<td class="nump">&#8364; 42,509<span></span>
</td>
<td class="nump">&#8364; 27,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities', window );">Derivatives</a></td>
<td class="nump">13,569<span></span>
</td>
<td class="nump">10,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other loans and similar borrowings</a></td>
<td class="nump">4,302<span></span>
</td>
<td class="nump">3,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">5,761<span></span>
</td>
<td class="nump">6,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued', window );">Royalty certificates liabilities</a></td>
<td class="nump">7,263<span></span>
</td>
<td class="nump">6,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">73,404<span></span>
</td>
<td class="nump">54,083<span></span>
</td>
<td class="nump">&#8364; 44,390<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less than 1 year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LoansReceived', window );">Bank borrowings</a></td>
<td class="nump">3,229<span></span>
</td>
<td class="nump">2,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other loans and similar borrowings</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">2,455<span></span>
</td>
<td class="nump">2,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">5,726<span></span>
</td>
<td class="nump">5,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember', window );">Between 1 and 3 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LoansReceived', window );">Bank borrowings</a></td>
<td class="nump">36,164<span></span>
</td>
<td class="nump">4,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities', window );">Derivatives</a></td>
<td class="nump">13,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other loans and similar borrowings</a></td>
<td class="nump">4,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">3,306<span></span>
</td>
<td class="nump">4,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">57,299<span></span>
</td>
<td class="nump">9,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember', window );">Between 3 and 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LoansReceived', window );">Bank borrowings</a></td>
<td class="nump">2,225<span></span>
</td>
<td class="nump">17,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities', window );">Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherBorrowings', window );">Other loans and similar borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">2,225<span></span>
</td>
<td class="nump">31,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">More than 5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LoansReceived', window );">Bank borrowings</a></td>
<td class="nump">890<span></span>
</td>
<td class="nump">1,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued', window );">Royalty certificates liabilities</a></td>
<td class="nump">7,263<span></span>
</td>
<td class="nump">6,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Total debt</a></td>
<td class="nump">&#8364; 8,153<span></span>
</td>
<td class="nump">&#8364; 7,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LoansReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of loans received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LoansReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current royalty certificates issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232122237168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Financial debt - Royalty Certificates liabilities (Details)<br> &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 18, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">&#8364; 109,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 91,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">73,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 44,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="nump">&#8364; 110,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=iva_RoyaltyCertificatesLiabilitiesMember', window );">Royalty certificates liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_RoyaltyCertificatesEffectiveInterestRate', window );">Royalty certificates, effective interest rate</a></td>
<td class="nump">31.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">&#8364; 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="nump">&#8364; 9,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_DiscountRateMeasurementInputMember', window );">Discount rate, measurement input [member] | Royalty certificates liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input, liabilities</a></td>
<td class="nump">27.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=iva_RoyaltyCertificateLiabilitiesMember', window );">Royalty Certificate Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of significant unobservable input used in the measurement of the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_RoyaltyCertificatesEffectiveInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate on royalty certificates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_RoyaltyCertificatesEffectiveInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=iva_RoyaltyCertificatesLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=iva_RoyaltyCertificatesLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_DiscountRateMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_DiscountRateMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=iva_RoyaltyCertificateLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=iva_RoyaltyCertificateLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232120618304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Net provision (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherProvisions', window );">Provisions</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitObligationAtPresentValue', window );">Retirement benefit obligations</a></td>
<td class="nump">1,555<span></span>
</td>
<td class="nump">1,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">Total Obligation</a></td>
<td class="nump">&#8364; 1,555<span></span>
</td>
<td class="nump">&#8364; 1,559<span></span>
</td>
<td class="nump">&#8364; 1,234<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitObligationAtPresentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 57<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_57_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitObligationAtPresentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 140<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilityAssetOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of provisions other than provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232122236624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Changes in the net provision (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">At beginning of period</a></td>
<td class="num">&#8364; (1,559)<span></span>
</td>
<td class="num">&#8364; (1,234)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss', window );">Expense for the period</a></td>
<td class="num">(70)<span></span>
</td>
<td class="num">(228)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset', window );">Actuarial gains or losses recognized in other comprehensive income</a></td>
<td class="nump">74<span></span>
</td>
<td class="num">(97)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans', window );">At end of period</a></td>
<td class="num">&#8364; (1,555)<span></span>
</td>
<td class="num">&#8364; (1,559)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the net defined benefit liability (asset) resulting from expense (income) included in profit or loss. [Refer: Net defined benefit liability (asset); Profit (loss)] [Contrast: Post-employment benefit expense in profit or loss, defined benefit plans]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 141<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_141&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilityAssetOfDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 140<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_140_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilityAssetOfDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232120618016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Breakdown of expense recognized for the year (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentServiceCostDefinedBenefitPlans', window );">Service cost for the period</a></td>
<td class="num">&#8364; (104)<span></span>
</td>
<td class="num">&#8364; (183)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseDefinedBenefitPlans', window );">Interest cost for the period</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans', window );">Benefits for the period</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans', window );">Total</a></td>
<td class="num">&#8364; (70)<span></span>
</td>
<td class="num">&#8364; (228)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentServiceCostDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of employee service in the current period arising from defined benefit plans. [Refer: Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase in net defined benefit liability (asset) resulting from current service cost]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentServiceCostDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense arising from defined benefit plans. [Refer: Interest expense; Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense (income) resulting from past service cost and losses (gains) arising from settlements. [Refer: Post-employment benefit expense in profit or loss, defined benefit plans; Past service cost, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from past service cost and losses (gains) arising from settlements]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of post-employment benefit expense included in profit or loss relating to defined benefit plans. [Refer: Profit (loss); Defined benefit plans [member]] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 5<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_5&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 135<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_135_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232116831856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Other current and non-current liabilities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_EmployeeRelatedPayables', window );">Employeerelated payables</a></td>
<td class="nump">&#8364; 1,739<span></span>
</td>
<td class="nump">&#8364; 1,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_AccruedPayrollAndOtherEmployeeRelatedTaxes', window );">Accrued payroll and other employeerelated taxes</a></td>
<td class="nump">1,801<span></span>
</td>
<td class="nump">1,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentValueAddedTaxPayables', window );">VAT payables</a></td>
<td class="nump">2,140<span></span>
</td>
<td class="nump">3,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_OtherAccruedTaxesAndEmployeeRelatedExpenses', window );">Other accrued taxes and employeerelated expenses</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentPayables', window );">Other miscellaneous payables</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">&#8364; 5,834<span></span>
</td>
<td class="nump">&#8364; 7,165<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentValueAddedTaxPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current value added tax payables. [Refer: Value added tax payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentValueAddedTaxPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_AccruedPayrollAndOtherEmployeeRelatedTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount pertaining to accrued payroll and other employee related taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_AccruedPayrollAndOtherEmployeeRelatedTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_EmployeeRelatedPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount pertaining to employee related payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_EmployeeRelatedPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_OtherAccruedTaxesAndEmployeeRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accrued taxes and employee related expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_OtherAccruedTaxesAndEmployeeRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232118909840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Other current and non-current liabilities - Additional information (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_TradePayableAndOtherCurrentLiabilitiesLineItems', window );"><strong>Trade Payable And Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">&#8364; 1,032<span></span>
</td>
<td class="nump">&#8364; 1,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LicensingAndCollaborationAgreementWithCttqMember', window );">Licensing and collaboration agreement with CTTQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_TradePayableAndOtherCurrentLiabilitiesLineItems', window );"><strong>Trade Payable And Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_TradePayableAndOtherCurrentLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_TradePayableAndOtherCurrentLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LicensingAndCollaborationAgreementWithCttqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LicensingAndCollaborationAgreementWithCttqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232123356944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Trade payables, short-term contract liabilities and other current liabilities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract', window );"><strong>Notes to the interim condensed consolidated statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">&#8364; 36,583<span></span>
</td>
<td class="nump">&#8364; 37,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Short-term contract liabilities</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">5,834<span></span>
</td>
<td class="nump">7,165<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_TradePayablesAndOtherCurrentLiabilities', window );">Trade payables and other current liabilities</a></td>
<td class="nump">36,586<span></span>
</td>
<td class="nump">&#8364; 37,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccrualsClassifiedAsCurrent', window );">Accrued expenses</a></td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_AccrualsClassifiedAsCurrentRelatingToScientificProjects', window );">Accrued liabilities relating to scientific projects</a></td>
<td class="nump">&#8364; 20,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccrualsClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals classified as current. [Refer: Accruals]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccrualsClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_AccrualsClassifiedAsCurrentRelatingToScientificProjects">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals classified as current relating to scientific projects</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_AccrualsClassifiedAsCurrentRelatingToScientificProjects</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_TradePayablesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade payables and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_TradePayablesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232117808800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Trade payables break down (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_TradePayableAndOtherCurrentLiabilitiesLineItems', window );"><strong>Trade Payable And Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade payable</a></td>
<td class="nump">&#8364; 36,583<span></span>
</td>
<td class="nump">&#8364; 37,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IncreaseDecreaseInTradeAccountsPayable', window );">Increase in trade accounts payable</a></td>
<td class="num">(1,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember', window );">Due in 30 days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_TradePayableAndOtherCurrentLiabilitiesLineItems', window );"><strong>Trade Payable And Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade payable</a></td>
<td class="nump">26,217<span></span>
</td>
<td class="nump">24,995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember', window );">Due in 30-60 days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_TradePayableAndOtherCurrentLiabilitiesLineItems', window );"><strong>Trade Payable And Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade payable</a></td>
<td class="nump">10,362<span></span>
</td>
<td class="nump">&#8364; 12,684<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=iva_LaterThanTwoMonthsMember', window );">Due in more than 60 days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_TradePayableAndOtherCurrentLiabilitiesLineItems', window );"><strong>Trade Payable And Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade payable</a></td>
<td class="nump">&#8364; 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IncreaseDecreaseInTradeAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in trade accounts payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IncreaseDecreaseInTradeAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_TradePayableAndOtherCurrentLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_TradePayableAndOtherCurrentLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneMonthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=iva_LaterThanTwoMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=iva_LaterThanTwoMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232119386896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of financial position - Financial assets and liabilities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">&#8364; 16,208<span></span>
</td>
<td class="nump">&#8364; 41,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">109,998<span></span>
</td>
<td class="nump">91,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">16,208<span></span>
</td>
<td class="nump">41,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="nump">110,933<span></span>
</td>
<td class="nump">92,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember', window );">Liabilities carried at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_LongtermBorrowingsMember', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">46,846<span></span>
</td>
<td class="nump">32,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="nump">45,994<span></span>
</td>
<td class="nump">29,701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_LongtermBorrowingsMember', window );">Long-term debt | Liabilities carried at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">46,846<span></span>
</td>
<td class="nump">32,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=iva_DerivativeInstrumentsMember', window );">Derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">13,569<span></span>
</td>
<td class="nump">10,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="nump">13,569<span></span>
</td>
<td class="nump">10,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=iva_RoyaltyCertificatesLiabilitiesMember', window );">Royalty certificates liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">7,263<span></span>
</td>
<td class="nump">6,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="nump">9,050<span></span>
</td>
<td class="nump">9,617<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=iva_RoyaltyCertificatesLiabilitiesMember', window );">Royalty certificates liabilities | Liabilities carried at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,327<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_ShorttermBorrowingsMember', window );">Short-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">5,726<span></span>
</td>
<td class="nump">5,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="nump">5,726<span></span>
</td>
<td class="nump">5,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_ShorttermBorrowingsMember', window );">Short-term debt | Liabilities carried at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">5,726<span></span>
</td>
<td class="nump">5,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=iva_TradePayablesMember', window );">Trade payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">36,583<span></span>
</td>
<td class="nump">37,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="nump">36,583<span></span>
</td>
<td class="nump">37,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=iva_TradePayablesMember', window );">Trade payables | Liabilities carried at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=iva_OtherMiscellaneousPayablesMember', window );">Other miscellaneous payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial liabilities, at fair value</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=iva_OtherMiscellaneousPayablesMember', window );">Other miscellaneous payables | Liabilities carried at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets carried at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">16,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">96,429<span></span>
</td>
<td class="nump">10,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember', window );">Financial assets carried at amortized cost | Derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember', window );">Financial assets carried at fair value through profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">13,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=iva_LongTermDepositAccountsMember', window );">Long-term deposit accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=iva_LongTermDepositAccountsMember', window );">Long-term deposit accounts | Financial assets carried at fair value through profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=iva_LongTermSecurityDepositsMember', window );">Long-term security deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=iva_LongTermSecurityDepositsMember', window );">Long-term security deposits | Financial assets carried at fair value through profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=iva_AdvancePaymentMember', window );">Advance payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">1,047<span></span>
</td>
<td class="nump">1,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">1,047<span></span>
</td>
<td class="nump">1,047<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=iva_AdvancePaymentMember', window );">Advance payment | Financial assets carried at fair value through profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">1,047<span></span>
</td>
<td class="nump">1,047<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=iva_AccruedIncomeMember', window );">Current accrued income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">1,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">1,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=iva_AccruedIncomeMember', window );">Current accrued income | Financial assets carried at fair value through profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">1,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=iva_ShortTermDepositAccountsMember', window );">Short-term deposit accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=iva_ShortTermDepositAccountsMember', window );">Short-term deposit accounts | Financial assets carried at fair value through profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">809<span></span>
</td>
<td class="nump">3,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">809<span></span>
</td>
<td class="nump">3,807<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables | Financial assets carried at fair value through profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">809<span></span>
</td>
<td class="nump">3,807<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=iva_OtherReceivablesMember', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">2,518<span></span>
</td>
<td class="nump">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">2,518<span></span>
</td>
<td class="nump">857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=iva_OtherReceivablesMember', window );">Other receivables | Financial assets carried at fair value through profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">2,518<span></span>
</td>
<td class="nump">857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=iva_IfrsCashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">10,147<span></span>
</td>
<td class="nump">26,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtFairValue', window );">Financial assets, at fair value</a></td>
<td class="nump">10,147<span></span>
</td>
<td class="nump">26,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=iva_IfrsCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Financial assets carried at fair value through profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">&#8364; 10,147<span></span>
</td>
<td class="nump">&#8364; 26,918<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial assets. [Refer: At fair value [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_LongtermBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_LongtermBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=iva_DerivativeInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=iva_DerivativeInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=iva_RoyaltyCertificatesLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=iva_RoyaltyCertificatesLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_ShorttermBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_ShorttermBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=iva_TradePayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=iva_TradePayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=iva_OtherMiscellaneousPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=iva_OtherMiscellaneousPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=iva_LongTermDepositAccountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=iva_LongTermDepositAccountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=iva_LongTermSecurityDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=iva_LongTermSecurityDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=iva_AdvancePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=iva_AdvancePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=iva_AccruedIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=iva_AccruedIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=iva_ShortTermDepositAccountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=iva_ShortTermDepositAccountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=iva_OtherReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=iva_OtherReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=iva_IfrsCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=iva_IfrsCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232120644192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of (income) loss - Revenues and other income (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ComponentsOfIncomeStatementAbstract', window );"><strong>Notes to the interim condensed consolidated statement of (income) loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">&#8364; 41<span></span>
</td>
<td class="nump">&#8364; 1,901<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">1,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_CurrentTaxCreditResearchIncome', window );">Tax Credits</a></td>
<td class="nump">2,630<span></span>
</td>
<td class="nump">3,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_SubsidiesIncome', window );">Subsidies</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsOtherOperatingIncome', window );">Other</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">1,087<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_OtherIncomeFromOrdinaryActivities', window );">Other income</a></td>
<td class="nump">2,693<span></span>
</td>
<td class="nump">4,721<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAndOperatingIncome', window );">Total revenues and other income</a></td>
<td class="nump">&#8364; 2,734<span></span>
</td>
<td class="nump">&#8364; 6,622<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAndOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of the entity's revenue and other operating income. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAndOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_ComponentsOfIncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_ComponentsOfIncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_CurrentTaxCreditResearchIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income from tax credit research.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_CurrentTaxCreditResearchIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_OtherIncomeFromOrdinaryActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other income from ordinary activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_OtherIncomeFromOrdinaryActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_SubsidiesIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income from subsidies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_SubsidiesIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232130965728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of (income) loss - Narratives (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Notes to the income statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_CurrentTaxCreditResearchCurrentYear', window );">Tax credits of current year</a></td>
<td class="nump">&#8364; 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_CirAndOtherResearchTaxCreditsReceivable', window );">Tax research credit</a></td>
<td class="nump">2,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Tax income</a></td>
<td class="nump">119<span></span>
</td>
<td class="num">&#8364; (7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=iva_InventivaIncMember', window );">Inventiva Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Notes to the income statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_CirAndOtherResearchTaxCreditsReceivable', window );">Tax research credit</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Tax income</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LicensingAndCollaborationAgreementWithCttqMember', window );">Licensing and collaboration agreement with CTTQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Notes to the income statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement', window );">Reinvoicing of share of costs incurred included in other income</a></td>
<td class="nump">&#8364; 2,600<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_ServiceContractWithAvantSanteMember', window );">Service contract with Avant Sante [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Notes to the income statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement', window );">Reinvoicing of specific costs related to CRO accrued liabilities included in other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_CirAndOtherResearchTaxCreditsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of CIR and other research tax credits receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_CirAndOtherResearchTaxCreditsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_CurrentTaxCreditResearchCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax credit research from current year, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_CurrentTaxCreditResearchCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount related to reinvoicing of specific costs incurred on services with customer research organization accrued liabilities included in other income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount related to reinvoicing of share of costs incurred under the licensing and collaboration agreements included in other income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=iva_InventivaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=iva_InventivaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LicensingAndCollaborationAgreementWithCttqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LicensingAndCollaborationAgreementWithCttqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_ServiceContractWithAvantSanteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_ServiceContractWithAvantSanteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232125203776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of (income) loss - Operating expenses (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_Disposables', window );">Disposables</a></td>
<td class="num">&#8364; (887)<span></span>
</td>
<td class="num">&#8364; (943)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_EnergyAndLiquids', window );">Energy and liquids</a></td>
<td class="num">(447)<span></span>
</td>
<td class="num">(479)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_Patents', window );">Patents</a></td>
<td class="num">(643)<span></span>
</td>
<td class="num">(257)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_Studies', window );">Studies</a></td>
<td class="num">(34,073)<span></span>
</td>
<td class="num">(42,847)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepairsAndMaintenanceExpense', window );">Maintenance</a></td>
<td class="num">(526)<span></span>
</td>
<td class="num">(459)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_Fees', window );">Fees</a></td>
<td class="num">(2,795)<span></span>
</td>
<td class="num">(1,945)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ItSystems', window );">IT systems</a></td>
<td class="num">(444)<span></span>
</td>
<td class="num">(498)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_SupportCosts', window );">Support costs (including taxes)</a></td>
<td class="num">(375)<span></span>
</td>
<td class="num">(343)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Personnel costs</a></td>
<td class="num">(10,391)<span></span>
</td>
<td class="num">(9,538)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DepreciationAmortizationAndProvisions', window );">Depreciation, amortization and provisions</a></td>
<td class="num">(1,854)<span></span>
</td>
<td class="num">(1,166)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InsuranceExpense', window );">Insurances</a></td>
<td class="num">(921)<span></span>
</td>
<td class="num">(1,121)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_OtherOperatingExpenses', window );">Other operating expenses</a></td>
<td class="num">(1,764)<span></span>
</td>
<td class="num">(1,985)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_OperatingExpenseExcludingOtherOperatingIncomeExpense', window );">Total operating expenses</a></td>
<td class="num">(55,122)<span></span>
</td>
<td class="num">(61,580)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=iva_IfrsResearchAndDevelopmentExpenseMember', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_Disposables', window );">Disposables</a></td>
<td class="num">(887)<span></span>
</td>
<td class="num">(943)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_EnergyAndLiquids', window );">Energy and liquids</a></td>
<td class="num">(447)<span></span>
</td>
<td class="num">(479)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_Patents', window );">Patents</a></td>
<td class="num">(643)<span></span>
</td>
<td class="num">(257)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_Studies', window );">Studies</a></td>
<td class="num">(34,073)<span></span>
</td>
<td class="num">(42,847)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepairsAndMaintenanceExpense', window );">Maintenance</a></td>
<td class="num">(526)<span></span>
</td>
<td class="num">(459)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_Fees', window );">Fees</a></td>
<td class="num">(118)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ItSystems', window );">IT systems</a></td>
<td class="num">(405)<span></span>
</td>
<td class="num">(440)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Personnel costs</a></td>
<td class="num">(7,637)<span></span>
</td>
<td class="num">(7,065)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DepreciationAmortizationAndProvisions', window );">Depreciation, amortization and provisions</a></td>
<td class="num">(1,732)<span></span>
</td>
<td class="num">(1,061)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_OtherOperatingExpenses', window );">Other operating expenses</a></td>
<td class="num">(352)<span></span>
</td>
<td class="num">(450)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_OperatingExpenseExcludingOtherOperatingIncomeExpense', window );">Total operating expenses</a></td>
<td class="num">(46,822)<span></span>
</td>
<td class="num">(54,062)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=iva_IfrsSalesAndMarketingExpenseMember', window );">Marketing - Business development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_Fees', window );">Fees</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ItSystems', window );">IT systems</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Personnel costs</a></td>
<td class="num">(153)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_OtherOperatingExpenses', window );">Other operating expenses</a></td>
<td class="num">(437)<span></span>
</td>
<td class="num">(570)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_OperatingExpenseExcludingOtherOperatingIncomeExpense', window );">Total operating expenses</a></td>
<td class="num">(598)<span></span>
</td>
<td class="num">(705)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=iva_IfrsGeneralAndAdministrativeExpenseMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_Fees', window );">Fees</a></td>
<td class="num">(2,675)<span></span>
</td>
<td class="num">(1,884)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ItSystems', window );">IT systems</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_SupportCosts', window );">Support costs (including taxes)</a></td>
<td class="num">(375)<span></span>
</td>
<td class="num">(343)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Personnel costs</a></td>
<td class="num">(2,600)<span></span>
</td>
<td class="num">(2,347)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_DepreciationAmortizationAndProvisions', window );">Depreciation, amortization and provisions</a></td>
<td class="num">(122)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InsuranceExpense', window );">Insurances</a></td>
<td class="num">(921)<span></span>
</td>
<td class="num">(1,121)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_OtherOperatingExpenses', window );">Other operating expenses</a></td>
<td class="num">(975)<span></span>
</td>
<td class="num">(964)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_OperatingExpenseExcludingOtherOperatingIncomeExpense', window );">Total operating expenses</a></td>
<td class="num">&#8364; (7,701)<span></span>
</td>
<td class="num">&#8364; (6,812)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from purchased insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepairsAndMaintenanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses incurred for the day-to-day servicing of assets, which may include the cost of labour, consumables or small parts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepairsAndMaintenanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_DepreciationAmortizationAndProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents information pertaining to depreciation, amortization and provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_DepreciationAmortizationAndProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_Disposables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to disposables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_Disposables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_EnergyAndLiquids">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to energy and liquids.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_EnergyAndLiquids</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_Fees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_Fees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_ItSystems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to it systems.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_ItSystems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_OperatingExpenseExcludingOtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_OperatingExpenseExcludingOtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_OtherOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to other operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_OtherOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_Patents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to patents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_Patents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_Studies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to studies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_Studies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_SupportCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to support costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_SupportCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=iva_IfrsResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=iva_IfrsResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=iva_IfrsSalesAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=iva_IfrsSalesAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=iva_IfrsGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=iva_IfrsGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232122024080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of (income) loss - Operating expenses - Personnel costs and headcount (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>employee</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;) </div>
<div>employee</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Number of employees | employee</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Wages, salaries and similar costs</a></td>
<td class="num">&#8364; (6,181)<span></span>
</td>
<td class="num">&#8364; (5,694)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_PayrollTaxes', window );">Payroll taxes</a></td>
<td class="num">(1,886)<span></span>
</td>
<td class="num">(1,708)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss', window );">Provisions for retirement benefit obligations</a></td>
<td class="num">(86)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payments</a></td>
<td class="num">(2,238)<span></span>
</td>
<td class="num">(2,046)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total personnel costs</a></td>
<td class="num">&#8364; (10,391)<span></span>
</td>
<td class="num">&#8364; (9,538)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=iva_InventivaS.aMember', window );">Inventiva S.A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Number of employees | employee</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=iva_InventivaIncMember', window );">Inventiva Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Number of employees | employee</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=iva_IfrsResearchAndDevelopmentExpenseMember', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Wages, salaries and similar costs</a></td>
<td class="num">&#8364; (4,824)<span></span>
</td>
<td class="num">&#8364; (4,399)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_PayrollTaxes', window );">Payroll taxes</a></td>
<td class="num">(1,312)<span></span>
</td>
<td class="num">(1,222)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss', window );">Provisions for retirement benefit obligations</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payments</a></td>
<td class="num">(1,450)<span></span>
</td>
<td class="num">(1,383)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total personnel costs</a></td>
<td class="num">(7,637)<span></span>
</td>
<td class="num">(7,065)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=iva_IfrsSalesAndMarketingExpenseMember', window );">Marketing - Business development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Wages, salaries and similar costs</a></td>
<td class="num">(120)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_PayrollTaxes', window );">Payroll taxes</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payments</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total personnel costs</a></td>
<td class="num">(153)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=iva_IfrsGeneralAndAdministrativeExpenseMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Wages, salaries and similar costs</a></td>
<td class="num">(1,237)<span></span>
</td>
<td class="num">(1,191)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_PayrollTaxes', window );">Payroll taxes</a></td>
<td class="num">(563)<span></span>
</td>
<td class="num">(476)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss', window );">Provisions for retirement benefit obligations</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based payments</a></td>
<td class="num">(765)<span></span>
</td>
<td class="num">(650)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total personnel costs</a></td>
<td class="num">&#8364; (2,600)<span></span>
</td>
<td class="num">&#8364; (2,347)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of personnel employed by the entity at a date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of post-employment benefit expense included in profit or loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 5<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_5&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_PayrollTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents payroll taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_PayrollTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=iva_InventivaS.aMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=iva_InventivaS.aMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=iva_InventivaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=iva_InventivaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=iva_IfrsResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=iva_IfrsResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=iva_IfrsSalesAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=iva_IfrsSalesAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=iva_IfrsGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=iva_IfrsGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232119764368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of (income) loss - Other operating income and expenses - (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ComponentsOfIncomeStatementAbstract', window );"><strong>Notes to the interim condensed consolidated statement of (income) loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">&#8364; 160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">&#8364; (44)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">Other operating income and expenses</a></td>
<td class="nump">&#8364; 138<span></span>
</td>
<td class="num">&#8364; (44)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income (expense) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_ComponentsOfIncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_ComponentsOfIncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232120019776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of (income) loss - Financial income and expenses (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ComponentsOfIncomeStatementAbstract', window );"><strong>Notes to the interim condensed consolidated statement of (income) loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestIncomeOnCashAndCashEquivalents', window );">Income from cash equivalents</a></td>
<td class="nump">&#8364; 430<span></span>
</td>
<td class="nump">&#8364; 564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ForeignExchangeGain', window );">Foreign exchange gains</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_FairValueVariationGains', window );">Gain on fair value variation</a></td>
<td class="nump">8,506<span></span>
</td>
<td class="nump">1,623<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Total financial income</a></td>
<td class="nump">9,093<span></span>
</td>
<td class="nump">2,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest cost</a></td>
<td class="num">(5,218)<span></span>
</td>
<td class="num">(1,941)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ForeignExchangeLoss', window );">Foreign exchange losses</a></td>
<td class="num">(323)<span></span>
</td>
<td class="num">(683)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceCost', window );">Other financial expenses</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Total financial expenses</a></td>
<td class="num">(5,586)<span></span>
</td>
<td class="num">(2,646)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Net financial income</a></td>
<td class="nump">3,507<span></span>
</td>
<td class="num">&#8364; (273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsFairValueAdjustmentOfWarrants', window );">Fair value of the EIB warrants</a></td>
<td class="nump">&#8364; 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ForeignExchangeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ForeignExchangeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income on cash and cash equivalents. [Refer: Interest income; Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_ComponentsOfIncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_ComponentsOfIncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_FairValueVariationGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gains recognized for variation in fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_FairValueVariationGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsFairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsFairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232119463520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of (income) loss - Share of net profit - Equity method (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 15, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Investments accounted for using the equity method</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (46,822)<span></span>
</td>
<td class="num">&#8364; (54,062)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,701)<span></span>
</td>
<td class="num">(6,812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Net operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,249)<span></span>
</td>
<td class="num">(55,003)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,093<span></span>
</td>
<td class="nump">2,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,586)<span></span>
</td>
<td class="num">(2,646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Net financial income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,507<span></span>
</td>
<td class="num">(273)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119)<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,029)<span></span>
</td>
<td class="num">(55,269)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange difference on translation of foreign operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items that will be reclassified subsequently to profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(220)<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax', window );">Items that will not be reclassified subsequently to profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,175)<span></span>
</td>
<td class="num">&#8364; (55,179)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod', window );">Share of net profit - Equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=iva_HepalysPharmaIncMember', window );">Hepalys Pharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Investments accounted for using the equity method</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Group's share in %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.64%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations', window );">Share of net profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_EliminationOfDownstreamSales', window );">Elimination of downstream sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod', window );">Share of net profit - Equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=iva_HepalysPharmaIncMember', window );">Hepalys Pharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Investments accounted for using the equity method</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,475)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Net operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,526)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Net financial income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,509)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (879)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange difference on translation of foreign operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,964)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Items that will be reclassified subsequently to profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,473)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (3,473)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Group's share in %</a></td>
<td class="nump">14.60%<span></span>
</td>
<td class="nump">14.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2023-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_EliminationOfDownstreamSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of elimination of downstream sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_EliminationOfDownstreamSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share of profit (loss) of associates accounted for using equity method before eliminations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=iva_HepalysPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=iva_HepalysPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=iva_HepalysPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=iva_HepalysPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232125528656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of (income) loss - Income tax (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ComponentsOfIncomeStatementAbstract', window );"><strong>Notes to the interim condensed consolidated statement of (income) loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods', window );">Projected tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods', window );">Current taxes</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Tax income</a></td>
<td class="nump">&#8364; 119<span></span>
</td>
<td class="num">&#8364; (7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 80<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_80&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from adjustments for the current tax of prior periods. [Refer: Average effective tax rate; Applicable tax rate; Adjustments for current tax of prior periods]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_ComponentsOfIncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_ComponentsOfIncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232122614704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the interim condensed consolidated statement of (income) loss - Basic and diluted loss per share (Details) - EUR (&#8364;)<br> &#8364; / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ComponentsOfIncomeStatementAbstract', window );"><strong>Notes to the interim condensed consolidated statement of (income) loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">&#8364; (49,029)<span></span>
</td>
<td class="num">&#8364; (55,269)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of shares outstanding used to calculate basic loss per share</a></td>
<td class="nump">51,982,093<span></span>
</td>
<td class="nump">42,044,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of shares outstanding used to calculate diluted loss per share</a></td>
<td class="nump">51,982,093<span></span>
</td>
<td class="nump">42,044,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per share</a></td>
<td class="num">&#8364; (0.94)<span></span>
</td>
<td class="num">&#8364; (1.31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted loss per share</a></td>
<td class="num">&#8364; (0.94)<span></span>
</td>
<td class="num">&#8364; (1.31)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_ComponentsOfIncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_ComponentsOfIncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232117475872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other financial information (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Other financial information [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCapitalCommitments', window );">Total commitments given</a></td>
<td class="nump">&#8364; 210,261<span></span>
</td>
<td class="nump">&#8364; 221,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_AgreementsConcerningProvisionOfFacilities', window );">Agreements concerning the provision of facilities</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ContractualCapitalCommitmentReceived', window );">Total commitments received</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_ContractCroWithResearchAssociatesGroupeB.vMember', window );">Contract CRO with Pharmaceutical Research Associates B.V.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Other financial information [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCapitalCommitments', window );">Total commitments given</a></td>
<td class="nump">158,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_CommitmentsAmountPayableForServicesReceivedUnderContract', window );">Amount committed to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=iva_ClinicalTrialsMember', window );">CRO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Other financial information [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCapitalCommitments', window );">Total commitments given</a></td>
<td class="nump">175,461<span></span>
</td>
<td class="nump">183,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=iva_ContractManufacturingOrganizationsMember', window );">CMO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Other financial information [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCapitalCommitments', window );">Total commitments given</a></td>
<td class="nump">6,846<span></span>
</td>
<td class="nump">5,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Other financial information [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCapitalCommitments', window );">Total commitments given</a></td>
<td class="nump">7,592<span></span>
</td>
<td class="nump">8,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_OtherContingentLiabilitiesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Other financial information [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCapitalCommitments', window );">Total commitments given</a></td>
<td class="nump">20,361<span></span>
</td>
<td class="nump">&#8364; 23,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=iva_PharmaceuticalResearchAssociatesMember', window );">Pharmaceutical Research Associates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Other financial information [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractualCapitalCommitments', window );">Total commitments given</a></td>
<td class="nump">254,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=iva_PharmaceuticalResearchAssociatesMember', window );">Pharmaceutical Research Associates | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Other financial information [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_CommitmentContractualBonusOrMalusCappedAmount', window );">Bonus or malus capped amount</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=iva_PharmaceuticalResearchAssociatesMember', window );">Pharmaceutical Research Associates | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Other financial information [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_CommitmentContractualBonusOrMalusCappedAmount', window );">Bonus or malus capped amount</a></td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=iva_ChiaTaiTianqingMember', window );">CTTQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Other financial information [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_CommitmentsAmountPayableForServicesReceivedUnderContract', window );">Amount committed to pay</a></td>
<td class="nump">&#8364; 20,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractualCapitalCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractualCapitalCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_AgreementsConcerningProvisionOfFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of agreements concerning provision of facilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_AgreementsConcerningProvisionOfFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_CommitmentContractualBonusOrMalusCappedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment contractual bonus or malus capped amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_CommitmentContractualBonusOrMalusCappedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_CommitmentsAmountPayableForServicesReceivedUnderContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment amount payable for services received under contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_CommitmentsAmountPayableForServicesReceivedUnderContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_ContractualCapitalCommitmentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual capital commitment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_ContractualCapitalCommitmentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_ContractCroWithResearchAssociatesGroupeB.vMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_ContractCroWithResearchAssociatesGroupeB.vMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=iva_ClinicalTrialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=iva_ClinicalTrialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=iva_ContractManufacturingOrganizationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=iva_ContractManufacturingOrganizationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_OtherContingentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=ifrs-full_OtherContingentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=iva_PharmaceuticalResearchAssociatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=iva_PharmaceuticalResearchAssociatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInAssociatesAxis=iva_ChiaTaiTianqingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInAssociatesAxis=iva_ChiaTaiTianqingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46232117354592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other financial information - Events after the reporting date (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 14, 2024 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 11, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jul. 18, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 05, 2024</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 28, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsotherFinancialInformationLineItems', window );"><strong>Events after the reporting date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value of share | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember', window );">Finance contract with EIB, first tranche (Tranche A)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsotherFinancialInformationLineItems', window );"><strong>Events after the reporting date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares per warrant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.20<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember', window );">Finance contract with EIB, first tranche (Tranche A) | Warrant agreement with the European Investment Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsotherFinancialInformationLineItems', window );"><strong>Events after the reporting date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares underlying in EIB | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember', window );">Indication of continuation of recruitment for Phase III trial NATiV3 of lanifibranor in non-cirrhotic NASH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsotherFinancialInformationLineItems', window );"><strong>Events after the reporting date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_MaximumDurationOfClinicalTrial', window );">Maximum duration of Phase III trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">840 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_PresentationOfResultsFromStudyMember', window );">Presentation of results from study | NATiV3 Phase III clinical trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsotherFinancialInformationLineItems', window );"><strong>Events after the reporting date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_PercentageOfPatientsInTrialEnrolledInMainCohort', window );">Percentage of patients in trial, enrolled in main cohort</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_PercentageOfPatientsInTrialEnrolledInExploratoryCohort', window );">Percentage of patients in trial, enrolled in exploratory cohort</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_IssuanceOfRoyaltyCertificatesMember', window );">Issuance of royalty certificates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsotherFinancialInformationLineItems', window );"><strong>Events after the reporting date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NumberOfRoyaltyCertificatesIssued', window );">Number of royalty certificates issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ProceedsFromFinancing', window );">Gross cash proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 20,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor', window );">Annual royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_MaximumDurationOfClinicalTrial', window );">Maximum duration of Phase III trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_FinancingAgreementInThreePhasesMember', window );">Financing agreement in three phases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsotherFinancialInformationLineItems', window );"><strong>Events after the reporting date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_NumberOfEqualTranches', window );">Number of equal tranches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany', window );">Aggregate amount to be received either in exchange for new shares or warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 348,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember', window );">Issuance of shares without preferential subscription rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsotherFinancialInformationLineItems', window );"><strong>Events after the reporting date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_StockIssuedDuringPeriodValue', window );">Stock issued during period</a></td>
<td class="nump">&#8364; 94,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_StockIssuedDuringPeriodShares', window );">Number of shares issued during the period | shares</a></td>
<td class="nump">34,600,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value of share | &#8364; / shares</a></td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ClassOfWarrantOrRightGranted', window );">Number of warrants granted | shares</a></td>
<td class="nump">35,399,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares per warrant | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember', window );">Issuance of shares or warrants without preferential subscription rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsotherFinancialInformationLineItems', window );"><strong>Events after the reporting date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_StockIssuedDuringPeriodValue', window );">Stock issued during period</a></td>
<td class="nump">&#8364; 21,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value of share | &#8364; / shares</a></td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember', window );">Issuance of shares or warrants subject to conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsotherFinancialInformationLineItems', window );"><strong>Events after the reporting date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_StockIssuedDuringPeriodValue', window );">Stock issued during period</a></td>
<td class="nump">&#8364; 116,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise price of warrant | &#8364; / shares</a></td>
<td class="nump">&#8364; 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant or right, value of number of securities</a></td>
<td class="nump">&#8364; 116,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_FinancingThroughFundRaisingMember', window );">Financing through fund raising | Licensing and collaboration agreement with CTTQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsotherFinancialInformationLineItems', window );"><strong>Events after the reporting date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_MinimumAmountCommittedForFundRaising', window );">Minimum amount committed for fund raising</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_FinancingThroughFundRaisingMember', window );">Financing through fund raising | Licensing and collaboration agreement with CTTQ | First tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsotherFinancialInformationLineItems', window );"><strong>Events after the reporting date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ProceedsFromLicensingArrangements', window );">Amount received on licensing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_PeriodWithinWhichPaymentIsReceivedFromSettlement', window );">Received from settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_FinancingThroughFundRaisingMember', window );">Financing through fund raising | Licensing and collaboration agreement with CTTQ | Second tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsotherFinancialInformationLineItems', window );"><strong>Events after the reporting date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ProceedsFromLicensingArrangements', window );">Amount received on licensing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_FinancingThroughFundRaisingMember', window );">Financing through fund raising | Licensing and collaboration agreement with CTTQ | Third tranche upon publication of pivotal data</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_IfrsotherFinancialInformationLineItems', window );"><strong>Events after the reporting date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iva_ProceedsFromLicensingArrangements', window );">Amount received on licensing arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount to be received by the company, either in exchange for new shares or warrants of the Company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual royalty on future net sales of Lanifibranor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_ClassOfWarrantOrRightGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_ClassOfWarrantOrRightGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of securities into which the class of warrant or right may be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsotherFinancialInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsotherFinancialInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_MaximumDurationOfClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum duration of the clinical trial of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_MaximumDurationOfClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_MinimumAmountCommittedForFundRaising">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount committed for borrowing under the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_MinimumAmountCommittedForFundRaising</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NumberOfEqualTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the information of number of equal tranches .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NumberOfEqualTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_NumberOfRoyaltyCertificatesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of royalty certificates issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_NumberOfRoyaltyCertificatesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_PercentageOfPatientsInTrialEnrolledInExploratoryCohort">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of patients in trail enrolled in exploratory cohort.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_PercentageOfPatientsInTrialEnrolledInExploratoryCohort</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_PercentageOfPatientsInTrialEnrolledInMainCohort">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of patients in trail enrolled in main cohort.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_PercentageOfPatientsInTrialEnrolledInMainCohort</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_PeriodWithinWhichPaymentIsReceivedFromSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period within which the payment is made from settlement date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_PeriodWithinWhichPaymentIsReceivedFromSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_ProceedsFromFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash proceeds from financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_ProceedsFromFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_ProceedsFromLicensingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount paid on licensing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_ProceedsFromLicensingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_StockIssuedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_StockIssuedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_StockIssuedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_StockIssuedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_WarrantAgreementWithEuropeanInvestmentBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_WarrantAgreementWithEuropeanInvestmentBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_PresentationOfResultsFromStudyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_PresentationOfResultsFromStudyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_IssuanceOfRoyaltyCertificatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_IssuanceOfRoyaltyCertificatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_FinancingAgreementInThreePhasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_FinancingAgreementInThreePhasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_FinancingThroughFundRaisingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=iva_FinancingThroughFundRaisingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LicensingAndCollaborationAgreementWithCttqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=iva_LicensingAndCollaborationAgreementWithCttqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=iva_ScenarioOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=iva_ScenarioOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=iva_ScenarioTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=iva_ScenarioTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=iva_ScenarioThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=iva_ScenarioThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M(WC<.GG<3NUNOK:=<8L6.PV;';R##5-:4F3\0HM.,+?/DN\P0+:CY+X_ZSO
MQBW8V&DXPX1E-FE7.=UT ;GU:YHK<'"<M1QG3I]%):6E8"JE.?D%5#KWS^W6
MZX51;Q ZN,Y;KO.WG:E3L"L<5%U4;J]7SE(8/-^&P3]!->?]1:Q7[+Y&+JJ3
M.SI\RQE?()A$J"7>K$_D!@Z=1&ZK( C"\2@>G7?FRS\I) 7(C2V7BJ2BXKJN
M*>UH6Y)G=2%ZGE[7\ULJ-XPKDL,:I4%_C/>"K$MDW=&BM&7I06@L<K:YQ<\*
MD&8"/E\+H8\=LT#[H9+\ 5!+ P04    " !K@4]9FP+9264&  "N'@  &
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MQ6RP&@(>/"L3 6@D285W:D(54< BZ;;R!ROU7+' #;9(@\!YTX^_7E_N3UY
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M975?8>"ULG59TU;<;D"^3.V(D.;Z8T1P"U48=_+R&.-?*"-+[9;R>CO;QW^
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MVU2Y"" X#P L%8M,HETWQ0')SC:>:1\=<4!*A7(AA$*OAS8DXA9>)#X_<K@
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MLCK?.5E5K@'O;(U_-561K],6'IH6/F!!6J?:.)N\3,LL3PMG7S4Y8OCE:0L
M8;>GF1C\G \>3 R>.+]79;MMG-<PWMI^_Q0FHF83R-F<!P<[_/>NG#FAYSJ!
M%T0'^@L5=D+J+_QKL,,'C\8'1W9\WNS3C/WR#/BM8?4M>_;JY[_YB??BP-0B
M-;7H4.\_>FH/#^Y$,^<[ @'=^<[/?UL$7OCBT9^7)8Q<=4U:KAOLEG5UU3A
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M[EE:8Q=@,DE0AZ&>Y<R3[IS;CS3!^^#8HO75<8,H'7D+PR@G-)2$2 IO<C'
MOAUUMT@(#32X:RU/RM>0/,JFV^^+G-S4G3!8X5OEDQJ3R"IXN]E7W+874TD5
M.>1KPVF0()(J2^ML"P[235K*J.L1KD7@ 4-\_(!6SRX7QIV!*(P%4FO4P3RJ
M@#(5/,?_#K9(5Q6,7M7W9.&7\)?4.<2;'A@*8$9<&K_= 2DP08_DQ"JC"\7O
M\MAJK.+2RQ LCOD(\\^%(@.KDX&M0[IL^,T*Z.XS]YE3E/T%6*[-\_\&!(7
M$;1)!.JF0%=JX6DQ%[H+;^Z<"P,Y))),Y M]?2V?9?.$FH,Z?J#][XHC'VX[
M1-P07*71D:IO@?9NE)"3RA1\B-!SUBFZ4..1CL$X8Z(A-)A\-&K-\GW+Q8($
M@ (B%Y\^_:?2[S4#PJS M05>A*;-GF487@#.:VP^PL;OSS[E?X8 'K@1X.JD
M7RP8$=^C)OC7ZNOO3VX7EQ\)3+)UM5"A\#&8[SF9]TD\=V(W!(N+SP9%_W(P
MV\"=>Q&VBP/GJF8DN-B7/3KW8"VZ'JCK"+I*P&ZMZO:1NE$^SSWG0N)P7-_Y
M;K*8&T^HH-[E8#^NR8)46PXGW.61#8.%IM<(3+]K,C]::VX&08>^=F-BUP-3
M[8/ G(F((("YAO&$_Q6Y<1QAX#-9)N--<$7,'M&[BQ?XX47:NQOGE#X- C,+
M7D"SE.(2\-;H2ALS%HZS,*=T,#4P-EI&]1;1&%'56,RE3Q>N<[?- 0IK3P=4
M1-?J 2.M*2<F<X@UK[88G+B\O 2S("_S#)2>X-9HMG@R@Z$CETUZS-^?/05U
M] <Z HO81U<_1)I8 F-R-[YU5FGYF8!+,<R*\A[\A,!9N,M%[)SCC[B+L:[3
MC0$O&-EA:+BKDOD.Q 8\UP?^"A)WZ2\(G E(-8V03:0YGP"5IBA&VDD&U&LR
M>L@RO#R[=N:SA<N;&F!SDN'[1\(=)1^"[6CBY,F(.#0%FHE42A'UF5Z]*9+W
MC;V_4:*.9DONBZM- (I+6]^ AL,MLU31=0S,.I\'@WBKL\XQ.H;B#1 6!VXT
MG[O^8N%LN@+(/NV @B@NZ8*%N6JR.E_A/&%"R%@GW5X&APF'*9BGZ'P5>C/X
M9[FCZ?FS'MC*#06U6<N8WR:OF]9I\B_*,-EP0,640&^V6XF\5FR\@;7T'->4
M*-P%=L\8:-ZR(]L9M:J.:_P(/?C43Q!+N[S;?3M ')_RR9!(2H H%*AOQ +]
MBKM)[].VDZ%<AE9/V:09#PS(1;+I2B"2K^YY6A#[ $T-0XU]4&.,'8!2"3QP
ML1/064F(Y.;[,5EM2!].>!K$IU9BQ-G;,^P.E&"ZVQN/J]S,"4E\_<81/6KA
M$B8@;19:B]) !N3C"1E#Z#G[*#6.LX@7;A(MC3:*>:S!Y,.8=6!N0BX1!G]A
M[[,QVB02[)DZQ4@?Q'G_P?8%H/]BR[K;FG5?T%?=%VDFV6I?L]L<=,%T#Q_6
MZ\HY_^T-AM!QW^.A_E'6B0@_<"- #O"#N*AP P+4'@@/,#'8'8]D^<$)L;/:
MM.Y*\C90-F.PAFMBEI-4Q[V>^YGSA_)"L54CJ30UMJSLC1L,MN;H#HN0?ZW\
MT\OK*_K+?W%,>SI*JB&OK#H>\6MPUVELW[25X5%#U*')0!MX&]Q-SQBW[.W]
M.-R'QAE4L(H4(<"?-?[%?/0>-3Z]!@E6LB\MV!WU9R8VIQZ]ZF*'K>7+@HCG
M&\W"[\%-<N5C$<"*^&1X 1&!^Z6T@T,+B.+^)L6T@Z=V![KJ;+"]UT>FV',<
M;&?*350T%&'Y!ON""!+W6GE>!/2%>Y! [@0)%UO[#FQ.,,A<"O.YM!G/9 9+
M!KV)S4E3\#U"%[D\ <+>&B3=#VCO>$(L0<'CR2-[\TU/VFY3W&BC#)^LE;30
MIT,^1;!>/NSY6T2U--&[M(;NT%0[OSZC[\^OKRY>'W,-<;(B6U>%^BPKZ3FX
M*/A2KZ,;_. ,(I=D#>N4M57="(:?NU+K"]. P +N R;LF1_>+ XCY\6CAQ*L
MK#A9#KEXRI#@NSPPHA!<./*O*0SDO,\_5V#8 ;4Y.R95YS4HOS6(3EQ%06,4
MAG;>O;O EGU@\1V5RO$4@/W' 1QXWP8P+/N___RW( Q?U/QC=^^\K8HUO'UC
M=W3UUOF-I46[S1 :>GL%KOO(\GSME,%SY5,&:@4VXI''@Y/W*57A#8@,D$*9
M<U$SOA][E>,.H'->5__L (0^\_PJB?=1&/9_+$E0YMWUNVOS_<?B##S4^'%D
M$OY/H6L@6'*52IG]P41#T]&/?9@5-OO?-+/0?W!FX6SI.S/'DLN4&.N :L+8
M.I!Q R93(P,LM@YU01LP\9:%$]X'*GPC5>>Y:(DDS&T'_LQ'/AOI@8=LUDRZ
M=L*S*C&'W ]FW)#'$/^UO2#\W?>53FRS?]-61-JVT'5GI9V,ZU6=$/$[^-\[
MZ2:/3+X9GU%#^X<#OP_5/GF*'>@\M5+'#[I7?_7G:TE3'XQDK*G&9INAVS?U
MR:E5/J$_A(%X]]$@OJG  LYQ;4^M7J31)[\ST[X^W>\9\"-2('FAN&9BFY><
ML$NTTM9J]FOG7;K'#_I1+"FGB1/G"DF->XC2YXI._>34^LKW9W/MVT4ASQ*=
MBOT^]-Q_7SY_^O#I[-TXL9JO]',=\%/^+C^1L-7<?/".P2U>GM*?R2Q9./X#
M_<G?_='^X/W@U(].Z<]D!MZW[R>'^Q._RT_LCPPG#S"].*4_ Q3S_@-P"; \
MNQ?3F_?"4P^G&F@$ASAEM9;?MGB]U_N0@#!^-"1A\DV0]%X/3<P^A9S]B+9*
MOAHA]NOB48"AOT<*I-B,_HI4]H]9%OFS N/$T;$7)-X>**1C=6QFT-=3/D=>
MIZU'P=T#C1-&B<+@&,W+WT.??_),HUXG#P$UGQ\>1/X^-X"A^-DPO19,)P0
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M:C@V+8#4N2+]%;V 0=[2C^@Q@D0L!,Y>PXL(/&$?H \>A)[C6,,NM][OP5)
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MN^:8"F<F=1U*GWV#6O=/$K-'GQ6\2S=*ECP/4>=;)>X\U,>/_RASRTRPT+[
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M)$-Z<:'QC300"?BLA)'19)*=6O["\^[7CEX!DXM'8K*4?S02D(SB>&@YC=Z
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MO&XNWOUR<TJ8,#>X8P#%'< ,A9^ W(S5[48U*";,&K5\1K1#8AP/?25UUOM
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M!ZP@9:;"BN+UT3NI"E[SDT0+C*$$1$2!4X!U^'@3MIUP;D(&!2FDR4J"QDX
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MOHVB_( @U*H"](K]T!D@B'6B#B[B#UWFVY1/NOVCDD6MD.(WJU'S4'?(.V@
M+:_"9[K:SP\9U42SV2^J0IIT]\@CM\>T\#K-Y\UU)-2.5"TUJ I(A4.8VF]J
M,['67%=H,[K@7%>^+CC.W!;('YN-VKR)'9_K$ "0 5!>-W"5>0PP5NYI>L3^
M5+8TMK +OD)E3L=7LA9H)DV[BNU&)/*"/@R%I=MJH9C"E1;%MY+K4IDN>F8J
M\0[RKL,"S=RU*YV^;F5U;&C[3S_=;#1<EU(RYJ/# N!<C&8Z8F+,C+5[_=@6
MB*8T_G&9>-_% @C78P+HG[P?3?3;ZZ<WG*3-<?'V<J=Y;:Z/V_M1XGP[:034
M:A\OU7<N@9]WZUA!-F, )9Y7*MX&)8Z!Y@ BNF1SB;QPA4K72A$LS/&;-P%;
M^$ZC Z1G!33B:M$B<__8OXT2'ASS9A9H[5"I4#;5X$A9V3L6G'3>CI4*Y8+>
M 7K!73J^*&N_;5\SWL:W:YOE\1WE+Z@V&O6S4'-L'0[.SWIHSOS>+SX$6_&[
MMID-P9;\<:DDIG=:@-_G%FA,#W1 ^_+UYC]02P,$%     @ :X%/6?Z%,\5'
M P  90@  !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&ULK59K;]LZ#/TK
MA(<-&]#%CS1IT24!DK;#,J"[1;-VGQ6;B87)DB?)<;M??RGYL71(LPOL D%L
M4GP<'DJB)[72WTV.:.&Q$-),@]S:\B(,39ICP<Q E2AI9:-TP2R)>AN:4B/+
MO%,APB2*QF'!N QF$Z^[U;.)JJS@$F\UF*HHF'Y:H%#U-(B#3G''M[EUBG V
M*=D65VCORUM-4MA'R7B!TG E0>-F&LSCB\7(V7N#!XZUV7L'5\E:J>].6&;3
M('* 4&!J701&CQU>HA N$,'XT<8,^I3.<?^]B_[1UTZUK)G!2R6^\<SFT^ \
M@ PWK!+V3M6?L*W' TR5,/X?ZL9V1,9I9:PJ6F="4'#9/-ECR\.>PWGT@D/2
M.B0>=Y/(H[QBELTF6M6@G35%<R^^5.]-X+AT35E93:N<_.QLP0PWH#9 +2V9
M9@U5,@-CF45BW[K%5!6EX$RF"&^_LK5 \VX26DKO@H1IFVK1I$I>2#6&&R5M
M;N!:9I@]]P\)=H\]Z; ODJ,!/U=R ,/H!)(H.3T2;]AS,?3QAO\3%X<H:#*<
M'L[@3MB%*5F*TX!R&-0[#&9O7L7CZ,,1_*<]_M-CT6<K.K%9)="A--7:\(PS
MS=$<PGD\TMS30/QBS^\)V!S!I'0=-"Q(HP3/&I*<Q(WU7K960%1Q2YD;)^*2
M%">PE#NWL&.P&LP'GEE./G$4O0952\Q^H7[:MU[*=' "= %!G?,T!ZGH)]]3
M4JN5(.Q;X-(B$6J!&J@Q55O)?V(V@#>OSI-H^.&OG[>HT[;_+YG0\</]]7^H
M(FUR7OXQ.)>ITJ5J-URG778E=8IYFJJ*&*%R;]#F*H/EEX?K+U^7#W-/$41Q
M&(WH.DYBQRF\AH^5$$]PV;?JZ*D;];ML])]W&3ZF.9-;!,)^>)\=C_6W;;G>
MSP]O[U=74**&Z_N[=W!@#[>Z*TRQ6)/=,/;ZX0%;TNU0TUAZ7J/?A7Y/H^;4
M@7@0G<?#'H\3H]_$L]]0,MLYH_0!SJ+1GD<<C:)G <;C3CS4O'#OZB]0;_V
M,^!W2C,%>FT_0^?-Z/AEW@S@&Z:W7!H0N"'7:'!&O=/-4&L$JTH_2-;*TECR
MKSE]!Z!V!K2^4<IV@DO0?UG,_@502P,$%     @ :X%/6<KZG,"T @  0P<
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MLC3V=.)K4\-&^FF'-V_QHCUX([@77)<*WO$,L]?YON'6$XPV!.?10<"/#;^
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MI)"?RI:5*E^+SU//\JK*5^+O+8\7O, .T+[,@46K"B[0?+#\[7\ 4$L#!!0
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M*V1=J255SDTM$E-)3",QG<0,$C-)S"(QF\0<$G-)S",QG\0"$@MO7AP$U,<
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M=TT=QE!>A[%W-%?.47??VJZ/X,1L-T_MC#JT\*+6V@MOUR]6WM"""E334<U
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MYJ&:CVH!JH64U@Z\IAYC+"]YZ)CP%JER+W9UM@]IIHRNE1]"_)G+)L!7+R;
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M2,F*',A"4[@O-BG..9PS,R)'\[U4/W0.8,C/@@N]\')CRFO?UVD.!=4C68+
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M*AM ^TLIS6YB/] ^\]$_4$L#!!0    ( &N!3UF?%4?T= ,   $1   9
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MH*D#Y=R/@F#HYY0)+QZYL8F*1[(TG F8**++/*?J]1RX7(R]T%L.W+%99NR
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M2 NK1=S[<'4?O,FTL7#L8#LM^^\9.]G0KM+ 2NU#XX\Y9SQG)L[,=U)]TR6
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M*BT#:!,21X R;V&2B7;)Q&V3CUW96&50_7*/9G30"Q("XUE47@;P1CZ) ->
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M(^H4E98!M(1 J]ZP:$U1=%$B<!<E4K$12I"U2P_4>D-@^WY@1A:5DP&<T 8
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M;0/U_4;*YN5-2W!Z%NSMWU!+ P04    " !K@4]9N-E-DJ\"  #+!P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6RU56M/VS 4_2M6D!!(@Z1YP2"-
M!&43F_9 ,+;/)KEI+!([LYT6_OVNG1"U(T0@;5\:.[GG^)SC^CI9"WFO2@!-
M'NJ*J[E3:MV<N*[*2JBI.A0-</Q2"%E3C5.Y=%4C@>865%>N[WFQ6U/&G32Q
M[ZYDFHA65XS#E22JK6LJ'\^A$NNY,W.>7ERS9:G-"S=-&KJ$&]"WS97$F3NP
MY*P&KIC@1$(Q=\YF)XO8U-N"GPS6:F-,C),[(>[-Y%,^=SPC""K(M&&@^%C!
M JK*$*&,WSVG,RQI@)OC)_:/UCMZN:,*%J+ZQ7)=SIUCA^10T+;2UV)]";V?
MR/!EHE+VEZS[6L\A6:NTJ'LP*J@9[Y[TH<]A S +7P#X/<!_+2#H 8$UVBFS
MMBZHIFDBQ9I(4XUL9F"SL6ATP[C9Q1LM\2M#G$Z_"0V*:$%T"81Q#9+5)!,\
MQXV"W(R4J%A.-4Z4Q@?NH":B( 7CE&>,5J01BMDM.2#?D442+OA!UDII*JE2
MH!79NP!-6:7VL>C#[379V]TY#N+P=)_T UR;_"A%JRC/5>)JM&8$NEEOX[RS
MX;]@XW/+#TG@O2.^YX<C\,4T_ (RA,\L/-B&NQCHD*H_I.I;ON#_ISJ61;=X
M.+ZX.?<GJJ$9S!T\V KD"IQT=V<6>Z=CR?PCLJV<@B&G8(H]_2+X$L.I\>!9
MOWBJ,]%R/?H/F*1ZJ^N.++)DIM.MTO>>YR7N:L1-.+@))]V<Y2O</" -?33[
MJ?"_OG$4QBR%SU3,O/!H4-%)[8KBEXJVI$:#U&A2Z@V@*J8?GX(?#7R2XJV!
M1\]<'(];B <+\:2%H==LMYHQ(_%K8AXK\J+H+Y'N1JLUU]Q7*I>,*U)!@3CO
M\ @)9'=U=!,M&MM][X3&7FZ')=ZV($T!?B\$]HI^8AKZ<'^G?P!02P,$%
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M[!SQJNE?C6%D[5K 4AIL*&Y:8LL'91UPOY#8!EK#=I7N3T3Z%U!+ P04
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MW]D)44&AVJ3M2^*S[[E[GK-]3K=2/>H2P)#GB@L]]TICZG/?UWD)%=4C68/
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M91UP?27QYG6&[8K](YC]!E!+ P04    " !K@4]9VI%T!YH$  "$'   &0
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M8[N,WD6LAH:O)9Z9S6<8ZMGS?)61+GS99HA-(E:M'1HU@"D#)72_\IM!ARU
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M5^IBU3X1XZ:HZV+9+BYT,M=ELX'Y_+8P::!;:7:P>ZC*]']02P,$%     @
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M>"<LU%X'S47<C7MAH5/.*)JM]=Y-Q[2Q=B\_::"SWL%I/^=!HPH4S1;=V.B
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M*^@'TVSYQUB+O:DV\DW[9<NM/M>S=0\U\J TIZ+MSSWWU*DH%YJA!Z7Y4%J
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MGB5Y%8DJ29?E3Y?#2O:\KC^<J5ZR;2_=([T,R?L\JQ8EH;)C\X[VL;V]XUH
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MAM(B10OVOO&I'TX//$@*+<LZRH9C;W)0-N[XH#.JQQ[M3W)4!TU=: ?8L5O
MG[.T(K>U..YK<73J .E)OH/2(D5S?&,K//*=@WT$U/(]4M:=ML<>Q_H7M(>@
MJ/Z9,M!FK?/=;NUUIS:@=BV4%D%I%$IC4%H,I7$4S92B=FV=E[=M':AO"Z5%
M4!J%TAB4%D-I'$4S9:KM6\?NWWX0Q4QD57+7R'26K]9)]NU?ZAP*,DO6:94L
M]WW=GTE:EANIY*0D#TE1IZM=@\5K>]W>6AUWC69&X:BUIXJ@92F4QJ"T&$KC
M*)HI0^T>.W;[F'Z5.DQ+H>Q#*46E+7UL;SOGYMJ.[ZVV+6V\?V; Q31H2PU9
MDT)I#$J+H31^ZMLU):3=9\=N/_=*HNRLWGJ9'IY)XOA^&/AMR2#+4BB-G;L0
M,;0L1]',4RNU:^W:'= GY%9V8E_M*)HE;(J@!2F4QDYW/X86Y"B:J1=M0KMV
M$[HSY#IS)V5']Q:.TYD)N6WQ((M2*(UU+4)'^ 4MRE$T4T#:RG;M5O8Y,9D=
MT5LH]@Y9@JT(VA$*I;%3B^6H:"M4R5;7@0VT1QQ%,Y6EO7'7[HW;\S%[X]Z:
M\LY(C2)H30JE,44[F8]!JW(4S92(MLE=NTW^E!S-CNPM'/]DQA1!*U(HC9W1
M_QA:D:-HIF2TI>Z>L-3[)VYV8F_%!(<9E#,9'89D$;0NA=)8QU*$$^_P:H,8
M6I:C:*9XM GN6MW+=BQW0C90=UO1VI&5-P[;JH$:UU :.[(0KM,.Z*!E.8IF
MJD9[TJ[=DZ[]F_K*ODZ10&UE*"V"TBB4QJ"T&$KC*)HI-^T]NY,73^I<J!\-
MI450&H72&)060VD<13-EJOUM]UQ_N]]5CG9L;RE"S[>&TBB4QMQ#/[S[\@QH
M68ZBF==Y:S_<L_OA'S<WY:Q(MP-#66&5;E;*[JR=\6TLW-?XM-?L*T$H+8+2
M*)3&%&UL'OVU_75H38ZBF?K3_KIG]]=;0?"K-"-B4^3EV5*#>NQ06@2E42B-
M*=J^U'PYT&A+#>K$HVBFU+03[]D=XB=$?W9B;W5!SRF'TBB4QKS#,\L/MF)0
M*QY%,Z6U-UV*W8I7(UB?_/5>U"+KG@ %.P,*=@H4[!PHV$E0L+.@8*=!>0Y_
MW]/^ON>_^%#6@_K_4%H$I5$HC4%I,93&4313ICI3\.R9PE.'LG9L;RE"3].'
MTBB4QA3M]*E=T+(<13-5IL,'SQX^/,]0%AI20&D1E$:A-*9HIX:RT!@#13/U
MIV,,SQYC?/=0%AIU0&D1E$:A-*9H]K.W8VA-CJ*94M,1A@>??<5.[*TN:$(!
MI5$HC7DG)X>)H04YBF9*2\<.GCUV^%-=AY'<%6([(V]S365]"A&56[.U2#+R
M:W8ORJIY\SK)OG3*#9I"0&D1E$:A- :EQ5 :1]',23]U5.&/7GRPZT.3"B@M
M@M(HE,:@M!A*XRB:*5.=:/CV1..3*%8DOY<[Y(=%.EN0^WPI=\KDH9GJOKZ.
M4KY57W[9'IE4>:UIV;A6;+;;P3]><UF_?R/4Q9B=4H8F(5!:!*71$RO F8R.
M36G$H!V)H32.HIFZU?&(?^:%"E4CX%OKU;YV5F^Q/?V*!6A'*)3&H+082N,H
MFBDV'9CX]L#D"4>9<A3]WV*>9DGQS3*(MM?M+4QHR *E42B-06DQE,91-%.K
M>[/-OWS(XD-#%B@M@M(HE,:@M!A*XRB:*5,=LOCGABQG>T)V8F\50O,5*(U"
M:0Q*BQ7MQ$R_J)JFNG2XXMO#E:?ML/?NT=2I/VBX J5%4!J%TAB4%D-I'$4S
M=:I#&'_\\CMK:# #I450&H72&)060VD<13-EJ@,<WQ[@?%I(ZB)?SDE5)/6D
M-8UC8?@]<NO9*49HC@.E1?YA5C)MSVP*K<B@M!A*XRB:*3$=Y/@GIN=_CM,A
M[#5[JP\:ZT!I5-'L)S P:,T82N,HFGD?+1W7!&?>'^ </]'.ZJLK*"V"TNB)
M;\WB=3)H1V(HC:-HIMATZ!+8/?_.P>_;N/M6;="@!$J+H#2J:)9S%QBT8 RE
M<13-U)0.1 )[[/#=0U[Y[,FW$X3F*U!:!*51*(U!:3&4QE$T4\XZ<@E>_IZ^
M 31M@=(B*(U":0Q*BZ$TCJ*9,M5I2V"UR??VY+N1\/%S'NRLWOJ#QBB*=OH>
M@]"R#$J+H32.HIG2VKNUKSTA>;:YS^UU>\L0>_M?E2ZT9E+WQVT58F_MB[VW
M+_;FOL^1I 0Z20GL2<KW3GUNQ_<6&S0T4;1ZQN]J[[)R)W#;:H/F(5!:#*5Q
M%,U4F\Y# OM%*>^3K^FJ-O[R2F[Z4KE]NROR4HZ/BWPFQ+PDMT6^(N)1DZ8!
M;9F\S5ZVMPJAF8BB&7?9<D:'<^]1:%D&I<50&D?13!7JN",X$7=(195R^%L/
M,F9Y*<4E'S3[UAZ*@P8?4%JD:/N*"PYOFD:A11F4%D-I'$4S]::SCP!^$<M3
MK)O.>XO9N]9;I]"(!$JC4!J#TF(HC:-HAIQ#':6$+W_E2PA-7*"T"$JC4!J#
MTF(HC:-HIDQU"!.>&\*<8=W86;WU=YAT=-^1!UJ60FD,2HNA-(ZBF=+264QH
MSV*>S;JQU^TM0[?3;&D/?R-H50JE,2@MAM(XBF:J4$<HH?VJE>^U;NSXWF+S
M#LY0Z;AK';0FA=(8E!9#:1Q%,Z6F8Y#0'H,\EV]C+]M;@O[!N-=Q_0ZK)8+6
MI5 :@])B*(VC:*8,=602VB,3A'%C+]%;<H<WUIAVZ0UZ^0B4QJ"T&$KC*-I6
M;\-R(405)55R=;D2Q9UX)Y;+4BIIDTE\/;#8O4H*<5O?]//U6W<PE"WUQZ\N
MU_*X[WU2W*5929;B5C8=78QE1XOZDOK')U6^KI%R#%Q5^:IYN!#)7!3U!^3[
MM[G<E*HG=8&'O/C2=._J_U!+ P04    " !K@4]9EHI_A2\$  #$%0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6R]6%UOVS84_2N$"A0)L$2B;,M.
M:AO(1X-U6(H@;;>'80^T1%M$)=(CJ3@%^N-W22F2%2M<'&A^L?EU#^^Y]XHZ
MXG0CY'>54JK18YYQ-?-2K=?GOJ_BE.9$G8HUY3"S%#(G&KIRY:NUI"2Q1GGF
MAT$0^3EAW)M/[=B=G$]%H3/&Z9U$JLAS(G]<TDQL9A[VG@;NV2K59L"?3]=D
M1;]0_6U])Z'GUR@)RRE73' DZ7+F7>#SJS P!G;%'XQNU%8;&2H+(;Z;SJ=D
MY@7&(YK16!L( G\/](IFF4$"/_ZI0+UZ3V.XW7Y"O['D@<R"*'HELC]9HM.9
M-_%00I>DR/2]V/Q**T(C@Q>+3-E?M*G6!AZ*"Z5%7AF#!SGCY3]YK *Q90 X
MW09A91 ^-XA>,!A4!@-+M/3,TKHFFLRG4FR0-*L!S31L;*PUL&'<I/&+EC#+
MP$[//PM-%=("Z90BQC65+$>QX EDBB:FI43&$J*AHS3\00HU$DNT9)SPF)$,
MK85B-B4GZ*8>3.A"P\#O%$*,,D86+(-%L-71-=6$9>H89C]^NT='[]]-!M'P
MPS&J&N %^IJ*0A&>J*FO@:1QU8\K0I<EH? %0A&Z%5RG"GT$#DF'_97;'H<.
M !^B6X<X? KQ9>A$_*W@IV@0_(+"(!QV.>0VOZ8QF&-K/G"X,Z@S/K!X@Y?P
MF(HSH0I)31H3FPU(+N/EF6"?K04\\&@A)$ SOE+H+P."&&1?_=V5DG+'8?>.
MYB0Z5VL2TYD'1XVB\H%Z\_?O<!1\Z I'3V"MX SKX Q=Z/.=>NUB6T*,+(0Y
M)A_FHW&$I_[#-HO=1=$H&M6+6MZ-:N]&3N\^\5A:!X\26K:.S=.2O<9I)_*^
M*1KMD#N9!$$WN:@F%SG)W;"%%"HF'(ZW.(7)3AI.C'UI] 36HCNNZ8X/_AB.
M^PQ.3V"MX$SJX$R<M7"1)/:58M],TKR)3\3RI( J)TI1W5D9DYV:'&Z59,G)
MN>L;.9W5G,Z<G&X99WF1HY_H=97N1-LWF3V!M8CCH-$8P<%KO=JRI_CTA=8.
MT)8(PZ]X[8#XRCNINHT'Z <ELJN&KMR6;Z45-K1"=\F3Q[U*W@VW=TY[0FN3
M;V06/KS.PKT*K;[0V@%JI!9^C=9ZL>C=QD-'T3LMWTJKT6C8+=)V/WE^HNKL
M[^39JS#K"ZW-O9%P.#I\S?<J^?I":P>H$7W8*9M P4.]4Z61A$_I3K:E/0ZW
M=$QP&N#)V3,IX][HK40:@8;="JVSRLOCOI-63\JKXOY_Z#C<"#E\=O@J[U7N
M]876ON]H]%[HE$O_7>65_?,J'^')LRIW;[0O$7_KGBRG<F6O#Q6*1<%U>656
MC]97E!?V8LYOEI?WF[=$KAA\GV1T":;!Z1@.7EE>&98=+=;VUFTAM!:Y;::4
M)%2:!3"_%$(_=<P&]<7M_%]02P,$%     @ :X%/69_A6BO@!0  J"4  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#DN>&ULO5I=;]LV%/TK@@L4+;#&(JDO
MIXZ!)=K0#>M6I.WV,.R!MNF8J"1Z(ATW_WZDK%@6R3".QN3%EN1[C^ZYM'B.
M*$UWK/[&UX2(X'M95/QBM!9B<SX>\\6:E)B?L0VIY"\K5I=8R-WZ9LPW-<'+
M)JDLQC ,DW&):36:39MCG^K9E&U%02ORJ0[XMBQQ?7=)"K:[&('1_8%K>K,6
MZL!X-MW@&_*9B*^;3[7<&Q]0EK0D%:>L"FJRNAC]",YS!%5"$_$G)3M^M!TH
M*G/&OJF=7Y87HU!51 JR$ H"RZ];<D6*0B').OYM04>'<ZK$X^U[])\;\I+,
M''-RQ8J_Z%*L+T;9*%B2%=X6XIKM/I"64*SP%JS@S6>P:V/#4;#8<L'*-EE6
M4-)J_XV_MXTX2@#1 PFP38"G)J V 9V:$+4)4=.9/96F#SD6>#:MV2ZH5;1$
M4QM-,YML29]6:MP_BUK^2F6>F/W.!.&!8(%8DX!6@M2T#!:L6LJA)4NUQ5E!
MEUC('2[DEQQS$;!5L*(5KA84%\&&<=J,X;O@(Q;;FHH[%5"PZN:=Q"OE,,Q%
M@*NE.LK7K!;[PW-6RV)I=<.;'YNH-SD1F!;\K03[Z>MU\.;UJPPET?NW0;LA
M:PR^K-F6RQ0^'0O9 D5DO&CI7N[IP@?H_KJMS@(4_A# $$:6]"MW>DX6,ATT
MZ<B2GI^>#OOI8]F*P^#!P^#!!@\]A$?YHF!\6Q/5VF73.CE.M-K/!\UU-9<7
M^W&K_U8@ 94#R?^Q]6]_QLA^1C4+G?,-7I"+D9QF.*EOR6CV^A5(PO>V;OH$
MRSV!]3J-#IU&+O39):Z^'771UK@]0-P J-GV=A;!.)Q,Q[?''3&C8 K#I!^5
M.XL92#4Z4(V<5',Y!=QB-1M;:>Z3DR," ,6)3M,2%<(DUF@Z"QE(,S[0C)TT
M_Y 37BTG*5SMIQ].2UK@^I%!C@U>$0JA1MX,0BG0.I0[JQO(/3EP3YS<?R-2
M*8."XCDMY-1M'^C$8!&G"="HFD%); RSLYB!5-,#U=1)]9K=X4(*TH+4@J[H
M BNY>X1Y:I!*88(TYF90@F"J,7?6-I!Y=F">.9E_84**LU)5&\?,Y(BB,-)(
MFE%Q%&9:*_+,G/DB- D/4;WR)X?R)X_\1[GT)6M<!2"X([BVD7 B/%6K?(+E
MGL!ZG0-AY^G"%_<%[2D]-=LK6NX+K=_N(PL-_J\Y:!%ZF@"AKIJ6*#B!F7:Y
MN:L9RK;SG,!IM 8*9PO:4TY=-RTQ&=3)/X<+!)T-!&X?>))RMAB]88SB6&=K
MB8(38["?PPJ"S@L"MQETBP@P;5XLI5(G:HE"H4'T.<P@Z-P@<-O!2R)VA"BQ
M4?]IU$B.?7 ]&;>V-S[1<E]H_1YVKA(D+R\[GLQCVVZ?:+DOM'Z[.V<+W-;V
M%-DQ72I*0*+;/$M8E*7&U/L<;A9T=A:X_>PC]Z7 ]*JV&U/W29[\#_"$UF])
M9Y&!VR,/E.*)18J34&^45S_L"ZV_3-898NAT@*?)=HO1NUB0OC1S98F2W=-O
M_-SU#.7;.5+H=J1NV8:FS92R/=$O%4O8!$2ASO0YW"@\6@%UN]%[W4;-!1 _
MK-MNG"<O;/I=V7P.4PL[4PO1RR\C>_*M;;M]HN6^T/KM[CPU='OJ$W0;FI89
M0JC?05BB0)I%NK-VES.4;N>LH=M9/Z+;[NPG_U',M5?;PK.OD_9;TAEEZ%Y_
M':;;;M G=\I<ND4)TA]$^#IGOU&=Q85NB_N(CIFVU7:56#PP2"-]/=Y=R5"F
MG;N%;G?[D<G9MUGN=&F83_-ZY14M]X76[U]GA>'DY37,Z_JR5[3<%UK_:6AG
MJ)';4)_R/-0TRME$O\NP!($XUA7,7<Q0LIV;1FXW/>09$C+-L^4ADB7*\A3)
M7=Y0^IW%1FZ+[9Z$V^3CIS\9B VB9E2:9;HLNPMY*M'QT5LQZAVFC[B^H5)Q
M"[*2\.%9*JNI]Z\%[7<$VS0ORLR9$*QL-M<$+TFM N3O*\;$_8YZ]^;P<M;L
M/U!+ P04    " !K@4]92E%4&%@%  !\)   &0   'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6R]FMMNXS80AE^%T :+7<"-CCYE;0.))6%;-$60-.U%L!>T
M1-O$2J(KTO$&Z,.7I!19LA4E;J>YB76:;TC^HZ$XX63'\N]\38A /](DXU-C
M+<3FPC1YM"8IYN=L0S)Y9\GR% MYFJ],OLD)CK51FIB.90W,%-/,F$WTM9M\
M-F%;D=",W.2(;],4YT]7)&&[J6$;SQ=NZ6HMU 5S-MG@%;DCXGYSD\LSLZ+$
M-"49IRQ#.5E.C4O[(K3'RD _\0<E.UX[1JHK"\:^JY.?XZEAJ1:1A$1"(;#\
M>21SDB2*)-OQ5PDU*I_*L'[\3 ]UYV5G%IB3.4O^I+%83XV1@6*RQ-M$W++=
M5U)VJ*]X$4NX_HMVY;.6@:(M%RPMC64+4IH5O_A'.1 U \=YP< I#9RW&KBE
M@?M6 Z\T\-YJT"\-^F\U&)0& SWVQ6#ID?:QP+-)SG8H5T]+FCK0<FEK.< T
M4Y%U)W)YETH[,?N-"<*18$BL":*9(#E-4<2R6 8/B=419PF-L9 G7,@?&54"
ML25:T@QG$<4)VC!.=93\A,+J8DP60EZX94\X$4]H3G)!ES3"REM"\8(FTD8>
M?_*)P#3AG]''#R-WX'V1C4"_K]F6XRSF/72FSJ]IDD@'?&(*V675<#,JNW=5
M=,]YH7L#=,TRL>8HD#V*F_:F'*IJO)SG\;IR.H&_;+-SY%H]Y%B.AX+[6_2I
M;/CGEM;-7X%A";-')>S^SD>?SMHP?C?&)Y%LDZTQ[JMM"KIAE]O5";#P[2US
MNF -+=PJ=EU-=U^B4QXEC&]SH@(RUH$DPY1F1<+5B6LALRE:L%RB:;;BZ$%!
M$)5QS+^UA5/AT6OWJ-+\!=_@B$P-F<<YR1^),?OXP1Y87]K4AX3YD+  $A8"
MP1HQX%4QX'719_N,4\LJ;<(6F+[&J.GV<69;X_%X-#$?ZY)U>CM5LF.?8WLX
M\IHN TB7(1"LH46_TJ+?J<55]9JU"5#8#FJ#,70]ZV PYIT>3AW_8Y=]SQJY
M!^,/Z3+L'TGN>>[8JEPV!G90#>R@<V#E)"V3F8SQRY1MY?3[-SIK&^%.R*FY
MJX"-:AUQ^LV!\R']!9"P$ C6$&M8B34\/2/U$!9HB6F.'G&R)6WJ#8\3E,Q0
M[D&TSCN=G_J"#(]>D+'3'Q\F*$B7(1"L(<VHDF;4*<WSUVCTPM=HFRR=Q%-?
M*DB8#PD+(&$A$*RA\;C2>/SN'X5CR!B A/F0L  2%@+!&C%@6_M5K77RF]Y#
M9+DDNI)1K'0)%RB7=UJ7E07?=FJYT3IW[?%!.NYNQZER@M("4%H(16LJ6JM3
MV/_AX[(TKL^>0]>R#L7J='&R6,<^!T<^ U"?(12M*8*S%\'Y7[YM2FQS)70L
M3Z?SD^6!I 6@M!"*UI1Q7S>Q.Y?D>H[4"PF5_7HH)5C-E[JR1[.-G!L?4I(N
M2/Y-KC3^S3=3M_M3)TQ0F@]*"T!I(12M&1;[4HKMO?NGDPU9W9B#TGQ06@!*
M"Z%HS5#85W+L[E+.'5UE^FV7*6&;L87R@!<)*?)#[]4$4-#M^LK2&9X??3R!
M5GM :0$H+82B->7<UX_L[@)2R[]AT*^U_\(\7!?YOE5+T+(2*,T'I06@M!"*
MUI1\7X6RA^^?S"$K07-0F@]*"T!I(12M&0K[JI?=7?9Z9>D$6N$"I?F@M*"D
MU5<A_:-52 CELRG6OGQE=U9&#FO]K8J!UJ- :3XH+2AIKRD&6FLR:YLI4I*O
M]+87CO2"J=A745VMMM9<Z@TEYO[Q8E_.-<Y7-)/+);*4IM;Y4'8D+[:Z%">"
M;?36C 43@J7Z<$UP3'+U@+R_9$P\GR@'U8:CV3]02P,$%     @ :X%/62@;
M 2*L @  9 @  !D   !X;"]W;W)K<VAE971S+W-H965T-3$N>&ULM99M3]LP
M$,>_BA4D!-(@:1XZ!FVD03=MD\:J MMK-[DT%HZ=V6[+OOW.3L@*"QE"[$UL
MQ_<_^W?GG#/92G6K2P!#[BHN]-0KC:E/?5]G)514'\L:!,X44E74X%"M?%TK
MH+D35=P/@V#L5Y0)+YVX=W.53N3:<"9@KHA>5Q55O\Z!R^W4&WGW+Q9L51K[
MPD\G-5W!%9B;>JYPY'=><E:!T$P*HJ"8>N]'I[/$VCN#[PRV>J=/+,E2REL[
M^)Q/O<!N"#ADQGJ@V&S@ CBWCG ;/UN?7K>D%>[V[[U_=.S(LJ0:+B3_P7)3
M3KT3C^10T#4W"[G]!"V/VV FN79/LFUM X]D:VUDU8IQ!Q4334OOVCCL"$;Q
M$X*P%83/%42M('JN(&X%L8M,@^+B,*.&IA,EMT19:_1F.RZ83HWX3-BT7QF%
MLPQU)KV4!C0QDI@2"!,&%*M()D6.F87<]K3D+*<&!]I@@RDW1!:D8(**C%%.
M:JF9R^$1F2NY8?9$:((G$H^%8:I1+$% P5"YY&Q%C3,Y(I=XKNM[#3F8@:&,
MZT.<^7"S( ?[>R?1.#X[)&T'-TBN2[G65.1ZXAODMQ1^UK*>-ZSA$ZQ?UN*8
M1,$;$@9AW"._&);/($/YR,FC'OGL^?+PH=S'I'69"[O,A<Y?]/\SUQ?*9O&X
M?W%;C$YU33.8>EAM-*@->.G^WF@<G/4%]C6=S5[)V8.@1UW0HR'OZ9\#WA>S
M1ILXK:VWFS28^)O=0/S38C:X_@OIXHXN'J1;#'ZO?<2-O_$.SRA)DD?0O4;O
M'G$/[NR%W$G'G0QR7TN#7\.W#K6/-/DK<SVDO4:/27N,PBCNC!H"?Z>DV_OW
M*U4KAC630X&RX/@MZE5SIS4#(VM7Y9?2X)WANB7^!H"R!CA?2*P7[<!>'-V/
M1?H;4$L#!!0    ( &N!3UGN;$VE' ,  )T(   9    >&PO=V]R:W-H965T
M<R]S:&5E=#4R+GAM;+56[V^;,!#]5RPF5:VT% ()]$>"U*:=MDF=HG;=/CMP
M :M@,]LDW?[ZG0UA:4K9E^U+L.'>\WMW!Y?95L@GE0-H\EP67,V=7.OJPG55
MDD-)U:FH@..3M9 EU;B5F:LJ"32UH+)P?<\+W9(R[L0S>V\IXYFH=<$X+"51
M=5E2^?,:"K&=.V-G=^.>9;DV-]QX5M$,'D _5DN).[=C25D)7#'!B83UW+D:
M7RPB$V\#OC'8JKTU,4Y60CR9S:=T[GA&$!20:,- \;*!!12%(4(9/UI.ISO2
M /?7._8/UCMZ65$%"U%\9ZG.Y\Z90U)8T[K0]V+[$5H_4\.7B$+97[)M8SV'
M)+72HFS!J*!DO+G2YS8/>P#DZ0?X+< _!(1O ((6$%BCC3)KZX9J&L^DV!)I
MHI'-+&QN+!K=,&ZJ^* E/F6(T_$7H4$1+8C.@3"N0;*2)(*G6"A(S4J)@J54
MXT9IO& %-1%KLF:<\H31@E1",5N2$5E*L6&FP(I@@V&5-9,-8@4<U@R1JX)E
M5-N0$5GDE&=X/N/V?(Y=6^THR/$-:,H*=8*!MX_WY/CHW5D03BY/2+LPL*^Y
MJ!7EJ9JY&M-A3+E):_VZL>Z_83TD=X+K7)%;=)OVX!?#^+$_0.!B';IB^+MB
M7/N#C)]K?DH"[SWQ/7_2)V@8?@,)PL<6'@S(";K>""Q?\/][HZ\ZS>&3_L/-
MU^M"532!N8.?)P5R TY\]&X<>I=]F?E'9"_R-.GR-!EBCZ],>V>,<\8S8[_"
M1(F^AKIN>*:6QWQ?-_%H/)V>S]S-OI>^*#^8=%$O1$X[D=-!D;?/E2F;?2]-
M/=\6V?"$^\='WH'$GAC?/^M7&'8*P^$T)KJFTG1-AM-'$11:"*6P!24D(N/L
M%_89OO("Y4OLOA)+F9MYLC'=B7OH<Q.^4AI-#LR\#AF=1_U>HLY+]+>6 )X.
M-T/4VPS3 W']4><'\MR]"5""S.Q@5)BDFNMF&'1WN]E[94>.^R>\&=QW5&8F
M_06L$>J=1GBV;(9AL]&BLO-D)31.)[O,\?\#2!. S]<"OQOMQAS0_2.)?P-0
M2P,$%     @ :X%/69F"J+\  P  I0@  !D   !X;"]W;W)K<VAE971S+W-H
M965T-3,N>&ULM59M3]LP$/XK5I 02(.D29MVT$:BA6E,8JIXV3Z[R;6Q<.S,
M=EO8K]_9"5GI0H2F[4MB._<\]]R+?!EOI7K4.8 A3P47>N+EQI1GOJ_3' JJ
M3V4) K\LI2JHP:U:^;I40#,'*K@?!D'L%Y0)+QF[L[E*QG)M.!,P5T2OBX*J
MYREPN9UX/>_EX):M<F,/_&1<TA7<@7DHYPIW?L.2L0*$9E(0!<N)=]$[FPVM
MO3/XQF"K=];$1K*0\M%NKK.)%UA!P"$UEH'B:P,SX-P2H8P?-:?7N+3 W?4+
M^R<7.\:RH!IFDG]GF<DGWL@C&2SIFIM;N?T,=3P#RY=*KMV3;&O;P"/I6AM9
MU&!44#!1O>E3G8<= /*T \(:$.X#XC< 40V(7*"5,A?6)34T&2NY)<I:(YM=
MN-PX-$;#A*WBG5'XE2'.)%^E 4V,)"8'PH0!Q0J22I%AH2"S*RTYRZC!C3;X
MP@H:(I=DR005*:.<E%(S5Y(3,E=RPVR!-<$&PRH;IBK$ @0L&2(7G*VH<28G
M9(J-]YC)K;",\%1:IXA*Y4JPG^C1DEAAST 5.;H$0QG7QPB\>K@E1X<'HRCN
MGQ^3>H'ZR7TNUYJ*3(]]@^FQ0?IIG8IIE8KPC53$Y$8*DVMRA=%G+?A9-[X7
M=A#X6)>F..%+<:9A)^.7M3@E4?"!A$'8;Q/4#;^$%.$]!X\ZY$1-KT2.+_K_
MO=)6G<IYO]VYO<W.=$E3F'AX76E0&_"2PX->')RW9>8?D;W*4[_)4[^+/;E#
M/I8")D2;IH5+S)9LZZII139P9/;2W20GO0#+O=F-I\UH%#5&KW0.&IV#3IW7
MMH2 &M\IM&*+=S6$@SV=+3;]N%UFW,B,.V5.JZM#OT-A_(?WP<<]@9V^_K(Q
MADTDP\Y([J6AO$WW\,_J#H,]X2TV83C:2ZV_,PD*4"LW(#46>"U,-12:TV8&
M7[C1X_\VKP;X#54KAK<TAR5"@],ANE;54*PV1I9NKBRDP2GEECG^1X"R!OA]
M*?&^J#?60?-GDOP"4$L#!!0    ( &N!3UE"_<<U_P(  /L(   9    >&PO
M=V]R:W-H965T<R]S:&5E=#4T+GAM;+66:V^;,!2&_XK%I*J5UG(G69L@]39M
MD[95O>VS R>)56,SV[GTW^_84)8F-.J'[0O8<-[CY[S&-J.55$]Z#F#(NN)"
MC[VY,?6I[^MB#A75)[(&@6^F4E748%?-?%TKH*435=R/@B#S*\J$EX_<LQN5
MC^3"<";@1A&]J"JJGB^ R]78"[V7![=L-C?V@9^/:CJ#.S /]8W"GM]E*5D%
M0C,IB(+IV#L/3R^'-MX%/#)8Z8TVL95,I'RRG:_EV LL$' HC,U \;:$2^#<
M)D*,WVU.KQO2"C?;+]D_N]JQE@G5<"GY+U::^=@;>J2$*5UP<RM77Z"M)[7Y
M"LFUNY)5&QMXI%AH(ZM6C 05$\V=KEL?-@1A\H8@:@71>P5Q*XA=H0V9*^N*
M&IJ/E%P19:,QFVTX;YP:JV'"SN*=4?B6H<[D/Z0!38PD9@Z$"0.*5:20HL2)
M@M*VM.2LI 8[VN -9] 0.253)J@H&.6DEIJY*3DF/S&+0FRE;!05)1%2'+_T
M.:,3QC$61SR\ D,9UT>HNGZX)8<''X9QEIP=D;:!,.1^+A<:L^B1;[!62^P7
M;5T735W1&W5]6X@3$@<?211$28_\<K_\"@J4ATX>OY;[Z'!G<]39'+E\\?^W
MN<^+9O"D?W"[$9SJFA8P]G"E:U!+\/*##V$6G/4Y\X^2O?(I[GR*]V7/KZN:
MRV< !=QY4=-G.N'0^P$TF5*7R6Y6RSP<Q)]&_G*SF)Z@8?8WZ!5DTD$F>R'/
MBT(M&C@E.7??N71?/FSA&[KN9V\&R%YA!>$6>T]0F@3][&G'GNYE?SR_WVMJ
MNC-F%&Z,V8#M!L7I6Z9F'5BV%ZS9.FAKK3/.&;MM*:QKNV9ZX;-=PY)HB[TG
M)DOZT0<=^N =Z!73!9Y&5 !N6GL]'NPB;%/NAMAMJ ]RV$$.WP'9LQ7W$0YW
M5DTZC),MQMV@09BE6Y3^QM%D?PN^4S5C0A,.4Y0%)P/4J^:H;3I&UNZTFDB#
M9Y]KSO'O!)0-P/=3B5MIV[$'8/>_D_\!4$L#!!0    ( &N!3UF&+S]OS@(
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MU<M/_.!19V!>E4WWTWLYM"4S+]\WHMH<#I86;(KMV^_L[T,D>@?0<.  _W"
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M5T"1T6O4V9M0AZ7!C =2"L<^-SJ<3+>\1J4C+#6UZ@[H*,*GHPB5CK#4U
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M[@61FRRCXNL-I'PWM5SK9>"!K1*E!^S99$U7\ CJ\_I>8,^N56*602X9SXF
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MSR:QJI \"N48X ..HUXS0K))XOK@+4BPGR1?I>;9L58!;(0A)J3K%6(0#I/
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MQ8F7YXGEC61Y<21WSZ1D:7&IC\4(UP;J_8HQ^7RC/U"?ZB[^ U!+ P04
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M0#M/A!: _9Q#Z]!-M('^#T+R#U!+ P04    " !K@4]9"ABT]CT'  "K,P
M&0   'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6R]FVUOVRH8AO\*RG1V-FEM
M#'Y)TK61UL;;>J1-5;>=\YDZI+%F0V9(7_[]P8X;!YO0>'JZ+VWL\-S@RP2X
M>>S3>U'\E$O&%'K(,R[/!DNE5B?#H4R6+*?R6*P8U]\L1)%3I0^+VZ%<%8S.
MJZ \&Q+/BX8Y3?E@>EJ=NRJFIV*MLI2SJP+)=9[3XO&<9>+^;( '3R>NT]NE
M*D\,IZ<K>LN^,?5C=57HH^%699[FC,M4<%2PQ=G@ SZ)_; ,J$K\F[)[N?,9
ME9=R(\3/\N!R?C;PRA:QC"6JE*#ZWQV[8%E6*NEV_*I%!]LZR\#=ST_J'ZN+
MUQ=S0R6[$-E_Z5PMSP;C 9JS!5UGZEK<?V;U!54-3$0FJ[_HOB[K#5"REDKD
M=;!N09[RS7_Z4(/8"<#!G@!2!Y!V0+@GP*\#_$-K".J H!T0[0D(ZX#JTH>;
M:Z_ S:BBT]-"W*.B+*W5R@\5_2I:\TIYV5&^J4)_F^HX-?TJ%)-(":26#*5<
ML2+-42+X7/<%-B\_29&E<ZKT@53ZG^XD"HD%>I/R1.3L+<J$E.@(?5O2@I5?
M<-V[5X58I$J?C7^M4_6(<J:68H[>S)BB:2;?EM_\N$9O7K\:^U'P_BVJ/^@6
MH.]+L9:4S^7I4.D++)LY3.J+N=A<#-ES,1'Z(KA:2A3K]L\M\;$['A.'P%"3
MW>(E3WC/B5/Q'\J/$0[?(>*1P'9!SX2O=;CO[0V?'1[NVW"XPV<LT>'8%F[
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M;-X,V1PHL:I>?;@12HF\^KAD=,Z*LH#^?B&$>CHH*]B^GS/]'U!+ P04
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M$BAK@/-SB86WZ=@%VK=7^A=02P,$%     @ :X%/6;.V^D"I!0  Q2H  !D
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M>AUT^?SD_YO/JQ8?%TFQ78Q9ZY5ZXFI]E];?QM1^;\$JN<^K**WGHJBWOM!
M']4<5'-1S4,U']4"5!.H%E*:7H-=H#_! _T)&NBCFH-J+JIYJ.:C6H!J M5"
M2M,KI OT)^9 _]M6:VB@/^D)] ^LUM \']4\5/-1+4 U@6HAI6WJX*Q<2%DY
M:A5T<[V4Q5S>RC0MU2)+#?97)_41M>VC:NS/ZN^*??G:/CE3+;NGWUROHKE\
M&Q7S)"NM5,Y4T\'IA1J@S>>/'^]4^:HFK;N\JO)E<W,AHZDLZB>HG\_RO'J\
M4W?PD!>?FLV[^1]02P,$%     @ :X%/6>T7B3^7 P  GQD   T   !X;"]S
M='EL97,N>&ULW5G1;MHP%/V5*&VG5IH:(&L@*R!M2)4F;5.E]F%OE2$.6'*<
MS#$=]''_LK=]Q3YE7S+?.(1 ?1GMPTH65&+?DWON\?6U@]5^KI:<WLPH5<XB
MX2(?N#.ELK>>ET]F-"'Y>9I1H9$XE0E1NBNG7IY)2J(<G!+N=5JMP$L($^ZP
M+^;)5:)R9Y+.A1JX[4YE<\SM0Z2MP1O7,7RC-*(#]^[TU==YJBY_?__IF-;1
MZZ.CUMW9Y6/DM(#.7,]*?+$7\7EK%[=&,?K 3G^,J#[>2W-WD[1X]D2S&*\3
MS*UGU_+K!R*F G:K"2UJ=$9:E2#H(,[=EMWYI.Z,#:C;1B)OAD9C=_:<^ITS
MCY'[5FTU89CC?I5>)GA'1:(!]J[XOT8P(;QR"0_[<2K6*]EWC4%K( EU[@D?
MN"/"V5@R\(I)POC2F#M@F*0\E8[26X@6U09+_F#@MNG![E+R)$RDLHAM(ICO
M<?GX%K#J@4#&>240=AHP#/L948I*<:4[Q<.%\1'DE.W;9:853B59MCL7[MJA
MN.D@XU1&5*YW-'=E&O8YC4&.9-,9W%6:>0 JE2:Z$3$R304I-*P\RH:FG5#.
M;V#K_1)O<"_BVNP6RTE432VH;!H:TP'^.IOAKM.&S^)U,G:?JO=S/1Q1]*%<
MZ+6D,5L4_45<"<#8VS@[R3*^?,?95"34#'[O@,,^6?DYLU2R!QT-2F6B#52Z
MSCV5BDWJEF^29+=TH5;EM(AQS9T&:OZW>9Y2027A==&Z]@\YR\]67/Y4>0G-
MQ;:RK=@JTN\>OL;RI]FABPR:(+(1T]UK@LBP 2*[+[9K/F$':D0BVTT0V6F"
M2+\)(AOPYBZ/;P<GTBN/$+5SRL8II;(Z<!H<N)_A!,K709WQG''%1-F;L2BB
MXM%A1=,K,N9TDU\_']&8S+FZK<"!NVY_HA&;)V'UU#4DHGQJW?X(PVL'U5%4
MQV(BH@L:C<JNG(Z+IJ,;.FIY@<,V<E5<=@3S,9@= 0R+@RG ?(P7%N=_&D\/
M'8_!,&T]*])#?7JHC_&R(:/B@\6Q^X3ZLH\T#'T_"+",CD96!2,L;T$ ?W8V
M3!MX8'$@TM-RC<\V7B&[ZP";TUT5@HT4KT1LI'BN ;'G#3S"T#[;6!SPP&8!
MJQV(;X\#-67W\7V854P;MH)Q) PQ!&K17J-!@&0G@(]]?K!5XOMA:$< LROP
M?0R!U8@CF +0@"&^7[P'M]Y'WNH]Y:W_)3/\ U!+ P04    " !K@4]9EXJ[
M',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6
M!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV
M)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O
M@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=
MI7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    (
M &N!3UG1 "N:4P0  &TN   /    >&PO=V]R:V)O;VLN>&ULQ=I=;]LV% ;@
MOT+XJKO(;/$K'X@#;'7;!1C:8&E[:S 2'1.52(.DD[6_OI2,=,>H>[ ;XEPY
MH@CZ%27R"65>/X?XY2&$+^S?H?=I.=OFO+N:SU.[M8-)OX>=]>7,)L3!Y'(8
M'^=I%ZWITM;://1SOECH^6"<G]U<O[1U%^?P(&3;9A=\*1P+/CO[G/X[/QZR
M)Y?<@^M=_KJ<37_W=L8&Y]W@OMEN.5O,6-J&Y[]"=-^"SZ:_;V/H^^6L.9SX
M;&-V[4_%]V/(C^8A3279//QC2I#E3"]*@QL74YYJ3.V;DO')ELJ'HWT.;UV?
M;5R9;-_%L-\Y_S@V4ZYB#BYCZH>7ST,G7L7_TXUALW&M785V/UB?#_T8;3\&
M]&GK=FG&O!GL<O92A1G?L3<^ETYBM_[05*D[7FGYZMON<-6YQ 5]&*]<.1%O
MNREXO9"?O-EW+MN..5\ZS0VL#;ZS/I62]B@D1T)RPI!K#D(*)*2@#"E 2(F$
ME)0A)0BID)"*,J0"(3424M<-^3H,.^._EHBG1O0Y$NR\;K _37*)A0TKT_W.
MQ*G"- 5-@080\@()>5$WY!]M&_9E2O2/["XZW[I=;Q.(=HE$NZP;[7UA+[$<
M6-[:$P\@G+87V+R]((QY-"<V*"^5??E0XL5"MC?E)IO^%\.EP7!I*NMR\EED
MK^Y"[UIW]%0V&"]-95_0<7U\PS%@FLK"_*(WR_]GY?,WF!(3IJE,##YZ(-8-
M9DQ3&1D\)N2ZP<1I*I.##/+QSL.8F#E-971.D,W.V*N5S<;UQ\\FYD]3&:#3
M,>_=HW>E!=B;' .(5P8(GX_@$.(80+PR0'A,.(0XNL(A0>B,O34NLJ>CFXXA
MQ"LC!&+N8,QW82QJ84P,(5X9(7S>A"L(CBG$2172,":F$"=5Z!S&Q!3BE17"
M8U[ F)A"O+)">,Q+&!-3B!,N@];3RN?'.Q=,(4&X#%I/*Y\?,3&%1&6%\)A'
M;[ PA41EA?"8T'2!OFFKK! >$YHN,(4$H4+K!BHD,(4$H4+K!BHD,(4$H4+K
M!BHD,(4$H4+K!BHD,(4$H4+K!BHD,(4$I4(<*B0QA22E0APJ)#&%)*5"'"HD
M,84DI4+\Z)<43"%96:&52VT?TC[:L@#Z.3.,B?[B0ZD0AUA*3"%)J1"'6$I,
M(4FI$(=82DPA2:D0AUA*3"%)J1"'6$I,(4FJ$,1280HI2H4$Q%)A"BE*A03$
M4F$**4J%!,1280HIRK60@%@J3"%%J9 XVGB [CR@5$A A12FD*)42$"%%*:0
MHE1(0(44II"B5$A A12FD*)42$"%-*:0IE1(0H4TII"F5$A"A32FD*942$*%
M-*:0IE1(0H4TII"F5$A"A32FD*942!YM@$-WP%$J)*%"&E-(4^Y.6%D8$U-(
M5U8(BWG&WL"8F$)Z4F@^54XWUYTM+=KN??F*5,I;T[=WD8T?AWU74HTO^S;[
MOG]=RC[XOX/I7G9+O^STOOD.4$L#!!0    ( &N!3UF7=W+D+ (  /8H   :
M    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-VDM.XT 4A>&M1%X E;JO
M0(LPZ@E3Q :L4'F()(Y<;@&[[R@,DF/UH"?(9V25+5__HT]6V8\O9=\.N^Y8
MM[M3G7T>]L>Z;+;#</J54EUMRZ&M=]VI',]7UEU_:(?SLM^D4[MZ;S<ER7P>
MJ;^=T3P]WLZ<O7Z=RO],[-;KW:K\[E9_#N4X_&-P^NCZ][HM96AFKVV_*<.R
M29_[Z^F:+H=\=Y[<S)[?EDW__):;-'600)!,'Z00I-,'&039]$$.03Y]4$!0
M3!^T@*#%]$'W$'0_?= #!#U,'Y3G*..<(&F$-8'6&;G.!%YG!#L3B)V1[$Q@
M=D:T,X':&=G.!&YGA#L3R)V1[DQ@=T:\,X'>@GH+@=Z">@N!WC)ZV2;06U!O
M(=!;4&\AT%M0;R'06U!O(=!;4&\AT%M0;R'06U!O(=!;46\ET%M1;R706U%O
M)=!;1YLE!'HKZJT$>BOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'H;ZFT$>AOJ
M;01Z&^IM!'H;ZFT$>MMHLYM ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]'
MO9U ;T>]G4!O1[V=0&]'O9U ;T>]G4!O'WVL)-#;46\GT-M1;R?0VU%O)]#;
M46\GT#M0[R#0.U#O(- [4.\@T#M0[R#0.U#O(- [4.\@T#M&/YL0Z!VH=Q#H
M':AW$.@=J'?\I-YU^-J7>NWY7N-/03])]7"^MUP??UE^GT2<%Q><TVU%??H+
M4$L#!!0    ( &N!3UG62",N]P$  "LH   3    6T-O;G1E;G1?5'EP97-=
M+GAM;,W:RT[#,! %T%^ILD6-ZR</T6Z +;#@!TPRI5&3V+)=*'^/DP(2""I0
MD;B;1JWMN1./=%8]OWOV%"?;KNWCO%BEY,\8B]6*.AM+YZG/*TL7.IORU_#
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M96>;_BV?C?\17+P 4$L! A0#%     @ :X%/60=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !K@4]9
M_U58^.X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " !K@4]9F5R<(Q &  "<)P  $P              @ ',
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( &N!3UF3)SI!LP(
M +0(   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    " !K@4]9FP+9264&  "N'@  &               @('V
M"@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ :X%/61YG
MD_NZ!   QA$  !@              ("!D1$  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( &N!3UER2?.'" ,  )T(   8
M  " @8$6  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !K
M@4]9L]:6 /4&   (,@  &               @(&_&0  >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ :X%/612./%7#!P  *"$  !@
M         ("!ZB   'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( &N!3UF#^ZV_E1P  +)5   8              " @>,H  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !K@4]9=;R,B+L)  ".'0
M&               @(&N10  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ :X%/68'8D1!%"@  T1L  !@              ("!GT\  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( &N!3UE:E7MQQBH
M ":=   9              " @1I:  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ :X%/67VL^$7E#   BRD  !D              ("!
M%X4  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !K@4]9
MPI^+I+P*  !]'   &0              @($SD@  >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( &N!3UF\V*W>G H  (@=   9
M      " @2:=  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ :X%/6?Z%,\5' P  90@  !D              ("!^:<  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !K@4]9ROJ<P+0"  !#!P
M&0              @(%WJP  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( &N!3UG8/7A )10  +Q<   9              " @6*N  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ :X%/69_D.W:T
M"   V!X  !D              ("!OL(  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    " !K@4]9"!$>F]P"  !C!@  &0
M@(&IRP  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( &N!
M3UD ?* T:1,  #8[ 0 9              " @;S.  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ :X%/6;&^"T60#@  5L$  !D
M         ("!7.(  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    " !K@4]9,W8 0&\#  # #   &0              @($C\0  >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( &N!3UD7VIJPO (  /('
M   9              " @<GT  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ :X%/69\51_1T P   1$  !D              ("!O/<
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !K@4]9K9MT
M()P"  !F"   &0              @(%G^P  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( &N!3UF!GAYIQ@(  %4)   9
M  " @3K^  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
M:X%/62(_3L\' P  /PH  !D              ("!-P$! 'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    " !K@4]9OG/MP#@#   1"P  &0
M            @(%U! $ >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( &N!3UE0;?3.6 ,  %,+   9              " @>0' 0!X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ :X%/6>9@.%-/"@
M%U8  !D              ("!<PL! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    " !K@4]9N-E-DJ\"  #+!P  &0              @('Y
M%0$ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( &N!3UE9
MJG?15 ,  %T+   9              " @=\8 0!X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ :X%/6687IQ:[ @  $PH  !D
M     ("!:AP! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M" !K@4]9CVE0[9P"  !0"   &0              @(%<'P$ >&PO=V]R:W-H
M965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( &N!3UF3L;Q)$@0  %H/   9
M              " @2\B 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L!
M A0#%     @ :X%/6=]E\P/9 @  +0<  !D              ("!>"8! 'AL
M+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " !K@4]9&*"--0 #
M   V"P  &0              @(&(*0$ >&PO=V]R:W-H965T<R]S:&5E=#,V
M+GAM;%!+ 0(4 Q0    ( &N!3UD7\9^TK0(  ! '   9              "
M@;\L 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ :X%/
M6=J1= >:!   A!P  !D              ("!HR\! 'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    " !K@4]9.QG0.G,"   M!P  &0
M        @(%T- $ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   ( &N!3UFC#<0[!04  'TJ   9              " @1XW 0!X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ :X%/6</GF*ZV!P  8$4
M !D              ("!6CP! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    " !K@4]9)"]B,3 )  #I6@  &0              @(%'1 $
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( &N!3UG'D=DX
M,P,  "P+   9              " @:Y- 0!X;"]W;W)K<VAE971S+W-H965T
M-#,N>&UL4$L! A0#%     @ :X%/6:+[:YX8!   8PX  !D
M ("!&%$! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " !K
M@4]98M:,SO$'  !23P  &0              @(%G50$ >&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( &N!3UGTN/4RU @   9B   9
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M970U,"YX;6Q02P$"% ,4    " !K@4]9*!L!(JP"  !D"   &0
M    @(%JA $ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (
M &N!3UGN;$VE' ,  )T(   9              " @4V' 0!X;"]W;W)K<VAE
M971S+W-H965T-3(N>&UL4$L! A0#%     @ :X%/69F"J+\  P  I0@  !D
M             ("!H(H! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"
M% ,4    " !K@4]90OW'-?\"  #["   &0              @('7C0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( &N!3UF&+S]OS@(
M '8(   9              " @0V1 0!X;"]W;W)K<VAE971S+W-H965T-34N
M>&UL4$L! A0#%     @ :X%/64>>P%,# P  <@D  !D              ("!
M$I0! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " !K@4]9
MM>>6\Y(#  #Q#@  &0              @(%,EP$ >&PO=V]R:W-H965T<R]S
M:&5E=#4W+GAM;%!+ 0(4 Q0    ( &N!3UDUPWNOS0H  ,-I   9
M      " @16; 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%
M  @ :X%/65ON#CX2 P  L0D  !D              ("!&:8! 'AL+W=O<FMS
M:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " !K@4]9)JQ3ATT$  !E%0
M&0              @(%BJ0$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+
M 0(4 Q0    ( &N!3UFVM3GC9 8  +\B   9              " @>:M 0!X
M;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ :X%/69UAU?:Q
M!0  X1T  !D              ("!@;0! 'AL+W=O<FMS:&5E=',O<VAE970V
M,BYX;6Q02P$"% ,4    " !K@4]9742 ,ZL"  "L!P  &0
M@(%IN@$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( &N!
M3UE5!QG^L ,  "P,   9              " @4N] 0!X;"]W;W)K<VAE971S
M+W-H965T-C0N>&UL4$L! A0#%     @ :X%/60H8M/8]!P  JS,  !D
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M=#8Y+GAM;%!+ 0(4 Q0    ( &N!3UGM%XD_EP,  )\9   -
M  "  9#B 0!X;"]S='EL97,N>&UL4$L! A0#%     @ :X%/69>*NQS
M$P(   L              ( !4N8! %]R96QS+RYR96QS4$L! A0#%     @
M:X%/6=$ *YI3!   ;2X   \              ( !.^<! 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( &N!3UF7=W+D+ (  /8H   :              "
M ;OK 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( &N!
M3UG62",N]P$  "LH   3              "  1_N 0!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@    !- $T $A4  $?P 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>318</ContextCount>
  <ElementCount>366</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>120</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>18</UnitCount>
  <MyReports>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Unaudited interim condensed consolidated statement of financial position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition</Role>
      <ShortName>Unaudited interim condensed consolidated statement of financial position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - Unaudited interim condensed consolidated statement of income (loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss</Role>
      <ShortName>Unaudited interim condensed consolidated statement of income (loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00300 - Statement - Unaudited interim condensed consolidated statement of comprehensive (income) loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss</Role>
      <ShortName>Unaudited interim condensed consolidated statement of comprehensive (income) loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00400 - Statement - Unaudited interim condensed consolidated statement of changes in shareholders' equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity</Role>
      <ShortName>Unaudited interim condensed consolidated statement of changes in shareholders' equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00500 - Statement - Unaudited interim condensed consolidated statement of cash flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows</Role>
      <ShortName>Unaudited interim condensed consolidated statement of cash flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Company information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureCompanyInformation</Role>
      <ShortName>Company information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Basis of preparation and statement of compliance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfCompliance</Role>
      <ShortName>Basis of preparation and statement of compliance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Accounting Principles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureAccountingPrinciples</Role>
      <ShortName>Accounting Principles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Notes to the interim condensed consolidated statement of financial position</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPosition</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLoss</Role>
      <ShortName>Notes to the interim condensed consolidated statement of (income) loss</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Other financial information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureOtherFinancialInformation</Role>
      <ShortName>Other financial information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>20302 - Disclosure - Accounting Principles (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies</Role>
      <ShortName>Accounting Principles (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.inventivapharma.com/role/DisclosureAccountingPrinciples</ParentRole>
      <Position>13</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Basis of preparation and statement of compliance (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceTables</Role>
      <ShortName>Basis of preparation and statement of compliance (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfCompliance</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Accounting Principles (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesTables</Role>
      <ShortName>Accounting Principles (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inventivapharma.com/role/DisclosureAccountingPrinciples</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Notes to the interim condensed consolidated statement of financial position (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPosition</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables</Role>
      <ShortName>Notes to the interim condensed consolidated statement of (income) loss (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPosition</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Other financial information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationTables</Role>
      <ShortName>Other financial information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inventivapharma.com/role/DisclosureOtherFinancialInformation</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Company information - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails</Role>
      <ShortName>Company information - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inventivapharma.com/role/DisclosureCompanyInformation</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>40102 - Disclosure - Company information - Significant events in the first half of 2024 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details</Role>
      <ShortName>Company information - Significant events in the first half of 2024 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Basis of preparation and statement of compliance - Significant Investments In Subsidiaries (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails</Role>
      <ShortName>Basis of preparation and statement of compliance - Significant Investments In Subsidiaries (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Basis of preparation and statement of compliance - Foreign Exchange Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails</Role>
      <ShortName>Basis of preparation and statement of compliance - Foreign Exchange Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Accounting Principles - Fair value measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails</Role>
      <ShortName>Accounting Principles - Fair value measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Accounting principles - Going concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails</Role>
      <ShortName>Accounting principles - Going concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Intangible assets (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Property, plant, and equipment (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Property, plant, and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40403 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Property, plant, and equipment - Additional Information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Property, plant, and equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40404 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Investments accounted for using the equity method - Additional Information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Investments accounted for using the equity method - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40405 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Investments accounted for using the equity method - investment in Hepalys accounted for using equity method of accounting (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Investments accounted for using the equity method - investment in Hepalys accounted for using equity method of accounting (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40406 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Other non-current assets (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Other non-current assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40407 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Other non-current assets - Long-term deposit accounts (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Other non-current assets - Long-term deposit accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40408 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Inventories (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInventoriesDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40409 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets - Trade Receivables (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets - Trade Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40410 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets- Other Current Assets and Receivables (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets- Other Current Assets and Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40411 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets - Additional Information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40412 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Cash and cash equivalents (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Cash and cash equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40413 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Share capital (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityShareCapitalDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Share capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40414 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Changes in share capital (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Changes in share capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40415 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Liquidity agreement (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityLiquidityAgreementDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Liquidity agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40416 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Options and share warrants (BSA and BSPCE) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Options and share warrants (BSA and BSPCE) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40417 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Movements in BSPCE and BSA share warrants (in number of shares issuable upon exercise) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Movements in BSPCE and BSA share warrants (in number of shares issuable upon exercise) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40418 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Free share awards and Performance units (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Free share awards and Performance units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40419 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Financial debt (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Financial debt - Financial debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40420 - Disclosure - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Movements in the period break down (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails</Role>
      <ShortName>Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Movements in the period break down (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40421 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - French state-guaranteed loan ("PGE") and equity recovery loans ("PPR") (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Financial debt - French state-guaranteed loan ("PGE") and equity recovery loans ("PPR") (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40422 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Credit facility agreement with the European Investment Bank (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Financial debt - Credit facility agreement with the European Investment Bank (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40423 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Derivatives (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Financial debt - Derivatives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40424 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Lease liabilities (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Financial debt - Lease liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40425 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Maturity of long-term debt and of short-term borrowings and debt (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Maturity of long-term debt and of short-term borrowings and debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40426 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Royalty Certificates liabilities (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Financial debt - Royalty Certificates liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40427 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Net provision (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsNetProvisionDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Net provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40428 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Changes in the net provision (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsChangesInNetProvisionDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Changes in the net provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40429 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Breakdown of expense recognized for the year (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Breakdown of expense recognized for the year (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>40430 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Other current and non-current liabilities (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Other current and non-current liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>40431 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Other current and non-current liabilities - Additional information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Other current and non-current liabilities - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>40432 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade payables, short-term contract liabilities and other current liabilities (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Trade payables, short-term contract liabilities and other current liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>40433 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade payables break down (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Trade payables break down (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>40434 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial assets and liabilities (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of financial position - Financial assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Revenues and other income (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of (income) loss - Revenues and other income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Narratives (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of (income) loss - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>40503 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Operating expenses (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of (income) loss - Operating expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>40504 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Operating expenses - Personnel costs and headcount (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of (income) loss - Operating expenses - Personnel costs and headcount (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>40505 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Other operating income and expenses - (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of (income) loss - Other operating income and expenses - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>40506 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Financial income and expenses (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of (income) loss - Financial income and expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>40507 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Share of net profit - Equity method (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of (income) loss - Share of net profit - Equity method (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>40508 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Income tax (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossIncomeTaxDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of (income) loss - Income tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>40509 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Basic and diluted loss per share (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossBasicAndDilutedLossPerShareDetails</Role>
      <ShortName>Notes to the interim condensed consolidated statement of (income) loss - Basic and diluted loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Other financial information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails</Role>
      <ShortName>Other financial information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="iva-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Other financial information - Events after the reporting date (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails</Role>
      <ShortName>Other financial information - Events after the reporting date (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>iva-20240630.xsd</File>
    <File>iva-20240630_cal.xml</File>
    <File>iva-20240630_def.xml</File>
    <File>iva-20240630_lab.xml</File>
    <File>iva-20240630_pre.xml</File>
    <File doctype="6-K" isDefinitelyFs="true" isIfrs="true" original="iva-20240630x6k.htm">iva-20240630x6k.htm</File>
    <File doctype="6-K" isDefinitelyFs="true" isIfrs="true" original="iva-20240630xex99d1.htm">iva-20240630xex99d1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>iva-20240630xex99d1001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="772">https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>87
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "iva-20240630x6k.htm iva-20240630xex99d1.htm": {
   "nsprefix": "iva",
   "nsuri": "http://www.inventivapharma.com/20240630",
   "dts": {
    "schema": {
     "local": [
      "iva-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "iva-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "iva-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "iva-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "iva-20240630_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "iva-20240630x6k.htm",
      "iva-20240630xex99d1.htm"
     ]
    }
   },
   "keyStandard": 187,
   "keyCustom": 179,
   "axisStandard": 23,
   "axisCustom": 1,
   "memberStandard": 32,
   "memberCustom": 83,
   "hidden": {
    "total": 11,
    "http://xbrl.sec.gov/dei/2023": 6,
    "http://www.inventivapharma.com/20240630": 1,
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 4
   },
   "contextCount": 318,
   "entityCount": 1,
   "segmentCount": 120,
   "elementCount": 590,
   "unitCount": 18,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 772,
    "http://xbrl.sec.gov/dei/2023": 8
   },
   "report": {
    "R1": {
     "role": "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630x6k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630x6k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition",
     "longName": "00100 - Statement - Unaudited interim condensed consolidated statement of financial position",
     "shortName": "Unaudited interim condensed consolidated statement of financial position",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:DeferredTaxAssets",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss",
     "longName": "00200 - Statement - Unaudited interim condensed consolidated statement of income (loss)",
     "shortName": "Unaudited interim condensed consolidated statement of income (loss)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:Revenue",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:SalesAndMarketingExpense",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss",
     "longName": "00300 - Statement - Unaudited interim condensed consolidated statement of comprehensive (income) loss",
     "shortName": "Unaudited interim condensed consolidated statement of comprehensive (income) loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity",
     "longName": "00400 - Statement - Unaudited interim condensed consolidated statement of changes in shareholders' equity",
     "shortName": "Unaudited interim condensed consolidated statement of changes in shareholders' equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_0VRJS0P300WTp8zcUcUTug",
      "name": "ifrs-full:Equity",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_XLIDsKCJTEm0UB5CIk-Tiw",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows",
     "longName": "00500 - Statement - Unaudited interim condensed consolidated statement of cash flows",
     "shortName": "Unaudited interim condensed consolidated statement of cash flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "iva:AdjustmentsForDepreciationAmortisationAndProvisions",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformation",
     "longName": "10101 - Disclosure - Company information",
     "shortName": "Company information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "iva:CompanyInformationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "iva:CompanyInformationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfCompliance",
     "longName": "10201 - Disclosure - Basis of preparation and statement of compliance",
     "shortName": "Basis of preparation and statement of compliance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:StatementOfIFRSCompliance",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:StatementOfIFRSCompliance",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciples",
     "longName": "10301 - Disclosure - Accounting Principles",
     "shortName": "Accounting Principles",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPosition",
     "longName": "10401 - Disclosure - Notes to the interim condensed consolidated statement of financial position",
     "shortName": "Notes to the interim condensed consolidated statement of financial position",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLoss",
     "longName": "10501 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss",
     "shortName": "Notes to the interim condensed consolidated statement of (income) loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "iva:DisclosureOfComponentsOfIncomeStatementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "iva:DisclosureOfComponentsOfIncomeStatementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformation",
     "longName": "10601 - Disclosure - Other financial information",
     "shortName": "Other financial information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "iva:DisclosureOfOtherFinancialInformationTextblock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "iva:DisclosureOfOtherFinancialInformationTextblock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies",
     "longName": "20302 - Disclosure - Accounting Principles (Policies)",
     "shortName": "Accounting Principles (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceTables",
     "longName": "30203 - Disclosure - Basis of preparation and statement of compliance (Tables)",
     "shortName": "Basis of preparation and statement of compliance (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesTables",
     "longName": "30303 - Disclosure - Accounting Principles (Tables)",
     "shortName": "Accounting Principles (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory",
       "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory",
       "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables",
     "longName": "30403 - Disclosure - Notes to the interim condensed consolidated statement of financial position (Tables)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables",
     "longName": "30503 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss (Tables)",
     "shortName": "Notes to the interim condensed consolidated statement of (income) loss (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "iva:RevenueAndOtherIncomeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "iva:DisclosureOfComponentsOfIncomeStatementTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "iva:RevenueAndOtherIncomeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "iva:DisclosureOfComponentsOfIncomeStatementTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationTables",
     "longName": "30603 - Disclosure - Other financial information (Tables)",
     "shortName": "Other financial information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "iva:DisclosureOfOtherFinancialInformationTextblock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "iva:DisclosureOfOtherFinancialInformationTextblock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
     "longName": "40101 - Disclosure - Company information - (Details)",
     "shortName": "Company information - (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_V_UnvG7OVU6Postqxl9qTw",
      "name": "iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details",
     "longName": "40102 - Disclosure - Company information - Significant events in the first half of 2024 (Details)",
     "shortName": "Company information - Significant events in the first half of 2024 (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "20",
     "firstAnchor": {
      "contextRef": "As_Of_1_18_2024_u8VUV2GPAUmg3FPfMqwLIg",
      "name": "ifrs-full:NotionalAmount",
      "unitRef": "Unit_Standard_USD_X6E05lIDQEullbfuSGuJCw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_TxixfQbZCE2_vJzh9SnQSQ",
      "name": "iva:PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised",
      "unitRef": "Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails",
     "longName": "40201 - Disclosure - Basis of preparation and statement of compliance - Significant Investments In Subsidiaries (Details)",
     "shortName": "Basis of preparation and statement of compliance - Significant Investments In Subsidiaries (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "iva:NumberOfEntitiesBeingConsolidated",
      "unitRef": "Unit_Standard_entity_-MmOzsDakEmzabilM8ZRiQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "iva:NumberOfEntitiesBeingConsolidated",
      "unitRef": "Unit_Standard_entity_-MmOzsDakEmzabilM8ZRiQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails",
     "longName": "40202 - Disclosure - Basis of preparation and statement of compliance - Foreign Exchange Rates (Details)",
     "shortName": "Basis of preparation and statement of compliance - Foreign Exchange Rates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:AverageForeignExchangeRate",
      "unitRef": "Unit_Divide_EUR_USD_sLQkfMeGDkaNmYTZmSqm9Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:AverageForeignExchangeRate",
      "unitRef": "Unit_Divide_EUR_USD_sLQkfMeGDkaNmYTZmSqm9Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails",
     "longName": "40301 - Disclosure - Accounting Principles - Fair value measurement (Details)",
     "shortName": "Accounting Principles - Fair value measurement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:FinancialLiabilities",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_iiyUwIL1okucU3luLH42uQ",
      "name": "ifrs-full:FinancialLiabilities",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory",
       "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails",
     "longName": "40302 - Disclosure - Accounting principles - Going concern (Details)",
     "shortName": "Accounting principles - Going concern (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R25": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails",
     "longName": "40401 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Intangible assets (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Intangible assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_na6RZmuG5U2D4vmO3x7mnw",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
       "iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails",
     "longName": "40402 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Property, plant, and equipment (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Property, plant, and equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_OjiU0SQcREq22dnbIpV6fg",
      "name": "ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails",
     "longName": "40403 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Property, plant, and equipment - Additional Information (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Property, plant, and equipment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:ChangesInPropertyPlantAndEquipment",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:ChangesInPropertyPlantAndEquipment",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails",
     "longName": "40404 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Investments accounted for using the equity method - Additional Information (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Investments accounted for using the equity method - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_10_11_2023_To_10_11_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_0ACGkUM49U6-A_OhxFep5w",
      "name": "iva:NumberOfSharesAcquiredInAssociate",
      "unitRef": "Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_11_2023_To_10_11_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_0ACGkUM49U6-A_OhxFep5w",
      "name": "iva:NumberOfSharesAcquiredInAssociate",
      "unitRef": "Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails",
     "longName": "40405 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Investments accounted for using the equity method - investment in Hepalys accounted for using equity method of accounting (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Investments accounted for using the equity method - investment in Hepalys accounted for using equity method of accounting (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_Nnjp7bngW0Ga6BDie0V6fw",
      "name": "iva:EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsDetails",
     "longName": "40406 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Other non-current assets (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Other non-current assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ",
      "name": "iva:NonCurrentLongTermDepositsFromCustomers",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ",
      "name": "iva:NonCurrentLongTermDepositsFromCustomers",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails",
     "longName": "40407 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Other non-current assets - Long-term deposit accounts (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Other non-current assets - Long-term deposit accounts (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "iva:IncreaseDecreaseInLongTermDepositAccounts",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "iva:IncreaseDecreaseInLongTermDepositAccounts",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInventoriesDetails",
     "longName": "40408 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Inventories (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:Inventories",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_SNcEwTle60O3eQH3YNWEsw",
      "name": "ifrs-full:Inventories",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "iva:IfrsScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails",
     "longName": "40409 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets - Trade Receivables (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets - Trade Receivables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:TradeAndOtherCurrentReceivables",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanThreeMonthsMember_2nR6xWsu-0CvgK_C4H2nmQ",
      "name": "ifrs-full:TradeAndOtherCurrentReceivables",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "iva:DisclosureOfTradeReceivablesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails",
     "longName": "40410 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets- Other Current Assets and Receivables (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets- Other Current Assets and Receivables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "iva:CirAndOtherResearchTaxCreditsReceivable",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "iva:OtherCurrentTaxReceivables",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails",
     "longName": "40411 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets - Additional Information (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Trade receivables, tax receivables and other current assets - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "iva:IncreaseDecreaseInShortTermDepositAccounts",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "iva:IncreaseDecreaseInShortTermDepositAccounts",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails",
     "longName": "40412 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Cash and cash equivalents (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Cash and cash equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "iva:DisclosureOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "iva:DisclosureOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityShareCapitalDetails",
     "longName": "40413 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Share capital (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Share capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:IssuedCapital",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R38": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails",
     "longName": "40414 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Changes in share capital (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Changes in share capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:Equity",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_3_25_2024_To_3_25_2024_avq7MDuDZ0qTbuTPxd88pQ",
      "name": "ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding",
      "unitRef": "Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityLiquidityAgreementDetails",
     "longName": "40415 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Liquidity agreement (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Liquidity agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_1_1_2024__TV_WDfEOkuUvGKOfMbQLg",
      "name": "iva:LiquidityAgreementTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_1_1_2024__TV_WDfEOkuUvGKOfMbQLg",
      "name": "iva:LiquidityAgreementTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails",
     "longName": "40416 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Options and share warrants (BSA and BSPCE) (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Options and share warrants (BSA and BSPCE) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2017_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DirectorsMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_tc0AHGj00kS5B7lAXTpurw",
      "name": "iva:WarrantsSubscriptionPrice",
      "unitRef": "Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2017_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DirectorsMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_tc0AHGj00kS5B7lAXTpurw",
      "name": "iva:WarrantsSubscriptionPrice",
      "unitRef": "Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails",
     "longName": "40417 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Movements in BSPCE and BSA share warrants (in number of shares issuable upon exercise) (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Shareholders' equity - Movements in BSPCE and BSA share warrants (in number of shares issuable upon exercise) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "Duration_3_25_2024_To_3_25_2024_avq7MDuDZ0qTbuTPxd88pQ",
      "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted",
      "unitRef": "Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspceAndBsaShareWarrantsMember_AXg3-r_gg0WamRv2dUykVQ",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails",
     "longName": "40418 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Free share awards and Performance units (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Free share awards and Performance units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "iva:NumberOfAwardPlansAttributed",
      "unitRef": "Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "iva:NumberOfAwardPlansAttributed",
      "unitRef": "Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails",
     "longName": "40419 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Financial debt (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Financial debt - Financial debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:LoansReceived",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R44": {
     "role": "http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails",
     "longName": "40420 - Disclosure - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Movements in the period break down (Details)",
     "shortName": "Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Movements in the period break down (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022__ShBeryiXEKxoX7Xx7OS6A",
      "name": "ifrs-full:Borrowings",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "iva:DisclosureOfChangesInBorrowingsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "iva:IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "iva:DisclosureOfChangesInBorrowingsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails",
     "longName": "40421 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - French state-guaranteed loan (\"PGE\") and equity recovery loans (\"PPR\") (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Financial debt - French state-guaranteed loan (\"PGE\") and equity recovery loans (\"PPR\") (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_6_1_2022_To_6_30_2022_ifrs-full_BorrowingsByNameAxis_iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember_rVGAMd543kWMTqS80gXZVA",
      "name": "iva:NumberOfLoanAgreements",
      "unitRef": "Unit_Standard_loan_rE4-q-dHoUqS2Tn_Pp9_NQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails",
     "longName": "40422 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Credit facility agreement with the European Investment Bank (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Financial debt - Credit facility agreement with the European Investment Bank (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "As_Of_1_18_2024_u8VUV2GPAUmg3FPfMqwLIg",
      "name": "ifrs-full:NotionalAmount",
      "unitRef": "Unit_Standard_USD_X6E05lIDQEullbfuSGuJCw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_5_16_2022_To_5_16_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_iCBdyRK5rUeePAFm5LecHg",
      "name": "iva:NumberOfEqualTranches",
      "unitRef": "Unit_Standard_tranche_EQcocZ7SkkmFtux0nXQhjQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails",
     "longName": "40423 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Derivatives (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Financial debt - Derivatives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "Duration_3_25_2024_To_3_25_2024_avq7MDuDZ0qTbuTPxd88pQ",
      "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted",
      "unitRef": "Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lpf5jlqhR0GVIbvPIhKnYw",
      "name": "iva:IfrsClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "iva:DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails",
     "longName": "40424 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Lease liabilities (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Financial debt - Lease liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:LeaseLiabilities",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA",
      "name": "iva:IncreaseDecreaseInLeaseLiabilities",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails",
     "longName": "40425 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Maturity of long-term debt and of short-term borrowings and debt (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Maturity of long-term debt and of short-term borrowings and debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:LoansReceived",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_o2Fe8k_JVUOuzAwFE3EH9g",
      "name": "ifrs-full:LoansReceived",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails",
     "longName": "40426 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial debt - Royalty Certificates liabilities (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Financial debt - Royalty Certificates liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:FinancialLiabilities",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_RoyaltyCertificatesLiabilitiesMember_mEPm5drgy0O0deuPued1-Q",
      "name": "iva:RoyaltyCertificatesEffectiveInterestRate",
      "unitRef": "Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsNetProvisionDetails",
     "longName": "40427 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Net provision (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Net provision (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:OtherProvisions",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:OtherProvisions",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsChangesInNetProvisionDetails",
     "longName": "40428 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Changes in the net provision (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Changes in the net provision (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ",
      "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "iva:DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "iva:DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails",
     "longName": "40429 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Breakdown of expense recognized for the year (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Provisions for retirement benefit obligations - Breakdown of expense recognized for the year (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:CurrentServiceCostDefinedBenefitPlans",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "iva:DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:CurrentServiceCostDefinedBenefitPlans",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "iva:DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails",
     "longName": "40430 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Other current and non-current liabilities (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Other current and non-current liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "iva:EmployeeRelatedPayables",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "iva:EmployeeRelatedPayables",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails",
     "longName": "40431 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Other current and non-current liabilities - Additional information (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Other current and non-current liabilities - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:OtherNoncurrentLiabilities",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_ZxMBck8Vv06CkTltj3JJkg",
      "name": "ifrs-full:OtherNoncurrentLiabilities",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails",
     "longName": "40432 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade payables, short-term contract liabilities and other current liabilities (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Trade payables, short-term contract liabilities and other current liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "iva:TradePayablesAndOtherCurrentLiabilities",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails",
     "longName": "40433 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Trade payables break down (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Trade payables break down (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:TradeAndOtherCurrentPayables",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:TradeAndOtherCurrentPayables",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails",
     "longName": "40434 - Disclosure - Notes to the interim condensed consolidated statement of financial position - Financial assets and liabilities (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of financial position - Financial assets and liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:FinancialAssets",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:FinancialAssets",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails",
     "longName": "40501 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Revenues and other income (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of (income) loss - Revenues and other income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "iva:RevenueAndOtherIncomeTableTextBlock",
       "iva:DisclosureOfComponentsOfIncomeStatementTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "iva:RevenueAndOtherIncomeTableTextBlock",
       "iva:DisclosureOfComponentsOfIncomeStatementTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails",
     "longName": "40502 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Narratives (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of (income) loss - Narratives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "iva:CurrentTaxCreditResearchCurrentYear",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "iva:DisclosureOfComponentsOfIncomeStatementTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_dei_LegalEntityAxis_iva_InventivaIncMember_yX8YJNqJxEeoquiF4wd66g",
      "name": "iva:CirAndOtherResearchTaxCreditsReceivable",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "iva:DisclosureOfComponentsOfIncomeStatementTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails",
     "longName": "40503 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Operating expenses (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of (income) loss - Operating expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "iva:Disposables",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "iva:ResearchAndDevelopmentMarketingTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "iva:Disposables",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "iva:ResearchAndDevelopmentMarketingTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails",
     "longName": "40504 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Operating expenses - Personnel costs and headcount (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of (income) loss - Operating expenses - Personnel costs and headcount (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:NumberOfEmployees",
      "unitRef": "Unit_Standard_employee_t09Loy2TV0yh-O2RJe0wMQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:NumberOfEmployees",
      "unitRef": "Unit_Standard_employee_t09Loy2TV0yh-O2RJe0wMQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails",
     "longName": "40505 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Other operating income and expenses - (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of (income) loss - Other operating income and expenses - (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:MiscellaneousOtherOperatingIncome",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:MiscellaneousOtherOperatingIncome",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails",
     "longName": "40506 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Financial income and expenses (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of (income) loss - Financial income and expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "iva:FinancialIncomeAndExpensesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "iva:FinancialIncomeAndExpensesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails",
     "longName": "40507 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Share of net profit - Equity method (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of (income) loss - Share of net profit - Equity method (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg",
      "name": "ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossIncomeTaxDetails",
     "longName": "40508 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Income tax (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of (income) loss - Income tax (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_oxFIDH8XQUKPgIUFQceRfA",
      "name": "ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods",
      "unitRef": "Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_oxFIDH8XQUKPgIUFQceRfA",
      "name": "ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods",
      "unitRef": "Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossBasicAndDilutedLossPerShareDetails",
     "longName": "40509 - Disclosure - Notes to the interim condensed consolidated statement of (income) loss - Basic and diluted loss per share (Details)",
     "shortName": "Notes to the interim condensed consolidated statement of (income) loss - Basic and diluted loss per share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R68": {
     "role": "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails",
     "longName": "40601 - Disclosure - Other financial information (Details)",
     "shortName": "Other financial information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:ContractualCapitalCommitments",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory",
       "iva:DisclosureOfOtherFinancialInformationTextblock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:ContractualCapitalCommitments",
      "unitRef": "Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory",
       "iva:DisclosureOfOtherFinancialInformationTextblock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails",
     "longName": "40602 - Disclosure - Other financial information - Events after the reporting date (Details)",
     "shortName": "Other financial information - Events after the reporting date (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ",
      "name": "ifrs-full:ParValuePerShare",
      "unitRef": "Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_IGbGo6uT7EO_KIZuumIllA",
      "name": "iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "iva-20240630xex99d1.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "iva_AccountingPrinciplesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "AccountingPrinciplesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Accounting Principles"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccrualsClassifiedAsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccrualsClassifiedAsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accruals classified as current",
        "terseLabel": "Accrued expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of accruals classified as current. [Refer: Accruals]"
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "iva_AccrualsClassifiedAsCurrentRelatingToScientificProjects": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "AccrualsClassifiedAsCurrentRelatingToScientificProjects",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of accruals classified as current relating to scientific projects",
        "label": "Accruals classified as current relating to scientific projects",
        "terseLabel": "Accrued liabilities relating to scientific projects"
       }
      }
     },
     "auth_ref": []
    },
    "iva_AccruedIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "AccruedIncomeMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for accrued income.",
        "label": "Current accrued income",
        "terseLabel": "Current accrued income"
       }
      }
     },
     "auth_ref": []
    },
    "iva_AccruedPayrollAndOtherEmployeeRelatedTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "AccruedPayrollAndOtherEmployeeRelatedTaxes",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails": {
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount pertaining to accrued payroll and other employee related taxes.",
        "label": "Accrued payroll and other employeerelated taxes",
        "terseLabel": "Accrued payroll and other employeerelated taxes"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated depreciation, amortisation and impairment [member]",
        "terseLabel": "Amortization",
        "verboseLabel": "Depreciation and impairment"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r46",
      "r49",
      "r71",
      "r76",
      "r79"
     ]
    },
    "ifrs-full_AccumulatedImpairmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccumulatedImpairmentMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories write-down"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated impairment. [Refer: Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r137",
      "r143",
      "r200",
      "r227",
      "r233",
      "r234",
      "r235"
     ]
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionsToRightofuseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions To Right of use Assets",
        "terseLabel": "Additions to right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossBasicAndDilutedLossPerShareDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjusted weighted average number of ordinary shares outstanding",
        "terseLabel": "Weighted average number of shares outstanding used to calculate diluted loss per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in inventories",
        "terseLabel": "Decrease / (increase) in inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in trade and other receivables",
        "terseLabel": "Decrease / (increase) in operating and other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "iva_AdjustmentsForDepreciationAmortisationAndProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "AdjustmentsForDepreciationAmortisationAndProvisions",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for depreciation, amortisation expense and provisions to reconcile profit (loss) to net cash flow from (used in) operating activities.",
        "label": "Adjustments for Depreciation, Amortisation and Provisions",
        "terseLabel": "Depreciation, amortization and provisions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForFairValueGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForFairValueGainsLosses",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for fair value losses (gains)",
        "terseLabel": "Fair value variation through profit and loss"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for fair value losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "ifrs-full_AdjustmentsForFinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForFinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for finance income (cost)",
        "negatedLabel": "Cost of debt"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "ifrs-full_AdjustmentsForIncomeTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncomeTaxExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for income tax expense",
        "terseLabel": "Deferred and current taxes"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in trade and other payables",
        "verboseLabel": "Increase / (decrease) in operating and other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile profit (loss) [abstract]",
        "terseLabel": "Elimination of non-cash or non-operating income and expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for share-based payments",
        "terseLabel": "Sharebased compensation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "iva_AdjustmentsForTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "AdjustmentsForTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for tax credit to reconcile profit (loss) to net cash flow from (used in) operating activities.",
        "label": "Adjustments For Tax Credits",
        "terseLabel": "Tax credits"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForUndistributedProfitsOfAssociates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForUndistributedProfitsOfAssociates",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for undistributed profits of associates",
        "negatedLabel": "Share of net profit of associates and joint ventures accounted for using the equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for undistributed profits of associates to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Associates [member]; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for unrealised foreign exchange losses (gains)",
        "terseLabel": "Exchange (gains) / losses"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r193",
      "r238"
     ]
    },
    "iva_AdvancePaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "AdvancePaymentMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for advance payment.",
        "label": "Advance payment",
        "terseLabel": "Advance payment"
       }
      }
     },
     "auth_ref": []
    },
    "iva_Aga2021Aga2021BisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "Aga2021Aga2021BisMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for AGA 2021 &amp; AGA 2021 bis.",
        "label": "AGA 2021 &amp; AGA 2021 bis [Member]",
        "terseLabel": "AGA 2021 &amp; AGA 2021 bis"
       }
      }
     },
     "auth_ref": []
    },
    "iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount to be received by the company, either in exchange for new shares of the Company or through the receipt of upfront or milestone payments, pursuant to the debt arrangement.",
        "label": "Aggregate Amount To Be Received Either In Exchange For New Shares Of The Company Or Through The Receipt Of Upfront Or Milestone Payments",
        "verboseLabel": "Aggregate amount to be received under the conditions precedent to the EIB Financing"
       }
      }
     },
     "auth_ref": []
    },
    "iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount to be received by the company, either in exchange for new shares or warrants of the Company.",
        "label": "Aggregate Amount To Be Received Either In Exchange For New Shares or Warrants Of The Company",
        "terseLabel": "Aggregate amount to be received either in exchange for new shares or warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AggregatedTimeBandsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregated time bands [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r121",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r139",
      "r183",
      "r202",
      "r207"
     ]
    },
    "iva_AgreementsConcerningProvisionOfFacilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "AgreementsConcerningProvisionOfFacilities",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails": {
       "parentTag": "iva_ContractualCapitalCommitmentReceived",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of agreements concerning provision of facilities.",
        "label": "Agreements concerning the provision of facilities",
        "terseLabel": "Agreements concerning the provision of facilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AllLevelsOfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AllLevelsOfFairValueHierarchyMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All levels of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r113"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "iva_AmountInvoicedToCounterpartyForInitialPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "AmountInvoicedToCounterpartyForInitialPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This amount represents the information of invoiced to counterparty for initial payment.",
        "label": "Amount Invoiced To Counterparty For Initial Payment",
        "terseLabel": "Amount invoiced to counterparty for milestone payment"
       }
      }
     },
     "auth_ref": []
    },
    "iva_AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of annual royalty on future net sales of Lanifibranor.",
        "label": "Annual Royalty Percentage on Future Net Sales of Lanifibranor",
        "terseLabel": "Annual royalty percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r112",
      "r113",
      "r115",
      "r162",
      "r166"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Attribution of expenses by nature to their function [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r215"
     ]
    },
    "ifrs-full_AverageForeignExchangeRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AverageForeignExchangeRate",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average foreign exchange rate",
        "terseLabel": "Average exchange rate for the period"
       }
      },
      "en": {
       "role": {
        "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "ifrs-full_BankOverdraftsClassifiedAsCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BankOverdraftsClassifiedAsCashEquivalents",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails": {
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank overdrafts",
        "negatedLabel": "Bank overdrafts",
        "terseLabel": "Bank overdrafts inclusive of cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that has been withdrawn from an account in excess of existing cash balances. This is considered a short-term extension of credit by the bank. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossBasicAndDilutedLossPerShareDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "terseLabel": "Basic loss per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65"
     ]
    },
    "iva_BonusShareAwardPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "BonusShareAwardPlansMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for bonus share award plans.",
        "label": "Bonus Share Award Plans [Member]",
        "terseLabel": "Bonus share award plans"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingCostsIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingCostsIncurred",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowing costs incurred",
        "terseLabel": "Borrowing costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest and other costs that an entity incurs in connection with the borrowing of funds."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "ifrs-full_Borrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Borrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Borrowings",
        "totalLabel": "Total debt"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of outstanding funds that the entity is obligated to repay."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "iva_BorrowingsActualizationRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "BorrowingsActualizationRate",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The actualization interest rate on borrowings.",
        "label": "Borrowings, Actualization Rate",
        "terseLabel": "Actualization rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsByNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsByNameAxis",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings by name [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "ifrs-full_BorrowingsByNameMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsByNameMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings by name [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "iva_BorrowingsEffectiveInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "BorrowingsEffectiveInterestRate",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate on borrowings.",
        "label": "Borrowings, effective interest rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings, interest rate",
        "terseLabel": "Interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "iva_BorrowingsMaximumExtensionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "BorrowingsMaximumExtensionTerm",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period up to which the maturity term of the borrowings can be extended.",
        "label": "Borrowings, Maximum Extension Term",
        "verboseLabel": "Extension of term of debt"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum",
        "terseLabel": "Minimum"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r129",
      "r133",
      "r196",
      "r197",
      "r244"
     ]
    },
    "iva_Bsa2017PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "Bsa2017PlanMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for BSA - 2017 plan.",
        "label": "BSA - 2017 plan"
       }
      }
     },
     "auth_ref": []
    },
    "iva_Bsa2018PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "Bsa2018PlanMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for BSA - 2018 plan.",
        "label": "BSA - 2018 plan"
       }
      }
     },
     "auth_ref": []
    },
    "iva_Bsa2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "Bsa2022Member",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the BSA 2022 share-based payment plan",
        "label": "BSA 2022 [Member]",
        "terseLabel": "BSA 2022"
       }
      }
     },
     "auth_ref": []
    },
    "iva_Bsa20231ShareWarrantPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "Bsa20231ShareWarrantPlanMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for BSA 2023-1 share warrants plan.",
        "label": "BSA 2023-1 Share Warrant Plan [Member]",
        "terseLabel": "BSA 2023 plan"
       }
      }
     },
     "auth_ref": []
    },
    "iva_Bsa20232ShareWarrantPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "Bsa20232ShareWarrantPlanMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for BSA 2023-2 share warrants plan.",
        "label": "BSA 2023-2 Share Warrant Plan [Member]",
        "terseLabel": "BSA- 2 2023 plan"
       }
      }
     },
     "auth_ref": []
    },
    "iva_Bsa2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "Bsa2024Member",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the BSA 2024 share-based payment plan",
        "label": "BSA 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "iva_BsaPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "BsaPlansMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for BSA plans.",
        "label": "BSA plans"
       }
      }
     },
     "auth_ref": []
    },
    "iva_BsaShareWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "BsaShareWarrantsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for BSA share warrants.",
        "label": "BSA share warrants"
       }
      }
     },
     "auth_ref": []
    },
    "iva_Bspce2021PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "Bspce2021PlanMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for BSPCE 2021 plan.",
        "label": "BSPCE 2021"
       }
      }
     },
     "auth_ref": []
    },
    "iva_BspceAndBsaShareWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "BspceAndBsaShareWarrantsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for BSPCE and BSA share warrants.",
        "label": "BSPCE and BSA Share Warrants",
        "verboseLabel": "BSPCE share warrants and BSA share warrants"
       }
      }
     },
     "auth_ref": []
    },
    "iva_BspcePlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "BspcePlansMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for BSPCE plans.",
        "label": "BSPCE plans"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CapitalReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CapitalReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital reserve",
        "terseLabel": "Capital reserve"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the capital reserves."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "iva_CapitalSurplusOthers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "CapitalSurplusOthers",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A component of equity representing the capital surplus-others.",
        "label": "Capital Surplus Others",
        "verboseLabel": "Capital surplus-others"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInventoriesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r71",
      "r72",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r137",
      "r143",
      "r144"
     ]
    },
    "ifrs-full_CarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CarryingAmountMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInventoriesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r47",
      "r72",
      "r75",
      "r77",
      "r78",
      "r137",
      "r143",
      "r144"
     ]
    },
    "ifrs-full_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails": {
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "terseLabel": "Cash at bank and at hand"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalent",
        "periodEndLabel": "Net cash and cash equivalents at the end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r87",
      "r105"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) decrease (increase) in short-term deposits and investments",
        "terseLabel": "Decrease / (Increase) in short-term deposit accounts"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Net cash from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r88"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities [abstract]",
        "terseLabel": "Cash flows used in financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Net cash from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r88"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities [abstract]",
        "terseLabel": "Cash flows used in investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r80",
      "r88"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities [abstract]",
        "terseLabel": "Cash flows used in operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows used in operations before tax, interest and changes in working capital",
        "totalLabel": "Cash flows used in operations before tax, interest and changes in working capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r239"
     ]
    },
    "iva_CashUnderLiquidityAgreementCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "CashUnderLiquidityAgreementCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash under liquidity agreement, classified as current.",
        "label": "Cash Under Liquidity Agreement, Current",
        "terseLabel": "Liquidity agreement - Cash"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsAxis",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails",
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ifrs-full_ChangesInPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ChangesInPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in property, plant and equipment",
        "terseLabel": "Increase in net value of property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "iva_ChiaTaiTianqingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ChiaTaiTianqingMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It Represents the member of chia tai tianqing.",
        "label": "Chia Tai Tianqing [Member]",
        "terseLabel": "CTTQ"
       }
      }
     },
     "auth_ref": []
    },
    "iva_CirAndOtherResearchTaxCreditsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "CirAndOtherResearchTaxCreditsReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": {
       "parentTag": "ifrs-full_CurrentTaxAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of CIR and other research tax credits receivable.",
        "label": "CIR and Other Research Tax Credits Receivable",
        "terseLabel": "CIR and other research tax credits receivable",
        "verboseLabel": "Tax research credit"
       }
      }
     },
     "auth_ref": []
    },
    "iva_ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price of warrants issued, represented as a percentage of volume-weighted average price of the Company's shares.",
        "label": "Class Of Warrant Or Right, Exercise Price Of Warrants As A Percentage Of Volume-Weighted Average Price Of The Company's Shares",
        "terseLabel": "Exercise price of warrants as a percentage of volume-weighted average price of the Company's shares"
       }
      }
     },
     "auth_ref": []
    },
    "iva_ClassOfWarrantOrRightGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ClassOfWarrantOrRightGranted",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights granted.",
        "label": "Class of Warrant or Right, Granted",
        "terseLabel": "Number of warrants granted",
        "verboseLabel": "Number of warrants issued"
       }
      }
     },
     "auth_ref": []
    },
    "iva_ClassOfWarrantOrRightMaturityTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ClassOfWarrantOrRightMaturityTerm",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity term of the warrants issued by the entity.",
        "label": "Class Of Warrant Or Right, Maturity Term",
        "terseLabel": "Maturity term of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialAssetsAxis",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r150",
      "r151",
      "r172",
      "r173"
     ]
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r172",
      "r173"
     ]
    },
    "ifrs-full_ClassesOfLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfLiabilitiesAxis",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfShareCapitalMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "iva_ClinicalTrialsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ClinicalTrialsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Clinical Trials(CRO).",
        "label": "Clinical Trials [Member]",
        "terseLabel": "CRO"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClosingForeignExchangeRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClosingForeignExchangeRate",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Closing foreign exchange rate",
        "terseLabel": "Exchange rate at period end"
       }
      },
      "en": {
       "role": {
        "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "iva_CommitmentContractualBonusOrMalusCappedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "CommitmentContractualBonusOrMalusCappedAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commitment contractual bonus or malus capped amount.",
        "label": "Commitment Contractual Bonus Or Malus Capped Amount",
        "terseLabel": "Bonus or malus capped amount"
       }
      }
     },
     "auth_ref": []
    },
    "iva_CommitmentsAmountPayableForServicesReceivedUnderContract": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "CommitmentsAmountPayableForServicesReceivedUnderContract",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment amount payable for services received under contract.",
        "label": "Commitments Amount Payable For Services Received Under Contract",
        "verboseLabel": "Amount committed to pay"
       }
      }
     },
     "auth_ref": []
    },
    "iva_CompanyInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "CompanyInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Company information"
       }
      }
     },
     "auth_ref": []
    },
    "iva_CompanyInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "CompanyInformationTextBlock",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on company information.",
        "label": "Company Information [Text Block]",
        "terseLabel": "Company information"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "iva_ComponentsOfIncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ComponentsOfIncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Notes to the interim condensed consolidated statement of (income) loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "totalLabel": "Total comprehensive loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r34",
      "r90",
      "r92",
      "r102",
      "r195"
     ]
    },
    "ifrs-full_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment in progress"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ContractCroWithPharmaceuticalResearchAssociatesB.vMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Contract CRO with PRA.",
        "label": "Contract CRO With Pharmaceutical Research Associates B.V [Member]",
        "terseLabel": "Contract CRO with Pharmaceutical Research Associates B.V."
       }
      }
     },
     "auth_ref": []
    },
    "iva_ContractCroWithResearchAssociatesGroupeB.vMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ContractCroWithResearchAssociatesGroupeB.vMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Contract CRO with PRA.",
        "label": "Contract CRO with Pharmaceutical Research Associates B.V.",
        "terseLabel": "Contract CRO with Pharmaceutical Research Associates B.V."
       }
      }
     },
     "auth_ref": []
    },
    "iva_ContractManufacturingOrganizationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ContractManufacturingOrganizationsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Contract Manufacturing Organizations(CMO).",
        "label": "Contract Manufacturing Organizations [Member]",
        "terseLabel": "CMO"
       }
      }
     },
     "auth_ref": []
    },
    "iva_ContractualCapitalCommitmentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ContractualCapitalCommitmentReceived",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual capital commitment received.",
        "label": "Contractual Capital Commitment Received",
        "totalLabel": "Total commitments received"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContractualCapitalCommitments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContractualCapitalCommitments",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual capital commitments",
        "terseLabel": "Total commitments given"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]"
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAccruedIncomeIncludingCurrentContractAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current accrued income including current contract assets",
        "terseLabel": "Current accrued income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current accrued income including current contract assets. [Refer: Accrued income including contract assets]"
       }
      }
     },
     "auth_ref": [
      "r218",
      "r220"
     ]
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets",
        "totalLabel": "Total current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r23",
      "r98",
      "r195"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets [abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "iva_CurrentAssetsExcludingDeferredAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "CurrentAssetsExcludingDeferredAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current assets excluding deferred assets",
        "label": "Current assets excluding deferred assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "auth_ref": []
    },
    "iva_CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current borrowings and current portion of non-current borrowings and current lease liabilities",
        "label": "Current borrowings and current portion of non-current borrowings and current lease liabilities",
        "terseLabel": "Shortterm debt"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "iva_TradePayablesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current contract liabilities",
        "terseLabel": "Short-term contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r100",
      "r195"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities [abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current prepaid expenses",
        "terseLabel": "Prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "ifrs-full_CurrentServiceCostDefinedBenefitPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentServiceCostDefinedBenefitPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails": {
       "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current service cost, defined benefit plans",
        "negatedLabel": "Service cost for the period"
       }
      },
      "en": {
       "role": {
        "documentation": "The expense of employee service in the current period arising from defined benefit plans. [Refer: Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase in net defined benefit liability (asset) resulting from current service cost]"
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "ifrs-full_CurrentTaxAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": {
       "parentTag": "iva_OtherCurrentAssetsAndReceivables",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current tax assets, current",
        "terseLabel": "Tax receivables",
        "totalLabel": "Tax receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of current tax assets. [Refer: Current tax assets]"
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "iva_CurrentTaxCreditResearchCurrentYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "CurrentTaxCreditResearchCurrentYear",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of tax credit research from current year, classified as current.",
        "label": "Current Tax Credit Research, Current Year",
        "terseLabel": "Receivable for current year",
        "verboseLabel": "Tax credits of current year"
       }
      }
     },
     "auth_ref": []
    },
    "iva_CurrentTaxCreditResearchIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "CurrentTaxCreditResearchIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails": {
       "parentTag": "iva_OtherIncomeFromOrdinaryActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income from tax credit research.",
        "label": "Current Tax Credit Research Income",
        "terseLabel": "Tax Credits"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current tax expense (income) and adjustments for current tax of prior periods",
        "terseLabel": "Current taxes"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]"
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "iva_CurrentTradeReceivablesAveragePaymentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "CurrentTradeReceivablesAveragePaymentPeriod",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the average payment period for trade receivables.",
        "label": "Current Trade Receivables, Average Payment Period",
        "terseLabel": "Average payment period for trade receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentValueAddedTaxPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentValueAddedTaxPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails": {
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current value added tax payables",
        "terseLabel": "VAT payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current value added tax payables. [Refer: Value added tax payables]"
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "iva_DailyDoseOfEmpagliflozinInTrial": {
     "xbrltype": "massItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DailyDoseOfEmpagliflozinInTrial",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of daily dosage of empagliflozin in the trial.",
        "label": "Daily Dose Of Empagliflozin In Trial",
        "terseLabel": "Daily dose of empagliflozin in trial"
       }
      }
     },
     "auth_ref": []
    },
    "iva_DailyDoseOfLanifibranorInTrial": {
     "xbrltype": "massItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DailyDoseOfLanifibranorInTrial",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Daily dose of lanifibranor in trial",
        "label": "Daily dose of lanifibranor in trial"
       }
      }
     },
     "auth_ref": []
    },
    "iva_DavidNikodemMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DavidNikodemMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for David Nikodem, a member of Sapidus Consulting Group LLC, a service provider to the Company.",
        "label": "David Nikodem",
        "terseLabel": "David Nikodem"
       }
      }
     },
     "auth_ref": []
    },
    "iva_DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in borrowings through repayment of lease liabilities.",
        "label": "Decrease in borrowings through repayment of lease liabilities",
        "negatedLabel": "Repayment of lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "iva_DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in borrowings through repayments of bank borrowings",
        "label": "Decrease in borrowings through repayments of bank borrowings",
        "negatedLabel": "Repayment of bank borrowings"
       }
      }
     },
     "auth_ref": []
    },
    "iva_DeferredAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DeferredAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred assets",
        "label": "Deferred assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets",
        "verboseLabel": "Deferred tax assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r17",
      "r20",
      "r45"
     ]
    },
    "ifrs-full_DefinedBenefitObligationAtPresentValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DefinedBenefitObligationAtPresentValue",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsNetProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit obligation, at present value",
        "verboseLabel": "Retirement benefit obligations"
       }
      },
      "en": {
       "role": {
        "documentation": "The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]"
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "iva_DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of increase of Hemoglobin in patients with MASH and T2D.",
        "label": "Demonstrated Increase of Hemoglobin in Patients With MASH And T2D",
        "terseLabel": "Percentage of increase observed in the placebo arm"
       }
      }
     },
     "auth_ref": []
    },
    "iva_DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of reduction in Hemoglobin among  patients with MASH and T2D.",
        "label": "Demonstrated Reduction of Hemoglobin in Patients With MASH And T2D",
        "terseLabel": "Percentage reduction in results on treatments"
       }
      }
     },
     "auth_ref": []
    },
    "iva_DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Demonstrated reduction of hepatic fat measured by proton magnetic resonance spectroscopy",
        "label": "Demonstrated reduction of hepatic fat measured by proton magnetic resonance spectroscopy"
       }
      }
     },
     "auth_ref": []
    },
    "iva_DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of reduction in Hepatic Steatosis measured by MRI-PDFF.",
        "label": "Demonstrated Reduction Of Hepatic Steatosis Measured By MRI-PDFF",
        "terseLabel": "Reduction in hepatic steatosis (in percent)"
       }
      }
     },
     "auth_ref": []
    },
    "iva_DemonstratedSignificantRelativeReductionInVatSatRatioInPatients": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DemonstratedSignificantRelativeReductionInVatSatRatioInPatients",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of significant relative reduction in VAT / SAT ratio in patients.",
        "label": "Demonstrated Significant Relative Reduction in VAT/SAT Ratio in Patients",
        "terseLabel": "Significant relative reduction in VAT/SAT ratio (in percent)"
       }
      }
     },
     "auth_ref": []
    },
    "iva_DepreciationAmortizationAndProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DepreciationAmortizationAndProvisions",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": {
       "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to depreciation, amortization and provisions.",
        "label": "Depreciation, amortization and provisions",
        "negatedLabel": "Depreciation, amortization and provisions"
       }
      }
     },
     "auth_ref": []
    },
    "iva_DerivativeInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DerivativeInstrumentsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for derivative instruments.",
        "label": "Derivative instruments",
        "terseLabel": "Derivative instruments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for fair value measurement [text block]",
        "terseLabel": "Fair value measurement"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "iva_DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific disclosure requirements for unaudited interim financial statements.",
        "label": "Description Of Accounting Policy For Specific Disclosure Requirements For Unaudited Interim Financial Statements [Policy Text Block]",
        "terseLabel": "Specific disclosure requirements for unaudited interim financial statements"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossBasicAndDilutedLossPerShareDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "terseLabel": "Diluted loss per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65"
     ]
    },
    "iva_DirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DirectorsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Directors.",
        "label": "Directors",
        "terseLabel": "Directors"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of accounting judgements and estimates [text block]",
        "terseLabel": "Use of estimates and judgment"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of attribution of expenses by nature to their function [line items]",
        "terseLabel": "Operating expenses",
        "verboseLabel": "Notes to the income statement"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of attribution of expenses by nature to their function [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to attribution of expenses by nature to analysis of expenses by function in the statement of profit or loss."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r215"
     ]
    },
    "iva_DisclosureOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DisclosureOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of cash and cash equivalents.",
        "label": "Disclosure Of Cash And Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of cash and cash equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "iva_DisclosureOfChangesInBorrowingsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DisclosureOfChangesInBorrowingsTableTextBlock",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of changes in borrowings.",
        "label": "Disclosure Of Changes In Borrowings [Table Text Block]",
        "verboseLabel": "Schedule of movements in the period break down"
       }
      }
     },
     "auth_ref": []
    },
    "iva_DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about change in the provision recorded in respect of defined benefit schemes.",
        "label": "Disclosure Of Changes In Provision Recorded In Respect Of Defined Benefit Schemes, Explanatory",
        "terseLabel": "Schedule of change in the provision recorded in respect of defined benefit schemes"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [text block]",
        "terseLabel": "Schedule of changes in share capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]"
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [line items]",
        "terseLabel": "Shareholders' equity"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "iva_DisclosureOfComponentsOfIncomeStatementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DisclosureOfComponentsOfIncomeStatementTextBlock",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for components of income statement.",
        "label": "Disclosure Of Components Of Income Statement [Text Block]",
        "terseLabel": "Notes to the interim condensed consolidated statement of (income) loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfContingentLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfContingentLiabilitiesExplanatory",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of contingent liabilities [text block]",
        "terseLabel": "Schedule of commitments given and received"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [text block]",
        "terseLabel": "Schedule of debt"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [line items]",
        "terseLabel": "Guarantee Details",
        "verboseLabel": "Financial debt"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of borrowings."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [text block]",
        "terseLabel": "Schedule of financial assets and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r141",
      "r145",
      "r152"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [text block]",
        "terseLabel": "Schedule of intangible assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [text block]",
        "terseLabel": "Schedule of property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of effect of changes in foreign exchange rates [text block]",
        "terseLabel": "Schedule of exchange rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for the effect of changes in foreign exchange rates."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "iva_DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about expense recognized in the statement of income (loss) for Retirement Benefit Obligations.",
        "label": "Disclosure Of Expenses Recognized In Statement Of Income (Loss) For Retirement Benefit Obligations, Explanatory",
        "terseLabel": "Schedule of expense recognized in the statement of income (loss)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value of financial instruments [text block]",
        "terseLabel": "Schedule of financial assets and liabilities measured at fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value of financial instruments. [Refer: Financial instruments, class [member]; At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [line items]",
        "terseLabel": "Foreign currency forwards contract",
        "verboseLabel": "Financial assets and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r145",
      "r152"
     ]
    },
    "ifrs-full_DisclosureOfGoingConcernExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGoingConcernExplanatory",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of going concern [text block]",
        "terseLabel": "Going concern"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the entity's ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [line items]",
        "verboseLabel": "Intangible Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIntangibleAssetsTable",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of intangible assets."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInterestsInSubsidiariesExplanatory",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of interests in subsidiaries [text block]",
        "terseLabel": "Schedule of subsidiaries"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of interests in subsidiaries. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureAccountingPrinciples"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of material accounting policy information [text block]",
        "terseLabel": "Accounting principles"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure of material accounting policy information applied by the entity."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "iva_DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for notes to the interim consolidated balance sheet.",
        "label": "Disclosure of Notes to the Interim Condensed Consolidated Statement of Financial Position [Text Block]",
        "terseLabel": "Notes to the interim condensed consolidated statement of financial position"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]",
        "terseLabel": "Schedule of movements in BSPCE and BSA share warrants and Bonus shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherCurrentAssetsExplanatory",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of other current assets [text block]",
        "terseLabel": "Schedule of other current assets and receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other current assets. [Refer: Other current assets]"
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherCurrentLiabilitiesExplanatory",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of other current liabilities [text block]",
        "terseLabel": "Schedule of other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other current liabilities. [Refer: Other current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "iva_DisclosureOfOtherFinancialInformationTextblock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DisclosureOfOtherFinancialInformationTextblock",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other financial information.",
        "label": "Disclosure Of Other Financial Information [TextBlock]",
        "terseLabel": "Other financial information"
       }
      }
     },
     "auth_ref": []
    },
    "iva_DisclosureOfOtherNoncurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DisclosureOfOtherNoncurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of other non current assets.",
        "label": "Disclosure Of Other Noncurrent Assets [Table Text Block]",
        "terseLabel": "Schedule of other non current assets"
       }
      }
     },
     "auth_ref": []
    },
    "iva_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DisclosureOfOtherOperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of other operating income (expense).",
        "label": "Disclosure Of Other Operating Income Expense [Table Text Block]",
        "terseLabel": "Schedule of other operating income and expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [line items]",
        "verboseLabel": "Property, Plant and Equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "iva_DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about provision recorded in respect of defined benefit schemes at the end of each reporting period.",
        "label": "Disclosure Of Provision Recorded In Respect Of Defined Benefit Schemes At End Of Each Reporting Period, Explanatory",
        "terseLabel": "Schedule of provision recorded in respect of defined benefit schemes at the end of each reporting period"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of reconciliation of summarised financial information of associate accounted for using equity method to carrying amount of interest in associate [text block]",
        "terseLabel": "Schedule of investment in Hepalys is accounted for using the equity method of accounting"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the reconciliation of the summarised financial information of an associate accounted for using the equity method to the carrying amount of the reporting entity's interest in the associate. [Refer: Carrying amount [member]; Associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "iva_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of share of profit loss of associates and joint ventures accounted for using equity method investments.",
        "label": "Disclosure Of Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method Investments [Table Text Block]",
        "terseLabel": "Schedule of share of net profit - Equity method"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesLineItems",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other financial information [line items]",
        "terseLabel": "Investments accounted for using the equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesTable",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of associates [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to associates."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r62",
      "r111"
     ]
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [line items]",
        "terseLabel": "General principles and statement of compliance"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to subsidiaries."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r62",
      "r110"
     ]
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]",
        "verboseLabel": "Notes to the interim condensed consolidated statement of financial position"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of trade and other payables [text block]",
        "terseLabel": "Schedule of trade payables break down by payment"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure for trade payables and other current liabilities.",
        "label": "Disclosure Of Trade Payables and Other Current Liabilities [Table Text Block]",
        "terseLabel": "Schedule of trade payables and other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "iva_DisclosureOfTradeReceivablesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DisclosureOfTradeReceivablesTableTextBlock",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of trade receivables.",
        "label": "Disclosure of Trade Receivables [Table Text Block]",
        "terseLabel": "Schedule of trade receivables and others break down"
       }
      }
     },
     "auth_ref": []
    },
    "iva_DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of valuation approach for BSA share-based payment arrangement",
        "label": "Disclosure of valuation approach for BSA share-based payment arrangement [table text block]",
        "terseLabel": "Schedule of valuation approach for BSA arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DiscountRateMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DiscountRateMeasurementInputMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount rate, measurement input [member]",
        "terseLabel": "Discount rate"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a discount rate used as a measurement input used in valuation techniques based on a present value calculation."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "iva_Disposables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "Disposables",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": {
       "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to disposables.",
        "label": "Disposables",
        "negatedLabel": "Disposables"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "iva_DrawdownOfBorrowingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "DrawdownOfBorrowingsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for drawdown of borrowings",
        "label": "Drawdown of borrowings [Member]",
        "terseLabel": "Drawdown of borrowings"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EarningsPerShareExplanatory",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share [text block]",
        "terseLabel": "Schedule of basic and diluted loss per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "terseLabel": "Exchange gains / (losses)"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85"
     ]
    },
    "iva_EliminationOfDownstreamSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "EliminationOfDownstreamSales",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails": {
       "parentTag": "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of elimination of downstream sales.",
        "label": "Elimination Of Downstream Sales",
        "negatedLabel": "Elimination of downstream sales"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EmployeeBenefitsExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": {
       "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee benefits expense",
        "negatedTerseLabel": "Personnel costs",
        "negatedTotalLabel": "Total personnel costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r40",
      "r174"
     ]
    },
    "iva_EmployeeRelatedPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "EmployeeRelatedPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails": {
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount pertaining to employee related payables.",
        "label": "Employee related payables",
        "verboseLabel": "Employeerelated payables"
       }
      }
     },
     "auth_ref": []
    },
    "iva_EnergyAndLiquids": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "EnergyAndLiquids",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": {
       "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to energy and liquids.",
        "label": "Energy and liquids",
        "negatedLabel": "Energy and liquids"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "iva_EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's share of net assets in investments accounted for using the equity method",
        "label": "Entity's share of net assets in investments accounted for using the equity method",
        "terseLabel": "Group's share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EntitysTotalForAssociatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForAssociatesMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity's total for associates [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r62",
      "r111"
     ]
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForRelatedPartiesMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity's total for related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ifrs-full_EntitysTotalForSubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForSubsidiariesMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity's total for subsidiaries [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r62",
      "r110"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity",
        "periodEndLabel": "Balance at the end",
        "periodStartLabel": "Balance at the beginning",
        "totalLabel": "Shareholders' equity",
        "verboseLabel": "Shareholders' equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r28",
      "r89",
      "r91",
      "r112",
      "r113",
      "r115"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [abstract]",
        "terseLabel": "Shareholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "terseLabel": "Total equity and liabilities",
        "totalLabel": "Total equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilitiesAbstract",
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity and liabilities [abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "iva_EquityRecoveryLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "EquityRecoveryLoansMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for equity recovery loans.",
        "label": "Equity Recovery Loans [Member]",
        "terseLabel": "Equity recovery loans"
       }
      }
     },
     "auth_ref": []
    },
    "iva_ExpectedVolatility": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ExpectedVolatility",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected volatility used to calculate fair value of warrants.",
        "label": "Expected volatility",
        "verboseLabel": "Volatility"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions with employees",
        "negatedLabel": "Share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "iva_FairValueOfWarrantsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "FairValueOfWarrantsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of warrants outstanding",
        "label": "Fair value of warrants outstanding",
        "terseLabel": "Fair Value (k\u20ac)"
       }
      }
     },
     "auth_ref": []
    },
    "iva_FairValueVariationGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "FairValueVariationGains",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gains recognized for variation in fair value.",
        "label": "Fair Value Variation Gains",
        "terseLabel": "Gain on fair value variation"
       }
      }
     },
     "auth_ref": []
    },
    "iva_Fees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "Fees",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": {
       "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to fees.",
        "label": "Fees",
        "negatedLabel": "Fees"
       }
      }
     },
     "auth_ref": []
    },
    "iva_FibroscanMachinesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "FibroscanMachinesMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for fibroscan machines.",
        "label": "Fibroscan machines"
       }
      }
     },
     "auth_ref": []
    },
    "iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "FinanceContractWithEuropeanInvestmentBankFirstTrancheMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to first tranche of the finance contract with European Investment Bank (\"EIB\").",
        "label": "Finance Contract With European Investment Bank, First Tranche [Member]",
        "terseLabel": "Finance contract with EIB, first tranche (Tranche A)",
        "verboseLabel": "Finance contract with EIB, Tranche A"
       }
      }
     },
     "auth_ref": []
    },
    "iva_FinanceContractWithEuropeanInvestmentBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "FinanceContractWithEuropeanInvestmentBankMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the Finance contract with the European Investment Bank",
        "label": "Finance contract with European Investment Bank [Member]",
        "terseLabel": "Finance contract with EIB"
       }
      }
     },
     "auth_ref": []
    },
    "iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "FinanceContractWithEuropeanInvestmentBankSecondTrancheMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to second tranche of the finance contract with European investment bank (\"EIB\").",
        "label": "Finance Contract With European Investment Bank, Second Tranche [Member]",
        "terseLabel": "Finance contract with EIB, second tranche (Tranche B)",
        "verboseLabel": "Finance contract with EIB, Tranche B"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance costs",
        "negatedTerseLabel": "Financial expenses",
        "negatedTotalLabel": "Total financial expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance income",
        "terseLabel": "Financial income",
        "totalLabel": "Total financial income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_FinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance income (cost)",
        "terseLabel": "Net financial income",
        "totalLabel": "Net financial income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income or cost associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_FinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial assets",
        "terseLabel": "Financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r140",
      "r143",
      "r144",
      "r147",
      "r200"
     ]
    },
    "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsAtAmortisedCostCategoryMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial assets carried at amortized cost",
        "terseLabel": "Financial assets carried at amortized cost"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]"
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "ifrs-full_FinancialAssetsAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial assets, at fair value",
        "terseLabel": "Financial assets, at fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial assets carried at fair value through profit or loss",
        "terseLabel": "Financial assets carried at fair value through profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "ifrs-full_FinancialAssetsCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsCategoryMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial assets, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ifrs-full_FinancialAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial assets, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r131",
      "r150",
      "r151",
      "r172",
      "r173"
     ]
    },
    "iva_FinancialIncomeAndExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "FinancialIncomeAndExpensesTableTextBlock",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of financial income and expense.",
        "label": "Financial Income and Expenses [Table Text Block]",
        "terseLabel": "Schedule of financial income and expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities",
        "terseLabel": "Financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities carried at amortized cost",
        "verboseLabel": "Liabilities carried at amortized cost"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]"
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCostMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesAtAmortisedCostMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities at amortised cost, class [member]",
        "terseLabel": "Financial liabilities at amortized cost"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities measured at amortised cost class. [Refer: Financial liabilities at amortised cost]"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities, at fair value",
        "verboseLabel": "Financial liabilities, at fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValueMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities at fair value, class [member]",
        "terseLabel": "Financial liabilities at fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities measured at fair value class. [Refer: Financial liabilities; At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities at fair value through profit or loss, category [member]",
        "terseLabel": "Financial liabilities carried at fair value through profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at fair value through profit or loss category. [Refer: Financial liabilities at fair value through profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "ifrs-full_FinancialLiabilitiesCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesCategoryMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails",
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ifrs-full_FinancialLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r172",
      "r173"
     ]
    },
    "iva_FinancingAgreementInThreePhasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "FinancingAgreementInThreePhasesMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for financing agreement entered in three phases.",
        "label": "Financing Agreement in Three Phases [Member]",
        "terseLabel": "Financing agreement in three phases"
       }
      }
     },
     "auth_ref": []
    },
    "iva_FinancingFromSyndicateOfFrenchBanksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "FinancingFromSyndicateOfFrenchBanksMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for financing from a syndicate of French banks.",
        "label": "Financing from a syndicate of French banks"
       }
      }
     },
     "auth_ref": []
    },
    "iva_FinancingPeriodOfLoan": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "FinancingPeriodOfLoan",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the financing period of loan.",
        "label": "Financing Period of Loan",
        "terseLabel": "Financing period of loan"
       }
      }
     },
     "auth_ref": []
    },
    "iva_FinancingThroughFundRaisingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "FinancingThroughFundRaisingMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for financing through fund raising.",
        "label": "Financing Through Fund Raising [Member]",
        "terseLabel": "Financing through fund raising"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ForeignExchangeGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ForeignExchangeGain",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign exchange gain",
        "terseLabel": "Foreign exchange gains"
       }
      },
      "en": {
       "role": {
        "documentation": "The gross gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r54"
     ]
    },
    "ifrs-full_ForeignExchangeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ForeignExchangeLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign exchange loss",
        "negatedLabel": "Foreign exchange losses"
       }
      },
      "en": {
       "role": {
        "documentation": "The gross loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r54"
     ]
    },
    "ifrs-full_ForeignExchangeRatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ForeignExchangeRatesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange rate (USD per EUR)"
       }
      }
     },
     "auth_ref": []
    },
    "iva_FredericCrenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "FredericCrenMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Frederic Cren",
        "label": "Frederic Cren [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsChangesInNetProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income",
        "terseLabel": "Actuarial gains or losses recognized in other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expense",
        "negatedLabel": "General and administrative expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "ifrs-full_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Goodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r67",
      "r68",
      "r137"
     ]
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GrossCarryingAmountMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInventoriesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross",
        "terseLabel": "Laboratory inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r46",
      "r71",
      "r76",
      "r79",
      "r137",
      "r144",
      "r147",
      "r200"
     ]
    },
    "iva_HepalysPharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "HepalysPharmaIncMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails",
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Hepalys Pharma, Inc.",
        "label": "Hepalys Pharma, Inc [Member]",
        "terseLabel": "Hepalys Pharma, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IfrsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IfrsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for cash and cash equivalents.",
        "label": "Cash and Cash equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "IFRS Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrant"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Ifrs Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of shares per warrant",
        "verboseLabel": "Number of shares per instrument"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "IFRS Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares underlying in EIB"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IfrsClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IfrsClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "IFRS Class of Warrant or Right, Outstanding",
        "terseLabel": "Number of share warrants outstanding",
        "verboseLabel": "Number of BSA outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of securities into which the class of warrant or right may be converted.",
        "label": "IFRS Class of Warrant or Right, Value of Number of Securities Called by Warrants or Rights",
        "terseLabel": "Class of warrant or right, value of number of securities"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Ifrs Collaborative Arrangement And Arrangement Other Than Collaborative [Line items]",
        "verboseLabel": "Collaborative Arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IfrsDebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IfrsDebtInstrumentTerm",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Ifrs Debt Instrument, Term",
        "verboseLabel": "Maturity term after the disbursement of the tranche"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IfrsFairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IfrsFairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "IFRS Fair Value Adjustment of Warrants",
        "terseLabel": "Fair value of the EIB warrants"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IfrsGeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IfrsGeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for general and administrative expense member.",
        "label": "General and administrative expenses"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IfrsOtherOperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IfrsOtherOperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails": {
       "parentTag": "iva_OtherIncomeFromOrdinaryActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.",
        "label": "Ifrs Other Operating Income",
        "terseLabel": "Other"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IfrsResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IfrsResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for research and development expense member.",
        "label": "Ifrs Research And Development Expense [Member]",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IfrsSalesAndMarketingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IfrsSalesAndMarketingExpenseMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for sales and marketing expense member.",
        "label": "Marketing - Business development expenses",
        "terseLabel": "Marketing - Business development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IfrsScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IfrsScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "IFRS Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventories"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IfrsotherFinancialInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IfrsotherFinancialInformationLineItems",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.",
        "label": "IFRSOther Financial Information [Line Items]",
        "terseLabel": "Events after the reporting date"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IfrsotherFinancialInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IfrsotherFinancialInformationTable",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule disclosing information related to other financial information.",
        "label": "IFRSOther Financial Information [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unaudited interim condensed consolidated statement of income (loss)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossIncomeTaxDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax expense (income)",
        "negatedLabel": "Income tax",
        "terseLabel": "Tax income"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r37",
      "r42",
      "r43",
      "r44",
      "r58",
      "r107",
      "r161"
     ]
    },
    "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes paid (refund), classified as operating activities",
        "negatedLabel": "Tax credit received"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]"
       }
      }
     },
     "auth_ref": [
      "r86",
      "r187"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "iva_IncreaseDecreaseInLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in lease liabilities during the period.",
        "label": "Increase (Decrease) in Lease Liabilities",
        "terseLabel": "Increase (decrease) in lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IncreaseDecreaseInLongTermDepositAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IncreaseDecreaseInLongTermDepositAccounts",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in long-term deposit accounts",
        "label": "Increase (decrease) in long-term deposit accounts",
        "terseLabel": "Increase (decrease) in long-term deposit accounts"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsChangesInNetProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss",
        "negatedLabel": "Expense for the period"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from expense (income) included in profit or loss. [Refer: Net defined benefit liability (asset); Profit (loss)] [Contrast: Post-employment benefit expense in profit or loss, defined benefit plans]"
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInNumberOfSharesOutstanding",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in number of shares outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]"
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "iva_IncreaseDecreaseInShortTermDepositAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IncreaseDecreaseInShortTermDepositAccounts",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in short-term deposit accounts.",
        "label": "Increase (Decrease) In Short-Term Deposit Accounts",
        "terseLabel": "Increase in short-term deposit accounts"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IncreaseDecreaseInTradeAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IncreaseDecreaseInTradeAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in trade accounts payable",
        "label": "Increase (decrease) in trade accounts payable",
        "terseLabel": "Increase in trade accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IncreaseDecreaseInTradeAndOtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IncreaseDecreaseInTradeAndOtherCurrentReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in trade and other current receivables.",
        "label": "Increase (Decrease) in Trade and other current receivables",
        "terseLabel": "Trade receivables decreased"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInWorkingCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in working capital",
        "negatedTotalLabel": "Tax, interest and changes in operating working capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in working capital."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughAppropriationOfRetainedEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through appropriation of retained earnings, equity",
        "terseLabel": "Appropriation of net income (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the appropriation of retained earnings. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "iva_IncreaseDecreaseThroughCapitalVariations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IncreaseDecreaseThroughCapitalVariations",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) through capital variations, equity",
        "label": "Increase (decrease) through capital variations",
        "terseLabel": "Capital variations"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IncreaseDecreaseThroughShareWarrantsSubscriptionPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IncreaseDecreaseThroughShareWarrantsSubscriptionPremium",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase decrease in reserves resulting from BSA share warrants subscription premium.",
        "label": "Increase (Decrease) Through Share Warrants Subscription Premium",
        "terseLabel": "BSA share warrants subscription premium"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through share-based payment transactions, equity",
        "terseLabel": "Share-based payment compensation expenses",
        "verboseLabel": "Capital increase arising from the vesting of bonus share awards"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through other changes, equity",
        "terseLabel": "Other"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughTreasuryShareTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through treasury share transactions, equity",
        "terseLabel": "Treasury shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "iva_IncreaseInBorrowingsThroughCapitalizedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IncreaseInBorrowingsThroughCapitalizedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in borrowings through capitalized interest.",
        "label": "Increase in borrowings through capitalized interest",
        "terseLabel": "Capitalized interests"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in borrowings through Subscription of derivatives instruments.",
        "label": "Increase in Borrowings Through Subscription Of Derivatives Instruments",
        "terseLabel": "Subscription of derivatives instruments"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase or decrease in borrowings due to change in fair value of derivatives instruments.",
        "label": "Increase Or Decrease In Borrowings Due To Change in Fair Value of Derivatives Instruments",
        "terseLabel": "Change in fair value of derivatives instruments"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase or decrease in borrowings due to exchange rate change.",
        "label": "Increase or Decrease in Borrowings Due to Changes in Exchange Rates",
        "terseLabel": "Exchange rate change"
       }
      }
     },
     "auth_ref": []
    },
    "iva_Increaseinborrowingsthroughborrowingsreceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "Increaseinborrowingsthroughborrowingsreceived",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in borrowings through borrowings received.",
        "label": "IncreaseInBorrowingsThroughBorrowingsReceived",
        "terseLabel": "Subscription of bank borrowings"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IncreasesInPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IncreasesInPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increases in property, plant and equipment",
        "label": "Increases in property, plant and equipment",
        "terseLabel": "Increases"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for indication of continuation of recruitment for Phase III trial NATiV3 of lanifibranor in non-cirrhotic NASH.",
        "label": "Indication Of Continuation Of Recruitment For Phase Iii Trial Nativ3 Of Lanifibranor In Non-Cirrhotic NashASH [Member]",
        "terseLabel": "Indication of continuation of recruitment for Phase III trial NATiV3 of lanifibranor in non-cirrhotic NASH"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InsuranceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InsuranceExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": {
       "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance expense",
        "negatedLabel": "Insurances"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from purchased insurance."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails": {
       "parentTag": "iva_NonCurrentAssetsExcludingDeferredAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill",
        "periodEndLabel": "Balance at the end",
        "periodStartLabel": "Balance at the beginning",
        "terseLabel": "Intangible assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r72"
     ]
    },
    "iva_IntercompanyEliminationsInAssociates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IntercompanyEliminationsInAssociates",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intercompany eliminations in associates",
        "label": "Intercompany Eliminations in Associates",
        "negatedLabel": "Elimination of unrealised profit on downstream sales"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestCostsCapitalised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestCostsCapitalised",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest costs capitalised",
        "terseLabel": "Capitalized interest"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "ifrs-full_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense",
        "negatedLabel": "Interest cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from interest."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r160",
      "r168"
     ]
    },
    "ifrs-full_InterestExpenseDefinedBenefitPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestExpenseDefinedBenefitPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails": {
       "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense, defined benefit plans",
        "negatedLabel": "Interest cost for the period"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense arising from defined benefit plans. [Refer: Interest expense; Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "ifrs-full_InterestIncomeOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestIncomeOnCashAndCashEquivalents",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails": {
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income on cash and cash equivalents",
        "terseLabel": "Income from cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest income on cash and cash equivalents. [Refer: Interest income; Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "iva_InterestOnRoyaltyCertificates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "InterestOnRoyaltyCertificates",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in borrowings through interests on royalty certificates.",
        "label": "Interest On Royalty Certificates",
        "verboseLabel": "Issue of royalty certificates"
       }
      }
     },
     "auth_ref": []
    },
    "iva_InventivaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "InventivaIncMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Inventiva Inc, U.S. affiliate.",
        "label": "Inventiva Inc [Member]",
        "terseLabel": "Inventiva Inc."
       }
      }
     },
     "auth_ref": []
    },
    "iva_InventivaS.aMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "InventivaS.aMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Inventiva S.A, U.S. affiliate.",
        "label": "Inventiva S.A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Inventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Inventories",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInventoriesDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current inventories",
        "terseLabel": "Inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r53",
      "r177"
     ]
    },
    "ifrs-full_InvestmentAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InvestmentAccountedForUsingEquityMethod",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments accounted for using equity method",
        "netLabel": "Carrying amount",
        "terseLabel": "Investments accounted for using the equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r109",
      "r163"
     ]
    },
    "iva_IssuanceOfRoyaltyCertificatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IssuanceOfRoyaltyCertificatesMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for issuance of royalty certificates.",
        "label": "Issuance of Royalty Certificates [Member]",
        "terseLabel": "Issuance of royalty certificates"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IssuanceOfSharesOrWarrantsSubjectToConditionsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for issue of shares or warrants subject to conditions.",
        "label": "Issuance of Shares or Warrants Subject to Conditions [Member]",
        "terseLabel": "Issuance of shares or warrants subject to conditions"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for issue of shares or warrants without preferential subscription rights.",
        "label": "Issuance of Shares or Warrants Without Preferential Subscription Rights [Member]",
        "terseLabel": "Issuance of shares or warrants without preferential subscription rights"
       }
      }
     },
     "auth_ref": []
    },
    "iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for issue of shares without preferential subscription rights.",
        "label": "Issuance of Shares Without Preferential Subscription Rights [Member]",
        "terseLabel": "Issuance of shares without preferential subscription rights"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssueOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssueOfEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue of equity",
        "terseLabel": "Issue of ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "iva_IssueOfRoyaltyCertificates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "IssueOfRoyaltyCertificates",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase in borrowings through issue of royalty certificates.",
        "label": "Issue of Royalty Certificates",
        "terseLabel": "Issue of royalty certificates"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityShareCapitalDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued capital",
        "terseLabel": "Share capital",
        "verboseLabel": "Capital stock"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share capital"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "iva_ItSystems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ItSystems",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": {
       "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to it systems.",
        "label": "IT Systems",
        "negatedLabel": "IT systems"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanFiveYearsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "More than 5 years"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r130",
      "r202",
      "r206",
      "r209"
     ]
    },
    "ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanOneMonthAndNotLaterThanTwoMonthsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due in 30 60 days",
        "terseLabel": "Due in 30-60 days"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one month and not later than two months."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r208",
      "r215"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanThreeYearsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Between 1 and 3 years"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than three years."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r204",
      "r209"
     ]
    },
    "ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanThreeYearsAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Between 3 and 5 years"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three years and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r205",
      "r209"
     ]
    },
    "iva_LaterThanTwoMonthsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "LaterThanTwoMonthsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for a time band of later than two months.",
        "label": "Due in more than 60 days",
        "terseLabel": "Due in more than 60 days"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ifrs-full_LeaseLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseLiabilitiesMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities [member]",
        "terseLabel": "Lease liabilities",
        "verboseLabel": "Lease"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r192",
      "r194"
     ]
    },
    "iva_LeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "LeaseTerm",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease term.",
        "label": "Lease Term",
        "terseLabel": "Lease term"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D",
        "label": "LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D [Member]",
        "terseLabel": "Combination of lanifibranor"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Level3OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Level3OfFairValueHierarchyMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 3"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyAxis",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r113"
     ]
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r112",
      "r113",
      "r115",
      "r162",
      "r167"
     ]
    },
    "ifrs-full_LiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilityAssetOfDefinedBenefitPlans",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsChangesInNetProvisionDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsNetProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net defined benefit liability (asset)",
        "negatedPeriodEndLabel": "At end of period",
        "negatedPeriodStartLabel": "At beginning of period",
        "totalLabel": "Total Obligation"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]"
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "iva_LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum additional amount receivable by the entity, upon the achievement of certain milestones, pursuant to licensing and collaborative arrangements.",
        "label": "License And Collaboration Agreement, Maximum Additional Amount Receivable Upon Achievement Of Certain Milestones",
        "terseLabel": "Maximum milestone payments receivable"
       }
      }
     },
     "auth_ref": []
    },
    "iva_LicenseAndCollaborationAgreementUpfrontFeeReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "LicenseAndCollaborationAgreementUpfrontFeeReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of upfront fee receivable by the entity, pursuant to licensing and collaborative arrangements.",
        "label": "License And Collaboration Agreement Upfront Fee Receivable",
        "terseLabel": "Upfront payment receivable"
       }
      }
     },
     "auth_ref": []
    },
    "iva_LicensingAgreementWithHepalysMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "LicensingAgreementWithHepalysMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Licensing agreement with Hepalys.",
        "label": "Licensing Agreement With Hepalys [Member]",
        "terseLabel": "Licensing agreement with Hepalys"
       }
      }
     },
     "auth_ref": []
    },
    "iva_LicensingAndCollaborationAgreementWithCttqMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "LicensingAndCollaborationAgreementWithCttqMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Licensing and collaboration agreement with CTTQ.",
        "label": "Licensing and collaboration agreement with CTTQ [Member]",
        "terseLabel": "Licensing and collaboration agreement with CTTQ"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LineItemsByFunctionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LineItemsByFunctionMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line items by function [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value of the \u2018Attribution of expenses by nature to their function' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r215"
     ]
    },
    "iva_LiquidityAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "LiquidityAgreementTerm",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityLiquidityAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days used to determine liquidity agreement term  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Liquidity Agreement Term",
        "terseLabel": "Liquidity agreement term"
       }
      }
     },
     "auth_ref": []
    },
    "iva_LoanAgreementsWithSyndicateOfFrenchBanksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "LoanAgreementsWithSyndicateOfFrenchBanksMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for loan agreements with a syndicate of French banks.",
        "label": "Loan Agreements With Syndicate of French Banks [Member]",
        "verboseLabel": "Loan agreements with a syndicate of French banks"
       }
      }
     },
     "auth_ref": []
    },
    "iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat)",
        "label": "Loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat) [Member]",
        "terseLabel": "Loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat)"
       }
      }
     },
     "auth_ref": []
    },
    "iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for loan agreements with a syndicate of French banks, under a stimulus economic plan.",
        "label": "Loan agreements with syndicate of French banks, under stimulus economic plan [Member]",
        "terseLabel": "Loan agreements with syndicate of French banks, under stimulus economic plan"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LoansReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LoansReceived",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans received",
        "terseLabel": "Bank borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of loans received."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "iva_LongTermDepositAccountsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "LongTermDepositAccountsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for long term deposit accounts.",
        "label": "Long-term deposit accounts",
        "terseLabel": "Long-term deposit accounts"
       }
      }
     },
     "auth_ref": []
    },
    "iva_LongTermDepositsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "LongTermDepositsTerm",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of the long-term deposits of the entity.",
        "label": "Long-Term Deposits Term",
        "terseLabel": "Period of long-term deposit"
       }
      }
     },
     "auth_ref": []
    },
    "iva_LongTermFinancialDebtDerivativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "LongTermFinancialDebtDerivativesMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Long-term financial debt, derivatives.",
        "label": "Derivatives",
        "terseLabel": "Long-term financial debt - derivatives"
       }
      }
     },
     "auth_ref": []
    },
    "iva_LongTermIncentivePlanInPerformanceUnits2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "LongTermIncentivePlanInPerformanceUnits2023Member",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for 2023 long-term incentive plan in performance units or \"PAGUP 2023\".",
        "label": "Long-Term Incentive Plan In Performance Units, 2023 [Member]",
        "terseLabel": "PAGUP 2023"
       }
      }
     },
     "auth_ref": []
    },
    "iva_LongTermIncentivePlanInPerformanceUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "LongTermIncentivePlanInPerformanceUnitsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for long-term incentive plan in performance units or \"PAGUP\".",
        "label": "Long-Term Incentive Plan In Performance Units [Member]",
        "terseLabel": "PAGUP"
       }
      }
     },
     "auth_ref": []
    },
    "iva_LongTermSecurityDepositsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "LongTermSecurityDepositsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for long-term security deposits.",
        "label": "Long-term security deposits",
        "terseLabel": "Long-term security deposits"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LongtermBorrowingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LongtermBorrowingsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term debt",
        "terseLabel": "Long-term debt"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for long-term borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r192",
      "r194"
     ]
    },
    "ifrs-full_LongtermDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LongtermDeposits",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term deposits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of long-term deposits held by the entity."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for non-derivative financial liabilities [text block]",
        "terseLabel": "Schedule of maturity of long-term and short-term debt"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r121",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r139",
      "r149",
      "r183",
      "r202"
     ]
    },
    "iva_MaximumDurationOfClinicalTrial": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "MaximumDurationOfClinicalTrial",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum duration of the clinical trial of the entity.",
        "label": "Maximum Duration Of The Clinical Trial",
        "verboseLabel": "Maximum duration of Phase III trial"
       }
      }
     },
     "auth_ref": []
    },
    "iva_MaximumGrossProceedsReceivableUponExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "MaximumGrossProceedsReceivableUponExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum gross proceeds from receivable upon exercise of warrants.",
        "label": "Maximum Gross Proceeds Receivable upon Exercise of Warrants",
        "terseLabel": "Maximum gross proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "iva_MaximumPotentialGrossProceedsFromExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "MaximumPotentialGrossProceedsFromExerciseOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of gross proceeds that the company will receive from exercise of warrants.",
        "label": "Maximum Potential Gross Proceeds From Exercise Of Warrants",
        "terseLabel": "Maximum potential gross proceeds from exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "iva_MinimumAmountCommittedForFundRaising": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "MinimumAmountCommittedForFundRaising",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount committed for borrowing under the agreement.",
        "label": "Minimum Amount Committed For Fund Raising",
        "terseLabel": "Minimum amount committed for fund raising"
       }
      }
     },
     "auth_ref": []
    },
    "iva_MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of minimum upfront payments for out-licensing, partnership or royalty transaction.",
        "label": "Minimum Upfront Payments For Out-Licensing, Partnership Or Royalty Transaction",
        "verboseLabel": "Minimum upfront payments for out-licensing, partnership or royalty transaction"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MiscellaneousOtherOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MiscellaneousOtherOperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails": {
       "parentTag": "ifrs-full_OtherOperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Miscellaneous other operating expense",
        "negatedLabel": "Other operating expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "ifrs-full_MiscellaneousOtherOperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MiscellaneousOtherOperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails": {
       "parentTag": "ifrs-full_OtherOperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Miscellaneous other operating income",
        "terseLabel": "Other operating income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for NATiV3 Phase III clinical trial with lanifibranor in patients with\nMASH/NASH.",
        "label": "NATiV3 Phase III Clinical Trial With Lanifibranor In Patients With MASH/NASH [Member]",
        "terseLabel": "NATiV3 Phase III clinical trial"
       }
      }
     },
     "auth_ref": []
    },
    "iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the NATiV3 Phase III trial of lanifibranor in non-cirrhotic NASH",
        "label": "NATiV3 Phase III trial of lanifibranor in non-cirrhotic NASH [Member]",
        "terseLabel": "NATiV3 Phase III trial of lanifibranor in non-cirrhotic NASH"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NetProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NetProceedsFromIssuingShares",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net proceeds from issuing shares",
        "label": "Net Proceeds From Issuing Shares",
        "verboseLabel": "Capital increase net of transaction cost"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NewBonusShareAwardPlan20231Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NewBonusShareAwardPlan20231Member",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for New bonus share award plans (AGA 2023-1).",
        "label": "New Bonus Share Award Plan 2023-1 [Member]",
        "terseLabel": "AGA Plan 2023-1"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NewBonusShareAwardPlan20232Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NewBonusShareAwardPlan20232Member",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for New bonus share award plans (AGA 2023-2).",
        "label": "AGA 2023-2 [Member]",
        "terseLabel": "AGA 2023-2"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NewBonusShareAwardPlanAga20211Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NewBonusShareAwardPlanAga20211Member",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for New bonus share award plans (AGA 2021-1)",
        "label": "AGA 2021-1"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NewBonusShareAwardPlanAga2021BisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NewBonusShareAwardPlanAga2021BisMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for New bonus share award plans (AGA 2021-bis).",
        "label": "AGA 2021-bis"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NewBsa2021ShareWarrantPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NewBsa2021ShareWarrantPlanMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for new BSA 2021 share warrant plan.",
        "label": "BSA 2021"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NewShareWarrantPlansBsa2019BisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NewShareWarrantPlansBsa2019BisMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for a new share warrant plan (\"BSA 2019 bis).",
        "label": "BSA 2019 bis"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NewShareWarrantPlansBsa2019Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NewShareWarrantPlansBsa2019Member",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for new share warrant plans (\"BSA 2019\").",
        "label": "BSA 2019"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NewShareWarrantPlansBsa2019TerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NewShareWarrantPlansBsa2019TerMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for a new share warrant plan (\"BSA 2019 ter).",
        "label": "BSA 2019 ter"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NonCurrentAdvancesToSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NonCurrentAdvancesToSuppliers",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount represents the non current advances of suppliers.",
        "label": "Non Current Advances To Suppliers",
        "terseLabel": "Advance payments - non-current",
        "verboseLabel": "Non-current advances to suppliers"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NonCurrentAssetsExcludingDeferredAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NonCurrentAssetsExcludingDeferredAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-current assets excluding deferred assets",
        "label": "Non-current assets excluding deferred assets",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NonCurrentLongTermDepositsFromCustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NonCurrentLongTermDepositsFromCustomers",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents information about non current long term deposits from customers.",
        "label": "Non Current Long Term Deposits From Customers",
        "terseLabel": "Longterm deposit accounts"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-current portion of non-current borrowings and non-current lease liabilities",
        "label": "Non-current portion of non-current borrowings and non-current lease liabilities",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The non-current portion of non-current royalty certificates issued.",
        "label": "Non-current Portion of Non-current Royalty Certificates Issued",
        "terseLabel": "Royalty certificates liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NonCurrentSecurityDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NonCurrentSecurityDeposits",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The non-current amount of security deposits.",
        "label": "Non-current Security Deposits",
        "terseLabel": "Security deposits"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "ifrs-full_NonadjustingEventsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonadjustingEventsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [member]",
        "terseLabel": "Non-adjusting events after reporting period [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "ifrs-full_NoncontrollingInterests": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncontrollingInterests",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controlling interests",
        "terseLabel": "Non-controlling interest"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r18",
      "r93",
      "r94"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets",
        "totalLabel": "Total non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r23",
      "r99",
      "r195"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets [abstract]",
        "terseLabel": "Noncurrent assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current contract liabilities",
        "terseLabel": "Long-term contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "ifrs-full_NoncurrentDerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentDerivativeFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current derivative financial liabilities",
        "netLabel": "Derivatives instruments",
        "terseLabel": "Long-term debt - derivatives",
        "verboseLabel": "Derivatives"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities",
        "totalLabel": "Total non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r24",
      "r101",
      "r195"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities [abstract]",
        "terseLabel": "Noncurrent liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentProvisionsForEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentProvisionsForEmployeeBenefits",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current provisions for employee benefits",
        "terseLabel": "Provisions for retirement benefit obligations"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]"
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "ifrs-full_NotLaterThanOneMonthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotLaterThanOneMonthMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due in 30 days",
        "terseLabel": "Due in 30 days"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one month."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r203",
      "r209"
     ]
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotLaterThanOneYearMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less than 1 year"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r125",
      "r126",
      "r130",
      "r202",
      "r209"
     ]
    },
    "ifrs-full_NotLaterThanThreeMonthsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotLaterThanThreeMonthsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "3 months or less"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than three months."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "iva_NotesToConsolidatedBalanceSheet": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NotesToConsolidatedBalanceSheet",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Trade payables, short-term contract liabilities and other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Notes to the interim condensed consolidated statement of financial position"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotionalAmount",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notional Amount",
        "terseLabel": "Notional amount",
        "verboseLabel": "Total amount of loan"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "iva_NotionalAmountPerTranche": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NotionalAmountPerTranche",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notional amount per tranche",
        "label": "Notional Amount Per Tranche",
        "terseLabel": "Notional amount per tranche"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NumberOfAwardPlansAttributed": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NumberOfAwardPlansAttributed",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of award plans attributed during the period.",
        "label": "Number Of Award Plans Attributed",
        "terseLabel": "Number of plans attributed"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NumberOfBiopsiesUnderClinicalTrials": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NumberOfBiopsiesUnderClinicalTrials",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the  number of clinical trial.",
        "label": "Number Of Biopsies Under Clinical Trials",
        "terseLabel": "Number of Biopsies Under the Phase III trial"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfEmployees",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of employees",
        "verboseLabel": "Number of employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of personnel employed by the entity at a date."
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "iva_NumberOfEntitiesBeingConsolidated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NumberOfEntitiesBeingConsolidated",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of entities being consolidated",
        "label": "Number of entities being consolidated",
        "terseLabel": "Number of entities being consolidated"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NumberOfEqualTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NumberOfEqualTranches",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the information of number of equal tranches .",
        "label": "Number of Equal Tranches",
        "terseLabel": "Number of equal tranches"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of other equity instruments granted in share-based payment arrangement",
        "terseLabel": "Issued",
        "verboseLabel": "Number of equity instruments granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r243"
     ]
    },
    "iva_NumberOfLoanAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NumberOfLoanAgreements",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of loan agreements.",
        "label": "Number of Loan Agreements",
        "terseLabel": "Number of loan agreements"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NumberOfLoansObtainedGuaranteedByFrenchState": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NumberOfLoansObtainedGuaranteedByFrenchState",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of loans obtained which are guaranteed by the french state.",
        "label": "Number Of Loans Obtained Guaranteed By The French State",
        "verboseLabel": "Number of loans obtained guaranteed by the french state"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of other equity instruments exercisable in share-based payment arrangement",
        "terseLabel": "Number of exercisable shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement",
        "negatedLabel": "Exercised/Vesting"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of other equity instruments expired in share-based payment arrangement",
        "verboseLabel": "Instruments lapsed"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) expired in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of other equity instruments forfeited in share-based payment arrangement",
        "negatedLabel": "Forfeited/ Lapsed"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of other equity instruments outstanding in share-based payment arrangement",
        "periodEndLabel": "Outstanding, Ending balance",
        "periodStartLabel": "Outstanding, Beginning balance"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "iva_NumberOfPatientsRandomizedClinicalTrialMainCohort": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NumberOfPatientsRandomizedClinicalTrialMainCohort",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of subjects randomized for main cohort.",
        "label": "Number of Patients Randomized, Clinical Trial, Main Cohort",
        "terseLabel": "Number of patients in main cohort"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NumberOfPatientsRandomizedForTreatment": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NumberOfPatientsRandomizedForTreatment",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of patients randomized for treatment.",
        "label": "Number of Patients Randomized For Treatment",
        "terseLabel": "Number of patients randomized"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NumberOfPatientsToBeTreatedForFortyEightWeeks": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NumberOfPatientsToBeTreatedForFortyEightWeeks",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of patients to be treated for 48 weeks.",
        "label": "Number of Patients to Be Treated For Forty Eight Weeks",
        "terseLabel": "Number of patients to be treated for 48 weeks"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NumberOfPatientsToBeTreatedForSeventyTwoWeeks": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NumberOfPatientsToBeTreatedForSeventyTwoWeeks",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of patients to be treated for 72 weeks.",
        "label": "Number of Patients to Be Treated For Seventy Two Weeks",
        "terseLabel": "Number of patients to be treated for 72 weeks"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NumberOfPlansOutstanding": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NumberOfPlansOutstanding",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plans outstanding",
        "label": "Number of plans outstanding",
        "terseLabel": "Number of award plans outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NumberOfRoyaltyCertificatesIssued": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NumberOfRoyaltyCertificatesIssued",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of royalty certificates issued.",
        "label": "Number of Royalty Certificates Issued",
        "terseLabel": "Number of royalty certificates issued"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NumberOfSharesAcquiredInAssociate": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NumberOfSharesAcquiredInAssociate",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares acquired in associate",
        "label": "Number of shares acquired in associate",
        "terseLabel": "Number of shares acquired in associate"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NumberOfSharesConverted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NumberOfSharesConverted",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents the information relating to number of shares converted.",
        "label": "Number Of Shares Converted",
        "terseLabel": "Number of shares converted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityShareCapitalDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "periodEndLabel": "Balance at the end (in shares)",
        "periodStartLabel": "Balance at the beginning (in shares)",
        "terseLabel": "Number of shares outstanding",
        "verboseLabel": "Number of fully authorized, subscribed and paid up shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "iva_NumberOfSharesPerOtherEquityInstrumentGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NumberOfSharesPerOtherEquityInstrumentGranted",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that each equity instruments other than share options granted in a share-based payment arrangement, entitles the holder.",
        "label": "Number Of Shares Per Other Equity Instrument Granted",
        "terseLabel": "Number of shares per AGA"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NumberOfSitesOperatingUnderCentralIrbOverseeing": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NumberOfSitesOperatingUnderCentralIrbOverseeing",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of sites operating under central IRB overseeing",
        "label": "Number of sites operating under central IRB overseeing"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NumberOfWarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NumberOfWarrantsIssued",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants issued",
        "label": "Number of warrants issued",
        "terseLabel": "Number of warrants issued"
       }
      }
     },
     "auth_ref": []
    },
    "iva_NumberOfWeeksUnderActiveTreatmentExtensionStudy": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "NumberOfWeeksUnderActiveTreatmentExtensionStudy",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of weeks under the active treatment extension study of the entity.",
        "label": "Number Of Weeks Under The Active Treatment Extension Study",
        "verboseLabel": "Number of weeks under the active treatment extension study"
       }
      }
     },
     "auth_ref": []
    },
    "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "OperatingExpenseExcludingOtherOperatingIncomeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to amount of all operating expenses.",
        "label": "Operating Expense Excluding Other Operating Income Expense",
        "negatedTotalLabel": "Total operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "iva_OptionToAcquireSharesInCompanyPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "OptionToAcquireSharesInCompanyPercentage",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option to acquire shares in company, percentage",
        "label": "Option to acquire shares in company, percentage",
        "terseLabel": "Percent of acquisition",
        "verboseLabel": "Option to acquire shares in company, percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares",
        "terseLabel": "Ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r221"
     ]
    },
    "iva_OtherAccruedTaxesAndEmployeeRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "OtherAccruedTaxesAndEmployeeRelatedExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails": {
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of accrued taxes and employee related expenses.",
        "label": "Other Accrued taxes And Employee Related Expenses",
        "terseLabel": "Other accrued taxes and employeerelated expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherAdjustmentsForNoncashItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherAdjustmentsForNoncashItems",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other adjustments for non-cash items",
        "terseLabel": "Other"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "ifrs-full_OtherBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails": {
       "parentTag": "ifrs-full_Borrowings",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFinancialDebtDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other borrowings",
        "terseLabel": "Other loans and similar borrowings",
        "verboseLabel": "Other loans and similar borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income",
        "verboseLabel": "Other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r33",
      "r39",
      "r104"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations",
        "terseLabel": "Currency translation differences",
        "verboseLabel": "Exchange difference on translation of foreign operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r25",
      "r39"
     ]
    },
    "iva_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations including effects of translation of investments accounted for using equity method",
        "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations including effects of translation of investments accounted for using equity method",
        "terseLabel": "Currency translation differences"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans",
        "terseLabel": "Remeasurement of defined benefit plans"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r25",
      "r39",
      "r228"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax",
        "totalLabel": "Items that will be reclassified subsequently to profit or loss",
        "verboseLabel": "Items that will be reclassified subsequently to profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax",
        "totalLabel": "Items that will not be reclassified subsequently to profit or loss",
        "verboseLabel": "Items that will not be reclassified subsequently to profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182"
     ]
    },
    "ifrs-full_OtherContingentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherContingentLiabilitiesMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other contingent liabilities [member]",
        "terseLabel": "Other"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for contingent liabilities that the entity does not separately disclose in the same statement or note. [Refer: Contingent liabilities [member]]"
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "ifrs-full_OtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": {
       "parentTag": "iva_OtherCurrentAssetsAndReceivables",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current assets",
        "terseLabel": "Other current assets",
        "totalLabel": "Other current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "iva_OtherCurrentAssetsAndReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "OtherCurrentAssetsAndReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other current assets and receivables as of balance sheet date.",
        "label": "Other Current Assets And Receivables",
        "totalLabel": "Other current assets and receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "ifrs-full_OtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails": {
       "parentTag": "ifrs-full_OtherCurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current payables",
        "terseLabel": "Other miscellaneous payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "ifrs-full_OtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current receivables",
        "terseLabel": "Other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "iva_OtherCurrentTaxReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "OtherCurrentTaxReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": {
       "parentTag": "ifrs-full_CurrentTaxAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other tax receivables, classified as current.",
        "label": "Other Current Tax Receivables",
        "terseLabel": "Other"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherFinanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherFinanceCost",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails": {
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other finance cost",
        "negatedLabel": "Other financial expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]"
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "iva_OtherFinancialInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "OtherFinancialInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Other financial information"
       }
      }
     },
     "auth_ref": []
    },
    "iva_OtherIncomeFromOrdinaryActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "OtherIncomeFromOrdinaryActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": {
       "parentTag": "ifrs-full_RevenueAndOperatingIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other income from ordinary activities.",
        "label": "Other income from ordinary activities",
        "terseLabel": "Other income",
        "totalLabel": "Other income"
       }
      }
     },
     "auth_ref": []
    },
    "iva_OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount related to reinvoicing of specific costs incurred on services with customer research organization accrued liabilities included in other income.",
        "label": "Other Income, Reinvoicing Of Specific Costs Under Service Agreement",
        "terseLabel": "Reinvoicing of specific costs related to CRO accrued liabilities included in other income"
       }
      }
     },
     "auth_ref": []
    },
    "iva_OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount related to reinvoicing of share of costs incurred under the licensing and collaboration agreements included in other income.",
        "label": "Other Income, Relating To Reinvoicing Of Share Of Costs Under Licensing And Collaboration Agreement",
        "terseLabel": "Reinvoicing of share of costs incurred included in other income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other inflows (outflows) of cash, classified as investing activities",
        "verboseLabel": "Increase / (Decrease) in other non-current financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "Inflows (outflows) of cash, classified as investing activities, that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other inflows (outflows) of cash, classified as operating activities",
        "verboseLabel": "Other"
       }
      },
      "en": {
       "role": {
        "documentation": "Inflows (outflows) of cash, classified as operating activities, that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "iva_OtherMiscellaneousPayablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "OtherMiscellaneousPayablesMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for other miscellaneous payables.",
        "label": "Other miscellaneous payables",
        "terseLabel": "Other miscellaneous payables"
       }
      }
     },
     "auth_ref": []
    },
    "iva_OtherNonCurrentAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "OtherNonCurrentAssetsLineItems",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.",
        "label": "Other Non Current Assets [Line Items]",
        "verboseLabel": "Other Non Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "iva_OtherNonCurrentAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "OtherNonCurrentAssetsTable",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsLongTermDepositAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule disclosing information related to other non-current assets.",
        "label": "Other Non Current Assets [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherNonCurrentAssetsDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non-current asset",
        "terseLabel": "Other non-current assets",
        "totalLabel": "Other noncurrent assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]"
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "ifrs-full_OtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherNoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non-current liabilities",
        "terseLabel": "Other non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "iva_OtherOperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "OtherOperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": {
       "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to other operating expenses.",
        "label": "Other operating expenses",
        "negatedLabel": "Other operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherOperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherOperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other operating income (expense)",
        "terseLabel": "Other operating income (expenses)",
        "totalLabel": "Other operating income and expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of operating income (expense) that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_OtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsNetProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other provisions",
        "terseLabel": "Provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of provisions other than provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r27",
      "r69"
     ]
    },
    "iva_OtherReceivablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "OtherReceivablesMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for other receivables.",
        "label": "Other receivables",
        "terseLabel": "Other receivables"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityShareCapitalDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Par value per share",
        "terseLabel": "Par value of share",
        "verboseLabel": "Nominal value"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "ifrs-full_PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails": {
       "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Past service cost and losses (gains) arising from settlements, defined benefit plans",
        "negatedLabel": "Benefits for the period"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense (income) resulting from past service cost and losses (gains) arising from settlements. [Refer: Post-employment benefit expense in profit or loss, defined benefit plans; Past service cost, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from past service cost and losses (gains) arising from settlements]"
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "iva_Patents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "Patents",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": {
       "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to patents.",
        "label": "Patents",
        "negatedLabel": "Patents"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of lease liabilities, classified as financing activities",
        "negatedLabel": "Repayment of lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "iva_PayrollTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "PayrollTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A class of employee benefits expense that represents payroll taxes.",
        "label": "Payroll taxes",
        "negatedLabel": "Payroll taxes"
       }
      }
     },
     "auth_ref": []
    },
    "iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Company's share capital outstanding, issued as warrants by the entity.",
        "label": "Percentage Of Company's Share Capital Outstanding, Issued As Warrants",
        "terseLabel": "Percentage of company's share capital outstanding, issued as warrants"
       }
      }
     },
     "auth_ref": []
    },
    "iva_PercentageOfLoanGuaranteedByFrenchState": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "PercentageOfLoanGuaranteedByFrenchState",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of loan guaranteed by French state.",
        "label": "Percentage of Loan Guaranteed by French State",
        "terseLabel": "Percentage of loan guaranteed by French state"
       }
      }
     },
     "auth_ref": []
    },
    "iva_PercentageOfPatientsInTrialEnrolledInExploratoryCohort": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "PercentageOfPatientsInTrialEnrolledInExploratoryCohort",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of patients in trail enrolled in exploratory cohort.",
        "label": "Percentage of Patients in Trial, Enrolled in Exploratory Cohort",
        "terseLabel": "Percentage of patients in trial, enrolled in exploratory cohort"
       }
      }
     },
     "auth_ref": []
    },
    "iva_PercentageOfPatientsInTrialEnrolledInMainCohort": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "PercentageOfPatientsInTrialEnrolledInMainCohort",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of patients in trail enrolled in main cohort.",
        "label": "Percentage of Patients in Trial, Enrolled in Main Cohort",
        "terseLabel": "Percentage of patients in trial, enrolled in main cohort"
       }
      }
     },
     "auth_ref": []
    },
    "iva_PercentageOfPatientsRandomizedInMainCohort": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "PercentageOfPatientsRandomizedInMainCohort",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of patients randomized in the main cohort",
        "label": "Percentage of patients randomized in the main cohort"
       }
      }
     },
     "auth_ref": []
    },
    "iva_PercentageOfPatientsTreatedInTrial": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "PercentageOfPatientsTreatedInTrial",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of patients treated in this trial.",
        "label": "Percentage of Patients Treated in The Trial",
        "terseLabel": "Percentage of patients treated in trial"
       }
      }
     },
     "auth_ref": []
    },
    "iva_PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of share capital held by counterparty if all outstanding warrants are exercised",
        "label": "Percentage of share capital held by counterparty if all outstanding warrants are exercised"
       }
      }
     },
     "auth_ref": []
    },
    "iva_PeriodWithinWhichPaymentIsReceivedFromSettlement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "PeriodWithinWhichPaymentIsReceivedFromSettlement",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period within which the payment is made from settlement date.",
        "label": "Period Within Which Payment is Received From Settlement",
        "terseLabel": "Received from settlement"
       }
      }
     },
     "auth_ref": []
    },
    "iva_PersonnelCostsAndHeadcount": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "PersonnelCostsAndHeadcount",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Personnel costs and headcount",
        "label": "Personnel costs and headcount",
        "terseLabel": "Schedule of personnel costs and headcount"
       }
      }
     },
     "auth_ref": []
    },
    "iva_PharmaceuticalResearchAssociatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "PharmaceuticalResearchAssociatesMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Pharmaceutical Research Associates.",
        "label": "Pharmaceutical Research Associates [Member]",
        "terseLabel": "Pharmaceutical Research Associates"
       }
      }
     },
     "auth_ref": []
    },
    "iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the Phase II clinical trial evaluating lanifibranor in patients with T2D and nonalcoholic fatty liver disease",
        "label": "Phase II clinical trial evaluating lanifibranor in patients with T2D and nonalcoholic fatty liver disease [Member]",
        "terseLabel": "Phase II clinical trial evaluating lanifibranor in patients with T2D and nonalcoholic fatty liver disease"
       }
      }
     },
     "auth_ref": []
    },
    "iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for phase II clinical trial evaluating placebo in patients with MASH/NASH and T2D.",
        "label": "Phase II Clinical Trial Evaluating Placebo In Patients With MASH/NASH And T2D [Member]",
        "terseLabel": "Phase II Clinical Trial Evaluating Placebo In Patients With MASH/NASH And T2D"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PostemploymentBenefitExpenseDefinedBenefitPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-employment benefit expense, defined benefit plans",
        "negatedTotalLabel": "Total"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of post-employment benefit expense included in profit or loss relating to defined benefit plans. [Refer: Profit (loss); Defined benefit plans [member]] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r228",
      "r230"
     ]
    },
    "ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PostemploymentBenefitExpenseInProfitOrLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-employment benefit expense in profit or loss",
        "negatedLabel": "Provisions for retirement benefit obligations"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of post-employment benefit expense included in profit or loss"
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "iva_PresentationOfResultsFromStudyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "PresentationOfResultsFromStudyMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the presentation of results from a study.",
        "label": "Presentation of results from study [Member]",
        "terseLabel": "Presentation of results from study"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from borrowings, classified as financing activities",
        "terseLabel": "Subscription of borrowings and warrants net of transaction cost",
        "verboseLabel": "Loan obtained"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "iva_ProceedsFromFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ProceedsFromFinancing",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash proceeds from financing.",
        "label": "Proceeds From Financing",
        "terseLabel": "Gross cash proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuing shares",
        "terseLabel": "Capital increase"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "iva_ProceedsFromLicensingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ProceedsFromLicensingArrangements",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount paid on licensing arrangements.",
        "label": "Proceeds From Licensing Arrangements",
        "terseLabel": "Amount received on licensing arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "iva_ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the disposal of property, plant and equipment and intangible assets, classified as investing activities.",
        "label": "Proceeds From Sales Of Property Plant And Equipment And Intangible Assets Classified As Investing Activities",
        "terseLabel": "Disposals of property, plant and equipment and intangible assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossBasicAndDilutedLossPerShareDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "terseLabel": "Net loss for the period",
        "totalLabel": "Net loss for the period",
        "verboseLabel": "Loss for the period"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r32",
      "r82",
      "r90",
      "r92",
      "r162",
      "r165",
      "r195",
      "r199"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "totalLabel": "Net operating loss",
        "verboseLabel": "Net operating loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r184",
      "r222"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment including right-of-use assets",
        "periodEndLabel": "Balance at the end",
        "periodStartLabel": "Balance at the beginning",
        "terseLabel": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of property, plant and equipment including right-of-use assets whose underlying assets would be presented as property, plant and equipment if they were owned. [Refer: Property, plant and equipment; Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r217",
      "r226"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r48",
      "r185",
      "r198"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInAssociate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInAssociate",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in associate",
        "terseLabel": "Group's share in %",
        "verboseLabel": "Proportion of ownership interest"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r59",
      "r61",
      "r97"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in subsidiary",
        "terseLabel": "Percent of ownership interest"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r59",
      "r61",
      "r95"
     ]
    },
    "iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase of interests in investments accounted for using equity method, price per share",
        "label": "Purchase of interests in investments accounted for using equity method, price per share",
        "terseLabel": "Purchase of interests in investments accounted for using equity method, price per share"
       }
      }
     },
     "auth_ref": []
    },
    "iva_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Of Property Plant And Equipment And Intangible Assets Classified As Investing Activities",
        "label": "Purchase Of Property Plant And Equipment And Intangible Assets Classified As Investing Activities",
        "negatedLabel": "Purchases of property, plant and equipment and intangible assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r129",
      "r133",
      "r196",
      "r197",
      "r244"
     ]
    },
    "ifrs-full_RangesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r129",
      "r133",
      "r196",
      "r197",
      "r244"
     ]
    },
    "ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of changes in intangible assets other than goodwill",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of changes in property, plant and equipment [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RepairsAndMaintenanceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RepairsAndMaintenanceExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": {
       "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repairs and maintenance expense",
        "negatedLabel": "Maintenance"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenses incurred for the day-to-day servicing of assets, which may include the cost of labour, consumables or small parts."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "iva_RepaymentPeriodOfLoan": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "RepaymentPeriodOfLoan",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period for repayment of loan.",
        "label": "Repayment Period of Loan",
        "terseLabel": "Repayment period for loan"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of borrowings, classified as financing activities",
        "negatedLabel": "Repayment of debt",
        "terseLabel": "Repayments of borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "negatedLabel": "Research and development costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "iva_ResearchAndDevelopmentMarketingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ResearchAndDevelopmentMarketingTableTextBlock",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of Research and Development, Marketing.",
        "label": "Research and Development, Marketing [Table Text Block]",
        "terseLabel": "Schedule of research and development, marketing"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserve of exchange differences on translation",
        "terseLabel": "Translation reserve"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserve of exchange differences on translation [member]",
        "terseLabel": "Translation reserves"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r55",
      "r176"
     ]
    },
    "ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarningsExcludingProfitLossForReportingPeriod",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained earnings, excluding profit (loss) for reporting period",
        "verboseLabel": "Earnings brought forward"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity\u2019s cumulative undistributed earnings or deficit excluding the profit or loss for the reporting period. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "iva_RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A component of equity representing retained earnings excluding profit (loss) for the reporting period, and treasury shares",
        "label": "Retained earnings excluding profit (loss) for the reporting period and treasury shares",
        "terseLabel": "Reserves"
       }
      }
     },
     "auth_ref": []
    },
    "iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember",
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member represent a component of equity consisting of retained earnings excluding the current reporting period, and treasury shares.",
        "label": "Retained earnings excluding profit (loss) from current reporting period and treasury shares [Member]",
        "terseLabel": "Reserves"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RetainedEarningsProfitLossForReportingPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarningsProfitLossForReportingPeriod",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained earnings, profit (loss) for reporting period",
        "terseLabel": "Net loss for the period"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarningsProfitLossForReportingPeriodMember",
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained earnings, profit (loss) for reporting period [member]",
        "terseLabel": "Net profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings [member]; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "ifrs-full_Revenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Revenue",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": {
       "parentTag": "ifrs-full_RevenueAndOperatingIncome",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue",
        "terseLabel": "Revenue",
        "totalLabel": "Total revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r103",
      "r138",
      "r159",
      "r164",
      "r169",
      "r170",
      "r171",
      "r174",
      "r175",
      "r195"
     ]
    },
    "ifrs-full_RevenueAndOperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueAndOperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue and other operating income",
        "totalLabel": "Total revenues and other income"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount of the entity's revenue and other operating income. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "iva_RevenueAndOperatingIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "RevenueAndOperatingIncomeAbstract",
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Revenue And Operating Income [Abstract]",
        "terseLabel": "Revenues and other income"
       }
      }
     },
     "auth_ref": []
    },
    "iva_RevenueAndOtherIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "RevenueAndOtherIncomeTableTextBlock",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue and other income.",
        "label": "Revenue and Other Income [Table Text Block]",
        "terseLabel": "Schedule of revenues and other income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromContractsWithCustomers",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails": {
       "parentTag": "ifrs-full_Revenue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from contracts with customers",
        "terseLabel": "Revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120"
     ]
    },
    "ifrs-full_RightofuseAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RightofuseAssetsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionPropertyPlantAndEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "iva_RoyaltyCertificateLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "RoyaltyCertificateLiabilitiesMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Royalty Certificate Liabilities.",
        "label": "Royalty Certificate Liabilities [Member]",
        "terseLabel": "Royalty Certificate"
       }
      }
     },
     "auth_ref": []
    },
    "iva_RoyaltyCertificatesEffectiveInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "RoyaltyCertificatesEffectiveInterestRate",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate on royalty certificates.",
        "label": "Royalty Certificates, Effective Interest Rate",
        "terseLabel": "Royalty certificates, effective interest rate"
       }
      }
     },
     "auth_ref": []
    },
    "iva_RoyaltyCertificatesLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "RoyaltyCertificatesLiabilitiesMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for royalty certificates liabilities.",
        "label": "Royalty Certificates Liabilities [Member]",
        "terseLabel": "Royalty certificates liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SalesAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SalesAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales and marketing expense",
        "negatedLabel": "Marketing - Business development expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to the marketing and selling of goods or services."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "iva_SalesTaxReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "SalesTaxReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of sales tax receivables, classified as current.",
        "label": "Sales Tax Receivable, Current",
        "terseLabel": "Sales tax receivable"
       }
      }
     },
     "auth_ref": []
    },
    "iva_ScenarioOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ScenarioOneMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for scenario one.",
        "label": "Scenario One [Member]",
        "terseLabel": "First tranche"
       }
      }
     },
     "auth_ref": []
    },
    "iva_ScenarioThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ScenarioThreeMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for scenario three.",
        "label": "Scenario Three [Member]",
        "terseLabel": "Third tranche upon publication of pivotal data"
       }
      }
     },
     "auth_ref": []
    },
    "iva_ScenarioTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ScenarioTwoMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for scenario two.",
        "label": "Scenario Two [Member]",
        "terseLabel": "Second tranche"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "iva_ScheduleOfInventoryDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ScheduleOfInventoryDisclosureLineItems",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.",
        "label": "Schedule of Inventory Disclosure [Line Items]",
        "terseLabel": "Inventories"
       }
      }
     },
     "auth_ref": []
    },
    "iva_ScheduleOfInventoryDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ScheduleOfInventoryDisclosureTable",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule disclosing information related to inventories.",
        "label": "Schedule of Inventory Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iva_ServiceContractWithAvantSanteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ServiceContractWithAvantSanteMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for service contract with Avant Sante.",
        "label": "Service contract with Avant Sante [Member]",
        "terseLabel": "Service contract with Avant Sante"
       }
      }
     },
     "auth_ref": []
    },
    "iva_ServiceProvidersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ServiceProvidersMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to service providers.",
        "label": "Service Providers",
        "terseLabel": "Service providers"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share of other comprehensive income of associates and joint ventures accounted for using equity method that will be reclassified to profit or loss, net of tax",
        "terseLabel": "Currency translation differences - equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "Share of the other comprehensive income of associates and joint ventures accounted for using the equity method that will be reclassified to profit or loss, net of tax."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share of profit (loss) of associates accounted for using equity method",
        "totalLabel": "Share of net profit - Equity method",
        "verboseLabel": "Share of net loss - Equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "iva_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails": {
       "parentTag": "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of profit (loss) of associates accounted for using equity method before eliminations",
        "label": "Share of profit (loss) of associates accounted for using equity method before eliminations",
        "terseLabel": "Share of net profit"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharePremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharePremium",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share premium",
        "terseLabel": "Premiums related to share capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "ifrs-full_SharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharePremiumMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Premiums related to share capital"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharebasedPaymentArrangementsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sharebased compensation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "iva_SharesIssuableUponExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "SharesIssuableUponExerciseOfWarrants",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issuable upon exercise of warrants.",
        "label": "Shares Issuable Upon Exercise of Warrants",
        "terseLabel": "Shares issuable upon exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "iva_ShortTermDepositAccountsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ShortTermDepositAccountsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": {
       "parentTag": "ifrs-full_OtherCurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short term deposits accounts, classified as current.",
        "label": "Short-Term Deposit Accounts, Current",
        "terseLabel": "Short-term deposit accounts"
       }
      }
     },
     "auth_ref": []
    },
    "iva_ShortTermDepositAccountsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "ShortTermDepositAccountsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for short-term deposit accounts.",
        "label": "Shortterm deposit accounts",
        "terseLabel": "Short-term deposit accounts"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShorttermBorrowingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShorttermBorrowingsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term debt",
        "terseLabel": "Short-term debt"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for short-term borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r192",
      "r194"
     ]
    },
    "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShorttermDepositsClassifiedAsCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails": {
       "parentTag": "ifrs-full_CashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term deposits, classified as cash equivalents",
        "verboseLabel": "Other cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "ifrs-full_SignificantInvestmentsInAssociatesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SignificantInvestmentsInAssociatesAxis",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Associates [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r62",
      "r111"
     ]
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SignificantInvestmentsInSubsidiariesAxis",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiaries [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r62",
      "r110"
     ]
    },
    "ifrs-full_SignificantUnobservableInputLiabilities": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SignificantUnobservableInputLiabilities",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Unobservable Input Liabilities",
        "terseLabel": "Significant unobservable input, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The value of significant unobservable input used in the measurement of the fair value of liabilities."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unaudited interim condensed consolidated statement of cash flows"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unaudited interim condensed consolidated statement of changes in shareholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]",
        "terseLabel": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "iva_StatementOfComplianceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "StatementOfComplianceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Basis of preparation and statement of compliance"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unaudited interim condensed consolidated statement of comprehensive (income) loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Unaudited interim condensed consolidated statement of financial position"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfIFRSCompliance": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfIFRSCompliance",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfCompliance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of IFRS compliance [text block]",
        "terseLabel": "Basis of preparation and statement of compliance"
       }
      },
      "en": {
       "role": {
        "documentation": "An explicit and unreserved statement of compliance with all the requirements of IFRSs."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "iva_StockIssuedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "StockIssuedDuringPeriodShares",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued during the period.",
        "label": "Stock Issued During Period, Shares",
        "terseLabel": "Number of shares issued during the period"
       }
      }
     },
     "auth_ref": []
    },
    "iva_StockIssuedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "StockIssuedDuringPeriodValue",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value",
        "terseLabel": "Stock issued during period"
       }
      }
     },
     "auth_ref": []
    },
    "iva_Studies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "Studies",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": {
       "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to studies.",
        "label": "Studies",
        "negatedLabel": "Studies"
       }
      }
     },
     "auth_ref": []
    },
    "iva_SubscriptionOfLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "SubscriptionOfLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureDisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtMovementsInPeriodBreakDownDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of subscription of lease liabilities.",
        "label": "Subscription Of Lease Liabilities",
        "terseLabel": "Subscription of lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "iva_SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subscription premium price per share of other equity instruments granted in share-based payment arrangement.",
        "label": "Subscription Premium Price Per Share Of Other Equity Instruments Granted",
        "terseLabel": "Subscription premium price per share (\u20ac)"
       }
      }
     },
     "auth_ref": []
    },
    "iva_SubsidiesIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "SubsidiesIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails": {
       "parentTag": "iva_OtherIncomeFromOrdinaryActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income from subsidies.",
        "label": "Subsidies income",
        "terseLabel": "Subsidies"
       }
      }
     },
     "auth_ref": []
    },
    "iva_SupportCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "SupportCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": {
       "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to support costs.",
        "label": "Support costs",
        "negatedLabel": "Support costs (including taxes)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax rate effect of adjustments for current tax of prior periods",
        "terseLabel": "Projected tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "Tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from adjustments for the current tax of prior periods. [Refer: Average effective tax rate; Applicable tax rate; Adjustments for current tax of prior periods]"
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "iva_TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the term over which volume weighted average price per share to determine number of warrants to be issued.",
        "label": "Term Over Which Volume Weighted Average Price Per Share To Determine Number Of Warrants To Be Issued",
        "terseLabel": "Term over which volume weighted average price per share to determine number of warrants to be issued"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtLeaseLiabilitiesDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum",
        "terseLabel": "Maximum"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r129",
      "r133",
      "r196",
      "r197",
      "r244"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other current payables",
        "terseLabel": "Trade payable"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "iva_TradePayablesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current trade payables",
        "terseLabel": "Trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r220"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other current receivables",
        "terseLabel": "Trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r26"
     ]
    },
    "iva_TradePayableAndOtherCurrentLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "TradePayableAndOtherCurrentLiabilitiesLineItems",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Trade Payable And Other Current Liabilities [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iva_TradePayableAndOtherCurrentLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "TradePayableAndOtherCurrentLiabilitiesTable",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Trade Payable And Other Current Liabilities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iva_TradePayablesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "TradePayablesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of trade payables and other current liabilities.",
        "label": "Trade Payables And Other Current Liabilities.",
        "totalLabel": "Trade payables and other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "iva_TradePayablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "TradePayablesMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for trade payables.",
        "label": "Trade payables",
        "terseLabel": "Trade payables"
       }
      }
     },
     "auth_ref": []
    },
    "iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.",
        "label": "Trade Receivables and Other Current Assets and Receivables [Line Items]",
        "terseLabel": "Trade receivables, tax receivables and other current assets"
       }
      }
     },
     "auth_ref": []
    },
    "iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule disclosing information related to trade receivables and other current assets and receivables.",
        "label": "Trade Receivables and Other Current Assets and Receivables [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeReceivablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeReceivablesMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade receivables",
        "terseLabel": "Trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r142",
      "r146",
      "r200",
      "r215"
     ]
    },
    "iva_TransactionCostsOnIssueOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "TransactionCostsOnIssueOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs on issue of warrants",
        "label": "Transaction costs on issue of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TreasuryShares",
     "crdr": "debit",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury shares",
        "negatedLabel": "Treasury Shares"
       }
      },
      "en": {
       "role": {
        "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r180"
     ]
    },
    "iva_TreatmentPeriodUnderStudy": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "TreatmentPeriodUnderStudy",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails",
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treatment period under study",
        "label": "Treatment period under study"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ifrs-full_UnobservableInputsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnobservableInputsAxis",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unobservable inputs [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r242"
     ]
    },
    "ifrs-full_UnobservableInputsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnobservableInputsMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtRoyaltyCertificatesLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unobservable inputs [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r242"
     ]
    },
    "ifrs-full_WagesAndSalaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WagesAndSalaries",
     "crdr": "debit",
     "calculation": {
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails": {
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesPersonnelCostsAndHeadcountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Wages and salaries",
        "negatedLabel": "Wages, salaries and similar costs"
       }
      },
      "en": {
       "role": {
        "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]"
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "iva_WarrantAgreementWithEuropeanInvestmentBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "WarrantAgreementWithEuropeanInvestmentBankMember",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails",
      "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationEventsAfterReportingDateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Warrant agreement with the European Investment Bank.",
        "label": "Warrant Agreement With The European Investment Bank [Member]",
        "terseLabel": "Warrant agreement with the European Investment Bank"
       }
      }
     },
     "auth_ref": []
    },
    "iva_WarrantAverageLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "WarrantAverageLife",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average life used to calculate fair value of warrant.",
        "label": "Warrant Average Life",
        "verboseLabel": "Maturity (years)"
       }
      }
     },
     "auth_ref": []
    },
    "iva_WarrantsCapOfPutOption": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "WarrantsCapOfPutOption",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cap of the put option used to calculate fair value of warrants.",
        "label": "Warrants, Cap of Put Option",
        "terseLabel": "Cap of the put option (m\u20ac)"
       }
      }
     },
     "auth_ref": []
    },
    "iva_WarrantsStockPrice": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "WarrantsStockPrice",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock price used to calculate fair value of warrants.",
        "label": "Warrants, Stock Price",
        "terseLabel": "Stock price (\u20ac)"
       }
      }
     },
     "auth_ref": []
    },
    "iva_WarrantsSubscriptionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "WarrantsSubscriptionPrice",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The subscription price per warrant.",
        "label": "Warrants, Subscription Price",
        "verboseLabel": "Subscription price per share"
       }
      }
     },
     "auth_ref": []
    },
    "iva_WarrantsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "WarrantsTerm",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureCompanyInformationSignificantEventsInFirstHalfOf2024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of warrants.",
        "label": "Warrants Term",
        "terseLabel": "Term of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "iva_WarrantsThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "WarrantsThresholdTradingDays",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of warrants must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Warrants, Threshold Trading Days",
        "terseLabel": "Threshold trading days of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "iva_WarrantsUnitFairValue": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.inventivapharma.com/20240630",
     "localname": "WarrantsUnitFairValue",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value per warranty unit outstanding",
        "label": "Warrants, Unit Fair Value",
        "verboseLabel": "Unit fair value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityOptionsAndShareWarrantsBsaAndBspceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of other equity instruments granted in share-based payment arrangement",
        "verboseLabel": "Exercise price"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFinancialDebtDerivativesDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails",
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityMovementsInBspceAndBsaShareWarrantsInNumberOfSharesIssuableUponExerciseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement",
        "terseLabel": "Exercise price (in euros)"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "ifrs-full_WeightedAverageSharePrice2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageSharePrice2019",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfFinancialPositionFreeShareAwardsAndPerformanceUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average share price",
        "verboseLabel": "Stock price at grant date (in euros)"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average share price. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossBasicAndDilutedLossPerShareDetails",
      "http://www.inventivapharma.com/role/StatementUnauditedInterimCondensedConsolidatedStatementOfIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share",
        "terseLabel": "Weighted average number of shares outstanding used to calculate basic loss per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_o&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "q",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_q&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "56",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_56&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "140",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_140_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "141",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS21_g51-57_TI",
   "URIDate": "2023-03-23"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "134",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "135",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_135_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "86",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_86&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "14",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_14&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Paragraph": "22",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "12",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "2",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_2_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_21_a_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B14",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B14_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B16&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B4",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "105",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "114",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "C32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
   "URIDate": "2023-03-23"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "51",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_51_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35H",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35M",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B2",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B2_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2023-01-01",
   "Paragraph": "7.2.34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2023-01-01",
   "Paragraph": "7.2.42",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "88",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_88&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "14",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_14_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "44C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44C&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2023-03-23"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "C Reconciliation of liabilities arising from financing activities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI",
   "URIDate": "2023-03-23"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_e&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_f&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG20D",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG20D&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "80",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "135",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_135_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "141",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "5",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_5&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "57",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_57_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "9",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_9&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>88
<FILENAME>0001104659-24-108585-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-24-108585-xbrl.zip
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MP_H[8?TV?*':,4GB2>**Y-!V$]S%LV?*1V/Y6=P($:/6^&T>!E=OE+M,;&Q
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ML\,Y%)%._(;[LP:G<2)53V(G1 MF@<3PDTE42V"IW>"2"9@A"D+D/EJ*KJN
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M,$CMW2R]ZZ6)JJV[B[//,*5;.$,E+Z>HH"/5V__R.RO-U!O%T#J^G<DFZ?&
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M7"14F."?JJ,'_V1'#_QRB'P+&8[BM_\!4$L#!!0    ( &N!3UG4'>8]8A<
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M_D>ZH27[$XWZ)/3C<2X0P(&C V3"X::(+ P+,&PI+  2'[9^\=BG?STR+R)
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M==;.:D]#Z$;-@2*#,M5(ZBB'4N[.ZD=S]-TYKY)Q'O'=9(J26BFH::V-=GP
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M>6J/AP>[<J0F)7'HPZV@JO>>LK;W\3@4?*24?_\_4$L#!!0    ( &N!3UD
MH.5RB%<   76!0 4    :79A+3(P,C0P-C,P7V1E9BYX;6SM?6MSXSB2X/>-
MN/^@JXNXFXU8U[-[IKMO>C=DV:YVA&WI;%77W:<.F(0D;E.$&B3MTO[Z T!2
M(B4\*9 $58R8Z;(D//*%1"*1F?CG?WQ;AZ,7B., 1;^^^?#V_9L1C#SD!]'R
MUS=ILKCXZ<U__/M_^Y=__O>+B_][^7@W\I&7KF&4C#P,00+]T6N0K$9SM-F
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MT*?B[ HY@%!>VX37AH^I RM!PARDAQ/7JU&5=,$P/9-PC4U"HZGP5LQ9X3^
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MGM-"#OV^35T!EI$+"6=K34@YX%&Q%(#EJ'87538?QS&BI0ZX9W73[A*]IS^
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ME08;\W#J']Y_;-:Y4<#Y;Z,-A?3?6&$16 ![+IX.(3?T71ZJ(5S12;M+&R'
M>K>-BNZ.^B7T&"VX=U2@O%=('YW=D80H* XTRG[.>"2,Q/LX-4>*I*-,I7L.
ML9^]S%=.L%AB&*LNF.6=G# N-(7U8+5*\7*5@X-#NN'P\%J*OS$B]6&K&-S4
M@YMZ<%.[Q:W!33VXJ?6V-3-_M<XPCCBN]3$6>[!5QL!WX<H6'Y!JN[ UAG1"
M==B0IU.(T ??M1"-V\@+4_I,-'OJ!BT(_)F/UMQY(!G*"5/B]+6CZ6"0$.),
MW=QCWP\R-&ZC!2*3TP^FON]/G?J^+T9[)$8E+ :G^. 4'YSB;L?@#7[PKOS@
MW"R=F^"9G,4]$-T#;T7L+G%:CK"E$P:#B<=:AHRCJV9P4W]?;NI>B.'@F3Y/
MS_1WZ.NTX-,^,U_GX7E8P611<R>\3OI,%*'A*),&A_3@D#;8O95.-/%>KM'5
MB:5N0SYTD.V#([EPDL5SI.TQEO9QKOI[70Y+L6SX??'(PQ#$1LM0NYMS)=L-
M&:2-:+]]\Z4*YGD);NC?(/R%/F%,D4RV]S!9(=^*J_Z'IG/P]X]8@@*9$8&6
ML(46%J>30(;3:,V0.GOOO?J)I]-?O#P:J_Z>$T/O[1*]D/42,!+0/ZC:RE D
M'_ZX@TL09H\H<7Q&W!:.^ML-64-U$A<]:QN^FOC9M%>Y5^.(\M6?NW6N2&2E
MH&05W.&]L@/J\9A]QL^2[9>=V1G5:#Q'#JLU:&#^(-F1'G/C.;(I V".QAXQ
M!#!\(B),[3OZ6C>(MON'X3D+5;^K<\?/NAPWPKK9P\HLQ=Z*F%DLSSA[*NE6
MVWJ=X<"#!%8&/8>U-@=W[F1Z O-MTJ59\2A>T,OD,Q=67_(2E5X?YTZQ)S!3
M ]T^N)+(4=R#T(]O")5NXS@E4I=A)(O7$/7HS>-BVGNS!-F></<<'Y;[>UN\
M[\>S<BTYK?;M;J/\S")M/UWLGZ$S]6W]Z)YO*]CU(7^.<@)P>U=[$AC _CF^
MP14VN,(&5]C@"AM<86?@"E,O-6DHIFYW1P,K:R@:<]P=Y7PFQ,3H2D!(;)\]
MU(IH*F4_5Z(HS42[RELED@*F=AH/J,G1GFJJP6G_73KMAT*,';O\39!NV*6+
MHDF*,0UQ9P!<?\OS8Z_@ I+O?7[\F$G/<_+5:R/=!S<@$[8*.L+%R6MZ-FY[
M*99]8.0$Q*MQY--_J*?M!804<7%PKZ#Y^?GI19@VJU-K*E3WM&FC#G5MC)ME
MEI(M73+@'PTSH(^[EBJ@O0,V_=2*,NL3D^BE*"1Z=Q,D0&+R5UNUR;*?VS'O
MJPCV@7,YL(\PAOA%?%-SV*Q59\W[EHR'*HH-&PW9;$\IWH1I=@[D&@G<9JU2
MOU%/BA#%/JR=1WJ)&T'_&N"(&#)[DR9[)IL^DGV#\"-D\0/D6TAP\H5+K.9H
MK<I".UZ2FI3HH\A8D12'!*11ATQ- O1!+N8T*2[%6T74W6&S5GG;CE/F$,4^
M<"^+=Q)?]^4_M\JM=CPN!6I]X-(#BKS, Z'SDK6@=:L\;"?"48!I'U@ZQ\"'
MX\@O>W)G8$OOV>(Y8K\^I9M-&'"LZYJ#M"H C3J$:A*@#W)1QD1GL0O;M\KM
M=OQ*0ES[P%@#GG;.SG9\3GWE9&8Y$*VCPTM^XU;C ]IQ0O$1[0,_]V<P(1?+
M35KE73O!0&7T^L"Q;"- ZPV&*QH7^ )O(P^MQ4Y@<8=6N=F.$TJ,;#L%A*Y@
M]N]\A5&Z7.5>TM\!SNH.\IS%^EU;Y5?303KZ:/=A59YILM['=KQ'%K/U3EK%
M61SQ$W-B31</, ]ZT$_TYBQO"V.VRO%&/5!VZ-&T*B=RYV5%':[#8!U$F2(J
M8\=5XSK=6F5ETY%!>BCW07TKXYX["F]NQY/40!ASH\'K!8Y&JMB\?ZN<;L>+
MI(U[O[/BV2G@, K\#D7+.<3K*\B2R7,"Q*;9[?]H-KN=@3Z*4'21>_='@$%/
M?J((7)#AUR,_0Z'(38\;STSG%Y#B49F;.JYH;&'/)A(^02&9#V&R![W ,<:T
M7'#^*D#ITRYWH]J<D^II;=CN<\VUF+7;U:T@;=\L.Q$L;H:ZS8$[SOZTO IL
M24-CJ?1D+V!/"TXP^AHDJRR9TX-I0K9'%@Y(*+C:;XR7;U^$R?;UA^HR^]7Z
MFMB%]M4FAW4F\S=R48:K1H?V4UBUL=B5&91H:C<J1QZZ[FXC@6VEX>V4].TR
MD=28:P9X]>&018%/]L"+;X>.&W:926K&-@D2S;J8#D0CIG]SU@J_69<9G<;+
M@H]":]G2_@LY8=&3I#">2-V^RX1+8WHK<.GWL?Z6S4 0@,:G]I^:KTF70];-
M6?S)6T$_#5EYV@R4[1Y=T9E<IY,K&]+PUJ9=?X"^P+3UNN9>-WUTUBP:GMK\
M'I[:Y&"F8+6DAQ,%LO3?6I1@XBBW2J);Y_73;I\X%49%U7KBU.X[IN:&ALPS
MH]NQ$P^-&5:%L:VSAYY7V;"=E2N]7=VUZ=B#4X.K?#SZ?6QBJ2"/T(-D$I8<
M KZ5/AUDD.3NQH,NIL>MGYL];C'P1G@/W[^-B("7OQB!R!\A=I=Z=(^:]2YA
MU\V1[9#&7$:0+RN<XQ_DZ@_EBFJY!TF*^?6[18V<.$:=RL2JTJDBV(<#T7BY
MQ'!)E^V<D.N2K#I5%5U)#U>.1CQA/+"YQ$@XRBBB@.\(O.P.<$YF@_?$!%FI
MF*7HY<391BF"AWFS4I2L&\PU-(3,C#YMN$Z,:QL4*$SN^OKVG QQ7NIO"6/A
M<E;VZ]A@MR8I^AA_=Z:]BJ"&IOZ']\Z:^D4P98[L*,.6-1^,_R'NLD<'A"$J
M<XC*M"H-C45EW@4>)4RTI 6=]S,2JA,CG0%$0PHG2?*7,!K3?(BSC,(T)\-P
M=!F.+@U&?4X"7(!<! $3<W."H1\D\1YH7GRU;L]S.7Z8X-QL+%P9_NKA0!0\
M+6C<<52G3=;(T.Q#;.X>] SM_+,X#D74ON-(4ONG?2&F/6+K#,,-"/SK;QMZ
M7E86RCIJWG&X:F-,/4*T6<7YM$(XX83O"Q:;3H\N'P6QK$*5N/9HP1'8B87D
M9W6"R'^SHM7YCT4NE.(]BSI#=?E$29,+U8@(39?KCU=?(D*!N^"O-/#IE5YQ
M>!*O8YU.7;Y;8MM0U4"W854+#CW7$B4K;MOEPR2VU:L8RSXH5M-K*2>NHX[>
M*VE$1]:_AW*,KXX_17CT_DGCW&QG1U,!K#C5\[MT^AA)@X=[/K;]OO%E==-6
M*"3$C+.2/9,5=2_'M]E/>?U$TUO<'YJ]Q2U#_;]&D,%-OLY!)^./8MIBY&70
M-WXGV])KW9.0WD3'TT69-=Q[7./NKNP)M-8JB@CO"9AY&61I5IV@>?=WM349
M>' $$J#GZ(9>U/R2Q@!6&[D2HRF7.UYY;L<#-"NO$"I8PFWK1# F3Z(DKRTZ
MSA.VZF<8KH-TK6 )KZD3B61JCO! =Y0A2MU\9!>:;[!W7=XYGX!IE:FZN]@Y
MA<4Z^*"75M7[.OSMU1->*:5)CEX\31-R8(BH4UC(*DF/+B^BK7%/@E\?&#H#
M^'<0IG &,<- R,?CAEW>.5MCWS%:?> :L[P*:UEN6^Y;=7F=;(U?!SCU@EE'
M]>3,M:C1&%W>3MMCM G&Y^8(G#+HJ;^3_?85T,#3)+Z, ?GJ,MYXT-0K^/=.
MO((Y'BQ1(W,+ON:HC/YV^31FWU\^S2;7_SKX"7OC)YR360L(*1O\&=BR .E]
M='0L]1SJ#W FOD1]A!W=PJ20Z[A35'U=\46:RC;'_:)"U?I%(MD5*KN$,!U#
MU- )=Z.!B!47A")\FJ P71H?RK/-0A#)*"WMX(3?HA[%I7@U1?F/II07=G#"
MYU"?\D*\'-TX)L1P7++22]/%(V25S<B)FSZJJJC8*>_6OEU0W_LGK< I1]-1
MIEZS=]_(@8=@=X-P%7+5%:1.7U>L 3WI/?#FZB!H74]>!1AZI*EX\S]JX<2N
M;R!*A28\0L1^%"O$+X$'9QB]!/1 *Z2IJ*$3VWL-THKPL2^N@$SP$/R)?"BX
MC14T<F+[KB.T'%P<U>[#Q6SO+V:Y:ZXX)3VES[&' P;.#)/ESEEZDK9.Z+::
MG)-CUH>[A*\P6*Z(LAF_0 R6\/H;,5B#&#(,I@L6,9MYD&^CF @..U!\I@C3
M+![9L>/C^P\_"]=SP[,ZH=1/508-TZ@/PEE<T/"1O?ZV(9:; EEE&,%)8Y_%
MC;452IS;A=D]>H'Y"[KL>HQ=DU6]@X<7B/0FF>[/7S8H*E:KZ:U:PR_("F[5
M=LC2:'MV?99?I(V/+ME(@XAA3>=@/Y)..>*CE& ^@CGJ9W,#1W.98U9I)_(9
M(17^?/W+N9HCNZ*>AWN[DT2C[I5>'VH_#_=[3M_O\3<TR1V(O(,3GK]:=R!R
MO)JA/+UE4="ZTJ3C$G9ZTE(A:07\9HA(OOV@N+?CM'*!E!SV5XAW"',35Z J
M$02="2 G!=A4 $'3X@?("?H?ZDOC:IO.18_'],IE<!7>ANCVDP;=?G(ELD&3
M;C\U2K<'^'IX1Q]G\_XLI*-&GXZ+]LGIJ@%_FW2^#,3*4J];Q^7T:E.[A$*;
M!"?GJCH$+W7KN-1=;8*74&B"X%G4CW[<F;I+QY7KE(16@#^$]I4)S*D%I[$!
M#O%[]<NU:9&W;T%ZI[C(CBXKK'I0[YR+$SB9/N(0@IK>R7-*^ZYSB5I*!&OY
MBMMP9N<B)RS+<@LD[/\MN#;"-6_"#<9W+NS"LCQ:(U2?I*Z,H2SF1"E>^@,Y
M%U71D!SI4Z1/ B,*(\F4MS_%O\-8&:-4.VS'<!;G2ABTJK*,R=5_.;Q!> &#
MIN1/>W3G*BJT*G?:9.J_O.5+C)ZLFM1X.N-WZ4CJ7N8,"-5LF>9; C +TYPN
M<H_.%#_2@XZD;(MVMRZ]60WR6!O_?H>AWF (&7'&KP#[E&PSB!>(3!9Y\ N!
MT/@%WI^:C2>E .<AHH"!S.)&2T"/4@KU$ EJVX\Y1((.D:!#).@0"7KJ;1J*
MTGB_XRC"PB2->QL!*L&ID?OWX_G&2W9!_4%Z!Z_NYL1E0 T.Z&'7+B\4\3Y:
M'9UPAMOF1\/A0)R)672!(3,J?9QP)EOC0P6U%EGPL08+/G;! J&3U2H+/C;&
M@CL4+:DM>4L.3_2PR<+%;Z/#<Z"0'8;]G?!#UF"-(9I=L8G*RJFL*H_AA NO
M.7:54;7.LGP+T]CBA2V=\*[5(+\0(4?/C-]7D3>+K@,5!?K@,+@>BL&Y5@SN
M!D."2N!-,!0'VO(:.>$6,!"H0F'R<'%TN0RQMD.L[<GGOOSFE+F_Y->0XJ9.
M.* :N7H4X]SL37$Q[]XU.4X2'#RGG' [97,G_%&-LH>/=Q]"2 X"G1D56)2S
M283Y82\G'%_M18<?HM]#O@_9"7T*K1RR$X;LA/Z$7 [9"7+Q<C,[H<LPRB$[
MX;O*3F@QFG/(3ABR$W9R][-S<C=D)YQ[=L*']\X)71?I"2T^43M?890N5T>(
MS0E>,? 8=84R5F^P5@6J"_=S/;+T07JNOVUH.L(-H:44F]OHZRKP5I\1\N,I
MSA^;B1^A!X,7Z%\%_@-*_D\*PF"Q91<_'EKFDA"/XQ@F8I%K$8)6Y;2+,@XM
MTK(=?SS#(B;4>8%8[HH_:MDJL[MQPQ_AW >-,[PT41:<+HLB?,>O4.R^N(+/
MR0V&D;=BS3^G@+E:H'^'0+19TF*X&86H$B3+;$N_CS<;;)@>^/%#P^F!NR]]
M@E&6+TB0RGI>+'=HC4("_^AO__.O%"7_>_;Y.OOC7UDR8?Y(!<XQ94WC7=O9
M8]'V3%(,,RRHI+/(2+;0GU&:7"*,T6L0+6/]I$+ML2PE-:.0@(,PH &>I65)
MI+7TB:WO^0I$U>:<N#YKPSJ:,FC(ZDHB],DT:2:M_02PKO*H.>LR4 S<<=B?
MY45B2QH*ZMB/D"?&.R%,M&0FPFY&0O4EA@R@KT&RFB3)7^( >>,A.BZR;G<-
M[(+GC<G@J)&]5VR7VP>PYBI]16-'0[CKJ'(%ICWAH2(@6]3<E1ALF4C*N=1@
M:A'8K^R8+NVG+3EAD>Y$T#(#^A)$?\I2P,P&<")(6RY7^SPB,]0Z8\X7<F+"
M3TFP3L,TOO;HN@L\:9UJ:R-WO ?6$U]3!BNIT!GG.2?V&8;)9_9%, /XCNP5
MR<EB8#9-QX^HM",39B2Q+B <CXR0RY*V3H31ZVEC"1;V4Y R5U*T9-<(9ANB
M05\GHN3UJ&^ E:.VI)D%?>0_/M'W=>=<>E(-&H@3DK2/)&ZE(#$M,GTFL$?0
MWROSRVW)'RZY<-/K[H2.M<%Y8\R;O2 =KU$:);?1"PH\Z,_1A'Z$> -P0J]L
M;RFM09A?W'"X:-C?"65MB8V&J/?A3G6&D4<D,*;[TYX"K(9GL B@/XYW6]C8
M2X*7@.;C"I5[S=&<RX(Z6<G7)$2S*W\/R#WX1DYEZVMZZ4A=,?2:F+/451V<
MRQXZ86VK<&TG:J5ZC%+LH>6&SB7.6-HMRSCV09\^H RB;*L0AYL<-',N7^5D
M#7B(8;/K9P8Q+5H$EC 3&WVC5+NG<WD>)ZPP;:2;Y=IN#R3P!,C/8)'Y!JKM
MG,N .($C A2;I?\CW&2VJH+^@G;N90.<P  !CGW8<W:@Q]/%Z39\S='<B^0_
M>0NK28DSBF^<8.@'R0WP@I @5 EEN$XQVD!:(/ %Q@G]EGHS36,;/[8<VY@A
M-%KD&(U @=+HE>#$)BT0&^TQ&U'4AN#%MH(7A^B6E@(5A^B6(;I%;)=#LF4D
M&'@2=:^XS3,8H4?Q+<:X=<>?FP#'+'W+6PF6R:FC=1S(4E-2C5G)0[T[MCY!
M:A%9XRMWN(ZC4=IB+!=W1S<^=O*@A6AW9NU= )ZI(:LLNJSN>8Y!NQIH.\IJ
M'L *.T?6Q15;1UN"JWR4H=8C!H[)23K OX,P5=FLFKV=,)K4HJIF)@<W1_E:
MK@=NKH:U.K>OB2W%36C6O#\+99PCM*VQD ^[.J.<#41;O:0/L>P1;\?)>(UP
M$C"O:2P( Z\S@K/ZFB_-.GJ;BZ>CO!Y"6;_+4-;O.]JCT=#6CJ(]B@"AZ[]2
M$.9G=UFPU$&[<PI)%:#8,/TKW)Y!G$_,8X&PZ=D$?4JQ[$/\P!Y!=FD,X^21
M$RNE;'XVT:!*3)M=7;=D?GKYOJ^L) C/%34\IUA0$8[]6E<::^D<8T#+V+45
MVGZ]6$ :C -ENDRGQSG%>RJ1;8L[8R^AQ2'_BT&OY RG]3G%?$H1[96"HX=_
MLD=Z*<:29QQ$S<\GCE2):A^X6F@&!OH$;(*$B&8LX:NXPQD&A8J1[0-O%9<O
M=2^D7"R0?#*GE3B?4:#O%1GBA94WBTU#>#^U',); G4(R1WJB0[U1(=ZHD,]
M44?JB7X%=.I$(U%$&+5H/L19UA,U)X.C%N<0M#@$+0Y!BQ:#%@6%#Z,E=8R+
MC'I)*4.]CLZ&KHC*$>JAY>A*FI-9%2]UR'6G_@#G&&VHC[VC_)="KE"I6GU=
MT:VF@E[ELQ:J]F\S8D"^^RA4J0>_.Z$Y#01J=SM11:,A,OZ@(.,/79!1:.35
M)N,/CF\XO<R+MA35,^1%#WG10]ZM _G20Y)M)YN:92[V,J.6;>SY;:Z>4^JX
M1_L;H*4H2!UGU#&Z?6*I8BN4]G%E/U3*J@;G'%^.4^P3+8.WV>NT"J;Q&SNQ
M+VK(8)59?%P<Y=*01O5=IE')+OSBI_0Y]G# P)GAP./%=4K:.F$'68KJE*#9
M;)0MTSK313[_%#\&RU7RF=5UY3U_+F]^3CE2<DS;*TP\0>L-B+9/Y5UAFB9Q
M B*B_I>W<9S2HI*% '%X=M)HYY1P=1(AFD_?X4K<]3<"=!!#I@QV/\;YK\)(
MJ%I#G4TNUDE4:);1^3L!,Y302$T0?L8HCLL//Q3P[4'C\+C6*.>4X56+ ,UR
MECHO8N#1 5F8]S1B2D3*1XT^9Y/@I8=NLSPJYIF3-O$*A=3C1-7]%=CRV"-O
M?DZY7G),^Y"D4.2T[W,^8Q8ZESUE6/I68-R>,-#9I)>=0(-FUVWU6 37 5']
M=/\F%ATSX*8+(U[;&/%\\L]L4*,/&N(KI!8>L>I?("9G@ -#D(]@^4@0R2[R
M/[[_\+-0I;0P\QDFS;5 M8X.=24H30YPE6[GDSNGC7)'W"HVPR?HI3BO?!:&
M]-6C:^"MJFU-V&DV;JO\;MJY9HDF[1P6GA+D_:GT3Y<:M<JJIIUF/ 1;H7NN
M]N^"A83NE4:MTKUI!Q8/P6;I?OUM SVRW_Z.0@(I?>F&0W=>HU;IWK1GB8=@
M.WIF C;3Q2Q-IFQLB:XY;-@J_9OV$8F0;/A1P2)!O^01EAIIJ@ZM\J1I[Y *
MV7;6QY<H$!>=$+=KE1--5_\1X-BP9QOB]93L0U]7@;<B>I$<M0[.9A5GP1P1
M!$D7@D-ASNW<B^@29E=K/&=X(].T&B70M)^F&1)U$&%P#Q)JWV\%10HU^K3*
MUT8='GKXME,<-XLE(_+#=:^(W:F&_5ME7M/."T/<SZ@ T!T$,2REU9I6 ?JA
MY2I #-Y1N =XJ 745BV@(0UM>)YS2$-3<\GQ,.Y#C:_@DZBY$P'W&BE,2D0<
M9=,CO>:2ZL%2BW.LAU-"SV46J=9/M9$KVNU(NCBT=WV%7*(D0>OI@@&KW&TX
M;9U083PA.MQ?.+ [RI,YVN@QY+BA$[D@:FX< ^XH*W;):#.:K8N3[2P$K#(=
M/=9N6"R%5L*KHOLYUA'2Q=U1S@NA5JQ)93]7=B\ST:[R5HED Y4'GC&*/1#=
M V\51)*B;,*63NQ4FF*U+QP@0,;153.DMWZ7Z:TMGK2US]B.&$-6I>$8QX9C
M 2,/TRFO8/;O;:1BAV:G<\J0U<&W#W'A8]]GG(CGB-V[H04!=$QLA..4+;T^
M9Y,SJX=NLTN1R93@FKCTVSGEKI;0ZL/ZZ>%+D(T&$2HQ[?<-<!&6,%T4]9+I
M53 QZ>D-.,+LJ<72(V61GU51-KL9_K'9F^$"!]H@)%A<T"B9[)881#[]-J:H
M9%\_[Y!A/[)6P[UQ_^^-"R&0>K*JC<[QGKB*X5XW?71VPQDOEQ@NZ5*?$WI=
MDD6IND>1]'#%+<63Q@,C3(R$HXPB2ON.P,N>+YE&\/]!@!6,DO1PPHVE%+VC
M%^Y%Z#C*LD-PR?Y=1H+6!V#?*V_^3<=QPFEAR%YC)%UG^A[B U1N@A<SMNN/
MY(1+I"[C]=%TG?7&'.Z4D4*W1UU&]H5?PT7#<-%@60,@$,6/T(-D!8BKXART
M<F*WMGO%4$6P#XZW!Y0]$1Z5'JGBO78EL;9U!W!BD[9;XD@;]SZ( DLYV>,N
MY/A1.R<V;:N,/4*Q#_SKR6UOHS<?G=WV$E4PR53!#&$Z['2Q_^H1;4&8;">0
M_+((R) P%F:PUAWH;*X^3J!!'U:IAH+M2K<V6I:!BUV_;[$J>8P<L3PAJ_'O
M+6<UYM"/RN /28YG=EFUBUHU?@C;@?>OF[_$$F/KZ%9BD$/7@T>NM=ZV;N-)
MZV--KB2T;B\G[I^4;UAKH>+HFM!^,UVL[,0]SS'+40-M1UFM?I3]B,>R+LXI
M1)4$5_DH0ZU'#!SO2U+5X"6GMQ,J5RVJ:F9R<'.4KU\B]!Q#_$*5SFVT21.Y
MXA4U/\?$/A&NO>&D8E&*.[BB7N7"J>*6XRN/RBE*(Q8C? \!%5CJ!V"P*SBG
MT]4)7:J2R>.K615:CC*SES6)+-W/##6)AII$=4_K<;WC.J^;$PI/[YET/80<
M729#1-)W&9'$7=#C*$I!F(MSZ;G-Z"9-Z)T-3)Y R!R&("*2_HQ!A'@KO.8X
M9Q.55)\$?;A&-8I1^E[BD1J./=+=?Z\7"^C16"A9+J=1U[.),#+"N@_K\"E8
M1@R-*#DZF.DL3>W^YQ>BI(UZ'^3 X;"6MA.U^\&P!Y1!-%Y3]X@DO+?:[/SB
MD0XQ[ /S%/<#=>],VF5OHR_.Z*/<[Q@T%JF<1T:R]+$B3+*,;EYY!80E*AI&
MI'WZT&Q$&L-CE$?3LQH)$8HNBL_E2+2+T1X?,N\.H<9#U$0OMOMP!K9TYZ;U
M*TKL*'& &U1FVMO2\Y0H)  @S)(52H^9DNE+GQ@D-*>MVISC@;8V;/<A9?78
M67F/\F0J-/,DZ0E@7>6N8>M<+P;NV+=M>5G8DH:".O9K804>)4RT)%"49B14
M7V+( /H:)*M)DOPE])V;#]&E']WZ&MB5V#(F@_U7U;34E=!?7F>$]CWD]?'<
M/7EFHM7/*2^78;K/4M1QR,BZ=.D;/U$*M/#K]U&@3)[X$D/PYQ5Z-;;S/S5K
MYS,@1YL<RM$S!7/D$S@'\[TEG=#+DF4GF.8"G!SU[ QUR?I9E^R>V <KL\)D
ME2Y.1)J<5IFL@H^C7#N"][#<UBMB7YN4)M,:QXFP@A-*DVDA:?^PJLD7:5,G
M[OGU2"_%8S@]#J?'=M_2HH@?8%R<+X2:4=[I'$Z0<@S;?E0B@\9C0>YQ#@;/
M6ZO9L4ME>?I2U<6RWP?]W1?9ZPF$3O4K37QJ[?ULP(!E5WMG6%ABA^?^M7:#
M4A*2WJYL!L=IJ;GTF>54ESMU[U:HQTI5 G49QS[40C\ 7#?OMMK:%5^#CIP*
M(D2J"-D_S.R>NF#ZL=B4Q"<:>7LG/ 92T=D=:>2(-$;H)^@QMU,^KYK2H@Y.
M'-Z-2"W"Q#JMQ_X+@8J:;.+W/87-G#B9:]&5#[]]:GH>.0'ZQ(Q%HEQ!42LG
M0N3U:,D#WSHI=^\(Z:I;50<G M"U"*S"Q%$SA!W5LNK)["RML$-$S9T(+5?S
M28F']17!#M-*^DH:.A'[K;4"1!@T$UT'8NH9I__0%XE?0 AE>D;=Q8D@;"TZ
MJW%Q5-=,0 *7Y&!F?*!5]7.T1)CIF5:%9@^/M3E.6[/C[6$O9XZY>@(L/>D>
MXM8//HZ3\9I6A68.TSBIQU;%("Z>K?F(2AFLP+(O_-XEZ\Q7&*7+U0RC19!,
M\1V*:ZYJLS%=//[7D@83I!T5CC.K[ZE5%^!DA_01HKW:OH?RG@K4'&4@]44F
ME8><54%5P@YN[<>:13S%Z%@_ANZ?'RJI".$)5-K:K<U.6:M:BLM0;*R^-[Q&
ME? >%1QC+E(CY23IX9;K75,[2?!I--!0O$JXK=SRNBL7!1>'9CRY]\1"A&$(
M(HC26$E<=1>W_.9*2JL1<E3U<#TWVH<8K<Z.EGVUX80\FZ.,J>-"TM69HXV!
M9*M/-SUQ2/#KRYSDHM0?R=ESD9%[2A_?7LF 3;=E[8&=/<[5EY S\&*J=L4[
MHPK'BA$<J6FLA:>XBK'$>#BGG)L#G[WNA88C"_U$?A\AU==:?$8*W1'/CRW>
M]:YTJ?B:K,9UHB/>(+L+T:Q>HDLL[7-]3*TJQ)96:G\K8F9AQ-3V>P X*]=E
MF /WX_N/UG+@_A8P</YU1(:BI2KW,)U+HMLX27#PG++:HXOK;QM*$?8P"7U1
M8([F*QC@FS3R6$4B[02X&J-V7QKQS,MAVF7_4"9S*),YE,D<RF1V42;S">(7
M @6Q(!(,/#;?^ 5$R1/YOSC-2JM7QP4MFF&9%N;63/\8>F^7Z(78E &S4N@?
ME(>9%4(^_'$'ER"\)F8CMVH=MX6C<?@G;9]<1%MD0S8M=Z<[_KG;_4HB-04E
MJ^ V4*DE/^B0 XHX%XC3J,--0,3D?7F58W =]0#4771FGO>:(SOBD3^)+F)/
M?0T=Y\;+@S.,/ C]^(;0;&^U[+=0WF%/HX]SGOG3^:Z'>+.EL/*R4'/P;8*A
M'R2/,(:$.*O\^_]'/G#XI=7+.7^\%8YIH=XLSY@1FGGL'F%(+-!H.4>/,(A>
M4."1#]/%TPI0A.GE?_PE(A12'Q]$T6[VYW'.M6]%+AHB5HN25 9U ST:CKR'
M-3_,:(N+X6#.W0C8EPE#BC2L]@-<% 8L%-A.H\7[E'^>ZM?MZ40DK'WUKXM^
M'R[X,M$D\.?4H*Z*($JIC)(3.E-%8@M>K[,3U2X:,M?U*-#3>\ <A6A9T,CT
M.M#>$QB'UX$[T$8PAVVX%NSR6K#)AQP,0)>&_)L/=)97AR?0P]$];*>C+[<%
MO*H$67$/5W( ZHK]0>JL&-%&;GX+@X@82%?P!89H0S5X#KZTDI-63R?"])7B
M5KZ3U4*K$58\@1#2DM;W /\)2[NXE NJ3DZXX(P8H,*H$=I_AA&Q3T)Z<>BO
M":'B)+LEU&&!9E\G7&M&G-!$S-%-9K@'&>Y!C*M)!/$&Q=QG/@Y_=4*Q6G>5
M5%!LUIUU393+<LN></@K#7P>P8^;.*%$K5/]&,]F23\C!W7!I5[QRWDZ_'?H
M-4O?IR3U.;DPY5_.TWF^0Z\/GM1'N $!SDQ-ZMJBN0&%;2/<^^6=SM!_KHEY
MLPOJ!G)74_;U&;JK=[@U_*96\K2-!0_<E7YSHBJS=0*7$&QX-T@W&X03=G'(
MVQ(J/[=)ZY_;VQ<J./9A<[A>;T*TA?"2G($701*K]@5A^U8]8.];WA.$6#>[
MHJ[@!D,OR.(N6-6,_\K^COP91B]!S+L$U>_7*LM:.J?K8]^'U7D;$;KHF&O'
M#5ME;DL'=PFZ+<0B'=TZB^*,. U;Y49[!WH1N@USXV#"ZV]>2,YCT;(*3A8O
M(%@YM8=IE9,MA@C6(L:YQ(_,((Y1%,&066YDH_@- I\]J60:66+OL56-R)*+
MT0YP,E"<O[VZ*F ?(D^&R),A\F2(/!DB3X;($SOVR!!Y,D2>U*3]$'G"X43;
MD2=#(OZ0B'_&B?A/;X$Z$;_4J ^)^"5PO\\*!A]K$FZH8#!$[O4Z<J]!R7M(
MZ<(@F.?W6F))XK1TPN!M2$8XZ/;AGN@K6#*+GECV ,NJ$Q\W=,)H;HB;Q]@V
M'6^X)=B'<_"->SE4_?E<(P_+./9A[<P0C8ZARYTJ[OR&/T?_-BH_/2!<529#
MG&% 9"TZ]$$T<M!I 1Q6((->D/A$PBEV<PRB&#"JQ+1\GGHKK3G:.<=:UB1)
M+V2GCX%5;5<IJ!]7Y>;%<EY&YP$FF;*[_BLE2-S#9(5\TYOD?S1VD\R@I#]$
M,"&4IH"2;S-81VL&[+E<'3\%RXB]71HEU#$0)ZQPV6TTCF-$0\1@K']AK#W6
M=^^?U3K9&[)F\,KVS"O[&]R <!O/F)*5.1A%#1WVSHI =M0642\U:92(;G='
M+X)J*!ISW!WE?";$Q)1)0'B#\!YJ132(LI\K,2%FHGU@?:J0%#"UTU +38[V
M5%.9K5NSBQ"C\1RY_JA! _&EA[8B/*>K#FFTD5!N%+V<NP(Y64X4"/?!XZ((
MIA'R6MG/N2N2D[FM1+D/_,Y<+-3M0OV'N_#XL4<PD;_1J='3N=N9DWFN@70?
MN)Z];0@SGYN0PP>MG+MT.9F;!PCVB'/<_'!!(^?N/FSQK4<9XA5)HW#K+;JL
MI7.7%W877H9D'[AX9N6TM<IGG,QK2T6T'6#_?O/7,(H<K,YAT?KI!\-8VNT$
MK3<8KJA+["77. \PF2Z81'HK^A#/5;!80 R)1HJG$;LR#YE<"ME\^L#N5?HX
M63I.)TJ?96J^ LG7( POX2/T0A#'A);0GZ-RP$Y!"6.Y,AO<O9(DC<F6&6'.
M0;X>4-*HB&F/[UYME,:E3)LV?1 T#IY"H>&V=:\<R\D"P,6S#\PD8DAKIK%H
MLNEK!'&\"C8L\HI0H40 F>&J.8![M5MLV+6:R#=<_"^+?-N;V=-%Z0K68_5(
MH'^#\!?ZJ%PY+NX2+A"&UV&P)B=K[CG4^O"MRD&C_D#KI&FX%O9^KNGB"KU&
M<8(A6+.$= [7Y<U;Y6*CWD$EJGW0X_7E4!QX=,*0K4I'.Z['4\C1<4 U,T\S
MUVD PMN(*)XU$W:SJ.B_O_]P&!7-1AXMBJ%'P7[L(8BYDR#F(7:QTR#I(79Q
MB%ULHEC$A#0@L(9S3-2L@ ?"9GT,G>1C8I^N*$HP\))[$*4+\F^*Z?T27H(H
MKULLH;5V5R<"UDSIKXV=HPKL#A*#XBX ST'( FQ4%?@$S9T(/S/AG1(C1_F5
M^U#I'>^2:&)]SJD[.A%.5HN':MSLEU%@QP@/I@E5O[O(5,7^;]#1B7 P0VVH
MBYO]_6D5@#D(Y@&(_B(R(-Z,^.V<".$RW7GXJ#12%W&"0D)$E,7?CC&FU\S4
M#J2QN?M/;!7.5R"J-N><?*P->T;97-9HXIP$<'-1;0[<\5G)\B*Q)0V-)<T6
M-N\$(UKSXEC-?\8HW<#+MR_*0X'^$%T>SJRO@</3@SX9'+5*'RGV4A]7J47[
M2MO2[;;$C55"SV46J0X)U4:N^*".I(M#>]?/;9<H2=!ZNF# *KC ;>N$=XHG
M1%5F<&%WE"=SM-%CR'%#)WQ5:FX< ^XH*X:<ZB&GVG;\769;I2"<@$U #M43
MM%X'&>Z22#QI+R>6O>60/"G"S8;:C)<8,J$BMG7D01P%T7+W_.%T<0.\W(W'
M.4(8]'7".6TI!L< [69Y)Q.<1^A!<N@Y"IK1[N:$*]H2Q_0P;II9NS4]7M,0
MG!G84I5_@_ 3Q"^!!^,"E"^1G_G2*<Q<!M8=R@F/MC6FUJ5"6XPNB=TEBM)X
MBN]!F,9$!#?0SV"6<E>KOQ..<^LLU4+=U6"UZQ<FE(L$XD?(PJZCY15!W#2(
M[:-)$-O%*)MV!.B\K/@G+B8?T6J?C8>Y"3W72$0H;CR:9B=7C-P'(F_^?Z8Q
M>R"+P_@9)%+J2QUS)D-T'X!FQ-2#9Q,,$'7TE'R,@L)Q(>[@BF_/7()57&WP
M)2*?;"Q9]'N>99]_(EL]3K.]@Q@ LQ517K=!P&*R'JC[_]-T<0?HOO2,083P
M;42@G@08KU 2> \@)AU6DK>-VIC6"?>B2K[W[R>U01+[,2,8Q@2P':AQ&B:L
MT-%3DOI;<<2(5C<G7!.Z#-1#R?X*CN.4%D8A4Z(M")/M!!(E0\U%6<2.5B\G
M? S:ZT<'(^O4S_?K:+GS8=Q&<](>LF4JIK]F/R=\!KH<T,2IP17 $G78HQ4H
M3<AZ9#4C$J(GG]+GV,,!F_0Q6*Y$1L:IHW5\HV\DC<<+IP;"C3-SBK\"&HB0
M6&9KS7&[W)%L,;@FZBVRF@#QG]!+YHB^ !+(8_%KC=+ESF:?C1)$F]OP"+PH
M7:YNTLA_!$$LBU#5Z..$']5XHQ/CX^AA^Q)AC%X)G.S=H+4\O(G?N/OPU!/\
M)7R4>L(L980-O[DK7A&9[,FYU+ R@X5OG+UVEF*T@2#:>]HO0?3G38!C]C":
MMQ*PX=31G/!5R"6NJOYJXNE<)/>9Q?)SK U#93D$[0]!^U:EH;&@_<S[63A$
M*VG#5"E5G:(STACF9YY[$*\>9/YI:R.?98B_->I8EXB[P*-+A1RL(K^$"*%Z
M<="B8$R2Y"\AZ\V'Z-@GT R/S<E@G9GY\;8R(=_0$#+3?(B./0/-,-.<#-:.
M1 L0/S.2Q#C)7G>$81+33_LG'LF'/W;/NCX1N0,X0!R[3-*N?4/KT%UN;&A)
ML&F?^OGT7Z)X SU6IY1K+"G:=FO_*,5H1W4Q!O;K,^9S32/QP9'3ID.[04L>
M=D40CT%OC(3S5Z0D8:E-A]MR+1*60&^.A-3)K"9BN56'&V(],I:!;^0(*E3Q
M=Z(4'H..[>?J&&-5/A>JMKO6LV_X02ID%Z>A&4M:Q3$_C]Q&[,!R'1$"A="_
MC>Z)4$W0"F%>#+'Q" X<"LPY:HQELX'?6N!<?]N$U/A%>'L:]S@#.7 8:(B)
M'&2;Y>5#2K'E!N?0BTUN7HU&GRX#9&IS2 .OAA<61AZ$/HM.VUUF<J/TN.VZ
MO*RMORSXN#2<#!A%*0AS/I<69G23)BFFS]RP0M/5 $X.(VJ.TV4J2VU&U<2U
M64;>@V_!.EU?I;@(T2U[/3D<4W7H\H&^VJQ1(=7.%G+]5TIG9->*/%-;T*[+
M9_).WBH.<&DZA7F)X9)L1UE>V!RQ%VQ8XM]U0%&@]D/V,-<-P@_P]3 @B4:P
MKS<@VO)4F<7!NWPNK[Y^LTB AM\629#W9V:17+$BL%GBRN\@3'E)9O+FG;Y>
M5YM9<IPZ(7\F#OKT+]IW^L2;;0842/7A@8X9P$Q>".0,;&$$UW'#3A],J\<S
M"38-IXG3)]:FBUQ+3C&+7OY,_^87;9 V[_2ALMJ+18Y3L^1G-Y>\^0L3Y@EZ
M9 '3,AX30)T0E]MKX*VJ;46Q.:>/V^D39">Y6"T@WQ'GK[^1TUL0PQD.:-CZ
MSG[)?A5&W=4:JM.GQ>SS5XEO1RQE&GVZ$(O?*4RN,7BG;Y'99WL-"C3L]R!4
M)2?^[*B251/)GKHJY3SPO!]:W3I]*JR^$T0+M_8<N/M(K7UP$&_9:?1IE2'6
M?"0:B#5^3T6.)#2H*HB^K@)O-0-;EM2UJY?$TL!ADF07GOP;*L,A6N65->>'
M.9[.6:VG['"N;FT?K3E,K*!>HP[5/]]E3 BR.DO__O\!4$L#!!0    ( &N!
M3UF_);)6-Z0  #E*"@ 4    :79A+3(P,C0P-C,P7VQA8BYX;6SLO7MSY#:6
M+_C_1.QWP'ICK^T(R>6RI^>V>V?F1NIEYZRJI)&R[-M1L=%!D4@EVDPRFV2J
M2OWI%P?@._D 01 \K.Z(F;9* LZ+.#\<  <'__Z_/N]]\D*CF(7!?WSU]KOO
MOR(T<$./!<__\=4QV9[_\:O_]9__Q[_\^_]Y?OZ_+QYNB1>ZQST-$N)&U$FH
M1SZQ9$<VX>'@!.0=C2+F^^0B8MXS)>3M]]_]\;OOO_OI#^3\_#\%C0LGYGW"
M@ AB/WSW-OO#94HN#/[$N[UY^X<W/WS_P[^2G_[TAQ_^].._D=6[K.$[+MN6
M];;T6?#[G^!_GCA'PI4,XC]]CME_?+5+DL.?WKSY].G3=Y]^_"Z,GGGW[]^^
M^=_O;A_='=T[YRR($R=PZ5>$M_]3+'YY&[I.(BQ4ZO[Y*?(S C^^R7FUMH!_
MG6?-SN%7YV]_./_Q[7>?8^^K5$3XLP*3K#G\U4OR#N7&?W@C_Y@W/2&=JO_V
MIY]^>B/^^M5__@LA_QZ%/GV@6R)^]:?D]4#_XZN8[0\^<!6_VT5TVRRD'T5O
MH/^;@":@X4^@X=M_ PW_+_ZK6^>)^E\1:/'A8=VJYT\YC;2#T$#)+&],JO ,
M(_)4#?'KH:J4.R%49\,1@&KI5.Z)4;$P<7P]Q4H]$2IV3R,6>M>!WDBL]T:K
MX&/B1(-QHZ7_4"7E' )];_E/%5WIYX0&'O4R;8%Q!V4A5PZQ0#IT*_1\F&#"
MZ-1X<0;K,76_>PY?WGB4P83W(_QP#C\(F_%__.4RY//XZBE.(L=-,DI"_/_X
MJNGOPZP!0@.M5525W(G<C!?_L<<.:8LW;L@GV$-R[J<?1G3?1N&^65+)+FSX
MXU_\I^$?-E.EHD=$X_ 8N730%RV+WV;I7$3> H(J&IQ_>!P@\W]>92&7$WCD
M.DA8\DK6P3:,]B(F^7<IQH0#*Q.@Q'3C/!6N7M*\HRG>X=:G7S;RVMKA'(2]
MTHX>CR7*Y*.@_?_-,A@Y.M-U0O>QFA7*S1<U*$_T[!B8>=O%#,Y3B<T.4*!/
M!(/Z*#6B:5*.@^=1=^[Y8<,I=BB?_AF_RY7UJ+L8_ VW2U4D'#VF@)J]$90O
M2ZYX!-^A8[T=_C'5J%E]<%4:X1YES:*.'FZ2+$<QCP#AZ4>>Q,L'^LP@6@^2
M]\Z^:>"U-,,[[KKTRH9=4QN<HZY34MU!ETZ5!54"9*<?<BL^TCT8[3>^\]R@
M;/WO> =9HR;9Z*K\$>>P:A91=SSEU B0FWX<71ZC"&1GL>OX?Z9.U#YO=C3%
M.[KZ],LWA%K:X1QSO=+J#K^4,)&4"9"V.(]F,WBAUPW_3=>*_+0EWJ'8HUT]
MCJLUPSD0^X0='<N5!Z(@;7L4RF!2;1Q6VRYE)#9HV#P62PV7,!J;Q#4U'M,E
MAJ41*8/,2\X_<OQUX-'/_R]];8UP3]OA'8F=FE67&+5&.$=@MZ@C%QDI62+H
M$DYX[,ACVR@6_!+G<QB$^U<Q_LZ___&<C\+MT??_ BV*G\[=,/I+T42,3_%[
MT>(QX4$".,G=]H8%3N R[H-AS&#_L.5$<7!GG"-9SP8PO(?UQ#?F->77=80/
M@7/T&*1XL2#A$+PG_*MX-(!\,/Y3'/K,$QE@<28-";=DF\E##JE N!QG%<<T
MB7M=Y*09=F=HUJLZ[*MM, _P%DFU%_J"'/GHI 3MGB=-I];CX_7F$9=_O>>#
M5:YK%3VMHP-VG^O3M>I];:TQ^V&OS+I#EQ,^3RD3!XEW3JEL55=<+KL.$JX7
M>_*IU/LNV=%HLW."G\/0^\3\=HNI],3NQ,K:5[VYMQMFMU877G?(%QPR]PZ!
M!TDX$_*<<IG"SP_U/-FY+'#A^' I@3@)5YH2&GC3J5O)F46B\!-]9D' @OJY
MBBTTGV&,XX+U^RCDHR-YO>?J):O N_[;D1UD3I/K'^&^T -[WB7A]ABG)FJU
MI18I[,"O;Y_J3#"<#N:I880VNGZ4L3PC!V JLN)HQI:PC"^)@/%YN#WGK)L]
MSN8,,H.AD$TI\UM@[CD&F[/@FH"NZ);R58^W<3[WS"]-+;%/'ZW:56>'DV:8
MP;]=6.VSO)0BX2-J0LQ^H=%3V.>M<V@W^]+^A<8)0,/*=<-CD%#O)HP^Q!R9
M *N2UW<TV85>J\G4^V-WUX&6J"_VE3IC=NVA*N@OBC(^,7$R3F0;1N0(O,1<
ME;R2O>!F% I.+Z'/:XE+)XI>065G#UQF6P;C^.XB8.WX]C,#I=@=J&\ MQJU
MK35V$.S4L@IYC4TQ URWP+K#6E E0?VT8B9GMJKC)(%:4J[1,(N2F$]BE %H
M@=BC!CM+0ASC8_3T4'0F%S2NF2C-T@\Q,[O?Y:#$A;;6V!VQ4\NJ-S8VQ>R2
MW0*/O:B!)5'!AI:X/!-6%P%GR&C[G%AM@]T+&S0ZW7-(&V#VN"8QQXY 5M"<
M<=5L2JMUJS8S.]4F<CRZ"CP1&J>V?Z N92]0&:;=T?K[87<^1<VK#MG3";.3
MJHJN'=X!?7$4);-\LB O*GC,Y,AV-&_7$T=$FY]XI/_NBRP:VF-WZ1Y-&^/:
M>F/,+MPG\M@YMSC!.LO<=][HUKBFG.#D@-2_M)Y'.PR[ZY552_?N7[TI=O!I
MUZ]A4[W2#C/D=$@[;A?6PAZ7XE[Z0K53W$2WKMW<T8X3[WBL!_^!L\T7QX?C
MR'8H;FN.'6ZZ]:R%.HUM,<-.C\3ZQ_'Q3BQ17/B!YI1G3"&=2-/W-)%*-F@;
MEY)'X;JNE'36-%++WUM8($\<G=8&*M&N9>WG"GOG57/NB4DI]%U:U*L0\"XF
MUC4;*G4>I5A>:1H]P<4<_?5XUV+<JLN?\#N2H>&VFM-SC+H,1E>1F9]\/KYE
MSA/S6<)H?[Y#3R?L;J6B<]79NGI@=D$EN;7+8\D<7HBY_(+\_#D1DRI]NUY=
MK&_7F_7U(UF]OR*/OZP>KG^YN[VZ?GC\FES_]X?UYL\H/5S1IQ?GQ2I^NQQ/
M->R;6'S1E%J/.R>BN]#W..>OTTL$N+QM'<='RA>W!\9G_%:SU%MA][5&K6I)
M2N4FF#VM65#ME!Y!C;B2W%PY2D95$DXVI49*5S3-ZI32(7$2NK_C0@QA[ON(
M[MEQWVJ-6B/L>-&D4ZWN9JD%9K1HE'.<9QTDM9FPPJA"*9V81-07!4"3D,0=
M\*'B:NS%@3+,__K]O_WXO725%^<O#S1Q6$"]:R>"O?KX^G-:5>$^"K<LN0WC
M^":,'N@AC!+XK=C'YTN 342=^!B]"JU/=H1,$D;JDL9M)]S8&-5Y73][$%V\
MM3;9X!B_ T;<<'\(@[2N;GIW-J(<2&+^.U$0)Y64T%140C-9.=Z L.0;GXO[
MK;B'"Z=^429U>NAU)A;R22JY].))=MT:\1:/L1]&6]*6(=O!'I,U8QJ]8$M"
M2Z6ZVW*K[+AB](IMMS2B'$;CNV 3.4'L-V*"%@6D,X.^-:J1G')WS&'><"5&
M>H0 \I07\0IF) Q(4K";*4BT9XX2+1))KMBPH@JD7?C98<]!1/ CQG";U$%#
MG0)NW-#0PUAH<M80D=2CD=D0Q*)A(,T-+)"'9(VJHSB'Z=DI7X#S5_5H.F_!
M[+ U"<>=K\R8,&I(#V1U1*?1:MK:H/U))(:T4CC\LK<];T\G-(5XAF3(]/7"
M#O)*6K?5ZUE8DHR:X"8J^:!*DYE<[0:M31T'<.II3NL]!))A<+<M?G411E'X
M"8+.5> 5O[ZE7+"2J@V;9H;((G5NPW;+#@),T,1]#&!40Q,X<I!BP!Y2N9#6
M4RZ*V((N_\D'<3H\<=*=_7_:S\"&/@HCWH;!\SD7<T\\^H2LQGPQXUSQY<8+
M=^87FC^)V8'[.@20(KRV+=HBN>[>RPCJ%'4P@2M>SJKT^.E4H*%:Y-J:)0KR
M,6$!CR/%I#K7I7YK:E<QD9R71L%\#QS,\=&M!/</X:OCPU/?_"];QDG26&8*
M#ITRNP@AA??1ME$*V5NI+#A([]=)^_QR1RN!8DMH&4D!B%N2@# APG=H0O'I
MK%2>).\+"Y5_G3(G9>Y$LL<5:T]GI8>F03)N]\1*O'T?A2\LYF:"L[WK_<$/
M7RF]H '=,J7"Y7W]D<*QKB7:@NW.SLN(M=54,+*$SSF)0U^:\B)/*;/9H\YI
M37%?53^B"8NH>"0Q-0 )GWSV+"9+M+AQ&09BLWG8XKRYUW(PHD/K-F1HZ+(,
M/.@2W 0*N"G]^7;F+"E=+#(55,90XK'Q=*G5>)U=L+MVO[Z=[RDMQ*D5I!Y7
M3C!H/BC%\;[27.JBF:N'S='+<N !OKLXMYUF"+<D-<S^1I%)'4\?*D+KII<G
MVJL^6;3,[*1^?1MKSRTL+TE!ZK%5Z5 E)-G5U]1I1=,)O.)!O7IBTB1,D'KY
MI#;-3D#,<\!].C*AOF-]LI9U,RQ'!T5^TS^-._6!#$(+/^XX8Z2I4$U/'=T[
MK^(YD$TH_OIX/!Q\QFW>.AT/)()T-AEED_Y7O]HH8(XKM?08"T2)>!WKD+)!
M] 389)IONC3&L6 <<@#3V06[\_?KV[A@7-BYBX+48]T8T8'+A-J*N7U1QRVG
M:^?NG>W&]MB]N$?3]@>V%N*_?2*/.W! =K:R>#V'O;PUAYXX@HP!P<6RX$@5
MB98%0A.,U_[=5UL>.8%RU==0T#JCBA<NR_UZ_6XA#F<T36AV#S/O6FA=JNF=
MB5:[M#3&[F1=.O8_D8+9[3KE'5<6J/XD"J)W4 SY)+6GIVIYG?GTG/O%B< -
M]_0Q<1*1 -Z;^='>'CL8]6A:>X^BN3%F2.H367<L?PB<H\>@/#L+.&XPL:OE
MT2"&ARO"( Y]YHGJ[7'&&@X&F9 F+2UHKH[["PV.8@_^0",':@!*K=N&K6(?
MI$-WB,9%8?6>#K@S#=3%UT\^)![=LH")(VSGQ6$^'+%8O4<YO98I!\)9D)P'
MD4S(Q]4\N5HV-9<Y"*'8ZY)8A&O>3<5L1?/B[TC!J4V3>J5>\4?,\V9=Q)$#
M;[:*N?BUZ _&36DAX^^H41?MZ$-LG$NTNN$^<!=Y+'"BUY6;L)>VU$N5/D@=
M?(C&6?31VP%W]*$N_IB"#\X^/,H@N3P]$3 ["5.6Q,EY6HU,IK? G8K.UN,2
MNWK;1=>YU<,1:9V&G'VS4&,/I&"MKFUC?';:? $16X?08Y=-Q=HAS!=/<[BN
M!94KH1+^55-,N3OLN!VNN,1^>(#I_/KS ;:C.HS7W0N_3RMH??JL4FL7W+ZM
M(KB^?TOJ8IA[!7U")8-I2BP^P_9HGW_/HK8;QB?%;N9^T-;Q*=R\>.=$OU/
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M^-,X!B(7?,]TB]SZJH7><V]RXEUWI>W^?MCQ0%'S*ACT=,*,!*JBCZL\YM3
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MKBH7,80]1=V"M&*ZK.+*^.)G(0'>$.!2[HX=I8;90><\#S/^#-3 SOD=GIR
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M[@)0:)@==,XK,./+0 WLG$_@.?J<PA9M1Y^&3B2L5E8!DZT"#_X#6<<OC@_
M*RNQ7V^WU$WNMMD33P\<N=/J[*V?P"0'[,!CW)I]15TTR6.&+_-*&BX3(QQ=
MU$N!'V@A4?9D !4R0;R0OP47<;&R^BHS02$>NP):ME1%;K4M+M3LL,Y=BUE;
MOXL>+>Q(.,)"5<S3((09W<:HH_T@8S<>D5#=[VSM2,UBILPXXG4^R(.5S_75
MW^G3SB&Y#/<')WA=!QQ@]R(UH2VEK*\Q4N]7TC'+'FEOB3MW1$%N[8DQ)![E
M:P8FCN.<%X?Y4._>ZD70"=5+24-N?D9[.M?:T,_)!2?PNY*.Y=9+<JX3+=N]
M*V^Z-/<Z%7Q,9A9GS2)Q?]OE\'Z$Y]7AY/MD9,[L=.:4SKRN1)Q\!/)$T+><
M+FI)V0D@YI$/60HC]VX+7'SF<%_MF,#[VN.%&25-,Z#I;(P;:M1$UY[,WZQL
M0LBTREPX,4OO_].#(Y](%.N%.&,KKM?EC'$MUTNV6=\\/!;V:5U_=/5 ZKCJ
MVE87V*W-,2^C^X76SI\K#VB@71K5Y&,"\^;3#/.F!<TM^'CCQ+J25^)9\'P?
ML<!E![_]KE5_<Z3>J:AG-JMVM<4]J2I)ON0%\J0*%L1)01W79'J5KYSNMN\X
M,$3,\4LV"7WFEF/[Z\]0* @D?&W%M%$DD3J\07M5YVM]>I@G= -:C:AOE6\%
M;,D^99Y5:@%7/ CVY44EADA@1I.58.HP!J::KUJ&"8TWX1J>IF#[RS#P:!!3
MC_\0<YT\2!8K!4$W63&*>ZBOT[VG;HXR4M Q;[W\KJ<9LKAC%]-*+CG,P6,+
M+@=)0E%UDTEI^"(D%0=^RN6I+E2**C6'5"93 %4&WI%FZCJEF(@-7NB:TJX9
MCDW! S>H3:JQV9,8>+<X:/'WPLN?'%]LQL0[2A.KF(C2E-7PM0*7J7 DEXZ4
MQ2.5K:Y<0I*)..\I$4I;(YR,8 ,P#.3="/FD;6Z*GNR2_EYXIXH!6I=/Q'NZ
MX ;R(0HL.?*THZ>F(T-A7"[1MP1RPZ8(*#NT5PT6%4G@]6Y=>S0%>2K]<?N]
MMC;F@S,W9P^^(%VA\(_98C$K5BG%67=;4K"$?TFFI8 *3>ADQ32XT%34T,V#
M0+5L6Y4^>/%26>,,('L[X$9$=?&7' =-KZ4LE5VL32;(FBMC4:M"@$1/"H&-
M$@&\;JIGBZ:@IK\W;@?6U,5\0!.V>\!LT8P%@U1C&0D#Q0;02:8P@CC&@E',
MHJ&E#(SB)/:_CMZS"*S@>9/K.&%PDAT/3;\81@\IUIJR5'OBQ0!B2\FZT%')
MS)YU*=/BKSEK^;)8QAQ;OH5-8WV(A94*6X!EP%# %1DRT;SV9-E&,A?E)HQN
M'!;]ZOA'^HXZ8$C00 FA1M-%CU1F+%=#K'%$42.7(=6T$8Q6JJR>)HM!=+GE
M0I 7D(+L"S%08-G,YKMIM(RQ16>/=H\'ZK(M<PM$?X K[U*(F#?X$#A'CR50
M+DAL9N6!9[YY%DMBG5ORLTB!%.CF_2KY&MJ^",@7XC,:1/N&3BI3>2T?E:02
MT'O,Y,KWHXN%7;X%;?>)Y27:NCS-W6U)^7J"G.:X6"3_(*6POBRZ:)0+GV>E
M%!L.A?SD8TIWUO.3!7XH@TZ!;$E16G7]'/+/< FS3#3X7DE[7Z0SIHX%VC<L
M6CJB#O$'B&]F(^(9N!!7LD$1IELPP<]EI?'ZOH!2&B?Q.H G+IC'G(@-W]]4
M(K,D1%"W2SLX]--8"DX,T,0,9+",H7CON\02&WQ8L,RCNZ/>T1=V*9L"+ZAD
M9>;2TG+K@ =OE#T'Y;)S@R%&@^B2 $?79NWP,Y3B4L!(6R\ST%24H<T*/<(;
MF5*$:B5(=&!EW7)EZ*J:!B]XY7NTI2L/ZR!.(K'C,QBV!I%;$F -MU,[5*G3
M6@I(:6AD!IY*AR.5"S*L8(X-EBS:J@Q(A6V<.*;IT7CI$9+L",4C3E(R*U[D
MVM!H#\?E<)-+9%C&=UOQ*BOH[J5OO:S@H4)YM+Z!W$NE+Z1+>4EX-LIZ[="F
M178I*#=..3. EX ,LLAV+H58*H$<YT(0DKTUY!2B<! $8>KX-[,[;SC7'AO&
MJ\^LO>S]  +8G7.H+:H^J-H;LZL-UD$[DQ<8*3@-#QT<S@^9TW3:YQW=/]&H
MU<1J?;&[R@ +U*I4]G?$["!#Q-<.&7,>XIX>#6*9PDT_P\_&RC5>Q >7\JGT
M(G8$Q]_2%Z6;QZ]*!Z2#5EG7++NDNS7N1!!%V?5O8#!8I@ M.&D./'D@??%X
M?WDM0J*+QY7$]/R%<JNY&1.K7]53<" 9"]LOKMO2MOHU6SZRL9IQ]--%&!QC
MH<Z*4_?NN? P$;]MQ265/GBA25GCO();7P?< *4NOF&,XHS)$W!.AZX#O GL
M],3DF]7/*R+"O;??VJW.-KDU0&W!(H4KP80 EU1A\E%RLI^?-;WR\%E+JII"
MJ=LP>(:=B#7W["!A+Q1XK(-[&HF;9ORW'P*6Q,"T%;5T:.!%,6V+9*@VF !N
ME--7QS#J 0?B<VG.8=L*2GU(>03PP4'BH1")'$$FPGM]=;_Z^<.]Z/R553RT
M;S?@> XL2<Y30L8Z("6V1/ ]D_:<#3'MFZ<8"+BV8,9L"M^R@*X3NF_?U#1%
M'2E@3V-%<T<2.6G,6T%F%9SY:((3I(2!1). 6M<Z%IE!YRT-:0DQKVCB,!_N
M-92*T83'9,TCFN"9/?ET)4ZHA^:>Z-%=$DJ.L%P[/FH070HRCE'-#"9ZJ025
M9Q\<D '<.Q4BR\A EJ@RA_7*&2LG!EH>I-U'(5_B)*\0*2=0VN%O1W90KE=@
MCL&7 ')#;#D<[52H+QWV!NDX.?X=4FG.Q&Y (DNU9!(M!0NMF+0,BIU6PPN0
M#Q1P@/G,D1=B'X_[O1,Q'M0VE>.ZV_*9)>2_3&AZ<Y:W"Z,/,0N>P<+)ZSN:
M[$)O$U[RA<0K_^UJ#ZV*"RKK(*<P%&K1B+HDT$9CM![XQR'G4B829-8R,R5%
M%:7D-;-,K>;"?:(V3R985J4'&L-M>-!.('#R2O9"/UB_NZF&Q!$JEB_YP;YW
M00W9//>%?/'J,N*%,Q)!!;?\+_3@^*\Q87'CAX1]E^K'K-1EFJR@[7MN]6,4
MP;Z26.J(U&'54OUJ%)!.)_K6:*UIV]T=]]F=KC)CJMHFSM/1=Z)RU0\^ZF55
MVX##7\H_787/6])V8G,TU;0M6))5NE$CN,Y;7L:R8<J(VC8R3*'CFD]-&3^8
M*EXX"SXK7$IFO= XL#M>7-2Q0P:*0_KB1D0M3;3AL!$*(2JH1W1.G/VE\I0<
M@<,9\00PC> &,"=$S\AS&'KQ&614[T-/7+<[@TR'^'@X^'#W;D=]&85LCPGP
MC!WPM @BR2?*0Q.Q@4+V3G#<.BYOP>4X(S&-7I@+(O&6ARCTCJZ(5OF/+HWM
MXK35C[2^>7@D94#*^9V1E",&B+9JDWK$"ZSTJF;T!JR;R/$H7RA0_@>NP[!8
MM;<S7C@>;H.F"+6[)VXHUM##?%R: &-8Q6><9PM()S9!==M",",E;A@@SJ(U
MR@!W,@3$-K@(2V/R%%'G=^*%GQ"G0(B(_;(<K@_=I>ZC@!1&]:W1OJ?;V7TI
M6ZUJ2IB!$KE^JZ[=L&U$3FN/T]5LS1J )R5\F>2-3B?>09(9_P_LE;[PD#\8
MN/&G2 (I%HRP1^,;G0K]EQ->#=+&?)#E<KXRE1-^H(4$\SW/:<,@M><Y07?.
M4_Y0XHHM]+)BFS)FM@X/O"'7I0_0GF7R7CH'ECC^T*A+@0A2L!UED_;8JX_"
M4L(O93W,1&"N9)=GQW,_$ARQ16&3FZ4"*D6!R8I1\&+*^R-<<^+(^QMES[N$
M>JL7&CG/]/HSC5P6T_N(N6 ]$<S* _$1M15-<EL22AFW<CN<&6.U%-PSK[ 9
M@ R$7"+$^)1*1API&J&I;.0@A"O6<&GB!N+:CWC,70;>??B2UKOBT-M5347^
MNBAC@#C<:TO8O0BC*/S$@F=CUXO:*"X)8K6L-3S)OI'<4J!23ZG)T^B?<O;8
MP,ZNP<J YM$G<\\ EL/AK))XH<*P_3J%_DAA0]<2C3MU?9T7M$VGK,H$>W3%
M>JD @?GVYR:W1&US+M5^S4.6$@1:V9CKJ8QFURRMD1SD)AUHQ$)OW)EH+RQ"
M-7,)[X=#%#KN[B:,LJIP%QVED55ATP3]9<"J,4LVP>YHXLN!97.JFHG?7C)Y
MB),*E%:N7/55QY@+SK\<"Z:ES\ELP3$ZRY9GC Z[MH]"([/&?12^L)ASACM'
MD0?KA <:'\23/5=TRP+J7=" _Y" O'L:KY+KP+O;7G,9'^@AC,1SJF)^ZUC*
MVV*ZC/EE6ILW33K3<%S.3#2Q_F-6%9[J%L,ATT'<G00E(+R,I!JRKU"$/$E-
M2"Q5@9=DQ(6Z0%RCHP N4:93&IK.MEY!^F&JBYQ<2)))">N=5$YHD$I*4E%)
M*BM9)81+"RU 7I(+3*3$9Z0D\ZRS(=+/4"NY,-GPGW27:K!MU>=14SR6,6T:
MM6CGCM@8!LN9%,VJ:V4.3%]SS+95-"%A_MVY62W>NH.G.\_AF<=P&/@TG6;L
MB)UB@KJ6;\G$8*'G@/T=;/285;.$FW)NN*>W81SSE?$#35@D_I!:[>[)9\_"
M,P=,5]-P7,;D-:&UFZ:R"=@M9V*;4GDKTUSZS), ":E !B"5<K-,*$*^X33C
M;\6&4:%-CM$E?6:;]S!^D.HLF$E("A%A[LN%A#;KU-RWPMPWO>;&,RUBM'_U
MF>[AXQU7TM,[!^H!)*^K .H:,3#D>R@8'?%/ 47Z\[I-M\5;OZWI&YK$D$Z$
M1FQ4S7+2H80YP6F4/F9.=O:I",1)91#S21 &YX48I;ILY2>K$20\S6+ RI%_
M9C[^<_'4"B1JQKLP2N0_ITJ($G>^[YU7<4ER%7CE6YLEA8=7B-"@B12$3%JL
MM9[$4(++B:C'J6<XZ0J 2=8>.*02%84'\AO$)8":MS*%=:M5 UM9L.*^;"A9
M3RTKT7-;1G)<%RKGL=]IB0NU888K(#VQ8V:_S)Y#$^\5B"#%_E$VZ7C1J(<"
MYH!32P]#[Q,)ERH\*7<N!&&D5;-TX$R1*$J>7K-L*KSXTH++8XKIM))9$L:H
MVT6MK$XSC:7@S !-IBBP@VS%:MDR[:5V%A'!M%UB*I5#U[[0K4][25@TTH+#
M;QGV$%X*:HU5;_*;A^6W$M#>N)[+BF78*PQ5JBXV#OT:=^8>Z L-CGGH* ]7
M>O?>U'HA19QA6F?[9PI=<.^0#5' ;"GL2'(N+:/DV9C5K2X;ZC^4%)7[5NDI
M+(*M*AOZEP$L_>CQR5<WAUPQY>X.1<RN."\_%,^9O7.BWRDDRRI@V+#^F-%,
MPQ(%K@WHC!WA=%0Q?\DZDT,,_9(D9R27Q3+TV;2+@O8X\-"F4:K(6#*05S;0
M/N-N"B/ON07"(*#^91@G<"CQ"W4\\3!5@T4Z&^-%OWX=,ZAK;XD;UQ3DUAV7
M.6GB FTQ)'<9=9L8]27IV(D[$RI:N8 T0&ES3]+=<;8. )@,+]-,ON$/TRG2
MP0M*HRS3^DB="A'<4#9.)?.AFER8A)D0>=)FFN/Y[;P/UUDQ3C4#0RY;<\;9
M C9EC2%PF\=*IT<2)X-&/*N=YBZ;0MC2EB/P@-?"4PZ]H#J@*UX<':I_!IVJ
M_7"CY6 MS -D><.^/LJM@J,U6^2,,NP#C?,;%P@ T)HEFL\C)D2[,K2+VC;B
MKO^6)7#;H_1P-(3-_Q6R(/F5.P]O'7>^)+W.'W,>EE1L1P*\V#O3UVB*?BVP
MQST3S&4,\Q.*K XM2V3 %32X'B4>3,]5$-#R5U""O*1:-+Z[7GUSO7BR?;X4
MZB5\F6JX+R1.J\; UP"AX9^%V.(Q&R$XR20GN>CB7J$0GDCIB12?E.3',&4N
M[2.59][<80*:9$YSGIE;#GY<J5#73A1 S=)[&@E;JZ0X=?=!.D<.T;B:DM31
M 7.JD8K8ND,^HPT[E^F81Y 6-*7&92?GOV&N/!!B_A&05<R+N2UP>7BEB$D8
MP";(N&1J!2+8,4#')AUO9/50P(P26GH8>B,K9X<Y@WIRHU1*^H3[/4LCL6?&
M ^K2.Z746"TY>+?^,O0YL3 2=YA+E6AY3%7ZE]BRW>R<H-)<Q$\-@9LINDC1
MP[3ELK6S$:*X5\1F530#/PTEX,HL*Q6FP0O+_Y:'"@D7L][I</"9*\M1AUE:
MW3E'C^SXP7%Y.W&;/S^4L%T^!\?'6-\\/)(*7;*J6;S\[[O"XM5.<L%:GREF
MP\;59W92?<4<V2\7&<MV,P6,0//+QL6*AMJ>6 +"I]=_HJ!-TYL"09 &#09>
MA7N'33'<<\)?+@Y6;6<*"275+QL+:SKJNN3E/^'/HK6- :"4QQ@$WN^X>&MV
MR=OQ+^EO(N;XU^E3*L'SK1.P+7OB<H71.KCGOX,5^V\LV6U^\+CUWH>!X[OA
M+N3#X,9)DM=;+F/$EQ^44WU'X8G8AD]B@R=>X+1F\3S!?&J&N.'6GOKZQ](L
M)GM!"XIU!IXL' BU.X7P9+TF;BH^24!^0G,%B%_2 $I^'E(=R">N!-G\<"7
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MVZ?<K8*Z#3L4"N=,Y$%ZRF;&3%VKVC=_[K&; 5LG?A)\XR@1^P!OJ)_$\"_
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MRA$FG5K?.0F\:OVZH=%>]1O4^BQL4FO2N'-&*G=8X'32*+[N<,^($>ZY^VS
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M90+8/7JH+09-\7EOS#X_6(<I)_A\=Q'G_&[.&#]'X?&0OT+,-?^_;5\GP3<
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M9;F XI_/(*)(*B@11'EJ6K5CSWEI2^-E^737&6E3R^7XDJ&CA<OZL$69S-R
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M^5I':_0^IR+[!+XG5F!O:X.5'#@CVWXXI0%*F@H.)&5!@,=\3WY8TEI\3L,
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MO/C6HUV&9"W-<&-6G]"&T2E;$I#_X>P/_T_Q3[Y"L I 4ZG=H=]\P#*#LJ:
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M^S",5F7<(\8\*,OOS,GKQ_*4+:/<;10GM.31+5XD+H]SB76HUM$M.G9XZXK
MY9$\8G+T@5.7+/7R-(U3$W/.EO($M_<<UO)V5LMSKP,27GU:X<I#\<"XLHUL
M@R.9*'J+(^5<39SM;!3JLICS48QH/+<+BV9;#[YY?NO.%4YO"4!M C05SMW'
M00KM?63RS_NXJ[6">[4J(26129C+:&V\!NX0;8+^L\^)55>WPT(8^; MQ/T
M859TQC_;4PH75_+JN6&G,94#F]Q7EOC8M(1DJ >[##48/#G%/MP+3!&9   3
M:07<YN_PTM(9@I)]JE_@)IES-9<-X;"PX9013 . IIR[MHVO@&N6\R7)'RA7
M:\-G]>N8_3>CZ<A$9Z@&4C[01]N>[O06QSSC&5=Z?A_.,KG\\T\$3CSCZLE=
MT*MXVS0%W/$5/Q^=R$]N!WNOGVF9SM1_6B.8/60NE+E^<\WR;XR!U]!X2_XD
M? ?9PT\*\!VKW(5OT]QG0DL7XT!3K=/C0KK-7(0330:SU(W^)-SH7U"[T61O
MN6"GF-;W+[&+F^[)GQ/8;X9 "F4OKC*0-]]:TGHSX;P"]EX\AK4GI7RG-.9>
M/*KSHE2Z\KV$UD8(PM<2)FSC7>(.GN;FW47MVYG?Z1G?K)N]7OJ4O-,H?[]A
M:1[N0EYK?.-8NQ;2WC<-=;GZJE$%][KL% #SC\(K7Y(J1).&[.:^A]/571=F
M&,'K[YTY3^!Q#:F_Q,E+QM(W^A*Q^_AXRH=#Q-[B2.E-$V=[A%67Q3S,CF@\
M__)'W2P)1;LHX\)S^"/AX4"%R^O(0\%B7^G+ZLR&R%C9G5$^GO4QS (X.O+$
MQXO/C&:G5!RZ%=88Z=I:5;%W<GW\[>X^7@]SQY^@_5P7*$60E,NXXM%I)44Z
MA._SCZY-8&_FF,V;.BJK(777B;C[)X_G=2YM]CB P/#T,2UF%$%#>'/ASO/\
MT8(A%'.H#.L,TB+\O@]NBL)6<7RB42'ML4JLOX[O3I 4_PO+GVDD%J!IS/5X
M26F<J#AM;CMX26Z194K6F]4(;AI<!FFN/]2"8,N""ATJ5H1''(1P$K.<9" >
M2C45<$J0?DPDI58KC4V+Q41*)EPT>5;9QSF+>K51V7'JET0LAH2WNQT+X#F2
M^YA;A&4BS-4;5_JJXF7-J?@'PD-E/=S<.!G%[(2;9:M\ B>;%1,;\'15J.@[
M/+1C!%6(>$5JTY3"R-/YG,]+F&C7#$'+#$S=0W"M>#V'^UBH'.=GZW\#%^]F
MU$?*F',MT5X TZR,>15L*H2YSM*00UHKPT*2OZMH7@UQ.ELBOUHXU[2\2AXE
ML$:XWGUDNS!FVVL6\[_DC]P4V09 #*XT:E3&SA93;'"^5CY6$S-/3-)_R6*Q
M% +3I*T40UZD''($0>1K#J(0[B -6.>!_^ ^9X?^ 75" Q?N(V>VF.0G5>T+
M]I5S#%;])8+47"'(0^8T(EW.8YJ\A? <:+]OG)?#[@(]R-H]O5,(<X?N4W5N
MOY69G(Y5@YY"/M.P'OL ^1Z=6ART?HG"O5A(6>6/,J>E,GWT].K8W7*:'3KC
MDE9=S$X\$<'L,:DS"B65H"M"<U)D457F-S9B!*V\2(YL\<3RL#CO<6X.9"11
MSG'?5UG&<F7@TFM.O;K8Z6&"!=1W1 8J8B:&*>K/SE[(\K/XM%SI>"<?X$Y4
MWGT=81GT?Y/08\:]C6T?17:GVW@[S LN3+'*"8NW$+#+E%/643_G-,U1X'YA
M^S".(>.6'?1EZ)?D-/(/> -JD'IPP<7WYPFXN(^VS= VTA/+3E'./]X=YTUX
M\BV&2D%RX/_GD2^,H^E#DO6/$C8E8A];K%N[/2)9$X=Y'+,/VG FNEAG4"1I
MJ26!3D68U)-\"(6FHJ&C4)8D*8FXNA8'E&%2Q?L!BK;%D<XZV2,N0OY$PQC
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M;\4 _5?6G5M!KQO@6F@0JS$TRL3KNN$N9-M55ABH=_(W7 <I/4Y!W%Y]&*B
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MFMU>?*3O'&:T@<,4BL&]\VND7M.#H[ZG5_\.=_RHU'1V6DD21#3+F@1^=NI
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M$A2!19QC394%_XLJP:-!%;TQ#82JU/"5W\V#: BD,S%!'1*\=J6GT'PB#8%
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MA?C:"58_4!C1;.9I6ELTO?>#KR%>MQ+\HO43BA;^5,O)]9GI;*P;6096)LP
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MB<*XUJQ0JI-&[)QMQ,H%[V:.L^>87(0;S^AX#L=QA"V"1V+SN!3AUN@37=1
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M"VQ@&H^V$:JT;%>C#X1N!DXT%)73(+$,TT1?P$XY[P!> 3IH( X$%M72K99
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M1"\V32>O,&AI)":B?LY!<M-/[7@S<J$R3PGS.W8S>_<G_R/)#T"S.CC^]#I
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M^'<GW)FI\'=X>JVJAIT(@E(AF][Q"'1W5J*[LS[H3B1D-_<4FM.]02"$R46
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ME1(*W62.0E(:<:(6"%Q1TB=S(R@E([2;GOL+H5*MRM6"IV&Y+A;W:E4%[>:
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M]"Y[V_$P]]!TSVR-L-&B>A;/I7+5^\2G&H@8R=\ A6C9VF)-T^J3A4P>)_*
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MKAC!)2.:64\O*]/^O_^2Z-Y)\LC_Q_\/4$L#!!0    ( &N!3UFL[/"]'T4
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M($$E. <3:-1B8)^9*JER3^ZW0"JIYKLY0E+MCLUE0N<F^Y-Z?C6IZQFN6.Q
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M67B@YSKH:8*9:9BZ%Z%FSK+"-,(&Y8_@AN%$ILL/.(4&3B301'>5OE!6#%4
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MY5R&2'=BG#M?+8XD0_>&=B>F(KT3V=T$;Y\$4_+\_\B.KOW]_P%02P,$%
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M<X>SV!]KSZQ1'34L!JAHX%T3:,T=O)!5.&JCUKP)=+ZZ/7@"\:G6YX"E U@
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MBS:.O 0_=7LM( (&M#(F I-L*_^\>UKRO*&K;*!V?J!DQ.0%Z#.\*TAW:>3
MGH%FB),W-Z#/?<&'DEQ9'*?C"<E&^AN>LMR8#KP^@D=!4K$;)GS2=8"=YP>N
M.T>^G9@IA0[.)W F$8]Q;W%LV.PDC)!K$?"P?"$F?$K9K/??NN?Z:&KPB>>G
M@\)A %N%8Z(S@ D-TR2%U<,+4S^APH5PPB.6K2V+]VD%)ZXY_32&5X*DC!/X
M+;\&%@GV@]X-&#;L_X&G<\.)+O1;LJ%KM.?S2:;N_&,$0C#'O[)UX2G?@E8>
M:_'/3 U&33$#_0T=V\W,QQX+9CZ"C11!RM7'M>SSU!\4?\SADHQ+7L>_8O^"
MXJ?7(?.+PV+N;C S+BZ3QW /8=U)6/QVS*8S'R$O*7Z(9U'\[%;X_LQG94N;
MA*B1PX'/? &26,PNSAQU\8MX5#9\ GR%)V8WE/ (R(=RP]4=CJ6^$0M@9RA5
MON*-B(DF!7K*@$$M))XW\WF1O!,<:5A>_"!,0/$94T(U;+G]6]8/T^3E?7LY
M/Y0)Y]26>O-0&S5@]"3AV#*N][4^0Y/:!\,=ISD47_F@C)-;9H@V9:58RD?L
MU,_($__"_N*;%E54N7!ZBSU?W1EOUU]^Z!T<]EX5_6D%E]B,&?K0*2]IPR*;
MDTP/>/L >(P?3A1S'H]YA"P3AB1N.(G"00H2"+C.@-(HXLRE,>-=JRBMHK0\
MI9'E"1R*U*::$A#PWU0*4S#SN!>E(E'Z6)R >(W!.N&D:1' 61 !X=#W*.$5
MY:*0D>K+=8B_]( N2-%((DP@JFBTHM&E:31/.PXP.09DZ7/0JE5OI[3OPP^4
M]H<D;:G,J*K&.*#\K0#C$U5=4LY!Z0'EVP']8$2^@&$4CBL2KDCX<=FL@_XV
M36$BN$&%7X;Y@+@">/4@2J^-2^+LPXEV0CAL,M&$CMJM^:W]N7[NP\F1?JXB
MU8I4'Z9[HK. 1=ZH=H<6JMP2TJJ7!GFEF%9D^ UD*+T=REE$OEV@1?P(R1+9
M:9\'?"B47RE%0U[ @2BE5-,@BY* 1_%(3&+;944T;GTG7W \$LRY9,*Y%"SX
M$W_W:<1@.AY/:9.=WZ(PG=2<X[!><]Y=GM0-KSV^O/R;9K8J[H$#ON43!)]2
MPV!(PLN>45]FCZD:,*-FJ!LGW5+VE9-\'M\2\>O49U1?!B(@"F] +S%:^,S]
MLW? >&(<YGF@2T5*J QU4*CP-O@">((8BG[$X(S0<?:>B4#&,48B@-6]Q=#&
M7_%_+C"R!4,?#4#B"?+CH?\% SNHC[UG'DOO^A&<PRV#__[.D/#()PO7< 0O
MB#B\3 S5BN%25FRE8BOWD6Y,IH(@(XE3H/XX'J:^/P6JETYD+F^O82B:4Z#*
MA:UJD?KA6=2^\@P&J12^@-&&PO>5L]I7NEVLXIFH_,%K1_:S#KL&DYH<@Q4U
M5]1\+[,BX^0R&A)1K,<2'B00!@+(S1-^15X5>3V461I* UYI\4&6XV3$.AE&
MU:(!?3$U47R;)HMFA-$R*DJM*/5AC- HSJ"M^Y1:D[%&8RP@W<'!?>$)*;Z3
M!%.5YJO,%1%61'@O=CG#TVJ*W+1E"N]+,=DBC<BG#-8-,5B=K:23'BK"JPCO
MH7+:I#'@K)1;6;$VLF%FV9R4VACZ PL?/DXL.LZX:$63%4W>BR9S/CQ*7:<\
M&%(&XQ3S;@4/O*D6O\ ,14*9H!KK5J=\6<2M4ZDHT\Y1D;D0A'@4%#U\"UV(
M$1.Q#L=DUX20=6OP)/=2Q;*GEAH!S#F(F9=EL#%OA"E@VLR"'>5Q$@9ZZC(G
M#8:1F4F5.E'=H/OIM)*$X=:D,6FIP+H]S@>QC%0C<:H<2J0QBSCMJZ"O%7P2
M4<R\YD3AE/EPGSS</.3XB:+8 >\GV9"UL@NXI'<K\V@5KZ4U5L0G;"I?*@*T
M&F'?P+@<8V@TH@0^S*#U*\E3W9L51HXNL3X%_MLD\M9_M9S3&\K,W&.Q*5GH
M<S^\52$=>1]1*8IU+JESRR)X7-F5,LLZDKDFY%SNQUXD^C)#&_.B602W8\1@
M/DY_JD+_8137*O*NR'M9\K:\:"K[*0K_X)ZE9)$PD#4!6-T%MB<2F>'E(AC
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M!^N'0!3[SL]BONI_GSCGO&#?_8*?XM?GBX-Y>5=&P;:U>@[E.A/!BW]/,>9
M0N8[MRLH982E%M*M0O^Z#B0KC"U;=,#["?DSQF&4T-?8L4ZGD"7L"]F34ATG
MOD!,B8E(^1*U+0R+N%%][3&E/)7]R?1)$E" (-@1NX41:&N1U+BI3=[:]@^-
M-(P%N<WRY%KI<[4[I&O"2$*9-"H9;Y2BO4XF&GD7C'<_YYV(R[PQ<NT:5[1U
MSDFYIG0%>#^8")2E&%]UFG!##AX54=32%1<CBK;F(HK*Z6LP485S*5?PR,D7
MC7+WPZ:GLK2V!T%TS@XOY>#Y/)&J2#"#$Z<;P&N FR+&T\*$\S5X> K, X1
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MU:#\.0\Q;.1,2G"#"(F=.2#7<.L)D%@R^@0#;M0(XI:3?ST-"LO!5ZA:L^(
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M_54U*) HBWD&,(\#Y:+AOJR9TB2!KT^TISJDF)MMKLK8C(QD,Q(D7&4/4>E
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M^Z><OT@&2VS[2"1\'P;PD'YQNW0Q0[W5K YB PX"C-YNKSJ)#3B)ZDILR$'
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M1OFYH?R"C6#7OACZX7\$M00T"Z;?9W/''Y]<-NNSFXQ]U_$/+Y$X1R+(3H3
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MOM6V3*J<A\=V*-2=M6U8YK\@9TR8VQYS(>QMFKL*!U1>H' 'M-\O/) @PB+
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M,XI")\A7\<LT5F#%;T0_"F./!;$#]CV^0+OS*I+;49(38#W%B4K<D6P(\WI
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M;!DC0K%<IQ3(;AW@4HH[&]B2S8436[+XD3G+#[BYOTPX#R;+SP:\A'P;]:"
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M-62&JW72'9' H<^]PXQU<?5Q$I1&LUEMK\3OL"]%^K#@&)" ATC [DA+_%)
M%U$<'SE.OHJ_)1:-#ZNS[0-I19KGEVLJCA6^*00OQ[W1=S;,/8M)?/\ D=YF
M'U :@,P-=6&!/"^(5+-99A:I5E$*E3V/AW=UVW&IOF)TT1=P.%=WJ)&MP[?
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M58_,] 6/$Y="L&ETYKL@T[S _2"9 ^G)'-@<]B+-\?PR[&-G5*]A93@]_WO
MT'[ _\; V1='2RP&IR]I0*;S[ Z'+R4<OK$&[\;L*$?GF!62*.&ZUBL&U9T5
M%A&5*UTJUU99FQPM2C)1OHY0^>)0I[M$ZEYKC6;$]W0S2#?Z'B8>(<7,9X<H
M]P/_ )X]?:P8?B>:9/A;#ME0./9:W/K;>),,6(F6)40'! 72H.AM@0&B2#.R
M_&--T\\O2'U+3LIHV8SDSCGZ"Q4T 8HFUR&'I=^ ;ZA QCO7.4W<)P\^NMB<
M;]9P"34:6N44I!%/#]I,HF<FECU /ZO*",57X!*0F]NX0LG99=NDU"2 LEND
M@,*S#'RPK/;3!O1"^C:1;!F2/G8D@" )E3$!!*&(F "")%3&(*&29 '%.*,N
M%MF7*<D#(;E!Z?!ED-R@CSIU#<MQYNWN<9?[G=)"K"]@'Z[<Q(4UMO#M"7F:
MX?*[]>X>%:(<"9Z((LU)K_$DZ:&PDJ$/=5-!-@'2-$W+S.#(%^2AZ.>94P^=
MFEJ[DNYW@4*NW;!*/REZR-Z3! Z+[(NJT;&#(Y[02*9"=@H@AU1US#YH-,X"
M[OB/STP0'QC9%K+>+)-D#VVN8"4L.XBEY1Q)#OJH=I0X(+/\,I 3H/N<@B[
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M$&HP;;J63?I*)U+O007\1.E)DM(CIT7CF:<Y!\83T(C42X)&$YNA]FF"<CJ
M_.9H^WCK-B2T%@/U96,1*- "M_OH?&*AE@R@L30GIZ9":VT,H+DN1#;WYY!@
MV5Z#93'N"?-:M'X\H,+18CY',&:GNE:J$29/YW@N<>&W=WNP;3"\,:E=@<@D
MC<\&G6>3' D*Q+W[Y+XP()SGN,3WXC])(]J(.-)?636 8B-X]H-7A/#BT:OV
MT6#YS:Z@G#"72H%DXMC7>_^_A>;0,ZF+!C)8]L\0M2*G"II2<QC+>B#C]YY6
MNO#%/Q5CHDR=X)2RG.5FG99_SM 3W0,E9F7Y+VK^([J-I:M$LQXB%[8PR\'_
MUN(TA^"S=QI@!U!QK=%/CLVBT1)#^&O8:EO("GL"4T1;P!I#1%U0J+X-NO_Y
M]H]FK?AM53]D]/.J>1W!1\BD02,UK"Y5M/!L#&>&J<I_]S+=!,6;JLU2O5RA
MSLK50K58+EQ3]=)-K=ZDSFIUJGE1HAKE!ZI2JS8O&E2I>EHZI2Y;U=*L+S'U
MO__M:V?;D_-:0L:(EV&9[/R% >;-/US$V"54]/\(^;[Z'3U!_0M>!?KFCU=(
MNH#K;(2C!R_T/WIC^;VQE_=G_6RD\Z'><)X9#/"!H. EX9<@9WD*;M! [>+T
MZ,2@OF)TPUE!-*6B$4#VXE?%+#?[:MCO=^F[/$TI\\0-^!F?96??PCW5*<T#
M:-FW\V47I@;1V', 'X+[@:+<,Q1[/@#GYT<'W7P.[T,9$_D$\3<,/K2'C*%,
M+<_]V=5?@+8*HA'$"?FU3TF+]D?P&.I%_>WOZ!\^=897NA#>'MS^V]H0WL"B
MBO//?^2E7/[7:S7KE1ZTQ%GW,T9IQI8+"ZE"KJUH()J'B-"0>86$"OYTH8-[
M!.LGNMNGN B^!U]R%[[!HV_8-G!&EHDG8$&L5M!7@.-:\+&1,D4H[$]Z+3:;
MM[/X'@67O/2,*5S%7RD[XY%+JMEJF8J8P5R:QY0""+KO!=V9;/X58LX&:Z*A
M;I[KV9 S(^W25J!41HS5<ER'^NZGS1FZ@@4U%!$_/H=V^Y[E=F%-  2C/[%N
M+N+"EAHTJF0/AL]I;W9%I><M47U9\JHQQ]NR3)BQ%8WJ3$,YF(M(T*B87"T.
MLU03?CYC3VCLGK$P6:_^3V4X^G4ZWPX:.1/II4_I#CR #B\)7FXH.]&?73 <
M6;9B3R&?\0+.U\=\S_9T%S.>8)[?"-X#$J7A(]5"4[_CJ9L^VE&Y7*94*% 1
MJ4#6J6/Q.]L=>KS1:A3JU'<'P&]:+J#8+)?U:[G87]3ZH2H-2'EZ%RX--P/&
MT3VLN&PT; 7O&)Y8LU0/'>$'@ACM,U;(5B$"P8M"FC<=O0H$!@.$_;31)]>E
M<Z@+SXZH^"<C$PA73"#D/C6!$*6].6\Y&P^@&<_W&*K&JW;XFL@0B0$'8&5Y
MHF#MH NEIC5Q/JQAKAVE^-5S$H6LS),A6'/N=,"I<+Q$ !$#0+!,EN,()&(
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M@V1OQB5#BJ2JQ000)%4M+I @)!$30!"2.%CVYM:"^T!)C.&+BO!+'5N'"U\
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M&POM<5]7?=/KYVNLP2J2F,VOS=N(F%&1]2VX9M>P)J&>&_Z>F=C*Z*?OWIC
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MI7TI_X92 ??,S4&AP!-7#R&+9&A)NZ0+H2[<7;RPG<$ 7%TW'X"5ZSZ^8+I
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M:8*-O27ODSA&R0P+!>UL*P%.SC]<Q.4E)/7_".66^AT]0?T+7A+ZYH]7Z+M
M!6Q$IPA>Z'_TQO(A1BM8+K;SFJ3Q@-7:3(?OM 5.E-I*IZNT-48112#*78UE
MOODXM!LH+:D<ZP0-W&C+5#P-ZEX:%A2VCBN%(* <^ G\":M9"OKS3$P@&M!-
M*&\ ]=VP'.<'M4,D^^CVWW']?_OO=]V$$L_R'*A7.6CKP+,MY\?N!?H^5(T
MB;IR+B]K*FAK(L>U!;7+MCN"*K5EM<-T<U)'ZP@A$H5HUU6Z788'T$H2E+;
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M#&HM">JM)$W=7!.2&'DQ\O8#L/^USW3> R\M#EO%;L;C!-HG0753$F<S]D.
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MDVF.3$H9+CV1DLR$DS))"NJU:9I+3^FDPE+DCY"'SD.EB"'^K.PZH6@:6'-
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M+93=+A9"^/F(P>_P3\?3#J#$]TWLD,(W(D1@B?E8Z#Q4ZD!6/EJ'>[S/!P\
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MATS\/V^,N(C=O#1D!3*EE_-M 7KFDZG?+?J57'"RL@<I4=P?NO*U ]'N%S&
M?+U?X=X3=V;+Q*I5I7/BMI/.IYST@)3KC^]*LF]LC;G?,G2![%@[WK]<M*&P
M-+T" !V\>\@HO8^8L$>.>B<U2'E,L*LN-4VH&YLV"VI!@"Y01@,F$&(ZWO3P
MX<2AO<M?8.6'?BVD,L,F__Z8^BN70Z749U-I5%(+*Z$Y J(<:'IJW<S5MG/^
MQS^9GZEGR?1O=-+75#P+22N*N]M+K+U6 5#F:?O3S#W ]@<&,<;>2+W]&0)_
M?_[&&U"<>P^D%&TX6IEK4'"C\<UI#C@>-!#JF@ZM'^CWN">)G1F/4KUAV>')
MYF;&"5Y3H?L>)#;-1%M:WF-2FQ)*^/1[37WWR!I]I#6PBL6SAM+= <C6_!MI
MCL-9(M;I&C;('6LKZ][]L86AH8Q7'W&."CG(PW$<:$817H#"17#81-[GX:%>
MM"Y<G7O*:CJIHUXSI;%I ZT8:$< _=YP>*L>>>QBF(1EGW0H]CH-C5%6O@9W
MYXV @ 81D.1UG^W.LNG6$AB=UFH]YB=>NGT*$1G<D/O# >$ZGM0,3."X<\V^
M_^9^3&BF0"/E@)Y^FUF/\VQ2,#IJ3MTP2TT6'Z&'?B-XFGAS>Q8?[F&8SEHV
M][2 ZT !,GGV(.X2]''XN%-6I]/=3%K2$[.4:10T9\BV?_S#1+72OPXFYSYW
M%_YVX(=CB^= UG!>IPR>QP%FA!/WX,3L.<5Z9/^Q!XF*V099<#@M 0E2=9_,
M<"]]J7OIBX*KD.7@ZV?X6'__(I2MH^#OH"L1J5<T:%Y;:RJ0*JV1%*Y:VG)T
MH\3(34LT^/Y.](=;.KT.GCLAA++XZ!SCX;?+8<1<92,P-;I D6QY03J9[(HN
M4X\8D7PC([9\1T&^3'-:QOB'WD?9#/U/G$//*_\_>V_:G+BRK(U^O[^"6#OV
M.=UQP5O,L-9[=P2#&&SFR< 70D@"!!I  X/C_?&WLDHC"&QW8X/=BCAGK[8M
MA%29E5-E/@\+5IOG2HK:AU> :7S]4.?UA<*U0"KH7;'Z^IXXL26*'\9VXS$5
MT8J#2CQ5[,5R<]!4GP#JG8&2*68(DTPQ=_5F==>83&;4LQY)[W.3^:,8/8OD
M\QW$_%9[\\%BGJ:9M=)4)YF5,=0+F7UQ6&2Z<QBPR9[*&1F3'+1]>^T%%?;)
M&8_*7EC,T)W%0[;L[YC<:::?A>NZ[^%CYUI'>?OESWD?%ZTPJ5RLK2C!\I&0
MVB-'KNGF0=&I-0;3!UU^$?Q>7$B"KL(UJ96O%4V/2"@B.H3,OEVS&G7\Y4P(
M5U+A,Z154N5GA@:G<\X7F>&LAGT\'(#9-3>KJHA^Q+>!:\G,!@0QK@CEEB4&
MIPT4&0M5)X=^I,UVIE@5*[0.:+6AX@6E<]W=SGBFH'/4JGBID(7+H8:V)CVA
M?9D<MZ)_=L$<&%!<VR(E@;*A:;>L9+_;[^8Z=GT#>B95;$I(*8>Q#OS0_L"B
MQ)VEQ'^CE 1_V*MOL-$Y(IZM(J+]2QI:UPSN7?.TA:+7@$FL%\;23$%"RH6W
MS]'IL*N5CE4%&#9EX$^X ,/QSJ$D)S!S6<'!K&HZ>=*EJEDE?+P!#%T1),F0
MK<YVK&L'58% F11N2>\F"G!1"(T\ 'PQN11I/%2TX!5 1>UO)D_HU+_,>B!6
M;8CA<5?AE+21%Z$?ON[<""V=).@ZSSM=S_6")9+K@7W$"=3'S39*TVI 3X<O
M]J#C^,VE*4Z'+BE*:X9$UMD>PB(MD0:N4D&0"J-#51D]CVZ8U>8.OQ706^45
M%/4[%>M.WAM+FDVQ9G1*5-:<3H(I$#"8.EH/:X#$D;/*2QC5%+T '&_AH1,H
MP)D50IA%L]06-WJCI(WG4!BZ$-!R2,S!P27!8?%I2[?3W6QNN3-W-QMD\+VX
M4Y6%K\(S+2C@@)D7JV' ? V[VHPT^O9J8A9 ?F%6@0P(0&.&,HN@_T.Q%DPC
MF1VQ9'[A9,P$FXMWS2R@N/%FJ^3?6V.Y(>)A3!45823%ZOI YF]JCW+-D!Z@
MMSIR6D35%%P]%GD8)_#8:>',V$/R(52TIA;PM /\GL']$*$X_#H)FJ@O\)F8
MJ_O=*U[/Q)<S5O:65[-"AM/IEX2]>\A\L*?M&4^SV2IDWL.#D>]_TQ2Q&3YW
MM.:>K)O:]D1%(K1^\C:36R-TKJ$MGV\,_0 G;FAO?D2P0VOH!T<A@.C:.W :
M2#YT](SD<=!]T&)+(<V 46B\N'8L0KJB2,,1XQQBA^8P7*4Q,U['TRDS0>2]
MDB7-6D@/X$\XI5ZO[97#/5QVZSSG'"":V@;)%40S,'.@F94QV6ZB1PY]@0R<
M5T%AV'?-H^]!GS6_P9EV,)?M+@)(UU:V(T![3A$/HYHMCTA*'#+.*BN(EN]
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M@W2&;V_+G-;L,YUJ?VDP+XW\ 8G41Z"V'=GB[S1+ 1#!DF_U[M<C8V,W?9S
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MHXLJ%>/S S5"]9[82NZ4]J!K/6IS5BUUNI#RB0)4*/ZRFI)V8DKL&=7>\ZK
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MR_[\<8%?<-,YOY,/?.2"SY/1URC<U?;+32<HKCJ19'K7SW^?5X<AWCIN5!2
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M2$0OAW8V0*C9VG*D18ZFH'59VKX-;X0CO3FK 2?Z\UOZ\.!;#OMX;X]5;TT
M (_#L9*B0E(W &M2=Y(Z/Z^O*,EVCQ-7"LT7UNW-ENDN#TSNLX*M=VG;&T'@
MR.T@[[X?4+CX0^S!C0J'A&-"&[AR[EOMXJH)I( #NRDO*KNP2],%64,ZX,!6
MF0^,@1%FSGL0BX8M--K!H87 JXS*+@YD8%TPL0=5GD>[?,N+V,_")\G&%.2U
MH0>8.0$Z A1):Z @))V*_AUJ&PJ87J1# (OP ]EJ#M:?YWX21PIE,V3VU17@
M[("W%&"[P\J8<1QX"C?V#HX"L2]!E^D'$A"R+,"NF7]P[4F,]7$!7R%0UD!9
M+66-_1VJ8CMF0G4@19-#&Z*^1$$M+4:YA&A * ?!'])BM\83_01+JTS1DVVQ
M@EE1(-9HMT(?PB%>P-_&H1R)U5'& UM MGX*5#=0W3>H;OSO4%]VZ1OQQQ?4
M[OV0,Y\-*6BF)ZZHQDK)2:[N1#B,/T;;$:CSN;@'7^B>:4G\_?GU/CO:1_^T
MWJOJ!&XG@7]958SUI-(OZN-I(IY;16+#QWBUT%NEZ=U16?;2I9/81^'OW);=
MX8MA[J0R#]0?.L3_9CZYF\STQQZB%TD; [G<1BZ9AT L=RB68+O<IUR"[7*7
M8@FVRWW*)=@N'RF6=TZ0F;'QC?$3+J[1!8J?O_Z;T[W))2 LP^FC 8U]./?$
MJ/0_";[_%0@8+]N4CU^-&V)MX(U[QT@;[UPM=U7Q:H3'@7I\0_6(!>H1J,=Y
M]?@]E![+ ]\7J>^YZ0T?!AYS0>S"JJ=*[*T&ZPOTAO,%$![.!%(Q5S3M>D-\
M9(/=V5)>;7*<[*#[0GJXK#B?,KD9"#T0>B#T+R3T7W.0MQ1L39'G$10N2*YC
M48Z?ZJ$(^H\J;'&A0?L*$>+['/^G;.5;!X9OF\MWKQ%A(8Y=8Z<' @\$'@C\
M_@1^&7S#FC_ \!NLL)=6CS5UW6?$0WVU+N_'7"1W&1');E.9%!B=GRLJRI5<
MO2DU)X/*[07-=;GO);K=W](C"58+YU=-M8:R*_,+#G4\%.'^9A$Z>RY^[9:9
M@.OK(<]G7U1$?J_H.+V3V^+$6'/UW%2L7N>C5\$7QOTN-.\9;??%VCXUHNA(
M\V4TK7#5?J3D@=J)Q-\%4.+WHC8T2=R&)C$.<:7<7L^D_F9>YG;]7J&8&[1-
M:))X.)G*7@_![4ZS_TN5CYZB>Y/\JU;'[FPE/CRD_U)F\:)>.$XR4(= '0)U
M"-3!HPZWC:@(T?2Y8,K\ZZ_%4=<+>&BYD**6\P5%-RM2AUFE*MM*:??Q 8]6
M%'BV+Q[F*V'0BZREZ>9E-6M/$A<#GI,C#ZO!_7C6\WY;GK];F_W)Y+/=:N^&
MGGNUPQVCK'S.V@2]ZT'O^EOW>=!.& CBC^X?O#,Y!!OB3@01;(C[D$.P(>Y$
M$,&&"%K*O8OR6@_Y2>;T'?K([YBV\=8G@K^[/%^U=SQ0B<]0B2_5+QZHQ&>H
MQ-?O$0^:PG]K[;YS;^B1)0AD%L@LD-EGRNS>.ZHOM5#C-H'H/U^\D?KZFG?O
M)__?H3DVD%H@M:\EM0_IHG'16P:-R6_HT]&:\:HHS[.U_J$\E;IQKI5D-I_0
MI_/8'N6-YV1T2L?6,:X279=SK<C.;$RFPK'4)2K;+YIR_J&=R$%SX8<ZJT"V
M@6P#V7ZX;&_0$7QGL<SU@@Y!./1WU5I461EL/RX:M4HB9GS"-%2MV2H,!B^Z
M3AF/I01GT(?TBMF9S<'G@HZ+S<'WR8/\R5W+O\HC_27IFK,!73.12D#7'- U
M_^%TS4P\WETCGS036,Z&Z#=)##$:/W)AP#CVUW\]-,R)LH*^#KD.EE?E23R5
M3:;3YB5^\PVOLJ6^@UL5QB$^BJY@R[Q*56:MED-HT'&M%KJ@;_&S50D]F^W8
MNS8+&[E9#SUS'IC ;'JS%MN+CX0RIU-\N[6H1^KMN;[;W9Y+]HU<9O?!719W
M<Y=9T@HYRAUR:S<F#3EEU/.CSKL5X=GE;KDNSVB*S( ! ].OK'FB_YK=&G<C
MIL5CVD+GR3!=$# H:L9TB9E-%8=!43/?)S03#: ;Q9^X&67DY;6O$I)5G=G?
M<K&=IP@)P#_+*G,9W<EF^?2G!45JSS/LPM9X)!U!X1Y"(#I"+HO,JJKRVEJ!
MCDM,DS?E-=WFM R!FS)$S#0Y/7@I3X%REH4_D+T)\W$HV4:!(GY*%3YMD?4
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M5&57-$B:[UIP] L6["9>:"?X)&$-KAGH(1$)5#>CKCV\J^D5<#RG.>H*3Z"
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M@-/;G! AFQ0"+RMA+,,TE)@8(B3Q^@(8U&YMW:8\BUP^WMGDP;0%VOX+]'9
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M:Y9;6+'N__'/Q7M?1 +TCMWL%\9]NZSG!A5S@0WPJBU^%^A3&.F(]I05@7?
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MJY&KQ,R\'//,&+6O#9.+C.X-Y@UU/ID,_.*V4PA%,+?=)V3OZ(AO ^+?%OC
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MXXGV=+":+>88G_0!KM_JWS^3---8(R-/V?6W#L -\!+,.]C1_]BV9DBZW6[
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MVQ;*PDP?=[W,,)<S+%6D0_\G@5%Q8_.XL?F=)DE_G$NH1;; *U:?TYE*>=/
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MPJE0S7X*4D!C#16[-@X(T:EYK@.W"0CZ)-16O<::S3=4A2_-47: M>;C:B.
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M\4 P%YF!<&]<\8,4Q:<[8GRJ9]O%6F( >I_5)XEU?C3H\0M?*O;GU;S!SU1
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M]8I$J2;,!B/<2K;7U( $G$ ^)J/#"8^OVQ6G"V9@ ?USJ<Z%>B"]7K1_T#X
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MZXOE@!NZB9--HD\V]_\R?_9ZV1D^'E %W1MX:Z'0FBYXFGNKX?1[''JA?M.
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M=E:V2KX:<-1';/Q;SJ0ER#B+]L:S:.F_"/JO\V'RI]Z#W?@=]/5G+1'D:[J
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MFBYP9:3)UVO--I*M-9%VGD=:A1Y2J57;^1;"5S-\!BD*5?[)5T3^^]]+[>P
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MY^V$C"D*C0_55:RT3H;JB=&H;..Q5G?#]IJ,5&(*M-(OR&%ZHC,F72O6[<6
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MWP"G%PW1O0Y4'6M@CEF47:S7Z2BY46Q8;XHPJQAH!PKX^5_>^6D9:UYSUH@
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MWY8==K[<">ZAI FZ-D%S6E3$H]J& /Y;!KN:$* /FD ]'&8D!,VH;$]^V2:
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MJV3:\_0(Q3MM+9T/RN- !)@WL0,7B4H)7Y>^ /31 !D"F1LE:9JV'-T61(S
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M"@ !* )/ '$%@$@HXDH D5#$E0 BDP#BI(#X]0R6]Y6E$\^'^LAG6%#E1X3
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MP\X;@!<!E4(%V.Y"J03$T2>AX 2N*DK+'L5IN4S;4.?=]F(Y8L9@IR_!4 C
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M;MWVCI%JKH8M)PMSM!#P\:HXK2\]R9R&<=0^<SC:Y:_;1/"O3T_[T(]T%Y1
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M)3)\HAOS6YO=M6;V;:B*$A3Y]YG+*O2E)%8 H\G#_%3 Y*/,&L9U87=@R&R
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M%9Y']NP5+40[RA^@YK$:! &7*7HD:$MV4<DNYYO>JCG,?GT?\QLN.*!/5&^
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M>XRJ1\&ON^H+\I$\$YA>40>Q)V4D9.I""?"_?"O_=OWJD68*VX]^_,-'=98
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M#&,3\.5*7&?]BJFZ19:BRI-2RDKKZQR<D'2P3V)&9EP]&"W1$KLL\XS,8'0
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MKC,5AOX)!=QP+>BNICN!_F^KM[<,?=>>Z#YBNXAI>PD'^'UU]X9Q0+:]FW$
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MVSBJY)S:F(_4/6CD?<3%;B!8EY>\*0* C,CP!W41@-LWU:3YU.TTN[U=BJ^
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MVT)OD0[7*\7W9D8^R_"E09BK8IN3]!-Z7^A9D_1$R#:<HK' 2]/0)VKEJLQ
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MRC@;@I4';Q^WUVR-GFSR@LKV)PR3YB>"U@$K#]X^*M263J!O'#;/6Y)(.VY
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M4OF6L*"X-F(4H;"W6!BE=BF?MG<[VH!$5_KPVC7;[$J41BW=[,F6F#;Q/=J
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MIG[\0R$/!))5S@I0"5!YWT['VY&*CEKS-6K8D&%K-G28I<?5J46*FO0:,/I
MT.\Y(&G$XM]^$H*YT!#!W<+X'S_*Y?'^$T+H=B#M7^#HD]-L_(B)/OHFNW6/
MB$$__G)7(DFDE*/:CJ\2R1^>[_AS5;=E)WZJ'VN(I+^;2%(HEH_YZO_\6SK\
MAD0@/76MVH'JQ7!*?LG=_99($"1)T<\6QPP[;W0%2S7H%HQN],*,")@^E_2U
M%N&7*_MT<63WUB(,KS (7_MU:8UVDY7HRY6X("\$C>0;;"!V73^_WBAA<D_V
M^#OU$F4R)9U=P2N2V,HUVC5Z8;+RZ#OM"ED+&DZ)@1NPATVVPW9OD-RN2%R)
M%]_I</VF3!(1"\VFD[Y*FZ9>"47L^.DFU*N.%HZ+&,..1(0;D<2,GB;BQRL#
MHM,4YF)/9QM+1"H+ZP4RF&HB<;QR,2"=X3KJ;PQUN!VN;+4PZ!A=D3Q>:?,R
M%0[Q:<A&RW$C&F"N7R1",7^\$E[R/N84A)Z =M$Q0T&H(P]#D3I>B72W=)'P
MB<C@*STS/_2[9:L7BO3CRIWD:0=6S!;R,VE:"MP4NC%!4W&*BWTGWC8&[_[B
MD[P+J\B\!J/Q*[D0W&_(5>919*ZE7R7=DTW'"UR5FQ4=:^G820M";E9+V8\_
M,&T_?F#!=&1C+S.GXL#O:B&GN2'+8X8PQ8V*&3#:3M;' D55&/^-=6*R#/F1
M4V-9O(RWXKNQ8#Z#XEL$GJ_/HA?(?DO=);C-$3\3Z;[K@WG\Y[N_[^5\)Q>#
M.*?'E')U*SF46&;$IF+R4VH%Q.>:&!S[X\TYL]R_=HC_GUQ,CM_3;B]T(D<R
M^5A\?YU8?G/WJ1F3["F7\2J*[BU-*?JEVZ9NJ] TX>"G7V>JL_W7ZPF!_/0X
M=F8=EAFT_RN5F'Y1C.38DC&/E>2/?XB?R([NNP-\B\L.VB(7JXM<JB]R._:Y
M-./HSS5Y^H:Z'_^&'/]KV7%3&'CZ)F?%_S[W<FI\SDJN'MAJ#H,?<HF4>DA?
MXNE'26IH]Q9GE'S[(V1L)4VF[01>/S'@CH5=O=+HP#-!5&&U/X#;D@-9Q47W
M3.+KKZV0U H]_,[>"Y$=TY26GOKK\,/3IR:L/M_QER5MH/28[4=S+ ')+RGP
MG<,'J3>Q^V3ON.S6//%D]FM^PXF"_SMY&]\][&O_/&3WEA_K$)O'?Y)O-IQ0
M]'7&]SOQ=\Y,)SP<VN'O4.+%_9JZJF1 87Q,_UDZGI[PU"]7-=.NO"^^<R\!
MTP<?EDK36)X'OGKP@N'=BUZG"Q"_R^.??^OL T)<!2'@=RZA TH 2'PS0@!(
MG)82?]C'_5TM_==O31V]]%NV,K=4$U/1UEZ:R.?%^^5H2V7%W/XP]AV;A<F'
M:53T<^>!8C_Q+RWIHY[[*[*:.-]_P"?\"R\E(\#[QR#XXN/X U^M9L>NFA,D
M\4<O"4>H@>MXCW[8E4/ESP3"JW&=$PD&^*N+6_\6"<_<\UL1EX 'SL8#V$E$
MX165XNYC/R=CZZ_.>I]L8M.!;V\YFWWJTK]/1AH_G;_>,V?9=:QBO(WD+;RA
M[L^+@1<?O>IFU7UXVY:)V'UV8O!+82A(1;G5$9/T&?KC'_Q<\Y^O@/$O7^X!
M$/(^0K"G",%$A^V5.WRWE#>*"&5T7+YOE$M_<WGK,PC)M]:2F<?'G&%)+;\C
M>_2@.--BA"15K0_T*>= G]\!S@#"^Y=+W(/2NPU[[@):[F8 >]%2]R_2=QF8
M7;=JVDIO+%TV\$53-D--<O*AB+^JU6Z5L[].C0$(7)%"RRI-G+2ID/(&-CL<
MXP0Q$GUIM$@@\(;:NB]?K2]M<K*K*KI_HEX_7_U^E_'7K@>Y-ZJ?UM*O8N"Z
M2?&;M"FF#-A3/55RY?FN5B0#K4JO2\WR)KT0HMJR2*X+XT9QGE0<)IUX'D@,
M!I[8)3RQ[\/[9U),G^']6;.T'M>GY8I1W S+45B0^):5\'ZLJ;"8]V_9P7JA
MDOA@ZNG*R69!W[H?]7W@=CY5\\A2K^*+F*YXU9\R7=;:-C>3'KRPFJ6D1CT9
M8W4^O?(]E,CW8>'S:8SW6=@(-$);3@037@V]0IDJM\K!-&'A1$6<7#U<DQ.3
MEAC?C:T'TDUWH7-J,]=+&?.Q0NI5Y$*(VVO[^7R>756:=59S7'DY2JX])<KG
M7!.DKH#3K\FK 9 XOP[[ TCD6WG/F0H294C56AXO5T0\[#(Q)-+('$R=9G+P
M=2:4N*P;1S=G;8)\TCWEDV+T/KG(E>2&.3<^8\F-F/@UUJ]US-CZ-"^N6\6Z
MP?FUXA0+9X,>PXC4/F1'9]FEM\KP(,UTW<@XGU[[##*B;J\Z,!:^#S?J*DE5
M-F-=U9(+[+&"PQ_RZ!VFGOZHD.+UN[?W8/D"'^]:I,*%ZB^2B]#O&KUPK^:'
MC9JDPY5)V/)+,@%U8Z.7WFG+/';./IU7  K@#MX<>BY4NO$A]+"R+_0VPK9C
MD,L55Y"V<-C!M!@]L48E'T@4_9,F4_]^UAOA:MC]*UI^O'FQ:>>K.D>7 /53
M[O?US?7G:NZ0.\TEM2R[=&KN7\G9H?!_BK5>^A/RG__)::J=[%*-S8I83*2M
M,V:ZZ_E/&V@XL_WG"7?EHOA[<Y(5"P8_;3H3?Q5&XO\Y2\^VWRK(ZK578PZ=
MMX2*3!=\Q=ULZ^'SEFW$7Z:9]Y^/X[\\ HG< :DMN:[(YL<.9NA+BFT(\X6J
M,^M: '=C)?3S..Z2BVEJ)L>@V^F-IISD[7_$?EZ$!YB4;,]NU#SL+<>7?)F3
M7#4^>VOI)-V"G-FO/^WH\7>[/ZB3)Y_XSC+]:[H'R)0B)_!_S?2-JF2A],G]
MYMT^#Z+DN2/PM,?.OY_^PU^]PPO=FFXOWOX;VI4ZTH[_Z[]H,D__YZ7:?J%"
MCR[BGJ<QT/ZCO13Y7Y*U_$\I%2*/$F4O36:Q4Y>KV;$JBATZ*?Y)WDN%A+-B
MN7"0T)?>]V7DD:+J8E/5)).-7]B/'J=D/!Y(?![[QJS1B!K7VZOZAE6=5:"7
M\5 A2>USHDMW#\V##N1X%&->3Y75>%$,F4SQ!:G-IC9?RW48'2S&RPJY6=L&
M\^,?Y&=6B=C7T.X@-A]2>13+)>7^..D=7^L/&*OHE>1UDQS66)4FE\RV4N1;
MX_#/&>O1L#PTI-JPFV72.RZYZ:+;00SHO:'IV%XF;]&\OQC($WK$\I/NQD6P
MQ:K9"W_\ __,2M1]+6\E>MB/Y=E!^1TI2ORW<7ED 0.M"+1BSE4AW5X[NKS7
M=,5^OYO +"?EEDE_[IC']B:SNL-18OO)B76I/'P?'8GMQ%8L7(H)+F(F3#O7
M,*XKV5K:@C)694_^EFJU_ERRGR\_R+^F+L='&9];_%M/5C@VH[EJ^@7I=3S?
M7QV&6<RL3;D]&$SA(D_,*V01JQO,YSR&)Z'L7MJ Q];Z3D]]9 )NQL^E73M3
MS_<$.T;;^]O-%*1XC>U%_<JZ( S;$A/EJ[Y9678309J5%/IB07HL.F,?(TC>
M/M>92YZ:JQUPX-B:D[#\_N-:+;>,#\R28HGI:(F@R,FF;J<_^*X>_]EF^OH
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M0F 4^9FX,U;\UT.O1?PG?B8RO8C 8D]24%)N[B:"[[_Z7#&SD=[[SD;J;<:
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MTI8J)I Q7\ K[YF:]W1(?]CL\/Q&WO-QV'^(&O[-9!K $+#I7F&<)Y?" )<
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M!NF&+ZX0O4^5]R76_JFFD3=U0F"&!NW G#T(Y8"DU1$2BM0N>X%1F9-' 8H
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M1O0^&:_&?F)?WU/^K1:S?WAV+T?P_%5=S1XZ5]-Q/^,LOJP!_YU Z*]4W/W
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M/O><&*"1V$]/= 0&;.,-S.+M#2%$ 3)" BU@'/\//YE5DA @,-BLMN+&[6-
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M<]]/XPOV"ZC3IFHFO3:G]6&RD_\:G.'L$^R%X3Z=CF;"=<41@:D2%;YGS0C
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M.Z(JO]M+^ O5IA#])W=;,NB?_#^_9Q^/EH,$M$%TAO9D#0;*9/:9(>\%>/T
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MI)=KQ, ###S @[/0;C3M)WDH\:Z1BI9.)^N3]S%_EA/O=+V2!1Y:JF07W+\
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M)P$1RB9;  SC*_+0DN&;"?WJH*<TLS,P[-9E,&&[G433VQK-N=3 TR66 S<
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MA[734#<4N.YL70R*HEKKPI\TP.2(W-29>"N9Z<FX+M=2+5&L)XO7PY7V!)7
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M/7,!'ZKJ12=5;8"12EJ<,+ /=1D^RW8B09B'@IFH,B;VRVV9AL80 $#3-XP
M.?$>KL4"0:K6[[._R#H1H)-W-:<AW$WLFY?<>;KR5K^-U:_?I;-.,W6?2#UU
M=FRF6F^-<;I:?QS42Y?/S6XN>ZW)R>S'3J?&4IK7<$?FPWMS)6X;>J]-V5CJ
MP+(3#9/B8D_/,TX^.O@Y:I):L7.3:*^#:,Y\J@];3Y6GY^3]?N*$=;U?ZPYC
MO%FXB-;.3:MZ(S]CR EL&!]8&^;9.M'"7],S6\>KL2DM/$=JMK5[)'+;7W";
M75G_=G(;1_2*4&:8I@WWB/:9..HHF96[,@"2/F$%#12CI*4-'!!"!B(F$<-
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M/4Q_<?T]NXBQ,?H>SR+!E?92T*O=':4W !72-8#OAY8\$A7Z%!.(#>ZDZ$?
MS1U+1!%(B!L%5(@;7%1ML2HCU%&+@5N#H0VL(A%O9R:;7.<PL)&TO9LK-K41
MBT>%V)K+.!<5^9X">MO!N29Q6XI-S7^S*YH<ABV;A"XC-?4CVW%0/N[+,J_#
MUM70)XGQ%@LPW@*,MYUCO/T5(+HY0[6'$(>5L;'NC@3IS;-!<V,$0:ZWP:1Q
MQ)_SF=KO?QB_C^&]'[*:QQ)V+Q6;-+@\O[U'B3MW0-BYXT"=.RCHG$>_;AN8
M8D6M]GIU[@'SK%5CO[LMC$62Z4#ZK7TNM-F6^@'Q[9 ;DU^&6OJ&NWEJ[/@U
M<,!ON($[@"K<-U+AGH *&9GNU0 (1,XW$#E\X/_L2N3L#_1N&9SCS@@G&DEG
M N;?(?/O302D5P(,!A+@1"0 @[W<GZ@Y *[F#BV954' 0)B=@B63@<4.Q-BN
MQ)B+/+I?X-%]XH[N'W9T9[RP#4SY;\@/)R7/TBMU4B#/MH3,>B!@UGFRV0I(
MZ[)CS0"D]5-G6\$"K7MR](.1D+8<30UH;MWCD8#F IK;"\WQAU:DWXOF6. X
MH+DU [(!R6TKO!>0W)K!LX#DMA6!"4ANS?C&#R8YV_.?C]4DIHG.1PK&D]XA
M%D^+2'*+UKC8-8MSF#G>8O:5@#F>A&"&KO-I$!Q\;EL<8>T83,.I;V-HKG9M
M3]]N,CT'RP-#G"MI<\9H5_;8=418@80I0RR-&JN2.C@@K$BR(66S?7B"!)?"
M5O2(R?54;:QRHL'A#(3H/UDS#)>%V:_T._X?7!+GY]JM\^5GX1IV'!?Y/)GY
MQ6@_BSZ"D8VCG*2-+V/(;Y_$EYG;S!U[?\>QF\> );/FM#\+)?,3MY4_5H7G
MCQHC? 9L96;..W><-YZR#3GRM7V=8D^D#X$NLM:FSJ[1UD%5]NN='G3:,Q3-
MO,YCHFB7B:>0*O'/0:K,&N>[]@9W)9*_+^VE=\UUG]^25=BLW]9-G&W$L3Y0
MJVKUFX3Z9%XD!*][".Z1 VHQB^HZ;<Q!41K 3_H\0NI:^*0Q^#]%V*FPSWQZ
M6]"@>W72CI:G3\%U(R.BGH3S=LR[?$(NW6R##!0RLTX>]TMN<Y9!6CXQH2F1
M@/M@H^2X7R1_!Y3SC;Q&&)BC#&05M!CJ)QMC_%C]Q<WW>1\8E8$7^?VG?2I>
M9%7L.TWA1&.;O'T0Q.BCV.WOX;?%^$CF>_AMW[C5AL=Q%)V.C>1-ZHIJA[#6
MC38[FS/ 0_:C=]FNXN-6%3,/3,19AXN9"W?2HF+_?NA*3,+C$5O[<4VWM!BN
MMTJ%U:GXJMOQV +O=1OM'0.'\^@=3O]CRKA CRBY/7>5.';'=1\>7."X?O]I
M[]=Q/=J9!^[K$2J$'^B^+NVL\6U]6O@H::HAMXC.)DC;2,)"ZG+3[B, E_1D
M\ NM 4?]5OL)BMS'G@ &,7$"BCAFS4)8QP-Z)W85<%HQ,!N!55EOQ7FF&/JZ
M-J(M3^BL?=QI8N[#FXXQ;_J#$07^=>!??^1?J_()G04'_G7@7Q_?9I^0?SVO
M3)GV:-F]G&T=Z*=8:>F)IN,IDDDO,F&XK#?,%%L$; J61_ +; ?$]@'];Q*5
M^\5'?W/NV?*<80*+"^K9'!-E1.!*X3='*1$K6F2M]3N( @11@" *$$0!@BA
M$ 5P.SV>9L>N>-"QB^U*T+%KAQV[O*U)^8@=(@MZ>,T$#X,>7D<,=1GT\ IZ
M> 4XL9]DGJ"'UY%L8-##ZSOMYJFQ8]##:V?L&/3P"D1.('*"'E[?LH-/T,/K
M.&AG>\P?]/ *)$#0PROHX?4MA%G0P^O$Q5C0PROHX77R_'!2\BSHX17T\ IZ
M> 4]O(YT@8(>7D$_I:"'5T!SWY_F@AY>00^OH(?7*2]HT,,KZ.$5]/ ZLA4*
M>GBMZN'U75 2E@,B='11Q?K]SP(CV$@(6%CX112$SS8$P^)KHH_L&LP^03!Y
MP^[P95]AB/AN@QLHHFJ_!T$0K,'\HY:@%DB:VI)9'2?>A_CR<*4'*R 6BPEA
M/KT,+.!&;&J6;F,5^"'4_Q>QZ<,KP.DC <# ,N;]M@ #71GF0@)T@0!=($ 7
M^!'H EAU'Z/8?4'!?5!P_^&T@X+[(^3J:=>QQ"ET'3O:+3[)^OIO[#]^MKF7
M+XQ>S@.CIX*[-= 0R@Z\0]N5,T((K--&L#IPZ< UZLM6W[]!USJ@<O/H;P&4
M6^!I+7A:DW!;UHT *CUPM@)GZZ<X6T* ;A8X6X&S%:";!=Y7X'V=CO>%YUS+
MW2]ZHL>U=4(\)VND/U"T"2$4F/1O! R'91 IE#CSOBBBMPS?KM<'&=VHC.M5
MP1>9%'A9@5\5^%6+?I5!\/PT<*Q^KF,52P>.U8]QK!++D*I9#D>+Z9HE"LR!
M;&L1B4;TI@H-KN\'YV*!JQ:X:B=Y+G;W=S;PP@(O[!MY82O/P)C.LO,/_VO\
MU]:%,YE]MB<VL'2I2_LL#5B*(=R^Z)517VOJQ<T=I,%CX!OV.DRVM/,E$0][
M$.+ =!.!,.V>3F-1QIX1=N:C-PO1?JI,C]Q6)",Z4[?=2SME4X0QHI%O*:8S
M//*&_A\K\IUYCCW5M5S-5&J^QS)GG^,E X<S<#A]'$X3_@G\S<#?#/S-8_8W
MM\;U>W5!C]H#/1&MLG._=,?DA4?'J4T[8^W;/ST16MB+R[HU6IAF=R9/)KOS
M1 AA+\[NU@CA1_J_GVJJC&JT11S52WW%Q9;)L][A6-11WQHK:N56>*<A9SQ-
MHI*V3)U1"31^!P;+/.<!/(4V1&'[9UB#CT@^"8L##C1Q.P,AGA96R^*J^0CZ
MO_Y-P-.MP>KUY-;R?V/ID&\J:]"=./"$/TQIU2P]*"#\R:XP'[C"/\@53C*O
M9"WMRC'"\'=ODD>?&'N\>F/?!["GL!*!S_L-?-Y4X/,&/J^?S^OT%?: $G]^
M^[Q=73W0QO8WCM/E;=,:X3.D_V'/U75Z!3M/'/BU<*6OCB3)%-HW$G5[!*NP
M..ZZHF^L<5$NBN_U@@SO?D/I)EJS[]FB"]N2C8$B3O[(*GU64]&DGDO,,?9Z
M1B(U&!)!9*&I[_V'^R7_QD-AR:+.N^<X6_=\[1YYS\+Y>,Z[_VMPL$YBA_0)
MAN6)V.?&78U#4T?53-^<9GC6+QG>/O= GYC%+["$% O9< 9,R 8:$G5PK[')
MAVR:A' T$ULS$$](9_A&!@?VNJ'IO]&W9^^?/W=@IPGV"#S!#L\4_%9C\<A?
MI8_#,EFT\.26+.(RT\E*FHHG\>S);+'8B@Y$W53MYTT3!F@)+9TSG8A$W$-^
MYWUF5S2YKHC;ANX(8C2I<(GHO(DA0#FW<V('@S2X/6Z9K@=DJ:WI> T]4N%,
M('8<C>6@@<L&-P7K=A(5%G?*V52DJ26)$1$JJ':-\C:],+.!FCC)'NR)H ?[
M5 \%/=AWU(-]=L7WW7']:WOF-HD0%HV6F4;K;?F-M/R4N6?@#O';QP>ZU[#\
M[%A3M*F]GZ?6E4T2!DJ0D'RP"X4SE/2":?J+_SUOZ,[9K@MT^=EE79>HW=,%
MVMX%U(ZB(-"?T\:&9:BU8:>UL6V)F'.W>',&YO (0:2A$X2J:1I,==\!B@P8
MQ "U/;1$Q=&<V#NG;_7=-NS3ONB@VV1#8>K-U8:_1%=[44.A"TI6:X>8D4 G
MBU. ?0.IZ5Q(QVVX!6$*CL'L8NF7J8NV.C=L9 QF@^BD8\&;X5% FSU"S9""
MI8,I\49!#<M@0J Y0"32<C(&#1-L!O>55E.1)31+8+?43H@#S@.%IZ!YU+(D
M-DD1GDX[KG%@,$K8/@QOYZ/_^1VB1Q;4%%NV_%/,R#6V $02_1:)C>T;_,-V
MQ;"D+C-;\+&LBQF'$Y-'<PB3<RB0 \6BYAAL "<.!C!=Y-L0M0'MQ]#']L4)
MOL=])!IA0 $@41>?*<,3<9N("(-B4;GE>9/N*1E\,+PK$EI":N[D8%-TAN8)
M>XDT+C:U$9FB1RZX;(%<W*Y<%(Y1+H*=WZ02\(* Z0]D<TL(,]C;'/8LYIQV
MQ8[=O1H0%J6 -F9!(<1#72U'T?ZW\Y$5&=PFV]>P\5H=B2B.68JS+9^HR/)U
M%.;= _@$C@.(%. 1G;$>V#0<F!2_N65I8)C_+'+FF"C@SOSB!7 +\7@$#X9E
MK?5[*= 0TQZX<%-$6% EXJ(LZP/-^FH&VP>6;;%%N!%(LCX)+TCXF:6<^KT.
MMNXFTKQEZ8XH9QIB5C?@JS3=3>HFID,:<Y/ZQW6B]S1N>Y_8KG 2^MDKW$'J
MS<)M./@F@<TEJJT+V2'YB*C45W4<ZT4-:;D"F"Y3++IXS=I+M8%63/PGM&Q*
M38+/I[7<\$YTD&W*L5]ICC6W;,!!)J82_Q^F9IN^6M:C80/UN4)]BH[ZY(J,
M;$48H,K64)R:=^SF3T@U8_Z->(\@P/5XCQ";26(WEA()< KI4X','K1*)']@
M6^%R>5ZYH1STL>E6R4'Q1.4@BSLU5XM!_P$[!OM&PS9 V4EX45O7^AYY^$5Q
M!W3K78PO2+N-?( O2CM@G3ZLV9RXV[)7$5J4BR'7V?.5BUYQZ JT+\C%65E(
MEC[S$')Q( *%@Q7<#1R, S@8L6-T,-82^=QQROR92,<'QN\'0G_[XXZMEN&V
M3<P4PSKR?-W)'H?YBO+<S[M"&]8.TCD"TY9T="5,3^EI"!<0ML>@8IV\22#2
M._3<#F9&LXA9-O.J3B6SN^EXD8L*1)RI#[;-6YA7R'%@<=UTXKQRV:E6<\(D
M+C4UV1&;J$BV_>@H0'"!V]2EG_&'<-6FJH6CIRJSHM\0Y99WLK^H]G@3^P-4
M1?!\_X7S+I;N+B/SE$%\X9FH@_B[0"1>]4%WUUD:.E+2@H<L/8QM$=(',]3$
M:W4-=A\8)S1_GFK/V+NN=)K.4OW"9<%3U;G[O/K0LR9.C-+?>=J.,;':RUK?
MFI#;,Z:$YQF!*1&8$A^8$O&3-B6.,(RVB2FQQSC:S[8E GFR+WF2.')Y\LOX
M[5"+"J_R;5,WH\\'EFY8M/);F]?J?N?+RXNYW!9QF56=X40')7'$!N($\A98
M!>2A$/U/A+O4Q@0VC?',_-D.>0,6-0S@._< VEC&7/ RQIRX&A0@QK57\84A
M6U?#7$#<L(B0V"-TMM8TE<T;Y?18H79@DUY*2_!8" 2_HZ?([E+*:(1BSAAI
MK; "3C-Q*ADD3@6)4T'B5* DD\>H)%V@KAFKTS&GG!ZQJY.@4%LM/YSUR[U:
M?*L' LVN66L2ZI3.-XM%QQ8]^B8F4QD&<Z[34?? WS]/:FAIIGU"MY%5[9K4
MGG-I9G."$)APOX3H[X\,Y!8,6'-B)=[%13_;7N"Y4XR5R^.BQFVX(.Y]?JD:
M7:(LA 78ID_M&!M\+<FO+CF''0OAIE/-C^]C,9_0;$9&TYJ@ZL/#4U@#OU0Y
M/C-3OXQD05/O6ZY--F_W_)(C),)=B:J%]"(D:&9+[/?"1.QY?(!:;D/KT2["
M_D.>&CJPXR-9LPS6L]@;=SFFH(9/,<TW$J^I8Q2O<R%$D3NK9EF^E8\7L5R&
MK@I?.D\,P:,&1*5RAUTOZ^#:B[HHP1MDV$G)8'*&OAI=%B!M/"U>$FE)NR+$
M%H8C46&O%=7Y.F/;TG=+5.;"M"#^9Z.TTT%33IYY ?A1P/8#C4W%CB)NE >[
MB7!>-D(:1W9W:_G6X)M!VBD:*P'RU2ZX0F++([WL06T2RUDA2/90.;F5PI?M
MC'.FE"TB)#<;^%Z'^N5AG*;'F]JFQ^MUGIB[.>,ZS7R%6BT6]7631YK<6N(E
M3RLUFUIK O]TS;[R[_\#4$L#!!0    ( &N!3UE;T4"Q<BL  , M   :
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M\O$+2%R6E)*^HJ2LHGI#3?W.71U=O7OZ!A:65@^L'SZR<7KF[.+ZW.V%GW]
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MPJN,DP>@I-"F2*B3K)\5^PC:0U=6@+._\9OH(]PAL>@05MN0R]-WMSY^^L<
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MP/^/,&?/LI%^>&9Y?(5@/J830=UMC__U'OT_&5#*['\!4$L! A0#%     @
M:X%/6=;0R1X,*0  Z]T! !               ( !     &EV82TR,#(T,#8S
M,"YX<V102P$"% ,4    " !K@4]9U!WF/6(7   68@$ %
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M2P$"% ,4    " !K@4]9K.SPO1]%  #90P, $P              @ %SL@$
M:79A+3(P,C0P-C,P>#9K+FAT;5!+ 0(4 Q0    ( &N!3UFTB1YHBQ8# "!I
M)0 7              "  </W 0!I=F$M,C R-# V,S!X97@Y.60Q+FAT;5!+
M 0(4 Q0    ( &N!3UE;T4"Q<BL  , M   :              "  8,.!0!I
M=F$M,C R-# V,S!X97@Y.60Q,# Q+FIP9U!+!08     "  ( !0"   M.@4
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>iva-20240630x6k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:iva="http://www.inventivapharma.com/20240630"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="iva-20240630.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_11_28_2022_To_11_28_2022_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_ixbJJMHX7k-KJKKJhzrKQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:WarrantAgreementWithEuropeanInvestmentBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:LongTermFinancialDebtDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-28</startDate>
            <endDate>2022-11-28</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20232ShareWarrantPlanMember_WOiJYiWPuUu4IuMxaS3vvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iva:DavidNikodemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa20232ShareWarrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20231ShareWarrantPlanMember_sPDxxV-HME-NOFivUfGJlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iva:DavidNikodemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa20231ShareWarrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_TXDD0JbjtEiPdT8-3ZzhYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iva:DavidNikodemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BsaShareWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_ue4H16UnJE-nSbm-Rv4i6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iva:DavidNikodemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BsaShareWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_hhwziOnPqEKcNx_7cuH5Ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iva:DavidNikodemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BsaShareWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_ServiceProvidersMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_DIqvoK9pK0yZ6htGpUYXzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iva:ServiceProvidersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BsaShareWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DirectorsMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_tc0AHGj00kS5B7lAXTpurw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iva:DirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BsaShareWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_IuzMYL65X0qu-JY8V6n_lw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_CSHhFS0Lg0Gzg_yzNEELZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_28_2022_To_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_3hNTQf5aEEemSQq6uYohDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-28</startDate>
            <endDate>2022-11-28</endDate>
        </period>
    </context>
    <context id="Duration_5_16_2024_To_5_16_2024_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember_VYGeDPPB2Ea8OgJWmGctxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-16</startDate>
            <endDate>2024-05-16</endDate>
        </period>
    </context>
    <context id="Duration_5_16_2024_To_5_16_2024_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember_2N4OlKpMhUqSYqUX-EXpVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-16</startDate>
            <endDate>2024-05-16</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_7_1_2022_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_mT6R0SioNkS8Jv1u9vcknw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:WarrantAgreementWithEuropeanInvestmentBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="As_Of_7_1_2022_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember__QhdYl76K0agjKJOQ6cDBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:WarrantAgreementWithEuropeanInvestmentBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:LongTermFinancialDebtDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="Duration_10_14_2024_To_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember_cd3Fteojp0CtXUqdXRXY6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-14</startDate>
            <endDate>2024-10-14</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_RoyaltyCertificatesLiabilitiesMember_mEPm5drgy0O0deuPued1-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:RoyaltyCertificatesLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_10_11_2023_To_10_11_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_LicensingAgreementWithHepalysMember_srt_OwnershipAxis_iva_HepalysPharmaIncMember_CJxE3L2F106Ij0r9Bq2I1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:LicensingAgreementWithHepalysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-11</startDate>
            <endDate>2023-10-11</endDate>
        </period>
    </context>
    <context id="Duration_10_11_2024_To_10_11_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingThroughFundRaisingMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_srt_StatementScenarioAxis_iva_ScenarioTwoMember_kF0Cffov6EiCtat91NJ6hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">iva:ScenarioTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:LicensingAndCollaborationAgreementWithCttqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:FinancingThroughFundRaisingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-11</startDate>
            <endDate>2024-10-11</endDate>
        </period>
    </context>
    <context id="Duration_10_11_2024_To_10_11_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingThroughFundRaisingMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_srt_StatementScenarioAxis_iva_ScenarioThreeMember_2KTwko-jbE6IA2FjFwUN0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">iva:ScenarioThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:LicensingAndCollaborationAgreementWithCttqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:FinancingThroughFundRaisingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-11</startDate>
            <endDate>2024-10-11</endDate>
        </period>
    </context>
    <context id="Duration_10_11_2024_To_10_11_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingThroughFundRaisingMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_srt_StatementScenarioAxis_iva_ScenarioOneMember_NOafy3B1GU-pPX7_lNErFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">iva:ScenarioOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:LicensingAndCollaborationAgreementWithCttqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:FinancingThroughFundRaisingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-11</startDate>
            <endDate>2024-10-11</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_TxixfQbZCE2_vJzh9SnQSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_7_5_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_PresentationOfResultsFromStudyMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember_rLZHQc4OiUGVcCmKg1glHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:PresentationOfResultsFromStudyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-05</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_BorrowingsByNameAxis_iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember_5BKdyoSBV0uhtWALpjAz8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_tfmxFNVVb0CS5hG6C3JkAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:LicensingAndCollaborationAgreementWithCttqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ServiceContractWithAvantSanteMember_cAPxNDRt4k2GvvKof24NwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:ServiceContractWithAvantSanteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_9_26_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_LicensingAgreementWithHepalysMember_srt_OwnershipAxis_iva_HepalysPharmaIncMember_rVQ3vZD64EmRdCdx3kiaUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:LicensingAgreementWithHepalysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="As_Of_3_7_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember_nuFto-sydEusuJsG2ypBGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-07</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_FredericCrenMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnits2023Member_rz9Dt9fkhka9C49bx8Vmng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iva:FredericCrenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:LongTermIncentivePlanInPerformanceUnits2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-25</instant>
        </period>
    </context>
    <context id="Duration_10_11_2023_To_10_11_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_0ACGkUM49U6-A_OhxFep5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-11</startDate>
            <endDate>2023-10-11</endDate>
        </period>
    </context>
    <context id="As_Of_1_1_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnitsMember_Zf-6fi4mZkOtN6iPVLbVdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:LongTermIncentivePlanInPerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="As_Of_5_16_2024_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_xI1dcdJgHkqTYSB3mreY5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-16</instant>
        </period>
    </context>
    <context id="As_Of_5_16_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_VAiorYC4kkm95pO29VSpPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-16</instant>
        </period>
    </context>
    <context id="As_Of_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_Wd7CtxBOkEO4WumvaOj3bA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-18</instant>
        </period>
    </context>
    <context id="Duration_6_1_2022_To_6_30_2022_ifrs-full_BorrowingsByNameAxis_iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember_rVGAMd543kWMTqS80gXZVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2022_To_6_30_2022_ifrs-full_BorrowingsByNameAxis_iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember_pRmHDD5O_EOFWPfNYEeiDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2022_To_6_30_2022_ifrs-full_BorrowingsByNameAxis_iva_FinancingFromSyndicateOfFrenchBanksMember_age9N1IGyke_9J5_9xJiwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinancingFromSyndicateOfFrenchBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingAgreementInThreePhasesMember_7BaMct8ywUiT7daaU6IKqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:FinancingAgreementInThreePhasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_5_16_2022_To_5_16_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_iCBdyRK5rUeePAFm5LecHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-16</startDate>
            <endDate>2022-05-16</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2024_To_2_1_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember_v79EQ1VlWE-l9YiRgeueOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-01</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember_fPmzQ4Ci5kCG21AG1O_ehw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:ContractCroWithPharmaceuticalResearchAssociatesB.vMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember_srRYIfYrLkGZMnq0Z1Nr_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:ContractCroWithPharmaceuticalResearchAssociatesB.vMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_11_2024_To_10_11_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingThroughFundRaisingMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_QkHCyd9NWU6y7zXQYpg3Tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:LicensingAndCollaborationAgreementWithCttqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:FinancingThroughFundRaisingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-11</startDate>
            <endDate>2024-10-11</endDate>
        </period>
    </context>
    <context id="Duration_7_18_2024_To_7_18_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfRoyaltyCertificatesMember_MVb6HJyb-0ClrMuNDVzHFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:IssuanceOfRoyaltyCertificatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-18</startDate>
            <endDate>2024-07-18</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_31_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember_VgrKJISxZU2hIPTccHR6Jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember_PRoFZMRi1kONFrYjiuvhAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_1_1_2024__TV_WDfEOkuUvGKOfMbQLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_1_2023_XlsK7X7SLkSjPHI4C13dFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_X8oeeeGhTk-MdYqDOV-oxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_18_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_LicensingAgreementWithHepalysMember_rgk-qPK2CUyR7D5r7W0aMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:LicensingAgreementWithHepalysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-18</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_iva_FibroscanMachinesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_u7Et-MI930eFeqmMLXteeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iva:FibroscanMachinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_iva_FibroscanMachinesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_zqYECmxrlUilNWtPkw19_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iva:FibroscanMachinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_RightofuseAssetsMember_PXbF8eDw90i06AiOGDMO3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:RightofuseAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_uKuO3UuYNECV4Eoeqzpd4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_7mIiNwJvsE-YWS6Oz_X7Sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_EIAsynD95kCXlu8TLaft8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_18_2024_To_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_DrawdownOfBorrowingsMember_qBP5Y6KUBkGy4f5mXUW39g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:DrawdownOfBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-18</startDate>
            <endDate>2024-01-18</endDate>
        </period>
    </context>
    <context id="Duration_1_18_2024_To_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_CZeedY0HkUOxo7vg14rQ7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-18</startDate>
            <endDate>2024-01-18</endDate>
        </period>
    </context>
    <context id="Duration_12_8_2022_To_12_8_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_Oji8AIqwMEebyNKqGL3bwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-08</startDate>
            <endDate>2022-12-08</endDate>
        </period>
    </context>
    <context id="Duration_10_14_2024_To_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember_imkRzVTcgUy0kGwnaok3JA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:IssuanceOfSharesOrWarrantsSubjectToConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-14</startDate>
            <endDate>2024-10-14</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_IGbGo6uT7EO_KIZuumIllA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:WarrantAgreementWithEuropeanInvestmentBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_e2AEajgpOke0pQ8o_y36nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:WarrantAgreementWithEuropeanInvestmentBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember_hobGW-4SUUqZmnmtlP6zCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:IssuanceOfSharesOrWarrantsSubjectToConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-14</instant>
        </period>
    </context>
    <context id="As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_YCO92YM7_064nsFEWIY8Jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:WarrantAgreementWithEuropeanInvestmentBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:LongTermFinancialDebtDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-04</instant>
        </period>
    </context>
    <context id="As_Of_1_3_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_rb4eejdyHUKzT5ws_uabwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-03</instant>
        </period>
    </context>
    <context id="As_Of_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_QTQ5vqXpNE2ib3CFSHvYaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:WarrantAgreementWithEuropeanInvestmentBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:LongTermFinancialDebtDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-28</instant>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_ifrs-full_BorrowingsByNameAxis_iva_EquityRecoveryLoansMember_FFIOm4lTLk6UQV8mUsy60w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:EquityRecoveryLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_rbMHeXRpfEGsAR3PJoBgWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_EFM8TpwCpkqu7FVPRM1rTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_V_UnvG7OVU6Postqxl9qTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-04</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ldh6EouHQke8vr_BH-JvxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lpf5jlqhR0GVIbvPIhKnYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-28</instant>
        </period>
    </context>
    <context id="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_JPcx_xU0GEGgRDmKGGAdGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-18</startDate>
            <endDate>2024-03-18</endDate>
        </period>
    </context>
    <context id="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember_tSDasQf4-kCHQTZLajBCXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-18</startDate>
            <endDate>2024-03-18</endDate>
        </period>
    </context>
    <context id="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_YgdXCEYNr0mNt92Z5wU9hQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-18</startDate>
            <endDate>2024-03-18</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_ChiaTaiTianqingMember_hYhPgbJT90qw9Zp638JTYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">iva:ChiaTaiTianqingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2021_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ContractCroWithResearchAssociatesGroupeB.vMember_Kg0rzj_ifUatIDFJkolJ6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:ContractCroWithResearchAssociatesGroupeB.vMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_PharmaceuticalResearchAssociatesMember_IkzQwodT60qRBSBD6WG1Kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">iva:PharmaceuticalResearchAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_PharmaceuticalResearchAssociatesMember_Co4XPbAvCk2OhAlYe5P1VA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">iva:PharmaceuticalResearchAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_4_2024_To_1_4_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_fmkw3aWeOU-HD1uNZ91qIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:WarrantAgreementWithEuropeanInvestmentBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-04</startDate>
            <endDate>2024-01-04</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_7_1_2022_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_XoSz7rHj_Umg-MPSR-Funw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:WarrantAgreementWithEuropeanInvestmentBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:LongTermFinancialDebtDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="Duration_10_14_2024_To_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember_cl4oX3dadE-dg27_9dl-_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-14</startDate>
            <endDate>2024-10-14</endDate>
        </period>
    </context>
    <context id="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_2nmqoYhWkkOgh_AeHuYFnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:WarrantAgreementWithEuropeanInvestmentBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:LongTermFinancialDebtDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-04</startDate>
            <endDate>2024-01-04</endDate>
        </period>
    </context>
    <context id="Duration_11_28_2022_To_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_FvqTByEiaEuWx4OtWlgNhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:WarrantAgreementWithEuropeanInvestmentBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:LongTermFinancialDebtDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-28</startDate>
            <endDate>2022-11-28</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2024_To_1_3_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_uBe1VaT84EOT7MGXjouVfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-03</startDate>
            <endDate>2024-01-03</endDate>
        </period>
    </context>
    <context id="As_Of_7_18_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfRoyaltyCertificatesMember_eaHX-tuX_E2XdHMM79Knaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:IssuanceOfRoyaltyCertificatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-18</instant>
        </period>
    </context>
    <context id="Duration_1_18_2024_To_1_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_O2DSQ9PKd0mIC5PRzMA_Qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:LicensingAndCollaborationAgreementWithCttqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-18</startDate>
            <endDate>2024-01-18</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingAgreementInThreePhasesMember_d8wjd7CfTESZ1LkHSB77Cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:FinancingAgreementInThreePhasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_T--Cv137BUS8bbvsblFtMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-18</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2024Member_o0JPxKp_cEaymg2N36omtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2022Member_lXOe9V-g3Uq8tzFzKYE_rw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20232ShareWarrantPlanMember_CWi27vgj8Eqzm6adcBi83g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iva:DavidNikodemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa20232ShareWarrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20231ShareWarrantPlanMember_r1Qe82njGE25vu439VQ9xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iva:DavidNikodemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa20231ShareWarrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanThreeMonthsMember_2nR6xWsu-0CvgK_C4H2nmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanThreeMonthsMember_--thiluYlEKqu2SkZv1ljQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_MaturityAxis_iva_LaterThanTwoMonthsMember_C5lqESZnOEmaIeMKVhSS8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">iva:LaterThanTwoMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneMonthMember_F44q34_t8kGRdNbcbz0SsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_PQdCvCveh0GtnvbOTvZTxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanTwoMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneMonthMember_L3zFOF6AbEGJqyvX3ksALQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_pgS3JPFyOUuBb8uDOr_KNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanTwoMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_oxFIDH8XQUKPgIUFQceRfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_RoyaltyCertificatesLiabilitiesMember_ifrs-full_UnobservableInputsAxis_ifrs-full_DiscountRateMeasurementInputMember_qerPupsvsEe_tn0yX52pFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:RoyaltyCertificatesLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:DiscountRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinancingFromSyndicateOfFrenchBanksMember_b3jNddOSCEqLn7eTIlNpJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinancingFromSyndicateOfFrenchBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_iva_InventivaIncMember_y49k90Wj0kC3K8Qnf_pclA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">iva:InventivaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_wYI-vlX-bEu9MV9dohB57g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_CpOwuIhEIkSyaCaql_vmYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_mbEhqIy-C0eGw1aDWsHwyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_2B9cJfzZu0-9iYr6nqkzSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_15_2024_To_1_15_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_9LZhfVa98kGYF3dksXsUBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-15</startDate>
            <endDate>2024-01-15</endDate>
        </period>
    </context>
    <context id="Duration_1_18_2024_To_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_Dck8WdQ5LUKx_AFlTUOcAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-18</startDate>
            <endDate>2024-01-18</endDate>
        </period>
    </context>
    <context id="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_f6IGXbNrJUeuXFjO7KpMzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-04</startDate>
            <endDate>2024-01-04</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lX6me24ptE-Xl7VzcNGlCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2020_To_5_31_2020_ifrs-full_BorrowingsByNameAxis_iva_FinancingFromSyndicateOfFrenchBanksMember_tgQsngIelEWdVjh0z4mOYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinancingFromSyndicateOfFrenchBanksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember_vlcJPhOGqkmmq2I0namEtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-14</instant>
        </period>
    </context>
    <context id="As_Of_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember_ZCF8RxUM3UKzcBgb7Q57Xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-14</instant>
        </period>
    </context>
    <context id="As_Of_3_25_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_31pg2jjAP0SNXoJC-UbdfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-25</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_8tc8znfKVkWA4XCDKyyrhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:LicensingAndCollaborationAgreementWithCttqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_I0kItXo1cEqfFv1DgQ0yfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20232Member_PqpzKUoY40ObENgyoIJeMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBonusShareAwardPlan20232Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20231Member_oKFel_ng9UWwaxcU0ACQvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBonusShareAwardPlan20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20232ShareWarrantPlanMember_XsJfOiE5YUuSxAlo8TUGSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa20232ShareWarrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20231ShareWarrantPlanMember_5P4HYxa_X02-U_TBazJ3bA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa20231ShareWarrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BonusShareAwardPlansMember_m2JRheJguUWiLC2OX9PVmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BonusShareAwardPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019TerMember_TDxn8LM_90OZE-wvpQKC8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewShareWarrantPlansBsa2019TerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019Member_KvhW3CTGVkaWP5uQm6usPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewShareWarrantPlansBsa2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019BisMember_U_5IV4QgEke3Pdy5mT4eiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewShareWarrantPlansBsa2019BisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBsa2021ShareWarrantPlanMember_3S7BOByx_EaWFm05q97Pbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBsa2021ShareWarrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlanAga2021BisMember_d8RDeqcJHUuuc8eyxeiD5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBonusShareAwardPlanAga2021BisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlanAga20211Member_eh-BJlC8R0G04APW_IIiGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBonusShareAwardPlanAga20211Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20232Member_FIpiNio7XkaVcs3vwtxlaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBonusShareAwardPlan20232Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20231Member_OTdPP5Od7kuR-ubUIX8ZDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBonusShareAwardPlan20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnitsMember_S5ghW2BBqEaaOZO3f2CIIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:LongTermIncentivePlanInPerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnits2023Member_bHs6Y4UJuEK6wcGSke6uGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:LongTermIncentivePlanInPerformanceUnits2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspcePlansMember_9R_vfCR8mE6QceWJxeNh0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BspcePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspceAndBsaShareWarrantsMember_AXg3-r_gg0WamRv2dUykVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BspceAndBsaShareWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bspce2021PlanMember_XXFm1fZ4IkuZuyUISjqE5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bspce2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaPlansMember_8Ot2N8tWskGDuiWnohiHRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BsaPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20232ShareWarrantPlanMember_TAkktSsoVU2p7FMQN4IObg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa20232ShareWarrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20231ShareWarrantPlanMember_47_9YfgmmkGE6SeeBfb7Ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa20231ShareWarrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2018PlanMember_-NNjSxGS3kGycvP-YnC6BA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa2018PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2017PlanMember_ps8c_6VsskWjdjMuB0dgAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa2017PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BonusShareAwardPlansMember_mvV1f-1wH0ac-WZpqG9HRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BonusShareAwardPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20232Member_-sKnyEocNkawleXgjslx_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBonusShareAwardPlan20232Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnitsMember_PlmUtIqdxEmw3YH5g0akfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:LongTermIncentivePlanInPerformanceUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_3_25_2024_To_3_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_FredericCrenMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnits2023Member_hzRrxOsqEEe8Ngy7ccwfuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">iva:FredericCrenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:LongTermIncentivePlanInPerformanceUnits2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-25</startDate>
            <endDate>2024-03-25</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlanAga2021BisMember_NCJt9ZQOW0SLSy6T5SliZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBonusShareAwardPlanAga2021BisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlanAga20211Member_Bsp6KVWZMUiZgeIpAPgY1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBonusShareAwardPlanAga20211Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019TerMember_jiHAAcRQ-UOqoX3-IPHL7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewShareWarrantPlansBsa2019TerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019Member_wyeHPWxpTUKLa573kCA9hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewShareWarrantPlansBsa2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019BisMember_MIIhZy39AEC1hyqkLyXkqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewShareWarrantPlansBsa2019BisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBsa2021ShareWarrantPlanMember_yiiLVd_BA0S9s5AhG-VVqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBsa2021ShareWarrantPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspcePlansMember_Ga9Y5xtaaE6GziTOhOfOyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BspcePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspceAndBsaShareWarrantsMember_bFYuyd66F0KcdJonswP3bA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BspceAndBsaShareWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bspce2021PlanMember_RcSn_5JQpk-SYrZAPBf-2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bspce2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaPlansMember_lUa0fx_8UUGbYRQd155C8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BsaPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2018PlanMember_ptHXov2J-0Wu9MZq69AtRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa2018PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2017PlanMember_weg2ddPVA0SxiMSra8AqSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa2017PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2024Member_SKyx2I-L-E2qRPd_8ZtRDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2022Member_rqfjl8o2ykC3r6A9zJWDeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Bsa2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BonusShareAwardPlansMember_4W-wr4J7bkuA5horxzjQWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BonusShareAwardPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_dei_LegalEntityAxis_iva_InventivaS.aMember_Cyc1aEXngEiGaWWQTrmH-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">iva:InventivaS.aMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_dei_LegalEntityAxis_iva_InventivaIncMember_yX8YJNqJxEeoquiF4wd66g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">iva:InventivaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_dei_LegalEntityAxis_iva_InventivaS.aMember_3oaek7qY7U2QTmeeOlV98g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">iva:InventivaS.aMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_dei_LegalEntityAxis_iva_InventivaIncMember_dCL3wkeOIU-E_D6kZe7BxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">iva:InventivaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_HZvpAkHv40a_7feAGh0Gmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-18</instant>
        </period>
    </context>
    <context id="As_Of_1_18_2024_u8VUV2GPAUmg3FPfMqwLIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
        </entity>
        <period>
            <instant>2024-01-18</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_BorrowingsByNameAxis_iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember_C9WbfUum90KUsBfHNequkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_5_16_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_m_1J6hotsk-dhzgHfJ6CBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-16</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_iva_InventivaIncMember_DGOb9XXQ8UK2Bub8zM5nQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">iva:InventivaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="Duration_3_25_2024_To_3_25_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_NWloX1BI0US4Lo97RBCE_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-25</startDate>
            <endDate>2024-03-25</endDate>
        </period>
    </context>
    <context id="Duration_3_25_2024_To_3_25_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_eylYkv54iU6BbmTMEduewg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-25</startDate>
            <endDate>2024-03-25</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_40Ly7mN0VUychMdZQFU0jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_hPvzcNBD1029LdKD5pm-Fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_7knLDQKU6EWqcXxngWZMRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_SNcEwTle60O3eQH3YNWEsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_gFqLBMPU_kmKcAPYZiVbAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_na6RZmuG5U2D4vmO3x7mnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_OjiU0SQcREq22dnbIpV6fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Aga2021Aga2021BisMember_94cRMy8qbkmwpgWKKI0Dmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:Aga2021Aga2021BisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_3_25_2024_To_3_25_2024_avq7MDuDZ0qTbuTPxd88pQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
        </entity>
        <period>
            <startDate>2024-03-25</startDate>
            <endDate>2024-03-25</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_InventivaIncMember_CsDcvL6WIEe96pAzGCSMYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">iva:InventivaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_Nnjp7bngW0Ga6BDie0V6fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_y3OYJVLzE0-whh_qoWeSDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueMember_4SVWIFElkkKFKpxz6K2mDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueMember_1nI2yYCJCEKKgVIHzRJEzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_1QUlLx6Y0E-OzYbHdIU-FQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:LongTermFinancialDebtDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_ShorttermBorrowingsMember_q5wyxdtsjkC9ATGXwBJ1zQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_LongtermBorrowingsMember_KhP49WhAa0S2SqllGaAZ3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_EnC60jgh0EOHmRak6HvHFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_TradePayablesMember_DT34R3eKL0K1egtpaQCcgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:TradePayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_RoyaltyCertificatesLiabilitiesMember_tzXibduYxE6YsqSgIdTn3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:RoyaltyCertificatesLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_OtherMiscellaneousPayablesMember_17V3AWgX9UGIGzCdKUHVpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:OtherMiscellaneousPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_DerivativeInstrumentsMember_USWamMRH70e5dMBuXB1kfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:DerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_ShorttermBorrowingsMember_HbTI56G8V0OVuMMfgkPm9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_LongtermBorrowingsMember_3_c4ZNJ7IkuGUZRsgL5KeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ad_CUhpQSUWO9uvSqmVOjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_sO3Ilng9LUyGbmS3dP5aqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:LongTermFinancialDebtDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_iiyUwIL1okucU3luLH42uQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_TradePayablesMember_hHYqQE9Yj0e7HSqbpfQXSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:TradePayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_RoyaltyCertificatesLiabilitiesMember_WaIiYd4PIUyNoJBmB4iA4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:RoyaltyCertificatesLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_OtherMiscellaneousPayablesMember_XvcehwIoO02CIQ32YJIxyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:OtherMiscellaneousPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_ShorttermBorrowingsMember_NB0TWpTDvU2mM9PCPaNmTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_LongtermBorrowingsMember_1DesxSZs7UeHW8u3NH0eGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_DerivativeInstrumentsMember_uAo9ZMcdJEO8cLUT1lE0MA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:DerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_TradePayablesMember_5cmgPsH920CfGPmJBDOp-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:TradePayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_RoyaltyCertificatesLiabilitiesMember_Sn-nL6ck_UCopAUgyhyLIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:RoyaltyCertificatesLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_OtherMiscellaneousPayablesMember_oeFuIUG-QkqzWRNtsHuxmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:OtherMiscellaneousPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_DerivativeInstrumentsMember_DXqbqfuw00aAGXk5irtJtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">iva:DerivativeInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_ShorttermBorrowingsMember_cHoNbFS0eUyuodyG6femhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_LongtermBorrowingsMember_LdqaexFubUm5bmzDhGaIFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_Ju8a20CjNUGvFkUgBgWStw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_tIb2x3EdLUOAPCEztcL7wA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_OtherReceivablesMember_X545crJT6E-s_K-iPNVWJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_IfrsCashAndCashEquivalentsMember_3DbfsjKIuEeTh95AuBI8Dw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AdvancePaymentMember_NT4vZl9PbkGiPUjsmpSqhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:AdvancePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AccruedIncomeMember_Ahk1q2K--0uCVDs0WN2cnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:AccruedIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_TradeReceivablesMember_1-tjX8tbt0GXwG43E2l8Mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_iva_OtherReceivablesMember_8JkciAHeZUmN1wIn0UqhJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_iva_IfrsCashAndCashEquivalentsMember_gUhZ2pkRhkGxOpcwP54F6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AdvancePaymentMember_Sx8nhE1j8ESlCSB49JWGVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:AdvancePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AccruedIncomeMember_rFAULMOIG0-nNmzcBonheQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:AccruedIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_TradeReceivablesMember_UhBYZg6XLkqb9t3xvxBEUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_xqxoBDc1zUiTY3urkmymcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_ShortTermDepositAccountsMember_374tsJrTKk6fJow5yHyCDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:ShortTermDepositAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_OtherReceivablesMember_nOSt24rbu06dp175BFWIVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_LongTermSecurityDepositsMember_VROn8csSH0i28NXJGx3Amg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:LongTermSecurityDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_LongTermDepositAccountsMember_fo_XM5MB2kOMXwNZMOkI5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:LongTermDepositAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_IfrsCashAndCashEquivalentsMember_OARfL4lhGkWF8cdGOx-xCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AdvancePaymentMember_qXVB1LZ70EWDaFdvLxmc5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:AdvancePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_TradeReceivablesMember_9Se6Eh9LEEyShj3tyGuJAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_ShortTermDepositAccountsMember_XX7WnZfsDkussQqjcn130w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:ShortTermDepositAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_OtherReceivablesMember_YRoI5LsEsEySxVU2J2oZVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_LongTermSecurityDepositsMember_Noxm4K7bX0S6jyxwkUADrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:LongTermSecurityDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_LongTermDepositAccountsMember_nJntFM5UfE6dEPYXAe50tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:LongTermDepositAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_IfrsCashAndCashEquivalentsMember_vrZZqx47o0a1hsDxw-vIxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AdvancePaymentMember_FkwbWhKujke__64KGmRGog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">iva:AdvancePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_TradeReceivablesMember_HDaVOBXSAEmTDP24XH8uQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_RtETuwSwJkCED4F2iCpqkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20231Member_7wRF3k96VkCeUYr4WvCKSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBonusShareAwardPlan20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_jiMyqJklS0yKSmn3ylKVjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iva:RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_wKPlEEy3A0SN-8jmJn4iCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_9dAqjQ8yFEOk2IPndtMWDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_LdYbre3bB0WUz88niJNlag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_NJmuaXv-XEWsTA9f3Xh5nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_IZqZC00jTUqIta0YcIIbug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iva:RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_cgKVo_3CWUmvwiGobzgKyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember__9pAKUrAQ0enxQqBYLGv9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_nwf6v9oBck-wKZOxfPU3tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_4J3_ocxV5ka2EE64Vzyuyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_oIEPc_uew0yPdBw1zj31_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iva:RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_7UXPGS9t8E2u0eKxHUgg6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_c6YRrAmJtkGBVTOn_KinpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_M0g6jdiCfU26v1gbb-hQNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_K1Cg_Yt_SUKODSLGGBA5mQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_hBnlt8OLjkOaEtHFXq1FfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iva:RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_RyNlENHuY0axEQhwJsaZbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_fEy91Y6Yw0uMQLNC3PBBYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_s4VMant100Wa1D_e2buNrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_1unH-qq8aU-PC_sPZcCATg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_0VRJS0P300WTp8zcUcUTug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_hTRe72PPekW3DzP4m38ewQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">iva:IfrsSalesAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">iva:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">iva:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_vilht6HmAUelr2hSPT_U_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">iva:IfrsSalesAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">iva:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">iva:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20231Member_dcxbZ8fZnk-mVxqgCGeiKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:NewBonusShareAwardPlan20231Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnits2023Member_JOCpA6ku3UiPydoMyQrkIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:LongTermIncentivePlanInPerformanceUnits2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspceAndBsaShareWarrantsMember_ChRxu3v9XU-QJcAaOJ0AgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">iva:BspceAndBsaShareWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_ZxMBck8Vv06CkTltj3JJkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:LicensingAndCollaborationAgreementWithCttqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_PharmaceuticalResearchAssociatesMember_qjG6YqkiB02s-QfK34PDzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">iva:PharmaceuticalResearchAssociatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_ContractManufacturingOrganizationsMember_H1GPzHoVzEiBnJra2bMeWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">iva:ContractManufacturingOrganizationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ContractCroWithResearchAssociatesGroupeB.vMember_z4AQiAhloUi2lSaBmH0sqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="iva:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">iva:ContractCroWithResearchAssociatesGroupeB.vMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_ClinicalTrialsMember_RKIovK8rokChycQgZSo2TQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">iva:ClinicalTrialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_ifrs-full_OtherContingentLiabilitiesMember_0hDuEC30xECEsYnHHr_kTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:OtherContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_ifrs-full_LeaseLiabilitiesMember_ida2CTwucUi4-oggFUrF2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_ContractManufacturingOrganizationsMember_e2L2HwPp40Smxh2nqL1VkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">iva:ContractManufacturingOrganizationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_ClinicalTrialsMember_ETYrQdfyDE6P4TNS-pt20A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">iva:ClinicalTrialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_ifrs-full_OtherContingentLiabilitiesMember_UcOuCRDpIESuiNmpO5AzcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:OtherContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_ifrs-full_LeaseLiabilitiesMember_8rBg4KqmyUuYuPxVzu5jrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInAssociatesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_dXCJhRzOSE-KI_4aE3GtUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iva:RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_buEEww87HUSIzmB9VHw_tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_7hzuZ7YABk6ls6oQfoETnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_yfheuy_9XU2H9yN_qkSwMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">iva:RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_XLIDsKCJTEm0UB5CIk-Tiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_SN5Ac_HGGEqXPhg8nVP1RQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_aUv8mHsKXUaaSWrxnxqKLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_ifrs-full_LeaseLiabilitiesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_dYFp-ujODEWkgQn22I6RnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_ifrs-full_LeaseLiabilitiesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_GsWMv1_qikSzfG5Yj-NJvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_DrawdownOfBorrowingsMember_MLnrGxu8pEeScrxg9appZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">iva:DrawdownOfBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-18</instant>
        </period>
    </context>
    <context id="As_Of_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_3l6sO3DqI0iZ8EqJu2kuhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-18</instant>
        </period>
    </context>
    <context id="As_Of_12_8_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_NZ-ZgvUE8kOsb70mJ03KSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-08</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_KCZ_rlJbTkm1DXPXbOCPUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_yNqR8syCVkyKUkjoBw5nlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_RoyaltyCertificatesLiabilitiesMember_MLWq4MeMoEelhaSNDyM6mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:RoyaltyCertificatesLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_o2Fe8k_JVUOuzAwFE3EH9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_BwJ5AiMcPkmDzrV1KCPF7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_1fmInCo2D0yp8z7M1kVwrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_De4o7giPiEinOd0qNd9GCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_ll91CELP_0CkxmWGnSWYxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_RoyaltyCertificatesLiabilitiesMember_BjRDFB3IN0mcC4Ynuq2iZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:RoyaltyCertificatesLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_GSGDF0mlWkuIQruwBsMsBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_mhRLXXxIVUimCeRsLCjpAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_C0Ff4EWJsU2Ar98sMx82wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_Ue5U6HHvckKiur1A8cLvgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2023_ifrs-full_ClassesOfLiabilitiesAxis_iva_RoyaltyCertificateLiabilitiesMember_h1XHuxF4ukeRQuZnn7VzCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">iva:RoyaltyCertificateLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022__ShBeryiXEKxoX7Xx7OS6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_18_2024_To_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_EpuGEvGLYke1tVD4Ocdy8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-18</startDate>
            <endDate>2024-01-18</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_0umwc-ynPU6vJhwvCODdKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">iva:HepalysPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_iva_FibroscanMachinesMember_HHDa7KgacE6IN6Bk1COxoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">iva:FibroscanMachinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001756594</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <unit id="Unit_Standard_item_EtvJ8tlaoECD45kd85NcIQ">
        <measure>iva:item</measure>
    </unit>
    <unit id="Unit_Standard_entity_-MmOzsDakEmzabilM8ZRiQ">
        <measure>iva:entity</measure>
    </unit>
    <unit id="Unit_Standard_tranche_EQcocZ7SkkmFtux0nXQhjQ">
        <measure>iva:tranche</measure>
    </unit>
    <unit id="Unit_Standard_loan_rE4-q-dHoUqS2Tn_Pp9_NQ">
        <measure>iva:loan</measure>
    </unit>
    <unit id="Unit_Standard_agreement_ds7eY0UVBEmjbbj4M4LxNQ">
        <measure>iva:agreement</measure>
    </unit>
    <unit id="Unit_Standard_plan_EJ5kyu86bkGE5-lgkh4BhQ">
        <measure>iva:plan</measure>
    </unit>
    <unit id="Unit_Standard_site_EHdbjuNCVEq0aAm2HNh22w">
        <measure>iva:site</measure>
    </unit>
    <unit id="Unit_Divide_JPY_shares_y82NH3aOoUmAVzUuXy27vw">
        <divide>
            <unitNumerator>
                <measure>iso4217:JPY</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_D_UN8jRVLLaEed_W_JH8a6Og">
        <measure>iva:D</measure>
    </unit>
    <unit id="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Divide_EUR_USD_sLQkfMeGDkaNmYTZmSqm9Q">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>iso4217:USD</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Divide_USD_EUR_wuIAVjvD9UylZ02vyQPaBQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>iso4217:EUR</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_USD_X6E05lIDQEullbfuSGuJCw">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_employee_t09Loy2TV0yh-O2RJe0wMQ">
        <measure>iva:employee</measure>
    </unit>
    <unit id="Unit_Standard_g_TXQl02imeU2G21yIajn9zQ">
        <measure>utr:g</measure>
    </unit>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tc_zODG2TrfOkm1o5H9ooyWBQ_1_1">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tc_8MeKvnBeMECOc40fhq9FUw_2_1">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tc_2nzr9Ey5qk-lHXO5sYJAMA_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tc_h4bAUDlQ0EWpG9eb5WqHfg_4_1">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tc_Qklv8IQB30SeVCYsxsYSlw_5_1">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tc_Ufoj0p44JUS46oRtaTtzDg_6_1">0001756594</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Narr_onsub5DjyE29dgA3aOe8cg">6-K</dei:DocumentType>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Narr_TNjndEwCCkKK_Y7-DMGW3A">Inventiva S.A.</dei:EntityRegistrantName>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Hidden_9rDgFmQBEUmZjQqm7DwPdg"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">9125000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ"
      decimals="-3"
      id="Hidden_tuNLjyeUjUStSiiPLbEZGg"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">21194000</ifrs-full:Equity>
    <ifrs-full:Borrowings
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Hidden_VVi9UZTcQEKJWAcPl8yJKQ"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">54083000</ifrs-full:Borrowings>
    <iva:LeaseTerm
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_iva_FibroscanMachinesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_zqYECmxrlUilNWtPkw19_A"
      id="Hidden_YoTGSGWkUUCAhZ-9bE1tcw">P3Y</iva:LeaseTerm>
    <ifrs-full:Borrowings
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Hidden_EHsAFhljaE2ILeQMiCBC4Q"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">54083000</ifrs-full:Borrowings>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_VYxDjgD-EEW4XzmW6kxpQQ_2_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">451000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_7EJWMAnjeEmYrw7b_JJw7g_2_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">541000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_QfuJ5E-bck-_8F10kvGExw_3_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">7979000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_OlTfRUur9kCSWazQL0Eoqw_3_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">9125000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_k0Xi2uSwkkGN8TRyVkwYBw_4_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">210000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_rqwfu8imRUm38uCfe5Hy6w_4_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">225000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_6Tc0UN7dekqDHCUbMN5npw_5_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1131000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_qIMrebn1e0WMDqu8fXMfSg_5_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1425000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_tPJuAWt2SkaSd9pNm4xCZA_6_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1047000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_YlSYnBGkKUat8yN8MEMSCQ_6_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10055000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_KhAsZz0Lokqq4plompWg1g_7_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10818000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_x6xV8IxPa0Cd6oZSWXNmvA_7_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">21371000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Inventories
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_LzgkgJWpdkarnb5aPmE6Pw_8_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">393000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_lK-yTMbsC0OX21KW3xE2kA_8_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">417000</ifrs-full:Inventories>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_ejaE84ZELUSbnC9i6trA9w_9_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">809000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_EZRy19IMT0uW_Bobn8CB7Q_9_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3807000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:CurrentTaxAssetsCurrent
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_nkmvoPQyEU-C4NiqSlRf1A_10_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2704000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CurrentTaxAssetsCurrent
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_zGUppoBQMEOxv0IwbAROgQ_10_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5352000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:OtherCurrentAssets
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_NI1uNpW3kkanqmxQ7mKTtA_11_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">14554000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_FdnuaTxZEEeaamnm1B2gHw_11_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">11696000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_7Cr43t17JkaaZVV0MwjLmA_12_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10147000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_NibWOs0wt0uP15ww_sDLUg_12_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">26918000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_PlKcwJC_UEy0Ix-3NqSs7w_13_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">28608000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_SUXDrsjCZUWZr5jG6zD-CQ_13_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">48189000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_b8yEo33S5UyNJTiTffZoWA_14_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">39426000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_AtBaJ3IXZ0e2vsf-iaM7jA_14_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">69561000</ifrs-full:Assets>
    <ifrs-full:IssuedCapital
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_NmBm3saD8k-FQSrQa5_Evg_16_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">525000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_aF2BvKx1ske3ZPbYpbZb9g_16_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">521000</ifrs-full:IssuedCapital>
    <ifrs-full:SharePremium
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_6y333sIj3Emacg5HWaEB0Q_17_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">201859000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_gMfTkgkOMkOCHgW7dtG-og_17_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">201862000</ifrs-full:SharePremium>
    <iva:RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_Q3FF9dpLbUaMh3nofyyQ3w_18_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-232789000</iva:RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares>
    <iva:RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_2ClFF5x1OE-IKYq4szRk2g_18_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-124584000</iva:RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_gd108Xld_06zwAv6FmgQJw_19_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">375000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:ReserveOfExchangeDifferencesOnTranslation
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_ir4QFj-KKEipa92vcqWO9w_19_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">596000</ifrs-full:ReserveOfExchangeDifferencesOnTranslation>
    <ifrs-full:RetainedEarningsProfitLossForReportingPeriod
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_cZe_05rl10usSs4yg3sQ2Q_20_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-49029000</ifrs-full:RetainedEarningsProfitLossForReportingPeriod>
    <ifrs-full:RetainedEarningsProfitLossForReportingPeriod
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_wxuRaKk8ok-58JEBDK3L7A_20_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-110426000</ifrs-full:RetainedEarningsProfitLossForReportingPeriod>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_MLyVapl2Zkqu_5_x7tiFUg_21_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-79060000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_tDJ7KDIfcUK_xjEw3SNGDw_21_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-32032000</ifrs-full:Equity>
    <iva:NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_Dg0xse5ncUeJuiyou22Dtg_22_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">46846000</iva:NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities>
    <iva:NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_rnkISbaCqUeC1dQHBuo2Hg_22_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">32181000</iva:NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_lE9HjN0m-0mZE6Kwp350aQ_23_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">13569000</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_SoiLZ4QDFEuNKVaE30RJ6A_23_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10265000</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <iva:NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_83YJ2PC8QkGGRAuMM_J8jA_24_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">7263000</iva:NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued>
    <iva:NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_4R4VHx1bkkeKLTXeo7fYxA_24_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">6327000</iva:NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued>
    <ifrs-full:NoncurrentProvisionsForEmployeeBenefits
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_4r8l8LEOD0-nx9z2BdFLLw_25_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1555000</ifrs-full:NoncurrentProvisionsForEmployeeBenefits>
    <ifrs-full:NoncurrentProvisionsForEmployeeBenefits
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_w85pQw4_IESP7ju6Izd7Rg_25_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1559000</ifrs-full:NoncurrentProvisionsForEmployeeBenefits>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_R7L1nBv68UWPMeaVlmC2Eg_26_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">76000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_kPlwD2K6U0eSxEJVcnWPrg_26_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">70000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_4f8BvzBxf02aDzzp8PlZUw_27_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1032000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_kMiL4sRwvUCZ2lUDzY45oA_27_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1032000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_W6ZbnwgSuU6HXjElU9koyA_28_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">70340000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_lhaaj13IaUGtYWSNa5r_-w_28_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">51434000</ifrs-full:NoncurrentLiabilities>
    <iva:CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_R9nS9C4RjUiFejJBXHfQoQ_29_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5726000</iva:CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities>
    <iva:CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_gwcA5c72C0yuZPphEH09sQ_29_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5308000</iva:CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_6i4wsR-KIkqiopUJixjnow_30_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">36583000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_nJcz6fstXkKlKx2nMG4Sqg_30_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">37679000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:CurrentContractLiabilities
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_zYlVa4eWq0yEei63PRD7QQ_31_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_3324QysLS0aHoagJIJpqQQ_31_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">6000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_ZSHk5U6gWEKZO2Ed78POrg_32_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5834000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_6STPiRI0cE-jHrMYuecEBQ_32_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">7165000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_KgoYstMkmUmQTUTfaG1kRQ_33_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">48146000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_Hya81dVsA0eoLc835OowJA_33_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">50158000</ifrs-full:CurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_WuIR_aAFVU2wRrLaevB_5Q_34_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">118486000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_A9xBxUEtLUOLToaW9Aq1GA_34_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">101592000</ifrs-full:Liabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_kcEHhd2Sg0eXYpnfmDluuQ_35_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">39426000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_xqc28PnwLU-fZZl3sj6NYg_35_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">69561000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Revenue
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_fFHML_VhbkKMkl98mMX3jA_3_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">41000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_8Wtn25q7cUCxbOYlgl5RdA_3_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1901000</ifrs-full:Revenue>
    <iva:OtherIncomeFromOrdinaryActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_4q1Sv-CsL0ifbW3AbQmKVA_4_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2693000</iva:OtherIncomeFromOrdinaryActivities>
    <iva:OtherIncomeFromOrdinaryActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_Qsv3IqnF8keytYNvKRYlrw_4_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">4721000</iva:OtherIncomeFromOrdinaryActivities>
    <ifrs-full:RevenueAndOperatingIncome
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_d87MWVsQGEuPFwO1dvNW1w_5_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2734000</ifrs-full:RevenueAndOperatingIncome>
    <ifrs-full:RevenueAndOperatingIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_AtWb2xYvKkWowhuK0PfGFA_5_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">6622000</ifrs-full:RevenueAndOperatingIncome>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_O6h29RBHhkKMfXnLcOq3Ow_6_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">46822000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc__7Kakv3Amk6FkRbAXivTUg_6_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">54062000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_3vQUQitlqEOhluyu7ZNGPg_7_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">598000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_3iqh4GyZk02wlCieKVIJZw_7_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">705000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_PeqQuPBTJ0uAAg3FiAif3w_8_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">7701000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_J6EIga0WeUOlBvlLiLBcLA_8_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">6812000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_6CvytaKy4kqsDxOuwPkncA_9_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">138000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_0N2deoThU0aDfTwJLvUmdQ_9_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-44000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_te-W9up0wEyPOv915m0qKQ_10_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-52249000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_aobvZUBaUEGwEicBCYRk7Q_10_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-55003000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc__McHQb1Lx0eUnfbOOtW-gA_11_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">9093000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_G6BwbAHrwEqDCNDXmYZsVA_11_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2373000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_dEWOC1Bg6kKpML3sV4i4YA_12_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5586000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_DZajbXz1YEWl_-eIpO5fwQ_12_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2646000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncomeCost
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_mNMV294-akiD7Stcb97uLw_13_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3507000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_k8TQlg5MUUmTZ7F-NmcQEg_13_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-273000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_CcJeL-Imyk6XdvYGPHsm-Q_14_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-168000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_pVj_z_8bD0is7hG7VtSDbw_15_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">119000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_YJm2Nboe3EaMhbH7mTkqcg_15_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-7000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_uFazCaAzsE-GlRnzJLndBg_16_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-49029000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_xcw4005xLEyZSikHVDXKwg_16_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-55269000</ifrs-full:ProfitLoss>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="2"
      id="Tc_7WNXPWdt10qeif166XN3Sw_17_4"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">-0.94</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="2"
      id="Tc_7WNXPWdt10qeif166XN3Sw_17_4_2"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">-0.94</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="2"
      id="Tc_3GC88Yvc10OC7z1JxejGCQ_17_6"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">-1.31</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="2"
      id="Tc_3GC88Yvc10OC7z1JxejGCQ_17_6_2"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">-1.31</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:WeightedAverageShares
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="0"
      id="Tc_GbxkG1rUoUGUDNMOfYFwRA_18_4"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">51982093</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="0"
      id="Tc_GbxkG1rUoUGUDNMOfYFwRA_18_4_2"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">51982093</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="0"
      id="Tc_wX18z8y9oUiEEcMkIm923A_18_6"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">42044796</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="0"
      id="Tc_wX18z8y9oUiEEcMkIm923A_18_6_2"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">42044796</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_mOkZblWSTU2djOxYrYd-dQ_3_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-49029000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_L6bC0DK99UGZcVoFnACx8g_3_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-55269000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_2BL3GkH8hEKdK5lDChP8pA_4_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-220000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_fGqpe2JZoU2xHiX7CN2Tgw_4_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">104000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_pOpQFtu2gUu44oVjefep5Q_5_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-286000</ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_T_1I5X6RXkWzYT8ptTOc4A_6_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">66000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_fyTdxBpHzk6xwvQt5ytQ8g_6_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">104000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_WvpDv4OkDUez8LstpclGZA_7_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">74000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_8Nb6yxjmMU-2MhGZ1EklKQ_7_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-14000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_ao-9qRoaoEibnwRbwmEyeg_8_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">74000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_dG4aZwrwa0OuBDtgKZZG8Q_8_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-14000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_BovdknLhtkG4tOoAHXt9Ow_9_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-49175000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_OnlcGdOoUEmv3equ47jT2Q_9_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-55179000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_4J3_ocxV5ka2EE64Vzyuyw"
      decimals="-3"
      id="Tc_0ulf_4FWdEi1fhQcWI5mWg_4_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">521000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_cgKVo_3CWUmvwiGobzgKyg"
      decimals="-3"
      id="Tc_rRe6ptfpAkG8K9j_04a_bQ_4_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">201862000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember__9pAKUrAQ0enxQqBYLGv9A"
      decimals="-3"
      id="Tc_Yat_E06fRUOUnmsEIcwxww_4_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-110426000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_nwf6v9oBck-wKZOxfPU3tw"
      decimals="-3"
      id="Tc_6lVwgyVF-0iaSAki60kgqQ_4_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">596000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_IZqZC00jTUqIta0YcIIbug"
      decimals="-3"
      id="Tc_8HEs2h-5dkqcSiRLc_z6mw_4_12"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-124584000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_7eTWYNdUM0G8THXPfwGJ0Q_4_14"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-32032000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_buEEww87HUSIzmB9VHw_tg"
      decimals="-3"
      id="Tc_XjaWyeFXNU216XGsbKjSxA_5_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-49029000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_Zg-FWl5h4E2BbZJnsCFsRA_5_14"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-49029000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_dXCJhRzOSE-KI_4aE3GtUQ"
      decimals="-3"
      id="Tc_gIbKSOqrxkiMAE9T8ZAcEA_6_12"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">74000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_Sb0hoGAYHkW6cPYeclOI_A_6_14"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">74000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <iva:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_7hzuZ7YABk6ls6oQfoETnw"
      decimals="-3"
      id="Tc_j8UDhib3bE2s3383MOpKSw_7_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-220000</iva:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod>
    <iva:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc__LbKTpDVo0-Yilsxpw83xA_7_14"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-220000</iva:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_buEEww87HUSIzmB9VHw_tg"
      decimals="-3"
      id="Tc_v_VbX8S1Z0e2gj0Fsx76xg_8_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-49029000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_7hzuZ7YABk6ls6oQfoETnw"
      decimals="-3"
      id="Tc_jBYQFZk5W0KhckG8MI4EdA_8_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-220000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_dXCJhRzOSE-KI_4aE3GtUQ"
      decimals="-3"
      id="Tc_jgj0iHgblEilnCesy2bkHQ_8_12"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">74000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_18JRxu2xc0iZQUeAGYMhWA_8_14"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-49175000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_buEEww87HUSIzmB9VHw_tg"
      decimals="-3"
      id="Tc_nS5IY_Mnq0-D-QLFrZoJ7g_9_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">110426000</ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings>
    <ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_dXCJhRzOSE-KI_4aE3GtUQ"
      decimals="-3"
      id="Tc_ohzyyCPea0qDnB-kCeE5vw_9_12"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-110426000</ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_dXCJhRzOSE-KI_4aE3GtUQ"
      decimals="-3"
      id="Tc_l6cb-nxTkU-6c1zzOu4T6g_10_12"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2238000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_BGu88dHMHkWv5qXSvYPSoA_10_14"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2238000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <iva:IncreaseDecreaseThroughShareWarrantsSubscriptionPremium
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_EIAsynD95kCXlu8TLaft8A"
      decimals="-3"
      id="Tc_ebe9wcVDXkyOlXb-9iXSxw_11_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">4000</iva:IncreaseDecreaseThroughShareWarrantsSubscriptionPremium>
    <iva:IncreaseDecreaseThroughShareWarrantsSubscriptionPremium
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_7mIiNwJvsE-YWS6Oz_X7Sw"
      decimals="-3"
      id="Tc_F8umWXBXKUWjuelgWwtx3Q_11_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-4000</iva:IncreaseDecreaseThroughShareWarrantsSubscriptionPremium>
    <iva:IncreaseDecreaseThroughShareWarrantsSubscriptionPremium
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_dXCJhRzOSE-KI_4aE3GtUQ"
      decimals="-3"
      id="Tc_eJvJ_PcZWUyBwNkFpS0PGg_11_12"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">6000</iva:IncreaseDecreaseThroughShareWarrantsSubscriptionPremium>
    <iva:IncreaseDecreaseThroughShareWarrantsSubscriptionPremium
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_dMe1q7j2eU-qWdYGk6Fb_g_11_14"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">6000</iva:IncreaseDecreaseThroughShareWarrantsSubscriptionPremium>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_dXCJhRzOSE-KI_4aE3GtUQ"
      decimals="-3"
      id="Tc_w_iBMQ6CUkCh6Br8Dzl3Xw_12_12"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-138000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_liI_dw7-8EC-MbpNEwgouQ_12_14"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-138000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_dXCJhRzOSE-KI_4aE3GtUQ"
      decimals="-3"
      id="Tc_zsL14tc5BUKAgpNA9Arurw_13_12"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">41000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_haHQs6tn60et11GxfRTFFw_13_14"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">41000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_NJmuaXv-XEWsTA9f3Xh5nw"
      decimals="-3"
      id="Tc_aLPRM5qsG0mrkzBpGGWjWQ_14_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">525000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_wKPlEEy3A0SN-8jmJn4iCw"
      decimals="-3"
      id="Tc_a-Wqv-bq8k-P8N9LDHYJ_A_14_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">201859000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_9dAqjQ8yFEOk2IPndtMWDw"
      decimals="-3"
      id="Tc_i5sFGxmkD06siSLQ4IEE8w_14_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-49029000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_LdYbre3bB0WUz88niJNlag"
      decimals="-3"
      id="Tc_gPnVwiBjOkWQWflFEECDdA_14_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">375000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_jiMyqJklS0yKSmn3ylKVjw"
      decimals="-3"
      id="Tc_fgvi9LqzQU6CJQdnwtu1Sw_14_12"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-232789000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_RQ9G6dLq3UuEmOwVb5F5gA_14_14"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-79060000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_0VRJS0P300WTp8zcUcUTug"
      decimals="-3"
      id="Tc__TlfpxNho0iDF3uSj_q_lg_4_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">421000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_fEy91Y6Yw0uMQLNC3PBBYg"
      decimals="-3"
      id="Tc_OY35qjmcWUyDpfoobI7Vdg_4_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">173886000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_s4VMant100Wa1D_e2buNrQ"
      decimals="-3"
      id="Tc_NpT3XLMZ9UeULwIakdwsMw_4_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-54274000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_1unH-qq8aU-PC_sPZcCATg"
      decimals="-3"
      id="Tc_lGmUwZxu5EuBQcvsHDKrMQ_4_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-271000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_hBnlt8OLjkOaEtHFXq1FfQ"
      decimals="-3"
      id="Tc_FeVB8U49lEmcJfQX8LtTZw_4_12"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-74286000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022__ShBeryiXEKxoX7Xx7OS6A"
      decimals="-3"
      id="Tc_L-vegZcTGEu9XfQIN_wlIg_4_14"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">45476000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_XLIDsKCJTEm0UB5CIk-Tiw"
      decimals="-3"
      id="Tc_cX0S6eAsKEW--93ePVDD-A_5_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-55269000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_f-Rd4ZribUWyFT1Yi7N8iQ_5_14"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-55269000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_yfheuy_9XU2H9yN_qkSwMA"
      decimals="-3"
      id="Tc_FSn156uwp0mzeuumqUM2xQ_6_12"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-14000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_VQFkdQDnu0iClxOSmp2u5Q_6_14"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-14000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <iva:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_SN5Ac_HGGEqXPhg8nVP1RQ"
      decimals="-3"
      id="Tc_v9i26wk8WUOny-9AlQhXzA_7_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">104000</iva:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod>
    <iva:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_z4-0xkLfFkmNCqFPrVdOPA_7_14"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">104000</iva:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_XLIDsKCJTEm0UB5CIk-Tiw"
      decimals="-3"
      id="Tc_qFFNZrQHLE6jI80mWFABag_8_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-55269000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_SN5Ac_HGGEqXPhg8nVP1RQ"
      decimals="-3"
      id="Tc_X8yOl6Ni1kao5DILF6Rwjg_8_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">104000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_yfheuy_9XU2H9yN_qkSwMA"
      decimals="-3"
      id="Tc_Gfix3wNsh06pB19dzPzlVA_8_12"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-14000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_FNIdtXbeu0SBbAZiAEQylw_8_14"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-55179000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_XLIDsKCJTEm0UB5CIk-Tiw"
      decimals="-3"
      id="Tc_EScjV5gje02wcqd1zj79bw_9_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">54274000</ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings>
    <ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_yfheuy_9XU2H9yN_qkSwMA"
      decimals="-3"
      id="Tc_0MKw0g2gkkmmOzmRpmZBSw_9_12"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-54274000</ifrs-full:IncreaseDecreaseThroughAppropriationOfRetainedEarnings>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_yfheuy_9XU2H9yN_qkSwMA"
      decimals="-3"
      id="Tc_D4cKrlI-7kqjZ64y4AnXVg_10_12"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2046000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_93V0TJFY9k6vpkFIsjJmaA_10_14"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2046000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <iva:IncreaseDecreaseThroughShareWarrantsSubscriptionPremium
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_yfheuy_9XU2H9yN_qkSwMA"
      decimals="-3"
      id="Tc_r2j_XAgpj0iEnMnJ8XUJsw_11_12"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2000</iva:IncreaseDecreaseThroughShareWarrantsSubscriptionPremium>
    <iva:IncreaseDecreaseThroughShareWarrantsSubscriptionPremium
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_CIbYhwR95kC36c7zQd1E6Q_11_14"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2000</iva:IncreaseDecreaseThroughShareWarrantsSubscriptionPremium>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_yfheuy_9XU2H9yN_qkSwMA"
      decimals="-3"
      id="Tc_nw_m7EzkqUCdhX9oDUPGFQ_12_12"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_adbIP01UW0CdTT9Jv998CQ_12_14"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_yfheuy_9XU2H9yN_qkSwMA"
      decimals="-3"
      id="Tc_0lc7owCxf0WyyVQELwz2kA_13_12"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-22000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_ARjG_T8Ef0edMEjA8J17AQ_13_14"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-22000</ifrs-full:IncreaseDecreaseThroughTransfersAndOtherChangesEquity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_K1Cg_Yt_SUKODSLGGBA5mQ"
      decimals="-3"
      id="Tc_NwNlgN9370CP3E7a3iq_dg_14_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">421000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_7UXPGS9t8E2u0eKxHUgg6Q"
      decimals="-3"
      id="Tc_xtosC7pEzEC7sAmNfMQPPA_14_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">173886000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_c6YRrAmJtkGBVTOn_KinpA"
      decimals="-3"
      id="Tc_1YIrRq_9NECWaQjSg0gkhg_14_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-55269000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_M0g6jdiCfU26v1gbb-hQNA"
      decimals="-3"
      id="Tc_ARqXIWvrcUO80xKjodYLLg_14_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-168000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember_oIEPc_uew0yPdBw1zj31_A"
      decimals="-3"
      id="Tc_yYHmghmzuUCotvdSenlitQ_14_12"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-126537000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2023_aUv8mHsKXUaaSWrxnxqKLg"
      decimals="-3"
      id="Tc_t0nvTXDu0EShIq9NNOtabQ_14_14"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-7667000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_gPEwBQ-W8E-3JDd5-WOMZA_2_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-49029000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_mL7jyxwY5UCGMo69XZfUUQ_2_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-55269000</ifrs-full:ProfitLoss>
    <iva:AdjustmentsForDepreciationAmortisationAndProvisions
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_oR_WmnyUjka77tOOnVk1Qg_4_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1878000</iva:AdjustmentsForDepreciationAmortisationAndProvisions>
    <iva:AdjustmentsForDepreciationAmortisationAndProvisions
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_2-v5XxaTb0qdpBd1GplpyA_4_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1138000</iva:AdjustmentsForDepreciationAmortisationAndProvisions>
    <ifrs-full:AdjustmentsForIncomeTaxExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_8xNXm7rtVU-8TQ6xSBuf3g_5_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">22000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:AdjustmentsForIncomeTaxExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_8KNbBKmXHkqTmeX7PyOAuQ_5_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-35000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <iva:AdjustmentsForTaxCredits
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_e4lYO5cruk610GKi6cHDkA_6_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-2657000</iva:AdjustmentsForTaxCredits>
    <iva:AdjustmentsForTaxCredits
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_9GTzzh_mOEyzRPKidoXlOg_6_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-3643000</iva:AdjustmentsForTaxCredits>
    <ifrs-full:AdjustmentsForFinanceIncomeCost
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_6tGhgq0FOkma7_Xogvbfew_7_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-5180000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_RgE2djdRxEmDuPP8iQMm1g_7_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-1900000</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_ZyiOJ9sNUkGO5ICC5j7pug_8_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2238000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_3s33ApejNE6CARcSg6IiGw_8_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2046000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForUndistributedProfitsOfAssociates
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_myVqa5kqw0O-pt_-WaOmjA_9_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-8000</ifrs-full:AdjustmentsForUndistributedProfitsOfAssociates>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_wtNx_rx6aEyb7zsV_XJg_A_10_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-73000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_Hu6nso5_X0qeyIst0l4cEQ_10_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">503000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForFairValueGainsLosses
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_RARE1rJ1ekSDsBloSITB0A_11_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-8506000</ifrs-full:AdjustmentsForFairValueGainsLosses>
    <ifrs-full:AdjustmentsForFairValueGainsLosses
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_lD8mIx9Gu0Ck3nA-AnfB3w_11_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-1623000</ifrs-full:AdjustmentsForFairValueGainsLosses>
    <ifrs-full:OtherAdjustmentsForNoncashItems
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_TOJ4H7G7PECzsOGlNWsCIQ_12_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">18000</ifrs-full:OtherAdjustmentsForNoncashItems>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_dhT4KJQKZ0WbLn_NJaqtPw_13_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-50939000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_OxFqnDV_f0SXinuQUCs_Ag_13_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-54965000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_gHHyg550p0-3gxZvCuUMaQ_14_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">4075000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_orwci5fQ-UqtNptnbTYQyg_14_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-2322000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_aeBd4GLUXU-sACx2WVFfQw_15_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-2409000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_wPhfvMGLTEuR32OlrODryA_15_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">8147000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_7fHgQwG9_UK3myFyonK2ig_16_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">24000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_PxlYCw6aGkqMJUjZxmwBeA_16_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-28000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_uXeETYQlKUWMo_G5R6wX4w_17_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-5333000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_EgPiC6ksYUe3Syzql-Qk1A_17_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-5220000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_TWUGjU3b4EOxZ-G96gQhvA_18_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-4426000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_JOwtQ6IgC0eWFrNP-6PTMA_18_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-1285000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_KMtGp9sqi0a-bxzrxWWe_w_19_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-2597000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_xZ1bhfjjZUGFh0VrF-05Bw_19_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-9732000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_7PDFFOvTf0avMWqae7MFKA_20_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-48342000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_YBCg2_o2AECWFdFtl6Aj7w_20_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-45233000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <iva:PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_XE8bZa9y6Em_t__MhDiM8A_21_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">255000</iva:PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities>
    <iva:PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_lYD-LEAmcEGc9lYUsonxCw_21_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">230000</iva:PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities>
    <iva:ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_soX0TsZI-kW4uLzUuK9z7Q_22_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">90000</iva:ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities>
    <iva:ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_Z3-0s-qRXUamYQ9vdo46hQ_22_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">130000</iva:ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_mOewzsdI3UqMzQkDAgsenw_23_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">70000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
    <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_p0BsZsqzQkCV-aJPlSGsJQ_23_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">998000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_CxSmd8Xr7EyDxhG9UYo7Ow_24_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">9008000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities>
    <ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_ve63TCBLrEGdMNsmTA9ImA_24_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-8600000</ifrs-full:OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_zPiVSCclI0mJnZHPOullTw_25_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">8912000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_IxaIigaEDUmUx8HYyixroA_25_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-7702000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <iva:NetProceedsFromIssuingShares
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_BGItyY-0r0W9NUR8uNVRrQ_26_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">6000</iva:NetProceedsFromIssuingShares>
    <iva:NetProceedsFromIssuingShares
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_TB0CywfNZU2HUTvzctDL7g_26_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2000</iva:NetProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_V9vGeKiTxEmcZ5RG720HQg_27_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">24911000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_qJeg7bb4rUKykWa38TOieQ_28_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1177000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_qvY28Jh4MUe8ixZB319UFQ_28_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1448000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_4AKYW3laskWdX-dR38BC2Q_29_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1173000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_MAe8Uybsp0SBNv2z8RfpNA_29_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">707000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_iTa6uOmGpEqfMB1lwy3vMg_30_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">22568000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_gkIfIvdzpkGkwCgIIbg8gw_30_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-2153000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_KZFjmOnwh0SUcPGr2D8WNQ_32_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-16863000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_sEzFU3wDv0Co_lTj-F6pcg_32_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-55087000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_Nipljd7GhEKXm_9sYoaanw_33_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">26918000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2022__ShBeryiXEKxoX7Xx7OS6A"
      decimals="-3"
      id="Tc_j9Mf_P1W50msYUSoo7VSLw_33_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">86736000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_s5hZKw4h10-uSnpByJp3_A_34_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">92000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_4XBmfdX64kqRkhlMhJpRvw_34_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-409000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_PMUZU_ZuuU6NeSsMtMWExw_35_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10147000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2023_aUv8mHsKXUaaSWrxnxqKLg"
      decimals="-3"
      id="Tc_qClyp_QUhkWV3oDCZoMPng_35_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">31240000</ifrs-full:CashAndCashEquivalents>
    <iva:CompanyInformationTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_NzCgCGX1ukq6tjXoJaeCxw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;1.&#160;&#160;&#160;&#160;Company information&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;1.1&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;Company information&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Inventiva S.A. is a public limited company registered and domiciled in France. Its head office is located at 50 rue de Dijon, 21121 Daix. The consolidated &#xfb01;nancial statements of the company Inventiva include Inventiva S.A. and its subsidiary Inventiva Inc., created in January 2021 (the group is designated as &#x201c;Inventiva&#x201d; or the &#x201c;Company&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Inventiva&#x2019;s ordinary shares have been listed on compartment B of Euronext Paris regulated market since February 2017 and Inventiva&#x2019;s American Depositary Shares (&#x201c;ADSs&#x201d;), each representing one ordinary share, have been listed on the Nasdaq Global Market since July 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (&#x201c;MASH&#x201d;), also known as non-alcoholic steatohepatitis (&#x201c;NASH&#x201d;) and other diseases with significant unmet medical need.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing lanifibranor for the treatment of MASH/NASH, as well as a pipeline of earlier stage programs in oncology discovery.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Lanifibranor, its lead product candidate, is being developed for the treatment of patients with MASH/NASH, a chronic and progressive liver disease. In 2020, the Company announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with MASH/NASH and announced that the U.S. Food and Drug Administration ("FDA") had granted the Company the status of Breakthrough Therapy and Fast Track designation. The Company initiated the pivotal Phase III trial of lanifibranor in MASH/NASH (&#x201c;NATiV3&#x201d;) in the second half of 2021. In March 2024, the Company announced positive results from its Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and Type 2 Diabetes (&#x201c;DT2&#x201d;) (&#x201c;LEGEND&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In the first half of 2022, the Company faced delays in its NATiV3 trial that were primarily due to a higher than originally projected screen failure rate resulting in slower than anticipated enrollment rate. In addition, the Company experienced slower than predicted site activation, screening and enrollment due to negative impacts from the COVID-19 pandemic, mainly during the years 2020 and 2021, and the Company was unable to conduct clinical trial activities at sites originally located in Ukraine due to the war between Ukraine and Russia and made the decision to put recruitment for its NATiV3 trial in Ukraine on hold and close all sites in Russia. Global geopolitical events that continue to impact the markets (including Russia's invasion of Ukraine or the state of war between Israel and Hamas) could affect the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In January 2023, the Company amended the protocol for the NATiV3 trial in part to potentially accelerate enrollment and identified additional sites to help compensate for the inability to use sites in Ukraine and Russia. The revised study design limits the planned duration of the trial to 120 weeks instead of up to seven years, reduces the number of biopsies from three to two and included a 48-week active treatment extension study. The Company expects that the changes to the clinical development plan of lanifibranor, including plans for a new Phase III trial in patients with MASH/NASH and compensated cirrhosis, will be beneficial to the lanifibranor clinical program by reducing the number of biopsies and the trial duration, eventually offering all patients in the trial access to treatment and potentially expanding the addressable patient population beyond patients with F2 and F3 fibrosis to patients with MASH/NASH and compensated cirrhosis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In September 2022, the Company entered into a license and collaboration agreement with Chia Tai Tianqing Pharmaceutical Group, Co., LTD (&#x201c;CTTQ&#x201d;), a Sino Biopharm group company, to develop and commercialize, subject to regulatory approval, lanifibranor for the treatment of MASH/NASH and other metabolic diseases in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan (&#x201c;CTTQ Territory&#x201d;). In May 2023, the Company announced that CTTQ had received the Investigational New Drug (&#x201c;IND&#x201d;) approval from the Chinese National Medicine Products Administration (&#x201c;NMPA&#x201d;) allowing CTTQ to initiate the clinical development of lanifibranor in MASH/NASH in mainland China. CTTQ is participating in the ongoing NATiV3 Phase III trial and is conducting a Phase I clinical pharmacology study. In the framework of its participation in the Company&#x2019;s NATiV3 Phase III global clinical trials, pursuant to the terms of the agreement, CTTQ bears all costs associated with these trials conducted in the CTTQ Territory.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In September 2023, the Company and Hepalys Pharma, Inc. (&#x201c;Hepalys&#x201d;) announced an exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea (the &#x201c;Hepalys License Agreement&#x201d;). Hepalys is a new company created by Catalys Pacific Fund II, LP (&#x201c;Catalys&#x201d;). Under the Hepalys License Agreement, the Company received a $10 million upfront payment (equal to &#x20ac;9.5 million) on October 18, 2023, and is eligible to receive up to $231 million if certain clinical, regulatory and commercial conditions are met; in addition to tiered royalties from mid double digits to low twenties based on net sales of lanifibranor in Japan and South Korea, subject to regulatory approval. In parallel with the Hepalys License Agreement, the Company entered into an option agreement with Catalys to acquire 30% of the shares of Hepalys (the &#x201c;Catalys Option Agreement&#x201d;). The Company exercised that option on September 26, 2023, with an effective date of October 11, 2023, at an aggregate exercise price of &#xa5;300 (equal to &#x20ac;1.90). Also on September 20, 2023, the Company entered into a shareholders agreement with Catalys and Hepalys (the &#x201c;Catalys Shareholders Agreement&#x201d;). Pursuant to the Catalys Shareholders Agreement, the Company has the option to acquire all outstanding shares of Hepalys at a pre-agreed multiple of post-money valuation and the Company has a right of first refusal if Hepalys receives an offer for the license or rights related to lanifibranor.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In the first quarter of 2024, following a routine visit during the Company&#x2019;s NATiV3 clinical trial of lanifibranor in MASH/NASH, a Suspected Unexpected Serious Adverse Reaction (&#x201c;SUSAR&#x201d;) was reported in a patient. As a result of this SUSAR, the Company decided to voluntarily pause screening and randomization to implement changes to the enrollment criteria to exclude patients diagnosed or with a predisposition to autoimmune liver or thyroid disease and more frequent liver monitoring for patients enrolled in the trial as recommended by the Data Monitoring Committee (&#x201c;DMC&#x201d;)&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;3&lt;/sup&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;On March 7, 2024, the Company announced that screening activities had resumed in American sites under central Institutional Review Board (&#x201c;IRB&#x201d;). The impact of the pause on the overall timeline of the trial remains unclear, as new exclusion criteria were added, which may increase the screen failure rate, and the SUSAR, new exclusion criteria and increased liver monitoring may discourage potential trial participants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;On March 18, 2024, the Company announced positive results from its LEGEND proof-of-concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and DT2.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company expects the first visit of the last patient to be in the fourth quarter of 2024 and to complete randomization in the first half of 2025. Due to a delay of around 3 to 5 months in recruitment, the Company is currently targeting the first visit of the last patient for the second half of 2024 and the publication of the main results for the beginning of the second half of 2026. The publication of the topline results of the part 1 of the NATiV3 trial is targeted for the second half of 2026 (versus the beginning of the second half of 2026 as previously announced). If the results of the trial confirm sufficient clinical benefit and a continued good safety profile, the Company plans to file an application for accelerated approval in the United States and conditional authorization in the European Union for the marketing of lanifibranor.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s pipeline also includes odiparcil, which it was previously developing for the treatment of patients with mucopolysaccharidosis type VI (&#x201c;MPS VI&#x201d;), a group of rare genetic diseases. As announced in 2020, the Company decided to focus its clinical efforts on the development of lanifibranor. Based on feedback from the FDA, the Company believes there is potential for an efficient development pathway for odiparcil for the treatment of MPS VI and it continues to review potential options to further develop odiparcil for the treatment of MPS VI, which may include pursuing or creating a partnership, license or other transaction.&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;3&lt;/sup&gt;&lt;i style="font-style:italic;"&gt; &lt;/i&gt;A DMC is an independent group of experts who monitor patient safety and treatment efficacy data while a clinical trial is ongoing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;1.2&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;Significant events in the first half of 2024&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;The Company issued &lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3,144,654&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt; warrants to EIB in connection with the drawdown of Tranche B (see Note 4.10 Financial debt)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On January 4, 2024, the Company issued 3,144,654 additional warrants to the European Investment Bank (&#x201c;&lt;b style="font-weight:bold;"&gt;EIB&lt;/b&gt;&#x201d;) and such warrants, the &#x201c;&lt;b style="font-weight:bold;"&gt;EIB Tranche B Warrants&lt;/b&gt;&#x201d;, in accordance with the terms of the 6&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;th&lt;/sup&gt; resolution of the combined general meeting of shareholders of January 25, 2023 and Article L.225-138 of the French Commercial Code, as a condition to the drawdown of the second tranche of &#x20ac;25.0 million (&#x201c;Tranche B&#x201d;) under the finance contract between the Company and EIB (&#x201c;Finance Contract&#x201d;). The 3,144,654 shares underlying the EIB Tranche B Warrants represented approximately 6.07% of the Company's then-outstanding share capital. If all the warrants issued to the EIB in connection with drawdown of the first tranche of &#x20ac;25.0 million (&#x201c;Tranche A&#x201d;) under the Finance Contract (the &#x201c;EIB Tranche A Warrants&#x201d; and, together with the EIB Tranche B Warrants, the &#x201c;EIB Warrants&#x201d;) and the EIB Tranche B Warrants were exercised, the EIB would hold approximately 9.9% of the Company's share capital as of June 30, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"&gt;The exercise price of the EIB Tranche B Warrants is equal to &#x20ac;3.95 and corresponds to 95% of the volume-weighted average price of the Company's shares on the regulated market of Euronext Paris during the last trading session preceding the decision to issue the warrants (i.e. January 3, 2024).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"&gt;The EIB Tranche B Warrants have a maturity of twelve years and shall be exercisable following the earliest to occur of (i) the maturity date of Tranche A (i.e., on December 8, 2026), (ii) a change of control event, (iii) an event of default under the Finance Contract, or (iv) a repayment demand by EIB under the Finance Contract. The EIB Warrants will automatically be deemed null and void if not exercised within the twelve-year period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"&gt;EIB has a put option which may require the Company to repurchase all or part of the unexercised EIB Tranche B Warrants then exercisable at their intrinsic value (subject to a cap equal to the amount drawn under the Finance Contract) under certain circumstances (for example, in the event of a change of control or on the maturity date of Tranche A or in the event of default). The Company (or a substitute third party) has a call option to require EIB to sell all shares and other securities of the Company, including the EIB Warrants, to the Company, subject to certain terms and conditions. In addition, the Company has a right of first refusal to buy-back all EIB Tranche B Warrants offered for sale to a third party, subject to certain terms and conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"&gt;On the basis of the 3,144,654 new shares of the Company issuable upon exercise of all the EIB Tranche B Warrants at a price of &#x20ac;3.95 per new share, the Company could potentially receive gross proceeds of up to &#x20ac;12,421,383. There is no assurance that EIB will exercise any or all of the EIB Warrants or that the Company will receive any proceeds from the exercise of the warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"&gt;The exercise ratio of EIB Tranche A Warrants has been adjusted following the issue of Tranche B Tranche B Warrants. As of the date of authorization of the issuance of these financial statements, one EIB Tranche A Warrant entitles its holder to subscribe for 1.27 ordinary shares in the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;The Company draws down Tranche B of &lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;&#x20ac;25&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt; million under Finance Contract with EIB (see Note 4.10 Financial debt)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"&gt;On January 18, 2024, the Company drew down Tranche B of &#x20ac;25 million under the Finance Contract with EIB.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"&gt;After the drawdown of Tranche A in December 2022, the Company had an option to access further &#x20ac;25 million tranche, Tranche B, subject to the achievement of certain conditions precedent. Following the achievement of those conditions, the Company decided to draw on Tranche B. The Company intends to use the proceeds to fund part of NATiV3.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"&gt;Tranche B carries a 7% interest capitalized annually and repayment in fine. The repayment is due in January 2027, three years after its disbursement. The disbursement of Tranche B was subject to, among other conditions, (i) the full drawdown of Tranche A, (ii) the receipt by the Company from the date of the Finance Contract of an aggregate amount of at least &#x20ac;70 million (inclusive of the &#x20ac;18 million that was a condition for the disbursement of Tranche A), paid either in exchange for shares of the Company, or through upfront or milestone payments, (iii) an out-licensing, partnership or royalty transaction with an upfront payment of at least &#x20ac;10 million, (iv) operational criteria based on patient enrollment and number of sites activated in the Company&#x2019;s NATiV3 Phase III clinical trial of lanifibranor in patients with NASH and (v) the Company issuing EIB Tranche B Warrants (see above - &lt;i style="font-style:italic;"&gt;The Company issued &lt;/i&gt;&lt;i style="font-style:italic;"&gt;3,144,654&lt;/i&gt;&lt;i style="font-style:italic;"&gt; warrants to EIB in connection with the drawdown of Tranche B&lt;/i&gt;) in accordance with the terms and conditions of the warrant agreement entered into on July 1, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Tranche B of &#x20ac;25 million was recognized as financial debt at amortized cost, which takes into account the fair value of the derivative instrument (warrants) at inception and the borrowing costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On June 12, 2024, the Company and EIB amended the warrant agreement to modify the rules for adjusting the exercise ratios of the EIB Warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Treatment-related Suspected Unexpected Serious Adverse Reaction in the first quarter of 2024&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On February 15, 2024, the Company announced that an adverse event of elevated aminotransferases in liver tests was reported in a patient enrolled in the NATiV3 trial following a scheduled visit. The patient had been without clinical symptoms throughout the period of observation. This event has been assessed as a treatment-related SUSAR. Other milder cases of elevation of aminotransferases among trial participants have also been reported in the trial. The Company decided to voluntarily pause screening and randomization to implement changes to the enrollment criteria to exclude patients diagnosed or with a predisposition to autoimmune liver or thyroid disease and more frequent liver monitoring for patients enrolled in the trial as recommended by the DMC in the first quarter of 2024. Patients enrolled in the trial continued to receive treatment under the new liver monitoring schedule recommended by the DMC. This SUSAR is the first reported in all clinical trials with lanifibranor.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On March 7, 2024, the Company received approval from the central IRB overseeing clinical research in the United States to resume screening activities in its sites. This was an important milestone as 152 sites of the NATiV3 clinical trial sites are operating under central IRB and have so far randomized over 60% of the patients in the main cohort.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Due to a delay of around 3 to 5 months in recruitment, the Company is currently targeting the first visit of the last patient for the second half of 2024, to complete randomization in the first half of 2025 and the main results for the second half of 2026 (versus the beginning of the second half of 2026 as previously disclosed).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;The Company presented the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On March 18, 2024, the Company announced positive results from its LEGEND proof-of-concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The LEGEND trial was designed as a multi-center, randomized, 24-week treatment, placebo-controlled Phase II Proof-of-Concept trial to assess the safety and efficacy of lanifibranor in combination with the SGLT2 inhibitor empagliflozin for the treatment of patients with non-cirrhotic MASH/NASH and T2D. The trial was double-blind for the placebo arm and lanifibranor (800mg daily) arm, and open-label for the combination of lanifibranor (800mg daily) and empagliflozin (10mg daily) arm. The diagnosis of non-cirrhotic MASH/NASH was based on historic histology evaluation or a combination of non-invasive methods including diagnostic methods including imaging. As planned per protocol, the interim analysis was done once half of the 63 planned randomized patients with MASH completed the 24-week treatment period or prematurely discontinued from treatment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The study achieved the primary efficacy endpoint with an absolute reduction in Hemoglobin A1c (HbA1c) of 1.14% and 1.59% in patients with MASH and T2D treated with lanifibranor (800mg daily) or in combination with empagliflozin (10mg daily) at week 24 compared to an increase of 0.26% observed in the placebo arm.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The study also demonstrated a statistically significant reduction in hepatic steatosis measured by MRI-PDFF, in patients treated with lanifibranor alone and in combination with empagliflozin, -47% and -38% respectively, compared to placebo (0%). 83% and 67% of patients treated with lanifibranor alone or in combination with empagliflozin respectively, showed a reduction greater or equal to 30% of their hepatic fat, compared to 0% in the placebo arm. In addition, the study demonstrated a statistically significant effect on several secondary and exploratory endpoints, including liver enzymes (alanine aminotransferase (&#x201c;ALT&#x201d;) and aspartate aminotransferase (&#x201c;AST&#x201d;)), insulin resistance (HOMA-IR), HDL, and adiponectin. Markers of liver inflammation and fibrosis (corrected T1 relaxation time (cT1) assessed by LiverMultiScan&#xae;) were assessed for the first time with lanifibranor and showed a significant effect with lanifibranor alone and in combination with empagliflozin.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The study also demonstrated that patients treated with lanifibranor in combination with empagliflozin maintained a stable weight throughout the 24 weeks study, addressing the moderate, metabolically healthy, weight gain that can be observed in some patients treated with lanifibranor alone. Furthermore, these results demonstrated a significant relative reduction in the VAT/SAT ratio (visceral and subcutaneous adipose tissue) in patients treated with lanifibranor alone or in combination with empagliflozin, -5% and -17% respectively, compared to an increase of 11% in patients under placebo. This result reflects a shift from pro-inflammatory visceral fat towards metabolically healthy adipose tissue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The treatment with lanifibranor 800mg/daily alone and in combination with empagliflozin 10mg/daily for 24 weeks appears to be well tolerated, with no safety concerns reported.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Given that the primary endpoint of LEGEND was met, and statistically significant results were achieved on several key additional markers, the Company has decided to stop the recruitment as defined per protocol. More details on these results are expected to be presented in upcoming scientific conferences and submitted for publication.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Additional results from NATIVE Phase IIb clinical trial&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On May 13, 2024, the Company announced the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Improvements were observed for insulin resistance (insulin levels, HOMA-IR), lipid metabolism (triglycerides, HDL-cholesterol, apolipoproteins), control of glycemia (HbA1c, fasting glucose (FG) levels), systemic inflammation (hs-CRP, ferritin), hepatic steatosis and diastolic blood pressure.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On May 16, 2024, the Company announced the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"&gt;The DMC recommended to continue the clinical trial without further modification of the protocol, as amended immediately after learning about SUSAR, based on the pre-planned review of safety data.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 9pt 0pt;"&gt;The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients that have been treated for more than 48 and 72 weeks, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The patient who experienced the adverse event of increased liver test results, which was reported as a SUSAR, had been without clinical symptoms throughout the period of observation and has fully recovered.&lt;/p&gt;</iva:CompanyInformationTextBlock>
    <iva:MaximumDurationOfClinicalTrial
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember_PRoFZMRi1kONFrYjiuvhAw"
      id="Narr_UXmnSSXunUmsO71P5HGcVA">P840D</iva:MaximumDurationOfClinicalTrial>
    <iva:MaximumDurationOfClinicalTrial
      contextRef="Duration_1_1_2023_To_1_31_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember_VgrKJISxZU2hIPTccHR6Jw"
      id="Narr_CrMzSDcob0mI4yK9rw1f5A">P7Y</iva:MaximumDurationOfClinicalTrial>
    <iva:NumberOfBiopsiesUnderClinicalTrials
      contextRef="Duration_1_1_2023_To_1_31_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember_VgrKJISxZU2hIPTccHR6Jw"
      decimals="INF"
      id="Narr_9RMfx4-R90eCpH8Kaj2QZQ"
      unitRef="Unit_Standard_item_EtvJ8tlaoECD45kd85NcIQ">3</iva:NumberOfBiopsiesUnderClinicalTrials>
    <iva:NumberOfBiopsiesUnderClinicalTrials
      contextRef="Duration_2_1_2024_To_2_1_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember_v79EQ1VlWE-l9YiRgeueOg"
      decimals="INF"
      id="Narr_DyI9yh0bU0W7-lt7-eS_ug"
      unitRef="Unit_Standard_item_EtvJ8tlaoECD45kd85NcIQ">2</iva:NumberOfBiopsiesUnderClinicalTrials>
    <iva:NumberOfWeeksUnderActiveTreatmentExtensionStudy
      contextRef="Duration_1_1_2023_To_1_31_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember_VgrKJISxZU2hIPTccHR6Jw"
      id="Narr_THAo7lT6Q0CGBYkndFU85g">P336D</iva:NumberOfWeeksUnderActiveTreatmentExtensionStudy>
    <iva:LicenseAndCollaborationAgreementUpfrontFeeReceivable
      contextRef="As_Of_10_18_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_LicensingAgreementWithHepalysMember_rgk-qPK2CUyR7D5r7W0aMQ"
      decimals="-6"
      id="Narr_R5W5t3wzKkiiEMmxQ6eLww"
      unitRef="Unit_Standard_USD_X6E05lIDQEullbfuSGuJCw">10000000</iva:LicenseAndCollaborationAgreementUpfrontFeeReceivable>
    <iva:LicenseAndCollaborationAgreementUpfrontFeeReceivable
      contextRef="As_Of_10_18_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_LicensingAgreementWithHepalysMember_rgk-qPK2CUyR7D5r7W0aMQ"
      decimals="-5"
      id="Narr_YHdFqEOYeUawil5vOCLyhA"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">9500000</iva:LicenseAndCollaborationAgreementUpfrontFeeReceivable>
    <iva:LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones
      contextRef="As_Of_10_18_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_LicensingAgreementWithHepalysMember_rgk-qPK2CUyR7D5r7W0aMQ"
      decimals="-6"
      id="Narr_9ZY5TXIrA0Oxg8EtOc2VtA"
      unitRef="Unit_Standard_USD_X6E05lIDQEullbfuSGuJCw">231000000</iva:LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones>
    <iva:OptionToAcquireSharesInCompanyPercentage
      contextRef="As_Of_9_26_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_LicensingAgreementWithHepalysMember_srt_OwnershipAxis_iva_HepalysPharmaIncMember_rVQ3vZD64EmRdCdx3kiaUQ"
      decimals="2"
      id="Narr_TRIdffzg_k2bnH9NFirX6Q"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.30</iva:OptionToAcquireSharesInCompanyPercentage>
    <iva:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare
      contextRef="Duration_10_11_2023_To_10_11_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_LicensingAgreementWithHepalysMember_srt_OwnershipAxis_iva_HepalysPharmaIncMember_CJxE3L2F106Ij0r9Bq2I1Q"
      decimals="0"
      id="Narr_cF0eX2wZZ0-sDVH36DT2Ag"
      unitRef="Unit_Divide_JPY_shares_y82NH3aOoUmAVzUuXy27vw">300</iva:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare>
    <iva:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare
      contextRef="Duration_10_11_2023_To_10_11_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_LicensingAgreementWithHepalysMember_srt_OwnershipAxis_iva_HepalysPharmaIncMember_CJxE3L2F106Ij0r9Bq2I1Q"
      decimals="2"
      id="Narr_b7apoOr_8kuXtC8xDXDaSg"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">1.90</iva:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare>
    <iva:NumberOfWarrantsIssued
      contextRef="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_f6IGXbNrJUeuXFjO7KpMzA"
      decimals="INF"
      id="Narr_BX66aBSsz0awVCRe09JqzA"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">3144654</iva:NumberOfWarrantsIssued>
    <iva:NumberOfWarrantsIssued
      contextRef="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_f6IGXbNrJUeuXFjO7KpMzA"
      decimals="INF"
      id="Narr_u5RHcyOlqkyRr_kul8-KqQ"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">3144654</iva:NumberOfWarrantsIssued>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_f6IGXbNrJUeuXFjO7KpMzA"
      decimals="-5"
      id="Narr_mWLMr0DyO0C3mOt1o2jRAA"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">25000000.0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_V_UnvG7OVU6Postqxl9qTw"
      decimals="INF"
      id="Narr_zK3PkPhGAECYXMPINEKfug"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">3144654</iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <iva:PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants
      contextRef="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_f6IGXbNrJUeuXFjO7KpMzA"
      decimals="4"
      id="Narr_wtXU4JjM00inhpL6yizpOw"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.0607</iva:PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lX6me24ptE-Xl7VzcNGlCA"
      decimals="-5"
      id="Narr_RKyJU4PQhkKaxyVedfE_cA"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">25000000.0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <iva:PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_TxixfQbZCE2_vJzh9SnQSQ"
      decimals="3"
      id="Narr_0_uH32Mhv0aZ8BQOx4bNaA"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.099</iva:PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised>
    <iva:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
      contextRef="As_Of_1_3_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_rb4eejdyHUKzT5ws_uabwg"
      decimals="2"
      id="Narr_FGR_1jos6k209YvqyVc2Qg"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">3.95</iva:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <iva:ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares
      contextRef="Duration_1_3_2024_To_1_3_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_uBe1VaT84EOT7MGXjouVfw"
      decimals="2"
      id="Narr_taeQvGdsOUaRIUjuazNByg"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.95</iva:ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares>
    <iva:ClassOfWarrantOrRightMaturityTerm
      contextRef="Duration_1_4_2024_To_1_4_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_fmkw3aWeOU-HD1uNZ91qIw"
      id="Narr_11g0rKjaEkO6uf0e4HUHnQ">P12Y</iva:ClassOfWarrantOrRightMaturityTerm>
    <iva:WarrantsTerm
      contextRef="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_f6IGXbNrJUeuXFjO7KpMzA"
      id="Narr_jLGUMcBqwUSYxjZBsbbvEw">P12Y</iva:WarrantsTerm>
    <iva:SharesIssuableUponExerciseOfWarrants
      contextRef="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_f6IGXbNrJUeuXFjO7KpMzA"
      decimals="INF"
      id="Narr_8cgMukPlX02yEHniTkG78w"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">3144654</iva:SharesIssuableUponExerciseOfWarrants>
    <iva:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
      contextRef="As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_V_UnvG7OVU6Postqxl9qTw"
      decimals="2"
      id="Narr_Nap-LpyvS0qyvAgWHhC1wA"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">3.95</iva:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <iva:MaximumGrossProceedsReceivableUponExerciseOfWarrants
      contextRef="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_f6IGXbNrJUeuXFjO7KpMzA"
      decimals="0"
      id="Narr_p5clXEh1C0GTcbQaTUPYpQ"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">12421383</iva:MaximumGrossProceedsReceivableUponExerciseOfWarrants>
    <iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_IGbGo6uT7EO_KIZuumIllA"
      decimals="INF"
      id="Narr_cXwRhuRvGEGLMYI6mH0f3Q"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">1.27</iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <iva:AmountInvoicedToCounterpartyForInitialPayment
      contextRef="Duration_1_18_2024_To_1_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_O2DSQ9PKd0mIC5PRzMA_Qw"
      decimals="-5"
      id="Narr_XQtJs7I00kqi8_kxeC6x4Q"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">25000000</iva:AmountInvoicedToCounterpartyForInitialPayment>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="Duration_1_18_2024_To_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_Dck8WdQ5LUKx_AFlTUOcAA"
      decimals="-6"
      id="Narr_3RRmQXk_9E6PGS4JZARO8Q"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">25000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="Duration_1_18_2024_To_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_Dck8WdQ5LUKx_AFlTUOcAA"
      decimals="-6"
      id="Narr_1RIYN2DQ6EGbV1muBkz61Q"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">25000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:BorrowingsInterestRate
      contextRef="As_Of_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_3l6sO3DqI0iZ8EqJu2kuhQ"
      decimals="2"
      id="Narr_Y03Y-ehKEEancy49DN-uqg"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.07</ifrs-full:BorrowingsInterestRate>
    <iva:IfrsDebtInstrumentTerm
      contextRef="Duration_1_18_2024_To_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_CZeedY0HkUOxo7vg14rQ7w"
      id="Narr_s-iAUhVJq0SM_CNRqQctzQ">P3Y</iva:IfrsDebtInstrumentTerm>
    <iva:AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments
      contextRef="As_Of_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_3l6sO3DqI0iZ8EqJu2kuhQ"
      decimals="-6"
      id="Narr_GBeMmOo_D0io952HaLVUmQ"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">70000000</iva:AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments>
    <iva:AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments
      contextRef="As_Of_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_T--Cv137BUS8bbvsblFtMg"
      decimals="-6"
      id="Narr_4SfIyxHpHUubQuoiEmp9Dw"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">18000000</iva:AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments>
    <iva:MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction
      contextRef="Duration_1_18_2024_To_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_CZeedY0HkUOxo7vg14rQ7w"
      decimals="-6"
      id="Narr_RJ_ahLSTx06AhODGk7dc3g"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10000000</iva:MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction>
    <iva:NumberOfWarrantsIssued
      contextRef="Duration_1_18_2024_To_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_CZeedY0HkUOxo7vg14rQ7w"
      decimals="INF"
      id="Narr_BMSDNaVfAUm3l5T-I6eR8g"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">3144654</iva:NumberOfWarrantsIssued>
    <ifrs-full:NotionalAmount
      contextRef="As_Of_1_18_2024_u8VUV2GPAUmg3FPfMqwLIg"
      decimals="-6"
      id="Narr_BP7S7Bt4Sk-pwDh7Ub49zQ"
      unitRef="Unit_Standard_USD_X6E05lIDQEullbfuSGuJCw">25000000</ifrs-full:NotionalAmount>
    <iva:NumberOfSitesOperatingUnderCentralIrbOverseeing
      contextRef="As_Of_3_7_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember_nuFto-sydEusuJsG2ypBGg"
      decimals="INF"
      id="Narr_DDHBRehBCkeZm3UPwCxIuQ"
      unitRef="Unit_Standard_site_EHdbjuNCVEq0aAm2HNh22w">152</iva:NumberOfSitesOperatingUnderCentralIrbOverseeing>
    <iva:PercentageOfPatientsRandomizedInMainCohort
      contextRef="As_Of_3_7_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember_nuFto-sydEusuJsG2ypBGg"
      decimals="2"
      id="Narr_4YrPC4p-6kGWdsU8zHmmBw"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.60</iva:PercentageOfPatientsRandomizedInMainCohort>
    <iva:DailyDoseOfLanifibranorInTrial
      contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_YgdXCEYNr0mNt92Z5wU9hQ"
      decimals="1"
      id="Narr_sR8ZniczqkGxAruAl6u-RA"
      unitRef="Unit_Standard_g_TXQl02imeU2G21yIajn9zQ">0.800</iva:DailyDoseOfLanifibranorInTrial>
    <iva:DailyDoseOfLanifibranorInTrial
      contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember_tSDasQf4-kCHQTZLajBCXw"
      decimals="1"
      id="Narr_zmAub5vzUUyWvCygeDDKag"
      unitRef="Unit_Standard_g_TXQl02imeU2G21yIajn9zQ">0.800</iva:DailyDoseOfLanifibranorInTrial>
    <iva:DailyDoseOfEmpagliflozinInTrial
      contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_YgdXCEYNr0mNt92Z5wU9hQ"
      decimals="2"
      id="Narr_w8AJwuEL9k6O5y5Pnl7ueg"
      unitRef="Unit_Standard_g_TXQl02imeU2G21yIajn9zQ">0.010</iva:DailyDoseOfEmpagliflozinInTrial>
    <iva:NumberOfPatientsRandomizedClinicalTrialMainCohort
      contextRef="As_Of_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_Wd7CtxBOkEO4WumvaOj3bA"
      decimals="INF"
      id="Narr_obTzB_3YWEGFH78rpX_O-w"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">63</iva:NumberOfPatientsRandomizedClinicalTrialMainCohort>
    <iva:DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d
      contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember_tSDasQf4-kCHQTZLajBCXw"
      decimals="4"
      id="Narr_Yn61cN5ubEaNLZlCYYkYbQ"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.0114</iva:DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d>
    <iva:DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d
      contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_YgdXCEYNr0mNt92Z5wU9hQ"
      decimals="4"
      id="Narr_s22I1g5DlkayTS6d6_PR3Q"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.0159</iva:DemonstratedReductionOfHemoglobinInPatientsWithMashAndT2d>
    <iva:DailyDoseOfLanifibranorInTrial
      contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_YgdXCEYNr0mNt92Z5wU9hQ"
      decimals="1"
      id="Narr_CmOLxiuzdUqM4_bRmuaiHw"
      unitRef="Unit_Standard_g_TXQl02imeU2G21yIajn9zQ">0.800</iva:DailyDoseOfLanifibranorInTrial>
    <iva:DailyDoseOfEmpagliflozinInTrial
      contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_YgdXCEYNr0mNt92Z5wU9hQ"
      decimals="2"
      id="Narr_fB7FkmI760GmVfpXX11pcg"
      unitRef="Unit_Standard_g_TXQl02imeU2G21yIajn9zQ">0.010</iva:DailyDoseOfEmpagliflozinInTrial>
    <iva:DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d
      contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_JPcx_xU0GEGgRDmKGGAdGA"
      decimals="4"
      id="Narr_SEp0rLnRt0KBcQLtC_Zo5Q"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.0026</iva:DemonstratedIncreaseOfHemoglobinInPatientsWithMashAndT2d>
    <iva:DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff
      contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember_tSDasQf4-kCHQTZLajBCXw"
      decimals="2"
      id="Narr_FvlFdaOfLkGb7DKDWhgskQ"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">-0.47</iva:DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff>
    <iva:DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff
      contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_YgdXCEYNr0mNt92Z5wU9hQ"
      decimals="2"
      id="Narr_ipdcQJIQIUaOv7PrPkjfqA"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">-0.38</iva:DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff>
    <iva:DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff
      contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_JPcx_xU0GEGgRDmKGGAdGA"
      decimals="2"
      id="Narr_LNzCXTG2BEiZXe1cIPXsvg"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0</iva:DemonstratedReductionOfHepaticSteatosisMeasuredByMriPdff>
    <iva:PercentageOfPatientsTreatedInTrial
      contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember_tSDasQf4-kCHQTZLajBCXw"
      decimals="2"
      id="Narr_9-I2AR6iu0qWBRORcsLpDA"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.83</iva:PercentageOfPatientsTreatedInTrial>
    <iva:PercentageOfPatientsTreatedInTrial
      contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_YgdXCEYNr0mNt92Z5wU9hQ"
      decimals="2"
      id="Narr_jTXHtsNWAECOm8cthAhapw"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.67</iva:PercentageOfPatientsTreatedInTrial>
    <iva:DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy
      contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember_tSDasQf4-kCHQTZLajBCXw"
      decimals="2"
      id="Narr_qrKRpcPivEOk_ZzFULvCNw"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.30</iva:DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy>
    <iva:DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy
      contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_JPcx_xU0GEGgRDmKGGAdGA"
      decimals="2"
      id="Narr_TlSk4s7QO0m2yQ4Ush1blw"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0</iva:DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy>
    <iva:DemonstratedSignificantRelativeReductionInVatSatRatioInPatients
      contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember_tSDasQf4-kCHQTZLajBCXw"
      decimals="2"
      id="Narr_mt6Ax8olP0GLxOHZaj7GEw"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">-0.05</iva:DemonstratedSignificantRelativeReductionInVatSatRatioInPatients>
    <iva:DemonstratedSignificantRelativeReductionInVatSatRatioInPatients
      contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_YgdXCEYNr0mNt92Z5wU9hQ"
      decimals="2"
      id="Narr_dCR6MQPQcEWD-9QBIAflCA"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">-0.17</iva:DemonstratedSignificantRelativeReductionInVatSatRatioInPatients>
    <iva:DemonstratedSignificantRelativeReductionInVatSatRatioInPatients
      contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_JPcx_xU0GEGgRDmKGGAdGA"
      decimals="2"
      id="Narr_gt3SXB07sk-cwRYICbYh1w"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.11</iva:DemonstratedSignificantRelativeReductionInVatSatRatioInPatients>
    <iva:DailyDoseOfLanifibranorInTrial
      contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember_tSDasQf4-kCHQTZLajBCXw"
      decimals="1"
      id="Narr_vTW5h9E4aE63otm_zPz_sQ"
      unitRef="Unit_Standard_g_TXQl02imeU2G21yIajn9zQ">0.800</iva:DailyDoseOfLanifibranorInTrial>
    <iva:DailyDoseOfEmpagliflozinInTrial
      contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_YgdXCEYNr0mNt92Z5wU9hQ"
      decimals="2"
      id="Narr_bVloj9-NkUS1RPs5z1sESQ"
      unitRef="Unit_Standard_g_TXQl02imeU2G21yIajn9zQ">0.010</iva:DailyDoseOfEmpagliflozinInTrial>
    <iva:TreatmentPeriodUnderStudy
      contextRef="Duration_3_18_2024_To_3_18_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember_YgdXCEYNr0mNt92Z5wU9hQ"
      id="Narr_gngW1OdmdUiNLBpbTrw-mg">P168D</iva:TreatmentPeriodUnderStudy>
    <iva:NumberOfPatientsRandomizedForTreatment
      contextRef="As_Of_5_16_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_VAiorYC4kkm95pO29VSpPA"
      decimals="INF"
      id="Narr_9ezjyu8H90Grh9ncQ85HQQ"
      unitRef="Unit_Standard_item_EtvJ8tlaoECD45kd85NcIQ">900</iva:NumberOfPatientsRandomizedForTreatment>
    <iva:NumberOfPatientsToBeTreatedForFortyEightWeeks
      contextRef="As_Of_5_16_2024_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_xI1dcdJgHkqTYSB3mreY5A"
      decimals="INF"
      id="Narr_DL5fNX1XuUuAfKznPn74gQ"
      unitRef="Unit_Standard_item_EtvJ8tlaoECD45kd85NcIQ">360</iva:NumberOfPatientsToBeTreatedForFortyEightWeeks>
    <iva:NumberOfPatientsToBeTreatedForSeventyTwoWeeks
      contextRef="As_Of_5_16_2024_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember_xI1dcdJgHkqTYSB3mreY5A"
      decimals="INF"
      id="Narr_cJA1JyU6i0yPaqTBAqM9hw"
      unitRef="Unit_Standard_item_EtvJ8tlaoECD45kd85NcIQ">80</iva:NumberOfPatientsToBeTreatedForSeventyTwoWeeks>
    <iva:TreatmentPeriodUnderStudy
      contextRef="Duration_5_16_2024_To_5_16_2024_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember_2N4OlKpMhUqSYqUX-EXpVQ"
      id="Narr_F7YEBgqySEOf5jJaz9Mg0g">P336D</iva:TreatmentPeriodUnderStudy>
    <iva:TreatmentPeriodUnderStudy
      contextRef="Duration_5_16_2024_To_5_16_2024_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember_VYGeDPPB2Ea8OgJWmGctxw"
      id="Narr_2gnXje66S06HQBEyqZcIzw">P504D</iva:TreatmentPeriodUnderStudy>
    <ifrs-full:StatementOfIFRSCompliance
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_wl6lTuITWkCcze3lc9m6pQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;2.&#160;&#160;&#160;&#160;Basis of preparation and statement of compliance&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;2.1.&lt;/b&gt;&lt;/span&gt;Basis of preparation for the consolidated financial statements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has prepared these unaudited interim condensed consolidated financial statements in accordance with International Financial Reporting Standards (&#x201c;IFRS&#x201d;) as adopted by the European Union and IFRS Accounting Standards as issued by the International Accounting Standard Board (&#x201c;IASB&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;These unaudited interim condensed consolidated financial statements as of June 30, 2024 were approved by the Board of Directors of the Company on 14 October, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;2.2.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Statement of compliance&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;These unaudited interim condensed consolidated financial statements were prepared in compliance with &lt;i style="font-style:italic;"&gt;International Accounting Standards (IAS)&#160;34 &#x2014; Interim Financial Reporting&lt;/i&gt;, which provides for the presentation of selected explanatory notes. The accompanying notes do not contain all the disclosures required for annual financial statements and should therefore be read in conjunction with the Company&#x2019;s financial statements prepared in accordance with IFRS &#xae;Accounting Standards, referred to as IFRS as of and for the year ended December&#160;31, 2023 except for the accounting principles described in Note 3 &#x2013; &lt;i style="font-style:italic;"&gt;Accounting principles&lt;/i&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;IFRS Accounting Standards basis adopted&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The accounting policies applied by the Company in the preparation of the unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2024, are identical to those used in the annual financial statements prepared in accordance with IFRS Accounting Standards as of and for the year ended December 31, 2023, with the exception of specific provisions for the preparation of unaudited interim condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Standards, amendments to existing standards and interpretations published by the IASB whose application has been mandatory since January 1, 2024&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The application of standards, amendments to existing standards and interpretations whose application has been mandatory since January 1, 2024 in the European Union primarily concern:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;-&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Amendment to IFRS 16 &#x2013; Lease liability in a sale and leaseback&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;-&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Amendment to IAS 1 &#x2013; Non-current liabilities with covenants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;-&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Amendment to IAS 7 and IFRS 7 &#x2013; Supplier finance arrangements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Those amendments had no material impact on the Company&#x2019;s unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2024. As of June 30, 2024, the IASB had not published any amendments that would be expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Standards, amendments to existing standards and interpretations published by the IASB whose application is not yet mandatory&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The new standards, interpretations and amendments to existing standards that have been published but are not yet applicable concern:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;-&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Amendments to IAS 21 &#x2013; Lack of Exchangeability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;-&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Amendment to IFRS 9 and IFRS 7 &#x2013; Classification and Measurement of Financial Instruments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;-&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;New Standard &#x2013; IFRS 18 &#x2013; Presentation and Disclosure in Financial Statements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;-&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;New standard &#x2013; IFRS 19 Subsidiaries without Public Accountability: Disclosures&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;These new standards, interpretations and amendments are under analysis to see if there are applicable to Inventiva.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;2.3.&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Scope and method of consolidation&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Accounting policy&lt;/i&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In accordance with IFRS 10 &lt;i style="font-style:italic;"&gt;Consolidated Financial Statements&lt;/i&gt;, an entity (subsidiary) is consolidated when it is controlled by the company (the parent). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Subsidiaries are all entities over which the Company has control. The Company controls an entity when it is exposed to, or has rights to, variable returns from its involvement with the entity and could affect those returns through its power to direct the activities of the entity. Subsidiaries are consolidated from the date on which control is transferred to the Company. They are deconsolidated from the date such control ceases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;All intercompany transactions, balances, and unrealized gains on transactions between group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries are consistent with the policies adopted by the Company. &lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Consolidated entities&lt;/i&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2024, the scope of consolidation consists of two entities, the parent, Inventiva S.A. and its 100% owned subsidiary, Inventiva Inc., for which no non-controlling interest is recognized.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percent&#160;of&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&#160;of&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Ownership&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;incorporation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounting&#160;Method&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;INVENTIVA Inc.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;01/05/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;Fully Consolidated&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Interests in associates and joint ventures&lt;/i&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Hepalys is incorporated and has its principal place of business in Japan. The Company&#x2019;s proportion of ownership interest is &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;14.6%&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; and is the same as the proportion of voting rights held. In accordance with IAS 28 &lt;/span&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Investments in Associates and Joint Ventures&lt;/i&gt;&lt;span style="font-weight:normal;"&gt;, Hepalys is an associate of the Company and is accounted for using the equity method (see Note 4.4. &#x2013; &lt;/span&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Investments accounted for using the equity method&lt;/i&gt;&lt;span style="font-weight:normal;"&gt;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;2.4&lt;/b&gt;&lt;/span&gt;Foreign currency translation&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Functional and presentation currency&lt;/i&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s consolidated financial statements are presented in euros, which is also the functional currency of the parent company, Inventiva S.A. The functional currency of Inventiva Inc. is the U.S. dollar. All amounts presented in these notes to the consolidated financial statements are denominated in euros unless otherwise stated.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Translation of financial statements into presentation currency&lt;/i&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The results and financial position of foreign operations that have a functional currency different from the presentation currency are translated into euros, the presentation currency, as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Assets and liabilities for each balance sheet presented are translated at the closing rate on the date of that balance sheet, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Income and expenses for each statement of (income) loss and statement of comprehensive (income) loss are translated at average exchange rates (which is an approximate value of the exchange rate on the transaction date in the absence of significant fluctuations. Income and expenses are translated at the transaction dates if the exchange rates fluctuate significantly), and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;All resulting exchange differences are recognized in other comprehensive income.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exchange rate (USD per EUR)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;June 30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Average exchange rate for the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.0813&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.0803&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.0807&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Exchange rate at period end&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.0705&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.1050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.0866&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ifrs-full:StatementOfIFRSCompliance>
    <ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Group_aaicjSTVr02euFCtcNNjrw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2024, the scope of consolidation consists of two entities, the parent, Inventiva S.A. and its 100% owned subsidiary, Inventiva Inc., for which no non-controlling interest is recognized.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percent&#160;of&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&#160;of&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Ownership&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;incorporation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounting&#160;Method&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;INVENTIVA Inc.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;01/05/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;Fully Consolidated&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory>
    <iva:NumberOfEntitiesBeingConsolidated
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="INF"
      id="Narr_lGH75e-ci0is-rYCR7yuAw"
      unitRef="Unit_Standard_entity_-MmOzsDakEmzabilM8ZRiQ">2</iva:NumberOfEntitiesBeingConsolidated>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_iva_InventivaIncMember_y49k90Wj0kC3K8Qnf_pclA"
      decimals="2"
      id="Narr_YwsryvAIK0O-YqkWPaPVbg"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:NoncontrollingInterests
      contextRef="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_iva_InventivaIncMember_DGOb9XXQ8UK2Bub8zM5nQg"
      decimals="-3"
      id="Narr_qfzrG2Y9WkSlihHYnT1u7g"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">0</ifrs-full:NoncontrollingInterests>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_iva_InventivaIncMember_y49k90Wj0kC3K8Qnf_pclA"
      decimals="2"
      id="Tc_iIHreCt_Kk2-nTnpCHq9yg_4_4"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_wYI-vlX-bEu9MV9dohB57g"
      decimals="3"
      id="Narr_tdrAGuEj00SbD8ZfczZscg"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.146</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_tXtJEeMcaEu0B6IrmvV0mw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exchange rate (USD per EUR)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;June 30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Average exchange rate for the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.0813&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.0803&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.0807&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:52.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Exchange rate at period end&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.0705&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.1050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.0866&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="4"
      id="Tc_LoRCxZjIY0aAN1lXD-8n2g_2_2"
      unitRef="Unit_Divide_EUR_USD_sLQkfMeGDkaNmYTZmSqm9Q">1.0813</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA"
      decimals="4"
      id="Tc_G7NfV0ZiKk209RSl2ZTDcA_2_4"
      unitRef="Unit_Divide_USD_EUR_wuIAVjvD9UylZ02vyQPaBQ">1.0803</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="4"
      id="Tc_ptOR1MoCNEigYLfJ_6_6iw_2_6"
      unitRef="Unit_Divide_EUR_USD_sLQkfMeGDkaNmYTZmSqm9Q">1.0807</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="4"
      id="Tc_pbQbPwy8VUG75mM4eKxOkg_3_2"
      unitRef="Unit_Divide_EUR_USD_sLQkfMeGDkaNmYTZmSqm9Q">1.0705</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="4"
      id="Tc_iwMvRgdKiES85Ttp1CsrgA_3_4"
      unitRef="Unit_Divide_USD_EUR_wuIAVjvD9UylZ02vyQPaBQ">1.1050</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="As_Of_6_30_2023_aUv8mHsKXUaaSWrxnxqKLg"
      decimals="4"
      id="Tc_Bx6ZSPI4AkSz9NZudXz-2g_3_6"
      unitRef="Unit_Divide_EUR_USD_sLQkfMeGDkaNmYTZmSqm9Q">1.0866</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_fdhQOKqhzka8-K0dOCWaeA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;3.&#160;&#160;&#160;&#160;Accounting principles&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;3.1.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Use of estimates and judgment&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements requires management to make judgments and estimates and apply assumptions that can affect the carrying amounts of assets, liabilities, income and expenses, as well as the information presented in the accompanying notes. Actual reported values may differ from the accounting estimates made.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;There have been no significant changes in the material judgments and main estimates used by management when applying the Company&#x2019;s accounting policies in the preparation of these unaudited interim condensed consolidated financial statements from those described in the annual financial statements prepared in accordance with IFRS Accounting Standards for the year ended December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The conflict in Ukraine and the state of war between Israel and Hamas have not led to any material changes in the estimates or judgements made by management in the preparation of the Company&#x2019;s unaudited interim condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;3.2.&lt;/b&gt;&lt;/span&gt;Fair value measurement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In the table below, financial instruments are measured at fair value according to a hierarchy comprising three levels of valuation inputs:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;2: Inputs other than quoted market prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;3: Unobservable inputs for the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The table below presents the financial assets and liabilities of the Company measured at fair value as of June 30, 2024:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;At June 30, 2024 (in thousands of euros)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Financial liabilities at fair value through profit or loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term financial debt - derivatives&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,569&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 13,569&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The table below presents the financial assets and liabilities of the Company measured at fair value as of December 31, 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;At December 31, 2023 (in thousands of euros)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Financial liabilities at fair value through profit or loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term financial debt &#x2013; derivatives&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,265&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 10,265&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;3.3.&lt;/b&gt;&lt;/span&gt;Specific disclosure requirements for unaudited interim financial statements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Seasonality of operations&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s operations are not subject to material seasonal fluctuations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Income tax&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Income tax is recognized in the financial statements for each interim period. The amount corresponds to a best estimate calculated by applying the expected weighted average tax rate for the entire year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The income tax amount recorded as due for an interim period may have to be adjusted in the subsequent interim period of the same year if the estimated annual average tax rate changes.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"&gt;&lt;b style="font-weight:bold;"&gt;3.4.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"&gt;&lt;b style="font-weight:bold;"&gt;Going concern&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;From inception, the Company has financed its growth through successive capital increases, debt, collaboration and license agreements and reimbursements of CIR receivables. The Company continues to pursue its research and development activities for its product candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has incurred operating losses and negative cash flows from operations since inception due to the innovative nature of the product candidates it is developing, which necessitates a research and development phase spanning several years. The Company does not expect to generate revenue from product sales in the near future. With the biopharmaceutical industry's product development phases requiring increasing investments, the Company's financing needs will continue to grow as clinical trials of the Company's drug candidates progress and the Company invests to develop existing and new product candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2024, the Company had &#x20ac;10.1 million of available cash and cash equivalents, consisting of cash and short-term deposit accounts that are liquid and easily convertible within 3 months without penalty or risk of change in value (refer to Note 4.8 &#x2013; &lt;i style="font-style:italic;"&gt;Cash and Cash equivalents&lt;/i&gt;). In accordance with IAS 7.8, bank overdrafts which are repayable on demand are included as a component of cash and cash equivalents in the amount of &#x20ac;1.3 million as of June 30, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of the date of authorization of the issuance of these financial statements, given its current cost structure, its projected expenditure commitments, and the events after the reporting period presented in Note 6.4 - &lt;i style="font-style:italic;"&gt;Events after the reporting period&lt;/i&gt;, mainly the issue of royalty certificates and the T1 capital increase, the Company estimates that it should have sufficient funds to finance its activities through the end of the second half of 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Accordingly, as of the date of authorization of the issuance of these financial statements, the Company's current cash and cash equivalents are not expected to be sufficient to cover its operating needs for at least the next 12 months. These events and conditions indicate that an uncertainty exists that may cast significant doubt on the Company&#x2019;s ability to continue as a going concern and, therefore, the Company may be unable to realize its assets and discharge its liabilities in the normal course of business.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;This estimate is based on the Company&#x2019;s current business plan and excludes (i) other expenses related to the potential development of odiparcil or resulting from any potential in-licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue, (ii) any potential milestone payments that may be received or paid by the Company or potential additional financing, including the issue of tranches 1bis and 2 as described in Note 6.4 &#x2013; &lt;i style="font-style:italic;"&gt;Events after the reporting period&lt;/i&gt;. The Company may have based this estimate on assumptions that may prove to be incorrect, and the Company may end up using its resources sooner than anticipated.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Based on the above, the unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2024, have been prepared on a going concern basis assuming the Company will continue to operate for the foreseeable future. As such, they do not include any adjustments related to the amount or classification of assets and liabilities that may be required if the Company were not able to continue as a going concern.&lt;/p&gt;</ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_1JmMGE1Q9kSNtiejogZjSg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;3.1.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Use of estimates and judgment&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements requires management to make judgments and estimates and apply assumptions that can affect the carrying amounts of assets, liabilities, income and expenses, as well as the information presented in the accompanying notes. Actual reported values may differ from the accounting estimates made.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;There have been no significant changes in the material judgments and main estimates used by management when applying the Company&#x2019;s accounting policies in the preparation of these unaudited interim condensed consolidated financial statements from those described in the annual financial statements prepared in accordance with IFRS Accounting Standards for the year ended December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The conflict in Ukraine and the state of war between Israel and Hamas have not led to any material changes in the estimates or judgements made by management in the preparation of the Company&#x2019;s unaudited interim condensed consolidated financial statements.&lt;/p&gt;</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_oo5QTdlkoEeCpQqvaSjyaA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;3.2.&lt;/b&gt;&lt;/span&gt;Fair value measurement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In the table below, financial instruments are measured at fair value according to a hierarchy comprising three levels of valuation inputs:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;2: Inputs other than quoted market prices included within Level&#160;1 that are observable for the asset or liability, either directly or indirectly.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level&#160;3: Unobservable inputs for the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The table below presents the financial assets and liabilities of the Company measured at fair value as of June 30, 2024:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;At June 30, 2024 (in thousands of euros)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Financial liabilities at fair value through profit or loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term financial debt - derivatives&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,569&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 13,569&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The table below presents the financial assets and liabilities of the Company measured at fair value as of December 31, 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;At December 31, 2023 (in thousands of euros)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Financial liabilities at fair value through profit or loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term financial debt &#x2013; derivatives&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,265&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 10,265&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
    <ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Group_HUDtZb43Ak-2XJ3ICTk7Ew">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;At June 30, 2024 (in thousands of euros)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Financial liabilities at fair value through profit or loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term financial debt - derivatives&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,569&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 13,569&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;At December 31, 2023 (in thousands of euros)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Financial liabilities at fair value through profit or loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term financial debt &#x2013; derivatives&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,265&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 10,265&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_1QUlLx6Y0E-OzYbHdIU-FQ"
      decimals="-3"
      id="Tc_uy3oGQpfmUqgGdwUTCDAVQ_3_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">13569000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_EnC60jgh0EOHmRak6HvHFw"
      decimals="-3"
      id="Tc_sDiecUlygkiVT-pmbqzkfQ_4_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">13569000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_sO3Ilng9LUyGbmS3dP5aqw"
      decimals="-3"
      id="Tc_JQYBuW51bE2p2dH1pGAP-w_3_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10265000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_iiyUwIL1okucU3luLH42uQ"
      decimals="-3"
      id="Tc_LOPCVVztt0uJF4duEy7kaw_4_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10265000</ifrs-full:FinancialLiabilities>
    <iva:DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_PcT3YiGdt0eQPhM-MQgtww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;3.3.&lt;/b&gt;&lt;/span&gt;Specific disclosure requirements for unaudited interim financial statements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Seasonality of operations&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s operations are not subject to material seasonal fluctuations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Income tax&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Income tax is recognized in the financial statements for each interim period. The amount corresponds to a best estimate calculated by applying the expected weighted average tax rate for the entire year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The income tax amount recorded as due for an interim period may have to be adjusted in the subsequent interim period of the same year if the estimated annual average tax rate changes.&lt;/p&gt;</iva:DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock>
    <ifrs-full:DisclosureOfGoingConcernExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_GJ7QH64HuUmbRIDhCOFWjw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"&gt;&lt;b style="font-weight:bold;"&gt;3.4.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"&gt;&lt;b style="font-weight:bold;"&gt;Going concern&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;From inception, the Company has financed its growth through successive capital increases, debt, collaboration and license agreements and reimbursements of CIR receivables. The Company continues to pursue its research and development activities for its product candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has incurred operating losses and negative cash flows from operations since inception due to the innovative nature of the product candidates it is developing, which necessitates a research and development phase spanning several years. The Company does not expect to generate revenue from product sales in the near future. With the biopharmaceutical industry's product development phases requiring increasing investments, the Company's financing needs will continue to grow as clinical trials of the Company's drug candidates progress and the Company invests to develop existing and new product candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2024, the Company had &#x20ac;10.1 million of available cash and cash equivalents, consisting of cash and short-term deposit accounts that are liquid and easily convertible within 3 months without penalty or risk of change in value (refer to Note 4.8 &#x2013; &lt;i style="font-style:italic;"&gt;Cash and Cash equivalents&lt;/i&gt;). In accordance with IAS 7.8, bank overdrafts which are repayable on demand are included as a component of cash and cash equivalents in the amount of &#x20ac;1.3 million as of June 30, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of the date of authorization of the issuance of these financial statements, given its current cost structure, its projected expenditure commitments, and the events after the reporting period presented in Note 6.4 - &lt;i style="font-style:italic;"&gt;Events after the reporting period&lt;/i&gt;, mainly the issue of royalty certificates and the T1 capital increase, the Company estimates that it should have sufficient funds to finance its activities through the end of the second half of 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Accordingly, as of the date of authorization of the issuance of these financial statements, the Company's current cash and cash equivalents are not expected to be sufficient to cover its operating needs for at least the next 12 months. These events and conditions indicate that an uncertainty exists that may cast significant doubt on the Company&#x2019;s ability to continue as a going concern and, therefore, the Company may be unable to realize its assets and discharge its liabilities in the normal course of business.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;This estimate is based on the Company&#x2019;s current business plan and excludes (i) other expenses related to the potential development of odiparcil or resulting from any potential in-licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue, (ii) any potential milestone payments that may be received or paid by the Company or potential additional financing, including the issue of tranches 1bis and 2 as described in Note 6.4 &#x2013; &lt;i style="font-style:italic;"&gt;Events after the reporting period&lt;/i&gt;. The Company may have based this estimate on assumptions that may prove to be incorrect, and the Company may end up using its resources sooner than anticipated.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Based on the above, the unaudited interim condensed consolidated financial statements for the six-month period ended June 30, 2024, have been prepared on a going concern basis assuming the Company will continue to operate for the foreseeable future. As such, they do not include any adjustments related to the amount or classification of assets and liabilities that may be required if the Company were not able to continue as a going concern.&lt;/p&gt;</ifrs-full:DisclosureOfGoingConcernExplanatory>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-5"
      id="Narr_x_m-sVbvVEOw_8P9nGXlZA"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10100000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-5"
      id="Narr_e94Mr5jXUEaJmTDpS2SXlg"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1300000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_W2fxsSQu5Uq8FHoj32PADQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note&#160;4.&#160;&#160;&#160;&#160;&lt;b style="color:#212529;font-weight:bold;"&gt;Notes to the interim condensed consolidated statement of financial position&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;4.1&lt;/b&gt;&lt;/span&gt;Intangible assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible assets, gross&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,947&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,926&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and impairment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,496)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,384)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intangible assets, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 451&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 541&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;4.2&lt;/b&gt;&lt;/span&gt;Property, plant and equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property, plant and equipment, gross&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,376&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,840&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Depreciation and impairment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,396)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,714)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Property, plant and equipment, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,979&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_9rDgFmQBEUmZjQqm7DwPdg;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt; 9,126&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As of June 30, 2024, the gross value of property, plant and equipment increased by &#x20ac;0.5 million mainly due to the recognition of the right of use related to the Fibroscans lease agreement for &#160;&#x20ac;0.4 million. Depreciation and impairment increased by &#x20ac;1.7 million mainly due to the depreciation of &#x20ac;1.2 million of the right of use and &#x20ac;0.3 million due to an impairment of the right of use related to Fibroscan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;4.3&lt;/b&gt;&lt;/span&gt;Deferred tax asset&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Inventiva S.A. and Inventiva Inc. are taxed as two separate entities and cannot apply the tax consolidation. For each entity, the deferred tax assets and deferred tax liabilities are offset in the consolidated financial statements. Deferred tax assets are recognized only when an entity has sufficient evidence that it will have a sufficient taxable benefit available to use the unused tax losses in the foreseeable future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As recovery of these losses in future periods is considered unlikely due to the uncertainty inherent to the Inventiva S.A.&#x2019;s activity, deferred tax assets were recognized on this basis on June 30, 2024 only for Inventiva Inc.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;4.4&lt;/b&gt;&lt;/span&gt;Investments accounted for using the equity method&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Inventiva became an equity shareholder in Hepalys with the acquisition of 1,500,000 ordinary shares on October 11, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On January 15, 2024, Hepalys&#x2019;s shareholders approved a capital increase of &#x20ac;1.6 million by issuing new shares to a new investor, NVCC. Inventiva opted not to participate in this capital increase. Consequently, the Company&#x2019;s ownership in Hepalys was diluted to 14.6%. As of June 30, 2024, the Company holds 14.6% of Hepalys's shares, down from 15% ownership as of December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company analyzed its ownership of Hepalys and concluded that, as of June 30, 2024, it has a significant influence but not control or joint control of Hepalys. The significant influence is reflected through the ownership of percentage of interests held, the percentage of potential voting rights owned by the Company including the option, under the Catalys Shareholders Agreement, to acquire all outstanding shares of Hepalys at a pre-agreed multiple of post-money valuation that was exercisable as at June 30, 2024, as well as the active participation in the business of Hepalys in the framework of the Hepalys License Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The investment in Hepalys is accounted for using the equity method of accounting as of June 30, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The tables below provide the summarized statement of financial position of Hepalys. The disclosed information reflects the amounts presented in the financial statements of Hepalys and not the Company's share of those amounts. They have been amended to reflect adjustments made by the Company when using the equity method, in this case fair value adjustments. The tables below provide also the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;reconciliation between the Hepalys statement of financial position and the carrying amount in the Company statement of financial position.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands of euros)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,278&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total non&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 17,217&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 20,278&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,997&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,082&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,126&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 19,233&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 21,444&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Capital stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 523&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 640&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Capital reserve&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,379&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,655&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Capital surplus-others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 774&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Earnings brought forward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,018)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (178)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss for the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,444)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,111)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Treasury Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (812)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shareholders&#x2019; equity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 19,214&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 21,194&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total non&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Trade payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 237&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 19&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 250&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total equity and liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 19,233&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 21,444&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Opening net assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_tuNLjyeUjUStSiiPLbEZGg;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt; 21,122&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 22,645&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss for the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,509)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (879)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other comprehensive income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,964)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Capital variations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,566&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (819)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Closing net assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 19,214&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 21,194&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Group's share in &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands of euros)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Group's share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,813&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,267&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Elimination of unrealised profit on downstream sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,718)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,881)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,131&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,425&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;4.5&lt;/b&gt;&lt;/span&gt;Other non-current assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term deposit accounts&lt;span style="display:inline-block;width:32.36pt;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Advance payments &#x2013; non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,047&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,047&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Security deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other non&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,047&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 10,055&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2024, long-term deposit accounts with more than a year of maturity decreased by &#x20ac;9.0 million, related to the early closure of a &#x20ac;9.0 million two-year deposit forward contract.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2024 and December 31, 2023, non-current advances to suppliers amounted to &#x20ac;1.0 million, corresponding to the advance paid under the contract research organization (&#x201c;&lt;b style="font-weight:bold;"&gt;CRO&lt;/b&gt;&#x201d;) contract with Pharmaceutical Research Associates Groupe B.V (&#x201c;PRA&#x201d;) (see Note 6.1 &#x2013; &lt;i style="font-style:italic;"&gt;Commitments related to operational activities&lt;/i&gt;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;4.6&lt;/b&gt;&lt;/span&gt;Inventories&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory inventories&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 402&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 426&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Inventories write&#x2011;down&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inventories&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 393&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 417&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;4.7&lt;/b&gt;&lt;/span&gt;Trade receivables, tax receivables and other current assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Trade receivables&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade receivables break down as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;3&#160;months or less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,807&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Between 3 and 6&#160;months&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Between 6 and 12&#160;months&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;More than 12&#160;months&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Trade receivables&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 809&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,807&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The average payment period is 30 days. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2024, trade receivables decreased by &#x20ac;3.0 million mainly due to the receipt of a payment from CTTQ for the reinvoicing of specific costs related to the NATiV3 trial.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Tax receivables and Other current assets&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-variant:small-caps;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;CIR and other research tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,657&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,333&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 47&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Tax receivables&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,704&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,352&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,039&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,656&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term deposit accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current accrued income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,047&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Liquidity agreement - Cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 289&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 422&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Sales tax receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,311&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,066&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,229&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 435&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 14,554&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 11,696&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other current assets and receivables&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 17,258&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 17,048&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2024, tax receivables are mainly composed of research tax credits receivable in the amount of &#x20ac;2.7 million corresponding to the 2024 CIR as of June 30, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Prepaid expenses, which increased by about &#x20ac;2.4 million, are mainly composed of costs related to the NATiV3 Phase III clinical trial.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;4.8&lt;/b&gt;&lt;/span&gt;Cash and cash equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net cash and cash equivalents&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other cash equivalents&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,273&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,933&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash at bank and at hand&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,212&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,985&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Bank overdrafts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,338)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash and cash equivalents&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 10,147&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 26,918&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Other cash equivalents correspond to short-term bank deposits.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In accordance with IAS 7.8, bank overdrafts which are repayable on demand are included as a component of cash and cash equivalents in the amount of &#x20ac;1.3 million as of June 30, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;4.9&lt;/b&gt;&lt;/span&gt;Shareholders&#x2019; equity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"&gt;Share capital&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The share capital is set at &#x20ac;524,772&#160;at June 30, 2024 divided into 52,477,188 fully authorized, subscribed and paid-up shares with a nominal value of &#x20ac;0.01.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Share capital variation during the first six months of 2024 is set forth in the table below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In euros, except number of shares&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Premiums&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Share&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;related&#160;to&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nominal&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nature&#160;of&#160;the&#160;transactions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;capital&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;share&#160;capital&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance at December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 521,158&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 201,862,263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,115,807&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.01&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;3/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;AGA 2021 &amp;amp; AGA 2021 bis&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,614&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,614)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 361,381&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.01&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 524,772&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 201,858,649&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 52,477,188&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 0.01&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"&gt;Liquidity agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On January 19, 2018, the Company entered into a liquidity agreement with Kepler Cheuvreux, replacing the previous liquidity agreement with Oddo BHF. This agreement with Kepler Cheuvreux, as amended in 2019, automatically renews for 12-month periods unless terminated by either party. Under the terms of the agreement, the investment services provider (&#x201c;ISP&#x201d;) is authorized to buy and sell the Company&#x2019;s treasury shares without interference from the Company in order to ensure the liquidity of the shares on the Euronext market.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The liquidity agreement with Kepler Cheuvreux was extended for a new period of 12 months from January 1, 2023, and has been renewed again for a new period of 12 months from January 1, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;At June 30, 2024, treasury shares acquired by the Company through its ISP, as well as the gains or losses resulting from share purchase, sale, issue and cancellation transactions during the first six months of 2024, were accounted for as a deduction from equity. Consequently, these transactions had no impact on the Company&#x2019;s results.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options and share warrants (BSA and BSPCE)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Share-based payments correspond to:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;-&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;BSA share warrants granted to Company directors in 2017, with a subscription price set at &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x20ac;0.534&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;-&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;BSA share warrants granted to Company service providers in 2018, with a subscription price set at &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x20ac;0.48&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;-&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;BSA share warrants granted in 2019 to David Nikodem, a member of Sapidus Consulting Group LLC, a service provider of Inventiva, with a subscription price set at &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x20ac;0.18&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;-&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;BSA share warrants granted in 2020 to David Nikodem, a member of Sapidus Consulting Group LLC, and J&#xe9;r&#xe9;my Goldberg, a member of PG Healthcare LLC, both service providers of Inventiva, with a subscription price set at &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x20ac;0.29&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;-&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;BSPCE founder share warrants granted in 2021, to Frederic Cren and Pierre Broqua, Company&#x2019;s Directors;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;-&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;BSA share warrants granted in 2021 to David Nikodem, a member of Sapidus Consulting Group LLC, a service provider of Inventiva, and ISLS Consulting with a subscription price set at &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x20ac;2.45&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;-&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;BSA share warrants granted in 2023 to David Nikodem, a member of Sapidus Consulting Group LLC, a service provider of Inventiva, with a subscription price set at &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x20ac;0.20&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; and an exercise price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x20ac;2.51&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;-&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;BSA share warrants granted in 2023 to David Nikodem, a member of Sapidus Consulting Group LLC, a service provider of Inventiva, with a subscription price set at &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x20ac;0.31&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; and an exercise price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x20ac;3.91&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;BSA and BSPCE plan characteristics&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of January 1, 2024, one BSPCE share warrant plan was outstanding: BSPCE 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The BSPCE and BSA share warrant plans are described in the note 12.3 &#x201c;&lt;i style="font-style:italic;"&gt;Share warrants&lt;/i&gt; &lt;i style="font-style:italic;"&gt;plans&lt;/i&gt;&#x201d; of the 2023 annual financial statements. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;No new share warrants plan has been attributed in the first six months of 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"&gt;Movements in BSPCE share warrants and BSA share warrants (in number of shares issuable upon exercise)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;at Jan&#160;1,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Forfeited /&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;at June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Type&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in euros)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issued&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercised&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lapsed&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;BSPCE - Plan 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;04/16/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 430,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 430,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 430,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL BSPCE share warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 430,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 430,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 430,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;BSA&#160;- Plan 2017&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;05/29/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;BSA&#160;- Plan 2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;12/14/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 116,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 116,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 116,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;BSA 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;06/28/2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;BSA 2019 bis&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;03/09/2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;BSA 2019 ter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;03/09/2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;BSA 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;04/16/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,333&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;BSA 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;05/25/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;BSA 2023 - 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;12/15/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL BSA share warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 346,333&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 346,333&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 316,333&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total share warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 776,333&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 776,333&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 746,333&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;At June 30, 2024, a total of 430,000 BSPCEs (or 430,000 shares) and 346,333 BSAs were outstanding, corresponding to a total of 776,333 shares, the maximum number of shares to be issued when all related conditions are met.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Free share awards&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AGA free share award plans&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of January 1, 2024, four free share award plans were outstanding: AGA 2021-1, AGA 2021-bis, AGA 2023-1, and AGA 2023-2.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;No bonus share award plan has been attributed in the first six months of 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"&gt;Movements in AGA free shares (in number of shares issuable upon exercise)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:26.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;at grant date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;at Jan&#160;1,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Forfeited /&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;at June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Type&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in euros)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Granted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Vested&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lapsed&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;AGA&#160;- Plan 2021 - 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;04/16/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 297,599&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (296,166)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,433)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;AGA&#160;- Plan 2021 - bis&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;12/08/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65,215&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (65,215)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;AGA 2023-1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;05/25/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 300,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 300,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 600,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;AGA 2023-2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;12/15/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 748,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23,350)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 724,650&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL free shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,410,814&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 300,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (361,381)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (24,783)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,324,650&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;At June 30, 2024, a total of 1,324,650 AGA bonus shares were outstanding. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Following the amendment of article L. 225-197-1 II of the French Commercial Code by law no. 2023-1107 of November 29, 2023, the Board of Directors decided on 25 March 2024 to grant 300,000 free shares to Frederic Cren in substitution for the PAGUP 2023. This allocation is governed by the regulations of the AGA 2023-1 plan. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Following the AGA 2021 and AGA 2021 bis acquisition period, a total of 361,381 shares were definitively acquired, resulting in a capital increase of &#x20ac;3,613.81.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Upon the completion of the acquisition period for the AGA 2021 and AGA 2021 bis plans, a total of 361,381 shares were acquired, resulting in a capital increase of &#x20ac;3,613.81.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The free share award plan is described in the Note 12.4 &#x201c;Bonus share award plans&#x201d; of the annual consolidated financial statements for the year ended on December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Share-based compensation expense with respect to AGA bonus shares and BSA share warrants totaled &#x20ac;2.2 million for the six months ended June 30, 2024, compared to &#x20ac;2.0 million for the six months ended June 30, 2023. They are recognized in personnel costs (see Note 5.2 &#x2013; &lt;i style="font-style:italic;"&gt;Operating expenses&lt;/i&gt;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Performance units (&#x201c;PAGUP&#x201d;)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of January 1, 2024, one performance units plan was outstanding: PAGUP 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;No performance units award plan has been attributed in the first six months of 2024.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reference&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price (in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;at&#160;Jan&#160;1,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;at&#160;June&#160;30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Type&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;euros)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issued&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercised&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Convert AGA&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;PAGUP 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;05/25/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 300,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (300,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL PAGUP&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 300,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (300,000)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;At June 30, 2024, no PAGUP shares were outstanding. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Following the changes introduced by the French law no.2023-1107, the PAGUP 2023 granted on May 25, 2023 can be converted into AGAs. On March 25, 2024, the Board of Directors converted 300,000 free shares (governed by the AGA 2023-1 regulations) to Fr&#xe9;d&#xe9;ric Cren, thereby lapsing the 300,000 PAGUP 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The performance units plan is described in the Note 12.5 &#x201c;Performance units&#x201d; of the annual consolidated financial statements for the year ended on December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;4.10&lt;/b&gt;&lt;/span&gt;Financial debt&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Bank borrowings&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,509&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,206&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Derivatives instruments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,569&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,265&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other loans and similar borrowings&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,302&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,719&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,761&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,565&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalty certificates liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,327&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total debt&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 73,404&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_VVi9UZTcQEKJWAcPl8yJKQ;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt; 54,082&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:italic;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;include accrued interests.&lt;/i&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Movements in the period break down as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January 1, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 54,083&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 44,390&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Subscription of derivatives instruments&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Subscription of bank borrowings&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,102&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Subscription of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 345&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,706&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Issue of royalty certificates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,100&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Repayment of bank borrowings&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,177)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,485)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Repayment of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,173)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,612)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Interests on royalty certificates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 936&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,227&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Capitalized interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,961&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,405&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in fair value of derivatives instruments&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,506)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 389&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Exchange rate change&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (38)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 73,404&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 54,083&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;span style="display:inline-block;width:10.42pt;"&gt;&lt;/span&gt;&lt;i style="font-style:italic;"&gt;Net proceed&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;span style="display:inline-block;width:10.42pt;"&gt;&lt;/span&gt;&lt;i style="font-style:italic;"&gt;EIB&#x2019;s loan and warrants.&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;French state-guaranteed loan (&#x201c;PGE&#x201d;) and equity recovery loans (&#x201c;PPR&#x201d;)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In May 2020, the Company entered into three credit agreements pursuant to which it received &#x20ac;10.0 million in the form of state-guaranteed loans (&lt;i style="font-style:italic;"&gt;Pr&#xea;ts Garantis par l&#x2019;Etat&lt;/i&gt;, or &#x201c;PGE&#x201d;) which are provided by a syndicate of French banks and guaranteed by the French government in the context of the COVID-19 pandemic and were initially set to mature in May 2021. These loans were extended until the third quarter of 2022. The amendments provide for reimbursements to be made over four years, beginning in July 2022 for the loan from Cr&#xe9;dit Agricole and in September 2022 for the loans from Bpifrance and Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In June 2022, the Company entered into three loan agreements with a syndicate of French banks for a total amount of &#x20ac;5.3 million. One loan agreement was part of a state-guaranteed PGE loan facility with Bpifrance and the other two loan agreements were part of a stimulus economic plan (&lt;i style="font-style:italic;"&gt;Pr&#xea;ts Participatifs Relance&lt;/i&gt;, or &#x201c;PPR&#x201d;) granted by Cr&#xe9;dit Agricole Champagne-Bourgogne and Soci&#xe9;t&#xe9; G&#xe9;n&#xe9;rale.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The PGE loan granted by Bpifrance in 2022 is guaranteed up to 90% by the French government with an initial term of twelve months. In May 2023, the Company exercised the option to extend the maturity to align with the 2020 PGE, until May 2026. The two PPR loans are guaranteed predominantly by the French government and feature an eight-year financing period and a four-year repayment period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The PGE repayments in the first six months of 2024 amounted to &#x20ac;1.2 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Credit facility agreement with the European Investment Bank&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On May 16, 2022, the Company entered into the Finance Contract with the EIB for up to &#x20ac;50 million, divided into two tranches of &#x20ac;25 million each. &lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;On December 8, 2022, the Company received the disbursement of Tranche A. Capitalized interest for Tranche A is &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;8%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; and repayment is due in December 2026, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;four years&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; after its disbursement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;On January 18, 2024, the Company received the disbursement of Tranche B (see Note 1.2. &#x2013; &lt;/span&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Significant events in the first six months of 2024&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;). Capitalized interest for Tranche B is &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;7%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; and repayment is due in January 2027, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three years&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; after its disbursement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Finance Contract may, in certain circumstances, be prepaid, in whole or in part, for a prepayment fee, either at the election of the Company or as a result of EIB&#x2019;s demand following certain prepayment events, including a change of control or change in senior management of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Subject to certain terms and conditions, upon the occurrence of usual events of default (i.e., including payment default, misrepresentation, cross default), EIB may demand immediate repayment by the Company of all or part of the outstanding loan. As of June 30, 2024 there was no demand of reimbursement of the outstanding loan. Tranche A of &#x20ac;25 million was recognized as financial debt at amortized cost, which takes into account the fair value of the derivative instrument (EIB Warrants) at inception and the borrowing costs of &#x20ac;0.1 million. The amortized cost of the loan is &#x20ac;15.4 million on December 31, 2023, and is &#x20ac; 21.1 million on June 30, 2024, with an effective interest rate of 21.9%. The fair value of the loan as of June 30, 2024, amount to &#x20ac;20.6 million, with a market rate of 22.9%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Tranche B of &#x20ac;25 million was recognized as financial debt at amortized cost, which takes into account the fair value of the derivative instrument (EIB Warrants) at inception and the borrowing costs of &#x20ac;0.1 million. The amortized cost of the loan is &#x20ac;15.0 million on June 30, 2024, with an effective interest rate of &#160;32.7%. The fair value of the loan as of June 30, 2024, amount to &#x20ac;14.7 million, with a market rate of 33.2%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The capitalized interest for both Tranche A and Tranche B in the period amounted to &#x20ac;4.0 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Derivatives&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On July 1, 2022, in connection with the Finance Contract (see section above &#x201c;Credit facility agreement with the European Investment Bank&#x201d;), the Company entered into a warrant agreement as a condition to the funding of the two tranches of the credit facility. Each EIB Warrant has a subscription price of &#x20ac;0.01 and gives the right to subscribe to one share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The number of EIB Warrants issued to EIB was determined based on (i) the aggregate amount raised by the Company through one or more equity offerings, or through upfront or milestone payments, from the date of the Finance Contract to the time of the disbursement of the relevant tranche, and (ii)(a) the average price per share paid for the Company&#x2019;s shares in its most recent qualifying equity offering or (ii)(b) for Tranche A only, in case of no qualifying equity offering, the volume weighted average price per share of the Company over the last 180 calendar days.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The EIB Warrants have a maturity of &#160;twelve years and are exercisable following the earliest to occur of (i) a change of control event, (ii) the maturity date of Tranche A, (iii) an event of default under the Finance Contract, or (iv) a repayment demand by the EIB under the Finance Contract. The EIB Warrants shall automatically be deemed null and void if they are not exercised within the twelve-year period. Each EIB Warrant will entitle EIB to one ordinary share of the Company in exchange for the exercise price (subject to anti-dilutive provisions). However, the exercise ratio of EIB Tranche A warrants has been adjusted on December 31, 2023 following the September 5, 2023 capital increase; One EIB Tranche A Warrant entitles its holder to subscribe for 1.20 ordinary shares in the Company. EIB is entitled to a put option at its intrinsic value to require the Company to buy back the exercisable EIB Warrants not yet exercised in certain of these occurrences.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On November 28, 2022, the Company issued 2,266,023 EIB Tranche A Warrants to EIB, in accordance with the terms of the 25th resolution of the Combined General Shareholders' Meeting of May 19, 2022 and Article L. 225-138 of the French Commercial Code, as a condition to the financing of Tranche A, representing approximately 4.7% of the Company&#x2019;s share capital as of June 30, 2024. The exercise price of the EIB Tranche A Warrants is &#x20ac;4.0152, if and when they may be exercised. The potential gross proceeds if all EIB Tranche A Warrants were exercised would amount to &#x20ac;9.1 million. The transactions costs for the issuance of the EIB Tranche A Warrants amounted to &#x20ac;56 thousands.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On January 4, 2024, the Company issued 3,144,654 EIB Tranche B Warrants to EIB, representing approximately 5.2% of the Company&#x2019;s share capital as of June 30, 2024, in accordance with the terms of the 6&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;th&lt;/sup&gt; resolution of the Combined General Shareholders' Meeting of January 25, 2023, and Article L. 225-138 of the French Commercial Code. The exercise price of the EIB Tranche B Warrants is &#x20ac;3.95, if and when they may be exercised. The potential gross proceeds if all EIB &#160;Tranche B Warrants were exercised would amount to &#x20ac;12.4 million. The transactions costs for the issuance of the EIB Tranche B Warrants amounted to &#x20ac;90 thousands.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The EIB Warrants do not meet the &#x201c;fixed for fixed&#x201d; criteria (non-cash settlement option which may result in exchanging a variable number of shares for a variable price) and are accounted for as standalone derivative instruments. The Company&#x2019;s put options meet the definition of a derivative that are valued with the EIB Warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The warrant agreement includes a put option: EIB may request the Company to buy back the EIB Warrants in cash. In this context the purchase price will be defined as the difference between the volume weighted average of the trading price of the ordinary shares over the last 90 trading days and the strike price. The amount is capped, and EIB may exercise the EIB Warrants for which they did not exercise the put option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;At inception, the financial debts are split between i) a debt component accounted for at amortized cost, and ii) a premium corresponding to the initial fair value of attached EIB Warrants (then remeasured at fair value through profit and loss) including a component corresponding to the put options.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Valuation approach&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of the EIB Warrants has been estimated based on a Longstaff Schwartz approach, including the put option and the attached cap.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;This approach enables the estimation of the value of American options (that may be exercised during a specific period of time) with complex way of exercise (the warrant holder may exercise the warrants on the market based on the Company&#x2019;s share price or exercise the put option based on the 90 days average share price of the Company).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Longstaff Schwartz approach is also based on the value of the underlying equity instrument at the valuation date, the volatility observed on the historical share price of the Company, and the contractual lifespan associated equity instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The hypothesis and results are detailed in the following tables:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;BSA 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;BSA 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Grant date&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;11/28/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;01/04/2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Expiration date&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;11/28/2034&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;01/04/2036&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Number of BSA issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,266,023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,144,654&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Number of shares per BSA&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Subscription premium price per share (&#x20ac;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.01&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Exercise price per share (&#x20ac;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.95&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Valuation method&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Longstaff Schwartz&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Longstaff Schwartz&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;November&#160;28,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EIB Tranche A Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;(Grant&#160;Date)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;June&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Number of BSA outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,266,023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,266,023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,266,023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Number of shares per BSA&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock price (&#x20ac;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maturity (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cap of the put option (m&#x20ac;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Euribor 6M&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Euribor 6M&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Euribor 6M&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividends&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value (k&#x20ac;)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 9,469&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 10,266&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,738&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Unit fair value (&#x20ac;)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 4.18&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 4.53&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 2.97&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;January 4,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EIB Tranche B Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;(Grant&#160;Date)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;June 30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Number of BSA outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,144,654&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,144,654&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Number of shares per BSA&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock price (&#x20ac;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maturity (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cap of the put option (m&#x20ac;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Euribor 6M&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Euribor 6M&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividends&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value (k&#x20ac;)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 11,809&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,830&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Unit fair value (&#x20ac;)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 3.76&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 2.17&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lease liabilities&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Lease liabilities amount to &#x20ac;5.8 million as of June 30, 2024, and decreased by &#x20ac;0.8 million compared to December 31, 2023. The lease liabilities are recognized each time a new Fibroscans is leased, on a period of &lt;span style="-sec-ix-hidden:Hidden_YoTGSGWkUUCAhZ-9bE1tcw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; or four years regarding the location of use. Lease liabilities are calculated using specific discount rates, in connection with the geographic area, the maturity of the debt, and the commencement date, according to the method described in Note 3.2 of the consolidated financial statements as of December 31, 2023. The rates for contracts in progress as of June 30, 2024 range from 1.89% to 5.18%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The breakdown between long-term and short-term debt is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Less than&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Between&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Between&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;More than&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1 year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1 and 3 years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3 and 5 years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;5 years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Bank borrowings&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,509&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,229&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 36,164&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,225&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 890&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Derivatives&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,569&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,569&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,302&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,260&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,761&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,455&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,306&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalty certificates liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,263&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total debt&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 73,404&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,726&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 57,299&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,225&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 8,153&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Less than&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Between&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Between&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;More than&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1 year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1 and 3 years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;3 and 5 years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5 years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Bank borrowings&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,206&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,928&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,872&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,848&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,558&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivatives&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other loans and similar borrowings&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,719&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 82&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,636&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,565&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,298&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,267&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Royalty certificates liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,327&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,327&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total debt&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_EHsAFhljaE2ILeQMiCBC4Q;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt; 54,082&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,308&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 9,140&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 31,749&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,885&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The maturity of long-term debt and of short-term borrowings and debt is determined according to contractual repayment terms as of June 30, 2024 and December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Royalty Certificates liabilities&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 31, 2023, the Company announced the issuance of the royalty certificates (&#x201c;2023 Royalty Certificates&#x201d;) for an aggregate amount of &#x20ac;5.1 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The 2023 Royalty Certificates are accounted at the inception at the fair value (&#x20ac;5.1 million on August 31, 2023), and then at the amortized cost (&#x20ac;7.3 million on June 30, 2024 vs. &#x20ac;6.3 million on December 31, 2023) with an effective interest rate of 31.9%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Fair value as of June 30, 2024&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 30, 2024, the fair value of the 2023 Royalty Certificates, calculated using discounted cash flow approach, amounts to &#x20ac;9.1 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value corresponds to the net present value of royalties, which depend on assumptions made by the Company with regards to the probability of success of its studies, the markets sales of lanifibranor and the discount rate (27.9%). The discount rate has been estimated based on a reconciliation between the Company&#x2019;s business plan and the Company&#x2019;s market capitalization as of June 30, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;4.11&lt;/b&gt;&lt;/span&gt;Provisions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company has no provisions as of June 30, 2024, and December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;4.12&lt;/b&gt;&lt;/span&gt;Provisions for retirement benefit obligations&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Retirement benefit obligations are determined based on the rights set forth in the national collective bargaining agreement for the French pharmaceutical industry (IDCC 176/Brochure 3104) and in accordance with IAS 19 &#x2013; &lt;i style="font-style:italic;"&gt;Employee Benefits&lt;/i&gt;. These rights depend on the employee&#x2019;s final salary and seniority within the Company at his/her retirement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net provision&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The provision recorded in respect of defined benefit schemes at the end of each reporting period is shown in the table below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Retirement benefit obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,555&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,559&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total obligation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,555&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,559&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Given the absence of plan assets at June 30, 2024 and December 31, 2023, the total amount of the provision corresponds to the estimated obligation at those dates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Changes in the net provision&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Changes in the provision recorded in respect of defined benefit schemes break down as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Provision at beginning of period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,559)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,234)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expense for the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (70)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (228)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Actuarial gains or losses recognized in other comprehensive income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (97)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Provision at end of period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,555)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,559)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;Breakdown of expense recognized for the period&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Service cost for the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (104)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (183)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Interest cost for the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (46)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Benefits for the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (70)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (228)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;4.13&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Other current and non-current liabilities&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Other non-current liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2024 and December 31, 2023 non-current liabilities amount to &#x20ac;1.0 million related to an agreement with CTTQ dated December 20, 2023 pursuant to which CTTQ paid the Company an advance for certain costs related to the NATiV3 clinical trial that the Company will incur and reinvoice to CTTQ.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Employee&#x2011;related payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,739&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,869&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued payroll and other employee-related taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,801&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,540&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Sales tax payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,140&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,569&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other accrued taxes and employee-related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 142&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other miscellaneous payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,834&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,165&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;No discounting has been performed on other current liabilities as their maturity is less than one year at the end of the period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Accrued payroll and other employee-related taxes mainly relate to payables to social security and employee-benefit organizations such as URSSAF, KLESIA and APGIS for the first half of 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Other accrued taxes and employee-related expenses concern provisions for payroll taxes, such as professional training charges, apprenticeship tax, the employer&#x2019;s contribution to construction investment in France and the payroll tax.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;4.14&lt;/b&gt;&lt;/span&gt;Trade payables and short-term contract liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,583&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,679&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term contract liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Trade payables and other current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 36,586&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 37,685&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;No calculations have been made to discount trade payables to present value as payment is due within one year at the end of the reporting period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Trade payables&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Trade payables break down as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Due in 30 days&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,995&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Due in 30-60 days&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,684&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Due in more than 60 days&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Trade payable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 36,583&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 37,679&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2024, trade payables mainly included accrued liabilities for &#160;&#x20ac;24.0 million of which &#x20ac;20.2 million relate to scientific projects.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As of June 30, 2024, trade payables decreased by &#x20ac;1.1 million compared to December 31, 2023. Trade payables, which depend on the frequency of CRO invoicing, were relatively stable (down by less than 3%).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;4.15&lt;/b&gt;&lt;/span&gt;Financial assets and liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The table below presents the carrying amount of financial assets and liabilities by IFRS 9 accounting category:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:49.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Book value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;assets/liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;on the&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;carried at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; statement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;carrieds at &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; carried at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; of financial&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; through&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;position&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;profit or loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term accrued income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term deposit accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Advance payment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,047&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,047&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,047&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current accrued income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,687&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term deposit accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 809&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,518&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,518&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,518&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,147&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 16,208&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 16,208&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 16,208&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term debt &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 45,994&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative instruments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,569&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,569&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,569&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Royalty certificates liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,050&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,726&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,726&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,726&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;36,583&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;36,583&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;36,583&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other miscellaneous payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;109,998&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 13,569&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;96,429&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;110,933&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;i style="font-style:italic;"&gt;See Note 4.10 Financial debt detailing amortized cost and fair value of the Credit facility with the EIB&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:49.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Book Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;assets/liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;on the&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;carried at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; assets &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;statement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;carrieds at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; carried at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of financial&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;through&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;position&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;profit or loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term deposit accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term security deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Advance payment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,047&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,047&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,047&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term deposit accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,807&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,807&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,807&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 857&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 857&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 857&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,918&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,918&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,918&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 41,706&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 41,706&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 41,706&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term debt (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,181&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,181&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,701&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative instruments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,265&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Royalty certificates liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,327&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,327&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,617&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,308&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,679&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other miscellaneous payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;23&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;91,784&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 10,265&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;81,518&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;92,594&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock>
    <ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_2NY3KSucI0mePNy2tlOwfQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible assets, gross&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,947&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,926&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and impairment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,496)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,384)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intangible assets, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 451&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 541&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_SNcEwTle60O3eQH3YNWEsw"
      decimals="-3"
      id="Tc_fKFKYY7HGEexsJAaiPo5XA_2_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3947000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_na6RZmuG5U2D4vmO3x7mnw"
      decimals="-3"
      id="Tc_lZobkBjLyEKEtWr4sn5y0w_2_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3926000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_gFqLBMPU_kmKcAPYZiVbAA"
      decimals="-3"
      id="Tc_TX6wl-A0R0Wm3oAVes_xYQ_3_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-3496000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_OjiU0SQcREq22dnbIpV6fg"
      decimals="-3"
      id="Tc_LPvcFUdOREG_7KfbuTF3ig_3_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-3384000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_oh59QuCz4ESJJGH31Zkdog_4_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">451000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_CwEKEGa6aUeMyGo4No6lWw_4_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">541000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Group_KqSUeLmZXkq_ApI9xYNIJw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property, plant and equipment, gross&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,376&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,840&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Depreciation and impairment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,396)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10,714)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Property, plant and equipment, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,979&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_9rDgFmQBEUmZjQqm7DwPdg;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt; 9,126&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets
      contextRef="As_Of_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_mbEhqIy-C0eGw1aDWsHwyA"
      decimals="-3"
      id="Tc_sEHXG0Rc10yJp_G9aq5ywA_2_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">20376000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets
      contextRef="As_Of_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_2B9cJfzZu0-9iYr6nqkzSg"
      decimals="-3"
      id="Tc_hXlL-Yupp0S-3136gIzyYg_2_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">19840000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets
      contextRef="As_Of_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_gFqLBMPU_kmKcAPYZiVbAA"
      decimals="-3"
      id="Tc_OkHHw27hDE2hUm55ITKwhg_3_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-12396000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets
      contextRef="As_Of_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_OjiU0SQcREq22dnbIpV6fg"
      decimals="-3"
      id="Tc_FUlKrpZpjU2a56B87DuDxA_3_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-10714000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_fMqWwGT8B0msKp2GOths_w_4_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">7979000</ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets>
    <ifrs-full:ChangesInPropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-5"
      id="Narr_NXX3WXMMsECG7C8sA3FPMQ"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">500000</ifrs-full:ChangesInPropertyPlantAndEquipment>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_iva_FibroscanMachinesMember_HHDa7KgacE6IN6Bk1COxoQ"
      decimals="-5"
      id="Narr_Ms3byD0zbkeZKvIStyTYVA"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">400000</ifrs-full:AdditionsToRightofuseAssets>
    <iva:IncreasesInPropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_uKuO3UuYNECV4Eoeqzpd4g"
      decimals="-5"
      id="Narr_qAfeGmM4Vk-nq3t7tS0-1g"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1700000</iva:IncreasesInPropertyPlantAndEquipment>
    <iva:IncreasesInPropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_RightofuseAssetsMember_PXbF8eDw90i06AiOGDMO3g"
      decimals="-5"
      id="Narr_LIpPkslCr0iHdMPWeLAYrw"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1200000</iva:IncreasesInPropertyPlantAndEquipment>
    <iva:IncreasesInPropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_iva_FibroscanMachinesMember_HHDa7KgacE6IN6Bk1COxoQ"
      decimals="-5"
      id="Narr_WUP1YY_p-kG8lUEyd_EBSw"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">300000</iva:IncreasesInPropertyPlantAndEquipment>
    <iva:NumberOfSharesAcquiredInAssociate
      contextRef="Duration_10_11_2023_To_10_11_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_0ACGkUM49U6-A_OhxFep5w"
      decimals="INF"
      id="Narr_AEWpPVR-uUWf_Z7bxw6QHQ"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">1500000</iva:NumberOfSharesAcquiredInAssociate>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_1_15_2024_To_1_15_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_9LZhfVa98kGYF3dksXsUBw"
      decimals="-5"
      id="Narr_crGglUzZp02wmI6w415XyA"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1600000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="Duration_1_15_2024_To_1_15_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_9LZhfVa98kGYF3dksXsUBw"
      decimals="3"
      id="Narr_BIeEhJJpvUam05LITWkiZQ"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.146</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ"
      decimals="3"
      id="Narr_y9FdSpKCU0qAcpzTRKHKGA"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.146</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_I0kItXo1cEqfFv1DgQ0yfA"
      decimals="2"
      id="Narr_7SoQXB3QvUy4coagEHK3Hg"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.15</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_nu4XPU_GAUKKQZAGnhBCQw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands of euros)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,278&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total non&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 17,217&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 20,278&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,997&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,082&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,015&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,126&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 19,233&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 21,444&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Capital stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 523&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 640&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Capital reserve&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,379&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,655&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Capital surplus-others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 774&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Earnings brought forward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,018)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (178)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss for the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,444)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,111)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Treasury Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (812)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shareholders&#x2019; equity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 19,214&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 21,194&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total non&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Trade payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 237&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 19&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 250&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total equity and liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 19,233&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 21,444&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Opening net assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_tuNLjyeUjUStSiiPLbEZGg;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt; 21,122&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 22,645&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss for the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,509)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (879)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other comprehensive income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,964)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Capital variations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,566&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (819)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Closing net assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 19,214&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 21,194&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Group's share in &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands of euros)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Group's share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,813&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,267&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Elimination of unrealised profit on downstream sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,718)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,881)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,131&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,425&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA"
      decimals="-3"
      id="Tc_Myqvsmo7hU-GJXliYFcJNg_2_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">17217000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ"
      decimals="-3"
      id="Tc__BLeO1KNX0qZxgoais6FdQ_2_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">20278000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <iva:NonCurrentAssetsExcludingDeferredAssets
      contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA"
      decimals="-3"
      id="Tc_I0MT8SwRp0uZhFDrV7fadg_3_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">17217000</iva:NonCurrentAssetsExcludingDeferredAssets>
    <iva:NonCurrentAssetsExcludingDeferredAssets
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ"
      decimals="-3"
      id="Tc_H-GXJyIwE0O8oPmM35qIOw_3_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">20278000</iva:NonCurrentAssetsExcludingDeferredAssets>
    <ifrs-full:OtherCurrentAssets
      contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA"
      decimals="-3"
      id="Tc_JDcGlRXws0i8oSCpEfoBmA_4_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">17000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ"
      decimals="-3"
      id="Tc_iQ3JPNsOGUSHNxZWtbLweA_4_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">44000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA"
      decimals="-3"
      id="Tc_VIM0__NjK0e5ym8ZBwvckw_5_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1997000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ"
      decimals="-3"
      id="Tc_q-IZs7q9I0KtcvVV7qDNcQ_5_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1082000</ifrs-full:CashAndCashEquivalents>
    <iva:CurrentAssetsExcludingDeferredAssets
      contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA"
      decimals="-3"
      id="Tc_GJTrdzEVW0KSiDypvDz9VA_6_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2015000</iva:CurrentAssetsExcludingDeferredAssets>
    <iva:CurrentAssetsExcludingDeferredAssets
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ"
      decimals="-3"
      id="Tc_taILsWCP4k2JuR_ooLxofw_6_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1126000</iva:CurrentAssetsExcludingDeferredAssets>
    <iva:DeferredAssets
      contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA"
      decimals="-3"
      id="Tc_skQsnaQO8EOBmGriVdJuTA_7_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2000</iva:DeferredAssets>
    <iva:DeferredAssets
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ"
      decimals="-3"
      id="Tc_Yc5ks7vLvEKaPiE9bw98pg_7_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">41000</iva:DeferredAssets>
    <ifrs-full:Assets
      contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA"
      decimals="-3"
      id="Tc_bFN9kTX0Q0ulLpfwGPd-hg_8_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">19233000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ"
      decimals="-3"
      id="Tc_uboyc7sMjEeytzqQkVcRUw_8_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">21444000</ifrs-full:Assets>
    <ifrs-full:IssuedCapital
      contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA"
      decimals="-3"
      id="Tc_VR2Kz0BJH0acScSA2pI8uw_10_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">523000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ"
      decimals="-3"
      id="Tc_bERWx8BjREWkbXGEOBbcmA_10_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">640000</ifrs-full:IssuedCapital>
    <ifrs-full:CapitalReserve
      contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA"
      decimals="-3"
      id="Tc_g09Eyvfx5kykCPLpCbL0xQ_11_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">20379000</ifrs-full:CapitalReserve>
    <ifrs-full:CapitalReserve
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ"
      decimals="-3"
      id="Tc_m8mCQ9fhg0GyUDaggPp5fw_11_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">22655000</ifrs-full:CapitalReserve>
    <iva:CapitalSurplusOthers
      contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA"
      decimals="-3"
      id="Tc_OS3QAvNox0O4T6hAej_qdA_12_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">774000</iva:CapitalSurplusOthers>
    <ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriod
      contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA"
      decimals="-3"
      id="Tc_al5vJxn-2U-OC5yYCT3ulQ_13_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-1018000</ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriod>
    <ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriod
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ"
      decimals="-3"
      id="Tc_0ZM7q-U7BkaB9zAas1xqyQ_13_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-178000</ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriod>
    <ifrs-full:RetainedEarningsProfitLossForReportingPeriod
      contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA"
      decimals="-3"
      id="Tc_qbTFBY-8Hk2pN2GhPzKJBw_14_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-1444000</ifrs-full:RetainedEarningsProfitLossForReportingPeriod>
    <ifrs-full:RetainedEarningsProfitLossForReportingPeriod
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ"
      decimals="-3"
      id="Tc_e7imXRuQSECHdh3PeDTnkg_14_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-1111000</ifrs-full:RetainedEarningsProfitLossForReportingPeriod>
    <ifrs-full:TreasuryShares
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ"
      decimals="-3"
      id="Tc_469a94_GgUWaR7oVx5-ZOQ_15_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">812000</ifrs-full:TreasuryShares>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA"
      decimals="-3"
      id="Tc_mRhU6p2Oi0O8ccfaIOmUTA_16_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">19214000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ"
      decimals="-3"
      id="Tc_tGmfYbzc70ucCa3G-nWgfA_16_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">21194000</ifrs-full:Equity>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA"
      decimals="-3"
      id="Tc_KG9wg-ZWRkei0xXLcciuOQ_18_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">7000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ"
      decimals="-3"
      id="Tc_a-PvAnoMuEiJIfYQ9UWlAg_18_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">237000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA"
      decimals="-3"
      id="Tc_Cch3uJ5-gkuKEHJy8vLKcA_19_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">12000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ"
      decimals="-3"
      id="Tc_ilzLUgNupkSKKds3Cf54dA_19_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">13000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA"
      decimals="-3"
      id="Tc_RW6MxItkv0qCyc0T0eHEWw_20_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">19000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ"
      decimals="-3"
      id="Tc_316OpchHQEagAKQihqpSpQ_20_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">250000</ifrs-full:CurrentLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA"
      decimals="-3"
      id="Tc_SJ4GPAUhuUePCoF5nEAgGQ_21_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">19233000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ"
      decimals="-3"
      id="Tc_rCdrbB_CNEeziInWfrNpUg_21_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">21444000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_RyNlENHuY0axEQhwJsaZbA"
      decimals="-3"
      id="Tc_weqK1WGTlECCFa1vtd17_A_23_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">22645000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ"
      decimals="-3"
      id="Tc_JQqaQxgK4k2sa_RVgziKNw_24_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-1509000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_I0kItXo1cEqfFv1DgQ0yfA"
      decimals="-3"
      id="Tc_Wcrsn-IwX0Og8-lxHYcPtQ_24_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-879000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ"
      decimals="-3"
      id="Tc_QQTUdivHB0uQP64QWOFmJg_25_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-1964000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_I0kItXo1cEqfFv1DgQ0yfA"
      decimals="-3"
      id="Tc_Axh8x9p1g0SvWL5VV8nHfg_25_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">247000</ifrs-full:OtherComprehensiveIncome>
    <iva:IncreaseDecreaseThroughCapitalVariations
      contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ"
      decimals="-3"
      id="Tc_NFMpHJzkL0ahFhII9c6VMg_26_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1566000</iva:IncreaseDecreaseThroughCapitalVariations>
    <iva:IncreaseDecreaseThroughCapitalVariations
      contextRef="Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_I0kItXo1cEqfFv1DgQ0yfA"
      decimals="-3"
      id="Tc_r92A8pw4c0WNXGa8ZV0Pcw_26_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-819000</iva:IncreaseDecreaseThroughCapitalVariations>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_yUjEQKNvDkiyBkeHChRmwA"
      decimals="-3"
      id="Tc_QUFfJK7X50ug_PpBeIxGAA_27_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">19214000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_o0pKlLmIZUeKdXrXuYJ0QQ"
      decimals="-3"
      id="Tc_sUKc4KgAHUS9dsl8atYNiA_27_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">21194000</ifrs-full:Equity>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_wYI-vlX-bEu9MV9dohB57g"
      decimals="2"
      id="Tc_s8Bg4bN5ckCmoh_VMzQsKQ_29_2"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.15</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_CpOwuIhEIkSyaCaql_vmYA"
      decimals="2"
      id="Tc_2dKRCtgHzEuZ_iws_jYIIQ_29_4"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.15</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <iva:EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod
      contextRef="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_Nnjp7bngW0Ga6BDie0V6fw"
      decimals="-3"
      id="Tc_vneZpeJj7U2VsVkXaGjk6A_31_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2813000</iva:EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod>
    <iva:EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod
      contextRef="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_y3OYJVLzE0-whh_qoWeSDg"
      decimals="-3"
      id="Tc_T78qSH9pnUqgY1R9SVpMFQ_31_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3267000</iva:EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod>
    <iva:IntercompanyEliminationsInAssociates
      contextRef="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_Nnjp7bngW0Ga6BDie0V6fw"
      decimals="-3"
      id="Tc_LZSFtYamokWHjUfYDBjFvg_32_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1718000</iva:IntercompanyEliminationsInAssociates>
    <iva:IntercompanyEliminationsInAssociates
      contextRef="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_y3OYJVLzE0-whh_qoWeSDg"
      decimals="-3"
      id="Tc_oxcnnJ0Ek0iPaWxm3sVLwA_32_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1881000</iva:IntercompanyEliminationsInAssociates>
    <ifrs-full:Goodwill
      contextRef="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_Nnjp7bngW0Ga6BDie0V6fw"
      decimals="-3"
      id="Tc_vX6-2JZqFkKsnCh6QUkM9w_33_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">37000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_y3OYJVLzE0-whh_qoWeSDg"
      decimals="-3"
      id="Tc_RcFuC5f8g0a8o66rpU5RnQ_33_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">39000</ifrs-full:Goodwill>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_Nnjp7bngW0Ga6BDie0V6fw"
      decimals="-3"
      id="Tc_wgZxKIQwqE6MvVYE8DKx0A_34_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1131000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_y3OYJVLzE0-whh_qoWeSDg"
      decimals="-3"
      id="Tc_9ppYaw-e_0OjlpFwAtAxuw_34_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1425000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_S0CWSpptp0OrJ4utg0Muaw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term deposit accounts&lt;span style="display:inline-block;width:32.36pt;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Advance payments &#x2013; non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,047&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,047&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Security deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other non&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,047&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 10,055&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock>
    <iva:NonCurrentLongTermDepositsFromCustomers
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_ZGdFDFVMB0-d_NKripD5lg_2_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">9000000</iva:NonCurrentLongTermDepositsFromCustomers>
    <iva:NonCurrentAdvancesToSuppliers
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_HE9-HZiJAkOVIXJzX0soew_3_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1047000</iva:NonCurrentAdvancesToSuppliers>
    <iva:NonCurrentAdvancesToSuppliers
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_KZ_yAdZnlkyztdqh1i33jw_3_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1047000</iva:NonCurrentAdvancesToSuppliers>
    <iva:NonCurrentSecurityDeposits
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_-94Kk9W_AUKMu3gXYJshiA_5_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">8000</iva:NonCurrentSecurityDeposits>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_D1tw1SshX0Ovnb2lUjIpsg_6_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1047000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_vbQQ0FR5r0eiBD84nf2aew_6_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10055000</ifrs-full:OtherNoncurrentAssets>
    <iva:IncreaseDecreaseInLongTermDepositAccounts
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-5"
      id="Narr_F4C8ZAVXAkK0oeD_QJjhBQ"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">9000000.0</iva:IncreaseDecreaseInLongTermDepositAccounts>
    <ifrs-full:LongtermDeposits
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-5"
      id="Narr_dhYaiALh5UijUCcg3x9vsg"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">9000000.0</ifrs-full:LongtermDeposits>
    <iva:LongTermDepositsTerm
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Narr_fu8rlW33gEOvcsRFXN6lQQ">P2Y</iva:LongTermDepositsTerm>
    <iva:NonCurrentAdvancesToSuppliers
      contextRef="As_Of_6_30_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember_fPmzQ4Ci5kCG21AG1O_ehw"
      decimals="-5"
      id="Narr_0Gn9DFI-90GRnPGRLS0JPw"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1000000.0</iva:NonCurrentAdvancesToSuppliers>
    <iva:NonCurrentAdvancesToSuppliers
      contextRef="As_Of_12_31_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember_srRYIfYrLkGZMnq0Z1Nr_w"
      decimals="-5"
      id="Narr_B03s_rj8_EKIA_euuOntjA"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1000000.0</iva:NonCurrentAdvancesToSuppliers>
    <iva:IfrsScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_QOceNNEpi0u37Ls1ZkfvYA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory inventories&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 402&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 426&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Inventories write&#x2011;down&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inventories&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 393&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 417&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</iva:IfrsScheduleOfInventoryCurrentTableTextBlock>
    <ifrs-full:Inventories
      contextRef="As_Of_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_SNcEwTle60O3eQH3YNWEsw"
      decimals="-3"
      id="Tc_zLIFwutvy0y1FEFTwXCwLw_2_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">402000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="As_Of_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_na6RZmuG5U2D4vmO3x7mnw"
      decimals="-3"
      id="Tc_m6gYib9qDkuZpQgphhZwJg_2_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">426000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="As_Of_6_30_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_40Ly7mN0VUychMdZQFU0jg"
      decimals="-3"
      id="Tc_1MXVCze3oUqJAh5lvY78Ww_3_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-9000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="As_Of_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedImpairmentMember_hPvzcNBD1029LdKD5pm-Fw"
      decimals="-3"
      id="Tc_fOfI3x_G3EaXcDwtvtzObg_3_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-9000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_VYjcW24fpkOc8T0nFljHrA_4_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">393000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_lkoVYHsN6EuVB_CL13uA9Q_4_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">417000</ifrs-full:Inventories>
    <iva:DisclosureOfTradeReceivablesTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_8zX9e-34x0Ge_lcjdeb_Yw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;3&#160;months or less&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,807&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Between 3 and 6&#160;months&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Between 6 and 12&#160;months&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;More than 12&#160;months&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Trade receivables&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 809&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,807&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</iva:DisclosureOfTradeReceivablesTableTextBlock>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanThreeMonthsMember_2nR6xWsu-0CvgK_C4H2nmQ"
      decimals="-3"
      id="Tc_e3Ju3vcnUEyHgVh7FO5QHg_2_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">809000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanThreeMonthsMember_--thiluYlEKqu2SkZv1ljQ"
      decimals="-3"
      id="Tc_l3BBn17qWUGNtOFyfBQCWw_2_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3807000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_t-2fHgFHwEqyK7057zMd3w_6_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">809000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_Q4tw6G-XKkCAW14t76KDDw_6_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3807000</ifrs-full:TradeAndOtherCurrentReceivables>
    <iva:CurrentTradeReceivablesAveragePaymentPeriod
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Narr_63un3OFOAUi1BsdCzLhUcA">P30D</iva:CurrentTradeReceivablesAveragePaymentPeriod>
    <iva:IncreaseDecreaseInTradeAndOtherCurrentReceivables
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-5"
      id="Narr_QsMKOhFMXE2TjZxmqp0E9w"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-3000000.0</iva:IncreaseDecreaseInTradeAndOtherCurrentReceivables>
    <ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_ncmxLu4Q10yYJUVjOltOaQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-variant:small-caps;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;CIR and other research tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,657&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,333&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 47&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Tax receivables&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,704&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,352&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,039&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,656&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term deposit accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current accrued income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,047&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Liquidity agreement - Cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 289&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 422&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Sales tax receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,311&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,066&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,229&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 435&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 14,554&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 11,696&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other current assets and receivables&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 17,258&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 17,048&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory>
    <iva:CirAndOtherResearchTaxCreditsReceivable
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_yH93a6escUamuHwYFixMBg_3_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2657000</iva:CirAndOtherResearchTaxCreditsReceivable>
    <iva:CirAndOtherResearchTaxCreditsReceivable
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_SufGEAyWuk6Lp7d-s1mcWA_3_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5333000</iva:CirAndOtherResearchTaxCreditsReceivable>
    <iva:OtherCurrentTaxReceivables
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_XCALXfHLUUaPP6sYlz-GmA_4_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">47000</iva:OtherCurrentTaxReceivables>
    <iva:OtherCurrentTaxReceivables
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_fjDkOug-CEavtG0vkkyeyQ_4_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">19000</iva:OtherCurrentTaxReceivables>
    <ifrs-full:CurrentTaxAssetsCurrent
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_UuBM9tTULUmkfWuDbGGlog_5_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2704000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CurrentTaxAssetsCurrent
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_4qFIEeoYAk6MLzQ1GjmPjg_5_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5352000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_e9D5q_7dAE6918OvejTNdg_6_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">7039000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_RpinGn2JeUaurAA2g_8JVA_6_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">4656000</ifrs-full:CurrentPrepaidExpenses>
    <iva:ShortTermDepositAccountsCurrent
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_B9xTL2fBg0iiBsVNeKxA-A_7_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">70000</iva:ShortTermDepositAccountsCurrent>
    <ifrs-full:CurrentAccruedIncomeIncludingCurrentContractAssets
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_MgG7TDw2OUmgZmffX751lA_8_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1687000</ifrs-full:CurrentAccruedIncomeIncludingCurrentContractAssets>
    <ifrs-full:CurrentAccruedIncomeIncludingCurrentContractAssets
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_PUMj7cOUKE-jUzTq3bm42w_8_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1047000</ifrs-full:CurrentAccruedIncomeIncludingCurrentContractAssets>
    <iva:CashUnderLiquidityAgreementCurrent
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_Cp1wTzwaXEeVDcUZ76WIWA_9_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">289000</iva:CashUnderLiquidityAgreementCurrent>
    <iva:CashUnderLiquidityAgreementCurrent
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_sHRlnfePn0q2fa5QBGA43g_9_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">422000</iva:CashUnderLiquidityAgreementCurrent>
    <iva:SalesTaxReceivableCurrent
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_SYbh9edrsUKcudbG907lDg_10_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3311000</iva:SalesTaxReceivableCurrent>
    <iva:SalesTaxReceivableCurrent
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_Q5BCm5oQdkOgT4qf-aa-OA_10_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5066000</iva:SalesTaxReceivableCurrent>
    <ifrs-full:OtherCurrentReceivables
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_LX5whK3bq0y3-ld0ZLRIpA_11_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2229000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_ie9K_YNAg0eIgFwablyePQ_11_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">435000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentAssets
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_85mNANC4R0C2UTFM1tf9Xg_12_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">14554000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_2ufMm2L1S0O5oMOrdk28SA_12_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">11696000</ifrs-full:OtherCurrentAssets>
    <iva:OtherCurrentAssetsAndReceivables
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_exBBTuY6bkyzdwGSX6MHbQ_13_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">17258000</iva:OtherCurrentAssetsAndReceivables>
    <iva:OtherCurrentAssetsAndReceivables
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_shz52Ne20kCyonYAzesCSA_13_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">17048000</iva:OtherCurrentAssetsAndReceivables>
    <ifrs-full:CurrentAccruedIncomeIncludingCurrentContractAssets
      contextRef="As_Of_6_30_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_ZxMBck8Vv06CkTltj3JJkg"
      decimals="-5"
      id="Narr_G_aHUDF_c0CqxDXpPVlpIA"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2700000</ifrs-full:CurrentAccruedIncomeIncludingCurrentContractAssets>
    <iva:IncreaseDecreaseInShortTermDepositAccounts
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-5"
      id="Narr_YwEzn58vJ0CBEgzEqIGzwA"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2400000</iva:IncreaseDecreaseInShortTermDepositAccounts>
    <iva:DisclosureOfCashAndCashEquivalentsTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_wHRCLgUJGECnzDKjV1f2Ew">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net cash and cash equivalents&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other cash equivalents&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,273&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,933&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash at bank and at hand&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,212&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,985&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Bank overdrafts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,338)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash and cash equivalents&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 10,147&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 26,918&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:baseline;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Other cash equivalents correspond to short-term bank deposits.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;</iva:DisclosureOfCashAndCashEquivalentsTableTextBlock>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_uHtsvTOQ10CKI_uwyb5l0A_3_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10273000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_GXgVPDxbDUOhsNk4ze5zSw_3_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">17933000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:Cash
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_ZzKDwO-bh02J7sNTgeNILA_4_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1212000</ifrs-full:Cash>
    <ifrs-full:Cash
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_FsShiKvo8Em-DlpXYA8tww_4_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">8985000</ifrs-full:Cash>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_D0cpAwx9v0e9T2ab6YAoqA_5_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1338000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_k-td-xK_GUi_AIYFhcJXNQ_6_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10147000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_MY5YYY5BmEO2NYkK2WPQpQ_6_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">26918000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-5"
      id="Narr_-DuoQHCvsEa09p1_4_UUkw"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1300000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:IssuedCapital
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="0"
      id="Narr_PmjRzCjIHUi1-7aEMShwsw"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">524772</ifrs-full:IssuedCapital>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="INF"
      id="Narr_xXQy8HQgeEKp-8Z0SpfNQw"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">52477188</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:ParValuePerShare
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="INF"
      id="Narr_iR9qxg4lcUKeOQc364Ln_A"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">0.01</ifrs-full:ParValuePerShare>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_n6vwj1f_sU24eHkRviH6tA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Premiums&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Share&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;related&#160;to&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nominal&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nature&#160;of&#160;the&#160;transactions&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;capital&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;share&#160;capital&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance at December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 521,158&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 201,862,263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,115,807&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.01&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;3/25/2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;AGA 2021 &amp;amp; AGA 2021 bis&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,614&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,614)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 361,381&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.01&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 524,772&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 201,858,649&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 52,477,188&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 0.01&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_4J3_ocxV5ka2EE64Vzyuyw"
      decimals="0"
      id="Tc_UokxfPctqUWSyolNr6N7iw_4_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">521158</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_cgKVo_3CWUmvwiGobzgKyg"
      decimals="0"
      id="Tc_vF9GPBEnoEqaEBp6iqU7qA_4_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">201862263</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="INF"
      id="Tc_mPh7yHdZXEqwaJYpNHlEmg_4_8"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">52115807</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:ParValuePerShare
      contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_4J3_ocxV5ka2EE64Vzyuyw"
      decimals="INF"
      id="Tc_yq4zu3BZFUmUlTu3q63whw_4_10"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">0.01</ifrs-full:ParValuePerShare>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_3_25_2024_To_3_25_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_eylYkv54iU6BbmTMEduewg"
      decimals="0"
      id="Tc_Tde80VIuuki5_X90XaZ66g_5_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3614</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_3_25_2024_To_3_25_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_NWloX1BI0US4Lo97RBCE_g"
      decimals="0"
      id="Tc_3IIEDjqT70ieeRFG1QN4Ow_5_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-3614</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="Duration_3_25_2024_To_3_25_2024_avq7MDuDZ0qTbuTPxd88pQ"
      decimals="INF"
      id="Tc_uZyC_VKWXEKXvs49DZQDsg_5_8"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">361381</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <ifrs-full:ParValuePerShare
      contextRef="As_Of_3_25_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_31pg2jjAP0SNXoJC-UbdfQ"
      decimals="INF"
      id="Tc_eETYbsFsEUOdzVcNIRXMzg_5_10"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">0.01</ifrs-full:ParValuePerShare>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_NJmuaXv-XEWsTA9f3Xh5nw"
      decimals="0"
      id="Tc_GV5E7F2OikKo_OTzwU6KVQ_6_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">524772</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_wKPlEEy3A0SN-8jmJn4iCw"
      decimals="0"
      id="Tc_1nUpoS-0BECuk6LNCDAarQ_6_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">201858649</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="INF"
      id="Tc_sDbQxSm8S0Kf3KUr21-VTQ_6_8"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">52477188</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:ParValuePerShare
      contextRef="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_NJmuaXv-XEWsTA9f3Xh5nw"
      decimals="INF"
      id="Tc_s3IxEfhRxkyooNZzznDFQw_6_10"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">0.01</ifrs-full:ParValuePerShare>
    <iva:LiquidityAgreementTerm
      contextRef="Duration_1_1_2019_To_12_31_2019_X8oeeeGhTk-MdYqDOV-oxQ"
      id="Narr_-gsszcRTfEWmU4kyo89Pig">P12M</iva:LiquidityAgreementTerm>
    <iva:LiquidityAgreementTerm
      contextRef="Duration_1_1_2023_To_1_1_2023_XlsK7X7SLkSjPHI4C13dFw"
      id="Narr_A3JpE3QquEGaAkBO6lMRCw">P12M</iva:LiquidityAgreementTerm>
    <iva:LiquidityAgreementTerm
      contextRef="Duration_1_1_2024_To_1_1_2024__TV_WDfEOkuUvGKOfMbQLg"
      id="Narr_LZMpw3JCfEyBGfpdzx0uSA">P12M</iva:LiquidityAgreementTerm>
    <iva:WarrantsSubscriptionPrice
      contextRef="As_Of_12_31_2017_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DirectorsMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_tc0AHGj00kS5B7lAXTpurw"
      decimals="3"
      id="Narr_bD1v90o6ZESj7hZnTXqrxg"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">0.534</iva:WarrantsSubscriptionPrice>
    <iva:WarrantsSubscriptionPrice
      contextRef="As_Of_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_ServiceProvidersMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_DIqvoK9pK0yZ6htGpUYXzw"
      decimals="2"
      id="Narr_Y7tDoZguJkmNJg-xy9qEhg"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">0.48</iva:WarrantsSubscriptionPrice>
    <iva:WarrantsSubscriptionPrice
      contextRef="As_Of_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_hhwziOnPqEKcNx_7cuH5Ug"
      decimals="2"
      id="Narr_gmaGO_ypWEOygjY2P0ZvJw"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">0.18</iva:WarrantsSubscriptionPrice>
    <iva:WarrantsSubscriptionPrice
      contextRef="As_Of_12_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_ue4H16UnJE-nSbm-Rv4i6Q"
      decimals="2"
      id="Narr_-i_mwJEyrEa11v0PuY4f_w"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">0.29</iva:WarrantsSubscriptionPrice>
    <iva:WarrantsSubscriptionPrice
      contextRef="As_Of_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_TXDD0JbjtEiPdT8-3ZzhYA"
      decimals="2"
      id="Narr_WLVYvn1YVU-AAfY6XBQXrA"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">2.45</iva:WarrantsSubscriptionPrice>
    <iva:WarrantsSubscriptionPrice
      contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20231ShareWarrantPlanMember_sPDxxV-HME-NOFivUfGJlA"
      decimals="2"
      id="Narr_8uRvvvWjsUWA_zHHW86oPQ"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">0.20</iva:WarrantsSubscriptionPrice>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20231ShareWarrantPlanMember_r1Qe82njGE25vu439VQ9xg"
      decimals="2"
      id="Narr__VaE2empb0aFuuYoYBmbWw"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">2.51</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <iva:WarrantsSubscriptionPrice
      contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20232ShareWarrantPlanMember_WOiJYiWPuUu4IuMxaS3vvg"
      decimals="2"
      id="Narr_ucR30CVtk0-O6FjxmaZNjA"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">0.31</iva:WarrantsSubscriptionPrice>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_DavidNikodemMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20232ShareWarrantPlanMember_CWi27vgj8Eqzm6adcBi83g"
      decimals="2"
      id="Narr_0pdtuJ2KOUmZd1o9Ty4Z3A"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">3.91</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="INF"
      id="Narr_pW0w8yNWWEOQjysUklxMUA"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspceAndBsaShareWarrantsMember_ChRxu3v9XU-QJcAaOJ0AgA"
      id="Group_ObzK56fSxk28WOWl-xdk6g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;at Jan&#160;1,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Forfeited /&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;at June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Type&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in euros)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issued&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercised&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lapsed&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;BSPCE - Plan 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;04/16/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 430,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 430,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 430,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL BSPCE share warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 430,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 430,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 430,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;BSA&#160;- Plan 2017&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;05/29/2017&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;BSA&#160;- Plan 2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;12/14/2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 116,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 116,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 116,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;BSA 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;06/28/2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;BSA 2019 bis&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;03/09/2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;BSA 2019 ter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;03/09/2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;BSA 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;04/16/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,333&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;BSA 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;05/25/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;BSA 2023 - 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;12/15/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL BSA share warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 346,333&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 346,333&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 316,333&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:21.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total share warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 776,333&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 776,333&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 746,333&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bspce2021PlanMember_RcSn_5JQpk-SYrZAPBf-2g"
      decimals="2"
      id="Tc_SrZP9A_IyESduQTU1PHdIg_4_4"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">11.74</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bspce2021PlanMember_XXFm1fZ4IkuZuyUISjqE5A"
      decimals="INF"
      id="Tc_sFswchMeQkiv9r8aCEKN-Q_4_6"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">430000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bspce2021PlanMember_RcSn_5JQpk-SYrZAPBf-2g"
      decimals="INF"
      id="Tc_d8LuV8QMDEy3ATiCZXeFXA_4_14"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">430000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bspce2021PlanMember_RcSn_5JQpk-SYrZAPBf-2g"
      decimals="INF"
      id="Tc_rxemUeuU60qJlfbv3y5knA_4_16"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">430000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspcePlansMember_9R_vfCR8mE6QceWJxeNh0A"
      decimals="INF"
      id="Tc_MujW0ZjVh06DvFCYfiuhEg_5_6"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">430000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspcePlansMember_Ga9Y5xtaaE6GziTOhOfOyw"
      decimals="INF"
      id="Tc_-9iokdYNZUW65uiW8TQnLw_5_14"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">430000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspcePlansMember_Ga9Y5xtaaE6GziTOhOfOyw"
      decimals="INF"
      id="Tc_8IpuWyZa302V6ONn4h9UGQ_5_16"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">430000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2017PlanMember_weg2ddPVA0SxiMSra8AqSg"
      decimals="2"
      id="Tc_qV9i-7d4JEa5pCQaoz1Qpg_6_4"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">6.68</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2017PlanMember_ps8c_6VsskWjdjMuB0dgAw"
      decimals="INF"
      id="Tc_wMvOUAvg5U2Jlyn0NrQiow_6_6"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">130000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2017PlanMember_weg2ddPVA0SxiMSra8AqSg"
      decimals="INF"
      id="Tc_xeJPIQg8WEOcqCRfD1C-oQ_6_14"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">130000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2017PlanMember_weg2ddPVA0SxiMSra8AqSg"
      decimals="INF"
      id="Tc_Y4vLaT9SvkaZhse2oz-bxw_6_16"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">130000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2018PlanMember_ptHXov2J-0Wu9MZq69AtRw"
      decimals="3"
      id="Tc_Yvqtl40ffkiqyZXH77lahg_7_4"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">6.07</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2018PlanMember_-NNjSxGS3kGycvP-YnC6BA"
      decimals="INF"
      id="Tc_VXuk38Y9kk2dA3SYJ54iRQ_7_6"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">116000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2018PlanMember_ptHXov2J-0Wu9MZq69AtRw"
      decimals="INF"
      id="Tc_H9X4lGpjuEGLARIdYbYDlA_7_14"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">116000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2018PlanMember_ptHXov2J-0Wu9MZq69AtRw"
      decimals="INF"
      id="Tc_IeIdVs94wEa1WAaPhm5TZg_7_16"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">116000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019Member_wyeHPWxpTUKLa573kCA9hg"
      decimals="2"
      id="Tc_wTXONOIhKEudc5BtzSr_9A_8_4"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">2.20</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019Member_KvhW3CTGVkaWP5uQm6usPQ"
      decimals="INF"
      id="Tc_zKTXyUT6REKW18WsJFeoEg_8_6"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">10000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019Member_wyeHPWxpTUKLa573kCA9hg"
      decimals="INF"
      id="Tc_lkh3Zs6q0EayBUDYxX0e3A_8_14"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">10000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019Member_wyeHPWxpTUKLa573kCA9hg"
      decimals="INF"
      id="Tc_dImNUx6izEaV97aKaY8TSQ_8_16"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">10000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019BisMember_MIIhZy39AEC1hyqkLyXkqA"
      decimals="2"
      id="Tc_26v73__qQ0K7HyV5ajOzaQ_9_4"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">3.68</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019BisMember_U_5IV4QgEke3Pdy5mT4eiw"
      decimals="INF"
      id="Tc_bmlag9Pe10Kb8EdqTInJrg_9_6"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">10000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019BisMember_MIIhZy39AEC1hyqkLyXkqA"
      decimals="INF"
      id="Tc_8cfygDOFHUutceFl7E750g_9_14"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">10000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019BisMember_MIIhZy39AEC1hyqkLyXkqA"
      decimals="INF"
      id="Tc_CAtruIxEF0ibG6oAzAE-ig_9_16"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">10000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019TerMember_jiHAAcRQ-UOqoX3-IPHL7Q"
      decimals="2"
      id="Tc_ah0uxTqG80u0d59xmjxPuw_10_4"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">3.68</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019TerMember_TDxn8LM_90OZE-wvpQKC8g"
      decimals="INF"
      id="Tc_lQ58r775F0mk-104hcwFAg_10_6"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">36000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019TerMember_jiHAAcRQ-UOqoX3-IPHL7Q"
      decimals="INF"
      id="Tc_vgB8fH6or0aLlg1qYIWbrA_10_14"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">36000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewShareWarrantPlansBsa2019TerMember_jiHAAcRQ-UOqoX3-IPHL7Q"
      decimals="INF"
      id="Tc_B6uBbn5vBEml9pky1ILUIg_10_16"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">36000</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBsa2021ShareWarrantPlanMember_yiiLVd_BA0S9s5AhG-VVqg"
      decimals="2"
      id="Tc_Ca822OyTOE6LVDMoTgP6MQ_11_4"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">11.74</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBsa2021ShareWarrantPlanMember_3S7BOByx_EaWFm05q97Pbw"
      decimals="INF"
      id="Tc_heE2OwQ2Yket05DvOrgomw_11_6"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">14333</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBsa2021ShareWarrantPlanMember_yiiLVd_BA0S9s5AhG-VVqg"
      decimals="INF"
      id="Tc_u5pvb2qKhU2uhU1v_LzgHA_11_14"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">14333</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBsa2021ShareWarrantPlanMember_yiiLVd_BA0S9s5AhG-VVqg"
      decimals="INF"
      id="Tc_-RKnJY0yl0-_yzwrFcoKwg_11_16"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">14333</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20231ShareWarrantPlanMember_5P4HYxa_X02-U_TBazJ3bA"
      decimals="2"
      id="Tc_7EjURt4keEmmlbUM0pBpEw_12_4"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">2.51</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20231ShareWarrantPlanMember_47_9YfgmmkGE6SeeBfb7Ig"
      decimals="INF"
      id="Tc_C84637mHd0WFNK7_XXCVtA_12_6"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">10000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20231ShareWarrantPlanMember_5P4HYxa_X02-U_TBazJ3bA"
      decimals="INF"
      id="Tc_h5_ISYIyP0ORB8jhmUyrUA_12_14"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">10000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20232ShareWarrantPlanMember_XsJfOiE5YUuSxAlo8TUGSQ"
      decimals="2"
      id="Tc_8yHx3hkUJEmoYUucLSZ-ww_13_4"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">3.91</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20232ShareWarrantPlanMember_TAkktSsoVU2p7FMQN4IObg"
      decimals="INF"
      id="Tc_mFKG3BYt_UOeu1k32EU7uw_13_6"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">20000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa20232ShareWarrantPlanMember_XsJfOiE5YUuSxAlo8TUGSQ"
      decimals="INF"
      id="Tc_5CMuxhi0XE-6xbsDVdbN7w_13_14"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">20000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaPlansMember_8Ot2N8tWskGDuiWnohiHRw"
      decimals="INF"
      id="Tc_pTxP2_LKSUuX5zMymCFIVw_14_6"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">346333</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaPlansMember_lUa0fx_8UUGbYRQd155C8g"
      decimals="INF"
      id="Tc_5XdkVwbIGU6skwFS_iR9fA_14_14"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">346333</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaPlansMember_lUa0fx_8UUGbYRQd155C8g"
      decimals="INF"
      id="Tc_X7bFDpXICE24Nc6IRrU6ug_14_16"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">316333</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspceAndBsaShareWarrantsMember_AXg3-r_gg0WamRv2dUykVQ"
      decimals="INF"
      id="Tc_nwS4SivnL0KWrv5vJ3th9A_15_6"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">776333</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspceAndBsaShareWarrantsMember_bFYuyd66F0KcdJonswP3bA"
      decimals="INF"
      id="Tc_-7tGaAZQFkmFUXT0hiU0PA_15_14"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">776333</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspceAndBsaShareWarrantsMember_bFYuyd66F0KcdJonswP3bA"
      decimals="INF"
      id="Tc_GNebjCZFHkyKagk0M5Gw1A_15_16"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">746333</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <iva:IfrsClassOfWarrantOrRightOutstanding
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaPlansMember_lUa0fx_8UUGbYRQd155C8g"
      decimals="INF"
      id="Narr_ffA1HEN2tkS7tEzgTOMjiA"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">430000</iva:IfrsClassOfWarrantOrRightOutstanding>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspcePlansMember_Ga9Y5xtaaE6GziTOhOfOyw"
      decimals="INF"
      id="Narr_IPAuoMuUskSsj3tAdPnE1A"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">430000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaPlansMember_lUa0fx_8UUGbYRQd155C8g"
      decimals="INF"
      id="Narr_HqH3q7tCC0SqI12j7mZyxg"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">346333</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspceAndBsaShareWarrantsMember_bFYuyd66F0KcdJonswP3bA"
      decimals="INF"
      id="Narr_Mt3XcQ-2UkqydaFdn_ZiiA"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">776333</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <iva:NumberOfAwardPlansAttributed
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="INF"
      id="Narr_koazVkK9v02v0qP57EprBg"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">0</iva:NumberOfAwardPlansAttributed>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20231Member_dcxbZ8fZnk-mVxqgCGeiKQ"
      id="Group_Eh8smjht5k6DkYZPT81TaQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:26.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Stock price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;at grant date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;at Jan&#160;1,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Forfeited /&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;at June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Type&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in euros)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Granted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Vested&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lapsed&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;AGA&#160;- Plan 2021 - 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;04/16/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 297,599&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (296,166)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,433)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;AGA&#160;- Plan 2021 - bis&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;12/08/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65,215&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (65,215)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;AGA 2023-1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;05/25/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 300,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 300,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 600,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;AGA 2023-2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;12/15/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 748,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23,350)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 724,650&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL free shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,410,814&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 300,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (361,381)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (24,783)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,324,650&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlanAga20211Member_Bsp6KVWZMUiZgeIpAPgY1Q"
      decimals="2"
      id="Tc_olA5KjFXrUeguTr03VyKFw_4_4"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">11.30</ifrs-full:WeightedAverageSharePrice2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlanAga20211Member_eh-BJlC8R0G04APW_IIiGQ"
      decimals="INF"
      id="Tc__PT8q_iPYUKfvPsBC-WG3Q_4_6"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">297599</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlanAga20211Member_Bsp6KVWZMUiZgeIpAPgY1Q"
      decimals="INF"
      id="Tc_Rxq9fQ6nBUKrs7nE2h2xSA_4_10"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">296166</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlanAga20211Member_Bsp6KVWZMUiZgeIpAPgY1Q"
      decimals="INF"
      id="Tc_YMn6sbHT0kyHha-bPAFzOw_4_12"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">1433</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlanAga2021BisMember_NCJt9ZQOW0SLSy6T5SliZA"
      decimals="2"
      id="Tc_TmSdYifc0kaN2sBqYR_icQ_5_4"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">12.20</ifrs-full:WeightedAverageSharePrice2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlanAga2021BisMember_d8RDeqcJHUuuc8eyxeiD5w"
      decimals="INF"
      id="Tc_AlKpsgUGWEu88dtHCuiv6g_5_6"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">65215</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlanAga2021BisMember_NCJt9ZQOW0SLSy6T5SliZA"
      decimals="INF"
      id="Tc_3BUH4vY51kWxsNII-JFjCw_5_10"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">65215</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20231Member_dcxbZ8fZnk-mVxqgCGeiKQ"
      decimals="2"
      id="Tc_-rg6TJsgMkSR4nhCmyWJlw_6_4"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">2.60</ifrs-full:WeightedAverageSharePrice2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20231Member_OTdPP5Od7kuR-ubUIX8ZDg"
      decimals="INF"
      id="Tc_9khjczkEdkyxWu5TYNyShA_6_6"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">300000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20231Member_dcxbZ8fZnk-mVxqgCGeiKQ"
      decimals="INF"
      id="Tc_gYQXhj8X_UOO98HSedLXtw_6_8"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">300000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20231Member_oKFel_ng9UWwaxcU0ACQvw"
      decimals="INF"
      id="Tc_V_aqGX1WF0u8TU-8cPdTkw_6_14"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">600000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20232Member_-sKnyEocNkawleXgjslx_A"
      decimals="2"
      id="Tc_dqZ0xLpork-2cegUrXIZHg_7_4"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">3.90</ifrs-full:WeightedAverageSharePrice2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20232Member_FIpiNio7XkaVcs3vwtxlaQ"
      decimals="INF"
      id="Tc_QQee2EIzZ0muQ12MPV9wow_7_6"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">748000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20232Member_-sKnyEocNkawleXgjslx_A"
      decimals="INF"
      id="Tc_EMUg92yWhUKfbj_1KB5_Fw_7_12"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">23350</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20232Member_PqpzKUoY40ObENgyoIJeMQ"
      decimals="INF"
      id="Tc_SgIwjNpbFkiKdihe7QU_EA_7_14"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">724650</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BonusShareAwardPlansMember_mvV1f-1wH0ac-WZpqG9HRQ"
      decimals="INF"
      id="Tc_TmkvzoT9uEm3WrU09UZr7Q_8_6"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">1410814</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BonusShareAwardPlansMember_4W-wr4J7bkuA5horxzjQWQ"
      decimals="INF"
      id="Tc_jlKBHXUAFkWrwLTIH1FYVA_8_8"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">300000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BonusShareAwardPlansMember_4W-wr4J7bkuA5horxzjQWQ"
      decimals="INF"
      id="Tc_Mnu37sDL1kWjf5nOLzhGmw_8_10"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">361381</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BonusShareAwardPlansMember_4W-wr4J7bkuA5horxzjQWQ"
      decimals="INF"
      id="Tc_sbhSZGQoUEGbNenCkdLe0A_8_12"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">24783</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BonusShareAwardPlansMember_m2JRheJguUWiLC2OX9PVmw"
      decimals="INF"
      id="Tc_Yv4iBrsCikGBEPJ36Opw4A_8_14"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">1324650</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BonusShareAwardPlansMember_m2JRheJguUWiLC2OX9PVmw"
      decimals="INF"
      id="Narr_zdMPLjAVH0CpRQ0Kp2ppyQ"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">1324650</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_3_25_2024_To_3_25_2024_avq7MDuDZ0qTbuTPxd88pQ"
      decimals="INF"
      id="Narr_NRFLUVah6EaUuXULnpxDkg"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">300000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Aga2021Aga2021BisMember_94cRMy8qbkmwpgWKKI0Dmw"
      decimals="INF"
      id="Narr_OPZ491uDzE6bKK-w7t7TLg"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">361381</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Aga2021Aga2021BisMember_94cRMy8qbkmwpgWKKI0Dmw"
      decimals="2"
      id="Narr_eNISM_bjQEGVfKnPoAEgFQ"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3613.81</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Aga2021Aga2021BisMember_94cRMy8qbkmwpgWKKI0Dmw"
      decimals="INF"
      id="Narr_2QoHwBtHyU-DPqNucCYsnw"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">361381</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Aga2021Aga2021BisMember_94cRMy8qbkmwpgWKKI0Dmw"
      decimals="2"
      id="Narr_oryTEskKV0SFp68kiLL6CA"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3613.81</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-5"
      id="Narr_FdmikPTU1UON9SyNxLMMyg"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2200000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20231Member_7wRF3k96VkCeUYr4WvCKSg"
      decimals="-5"
      id="Narr_02sHp7BFzU-tnpR_NSaI3w"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2000000.0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnits2023Member_JOCpA6ku3UiPydoMyQrkIg"
      id="Tb_ay7MsI-b2EK7cmoYEWpNsQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of January 1, 2024, one performance units plan was outstanding: PAGUP 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;No performance units award plan has been attributed in the first six months of 2024.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:29.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reference&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price (in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;at&#160;Jan&#160;1,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;at&#160;June&#160;30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Type&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;euros)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issued&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercised&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Convert AGA&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;PAGUP 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;05/25/2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 300,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (300,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:29.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL PAGUP&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 300,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (300,000)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
    <iva:NumberOfPlansOutstanding
      contextRef="As_Of_1_1_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnitsMember_Zf-6fi4mZkOtN6iPVLbVdw"
      decimals="INF"
      id="Narr_xRCOlIHTy0mjQlnUQ_YXeQ"
      unitRef="Unit_Standard_plan_EJ5kyu86bkGE5-lgkh4BhQ">1</iva:NumberOfPlansOutstanding>
    <iva:NumberOfAwardPlansAttributed
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnitsMember_PlmUtIqdxEmw3YH5g0akfg"
      decimals="INF"
      id="Narr_HAzUrCXqsUyhhIFWq2m0Dg"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">0</iva:NumberOfAwardPlansAttributed>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnits2023Member_JOCpA6ku3UiPydoMyQrkIg"
      decimals="2"
      id="Tc_5tcC0DevpEaET1SCQVmKxw_4_4"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">2.60</ifrs-full:WeightedAverageSharePrice2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnits2023Member_bHs6Y4UJuEK6wcGSke6uGA"
      decimals="INF"
      id="Tc_uN4DlrpLVESNqRRnr604vg_4_6"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">300000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnits2023Member_JOCpA6ku3UiPydoMyQrkIg"
      decimals="INF"
      id="Tc_kSKb6nETC0mJJtUQJPnziw_4_12"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">300000</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnitsMember_S5ghW2BBqEaaOZO3f2CIIQ"
      decimals="INF"
      id="Tc_SUxF_fCFAkS5W9gXActAdg_5_6"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">300000</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnitsMember_PlmUtIqdxEmw3YH5g0akfg"
      decimals="INF"
      id="Tc_EeMVGijbokqqX6YjwNy3mw_5_12"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">300000</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="INF"
      id="Narr_frWTtlb7gE-LP_s20CZ0Wg"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <iva:NumberOfSharesConverted
      contextRef="As_Of_3_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_FredericCrenMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnits2023Member_rz9Dt9fkhka9C49bx8Vmng"
      decimals="INF"
      id="Narr_gDzY7qMEzUa8xRP_WBWTkg"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">300000</iva:NumberOfSharesConverted>
    <ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement
      contextRef="Duration_3_25_2024_To_3_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_iva_FredericCrenMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_LongTermIncentivePlanInPerformanceUnits2023Member_hzRrxOsqEEe8Ngy7ccwfuw"
      decimals="INF"
      id="Narr_nWkvVmfxCUa0tMpMAPDP5w"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">300000</ifrs-full:NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_9Y5KlPdCzUm9w5730DXvfA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Bank borrowings&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,509&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,206&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Derivatives instruments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,569&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,265&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other loans and similar borrowings&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,302&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,719&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,761&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,565&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalty certificates liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,327&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total debt&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 73,404&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_VVi9UZTcQEKJWAcPl8yJKQ;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt; 54,082&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:italic;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;include accrued interests.&lt;/i&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory>
    <ifrs-full:LoansReceived
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_1Ciq5vID50ygAln6Oh114Q_2_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">42509000</ifrs-full:LoansReceived>
    <ifrs-full:LoansReceived
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_TJOKh_FuRUGxt3Q9g1NV2A_2_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">27206000</ifrs-full:LoansReceived>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_TfxHbWZXckOTUVfQ1mwgQA_3_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">13569000</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_Zzx8zbegUkqFxFLpMgoWfg_3_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10265000</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:OtherBorrowings
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_3W1QRxOnekqytlv9wF7IHg_4_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">4302000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_aaPPQSdLRku5W9Z5p7SSDw_4_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3719000</ifrs-full:OtherBorrowings>
    <ifrs-full:LeaseLiabilities
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_Cl8cHJSYW0W9srmBiZxlFw_5_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5761000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_n0P0tpIgu0WTTiFb3ZOQdA_5_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">6565000</ifrs-full:LeaseLiabilities>
    <iva:NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_EoUMzQYJUkqKBAjOFVOsjw_6_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">7263000</iva:NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued>
    <iva:NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_12PE9YXF5EK8BC9jrAv9gQ_6_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">6327000</iva:NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued>
    <ifrs-full:Borrowings
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_sn4X4xfpskmB9bGewx11iw_7_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">73404000</ifrs-full:Borrowings>
    <iva:DisclosureOfChangesInBorrowingsTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_AlAi80OtDUSEtW5zkNUZ8Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January 1, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 54,083&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 44,390&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Subscription of derivatives instruments&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Subscription of bank borrowings&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,102&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Subscription of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 345&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,706&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Issue of royalty certificates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,100&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Repayment of bank borrowings&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,177)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,485)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Repayment of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,173)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,612)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Interests on royalty certificates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 936&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,227&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Capitalized interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,961&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,405&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Change in fair value of derivatives instruments&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,506)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 389&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Exchange rate change&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (38)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 73,404&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 54,083&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</iva:DisclosureOfChangesInBorrowingsTableTextBlock>
    <ifrs-full:Borrowings
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_ren-pNL6WU6vUGRr9K7CpQ_2_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">54083000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="As_Of_12_31_2022__ShBeryiXEKxoX7Xx7OS6A"
      decimals="-3"
      id="Tc_vFG_f3BTkkuRBoPLFUzK6g_2_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">44390000</ifrs-full:Borrowings>
    <iva:IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_auTBxKwjQEGyzxBuqa8hvQ_3_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">11809000</iva:IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments>
    <iva:Increaseinborrowingsthroughborrowingsreceived
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_ZqK_cQ_WzEO96mnTuVWF0A_4_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">13102000</iva:Increaseinborrowingsthroughborrowingsreceived>
    <iva:SubscriptionOfLeaseLiabilities
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_XNMS_rW-OEas1QyCz89-cA_5_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">345000</iva:SubscriptionOfLeaseLiabilities>
    <iva:SubscriptionOfLeaseLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA"
      decimals="-3"
      id="Tc_4-1t1IBiNUSWpctxqC-0rw_5_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3706000</iva:SubscriptionOfLeaseLiabilities>
    <iva:IssueOfRoyaltyCertificates
      contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA"
      decimals="-3"
      id="Tc_skefifQSCUqkpXKZD1BMtg_6_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5100000</iva:IssueOfRoyaltyCertificates>
    <iva:DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_IKGN-RrlJ064ekZ7wTMATQ_7_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1177000</iva:DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings>
    <iva:DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings
      contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA"
      decimals="-3"
      id="Tc_xcVmPmT6wUOtNPknZVzKSQ_7_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2485000</iva:DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings>
    <iva:DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_xAA0b8nxckaIq4g9-YYQzA_8_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1173000</iva:DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities>
    <iva:DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA"
      decimals="-3"
      id="Tc_ROik2OJisE6ZNEu0HCCcZg_8_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1612000</iva:DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities>
    <iva:InterestOnRoyaltyCertificates
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_NQwvw7Lk8EGr1ZR8iOAinA_9_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">936000</iva:InterestOnRoyaltyCertificates>
    <iva:InterestOnRoyaltyCertificates
      contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA"
      decimals="-3"
      id="Tc_W5PtJnGxrkG_0UYNEOi8RA_9_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1227000</iva:InterestOnRoyaltyCertificates>
    <iva:IncreaseInBorrowingsThroughCapitalizedInterest
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_V9uehGNfhU2WNxEka56u-Q_10_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3961000</iva:IncreaseInBorrowingsThroughCapitalizedInterest>
    <iva:IncreaseInBorrowingsThroughCapitalizedInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA"
      decimals="-3"
      id="Tc_r4kwdPjtbU-lygG99o5UEw_10_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3405000</iva:IncreaseInBorrowingsThroughCapitalizedInterest>
    <iva:IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_OtcVFi_BrEiKeK-tDe_5zQ_11_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-8506000</iva:IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments>
    <iva:IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments
      contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA"
      decimals="-3"
      id="Tc_EeFdgWjGckWQQMeRjCEoow_11_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">389000</iva:IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments>
    <iva:IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_pSSAnVC9_0yRJ8u4OeNikA_12_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">24000</iva:IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates>
    <iva:IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates
      contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA"
      decimals="-3"
      id="Tc_mBuAoNcT50O7o99cJvhxXw_12_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-38000</iva:IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates>
    <ifrs-full:Borrowings
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_9k2gYw2ZYUug5_249Ijrpg_13_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">73404000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_KiY9re9oKk-akz-WCXMa7w_13_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">54083000</ifrs-full:Borrowings>
    <iva:NumberOfLoansObtainedGuaranteedByFrenchState
      contextRef="Duration_5_1_2020_To_5_31_2020_ifrs-full_BorrowingsByNameAxis_iva_FinancingFromSyndicateOfFrenchBanksMember_tgQsngIelEWdVjh0z4mOYQ"
      decimals="0"
      id="Narr_gZQTYXW48U6dVVoxqQLexg"
      unitRef="Unit_Standard_agreement_ds7eY0UVBEmjbbj4M4LxNQ">3</iva:NumberOfLoansObtainedGuaranteedByFrenchState>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="Duration_5_1_2020_To_5_31_2020_ifrs-full_BorrowingsByNameAxis_iva_FinancingFromSyndicateOfFrenchBanksMember_tgQsngIelEWdVjh0z4mOYQ"
      decimals="-5"
      id="Narr_6xFX2TznLkudpy5umLB2Pw"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10000000.0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <iva:BorrowingsMaximumExtensionTerm
      contextRef="Duration_5_1_2020_To_5_31_2020_ifrs-full_BorrowingsByNameAxis_iva_FinancingFromSyndicateOfFrenchBanksMember_tgQsngIelEWdVjh0z4mOYQ"
      id="Narr_ltxb78CjMUWme4D6C7pPlA">P4Y</iva:BorrowingsMaximumExtensionTerm>
    <iva:BorrowingsMaximumExtensionTerm
      contextRef="Duration_5_1_2020_To_5_31_2020_ifrs-full_BorrowingsByNameAxis_iva_FinancingFromSyndicateOfFrenchBanksMember_tgQsngIelEWdVjh0z4mOYQ"
      id="Narr_Cxe9f7oEUE-CIFnTIXHOBQ">P4Y</iva:BorrowingsMaximumExtensionTerm>
    <iva:NumberOfLoanAgreements
      contextRef="Duration_6_1_2022_To_6_30_2022_ifrs-full_BorrowingsByNameAxis_iva_FinancingFromSyndicateOfFrenchBanksMember_age9N1IGyke_9J5_9xJiwA"
      decimals="0"
      id="Narr_Zr9ZNGo7fEqmev1hJxPsOQ"
      unitRef="Unit_Standard_loan_rE4-q-dHoUqS2Tn_Pp9_NQ">3</iva:NumberOfLoanAgreements>
    <ifrs-full:NotionalAmount
      contextRef="As_Of_6_30_2022_ifrs-full_BorrowingsByNameAxis_iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember_C9WbfUum90KUsBfHNequkg"
      decimals="-5"
      id="Narr_xS2SNKyk5UycaOAHrnU2fQ"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5300000</ifrs-full:NotionalAmount>
    <iva:NumberOfLoanAgreements
      contextRef="Duration_6_1_2022_To_6_30_2022_ifrs-full_BorrowingsByNameAxis_iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember_pRmHDD5O_EOFWPfNYEeiDw"
      decimals="0"
      id="Narr_MUIM9UKuQUaBcVurFwQ-4g"
      unitRef="Unit_Standard_loan_rE4-q-dHoUqS2Tn_Pp9_NQ">1</iva:NumberOfLoanAgreements>
    <iva:NumberOfLoanAgreements
      contextRef="Duration_6_1_2022_To_6_30_2022_ifrs-full_BorrowingsByNameAxis_iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember_rVGAMd543kWMTqS80gXZVA"
      decimals="0"
      id="Narr_hUB6WWdhFUGH1qLkwCTEuQ"
      unitRef="Unit_Standard_loan_rE4-q-dHoUqS2Tn_Pp9_NQ">2</iva:NumberOfLoanAgreements>
    <iva:PercentageOfLoanGuaranteedByFrenchState
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_BorrowingsByNameAxis_iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember_5BKdyoSBV0uhtWALpjAz8A"
      decimals="2"
      id="Narr_tYmr5lrKrEqS6mDWuMWUWg"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.90</iva:PercentageOfLoanGuaranteedByFrenchState>
    <iva:FinancingPeriodOfLoan
      contextRef="Duration_5_1_2023_To_5_31_2023_ifrs-full_BorrowingsByNameAxis_iva_EquityRecoveryLoansMember_FFIOm4lTLk6UQV8mUsy60w"
      id="Narr_6mpahCKQWk6Hl8QMqmnRcA">P8Y</iva:FinancingPeriodOfLoan>
    <iva:RepaymentPeriodOfLoan
      contextRef="Duration_5_1_2023_To_5_31_2023_ifrs-full_BorrowingsByNameAxis_iva_EquityRecoveryLoansMember_FFIOm4lTLk6UQV8mUsy60w"
      id="Narr_ydZsETqzG0-LSOkDbCKLMQ">P4Y</iva:RepaymentPeriodOfLoan>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinancingFromSyndicateOfFrenchBanksMember_b3jNddOSCEqLn7eTIlNpJw"
      decimals="-5"
      id="Narr_NcpSOzSvBE-17FlkOVKHuA"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1200000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:NotionalAmount
      contextRef="As_Of_5_16_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_m_1J6hotsk-dhzgHfJ6CBA"
      decimals="-6"
      id="Narr_K7hdsHFG5EqhqQbtkX4omw"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">50000000</ifrs-full:NotionalAmount>
    <iva:NumberOfEqualTranches
      contextRef="Duration_5_16_2022_To_5_16_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_iCBdyRK5rUeePAFm5LecHg"
      decimals="INF"
      id="Narr_gFIA6jfqK0CjfpY0vlLg2w"
      unitRef="Unit_Standard_tranche_EQcocZ7SkkmFtux0nXQhjQ">2</iva:NumberOfEqualTranches>
    <iva:NotionalAmountPerTranche
      contextRef="As_Of_5_16_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_m_1J6hotsk-dhzgHfJ6CBA"
      decimals="-6"
      id="Narr_cgjkbXJGZE2f3yxNtfhxlw"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">25000000</iva:NotionalAmountPerTranche>
    <ifrs-full:BorrowingsInterestRate
      contextRef="As_Of_12_8_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_NZ-ZgvUE8kOsb70mJ03KSw"
      decimals="2"
      id="Narr_36FmphlPt0mETskA92GkMg"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.08</ifrs-full:BorrowingsInterestRate>
    <iva:IfrsDebtInstrumentTerm
      contextRef="Duration_12_8_2022_To_12_8_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_Oji8AIqwMEebyNKqGL3bwA"
      id="Narr_AtuuxEvetkqSc-aeYS3QEw">P4Y</iva:IfrsDebtInstrumentTerm>
    <ifrs-full:BorrowingsInterestRate
      contextRef="As_Of_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_DrawdownOfBorrowingsMember_MLnrGxu8pEeScrxg9appZw"
      decimals="2"
      id="Narr_AJs_DaejeUWtXI0wB_sXmA"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.07</ifrs-full:BorrowingsInterestRate>
    <iva:IfrsDebtInstrumentTerm
      contextRef="Duration_1_18_2024_To_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_DrawdownOfBorrowingsMember_qBP5Y6KUBkGy4f5mXUW39g"
      id="Narr_zMulVsKTBEuW1LD-mhhA0g">P3Y</iva:IfrsDebtInstrumentTerm>
    <ifrs-full:NotionalAmount
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_yNqR8syCVkyKUkjoBw5nlA"
      decimals="-6"
      id="Narr_2P8vMcl5V0mC0r0hJa6vBQ"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">25000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingCostsIncurred
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_0umwc-ynPU6vJhwvCODdKw"
      decimals="-5"
      id="Narr_UZkXqpvim0aPwZImf-uSpQ"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">100000</ifrs-full:BorrowingCostsIncurred>
    <ifrs-full:Borrowings
      contextRef="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_ll91CELP_0CkxmWGnSWYxw"
      decimals="-5"
      id="Narr_c9V_gN11mUeJSXqq20jWuA"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">15400000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_yNqR8syCVkyKUkjoBw5nlA"
      decimals="-5"
      id="Narr_kggvS2wzXkGkC102UcOeAg"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">21100000</ifrs-full:Borrowings>
    <iva:BorrowingsEffectiveInterestRate
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_yNqR8syCVkyKUkjoBw5nlA"
      decimals="3"
      id="Narr_5IDsAGgMTkaaTUIEco20nA"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.219</iva:BorrowingsEffectiveInterestRate>
    <iva:BorrowingsEffectiveInterestRate
      contextRef="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_ll91CELP_0CkxmWGnSWYxw"
      decimals="3"
      id="Narr_D7_NT5u0P0CTiegSHXlacQ"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.219</iva:BorrowingsEffectiveInterestRate>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueMember_1nI2yYCJCEKKgVIHzRJEzA"
      decimals="-5"
      id="Narr__uJp5d8pn0qAoxbUwQQxvQ"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">20600000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <iva:BorrowingsActualizationRate
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueMember_1nI2yYCJCEKKgVIHzRJEzA"
      decimals="3"
      id="Narr_wj-XP0Dwvkq-r1n5exfGaw"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.229</iva:BorrowingsActualizationRate>
    <ifrs-full:NotionalAmount
      contextRef="As_Of_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_HZvpAkHv40a_7feAGh0Gmg"
      decimals="-6"
      id="Narr_OTaLzXzfPkKJ0j3bUVSY6g"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">25000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingCostsIncurred
      contextRef="Duration_1_18_2024_To_1_18_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_EpuGEvGLYke1tVD4Ocdy8Q"
      decimals="-5"
      id="Narr_dy7ErOIJTkex-X0EoAAWzA"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">100000</ifrs-full:BorrowingCostsIncurred>
    <ifrs-full:Borrowings
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_KCZ_rlJbTkm1DXPXbOCPUg"
      decimals="-5"
      id="Narr_Jfp45C80n0WLjS2s4QQASg"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">15000000.0</ifrs-full:Borrowings>
    <iva:BorrowingsEffectiveInterestRate
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_KCZ_rlJbTkm1DXPXbOCPUg"
      decimals="3"
      id="Narr_DNXrJmIFT0y3GkvuRL0tIA"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.327</iva:BorrowingsEffectiveInterestRate>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueMember_4SVWIFElkkKFKpxz6K2mDw"
      decimals="-5"
      id="Narr_q33CHbIBkEupQo3ZuShCdQ"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">14700000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <iva:BorrowingsActualizationRate
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueMember_4SVWIFElkkKFKpxz6K2mDw"
      decimals="3"
      id="Narr_SZUhKKFXKkiqcOY0pEmRfQ"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.332</iva:BorrowingsActualizationRate>
    <ifrs-full:InterestCostsCapitalised
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_7knLDQKU6EWqcXxngWZMRA"
      decimals="-5"
      id="Narr_q5AqoKiSSE6uxCf6E6hgQg"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">4000000.0</ifrs-full:InterestCostsCapitalised>
    <iva:SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted
      contextRef="As_Of_7_1_2022_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember__QhdYl76K0agjKJOQ6cDBQ"
      decimals="2"
      id="Narr_Xhf6WXgTEUaBb-XxX8NQuA"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">0.01</iva:SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted>
    <iva:TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued
      contextRef="Duration_7_1_2022_To_7_1_2022_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_mT6R0SioNkS8Jv1u9vcknw"
      id="Narr_DCdqCN-rlkiCLZqcE4Rz4A">P180D</iva:TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued>
    <iva:ClassOfWarrantOrRightMaturityTerm
      contextRef="Duration_7_1_2022_To_7_1_2022_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_XoSz7rHj_Umg-MPSR-Funw"
      id="Narr_1h-64P0QHEeKZFerbS4TGw">P12Y</iva:ClassOfWarrantOrRightMaturityTerm>
    <iva:ClassOfWarrantOrRightMaturityTerm
      contextRef="Duration_7_1_2022_To_7_1_2022_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_XoSz7rHj_Umg-MPSR-Funw"
      id="Narr_hiAj5NzMyUyVnQRkF_durg">P12Y</iva:ClassOfWarrantOrRightMaturityTerm>
    <iva:NumberOfSharesPerOtherEquityInstrumentGranted
      contextRef="Duration_7_1_2022_To_7_1_2022_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_XoSz7rHj_Umg-MPSR-Funw"
      decimals="INF"
      id="Narr_69mVzpTUc0-Pc0Kj-_G_WA"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">1</iva:NumberOfSharesPerOtherEquityInstrumentGranted>
    <iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_e2AEajgpOke0pQ8o_y36nw"
      decimals="2"
      id="Narr_Rj7JMiviR0mYUiiNRzd9qQ"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">1.20</iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <iva:ClassOfWarrantOrRightGranted
      contextRef="Duration_11_28_2022_To_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_FvqTByEiaEuWx4OtWlgNhA"
      decimals="INF"
      id="Narr_NoPpdwCGMUCKQRSQZysnzA"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">2266023</iva:ClassOfWarrantOrRightGranted>
    <iva:PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants
      contextRef="Duration_11_28_2022_To_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_FvqTByEiaEuWx4OtWlgNhA"
      decimals="3"
      id="Narr_DEl3_rNah0aaNSq-0EI0xQ"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.047</iva:PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants>
    <iva:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
      contextRef="As_Of_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_QTQ5vqXpNE2ib3CFSHvYaw"
      decimals="4"
      id="Narr_NvesCX4_20iUeHMFKIE6vA"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">4.0152</iva:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <iva:MaximumPotentialGrossProceedsFromExerciseOfWarrants
      contextRef="Duration_11_28_2022_To_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_FvqTByEiaEuWx4OtWlgNhA"
      decimals="-5"
      id="Narr_TUEPiVyggUqZtjPDh6WZPQ"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">9100000</iva:MaximumPotentialGrossProceedsFromExerciseOfWarrants>
    <iva:TransactionCostsOnIssueOfWarrants
      contextRef="Duration_11_28_2022_To_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_FvqTByEiaEuWx4OtWlgNhA"
      decimals="-3"
      id="Narr_M-iTbdjBBUm1yEkOy7vXsA"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">56000</iva:TransactionCostsOnIssueOfWarrants>
    <iva:ClassOfWarrantOrRightGranted
      contextRef="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_2nmqoYhWkkOgh_AeHuYFnQ"
      decimals="INF"
      id="Narr__lfkNnoO4kCmVVdH-5l1NA"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">3144654</iva:ClassOfWarrantOrRightGranted>
    <iva:PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants
      contextRef="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_2nmqoYhWkkOgh_AeHuYFnQ"
      decimals="3"
      id="Narr_u5RjKAEMeUOTtoGsrs6zMA"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.052</iva:PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants>
    <iva:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
      contextRef="As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_YCO92YM7_064nsFEWIY8Jw"
      decimals="2"
      id="Narr_vDhRktBldU6FwxHSEp-frQ"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">3.95</iva:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <iva:MaximumPotentialGrossProceedsFromExerciseOfWarrants
      contextRef="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_2nmqoYhWkkOgh_AeHuYFnQ"
      decimals="-5"
      id="Narr_5NZbbQkTAk6zDEz10sCNVg"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">12400000</iva:MaximumPotentialGrossProceedsFromExerciseOfWarrants>
    <iva:TransactionCostsOnIssueOfWarrants
      contextRef="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_2nmqoYhWkkOgh_AeHuYFnQ"
      decimals="-3"
      id="Narr_HIOTqcyT-E-U1Ip7lx05VQ"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">90000</iva:TransactionCostsOnIssueOfWarrants>
    <iva:WarrantsThresholdTradingDays
      contextRef="Duration_11_28_2022_To_11_28_2022_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_ixbJJMHX7k-KJKKJhzrKQw"
      decimals="INF"
      id="Narr_YxOSjZZr-EmRoGICvQbxlg"
      unitRef="Unit_Standard_D_UN8jRVLLaEed_W_JH8a6Og">90</iva:WarrantsThresholdTradingDays>
    <iva:WarrantsThresholdTradingDays
      contextRef="Duration_11_28_2022_To_11_28_2022_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_ixbJJMHX7k-KJKKJhzrKQw"
      decimals="INF"
      id="Narr_hExtM_3rLk6L_M3XtPoFKA"
      unitRef="Unit_Standard_D_UN8jRVLLaEed_W_JH8a6Og">90</iva:WarrantsThresholdTradingDays>
    <iva:DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_vcx65z1y40-zgHnk-LDwhw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;BSA 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;BSA 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Grant date&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;11/28/2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;01/04/2024&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Expiration date&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;11/28/2034&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;01/04/2036&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Number of BSA issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,266,023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,144,654&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Number of shares per BSA&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Subscription premium price per share (&#x20ac;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.01&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Exercise price per share (&#x20ac;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.95&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Valuation method&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Longstaff Schwartz&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Longstaff Schwartz&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;November&#160;28,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EIB Tranche A Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;(Grant&#160;Date)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;June&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Number of BSA outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,266,023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,266,023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,266,023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Number of shares per BSA&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock price (&#x20ac;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maturity (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cap of the put option (m&#x20ac;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Euribor 6M&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Euribor 6M&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Euribor 6M&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividends&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value (k&#x20ac;)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 9,469&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 10,266&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,738&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:40.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Unit fair value (&#x20ac;)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 4.18&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 4.53&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 2.97&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</iva:DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2022Member_rqfjl8o2ykC3r6A9zJWDeQ"
      decimals="INF"
      id="Tc_IJEo5qkh1UOtgULz8Ojw5Q_4_2"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">2266023</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2024Member_SKyx2I-L-E2qRPd_8ZtRDQ"
      decimals="INF"
      id="Tc_pMILG-C2NkOJIs-FPmF2_A_4_4"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">3144654</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2022Member_lXOe9V-g3Uq8tzFzKYE_rw"
      decimals="0"
      id="Tc_nmdX6hBMf06uyg-O4EtakA_5_2"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">1</iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2024Member_o0JPxKp_cEaymg2N36omtQ"
      decimals="0"
      id="Tc_vI1Wx3plAkGVE1MY3OfwRg_5_4"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">1</iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <iva:SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2022Member_lXOe9V-g3Uq8tzFzKYE_rw"
      decimals="2"
      id="Tc_0pbR7PUyx06WKUNJXD4Zvg_6_2"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">0.01</iva:SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted>
    <iva:SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2024Member_o0JPxKp_cEaymg2N36omtQ"
      decimals="2"
      id="Tc_slvYieah5UCTQrx1d2PM6g_6_4"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">0.01</iva:SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2022Member_lXOe9V-g3Uq8tzFzKYE_rw"
      decimals="2"
      id="Tc_86Z-96VKT0yK6Lhl68ni1w_7_2"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">4.02</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="As_Of_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2024Member_o0JPxKp_cEaymg2N36omtQ"
      decimals="2"
      id="Tc_YCF7l-6FtUWHDxhHQTaLrg_7_4"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">3.95</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <iva:IfrsClassOfWarrantOrRightOutstanding
      contextRef="As_Of_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lpf5jlqhR0GVIbvPIhKnYw"
      decimals="INF"
      id="Tc_Q8HrdidQ1kS4H9L3U_Nm9w_3_2"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">2266023</iva:IfrsClassOfWarrantOrRightOutstanding>
    <iva:IfrsClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ldh6EouHQke8vr_BH-JvxQ"
      decimals="INF"
      id="Tc_HMUMUFb02Uez6mJMGlb3kQ_3_4"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">2266023</iva:IfrsClassOfWarrantOrRightOutstanding>
    <iva:IfrsClassOfWarrantOrRightOutstanding
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_EFM8TpwCpkqu7FVPRM1rTQ"
      decimals="INF"
      id="Tc_gS093KdbK0ajdpWUW-pQRA_3_6"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">2266023</iva:IfrsClassOfWarrantOrRightOutstanding>
    <iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lpf5jlqhR0GVIbvPIhKnYw"
      decimals="2"
      id="Tc_sQxUcwcMH0CbvJP9pZlL2A_4_2"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">1.00</iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ldh6EouHQke8vr_BH-JvxQ"
      decimals="2"
      id="Tc_3nGYrfTNnUSNT91etaZ-Fw_4_4"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">1.20</iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_EFM8TpwCpkqu7FVPRM1rTQ"
      decimals="2"
      id="Tc__EMDxv-Pi0yEOEMGwbPQxw_4_6"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">1.27</iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <iva:WarrantsStockPrice
      contextRef="As_Of_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lpf5jlqhR0GVIbvPIhKnYw"
      decimals="2"
      id="Tc_qos2RFNwXE28MmXWrSQcAQ_5_2"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">4.13</iva:WarrantsStockPrice>
    <iva:WarrantsStockPrice
      contextRef="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ldh6EouHQke8vr_BH-JvxQ"
      decimals="2"
      id="Tc_OjpM1lbFn06DvCl9oYhemg_5_4"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">4.10</iva:WarrantsStockPrice>
    <iva:WarrantsStockPrice
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_EFM8TpwCpkqu7FVPRM1rTQ"
      decimals="2"
      id="Tc_sp8ha_mSP0-R11Sbd_fTMA_5_6"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">2.79</iva:WarrantsStockPrice>
    <iva:WarrantAverageLife
      contextRef="Duration_11_28_2022_To_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_3hNTQf5aEEemSQq6uYohDA"
      id="Tc_UQ2guG79dESNtQd1Q5Gfkg_6_2">P12Y</iva:WarrantAverageLife>
    <iva:WarrantAverageLife
      contextRef="Duration_1_1_2023_To_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_CSHhFS0Lg0Gzg_yzNEELZQ"
      id="Tc_Wspmtr-MCkSUR4usXNK3Sw_6_4">P10Y10M24D</iva:WarrantAverageLife>
    <iva:WarrantAverageLife
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lX6me24ptE-Xl7VzcNGlCA"
      id="Tc_qqozQYndg0qAYgWSaLM8_g_6_6">P10Y4M24D</iva:WarrantAverageLife>
    <iva:ExpectedVolatility
      contextRef="As_Of_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lpf5jlqhR0GVIbvPIhKnYw"
      decimals="2"
      id="Tc_RjNW41fDtUehYbYzIV-MGA_7_2"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.68</iva:ExpectedVolatility>
    <iva:ExpectedVolatility
      contextRef="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ldh6EouHQke8vr_BH-JvxQ"
      decimals="2"
      id="Tc_QNXWE3ZOM06L4dDLl-zB-g_7_4"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.62</iva:ExpectedVolatility>
    <iva:ExpectedVolatility
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_EFM8TpwCpkqu7FVPRM1rTQ"
      decimals="3"
      id="Tc_MDRjOaAxa0KjNVkDz0Pd7A_7_6"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.596</iva:ExpectedVolatility>
    <iva:WarrantsCapOfPutOption
      contextRef="As_Of_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lpf5jlqhR0GVIbvPIhKnYw"
      decimals="1"
      id="Tc_Ww56_2AxDkSI0QDCIv8ujw_8_2"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">25.0</iva:WarrantsCapOfPutOption>
    <iva:WarrantsCapOfPutOption
      contextRef="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ldh6EouHQke8vr_BH-JvxQ"
      decimals="1"
      id="Tc_igi6pg9chEeUU3u5Qqza5A_8_4"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">25.0</iva:WarrantsCapOfPutOption>
    <iva:WarrantsCapOfPutOption
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_EFM8TpwCpkqu7FVPRM1rTQ"
      decimals="1"
      id="Tc_wEh-Qx8boUqG8TbWcKr8yw_8_6"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">25.0</iva:WarrantsCapOfPutOption>
    <iva:FairValueOfWarrantsOutstanding
      contextRef="As_Of_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lpf5jlqhR0GVIbvPIhKnYw"
      decimals="-3"
      id="Tc_8aEkWM9GbkiMPc-Xiea5qA_11_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">9469000</iva:FairValueOfWarrantsOutstanding>
    <iva:FairValueOfWarrantsOutstanding
      contextRef="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ldh6EouHQke8vr_BH-JvxQ"
      decimals="-3"
      id="Tc_SE0oRmnwakS-AedKs28YTQ_11_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10266000</iva:FairValueOfWarrantsOutstanding>
    <iva:FairValueOfWarrantsOutstanding
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_EFM8TpwCpkqu7FVPRM1rTQ"
      decimals="-3"
      id="Tc_NpeuFf64C0SsA8X3gm7AMw_11_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">6738000</iva:FairValueOfWarrantsOutstanding>
    <iva:WarrantsUnitFairValue
      contextRef="As_Of_11_28_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_lpf5jlqhR0GVIbvPIhKnYw"
      decimals="4"
      id="Tc_ceLd-01KQUu29UW53yMH4g_12_2"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.0418</iva:WarrantsUnitFairValue>
    <iva:WarrantsUnitFairValue
      contextRef="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_ldh6EouHQke8vr_BH-JvxQ"
      decimals="4"
      id="Tc_ZJvuXSqJ7UuWR2KKVwKxbg_12_4"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.0453</iva:WarrantsUnitFairValue>
    <iva:WarrantsUnitFairValue
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_EFM8TpwCpkqu7FVPRM1rTQ"
      decimals="4"
      id="Tc_qC4Ht0bxDU2g93AD1ikrmw_12_6"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.0297</iva:WarrantsUnitFairValue>
    <iva:IfrsClassOfWarrantOrRightOutstanding
      contextRef="As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_V_UnvG7OVU6Postqxl9qTw"
      decimals="INF"
      id="Tc_WxOXN_1wsk2fVqTzq3HfNQ_3_2"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">3144654</iva:IfrsClassOfWarrantOrRightOutstanding>
    <iva:IfrsClassOfWarrantOrRightOutstanding
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_rbMHeXRpfEGsAR3PJoBgWg"
      decimals="INF"
      id="Tc_ctAgbj5kiUOzRUvh6UV7xA_3_4"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">3144654</iva:IfrsClassOfWarrantOrRightOutstanding>
    <iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_V_UnvG7OVU6Postqxl9qTw"
      decimals="2"
      id="Tc_ySGPc0unK0-at0MufKGqBw_4_2"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">1.00</iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_rbMHeXRpfEGsAR3PJoBgWg"
      decimals="2"
      id="Tc_i2N8s6639kaALnvAzyjH-g_4_4"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">1.00</iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <iva:WarrantsStockPrice
      contextRef="As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_V_UnvG7OVU6Postqxl9qTw"
      decimals="2"
      id="Tc_z9ReFZqoQkqfeLyA5KYZhw_5_2"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">4.12</iva:WarrantsStockPrice>
    <iva:WarrantsStockPrice
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_rbMHeXRpfEGsAR3PJoBgWg"
      decimals="2"
      id="Tc_ZHE-0SPuJUm2IDbrTxy_Hg_5_4"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">2.79</iva:WarrantsStockPrice>
    <iva:WarrantAverageLife
      contextRef="Duration_1_4_2024_To_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_f6IGXbNrJUeuXFjO7KpMzA"
      id="Tc_O24pMw0jCkW0KUVJGZxluw_6_2">P12Y</iva:WarrantAverageLife>
    <iva:WarrantAverageLife
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_IuzMYL65X0qu-JY8V6n_lw"
      id="Tc_h5Niox4Tx0GjEdY8BfrKSg_6_4">P11Y6M</iva:WarrantAverageLife>
    <iva:ExpectedVolatility
      contextRef="As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_V_UnvG7OVU6Postqxl9qTw"
      decimals="2"
      id="Tc_n-X4RbicL0WzdjILurRtwA_7_2"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.62</iva:ExpectedVolatility>
    <iva:ExpectedVolatility
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_rbMHeXRpfEGsAR3PJoBgWg"
      decimals="3"
      id="Tc_J_oIzhE550m225eYMCMu_w_7_4"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.596</iva:ExpectedVolatility>
    <iva:WarrantsCapOfPutOption
      contextRef="As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_V_UnvG7OVU6Postqxl9qTw"
      decimals="1"
      id="Tc_jGosOM14cU6XSQPbd_UssQ_8_2"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">25.0</iva:WarrantsCapOfPutOption>
    <iva:WarrantsCapOfPutOption
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_rbMHeXRpfEGsAR3PJoBgWg"
      decimals="1"
      id="Tc_dBO4x_AKCUuLJEqVMrGx0A_8_4"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">25.0</iva:WarrantsCapOfPutOption>
    <iva:FairValueOfWarrantsOutstanding
      contextRef="As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_V_UnvG7OVU6Postqxl9qTw"
      decimals="-3"
      id="Tc_U7Mbw5UT4EqS78iF9ptFYg_11_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">11809000</iva:FairValueOfWarrantsOutstanding>
    <iva:FairValueOfWarrantsOutstanding
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_rbMHeXRpfEGsAR3PJoBgWg"
      decimals="-3"
      id="Tc_8h4ZIs_Pa06NLrcQGXgtaw_11_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">6830000</iva:FairValueOfWarrantsOutstanding>
    <iva:WarrantsUnitFairValue
      contextRef="As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_V_UnvG7OVU6Postqxl9qTw"
      decimals="4"
      id="Tc_3U6dXzqVrkK_btt9UAifTA_12_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">0.0376</iva:WarrantsUnitFairValue>
    <iva:WarrantsUnitFairValue
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember_rbMHeXRpfEGsAR3PJoBgWg"
      decimals="4"
      id="Tc_Gc_p6o8XWEaChm5_k4iZDA_12_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">0.0217</iva:WarrantsUnitFairValue>
    <ifrs-full:LeaseLiabilities
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-5"
      id="Narr_hJXDPFboeEOc-NWYoIOToQ"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5800000</ifrs-full:LeaseLiabilities>
    <iva:IncreaseDecreaseInLeaseLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA"
      decimals="-5"
      id="Narr_EVaZ50LrLUy_AJ5yAHBw6Q"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-800000</iva:IncreaseDecreaseInLeaseLiabilities>
    <iva:LeaseTerm
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_iva_FibroscanMachinesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_u7Et-MI930eFeqmMLXteeg"
      id="Narr_YVjI7Pm5Z02QPg5CuHbu_Q">P4Y</iva:LeaseTerm>
    <ifrs-full:BorrowingsInterestRate
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_ifrs-full_LeaseLiabilitiesMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_GsWMv1_qikSzfG5Yj-NJvg"
      decimals="4"
      id="Narr_NStT6oYiu027XLGjA2cYMw"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.0189</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsInterestRate
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_ifrs-full_LeaseLiabilitiesMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_dYFp-ujODEWkgQn22I6RnQ"
      decimals="4"
      id="Narr_O76qJzaEdUurHMav2isOHw"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.0518</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_2QrKLgieJUC04ljUPtM5gw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Less than&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Between&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Between&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;More than&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1 year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1 and 3 years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3 and 5 years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;5 years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Bank borrowings&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42,509&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,229&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 36,164&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,225&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 890&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Derivatives&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,569&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,569&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,302&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,260&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,761&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,455&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,306&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalty certificates liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,263&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total debt&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 73,404&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,726&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 57,299&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,225&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 8,153&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Less than&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Between&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Between&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;More than&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1 year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1 and 3 years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;3 and 5 years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5 years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Bank borrowings&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,206&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,928&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,872&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,848&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,558&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivatives&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other loans and similar borrowings&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,719&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 82&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,636&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,565&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,298&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,267&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Royalty certificates liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,327&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,327&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total debt&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_EHsAFhljaE2ILeQMiCBC4Q;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt; 54,082&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,308&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 9,140&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 31,749&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,885&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities>
    <ifrs-full:LoansReceived
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_MBBdK9kEVESCRXyS3shcmw_3_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">42509000</ifrs-full:LoansReceived>
    <ifrs-full:LoansReceived
      contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_o2Fe8k_JVUOuzAwFE3EH9g"
      decimals="-3"
      id="Tc_uzmixvYnzESGgwbRBnMISA_3_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3229000</ifrs-full:LoansReceived>
    <ifrs-full:LoansReceived
      contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_1fmInCo2D0yp8z7M1kVwrg"
      decimals="-3"
      id="Tc_osheILzpck-frN3XJV4Qhg_3_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">36164000</ifrs-full:LoansReceived>
    <ifrs-full:LoansReceived
      contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_BwJ5AiMcPkmDzrV1KCPF7Q"
      decimals="-3"
      id="Tc_5eNbwXv1hkiJEf5cDJtC9w_3_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2225000</ifrs-full:LoansReceived>
    <ifrs-full:LoansReceived
      contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_De4o7giPiEinOd0qNd9GCA"
      decimals="-3"
      id="Tc_8Iv6Tmsib0O5K1RuS6Vy_Q_3_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">890000</ifrs-full:LoansReceived>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_3x5oup0ZAkmV-Oq9QKQaHA_4_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">13569000</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities
      contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_1fmInCo2D0yp8z7M1kVwrg"
      decimals="-3"
      id="Tc_RMECbYw9eECGHlOjaBHgRA_4_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">13569000</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:OtherBorrowings
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_rDQuCSFbikygAsNfwaKP2A_5_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">4302000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings
      contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_o2Fe8k_JVUOuzAwFE3EH9g"
      decimals="-3"
      id="Tc_7M2G7KJWkkmOUcOsQBvelA_5_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">42000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings
      contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_1fmInCo2D0yp8z7M1kVwrg"
      decimals="-3"
      id="Tc_zJ8InSbNDEuIZ_-09Tl2mw_5_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">4260000</ifrs-full:OtherBorrowings>
    <ifrs-full:LeaseLiabilities
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_rA3M0S0d3E6TSsGMOctvjA_6_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5761000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_o2Fe8k_JVUOuzAwFE3EH9g"
      decimals="-3"
      id="Tc_FRGdV1QQikmckL21k9LHDQ_6_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2455000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_1fmInCo2D0yp8z7M1kVwrg"
      decimals="-3"
      id="Tc_llmpOZRq4Em-Hd5JEBEm6A_6_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3306000</ifrs-full:LeaseLiabilities>
    <iva:NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_6kgxncLLjku5u5QDFD__JA_7_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">7263000</iva:NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued>
    <iva:NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued
      contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_De4o7giPiEinOd0qNd9GCA"
      decimals="-3"
      id="Tc_B4cWlJHaBk2pNIRTmEb2rg_7_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">7263000</iva:NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued>
    <ifrs-full:Borrowings
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_HI7ozYvgckuYv9Q1aq7dqQ_8_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">73404000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_o2Fe8k_JVUOuzAwFE3EH9g"
      decimals="-3"
      id="Tc_fMZLu61vqUqtqhIZH3EtHg_8_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5726000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_1fmInCo2D0yp8z7M1kVwrg"
      decimals="-3"
      id="Tc_fA1Y0txlSk2uxXmZbJCc8Q_8_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">57299000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_BwJ5AiMcPkmDzrV1KCPF7Q"
      decimals="-3"
      id="Tc_Nye7n6wPAESyzpMLO_OLDw_8_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2225000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_De4o7giPiEinOd0qNd9GCA"
      decimals="-3"
      id="Tc_Cm0L9umsXU-FAWrPWGbQlQ_8_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">8153000</ifrs-full:Borrowings>
    <ifrs-full:LoansReceived
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_0QQVwLuM80uhZtUHbOJupA_3_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">27206000</ifrs-full:LoansReceived>
    <ifrs-full:LoansReceived
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_GSGDF0mlWkuIQruwBsMsBA"
      decimals="-3"
      id="Tc_3jwbJX3CqUGTmg3hbk5yGA_3_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2928000</ifrs-full:LoansReceived>
    <ifrs-full:LoansReceived
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_C0Ff4EWJsU2Ar98sMx82wg"
      decimals="-3"
      id="Tc_x1p73mOPX0S-Gb_liiPXng_3_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">4872000</ifrs-full:LoansReceived>
    <ifrs-full:LoansReceived
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_mhRLXXxIVUimCeRsLCjpAQ"
      decimals="-3"
      id="Tc_GDT3JMcTFUiwVsDXGjUh1A_3_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">17848000</ifrs-full:LoansReceived>
    <ifrs-full:LoansReceived
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_Ue5U6HHvckKiur1A8cLvgw"
      decimals="-3"
      id="Tc_M2g_vALL0EyWE-jUpXb_VQ_3_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1558000</ifrs-full:LoansReceived>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_HNOVsNbh_0q0hrQ_dbJ0dg_4_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10265000</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_mhRLXXxIVUimCeRsLCjpAQ"
      decimals="-3"
      id="Tc_2NoZjV6cJEC_HrVPgkzryQ_4_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10265000</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:OtherBorrowings
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_ioRwSHX5Y0SH1If2HfoyqA_5_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3719000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_GSGDF0mlWkuIQruwBsMsBA"
      decimals="-3"
      id="Tc_68ZWJRfqE0SZ4536jOl64g_5_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">82000</ifrs-full:OtherBorrowings>
    <ifrs-full:OtherBorrowings
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_mhRLXXxIVUimCeRsLCjpAQ"
      decimals="-3"
      id="Tc_0nbG0Yt-mEybNUDBnU-MLw_5_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3636000</ifrs-full:OtherBorrowings>
    <ifrs-full:LeaseLiabilities
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_5nSAlDl9F0iMxukjdEtT_A_6_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">6565000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_GSGDF0mlWkuIQruwBsMsBA"
      decimals="-3"
      id="Tc_lgzYM9yMX0ComZfIQXZQQg_6_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2298000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_C0Ff4EWJsU2Ar98sMx82wg"
      decimals="-3"
      id="Tc_7Xfjo10rv0ClWtMVdQdknw_6_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">4267000</ifrs-full:LeaseLiabilities>
    <iva:NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_sspKhFVrAUugSwsBJtqyWg_7_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">6327000</iva:NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued>
    <iva:NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_Ue5U6HHvckKiur1A8cLvgw"
      decimals="-3"
      id="Tc_wXX6zU4350KRsjrsb7Bhug_7_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">6327000</iva:NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued>
    <ifrs-full:Borrowings
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_GSGDF0mlWkuIQruwBsMsBA"
      decimals="-3"
      id="Tc_OtqNpbpEq0GgEwOaTQ1zAA_8_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5308000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_C0Ff4EWJsU2Ar98sMx82wg"
      decimals="-3"
      id="Tc_OLbJ5jB7LUut0OBvB1DEJQ_8_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">9140000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_mhRLXXxIVUimCeRsLCjpAQ"
      decimals="-3"
      id="Tc_4s4EOBa-306dSmlDEIX3jw_8_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">31749000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanFiveYearsMember_Ue5U6HHvckKiur1A8cLvgw"
      decimals="-3"
      id="Tc_GZKv9gV3_kqdDbiACtDmcA_8_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">7885000</ifrs-full:Borrowings>
    <ifrs-full:NotionalAmount
      contextRef="As_Of_8_31_2023_ifrs-full_ClassesOfLiabilitiesAxis_iva_RoyaltyCertificateLiabilitiesMember_h1XHuxF4ukeRQuZnn7VzCw"
      decimals="-5"
      id="Narr_0Xd5HUWw4EmgaCSg-Cz_0w"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5100000</ifrs-full:NotionalAmount>
    <ifrs-full:Borrowings
      contextRef="As_Of_8_31_2023_ifrs-full_ClassesOfLiabilitiesAxis_iva_RoyaltyCertificateLiabilitiesMember_h1XHuxF4ukeRQuZnn7VzCw"
      decimals="-5"
      id="Narr_V_4SX-ZSOUmHO2cOm87hYg"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5100000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_RoyaltyCertificatesLiabilitiesMember_MLWq4MeMoEelhaSNDyM6mw"
      decimals="-5"
      id="Narr_z_5q7iIRnkaY-LOGowWTZg"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">7300000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_RoyaltyCertificatesLiabilitiesMember_BjRDFB3IN0mcC4Ynuq2iZQ"
      decimals="-5"
      id="Narr_nqft7Qx-DESTYFg_CKNETA"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">6300000</ifrs-full:Borrowings>
    <iva:RoyaltyCertificatesEffectiveInterestRate
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_RoyaltyCertificatesLiabilitiesMember_mEPm5drgy0O0deuPued1-Q"
      decimals="3"
      id="Narr_TR2P4a1rOUevi0LkCJl3ew"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.319</iva:RoyaltyCertificatesEffectiveInterestRate>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_RoyaltyCertificatesLiabilitiesMember_MLWq4MeMoEelhaSNDyM6mw"
      decimals="-5"
      id="Narr_msWMn334XkOgzL25vex9ww"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">9100000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_6_30_2024_ifrs-full_BorrowingsByNameAxis_iva_RoyaltyCertificatesLiabilitiesMember_ifrs-full_UnobservableInputsAxis_ifrs-full_DiscountRateMeasurementInputMember_qerPupsvsEe_tn0yX52pFQ"
      decimals="1"
      id="Narr_8Vue_Q-wlkqb8FhE0UjUyw"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">27.9</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:OtherProvisions
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-5"
      id="Narr_9tIyyTwmbUuYq9N13N3MlQ"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">0</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-5"
      id="Narr_K3ybfaXR_0WWxPb2M48QrA"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">0</ifrs-full:OtherProvisions>
    <iva:DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_itY3hlszIEKZ3-ryj0kmHQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Retirement benefit obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,555&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,559&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total obligation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,555&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,559&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</iva:DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_FvDOezAwzEya8TpyZLFRpg_2_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1555000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_xGyg6ptheESlZ92FpuwZ2Q_2_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1559000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_5eSaiQCdUE-KdG_TvMePqQ_3_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1555000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_yVfqC5fBjkGZy0oG7RPLWQ_3_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1559000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <iva:DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_9_YvchsFWUWtJyTUBlFuJA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Provision at beginning of period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,559)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,234)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expense for the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (70)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (228)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Actuarial gains or losses recognized in other comprehensive income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 74&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (97)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Provision at end of period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,555)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,559)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</iva:DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_gQdZg2LUkUO5LIMR8T-oXA_2_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1559000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="As_Of_12_31_2022__ShBeryiXEKxoX7Xx7OS6A"
      decimals="-3"
      id="Tc_tnBWeSJpo0i1M3eD8HhlDA_2_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1234000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_BK1vfqlZqU2bxFhLvsalhw_3_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">70000</ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss>
    <ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA"
      decimals="-3"
      id="Tc_E4PgZN2rDUqMioZNUCnsvA_3_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">228000</ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_SK_ytCydNEG0RRdtC422zw_4_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">74000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset
      contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA"
      decimals="-3"
      id="Tc_uQ3wxztSxk6j3-h2PIWQQQ_4_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-97000</ifrs-full:GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_AQsT53Mw6k6OawXSjFPj5A_5_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1555000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_QbebMeiLVEWUz53jLuZuMg_5_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1559000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <iva:DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_Z0W683OYZUqRE6jF75C1xw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Service cost for the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (104)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (183)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Interest cost for the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (46)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Benefits for the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (70)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (228)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</iva:DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory>
    <ifrs-full:CurrentServiceCostDefinedBenefitPlans
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_outIUzTlJEOzJdnGhfwT-g_2_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">104000</ifrs-full:CurrentServiceCostDefinedBenefitPlans>
    <ifrs-full:CurrentServiceCostDefinedBenefitPlans
      contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA"
      decimals="-3"
      id="Tc_HoPYBNl3U0CauwaLNS96og_2_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">183000</ifrs-full:CurrentServiceCostDefinedBenefitPlans>
    <ifrs-full:InterestExpenseDefinedBenefitPlans
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_BRYd9Vd9uE27WvZQAgNarQ_3_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">25000</ifrs-full:InterestExpenseDefinedBenefitPlans>
    <ifrs-full:InterestExpenseDefinedBenefitPlans
      contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA"
      decimals="-3"
      id="Tc_kms-Fsl3Bk-1cETdUhOeLA_3_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">46000</ifrs-full:InterestExpenseDefinedBenefitPlans>
    <ifrs-full:PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_Aj9bE3M33UKUIoUg6F0KPg_4_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-59000</ifrs-full:PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_OQPtKpClYkOm4q6DRSH9rg_5_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">70000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="Duration_1_1_2023_To_12_31_2023_kzwvvp3aW0urQssQBeD-RA"
      decimals="-3"
      id="Tc_YPuXSwuB0kKSkoDHFsIwOw_5_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">228000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="As_Of_6_30_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_ZxMBck8Vv06CkTltj3JJkg"
      decimals="-5"
      id="Narr_Urtko8hYSUOTjMN0c1B0bA"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1000000.0</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="As_Of_12_31_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_8tc8znfKVkWA4XCDKyyrhw"
      decimals="-5"
      id="Narr_MmS7sfsi20Gp203Y2licAA"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1000000.0</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_U2c68ZUgvEqI9vmzVxNY9A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Employee&#x2011;related payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,739&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,869&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued payroll and other employee-related taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,801&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,540&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Sales tax payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,140&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,569&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other accrued taxes and employee-related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 142&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other miscellaneous payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,834&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,165&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory>
    <iva:EmployeeRelatedPayables
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_p5WeURVGGkO20ussSGDrEQ_2_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1739000</iva:EmployeeRelatedPayables>
    <iva:EmployeeRelatedPayables
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_7Nyq1gXReE2v9eAUF3_ltw_2_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1869000</iva:EmployeeRelatedPayables>
    <iva:AccruedPayrollAndOtherEmployeeRelatedTaxes
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_s5NVrTNz9UikUeKXmKosrQ_3_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1801000</iva:AccruedPayrollAndOtherEmployeeRelatedTaxes>
    <iva:AccruedPayrollAndOtherEmployeeRelatedTaxes
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_9yLSJrNNskKED8OuD14cPA_3_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1540000</iva:AccruedPayrollAndOtherEmployeeRelatedTaxes>
    <ifrs-full:CurrentValueAddedTaxPayables
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_QH3g9T0F5EivASrZeFoSlA_4_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2140000</ifrs-full:CurrentValueAddedTaxPayables>
    <ifrs-full:CurrentValueAddedTaxPayables
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_nvJqMF3sSU-289eVqut8kg_4_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3569000</ifrs-full:CurrentValueAddedTaxPayables>
    <iva:OtherAccruedTaxesAndEmployeeRelatedExpenses
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_rWZMbksSqkiVD1A6pnOjPg_5_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">142000</iva:OtherAccruedTaxesAndEmployeeRelatedExpenses>
    <iva:OtherAccruedTaxesAndEmployeeRelatedExpenses
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_V4Wo5ZLCzE-KudQP2Ep3wQ_5_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">164000</iva:OtherAccruedTaxesAndEmployeeRelatedExpenses>
    <ifrs-full:OtherCurrentPayables
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_qU5Maiw3a0-tPkF3gkPTRg_6_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">12000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:OtherCurrentPayables
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_U8ig8xHvYkOioxU1z-Pj3g_6_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">23000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_vTljXZFWS0e5UUnJeMeqCw_7_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5834000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_RWPeAVFqYEKphu-BlYNVKg_7_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">7165000</ifrs-full:OtherCurrentLiabilities>
    <iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_eZacGoOw9EqCkQc8KDz_Fw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36,583&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,679&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term contract liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Trade payables and other current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 36,586&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 37,685&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_hJa4pCIzJ0uaA_hZdvqeww_2_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">36583000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_eXFNfK2eSEuBvFx2JLb4FA_2_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">37679000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:CurrentContractLiabilities
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_vK0Fv9c8CUmHm9PcTu4QpQ_3_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_cQBIxp3kdUGBif6pdy3Gpw_3_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">6000</ifrs-full:CurrentContractLiabilities>
    <iva:TradePayablesAndOtherCurrentLiabilities
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_zm1BU-7z4E-Eb7jqIdSzOA_5_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">36586000</iva:TradePayablesAndOtherCurrentLiabilities>
    <iva:TradePayablesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_opg5A0T6mkC5ipQsHoL3XA_5_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">37685000</iva:TradePayablesAndOtherCurrentLiabilities>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_q-105LEs4k2N_W0bMF3GQA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Due in 30 days&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,217&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,995&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Due in 30-60 days&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,684&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Due in more than 60 days&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Trade payable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 36,583&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 37,679&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneMonthMember_F44q34_t8kGRdNbcbz0SsA"
      decimals="-3"
      id="Tc_U3Ho-sFYXUCEl4toByJWzA_2_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">26217000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneMonthMember_L3zFOF6AbEGJqyvX3ksALQ"
      decimals="-3"
      id="Tc_iNpZUW3w5EOGzelyIcTjhQ_2_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">24995000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_PQdCvCveh0GtnvbOTvZTxg"
      decimals="-3"
      id="Tc__KLVJ0TwkkawlZczTt8NQQ_3_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10362000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember_pgS3JPFyOUuBb8uDOr_KNw"
      decimals="-3"
      id="Tc_rkVHFsB0Yk6IOwoUgtPVHA_3_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">12684000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_6_30_2024_ifrs-full_MaturityAxis_iva_LaterThanTwoMonthsMember_C5lqESZnOEmaIeMKVhSS8Q"
      decimals="-3"
      id="Tc_U2WqgttELkmAhRoE8GOLkg_4_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">4000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_9KbviufLYUuVpH9EZu9cUQ_5_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">36583000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_NjAB_X5Rx0GyceFucHHYSA_5_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">37679000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:AccrualsClassifiedAsCurrent
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-5"
      id="Narr_FvMxz7ZprkefxC3qt_aGeA"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">24000000.0</ifrs-full:AccrualsClassifiedAsCurrent>
    <iva:AccrualsClassifiedAsCurrentRelatingToScientificProjects
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-5"
      id="Narr_aICmefT3Tka6vHxHQn-Y5A"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">20200000</iva:AccrualsClassifiedAsCurrentRelatingToScientificProjects>
    <iva:IncreaseDecreaseInTradeAccountsPayable
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-5"
      id="Narr_swXpe2Ue106ljkboFM8cXA"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-1100000</iva:IncreaseDecreaseInTradeAccountsPayable>
    <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Group_I7bbA6lcz0ylRY7g1M2WDA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:49.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Book value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;assets/liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;on the&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;carried at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; statement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;carrieds at &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; carried at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; of financial&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; through&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;position&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;profit or loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term accrued income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term deposit accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Advance payment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,047&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,047&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,047&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current accrued income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,687&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,687&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term deposit accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 809&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 809&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,518&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,518&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,518&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,147&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 16,208&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 16,208&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 16,208&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term debt &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 45,994&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative instruments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,569&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,569&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,569&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Royalty certificates liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,263&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,050&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,726&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,726&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,726&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;36,583&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;36,583&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;36,583&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other miscellaneous payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;12&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;109,998&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 13,569&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;96,429&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;110,933&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;i style="font-style:italic;"&gt;See Note 4.10 Financial debt detailing amortized cost and fair value of the Credit facility with the EIB&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:49.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dec. 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Book Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;assets/liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;on the&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;carried at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; assets &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;statement&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;carrieds at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; carried at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;of financial&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;through&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;position&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;profit or loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term deposit accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term security deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Advance payment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,047&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,047&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,047&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term deposit accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,807&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,807&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,807&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 857&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 857&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 857&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,918&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,918&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,918&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 41,706&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 41,706&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 41,706&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term debt (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,181&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,181&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,701&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative instruments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,265&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Royalty certificates liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,327&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,327&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,617&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short-term debt&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,308&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,679&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other miscellaneous payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;23&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:48.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;91,784&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 10,265&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;81,518&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;92,594&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AdvancePaymentMember_Sx8nhE1j8ESlCSB49JWGVQ"
      decimals="-3"
      id="Tc_iQD3a6ljfU6sAeaR1pJi9w_10_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1047000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AdvancePaymentMember_NT4vZl9PbkGiPUjsmpSqhg"
      decimals="-3"
      id="Tc_qRNErQJFJ0eMKOD-WsUdkQ_10_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1047000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AdvancePaymentMember_Sx8nhE1j8ESlCSB49JWGVQ"
      decimals="-3"
      id="Tc_qN8ALsBvhk6f-EggjkoeVA_10_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1047000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AccruedIncomeMember_rFAULMOIG0-nNmzcBonheQ"
      decimals="-3"
      id="Tc_TH0KuiiOd0CTqcRt1op7lA_11_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1687000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AccruedIncomeMember_Ahk1q2K--0uCVDs0WN2cnA"
      decimals="-3"
      id="Tc_UUpI24pd9UigQOTchKDOYA_11_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1687000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AccruedIncomeMember_rFAULMOIG0-nNmzcBonheQ"
      decimals="-3"
      id="Tc_HF5MwrcOBE2yumNq1NAwZg_11_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1687000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_TradeReceivablesMember_UhBYZg6XLkqb9t3xvxBEUA"
      decimals="-3"
      id="Tc_6Q5m1pfS5kOnbYW7yl2t1g_13_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">809000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_TradeReceivablesMember_1-tjX8tbt0GXwG43E2l8Mg"
      decimals="-3"
      id="Tc_RnsXyo0NLESndy69SIb6Ig_13_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">809000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_TradeReceivablesMember_UhBYZg6XLkqb9t3xvxBEUA"
      decimals="-3"
      id="Tc_LxGg_cJ0pUeLEK0gjFwwQQ_13_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">809000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_iva_OtherReceivablesMember_8JkciAHeZUmN1wIn0UqhJA"
      decimals="-3"
      id="Tc_KtKMNXKmn0y8pTB0Ag4bLg_14_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2518000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_OtherReceivablesMember_X545crJT6E-s_K-iPNVWJw"
      decimals="-3"
      id="Tc_XXBAez69H0KDFQXjN6f8nw_14_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2518000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_iva_OtherReceivablesMember_8JkciAHeZUmN1wIn0UqhJA"
      decimals="-3"
      id="Tc_Le7cr3pIH02HP20dBpKbTg_14_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2518000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_iva_IfrsCashAndCashEquivalentsMember_gUhZ2pkRhkGxOpcwP54F6A"
      decimals="-3"
      id="Tc_0fYxnkgyz0Gjp1T4jZTd_A_15_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10147000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_IfrsCashAndCashEquivalentsMember_3DbfsjKIuEeTh95AuBI8Dw"
      decimals="-3"
      id="Tc_kG9gY1ETVUGGkpIONwPzrg_15_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10147000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialAssetsAxis_iva_IfrsCashAndCashEquivalentsMember_gUhZ2pkRhkGxOpcwP54F6A"
      decimals="-3"
      id="Tc_O4vbwrX1Zky5SynTXNGDKg_15_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10147000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_NtDp_NR6jUidog--iI6Itg_16_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">16208000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_xqxoBDc1zUiTY3urkmymcw"
      decimals="-3"
      id="Tc_OEWFmXhUOkWh9wZmymtVGg_16_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">16208000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_KBc37KH6oECx9ic_TUlnHw_16_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">16208000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_LongtermBorrowingsMember_3_c4ZNJ7IkuGUZRsgL5KeA"
      decimals="-3"
      id="Tc_t_yW9x6I_0-rqtWUfAs7cw_19_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">46846000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_LongtermBorrowingsMember_KhP49WhAa0S2SqllGaAZ3A"
      decimals="-3"
      id="Tc_QwnNi8Y5O0yPJ-yMMmMPKQ_19_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">46846000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_LongtermBorrowingsMember_3_c4ZNJ7IkuGUZRsgL5KeA"
      decimals="-3"
      id="Tc__9oKYP7LZUe9A5xsJo6Khg_19_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">45994000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_DerivativeInstrumentsMember_USWamMRH70e5dMBuXB1kfg"
      decimals="-3"
      id="Tc_O6Hd3bFLFkKcNajG2Mfmzg_20_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">13569000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_DerivativeInstrumentsMember_USWamMRH70e5dMBuXB1kfg"
      decimals="-3"
      id="Tc_dBNqRrumqkeaM3NoAC2yKQ_20_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">13569000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_DerivativeInstrumentsMember_USWamMRH70e5dMBuXB1kfg"
      decimals="-3"
      id="Tc_AGcOruLIykWjj-fmDm24LA_20_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">13569000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_RoyaltyCertificatesLiabilitiesMember_tzXibduYxE6YsqSgIdTn3A"
      decimals="-3"
      id="Tc_7IvVzRsz10SYVD6XEAc8Hg_21_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">7263000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_RoyaltyCertificatesLiabilitiesMember_tzXibduYxE6YsqSgIdTn3A"
      decimals="-3"
      id="Tc_1Sz7QzgtsUSS0duW7FRlpA_21_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">7263000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_RoyaltyCertificatesLiabilitiesMember_tzXibduYxE6YsqSgIdTn3A"
      decimals="-3"
      id="Tc_wGjwPI1K8U2KKpu25G6xEQ_21_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">9050000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_ShorttermBorrowingsMember_HbTI56G8V0OVuMMfgkPm9w"
      decimals="-3"
      id="Tc_pZXZdDBaGkWYbAnDdoF2AQ_22_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5726000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_ShorttermBorrowingsMember_q5wyxdtsjkC9ATGXwBJ1zQ"
      decimals="-3"
      id="Tc_nf5fU9MpFkq2Ghwt3KHJcA_22_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5726000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_ShorttermBorrowingsMember_HbTI56G8V0OVuMMfgkPm9w"
      decimals="-3"
      id="Tc_96xDWIkCIEOBJkBbK5DzWw_22_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5726000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_TradePayablesMember_DT34R3eKL0K1egtpaQCcgw"
      decimals="-3"
      id="Tc_hW_FIHvF3kSSRYGRYpOAXQ_23_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">36583000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_TradePayablesMember_DT34R3eKL0K1egtpaQCcgw"
      decimals="-3"
      id="Tc_3wdefbUY5kyz61OyBZtnbA_23_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">36583000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_TradePayablesMember_DT34R3eKL0K1egtpaQCcgw"
      decimals="-3"
      id="Tc_3pcDD9wjHEawJ3Rs-eu_qg_23_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">36583000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_OtherMiscellaneousPayablesMember_17V3AWgX9UGIGzCdKUHVpA"
      decimals="-3"
      id="Tc_k3oe4eWXHEyDaSvBQwu_OQ_24_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">12000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_OtherMiscellaneousPayablesMember_17V3AWgX9UGIGzCdKUHVpA"
      decimals="-3"
      id="Tc_ds3AmoZhUEGe_PlWYcwxBg_24_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">12000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_OtherMiscellaneousPayablesMember_17V3AWgX9UGIGzCdKUHVpA"
      decimals="-3"
      id="Tc_GQLaIFBR30ODOubIpdsGng_24_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">12000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_38dGII73dEaQYz0K8olqXQ_25_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">109998000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ad_CUhpQSUWO9uvSqmVOjw"
      decimals="-3"
      id="Tc_hlxKNtszZ0G58Iz9hdsIfw_25_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">13569000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_xqxoBDc1zUiTY3urkmymcw"
      decimals="-3"
      id="Tc_pEi7ehW_U06rXH0yIMPuGA_25_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">96429000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_eY9Mgc_b5UGepZU0gj8uIA_25_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">110933000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_LongTermDepositAccountsMember_nJntFM5UfE6dEPYXAe50tg"
      decimals="-3"
      id="Tc_fZvSiZ5Dq0evhkJMnl7Z6w_8_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">9000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_LongTermDepositAccountsMember_fo_XM5MB2kOMXwNZMOkI5g"
      decimals="-3"
      id="Tc_6e1goRscwkSKXZtmsJYCfw_8_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">9000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_LongTermDepositAccountsMember_nJntFM5UfE6dEPYXAe50tg"
      decimals="-3"
      id="Tc_aK7MHgUB4ky9ccqsmWy86A_8_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">9000000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_LongTermSecurityDepositsMember_Noxm4K7bX0S6jyxwkUADrg"
      decimals="-3"
      id="Tc_Y9awdcChXkWyUjEoTMpvAQ_9_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">8000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_LongTermSecurityDepositsMember_VROn8csSH0i28NXJGx3Amg"
      decimals="-3"
      id="Tc_EIME4aNe_UmbI7CVyyAliA_9_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">8000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_LongTermSecurityDepositsMember_Noxm4K7bX0S6jyxwkUADrg"
      decimals="-3"
      id="Tc_5OUXgK6YFke7nG7rzeFRKw_9_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">8000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AdvancePaymentMember_FkwbWhKujke__64KGmRGog"
      decimals="-3"
      id="Tc_07pBw8fhrEKafzx8oyM0xQ_10_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1047000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AdvancePaymentMember_qXVB1LZ70EWDaFdvLxmc5Q"
      decimals="-3"
      id="Tc_dVe2MIHMiEG_wWSrwhLBSg_10_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1047000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_AdvancePaymentMember_FkwbWhKujke__64KGmRGog"
      decimals="-3"
      id="Tc_3ARvzItFo0WQyLgFm4qs0Q_10_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1047000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_ShortTermDepositAccountsMember_XX7WnZfsDkussQqjcn130w"
      decimals="-3"
      id="Tc_7MSbuQXHok6wAv-ctoP2YQ_11_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">70000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_ShortTermDepositAccountsMember_374tsJrTKk6fJow5yHyCDA"
      decimals="-3"
      id="Tc_gfXUTsyhyUqHsiulAxUxLQ_11_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">70000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_ShortTermDepositAccountsMember_XX7WnZfsDkussQqjcn130w"
      decimals="-3"
      id="Tc_Z5nQLBp50EeABVPfATAXsg_11_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">70000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_TradeReceivablesMember_HDaVOBXSAEmTDP24XH8uQQ"
      decimals="-3"
      id="Tc_JP1X57AbMk621FQ5nt-1_g_12_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3807000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_TradeReceivablesMember_9Se6Eh9LEEyShj3tyGuJAg"
      decimals="-3"
      id="Tc_XfooHZ8-SEGj4a4jZk-clg_12_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3807000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_ifrs-full_TradeReceivablesMember_HDaVOBXSAEmTDP24XH8uQQ"
      decimals="-3"
      id="Tc_3-dXre4zQk2dg8xBdDLcRA_12_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3807000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_OtherReceivablesMember_YRoI5LsEsEySxVU2J2oZVw"
      decimals="-3"
      id="Tc_LOqJExAYUkWP6NzcbRmOXg_13_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">857000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_OtherReceivablesMember_nOSt24rbu06dp175BFWIVg"
      decimals="-3"
      id="Tc_b5me_10mW0KfNVWEP2sDzg_13_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">857000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_OtherReceivablesMember_YRoI5LsEsEySxVU2J2oZVw"
      decimals="-3"
      id="Tc_to5F9lG6K0yGJHYAV6pR0g_13_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">857000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_IfrsCashAndCashEquivalentsMember_vrZZqx47o0a1hsDxw-vIxA"
      decimals="-3"
      id="Tc_hR97XKPsqkWk_mYh68RY6Q_14_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">26918000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_ClassesOfFinancialAssetsAxis_iva_IfrsCashAndCashEquivalentsMember_OARfL4lhGkWF8cdGOx-xCQ"
      decimals="-3"
      id="Tc_-HbJoJias0SOMoKv4axjGg_14_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">26918000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialAssetsAxis_iva_IfrsCashAndCashEquivalentsMember_vrZZqx47o0a1hsDxw-vIxA"
      decimals="-3"
      id="Tc_oFt_tMW9a0KEgh_VRti8AQ_14_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">26918000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_DW49MvthZkSRA1VNj2G1Ug_15_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">41706000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_RtETuwSwJkCED4F2iCpqkA"
      decimals="-3"
      id="Tc_Fer_kVX0wUuPRmAuK1GrgQ_15_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">41706000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssetsAtFairValue
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_dMOjuddheEqlB0NMLfk5ow_15_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">41706000</ifrs-full:FinancialAssetsAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_LongtermBorrowingsMember_LdqaexFubUm5bmzDhGaIFQ"
      decimals="-3"
      id="Tc_eBrmu057_kqU-bCbdDTNXQ_18_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">32181000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_LongtermBorrowingsMember_1DesxSZs7UeHW8u3NH0eGg"
      decimals="-3"
      id="Tc_AL0ZPxn2YkOSBwg8MucYEg_18_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">32181000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_LongtermBorrowingsMember_LdqaexFubUm5bmzDhGaIFQ"
      decimals="-3"
      id="Tc__hK6pT4ml06XQ3Fnc8eUJQ_18_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">29701000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_DerivativeInstrumentsMember_DXqbqfuw00aAGXk5irtJtw"
      decimals="-3"
      id="Tc_MAozsp5xKE-Y_y7ahasmtQ_19_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10265000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_DerivativeInstrumentsMember_uAo9ZMcdJEO8cLUT1lE0MA"
      decimals="-3"
      id="Tc_7CJ1FV66oUm0mnB3UHkXPg_19_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10265000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_DerivativeInstrumentsMember_DXqbqfuw00aAGXk5irtJtw"
      decimals="-3"
      id="Tc_wu9A5CxarkqyX6zCuSvtRA_19_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10265000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_RoyaltyCertificatesLiabilitiesMember_Sn-nL6ck_UCopAUgyhyLIw"
      decimals="-3"
      id="Tc_GMux-DYZyUy1uecHahHx-Q_20_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">6327000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_RoyaltyCertificatesLiabilitiesMember_WaIiYd4PIUyNoJBmB4iA4A"
      decimals="-3"
      id="Tc_KM9fxhmwc0CV9lptW4iBew_20_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">6327000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_RoyaltyCertificatesLiabilitiesMember_Sn-nL6ck_UCopAUgyhyLIw"
      decimals="-3"
      id="Tc_mAwhU9tGU0O-0iNlZycPDA_20_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">9617000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_ShorttermBorrowingsMember_cHoNbFS0eUyuodyG6femhw"
      decimals="-3"
      id="Tc_2JkKS4HHKkegGbujPeMYNQ_21_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5308000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_ShorttermBorrowingsMember_NB0TWpTDvU2mM9PCPaNmTg"
      decimals="-3"
      id="Tc_eBBG3UUWEEmlcJOC7t-KRg_21_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5308000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_ifrs-full_ShorttermBorrowingsMember_cHoNbFS0eUyuodyG6femhw"
      decimals="-3"
      id="Tc_a7gI-UKf10WLNYymmw6_SQ_21_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5308000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_TradePayablesMember_5cmgPsH920CfGPmJBDOp-w"
      decimals="-3"
      id="Tc_RiOJ2XTQlkiwe4lyydYXlg_22_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">37679000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_TradePayablesMember_hHYqQE9Yj0e7HSqbpfQXSg"
      decimals="-3"
      id="Tc_ftfx4N1e8UurUf8d4yalsA_22_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">37679000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_TradePayablesMember_5cmgPsH920CfGPmJBDOp-w"
      decimals="-3"
      id="Tc_yZ_rdrz1b0C3VG99a_NvKw_22_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">37679000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_OtherMiscellaneousPayablesMember_oeFuIUG-QkqzWRNtsHuxmQ"
      decimals="-3"
      id="Tc_iJldYYyCZEqaBwHOnNVH1g_23_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">23000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_OtherMiscellaneousPayablesMember_XvcehwIoO02CIQ32YJIxyg"
      decimals="-3"
      id="Tc_nirxdqJ9HE--g5pgmPf6zg_23_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">23000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_OtherMiscellaneousPayablesMember_oeFuIUG-QkqzWRNtsHuxmQ"
      decimals="-3"
      id="Tc_E1BWB_d81kqaKvUetHjhcQ_23_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">23000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_N_XtJioBYkWCPq4dvwSjkA_24_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">91784000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember_tIb2x3EdLUOAPCEztcL7wA"
      decimals="-3"
      id="Tc_xgo_4OQ4nEGu9vC_st9cOA_24_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10265000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_Ju8a20CjNUGvFkUgBgWStw"
      decimals="-3"
      id="Tc_mhEb-uA2vkO9750Lflrt4w_24_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">81518000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_PeItg8WKc0mfWoApsOJ8jw_24_10"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">92594000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <iva:DisclosureOfComponentsOfIncomeStatementTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_VtQgwOgrwES3kUb4kGluAg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Note 5.&lt;/b&gt;&#160;&#160;&#160;&#160;&lt;b style="font-weight:bold;"&gt;Notes to the interim condensed consolidated statement of (income) loss&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;5.1&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Revenues and other income&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;For the six months ended June 30, 2024, and June 30, 2023&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,901&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total revenue&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 41&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,901&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,630&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,631&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Subsidies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,087&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,693&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4,721&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total revenue and other income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,734&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,622&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Other operating income&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Research Tax Credit (&#x201c;CIR&#x201d;) generated over the first six months of the fiscal year amounts to &#x20ac;2.7 million in 2024 as in 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2023, other operating income are composed of:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The R&amp;amp;D Tax Research Credit from Inventiva Inc amounting to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x20ac;1.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; million, compared to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x20ac;0.8&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; million in tax income as of June 30, 2024;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The re-invoicing to CTTQ for a portion of the expenses incurred, amounting to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x20ac;0.3&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; million as of June 30, 2023, under Phase I of the ongoing Phase III pharmacological clinical trial NATiV3, and the re-invoicing to CTTQ for specific expenses related to CRO provisions amounting to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x20ac;0.7&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; million, compared to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#x20ac;2.6&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; million in CTTQ re-invoicing as of June 30, 2024, accounted as a reduction in research and development expenses.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;5.2&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Operating expenses&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;For the six months ended June 30, 2024 and June 30, 2023&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Research&#160;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Marketing&#160;&#x2013;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;General&#160;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;development&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Business&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;administrative&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;costs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;development&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Disposables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (887)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (887)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Energy and liquids&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (447)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (447)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Patents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (643)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (643)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Studies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (34,073)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (34,073)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Maintenance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (526)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (526)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (118)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,675)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,795)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;IT systems&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (405)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (444)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Support costs (including taxes)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (375)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (375)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Personnel costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,637)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (153)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,600)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,391)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation, amortization and provisions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,732)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (122)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,854)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Insurances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (921)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (921)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (352)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (437)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (975)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,764)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total operating expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (46,822)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (598)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (7,701)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (55,122)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Research&#160;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Marketing&#160;&#x2013;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;General&#160;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;development&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Business&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;administrative&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;en milliers d'euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;costs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;development&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Disposables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (943)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (943)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Energy and liquids&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (479)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (479)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Patents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (257)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (257)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Studies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (42,847)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (42,847)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Maintenance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (459)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (459)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (61)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,884)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,945)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;IT systems&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (440)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (50)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (498)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Support costs (including taxes)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (343)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (343)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Personnel costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,065)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (126)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,347)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,538)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation, amortization and provisions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,061)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (104)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,166)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Insurances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,121)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,121)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Other operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (450)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (570)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (964)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,985)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total operating expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (54,062)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (705)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (6,812)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (61,580)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="font-style:italic;"&gt;Personnel costs and headcount&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Marketing - &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Research and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Business&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;General and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;development&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;development&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;administrative&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;costs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Wages, salaries and similar costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,824)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (120)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,237)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,181)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,312)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (563)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,886)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provisions for retirement benefit obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (35)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (86)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Share-based payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,450)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (24)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (765)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,238)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total personnel costs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (7,637)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (153)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (2,600)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (10,391)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company has 123 employees as of June 30, 2024, of which 112 are employed by Inventiva S.A. and 11 are employed by Inventiva Inc.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Marketing -&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Research and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Business&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;General and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;development&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;development&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; administrative&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;costs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Wages, salaries and similar costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,399)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (104)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,191)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (5,694)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Payroll taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,222)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (476)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,708)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Provisions for retirement benefit obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (61)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (90)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share-based payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,383)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (650)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (2,046)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total personnel costs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (7,065)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (126)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (2,347)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (9,538)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company had 117 employees as of June 30, 2023, including 105 people employed by Inventiva S.A. and 12 people employed by Inventiva Inc.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;5.3&lt;/b&gt;&lt;/span&gt;Other operating income and expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other operating income and expenses break down as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other operating income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 160&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (22)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (44)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other operating income and expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 138&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (44)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;5.4&lt;/b&gt;&lt;/span&gt;Financial income and expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;For the six months ended June 30, 2024 and June 30, 2023&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Income from cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 430&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 564&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign exchange gains&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 157&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 187&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Gain on fair value variation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,506&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,623&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total financial income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 9,093&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,373&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Interest cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,218)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,941)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign exchange losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (323)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (683)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other financial expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (46)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total financial expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (5,586)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (2,646)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net financial income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,507&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (273)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In the first six months of 2024, financial income is mainly composed of a &#x20ac;8.5 million change in fair value of the EIB Warrants issued in connection with Tranches A and B.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Financial expenses mainly include exchange losses, financial interests related to PGE and PPR credit agreements and the financing agreement with the EIB, and financial interests related to lease liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;5.5&lt;/b&gt;&lt;/span&gt;Share of net profit &#x2013; Equity method&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;The tables below provide the summarized statement of income (loss) for the associate Hepalys. The information disclosed reflects the amounts presented in the financial statements of Hepalys and not the Company's share of those amounts. They have been amended to reflect adjustments made by the Company when using the equity method, in this case fair value adjustments. The tables below provide also the reconciliation between Hepalys' loss and the share of net loss recognized in the Company statement of financial position.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;width:98.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands of euros)&lt;/i&gt; &lt;b style="font-weight:bold;"&gt;For the period started January 1, 2024, to June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,475)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net operating loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,526)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Financial income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Financial expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net financial income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 17&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income (expense) tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net loss for the period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,509)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exchange difference on translation of foreign operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,964)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Items that will be reclassified subsequently to profit or loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (3,473)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total comprehensive loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (3,473)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Group's share in &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Share of net profit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 235&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Elimination of downstream sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (66)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Share of net profit - Equity method&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 168&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2024, Hepalys did not generate any sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;5.6&lt;/b&gt;&lt;/span&gt;Income tax&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The income tax calculation for interim periods is set out in Note 3.3 &#x2013; &lt;i style="font-style:italic;"&gt;Specific disclosure requirements for unaudited interim financial statements.&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As the imputation of tax benefits on tax losses of Inventiva S.A., at short or mid-term, were considered unlikely due to the growth phase of the Company and regarding the nil projected tax rate as of December 31, 2024, no current taxes were recorded as of June 30, 2024, for Inventiva S.A.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The &#x20ac;119 thousand income tax recorded was related Inventiva Inc.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;5.7&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Basic and diluted loss per share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Basic earnings (loss) per share are calculated by dividing net income (loss) attributable to owners of the Company by the weighted average number of ordinary shares outstanding during the six-month period ended June 30, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;For the six months ended June 30, 2024 and June 30, 2023&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net loss for the period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (49,029)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (55,269)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average number of shares outstanding used to calculate basic/diluted loss per share&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51,982,093&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,044,796&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Basic/diluted loss per share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (0.94)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1.31)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In accordance with IAS 33.19, basic/diluted earnings per share exclude treasury shares held by the Group as of June 30, 2024 and 2023&lt;/i&gt;.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As a loss was recorded in the first six months of 2024 and 2023, diluted earnings (loss) per share are the same as basic earnings (loss) per share. Share-based payment plans (BSAs, BSPCEs, AGAs and PAGUP) are not included as their effects would be anti-dilutive.&lt;/p&gt;</iva:DisclosureOfComponentsOfIncomeStatementTextBlock>
    <iva:RevenueAndOtherIncomeTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_JGKP0fU_e0eTV0Nao-mCjQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,901&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total revenue&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 41&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,901&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,630&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,631&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Subsidies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,087&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,693&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4,721&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total revenue and other income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,734&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 6,622&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</iva:RevenueAndOtherIncomeTableTextBlock>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_szMl1nTEZkSpUWUaCcMP_w_3_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">41000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_7Mval74YOkmaMtPcs9VCfg_3_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1901000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:Revenue
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_vMIgqiKprEut_lclwgao7w_4_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">41000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_PZN8w8sVnEWY455X_taXjw_4_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1901000</ifrs-full:Revenue>
    <iva:CurrentTaxCreditResearchIncome
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_dRQ8f7l9jUyIpC6vBYKChg_5_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2630000</iva:CurrentTaxCreditResearchIncome>
    <iva:CurrentTaxCreditResearchIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_fLDvYJbFGkCxWFywBaSMmg_5_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3631000</iva:CurrentTaxCreditResearchIncome>
    <iva:SubsidiesIncome
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_5bqSetbAQEmzLxZR0jmLDQ_6_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5000</iva:SubsidiesIncome>
    <iva:SubsidiesIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_kug5gpZUl0qWsBF8FMFubQ_6_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3000</iva:SubsidiesIncome>
    <iva:IfrsOtherOperatingIncome
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_-1rRNt777EqGLJEgorcpXw_7_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">58000</iva:IfrsOtherOperatingIncome>
    <iva:IfrsOtherOperatingIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_7M7sobUa8kaHI74FG_4wQA_7_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1087000</iva:IfrsOtherOperatingIncome>
    <iva:OtherIncomeFromOrdinaryActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_zt9S_vMCJkOtICb3wfVRAA_8_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2693000</iva:OtherIncomeFromOrdinaryActivities>
    <iva:OtherIncomeFromOrdinaryActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_yQRHVkjtt0KJe68GxYiegw_8_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">4721000</iva:OtherIncomeFromOrdinaryActivities>
    <ifrs-full:RevenueAndOperatingIncome
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_0RItwKIai0GZwMtDc5-QQA_9_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2734000</ifrs-full:RevenueAndOperatingIncome>
    <ifrs-full:RevenueAndOperatingIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_EctURxUzPk6pqOBaz0wP3g_9_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">6622000</ifrs-full:RevenueAndOperatingIncome>
    <iva:CurrentTaxCreditResearchCurrentYear
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-5"
      id="Narr_E7Yo3kip8EKUhjeiAvIu0Q"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2700000</iva:CurrentTaxCreditResearchCurrentYear>
    <iva:CirAndOtherResearchTaxCreditsReceivable
      contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_InventivaIncMember_yX8YJNqJxEeoquiF4wd66g"
      decimals="-5"
      id="Narr_-eLLghvcJ02VjYpG6xvnkA"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1000000.0</iva:CirAndOtherResearchTaxCreditsReceivable>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_InventivaIncMember_CsDcvL6WIEe96pAzGCSMYw"
      decimals="-5"
      id="Narr_9StjVcZ9XESZQxr13jqLRw"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">800000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <iva:OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement
      contextRef="As_Of_6_30_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_tfmxFNVVb0CS5hG6C3JkAQ"
      decimals="-5"
      id="Narr_4IERyTGvBUWNaAy7HtlGpQ"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">300000</iva:OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement>
    <iva:OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement
      contextRef="As_Of_6_30_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ServiceContractWithAvantSanteMember_cAPxNDRt4k2GvvKof24NwQ"
      decimals="-5"
      id="Narr_wZ9ER9fynk2rsSGLfFMsyA"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">700000</iva:OtherIncomeReinvoicingOfSpecificCostsUnderServiceAgreement>
    <iva:OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement
      contextRef="As_Of_6_30_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_ZxMBck8Vv06CkTltj3JJkg"
      decimals="-5"
      id="Narr_uY2FtyizFEeGSSCAQgbeGQ"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2600000</iva:OtherIncomeRelatingToReinvoicingOfShareOfCostsUnderLicensingAndCollaborationAgreement>
    <iva:ResearchAndDevelopmentMarketingTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_2z2jxUhVxUu1eCC5a79yEw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Research&#160;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Marketing&#160;&#x2013;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;General&#160;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;development&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Business&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;administrative&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;costs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;development&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Disposables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (887)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (887)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Energy and liquids&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (447)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (447)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Patents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (643)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (643)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Studies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (34,073)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (34,073)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Maintenance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (526)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (526)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (118)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,675)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,795)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;IT systems&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (405)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (444)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Support costs (including taxes)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (375)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (375)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Personnel costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,637)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (153)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,600)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,391)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation, amortization and provisions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,732)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (122)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,854)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Insurances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (921)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (921)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (352)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (437)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (975)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,764)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total operating expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (46,822)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (598)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (7,701)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (55,122)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Research&#160;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Marketing&#160;&#x2013;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;General&#160;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;development&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Business&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;administrative&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;en milliers d'euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;costs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;development&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Disposables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (943)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (943)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Energy and liquids&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (479)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (479)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Patents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (257)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (257)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Studies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (42,847)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (42,847)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Maintenance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (459)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (459)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (61)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,884)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,945)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;IT systems&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (440)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (50)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (498)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Support costs (including taxes)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (343)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (343)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Personnel costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,065)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (126)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,347)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,538)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation, amortization and provisions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,061)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (104)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,166)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Insurances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,121)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,121)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Other operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (450)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (570)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (964)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,985)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total operating expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (54,062)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (705)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (6,812)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (61,580)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</iva:ResearchAndDevelopmentMarketingTableTextBlock>
    <iva:Disposables
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA"
      decimals="-3"
      id="Tc_uhnew7qNdEOVUzeWQmSKjw_4_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">887000</iva:Disposables>
    <iva:Disposables
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_bkG4rVN190murpgzPZxnRQ_4_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">887000</iva:Disposables>
    <iva:EnergyAndLiquids
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA"
      decimals="-3"
      id="Tc_ipVVlxHBM0ioPJ6hMWSVTg_5_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">447000</iva:EnergyAndLiquids>
    <iva:EnergyAndLiquids
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_1YXbc1_x_EmGzjWoBD_Phw_5_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">447000</iva:EnergyAndLiquids>
    <iva:Patents
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA"
      decimals="-3"
      id="Tc_fMhCURC9REuEu4xPWCD0CQ_6_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">643000</iva:Patents>
    <iva:Patents
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_K3jzwHreHkGWqgjh9C3jvQ_6_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">643000</iva:Patents>
    <iva:Studies
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA"
      decimals="-3"
      id="Tc_821CE75x_kekh8sym9g6qg_7_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">34073000</iva:Studies>
    <iva:Studies
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_2NDC6tiB00iWA2FHhAZptw_7_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">34073000</iva:Studies>
    <ifrs-full:RepairsAndMaintenanceExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA"
      decimals="-3"
      id="Tc_y1GOhj6Sc0eZmRTX5Wyi2g_8_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">526000</ifrs-full:RepairsAndMaintenanceExpense>
    <ifrs-full:RepairsAndMaintenanceExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_HJjFDP8Zmk2j_sASLdoWeA_8_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">526000</ifrs-full:RepairsAndMaintenanceExpense>
    <iva:Fees
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA"
      decimals="-3"
      id="Tc_zsYchosqpUusl_zO8FyBsQ_9_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">118000</iva:Fees>
    <iva:Fees
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_hTRe72PPekW3DzP4m38ewQ"
      decimals="-3"
      id="Tc_Aq_AzLc19Eup00aOSqh7Pg_9_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2000</iva:Fees>
    <iva:Fees
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg"
      decimals="-3"
      id="Tc_35HRL0-CBUWLnWG4zH_v-Q_9_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2675000</iva:Fees>
    <iva:Fees
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_k7fzYR0MkUeDookT7a3qTA_9_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2795000</iva:Fees>
    <iva:ItSystems
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA"
      decimals="-3"
      id="Tc_s0vx7wPVUkOS4kHsRZXFVw_10_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">405000</iva:ItSystems>
    <iva:ItSystems
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_hTRe72PPekW3DzP4m38ewQ"
      decimals="-3"
      id="Tc_k4yFbDtVkkSg7jLsE1oegw_10_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">6000</iva:ItSystems>
    <iva:ItSystems
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg"
      decimals="-3"
      id="Tc_uIIbc8qSYUOtK37BDs1OEg_10_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">33000</iva:ItSystems>
    <iva:ItSystems
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_z8zX2cfSDkuLoAGSmooJWA_10_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">444000</iva:ItSystems>
    <iva:SupportCosts
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg"
      decimals="-3"
      id="Tc_94UpcMCJzkSzLY2kw7mNxQ_11_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">375000</iva:SupportCosts>
    <iva:SupportCosts
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_4mi3NlCRhUCw-a8t-GJ5wg_11_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">375000</iva:SupportCosts>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA"
      decimals="-3"
      id="Tc_cTv193VLY0iO0N7rmXsm-Q_12_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">7637000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_hTRe72PPekW3DzP4m38ewQ"
      decimals="-3"
      id="Tc__HqvyQjMRkyON9TSu7VjXA_12_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">153000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg"
      decimals="-3"
      id="Tc_b3r8Uu8pgEigDQxyaHd-Ng_12_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2600000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_5jUl_OBmnU6dLKiFA1svfw_12_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10391000</ifrs-full:EmployeeBenefitsExpense>
    <iva:DepreciationAmortizationAndProvisions
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA"
      decimals="-3"
      id="Tc_RZ6sxIrEWUqDja0-XPQ8vg_13_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1732000</iva:DepreciationAmortizationAndProvisions>
    <iva:DepreciationAmortizationAndProvisions
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg"
      decimals="-3"
      id="Tc_AvEbpUDKlkWiEilWkyQV_w_13_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">122000</iva:DepreciationAmortizationAndProvisions>
    <iva:DepreciationAmortizationAndProvisions
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_tG2g1H_pZECE8ASUYcFb_A_13_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1854000</iva:DepreciationAmortizationAndProvisions>
    <ifrs-full:InsuranceExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg"
      decimals="-3"
      id="Tc_pelBefyQ6U-SV1RPsQg_Uw_14_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">921000</ifrs-full:InsuranceExpense>
    <ifrs-full:InsuranceExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_OBYg6pq6p0mPk8UlNZOVJA_14_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">921000</ifrs-full:InsuranceExpense>
    <iva:OtherOperatingExpenses
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA"
      decimals="-3"
      id="Tc_BdzbKYdavkGfppWqJr6zig_15_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">352000</iva:OtherOperatingExpenses>
    <iva:OtherOperatingExpenses
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_hTRe72PPekW3DzP4m38ewQ"
      decimals="-3"
      id="Tc_OpZggUSxlUG0wZVe9gq8rQ_15_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">437000</iva:OtherOperatingExpenses>
    <iva:OtherOperatingExpenses
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg"
      decimals="-3"
      id="Tc_b2DHQwLowES-aZRjsUoH1w_15_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">975000</iva:OtherOperatingExpenses>
    <iva:OtherOperatingExpenses
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_tG7U4lFxO0u64iU9wgdg8A_15_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1764000</iva:OtherOperatingExpenses>
    <iva:OperatingExpenseExcludingOtherOperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA"
      decimals="-3"
      id="Tc_ZHaS17f9k0inHP0OY9to1g_16_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">46822000</iva:OperatingExpenseExcludingOtherOperatingIncomeExpense>
    <iva:OperatingExpenseExcludingOtherOperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_hTRe72PPekW3DzP4m38ewQ"
      decimals="-3"
      id="Tc_uGulyfdTrUCamANqDMs5fw_16_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">598000</iva:OperatingExpenseExcludingOtherOperatingIncomeExpense>
    <iva:OperatingExpenseExcludingOtherOperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg"
      decimals="-3"
      id="Tc_dlEa7qlPCUiAL6scPaqDgw_16_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">7701000</iva:OperatingExpenseExcludingOtherOperatingIncomeExpense>
    <iva:OperatingExpenseExcludingOtherOperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_Loa5oFNGBUOYUdV6gxNi1w_16_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">55122000</iva:OperatingExpenseExcludingOtherOperatingIncomeExpense>
    <iva:Disposables
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw"
      decimals="-3"
      id="Tc_svRbtCXxkkeXTRdFp9XDFA_4_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">943000</iva:Disposables>
    <iva:Disposables
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_rPEo7c3JqkCuYibA2ahYyg_4_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">943000</iva:Disposables>
    <iva:EnergyAndLiquids
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw"
      decimals="-3"
      id="Tc_t46XMjzveUW-QEu99VI9eQ_5_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">479000</iva:EnergyAndLiquids>
    <iva:EnergyAndLiquids
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_yEVmeSX8Gk6F2izVLb9snA_5_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">479000</iva:EnergyAndLiquids>
    <iva:Patents
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw"
      decimals="-3"
      id="Tc_PUz52kyYOkiVQfb83S3C6Q_6_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">257000</iva:Patents>
    <iva:Patents
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_kmSjDyVnD0SLsy4zZKaOoQ_6_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">257000</iva:Patents>
    <iva:Studies
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw"
      decimals="-3"
      id="Tc_T4sypuz6YEuCrghVFMwkVw_7_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">42847000</iva:Studies>
    <iva:Studies
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_oFeVSRpbjUKI-D1WDLjETQ_7_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">42847000</iva:Studies>
    <ifrs-full:RepairsAndMaintenanceExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw"
      decimals="-3"
      id="Tc_9XRMzKycv0SRgQyKcvFgAg_8_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">459000</ifrs-full:RepairsAndMaintenanceExpense>
    <ifrs-full:RepairsAndMaintenanceExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_ArFSPcFRMkO857RNucu1tQ_8_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">459000</ifrs-full:RepairsAndMaintenanceExpense>
    <iva:Fees
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw"
      decimals="-3"
      id="Tc_WyCH3K0wj0WBu4Xe9Q1DHg_9_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">61000</iva:Fees>
    <iva:Fees
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g"
      decimals="-3"
      id="Tc_8e8OBLRyv0CMbc-f1UpNFw_9_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1884000</iva:Fees>
    <iva:Fees
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_hON56dyDIkWZsOhS6jH-tA_9_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1945000</iva:Fees>
    <iva:ItSystems
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw"
      decimals="-3"
      id="Tc_ELLPPBaXI0qie5DicC1sdA_10_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">440000</iva:ItSystems>
    <iva:ItSystems
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_vilht6HmAUelr2hSPT_U_w"
      decimals="-3"
      id="Tc_e2FDT7EaNk--stnPDKYNdA_10_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">9000</iva:ItSystems>
    <iva:ItSystems
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g"
      decimals="-3"
      id="Tc_UvtVe_9eCUypCZpdfPJt4g_10_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">50000</iva:ItSystems>
    <iva:ItSystems
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_6-HFy9Cd00u81TsJDrF9NQ_10_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">498000</iva:ItSystems>
    <iva:SupportCosts
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g"
      decimals="-3"
      id="Tc_FMoi3FP-9UK0aO7RR_DBHg_11_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">343000</iva:SupportCosts>
    <iva:SupportCosts
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_VbrI6lQZDkmNA5vSSriY4Q_11_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">343000</iva:SupportCosts>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw"
      decimals="-3"
      id="Tc_lQ9d_pf9w0O4sws6Ov6-BA_12_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">7065000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_vilht6HmAUelr2hSPT_U_w"
      decimals="-3"
      id="Tc_vNy9tgkJT0OwTJ-3G6Awbw_12_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">126000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g"
      decimals="-3"
      id="Tc_AMgWfJzgsEarbIUvAy7hrg_12_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2347000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_xKhVYZJpxkmEAezNwIumiA_12_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">9538000</ifrs-full:EmployeeBenefitsExpense>
    <iva:DepreciationAmortizationAndProvisions
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw"
      decimals="-3"
      id="Tc_ZxLgeM-hAkm6tSeIEhQ65Q_13_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1061000</iva:DepreciationAmortizationAndProvisions>
    <iva:DepreciationAmortizationAndProvisions
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g"
      decimals="-3"
      id="Tc_a34QF1OXREKX8nNI9LdVbA_13_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">104000</iva:DepreciationAmortizationAndProvisions>
    <iva:DepreciationAmortizationAndProvisions
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_RZph67r4VkOcPQJRD5tquw_13_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1166000</iva:DepreciationAmortizationAndProvisions>
    <ifrs-full:InsuranceExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g"
      decimals="-3"
      id="Tc_4GaHcAF9B0mwBxS2jBJYTw_14_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1121000</ifrs-full:InsuranceExpense>
    <ifrs-full:InsuranceExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc__xZRcqq_REKdGnZMKHeW8A_14_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1121000</ifrs-full:InsuranceExpense>
    <iva:OtherOperatingExpenses
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw"
      decimals="-3"
      id="Tc_OgKxODTPYk-NOTJAWT1dLg_15_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">450000</iva:OtherOperatingExpenses>
    <iva:OtherOperatingExpenses
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_vilht6HmAUelr2hSPT_U_w"
      decimals="-3"
      id="Tc_29lWrqHXmEG7G40rkC3AaA_15_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">570000</iva:OtherOperatingExpenses>
    <iva:OtherOperatingExpenses
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g"
      decimals="-3"
      id="Tc_MBu-h1Q2LEWsybcsIWCe6Q_15_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">964000</iva:OtherOperatingExpenses>
    <iva:OtherOperatingExpenses
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_YEicAZlM40SVwICdQWuYdg_15_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1985000</iva:OtherOperatingExpenses>
    <iva:OperatingExpenseExcludingOtherOperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw"
      decimals="-3"
      id="Tc_mHv3IH2EukOtSM82BXnL2Q_16_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">54062000</iva:OperatingExpenseExcludingOtherOperatingIncomeExpense>
    <iva:OperatingExpenseExcludingOtherOperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_vilht6HmAUelr2hSPT_U_w"
      decimals="-3"
      id="Tc_lYKg_ZSfbkayvWnv4VMc_Q_16_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">705000</iva:OperatingExpenseExcludingOtherOperatingIncomeExpense>
    <iva:OperatingExpenseExcludingOtherOperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g"
      decimals="-3"
      id="Tc_5NKJ4fgIxUSSzeXiDwdKng_16_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">6812000</iva:OperatingExpenseExcludingOtherOperatingIncomeExpense>
    <iva:OperatingExpenseExcludingOtherOperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_7ssVlLK55UOz-dLpsoKovA_16_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">61580000</iva:OperatingExpenseExcludingOtherOperatingIncomeExpense>
    <iva:PersonnelCostsAndHeadcount
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Group_t1D2uEQm0USgOJpJdNSKUg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Marketing - &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Research and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Business&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;General and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;development&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;development&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;administrative&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;costs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Wages, salaries and similar costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,824)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (120)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,237)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,181)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,312)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (563)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,886)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provisions for retirement benefit obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (35)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (86)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Share-based payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,450)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (24)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (765)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,238)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total personnel costs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (7,637)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (153)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (2,600)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (10,391)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Marketing -&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Research and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Business&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;General and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;development&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;development&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; administrative&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;costs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Wages, salaries and similar costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,399)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (104)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,191)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (5,694)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Payroll taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,222)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (476)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,708)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Provisions for retirement benefit obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (61)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (90)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share-based payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,383)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (650)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (2,046)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total personnel costs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (7,065)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (126)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (2,347)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (9,538)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</iva:PersonnelCostsAndHeadcount>
    <ifrs-full:WagesAndSalaries
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA"
      decimals="-3"
      id="Tc__e7eZIslcka8aNNUAAnmBg_5_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">4824000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_hTRe72PPekW3DzP4m38ewQ"
      decimals="-3"
      id="Tc_K_-O-yHmhU6Y2HMu-sQjtg_5_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">120000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg"
      decimals="-3"
      id="Tc_8WtPBkR-iky4bj8VQE2PPw_5_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1237000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_XxJGzzkou023_G59-e0lfQ_5_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">6181000</ifrs-full:WagesAndSalaries>
    <iva:PayrollTaxes
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA"
      decimals="-3"
      id="Tc_en1vtP6BREaYgwNWbwbTzg_6_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1312000</iva:PayrollTaxes>
    <iva:PayrollTaxes
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_hTRe72PPekW3DzP4m38ewQ"
      decimals="-3"
      id="Tc_AQqyFG3ORk2bsFFKv_HTUg_6_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10000</iva:PayrollTaxes>
    <iva:PayrollTaxes
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg"
      decimals="-3"
      id="Tc_Fyek47q48UyRwXFcy03j9Q_6_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">563000</iva:PayrollTaxes>
    <iva:PayrollTaxes
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_UQmjj_p6hUWl4zvc5MFb8w_6_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1886000</iva:PayrollTaxes>
    <ifrs-full:PostemploymentBenefitExpenseInProfitOrLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA"
      decimals="-3"
      id="Tc_SbbILS4f6kOXxNzZ4hqI1A_7_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">51000</ifrs-full:PostemploymentBenefitExpenseInProfitOrLoss>
    <ifrs-full:PostemploymentBenefitExpenseInProfitOrLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg"
      decimals="-3"
      id="Tc_Bd5OECv2Z0SdH4d9aLb0SA_7_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">35000</ifrs-full:PostemploymentBenefitExpenseInProfitOrLoss>
    <ifrs-full:PostemploymentBenefitExpenseInProfitOrLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_iwO7SBzZy0aVDsaXBUfkOA_7_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">86000</ifrs-full:PostemploymentBenefitExpenseInProfitOrLoss>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA"
      decimals="-3"
      id="Tc_LVWihdDLGkaqglEoCHvJrg_8_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1450000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_hTRe72PPekW3DzP4m38ewQ"
      decimals="-3"
      id="Tc_LoPpUdDahECREjXNda1xWA_8_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">24000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg"
      decimals="-3"
      id="Tc_tSBClmyFykKuDG3CYqDurg_8_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">765000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_aXGPr-wu1kCvMOiWahzqTA_8_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2238000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_gU8-26zzukuGb3eEY4SdsA"
      decimals="-3"
      id="Tc_oXfb7pynkkKtBmeQSnmouw_9_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">7637000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_hTRe72PPekW3DzP4m38ewQ"
      decimals="-3"
      id="Tc_YSJi_a-YW0CPjicTf_xfwA_9_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">153000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_4H-YNCcGCE2soOIWFYltcg"
      decimals="-3"
      id="Tc_-jwQ89KlEUO-8LLS43yJKA_9_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2600000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_CWNANopA20W6klWljHvvIg_9_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10391000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:NumberOfEmployees
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="INF"
      id="Narr_Q9eqSD8EiEy-KwusplpvPg"
      unitRef="Unit_Standard_employee_t09Loy2TV0yh-O2RJe0wMQ">123</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_InventivaS.aMember_Cyc1aEXngEiGaWWQTrmH-A"
      decimals="INF"
      id="Narr_SPcQrZzWOUmp1MpGDeQ2uw"
      unitRef="Unit_Standard_employee_t09Loy2TV0yh-O2RJe0wMQ">112</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="As_Of_6_30_2024_dei_LegalEntityAxis_iva_InventivaIncMember_yX8YJNqJxEeoquiF4wd66g"
      decimals="INF"
      id="Narr_pAOHToGeZkiDfAGPWQqvAQ"
      unitRef="Unit_Standard_employee_t09Loy2TV0yh-O2RJe0wMQ">11</ifrs-full:NumberOfEmployees>
    <ifrs-full:WagesAndSalaries
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw"
      decimals="-3"
      id="Tc_34zemMrAH0mkmExxTtSvUg_5_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">4399000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_vilht6HmAUelr2hSPT_U_w"
      decimals="-3"
      id="Tc_QkUHTNL4nE6-un8Tyc2T5g_5_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">104000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g"
      decimals="-3"
      id="Tc_1zYK5tzDp0eX4NKLiIoe6w_5_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1191000</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_x9_bHrGmzki2xY_5jzH-Pw_5_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5694000</ifrs-full:WagesAndSalaries>
    <iva:PayrollTaxes
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw"
      decimals="-3"
      id="Tc_YxDIjAWvCUaB1vnh55Y6hQ_6_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1222000</iva:PayrollTaxes>
    <iva:PayrollTaxes
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_vilht6HmAUelr2hSPT_U_w"
      decimals="-3"
      id="Tc_GoDhc7xY1E6FhpdtKO2CGw_6_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10000</iva:PayrollTaxes>
    <iva:PayrollTaxes
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g"
      decimals="-3"
      id="Tc_cDm19Xt8NU2R-2xJUEdzaw_6_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">476000</iva:PayrollTaxes>
    <iva:PayrollTaxes
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_kcgvDIcyvEar6afatVjTAA_6_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1708000</iva:PayrollTaxes>
    <ifrs-full:PostemploymentBenefitExpenseInProfitOrLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw"
      decimals="-3"
      id="Tc_tVqGujUIAU2Tn1jQCj1qxQ_7_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">61000</ifrs-full:PostemploymentBenefitExpenseInProfitOrLoss>
    <ifrs-full:PostemploymentBenefitExpenseInProfitOrLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g"
      decimals="-3"
      id="Tc_cSHSF8Itp0mywWUJZM53Cg_7_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">29000</ifrs-full:PostemploymentBenefitExpenseInProfitOrLoss>
    <ifrs-full:PostemploymentBenefitExpenseInProfitOrLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_mvgfoggZE0ug4l8xxQk9Ew_7_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">90000</ifrs-full:PostemploymentBenefitExpenseInProfitOrLoss>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw"
      decimals="-3"
      id="Tc_Li5UAWk9o0OnVwcu69eX1w_8_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1383000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_vilht6HmAUelr2hSPT_U_w"
      decimals="-3"
      id="Tc_lm1GCObnd0iCn8gS6e8mVQ_8_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">13000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g"
      decimals="-3"
      id="Tc_kGH28at96k-QwRe7QpTgrw_8_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">650000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_Q4HhdxlqfEy3wNS2769s3A_8_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2046000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsResearchAndDevelopmentExpenseMember_3lJs1l82Z0yMn4EVU0AJaw"
      decimals="-3"
      id="Tc_-tSIiIS7D0-8mOREROdvyQ_9_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">7065000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsSalesAndMarketingExpenseMember_vilht6HmAUelr2hSPT_U_w"
      decimals="-3"
      id="Tc_Lr7tiEgD6kef_XE0bVpCng_9_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">126000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_iva_IfrsGeneralAndAdministrativeExpenseMember_XAFOPsEemkerWxAKWbMh-g"
      decimals="-3"
      id="Tc_MWlR6Z2DEUOGlZlG-Cq4Cw_9_6"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2347000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_E435wzLUREWRbUqOU7XwVQ_9_8"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">9538000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:NumberOfEmployees
      contextRef="As_Of_6_30_2023_aUv8mHsKXUaaSWrxnxqKLg"
      decimals="INF"
      id="Narr_VAAPwjvtAkyFGUD9QdCUOg"
      unitRef="Unit_Standard_employee_t09Loy2TV0yh-O2RJe0wMQ">117</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="As_Of_6_30_2023_dei_LegalEntityAxis_iva_InventivaS.aMember_3oaek7qY7U2QTmeeOlV98g"
      decimals="INF"
      id="Narr_Xrl7lA-vnUiSOZnLt9w03Q"
      unitRef="Unit_Standard_employee_t09Loy2TV0yh-O2RJe0wMQ">105</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="As_Of_6_30_2023_dei_LegalEntityAxis_iva_InventivaIncMember_dCL3wkeOIU-E_D6kZe7BxQ"
      decimals="INF"
      id="Narr_KQVcQFalsUeXFahbfLpoBQ"
      unitRef="Unit_Standard_employee_t09Loy2TV0yh-O2RJe0wMQ">12</ifrs-full:NumberOfEmployees>
    <iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_cLABaFsmJE2dfIo2RDkXPA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other operating income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 160&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (22)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (44)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other operating income and expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 138&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (44)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_HS6J34bwuk6mP-dVnmhV4A_3_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">160000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_r-t8WHIy00ia3WJyzgR5Og_4_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">22000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_rMPzfxKz1kOYoEdP_9_ZeA_4_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">44000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_Wbf_W-cC1UWB5RbSpT9uDw_5_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">138000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_0aGo02CVd0yxAz0oHr4dTw_5_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-44000</ifrs-full:OtherOperatingIncomeExpense>
    <iva:FinancialIncomeAndExpensesTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_LQtadgmQQE6JJOjLZ8qXjA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Income from cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 430&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 564&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign exchange gains&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 157&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 187&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Gain on fair value variation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,506&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,623&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total financial income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 9,093&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,373&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Interest cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,218)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,941)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign exchange losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (323)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (683)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other financial expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (46)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total financial expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (5,586)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (2,646)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net financial income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,507&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (273)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</iva:FinancialIncomeAndExpensesTableTextBlock>
    <ifrs-full:InterestIncomeOnCashAndCashEquivalents
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_0SNEQga3f0yVhMI9iZSEjQ_3_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">430000</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
    <ifrs-full:InterestIncomeOnCashAndCashEquivalents
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_dCTdWTokmkyUX5q7G8TF_g_3_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">564000</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
    <ifrs-full:ForeignExchangeGain
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_QPnrCnm6dEqenj3GoR01BA_4_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">157000</ifrs-full:ForeignExchangeGain>
    <ifrs-full:ForeignExchangeGain
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_ZP1wHdJfZ0-aHMgai9urcg_4_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">187000</ifrs-full:ForeignExchangeGain>
    <iva:FairValueVariationGains
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_4hiO7NJhUUCdVohySv3vOQ_5_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">8506000</iva:FairValueVariationGains>
    <iva:FairValueVariationGains
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_xkds9Piti0WsBVyn3QhEwA_5_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1623000</iva:FairValueVariationGains>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_-SoLj_e5zUmQDj_Bm8ayZQ_6_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">9093000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_31mqaW5oOUis4fbSUvtDmw_6_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2373000</ifrs-full:FinanceIncome>
    <ifrs-full:InterestExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_DD0lpxEjQU6fhGXtmF2A9g_7_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5218000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_JsIbDjU_q0eG9pdbR7QLtw_7_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1941000</ifrs-full:InterestExpense>
    <ifrs-full:ForeignExchangeLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_LAUSDDTwBEeZL4gFLOjM6A_8_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">323000</ifrs-full:ForeignExchangeLoss>
    <ifrs-full:ForeignExchangeLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_bgfkLfnTFEm0b8w3i5r8QQ_8_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">683000</ifrs-full:ForeignExchangeLoss>
    <ifrs-full:OtherFinanceCost
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_HBkjlxZW6UuJVh2tx2jVnQ_9_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">46000</ifrs-full:OtherFinanceCost>
    <ifrs-full:OtherFinanceCost
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_7VNqVsduA06_COz2mDIF8Q_9_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">23000</ifrs-full:OtherFinanceCost>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_dtVCKnsBt0Cc1EnyqWeSnw_10_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5586000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_Ks-HuxyHRECiMUn0MPx3Pg_10_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">2646000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncomeCost
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_qANhEHNS9UGA1rQQQWqOyQ_11_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3507000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_cqtxqhsznEqcOERosTsBSw_11_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-273000</ifrs-full:FinanceIncomeCost>
    <iva:IfrsFairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-5"
      id="Narr_yxpDYW3LoEi22q3G97gpYQ"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">8500000</iva:IfrsFairValueAdjustmentOfWarrants>
    <iva:DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_FUzQ0WfY2kStPOpDJhKXTg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;width:98.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(in thousands of euros)&lt;/i&gt; &lt;b style="font-weight:bold;"&gt;For the period started January 1, 2024, to June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (51)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,475)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net operating loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,526)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Financial income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Financial expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net financial income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 17&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income (expense) tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net loss for the period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,509)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exchange difference on translation of foreign operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,964)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Items that will be reclassified subsequently to profit or loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (3,473)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total comprehensive loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (3,473)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Group's share in &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Share of net profit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 235&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Elimination of downstream sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (66)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Share of net profit - Equity method&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 168&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</iva:DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ"
      decimals="-3"
      id="Tc_yuNi4m28WE6_hK4qLm_b1g_2_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">51000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ"
      decimals="-3"
      id="Tc_0Ogv8TqpWEqLdOy23_NjAg_3_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">1475000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ"
      decimals="-3"
      id="Tc_zQAd-nq9aEK6Ekt6n2BWXA_4_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-1526000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ"
      decimals="-3"
      id="Tc_87MVFODIRkqAvnwko3A4aw_5_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">20000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ"
      decimals="-3"
      id="Tc_ME8Py6RnZ0Ck0aOqJPE69Q_6_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncomeCost
      contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ"
      decimals="-3"
      id="Tc_O7KYrnEvmkSZzpMdS_7g3w_7_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">17000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ"
      decimals="-3"
      id="Tc_ImnB4SuhZkqJeLfvE9hzTA_9_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-1509000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ"
      decimals="-3"
      id="Tc_wzkFXdeiP0uc3DAOLniGIg_10_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-1964000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ"
      decimals="-3"
      id="Tc_v1kqECpzNEq6GhX-vUIerQ_11_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-3473000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2024_To_6_30_2024_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_cPiW4KlpSke6ctMDnG2rMQ"
      decimals="-3"
      id="Tc_BVH6IBrmKUaD3kYc_XfyDg_12_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-3473000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_wYI-vlX-bEu9MV9dohB57g"
      decimals="4"
      id="Tc_VP9Co8q5S0G7ejVutKr1Ug_13_2"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.1464</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <iva:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_wYI-vlX-bEu9MV9dohB57g"
      decimals="-3"
      id="Tc_ANUbomMR7EaEemm91TNvAw_14_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">235000</iva:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations>
    <iva:EliminationOfDownstreamSales
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_wYI-vlX-bEu9MV9dohB57g"
      decimals="-3"
      id="Tc_d56HvwFPlk24VQzZWxcy-w_15_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">66000</iva:EliminationOfDownstreamSales>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_wYI-vlX-bEu9MV9dohB57g"
      decimals="-3"
      id="Tc_hiwvzrUYJkq1zcEqvt0KrA_16_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">168000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods
      contextRef="Duration_1_1_2024_To_12_31_2024_oxFIDH8XQUKPgIUFQceRfA"
      decimals="2"
      id="Narr_U8URKTLddkSakvNLL_Sy2Q"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0</ifrs-full:TaxRateEffectOfAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Narr_ZklF7vdhhEaZPxcnXaYNLw"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">0</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Narr_2s9YVqXuNEyWIGcybDf_uQ"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">119000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:EarningsPerShareExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_JHZ7byDsyUGyg7zUKcFqBg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net loss for the period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (49,029)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (55,269)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average number of shares outstanding used to calculate basic/diluted loss per share&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51,982,093&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,044,796&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Basic/diluted loss per share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (0.94)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1.31)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In accordance with IAS 33.19, basic/diluted earnings per share exclude treasury shares held by the Group as of June 30, 2024 and 2023&lt;/i&gt;.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="-3"
      id="Tc_DQhTRkV7A0-qtJj4UFc1IQ_3_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-49029000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="-3"
      id="Tc_A21lGxZ1PE2Lk-6lyB2brA_3_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">-55269000</ifrs-full:ProfitLoss>
    <ifrs-full:WeightedAverageShares
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="0"
      id="Tc_gETjJLhWHEWqNcz1wu3ngw_4_2"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">51982093</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="0"
      id="Tc_gETjJLhWHEWqNcz1wu3ngw_4_2_2"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">51982093</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="0"
      id="Tc_1I_Ext8SC0-ynUHbx6TUWQ_4_4"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">42044796</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="0"
      id="Tc_1I_Ext8SC0-ynUHbx6TUWQ_4_4_2"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">42044796</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="2"
      id="Tc_01DAIR9xQEikBaTS326m1Q_5_2"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">-0.94</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      decimals="2"
      id="Tc_01DAIR9xQEikBaTS326m1Q_5_2_2"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">-0.94</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="2"
      id="Tc_eDxqHAVzNU2aJ1sD4L-99w_5_4"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">-1.31</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_1_1_2023_To_6_30_2023_oERFPSQD7kC18kPrSTkFDg"
      decimals="2"
      id="Tc_eDxqHAVzNU2aJ1sD4L-99w_5_4_2"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">-1.31</ifrs-full:DilutedEarningsLossPerShare>
    <iva:DisclosureOfOtherFinancialInformationTextblock
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_LKaeaGOaY0C8RDgV_4PCIg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Note 6.&#160;&#160;&#160;&#160;Other financial information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;6.1&lt;/b&gt;&lt;/span&gt;&lt;b style="font-weight:bold;"&gt;Commitments related to operational activities&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Obligations under the terms of subcontracting agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In the ordinary course of its business, the Company enters into agreements with CROs for clinical trials, as well as with contract manufacturing organizations (&#x201c;CMOs&#x201d;) for clinical and commercial supply manufacturing, commercial and pre-commercial activities, research and development activities and other services and products for operating purposes. The Company&#x2019;s agreements generally provide for termination with specified periods of advance notice.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Such agreements are generally cancellable contracts and are not included in the description of the Company&#x2019;s contractual obligations and commitments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Commitments given and received&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;CRO&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;1&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 175,461&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 183,366&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;CMO&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,733&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,592&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,595&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,442&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total commitments given&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 210,261&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 221,136&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Agreements concerning the provision of facilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 260&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total commitments received&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 296&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 260&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"&gt;&lt;sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;"&gt;1&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"&gt;&lt;i style="font-style:italic;"&gt;Including CRO with Pharmaceutical Research Associates B.V.&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;CRO Contract with Pharmaceutical Research Associates Group B.V.&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In April 2021, in connection with the NATiV3 Phase III trial in MASH/NASH, the Company entered into an agreement, with retroactive effect in January 2021, with PRA, acting as a CRO. The contract aims to support the regulatory approval of lanifibranor in adult patients in Europe and in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company also entered into a CRO agreement with PRA in connection with the LEGEND Phase IIa clinical trial, effective January 14, 2022. Under the terms of the agreement, PRA will conduct a clinical trial to evaluate the benefit for patients of the combination of lanifibranor with empagliflozin, an SGLT2 inhibitor, in patients with T2D and non-cirrhotic MASH/NASH. The commitment to PRA under this agreement amounts to an aggregate of &#x20ac;13.3 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On June 26, 2023, in connection with the NATiV3 Phase III trial in MASH/NASH, the Company entered into a new amendment to the April 2021 agreement with retroactive effect in January 2021 with PRA. The amendment updates the provisions relating to study information following changes to the trial protocol. In June 2024, the Company entered into a new amendment, the new commitment amount to PRA is &#x20ac;254.3, with a bonus or malus will decrease from &#x20ac;3.4 million to &#x20ac;0.7 million in 2026. The commitment also includes &#x20ac;20.2 million to be paid by CTTQ.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2024, the amount remaining to be paid under the contract is &#x20ac;158.6 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;6.2.&lt;/b&gt;&lt;/span&gt;Related-party transactions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;No other new material transactions were entered into with related parties of the Company during the first six months of 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;6.3&lt;/b&gt;&lt;/span&gt;Financial risk management&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Through its business activities, the Company is exposed to various types of financial risk: foreign exchange risk, credit risk and liquidity risk.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The financial risks are those described in the financial statements prepared in accordance with IFRS for the year ended December 31, 2023, as updated for risks regarding liquidity which are described in the Note 3.4 &#x2014; &lt;i style="font-style:italic;"&gt;Going Concern&lt;/i&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;6.4&lt;/b&gt;&lt;/span&gt;Events after the reporting date&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Update on NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On July 5, 2024, the Company provided an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH. Recruitment in NATiV3 clinical trial continues in both cohorts with over 80% of the targeted number of patients enrolled in the main cohort and 100% in the exploratory cohort of NATiV3.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The first visit of the last patient of NATiV3 is anticipated to occur during the fourth quarter of 2024, and topline results are expected at the beginning of the second half of 2026. The Company&#x2019;s patent portfolio strengthened with new a patent secured in Japan that that provides intellectual property rights on protects the potential use of lanifibranor for the treatment of patients with cirrhosis until 2039, excluding any potential patent term adjustments or extensions that may provide additional protection until 2043.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Issuance of royalty certificates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On July 18, 2024, the Company announced the issuance of 201 royalty certificates (the &#x201c;&lt;b style="font-weight:bold;"&gt;2024 Royalty Certificates&lt;/b&gt;&#x201d;) for aggregate gross proceeds of approximately &#x20ac;20.1 million. The 2024 Royalty Certificates will provide the holders thereof with the right to an annual payment of royalties equal to 3% of the future net sales, if any, of lanifibranor beginning on the fiscal year following the start of the sales of lanifibranor following the granting of the market authorization for lanifibranor in (i) the United States of America, (ii) the countries of the European Union or (iii) the United Kingdom, whichever occurs the first, if at all. The 2024 Royalty Certificates have a term of 14 years following the date of issue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Approving of patent application&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On July 25, 2024 the Company announced that the Japan Patent Office (&#x201c;JPO&#x201d;) approved Inventiva&#x2019;s patent application No. JP 2019-203498, protecting the use of lanifibranor for the treatment of patients with cirrhosis. This new patent will be valid until November 8, 2039, excluding any potential patent term adjustments or extensions that may provide additional protection.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Financing in &lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;three&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt; tranches for a maximum amount of &lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;&#x20ac;348&lt;/span&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt; million&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company announced the following financing on 14 October 2024 structured in three tranches:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;(i) the issuance , through a capital increase without preferential subscription rights reserved to a specific category of beneficiaries (&#x201c;&lt;i style="font-style:italic;"&gt;&#xe0; cat&#xe9;gorie de personnes&lt;/i&gt;&#x201d;), of new ordinary shares at a gross value, including issuance premium, of &#x20ac;94.1 million through the issuance of 34,600,507 new ordinary shares, par value &#x20ac;0.01 per share (each, a &#x201c;&lt;b style="font-weight:bold;"&gt;T1 New Shares&lt;/b&gt;&#x201d;), and 35,399,481 &#160;prefunded warrants to subscribe for shares in the Company at a price outstanding of &#x20ac;0.01 per new ordinary share, each giving the right, in the event of exercise, to one new ordinary share (the &#x201c;&lt;b style="font-weight:bold;"&gt;T1 BSAs&lt;/b&gt;&#x201d;);&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;(ii) the issuance, in a second phase, as part of a new capital increase without preferential subscription rights reserved to certain identified investors (&#x201c;&lt;i style="font-style:italic;"&gt;&#xe0; personne d&#xe9;nomm&#xe9;e&lt;/i&gt;&#x201d;), of new ordinary shares, par value &#x20ac;0.01 per share or of prefunded warrants to subscribe for ordinary shares of the Company (each, a &#x201c;&lt;b style="font-weight:bold;"&gt;T1bis New Shares&lt;/b&gt;&#x201d;), for a total amount of &#x20ac;21.4 &#160;million (excluding exercise of pre-funded warrants);&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;(iii) the issuance, in a third phase, as part of a new capital increase without preferential subscription rights reserved to certain identified investors (&#x201c;&lt;i style="font-style:italic;"&gt;&#xe0; personne d&#xe9;nomm&#xe9;e&lt;/i&gt;&#x201d;) subject to operational conditions to be met and the adoption of the necessary resolutions by the Shareholders' Meeting to be held before December 16, 2024, (or prefunded warrants) to which share warrants (the &#x201c;&lt;b style="font-weight:bold;"&gt;ABSAs&lt;/b&gt;&#x201d;) are attached for a total amount of &#x20ac;116,000,000. Each ABSA will consist of a number of new ordinary shares with a par value of &#x20ac;0.01 (or pre-funded warrants) to be determined by the Company's Board of Directors (each, a &#x201c;&lt;b style="font-weight:bold;"&gt;T2 New Share&lt;/b&gt;&#x201d;) to which will be attached a number warrants exercisable at an exercise price of &#x20ac;1.50 (each, a &#x201c;&lt;b style="font-weight:bold;"&gt;T3 BSA&lt;/b&gt;&#x201d;) allowing the subscription of a number of new ordinary shares of the Company for a maximum total amount of &#x20ac;116,000,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The subscription agreements for the T1 New Shares and the T1 BSA were signed on October 11, 2024, and the settlement-delivery of the T1 New Shares and the T1 BSA is expected to take place on October 17, 2024, subject to the absence of any material adverse event between the signing of the agreements and the settlement-delivery of the T1 New Shares and the T1 BSA.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Amendment to the exclusive license and collaboration agreement with CTTQ&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt;"&gt;On October 11, 2024, the Company has entered into an amendment (the &#x201c;&lt;b style="font-weight:bold;"&gt;Amendment&lt;/b&gt;&#x201d;) to the exclusive license and collaboration agreement with Chia Tai Tianqing Pharmaceutical Group, Co., Ltd (&#x201c;&lt;b style="font-weight:bold;"&gt;CTTQ&lt;/b&gt;&#x201d;), dated September 21, 2022, as amended. Under the Amendment, if the Company receives subscription commitments, before December 31, 2024, from investors to subscribe to a fundraising, in two or three tranches, for a total gross amount of at least &#x20ac;180,000,000 (the &#x201c;&lt;b style="font-weight:bold;"&gt;Fund Raising&lt;/b&gt;&#x201d;), CTTQ shall pay to the Company (i) $10,000,000 within 30 days of settlement-delivery of the T1 New Shares and T1 Warrants in the event of the issuance of the first tranche of the Fund Raising to be paid by CTTQ, (ii) $10,000,000 in the event of the issuance of the second tranche of the Fund Raising, and (iii) $10,000,000 upon publication by the Company of the pivotal data announcing that the primary endpoint or one of the two key secondary endpoints of NATiV3, with one of the dosing regimens tested in the trial, have been met. Under the terms of the Amendment, the total amount of potential clinical, regulatory and commercial milestone payments remains unchanged, while the royalties that Inventiva is likely to receive have been reduced to a low figure.&lt;/p&gt;</iva:DisclosureOfOtherFinancialInformationTextblock>
    <ifrs-full:DisclosureOfContingentLiabilitiesExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_t6Sr0e1hI02eBVr-0TKcHA"
      id="Tb_VWZOnsFS90iZB-YPfw8l9g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;In thousands of euros&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;CRO&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;1&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 175,461&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 183,366&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;CMO&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,733&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,592&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,595&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,442&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total commitments given&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 210,261&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 221,136&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Agreements concerning the provision of facilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 260&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total commitments received&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 296&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 260&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"&gt;&lt;sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;"&gt;1&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"&gt;&lt;i style="font-style:italic;"&gt;Including CRO with Pharmaceutical Research Associates B.V.&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfContingentLiabilitiesExplanatory>
    <ifrs-full:ContractualCapitalCommitments
      contextRef="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_ClinicalTrialsMember_RKIovK8rokChycQgZSo2TQ"
      decimals="-3"
      id="Tc_5lBCKWfYv0GMQORja9MJdg_2_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">175461000</ifrs-full:ContractualCapitalCommitments>
    <ifrs-full:ContractualCapitalCommitments
      contextRef="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_ClinicalTrialsMember_ETYrQdfyDE6P4TNS-pt20A"
      decimals="-3"
      id="Tc_xIwNVaqHC0CiXVrhaZQypw_2_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">183366000</ifrs-full:ContractualCapitalCommitments>
    <ifrs-full:ContractualCapitalCommitments
      contextRef="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_ContractManufacturingOrganizationsMember_H1GPzHoVzEiBnJra2bMeWA"
      decimals="-3"
      id="Tc_Bablq-16RUG91lTezGVQ7w_3_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">6846000</ifrs-full:ContractualCapitalCommitments>
    <ifrs-full:ContractualCapitalCommitments
      contextRef="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_ContractManufacturingOrganizationsMember_e2L2HwPp40Smxh2nqL1VkQ"
      decimals="-3"
      id="Tc_UOXwTOZQ_EWrMClVNvNX8Q_3_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">5733000</ifrs-full:ContractualCapitalCommitments>
    <ifrs-full:ContractualCapitalCommitments
      contextRef="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_ifrs-full_LeaseLiabilitiesMember_ida2CTwucUi4-oggFUrF2g"
      decimals="-3"
      id="Tc_W5DPODtsX0qXhX1zyu_YhQ_4_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">7592000</ifrs-full:ContractualCapitalCommitments>
    <ifrs-full:ContractualCapitalCommitments
      contextRef="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_ifrs-full_LeaseLiabilitiesMember_8rBg4KqmyUuYuPxVzu5jrg"
      decimals="-3"
      id="Tc_I5Otr-gTI0qDLsBe7R4_Xw_4_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">8595000</ifrs-full:ContractualCapitalCommitments>
    <ifrs-full:ContractualCapitalCommitments
      contextRef="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_ifrs-full_OtherContingentLiabilitiesMember_0hDuEC30xECEsYnHHr_kTA"
      decimals="-3"
      id="Tc_vpTxbJKJ0EuPfkv0AwAlYA_5_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">20361000</ifrs-full:ContractualCapitalCommitments>
    <ifrs-full:ContractualCapitalCommitments
      contextRef="As_Of_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_ifrs-full_OtherContingentLiabilitiesMember_UcOuCRDpIESuiNmpO5AzcQ"
      decimals="-3"
      id="Tc_f0W0WqPYaEC8NtFqvUU42A_5_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">23442000</ifrs-full:ContractualCapitalCommitments>
    <ifrs-full:ContractualCapitalCommitments
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_VpbBYSOE2ECu_bGs22XzzA_6_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">210261000</ifrs-full:ContractualCapitalCommitments>
    <ifrs-full:ContractualCapitalCommitments
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_Hb5pDHNaqk-sY180362J9w_6_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">221136000</ifrs-full:ContractualCapitalCommitments>
    <iva:AgreementsConcerningProvisionOfFacilities
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_7CKDU-QwlUmizEBSPryYgA_7_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">296000</iva:AgreementsConcerningProvisionOfFacilities>
    <iva:AgreementsConcerningProvisionOfFacilities
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_XUD_tnr9ikCcClAfaPoSJg_7_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">260000</iva:AgreementsConcerningProvisionOfFacilities>
    <iva:ContractualCapitalCommitmentReceived
      contextRef="As_Of_6_30_2024_mRNqYO2hMUGc9BtdrxzJwQ"
      decimals="-3"
      id="Tc_IyWRc7hKmEWH-lMHpsfdug_8_2"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">296000</iva:ContractualCapitalCommitmentReceived>
    <iva:ContractualCapitalCommitmentReceived
      contextRef="As_Of_12_31_2023_lKwObJqapUqAKS72RXniRQ"
      decimals="-3"
      id="Tc_5zoeRo886Uyzw1BCaNrrRA_8_4"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">260000</iva:ContractualCapitalCommitmentReceived>
    <iva:CommitmentsAmountPayableForServicesReceivedUnderContract
      contextRef="As_Of_4_30_2021_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ContractCroWithResearchAssociatesGroupeB.vMember_Kg0rzj_ifUatIDFJkolJ6g"
      decimals="-5"
      id="Narr_ZNhrBzsZTEapfEvz3tF5VQ"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">13300000</iva:CommitmentsAmountPayableForServicesReceivedUnderContract>
    <ifrs-full:ContractualCapitalCommitments
      contextRef="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_PharmaceuticalResearchAssociatesMember_qjG6YqkiB02s-QfK34PDzg"
      decimals="-5"
      id="Narr_FGS9r6Vos0SIxWyaLr4k7g"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">254300000</ifrs-full:ContractualCapitalCommitments>
    <iva:CommitmentContractualBonusOrMalusCappedAmount
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_PharmaceuticalResearchAssociatesMember_IkzQwodT60qRBSBD6WG1Kw"
      decimals="-5"
      id="Narr_MUvPSAoOL02FbEqpJ-20xg"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">3400000</iva:CommitmentContractualBonusOrMalusCappedAmount>
    <iva:CommitmentContractualBonusOrMalusCappedAmount
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_PharmaceuticalResearchAssociatesMember_Co4XPbAvCk2OhAlYe5P1VA"
      decimals="-5"
      id="Narr_6IYqN7Vmj0-5OaUMknwnbw"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">700000</iva:CommitmentContractualBonusOrMalusCappedAmount>
    <iva:CommitmentsAmountPayableForServicesReceivedUnderContract
      contextRef="As_Of_6_30_2024_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_ChiaTaiTianqingMember_hYhPgbJT90qw9Zp638JTYA"
      decimals="-5"
      id="Narr__4z7XKW40EG2_Lj5FjU73A"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">20200000</iva:CommitmentsAmountPayableForServicesReceivedUnderContract>
    <ifrs-full:ContractualCapitalCommitments
      contextRef="As_Of_6_30_2024_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ContractCroWithResearchAssociatesGroupeB.vMember_z4AQiAhloUi2lSaBmH0sqA"
      decimals="-5"
      id="Narr_IoyC9HnZ9ESychV7fgfVOg"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">158600000</ifrs-full:ContractualCapitalCommitments>
    <iva:PercentageOfPatientsInTrialEnrolledInMainCohort
      contextRef="As_Of_7_5_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_PresentationOfResultsFromStudyMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember_rLZHQc4OiUGVcCmKg1glHQ"
      decimals="2"
      id="Narr_kHxlpW2Q0kCZtsyMCMjQcw"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.80</iva:PercentageOfPatientsInTrialEnrolledInMainCohort>
    <iva:PercentageOfPatientsInTrialEnrolledInExploratoryCohort
      contextRef="As_Of_7_5_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_PresentationOfResultsFromStudyMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember_rLZHQc4OiUGVcCmKg1glHQ"
      decimals="INF"
      id="Narr_D7Yq5LwUoEiv9Xip763i_Q"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">1</iva:PercentageOfPatientsInTrialEnrolledInExploratoryCohort>
    <iva:NumberOfRoyaltyCertificatesIssued
      contextRef="As_Of_7_18_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfRoyaltyCertificatesMember_eaHX-tuX_E2XdHMM79Knaw"
      decimals="INF"
      id="Narr_TRSGtxC-TkiFb8eBhn2Y1A"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">201</iva:NumberOfRoyaltyCertificatesIssued>
    <iva:ProceedsFromFinancing
      contextRef="Duration_7_18_2024_To_7_18_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfRoyaltyCertificatesMember_MVb6HJyb-0ClrMuNDVzHFA"
      decimals="-5"
      id="Narr_4b656DJukkmVrrVL3X-TyQ"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">20100000</iva:ProceedsFromFinancing>
    <iva:AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor
      contextRef="As_Of_7_18_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfRoyaltyCertificatesMember_eaHX-tuX_E2XdHMM79Knaw"
      decimals="INF"
      id="Narr_3nEw6EGrY0mC3ZYQzt_y-w"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">0.03</iva:AnnualRoyaltyPercentageOnFutureNetSalesOfLanifibranor>
    <iva:MaximumDurationOfClinicalTrial
      contextRef="Duration_7_18_2024_To_7_18_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfRoyaltyCertificatesMember_MVb6HJyb-0ClrMuNDVzHFA"
      id="Narr_LU2362ak-U6wiWys17NQ2A">P14Y</iva:MaximumDurationOfClinicalTrial>
    <iva:NumberOfEqualTranches
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingAgreementInThreePhasesMember_7BaMct8ywUiT7daaU6IKqw"
      decimals="INF"
      id="Narr_wM42o14tA0GULlLv0t-BsA"
      unitRef="Unit_Standard_pure_avV6SgB7PkemRPqvZAbt7Q">3</iva:NumberOfEqualTranches>
    <iva:AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany
      contextRef="As_Of_6_30_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingAgreementInThreePhasesMember_d8wjd7CfTESZ1LkHSB77Cw"
      decimals="-5"
      id="Narr_pWbXJ1zutkibY3vdJndRjA"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">348000000</iva:AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany>
    <iva:StockIssuedDuringPeriodValue
      contextRef="Duration_10_14_2024_To_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember_cl4oX3dadE-dg27_9dl-_w"
      decimals="-5"
      id="Narr_8MaeS0gaPUuRBGr084U_CA"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">94100000</iva:StockIssuedDuringPeriodValue>
    <iva:StockIssuedDuringPeriodShares
      contextRef="Duration_10_14_2024_To_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember_cl4oX3dadE-dg27_9dl-_w"
      decimals="INF"
      id="Narr_KzROLtQS1EilbND_fRGH4A"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">34600507</iva:StockIssuedDuringPeriodShares>
    <ifrs-full:ParValuePerShare
      contextRef="As_Of_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember_vlcJPhOGqkmmq2I0namEtA"
      decimals="2"
      id="Narr__FYg2gb5zEK9dDFLrlKj_g"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">0.01</ifrs-full:ParValuePerShare>
    <iva:ClassOfWarrantOrRightGranted
      contextRef="Duration_10_14_2024_To_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember_cl4oX3dadE-dg27_9dl-_w"
      decimals="INF"
      id="Narr_V5xZhGd2TUSW4D_U06X0EQ"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">35399481</iva:ClassOfWarrantOrRightGranted>
    <ifrs-full:ParValuePerShare
      contextRef="As_Of_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember_vlcJPhOGqkmmq2I0namEtA"
      decimals="2"
      id="Narr_0rWUsJTlO0S99buY1EPvzw"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">0.01</ifrs-full:ParValuePerShare>
    <iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember_vlcJPhOGqkmmq2I0namEtA"
      decimals="INF"
      id="Narr_ReZ8DYt1JkC04oGhTAQkOg"
      unitRef="Unit_Standard_shares_HJF_mVYtt0WI3XrOlY4hTQ">1</iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <ifrs-full:ParValuePerShare
      contextRef="As_Of_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember_ZCF8RxUM3UKzcBgb7Q57Xg"
      decimals="2"
      id="Narr_ux_w8SUWpUOHYbhCAKoi6A"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">0.01</ifrs-full:ParValuePerShare>
    <iva:StockIssuedDuringPeriodValue
      contextRef="Duration_10_14_2024_To_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember_cd3Fteojp0CtXUqdXRXY6Q"
      decimals="-5"
      id="Narr_UrmThq31tEG0TFtuSLiY4A"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">21400000</iva:StockIssuedDuringPeriodValue>
    <iva:StockIssuedDuringPeriodValue
      contextRef="Duration_10_14_2024_To_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember_imkRzVTcgUy0kGwnaok3JA"
      decimals="0"
      id="Narr_kze1oslnn0CFDGBI7ZlbfA"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">116000000</iva:StockIssuedDuringPeriodValue>
    <iva:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
      contextRef="As_Of_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember_hobGW-4SUUqZmnmtlP6zCA"
      decimals="2"
      id="Narr_xOge3gNeakee8CXxmJuE5w"
      unitRef="Unit_Divide_EUR_shares_StOIwN__f0Wt-7xA_gJl1A">1.50</iva:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <iva:IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="Duration_10_14_2024_To_10_14_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfSharesOrWarrantsSubjectToConditionsMember_imkRzVTcgUy0kGwnaok3JA"
      decimals="0"
      id="Narr_KKnUE0ZCGE2a_Np_VgREaw"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">116000000</iva:IfrsClassOfWarrantOrRightValueOfNumberOfSecuritiesCalledByWarrantsOrRights>
    <iva:MinimumAmountCommittedForFundRaising
      contextRef="Duration_10_11_2024_To_10_11_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingThroughFundRaisingMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_QkHCyd9NWU6y7zXQYpg3Tg"
      decimals="0"
      id="Narr_r6I48xLy2kafXg93-CylsQ"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">180000000</iva:MinimumAmountCommittedForFundRaising>
    <iva:ProceedsFromLicensingArrangements
      contextRef="Duration_10_11_2024_To_10_11_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingThroughFundRaisingMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_srt_StatementScenarioAxis_iva_ScenarioOneMember_NOafy3B1GU-pPX7_lNErFQ"
      decimals="0"
      id="Narr_0hJWETvWBEKMeAKlPCbvZg"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10000000</iva:ProceedsFromLicensingArrangements>
    <iva:PeriodWithinWhichPaymentIsReceivedFromSettlement
      contextRef="Duration_10_11_2024_To_10_11_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingThroughFundRaisingMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_srt_StatementScenarioAxis_iva_ScenarioOneMember_NOafy3B1GU-pPX7_lNErFQ"
      id="Narr_KZtIN1CouEC7cUbpXFfzeA">P30D</iva:PeriodWithinWhichPaymentIsReceivedFromSettlement>
    <iva:ProceedsFromLicensingArrangements
      contextRef="Duration_10_11_2024_To_10_11_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingThroughFundRaisingMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_srt_StatementScenarioAxis_iva_ScenarioTwoMember_kF0Cffov6EiCtat91NJ6hw"
      decimals="0"
      id="Narr_-HW5-GsVD0uUM58Ek0Xqeg"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10000000</iva:ProceedsFromLicensingArrangements>
    <iva:ProceedsFromLicensingArrangements
      contextRef="Duration_10_11_2024_To_10_11_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_FinancingThroughFundRaisingMember_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_LicensingAndCollaborationAgreementWithCttqMember_srt_StatementScenarioAxis_iva_ScenarioThreeMember_2KTwko-jbE6IA2FjFwUN0A"
      decimals="0"
      id="Narr_pmgWiGWF4k60O80m0sOp8A"
      unitRef="Unit_Standard_EUR_cixmkJLrpUalyMkpGxZd-A">10000000</iva:ProceedsFromLicensingArrangements>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
